APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2001

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2000.

21ST EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2001

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

CONTENTS

		PAGE
PREFACE TO TWENTY FIRST EDITION		v
1.	INTRODUCTION	vii
1.1	Content and Exclusion	vii
1.2	Therapeutic Equivalence-Related Terms	vii
1.3	Statistical Criteria for Bioequivalence	ix
1.4	Reference Listed Drug	xi
1.5	General Policies and Legal Status	xii
1.6	Practitioner/User Responsibilities	xi
1.7	Therapeutic Equivalence Evaluations Codes	xiv
1.8	Description of Special Situations	xxi
1.9	Therapeutic Equivalence Code Change for a Drug Entity	xxii
1.10	Change of the Therapeutic Equivalence Evaluation for a Single Product	xxiii
1.11	Availability of Internal Policy and Procedure Guides	xxiii
1.12	Discontinued Section	xxiii
2.	HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1	Key Sections for Using the Drug Product Lists	2-1
2.2	Drug Product Illustration	2-3
2.3	Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS		
	Prescription Drug Product List	3-1
	OTC Drug Product List	4-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
	Discontinued Drug Product List	6-1
	Orphan Products Designations and Approvals List	7-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES		
	A. Product Name Index	A-1
	B. Product Name Index Listed by Applicant	B-1
	C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		AD1
	A. Patent and Exclusivity Lists	ADA1
	B. Patent and Exclusivity Terms	ADB1

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

PREFACE TO TWENTY FIRST EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the approved multisource prescription drug products on the List. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

FDA data supplied by DrugPatentWatch.com

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Data Management and Services , Office of Information Technology, Center for Drug and Evaluation and Research, HFD-90, 5600 Fishers Lane, Rockville, MD 20857. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

FDA data supplied by DrugPatentWatch.com

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided. An *Addendum* contains drug patent and exclusivity information for the Prescription and OTC Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research.

This publication also includes additional information, such as Orphan Drug Product Designations and other data that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products were given tentative approvals. Prior to the effective date, the Agency will not include drug products with tentative approval in the List; however, they are available in the *FDA Drug Product Approvals List* on the Internet World Wide Web. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final, effective approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics

FDA data supplied by DrugPatentWatch.com

such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

FDA data supplied by DrugPatentWatch.com

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharamaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(7)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters

FDA data supplied by DrugPatentWatch.com

characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (Cmax), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and Cmax) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (Cmax and AUC). The confidence interval for both pharmacokinetic parameters, AUC and Cmax, must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials, pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both, differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997.

FDA data supplied by DrugPatentWatch.com

The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and Cmax. The observed average differences between the reference and generic products were ± 3.47% (SD 2.84) for $AUC_{(0-t)}$, ± 3.25% (SD 2.97) for $AUC_{(0-inf)}$, and ± 4.29% (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes — Products meeting necessary bioequivalence requirements* explains the ***(AB, AB1, AB2, AB3...*** coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two NDA drug products that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two NDA drug products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

Acyclovir 200MG Tablet-Reference Listed. Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution

FDA data supplied by DrugPatentWatch.com

test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which may be purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

FDA data supplied by DrugPatentWatch.com

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form and route of administration) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions

FDA data supplied by DrugPatentWatch.com

of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A — Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B — Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

FDA data supplied by DrugPatentWatch.com

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the

FDA data supplied by DrugPatentWatch.com

additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA — Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... — Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents)* generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific

FDA data supplied by DrugPatentWatch.com
listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Once generic drug products deemed by FDA to be bioequivalent to either Adalat® CC or Procardia XL® are approved, Adalat® CC and Procardia XL® would be assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN — Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vivo* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO — Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP — Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, *Injectable; Injection*. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are all considered to be pharmaceutically and therapeutically equivalent provided they are designed to produce the same

FDA data supplied by DrugPatentWatch.com

concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

AT — Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including solutions, creams, ointments, gels, lotions, pastes, sprays, and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

FDA data supplied by DrugPatentWatch.com

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* — Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC — Extended-release dosage forms (capsules, injectables and tablets)

An extended-release dosage form is defined by the official compendia as one that allows at least a twofold reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form).

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD — Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE — Delayed-release oral dosage forms

FDA data supplied by DrugPatentWatch.com

A delayed-release dosage form is defined by the official compendia as one that releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed-release dosage forms.

Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN — Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard.

BP — Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence.

BR — Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS — Products having drug standard deficiencies

FDA data supplied by DrugPatentWatch.com

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT — Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX — Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs present special situations that deserve a more complete explanation than can be provided by the two-letter codes used in the List. These drugs have particular problems with standards of identity, analytical methodology, or bioequivalence that are in the process of resolution. The following drugs are in this category:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Diclofenac Sodium Ophthalmic Solution 0.1%. Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to

FDA data supplied by DrugPatentWatch.com

support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

Ribavirin 200MG Oral Capsule. Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon® 's activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid*. A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change, and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency,

FDA data supplied by DrugPatentWatch.com

including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of a bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Availability of Internal Policy and Procedure Guides

The Office of Generic Drugs maintains internal policy and procedure guides. Although these guides are designed for Office personnel and are subject to change without public notice, they are available to members of the public who may wish to know more about the Office's policies and procedures. Copies of these guides may be obtained from the FDA, Center for Drug Evaluation and Research, HFD-210, Division of Communications Management, Drug Information Branch, 5600 Fishers Lane, Rockville, MD 20857. The Agency welcomes public comment on the policies, procedures, and practices employed in the approval of generic drugs. Such comments may be sent to the Director, Office of Generic Drugs, (MPN-2) HFD-600, 7500 Standish Place, Rockville, MD 20855.

1.12 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not marketed or withdrawn for safety or efficacy reasons have been designated by the symbol "*". Those drug products with the symbol "*" are only reflective of citizen petitions approved since 1995.

The identification of these drug products in the Discontinued Section of the Orange Book with the symbol "*" should avoid the submission of multiple citizen petitions for the same drug product.

FDA data supplied by DrugPatentWatch.com

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration,* see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration,* see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Drug Product Lists, arranged alphabetically by active ingredient, contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982.

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with **"A"** and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine.* A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly. The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 18th Edition List have been added to the Discontinued Drug Product List appearing in the 19th Edition.

Orphan Drug Product Designations. Drugs and biologicals that have been granted Orphan Designation pursuant to Section 526 as amended by the Orphan Drug Act [P.L. 97-414, January 4, 1983] are listed in Section 3.5.

FDA data supplied by DrugPatentWatch.com

Product Name Index (Prescription and OTC Drug Product Lists). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (Prescription and OTC Drug Product Lists). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

FDA data supplied by DrugPatentWatch.com

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT → MEPERIDINE HYDROCHLORIDE

DOSAGE FORM; ROUTE OF ADMINISTRATION → INJECTABLE; INJECTION

TRADE OR GENERIC NAMES → HEXANON

REFERENCE LISTED DRUG →

AP	+	METRO-PHYS	25MG/ML	N13111 001
AP	+		50MG/ML	N13111 002
AP	+		75MG/ML	N13111 003 AUG 22, 1983
AP	+		100MG/ML	N13111 004 JAN 04, 1985

MEPERIDINE HCL

THERAPEUTIC EQUIVALENCE (TE) CODE FOR MULTISOURCE PRODUCT →

AP	ANDER SON PHARM	25MG/ML	N42242 001
AP		50MG/ML	N42296 001
AP		75MG/ML	N42301 002 AUG 27, 1987
AP		100MG/ML	N42301 003

FINAL APPROVAL DATE → AUG 27, 1987

SINGLE SOURCE PRODUCT (NO TE CODE) →

	HOLLEY MED	10MG/ML	N40000 001
AP	PARKLAND	25MG/ML	N47222 001
	SFD PHARM	150MG/ML	N47100 001

APPLICANT →

AVAILABLE STRENGTH(S) OF A PRODUCT →

APPLICATION NUMBER AND PRODUCT NUMBER →
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY →

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY ACTIVE INGREDIENT → HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

PRODUCT INFORMATION →

TABLET; ORAL

HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL			
MADISON	25MG;15MG;0.1MG	N41290 001	JAN 18, 1982

WITH CROSS-REFERENCE

ALPHABETICALLY SECOND ACTIVE INGREDIENT → HYDROCHLOROTHIAZIDE: *MULTIPLE*

CROSS-REFERENCE TO PRODUCT INFORMATION → SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED AB (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED AB (OR ANY CODE BEGINNING WITH AN A") AND NOT TO THOSE CODED BP (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED BP (OR ANY CODE BEGINNING WITH A "B") ARE NOT CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE TE CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*

PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE			
	TABLET; ORAL			
	FAZINE			
AB	PARKLAND	**500MG**	N42999 001
	SULAZINE		
AB	URSA	**500MG**	N40222 001
	SULFASALAZINE		
BP	BROWN	500MG	N41297 001

PRODUCTS CONSIDERED NOT THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED NOT THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE			
	TABLET; ORAL			
	FAZINE			
AB	PARKLAND	**500MG**	N42999 001
	SULFASALAZINE		
BP	BROWN	500MG	N41297 001
BP	SOUTH	500MG	N40627 001

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

ABACAVIR SULFATE

SOLUTION; ORAL
ZIAGEN
+ GLAXO WELLCOME — EQ 20MG BASE/ML — N20978 001 DEC 17, 1998

TABLET; ORAL
ZIAGEN
+ GLAXO WELLCOME — EQ 300MG BASE — N20977 001 DEC 17, 1998

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
TRIZIVIR
+ GLAXO WELLCOME — EQ 300MG BASE;150MG;300MG — N21205 001 NOV 14, 2000

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER — 25MG — N20482 004 MAY 29, 1997
50MG — N20482 001 SEP 06, 1995
+ 100MG — N20482 002 SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HCL

AB	MYLAN	**EQ 200MG BASE**	**N74288 001**	APR 24, 1995
AB		**EQ 400MG BASE**	**N74288 002**	APR 24, 1995
AB	PAR PHARM	**EQ 200MG BASE**	**N75047 001**	DEC 30, 1999
AB		**EQ 400MG BASE**	**N75047 002**	DEC 30, 1999
AB	WATSON LABS	**EQ 200MG BASE**	**N74007 001**	OCT 18, 1995
AB		**EQ 400MG BASE**	**N74007 002**	OCT 18, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
SECTRAL

AB	WYETH AYERST	**EQ 200MG BASE**	**N18917 001**	DEC 28, 1984
AB +		**EQ 400MG BASE**	**N18917 003**	DEC 28, 1984

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
+ MIKART — 150MG;180MG;15MG — N81095 001 OCT 26, 1990
+ — 150MG;180MG;30MG — N81096 001 OCT 26, 1990
+ — 150MG;180MG;60MG — N81097 001 OCT 26, 1990

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BUCET

AB	MALLINCKRODT	**650MG;50MG**	**N88991 001**	JUN 28, 1985

PHRENILIN FORTE

AB +	AMARIN PHARMS	**650MG;50MG**	**N88831 001**	JUN 19, 1985

TENCON

AB	MALLINCKRODT	**650MG;50MG**	**N89405 001**	MAY 15, 1990

TRIAPRIN
DUNHALL — 325MG;50MG — N89268 001 JUL 02, 1987

TABLET; ORAL
BUTAPAP

AB	MIKART	**325MG;50MG**	**N89987 001**	OCT 26, 1992
AB		**650MG;50MG**	**N89988 001**	OCT 26, 1992

PHRENILIN

AB +	AMARIN PHARMS	**325MG;50MG**	**N87811 001**	JUN 19, 1985

SEDAPAP

AB +	MAYRAND	**650MG;50MG**	**N88944 001**	OCT 17, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

		ACETAMINOPHEN, BUTALBITAL AND CAFFEINE			
AB	+	GILBERT LABS	**325MG;50MG;40MG**	**N88825 001**	DEC 05, 1984
		ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE			
AB		MIKART	**325MG;50MG;40MG**	**N89007 001**	MAR 17, 1986
		ANOQUAN			
AB		ROBERTS AND HAUCK	**325MG;50MG;40MG**	**N87628 001**	OCT 01, 1986
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB		WEST WARD	**500MG;50MG;40MG**	**N40261 001**	OCT 28, 1998
		ESGIC-PLUS			
AB	+	MIKART	**500MG;50MG;40MG**	**N40085 001**	MAR 28, 1996

TABLET; ORAL

		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB		MALLINCKRODT	**325MG;50MG;40MG**	**N87804 001**	JAN 24, 1985
AB		MIKART	**325MG;50MG;40MG**	**N89175 001**	JAN 21, 1987
AB	+		**500MG;50MG;40MG**	**N89451 001**	MAY 23, 1988
AB		WATSON LABS	**500MG;50MG;40MG**	**N40267 001**	JUL 30, 1998
AB		WEST WARD	**325MG;50MG;40MG**	**N89718 001**	JUN 12, 1995
		BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE			
AB		WEST WARD	**500MG;50MG;40MG**	**N40336 001**	AUG 18, 1999
		BUTALBITAL, APAP, AND CAFFEINE			
AB		HALSEY	**325MG;50MG;40MG**	**N89536 001**	FEB 16, 1988
		FIORICET			
AB	+	NOVARTIS	**325MG;50MG;40MG**	**N88616 001**	NOV 09, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		FIORICET W/ CODEINE			
	+	NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE			
AA		MIKART	**356.4MG;30MG;16MG**	**N40109 001**	AUG 26, 1997
		DHC PLUS			
AA	+	PURDUE FREDERICK	**356.4MG;30MG;16MG**	**N88584 001**	MAR 04, 1986

TABLET; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE		
	+	MIKART	712.8MG;60MG;32MG	N40316 001 APR 28, 1999

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

		PHENAPHEN W/ CODEINE NO. 2		
	+	ROBINS AH	325MG;15MG	N84444 001
		PHENAPHEN W/ CODEINE NO. 3		
	+	ROBINS AH	325MG;30MG	N84445 001
		PHENAPHEN W/ CODEINE NO. 4		
	+	ROBINS AH	325MG;60MG	N84446 001

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		ALPHARMA	**120MG/5ML;12MG/5ML**	**N85861 001**	
AA		HI TECH PHARMA	**120MG/5ML;12MG/5ML**	**N40119 001**	APR 26, 1996
AA		MIKART	**120MG/5ML;12MG/5ML**	**N89450 001**	OCT 27, 1992
AA		MORTON GROVE	**120MG/5ML;12MG/5ML**	**N87006 001**	
AA		MOVA	**120MG/5ML;12MG/5ML**	**N40098 001**	SEP 20, 1996
AA		PHARM ASSOC	**120MG/5ML;12MG/5ML**	**N87508 001**	
		ACETAMINOPHEN W/ CODEINE			
AA		ROXANE	**120MG/5ML;12MG/5ML**	**N86366 001**	
		TYLENOL W/ CODEINE			
AA	+	JOHNSON RW	**120MG/5ML;12MG/5ML**	**N85057 001**	

SUSPENSION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		AMARIN PHARMS	**120MG/5ML;12MG/5ML**	**N86024 001**	
		CAPITAL AND CODEINE			
AA		ALPHARMA	**120MG/5ML;12MG/5ML**	**N85883 001**	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	DURAMED	300MG;15MG	N40223 001	NOV 18, 1997
AA		300MG;30MG	N40223 002	NOV 18, 1997
AA		300MG;60MG	N40223 003	NOV 18, 1997
AA	GENEVA PHARMS	300MG;30MG	N81250 001	JUL 16, 1992
AA		300MG;60MG	N81249 001	JUL 16, 1992
AA	MIKART	300MG;30MG	N89238 001	FEB 25, 1986
+		650MG;30MG	N89231 001	MAR 03, 1986
+		650MG;60MG	N89363 001	SEP 09, 1991
AA	MUTUAL PHARM	300MG;15MG	N89671 001	FEB 10, 1988
AA		300MG;30MG	N89672 001	FEB 10, 1988
AA		300MG;60MG	N89673 001	FEB 10, 1988
AA	PHARMERAL	300MG;30MG	N87762 001	DEC 10, 1982
AA	PUREPAC PHARM	300MG;30MG	N86681 001	
AA		300MG;60MG	N86683 001	
AA	TEVA	300MG;15MG	N88627 001	MAR 06, 1985
AA		300MG;30MG	N88628 001	MAR 06, 1985
AA		300MG;60MG	N88629 001	MAR 06, 1985
AA	VINTAGE PHARMS	300MG;15MG	N89990 001	SEP 30, 1988
AA		300MG;30MG	N89805 001	SEP 30, 1988
AA		300MG;60MG	N89828 001	SEP 30, 1988
AA	WATSON LABS	300MG;15MG	N89997 001	DEC 28, 1994
AA		300MG;30MG	N89998 001	DEC 28, 1994
AA		300MG;60MG	N89999 001	DEC 28, 1994
AA	ZENITH GOLDLINE	300MG;60MG	N87083 001	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE #2

AA	SUPERPHARM	300MG;15MG	N89183 001	OCT 18, 1985

ACETAMINOPHEN W/ CODEINE NO. 3

AA	ROXANE	300MG;30MG	N84656 001	

ACETAMINOPHEN W/ CODEINE PHOSPHATE #3

AA	ZENITH GOLDLINE	300MG;30MG	N85868 001	

CAPITAL WITH CODEINE

+	CARNRICK	325MG;30MG	N83643 001	

TYLENOL W/ CODEINE NO. 1

+	JOHNSON RW	300MG;7.5MG	N85055 001	

TYLENOL W/ CODEINE NO. 2

AA	+ JOHNSON RW	300MG;15MG	N85055 002	

TYLENOL W/ CODEINE NO. 3

AA	+ JOHNSON RW	300MG;30MG	N85055 003	

TYLENOL W/ CODEINE NO. 4

AA	+ JOHNSON RW	300MG;60MG	N85055 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA	CENT PHARMS	500MG;5MG	N88898 001	MAR 27, 1985

ALLAY

AA	ZENITH GOLDLINE	500MG;5MG	N89907 001	JAN 13, 1989

HYDROCET

AA	MALLINCKRODT	500MG;5MG	N89006 001	AUG 09, 1985

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985
AA	MIKART	500MG;5MG	N81067 001	NOV 30, 1989
AA		500MG;5MG	N81068 001	NOV 30, 1989
AA		500MG;5MG	N81069 001	NOV 30, 1989
AA		500MG;5MG	N81070 001	NOV 30, 1989
AA		500MG;5MG	N89008 001	FEB 21, 1986

LORCET-HD

AA	+ MALLINCKRODT	500MG;5MG	N87336 001	JUL 08, 1982

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992
		500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992
	+	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998

TABLET; ORAL

ANEXSIA

AA	MALLINCKRODT	500MG;5MG	N89160 001	APR 23, 1987

ANEXSIA 10/660

AA	+ MALLINCKRODT	660MG;10MG	N40084 003	JUL 29, 1996

ANEXSIA 7.5/650

AA	MALLINCKRODT	650MG;7.5MG	N89725 001	SEP 30, 1987

CO-GESIC

AA	SCHWARZ PHARMA	500MG;5MG	N87757 001	MAY 03, 1982

HY-PHEN

AA	ASCHER	500MG;5MG	N87677 001	MAY 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	BARR	500MG;2.5MG	N40307 001	JUL 26, 2000
AA		500MG;5MG	N40308 001	JUL 26, 2000
AA		500MG;7.5MG	N40307 002	JUL 26, 2000
AA		500MG;10MG	N40309 001	JUL 26, 2000
AA		650MG;7.5MG	N40307 003	JUL 26, 2000
AA		650MG;10MG	N40307 004	JUL 26, 2000
AA		750MG;7.5MG	N40308 002	JUL 26, 2000
AA	ENDO PHARMS	500MG;5MG	N40281 001	SEP 30, 1998
AA		500MG;7.5MG	N40280 001	SEP 30, 1998

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ENDO PHARMS	650MG;7.5MG	N40280 002	SEP 30, 1998
AA		650MG;10MG	N40280 003	SEP 30, 1998
AA		750MG;7.5MG	N40281 002	SEP 30, 1998
		400MG;5MG	N40288 001	NOV 27, 1998
		400MG;7.5MG	N40288 002	NOV 27, 1998
		400MG;10MG	N40288 003	NOV 27, 1998
AA	EON	500MG;5MG	N40149 001	JAN 27, 1997
AA		750MG;7.5MG	N40149 002	JAN 27, 1997
AA	HALSEY	500MG;5MG	N40236 001	SEP 25, 1997
AA		650MG;7.5MG	N40240 002	NOV 26, 1997
AA		650MG;10MG	N40240 001	NOV 26, 1997
AA		750MG;7.5MG	N40236 002	SEP 25, 1997
AA	MALLINCKRODT	325MG;5MG	N40409 001	OCT 20, 2000
AA		325MG;7.5MG	N40405 001	SEP 08, 2000
AA		325MG;10MG	N40400 001	JUL 26, 2000
AA		500MG;5MG	N40084 002	JUN 01, 1995
AA		500MG;7.5MG	N40201 001	FEB 27, 1998
AA		500MG;10MG	N40201 002	FEB 27, 1998
AA		750MG;7.5MG	N40084 001	JUN 01, 1995
AA	+ MIKART	500MG;2.5MG	N89698 001	AUG 25, 1989
AA		500MG;5MG	N89271 001	JUL 16, 1986
AA		500MG;5MG	N89697 001	JAN 28, 1992

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	500MG;7.5MG	N89699 001	AUG 25, 1989
AA	+		650MG;7.5MG	N89689 001	JUN 29, 1988
AA	+		650MG;10MG	N81223 001	MAY 29, 1992
AA		PEACHTREE	500MG;10MG	N40210 001	AUG 13, 1997
AA		UCB	650MG;7.5MG	N40134 001	NOV 21, 1996
AA		VINTAGE PHARMS	325MG;10MG	N40355 001	MAY 31, 2000
AA			500MG;2.5MG	N40144 002	APR 25, 1997
AA			500MG;5MG	N89831 001	SEP 07, 1988
AA			500MG;5MG	N89971 001	DEC 02, 1988
AA			500MG;7.5MG	N40144 001	FEB 22, 1996
AA			500MG;10MG	N40356 001	MAY 31, 2000
AA			650MG;7.5MG	N40155 001	APR 14, 1997
AA			650MG;10MG	N40143 001	FEB 22, 1996
AA			660MG;10MG	N40358 001	MAY 31, 2000
AA			750MG;7.5MG	N40157 001	APR 12, 1996
AA	+	WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000
AA			325MG;10MG	N40248 002	APR 28, 2000
AA			500MG;2.5MG	N40123 003	MAR 04, 1996
AA			500MG;2.5MG	N81079 001	AUG 30, 1991
AA			500MG;5MG	N40122 001	MAR 04, 1996
AA			500MG;5MG	N89883 001	DEC 01, 1988
AA			500MG;7.5MG	N40123 004	MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		WATSON LABS	500MG;7.5MG	N81080 001	AUG 30, 1991
AA			500MG;10MG	N40148 002	FEB 14, 1997
AA			650MG;7.5MG	N40094 001	SEP 29, 1995
AA			650MG;7.5MG	N40123 001	MAR 04, 1996
AA			650MG;10MG	N40094 002	SEP 29, 1995
AA			650MG;10MG	N40123 002	MAR 04, 1996
AA			660MG;10MG	N40094 003	AUG 08, 2000
AA			750MG;7.5MG	N40122 002	MAR 04, 1996
AA			750MG;7.5MG	N81083 001	AUG 30, 1991
AA		ZENITH GOLDLINE	500MG;5MG	N89696 001	APR 21, 1988
		LORTAB			
AA		MALLINCKRODT	500MG;5MG	N87722 001	JUL 09, 1982
AA	+	UCB	325MG;5MG	N40099 001	JUN 25, 1997
AA	+		500MG;10MG	N40100 001	JAN 26, 1996
		NORCO			
AA	+	WATSON LABS	325MG;10MG	N40148 001	FEB 14, 1997
		VICODIN			
AA	+	KNOLL PHARM	500MG;5MG	N88058 001	JAN 07, 1983
		VICODIN ES			
AA	+	KNOLL PHARM	750MG;7.5MG	N89736 001	DEC 09, 1988
		VICODIN HP			
AA		KNOLL PHARM	660MG;10MG	N40117 001	SEP 23, 1996

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMIDE PHARM	500MG;5MG	N40199 001	DEC 30, 1998
AA	BARR	500MG;5MG	N40304 001	OCT 02, 2000
AA	DURAMED	500MG;5MG	N40289 001	MAR 16, 1999
AA	ENDO PHARMS	500MG;5MG	N40303 001	DEC 30, 1999
AA	HALSEY	500MG;5MG	N40219 001	JAN 22, 1998
AA	MALLINCKRODT	500MG;5MG	N40257 001	AUG 04, 1998
AA	VINTAGE PHARMS	500MG;5MG	N40106 001	JUL 30, 1996
AA	WATSON LABS	500MG;5MG	N40234 001	OCT 30, 1997

ROXILOX

AA	ROXANE	500MG;5MG	N40061 001	JUL 03, 1995

TYLOX

AA	+ JOHNSON RW	500MG;5MG	N88790 001	DEC 12, 1984

SOLUTION; ORAL

ROXICET

	ROXANE	325MG/5ML;5MG/5ML	N89351 001	DEC 03, 1986

TABLET; ORAL

OXYCET

AA	MALLINCKRODT	325MG;5MG	N87463 001	DEC 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA	AMIDE PHARM	325MG;5MG	N40203 001	MAR 15, 1999
AA	BARR	325MG;5MG	N87406 001	
AA	DURAMED	325MG;5MG	N40272 001	JUN 30, 1998
AA	VINTAGE PHARMS	325MG;5MG	N40105 001	JUL 30, 1996
AA	WATSON LABS	325MG;5MG	N40171 001	OCT 30, 1997
AA		500MG;7.5MG	N40371 001	DEC 29, 2000

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	WATSON LABS	650MG;10MG	N40371 002	DEC 29, 2000

PERCOCET

AA	ENDO PHARMS	325MG;5MG	N40330 002	JUN 25, 1999
AA	+	325MG;5MG	N85106 002	
AA	+	500MG;7.5MG	N40341 001	JUL 26, 1999
AA	+	650MG;10MG	N40341 002	JUL 26, 1999
	+	325MG;2.5MG	N40330 001	JUN 25, 1999

ROXICET

AA	ROXANE	325MG;5MG	N87003 001	

ROXICET 5/500

	+ ROXANE	500MG;5MG	N89775 001	JAN 12, 1989

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE HCL AND ACETAMINOPHEN

AB	WATSON LABS	650MG;EQ 25MG BASE	N74699 001	MAR 24, 2000

TALACEN

AB	+ SANOFI SYNTHELABO	650MG;EQ 25MG BASE	N18458 001	SEP 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	GENEVA PHARMS	650MG;65MG	N89959 001	JUL 18, 1989
AA	MYLAN	650MG;65MG	N83978 001	
AA	WATSON LABS	650MG;65MG	N40139 001	DEC 16, 1996

WYGESIC

AA	+ WYETH AYERST	650MG;65MG	N84999 001	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	DARVOCET-N 100			
AB	+ LILLY	650MG;100MG	N17122 002	
	DARVOCET-N 50			
AB	LILLY	325MG;50MG	N17122 001	
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
AB	GENEVA PHARMS	650MG;100MG	N70443 001	JAN 23, 1986
AB	HALSEY	325MG;50MG	N70115 001	JUN 12, 1985
AB		650MG;100MG	N70116 001	JUN 12, 1985
AB		650MG;100MG	N70615 001	MAR 21, 1986
AB		650MG;100MG	N70771 001	MAR 21, 1986
AB		650MG;100MG	N70775 001	MAR 21, 1986
AB	MYLAN	650MG;100MG	N70145 001	JUN 12, 1985
AB		650MG;100MG	N72195 001	FEB 16, 1988
AB	PUREPAC PHARM	650MG;100MG	N70910 001	JAN 02, 1987
AB	TEVA	650MG;100MG	N74119 001	DEC 19, 1994
AB	VINTAGE PHARMS	650MG;100MG	N74843 001	FEB 12, 1997
AB	ZENITH GOLDLINE	650MG;100MG	N70146 001	AUG 02, 1985

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX			
	+ LEDERLE	500MG	N12945 003	APR 25, 1995

TABLET; ORAL

	ACETAZOLAMIDE			
AB	DANBURY PHARMA	250MG	N88882 001	OCT 22, 1985
AB	LANNETT	250MG	N84840 001	
AB	MUTUAL PHARM	125MG	N89752 001	JUN 22, 1988

ACETAZOLAMIDE

TABLET; ORAL

	ACETAZOLAMIDE			
AB	MUTUAL PHARM	250MG	N89753 001	JUN 22, 1988
AB	TARO	125MG	N40195 001	MAY 28, 1997
AB		250MG	N40195 002	MAY 28, 1997
	DIAMOX			
AB	LEDERLE	125MG	N08943 001	
AB	+	250MG	N08943 002	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	ABBOTT	EQ 500MG BASE/VIAL	N40108 001	OCT 30, 1995
AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
	DIAMOX			
AP	+ LEDERLE	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

	ACETIC ACID 0.25% IN PLASTIC CONTAINER			
AT	ABBOTT	250MG/100ML	N17656 001	
AT	B BRAUN	250MG/100ML	N18161 001	
AT	BAXTER HLTHCARE	250MG/100ML	N18523 001	FEB 19, 1982

SOLUTION/DROPS; OTIC

	ACETASOL			
AT	ALPHARMA	2%	N87146 001	
	ACETIC ACID			
AT	MORTON GROVE	2%	N40166 001	JUL 26, 1996
AT	THAMES	2%	N88638 001	SEP 06, 1984
	VOSOL			
AT	+ WALLACE LABS	2%	N12179 001	

FDA data supplied by DrugPatentWatch.com

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	2%;0.79%	N40063 001	FEB 25, 1994
	DOMEBORO			
AT	+ BAYER	2%;0.79%	N84476 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

	ACETASOL HC			
AT	ALPHARMA	2%;1%	N87143 001	JAN 13, 1982
	HYDROCORTISONE AND ACETIC ACID			
AT	MORTON GROVE	2%;1%	N40168 001	AUG 30, 1996
AT	THAMES	2%;1%	N88759 001	MAR 04, 1985
	VOSOL HC			
AT	+ WALLACE LABS	2%;1%	N12770 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

	NEO-CORT-DOME			
	+ BAYER	2%;1%;EQ 0.35% BASE	N50238 001	

ACETOHEXAMIDE

TABLET; ORAL

	ACETOHEXAMIDE			
AB	BARR	250MG	N70869 001	FEB 09, 1987
AB	+	500MG	N70870 001	FEB 09, 1987
AB	DANBURY PHARMA	250MG	N71893 001	NOV 25, 1987
AB		500MG	N71894 001	NOV 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

	LITHOSTAT			
	+ MISSION PHARMA	250MG	N18749 001	MAY 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

	MIOCHOL			
	+ CIBA	20MG/VIAL	N16211 001	
	MIOCHOL-E			
	+ CIBA	20MG/VIAL	N20213 001	SEP 22, 1993

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	ABBOTT	10%	N73664 001	AUG 30, 1994
AN		20%	N74037 001	AUG 30, 1994
AN	BEDFORD	10%	N72323 001	APR 30, 1992
AN		20%	N72324 001	APR 30, 1992
AN	FAULDING	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	LUITPOLD	10%	N72489 001	JUL 28, 1995
AN		20%	N72547 001	JUL 28, 1995
AN	ROXANE	10%	N72621 001	SEP 30, 1992
AN		20%	N72622 001	SEP 30, 1992
	MUCOMYST			
AN	+ APOTHECON	10%	N13601 002	
AN	+	20%	N13601 001	
	MUCOSIL-10			
AN	DEY	10%	N70575 001	OCT 14, 1986

FDA data supplied by DrugPatentWatch.com

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	MUCOSIL-20			
AN	DEY	**20%**	**N70576 001**	OCT 14, 1986

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D			
+	MEDEVA	8MG;60MG	N19806 001	MAR 25, 1994

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	AESGEN	**200MG**	**N74833 001**	APR 22, 1997
AB	APOTHECON	**200MG**	**N74889 001**	OCT 31, 1997
AB	CHELSEA LABS	**200MG**	**N75101 001**	APR 15, 1998
AB	COPLEY PHARM	**200MG**	**N74914 001**	NOV 26, 1997
AB	ESI LEDERLE	**200MG**	**N74872 001**	APR 22, 1997
AB	GENPHARM	**200MG**	**N74977 001**	APR 13, 1998
AB	MYLAN	**200MG**	**N74727 001**	APR 22, 1997
AB	NOVOPHARM	**200MG**	**N74578 001**	APR 22, 1997
AB	PUREPAC PHARM	**200MG**	**N74906 001**	AUG 26, 1997

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	RANBAXY	**200MG**	**N74975 001**	SEP 30, 1998
AB	STASON	**200MG**	**N75090 001**	JAN 26, 1999
AB	TEVA	**200MG**	**N74828 001**	APR 22, 1997
AB	ZENITH GOLDLINE	**200MG**	**N74674 001**	APR 22, 1997
	ZOVIRAX			
AB	+ GLAXO WELLCOME	**200MG**	**N18828 001**	JAN 25, 1985

OINTMENT; TOPICAL

	ZOVIRAX			
+	GLAXO WELLCOME	5%	N18604 001	MAR 29, 1982

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	**200MG/5ML**	**N74738 001**	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXO WELLCOME	**200MG/5ML**	**N19909 001**	DEC 22, 1989

TABLET; ORAL

	ACYCLOVIR			
AB	AESGEN	**400MG**	**N74946 001**	NOV 19, 1997
AB		**800MG**	**N74946 002**	NOV 19, 1997
AB	APOTHECON	**400MG**	**N74891 001**	OCT 31, 1997
AB		**800MG**	**N74891 002**	OCT 31, 1997
AB	CARLSBAD	**400MG**	**N75382 001**	APR 30, 1999
AB		**800MG**	**N75382 002**	APR 30, 1999
AB	COPLEY PHARM	**400MG**	**N75021 001**	MAR 18, 1998
AB		**800MG**	**N75021 002**	MAR 18, 1998
AB	ESI LEDERLE	**400MG**	**N74834 001**	APR 24, 1997

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

AB	ESI LEDERLE	800MG	N74834 002	APR 24, 1997
AB	GENPHARM	400MG	N74976 001	APR 13, 1998
AB		800MG	N74976 002	APR 13, 1998
AB	MYLAN	400MG	N75211 001	SEP 28, 1998
AB		800MG	N75211 002	SEP 28, 1998
AB	NOVOPHARM	400MG	N74556 002	APR 22, 1997
AB		800MG	N74556 003	APR 22, 1997
AB	PUREPAC PHARM	400MG	N74870 001	JUN 05, 1997
AB		800MG	N74870 002	JUN 05, 1997
AB	RANBAXY	400MG	N74980 001	SEP 30, 1998
AB		800MG	N74980 002	SEP 30, 1998
AB	ZENITH GOLDLINE	400MG	N74836 001	APR 22, 1997
AB		800MG	N74836 002	APR 22, 1997

ZOVIRAX

AB	GLAXO WELLCOME	400MG	N20089 001	APR 30, 1991
AB +		800MG	N20089 002	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP	ABBOTT	EQ 50MG BASE/ML	N75114 001	JUL 26, 1999

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+	ESI LEDERLE	EQ 500MG BASE/VIAL	N74885 001	DEC 19, 1997
		EQ 1GM BASE/VIAL	N74885 002	DEC 19, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	ABBOTT	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
AP		EQ 500MG BASE/VIAL	N74758 001	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74758 002	APR 22, 1997
AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001	APR 30, 1998
AP +	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998
AP	BEDFORD	EQ 500MG BASE/VIAL	N74596 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74596 001	APR 22, 1997
AP	ESI LEDERLE	EQ 500MG BASE/VIAL	N74913 001	OCT 15, 1997
AP		EQ 1GM BASE/VIAL	N74913 002	OCT 15, 1997
+	FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N74969 001	AUG 26, 1997
AP		EQ 1GM BASE/VIAL	N74969 002	AUG 26, 1997
AP	MERIDIAN MEDCL TECHN	EQ 50MG BASE/ML	N75065 001	FEB 25, 1999

ZOVIRAX

AP +	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N18603 001	OCT 22, 1982
AP +		EQ 1GM BASE/VIAL	N18603 002	JUN 29, 1989

ADAPALENE

CREAM; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N20748 001	MAY 26, 2000

GEL; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N20380 001	MAY 31, 1996

FDA data supplied by DrugPatentWatch.com

ADAPALENE

SOLUTION; TOPICAL
DIFFERIN
+ GALDERMA LABS LP 0.1% N20338 001 MAY 31, 1996

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD
+ FUJISAWA HLTHCARE 3MG/ML N19937 002 OCT 30, 1989

ADENOSCAN
+ FUJISAWA HLTHCARE 3MG/ML N20059 001 MAY 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION
TROVAN PRESERVATIVE FREE
PFIZER EQ 200MG BASE/VIAL N20760 001 DEC 18, 1997
+ EQ 300MG BASE/VIAL N20760 002 DEC 18, 1997

ALBENDAZOLE

TABLET; ORAL
ALBENZA
+ SMITHKLINE BEECHAM 200MG N20666 001 JUN 11, 1996

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION
CHROMALBIN
ISO TEX 100 uCi/VIAL N17835 001

ALBUMIN HUMAN

INJECTABLE; INJECTION
OPTISON
+ MALLINCKRODT 10MG/ML N20899 001 DEC 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
MALLINCKRODT 6.67 uCi/ML N17844 003
10 uCi/ML N17844 001
100 uCi/ML N17844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION
MEGATOPE
ISO TEX 0.5mCi/VIAL N17837 001
1mCi/VIAL N17837 002

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB ALPHARMA **0.09MG/INH** **N73045 001** AUG 19, 1997
AB MEDEVA PHARMS MA **0.09MG/INH** **N72273 001** AUG 14, 1996
AB NORTON WATERFORD **0.09MG/INH** **N73272 001** DEC 28, 1995
AB SIDMAK LABS **0.09MG/INH** **N74072 001** AUG 01, 1996

PROVENTIL
BN SCHERING 0.09MG/INH N17559 001
VENTOLIN
AB + GLAXO WELLCOME **0.09MG/INH** **N18473 001**

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA
+ 3M EQ 0.09MG BASE/INH N20503 001 AUG 15, 1996

CAPSULE; INHALATION
VENTOLIN ROTACAPS
+ GLAXO WELLCOME EQ 0.2MG BASE N19489 001 MAY 04, 1988

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN ALPHARMA **EQ 0.083% BASE** **N73533 001** SEP 26, 1995

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE			
AN	BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001	MAR 29, 2000
AN		EQ 0.5% BASE	N75050 001	JUN 18, 1998
AN	DEY	EQ 0.083% BASE	N72652 001	FEB 21, 1992
AN	HI TECH PHARMA	EQ 0.083% BASE	N75063 001	FEB 09, 1999
AN		EQ 0.5% BASE	N74543 001	JAN 15, 1998
AN	MORTON GROVE	EQ 0.083% BASE	N75394 001	NOV 22, 1999
AN	NEPHRON	EQ 0.083% BASE	N74880 001	SEP 17, 1997
AN	STERIPAK	EQ 0.083% BASE	N75343 001	NOV 09, 1999
	PROVENTIL			
AN +	SCHERING	EQ 0.083% BASE	N19243 002	JAN 14, 1987
AN +		EQ 0.5% BASE	N19243 001	JAN 14, 1987
	VENTOLIN			
AN +	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992
AN +		EQ 0.5% BASE	N19269 002	JAN 16, 1987

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	ALPHARMA	EQ 2MG BASE/5ML	N74454 001	SEP 25, 1995
AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001	JAN 30, 1998
AA	TEVA	EQ 2MG BASE/5ML	N73419 001	MAR 30, 1992
AA	UDL	EQ 2MG BASE/5ML	N75262 001	MAR 30, 1999
	PROVENTIL			
AA +	SCHERING	EQ 2MG BASE/5ML	N18062 001	JAN 19, 1983

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	DANBURY PHARMA	EQ 2MG BASE	N72629 001	JAN 31, 1991

ALBUTEROL SULFATE

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	DANBURY PHARMA	EQ 4MG BASE	N72630 001	JAN 31, 1991
AB	GENEVA PHARMS	EQ 2MG BASE	N72151 001	DEC 05, 1989
AB		EQ 4MG BASE	N72152 001	DEC 05, 1989
AB	LEDERLE	EQ 2MG BASE	N72859 001	DEC 20, 1989
AB		EQ 4MG BASE	N72860 001	DEC 20, 1989
AB	MUTUAL PHARM	EQ 2MG BASE	N72636 001	DEC 05, 1989
AB		EQ 4MG BASE	N72637 001	DEC 05, 1989
AB	MYLAN	EQ 2MG BASE	N72893 001	JAN 17, 1991
AB		EQ 4MG BASE	N72894 001	JAN 17, 1991
AB	NOVOPHARM	EQ 2MG BASE	N72779 001	JUN 25, 1993
AB		EQ 4MG BASE	N72780 001	JUN 25, 1993
AB	SIDMAK LABS NJ	EQ 2MG BASE	N72316 001	DEC 05, 1989
AB		EQ 4MG BASE	N72317 001	DEC 05, 1989
AB	TEVA	EQ 2MG BASE	N72619 001	DEC 05, 1989
AB		EQ 2MG BASE	N72938 001	MAR 30, 1990
AB		EQ 4MG BASE	N72620 001	DEC 05, 1989
AB		EQ 4MG BASE	N72939 001	MAR 30, 1990
AB	WATSON LABS	EQ 2MG BASE	N72764 001	AUG 28, 1991
AB		EQ 4MG BASE	N72765 001	AUG 28, 1991
	PROVENTIL			
AB	SCHERING	EQ 2MG BASE	N17853 001	MAY 07, 1982
AB +		EQ 4MG BASE	N17853 002	MAY 07, 1982
	VENTOLIN			
AB	GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

TABLET; ORAL

	VENTOLIN			
AB	GLAXO WELLCOME	**EQ 4MG BASE**	**N19112 002**	JUL 10, 1986

TABLET, EXTENDED RELEASE; ORAL

	PROVENTIL			
BC	SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987
	VOLMAX			
BC	+ MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992
	+	EQ 8MG BASE	N19604 001	DEC 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

	COMBIVENT			
	+ BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N20291 001	OCT 24, 1996

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

	ACLOVATE			
	+ GLAXO WELLCOME	0.05%	N18707 001	DEC 14, 1982

OINTMENT; TOPICAL

	ACLOVATE			
	+ GLAXO WELLCOME	0.05%	N18702 001	DEC 14, 1982

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

	ALCOHOL 10% AND DEXTROSE 5%			
	+ B BRAUN	10ML/100ML;5GM/100ML	N04589 006	
	ALCOHOL 5% AND DEXTROSE 5%			
AP	+ B BRAUN	**5ML/100ML;5GM/100ML**	**N04589 004**	
	ALCOHOL 5% IN D5-W			
AP	ABBOTT	**5ML/100ML;5GM/100ML**	**N83263 001**	

ALENDRONATE SODIUM

TABLET; ORAL

	FOSAMAX			
	MERCK	EQ 5MG BASE	N20560 003	APR 25, 1997
		EQ 10MG BASE	N20560 001	SEP 29, 1995
		EQ 35MG BASE	N20560 004	OCT 20, 2000
		EQ 40MG BASE	N20560 002	SEP 29, 1995
	+	EQ 70MG BASE	N20560 005	OCT 20, 2000

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

	ALFENTA			
AP	+ AKORN	**EQ 0.5MG BASE/ML**	**N19353 001**	DEC 29, 1986
	ALFENTANIL			
AP	ABBOTT	**EQ 0.5MG BASE/ML**	**N75221 001**	OCT 28, 1999

ALGLUCERASE

INJECTABLE; INJECTION

	CEREDASE			
	GENZYME	10 UNITS/ML	N20057 004	MAY 08, 1992
	+	80 UNITS/ML	N20057 003	APR 05, 1991

ALITRETINOIN

GEL; TOPICAL

	PANRETIN			
	+ LIGAND	EQ 0.1% BASE	N20886 001	FEB 02, 1999

FDA data supplied by DrugPatentWatch.com

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	DANBURY PHARMA	100MG	N18832 002	SEP 28, 1984
AB		300MG	N18877 001	SEP 28, 1984
AB	GENEVA PHARMS	100MG	N70268 001	DEC 31, 1985
AB		300MG	N70269 001	DEC 31, 1985
AB	MUTUAL PHARM	100MG	N71449 001	JAN 09, 1987
AB		300MG	N71450 001	JAN 09, 1987
AB	MYLAN	100MG	N18659 001	OCT 24, 1986
AB		300MG	N18659 002	OCT 24, 1986
AB	PAR PHARM	100MG	N70150 001	DEC 10, 1985
AB		300MG	N70147 001	DEC 10, 1985
AB	SUPERPHARM	300MG	N70951 001	NOV 30, 1988

LOPURIN

AB	BASF	100MG	N71586 001	APR 02, 1987
AB		300MG	N71587 001	APR 02, 1987

ZYLOPRIM

AB	FARO PHARMS	100MG	N16084 001	
AB +		300MG	N16084 002	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM

+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
LOTRONEX

+	GLAXO WELLCOME	EQ 1MG BASE	N21107 001 FEB 09, 2000

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12

+	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL	N20924 001 APR 06, 1999

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION
MULTI-12

+	SABEX	2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML	N21163 001 MAY 18, 2000

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM

+	ROXANE	1MG/ML	N74312 001 OCT 31, 1993

SOLUTION; ORAL
ALPRAZOLAM

+	ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993

TABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	0.25MG	N74046 001 OCT 19, 1993
AB		0.5MG	N74046 002 OCT 19, 1993
AB		1MG	N74046 003 OCT 19, 1993

FDA data supplied by DrugPatentWatch.com

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ALPHAPHARM	2MG	N74046 004	MAY 07, 1997
AB	CHELSEA LABS	0.25MG	N74456 001	AUG 31, 1995
AB		0.5MG	N74456 002	AUG 31, 1995
AB		1MG	N74456 003	AUG 31, 1995
AB	GENEVA PHARMS	0.25MG	N74112 001	DEC 29, 1995
AB		0.5MG	N74112 002	DEC 29, 1995
AB		1MG	N74112 003	DEC 29, 1995
AB		2MG	N74909 001	MAR 25, 1998
AB	LEDERLE	0.25MG	N74174 001	OCT 19, 1993
AB		0.5MG	N74174 002	OCT 19, 1993
AB		1MG	N74174 003	OCT 19, 1993
AB		2MG	N74174 004	OCT 19, 1993
AB	MYLAN	0.25MG	N74215 001	JAN 27, 1994
AB		0.5MG	N74215 002	JAN 27, 1994
AB		1MG	N74215 003	JAN 27, 1994
AB		2MG	N74215 004	JAN 27, 1994
AB	NOVOPHARM NC	0.25MG	N74085 001	FEB 16, 1994
AB		0.5MG	N74085 002	FEB 16, 1994
AB		1MG	N74085 003	FEB 16, 1994
AB		2MG	N74085 004	FEB 26, 1996
AB	PUREPAC PHARM	0.25MG	N74342 001	OCT 31, 1993
AB		0.5MG	N74342 002	OCT 31, 1993

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	PUREPAC PHARM	1MG	N74342 003	OCT 31, 1993
AB		2MG	N74342 004	OCT 31, 1993
AB	WATSON LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997
AB	ZENITH GOLDLINE	0.25MG	N74294 001	JUL 29, 1994
AB		0.5MG	N74294 002	JUL 29, 1994
AB		1MG	N74294 003	JUL 29, 1994
AB		2MG	N74294 004	JUL 29, 1994

XANAX

AB	PHARMACIA AND UPJOHN	0.25MG	N18276 001	
AB		0.5MG	N18276 002	
AB	+	1MG	N18276 003	
AB		2MG	N18276 004	NOV 27, 1985

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	BEDFORD	0.5MG/ML	N74815 001	JAN 20, 1998
AP	GENSIA SICOR PHARMS	0.5MG/ML	N75196 001	APR 30, 1999

CAVERJECT

AP	PHARMACIA AND UPJOHN	0.01MG/VIAL	N20379 001	JUL 06, 1995
AP		0.02MG/VIAL	N20379 002	JUL 06, 1995
AP	+	0.04MG/VIAL	N20379 004	MAY 19, 1997
		0.005MG/VIAL	N20379 003	JUN 27, 1996
		0.01MG/ML	N20755 002	OCT 01, 1997

FDA data supplied by DrugPatentWatch.com

ALPROSTADIL

INJECTABLE; INJECTION

		CAVERJECT			
	+	PHARMACIA AND UPJOHN	0.02MG/ML	N20755 003	
				OCT 01, 1997	
		EDEX			
AP		SCHWARZ PHARMA	**0.01MG/VIAL**	**N20649 002**	
				JUN 12, 1997	
AP			**0.02MG/VIAL**	**N20649 003**	
				JUN 12, 1997	
AP	+		**0.04MG/VIAL**	**N20649 004**	
				JUN 12, 1997	
	+		0.01MG/VIAL	N20649 005	
				JUL 30, 1998	
	+		0.02MG/VIAL	N20649 006	
				JUL 30, 1998	
	+		0.04MG/VIAL	N20649 007	
				JUL 30, 1998	
		PROSTIN VR PEDIATRIC			
AP	+	PHARMACIA AND UPJOHN	**0.5MG/ML**	**N18484 001**	

SUPPOSITORY; URETHRAL

	MUSE			
	VIVUS	0.125MG	N20700 001	
			NOV 19, 1996	
		0.25MG	N20700 002	
			NOV 19, 1996	
		0.5MG	N20700 003	
			NOV 19, 1996	
+		1MG	N20700 004	
			NOV 19, 1996	

ALTRETAMINE

CAPSULE; ORAL

HEXALEN			
+	MGI PHARMA	50MG	N19926 001
			DEC 26, 1990

ALUMINUM ACETATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

		AMANTADINE HCL			
AB		GENEVA PHARMS TECH	**100MG**		**N71293 001**
					FEB 18, 1987
AB	+	ROSEMONT	**100MG**		**N70589 001**
					AUG 05, 1986

SYRUP; ORAL

	AMANTADINE HCL			
AA	ALPHARMA	**50MG/5ML**		**N72655 001**
				OCT 30, 1990
AA	COPLEY PHARM	**50MG/5ML**		**N73115 001**
				AUG 23, 1991
AA	HI TECH PHARMA	**50MG/5ML**		**N74170 001**
				OCT 28, 1994
AA	MIKART	**50MG/5ML**		**N74028 001**
				JUN 28, 1993
AA	MORTON GROVE	**50MG/5ML**		**N75060 001**
				DEC 24, 1998
AA	PHARM ASSOC	**50MG/5ML**		**N74509 001**
				JUL 17, 1995
	SYMMETREL			
AA +	ENDO PHARMS	**50MG/5ML**		**N16023 002**

TABLET; ORAL

SYMMETREL			
+	ENDO PHARMS	100MG	N18101 001

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE			
+	SANOFI SYNTHELABO	10MG	N10155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N18116 002

LOTION; TOPICAL

CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N19729 001
			JUN 13, 1988

FDA data supplied by DrugPatentWatch.com

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT
\+ FUJISAWA HLTHCARE 0.1% N18498 001

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL
MEDIMMUNE ONCOLOGY 375MG/VIAL N20221 002 SEP 10, 1999
\+ 500MG/VIAL N20221 001 DEC 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

AP	ABBOTT	**EQ 50MG BASE/ML**	**N63263 001** NOV 30, 1994
AP		**EQ 250MG BASE/ML**	**N63264 001** NOV 30, 1994
AP		**EQ 250MG BASE/ML**	**N63265 001** NOV 30, 1994
AP		**EQ 250MG BASE/ML**	**N63266 001** OCT 31, 1994
AP		**EQ 250MG BASE/ML**	**N64098 001** JUN 26, 1995
AP		**EQ 250MG BASE/ML**	**N64099 001** JUN 20, 1995
		EQ 62.5MG BASE/ML	N63283 001 OCT 31, 1994
AP	BEDFORD	**EQ 50MG BASE/ML**	**N63313 001** APR 11, 1994
AP		**EQ 250MG BASE/ML**	**N63315 001** APR 11, 1994
AP	ELKINS SINN	**EQ 250MG BASE/ML**	**N63275 001** MAY 18, 1992
AP	FAULDING	**EQ 50MG BASE/ML**	**N63350 001** JUL 30, 1993
AP		**EQ 250MG BASE/ML**	**N63350 002** JUL 30, 1993
AP	GENSIA SICOR PHARMS	**EQ 50MG BASE/ML**	**N64045 001** SEP 28, 1993
AP		**EQ 250MG BASE/ML**	**N64045 002** SEP 28, 1993

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT EQ 500MG BASE/100ML N64146 001 APR 02, 1997

AMIKIN

AP	\+ APOTHECON	**EQ 50MG BASE/ML**	**N62311 001**
AP	\+	**EQ 250MG BASE/ML**	**N62311 002**

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
AMILORIDE HCL

AB	PAR PHARM	**5MG**	**N70346 001** JAN 22, 1986

MIDAMOR

AB	\+ MERCK	**5MG**	**N18200 001**

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB	BARR	**EQ 5MG ANHYDROUS;50MG**	**N71111 001** MAY 10, 1988
AB	GENEVA PHARMS	**EQ 5MG ANHYDROUS;50MG**	**N73357 001** NOV 27, 1991
AB	MYLAN	**EQ 5MG ANHYDROUS;50MG**	**N73209 001** OCT 31, 1991
AB	TEVA	**EQ 5MG ANHYDROUS;50MG**	**N70795 001** APR 17, 1988
AB	WATSON LABS	**EQ 5MG ANHYDROUS;50MG**	**N73334 001** JUL 19, 1991

HYDRO-RIDE

AB	PAR PHARM	**EQ 5MG ANHYDROUS;50MG**	**N70347 001** DEC 25, 1990

MODURETIC 5-50

AB	\+ MERCK	**EQ 5MG ANHYDROUS;50MG**	**N18201 001**

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
FRESENIUS KABI 5.2% N18901 001 APR 06, 1984

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%		
ABBOTT	10%	N17673 003
AMINOSYN 10% (PH6)		
ABBOTT	10%	N17673 008 NOV 18, 1985
AMINOSYN 3.5%		
ABBOTT	3.5%	N17789 004
AMINOSYN 5%		
ABBOTT	5%	N17673 001
AMINOSYN 7%		
ABBOTT	7%	N17673 002
AMINOSYN 7% (PH6)		
ABBOTT	7%	N17673 006 NOV 18, 1985
AMINOSYN 8.5%		
ABBOTT	8.5%	N17673 004
AMINOSYN 8.5% (PH6)		
ABBOTT	8.5%	N17673 007 NOV 18, 1985
AMINOSYN II 10%		
ABBOTT	10%	N19438 005 APR 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER		
ABBOTT	10%	N20015 001 DEC 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER		
ABBOTT	15%	N20041 001 DEC 19, 1991
AMINOSYN II 3.5%		
ABBOTT	3.5%	N19438 001 APR 03, 1986
AMINOSYN II 7%		
ABBOTT	7%	N19438 003 APR 03, 1986
AMINOSYN II 8.5%		
ABBOTT	8.5%	N19438 004 APR 03, 1986
AMINOSYN-HBC 7%		
ABBOTT	7%	N19374 001 JUL 12, 1985
AMINOSYN-HF 8%		
ABBOTT	8%	N20345 001 APR 04, 1996
AMINOSYN-PF 10%		
ABBOTT	10%	N19492 002 OCT 17, 1986

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN-PF 7%		
ABBOTT	7%	N19398 001 SEP 06, 1985
AMINOSYN-RF 5.2%		
ABBOTT	5.2%	N18429 001
BRANCHAMIN 4%		
BAXTER HLTHCARE	4%	N18678 001 SEP 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4%	N18684 001 SEP 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER		
CLINTEC NUTR	15%	N20512 001 AUG 30, 1996
FREAMINE HBC 6.9%		
B BRAUN	6.9%	N16822 006 MAY 17, 1983
FREAMINE III 10%		
B BRAUN	10%	N16822 005
FREAMINE III 8.5%		
B BRAUN	8.5%	N16822 004
HEPATAMINE 8%		
B BRAUN	8%	N18676 001 AUG 03, 1982
HEPATASOL 8%		
BAXTER HLTHCARE	8%	N20360 001 APR 04, 1996
NEPHRAMINE 5.4%		
B BRAUN	5.4%	N17766 001
NOVAMINE 11.4%		
FRESENIUS KABI	11.4%	N17957 003 AUG 09, 1982
NOVAMINE 15%		
FRESENIUS KABI	15%	N17957 004 NOV 28, 1986
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER		
+ BAXTER HLTHCARE	20%	N20849 001 AUG 26, 1998
RENAMIN W/O ELECTROLYTES		
BAXTER HLTHCARE	6.5%	N17493 007 OCT 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	10%	N18931 003 AUG 23, 1984
TRAVASOL 10% W/O ELECTROLYTES		
BAXTER HLTHCARE	10%	N17493 006

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION

TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5%	N18931 001	AUG 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	5.5%	N17493 004	
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5%	N18931 002	AUG 23, 1984
TRAVASOL 8.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	8.5%	N17493 005	
TROPHAMINE			
+ B BRAUN	6%	N19018 001	JUL 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10%	N19018 003	SEP 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE			
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML; 41MG/100ML;150MG/100ML;200MG/100ML; 120MG/100ML	N18582 001	MAY 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 001	NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 002	NOV 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 003	NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 002	MAR 26, 1997
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 005	MAR 26, 1997
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 001	MAR 26, 1997
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 009	MAR 26, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19681 001 NOV 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML N19681 002 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;10GM/100ML N19681 004 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ABBOTT 4.25%;20GM/100ML N19681 005 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML N19681 003 NOV 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 5%;25GM/100ML N19681 006 NOV 01, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10% N20734 002 SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005 SEP 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001 SEP 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008 SEP 29, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010 SEP 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011 SEP 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007 SEP 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;10GM/100ML N20734 014 SEP 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;15GM/100ML N20734 015 SEP 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;20GM/100ML N20734 016 SEP 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;25GM/100ML N20734 017 SEP 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;35GM/100ML N20734 018 SEP 29, 1997
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N19520 002 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML N19520 003 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML N19520 004 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N19520 005 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N19520 001 SEP 23, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N19520 007 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML N19520 008 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N19520 009 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N19520 010 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N19520 006 SEP 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 001 NOV 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 002 NOV 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 002 OCT 23, 1995

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 003 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 004 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 005 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 001 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 007 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 008 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 009 OCT 23, 1995

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 006 OCT 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES
B BRAUN — 8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML — N16822 007 JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M
ABBOTT — 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML — N17789 003

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES
B BRAUN — 3%;54MG/100ML;40MG/100ML; 150MG/100ML;200MG/100ML; 120MG/100ML — N16822 003

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 10% W/ ELECTROLYTES
ABBOTT 10%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 004 APR 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 005 APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N20177 001 OCT 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N17493 003

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N20173 001 OCT 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N17493 001

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N20173 002 OCT 27, 1995

TRAVASOL 8.5% W/ ELECTROLYTES
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N17493 002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;522MG/100ML; 410MG/100ML N17789 002

AMINOSYN 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;522MG/100ML; 410MG/100ML N17673 005

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMICAR
AP + IMMUNEX **250MG/ML** **N15229 002**
AMINOCAPROIC ACID
AP ABBOTT **250MG/ML** **N70888 001** JUN 16, 1988
AP + ELKINS SINN **250MG/ML** **N18590 001** OCT 29, 1982
AP LUITPOLD **250MG/ML** **N71192 001** DEC 01, 1987
AMINOCAPROIC ACID IN PLASTIC CONTAINER
AP ABBOTT **250MG/ML** **N70010 001** MAR 09, 1987

SYRUP; ORAL
AMICAR
AA + IMMUNEX **1.25GM/5ML** **N15230 002**
AMINOCAPROIC ACID
AA MIKART **1.25GM/5ML** **N74759 001** SEP 02, 1998

TABLET; ORAL
AMICAR
+ IMMUNEX 500MG N15197 001

AMINOGLUTETHIMIDE

TABLET; ORAL
CYTADREN
+ NOVARTIS 250MG N18202 001

FDA data supplied by DrugPatentWatch.com

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
AMINOHIPPURATE SODIUM
+ MERCK 20% N05619 001

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL
LEVULAN
+ DUSA 20% N20965 001 DEC 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP ABBOTT **25MG/ML** **N87242 001** OCT 26, 1983
AP **25MG/ML** **N87601 001** JUL 23, 1982
AP + ELKINS SINN **25MG/ML** **N87239 001**
AP GENSIA SICOR PHARMS **25MG/ML** **N81142 001** SEP 25, 1991
AP INTL MEDICATION **25MG/ML** **N87209 001** FEB 01, 1982
AP LUITPOLD **25MG/ML** **N87240 001**
AP **25MG/ML** **N87600 001**
AP PHARMA SERVE NY **25MG/ML** **N87392 001** DEC 15, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
+ ABBOTT 100MG/100ML N88147 002 MAY 03, 1983
+ 200MG/100ML N88147 003 MAY 03, 1983

SOLUTION; ORAL
AMINOPHYLLINE
AA + ROXANE **105MG/5ML** **N88126 001** AUG 19, 1983

AMINOPHYLLINE DYE FREE
AA + ALPHARMA **105MG/5ML** **N87727 001** APR 16, 1982

SUPPOSITORY; RECTAL
TRUPHYLLINE
G AND W LABS 250MG N85498 001 MAR 23, 1983

AMINOPHYLLINE

SUPPOSITORY; RECTAL
TRUPHYLLINE
+ G AND W LABS 500MG N85498 002 JAN 03, 1983

TABLET; ORAL
AMINOPHYLLINE
AB GENEVA PHARMS **100MG** **N85262 002**
AB **200MG** **N85261 002**
AB + ROXANE **100MG** **N87500 001** FEB 09, 1982
AB + **200MG** **N87501 001** FEB 09, 1982
AB WEST WARD **100MG** **N84540 001**
AB **200MG** **N85003 001**

AMINOSALICYLATE SODIUM

TABLET; ORAL
SODIUM P.A.S.
+ LANNETT 500MG N80138 002

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER
+ JACOBUS 4GM/PACKET N74346 001 JUN 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
CORDARONE
+ WYETH AYERST 50MG/ML N20377 001 AUG 03, 1995

TABLET; ORAL
AMIODARONE HCL
AB ALPHAPHARM **200MG** **N75188 001** FEB 24, 1999
AB COPLEY PHARM **200MG** **N74739 001** NOV 30, 1998
AB EON **200MG** **N75315 001** DEC 23, 1998

FDA data supplied by DrugPatentWatch.com

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL				
	+ EON	400MG	N75315 002	AB	
			JUN 30, 2000		
AB	NOVOPHARM	**200MG**	**N74895 001**	AB	
			APR 16, 1999		
	CORDARONE			AB	
AB	+ WYETH AYERST	**200MG**	**N18972 001**		
			DEC 24, 1985	AB	
	PACERONE				
AB	UPSHER SMITH	**200MG**	**N75135 001**	AB	
			APR 30, 1998		
				AB	
				AB	
				AB	

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ELAVIL			
AB	+ ASTRAZENECA	25MG	N12703 003	
AB		50MG	N12703 004	
AB		75MG	N12703 005	
AB		100MG	N12703 006	
AB		150MG	N12703 007	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

	CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL			
AB	DANBURY PHARMA	EQ 12.5MG BASE;5MG	N72052 001	DEC 16, 1988
AB		EQ 25MG BASE;10MG	N72053 001	DEC 16, 1988
AB	MYLAN	EQ 12.5MG BASE;5MG	N71296 001	DEC 10, 1986
AB		EQ 25MG BASE;10MG	N71297 001	DEC 10, 1986
AB	PAR PHARM	EQ 12.5MG BASE;5MG	N72277 001	MAY 09, 1988
AB		EQ 25MG BASE;10MG	N72278 001	MAY 09, 1988
	LIMBITROL			
AB	ICN	EQ 12.5MG BASE;5MG	N16949 001	
	LIMBITROL DS			
AB	+ ICN	EQ 25MG BASE;10MG	N16949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	ETRAFON 2-10			
BP	SCHERING	10MG;2MG	N14713 007	
	ETRAFON 2-25			
BP	SCHERING	25MG;2MG	N14713 004	
	ETRAFON-FORTE			
BP	SCHERING	25MG;4MG	N14713 006	
	PERPHENAZINE AND AMITRIPTYLINE HCL			
AB	GENEVA PHARMS	10MG;2MG	N71062 001	NOV 27, 1987
AB		10MG;4MG	N71862 001	DEC 21, 1987
AB		25MG;2MG	N71063 001	NOV 27, 1987

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE AND AMITRIPTYLINE HCL			
AB	GENEVA PHARMS	25MG;4MG	N71064 001	NOV 27, 1987
AB		50MG;4MG	N71863 001	DEC 21, 1987
AB	MYLAN	10MG;2MG	N70336 001	NOV 10, 1988
AB		10MG;4MG	N71442 001	NOV 10, 1988
AB		25MG;2MG	N70337 001	NOV 10, 1988
AB	+	25MG;4MG	N70338 001	NOV 10, 1988
AB	+	50MG;4MG	N71443 001	NOV 10, 1988
AB	WATSON LABS	10MG;2MG	N73007 001	OCT 17, 1991
AB		10MG;4MG	N73009 001	OCT 17, 1991
AB		25MG;2MG	N73008 001	OCT 17, 1991
AB		25MG;4MG	N73010 001	OCT 17, 1991

AMLEXANOX

PASTE; DENTAL

	APHTHASOL		
+	BLOCK DRUG	5%	N20511 001 DEC 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL

	NORVASC		
	PFIZER	EQ 2.5MG BASE	N19787 001 JUL 31, 1992
		EQ 5MG BASE	N19787 002 JUL 31, 1992
+		EQ 10MG BASE	N19787 003 JUL 31, 1992

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

NOVARTIS	EQ 2.5MG BASE;10MG	N20364 002 MAR 03, 1995		
	EQ 5MG BASE;10MG	N20364 003 MAR 03, 1995		
+	EQ 5MG BASE;20MG	N20364 004 MAR 03, 1995		

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ ABBOTT	5MEQ/ML	N88366 001 JUN 13, 1984		

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN

+ WESTWOOD SQUIBB	EQ 12% BASE	N20508 001 AUG 29, 1996		

LOTION; TOPICAL
LAC-HYDRIN

+ WESTWOOD SQUIBB	EQ 12% BASE	N19155 001 APR 24, 1985		

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	DANBURY PHARMA	25MG	**N72688 001** AUG 28, 1992	
AB		50MG	**N72689 001** AUG 28, 1992	
AB		100MG	**N72690 001** AUG 28, 1992	
AB		150MG	**N72691 001** AUG 28, 1992	
AB	GENEVA PHARMS	25MG	**N72943 001** JUN 28, 1991	
AB		50MG	**N72944 001** JUN 28, 1991	

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	GENEVA PHARMS	100MG	**N72878 001** JUN 28, 1991	
AB		150MG	**N72879 001** JUN 28, 1991	
AB	WATSON LABS	25MG	**N72418 001** MAY 11, 1989	
AB		50MG	**N72419 001** MAY 11, 1989	
AB		100MG	**N72420 001** MAY 11, 1989	
AB	+	150MG	**N72421 001** MAY 11, 1989	

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	BIOCHEMIE	250MG	**N64076 001** SEP 30, 1994	
AB		500MG	**N64076 002** SEP 30, 1994	
AB	CLONMEL	250MG	**N62884 001** FEB 25, 1988	
AB		500MG	**N62881 001** FEB 25, 1988	
AB	CONSOLIDATED PHARM	250MG	**N62058 001**	
AB		500MG	**N62058 002**	
AB	LABS ATRAL	250MG	**N62528 001** AUG 07, 1985	
AB		500MG	**N62528 002** AUG 07, 1985	
AB	MYLAN	250MG	**N62067 001**	
AB		500MG	**N62067 002**	
AB	NOVOPHARM	250MG	**N62853 001** DEC 22, 1987	
AB		500MG	**N62854 001** DEC 22, 1987	
AB	RANBAXY	250MG	**N65016 001** APR 08, 1999	
AB		500MG	**N65016 002** APR 08, 1999	
AB	TEVA	250MG	**N61926 001**	
AB		250MG	**N63030 001** FEB 28, 1989	

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	TEVA	500MG	N61926 003	
AB		500MG	N63031 001	
			FEB 28, 1989	
	AMOXIL			
AB	SMITHKLINE BEECHAM	250MG	N62216 001	
AB +		500MG	N62216 004	
	TRIMOX			
AB	APOTHECON	250MG	N61885 001	
AB		250MG	N63099 001	
			MAR 20, 1992	
AB		500MG	N61885 002	
AB		500MG	N63099 002	
			MAR 20, 1992	
	WYMOX			
AB	WYETH AYERST	250MG	N62120 001	
AB		500MG	N62120 002	

FOR SUSPENSION; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG/5ML	N62927 001	
			NOV 25, 1988	
AB		250MG/5ML	N62927 002	
			NOV 25, 1988	
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
AB	NOVOPHARM	125MG/5ML	N62946 001	
			NOV 01, 1988	
AB		250MG/5ML	N63001 001	
			JAN 06, 1989	
AB	TEVA	125MG/5ML	N61931 001	
AB		250MG/5ML	N61931 002	
	AMOXICILLIN PEDIATRIC			
AB	TEVA	50MG/ML	N61931 003	
			DEC 01, 1982	
	AMOXIL			
AB	SMITHKLINE BEECHAM	125MG/5ML	N62226 001	
AB +		250MG/5ML	N62226 002	
AB +		50MG/ML	N62226 005	
		200MG/5ML	N50760 001	
			APR 15, 1999	
+		400MG/5ML	N50760 002	
			APR 15, 1999	
	LAROTID			
AB	SMITHKLINE BEECHAM	125MG/5ML	N62226 003	
AB		250MG/5ML	N62226 004	

AMOXICILLIN

FOR SUSPENSION; ORAL

	TRIMOX			
AB	APOTHECON	125MG/5ML	N61886 002	
AB		125MG/5ML	N62885 001	
			MAR 08, 1988	
AB		50MG/ML	N61886 001	
AB		250MG/5ML	N61886 003	
AB		250MG/5ML	N62885 002	
			MAR 08, 1988	
	WYMOX			
AB	WYETH AYERST	125MG/5ML	N62131 001	
AB		250MG/5ML	N62131 002	

TABLET; ORAL

	AMOXICILLIN			
AB	RANBAXY	500MG	N65059 001	
			NOV 24, 2000	
AB		875MG	N65059 002	
			NOV 24, 2000	
AB	TEVA	500MG	N65056 001	
			SEP 18, 2000	
AB		875MG	N65056 002	
			SEP 18, 2000	
	AMOXIL			
AB	SMITHKLINE BEECHAM	500MG	N50754 002	
			JUL 10, 1998	
AB +		875MG	N50754 001	
			JUL 10, 1998	

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	APOTHECON	125MG	N64131 001	
			MAY 06, 1996	
AB		250MG	N64131 002	
			MAY 06, 1996	
AB	CLONMEL	125MG	N64139 001	
			JAN 29, 1996	
AB		250MG	N64139 002	
			JAN 29, 1996	
AB	NOVOPHARM	125MG	N64031 001	
			DEC 19, 1996	
AB		250MG	N64031 002	
			DEC 19, 1996	
AB	RANBAXY	125MG	N65021 001	
			DEC 23, 1999	
AB		200MG	N65060 001	
			NOV 29, 2000	

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	RANBAXY	**250MG**	**N65021 002**	DEC 23, 1999
AB		**400MG**	**N65060 002**	NOV 29, 2000
AB	TEVA	**125MG**	**N64013 002**	SEP 11, 1995
AB		**250MG**	**N64013 001**	DEC 22, 1992
	AMOXIL			
AB	SMITHKLINE BEECHAM	**125MG**	**N50542 002**	
AB		**200MG**	**N50761 001**	APR 15, 1999
AB		**250MG**	**N50542 001**	
AB	+	**400MG**	**N50761 002**	APR 15, 1999

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL

	PREVPAC			
+	TAP PHARM	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A, 30MG	N50757 001	DEC 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AUGMENTIN '125'			
	SMITHKLINE BEECHAM	125MG/5ML; EQ 31.25MG BASE/5ML	N50575 001	AUG 06, 1984
	AUGMENTIN '200'			
	SMITHKLINE BEECHAM	200MG/5ML; EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996
	AUGMENTIN '250'			
+	SMITHKLINE BEECHAM	250MG/5ML; EQ 62.5MG BASE/5ML	N50575 002	AUG 06, 1984
	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG/5ML; EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

	AUGMENTIN '250'			
	SMITHKLINE BEECHAM	250MG;EQ 125MG BASE	N50564 001	AUG 06, 1984
	AUGMENTIN '500'			
	SMITHKLINE BEECHAM	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984
	AUGMENTIN '875'			
+	SMITHKLINE BEECHAM	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996

TABLET, CHEWABLE; ORAL

	AUGMENTIN '125'			
	SMITHKLINE BEECHAM	125MG;EQ 31.25MG BASE	N50597 001	JUL 22, 1985
	AUGMENTIN '200'			
	SMITHKLINE BEECHAM	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996
	AUGMENTIN '250'			
+	SMITHKLINE BEECHAM	250MG;EQ 62.5MG BASE	N50597 002	JUL 22, 1985
	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	ADDERALL 10			
	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996
	ADDERALL 12.5			
	SHIRE	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012	AUG 31, 2000
	ADDERALL 15			
	SHIRE	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013	AUG 31, 2000
	ADDERALL 20			
	SHIRE	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996
	ADDERALL 30			
+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	MAY 12, 1997

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 5			
SHIRE	1.25MG;1.25MG;1.25MG; 1.25MG	N11522 009 MAY 12, 1997	
ADDERALL 7.5			
+ SHIRE	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011 AUG 31, 2000	

AMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE			
+ APOTHECON	3%	N50314 001	

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	ABBOTT	**50MG/VIAL**	**N64141 001** DEC 23, 1996
AP	GENSIA SICOR PHARMS	**50MG/VIAL**	**N64062 001** MAR 31, 1995
AP	PHARMA TEK	**50MG/VIAL**	**N63206 001** APR 29, 1992

FUNGIZONE

AP	+ APOTHECON	**50MG/VIAL**	**N60517 001**

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET		
+ LIPOSOME	5MG/ML	N50724 001 NOV 20, 1995
AMPHOTEC		
+ ALZA	50MG/VIAL	N50729 001 NOV 22, 1996
+	100MG/VIAL	N50729 002 NOV 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME		
+ FUJISAWA HLTHCARE	50MG/VIAL	N50740 001 AUG 11, 1997

AMPHOTERICIN B

LOTION; TOPICAL

FUNGIZONE		
+ APOTHECON	3%	N60570 001

SUSPENSION; ORAL

FUNGIZONE		
+ BRISTOL MYERS SQUIBB	100MG/ML	N50341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	APOTHECON	**EQ 125MG BASE/VIAL**	**N61395 001**
AP		**EQ 125MG BASE/VIAL**	**N62860 001** FEB 05, 1988
AP		**EQ 250MG BASE/VIAL**	**N61395 002**
AP		**EQ 250MG BASE/VIAL**	**N62860 002** FEB 05, 1988
AP		**EQ 500MG BASE/VIAL**	**N61395 003**
AP		**EQ 500MG BASE/VIAL**	**N62860 003** FEB 05, 1988
AP		**EQ 1GM BASE/VIAL**	**N61395 004**
AP		**EQ 1GM BASE/VIAL**	**N62738 001** FEB 19, 1987
AP		**EQ 1GM BASE/VIAL**	**N62860 004** FEB 05, 1988
AP		**EQ 2GM BASE/VIAL**	**N61395 005**
AP		**EQ 2GM BASE/VIAL**	**N62738 002** FEB 19, 1987
AP		**EQ 2GM BASE/VIAL**	**N62860 005** FEB 05, 1988
AP		**EQ 10GM BASE/VIAL**	**N61395 006**
AP	ELKINS SINN	**EQ 125MG BASE/VIAL**	**N62692 001** JUN 24, 1986
AP		**EQ 250MG BASE/VIAL**	**N62692 002** JUN 24, 1986
AP		**EQ 500MG BASE/VIAL**	**N62692 003** JUN 24, 1986
AP		**EQ 1GM BASE/VIAL**	**N62692 004** JUN 24, 1986
AP		**EQ 2GM BASE/VIAL**	**N62692 005** JUN 24, 1986
AP		**EQ 10GM BASE/VIAL**	**N62692 006** JUN 24, 1986
AP	HANFORD GC	**EQ 1GM BASE/VIAL**	**N62772 001** APR 15, 1993

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	HANFORD GC	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993
AP		EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993
AP	IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993
AP		EQ 250MG BASE/VIAL	N62719 001	MAY 12, 1987
AP		EQ 500MG BASE/VIAL	N62719 003	MAY 12, 1987
AP		EQ 1GM BASE/VIAL	N62719 002	MAY 12, 1987
AP		EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993
AP	MARSAM	EQ 125MG BASE/VIAL	N62816 001	OCT 24, 1988
AP		EQ 250MG BASE/VIAL	N62816 002	OCT 24, 1988
AP		EQ 500MG BASE/VIAL	N62816 003	OCT 24, 1988
AP		EQ 1GM BASE/VIAL	N62816 004	OCT 24, 1988
AP		EQ 2GM BASE/VIAL	N62816 005	OCT 24, 1988
AP		EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988

OMNIPEN-N

AP	+ WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001	
AP		EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986
AP	+	EQ 250MG BASE/VIAL	N60626 002	
AP		EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

AP	+ WYETH AYERST	EQ 500MG BASE/VIAL	N60626 003	
AP		EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986
AP	+	EQ 1GM BASE/VIAL	N60626 004	
AP		EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986
AP	+	EQ 2GM BASE/VIAL	N60626 005	
AP		EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986

TOTACILLIN-N

AP	SMITHKLINE BEECHAM	EQ 125MG BASE/VIAL	N60677 001	
AP		EQ 250MG BASE/VIAL	N60677 002	
AP		EQ 500MG BASE/VIAL	N60677 003	
AP		EQ 1GM BASE/VIAL	N60677 004	
AP		EQ 2GM BASE/VIAL	N60677 005	
AP		EQ 10GM BASE/VIAL	N60677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

+	PFIZER	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986
		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N62901 001	NOV 23, 1988
+		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986
+		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995
AB		EQ 500MG BASE	N64082 002	AUG 29, 1995

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CLONMEL	EQ 250MG BASE	N62883 001	
			FEB 25, 1988	
AB		EQ 500MG BASE	N62882 001	
			FEB 25, 1988	
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	PUREPAC PHARM	EQ 500MG BASE	N61853 002	
AB	TEVA	EQ 250MG BASE	N61502 001	
AB		EQ 500MG BASE	N61502 002	
	OMNIPEN (AMPICILLIN)			
AB	WYETH AYERST	250MG	N60624 001	
AB		500MG	N60624 002	
	PRINCIPEN			
AB	APOTHECON	EQ 250MG BASE	N61392 001	
AB		EQ 500MG BASE	N61392 002	
AB		EQ 250MG BASE	N62888 001	
			MAR 04, 1988	
AB +		EQ 500MG BASE	N62888 002	
			MAR 04, 1988	
	TOTACILLIN			
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62212 001	
AB		EQ 500MG BASE	N62212 002	

FOR SUSPENSION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CLONMEL	EQ 125MG BASE/5ML	N62982 001	
			FEB 10, 1989	
AB		EQ 250MG BASE/5ML	N62982 002	
			FEB 10, 1989	
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	MYLAN	EQ 125MG BASE/5ML	N61829 002	
AB		EQ 250MG BASE/5ML	N61829 001	
AB	PUREPAC PHARM	EQ 250MG BASE/5ML	N61980 002	
AB	TEVA	EQ 125MG BASE/5ML	N61370 001	
AB		EQ 250MG BASE/5ML	N61370 002	
	OMNIPEN (AMPICILLIN)			
AB	WYETH AYERST	100MG/ML	N60625 001	
AB		125MG/5ML	N60625 002	
AB		250MG/5ML	N60625 003	
	PRINCIPEN			
AB	APOTHECON	EQ 100MG BASE/ML	N61394 001	
AB		EQ 125MG BASE/5ML	N61394 002	
AB +		EQ 250MG BASE/5ML	N61394 003	
	TOTACILLIN			
AB	SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

	TOTACILLIN			
AB	SMITHKLINE BEECHAM	EQ 250MG BASE/5ML	N60666 002	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

	PROBAMPACIN			
+	TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	

AMPRENAVIR

CAPSULE; ORAL

	AGENERASE			
	GLAXO WELLCOME	50MG	N21007 001	
			APR 15, 1999	
+		150MG	N21007 002	
			APR 15, 1999	

SOLUTION; ORAL

	AGENERASE			
+	GLAXO WELLCOME	15MG/ML	N21039 001	
			APR 15, 1999	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

	AGRYLIN			
	SHIRE	EQ 0.5MG BASE	N20333 001	
			MAR 14, 1997	
+		EQ 1MG BASE	N20333 002	
			MAR 14, 1997	

ANASTROZOLE

TABLET; ORAL

	ARIMIDEX			
+	ASTRAZENECA	1MG	N20541 001	
			DEC 27, 1995	

FDA data supplied by DrugPatentWatch.com

ANISINDIONE

TABLET; ORAL
MIRADON
+ SCHERING 50MG N10909 003

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
IOPIDINE
+ ALCON EQ 0.5% BASE N20258 001 JUL 30, 1993
+ EQ 1% BASE N19779 001 DEC 31, 1987

APROTININ BOVINE

INJECTABLE; INJECTION
TRASYLOL
+ BAYER 10,000KIU/ML N20304 001 DEC 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA
+ GENSIA AUTOMEDICS 0.05MG/ML N20420 001 SEP 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO
+ WYETH AYERST 5,000 UNITS/0.5ML N20227 002 MAY 23, 1997
+ 10,000 UNITS/0.5ML N20227 001 MAY 23, 1997

ARGATROBAN

INJECTABLE; INJECTION
ACOVA
+ TX BIOTECH 100MG/ML N20883 001 JUN 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION
R-GENE 10
+ PHARMACIA AND UPJOHN 10GM/100ML N16931 001

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
TRISENOX
+ CELL THERAP 1MG/ML N21248 001 SEP 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE
+ DEPROCO 4%;EQ 0.01MG BASE/ML N20971 001 APR 03, 2000

ASCORBIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12
AP + ASTRAZENECA **10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML** **N08809 004** AUG 08, 1985

FDA data supplied by DrugPatentWatch.com

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

	MVC PLUS			
AP	+ STERIS	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	**N18439 002** AUG 08, 1985	

ASPIRIN; *MULTIPLE*

SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	FIORINAL			
AB	+ NOVARTIS	325MG;50MG;40MG	**N17534 005** APR 16, 1986	
	LANORINAL			
AB	LANNETT	325MG;50MG;40MG	**N86996 002** OCT 11, 1985	

TABLET; ORAL

	ASPIRIN AND CAFFEINE W/ BUTALBITAL			
AB	PUREPAC PHARM	325MG;50MG;40MG	**N86710 002** AUG 23, 1983	
	BUTAL COMPOUND			
AB	GENEVA PHARMS	325MG;50MG;40MG	**N86398 002** APR 06, 1984	
	BUTALBITAL W/ ASPIRIN & CAFFEINE			
AB	PHARMERAL	325MG;50MG;40MG	**N87048 002** DEC 09, 1983	
	BUTALBITAL, ASPIRIN AND CAFFEINE			
AB	WEST WARD	325MG;50MG;40MG	**N86162 002** FEB 16, 1984	
	FIORINAL			
AB	+ NOVARTIS	325MG;50MG;40MG	**N17534 003** APR 16, 1986	
	LANORINAL			
AB	LANNETT	325MG;50MG;40MG	**N86986 002** OCT 18, 1985	

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
AB	ENDO PHARMS	325MG;50MG;40MG;30MG	**N75351 001** MAR 05, 1999	
AB	STEVENS J	325MG;50MG;40MG;30MG	**N74951 001** AUG 31, 1998	
AB	WATSON LABS	325MG;50MG;40MG;30MG	**N74359 001** AUG 31, 1995	
	FIORINAL W/CODEINE NO 3			
AB	+ NOVARTIS	325MG;50MG;40MG;30MG	**N19429 003** OCT 26, 1990	

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	SYNALGOS-DC			
	+ WYETH AYERST	356.4MG;30MG;16MG	N11483 004 SEP 06, 1983	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	INVAGESIC			
AB	INVAMED	385MG;30MG;25MG	**N74817 001** NOV 27, 1996	
	INVAGESIC FORTE			
AB	INVAMED	770MG;60MG;50MG	**N74817 002** NOV 27, 1996	
	NORGESIC			
AB	3M	385MG;30MG;25MG	**N13416 003** OCT 27, 1982	
	NORGESIC FORTE			
AB	+ 3M	770MG;60MG;50MG	**N13416 004** OCT 27, 1982	
	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE			
AB	EON	385MG;30MG;25MG	**N74654 001** DEC 31, 1996	
AB		770MG;60MG;50MG	**N74654 002** DEC 31, 1996	
AB	STEVENS J	385MG;30MG;25MG	**N74988 001** APR 30, 1999	
AB		770MG;60MG;50MG	**N74988 002** APR 30, 1999	
	ORPHENGESIC			
AB	PAR PHARM	385MG;30MG;25MG	**N75141 001** MAY 29, 1998	

FDA data supplied by DrugPatentWatch.com

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	ORPHENGESIC FORTE			
AB	PAR PHARM	**770MG;60MG;50MG**	**N75141 002**	MAY 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON COMPOUND			
	+ LILLY	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983
	DARVON COMPOUND-65			
AA	+ LILLY	**389MG;32.4MG;65MG**	**N10996 007**	MAR 08, 1983
	PROPOXYPHENE COMPOUND 65			
AA	EON	**389MG;32.4MG;65MG**	**N80044 002**	SEP 16, 1983
AA	TEVA	**389MG;32.4MG;65MG**	**N89025 001**	MAR 29, 1985
	PROPOXYPHENE COMPOUND-65			
AA	GENEVA PHARMS	**389MG;32.4MG;65MG**	**N83101 002**	JUN 24, 1985

ASPIRIN; CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL AND ASPIRIN			
AB	AMIDE PHARM	**325MG;200MG**	**N40252 001**	DEC 10, 1997
AB	EON	**325MG;200MG**	**N40116 001**	APR 25, 1996
AB	PAR PHARM	**325MG;200MG**	**N89594 001**	MAR 31, 1989
	SOMA COMPOUND			
AB	+ WALLACE PHARMS	**325MG;200MG**	**N12365 005**	JUL 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

	CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE			
AB	AMIDE PHARM	**325MG;200MG;16MG**	**N40283 001**	DEC 29, 1998
AB	EON	**325MG;200MG;16MG**	**N40118 001**	APR 16, 1996
	SOMA COMPOUND W/ CODEINE			
AB	+ WALLACE PHARMS	**325MG;200MG;16MG**	**N12366 002**	JUL 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX			
+ BOEHRINGER INGELHEIM	25MG;200MG	N20884 001	NOV 22, 1999

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE			
+ CENT PHARMS	500MG;5MG	N89420 001	JAN 25, 1988

ASPIRIN; MEPROBAMATE

TABLET; ORAL

	EQUAGESIC			
AB	+ WYETH AYERST	**325MG;200MG**	**N11702 003**	DEC 29, 1983
	MICRAININ			
AB	WALLACE PHARMS	**325MG;200MG**	**N84978 001**	

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	PAR PHARM	**325MG;400MG**	**N89657 001**	NOV 04, 1988
AB	STEVENS J	**325MG;400MG**	**N81145 001**	JAN 31, 1995
AB	ZENITH GOLDLINE	**325MG;400MG**	**N87211 001**	DEC 22, 1982
	ROBAXISAL			
AB	+ ROBINS AH	**325MG;400MG**	**N12281 001**	

FDA data supplied by DrugPatentWatch.com

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	OXYCODONE AND ASPIRIN			
AA	HALSEY	325MG;4.5MG;0.38MG	**N40260 001** JUL 17, 1998	
AA		325MG;4.5MG;0.38MG	**N87794 001** MAY 26, 1982	
AA	WATSON LABS	325MG;4.5MG;0.38MG	**N40255 001** FEB 27, 1998	
	PERCODAN			
AA	+ ENDO PHARMS	325MG;4.5MG;0.38MG	**N07337 006**	
	PERCODAN-DEMI			
AA	+ ENDO PHARMS	325MG;2.25MG;0.19MG	**N07337 005**	
	ROXIPRIN			
AA	ROXANE	325MG;4.5MG;0.38MG	**N87743 001** JUN 04, 1982	

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	TALWIN COMPOUND		
	+ SANOFI SYNTHELABO	325MG;EQ 12.5MG BASE	N16891 001

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON W/ ASA		
	+ LILLY	325MG;65MG	N10996 005

ATENOLOL

INJECTABLE; INJECTION

	TENORMIN		
	+ ASTRAZENECA	0.5MG/ML	N19058 001 SEP 13, 1989

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	**N74120 001** FEB 24, 1995	
AB		100MG	**N74120 002** FEB 24, 1995	
AB	DANBURY PHARMA	50MG	**N73352 001** DEC 27, 1991	

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	DANBURY PHARMA	100MG	**N73353 001** DEC 27, 1991	
AB	GENEVA PHARMS	25MG	**N74052 001** MAY 01, 1992	
AB		50MG	**N73025 001** SEP 17, 1991	
AB		100MG	**N73026 001** SEP 17, 1991	
AB	GENEVA PHARMS TECH	25MG	**N74265 001** FEB 28, 1994	
AB		50MG	**N74265 002** FEB 28, 1994	
AB		100MG	**N74265 003** FEB 28, 1994	
AB	GENPHARM	25MG	**N74126 003** AUG 26, 1998	
AB		50MG	**N74126 001** MAR 23, 1994	
AB		100MG	**N74126 002** MAR 23, 1994	
AB	IPR	25MG	**N73646 001** JUL 31, 1992	
AB		50MG	**N72303 001** JUL 15, 1988	
AB		100MG	**N72304 001** JUL 15, 1988	
AB	LEDERLE	25MG	**N74099 001** APR 28, 1992	
AB		50MG	**N73542 001** DEC 19, 1991	
AB		100MG	**N73543 001** DEC 19, 1991	
AB	MARTEC	50MG	**N74127 001** FEB 21, 1995	
AB		100MG	**N74127 002** FEB 21, 1995	
AB	MUTUAL PHARM	25MG	**N74499 001** JUL 30, 1997	
AB		50MG	**N73475 001** MAR 30, 1993	
AB		100MG	**N73476 001** MAR 30, 1993	
AB	MYLAN	50MG	**N73456 001** JAN 24, 1992	

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MYLAN	**100MG**	**N73457 001**	JAN 24, 1992
		25MG	N73457 002	APR 26, 1999
AB	NOVOPHARM NC	**50MG**	**N73315 001**	MAY 28, 1993
AB		**100MG**	**N73316 001**	MAY 28, 1993
AB	SCS	**50MG**	**N73676 001**	OCT 30, 1992
AB		**100MG**	**N73676 002**	OCT 30, 1992
AB	SIDMAK LABS NJ	**25MG**	**N74101 001**	JUL 17, 1997
AB		**50MG**	**N74101 002**	JUL 17, 1997
AB		**100MG**	**N74101 003**	JUL 17, 1997
AB	TEVA	**50MG**	**N74056 001**	JAN 18, 1995
AB		**100MG**	**N74056 002**	JAN 18, 1995

TENORMIN

AB	ASTRAZENECA	**25MG**	**N18240 004**	APR 09, 1990
AB		**50MG**	**N18240 001**	
AB	+	**100MG**	**N18240 002**	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	DANBURY PHARMA	**50MG;25MG**	**N73665 001**	JUL 02, 1992
AB		**100MG;25MG**	**N73665 002**	JUL 02, 1992
AB	IPR	**50MG;25MG**	**N72301 001**	MAY 31, 1990
AB		**100MG;25MG**	**N72302 001**	MAY 31, 1990
AB	MARTEC	**50MG;25MG**	**N74404 001**	MAY 14, 1998
AB		**100MG;25MG**	**N74404 002**	MAY 14, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	MUTUAL PHARM	**50MG;25MG**	**N73581 001**	APR 29, 1993
AB		**100MG;25MG**	**N73582 001**	APR 29, 1993
AB	MYLAN	**50MG;25MG**	**N74203 001**	OCT 31, 1993
AB		**100MG;25MG**	**N74203 002**	OCT 31, 1993
AB	SIDMAK LABS NJ	**50MG;25MG**	**N74107 001**	SEP 24, 1997
AB		**100MG;25MG**	**N74107 002**	SEP 24, 1997

TENORETIC 100

AB	+ ASTRAZENECA	**100MG;25MG**	**N18760 001**	JUN 08, 1984

TENORETIC 50

AB	ASTRAZENECA	**50MG;25MG**	**N18760 002**	JUN 08, 1984

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PFIZER IRELAND PHARM	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
		EQ 40MG BASE	N20702 003	DEC 17, 1996
	+	EQ 80MG BASE	N20702 004	APR 07, 2000

ATOVAQUONE

SUSPENSION; ORAL
MEPRON

	+ GLAXO WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

TABLET; ORAL
MEPRON

	+ GLAXO WELLCOME	250MG	N20259 001	NOV 25, 1992

FDA data supplied by DrugPatentWatch.com

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

	MALARONE			
+	GLAXO WELLCOME	250MG;100MG	N21078 001	JUL 14, 2000
	MALARONE PEDIATRIC			
+	GLAXO WELLCOME	62.5MG;25MG	N21078 002	JUL 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	ATRACURIUM BESYLATE			
AP	ABBOTT	**10MG/ML**	**N74632 001**	DEC 23, 1996
AP	BEDFORD	**10MG/ML**	**N74901 001**	JUL 18, 1997
AP	ESI LEDERLE	**10MG/ML**	**N74824 001**	SEP 30, 1997
AP	FAULDING	**10MG/ML**	**N74740 001**	MAR 28, 1997
AP	GENSIA SICOR PHARMS	**10MG/ML**	**N74784 001**	JUN 11, 1997
AP	MARSAM	**10MG/ML**	**N74945 001**	JUL 28, 1998
AP	OHMEDA	**10MG/ML**	**N74753 001**	JAN 23, 1997
	ATRACURIUM BESYLATE PRESERVATIVE FREE			
AP	ABBOTT	**10MG/ML**	**N74633 001**	DEC 23, 1996
AP		**10MG/ML**	**N74639 001**	MAR 25, 1997
AP	BEDFORD	**10MG/ML**	**N74900 001**	JUL 18, 1997
AP	ESI LEDERLE	**10MG/ML**	**N74825 001**	SEP 30, 1997
AP	FAULDING	**10MG/ML**	**N74741 001**	MAR 28, 1997
AP	MARSAM	**10MG/ML**	**N74944 001**	JUL 28, 1998
AP	OHMEDA	**10MG/ML**	**N74768 001**	JAN 23, 1997
	TRACRIUM			
AP	+ ABBOTT	**10MG/ML**	**N18831 002**	JUN 20, 1985
	TRACRIUM PRESERVATIVE FREE			
AP	+ ABBOTT	**10MG/ML**	**N18831 001**	NOV 23, 1983

ATROPINE

INJECTABLE; INJECTION

	ATROPEN			
+	MERIDIAN MEDCL TECHN	EQ 2MG SULFATE/0.7ML	N17106 001	

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

	MOTOFEN			
+	AMARIN PHARMS	0.025MG;1MG	N17744 002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
	SCHERER RP	0.025MG;2.5MG	N86440 001	

SOLUTION; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE			
AA	ROXANE	**0.025MG/5ML;2.5MG/5ML**	**N87708 001**	MAY 03, 1982
	LOMOTIL			
AA	+ SEARLE	**0.025MG/5ML;2.5MG/5ML**	**N12699 001**	

TABLET; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE			
AA	ABLE	**0.025MG;2.5MG**	**N40395 001**	NOV 27, 2000
AA	INWOOD LABS	**0.025MG;2.5MG**	**N85509 001**	
AA	MYLAN	**0.025MG;2.5MG**	**N85762 001**	
AA	PAR PHARM	**0.025MG;2.5MG**	**N40357 001**	MAY 02, 2000
AA	R AND S PHARMA	**0.025MG;2.5MG**	**N85035 001**	
AA	WEST WARD	**0.025MG;2.5MG**	**N87765 001**	MAR 15, 1982
	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
AA	PVT FORM	**0.025MG;2.5MG**	**N85766 001**	
AA	ZENITH GOLDLINE	**0.025MG;2.5MG**	**N86727 001**	
	LOMOTIL			
AA	+ SEARLE	**0.025MG;2.5MG**	**N12462 001**	
	LONOX			
AA	GENEVA PHARMS	**0.025MG;2.5MG**	**N85311 002**	

FDA data supplied by DrugPatentWatch.com

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER PHARM PROD 0.14MG/ML;10MG/ML N19677 001 NOV 06, 1991
+ 0.14MG/ML;10MG/ML N19678 001 NOV 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ATROPINE AND DEMEROL
+ ABBOTT 0.4MG/ML;50MG/ML N87853 001 NOV 26, 1982
+ 0.4MG/ML;75MG/ML N87847 001 NOV 26, 1982
+ 0.4MG/ML;100MG/ML N87848 001 NOV 26, 1982

AURANOFIN

CAPSULE; ORAL
RIDAURA
+ CONNETICS 3MG N18689 001 MAY 24, 1985

AZATADINE MALEATE

TABLET; ORAL
OPTIMINE
+ SCHERING 1MG N17601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
TRINALIN
+ SCHERING 1MG;120MG N18506 001 MAR 23, 1982

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE
AB APPLIED ANAL **50MG** **N75252 001** JUN 07, 1999
AB GENPHARM **50MG** **N75568 001** DEC 13, 1999
AB ROXANE **50MG** **N74069 001** FEB 16, 1996

IMURAN
AB + FARO PHARMS **50MG** **N16324 001**

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE SODIUM
AP BEDFORD **EQ 100MG BASE/VIAL** **N74419 001** MAR 31, 1995

IMURAN
AP + FARO PHARMS **EQ 100MG BASE/VIAL** **N17391 001**

AZELAIC ACID

CREAM; TOPICAL
AZELEX
+ ALLERGAN 20% N20428 001 SEP 13, 1995

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIVAR
+ ASTA 0.05% N21127 001 MAY 22, 2000

SPRAY, METERED; NASAL
ASTELIN
+ WALLACE LABS EQ 0.125MG BASE/SPRAY N20114 001 NOV 01, 1996

FDA data supplied by DrugPatentWatch.com

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL
ZITHROMAX
+ PFIZER — EQ 250MG BASE — N50670 001 NOV 01, 1991

FOR SUSPENSION; ORAL
ZITHROMAX
+ PFIZER — EQ 1GM BASE/PACKET — N50693 001 SEP 28, 1994
EQ 100MG BASE/5ML — N50710 001 OCT 19, 1995
+ EQ 200MG BASE/5ML — N50710 002 OCT 19, 1995

INJECTABLE; INJECTION
ZITHROMAX
+ PFIZER — EQ 500MG BASE/VIAL — N50733 001 JAN 30, 1997

TABLET; ORAL
ZITHROMAX
PFIZER — EQ 250MG BASE — N50711 001 JUL 18, 1996
+ EQ 600MG BASE — N50730 001 JUN 12, 1996

AZTREONAM

INJECTABLE; INJECTION
AZACTAM
+ BRISTOL MYERS SQUIBB 500MG/VIAL — N50580 001 DEC 31, 1986
+ 1GM/VIAL — N50580 002 DEC 31, 1986
+ 2GM/VIAL — N50580 003 DEC 31, 1986

AZACTAM IN PLASTIC CONTAINER
+ BRISTOL MYERS SQUIBB 20MG/ML — N50632 002 MAY 24, 1989
+ 40MG/ML — N50632 001 MAY 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL
SPECTROBID
+ PFIZER — 125MG/5ML — N50556 001 MAR 23, 1982

TABLET; ORAL
SPECTROBID
+ PFIZER — 400MG — N50520 001

BACITRACIN

INJECTABLE; INJECTION
BACIIM
AP PHARMA TEK — **50,000 UNITS/VIAL** — **N64153 001** MAY 09, 1997

BACITRACIN
AP + PHARMACIA AND UPJOHN — **50,000 UNITS/VIAL** — **N60733 002**
10,000 UNITS/VIAL — N60733 001

OINTMENT; OPHTHALMIC
BACITRACIN
+ ALTANA — 500 UNITS/GM — N61212 001

POWDER; FOR RX COMPOUNDING
BACI-RX
AA PHARMA TEK — **5,000,000 UNITS/BOT** — **N61580 001**
BACITRACIN
AA APOTHEKERNES — **5,000,000 UNITS/BOT** — **N61699 001**

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE
+ PHARMADERM — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N62166 002

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING
ZIBA-RX
PHARMA TEK — 500,000 UNITS/BOT — N61737 001

FDA data supplied by DrugPatentWatch.com

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT	+	MONARCH PHARMS	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64068 001** OCT 30, 1995

OINTMENT; TOPICAL

CORTISPORIN

	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN

AT		ALTANA	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N60764 002**

NEO-POLYCIN

		DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60647 001

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64064 001** OCT 30, 1995

NEOSPORIN

AT	+	MONARCH PHARMS	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001** JAN 30, 1995
AT		BAUSCH AND LOMB	**500 UNITS/GM; 10,000 UNITS/GM**	**N64046 001** JAN 26, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

POLYSPORIN

AT	+	MONARCH PHARMS	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**

BACLOFEN

INJECTABLE; INTRATHECAL

LIORESAL

	+	MEDTRONIC	0.05MG/ML	N20075 003 NOV 07, 1996
	+		0.5MG/ML	N20075 001 JUN 17, 1992
	+		2MG/ML	N20075 002 JUN 17, 1992

TABLET; ORAL

BACLOFEN

AB		CHELSEA LABS	**10MG**	**N74698 001** AUG 20, 1996
AB			**20MG**	**N74698 002** AUG 20, 1996
AB		DANBURY PHARMA	**10MG**	**N72824 001** SEP 18, 1991
AB			**20MG**	**N72825 001** SEP 18, 1991
AB		ROSEMONT	**10MG**	**N74584 001** AUG 19, 1996
AB			**20MG**	**N74584 002** AUG 19, 1996
AB		TEVA	**10MG**	**N73043 001** FEB 27, 1992
AB			**20MG**	**N73044 001** FEB 27, 1992
AB		WATSON LABS	**10MG**	**N73092 001** JAN 28, 1994
AB			**20MG**	**N73093 001** JAN 28, 1994
AB		ZENITH GOLDLINE	**10MG**	**N72234 001** JUL 21, 1988
AB			**20MG**	**N72235 001** JUL 21, 1988

LIORESAL

AB		NOVARTIS	**10MG**	**N17851 001**
AB	+		**20MG**	**N17851 003** JAN 20, 1982

FDA data supplied by DrugPatentWatch.com

BALSALAZIDE DISODIUM

CAPSULE; ORAL

	COLAZAL			
+	SALIX	750MG	N20610 001	JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

	BECLOVENT			
BN	GLAXO WELLCOME	0.042MG/INH	N18153 001	
	QVAR 40			
+	3M	0.04MG/INH	N20911 002	SEP 15, 2000
	QVAR 80			
+	3M	0.08MG/INH	N20911 001	SEP 15, 2000
	VANCERIL			
BN +	SCHERING	0.042MG/INH	N17573 001	
	VANCERIL DOUBLE STRENGTH			
+	SCHERING	0.084MG/INH	N20486 001	DEC 24, 1996

AEROSOL, METERED; NASAL

	BECONASE			
BN +	GLAXO WELLCOME	0.042MG/INH	N18584 001	
	VANCENASE			
BN	SCHERING	0.042MG/INH	N18521 001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

	BECONASE AQ			
BN +	GLAXO WELLCOME	EQ 0.042MG DIPROP/SPRAY	N19389 001	JUL 27, 1987
	VANCENASE AQ			
BN +	SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001	DEC 23, 1987
+		EQ 0.084MG DIPROP/SPRAY	N20469 001	JUN 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

	LOTENSIN			
	NOVARTIS	5MG	N19851 001	JUN 25, 1991
		10MG	N19851 002	JUN 25, 1991
		20MG	N19851 003	JUN 25, 1991
+		40MG	N19851 004	JUN 25, 1991

BENAZEPRIL HYDROCHLORIDE; *MULTIPLE*

SEE AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	LOTENSIN HCT			
	NOVARTIS	5MG;6.25MG	N20033 001	MAY 19, 1992
		10MG;12.5MG	N20033 002	MAY 19, 1992
		20MG;12.5MG	N20033 004	MAY 19, 1992
+		20MG;25MG	N20033 003	MAY 19, 1992

BENDROFLUMETHIAZIDE

TABLET; ORAL

	NATURETIN-10			
+	APOTHECON	10MG	N12164 003	
	NATURETIN-5			
	APOTHECON	5MG	N12164 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

	CORZIDE			
	APOTHECON	5MG;40MG	N18647 001	MAY 25, 1983
+		5MG;80MG	N18647 002	MAY 25, 1983

FDA data supplied by DrugPatentWatch.com

BENZONATATE

CAPSULE; ORAL

	BENZONATATE			
AA	BANNER PHARMACAPS	100MG	N81297 001	JAN 29, 1993
	TESSALON			
AA +	FOREST LABS	100MG	N11210 001	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	BENZACLIN			
+	DERMIK LABS	5%;EQ 1% BASE	N50756 001	DEC 21, 2000

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

	BENZAMYCIN			
+	DERMIK LABS	5%;3%	N50557 001	OCT 26, 1984
	BENZAMYCIN PAK			
+	DERMIK LABS	5%;3%	N50769 001	NOV 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	DIDREX		
+	PHARMACIA AND UPJOHN	50MG	N12427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	EMETE-CON		
+	ROERIG	EQ 50MG BASE/VIAL	N16820 001

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

	COGENTIN		
+	MERCK	1MG/ML	N12015 001

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE			
AA	GENEVA PHARMS TECH	0.5MG	N72264 001	FEB 27, 1989
AA		1MG	N72265 001	FEB 27, 1989
AA		2MG	N72266 001	FEB 27, 1989
AA	MUTUAL PHARM	1MG	N81264 001	JAN 23, 1992
AA		2MG	N81265 001	JAN 23, 1992
AA	PAR PHARM	0.5MG	N88877 001	APR 11, 1985
AA		1MG	N88894 001	APR 11, 1985
AA		2MG	N88895 001	APR 11, 1985
AA	ROSEMONT	0.5MG	N40103 001	DEC 12, 1996
AA		1MG	N40103 002	DEC 12, 1996
AA		2MG	N40103 003	DEC 12, 1996
AA	SIDMAK LABS NJ	0.5MG	N89058 001	AUG 10, 1988
AA		1MG	N89059 001	AUG 10, 1988
AA		2MG	N89060 001	AUG 10, 1988
	COGENTIN			
AA +	MERCK	0.5MG	N09193 004	
AA +		1MG	N09193 003	
AA +		2MG	N09193 002	

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

	PRE-PEN		
+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

FDA data supplied by DrugPatentWatch.com

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR
JOHNSON RW 200MG N19002 001 DEC 28, 1990
\+ 300MG N19002 002 DEC 28, 1990

BERACTANT

SUSPENSION; INTRATRACHEAL
SURVANTA
\+ ROSS LABS 25MG/ML N20032 001 JUL 01, 1991

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE
\+ ORPHAN MEDCL 1GM/SCOOPFUL N20576 001 OCT 25, 1996

BETAMETHASONE

SYRUP; ORAL
CELESTONE
\+ SCHERING 0.6MG/5ML N14215 002

TABLET; ORAL
CELESTONE
\+ SCHERING 0.6MG N12657 003

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
CELESTONE SOLUSPAN
\+ SCHERING 3MG/ML;EQ 3MG BASE/ML N14602 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
ALPHATREX
AB SAVAGE LABS **EQ 0.05% BASE** **N19138 001** JUN 26, 1984

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
AB CLAY PARK **EQ 0.05% BASE** **N74579 001** NOV 26, 1997
AB FOUGERA **EQ 0.05% BASE** **N19137 001** JUN 26, 1984
AB NMC **EQ 0.05% BASE** **N70885 001** FEB 03, 1987
AB TARO **EQ 0.05% BASE** **N73552 001** APR 30, 1992
AB TEVA **EQ 0.05% BASE** **N71476 001** AUG 10, 1987
AB THAMES **EQ 0.05% BASE** **N71143 001** JUN 17, 1987
DIPROSONE
AB \+ SCHERING **EQ 0.05% BASE** **N17536 001**

CREAM, AUGMENTED; TOPICAL
DIPROLENE AF
\+ SCHERING EQ 0.05% BASE N19555 001 APR 27, 1987

DISC; TOPICAL
DIPROSONE
\+ SCHERING EQ 0.1% BASE N17829 001

GEL; TOPICAL
DIPROLENE
\+ SCHERING EQ 0.05% BASE N19408 002 NOV 22, 1991

LOTION; TOPICAL
ALPHATREX
AB SAVAGE LABS **EQ 0.05% BASE** **N70273 001** AUG 12, 1985
BETAMETHASONE DIPROPIONATE
AB ALPHARMA **EQ 0.05% BASE** **N70281 001** JUL 31, 1985
AB CLAY PARK **EQ 0.05% BASE** **N72538 001** JAN 31, 1990
AB COPLEY PHARM **EQ 0.05% BASE** **N71882 001** JUN 06, 1988
AB FOUGERA **EQ 0.05% BASE** **N70275 001** AUG 12, 1985
AB TARO **EQ 0.05% BASE** **N74272 001** SEP 30, 1994

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	TEVA	**EQ 0.05% BASE**	**N71467 001**	AUG 10, 1987
AB	THAMES	**EQ 0.05% BASE**	**N72276 001**	AUG 24, 1988
	DIPROSONE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N17781 001**	

LOTION, AUGMENTED; TOPICAL

	DIPROLENE			
	+ SCHERING	EQ 0.05% BASE	N19716 001	AUG 01, 1988

OINTMENT; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	**EQ 0.05% BASE**	**N19143 001**	SEP 04, 1984
	BETAMETHASONE DIPROPIONATE			
AB	FOUGERA	**EQ 0.05% BASE**	**N19141 001**	SEP 04, 1984
AB	NMC	**EQ 0.05% BASE**	**N71012 001**	FEB 03, 1987
AB	TARO	**EQ 0.05% BASE**	**N74271 001**	SEP 15, 1994
AB	TEVA	**EQ 0.05% BASE**	**N71477 001**	AUG 10, 1987
	DIPROSONE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N17691 001**	

OINTMENT, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	ALTANA	**EQ 0.05% BASE**	**N75373 001**	JUN 22, 1999
AB	NMC	**EQ 0.05% BASE**	**N74304 001**	AUG 31, 1995
	DIPROLENE			
AB	+ SCHERING	**EQ 0.05% BASE**	**N18741 001**	JUL 27, 1983

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

	LOTRISONE			
	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

	LOTRISONE			
	+ SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	DEC 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	BETAMETHASONE SODIUM PHOSPHATE		
AP	STERIS	**EQ 3MG BASE/ML**	**N85738 001**
	CELESTONE		
AP	+ SCHERING	**EQ 3MG BASE/ML**	**N17561 001**

BETAMETHASONE SODIUM PHOSPHATE; *MULTIPLE*

SEE BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

BETAMETHASONE VALERATE

AEROSOL; TOPICAL

	LUXIQ			
	+ CONNETICS	EQ 0.12% BASE	N20934 001	FEB 28, 1999

CREAM; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N18642 001**	MAR 24, 1983
	BETADERM			
AB	ROACO	**EQ 0.1% BASE**	**N18839 001**	JUN 30, 1983
	BETAMETHASONE VALERATE			
AB	+ FOUGERA	**EQ 0.1% BASE**	**N18861 001**	AUG 31, 1983
AB	THAMES	**EQ 0.1% BASE**	**N70062 001**	MAY 14, 1985
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18862 001**	AUG 31, 1983
	DERMABET			
AB	TARO	**EQ 0.1% BASE**	**N72041 001**	JAN 06, 1988
	VALNAC			
AB	NMC	**EQ 0.1% BASE**	**N70050 001**	OCT 10, 1984

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE VALERATE

LOTION; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N70072 001**	JUN 27, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA	**EQ 0.1% BASE**	**N70052 001**	JUL 31, 1985
AB	COPLEY PHARM	**EQ 0.1% BASE**	**N71883 001**	APR 22, 1988
AB +	FOUGERA	**EQ 0.1% BASE**	**N18866 001**	AUG 31, 1983
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18867 001**	AUG 31, 1983

OINTMENT; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N70069 001**	DEC 19, 1985
	BETAMETHASONE VALERATE			
AB +	FOUGERA	**EQ 0.1% BASE**	**N18865 001**	AUG 31, 1983
AB	NMC	**EQ 0.1% BASE**	**N70051 001**	OCT 10, 1984
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18863 001**	AUG 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	**EQ 0.5% BASE**	**N75386 001**	JUN 30, 2000
AT	NOVEX	**EQ 0.5% BASE**	**N75446 001**	SEP 28, 2000
	BETOPTIC			
AT +	ALCON	**EQ 0.5% BASE**	**N19270 001**	AUG 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

	BETOPTIC S		
+	ALCON	EQ 0.25% BASE	N19845 001 DEC 29, 1989

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	**10MG**	**N75541 001**	OCT 22, 1999
AB		**20MG**	**N75541 002**	OCT 22, 1999
	KERLONE			
AB	LOREX	**10MG**	**N19507 001**	OCT 27, 1989
AB +		**20MG**	**N19507 002**	OCT 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

	KERLEDEX		
	LOREX	5MG;12.5MG	N19807 001 OCT 30, 1992
+		10MG;12.5MG	N19807 002 OCT 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

	BETOPTIC PILO		
+	ALCON	EQ 0.25% BASE;1.75%	N20619 001 APR 17, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL

	URECHOLINE		
+	ODYSSEY PHARMS	5MG	N89095 001 DEC 19, 1985
+		10MG	N88440 001 MAY 29, 1984
+		25MG	N88441 001 MAY 29, 1984
+		50MG	N89096 001 DEC 19, 1985

FDA data supplied by DrugPatentWatch.com

BEXAROTENE

CAPSULE; ORAL
TARGRETIN
+ LIGAND 75MG N21055 001 DEC 29, 1999

GEL; TOPICAL
TARGRETIN
+ LIGAND 1% N21056 001 JUN 28, 2000

BICALUTAMIDE

TABLET; ORAL
CASODEX
+ ASTRAZENECA 50MG N20498 001 OCT 04, 1995

BIOTIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

BIOTIN, D-; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL
AKINETON
+ KNOLL PHARM 2MG N12003 001

BIPERIDEN LACTATE

INJECTABLE; INJECTION
AKINETON
+ KNOLL PHARM 5MG/ML N12418 002

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE, TABLET, CAPSULE; ORAL
HELIDAC
+ PROMETHEUS LABS 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG N50719 001 AUG 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE
AB EON **5MG** **N75643 001** NOV 16, 2000
AB **10MG** **N75643 002** NOV 16, 2000
ZEBETA
AB LEDERLE **5MG** **N19982 002** JUL 31, 1992
AB + **10MG** **N19982 001** JUL 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
AB APOTHECON **2.5MG;6.25MG** **N75642 002** DEC 27, 2000
AB **5MG;6.25MG** **N75642 001** DEC 27, 2000
AB **10MG;6.25MG** **N75642 003** DEC 27, 2000
AB CHELSEA LABS **2.5MG;6.25MG** **N75469 001** SEP 25, 2000
AB **5MG;6.25MG** **N75469 002** SEP 25, 2000
AB **10MG;6.25MG** **N75469 003** SEP 25, 2000
AB EON **2.5MG;6.25MG** **N75579 001** SEP 25, 2000

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	EON	5MG;6.25MG	N75579 002	SEP 25, 2000
AB		10MG;6.25MG	N75579 003	SEP 25, 2000
AB	GENEVA PHARMS TECH	2.5MG;6.25MG	N75527 001	SEP 25, 2000
AB		5MG;6.25MG	N75527 003	SEP 25, 2000
AB		10MG;6.25MG	N75527 002	SEP 25, 2000
AB	MYLAN	2.5MG;6.25MG	N75768 001	SEP 25, 2000
AB		5MG;6.25MG	N75768 002	SEP 25, 2000
AB		10MG;6.25MG	N75768 003	SEP 25, 2000
AB	PUREPAC PHARM	2.5MG;6.25MG	N75672 001	SEP 25, 2000
AB		5MG;6.25MG	N75672 002	SEP 25, 2000
AB		10MG;6.25MG	N75672 003	SEP 25, 2000
AB	ZENITH GOLDLINE	2.5MG;6.25MG	N75632 001	SEP 27, 2000
AB		5MG;6.25MG	N75632 002	SEP 27, 2000
AB		10MG;6.25MG	N75632 003	SEP 27, 2000
	ZIAC			
AB	LEDERLE	2.5MG;6.25MG	N20186 003	MAR 26, 1993
AB		5MG;6.25MG	N20186 001	MAR 26, 1993
AB +		10MG;6.25MG	N20186 002	MAR 26, 1993

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

	TORNALATE			
+	SANOFI SYNTHELABO	0.37MG/INH	N18770 001	DEC 28, 1984

BITOLTEROL MESYLATE

SOLUTION; INHALATION

	TORNALATE			
	SANOFI SYNTHELABO	0.2%	N19548 001	FEB 19, 1992

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

	ANGIOMAX			
+	MEDS (TMC)	250MG/VIAL	N20873 001	DEC 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLENOXANE			
AP +	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N50443 001	
AP +		EQ 30 UNITS BASE/VIAL	N50443 002	SEP 07, 1995
	BLEOMYCIN			
AP	FAULDING	EQ 15 UNITS BASE/VIAL	N65031 001	MAR 10, 2000
AP		EQ 30 UNITS BASE/VIAL	N65031 002	MAR 10, 2000
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N65033 001	JUN 27, 2000
AP		EQ 30 UNITS BASE/VIAL	N65033 002	JUN 27, 2000
	BLEOMYCIN SULFATE			
AP	PHARMACIA AND UPJOHN	EQ 15 UNITS BASE/VIAL	N64084 001	JUN 01, 1996
AP		EQ 30 UNITS BASE/VIAL	N64084 002	JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP +	ABBOTT	50MG/ML	N19033 001	APR 29, 1986
AP	ELKINS SINN	50MG/ML	N70545 001	MAY 14, 1986
AP		50MG/ML	N70546 001	MAY 14, 1986

FDA data supplied by DrugPatentWatch.com

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	INTL MEDICATION	**50MG/ML**	**N70119 001**	
			APR 29, 1986	
AP	LUITPOLD	**50MG/ML**	**N70891 001**	
			JUL 26, 1988	
	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ ABBOTT	**200MG/100ML**	**N19008 002**	
			APR 29, 1986	
AP	+	**400MG/100ML**	**N19008 003**	
			APR 29, 1986	
AP	+ B BRAUN	**200MG/100ML**	**N19121 002**	
			APR 29, 1986	
AP	+	**400MG/100ML**	**N19121 003**	
			APR 29, 1986	
	+	100MG/100ML	N19121 001	
			APR 29, 1986	
	BRETYLIUM TOSYLATE IN PLASTIC CONTAINER			
AP	+ ABBOTT	**50MG/ML**	**N19030 001**	
			APR 29, 1986	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

	ALPHAGAN		
	+ ALLERGAN	0.2%	N20613 001
			SEP 06, 1996
	+	0.5%	N20490 001
			MAR 13, 1997

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

	AZOPT		
	+ ALCON	1%	N20816 001
			APR 01, 1998

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

	PARLODEL		
	+ NOVARTIS	EQ 5MG BASE	N17962 002
			MAR 01, 1982

BROMOCRIPTINE MESYLATE

TABLET; ORAL

	PARLODEL		
	+ NOVARTIS	EQ 2.5MG BASE	N17962 001

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

	AMBENYL			
AA	+ FORREST LABS	**12.5MG/5ML;10MG/5ML**	**N09319 006**	
			JAN 10, 1984	
	BROMANYL			
AA	ALPHARMA	**12.5MG/5ML;10MG/5ML**	**N88343 001**	
			AUG 15, 1984	
	MYBANIL			
AA	MORTON GROVE	**12.5MG/5ML;10MG/5ML**	**N88626 001**	
			OCT 12, 1984	

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

	BROMPHENIRAMINE MALEATE		
	+ KV PHARM	2MG/5ML	N85466 001

INJECTABLE; INJECTION

	BROMPHENIRAMINE MALEATE		
	+ STERIS	10MG/ML	N83821 001

TABLET; ORAL

	BROMPHENIRAMINE MALEATE		
AA	NYLOS	**4MG**	**N85592 001**
AA	PHOENIX LABS NY	**4MG**	**N85521 001**
AA	PVT FORM	**4MG**	**N85888 001**
	VELTANE		
AA	LANNETT	**4MG**	**N84088 001**

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	BROMANATE DC			
AA	ALPHARMA	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N88723 001**	
			FEB 25, 1985	

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

		MYPHETANE DC			
AA	+	MORTON GROVE	**2MG/5ML;10MG/5ML; 12.5MG/5ML**		**N88904 001** FEB 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

		BROMANATE DM			
AA		ALPHARMA	**2MG/5ML;10MG/5ML;30MG/5ML**		**N88722 001** MAR 07, 1985
		BROMFED-DM			
AA		MURO	**2MG/5ML;10MG/5ML;30MG/5ML**		**N89681 001** DEC 22, 1988
		DIMETANE-DX			
AA	+	ROBINS AH	**2MG/5ML;10MG/5ML;30MG/5ML**		**N19279 001** AUG 24, 1984
		MYPHETANE DX			
AA		MORTON GROVE	**2MG/5ML;10MG/5ML;30MG/5ML**		**N88811 001** JUN 07, 1985

BUDESONIDE

AEROSOL, METERED; NASAL

		RHINOCORT			
	+	ASTRAZENECA	0.032MG/INH		N20233 001 FEB 14, 1994

POWDER, METERED; INHALATION

		PULMICORT			
	+	ASTRAZENECA	0.16MG/INH		N20441 002 JUN 24, 1997

SPRAY, METERED; NASAL

		RHINOCORT			
		ASTRAZENECA	0.032MG/INH		N20746 001 OCT 01, 1999
	+		0.064MG/INH		N20746 002 OCT 01, 1999

SUSPENSION; INHALATION

		PULMICORT RESPULES			
		ASTRAZENECA	0.25MG/2ML		N20929 001 AUG 08, 2000

BUDESONIDE

SUSPENSION; INHALATION

		PULMICORT RESPULES			
	+	ASTRAZENECA	0.5MG/2ML		N20929 002 AUG 08, 2000

BUMETANIDE

INJECTABLE; INJECTION

		BUMETANIDE			
AP		ABBOTT	**0.25MG/ML**		**N74160 001** OCT 30, 1997
AP			**0.25MG/ML**		**N74332 001** OCT 31, 1994
AP		BEDFORD	**0.25MG/ML**		**N74441 001** JAN 27, 1995
AP		GENSIA SICOR PHARMS	**0.25MG/ML**		**N74613 001** NOV 18, 1997
		BUMEX			
AP	+	ROCHE	**0.25MG/ML**		**N18226 001** FEB 28, 1983

TABLET; ORAL

		BUMETANIDE			
AB		EON	**0.5MG**		**N74700 001** NOV 21, 1996
AB			**1MG**		**N74700 002** NOV 21, 1996
AB			**2MG**		**N74700 003** NOV 21, 1996
AB		ZENITH GOLDLINE	**0.5MG**		**N74225 001** APR 24, 1995
AB			**1MG**		**N74225 002** APR 24, 1995
AB			**2MG**		**N74225 003** APR 24, 1995
		BUMEX			
AB		ROCHE	**0.5MG**		**N18225 002** FEB 28, 1983
AB			**1MG**		**N18225 001** FEB 28, 1983
AB	+		**2MG**		**N18225 003** JUN 14, 1985

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL

AP	ABBOTT	0.25%	N18053 002	
AP		0.25%	N70583 001	FEB 17, 1987
AP		0.25%	N70586 001	MAR 03, 1987
AP		0.25%	N70590 001	FEB 17, 1987
AP		0.5%	N18053 001	
AP		0.5%	N70584 001	FEB 17, 1986
AP		0.5%	N70597 001	MAR 03, 1987
AP		0.5%	N70609 001	MAR 03, 1987
AP		0.75%	N18053 003	
AP		0.75%	N70585 001	MAR 03, 1987
AP		0.75%	N70587 001	MAR 03, 1987

BUPIVACAINE HCL KIT

	ABBOTT	0.075%	N19978 001	SEP 03, 1992
		0.114%	N19978 002	SEP 03, 1992
		0.23%	N19978 003	SEP 03, 1992

MARCAINE HCL

AP	+ ABBOTT	0.25%	N16964 001	
AP	+	0.5%	N16964 006	

MARCAINE HCL PRESERVATIVE FREE

AP	+ ABBOTT	0.25%	N16964 012	
AP	+	0.5%	N16964 005	
AP	+	0.75%	N16964 009	

SENSORCAINE

AP	ASTRAZENECA	0.25%	N18304 001	
AP		0.25%	N70552 001	MAY 21, 1986
AP		0.5%	N18304 002	
AP		0.5%	N70553 001	MAY 21, 1986
AP		0.75%	N18304 003	
AP		0.75%	N70554 001	MAY 21, 1986

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

BUPIVACAINE

AP	ABBOTT	0.75%	N71810 001	DEC 11, 1987

MARCAINE

AP	+ SANOFI SYNTHELABO	0.75%	N18692 001	MAY 04, 1984

SENSORCAINE

AP	ASTRAZENECA	0.75%	N71202 001	APR 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

	+ ABBOTT	0.25%;0.005MG/ML	N71165 001	JUN 16, 1988
		0.25%;0.005MG/ML	N71166 001	JUN 16, 1988
		0.25%;0.005MG/ML	N71167 001	JUN 16, 1988
	+	0.5%;0.005MG/ML	N71168 001	JUN 16, 1988
		0.5%;0.005MG/ML	N71169 001	JUN 16, 1988
		0.5%;0.005MG/ML	N71170 001	JUN 16, 1988
	+	0.75%;0.005MG/ML	N71171 001	JUN 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP	+ ABBOTT	0.25%;0.0091MG/ML	N16964 004	
AP	+	0.5%;0.0091MG/ML	N16964 008	

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

AP	+ ABBOTT	0.25%;0.0091MG/ML	N16964 013	
AP	+	0.5%;0.0091MG/ML	N16964 007	
AP	+	0.75%;0.0091MG/ML	N16964 010	

SENSORCAINE

AP	ASTRAZENECA	0.25%;0.0091MG/ML	N70966 001	OCT 13, 1987
AP		0.25%;0.0091MG/ML	N70967 001	OCT 13, 1987

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	SENSORCAINE			
AP	ASTRAZENECA	0.5%;0.0091MG/ML	N18304 004	SEP 02, 1983
AP		0.5%;0.0091MG/ML	N70968 001	OCT 13, 1987
AP		0.75%;0.0091MG/ML	N18304 005	SEP 02, 1983

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPRENEX			
AP	+ RECKITT AND COLMAN	EQ 0.3MG BASE/ML	N18401 001	
	BUPRENORPHINE HCL			
AP	ABBOTT	EQ 0.3MG BASE/ML	N74137 001	JUN 03, 1996

BUPROPION HYDROCHLORIDE

TABLET; ORAL

	BUPROPION HCL			
AB	EON	75MG	N75613 002	OCT 10, 2000
AB		100MG	N75613 001	OCT 10, 2000
AB	GENEVA PHARMS TECH	75MG	N75584 001	FEB 07, 2000
AB		100MG	N75584 002	FEB 07, 2000
AB	MYLAN	75MG	N75491 001	APR 17, 2000
AB		100MG	N75491 002	APR 17, 2000
AB	TEVA	75MG	N75310 001	NOV 29, 1999
AB		100MG	N75310 002	NOV 29, 1999
	WELLBUTRIN			
AB	GLAXO WELLCOME	75MG	N18644 002	DEC 30, 1985
AB +		100MG	N18644 003	DEC 30, 1985

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN SR			
+	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996
+		100MG	N20358 002	OCT 04, 1996
+		150MG	N20358 003	OCT 04, 1996
	ZYBAN			
+	GLAXO WELLCOME	150MG	N20711 003	MAY 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR			
BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000
	7.5MG	N21190 002	DEC 20, 2000
	10MG	N21190 003	DEC 20, 2000
+	15MG	N21190 004	DEC 20, 2000

TABLET; ORAL

BUSPAR			
BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986
	10MG	N18731 002	SEP 29, 1986
	15MG	N18731 003	APR 22, 1996
+	30MG	N18731 004	APR 22, 1996

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX			
+ ORPHAN MEDCL	6MG/ML	N20954 001	FEB 04, 1999

TABLET; ORAL

MYLERAN			
+ GLAXO WELLCOME	2MG	N09386 001	

FDA data supplied by DrugPatentWatch.com

BUTABARBITAL SODIUM

ELIXIR; ORAL

	BUTISOL SODIUM			
	+ WALLACE LABS	30MG/5ML	N85380 001	

TABLET; ORAL

	BUTABARBITAL			
AA	BUNDY	**30MG**	**N85550 001**	
	BUTISOL SODIUM			
AA	+ WALLACE LABS	**15MG**	**N00793 002**	
AA	+	**30MG**	**N00793 004**	
	+	50MG	N00793 003	
	+	100MG	N00793 005	
	SODIUM BUTABARBITAL			
AA	LANNETT	**15MG**	**N85849 001**	
AA		**30MG**	**N85866 001**	
	MARSHALL PHARMA	16.2MG	N83524 001	
		32.4MG	N83858 001	

BUTALBITAL; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX			
+ BERTEK PHARMS	1%	N20524 001	
		OCT 18, 1996	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE			
+ KV PHARM	2%	N19881 001	
		FEB 07, 1997	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	ABBOTT	**1MG/ML**	**N75559 001**	
			MAR 20, 2000	
AP		**2MG/ML**	**N75559 002**	
			MAR 20, 2000	
AP	BEDFORD	**2MG/ML**	**N75046 001**	
			AUG 12, 1998	
AP	MERIDIAN MEDCL TECHN	**1MG/ML**	**N75342 001**	
			NOV 04, 1999	
AP		**2MG/ML**	**N75342 002**	
			NOV 04, 1999	
	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	**1MG/ML**	**N74620 001**	
			JAN 22, 1997	
AP		**1MG/ML**	**N74626 001**	
			JAN 23, 1997	
AP		**2MG/ML**	**N74620 002**	
			JAN 22, 1997	
AP		**2MG/ML**	**N74626 002**	
			JAN 23, 1997	
AP	BEDFORD	**1MG/ML**	**N75045 001**	
			AUG 12, 1998	
AP		**2MG/ML**	**N75045 002**	
			AUG 12, 1998	
AP	FAULDING	**1MG/ML**	**N75170 001**	
			SEP 28, 1998	
AP		**2MG/ML**	**N75170 002**	
			SEP 28, 1998	
	STADOL			
AP	+ APOTHECON	**2MG/ML**	**N17857 004**	
	STADOL PRESERVATIVE FREE			
AP	+ APOTHECON	**1MG/ML**	**N17857 001**	
AP	+	**2MG/ML**	**N17857 002**	

SPRAY, METERED; NASAL

STADOL			
+ BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	
		DEC 12, 1991	

CABERGOLINE

TABLET; ORAL

DOSTINEX			
+ PHARMACIA AND UPJOHN	0.5MG	N20664 001	
		DEC 23, 1996	

FDA data supplied by DrugPatentWatch.com

CAFFEINE; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

	CAFERGOT			
+	NOVARTIS	100MG;2MG		N09000 002

TABLET; ORAL

	ERCATAB			
AA	+ GENEVA PHARMS	**100MG;1MG**		**N84294 001**
	WIGRAINE			
AA	ORGANON	**100MG;1MG**		**N86562 001**

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

	CAFCIT			
+	OPR DEVELOP LP	EQ 10MG BASE/ML		N20793 001 SEP 21, 1999

CALCIFEDIOL

CAPSULE; ORAL

	CALDEROL			
	ORGANON	0.02MG		N18312 001
+		0.05MG		N18312 002

CALCIPOTRIENE

CREAM; TOPICAL

	DOVONEX			
+	BRISTOL MYERS SQUIBB	0.005%		N20554 001 JUL 22, 1996

OINTMENT; TOPICAL

	DOVONEX			
+	WESTWOOD SQUIBB	0.005%		N20273 001 DEC 29, 1993

CALCIPOTRIENE

SOLUTION; TOPICAL

	DOVONEX			
+	WESTWOOD SQUIBB	0.005%		N20611 001 MAR 03, 1997

CALCITONIN, SALMON

INJECTABLE; INJECTION

	CALCIMAR			
AP	+ AVENTIS	**200 IU/ML**		**N17769 001**
	CALCITONIN-SALMON			
AP	ASTRAZENECA	**200 IU/ML**		**N73690 001** APR 14, 1995
	MIACALCIN			
AP	+ NOVARTIS	**200 IU/ML**		**N17808 002** MAR 29, 1991

SPRAY, METERED; NASAL

	MIACALCIN			
+	NOVARTIS	200 IU/SPRAY		N20313 002 AUG 17, 1995

CALCITRIOL

CAPSULE; ORAL

	ROCALTROL			
	ROCHE	0.25 UGM		N18044 001
+		0.5 UGM		N18044 002

INJECTABLE; INJECTION

	CALCIJEX			
+	ABBOTT	0.001MG/ML		N18874 001 SEP 25, 1986
+		0.002MG/ML		N18874 002 SEP 25, 1986

SOLUTION; ORAL

	ROCALTROL			
+	ROCHE	1 UGM/ML		N21068 001 NOV 20, 1998

FDA data supplied by DrugPatentWatch.com

CALCIUM ACETATE

TABLET; ORAL
PHOSLO
\+ BRAINTREE EQ 169MG CALCIUM N19976 001
DEC 10, 1990

CALCIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
\+ ABBOTT 100MG/ML N21117 001
JAN 28, 2000

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
BSS PLUS
AT ALCON 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N18469 001

ENDOSOL EXTRA
AT AKORN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001
NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001
DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 37MG/100ML;5GM/100ML;30MG/100ML; 119MG/100ML;161MG/100ML;94MG/100ML; 138MG/100ML N17390 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
B BRAUN 510MG/100ML;30GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 001
AUG 26, 1983
510MG/100ML;30GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 003
AUG 26, 1983
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
B BRAUN 510MG/100ML;50GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 002
AUG 26, 1983

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
B BRAUN 510MG/100ML;50GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 004
AUG 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 002**
AT 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 001**
NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 004**
NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 001**
AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 003**
AT 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 002**
NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 005**
NOV 30, 1984

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 002**
AUG 19, 1992

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 007**
JUN 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 001**
AT 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 003**
NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 006**
NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 003**
AUG 19, 1992

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 004**
JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 005**
JUL 07, 1982

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 008** JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 006** JUL 07, 1982

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;1.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 007 JAN 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;2.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 005 NOV 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;4.25GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 009 JAN 29, 1986

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 001**

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 003**

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 002**

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 001** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 002** DEC 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 003** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 004** DEC 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 007** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 008** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 010** NOV 18, 1985

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 009** JUL 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 004**

AT 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 001** DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 005**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 002** DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 011** NOV 18, 1985

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 006**

AT 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 003** DEC 04, 1992

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 001** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 002** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 003** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 004** JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

\+ ORPHAN MEDCL 0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML; 0.2MG/ML N20577 001 SEP 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML; 380MG/100ML;600MG/100ML N18258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP ABBOTT 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML **N18254 001**

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML **N18256 001**

AP 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML **N20000 001** APR 17, 1992

AP BAXTER HLTHCARE 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML **N16695 001**

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML;160MG/100ML N19634 001 FEB 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP ABBOTT 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML **N17608 001**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N19634 003**	FEB 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N16679 001**	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 002	APR 05, 1985
		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 003	APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 006**	APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 002**	OCT 17, 1988
AP		**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 008**	OCT 17, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 004**	APR 05, 1985
AP		**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 005**	APR 05, 1985

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 007**	APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 004**	OCT 17, 1988

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 008**	APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 001	APR 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML	N18895 001	JUL 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001	SEP 29, 1989

SOLUTION; IRRIGATION

BSS +	ALCON	0.48MG/ML;0.3MG/ML;0.75MG/ML; 3.9MG/ML;6.4MG/ML; 1.7MG/ML	N20742 001	DEC 10, 1997

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
PLASMA-LYTE R IN PLASTIC CONTAINER

	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML; 74.6MG/100ML;640MG/100ML; 496MG/100ML;89.6MG/100ML	N17438	001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N75323	001	APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+ ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608	001	FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	33MG/100ML;30MG/100ML; 860MG/100ML	N18251	001	
AP	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18721	001	NOV 09, 1982
AP		33MG/100ML;30MG/100ML; 860MG/100ML	N20002	001	APR 17, 1992
AP	BAXTER HLTHCARE	33MG/100ML;30MG/100ML; 860MG/100ML	N16693	001	

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	33MG/100ML;30MG/100ML; 860MG/100ML	N17635	001	
AT	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18156	001	
AT	BAXTER HLTHCARE	33MG/100ML;30MG/100ML; 860MG/100ML	N18495	001	FEB 19, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N17641	001	
AP	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19632	001	FEB 29, 1988
AP	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N16682	001	

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19416	001	JAN 17, 1986
AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681	001	DEC 27, 1982
AT	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18494	001	FEB 19, 1982
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18921	001	APR 03, 1984
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19933	001	AUG 29, 1989

CALFACTANT

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521	001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

ASTRAZENECA	4MG	N20838	001 JUN 04, 1998
	8MG	N20838	002 JUN 04, 1998

FDA data supplied by DrugPatentWatch.com

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
ASTRAZENECA 16MG N20838 003 JUN 04, 1998
\+ 32MG N20838 004 JUN 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ATACAND HCT
ASTRAZENECA 16MG;12.5MG N21093 001 SEP 05, 2000
\+ 32MG;12.5MG N21093 002 SEP 05, 2000

CAPECITABINE

TABLET; ORAL
XELODA
HLR 150MG N20896 001 APR 30, 1998
\+ 500MG N20896 002 APR 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION
CAPASTAT SULFATE
\+ LILLY EQ 1GM BASE/VIAL N50095 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN
AB BRISTOL MYERS SQUIBB **12.5MG** **N18343 005** JAN 17, 1985
AB **25MG** **N18343 002**
AB **50MG** **N18343 001**
AB \+ **100MG** **N18343 003**
CAPTOPRIL
AB APOTHECON **12.5MG** **N74472 001** MAR 31, 1995

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL
AB APOTHECON **25MG** **N74472 002** MAR 31, 1995
AB **50MG** **N74472 003** MAR 31, 1995
AB **100MG** **N74472 004** MAR 31, 1995
AB CHELSEA LABS **12.5MG** **N74576 001** APR 23, 1996
AB **25MG** **N74576 002** APR 23, 1996
AB **50MG** **N74576 003** APR 23, 1996
AB **100MG** **N74576 004** APR 23, 1996
AB COPLEY PHARM **12.5MG** **N74462 001** FEB 13, 1996
AB **25MG** **N74462 002** FEB 13, 1996
AB **50MG** **N74462 003** FEB 13, 1996
AB **100MG** **N74462 004** FEB 13, 1996
AB DANBURY PHARMA **12.5MG** **N74386 001** MAY 23, 1996
AB **25MG** **N74386 002** MAY 23, 1996
AB **50MG** **N74386 003** MAY 23, 1996
AB **100MG** **N74386 004** MAY 23, 1996
AB EGIS PHARMS **12.5MG** **N74748 004** MAY 29, 1997
AB **25MG** **N74748 002** MAY 29, 1997
AB **50MG** **N74748 001** MAY 29, 1997
AB **100MG** **N74748 003** MAY 29, 1997
AB ENDO LABS **12.5MG** **N74418 001** FEB 13, 1996
AB **25MG** **N74418 002** FEB 13, 1996
AB **50MG** **N74418 003** FEB 13, 1996

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	ENDO LABS	100MG	N74418 004	FEB 13, 1996
AB	EON	12.5MG	N74519 001	FEB 13, 1996
AB		25MG	N74519 002	FEB 13, 1996
AB		50MG	N74519 003	FEB 13, 1996
AB		100MG	N74519 004	FEB 13, 1996
AB	GENEVA PHARMS	12.5MG	N74363 001	NOV 09, 1995
AB		25MG	N74363 002	NOV 09, 1995
AB		50MG	N74363 003	NOV 09, 1995
AB		100MG	N74363 004	NOV 09, 1995
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	INVAMED	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	MOVA	12.5MG	N74423 001	FEB 13, 1996
AB		25MG	N74423 002	FEB 13, 1996
AB		50MG	N74423 003	FEB 13, 1996
AB		100MG	N74423 004	FEB 13, 1996
AB	MYLAN	12.5MG	N74434 001	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	MYLAN	25MG	N74434 002	FEB 13, 1996
AB		50MG	N74434 003	FEB 13, 1996
AB		100MG	N74434 004	FEB 13, 1996
AB	NOVOPHARM NC	12.5MG	N74322 001	FEB 13, 1996
AB		25MG	N74322 002	FEB 13, 1996
AB		50MG	N74322 003	FEB 13, 1996
AB		100MG	N74322 004	FEB 13, 1996
AB	PAR PHARM	12.5MG	N74493 001	FEB 13, 1996
AB		25MG	N74493 002	FEB 13, 1996
AB		50MG	N74493 003	FEB 13, 1996
AB		100MG	N74493 004	FEB 13, 1996
AB	STASON	12.5MG	N74677 004	MAY 30, 1997
AB		25MG	N74677 002	MAY 30, 1997
AB		50MG	N74677 001	MAY 30, 1997
AB		100MG	N74677 003	MAY 30, 1997
AB	TEVA	12.5MG	N74433 001	FEB 13, 1996
AB		12.5MG	N74483 001	FEB 13, 1996
AB		25MG	N74433 002	FEB 13, 1996
AB		25MG	N74483 002	FEB 13, 1996
AB		50MG	N74433 003	FEB 13, 1996
AB		50MG	N74483 003	FEB 13, 1996
AB		100MG	N74433 004	FEB 13, 1996

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	TEVA	100MG	N74483 004	FEB 13, 1996
AB	TORPHARM	12.5MG	N74737 001	OCT 28, 1998
AB		25MG	N74737 002	OCT 28, 1998
AB		50MG	N74737 003	OCT 28, 1998
AB		100MG	N74737 004	OCT 28, 1998
AB	WATSON LABS	12.5MG	N74451 001	FEB 13, 1996
AB		25MG	N74451 002	FEB 13, 1996
AB		50MG	N74451 003	FEB 13, 1996
AB		100MG	N74451 004	FEB 13, 1996
AB	WEST WARD	12.5MG	N74505 001	FEB 13, 1996
AB		25MG	N74505 002	FEB 13, 1996
AB		50MG	N74505 003	FEB 13, 1996
AB		100MG	N74505 004	FEB 13, 1996
AB	WOCKHARDT	12.5MG	N74532 001	MAR 28, 1997
AB		25MG	N74532 002	MAR 28, 1997
AB		50MG	N74532 003	MAR 28, 1997
AB		100MG	N74532 004	MAR 28, 1997
AB	ZENITH GOLDLINE	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

AB	APOTHECON	25MG;15MG	N18709 001	OCT 12, 1984

CAPOZIDE 25/25

AB	+ APOTHECON	25MG;25MG	N18709 002	OCT 12, 1984

CAPOZIDE 50/15

AB	+ APOTHECON	50MG;15MG	N18709 004	OCT 12, 1984

CAPOZIDE 50/25

AB	APOTHECON	50MG;25MG	N18709 003	OCT 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	ENDO LABS	25MG;15MG	N74788 001	DEC 29, 1997
AB		25MG;25MG	N74788 002	DEC 29, 1997
AB		50MG;15MG	N74788 004	DEC 29, 1997
AB		50MG;25MG	N74788 003	DEC 29, 1997
AB	MYLAN	25MG;15MG	N74896 001	DEC 29, 1997
AB		25MG;25MG	N74896 002	DEC 29, 1997
AB		50MG;15MG	N74896 004	DEC 29, 1997
AB		50MG;25MG	N74896 003	DEC 29, 1997
AB	TEVA	25MG;15MG	N74827 001	DEC 29, 1997
AB		25MG;25MG	N74827 002	DEC 29, 1997
AB		50MG;15MG	N74827 004	DEC 29, 1997
AB		50MG;25MG	N74827 003	DEC 29, 1997
AB	ZENITH GOLDLINE	25MG;15MG	N75055 001	JUN 18, 1998
AB		25MG;25MG	N75055 002	JUN 18, 1998
AB		50MG;15MG	N75055 004	JUN 18, 1998
AB		50MG;25MG	N75055 003	JUN 18, 1998

FDA data supplied by DrugPatentWatch.com

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT			
AT	CIBA	**0.01%**	**N73677 001**	APR 28, 1995
	MIOSTAT			
AT	+ ALCON	**0.01%**	**N16968 001**	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

	CARBATROL			
	+ SHIRE	100MG	N20712 003	DEC 22, 1999
	+	200MG	N20712 001	SEP 30, 1997
	+	300MG	N20712 002	SEP 30, 1997

SUSPENSION; ORAL

	CARBAMAZEPINE			
AB	TARO	**100MG/5ML**	**N75875 001**	DEC 21, 2000
	TEGRETOL			
AB	+ NOVARTIS	**100MG/5ML**	**N18927 001**	DEC 18, 1987

TABLET; ORAL

	CARBAMAZEPINE			
AB	INWOOD LABS	**200MG**	**N70231 001**	AUG 14, 1986
AB	PUREPAC PHARM	**200MG**	**N71696 001**	NOV 09, 1987
AB	SIDMAK LABS NJ	**200MG**	**N71479 001**	JUL 24, 1987
AB	TARO	**200MG**	**N74649 001**	OCT 03, 1996
	EPITOL			
AB	TEVA	**200MG**	**N70541 001**	SEP 17, 1986
	TEGRETOL			
AB	+ NOVARTIS	**200MG**	**N16608 001**	

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	TARO PHARM INDS	**100MG**	**N75687 001**	OCT 24, 2000

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	WARNER CHILCOTT	**100MG**	**N71940 001**	FEB 01, 1988
	EPITOL			
AB	TEVA	**100MG**	**N73524 001**	JUL 29, 1992
	TEGRETOL			
AB	+ NOVARTIS	**100MG**	**N18281 001**	

TABLET, EXTENDED RELEASE; ORAL

	TEGRETOL-XR			
	+ NOVARTIS	100MG	N20234 001	MAR 25, 1996
	+	200MG	N20234 002	MAR 25, 1996
	+	400MG	N20234 003	MAR 25, 1996

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

	GEOCILLIN		
	+ PFIZER	EQ 382MG BASE	N50435 001

CARBIDOPA

TABLET; ORAL

	LODOSYN		
	+ DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	GENEVA PHARMS	**10MG;100MG**	**N73586 001**	JUN 29, 1995
AB		**25MG;100MG**	**N73587 001**	JUN 29, 1995
AB		**25MG;250MG**	**N73620 001**	JUN 29, 1995
AB	PUREPAC PHARM	**10MG;100MG**	**N74260 001**	SEP 03, 1993

FDA data supplied by DrugPatentWatch.com

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	PUREPAC PHARM	25MG;100MG	N74260 002	SEP 03, 1993
AB		25MG;250MG	N74260 003	SEP 03, 1993
AB	SCS	10MG;100MG	N74080 001	MAR 25, 1994
AB		25MG;100MG	N74080 002	MAR 25, 1994
AB		25MG;250MG	N74080 003	MAR 25, 1994
AB	TEVA	10MG;100MG	N73618 001	AUG 28, 1992
AB		25MG;100MG	N73589 001	AUG 28, 1992
AB		25MG;250MG	N73607 001	AUG 28, 1992

SINEMET

AB	DUPONT PHARMS	10MG;100MG	N17555 001	
AB		25MG;100MG	N17555 003	
AB	+	25MG;250MG	N17555 002	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	MYLAN	25MG;100MG	N75091 002	APR 21, 2000
AB		50MG;200MG	N75091 001	SEP 30, 1999

SINEMET CR

AB	DUPONT PHARMS	25MG;100MG	N19856 002	DEC 24, 1992
AB	+	50MG;200MG	N19856 001	MAY 30, 1991

CARBOPLATIN

INJECTABLE; INJECTION

PARAPLATIN

+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	MAR 03, 1989
+		150MG/VIAL	N19880 002	MAR 03, 1989
+		450MG/VIAL	N19880 003	MAR 03, 1989

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N17989 001

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	AMIDE PHARM	350MG	N40188 001	MAR 07, 1997
AA	CHELSEA LABS	350MG	N86179 001	
AA	COREPHARMA	350MG	N40397 001	SEP 21, 2000
AA	DANBURY PHARMA	350MG	N87499 001	APR 20, 1982
AA	GENEVA PHARMS	350MG	N81025 001	APR 13, 1989
AA	MUTUAL PHARM	350MG	N89346 001	OCT 17, 1991
AA	VINTAGE PHARMS	350MG	N40245 001	SEP 08, 1997
AA	WATSON LABS	350MG	N40152 001	DEC 03, 1996
AA	WEST WARD	350MG	N40124 001	JAN 24, 1996

SOMA

AA	+ WALLACE LABS	350MG	N11792 001	

CARISOPRODOL; *MULTIPLE*

SEE ASPIRIN; CARISOPRODOL

SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	GUILFORD PHARMS	7.7MG	N20637 001	SEP 23, 1996

INJECTABLE; INJECTION

BICNU

+	BRISTOL	100MG/VIAL	N17422 001	

FDA data supplied by DrugPatentWatch.com

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CARTEOLOL HCL				
AT	ALCON	1%	N75476 001		JAN 03, 2000
AT	BAUSCH AND LOMB	1%	N75546 001		JAN 20, 2000
	OCUPRESS				
AT +	CIBA	1%	N19972 001		MAY 23, 1990

TABLET; ORAL

	CARTROL				
	ABBOTT	2.5MG	N19204 001		DEC 28, 1988
+		5MG	N19204 002		DEC 28, 1988

CARVEDILOL

TABLET; ORAL

	COREG				
	SMITHKLINE BEECHAM	3.125MG	N20297 004		MAY 29, 1997
		6.25MG	N20297 003		SEP 14, 1995
		12.5MG	N20297 002		SEP 14, 1995
+		25MG	N20297 001		SEP 14, 1995

CEFACLOR

CAPSULE; ORAL

	CECLOR				
AB	LILLY	EQ 250MG BASE	N50521 001		
AB		EQ 250MG BASE	N62205 001		
AB +		EQ 500MG BASE	N50521 002		
AB		EQ 500MG BASE	N62205 002		
	CEFACLOR				
AB	MARSAM	EQ 250MG BASE	N64148 001		MAY 23, 1996
AB		EQ 500MG BASE	N64148 002		MAY 23, 1996
AB	NOVOPHARM NC	EQ 250MG BASE	N64145 001		JUN 24, 1996

CEFACLOR

CAPSULE; ORAL

	CEFACLOR				
AB	NOVOPHARM NC	EQ 500MG BASE	N64145 002		JUN 24, 1996
AB	RANBAXY	EQ 250MG BASE	N64156 001		AUG 28, 1997
AB		EQ 500MG BASE	N64156 002		AUG 28, 1997
AB	ZENITH GOLDLINE	EQ 250MG BASE	N64061 001		APR 27, 1995
AB		EQ 500MG BASE	N64061 002		APR 27, 1995

FOR SUSPENSION; ORAL

	CECLOR				
AB	LILLY	EQ 125MG BASE/5ML	N50522 001		
AB		EQ 125MG BASE/5ML	N62206 001		
AB		EQ 187MG BASE/5ML	N62206 003		APR 20, 1988
AB +		EQ 250MG BASE/5ML	N50522 002		
AB		EQ 250MG BASE/5ML	N62206 002		
AB +		EQ 375MG BASE/5ML	N62206 004		APR 20, 1988
	CEFACLOR				
AB	MARSAM	EQ 125MG BASE/5ML	N64204 001		FEB 18, 1998
AB		EQ 187MG BASE/5ML	N64205 001		FEB 18, 1998
AB		EQ 250MG BASE/5ML	N64206 001		FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001		FEB 18, 1998
AB	RANBAXY	EQ 125MG BASE/5ML	N64166 001		OCT 02, 1997
AB		EQ 187MG BASE/5ML	N64165 001		OCT 02, 1997
AB		EQ 250MG BASE/5ML	N64164 001		OCT 02, 1997
AB		EQ 375MG BASE/5ML	N64155 001		OCT 02, 1997
AB	ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001		APR 28, 1995
AB		EQ 187MG BASE/5ML	N64086 001		APR 28, 1995
AB		EQ 250MG BASE/5ML	N64085 001		APR 28, 1995

FDA data supplied by DrugPatentWatch.com

CEFACLOR

FOR SUSPENSION; ORAL

	CEFACLOR			
AB	ZENITH GOLDLINE	**EQ 375MG BASE/5ML**	**N64070 001**	APR 28, 1995

TABLET, EXTENDED RELEASE; ORAL

	CECLOR CD			
+	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996
+		EQ 500MG BASE	N50673 002	JUN 28, 1996

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	APOTHECON	**EQ 500MG BASE**	**N62291 001**	
AB	BARR	**EQ 500MG BASE**	**N65015 001**	JUN 22, 1999
AB	ZENITH GOLDLINE	**EQ 500MG BASE**	**N62766 001**	MAR 03, 1987
	DURICEF			
AB	+ BRISTOL MYERS SQUIBB	**EQ 500MG BASE**	**N50512 001**	

FOR SUSPENSION; ORAL

	DURICEF			
	BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002	
		EQ 250MG BASE/5ML	N50527 003	
+		EQ 500MG BASE/5ML	N50527 001	

TABLET; ORAL

	CEFADROXIL			
AB	RANBAXY	**EQ 1GM BASE**	**N65018 001**	APR 23, 1999
AB	ZENITH GOLDLINE	**EQ 1GM BASE**	**N62774 001**	APR 08, 1987
	DURICEF			
AB	+ BRISTOL MYERS SQUIBB	**EQ 1GM BASE**	**N50528 001**	

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL			
+	LILLY	EQ 1GM BASE/VIAL	N50504 002	

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL			
	LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985
+		EQ 2GM BASE/VIAL	N50504 003	
		EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985
+		EQ 10GM BASE/VIAL	N50504 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF			
AP	+ SMITHKLINE BEECHAM	**EQ 500MG BASE/VIAL**	**N50461 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N50461 003**	
AP	+	**EQ 5GM BASE/VIAL**	**N50461 004**	
AP	+	**EQ 10GM BASE/VIAL**	**N50461 005**	
	ANCEF IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N63002 001	MAR 28, 1991
+		EQ 20MG BASE/ML	N63002 002	MAR 28, 1991
	CEFAZOLIN AND DEXTROSE			
+	B BRAUN	EQ 500MG BASE/VIAL	N50779 001	JUL 27, 2000
+		EQ 1GM BASE/VIAL	N50779 002	JUL 27, 2000
	CEFAZOLIN SODIUM			
AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N64169 002**	AUG 14, 1998
AP		**EQ 10GM BASE/VIAL**	**N64170 001**	MAR 18, 1998
AP		**EQ 20GM BASE/VIAL**	**N64170 002**	MAR 18, 1998
AP		**EQ 500MG BASE/VIAL**	**N64169 001**	AUG 14, 1998
AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N62831 001**	DEC 09, 1988
AP		**EQ 1GM BASE/VIAL**	**N62831 002**	DEC 09, 1988
AP		**EQ 10GM BASE/VIAL**	**N62831 003**	SEP 25, 1992
AP	HANFORD GC	**EQ 1GM BASE/VIAL**	**N63207 001**	DEC 27, 1991
AP		**EQ 1GM BASE/VIAL**	**N63208 001**	DEC 27, 1991

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HANFORD GC	EQ 10GM BASE/VIAL	N63209 001	DEC 27, 1991
AP		EQ 500MG BASE/VIAL	N63214 001	DEC 27, 1991
AP		EQ 500MG BASE/VIAL	N63216 001	DEC 27, 1991
AP	MARSAM	EQ 1GM BASE/VIAL	N62988 003	DEC 29, 1989
AP		EQ 5GM BASE/VIAL	N62989 001	DEC 29, 1989
AP		EQ 10GM BASE/VIAL	N62989 002	DEC 29, 1989
AP		EQ 20GM BASE/VIAL	N62989 003	DEC 29, 1989
AP		EQ 250MG BASE/VIAL	N62988 001	DEC 29, 1989
AP		EQ 500MG BASE/VIAL	N62988 002	DEC 29, 1989
AP	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N64033 001	OCT 31, 1993
AP	TEVA	EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989
AP		EQ 5GM BASE/VIAL	N63018 001	MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002	MAR 05, 1990
AP		EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989
AP		EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989

KEFZOL

AP	+ LILLY	EQ 250MG BASE/VIAL	N61773 001	
AP		EQ 500MG BASE/VIAL	N61773 002	
AP		EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985
AP		EQ 1GM BASE/VIAL	N61773 003	
AP		EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985
AP		EQ 10GM BASE/VIAL	N61773 004	
AP	+	EQ 20GM BASE/VIAL	N61773 005	SEP 08, 1987

CEFDINIR

CAPSULE; ORAL

OMNICEF

+	ABBOTT	300MG	N50739 001	DEC 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

+	ABBOTT	125MG/5ML	N50749 001	DEC 04, 1997

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION

MAXIPIME

+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001	JAN 18, 1996
+		EQ 1GM BASE/VIAL	N50679 002	JAN 18, 1996
+		EQ 2GM BASE/VIAL	N50679 003	JAN 18, 1996

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+	LEDERLE	100MG/5ML	N50622 001	APR 28, 1989

TABLET; ORAL

SUPRAX

+	LEDERLE	200MG	N50621 001	APR 28, 1989
+		400MG	N50621 002	APR 28, 1989

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N50637 001	DEC 11, 1989

FDA data supplied by DrugPatentWatch.com

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

+	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N50579 001 MAY 23, 1984
+		EQ 1GM BASE/VIAL	N50579 002 MAY 23, 1984
		EQ 1GM BASE/VIAL	N63295 001 JUL 26, 1993
+		EQ 10GM BASE/VIAL	N50579 004 MAY 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

+	PFIZER	EQ 1GM BASE/VIAL	N50551 001 NOV 18, 1982
		EQ 1GM BASE/VIAL	N63333 001 MAR 31, 1995
+		EQ 2GM BASE/VIAL	N50551 002 NOV 18, 1982
		EQ 2GM BASE/VIAL	N63333 002 MAR 31, 1995
+		EQ 10GM BASE/VIAL	N50551 003 MAR 05, 1990

CEFOBID IN PLASTIC CONTAINER

+	PFIZER	EQ 20MG BASE/ML	N50613 002 JUL 31, 1987
+		EQ 40MG BASE/ML	N50613 001 JUL 23, 1986

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

	APOTHECON	500MG/VIAL	N62579 001 NOV 26, 1984
		1GM/VIAL	N62579 002 NOV 26, 1984
		2GM/VIAL	N62579 003 NOV 26, 1984
		10GM/VIAL	N62579 004 NOV 26, 1984
		20GM/VIAL	N62579 005 NOV 26, 1984

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

+	BRISTOL	500MG/VIAL	N50554 001 MAY 24, 1984
+		1GM/VIAL	N50554 002 MAY 24, 1984
+		2GM/VIAL	N50554 003 MAY 24, 1984
+		10GM/VIAL	N50554 004 MAY 24, 1984
+		20GM/VIAL	N50554 005 MAY 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP		AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N64200 002** MAR 24, 2000
AP			**EQ 2GM BASE/VIAL**	**N64200 003** MAR 24, 2000
AP			**EQ 10GM BASE/VIAL**	**N64201 001** MAR 24, 2000
AP			**EQ 500MG BASE/VIAL**	**N64200 001** MAR 24, 2000
	+		EQ 20GM BASE/VIAL	N64201 002 MAR 24, 2000

CLAFORAN

AP	+	AVENTIS PHARMS	**EQ 500MG BASE/VIAL**	**N50547 001** DEC 29, 1983
AP	+		**EQ 1GM BASE/VIAL**	**N50547 002** JAN 13, 1987
AP	+		**EQ 2GM BASE/VIAL**	**N50547 003** JAN 13, 1987
AP	+		**EQ 10GM BASE/VIAL**	**N50547 004** MAY 20, 1985

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 002 MAY 20, 1985
+		EQ 40MG BASE/ML	N50596 004 MAY 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 001 MAY 20, 1985

FDA data supplied by DrugPatentWatch.com

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	AVENTIS PHARMS	EQ 40MG BASE/ML	N50596 003	MAY 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

+	ASTRAZENECA	EQ 1GM BASE/VIAL	N50588 001	DEC 27, 1985
		EQ 1GM BASE/VIAL	N63293 001	APR 29, 1993
+		EQ 2GM BASE/VIAL	N50588 002	DEC 27, 1985
		EQ 2GM BASE/VIAL	N63293 002	APR 29, 1993
+		EQ 10GM BASE/VIAL	N50588 003	APR 25, 1988

CEFOTAN IN PLASTIC CONTAINER

+	ASTRAZENECA	EQ 20MG BASE/ML	N50694 002	JUL 30, 1993
+		EQ 40MG BASE/ML	N50694 001	JUL 30, 1993

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N65012 001**	JUL 03, 2000
AP		**EQ 2GM BASE/2VIAL**	**N65012 002**	JUL 03, 2000
AP		**EQ 10GM BASE/VIAL**	**N65011 001**	JUL 03, 2000
AP	ESI LEDERLE	**EQ 1GM BASE/VIAL**	**N65051 001**	SEP 11, 2000
AP		**EQ 2GM BASE/VIAL**	**N65051 002**	SEP 11, 2000
AP		**EQ 10GM BASE/VIAL**	**N65050 001**	SEP 11, 2000

MEFOXIN

AP	+ MERCK	**EQ 1GM BASE/VIAL**	**N50517 001**	JAN 08, 1987
AP		**EQ 1GM BASE/VIAL**	**N62757 001**	

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

AP	+ MERCK	**EQ 2GM BASE/VIAL**	**N50517 002**	
AP		**EQ 2GM BASE/VIAL**	**N62757 002**	JAN 08, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N50517 003**	

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984
+		EQ 40MG BASE/ML	N50581 004	SEP 20, 1984

MEFOXIN IN PLASTIC CONTAINER

	MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993
		EQ 40MG BASE/ML	N63182 002	JAN 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
VANTIN

	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992
+		EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992

TABLET; ORAL
VANTIN

	PHARMACIA AND UPJOHN	EQ 100MG BASE	N50674 001	AUG 07, 1992
+		EQ 200MG BASE	N50674 002	AUG 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	125MG/5ML	N50665 001	DEC 23, 1991
+		250MG/5ML	N50665 002	DEC 23, 1991

TABLET; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	250MG	N50664 001	DEC 23, 1991

FDA data supplied by DrugPatentWatch.com

CEFPROZIL

TABLET; ORAL
CEFZIL
+ BRISTOL MYERS SQUIBB 500MG — N50664 002 DEC 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

AP	+ GLAXO WELLCOME	**500MG/VIAL**	**N50578 001** JUL 19, 1985
AP	+	**1GM/VIAL**	**N50578 002** JUL 19, 1985
AP	+	**2GM/VIAL**	**N50578 003** JUL 19, 1985
AP	+	**6GM/VIAL**	**N50578 004** JUL 19, 1985

TAZICEF

AP	SMITHKLINE BEECHAM	**500MG/VIAL**	**N62662 001** MAR 06, 1986
AP		**1GM/VIAL**	**N62662 002** MAR 06, 1986
AP		**1GM/VIAL**	**N64032 001** OCT 31, 1993
AP		**2GM/VIAL**	**N62662 003** MAR 06, 1986
AP		**2GM/VIAL**	**N64032 002** OCT 31, 1993
AP		**6GM/VIAL**	**N62662 004** MAR 06, 1986

TAZIDIME

AP	LILLY	**1GM/VIAL**	**N62640 002** NOV 20, 1985
AP		**1GM/VIAL**	**N62655 001** NOV 20, 1985
AP		**2GM/VIAL**	**N62640 003** NOV 20, 1985
AP		**2GM/VIAL**	**N62655 002** NOV 20, 1985
AP		**500MG/VIAL**	**N62640 001** NOV 20, 1985

TAZIDIME IN PLASTIC CONTAINER

AP	LILLY	**1GM/VIAL**	**N62739 001** JUL 10, 1986
AP		**2GM/VIAL**	**N62739 002** JUL 10, 1986

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

+	GLAXO WELLCOME	1GM/VIAL	N50646 002 SEP 27, 1990
+		2GM/VIAL	N50646 003 SEP 27, 1990
+		10GM/VIAL	N50646 004 SEP 27, 1990

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**EQ 20MG BASE/ML**	**N63221 002** APR 29, 1993
AP		**EQ 40MG BASE/ML**	**N63221 003** APR 29, 1993
+		EQ 10MG BASE/ML	N63221 001 APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP	+ GLAXO WELLCOME	**EQ 20MG BASE/ML**	**N50634 002** APR 28, 1989
AP	+	**EQ 40MG BASE/ML**	**N50634 003** APR 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

+	BIOVAIL	EQ 400MG BASE	N50685 002 DEC 20, 1995

FOR SUSPENSION; ORAL
CEDAX

	BIOVAIL	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
+		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N63294 002 MAR 31, 1994

FDA data supplied by DrugPatentWatch.com

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	AM PHARM PARTNERS	EQ 2GM BASE/VIAL	N63294 003 MAR 31, 1994
+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFIZOX IN PLASTIC CONTAINER

+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
+		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+	HLR	EQ 20MG BASE/ML	N50624 002 FEB 11, 1987

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+	HLR	EQ 40MG BASE/ML	N50624 003 FEB 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

+	HLR	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL
CEFTIN

	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002 APR 29, 1997

TABLET; ORAL
CEFTIN

	GLAXO WELLCOME	EQ 125MG BASE	N50605 001 DEC 28, 1987
		EQ 250MG BASE	N50605 002 DEC 28, 1987
+		EQ 500MG BASE	N50605 003 DEC 28, 1987

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM

AB	MARSAM	**EQ 750MG BASE/VIAL**	**N64035 001** FEB 26, 1993

INJECTABLE; INJECTION
CEFUROXIME

AB	TEVA	**EQ 750MG BASE/VIAL**	**N64192 002** APR 16, 1998

FDA data supplied by DrugPatentWatch.com

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME			
AP	TEVA	EQ 1.5GM BASE/VIAL	N64192 001	APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001	APR 16, 1998
	CEFUROXIME SODIUM			
AP	AM PHARM PARTNERS	EQ 7.5GM BASE/VIAL	N65002 001	SEP 28, 1998
AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997
AP		EQ 1.5GM BASE/VIAL	N64125 002	MAY 30, 1997
AP		EQ 7.5GM BASE/VIAL	N64124 001	MAY 30, 1997
AP	MARSAM	EQ 1.5GM BASE/VIAL	N64035 002	FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	N64036 001	FEB 26, 1993
	KEFUROX			
AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986
AP		EQ 1.5GM BASE/VIAL	N62591 002	JAN 10, 1986
AP		EQ 1.5GM BASE/VIAL	N62592 002	JAN 10, 1986
AP		EQ 7.5GM BASE/VIAL	N62591 003	DEC 17, 1987
	KEFUROX IN PLASTIC CONTAINER			
AP	LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986
AP		EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986
	ZINACEF			
AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983
AP	+	EQ 1.5GM BASE/VIAL	N50558 003	OCT 19, 1983
AP	+	EQ 7.5GM BASE/VIAL	N50558 004	OCT 23, 1986
	ZINACEF IN PLASTIC CONTAINER			
	+ GLAXO WELLCOME	EQ 15MG BASE/ML	N50643 001	APR 28, 1989
	+	EQ 30MG BASE/ML	N50643 002	APR 28, 1989

CEFUROXIME SODIUM

INJECTABLE; INTRAVENOUS

	KEFUROX			
AP	LILLY	EQ 750MG BASE/VIAL	N62592 001	JAN 10, 1986

CELECOXIB

CAPSULE; ORAL

	CELEBREX			
	SEARLE	100MG	N20998 001	DEC 31, 1998
	+	200MG	N20998 002	DEC 31, 1998

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

	CALCIBIND			
	+ MISSION PHARMA	300GM/BOT	N18757 003	OCT 16, 1984

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	APOTHECON	EQ 250MG BASE	N63063 001	SEP 29, 1989
AB		EQ 250MG BASE	N63186 001	DEC 30, 1994
AB		EQ 500MG BASE	N63063 002	SEP 29, 1989
AB		EQ 500MG BASE	N63186 002	DEC 30, 1994
AB	BARR	EQ 250MG BASE	N62773 001	JUN 26, 1987
AB		EQ 500MG BASE	N62775 001	APR 22, 1987
AB	LABS ATRAL	EQ 250MG BASE	N62713 001	JUL 15, 1988
AB		EQ 500MG BASE	N62713 002	JUL 15, 1988
AB	MJ PHARMS	EQ 250MG BASE	N62791 001	JUN 11, 1987

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	MJ PHARMS	EQ 500MG BASE	N62791 002	JUN 11, 1987
AB	NOVOPHARM	EQ 250MG BASE	N62760 001	APR 24, 1987
AB		EQ 500MG BASE	N62761 001	APR 24, 1987
AB	RANBAXY	EQ 250MG BASE	N65007 001	SEP 16, 1999
AB		EQ 500MG BASE	N65007 002	SEP 16, 1999
AB	STEVENS J	EQ 250MG BASE	N62870 001	MAR 17, 1988
AB		EQ 500MG BASE	N62869 001	MAR 17, 1988
AB	TEVA	EQ 250MG BASE	N62702 001	FEB 13, 1987
AB		EQ 250MG BASE	N62821 001	FEB 05, 1988
AB		EQ 500MG BASE	N62702 002	FEB 13, 1987
AB		EQ 500MG BASE	N62823 001	FEB 05, 1988
AB	ZENITH GOLDLINE	EQ 250MG BASE	N61969 001	
AB		EQ 500MG BASE	N61969 002	
	KEFLEX			
AB	LILLY	EQ 250MG BASE	N50405 002	
AB		EQ 250MG BASE	N62118 001	
AB	+	EQ 500MG BASE	N50405 003	
AB		EQ 500MG BASE	N62118 002	

FOR SUSPENSION; ORAL

	CEPHALEXIN			
AB	APOTHECON	EQ 125MG BASE/5ML	N62986 001	APR 18, 1991
AB		EQ 250MG BASE/5ML	N62987 001	JUL 25, 1989
AB	BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987
AB		EQ 250MG BASE/5ML	N62777 001	AUG 06, 1987
AB	NOVOPHARM	EQ 125MG BASE/5ML	N62767 001	JUN 16, 1987
AB		EQ 250MG BASE/5ML	N62768 001	JUN 16, 1987

CEPHALEXIN

FOR SUSPENSION; ORAL

	CEPHALEXIN			
AB	TEVA	EQ 125MG BASE/5ML	N62703 001	FEB 13, 1987
AB		EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988
AB		EQ 250MG BASE/5ML	N62703 002	FEB 13, 1987
AB		EQ 250MG BASE/5ML	N62867 001	APR 15, 1988
	KEFLEX			
AB	LILLY	EQ 125MG BASE/5ML	N62117 002	
AB	+	EQ 250MG BASE/5ML	N62117 003	
	+	EQ 100MG BASE/ML	N62117 001	

TABLET; ORAL

	CEPHALEXIN			
AB	TEVA	EQ 250MG BASE	N63023 001	JAN 12, 1989
AB		EQ 500MG BASE	N63024 001	JAN 12, 1989
	KEFLET			
AB	LILLY	EQ 250MG BASE	N50440 003	FEB 26, 1987
AB		EQ 250MG BASE	N62745 001	DEC 01, 1986
AB	+	EQ 500MG BASE	N50440 001	
AB		EQ 500MG BASE	N62745 002	DEC 01, 1986
	+	EQ 1GM BASE	N50440 002	

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

	KEFTAB			
	+ LILLY	EQ 500MG BASE	N50614 002	OCT 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

	KAFOCIN			
	+ LILLY	250MG	N50219 001	

FDA data supplied by DrugPatentWatch.com

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

	CEPHALOTHIN SODIUM				
AP	BRISTOL	**EQ 1GM BASE/VIAL**	**N62464 001**		
			MAY 07, 1984		
AP		**EQ 2GM BASE/VIAL**	**N62464 002**		
			MAY 07, 1984		
AP		**EQ 4GM BASE/VIAL**	**N62464 003**		
			MAY 07, 1984		
	KEFLIN				
AP	+ LILLY	**EQ 1GM BASE/VIAL**	**N50482 001**		
AP	+	**EQ 2GM BASE/VIAL**	**N50482 002**		
AP	+	**EQ 4GM BASE/VIAL**	**N50482 003**		
	+	EQ 20GM BASE/VIAL	N50482 007		
	KEFLIN IN PLASTIC CONTAINER				
AP	+ LILLY	**EQ 1GM BASE/VIAL**	**N62549 001**		
			SEP 10, 1985		
AP	+	**EQ 2GM BASE/VIAL**	**N62549 002**		
			SEP 10, 1985		

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL			
APOTHECON	EQ 1GM BASE/VIAL	N61769 001	
	EQ 1GM BASE/VIAL	N62961 002	
		SEP 20, 1988	
	EQ 2GM BASE/VIAL	N61769 002	
	EQ 2GM BASE/VIAL	N62961 003	
		SEP 20, 1988	
	EQ 4GM BASE/VIAL	N61769 003	
	EQ 4GM BASE/VIAL	N62961 004	
		SEP 20, 1988	
	EQ 500MG BASE/VIAL	N62961 001	
		SEP 20, 1988	

CEPHRADINE

CAPSULE; ORAL

	ANSPOR				
AB	SMITHKLINE BEECHAM	**250MG**	**N61859 001**		
AB		**500MG**	**N61859 002**		
	CEPHRADINE				
AB	TEVA	**250MG**	**N62683 001**		
			JAN 09, 1987		

CEPHRADINE

CAPSULE; ORAL

	CEPHRADINE				
AB	TEVA	**500MG**	**N62683 002**		
			JAN 09, 1987		
	VELOSEF				
AB	APOTHECON	**250MG**	**N61764 001**		
AB	+	**500MG**	**N61764 002**		

FOR SUSPENSION; ORAL

	ANSPOR				
AB	SMITHKLINE BEECHAM	**125MG/5ML**	**N61866 001**		
AB		**250MG/5ML**	**N61866 002**		
	CEPHRADINE				
AB	TEVA	**125MG/5ML**	**N62693 001**		
			JAN 09, 1987		
AB		**250MG/5ML**	**N62693 002**		
			JAN 09, 1987		
	VELOSEF '125'				
AB	+ APOTHECON	**125MG/5ML**	**N61763 001**		
	VELOSEF '250'				
AB	+ APOTHECON	**250MG/5ML**	**N61763 002**		

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL			
BAYER	0.2MG	N20740 003	
		JUN 26, 1997	
	0.3MG	N20740 004	
		JUN 26, 1997	
	0.4MG	N20740 005	
		MAY 24, 1999	
+	0.8MG	N20740 006	
		JUL 24, 2000	

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

ZYRTEC			
+ PFIZER	5MG/5ML	N20346 001	
		SEP 27, 1996	

TABLET; ORAL

ZYRTEC			
PFIZER	5MG	N19835 001	
		DEC 08, 1995	

FDA data supplied by DrugPatentWatch.com

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL
ZYRTEC
+ PFIZER — 10MG — N19835 002 DEC 08, 1995

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE
+ SERONO INC — EQ 0.25MG BASE/ML — N21197 001 AUG 11, 2000
+ — EQ 3MG BASE/ML — N21197 002 AUG 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL
EXOSURF NEONATAL
+ GLAXO WELLCOME — 12MG/VIAL;108MG/VIAL; 8MG/VIAL — N20044 001 AUG 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC
+ SNOWBRAND — EQ 30MG BASE — N20989 002 JAN 11, 2000

CHLORAMBUCIL

TABLET; ORAL
LEUKERAN
+ GLAXO WELLCOME — 2MG — N10669 002

CHLORAMPHENICOL

CAPSULE; ORAL
CHLORAMPHENICOL
AB ZENITH GOLDLINE — **250MG** — **N62247 001**
CHLOROMYCETIN
AB + PARKEDALE — **250MG** — **N60591 002**

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN
PARKEDALE — 50MG — N60591 001
100MG — N60591 003
MYCHEL
AB ARMENPHARM — **250MG** — **N60851 001**

FOR SOLUTION; OPHTHALMIC
CHLOROMYCETIN
+ PARKEDALE — 25MG/VIAL — N50143 001

OINTMENT; OPHTHALMIC
CHLORAMPHENICOL
AT ALTANA — **1%** — **N60133 001**
CHLOROMYCETIN
AT + PARKEDALE — **1%** — **N50156 001**
CHLOROPTIC S.O.P.
AT ALLERGAN — **1%** — **N61187 001**

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL
AT AKORN — **0.5%** — **N62042 001**
AT ALCON — **0.5%** — **N62628 001** SEP 25, 1985
CHLOROPTIC
AT + ALLERGAN — **0.5%** — **N50091 001**

SOLUTION/DROPS; OTIC
CHLOROMYCETIN
+ PARKEDALE — 0.5% — N50205 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL
ELASE-CHLOROMYCETIN
+ PARKE DAVIS — 10MG/GM;666 UNITS/GM; 1 UNIT/GM — N50294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE
+ PARKEDALE — 12.5MG/VIAL;25MG/VIAL — N50202 001

FDA data supplied by DrugPatentWatch.com

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

	CHLOROMYCETIN PALMITATE			
+	PARKE DAVIS	EQ 150MG BASE/5ML	N50152	001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

	CHLORAMPHENICOL SODIUM SUCCINATE			
AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N62365**	**001**
			AUG 25, 1982	
AP	GRUPPO LEPETIT	**EQ 1GM BASE/VIAL**	**N62278**	**001**
	CHLOROMYCETIN			
AP +	PARKEDALE	**EQ 1GM BASE/VIAL**	**N50155**	**001**

CHLORDIAZEPOXIDE; *MULTIPLE*

SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZACHEL			
AB	RACHELLE	**5MG**	**N85086**	**001**
AB		**10MG**	**N84639**	**001**
AB		**25MG**	**N85087**	**001**
	CHLORDIAZEPOXIDE HCL			
AB	BARR	**5MG**	**N84768**	**001**
AB		**10MG**	**N83116**	**001**
AB		**25MG**	**N84769**	**001**
AB	CHELSEA LABS	**5MG**	**N86383**	**001**
AB		**10MG**	**N86294**	**001**
AB		**25MG**	**N86382**	**001**
AB	FERRANTE	**5MG**	**N85118**	**001**
AB		**10MG**	**N85119**	**001**
AB		**25MG**	**N85120**	**001**
AB	GENEVA PHARMS	**5MG**	**N84678**	**001**
AB		**10MG**	**N84041**	**001**
AB		**25MG**	**N84679**	**002**
AB	IMPAX LABS	**5MG**	**N86213**	**001**
AB		**10MG**	**N85113**	**001**
AB		**25MG**	**N86212**	**001**
AB	ROSEMONT	**5MG**	**N84644**	**001**
AB		**10MG**	**N84623**	**001**
AB		**25MG**	**N84645**	**001**
	LIBRIUM			
AB	ICN	**5MG**	**N85461**	**001**

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	LIBRIUM			
AB	ICN	**10MG**	**N85472**	**001**
AB +		**25MG**	**N85475**	**001**

INJECTABLE; INJECTION

	LIBRIUM			
+	ICN	100MG/AMP	N12301	001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	CHLORHEXIDINE GLUCONATE			
AT	ALPHARMA	**0.12%**	**N74291**	**001**
			DEC 28, 1995	
AT	HI TECH PHARMA	**0.12%**	**N74356**	**001**
			MAY 07, 1996	
AT	NOVEX	**0.12%**	**N75561**	**001**
			NOV 14, 2000	
AT	TEVA	**0.12%**	**N74522**	**001**
			DEC 15, 1995	
	PERIDEX			
AT +	ZILA	**0.12%**	**N19028**	**001**
			AUG 13, 1986	
	PERIOGARD			
AT	COLGATE	**0.12%**	**N73695**	**001**
			JAN 14, 1994	

TABLET; DENTAL

	PERIOCHIP			
+	PERIO PRODS	2.5MG	N20774	001
			MAY 15, 1998	

CHLORMEZANONE

TABLET; ORAL

	TRANCOPAL			
+	SANOFI SYNTHELABO	100MG	N11467	003
+		200MG	N11467	005

FDA data supplied by DrugPatentWatch.com

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLOROPROCAINE HCL			
AP	ABBOTT	**2%**	**N87447 001**	
			APR 16, 1982	
AP		**3%**	**N87446 001**	
			APR 16, 1982	
AP	BEDFORD	**2%**	**N40273 001**	
			SEP 09, 1998	
AP		**3%**	**N40273 002**	
			SEP 09, 1998	
	NESACAINE			
	+ ASTRAZENECA	1%	N09435 001	
		2%	N09435 002	
	NESACAINE-MPF			
AP	+ ASTRAZENECA	**2%**	**N09435 006**	
			MAY 02, 1996	
AP	+	**3%**	**N09435 007**	
			MAY 02, 1996	

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ARALEN HCL		
	+ SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	ARALEN		
AA	+ SANOFI SYNTHELABO	**EQ 300MG BASE**	**N06002 001**
	CHLOROQUINE PHOSPHATE		
AA	+ DANBURY PHARMA	**EQ 150MG BASE**	**N87979 001**
			DEC 21, 1982
AA		**EQ 300MG BASE**	**N88030 001**
			DEC 21, 1982
AA	IMPAX LABS	**EQ 150MG BASE**	**N80880 001**
AA	TEVA	**EQ 150MG BASE**	**N87504 001**
			JAN 13, 1982
AA	WEST WARD	**EQ 150MG BASE**	**N83082 001**
AA		**EQ 300MG BASE**	**N83082 002**
			SEP 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

	DIURIL		
	+ MERCK	250MG/5ML	N11870 001

TABLET; ORAL

	CHLOROTHIAZIDE		
AB	CAMALL	**250MG**	**N85569 001**
AB	CHELSEA LABS	**250MG**	**N86795 001**
			AUG 15, 1983
AB	DANBURY PHARMA	**250MG**	**N85173 001**
AB	MYLAN	**250MG**	**N84388 001**
AB		**500MG**	**N84217 001**
AB	WEST WARD	**250MG**	**N86028 001**
			JUL 14, 1982
AB		**500MG**	**N87736 001**
			JUL 14, 1982
	DIURIL		
AB	MERCK	**250MG**	**N11145 004**
AB	+	**500MG**	**N11145 002**

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDOCLOR-150		
	MERCK	150MG;250MG	N16016 001
	ALDOCLOR-250		
	+ MERCK	250MG;250MG	N16016 002

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	CHLOROTHIAZIDE AND RESERPINE		
BP	WEST WARD	250MG;0.125MG	N88557 001
			DEC 22, 1983
BP		500MG;0.125MG	N88365 001
			DEC 22, 1983
	CHLOROTHIAZIDE-RESERPINE		
BP	MYLAN	250MG;0.125MG	N87744 001
			MAY 06, 1982
BP		500MG;0.125MG	N87745 001
			MAY 06, 1982
	DIUPRES-250		
BP	MERCK	250MG;0.125MG	N11635 003
			AUG 26, 1987

FDA data supplied by DrugPatentWatch.com

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
DIUPRES-500

BP	+ MERCK	500MG;0.125MG	N11635 006	AUG 26, 1987

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
DIURIL

+	MERCK	EQ 500MG BASE/VIAL	N11145 005

CHLOROTRIANISENE

CAPSULE; ORAL
TACE

+	AVENTIS PHARMS	12MG	N08102 004

CHLOROXINE

SHAMPOO; TOPICAL
CAPITROL

+	WESTWOOD SQUIBB	2%	N17594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL
MAOLATE

+	PHARMACIA AND UPJOHN	400MG	N14217 002

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

+	STERIS	10MG/ML	N86096 001

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	+ GENEVA PHARMS	**4MG**	**N80961 001**	
AA	ICN	**4MG**	**N80598 001**	
AA	MARSHALL PHARMA	**4MG**	**N83286 001**	
AA	PHARMAVITE	**4MG**	**N85104 001**	
AA	PHOENIX LABS NY	**4MG**	**N85522 001**	

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	SUPERPHARM	**4MG**	**N87747 001**	APR 20, 1982
AA	TABLICAPS	**4MG**	**N83394 001**	
AA	WEST WARD	**4MG**	**N83787 001**	

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL

AB	GENEVA PHARMS	**12MG;75MG**	**N88940 001**	JAN 26, 1989
	DRIZE			
BC	ASCHER	12MG;75MG	N88359 001	FEB 13, 1986
	ORNADE			
AB	+ SMITHKLINE BEECHAM	**12MG;75MG**	**N12152 004**	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
TUSSIONEX

+	MEDEVA	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001	DEC 31, 1987

CHLORPROMAZINE

SUPPOSITORY; RECTAL
THORAZINE

+	SMITHKLINE BEECHAM	25MG	N09149 024
+		100MG	N09149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
THORAZINE

+	SMITHKLINE BEECHAM	30MG	N11120 016
+		75MG	N11120 017
+		150MG	N11120 018
+		200MG	N11120 019
+		300MG	N11120 020

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	CHLORPROMAZINE HCL				
AA	ALPHARMA	100MG/ML	N86863 001		
AA	PHARM ASSOC	30MG/ML	N40231 001		
			DEC 30, 1999		
AA		100MG/ML	N40224 001		
			JAN 26, 1999		
	CHLORPROMAZINE HCL INTENSOL				
AA	ROXANE	30MG/ML	N88157 001		
			APR 27, 1983		
AA		100MG/ML	N88158 001		
			APR 27, 1983		
	SONAZINE				
AA	GENEVA PHARMS	30MG/ML	N80983 004		
AA		100MG/ML	N80983 005		
	THORAZINE				
AA +	SMITHKLINE BEECHAM	30MG/ML	N09149 032		
AA +		100MG/ML	N09149 043		

INJECTABLE; INJECTION

CHLORPROMAZINE HCL			
AP	ELKINS SINN PHARM	25MG/ML	N83329 001
AP	STERIS	25MG/ML	N80365 001
THORAZINE			
AP +	SMITHKLINE BEECHAM	25MG/ML	N09149 011

SYRUP; ORAL

SONAZINE			
AA	GENEVA PHARMS	10MG/5ML	N83040 001
THORAZINE			
AA +	SMITHKLINE BEECHAM	10MG/5ML	N09149 022

TABLET; ORAL

CHLORPROMAZINE HCL			
BP	GENEVA PHARMS	10MG	N80439 001
BP		25MG	N80439 002
BP		50MG	N80439 003
BP		100MG	N80439 004
BP		200MG	N80439 005
BP	LEDERLE	10MG	N84803 001
BP	ROSEMONT	10MG	N83386 001
BP		25MG	N84112 001
BP		50MG	N84113 001
BP		100MG	N84114 001
BP		200MG	N84115 001
THORAZINE			
BP +	SMITHKLINE BEECHAM	10MG	N09149 002

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

THORAZINE			
BP	SMITHKLINE BEECHAM	25MG	N09149 007
BP		50MG	N09149 013
BP +		100MG	N09149 018
BP		200MG	N09149 020

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE			
AB	DANBURY PHARMA	100MG	N88852 001
			SEP 26, 1984
AB		250MG	N88826 001
			SEP 26, 1984
AB	GENEVA PHARMS	100MG	N88725 001
			AUG 31, 1984
AB		250MG	N88726 001
			AUG 31, 1984
AB	LEDERLE	100MG	N89561 001
			SEP 04, 1987
AB		250MG	N89562 001
			SEP 04, 1987
AB	MYLAN	100MG	N88548 001
			JUN 01, 1984
AB		250MG	N88549 001
			JUN 01, 1984
AB	PAR PHARM	100MG	N88175 001
			FEB 27, 1984
AB		250MG	N88176 001
			FEB 27, 1984
AB	SIDMAK LABS NJ	100MG	N88921 001
			APR 12, 1985
AB		250MG	N88922 001
			APR 12, 1985
AB	SUPERPHARM	100MG	N88694 001
			SEP 17, 1984
DIABINESE			
AB	PFIZER	100MG	N11641 003
AB +		250MG	N11641 006

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN			
+	LEDERLE	1%	N50404 001

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	CHELSEA LABS	25MG	N87100 001	
AB	GENEVA PHARMS	25MG	N87380 001	
AB		50MG	N87381 001	
AB	MUTUAL PHARM	25MG	N89285 001	JUL 21, 1986
AB		50MG	N89286 001	JUL 21, 1986
AB	MYLAN	25MG	N87180 001	
AB		50MG	N86831 001	
AB	ROSEMONT	25MG	N89051 001	JUN 01, 1987
AB	SIDMAK LABS NJ	25MG	N88902 001	SEP 19, 1985
AB		50MG	N88903 001	SEP 19, 1985
AB	ZENITH GOLDLINE	25MG	N88164 001	JAN 09, 1984
AB		50MG	N87176 001	
	HYGROTON			
AB	AVENTIS	25MG	N12283 004	
AB +		50MG	N12283 003	
	THALITONE			
BX	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992
+		15MG	N19574 001	DEC 20, 1988

CHLORTHALIDONE; *MULTIPLE*

SEE ATENOLOL; CHLORTHALIDONE

SEE BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLONIDINE HCL AND CHLORTHALIDONE			
AB	PAR PHARM	15MG;0.1MG	N71179 001	DEC 16, 1987
AB		15MG;0.2MG	N71178 001	DEC 16, 1987
AB		15MG;0.3MG	N71142 001	DEC 16, 1987
	CLORPRES			
AB	MYLAN	15MG;0.1MG	N71323 001	FEB 09, 1987

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLORPRES			
AB	MYLAN	15MG;0.2MG	N71324 001	FEB 09, 1987
AB		15MG;0.3MG	N71325 001	FEB 09, 1987
	COMBIPRES			
AB	BOEHRINGER INGELHEIM	15MG;0.1MG	N17503 001	
AB		15MG;0.2MG	N17503 002	
AB +		15MG;0.3MG	N17503 003	APR 10, 1984

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

	DEMI-REGROTON		
	AVENTIS	25MG;0.125MG	N15103 002
	REGROTON		
+	AVENTIS	50MG;0.25MG	N15103 001

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	AMIDE PHARM	250MG	N88928 001	MAY 08, 1987
AA		500MG	N40113 001	SEP 29, 1995
AA	BARR	500MG	N89895 001	MAY 04, 1988
AA	CHELSEA LABS	500MG	N40137 001	AUG 09, 1996
AA	DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991
AA	GENEVA PHARMS	250MG	N89852 001	MAY 04, 1988
AA		500MG	N89853 001	MAY 04, 1988
AA	MUTUAL PHARM	500MG	N89970 001	SEP 27, 1990
AA	OHM	250MG	N81298 001	DEC 29, 1993
AA		500MG	N81299 001	DEC 29, 1993

FDA data supplied by DrugPatentWatch.com

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	PAR PHARM	250MG	N87981 001	SEP 20, 1983
AA	TEVA	500MG	N89859 001	MAY 04, 1988
AA	WATSON LABS	500MG	N81040 001	AUG 22, 1989
	PARAFON FORTE DSC			
AA	+ JOHNSON RW	500MG	N11529 002	JUN 15, 1987
	STRIFON FORTE DSC			
AA	FERNDALE LABS	500MG	N81008 001	DEC 23, 1988

CHOLECALCIFEROL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554 001	OCT 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	OCT 02, 1996
AB	EON	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002	MAY 28, 1998
AB	ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	ZENITH GOLDLINE	EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001	SEP 30, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74555 002	SEP 30, 1998
AB	EON	EQ 4GM RESIN/PACKET	N74558 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002	AUG 15, 1996
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002	MAY 28, 1998
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	PREVALITE			
AB	UPSHER SMITH	EQ 4GM RESIN/PACKET	N73263 001	FEB 22, 1996
	QUESTRAN			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N16640 001	
AB		EQ 4GM RESIN/SCOOPFUL	N16640 003	
	QUESTRAN LIGHT			
AB	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N19669 001	DEC 05, 1988
AB		EQ 4GM RESIN/SCOOPFUL	N19669 003	DEC 05, 1988

TABLET; ORAL

	QUESTRAN			
	+ APOTHECON	EQ 800MG RESIN	N73403 002	DEC 27, 1999

FDA data supplied by DrugPatentWatch.com

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
OVIDREL
+ SERONO 0.25MG/VIAL N21149 001 SEP 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE IN PLASTIC CONTAINER
+ ABBOTT EQ 0.004MG CHROMIUM/ML N18961 001 JUN 26, 1986

CHROMIC PHOSPHATE, P-32

INJECTABLE; INJECTION
PHOSPHOCOL P32
+ MALLINCKRODT 5mCi/ML N17084 001

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN
+ KNOLL PHARM 4,000 UNITS/VIAL N18663 002 AUG 21, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC
ZOLYSE
+ ALCON 750 UNITS/VIAL N11903 001

CICLOPIROX

CREAM; TOPICAL
LOPROX
+ AVENTIS PHARMS 0.77% N18748 001 DEC 30, 1982

GEL; TOPICAL
LOPROX
+ AVENTIS PHARMS 0.77% N20519 001 JUL 21, 1997

CICLOPIROX

LOTION; TOPICAL
LOPROX
+ AVENTIS PHARMS 0.77% N19824 001 DEC 30, 1988

SOLUTION; TOPICAL
PENLAC
+ AVENTIS PHARMS 8% N21022 001 DEC 17, 1999

CIDOFOVIR

INJECTABLE; INJECTION
VISTIDE
+ GILEAD EQ 75MG BASE/ML N20638 001 JUN 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN
+ MERCK EQ 250MG BASE/VIAL; 250MG/VIAL N50587 001 NOV 26, 1985
EQ 250MG BASE/VIAL; 250MG/VIAL N62756 001 JAN 08, 1987
+ EQ 500MG BASE/VIAL; 500MG/VIAL N50587 002 NOV 26, 1985
EQ 500MG BASE/VIAL; 500MG/VIAL N50630 001 DEC 14, 1990
EQ 500MG BASE/VIAL; 500MG/VIAL N62756 002 JAN 08, 1987
+ EQ 750MG BASE/VIAL; 750MG/VIAL N50630 002 DEC 14, 1990

FDA data supplied by DrugPatentWatch.com

CILOSTAZOL

TABLET; ORAL

PLETAL				
OTSUKA	50MG	N20863 001 JAN 15, 1999		
+	100MG	N20863 002 JAN 15, 1999		

CIMETIDINE

SOLUTION; ORAL

CIMETIDINE HCL				
AA DURAMED	**300MG/5ML**	**N75110 001** JUN 18, 1998		

TABLET; ORAL

CIMETIDINE				
AB DANBURY PHARMA	**200MG**	**N74349 001** AUG 30, 1996		
AB	**300MG**	**N74349 002** AUG 30, 1996		
AB	**400MG**	**N74349 003** AUG 30, 1996		
AB	**800MG**	**N74316 001** FEB 28, 1996		
AB ENDO PHARMS	**200MG**	**N74281 001** MAY 17, 1994		
AB	**300MG**	**N74281 002** MAY 17, 1994		
AB	**400MG**	**N74281 003** MAY 17, 1994		
AB	**800MG**	**N74329 001** MAY 17, 1994		
AB GENEVA PHARMS	**200MG**	**N74100 001** JAN 31, 1995		
AB	**300MG**	**N74100 002** JAN 31, 1995		
AB	**400MG**	**N74100 003** JAN 31, 1995		
AB	**800MG**	**N74100 004** JAN 31, 1995		
AB INVAMED	**200MG**	**N74506 001** JAN 24, 1996		
AB	**300MG**	**N74506 002** JAN 24, 1996		
AB	**400MG**	**N74506 003** JAN 24, 1996		

CIMETIDINE

TABLET; ORAL

CIMETIDINE				
AB INVAMED	**800MG**	**N74506 004** JAN 24, 1996		
AB MOVA	**300MG**	**N74340 001** JUN 23, 1995		
AB	**400MG**	**N74340 002** JUN 23, 1995		
AB	**800MG**	**N74339 001** JUN 23, 1995		
AB MYLAN	**200MG**	**N74246 001** MAY 17, 1994		
AB	**300MG**	**N74246 002** MAY 17, 1994		
AB	**400MG**	**N74246 003** MAY 17, 1994		
AB	**800MG**	**N74246 004** MAY 17, 1994		
AB NOVOPHARM	**200MG**	**N74151 001** MAY 17, 1994		
AB	**300MG**	**N74151 002** MAY 17, 1994		
AB	**400MG**	**N74151 003** MAY 17, 1994		
AB	**800MG**	**N74463 001** MAY 17, 1994		
AB SIDMAK LABS NJ	**200MG**	**N74568 001** FEB 27, 1997		
AB	**300MG**	**N74568 002** FEB 27, 1997		
AB	**400MG**	**N74568 003** FEB 27, 1997		
AB	**800MG**	**N74566 001** FEB 27, 1997		
AB TEVA	**200MG**	**N74365 001** FEB 28, 1995		
AB	**300MG**	**N74365 002** FEB 28, 1995		
AB	**400MG**	**N74365 003** FEB 28, 1995		
AB	**800MG**	**N74365 004** FEB 28, 1995		
AB TORPHARM	**200MG**	**N74890 001** DEC 18, 1998		
AB	**300MG**	**N74890 002** DEC 18, 1998		

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

TABLET; ORAL

	CIMETIDINE				
AB	TORPHARM	400MG	N74890 003		DEC 18, 1998
AB		800MG	N74890 004		DEC 18, 1998
AB	ZENITH GOLDLINE	200MG	N74401 001		MAY 30, 1995
AB		200MG	N74424 001		JUL 28, 1995
AB		300MG	N74401 002		MAY 30, 1995
AB		300MG	N74424 002		JUL 28, 1995
AB		400MG	N74401 003		MAY 30, 1995
AB		400MG	N74424 003		JUL 28, 1995
AB		800MG	N74402 001		MAY 30, 1995
AB		800MG	N74424 004		JUL 28, 1995
	TAGAMET				
AB	SMITHKLINE BEECHAM	200MG	N17920 002		
AB		300MG	N17920 003		
AB		400MG	N17920 004		DEC 14, 1983
AB	+	800MG	N17920 005		APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL				
AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001		MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74344 001		JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001		JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74412 001		MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74422 001		JAN 31, 1995
AP	ENDO PHARMS	EQ 300MG BASE/2ML	N74005 001		AUG 31, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL				
AP	GENSIA SICOR PHARMS	EQ 300MG BASE/2ML	N74252 001		NOV 26, 1997
AP	LUITPOLD	EQ 300MG BASE/2ML	N74353 001		DEC 20, 1994
AP	MOVA	EQ 300MG BASE/2ML	N74428 001		APR 25, 1996
	CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ABBOTT	EQ 6MG BASE/ML	N74269 001		DEC 27, 1994
+		EQ 90MG BASE/100ML	N74468 005		DEC 29, 1994
+		EQ 120MG BASE/100ML	N74468 006		DEC 29, 1994
+		EQ 180MG BASE/100ML	N74468 003		DEC 29, 1994
+		EQ 240MG BASE/100ML	N74468 004		DEC 29, 1994
+		EQ 360MG BASE/100ML	N74468 001		DEC 29, 1994
+		EQ 480MG BASE/100ML	N74468 002		DEC 29, 1994
	TAGAMET				
AP	+ SMITHKLINE BEECHAM	EQ 300MG BASE/2ML	N17939 002		
	TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	+ SMITHKLINE BEECHAM	EQ 6MG BASE/ML	N19434 001		OCT 31, 1985

SOLUTION; ORAL

	CIMETIDINE HCL				
AA	ALPHARMA	EQ 300MG BASE/5ML	N74176 001		JUN 01, 1994
AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001		JUL 09, 1998
AA	ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001		DEC 22, 1994
AA	HI TECH PHARMA	EQ 300MG BASE/5ML	N74664 001		OCT 28, 1997
AA	MORTON GROVE	EQ 300MG BASE/5ML	N74757 001		OCT 17, 1997
AA	NOVEX	EQ 300MG BASE/5ML	N75560 001		MAR 15, 2000
AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001		JAN 27, 1997
AA	ROXANE	EQ 300MG BASE/5ML	N74541 001		AUG 05, 1997

FDA data supplied by DrugPatentWatch.com

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	TEVA	EQ 300MG BASE/5ML	N74610 001	SEP 26, 1996
	TAGAMET			
AA	+ SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001	

CINOXACIN

CAPSULE; ORAL

	CINOBAC			
AB	LILLY	250MG	N18067 001	
AB	+	500MG	N18067 002	
	CINOXACIN			
AB	TEVA	250MG	N73005 001	FEB 28, 1992
AB		500MG	N73006 001	FEB 28, 1992

CIPROFLOXACIN

FOR SUSPENSION; ORAL

	CIPRO			
	BAYER	250MG/5ML	N20780 001	SEP 26, 1997
	+	500MG/5ML	N20780 002	SEP 26, 1997

INJECTABLE; INJECTION

	CIPRO			
	+ BAYER	10MG/ML	N19847 001	DEC 26, 1990
	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER			
	+ BAYER	200MG/100ML	N19857 001	DEC 26, 1990

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

	CILOXAN			
	+ ALCON	EQ 0.3% BASE	N20369 001	MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CILOXAN			
	+ ALCON	EQ 0.3% BASE	N19992 001	DEC 31, 1990

TABLET; ORAL

	CIPRO			
	BAYER	EQ 100MG BASE	N19537 001	APR 08, 1996
		EQ 250MG BASE	N19537 002	OCT 22, 1987
		EQ 500MG BASE	N19537 003	OCT 22, 1987
	+	EQ 750MG BASE	N19537 004	OCT 22, 1987

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

	CIPRO HC			
	+ ALCON	EQ 0.2% BASE;1%	N20805 001	FEB 10, 1998

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

	NIMBEX			
	+ ABBOTT	EQ 2MG BASE/ML	N20551 001	DEC 15, 1995
	NIMBEX PRESERVATIVE FREE			
	+ ABBOTT	EQ 2MG BASE/ML	N20551 003	DEC 15, 1995
	+	EQ 10MG BASE/ML	N20551 002	DEC 15, 1995

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN			
AP	AM PHARM PARTNERS	1MG/ML	N74735 001	JUL 16, 1999
AP	BEDFORD	1MG/ML	N75036 001	NOV 07, 2000

FDA data supplied by DrugPatentWatch.com

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN			
AP	BEDFORD	**10MG/VIAL**	**N74713 001**	NOV 14, 2000
AP		**50MG/VIAL**	**N74713 002**	NOV 14, 2000
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N74814 001**	MAY 16, 2000
AP	PHARMACHEMIE	**1MG/ML**	**N74656 001**	MAY 16, 2000
	PLATINOL			
AP	+ BRISTOL MYERS	**10MG/VIAL**	**N18057 001**	
AP	+	**50MG/VIAL**	**N18057 002**	
	PLATINOL-AQ			
AP	+ BRISTOL MYERS	**1MG/ML**	**N18057 004**	NOV 08, 1988

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

	CELEXA			
	+ FOREST LABS	EQ 10MG BASE/5ML	N21046 001	DEC 22, 1999

TABLET; ORAL

	CELEXA			
	FOREST LABS	EQ 10MG BASE	N20822 001	APR 27, 2000
		EQ 20MG BASE	N20822 002	JUL 17, 1998
	+	EQ 40MG BASE	N20822 003	JUL 17, 1998

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

	RENACIDIN			
	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001	OCT 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

	IRRIGATING SOLUTION G IN PLASTIC CONTAINER			
AT	BAXTER HLTHCARE	**3.24GM/100ML;380MG/100ML; 430MG/100ML**	**N18519 001**	JUN 22, 1982
	UROLOGIC G IN PLASTIC CONTAINER			
AT	ABBOTT	**3.24GM/100ML;380MG/100ML; 430MG/100ML**	**N18904 001**	MAY 27, 1983

CLADRIBINE

INJECTABLE; INJECTION

	CLADRIBINE			
AP	BEDFORD	**1MG/ML**	**N75405 001**	FEB 28, 2000
	LEUSTATIN			
	+ JOHNSON RW	1MG/ML	N20229 001	FEB 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

	BIAXIN			
	ABBOTT	125MG/5ML	N50698 001	DEC 23, 1993
		187MG/5ML	N50698 003	SEP 30, 1998
	+	250MG/5ML	N50698 002	DEC 23, 1993

TABLET; ORAL

	BIAXIN			
	+ ABBOTT	250MG	N50662 001	OCT 31, 1991
	+	500MG	N50662 002	OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL

	BIAXIN XL			
	+ ABBOTT	500MG	N50775 001	MAR 03, 2000

CLARITHROMYCIN; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

FDA data supplied by DrugPatentWatch.com

CLAVULANATE POTASSIUM; *MULTIPLE*
SEE AMOXICILLIN; CLAVULANATE POTASSIUM

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TIMENTIN

+	SMITHKLINE BEECHAM	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 001	APR 01, 1985
		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N62691 001	DEC 19, 1986
+		EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 002	APR 01, 1985
+		EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N50590 003	AUG 18, 1987

TIMENTIN IN PLASTIC CONTAINER

+	SMITHKLINE BEECHAM	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N50658 001	DEC 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	ALPHARMA	**EQ 0.5MG BASE/5ML**	**N74075 001**	OCT 31, 1993
AA	COPLEY PHARM	**EQ 0.5MG BASE/5ML**	**N73095 001**	APR 21, 1992
AA	MORTON GROVE	**EQ 0.5MG BASE/5ML**	**N74863 001**	MAR 13, 1998
AA	NOVEX	**EQ 0.5MG BASE/5ML**	**N75703 001**	NOV 27, 2000
AA	SILARX	**EQ 0.5MG BASE/5ML**	**N74884 001**	DEC 17, 1997
AA	TEVA	**EQ 0.5MG BASE/5ML**	**N73399 001**	JUN 30, 1994

TAVIST

AA	+ NOVARTIS	**EQ 0.5MG BASE/5ML**	**N18675 001**	JUN 28, 1985

TABLET; ORAL
CLEMASTINE FUMARATE

AB	GENEVA PHARMS	**2.68MG**	**N73459 001**	OCT 31, 1993

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

AB	TEVA	**2.68MG**	**N73283 001**	JAN 31, 1992

TAVIST

AB	+ NOVARTIS	**2.68MG**	**N17661 001**	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL

AB	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N50162 001**	
AB		**EQ 150MG BASE**	**N50162 002**	
+		EQ 300MG BASE	N50162 003	APR 14, 1988

CLINDAMYCIN HCL

AB	DANBURY PHARMA	**EQ 150MG BASE**	**N63083 001**	JUL 31, 1991
AB	TEVA	**EQ 75MG BASE**	**N63027 001**	SEP 20, 1989
AB		**EQ 150MG BASE**	**N63029 001**	SEP 20, 1989

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN

	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644 001	APR 07, 1986

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN

+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	MAR 02, 1998

GEL; TOPICAL
CLEOCIN T

AB	+ PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50615 001**	JAN 07, 1987

CLINDAMYCIN PHOSPHATE

AB	ALTANA	**EQ 1% BASE**	**N64160 001**	JAN 28, 2000

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	CLINDAMYCIN PHOSPHATE			
BT	TARGET RES	EQ 1% BASE	N50782 001	
			NOV 27, 2000	

INJECTABLE; INJECTION

	CLEOCIN PHOSPHATE			
AP	+ PHARMACIA AND UPJOHN	**EQ 150MG BASE/ML**	**N50441 001**	
AP		**EQ 150MG BASE/ML**	**N62803 001**	
			OCT 16, 1987	
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ PHARMACIA AND UPJOHN	**EQ 6MG BASE/ML**	**N50639 001**	
			AUG 30, 1989	
AP	+	**EQ 12MG BASE/ML**	**N50639 002**	
			AUG 30, 1989	
	+	EQ 18MG BASE/ML	N50639 003	
			APR 10, 1991	
	CLINDAMYCIN PHOSPHATE			
AP	ABBOTT	**EQ 150MG BASE/ML**	**N62800 001**	
			JUL 24, 1987	
AP		**EQ 150MG BASE/ML**	**N62801 001**	
			JUL 24, 1987	
AP		**EQ 150MG BASE/ML**	**N62943 001**	
			SEP 29, 1988	
AP	ELKINS SINN	**EQ 150MG BASE/ML**	**N62806 001**	
			OCT 15, 1987	
AP		**EQ 150MG BASE/ML**	**N62953 001**	
			APR 21, 1988	
AP	GENSIA SICOR PHARMS	**EQ 150MG BASE/ML**	**N63041 001**	
			DEC 29, 1989	
AP		**EQ 150MG BASE/ML**	**N63282 001**	
			MAY 29, 1992	
AP	LEDERLE	**EQ 150MG BASE/ML**	**N62889 001**	
			APR 25, 1988	
AP		**EQ 150MG BASE/ML**	**N63068 001**	
			AUG 28, 1989	
AP	LOCH	**EQ 150MG BASE/ML**	**N62905 001**	
			MAY 09, 1988	
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%			
AP	+ AM PHARM PARTNERS	**EQ 900MG BASE/100ML**	**N50635 001**	
			DEC 22, 1989	
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	**EQ 6MG BASE/ML**	**N50648 001**	
			DEC 29, 1989	
AP	+	**EQ 900MG BASE/100ML**	**N50648 003**	
			DEC 29, 1989	

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	**EQ 12MG BASE/ML**	**N50648 002**	
			DEC 29, 1989	

LOTION; TOPICAL

	CLEOCIN T			
	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001	
			MAY 31, 1989	

SOLUTION; TOPICAL

	CLEOCIN T			
AT	+ PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50537 001**	
	CLINDA-DERM			
AT	PADDOCK	**EQ 1% BASE**	**N63329 001**	
			SEP 30, 1992	
	CLINDAMYCIN PHOSPHATE			
AT	ALPHARMA	**EQ 1% BASE**	**N62811 001**	
			SEP 01, 1988	
AT	CLAY PARK	**EQ 1% BASE**	**N64050 001**	
			NOV 30, 1995	
AT		**EQ 1% BASE**	**N65049 001**	
			MAY 25, 2000	
AT	COPLEY PHARM	**EQ 1% BASE**	**N62944 001**	
			JAN 11, 1989	
AT	FOUGERA	**EQ 1% BASE**	**N64159 001**	
			JUN 05, 1997	
AT	MORTON GROVE	**EQ 1% BASE**	**N63304 001**	
			JUL 15, 1997	
AT	STIEFEL	**EQ 1% BASE**	**N64108 001**	
			SEP 27, 1996	
AT	TEVA	**EQ 1% BASE**	**N62930 001**	
			JUN 28, 1989	

SUPPOSITORY; VAGINAL

	CLEOCIN			
	+ PHARMACIA AND UPJOHN	100MG	N50767 001	
			AUG 13, 1999	

SWAB; TOPICAL

	CLEOCIN			
AT	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50537 002**	
			FEB 22, 1994	
	CLINDETS			
AT	STIEFEL	**EQ 1% BASE**	**N64136 001**	
			SEP 30, 1996	

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE; *MULTIPLE*
SEE BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL

	OLUX FOAM		
+	CONNETICS	0.05%	N21142 001 MAY 26, 2000

CREAM; TOPICAL

	CLOBETASOL PROPIONATE		
AB1	ALPHARMA US PHARM	0.05%	**N74139 001** AUG 03, 1994
AB1	COPLEY PHARM	0.05%	**N74087 001** FEB 16, 1994
AB1	FOUGERA	0.05%	**N74392 001** SEP 30, 1996
AB1	TARO	0.05%	**N74249 001** JUL 08, 1996
	CLOBETASOL PROPIONATE (EMOLLIENT)		
AB2	ALTANA	0.05%	**N75430 001** MAY 26, 1999
AB2	TARO	0.05%	**N75633 001** MAY 17, 2000
	CORMAX		
AB1	HEALTHPOINT	0.05%	**N74220 001** MAY 16, 1997
	EMBELINE E		
AB2	HEALTHPOINT	0.05%	**N75325 001** DEC 24, 1998
	TEMOVATE		
AB1 +	GLAXO WELLCOME	0.05%	**N19322 001** DEC 27, 1985
	TEMOVATE E		
AB2 +	GLAXO WELLCOME	0.05%	**N20340 001** JUN 17, 1994

GEL; TOPICAL

	CLOBETASOL PROPIONATE		
AB	ALTANA	0.05%	**N75368 001** FEB 15, 2000
AB	STIEFEL	0.05%	**N75027 001** OCT 31, 1997
AB	TARO	0.05%	**N75279 001** MAY 28, 1999
	TEMOVATE		
AB +	GLAXO WELLCOME	0.05%	**N20337 001** APR 29, 1994

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE		
AB	COPLEY PHARM	0.05%	**N74089 001** FEB 16, 1994
AB	FOUGERA	0.05%	**N74407 001** FEB 23, 1996
AB	NMC	0.05%	**N74128 001** AUG 03, 1994
AB	STIEFEL	0.05%	**N75057 001** AUG 12, 1998
AB	TARO	0.05%	**N74248 001** JUL 12, 1996
	EMBELINE		
AB	HEALTHPOINT	0.05%	**N74221 001** MAR 31, 1995
	TEMOVATE		
AB +	GLAXO WELLCOME	0.05%	**N19323 001** DEC 27, 1985

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE		
AT	ALTANA	0.05%	**N75391 001** FEB 08, 1999
AT	MORTON GROVE	0.05%	**N75205 001** NOV 13, 1998
AT	NMC	0.05%	**N74331 001** DEC 15, 1995
AT	TARO	0.05%	**N75224 001** NOV 16, 1998
AT	THAMES	0.05%	**N75363 001** DEC 29, 2000
	EMBELINE		
AT	DPT	0.05%	**N74222 001** DEC 06, 1995
	TEMOVATE		
AT +	GLAXO WELLCOME	0.05%	**N19966 001** FEB 22, 1990

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

	CLODERM		
+	HEALTHPOINT	0.1%	N17765 001

FDA data supplied by DrugPatentWatch.com

CLOFAZIMINE

CAPSULE; ORAL

	LAMPRENE			
	NOVARTIS	50MG	N19500 002	DEC 15, 1986
+		100MG	N19500 001	DEC 15, 1986

CLOFIBRATE

CAPSULE; ORAL

	ATROMID-S			
AB	+ WYETH AYERST	**500MG**	**N16099 002**	
	CLOFIBRATE			
AB	BANNER PHARMACAPS	**500MG**	**N73396 001**	MAR 20, 1992
AB	NOVOPHARM	**500MG**	**N72600 001**	JUL 25, 1991
AB	ROSEMONT	**500MG**	**N70531 001**	JUN 16, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

	CLOMID			
AB	+ AVENTIS PHARMS	**50MG**	**N16131 002**	
	CLOMIPHENE CITRATE			
AB	PAR PHARM	**50MG**	**N75528 001**	AUG 30, 1999
	MILOPHENE			
AB	MILEX	**50MG**	**N72196 001**	DEC 20, 1988
	SEROPHENE			
AB	SERONO	**50MG**	**N18361 001**	MAR 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL			
AB	NOVARTIS	**25MG**	**N19906 001**	DEC 29, 1989
AB	+	**50MG**	**N19906 002**	DEC 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL			
AB	NOVARTIS	**75MG**	**N19906 003**	DEC 29, 1989
	CLOMIPRAMINE HCL			
AB	CHELSEA LABS	**25MG**	**N74751 001**	SEP 30, 1998
AB		**50MG**	**N74751 002**	SEP 30, 1998
AB		**75MG**	**N74751 003**	SEP 30, 1998
AB	GENEVA PHARMS	**25MG**	**N74364 001**	MAR 29, 1996
AB		**50MG**	**N74364 002**	MAR 29, 1996
AB		**75MG**	**N74364 003**	MAR 29, 1996
AB	GENEVA PHARMS TECH	**25MG**	**N74953 001**	JUN 25, 1997
AB		**50MG**	**N74953 002**	JUN 25, 1997
AB		**75MG**	**N74953 003**	JUN 25, 1997
AB	MYLAN	**25MG**	**N74947 001**	APR 30, 1998
AB		**50MG**	**N74947 002**	APR 30, 1998
AB		**75MG**	**N74947 003**	APR 30, 1998
AB	NOVOPHARM	**25MG**	**N74849 001**	APR 04, 1997
AB		**50MG**	**N74849 002**	APR 04, 1997
AB		**75MG**	**N74849 003**	APR 04, 1997
AB	TARO	**25MG**	**N74694 001**	DEC 31, 1996
AB		**50MG**	**N74694 002**	DEC 31, 1996
AB		**75MG**	**N74694 003**	DEC 31, 1996
AB	TEVA	**25MG**	**N74958 001**	AUG 26, 1997
AB		**50MG**	**N74958 002**	AUG 26, 1997
AB		**75MG**	**N74958 003**	AUG 26, 1997

FDA data supplied by DrugPatentWatch.com

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	WATSON LAB	25MG	**N74600 001**	NOV 27, 1996
AB		50MG	**N74600 002**	NOV 27, 1996
AB		75MG	**N74600 003**	NOV 27, 1996

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB	ALPHAPHARM	0.5MG	**N74940 001**	OCT 30, 1997
AB		1MG	**N74940 002**	OCT 30, 1997
AB		2MG	**N74940 003**	OCT 30, 1997
AB	EON	0.5MG	**N74979 001**	AUG 29, 1997
AB		1MG	**N74979 002**	AUG 29, 1997
AB		2MG	**N74979 003**	AUG 29, 1997
AB	GENEVA PHARMS TECH	0.5MG	**N74925 001**	SEP 30, 1997
AB		1MG	**N74925 002**	SEP 30, 1997
AB		2MG	**N74925 003**	SEP 30, 1997
AB	MYLAN	0.5MG	**N75150 001**	OCT 05, 1998
AB		1MG	**N75150 002**	OCT 05, 1998
AB		2MG	**N75150 003**	OCT 05, 1998
AB	NOVOPHARM	0.5MG	**N74920 001**	AUG 04, 1998
AB		1MG	**N74920 002**	AUG 04, 1998
AB		2MG	**N74920 003**	AUG 04, 1998
AB	PUREPAC PHARM	0.5MG	**N74869 001**	OCT 31, 1996

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB	PUREPAC PHARM	1MG	**N74869 002**	OCT 31, 1996
AB		2MG	**N74869 003**	OCT 31, 1996
AB	TEVA	0.5MG	**N74569 001**	SEP 10, 1996
AB		1MG	**N74569 002**	SEP 10, 1996
AB		2MG	**N74569 003**	SEP 10, 1996
AB	TORPHARM	0.5MG	**N75468 001**	OCT 06, 2000
AB		1MG	**N75468 002**	OCT 06, 2000
AB		2MG	**N75468 003**	OCT 06, 2000
AB	WATSON LABS	0.5MG	**N74964 001**	DEC 30, 1997
AB		1MG	**N74964 002**	DEC 30, 1997
AB		2MG	**N74964 003**	DEC 30, 1997

KLONOPIN

AB	ROCHE	0.5MG	**N17533 001**	
AB	+	1MG	**N17533 002**	
AB		2MG	**N17533 003**	
	+	0.125MG	N17533 005	APR 09, 1997
		0.25MG	N17533 006	APR 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG	N20813 001	DEC 23, 1997
		0.25MG	N20813 002	DEC 23, 1997
		0.5MG	N20813 003	DEC 23, 1997
	+	1MG	N20813 004	DEC 23, 1997
		2MG	N20813 005	DEC 23, 1997

FDA data supplied by DrugPatentWatch.com

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1				
+	BOEHRINGER INGELHEIM	0.1MG/24HR	N18891 001	OCT 10, 1984
CATAPRES-TTS-2				
+	BOEHRINGER INGELHEIM	0.2MG/24HR	N18891 002	OCT 10, 1984
CATAPRES-TTS-3				
+	BOEHRINGER INGELHEIM	0.3MG/24HR	N18891 003	OCT 10, 1984

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON				
+	ROXANE	0.1MG/ML	N20615 001	OCT 02, 1996

TABLET; ORAL

CATAPRES				
AB	BOEHRINGER INGELHEIM	0.1MG	N17407 001	
AB		0.2MG	N17407 002	
AB	+	0.3MG	N17407 003	
CLONIDINE HCL				
AB	DANBURY PHARMA	0.1MG	N70965 001	JUL 08, 1986
AB		0.2MG	N70964 001	JUL 08, 1986
AB		0.3MG	N70963 001	JUL 08, 1986
AB	GENEVA PHARMS	0.1MG	N70887 001	AUG 31, 1988
AB		0.2MG	N70886 001	AUG 31, 1988
AB		0.3MG	N71294 001	AUG 31, 1988
AB	HALSEY	0.1MG	N70925 001	SEP 04, 1987
AB	LEDERLE	0.1MG	N71783 001	APR 05, 1988
AB		0.2MG	N71784 001	APR 05, 1988
AB		0.3MG	N71785 001	APR 05, 1988
AB	MYLAN	0.1MG	N70315 001	JUN 09, 1987

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL				
AB	MYLAN	0.2MG	N70316 001	JUN 09, 1987
AB		0.3MG	N70317 001	JUN 09, 1987
AB	PUREPAC PHARM	0.1MG	N70974 001	DEC 16, 1986
AB		0.2MG	N70975 001	DEC 16, 1986
AB		0.3MG	N70976 001	DEC 16, 1986

CLONIDINE HYDROCHLORIDE; *MULTIPLE*

SEE CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

CLOPIDOGREL BISULFATE

TABLET; ORAL

PLAVIX				
+	SANOFI SYNTHELABO	EQ 75MG BASE	N20839 001	NOV 17, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM				
AB	ABLE	3.75MG	N71777 001	JUL 14, 1987
AB		7.5MG	N71778 001	JUL 14, 1987
AB		15MG	N71779 001	JUL 14, 1987
AB	GENEVA PHARMS	3.75MG	N72219 001	AUG 26, 1988
AB		7.5MG	N72220 001	AUG 26, 1988
AB		15MG	N72112 001	AUG 26, 1988
AB	LEDERLE	3.75MG	N71742 001	DEC 14, 1987
AB		7.5MG	N71743 001	DEC 14, 1987

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

AB		LEDERLE	15MG	N71744 001 DEC 14, 1987
AB		MYLAN	3.75MG	N71509 001 OCT 19, 1987
AB			7.5MG	N71510 001 OCT 19, 1987
AB	+		15MG	N71511 001 OCT 19, 1987

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB		ABLE	3.75MG	N71780 001 JUN 26, 1987
AB			7.5MG	N71781 001 JUN 26, 1987
AB			15MG	N71782 001 JUN 26, 1987
AB		GENEVA PHARMS	3.75MG	N72512 001 MAY 11, 1990
AB			7.5MG	N72513 001 MAY 11, 1990
AB			15MG	N72514 001 MAY 11, 1990
AB		MYLAN	3.75MG	N71856 001 JUL 17, 1987
AB			7.5MG	N71857 001 JUL 17, 1987
AB			15MG	N71858 001 JUL 17, 1987
AB		TARO	3.75MG	N75731 003 APR 27, 2000
AB			7.5MG	N75731 002 APR 27, 2000
AB			15MG	N75731 001 APR 27, 2000
AB		WATSON LABS	3.75MG	N71852 001 FEB 09, 1988
AB			7.5MG	N71853 001 FEB 09, 1988
AB			15MG	N71854 001 FEB 09, 1988

GEN-XENE

AB		ALRA	3.75MG	N71787 001 APR 26, 1988

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

GEN-XENE

AB		ALRA	7.5MG	N71788 001 APR 26, 1988
AB			15MG	N71789 001 APR 26, 1988

TRANXENE

AB		ABBOTT	3.75MG	N17105 006
AB			7.5MG	N17105 007
AB	+		15MG	N17105 008

TRANXENE SD

		ABBOTT	11.25MG	N17105 005
	+		22.5MG	N17105 004

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB		TARO	1%	N72640 001 AUG 31, 1993

LOTRIMIN

AB	+	SCHERING PLOUGH	1%	N17619 001

MYCELEX

BT		BAYER	1%	N18183 001

LOTION; TOPICAL

LOTRIMIN

	+	SCHERING	1%	N18813 001 FEB 17, 1984

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT		TARO	1%	N74580 001 JUL 29, 1996
AT		TEVA	1%	N73306 001 FEB 28, 1995

LOTRIMIN

AT	+	SCHERING PLOUGH	1%	N17613 001

MYCELEX

AT	+	BAYER	1%	N18181 001

TROCHE/LOZENGE; ORAL

MYCELEX

	+	BAYER	10MG	N18713 001 JUN 17, 1983

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE; *MULTIPLE*
SEE BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXACILLIN SODIUM			
AB	TEVA	EQ 250MG BASE	N62240 001	
AB		EQ 500MG BASE	N62240 002	
	CLOXAPEN			
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N61806 001	
AB	+	EQ 500MG BASE	N61806 002	

FOR SOLUTION; ORAL

	CLOXACILLIN SODIUM			
	+ TEVA	EQ 125MG BASE/5ML	N62268 001	

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	MYLAN	25MG	N75417 001	MAY 27, 1999
AB		100MG	N75417 002	MAY 27, 1999
AB	ZENITH GOLDLINE	25MG	N74949 001	NOV 26, 1997
AB		100MG	N74949 002	NOV 26, 1997
	CLOZARIL			
AB	+ NOVARTIS	25MG	N19758 001	SEP 26, 1989
AB		100MG	N19758 002	SEP 26, 1989

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

	RUBRATOPE-57 KIT		
	BRACCO	N/A;N/A;N/A;N/A	N16089 001

CODEINE PHOSPHATE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CODEINE PHOSPHATE; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
SEE BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC W/ CODEINE			
AA	+ WYETH AYERST	10MG/5ML;5MG/5ML; 6.25MG/5ML	N08306 005	APR 02, 1984
	PROMETH VC W/ CODEINE			
AA	ALPHARMA	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88764 001	OCT 31, 1984
	PROMETHAZINE VC W/ CODEINE			
AA	MORTON GROVE	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001	JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN W/ CODEINE			
AA	+ WYETH AYERST	10MG/5ML;6.25MG/5ML	N08306 004	APR 02, 1984
	PROMETH W/ CODEINE			
AA	ALPHARMA	10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984
	PROMETHAZINE HCL AND CODEINE PHOSPHATE			
AA	HI TECH PHARMA	10MG/5ML;6.25MG/5ML	N40151 001	AUG 26, 1997
AA	PHARM ASSOC	10MG/5ML;6.25MG/5ML	N89647 001	DEC 22, 1988
	PROMETHAZINE W/ CODEINE			
AA	MORTON GROVE	10MG/5ML;6.25MG/5ML	N88875 001	DEC 17, 1984

FDA data supplied by DrugPatentWatch.com

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

	TRIACIN-C			
AA	ALPHARMA	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88704 001**	MAR 22, 1985
	TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
AA	+ MORTON GROVE	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88833 001**	NOV 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

	COL-PROBENECID			
BP	DANBURY PHARMA	0.5MG;500MG	N84279 001	
	COLBENEMID			
BP	+ MERCK	0.5MG;500MG	N12383 001	
	PROBENECID AND COLCHICINE			
BP	IMPAX LABS	0.5MG;500MG	N83720 002	
BP	ZENITH GOLDLINE	0.5MG;500MG	N83734 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

	WELCHOL			
	+ SANKYO	375MG	N21141 001	MAY 26, 2000

TABLET; ORAL

	WELCHOL			
	+ SANKYO	625MG	N21176 001	MAY 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

	COLESTID			
	PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563 003	SEP 22, 1995
	+	5GM/PACKET	N17563 004	SEP 22, 1995
	FLAVORED COLESTID			
	+ PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001	

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

FLAVORED COLESTID			
PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563 002	

TABLET; ORAL

COLESTID			
PHARMACIA AND UPJOHN	1GM	N20222 001	JUL 19, 1994

COLFOSCERIL PALMITATE; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

	COLISTIMETHATE			
AP	PHARMA TEK	**EQ 150MG BASE/VIAL**	**N64216 001**	FEB 26, 1999
	COLY-MYCIN M			
AP	+ PARKEDALE	**EQ 150MG BASE/VIAL**	**N50108 002**	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S			
+ PARKEDALE	EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001	

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

COPPER T MODEL TCU 380A			
+ POPULATION COUNCIL	309MG/COPPER	N18680 001	NOV 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL			
+ FERRING	EQ 0.1MG BASE/VIAL	N20162 001	MAY 23, 1996

FDA data supplied by DrugPatentWatch.com

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN

BC	ORGANICS LAGRANGE	40 UNITS/ML	N10831 001	
BC		80 UNITS/ML	N10831 002	
	H.P. ACTHAR GEL			
BC +	AVENTIS	40 UNITS/ML	N08372 006	
BC +		80 UNITS/ML	N08372 008	

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTONE

	MERCK	25MG/ML	N07110 002
+		50MG/ML	N07110 003

TABLET; ORAL
CORTISONE ACETATE

BP	CHELSEA LABS	25MG	N85884 001
BP	PHARMACIA AND UPJOHN	25MG	N08126 001
		5MG	N08126 003
		10MG	N08126 004
BP	WEST WARD	25MG	N80776 002
	CORTONE		
BP +	MERCK	25MG	N07750 003

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

+	ORGANON	0.25MG/VIAL	N16750 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

+	AVENTIS	0.8MG/INH	N18887 001
			DEC 05, 1985

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	ALPHARMA	**10MG/ML**	**N75067 001**
			JUL 19, 1999
AN	BAUSCH AND LOMB	**10MG/ML**	**N75585 001**
			DEC 21, 2000

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	DEY	**10MG/ML**	**N74209 001**
			APR 26, 1994
AN	MORTON GROVE	**10MG/ML**	**N75346 001**
			OCT 25, 1999
AN	ROXANE	**10MG/ML**	**N75175 001**
			SEP 30, 1999
AN	STERIPAK	**10MG/ML**	**N75271 001**
			JAN 18, 2000
AN	WARRICK PHARMS	**10MG/ML**	**N75437 001**
			APR 21, 2000
	INTAL		
AN +	AVENTIS	**10MG/ML**	**N18596 001**
			MAY 28, 1982

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

+	MEDEVA	100MG/5ML	N20479 001
			FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC
CROLOM

AT	BAUSCH AND LOMB	**4%**	**N74443 001**
			JAN 30, 1995
	CROMOLYN SODIUM		
AT	AKORN	**4%**	**N74706 001**
			APR 29, 1998
AT	ALCON	**4%**	**N75282 001**
			JUN 16, 1999
	CROMOPTIC		
AT	KING PHARMS	**4%**	**N75088 001**
			APR 27, 1999
	OPTICROM		
AT +	ALLERGAN	**4%**	**N18155 001**
			OCT 03, 1984

CROTAMITON

CREAM; TOPICAL
EURAX

+	WESTWOOD SQUIBB	10%	N06927 001

LOTION; TOPICAL
CROTAN

AT	SUMMERS	**10%**	**N87204 001**

FDA data supplied by DrugPatentWatch.com

CROTAMITON

LOTION; TOPICAL
EURAX
AT + WESTWOOD SQUIBB **10%** **N09112 003**

CUPRIC CHLORIDE

INJECTABLE; INJECTION
CUPRIC CHLORIDE IN PLASTIC CONTAINER
+ ABBOTT EQ 0.4MG COPPER/ML N18960 001
JUN 26, 1986

CYANOCOBALAMIN

GEL, METERED; NASAL
NASCOBAL
+ NASTECH 0.5MG/INH N19722 001
NOV 05, 1996

INJECTABLE; INJECTION
CYANOCOBALAMIN
AP AM PHARM PARTNERS **0.1MG/ML** **N80557 002**
AP ELKINS SINN **1MG/ML** **N80515 002**
AP LUITPOLD **1MG/ML** **N80737 001**
AP STERIS **0.1MG/ML** **N80573 002**
AP **1MG/ML** **N80573 001**
AP **1MG/ML** **N83120 002**
AP WYETH AYERST **0.1MG/ML** **N80554 001**
AP **1MG/ML** **N80554 002**
RUBRAMIN PC
AP + BRISTOL MYERS SQUIBB **1MG/ML** **N06799 004**
VIBISONE
AP AM PHARM PARTNERS **1MG/ML** **N80557 003**

TABLET; ORAL
CYANOCOBALAMIN
+ WEST WARD 1MG N84264 001

CYANOCOBALAMIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

CYANOCOBALAMIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT
NYCOMED AMERSHAM N/A;N/A;N/A N17406 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT
MALLINCKRODT 0.1MG;0.5 uCi;60MG N16635 001

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
RUBRATOPE-57
BRACCO 0.5-1 uCi N16089 002

CYANOCOBALAMIN, CO-57; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN, CO-58; *MULTIPLE*
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

FDA data supplied by DrugPatentWatch.com

CYCLACILLIN

TABLET; ORAL

	CYCLACILLIN			
	TEVA	250MG	N62895 001	AUG 04, 1988
+		500MG	N62895 002	AUG 04, 1988

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	DANBURY PHARMA	**10MG**	**N71611 001**	MAY 03, 1989
AB	GENEVA PHARMS	**10MG**	**N72854 001**	NOV 19, 1991
AB	GENEVA PHARMS TECH	**10MG**	**N73683 001**	FEB 26, 1993
AB	HALSEY	**10MG**	**N73541 001**	MAY 23, 1995
AB	MYLAN	**10MG**	**N73144 001**	MAY 30, 1991
AB	SIDMAK LABS NJ	**10MG**	**N74421 001**	SEP 29, 1995
AB	WATSON LABS	**10MG**	**N73143 001**	NOV 27, 1991
AB		**10MG**	**N74436 001**	NOV 30, 1994
	FLEXERIL			
AB	+ MERCK	**10MG**	**N17821 002**	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPENTOLATE			
AT	AKORN	**1%**	**N40164 001**	JAN 13, 1997
AT		**2%**	**N40165 001**	JAN 13, 1997
	CYCLOGYL			
AT	+ ALCON	**0.5%**	**N84109 001**	
AT	+	**1%**	**N84110 001**	
AT	+	**2%**	**N84108 001**	
	CYCLOPENTOLATE HCL			
AT	ALCON UNIVERSAL	**1%**	**N89162 001**	JAN 24, 1991

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	PENTOLAIR			
AT	BAUSCH AND LOMB	**1%**	**N40075 001**	APR 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CYCLOMYDRIL			
+	ALCON	0.2%;1%	N84300 001	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ASTA	**1GM/VIAL**	**N88374 001**	SEP 24, 1986
AP		**100MG/VIAL**	**N88371 001**	JUL 03, 1986
AP		**200MG/VIAL**	**N88372 001**	JUL 03, 1986
AP		**500MG/VIAL**	**N88373 001**	JUL 03, 1986
	LYOPHILIZED CYTOXAN			
AP	+ BRISTOL MYERS SQUIBB	**100MG/VIAL**	**N12142 006**	DEC 05, 1985
AP	+	**200MG/VIAL**	**N12142 007**	DEC 10, 1985
AP	+	**500MG/VIAL**	**N12142 008**	JAN 04, 1984
AP	+	**1GM/VIAL**	**N12142 010**	SEP 24, 1985
AP	+	**2GM/VIAL**	**N12142 009**	DEC 10, 1984
	NEOSAR			
AP	PHARMACIA AND UPJOHN	**100MG/VIAL**	**N40015 001**	APR 29, 1993
AP		**100MG/VIAL**	**N87442 001**	FEB 16, 1982
AP		**200MG/VIAL**	**N40015 002**	APR 29, 1993
AP		**200MG/VIAL**	**N87442 002**	FEB 16, 1982
AP		**500MG/VIAL**	**N40015 003**	APR 29, 1993

FDA data supplied by DrugPatentWatch.com

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	NEOSAR			
AP	PHARMACIA AND UPJOHN	500MG/VIAL	**N87442 003**	FEB 16, 1982
AP		1GM/VIAL	**N40015 004**	APR 29, 1993
AP		1GM/VIAL	**N87442 004**	JUL 08, 1983
AP		2GM/VIAL	**N40015 005**	APR 29, 1993
AP		2GM/VIAL	**N87442 005**	MAR 30, 1989

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	25MG	**N40032 001**	AUG 17, 1999
AB		50MG	**N40032 002**	AUG 17, 1999
	CYTOXAN			
AB	BRISTOL MYERS SQUIBB	25MG	**N12141 002**	
AB	+	50MG	**N12141 001**	

CYCLOSERINE

CAPSULE; ORAL

	SEROMYCIN			
	+ LILLY	250MG	N60593 001	

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB	ABBOTT	25MG	**N65003 001**	MAY 12, 2000
AB		100MG	**N65003 003**	MAY 12, 2000
		50MG	N65003 002	MAY 12, 2000
AB	EON	25MG	**N65017 002**	JAN 13, 2000
AB		100MG	**N65017 001**	JAN 13, 2000
AB	SIDMAK LABS	25MG	**N65044 002**	DEC 20, 2000

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB	SIDMAK LABS	100MG	**N65044 001**	DEC 20, 2000
	NEORAL			
AB	NOVARTIS	25MG	**N50715 001**	JUL 14, 1995
AB	+	100MG	**N50715 002**	JUL 14, 1995
	SANDIMMUNE			
BX	NOVARTIS	25MG	N50625 001	MAR 02, 1990
BX		50MG	N50625 003	NOV 23, 1992
BX	+	100MG	N50625 002	MAR 02, 1990

INJECTABLE; INJECTION

	CYCLOSPORINE			
AP	BEDFORD	50MG/ML	**N65004 001**	OCT 29, 1999
	SANDIMMUNE			
AP	+ NOVARTIS	50MG/ML	**N50573 001**	NOV 14, 1983

SOLUTION; ORAL

	NEORAL			
	+ NOVARTIS	100MG/ML	N50716 001	JUL 14, 1995
	SANDIMMUNE			
BX	+ NOVARTIS	100MG/ML	N50574 001	NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

	CYPROHEPTADINE HCL		
AA	ALPHARMA	2MG/5ML	**N86833 001**
	PERIACTIN		
AA	+ MERCK	2MG/5ML	**N13220 002**

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	CAMALL	4MG	**N88212 001**	MAY 26, 1983
AA	GENEVA PHARMS	4MG	**N86808 001**	

FDA data supplied by DrugPatentWatch.com

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	PAR PHARM	4MG	N87129 001	
AA	SIDMAK LABS NJ	4MG	N88205 001	
			JUL 26, 1983	
AA	ZENITH GOLDLINE	4MG	N87056 001	
	PERIACTIN			
AA	+ MERCK	4MG	N12649 001	

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

	CYSTAGON			
	MYLAN	EQ 50MG BASE	N20392 001	
			AUG 15, 1994	
	+	EQ 150MG BASE	N20392 002	
			AUG 15, 1994	

CYTARABINE

INJECTABLE; INJECTION

	CYTARABINE			
AP	BEDFORD	1GM/VIAL	N74245 001	
			AUG 31, 1994	
AP		2GM/VIAL	N74245 002	
			AUG 31, 1994	
AP		100MG/VIAL	N71471 001	
			AUG 02, 1989	
AP		500MG/VIAL	N71472 001	
			AUG 02, 1989	
AP	FAULDING	2GM/VIAL	N75383 001	
			NOV 22, 1999	
	+	20MG/ML	N71868 001	
			JUN 04, 1990	
	+	20MG/ML	N72168 001	
			AUG 31, 1990	
	+	20MG/ML	N72945 001	
			FEB 28, 1994	
AP	GENSIA SICOR PHARMS	100MG/VIAL	N75206 001	
			DEC 30, 1998	
AP		500MG/VIAL	N75206 002	
			DEC 30, 1998	
AP		1GM/VIAL	N75206 004	
			DEC 30, 1998	

CYTARABINE

INJECTABLE; INJECTION

	CYTARABINE			
AP	GENSIA SICOR PHARMS	2GM/VIAL	N75206 003	
			DEC 30, 1998	
	CYTOSAR-U			
AP	+ PHARMACIA AND UPJOHN	100MG/VIAL	N16793 001	
AP	+	500MG/VIAL	N16793 002	
AP	+	1GM/VIAL	N16793 003	
			DEC 21, 1987	
AP	+	2GM/VIAL	N16793 004	
			DEC 21, 1987	

INJECTABLE, LIPOSOMAL; INJECTION

	DEPOCYT			
	+ SKYEPHARMA	10MG/ML	N21041 001	
			APR 01, 1999	

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	
			AUG 27, 1999	
AP		200MG/VIAL	N75371 002	
			AUG 27, 1999	
AP	GENSIA SICOR PHARMS	200MG/VIAL	N75259 002	
			AUG 27, 1998	
AP		500MG/VIAL	N75259 001	
			SEP 22, 2000	
	DTIC-DOME			
AP	+ BAYER	100MG/VIAL	N17575 001	
AP	+	200MG/VIAL	N17575 002	

DACTINOMYCIN

INJECTABLE; INJECTION

	COSMEGEN			
	+ MERCK	0.5MG/VIAL	N50682 001	

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

	SYNERCID			
	AVENTIS	350MG/VIAL;150MG/VIAL	N50748 001	
			SEP 21, 1999	

FDA data supplied by DrugPatentWatch.com

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)
SYNERCID
+ AVENTIS — 420MG/VIAL;180MG/VIAL — N50748 002 AUG 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
+ PHARMACIA AND UPJOHN — 10,000 IU/ML — N20287 004 JAN 30, 1998
+ — 2,500 IU/0.2ML — N20287 001 DEC 22, 1994
+ — 5,000 IU/0.2ML — N20287 003 MAR 18, 1996

DANAPAROID SODIUM

INJECTABLE; INJECTION
ORGARAN
+ ORGANON — 750 UNITS/0.6ML — N20430 001 DEC 24, 1996

DANAZOL

CAPSULE; ORAL
DANAZOL
AB BARR — **50MG** — **N74582 003** MAY 29, 1998
AB — **100MG** — **N74582 002** MAY 29, 1998
AB — **200MG** — **N74582 001** AUG 09, 1996

DANOCRINE
AB SANOFI SYNTHELABO — **50MG** — **N17557 003**
AB — **100MG** — **N17557 004**
AB + — **200MG** — **N17557 002**

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM
PROCTER AND GAMBLE — 25MG — N17443 001

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM
PROCTER AND GAMBLE — 50MG — N17443 003
+ — 100MG — N17443 002

INJECTABLE; INJECTION
DANTRIUM
+ PROCTER AND GAMBLE — 20MG/VIAL — N18264 001

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
REV-EYES
+ ANGELINI — 0.5% — N19849 001 DEC 31, 1990

DAPSONE

TABLET; ORAL
DAPSONE
JACOBUS — 25MG — N86841 001
+ — 100MG — N86842 001

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ GILEAD — EQ 2MG BASE/ML — N50704 002 APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
AP + BEDFORD — **EQ 20MG BASE/VIAL** — **N64103 001** FEB 03, 1995

DAUNORUBICIN HCL
AP + BEDFORD — **EQ 5MG BASE/ML** — **N50731 001** JAN 30, 1998
AP BIGMAR — **EQ 20MG BASE/VIAL** — **N65000 001** MAY 25, 1999
AP GENSIA SICOR PHARMS — **EQ 5MG BASE/ML** — **N65035 001** JAN 24, 2000

FDA data supplied by DrugPatentWatch.com

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		DAUNORUBICIN HCL		
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001	JUN 23, 1998
+		EQ 50MG BASE/VIAL	N64212 002	MAY 03, 1999

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

	DESFERAL		
+	NOVARTIS	500MG/VIAL	N16267 001

DELAVIRDINE MESYLATE

TABLET; ORAL

	RESCRIPTOR			
+	AGOURON	100MG	N20705 001	APR 04, 1997

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

	HUMORSOL		
+	MERCK	0.125%	N11860 002
+		0.25%	N11860 001

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

	DECLOMYCIN		
	LEDERLE	75MG	N50261 001
		150MG	N50261 002
+		300MG	N50261 003

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	ORETICYL 25		
	ABBOTT	0.125MG;25MG	N12148 001
	ORETICYL 50		
+	ABBOTT	0.125MG;50MG	N12148 003

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	ORETICYL FORTE		
	ABBOTT	0.25MG;25MG	N12148 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

	ENDURONYL		
	ABBOTT	0.25MG;5MG	N12775 001
	ENDURONYL FORTE		
+	ABBOTT	0.5MG;5MG	N12775 002

DESFLURANE

LIQUID; INHALATION

	SUPRANE		
	OHMEDA	99.9%	N20118 001 SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

		DESIPRAMINE HCL		
AB	EON	10MG	N74430 001	FEB 09, 1996
AB		25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
AB		150MG	N74430 002	FEB 09, 1996
AB	GENEVA PHARMS	10MG	N72099 001	MAY 24, 1988
AB		25MG	N72100 001	MAY 24, 1988
AB		50MG	N72101 001	MAY 24, 1988
AB		75MG	N72102 001	JUN 20, 1988

FDA data supplied by DrugPatentWatch.com

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
AB	GENEVA PHARMS	**100MG**	**N72103 001**	
			JUN 20, 1988	
AB		**150MG**	**N72104 001**	
			JUN 20, 1988	
AB	SIDMAK LABS NJ	**25MG**	**N71800 001**	
			DEC 08, 1987	
AB		**50MG**	**N71801 001**	
			DEC 08, 1987	
AB		**75MG**	**N71802 001**	
			DEC 08, 1987	
AB		**100MG**	**N71803 001**	
			MAY 29, 1997	
AB		**150MG**	**N71804 001**	
			MAY 29, 1997	
	NORPRAMIN			
AB	AVENTIS	**10MG**	**N14399 007**	
			FEB 11, 1982	
AB		**25MG**	**N14399 001**	
AB	+	**50MG**	**N14399 003**	
AB		**75MG**	**N14399 004**	
AB	+	**100MG**	**N14399 005**	
AB		**150MG**	**N14399 006**	

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

	DDAVP			
AP	+ AVENTIS	**0.004MG/ML**	**N18938 001**	
			MAR 30, 1984	
	+	0.015MG/ML	N18938 002	
			APR 25, 1995	
	DESMOPRESSIN ACETATE			
AP	ABBOTT	**0.004MG/ML**	**N75220 001**	
			AUG 28, 2000	
AP	BEDFORD	**0.004MG/ML**	**N74575 001**	
			FEB 18, 2000	
AP	GENSIA SICOR PHARMS	**0.004MG/ML**	**N74888 001**	
			OCT 15, 1997	
	DESMOPRESSIN ACETATE PRESERVATIVE FREE			
AP	BEDFORD	**0.004MG/ML**	**N74574 001**	
			FEB 18, 2000	

SOLUTION; NASAL

	CONCENTRAID			
BX	FERRING	0.01%	N19776 001	
			DEC 26, 1990	

DESMOPRESSIN ACETATE

SOLUTION; NASAL

	DDAVP			
BX	+ AVENTIS	0.01%	N17922 001	

SPRAY, METERED; NASAL

	DDAVP			
AB	+ AVENTIS	**0.01MG/SPRAY**	**N17922 002**	
			FEB 06, 1989	
	DDAVP (NEEDS NO REFRIGERATION)			
AB	+ AVENTIS	**0.01MG/SPRAY**	**N17922 003**	
			AUG 07, 1996	
	DESMOPRESSIN ACETATE			
AB	BAUSCH AND LOMB	**0.01MG/SPRAY**	**N74830 001**	
			JAN 25, 1999	
	STIMATE			
	+ AVENTIS BEHRING	0.15MG/SPRAY	N20355 001	
			MAR 07, 1994	

TABLET; ORAL

DDAVP			
AVENTIS	0.1MG	N19955 001	
		SEP 06, 1995	
+	0.2MG	N19955 002	
		SEP 06, 1995	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

	DESOGESTREL AND ETHINYL ESTRADIOL			
AB	DURAMED	**0.15MG;0.03MG**	**N75256 001**	
			AUG 12, 1999	
	ORTHO-CEPT			
AB	+ JOHNSON RW	**0.15MG;0.03MG**	**N20301 001**	
			DEC 14, 1992	

TABLET; ORAL-28

CYCLESSA			
+ ORGANON INC	0.1MG,0.125MG,0.15MG;0.025MG, 0.025MG,0.025MG	N21090 001	
		DEC 20, 2000	
DESOGEN			
AB ORGANON	**0.15MG;0.03MG**	**N20071 002**	
		DEC 10, 1992	
DESOGESTREL AND ETHINYL ESTRADIOL			
AB DURAMED	**0.15MG;0.03MG**	**N75256 002**	
		AUG 12, 1999	

FDA data supplied by DrugPatentWatch.com

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

	MIRCETTE			
	+ ORGANON	0.15MG,N/A;0.02MG,0.01MG	N20713 001	
			APR 22, 1998	
	ORTHO-CEPT			
AB	JOHNSON RW	**0.15MG;0.03MG**	**N20301 002**	
			DEC 14, 1992	

DESONIDE

CREAM; TOPICAL

	DESONIDE			
AB	COPLEY PHARM	**0.05%**	**N74027 001**	
			SEP 28, 1992	
AB	TARO	**0.05%**	**N73548 001**	
			JUN 30, 1992	
	DESOWEN			
AB	GALDERMA LABS LP	**0.05%**	**N19048 001**	
			DEC 14, 1984	
	TRIDESILON			
AB	+ CLAY PARK	**0.05%**	**N17010 001**	

LOTION; TOPICAL

	DESOWEN			
	+ GALDERMA LABS LP	0.05%	N72354 001	
			JAN 24, 1992	

OINTMENT; TOPICAL

	DESONIDE			
AB	TARO	**0.05%**	**N74254 001**	
			AUG 03, 1994	
	DESOWEN			
AB	GALDERMA LABS LP	**0.05%**	**N71425 001**	
			JUN 15, 1988	
	TRIDESILON			
AB	+ CLAY PARK	**0.05%**	**N17426 001**	

DESOXIMETASONE

CREAM; TOPICAL

	DESOXIMETASONE			
AB	TARO	**0.05%**	**N73210 001**	
			NOV 30, 1990	
AB		**0.25%**	**N73193 001**	
			NOV 30, 1990	

DESOXIMETASONE

CREAM; TOPICAL

	TOPICORT			
AB	+ AVENTIS PHARMS	**0.25%**	**N17856 001**	
	TOPICORT LP			
AB	+ AVENTIS PHARMS	**0.05%**	**N18309 001**	

GEL; TOPICAL

	DESOXIMETASONE			
AB	TARO	**0.05%**	**N74904 001**	
			JUL 14, 1998	
	TOPICORT			
AB	+ AVENTIS PHARMS	**0.05%**	**N18586 001**	
			MAR 29, 1982	

OINTMENT; TOPICAL

	DESOXIMETASONE			
AB	ALTANA	**0.25%**	**N73440 001**	
			APR 01, 1998	
AB	TARO	**0.25%**	**N74286 001**	
			JUN 07, 1996	
	TOPICORT			
AB	+ AVENTIS PHARMS	**0.25%**	**N18763 001**	
			SEP 30, 1983	

DESOXYRIBONUCLEASE; *MULTIPLE*

SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

DEXAMETHASONE

CONCENTRATE; ORAL

	DEXAMETHASONE INTENSOL		
	+ ROXANE	1MG/ML	N88252 001
			SEP 01, 1983

DISC; TOPICAL

	DECASPRAY		
	+ MERCK	0.04%	N12731 002

ELIXIR; ORAL

	DECADRON		
AA	+ MERCK	**0.5MG/5ML**	**N12376 002**
	DEXAMETHASONE		
AA	ALPHARMA	**0.5MG/5ML**	**N84754 001**
	HEXADROL		
AA	ORGANON	**0.5MG/5ML**	**N12674 001**

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

ELIXIR; ORAL

	MYMETHASONE			
AA	MORTON GROVE	**0.5MG/5ML**	**N88254 001**	JUL 27, 1983

SOLUTION; ORAL

	DEXAMETHASONE			
+	ROXANE	0.5MG/5ML	N88248 001	SEP 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

	MAXIDEX			
+	ALCON	0.1%	N13422 001	

TABLET; ORAL

	DECADRON			
AB	MERCK	**0.5MG**	**N11664 001**	
AB	+	**0.75MG**	**N11664 002**	
AB		**1.5MG**	**N11664 003**	
AB		**4MG**	**N11664 005**	
BP		0.25MG	N11664 004	
BP	+	6MG	N11664 006	JUL 30, 1982
	DEXAMETHASONE			
BP	DANBURY PHARMA	0.25MG	N85455 001	
BP		0.5MG	N85458 001	
BP		0.75MG	N80968 001	
BP		1.5MG	N85456 001	
BP	PAR PHARM	0.25MG	N88149 001	APR 28, 1983
BP		0.5MG	N88148 001	APR 28, 1983
BP		0.75MG	N88160 001	APR 28, 1983
BP		1.5MG	N88237 001	APR 28, 1983
BP		4MG	N88238 001	APR 28, 1983
BP		6MG	N88481 001	NOV 28, 1983
AB	ROXANE	**0.5MG**	**N84611 001**	
AB		**0.75MG**	**N84613 001**	
AB		**1.5MG**	**N84610 001**	
AB		**4MG**	**N84612 001**	
BP		6MG	N88316 001	SEP 15, 1983

DEXAMETHASONE

TABLET; ORAL

	DEXAMETHASONE			
	ROXANE	1MG	N88306 001	SEP 15, 1983
		2MG	N87916 001	AUG 26, 1982
	HEXADROL			
BP	ORGANON	4MG	N12675 010	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	DEXACIDIN			
AT	CIBA	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N62566 001**	FEB 22, 1985
	MAXITROL			
AT	+ FALCON PHARMS	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50065 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE			
AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64063 001**	JUL 25, 1994
AT	FOUGERA	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N62938 001**	JUL 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

	DEXACIDIN			
AT	CIBA	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62544 001**	OCT 29, 1984
	DEXASPORIN			
AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64135 001**	SEP 13, 1995
	MAXITROL			
AT	ALCON	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62341 001**	MAY 22, 1984
AT	+ FALCON PHARMS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50023 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE			
AT	ALCON UNIVERSAL	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62721 001**	NOV 17, 1986

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

	TOBRADEX			
	+ ALCON	0.1%;0.3%	N50616 001	
			SEP 28, 1988	

SUSPENSION/DROPS; OPHTHALMIC

	TOBRADEX			
AB	+ ALCON	**0.1%;0.3%**	**N50592 001**	
			AUG 18, 1988	
	TOBRAMYCIN AND DEXAMETHASONE			
AB	BAUSCH AND LOMB	**0.1%;0.3%**	**N64134 001**	
			OCT 27, 1999	

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

	DECADRON-LA			
BP	+ MERCK	EQ 8MG BASE/ML	N16675 001	
	DEXAMETHASONE ACETATE			
BP	STERIS	EQ 8MG BASE/ML	N84315 001	
	+	EQ 16MG BASE/ML	N87711 001	
			MAY 24, 1982	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DECADRON			
AP	+ MERCK	**EQ 4MG PHOSPHATE/ML**	**N12071 002**	
	+	EQ 24MG PHOSPHATE/ML	N12071 004	
	DEXAMETHASONE			
AP	AM PHARM PARTNERS	**EQ 10MG PHOSPHATE/ML**	**N88469 001**	
			JAN 25, 1984	
AP	ELKINS SINN	**EQ 4MG PHOSPHATE/ML**	**N84282 001**	
AP		**EQ 10MG PHOSPHATE/ML**	**N87702 001**	
			SEP 07, 1982	
	DEXAMETHASONE SODIUM PHOSPHATE			
AP	AM PHARM PARTNERS	**EQ 4MG PHOSPHATE/ML**	**N84916 001**	
AP	DELL LABS	**EQ 4MG PHOSPHATE/ML**	**N83161 001**	
AP	GENSIA SICOR PHARMS	**EQ 4MG PHOSPHATE/ML**	**N81125 001**	
			AUG 31, 1990	
AP		**EQ 10MG PHOSPHATE/ML**	**N81126 001**	
			AUG 31, 1990	
AP	LUITPOLD	**EQ 4MG PHOSPHATE/ML**	**N87440 001**	
			JUL 21, 1982	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DEXAMETHASONE SODIUM PHOSPHATE			
AP	STERIS	**EQ 4MG PHOSPHATE/ML**	**N89169 001**	
			APR 09, 1986	
AP		**EQ 10MG PHOSPHATE/ML**	**N87668 001**	
			JUL 01, 1982	
	HEXADROL			
AP	+ ORGANON	**EQ 4MG PHOSPHATE/ML**	**N14694 002**	
AP	+	**EQ 10MG PHOSPHATE/ML**	**N14694 003**	

OINTMENT; OPHTHALMIC

	DECADRON			
AT	+ MERCK	**EQ 0.05% PHOSPHATE**	**N11977 001**	
	MAXIDEX			
AT	ALCON	**EQ 0.05% PHOSPHATE**	**N83342 001**	

SOLUTION/DROPS; OPHTHALMIC, OTIC

	DECADRON			
AT	+ MERCK	**EQ 0.1% PHOSPHATE**	**N11984 001**	
	DEXAMETHASONE SODIUM PHOSPHATE			
AT	ALCON UNIVERSAL	**EQ 0.1% PHOSPHATE**	**N88771 001**	
			JAN 16, 1985	
AT	BAUSCH AND LOMB	**EQ 0.1% PHOSPHATE**	**N40069 001**	
			JUL 26, 1996	

SOLUTION/DROPS; OTIC

	DEXAMETHASONE SODIUM PHOSPHATE			
AT	AKORN	**EQ 0.1% PHOSPHATE**	**N84855 001**	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DECADRON W/ XYLOCAINE			
	+ MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N13334 002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEODECADRON			
AT	+ MERCK	**EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML**	**N50322 001**	
	NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE			
AT	ALCON UNIVERSAL	**EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML**	**N62714 001**	
			JUL 21, 1986	

FDA data supplied by DrugPatentWatch.com

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

	MYLARAMINE			
AA	MORTON GROVE	2MG/5ML	N88251 001	MAR 23, 1984
	POLARAMINE			
AA	SCHERING	2MG/5ML	N86837 001	JUL 19, 1982

TABLET; ORAL

	DEXCHLORPHENIRAMINE MALEATE			
AA	SIDMAK LABS NJ	2MG	N88682 001	JAN 17, 1986
	POLARAMINE			
AA	+ SCHERING	2MG	N86835 001	

DEXMEDETOMIDINE

INJECTABLE; INJECTION

	PRECEDEX			
	+ ABBOTT	EQ 100 UGM BASE/ML	N21038 001	DEC 17, 1999

DEXPANTHENOL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

	ZINECARD			
	+ PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212 001	MAY 26, 1995
	+	EQ 500MG BASE/VIAL	N20212 002	MAY 26, 1995

DEXTROAMPHETAMINE SACCHARATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	DEXEDRINE			
	+ SMITHKLINE BEECHAM	5MG	N17078 001	
	+	10MG	N17078 002	
	+	15MG	N17078 003	

TABLET; ORAL

	DEXEDRINE			
AA	SMITHKLINE BEECHAM	**5MG**	**N84935 001**	
	DEXTROAMPHETAMINE SULFATE			
AA	ENDO PHARMS	**5MG**	**N40299 001**	MAY 13, 1999
	DEXTROSTAT			
AA	+ SHIRE RICHWOOD	**5MG**	**N84051 001**	
	+	10MG	N84051 002	

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; *MULTIPLE*

SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN W/ DEXTROMETHORPHAN			
AA	+ WYETH AYERST	**15MG/5ML;6.25MG/5ML**	**N11265 002**	APR 02, 1984
	PROMETH W/ DEXTROMETHORPHAN			
AA	ALPHARMA	**15MG/5ML;6.25MG/5ML**	**N88762 001**	OCT 31, 1984
	PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE			
AA	HI TECH PHARMA	**15MG/5ML;6.25MG/5ML**	**N40027 001**	JUL 31, 1996
	PROMETHAZINE W/ DEXTROMETHORPHAN			
AA	MORTON GROVE	**15MG/5ML;6.25MG/5ML**	**N88864 001**	JAN 04, 1985

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 10% IN PLASTIC CONTAINER			
AP	ABBOTT	10GM/100ML	N18080 001	
AP	B BRAUN	10GM/100ML	N18046 001	
AP		10GM/100ML	N19626 004	FEB 02, 1988
AP	BAXTER HLTHCARE	10GM/100ML	N16694 001	
	DEXTROSE 2.5% IN PLASTIC CONTAINER			
	B BRAUN	2.5GM/100ML	N18358 001	
	DEXTROSE 20% IN PLASTIC CONTAINER			
AP	ABBOTT	20GM/100ML	N18564 001	MAR 23, 1982
AP	BAXTER HLTHCARE	20GM/100ML	N17521 004	
	DEXTROSE 25%			
	ABBOTT	250MG/ML	N19445 002	NOV 23, 1998
	DEXTROSE 30% IN PLASTIC CONTAINER			
AP	ABBOTT	30GM/100ML	N19345 001	JAN 26, 1985
AP	BAXTER HLTHCARE	30GM/100ML	N17521 003	
	DEXTROSE 40% IN PLASTIC CONTAINER			
AP	ABBOTT	40GM/100ML	N18562 001	MAR 23, 1982
AP	BAXTER HLTHCARE	40GM/100ML	N17521 002	
	DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	5GM/100ML	N19466 001	JUL 15, 1985
AP		5GM/100ML	N19479 001	SEP 17, 1985
AP		50MG/ML	N16367 002	
AP		50MG/ML	N19222 001	JUL 13, 1984
AP	B BRAUN	5GM/100ML	N16730 001	
AP		50MG/ML	N16730 002	
AP		5GM/100ML	N19626 002	FEB 02, 1988
AP	BAXTER HLTHCARE	5GM/100ML	N16673 001	
AP		50MG/ML	N16673 003	OCT 30, 1985
AP		5GM/100ML	N20179 001	DEC 07, 1992
AP		50MG/ML	N20179 002	DEC 07, 1992
AP	DHL	5GM/100ML	N19971 001	SEP 28, 1995
	DEXTROSE 50% IN PLASTIC CONTAINER			
AP	ABBOTT	50GM/100ML	N18563 001	MAR 23, 1982

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 50% IN PLASTIC CONTAINER			
AP	ABBOTT	50GM/100ML	N19894 001	DEC 26, 1989
AP	BAXTER HLTHCARE	50GM/100ML	N17521 001	
AP		50GM/100ML	N20047 001	JUL 02, 1991
	DEXTROSE 60% IN PLASTIC CONTAINER			
AP	ABBOTT	60GM/100ML	N19346 001	JAN 25, 1985
AP	BAXTER HLTHCARE	60GM/100ML	N17521 005	MAR 26, 1982
	DEXTROSE 70% IN PLASTIC CONTAINER			
AP	ABBOTT	70GM/100ML	N18561 001	MAR 23, 1982
AP		70GM/100ML	N19893 001	DEC 26, 1989
AP	BAXTER HLTHCARE	70GM/100ML	N17521 006	MAR 26, 1982
AP		70GM/100ML	N20047 003	JUL 02, 1991

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

DEXTROSE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML N17610 001

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;32MG/100ML;128MG/100ML; 234MG/100ML N17385 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19873 001 JUN 10, 1993
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19025 001 DEC 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC

INJECTABLE; INJECTION
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML; 16MG/100ML N19515 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML; 20MG/100ML;12MG/100ML; 260MG/100ML N17484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC

INJECTABLE; INJECTION
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML; 25MG/100ML N19513 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N18273 001

FDA data supplied by DrugPatentWatch.com

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001 AUG 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;30MG/100ML;37MG/100ML; 222MG/100ML;526MG/100ML; 502MG/100ML	N17609 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100ML; 502MG/100ML	N17451 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;75MG/100ML	N17634 004

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;150MG/100ML	N17634 001

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;224MG/100ML	N17634 003

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BRISTOL MYERS SQUIBB	5GM/100ML;300MG/100ML	N17634 002

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N18744 001 NOV 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML	N18744 002 NOV 09, 1982
AP		5GM/100ML;150MG/100ML	N19699 004 SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML	N18744 003 NOV 09, 1982

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML	N18744 004 NOV 09, 1982
AP		5GM/100ML;300MG/100ML	N19699 006 SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML	N18371 001

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML	N18371 003

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML	N18371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;111MG/100ML;256MG/100ML; 146MG/100ML;207MG/100ML	N19514 001 MAY 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N18270 001

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML; 120MG/100ML;220MG/100ML N18840 001 JUN 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 200MG/100ML N18037 006 APR 13, 1982

AP 5GM/100ML;150MG/100ML; 200MG/100ML N18037 007 APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 200MG/100ML N18037 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 200MG/100ML N18037 008 APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 200MG/100ML N18037 001

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 200MG/100ML N18037 005 APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 200MG/100ML N18037 009 APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 200MG/100ML N18037 002

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 200MG/100ML N18037 003

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML N18629 005 MAR 23, 1982

AP 5GM/100ML;150MG/100ML; 330MG/100ML N18629 002 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML N18629 003 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 330MG/100ML N18629 004 MAR 23, 1982

AP 5GM/100ML;300MG/100ML; 330MG/100ML N18629 006 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML N18629 007 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 330MG/100ML N18629 008 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML N18629 001 MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 450MG/100ML N18008 010

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;200MG/100ML N19630 031 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;450MG/100ML N19630 037 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N19630 043 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N19630 001 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N19630 007 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N19630 013 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N19630 019 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N19630 025 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N19630 032 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N19630 038 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N19630 044 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N19630 049 MAY 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;200MG/100ML** **N19630 008** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;330MG/100ML** **N19630 014** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;450MG/100ML** **N19630 020** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;900MG/100ML** **N19630 026** FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N19630 033 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 450MG/100ML N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 900MG/100ML N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML; 300MG/100ML N19630 050 MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 110MG/100ML N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 200MG/100ML N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 330MG/100ML N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 450MG/100ML N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 900MG/100ML N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 200MG/100ML N19630 034 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 450MG/100ML N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 900MG/100ML N19630 046 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML; 300MG/100ML N19630 051 MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML; 110MG/100ML N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 200MG/100ML** **N19630 010** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 330MG/100ML** **N19630 016** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 450MG/100ML** **N19630 022** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 900MG/100ML** **N19630 028** FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 200MG/100ML N19630 035 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 450MG/100ML N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 900MG/100ML N19630 047 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML; 300MG/100ML N19630 052 MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 110MG/100ML N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 200MG/100ML N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 330MG/100ML N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 450MG/100ML N19630 023 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 900MG/100ML N19630 029 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML; 200MG/100ML N19630 036 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML; 450MG/100ML N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML; 900MG/100ML N19630 048 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML; 300MG/100ML N19630 053 MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML; 110MG/100ML N19630 006 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;300MG/100ML; 200MG/100ML** **N19630 012** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;300MG/100ML; 330MG/100ML** **N19630 018** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;300MG/100ML; 450MG/100ML** **N19630 024** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;300MG/100ML; 900MG/100ML** **N19630 030** FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;74.5MG/100ML; 225MG/100ML N18365 002 JUL 05, 1983

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001 JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 005** MAR 28, 1988
AP		**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 009** JUL 05, 1983
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML; 450MG/100ML**	**N18008 005** APR 28, 1982
AP		**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 006** APR 28, 1982

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 900MG/100ML**	**N19691 002** MAR 24, 1988
AP		**5GM/100ML;149MG/100ML; 900MG/100ML**	**N19691 004** MAR 24, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML; 900MG/100ML**	**N19308 004** APR 05, 1985
AP		**5GM/100ML;150MG/100ML; 900MG/100ML**	**N19308 002** APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 008 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 007 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 450MG/100ML**	**N18362 006** MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;224MG/100ML; 900MG/100ML**	**N19691 006** MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001
		5GM/100ML;298MG/100ML; 225MG/100ML	N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 008 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;149MG/100ML; 450MG/100ML**	**N18362 010** JUL 05, 1983
AP		**5GM/100ML;298MG/100ML; 450MG/100ML**	**N18362 007** MAR 28, 1988
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 007** APR 28, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;149MG/100ML; 900MG/100ML**	**N19691 005** MAR 24, 1988
AP		**5GM/100ML;298MG/100ML; 900MG/100ML**	**N19691 008** MAR 24, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 005	APR 05, 1985
AP		5GM/100ML;300MG/100ML; 900MG/100ML	N19308 003	APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002	JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 003	JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 003	JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 002	
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 450MG/100ML	N18008 008	APR 28, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 900MG/100ML	N19691 007	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 900MG/100ML	N19308 006	APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 225MG/100ML	N18365 004	JUL 05, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 004	MAR 28, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 450MG/100ML	N18362 003	
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 009	APR 28, 1982

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 900MG/100ML	N19691 009	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 900MG/100ML	N19308 007	APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 007	MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 009	MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 450MG/100ML	N18362 008	MAR 28, 1988
AP		5GM/100ML;149MG/100ML; 450MG/100ML	N18362 004	MAR 28, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 450MG/100ML	N18008 004	

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 900MG/100ML	N19691 001	MAR 24, 1988
AP		5GM/100ML;149MG/100ML; 900MG/100ML	N19691 003	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 001	APR 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML	N19631 011	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;200MG/100ML	N19631 012	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;330MG/100ML	N19631 013	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;450MG/100ML	N19631 014	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML;900MG/100ML	N19631 015	FEB 24, 1988
AP	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N16696 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N19631 001	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N19631 002	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N19631 003	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	2.5GM/100ML;450MG/100ML	N18096 001	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	2.5GM/100ML;450MG/100ML	N19631 004	FEB 24, 1988
AP	BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N16697 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N19631 005	FEB 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N19631 016	JAN 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N19631 006	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;200MG/100ML	N19631 007	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;225MG/100ML	N17606 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;300MG/100ML	N17799 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;330MG/100ML	N19631 008	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;450MG/100ML	N17607 001	
AP	B BRAUN	5GM/100ML;450MG/100ML	N19631 009	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;900MG/100ML	N17585 001	
AP	B BRAUN	5GM/100ML;900MG/100ML	N19631 010	FEB 24, 1988

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N16689 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N16687 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N16683 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N16678 001	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

+	BRACCO	76%	N10040 017	

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

	HYPAQUE			
AP	+ NYCOMED	**30%**	**N16403**	**002**
AP	+	**60%**	**N16403**	**001**
	RENO-60			
AP	+ BRACCO	**60%**	**N10040**	**016**
	RENO-DIP			
AP	+ BRACCO	**30%**	**N10040**	**012**

SOLUTION; URETERAL

	RENO-30			
	BRACCO	30%	N10040	021

SOLUTION; URETHRAL

	CYSTOGRAFIN			
AT	BRACCO	**30%**	**N10040**	**018**
	CYSTOGRAFIN DILUTE			
	BRACCO	18%	N10040	022
			NOV 09,	1982
	HYPAQUE-CYSTO			
AT	NYCOMED	**30%**	**N16403**	**003**

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	HYPAQUE-76			
AP	NYCOMED	**66%;10%**	**N86505**	**001**
	MD-76R			
AP	+ MALLINCKRODT	**66%;10%**	**N19292**	**001**
			SEP 29,	1989
	RENOCAL-76			
AP	BRACCO	**66%;10%**	**N89347**	**001**
			JUN 01,	1988
	RENOGRAFIN-60			
	+ BRACCO	52%;8%	N10040	006
	RENOGRAFIN-76			
AP	+ BRACCO	**66%;10%**	**N10040**	**001**
	RENOVIST			
	+ BRACCO	34.3%;35%	N10040	020
	RENOVIST II			
	+ BRACCO	28.5%;29.1%	N10040	019

SOLUTION; ORAL, RECTAL

	GASTROGRAFIN			
AA	+ BRACCO	**66%;10%**	**N11245**	**003**
	MD-GASTROVIEW			
AA	MALLINCKRODT	**66%;10%**	**N87388**	**001**

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN			
BRACCO	52.7%;26.8%	N11324	002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE			
NYCOMED	100%	N11386	001

INJECTABLE; INJECTION

HYPAQUE			
+ NYCOMED	25%	N09561	003
+	50%	N09561	001

SOLUTION; ORAL, RECTAL

HYPAQUE			
NYCOMED	40%	N11386	003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%			
+ NYCOMED	20%	N09561	002

DIATRIZOATE SODIUM; *MULTIPLE*

SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL			
+ ROXANE	5MG/ML	N71415	001
		APR 03,	1987

GEL; RECTAL

DIASTAT			
+ ELAN PHARMS	2.5MG/0.5ML	N20648	001
		JUL 29,	1997
	5MG/ML	N20648	002
		JUL 29,	1997
	10MG/2ML	N20648	003
		JUL 29,	1997
	15MG/3ML	N20648	004
		JUL 29,	1997

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

GEL; RECTAL

DIASTAT

+	ELAN PHARMS	20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP	ABBOTT	**5MG/ML**	**N71583 001**	OCT 13, 1987
AP		**5MG/ML**	**N71584 001**	OCT 13, 1987
AP		**5MG/ML**	**N72079 001**	DEC 20, 1988
AP	ELKINS SINN	**5MG/ML**	**N70311 001**	DEC 16, 1985
AP		**5MG/ML**	**N70312 001**	DEC 16, 1985
AP		**5MG/ML**	**N70313 001**	DEC 16, 1985
AP	LEDERLE	**5MG/ML**	**N71309 001**	JUL 17, 1987
AP		**5MG/ML**	**N71310 001**	JUL 17, 1987
AP	MARSAM	**5MG/ML**	**N72370 001**	JAN 29, 1993
AP		**5MG/ML**	**N72397 001**	JAN 29, 1993
AP	STERIS	**5MG/ML**	**N70296 001**	FEB 12, 1986

VALIUM

AP	+ ROCHE	**5MG/ML**	**N16087 001**	

SOLUTION; ORAL

DIAZEPAM

+	ROXANE	5MG/5ML	N70928 001	APR 03, 1987

TABLET; ORAL

DIAZEPAM

AB	BARR	**2MG**	**N70152 001**	NOV 01, 1985
AB		**5MG**	**N70153 001**	NOV 01, 1985
AB		**10MG**	**N70154 001**	NOV 01, 1985
AB	DANBURY PHARMA	**2MG**	**N71134 001**	FEB 03, 1987

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	DANBURY PHARMA	**5MG**	**N71135 001**	FEB 03, 1987
AB		**10MG**	**N71136 001**	FEB 03, 1987
AB	GENEVA PHARMS	**2MG**	**N70302 001**	DEC 20, 1985
AB		**5MG**	**N70303 001**	DEC 20, 1985
AB		**10MG**	**N70304 001**	DEC 20, 1985
AB	LEDERLE	**2MG**	**N70226 001**	SEP 26, 1985
AB		**5MG**	**N70227 001**	SEP 26, 1985
AB		**10MG**	**N70228 001**	SEP 26, 1985
AB	MYLAN	**2MG**	**N70323 001**	SEP 04, 1985
AB		**5MG**	**N70324 001**	SEP 04, 1985
AB		**10MG**	**N70325 001**	SEP 04, 1985
AB	PAR PHARM	**2MG**	**N70462 001**	FEB 25, 1986
AB		**5MG**	**N70463 001**	FEB 25, 1986
AB		**10MG**	**N70464 001**	FEB 25, 1986
AB	PUREPAC PHARM	**2MG**	**N70781 001**	MAR 19, 1986
AB		**5MG**	**N70706 001**	MAR 19, 1986
AB		**10MG**	**N70707 001**	MAR 19, 1986
AB	ZENITH GOLDLINE	**2MG**	**N71307 001**	DEC 10, 1986
AB		**5MG**	**N71321 001**	DEC 10, 1986
AB		**10MG**	**N71322 001**	DEC 10, 1986

VALIUM

AB	ROCHE	**2MG**	**N13263 002**	
AB		**5MG**	**N13263 004**	
AB	+	**10MG**	**N13263 006**	

FDA data supplied by DrugPatentWatch.com

DIAZOXIDE

CAPSULE; ORAL
PROGLYCEM
+ BAKER NORTON 50MG N17425 001

INJECTABLE; INJECTION
HYPERSTAT
+ SCHERING 15MG/ML N16996 001

SUSPENSION; ORAL
PROGLYCEM
+ BAKER NORTON 50MG/ML N17453 001

DICHLORPHENAMIDE

TABLET; ORAL
DARANIDE
+ MERCK 50MG N11366 001

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM
AB + NOVARTIS **50MG** **N20142 002** NOV 24, 1993

DICLOFENAC POTASSIUM
AB GENEVA PHARMS TECH **50MG** **N75229 001** NOV 20, 1998
AB MYLAN **50MG** **N75463 001** JUL 26, 1999
AB TEVA **50MG** **N75219 001** AUG 06, 1998
AB WATSON LABS **50MG** **N75152 001** NOV 27, 1998

DICLOFENAC SODIUM

GEL; TOPICAL
SOLARAZE
+ SKYEPHARMA 3% N21005 001 OCT 16, 2000

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN
+ CIBA 0.1% N20037 001 MAR 28, 1991

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
AB CARLSBAD **25MG** **N75185 002** NOV 13, 1998
AB **50MG** **N75185 003** NOV 13, 1998
AB **75MG** **N75185 001** NOV 13, 1998
AB COPLEY PHARM **25MG** **N74459 001** JUN 25, 1997
AB **50MG** **N74459 002** JUN 25, 1997
AB **75MG** **N74459 003** JUN 25, 1997
AB GENEVA PHARMS **25MG** **N74376 001** SEP 28, 1995
AB **50MG** **N74376 002** SEP 28, 1995
AB **75MG** **N74394 001** NOV 30, 1995
AB MARTEC **50MG** **N74986 001** FEB 26, 1999
AB **75MG** **N74986 002** FEB 26, 1999
AB NOVOPHARM **50MG** **N74723 001** MAR 30, 1999
AB **75MG** **N74390 001** AUG 15, 1996
AB PUREPAC PHARM **50MG** **N74514 001** MAR 26, 1996
AB **75MG** **N74514 002** MAR 26, 1996
AB ROXANE **25MG** **N74391 001** JUN 29, 1995
AB **50MG** **N74391 002** JUN 29, 1995
AB **75MG** **N74391 003** JUN 29, 1995
AB SIDMAK LABS NJ **50MG** **N74432 002** JUL 29, 1999
AB **75MG** **N74432 003** JUL 29, 1999

VOLTAREN
AB + NOVARTIS **25MG** **N19201 001** JUL 28, 1988
AB + **50MG** **N19201 002** JUL 28, 1988

FDA data supplied by DrugPatentWatch.com

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	VOLTAREN			
AB	+ NOVARTIS	**75MG**	**N19201 003**	JUL 28, 1988

TABLET, EXTENDED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	BIOVAIL	**100MG**	**N75492 001**	FEB 11, 2000
	VOLTAREN-XR			
AB	+ NOVARTIS	**100MG**	**N20254 001**	MAR 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

	ARTHROTEC			
	+ SEARLE	50MG;0.2MG	N20607 001	DEC 24, 1997
	+	75MG;0.2MG	N20607 002	DEC 24, 1997

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	**EQ 250MG BASE**	**N61454 001**	
AB	+	**EQ 500MG BASE**	**N61454 003**	
		EQ 125MG BASE	N61454 002	
AB	TEVA	**EQ 250MG BASE**	**N62286 001**	JUN 03, 1982
AB		**EQ 500MG BASE**	**N62286 002**	JUN 03, 1982
	DYCILL			
AB	SMITHKLINE BEECHAM	**EQ 250MG BASE**	**N62238 001**	
AB		**EQ 500MG BASE**	**N62238 002**	
	PATHOCIL			
AB	WYETH AYERST	**EQ 250MG BASE**	**N50011 002**	
AB		**EQ 500MG BASE**	**N50011 003**	MAR 28, 1983

FOR SUSPENSION; ORAL

	DICLOXACILLIN SODIUM			
AB	+ APOTHECON	**EQ 62.5MG BASE/5ML**	**N61455 001**	
	PATHOCIL			
AB	WYETH AYERST	**EQ 62.5MG BASE/5ML**	**N50092 001**	

DICUMAROL

TABLET; ORAL

	DICUMAROL		
	+ ABBOTT	25MG	N05545 003

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	**10MG**	**N07409 003**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	CHELSEA LABS	**10MG**	**N85082 001**	JUN 19, 1986
AB	HALSEY	**10MG**	**N84505 001**	OCT 21, 1986
AB	LANNETT	**10MG**	**N84285 001**	
AB	MYLAN	**10MG**	**N40319 001**	SEP 07, 1999
AB	WEST WARD	**10MG**	**N40204 001**	FEB 28, 1997

INJECTABLE; INJECTION

	BENTYL			
AP	+ AVENTIS PHARMS	**10MG/ML**	**N08370 001**	OCT 15, 1984
	BENTYL PRESERVATIVE FREE			
AP	AVENTIS PHARMS	**10MG/ML**	**N08370 002**	OCT 15, 1984
	DICYCLOMINE HCL			
AP	STERIS	**10MG/ML**	**N80614 001**	FEB 11, 1986

SYRUP; ORAL

	BENTYL			
	+ AVENTIS PHARMS	10MG/5ML	N07961 002	OCT 15, 1984

TABLET; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	**20MG**	**N07409 001**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	CHELSEA LABS	**20MG**	**N85223 001**	JUL 30, 1986
AB	LANNETT	**20MG**	**N40230 001**	FEB 26, 1999

FDA data supplied by DrugPatentWatch.com

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

AB	MYLAN	20MG	N40317 001	SEP 07, 1999
AB	WEST WARD	20MG	N40161 001	OCT 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL
VIDEX EC

+	BRISTOL MYERS SQUIBB	125MG	N21183 001	OCT 31, 2000
+		200MG	N21183 002	OCT 31, 2000
+		250MG	N21183 003	OCT 31, 2000
+		400MG	N21183 004	OCT 31, 2000

FOR SOLUTION; ORAL
VIDEX

	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	OCT 09, 1991
		100MG/PACKET	N20155 003	OCT 09, 1991
		167MG/PACKET	N20155 004	OCT 09, 1991
+		250MG/PACKET	N20155 005	OCT 09, 1991

TABLET, CHEWABLE; ORAL
VIDEX

+	BRISTOL MYERS SQUIBB	25MG	N20154 002	OCT 09, 1991
		50MG	N20154 003	OCT 09, 1991
		100MG	N20154 004	OCT 09, 1991
		150MG	N20154 005	OCT 09, 1991
		200MG	N20154 006	OCT 28, 1999

DIENESTROL

CREAM; VAGINAL
DIENESTROL

+	JOHNSON RW	0.01%	N06110 005	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL

AA	CAMALL	25MG	N88267 001	AUG 25, 1983
AA		25MG	N88268 001	AUG 25, 1983

TENUATE

AA	+ AVENTIS PHARMS	25MG	N11722 002	

TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN

BC	+ AVENTIS PHARMS	75MG	N12546 001	

TEPANIL TEN-TAB

BC	3M	75MG	N17956 001	

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75187 001	MAR 30, 1998
AB	TARO	0.05%	N75508 001	APR 24, 2000

FLORONE

BX	+ PHARMACIA AND UPJOHN	0.05%	N17741 001	

FLORONE E

BX	+ PHARMACIA AND UPJOHN	0.05%	N19259 001	AUG 28, 1985

PSORCON

AB	+ DERMIK LABS	0.05%	N20205 001	NOV 20, 1992

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75374 001	APR 27, 1999

FDA data supplied by DrugPatentWatch.com

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE			
AB	TARO	**0.05%**	**N75331 001**	MAY 14, 1999
	FLORONE			
+	PHARMACIA AND UPJOHN	0.05%	N17994 001	
	PSORCON			
AB +	PHARMACIA AND UPJOHN	**0.05%**	**N19260 001**	AUG 28, 1985

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL			
AB	DANBURY PHARMA	**250MG**	**N74400 001**	JUL 17, 1997
AB		**500MG**	**N74400 002**	JUL 17, 1997
AB	GENEVA PHARMS	**500MG**	**N74604 001**	JUN 10, 1996
AB	ROXANE	**250MG**	**N73562 001**	NOV 27, 1992
AB		**500MG**	**N73563 001**	NOV 27, 1992
AB	TEVA	**250MG**	**N73679 001**	JUL 31, 1992
AB		**500MG**	**N73673 001**	JUL 31, 1992
	DOLOBID			
AB	MERCK	**250MG**	**N18445 001**	APR 19, 1982
AB +		**500MG**	**N18445 002**	APR 19, 1982

DIGOXIN

CAPSULE; ORAL

	LANOXICAPS			
	GLAXO WELLCOME	0.05MG	N18118 002	JUL 26, 1982
		0.1MG	N18118 003	JUL 26, 1982
+		0.2MG	N18118 001	JUL 26, 1982

DIGOXIN

INJECTABLE; INJECTION

	DIGOXIN			
AP	ABBOTT	**0.25MG/ML**	**N40093 001**	MAY 16, 1996
AP		**0.25MG/ML**	**N40206 001**	AUG 28, 1998
AP	ELKINS SINN	**0.25MG/ML**	**N83391 001**	
AP	WYETH AYERST	**0.25MG/ML**	**N84386 001**	
	DIGOXIN PEDIATRIC			
AP	ABBOTT	**0.1MG/ML**	**N40092 001**	APR 25, 1996
	LANOXIN			
AP +	GLAXO WELLCOME	**0.25MG/ML**	**N09330 002**	
	LANOXIN PEDIATRIC			
AP +	GLAXO WELLCOME	**0.1MG/ML**	**N09330 004**	

TABLET; ORAL

	DIGOXIN			
AB	AMIDE PHARM	**0.125MG**	**N40282 001**	DEC 23, 1999
AB		**0.25MG**	**N40282 002**	DEC 23, 1999
	LANOXIN			
AB	GLAXO WELLCOME	**0.125MG**	**N20405 002**	SEP 30, 1997
AB +		**0.25MG**	**N20405 004**	SEP 30, 1997

DIHYDROCODEINE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

	D.H.E. 45		
+	NOVARTIS	1MG/ML	N05929 001

SPRAY, METERED; NASAL

	MIGRANAL		
+	NOVARTIS	0.5MG/INH	N20148 001 DEC 08, 1997

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD					
AB3 +	CARDERM	120MG	N20062 001		
			AUG 10, 1992		
AB3 +		180MG	N20062 002		
			DEC 27, 1991		
AB3 +		240MG	N20062 003		
			DEC 27, 1991		
AB3 +		300MG	N20062 004		
			DEC 27, 1991		
CARDIZEM SR					
AB1 +	AVENTIS PHARMS	60MG	N19471 001		
			JAN 23, 1989		
AB1 +		90MG	N19471 002		
			JAN 23, 1989		
AB1 +		120MG	N19471 003		
			JAN 23, 1989		
CARTIA XT					
AB3	ANDRX PHARMS	120MG	N74752 002		
			JUL 09, 1998		
AB3		180MG	N74752 001		
			JUL 09, 1998		
AB3		240MG	N74752 003		
			JUL 09, 1998		
AB3		300MG	N74752 004		
			JUL 09, 1998		
DILACOR XR					
AB2 +	WATSON LABS	120MG	N20092 001		
			MAY 29, 1992		
AB2 +		180MG	N20092 002		
			MAY 29, 1992		
AB2 +		240MG	N20092 003		
			MAY 29, 1992		
DILTIAZEM HCL					
AB2	ANDRX	120MG	N74852 001		
			OCT 10, 1997		
AB2		180MG	N74852 002		
			OCT 10, 1997		
AB2		240MG	N74852 003		
			OCT 10, 1997		
AB1	BIOVAIL	60MG	N74845 001		
			SEP 15, 1999		
AB1		90MG	N74845 002		
			SEP 15, 1999		
AB3		120MG	N20939 001		
			JAN 28, 2000		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL					
AB1	BIOVAIL	120MG	N74845 003		
			SEP 15, 1999		
AB3		120MG	N75116 001		
			DEC 23, 1999		
AB3		180MG	N20939 002		
			JAN 28, 2000		
AB3		180MG	N75116 002		
			DEC 23, 1999		
AB3		240MG	N20939 003		
			JAN 28, 2000		
AB3		240MG	N75116 003		
			DEC 23, 1999		
AB3		300MG	N20939 004		
			JAN 28, 2000		
AB3		300MG	N75116 004		
			DEC 23, 1999		
AB1	MYLAN	60MG	N74910 001		
			MAY 02, 1997		
AB1		90MG	N74910 002		
			MAY 02, 1997		
AB1		120MG	N74910 003		
			MAY 02, 1997		
AB1		120MG	N75124 002		
			MAR 18, 1998		
AB2		180MG	N75124 003		
			MAR 18, 1998		
AB2		240MG	N75124 001		
			MAR 18, 1998		
AB3	PUREPAC PHARM	120MG	N74984 001		
			DEC 20, 1999		
AB3		180MG	N74984 002		
			DEC 20, 1999		
AB3		240MG	N74984 003		
			DEC 20, 1999		
AB3		300MG	N74984 004		
			DEC 20, 1999		
AB1	TEVA	60MG	N74079 001		
			NOV 30, 1993		
AB1		90MG	N74079 002		
			NOV 30, 1993		
AB1		120MG	N74079 003		
			NOV 30, 1993		
AB2	TORPHARM	120MG	N74943 003		
			DEC 19, 2000		

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL				
AB2	TORPHARM	**180MG**	**N74943 002**		
			DEC 19, 2000		
AB2		**240MG**	**N74943 001**		
			AUG 06, 1998		
	TIAZAC				
BC	+ BIOVAIL	120MG	N20401 001		
			SEP 11, 1995		
BC	+	180MG	N20401 002		
			SEP 11, 1995		
BC	+	240MG	N20401 003		
			SEP 11, 1995		
BC	+	300MG	N20401 004		
			SEP 11, 1995		
	+	360MG	N20401 005		
			SEP 11, 1995		
	+	420MG	N20401 006		
			OCT 16, 1998		

INJECTABLE; INJECTION

	CARDIZEM				
AP	+ AVENTIS PHARMS	**5MG/ML**	**N20027 001**		
			OCT 24, 1991		
AP	+	**100MG/VIAL**	**N20792 001**		
			SEP 05, 1997		
	+	25MG/VIAL	N20027 003		
			AUG 18, 1995		
	DILTIAZEM HCL				
AP	ABBOTT	**5MG/ML**	**N74941 001**		
			APR 15, 1998		
AP		**5MG/ML**	**N75004 001**		
			FEB 16, 2000		
AP	APOTEX	**5MG/ML**	**N75375 001**		
			SEP 30, 1999		
AP	BEDFORD	**5MG/ML**	**N74617 001**		
			FEB 28, 1996		
AP	GENSIA SICOR PHARMS	**5MG/ML**	**N74894 001**		
			AUG 26, 1997		
AP	MERIDIAN MEDCL TECHN	**5MG/ML**	**N75106 001**		
			APR 29, 1999		
AP	TAYLOR PHARMA	**5MG/ML**	**N75086 001**		
			APR 09, 1998		

TABLET; ORAL

	CARDIZEM				
AB	AVENTIS PHARMS	**30MG**	**N18602 001**		
			NOV 05, 1982		
AB		**60MG**	**N18602 002**		
			NOV 05, 1982		
AB		**90MG**	**N18602 003**		
			DEC 08, 1986		
AB	+	**120MG**	**N18602 004**		
			DEC 08, 1986		
	DILTIAZEM HCL				
AB	APOTHECON	**30MG**	**N74051 001**		
			MAR 31, 1993		
AB		**60MG**	**N74051 002**		
			MAR 31, 1993		
AB		**90MG**	**N74051 003**		
			MAR 31, 1993		
AB		**120MG**	**N74051 004**		
			MAR 31, 1993		
AB	COPLEY PHARM	**30MG**	**N74067 001**		
			NOV 05, 1992		
AB		**60MG**	**N74067 002**		
			NOV 05, 1992		
AB		**90MG**	**N74067 003**		
			NOV 05, 1992		
AB		**120MG**	**N74067 004**		
			NOV 05, 1992		
AB	LEDERLE	**30MG**	**N74093 001**		
			NOV 05, 1992		
AB		**60MG**	**N74093 002**		
			NOV 05, 1992		
AB		**90MG**	**N74093 003**		
			NOV 05, 1992		
AB		**120MG**	**N74093 004**		
			NOV 05, 1992		
AB	MYLAN	**30MG**	**N73185 001**		
			NOV 05, 1992		
AB		**60MG**	**N73186 001**		
			NOV 05, 1992		
AB		**90MG**	**N72837 001**		
			NOV 05, 1992		
AB		**120MG**	**N72838 001**		
			NOV 05, 1992		
AB	TEVA	**30MG**	**N74185 001**		
			MAY 31, 1995		
AB		**60MG**	**N74185 002**		
			MAY 31, 1995		
AB		**90MG**	**N74185 003**		
			MAY 31, 1995		

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	TEVA	120MG	N74185 004	MAY 31, 1995
AB	ZENITH GOLDLINE	30MG	N74168 001	MAR 03, 1995
AB		60MG	N74168 002	MAR 03, 1995
AB		90MG	N74168 003	MAR 03, 1995
AB		120MG	N74168 004	MAR 03, 1995

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM

+	MERCK	EQ 180MG HCL;5MG	N20507 001	OCT 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP	+ STERIS	50MG/ML	N80615 001	
AP	+ WYETH AYERST	50MG/ML	N84316 001	

DIMERCAPROL

INJECTABLE; INJECTION
BAL

+	AKORN	10%	N05939 001	

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL
RIMSO-50

+	RES INDS	50%	N17788 001	

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL

+	PHARMACIA AND UPJOHN	0.5MG/3GM	N19617 001	DEC 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	CONTROLLED THERAP	10MG	N20411 001	MAR 30, 1995

SUPPOSITORY; VAGINAL
PROSTIN E2

+	PHARMACIA AND UPJOHN	20MG	N17810 001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	BARR	50MG	N80738 001	
AA	CHELSEA LABS	50MG	N85083 001	
AA	DANBURY PHARMA	25MG	N80728 001	
AA		50MG	N80727 001	
AA	+ GENEVA PHARMS	25MG	N80832 001	
AA	+	50MG	N80832 002	
AA	HALSEY	25MG	N84506 001	
AA	ICN	25MG	N80596 001	
AA		50MG	N80592 001	
AA	IMPAX LABS	25MG	N80807 001	
AA	LNK	25MG	N87977 001	JAN 27, 1983
AA		50MG	N87978 001	JAN 27, 1983
AA	MK LABS	25MG	N83087 001	
AA		50MG	N83087 002	
AA	MUTUAL PHARM	25MG	N89488 001	JAN 02, 1987
AA		50MG	N89489 001	JAN 02, 1987
AA	NEWTRON PHARMS	25MG	N86543 001	

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL			
AA	NEWTRON PHARMS	50MG	N86544 001	
AA	PVT FORM	25MG	N83027 001	
AA		50MG	N83027 002	
AA	SUPERPHARM	25MG	N89040 001	
			MAY 15, 1985	

ELIXIR; ORAL

	DIPHENHYDRAMINE HCL			
AA	LANNETT	12.5MG/5ML	N80939 002	
AA	MK LABS	12.5MG/5ML	N83088 002	
AA	PHARM ASSOC	12.5MG/5ML	N87513 001	
			FEB 10, 1982	
AA	+ ROXANE	12.5MG/5ML	N80643 001	

INJECTABLE; INJECTION

	BENADRYL			
AP	+ PARKE DAVIS	50MG/ML	N06146 002	
	BENADRYL PRESERVATIVE FREE			
AP	+ PARKE DAVIS	50MG/ML	N09486 001	
	DIPHENHYDRAMINE HCL			
AP	ABBOTT	50MG/ML	N40140 001	
			NOV 20, 1998	
AP	ELKINS SINN	50MG/ML	N80817 002	
AP	STERIS	50MG/ML	N80873 002	
	+	10MG/ML	N80873 001	
AP	WYETH AYERST	50MG/ML	N80577 001	
	DIPHENHYDRAMINE HCL PRESERVATIVE FREE			
AP	AM PHARM PARTNERS	50MG/ML	N80586 002	
AP	INTL MEDICATION	50MG/ML	N84094 001	
AP	STERIS	50MG/ML	N80873 003	

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

	VONTROL		
+	SMITHKLINE BEECHAM	EQ 25MG BASE	N16033 001

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*

SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPRO			
AT	AKORN	0.1%	N74382 001	
			SEP 29, 1995	
	DIPIVEFRIN HCL			
AT	BAUSCH AND LOMB	0.1%	N74188 001	
			MAY 19, 1995	
AT	FALCON PHARMS	0.1%	N73636 001	
			JUN 30, 1994	
	PROPINE			
AT	+ ALLERGAN	0.1%	N18239 001	

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE			
AP	ABBOTT	5MG/ML	N74601 001	
			DEC 19, 1997	
AP	AM PHARM PARTNERS	5MG/ML	N74956 001	
			SEP 30, 1998	
AP	BEDFORD	5MG/ML	N74939 001	
			APR 13, 1998	
AP	ELKINS SINN	5MG/ML	N74521 001	
			OCT 18, 1996	
AP	GENSIA SICOR PHARMS	5MG/ML	N74952 001	
			NOV 26, 1997	
	IV PERSANTINE			
AP	+ BOEHRINGER INGELHEIM	5MG/ML	N19817 001	
			DEC 13, 1990	

TABLET; ORAL

	DIPYRIDAMOLE			
AB	BARR	25MG	N87184 001	
			OCT 03, 1990	
AB		50MG	N87716 001	
			OCT 03, 1990	
AB		75MG	N87717 001	
			OCT 03, 1990	
AB	CHELSEA LABS	50MG	N87160 001	
			JUN 07, 1996	
AB	GENEVA PHARMS	25MG	N86944 002	
			APR 16, 1991	
AB		50MG	N87562 001	
			FEB 25, 1992	
AB		75MG	N87561 001	
			FEB 25, 1992	

FDA data supplied by DrugPatentWatch.com

DIPYRIDAMOLE

TABLET; ORAL

	DIPYRIDAMOLE			
AB	LEDERLE	25MG	**N88999 001**	FEB 05, 1991
AB		50MG	**N89000 001**	FEB 05, 1991
AB		75MG	**N89001 001**	FEB 05, 1991
AB	PUREPAC PHARM	25MG	**N89425 001**	JUL 12, 1990
	PERSANTINE			
AB	BOEHRINGER INGELHEIM	25MG	**N12836 003**	DEC 22, 1986
AB	+	50MG	**N12836 004**	FEB 06, 1987
AB		75MG	**N12836 005**	FEB 06, 1987

DIPYRIDAMOLE; *MULTIPLE*
SEE ASPIRIN; DIPYRIDAMOLE

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC			
	+ LILLY RES LABS	250MG	N50678 001	JUN 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	DANBURY PHARMA	EQ 100MG BASE	**N70173 001**	MAY 31, 1985
AB		EQ 150MG BASE	**N70174 001**	MAY 31, 1985
AB	GENEVA PHARMS	EQ 100MG BASE	**N70470 001**	DEC 10, 1985
AB		EQ 150MG BASE	**N70471 001**	DEC 10, 1985
AB	SUPERPHARM	EQ 100MG BASE	**N70940 001**	FEB 09, 1987
AB	TEVA	EQ 100MG BASE	**N70101 001**	FEB 22, 1985

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	TEVA	EQ 150MG BASE	**N70102 001**	FEB 22, 1985
AB	ZENITH GOLDLINE	EQ 100MG BASE	**N70186 001**	NOV 18, 1985
AB		EQ 150MG BASE	**N70187 001**	NOV 18, 1985
	NORPACE			
AB	SEARLE	EQ 100MG BASE	**N17447 001**	
AB	+	EQ 150MG BASE	**N17447 002**	

CAPSULE, EXTENDED RELEASE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	KV PHARM	EQ 150MG BASE	**N71200 001**	DEC 15, 1987
	NORPACE CR			
AB	+ SEARLE	EQ 150MG BASE	**N18655 002**	JUL 20, 1982
		EQ 100MG BASE	N18655 001	JUL 20, 1982

DISULFIRAM

TABLET; ORAL

	ANTABUSE			
	SIDMAK LABS NJ	250MG	N88482 001	DEC 08, 1983
	+	500MG	N88483 001	DEC 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	DEPAKOTE			
	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680 001	SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL

	DEPAKOTE			
	+ ABBOTT	EQ 125MG VALPROIC ACID	N18723 003	OCT 26, 1984
	+	EQ 250MG VALPROIC ACID	N18723 001	MAR 10, 1983

FDA data supplied by DrugPatentWatch.com

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE
+ ABBOTT — EQ 500MG VALPROIC ACID — N18723 002 MAR 10, 1983

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER
+ ABBOTT — EQ 500MG VALPROIC ACID — N21168 001 AUG 04, 2000

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP		ABBOTT	**EQ 1.25GM BASE/100ML**	**N74634 001** SEP 27, 1996
AP			**EQ 12.5MG BASE/ML**	**N74086 001** NOV 29, 1993
AP			**EQ 12.5MG BASE/ML**	**N74292 001** FEB 16, 1995
AP		ASTRAZENECA	**EQ 12.5MG BASE/ML**	**N74098 001** FEB 21, 1995
AP		BEDFORD	**EQ 12.5MG BASE/ML**	**N74277 001** OCT 31, 1994
AP		ELKINS SINN	**EQ 12.5MG BASE/ML**	**N74381 001** SEP 26, 1996
AP		GENSIA SICOR PHARMS	**EQ 12.5MG BASE/ML**	**N74206 001** OCT 19, 1993
AP		LUITPOLD	**EQ 12.5MG BASE/ML**	**N74545 001** JUN 25, 1998
AP		MARSAM	**EQ 12.5MG BASE/ML**	**N74279 001** FEB 18, 1998
AP			**EQ 12.5MG BASE/ML**	**N74995 001** MAR 31, 1998
AP		STERIS	**EQ 12.5MG BASE/ML**	**N74114 001** NOV 30, 1993

DOBUTAMINE HCL IN DEXTROSE 5%

AP	+	ABBOTT	**EQ 50MG BASE/100ML**	**N20269 001** OCT 19, 1993
AP	+		**EQ 100MG BASE/100ML**	**N20269 002** OCT 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N20269 003** OCT 19, 1993

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	**EQ 50MG BASE/100ML**	**N20201 003** OCT 19, 1993

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	**EQ 100MG BASE/100ML**	**N20201 002** OCT 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N20201 001** OCT 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N20201 006** JUL 07, 1994
AP	+	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N20255 001** OCT 19, 1993
AP	+		**EQ 100MG BASE/100ML**	**N20255 003** OCT 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N20255 004** OCT 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N20255 005** OCT 19, 1993

DOBUTREX

AP	+	LILLY	**EQ 12.5MG BASE/ML**	**N17820 002**

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE
+ AVENTIS — EQ 40MG BASE/ML — N20449 001 MAY 14, 1996

DOFETILIDE

CAPSULE; ORAL
TIKOSYN
PFIZER — 0.125MG — N20931 001 OCT 01, 1999
0.25MG — N20931 002 OCT 01, 1999
+ 0.5MG — N20931 003 OCT 01, 1999

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION
ANZEMET
+ AVENTIS PHARMS — EQ 20MG BASE/ML — N20624 001 SEP 11, 1997

FDA data supplied by DrugPatentWatch.com

DOLASETRON MESYLATE MONOHYDRATE

TABLET; ORAL
ANZEMET

	AVENTIS PHARMS	EQ 50MG BASE	N20623 001	
			SEP 11, 1997	
+		EQ 100MG BASE	N20623 002	
			SEP 11, 1997	

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
ARICEPT

	EISAI	5MG	N20690 002	
			NOV 25, 1996	
+		10MG	N20690 001	
			NOV 25, 1996	

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	+	ABBOTT	**80MG/100ML**	**N18132 002**	
				FEB 04, 1982	
AP	+		**160MG/100ML**	**N18132 003**	
				FEB 04, 1982	
AP	+		**40MG/ML**	**N18132 001**	
AP			**40MG/ML**	**N74403 001**	
				MAY 23, 1996	
AP	+		**80MG/ML**	**N18132 004**	
				JUL 09, 1982	
AP		AM PHARM PARTNERS	**80MG/ML**	**N70013 001**	
				JUN 12, 1985	
AP	+	ASTRAZENECA	**40MG/ML**	**N18656 001**	
				JUN 28, 1983	
AP			**80MG/ML**	**N70091 001**	
				OCT 23, 1985	
AP			**160MG/ML**	**N70092 001**	
				OCT 23, 1985	
AP	+	ELKINS SINN	**40MG/ML**	**N18398 001**	
AP	+		**80MG/ML**	**N18398 002**	
				MAR 22, 1982	
AP		GENSIA SICOR PHARMS	**40MG/ML**	**N72999 001**	
				OCT 23, 1991	
AP			**80MG/ML**	**N73000 001**	
				OCT 23, 1991	
AP	+	INTL MEDICATION	**40MG/ML**	**N18014 001**	

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP		LUITPOLD	**40MG/ML**	**N70799 001**	
				FEB 11, 1987	
AP			**80MG/ML**	**N70820 001**	
				FEB 11, 1987	
AP			**160MG/ML**	**N70826 001**	
				FEB 11, 1987	

DOPAMINE HCL AND DEXTROSE 5%

AP	+	B BRAUN	**80MG/100ML**	**N19099 002**	
				OCT 15, 1986	
AP	+		**320MG/100ML**	**N19099 004**	
				OCT 15, 1986	

DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	**160MG/100ML**	**N19099 003**	
				OCT 15, 1986	
	+		40MG/100ML	N19099 001	
				OCT 15, 1986	

DOPAMINE HCL IN DEXTROSE 5%

AP	+	ABBOTT	**1.6MG/ML**	**N20542 001**	
				AUG 30, 1995	

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	**80MG/100ML**	**N18826 001**	
				SEP 30, 1983	
AP	+		**160MG/100ML**	**N18826 002**	
				SEP 30, 1983	
AP	+		**320MG/100ML**	**N18826 003**	
				SEP 30, 1983	
AP	+	BAXTER HLTHCARE	**80MG/100ML**	**N19615 001**	
				MAR 27, 1987	
AP	+		**160MG/100ML**	**N19615 002**	
				MAR 27, 1987	
AP	+		**320MG/100ML**	**N19615 003**	
				MAR 27, 1987	
	+		640MG/100ML	N19615 004	
				MAR 27, 1987	

INTROPIN

AP	+	FAULDING	**40MG/ML**	**N17395 001**	
AP	+		**80MG/ML**	**N17395 002**	
AP	+		**160MG/ML**	**N17395 003**	

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
TRUSOPT

+	MERCK	EQ 2% BASE	N20408 001	
			DEC 09, 1994	

FDA data supplied by DrugPatentWatch.com

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	COSOPT				
	+ MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998		

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

	NUROMAX				
	+ ABBOTT	EQ 1MG BASE/ML	N19946 001 MAR 07, 1991		

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

	DOPRAM				
AP	+ ROBINS AH	**20MG/ML**	**N14879 001**		
	DOXAPRAM HCL				
AP	STERIS	**20MG/ML**	**N73529 001** JAN 30, 1992		

DOXAZOSIN MESYLATE

TABLET; ORAL

	CARDURA				
AB	+ PFIZER	**EQ 1MG BASE**	**N19668 001** NOV 02, 1990		
AB		**EQ 2MG BASE**	**N19668 002** NOV 02, 1990		
AB		**EQ 4MG BASE**	**N19668 003** NOV 02, 1990		
AB		**EQ 8MG BASE**	**N19668 004** NOV 02, 1990		
	DOXAZOSIN MESYLATE				
AB	CHELSEA LABS	**EQ 1MG BASE**	**N75426 001** OCT 18, 2000		
AB		**EQ 2MG BASE**	**N75426 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75426 003** OCT 18, 2000		
AB		**EQ 8MG BASE**	**N75426 004** OCT 18, 2000		
AB	EON	**EQ 1MG BASE**	**N75646 001** OCT 18, 2000		

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE				
AB	EON	**EQ 2MG BASE**	**N75646 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75646 003** OCT 18, 2000		
AB		**EQ 8MG BASE**	**N75646 004** OCT 18, 2000		
AB	GENEVA PHARMS TECH	**EQ 1MG BASE**	**N75432 001** OCT 18, 2000		
AB		**EQ 2MG BASE**	**N75432 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75432 003** OCT 18, 2000		
AB		**EQ 8MG BASE**	**N75432 004** OCT 18, 2000		
AB	GENPHARM	**EQ 1MG BASE**	**N75466 001** OCT 18, 2000		
AB		**EQ 2MG BASE**	**N75466 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75466 003** OCT 18, 2000		
AB		**EQ 8MG BASE**	**N75466 004** OCT 18, 2000		
AB	KV PHARM	**EQ 1MG BASE**	**N75609 001** OCT 18, 2000		
AB		**EQ 2MG BASE**	**N75609 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75609 003** OCT 18, 2000		
AB		**EQ 8MG BASE**	**N75609 004** OCT 18, 2000		
AB	MYLAN	**EQ 1MG BASE**	**N75509 001** OCT 19, 2000		
AB		**EQ 2MG BASE**	**N75509 002** OCT 19, 2000		
AB		**EQ 4MG BASE**	**N75509 003** OCT 19, 2000		
AB		**EQ 8MG BASE**	**N75509 004** OCT 19, 2000		
AB	PUREPAC PHARM	**EQ 1MG BASE**	**N75574 001** OCT 18, 2000		
AB		**EQ 2MG BASE**	**N75574 002** OCT 18, 2000		
AB		**EQ 4MG BASE**	**N75574 003** OCT 18, 2000		

FDA data supplied by DrugPatentWatch.com

DOXAZOSIN MESYLATE

TABLET; ORAL

		DOXAZOSIN MESYLATE	
AB	PUREPAC PHARM	EQ 8MG BASE	N75574 004 OCT 18, 2000
AB	TEVA	EQ 1MG BASE	N75536 001 OCT 18, 2000
AB		EQ 2MG BASE	N75536 002 OCT 18, 2000
AB		EQ 4MG BASE	N75536 003 OCT 18, 2000
AB		EQ 8MG BASE	N75536 004 OCT 18, 2000
AB	TORPHARM	EQ 1MG BASE	N75580 001 OCT 18, 2000
AB		EQ 2MG BASE	N75580 002 OCT 18, 2000
AB		EQ 4MG BASE	N75580 003 OCT 18, 2000
AB		EQ 8MG BASE	N75580 004 OCT 18, 2000
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75453 001 OCT 18, 2000
AB		EQ 2MG BASE	N75453 002 OCT 18, 2000
AB		EQ 4MG BASE	N75453 003 OCT 18, 2000
AB		EQ 8MG BASE	N75453 004 OCT 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

		DOXEPIN HCL	
AB	DANBURY PHARMA	EQ 10MG BASE	N71485 001 APR 30, 1987
AB		EQ 25MG BASE	N71486 001 APR 30, 1987
AB		EQ 50MG BASE	N71238 001 APR 30, 1987
AB		EQ 75MG BASE	N71326 001 APR 30, 1987
AB		EQ 100MG BASE	N71239 001 APR 30, 1987
AB	GENEVA PHARMS	EQ 10MG BASE	N71487 001 MAR 02, 1987

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

		DOXEPIN HCL	
AB	GENEVA PHARMS	EQ 25MG BASE	N70827 001 MAY 15, 1986
AB		EQ 50MG BASE	N70828 001 MAY 15, 1986
AB		EQ 75MG BASE	N70825 001 MAY 15, 1986
AB		EQ 100MG BASE	N71562 001 MAR 02, 1987
AB	LEDERLE	EQ 10MG BASE	N71685 001 JAN 05, 1988
AB		EQ 25MG BASE	N71686 001 JAN 05, 1988
AB		EQ 50MG BASE	N71673 001 JAN 05, 1988
AB		EQ 75MG BASE	N71674 001 JAN 05, 1988
AB		EQ 100MG BASE	N71675 001 JAN 05, 1988
AB		EQ 150MG BASE	N71676 001 JAN 05, 1988
AB	MYLAN	EQ 10MG BASE	N70789 001 MAY 13, 1986
AB		EQ 25MG BASE	N70790 001 MAY 13, 1986
AB		EQ 50MG BASE	N70791 001 MAY 13, 1986
AB		EQ 75MG BASE	N70792 001 MAY 13, 1986
AB		EQ 100MG BASE	N70793 001 MAY 13, 1986
AB	PAR PHARM	EQ 10MG BASE	N71697 001 NOV 09, 1987
AB		EQ 25MG BASE	N71437 001 NOV 09, 1987
AB		EQ 50MG BASE	N71595 001 NOV 09, 1987
AB		EQ 75MG BASE	N71608 001 NOV 09, 1987
AB		EQ 100MG BASE	N71422 001 NOV 09, 1987
AB		EQ 150MG BASE	N71669 001 NOV 09, 1987
AB	WATSON LABS	EQ 10MG BASE	N72985 001 MAR 29, 1991

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	DOXEPIN HCL			
AB	WATSON LABS	EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991
	SINEQUAN			
AB	PFIZER	EQ 10MG BASE	N16798 003	
AB	+	EQ 25MG BASE	N16798 001	
AB		EQ 50MG BASE	N16798 002	
AB		EQ 75MG BASE	N16798 006	
AB	+	EQ 100MG BASE	N16798 005	
AB		EQ 150MG BASE	N16798 007	

CONCENTRATE; ORAL

	DOXEPIN HCL			
AA	COPLEY PHARM	EQ 10MG BASE/ML	N71609 001	NOV 09, 1987
AA	MORTON GROVE	EQ 10MG BASE/ML	N71918 001	JUL 20, 1988
AA	SILARX	EQ 10MG BASE/ML	N74721 001	DEC 29, 1998
	SINEQUAN			
AA	+ PFIZER	EQ 10MG BASE/ML	N17516 001	

CREAM; TOPICAL

	ZONALON			
	+ BIOGLAN PHAR	5%	N20126 001	APR 01, 1994

DOXERCALCIFEROL

CAPSULE; ORAL

	HECTOROL			
	+ BONE CARE	2.5 UGM	N20862 001	JUN 09, 1999

INJECTABLE; INJECTION

	HECTOROL			
	+ BONE CARE	2 UGM/ML	N21027 001	APR 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	ADRIAMYCIN PFS			
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N50629 001	DEC 23, 1987
AP	+	200MG/100ML	N50629 002	MAY 03, 1988
AP		2MG/ML	N63165 001	JAN 30, 1991
AP		200MG/100ML	N63165 002	JAN 30, 1991
	ADRIAMYCIN RDF			
AP	+ PHARMACIA AND UPJOHN	10MG/VIAL	N50467 001	
AP	+	20MG/VIAL	N50467 003	MAY 20, 1985
AP	+	50MG/VIAL	N50467 002	
	+	150MG/VIAL	N50467 004	JUL 22, 1987
	DOXORUBICIN HCL			
AP	AM PHARM PARTNERS	2MG/ML	N63277 001	OCT 26, 1995
AP	BEDFORD	2MG/ML	N62975 001	MAR 17, 1989
AP		200MG/100ML	N64097 001	SEP 13, 1994
AP		10MG/VIAL	N62921 001	MAR 17, 1989
AP		20MG/VIAL	N62921 002	MAR 17, 1989
AP		50MG/VIAL	N62921 003	MAR 17, 1989
AP	GENSIA SICOR PHARMS	2MG/ML	N64140 001	JUL 28, 1995
AP		200MG/100ML	N64140 002	JUL 28, 1995
AP	PHARMACHEMIE	2MG/ML	N63336 001	FEB 28, 1995
AP		200MG/100ML	N63336 004	FEB 28, 1995
AP		10MG/VIAL	N63097 001	MAY 21, 1990
AP		20MG/VIAL	N63097 002	MAY 21, 1990
AP		50MG/VIAL	N63097 003	MAY 21, 1990
	RUBEX			
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001	APR 13, 1989

FDA data supplied by DrugPatentWatch.com

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

RUBEX

AP	BRISTOL MYERS SQUIBB	50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	ALZA	2MG/ML	N50718 001	NOV 17, 1995

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	EON	EQ 50MG BASE	N65032 001	JUN 30, 2000
AB		EQ 100MG BASE	N65032 002	JUN 30, 2000
AB	HALSEY	EQ 50MG BASE	N65041 001	APR 28, 2000
AB		EQ 100MG BASE	N65041 002	APR 28, 2000
AB	PAR PHARM	EQ 50MG BASE	N65055 001	DEC 01, 2000
AB		EQ 100MG BASE	N65055 002	DEC 01, 2000
AB	RANBAXY	EQ 50MG BASE	N65053 001	NOV 22, 2000
AB		EQ 100MG BASE	N65053 002	NOV 22, 2000

MONODOX

AB	OCLASSEN	EQ 50MG BASE	N50641 002	FEB 10, 1992
AB	+	EQ 100MG BASE	N50641 001	DEC 29, 1989

FOR SUSPENSION; ORAL

DOXYCHEL

AB	RACHELLE	EQ 25MG BASE/5ML	N61720 001	

VIBRAMYCIN

AB	+ PFIZER	EQ 25MG BASE/5ML	N50006 001	

TABLET; ORAL

DOXYCYCLINE

	PAR PHARM	EQ 50MG BASE	N65070 001	DEC 15, 2000

DOXYCYCLINE

TABLET; ORAL

DOXYCYCLINE

+	PAR PHARM	EQ 100MG BASE	N65070 002	DEC 15, 2000

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+	PFIZER	EQ 50MG BASE/5ML	N50480 001	

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

AB	TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984
AB		EQ 100MG BASE	N62497 002	JUN 15, 1984

DOXYCYCLINE HYCLATE

AB	CHELSEA LABS	EQ 50MG BASE	N62142 001	
AB		EQ 100MG BASE	N62142 002	
AB	DANBURY PHARMA	EQ 50MG BASE	N62031 002	OCT 13, 1982
AB		EQ 100MG BASE	N62031 001	
AB	HALSEY	EQ 50MG BASE	N62418 001	JAN 28, 1983
AB		EQ 100MG BASE	N62418 002	JAN 28, 1983
AB	HOUBA	EQ 50MG BASE	N61717 001	
AB		EQ 100MG BASE	N61717 002	
AB	MUTUAL PHARM	EQ 50MG BASE	N62675 001	JUL 10, 1986
AB		EQ 100MG BASE	N62676 001	JUL 10, 1986
AB	MYLAN	EQ 50MG BASE	N62337 001	MAR 29, 1982
AB		EQ 100MG BASE	N62337 002	MAR 29, 1982
AB	WEST WARD	EQ 50MG BASE	N62396 002	NOV 07, 1984
AB		EQ 100MG BASE	N62396 001	MAY 07, 1984
AB	ZENITH GOLDLINE	EQ 50MG BASE	N62500 001	SEP 11, 1984

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE			
AB	ZENITH GOLDLINE	EQ 100MG BASE	N62500 002	SEP 11, 1984
	PERIOSTAT			
+	COLLAGENEX	EQ 20MG BASE	N50744 001	SEP 30, 1998
	VIBRAMYCIN			
AB	PFIZER	EQ 50MG BASE	N50007 001	
AB	+	EQ 100MG BASE	N50007 002	

CAPSULE, COATED PELLETS; ORAL

	DORYX			
AB	+ FAULDING	EQ 100MG BASE	N50582 001	JUL 22, 1985
AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001	OCT 30, 1985
	DOXYCYCLINE HYCLATE			
AB	SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992

INJECTABLE; INJECTION

	DOXY 100			
AP	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983
	DOXY 200			
AP	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983
	DOXYCHEL HYCLATE			
AP	RACHELLE	EQ 100MG BASE/VIAL	N61953 001	
	DOXYCYCLINE			
AP	BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988
AP		EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988
AP	ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983
AP		EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983
	DOXYCYCLINE HYCLATE			
AP	LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989
AP		EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989
	VIBRAMYCIN			
AP	+ PFIZER	EQ 100MG BASE/VIAL	N50442 002	
AP	+	EQ 200MG BASE/VIAL	N50442 001	

DOXYCYCLINE HYCLATE

LIQUID, EXTENDED RELEASE; PERIODONTAL

	ATRIDOX			
+	ATRIX	EQ 10% W/W	N50751 001	SEP 03, 1998

TABLET; ORAL

	DOXY-LEMMON			
AB	TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985
	DOXYCYCLINE HYCLATE			
AB	DANBURY PHARMA	EQ 100MG BASE	N62421 001	FEB 02, 1983
AB	HALSEY	EQ 100MG BASE	N62391 001	SEP 30, 1982
AB	HOUBA	EQ 100MG BASE	N62269 001	
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982
AB	MUTUAL PHARM	EQ 100MG BASE	N62677 001	JUL 10, 1986
AB	MYLAN	EQ 100MG BASE	N62432 001	FEB 15, 1983
AB	VINTAGE PHARMS	EQ 100MG BASE	N62538 001	APR 07, 1986
AB	ZENITH GOLDLINE	EQ 100MG BASE	N62505 001	SEP 11, 1984
	VIBRA-TABS			
AB	+ PFIZER	EQ 100MG BASE	N50533 001	

DRONABINOL

CAPSULE; ORAL

	MARINOL			
	UNIMED	2.5MG	N18651 001	MAY 31, 1985
		5MG	N18651 002	MAY 31, 1985
+		10MG	N18651 003	MAY 31, 1985

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	ABBOTT	2.5MG/ML	N71981 001	FEB 29, 1988

FDA data supplied by DrugPatentWatch.com

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	ABBOTT	2.5MG/ML	N72272 001	
			AUG 31, 1995	
AP	FAULDING	2.5MG/ML	N71645 001	
			APR 07, 1988	
AP	LUITPOLD	2.5MG/ML	N72123 001	
			OCT 24, 1988	
AP		2.5MG/ML	N72335 001	
			OCT 24, 1988	
	INAPSINE			
AP	+ AKORN	2.5MG/ML	N16796 001	

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

	FENTANYL CITRATE AND DROPERIDOL			
AP	+ ABBOTT	2.5MG/ML; EQ 0.05MG BASE/ML	N71982 001	
			MAY 04, 1988	
AP	ASTRAZENECA	2.5MG/ML; EQ 0.05MG BASE/ML	N72026 001	
			APR 13, 1989	
AP		2.5MG/ML; EQ 0.05MG BASE/ML	N72027 001	
			APR 13, 1989	

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

	DYCLONE			
	+ ASTRAZENECA	0.5%	N09925 002	
	+	1%	N09925 001	

DYPHYLLINE

TABLET; ORAL

	DILOR			
BP	SAVAGE LABS	200MG	N84514 001	
	DILOR-400			
BP	+ SAVAGE LABS	400MG	N84751 001	
	LUFYLLIN			
BP	WALLACE LABS	200MG	N84566 001	
BP		400MG	N84566 002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

	PHOSPHOLINE IODIDE			
	+ AYERST	0.03%	N11963 002	
	+	0.06%	N11963 004	
	+	0.125%	N11963 001	
	+	0.25%	N11963 003	

ECONAZOLE NITRATE

CREAM; TOPICAL

	SPECTAZOLE			
	+ JOHNSON AND JOHNSON	1%	N18751 001	
			DEC 23, 1982	

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

	CALCIUM DISODIUM VERSENATE			
	+ 3M	200MG/ML	N08922 001	

EDETATE DISODIUM

INJECTABLE; INJECTION

	EDETATE DISODIUM			
AP	STERIS	150MG/ML	N80391 001	
	ENDRATE			
AP	+ ABBOTT	150MG/ML	N11355 001	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

	EDROPHONIUM CHLORIDE			
AP	ABBOTT	10MG/ML	N40131 001	
			FEB 24, 1998	
	ENLON			
AP	OHMEDA	10MG/ML	N88873 001	
			AUG 06, 1985	
	REVERSOL			
AP	ORGANON	10MG/ML	N89624 001	
			MAY 13, 1988	
	TENSILON			
AP	+ ICN	10MG/ML	N07959 001	
	TENSILON PRESERVATIVE FREE			
AP	+ ICN	10MG/ML	N07959 002	

FDA data supplied by DrugPatentWatch.com

EDROPHONIUM CHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; EDROPHONIUM CHLORIDE

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA

	DUPONT PHARMS	50MG		N20972 001 SEP 17, 1998
		100MG		N20972 002 SEP 17, 1998
+		200MG		N20972 003 SEP 17, 1998

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA

+	WESTWOOD SQUIBB CLTN	13.9%		N21145 001 JUL 27, 2000

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC
EMADINE

+	ALCON	0.05%		N20706 001 DEC 29, 1997

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	APOTHECON	**2.5MG**		**N75583 001** AUG 22, 2000
AB		**5MG**		**N75583 002** AUG 22, 2000
AB		**10MG**		**N75583 003** AUG 22, 2000
AB		**20MG**		**N75583 004** AUG 22, 2000
AB	CHELSEA LABS	**2.5MG**		**N75501 001** AUG 22, 2000
AB		**5MG**		**N75501 002** AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	CHELSEA LABS	**10MG**		**N75501 003** AUG 22, 2000
AB		**20MG**		**N75501 004** AUG 22, 2000
AB	EON	**2.5MG**		**N75621 001** AUG 22, 2000
AB		**5MG**		**N75621 002** AUG 22, 2000
AB		**10MG**		**N75621 003** AUG 22, 2000
AB		**20MG**		**N75621 004** AUG 22, 2000
AB	GENEVA PHARMS	**2.5MG**		**N75048 001** AUG 22, 2000
AB		**5MG**		**N75048 002** AUG 22, 2000
AB		**10MG**		**N75048 003** AUG 22, 2000
AB		**20MG**		**N75048 004** AUG 22, 2000
AB	GENPHARM	**2.5MG**		**N75472 001** AUG 22, 2000
AB		**5MG**		**N75472 002** AUG 22, 2000
AB		**10MG**		**N75472 003** AUG 22, 2000
AB		**20MG**		**N75472 004** AUG 22, 2000
AB	KRKA DD NOVO MESTO	**2.5MG**		**N75370 001** AUG 22, 2000
AB		**5MG**		**N75370 002** AUG 22, 2000
AB		**10MG**		**N75369 001** AUG 22, 2000
AB		**20MG**		**N75369 002** AUG 22, 2000
AB	LEK PHARM	**2.5MG**		**N75496 001** AUG 22, 2000
AB		**5MG**		**N75496 002** AUG 22, 2000
AB		**10MG**		**N75459 001** AUG 22, 2000
AB		**20MG**		**N75459 002** AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL

	ENALAPRIL MALEATE			
AB	MYLAN	2.5MG	N75480 001	AUG 22, 2000
AB		5MG	N75480 002	AUG 22, 2000
AB		10MG	N75480 003	AUG 22, 2000
AB		20MG	N75480 004	AUG 22, 2000
AB	RANBAXY	2.5MG	N75556 001	AUG 22, 2000
AB		5MG	N75556 002	AUG 22, 2000
AB		10MG	N75556 003	AUG 22, 2000
AB		20MG	N75556 004	AUG 22, 2000
AB	TEVA	2.5MG	N75479 001	AUG 22, 2000
AB		5MG	N75479 002	AUG 22, 2000
AB		10MG	N75479 003	AUG 22, 2000
AB		20MG	N75479 004	AUG 22, 2000
AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
AB		5MG	N75483 002	AUG 22, 2000
AB		10MG	N75483 003	AUG 22, 2000
AB		20MG	N75483 004	AUG 22, 2000
AB	ZENITH GOLDLINE	2.5MG	N75482 001	AUG 22, 2000
AB		5MG	N75482 002	AUG 22, 2000
AB		10MG	N75482 003	AUG 22, 2000
AB		20MG	N75482 004	AUG 22, 2000
	VASOTEC			
AB	MERCK	2.5MG	N18998 005	JUL 26, 1988
AB		5MG	N18998 001	DEC 24, 1985

ENALAPRIL MALEATE

TABLET; ORAL

	VASOTEC			
AB	MERCK	10MG	N18998 002	DEC 24, 1985
AB +		20MG	N18998 003	DEC 24, 1985

ENALAPRIL MALEATE; *MULTIPLE*

SEE DILTIAZEM MALATE; ENALAPRIL MALEATE

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

	LEXXEL			
+	ASTRAZENECA	5MG;2.5MG	N20668 002	OCT 28, 1998
+		5MG;5MG	N20668 001	DEC 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	VASERETIC			
	MERCK	5MG;12.5MG	N19221 003	JUL 12, 1995
+		10MG;25MG	N19221 001	OCT 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

	ENALAPRILAT			
AP	ABBOTT	1.25MG/ML	N75456 001	AUG 22, 2000
AP		1.25MG/ML	N75458 001	AUG 22, 2000
AP	BEDFORD	1.25MG/ML	N75634 001	AUG 22, 2000
AP	FAULDING	1.25MG/ML	N75571 001	AUG 22, 2000
AP	GENSIA SICOR PHARMS	1.25MG/ML	N75578 001	AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC
AP + MERCK 1.25MG/ML N19309 001 FEB 09, 1988

ENFLURANE

LIQUID; INHALATION
ENFLURANE
AN ABBOTT 99.9% N70803 001 SEP 08, 1987
AN INHALON 99.9% N74396 001 JUL 29, 1994

ETHRANE
AN + BAXTER PHARM PROD 99.9% N17087 001

ENOXACIN

TABLET; ORAL
PENETREX
AVENTIS 200MG N19616 004 DEC 31, 1991
+ 400MG N19616 005 DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS
LOVENOX
+ AVENTIS 30MG/0.3ML N20164 001 MAR 29, 1993
+ 40MG/0.4ML N20164 002 JAN 30, 1998
+ 60MG/0.6ML N20164 003 MAR 27, 1998
+ 80MG/0.8ML N20164 004 MAR 27, 1998
+ 100MG/ML N20164 005 MAR 27, 1998
+ 90MG/0.6ML N20164 006 JUN 02, 2000
+ 120MG/0.8ML N20164 007 JUN 02, 2000

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS
LOVENOX
+ AVENTIS 150MG/ML N20164 008 JUN 02, 2000

ENTACAPONE

TABLET; ORAL
COMTAN
+ ORION 200MG N20796 001 OCT 19, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE SULFITE-FREE
FORREST LABS 1.5MG/AMP N07942 003 FEB 05, 1999
+ 5MG/ML N07942 001

INJECTABLE; INTRAMUSCULAR
EPI E Z PEN JR
+ MERIDIAN MEDCL TECHN 0.15MG/DELIVERY N19430 004 AUG 03, 1995

EPIPEN
+ MERIDIAN MEDCL TECHN 0.3MG/DELIVERY N19430 001 DEC 22, 1987

EPIPEN E Z PEN
+ MERIDIAN MEDCL TECHN 0.3MG/DELIVERY N19430 003 AUG 03, 1995

EPIPEN JR.
+ MERIDIAN MEDCL TECHN 0.15MG/DELIVERY N19430 002 DEC 22, 1987

EPINEPHRINE; *MULTIPLE*
SEE ARTICAINE HYDROCHLORIDE; EPINEPHRINE
SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE
AP ABBOTT 0.005MG/ML;0.5% N89635 001 JUN 21, 1988

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP		ABBOTT	0.005MG/ML;1%	N89649 001 JUN 21, 1988
AP			0.005MG/ML;1.5%	N88571 001 SEP 13, 1985
AP			0.005MG/ML;1.5%	N89645 001 JUN 21, 1988
AP			0.005MG/ML;1.5%	N89650 001 JUN 21, 1988
AP			0.005MG/ML;2%	N89651 001 JUN 21, 1988
AP			0.01MG/ML;1%	N89644 001 JUN 21, 1988
AP			0.01MG/ML;2%	N89646 001 JUN 21, 1988
AP		EASTMAN KODAK	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP			0.02MG/ML;2%	N40057 001 FEB 26, 1993
AP		ELKINS SINN	0.01MG/ML;1%	N80406 001
AP			0.01MG/ML;2%	N80406 002
AP		GRAHAM CHEM	0.01MG/ML;2%	N80504 004 OCT 19, 1983
AP			0.02MG/ML;2%	N80504 005 OCT 19, 1983

LIDOCAINE HCL W/ EPINEPHRINE

AP		DELL LABS	0.01MG/ML;1%	N83389 001
AP			0.01MG/ML;2%	N83390 001
AP		INTL MEDICATION	0.01MG/ML;1%	N86402 001
AP		STERIS	0.01MG/ML;1%	N80377 003
AP			0.01MG/ML;2%	N80377 004

LIDOCATON

AP		PHARMATON	0.01MG/ML;2%	N84729 001 AUG 17, 1983
AP			0.02MG/ML;2%	N84728 001 AUG 17, 1983

OCTOCAINE

AP		SEPTODONT	0.01MG/ML;2%	N84048 001
AP	+		0.02MG/ML;2%	N84048 002

XYLOCAINE W/ EPINEPHRINE

AP	+	ASTRAZENECA	0.005MG/ML;0.5%	N06488 012
AP	+		0.005MG/ML;1%	N06488 018 NOV 13, 1986
AP	+		0.005MG/ML;1.5%	N06488 017
AP	+		0.005MG/ML;2%	N06488 019 NOV 13, 1986

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

AP	+	ASTRAZENECA	0.01MG/ML;1%	N06488 004
AP	+		0.01MG/ML;2%	N06488 003

SOLUTION; IONTOPHORESIS

IONTOCAINE

+	IOMED	0.01MG/ML;2%	N20530 001 DEC 21, 1995

EPINEPHRINE BITARTRATE; *MULTIPLE*

SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+	ASTRAZENECA	0.005MG/ML;1%	N17751 006
+		0.005MG/ML;1.5%	N17751 007

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+	DEPROCO	EQ 0.02MG BASE/ML;2%	N88389 001 JAN 22, 1985

LIGNOSPAN STANDARD

+	DEPROCO	EQ 0.01MG BASE/ML;2%	N88390 001 JAN 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

+	ASTRAZENECA	0.005MG/ML;4%	N14763 008

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENCE

+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001 SEP 15, 1999

FDA data supplied by DrugPatentWatch.com

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
FLOLAN
+ GLAXO WELLCOME — EQ 0.5MG BASE/VIAL — N20444 001 SEP 20, 1995
+ — EQ 1.5MG BASE/VIAL — N20444 002 SEP 20, 1995

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
UNIMED PHARMS — EQ 300MG BASE — N20738 004 DEC 22, 1997
EQ 400MG BASE — N20738 005 DEC 22, 1997
+ EQ 600MG BASE — N20738 006 MAY 27, 1999

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN
+ COR — 75MG/100ML — N20718 002 MAY 18, 1998
+ — 2MG/ML — N20718 001 MAY 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL
DRISDOL
AA + SANOFI SYNTHELABO — **50,000 IU** — **N03444 001**
VITAMIN D
AA BANNER PHARMACAPS — **50,000 IU** — **N80704 001**
AA IMPAX LABS — **50,000 IU** — **N80951 001**

ERGOCALCIFEROL; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

ERGOLOID MESYLATES

CAPSULE; ORAL
HYDERGINE LC
+ NOVARTIS — 1MG — N18706 001 JAN 18, 1983

SOLUTION; ORAL
HYDERGINE
NOVARTIS — 1MG/ML — N18418 001

TABLET; ORAL
ERGOLOID MESYLATES
AB DANBURY PHARMA — **1MG** — **N87244 001** AUG 16, 1982
AB MUTUAL PHARM — **1MG** — **N81113 001** OCT 31, 1991
HYDERGINE
AB + NOVARTIS — **1MG** — **N17993 001**

TABLET; SUBLINGUAL
ERGOLOID MESYLATES
AA DANBURY PHARMA — **0.5MG** — **N87233 001**
AA — **1MG** — **N87183 001**
GERIMAL
AA CHELSEA LABS — **0.5MG** — **N86189 001**
AA — **1MG** — **N86188 001**
HYDERGINE
AA + NOVARTIS — **0.5MG** — **N09087 002**
AA + — **1MG** — **N09087 001**
HYDROGENATED ERGOT ALKALOIDS
AA ZENITH GOLDLINE — **1MG** — **N87185 001**

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
+ LOTUS BIOCHEM — 2MG — N87693 001 FEB 24, 1983

ERGOTAMINE TARTRATE; *MULTIPLE*
SEE CAFFEINE; ERGOTAMINE TARTRATE

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ FAULDING	250MG	N50536 001	
	ERYTHROMYCIN			
AB	ABBOTT	250MG	N62746 001	DEC 22, 1986
AB	BARR	250MG	N63098 001	MAY 04, 1989

GEL; TOPICAL

	EMGEL			
AT	GLAXO WELLCOME	2%	N63107 001	AUG 23, 1991
	ERYGEL			
AT	+ ALLERGAN HERBERT	2%	N50617 001	OCT 21, 1987
	ERYTHROMYCIN			
AT	ALTANA	2%	N64184 001	SEP 30, 1997
AT	STIEFEL	2%	N63211 001	JAN 29, 1993

LOTION; TOPICAL

	E-SOLVE 2			
	+ SYOSSET	2%	N62467 001	JUL 03, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN			
AT	AKORN	0.5%	N64030 001	JUL 18, 1996
AT	BAUSCH AND LOMB	0.5%	N64067 001	JUL 29, 1994
AT	FOUGERA	0.5%	N62447 001	SEP 26, 1983
	ILOTYCIN			
AT	+ DISTA	0.5%	N50368 001	

OINTMENT; TOPICAL

	AKNE-MYCIN			
	+ HEALTHPOINT	2%	N50584 001	JAN 10, 1985

SOLUTION; TOPICAL

	A/T/S			
AT	AVENTIS PHARMS	2%	N62405 001	NOV 18, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

	C-SOLVE-2			
AT	BIOGLAN PHAR	2%	N62468 001	JUL 03, 1985
	ERYDERM			
AT	ABBOTT	2%	N62290 001	
	ERYMAX			
AT	ALLERGAN HERBERT	2%	N62508 002	JUL 11, 1985
	ERYTHRA-DERM			
AT	PADDOCK	2%	N62687 001	FEB 05, 1988
	ERYTHRO-STATIN			
AT	HI TECH PHARMA	2%	N64101 001	OCT 22, 1996
	ERYTHROMYCIN			
AT	ALPHARMA	2%	N62326 001	APR 19, 1982
AT	ALTANA	2%	N64187 001	SEP 30, 1997
AT	BAUSCH AND LOMB	2%	N64039 001	JAN 27, 1994
AT	CLAY PARK	2%	N63038 001	JAN 11, 1991
AT	MORTON GROVE	2%	N62825 001	OCT 23, 1987
AT	STIEFEL	2%	N64127 001	FEB 14, 1997
	SANSAC			
AT	HEALTHPOINT	2%	N62522 001	JAN 24, 1985
	STATICIN			
AT	+ WESTWOOD SQUIBB	1.5%	N50526 001	
	T-STAT			
AT	+ WESTWOOD SQUIBB	2%	N62436 001	MAR 09, 1983

SWAB; TOPICAL

	C-SOLVE-2			
AT	ZENITH GOLDLINE	2%	N62751 001	JUL 30, 1993
	ERYCETTE			
AT	+ J AND J	2%	N50594 001	FEB 15, 1985
	ERYTHROMYCIN			
AT	STIEFEL	2%	N64126 001	JUL 03, 1996

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

SWAB; TOPICAL

	ERYTHROMYCIN			
AT	STIEFEL	2%	N64128 001	
			JUL 03, 1996	
	T-STAT			
AT	WESTWOOD SQUIBB	2%	N62748 001	
			JUL 23, 1987	

TABLET; ORAL

	ERYTHROMYCIN			
	ABBOTT	250MG	N61621 001	
+		500MG	N61621 002	

TABLET, COATED PARTICLES; ORAL

	PCE			
	ABBOTT	333MG	N50611 001	
			SEP 09, 1986	
+		500MG	N50611 002	
			AUG 22, 1990	

TABLET, DELAYED RELEASE; ORAL

	E-BASE			
AB	BARR	333MG	N63028 001	
			MAY 15, 1990	
AB		333MG	N63086 001	
			MAY 15, 1990	
AB		500MG	N62999 001	
			NOV 25, 1988	
	E-MYCIN			
AB	KNOLL PHARM	250MG	N60272 001	
AB		333MG	N60272 002	
	ERY-TAB			
AB	+ ABBOTT	250MG	N62298 001	
AB	+	333MG	N62298 003	
			MAR 29, 1982	
AB	+	500MG	N62298 002	
	ILOTYCIN			
AB	DISTA	250MG	N61910 001	

ERYTHROMYCIN; *MULTIPLE*
SEE BENZOYL PEROXIDE; ERYTHROMYCIN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

	ERYTHROMYCIN ESTOLATE			
AB	BARR	EQ 250MG BASE	N62162 002	
AB	DANBURY PHARMA	EQ 250MG BASE	N62087 001	
	ILOSONE			
AB	+ LILLY	EQ 250MG BASE	N61897 002	
		EQ 125MG BASE	N61897 001	

FOR SUSPENSION; ORAL

	ILOSONE			
	+ DISTA	EQ 125MG BASE/5ML	N61893 001	

SUSPENSION; ORAL

	ERYTHROMYCIN ESTOLATE			
AB	ALPHARMA	EQ 125MG BASE/5ML	N62353 001	
			NOV 18, 1982	
AB		EQ 250MG BASE/5ML	N62409 001	
			DEC 16, 1982	
	ILOSONE			
AB	LILLY	EQ 125MG BASE/5ML	N50010 001	
AB	+	EQ 250MG BASE/5ML	N50010 002	

SUSPENSION/DROPS; ORAL

	ILOSONE			
	+ LILLY	EQ 100MG BASE/ML	N61894 003	

TABLET; ORAL

	ILOSONE			
	+ LILLY	EQ 500MG BASE	N61896 001	

TABLET, CHEWABLE; ORAL

	ILOSONE			
	DISTA	EQ 125MG BASE	N61895 001	
	+	EQ 250MG BASE	N61895 002	

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

	E.E.S.			
AB	ABBOTT	EQ 200MG BASE/5ML	N50207 001	
	ERYPED			
AB	ABBOTT	EQ 200MG BASE/5ML	N50207 003	
			MAR 30, 1987	
	+	EQ 400MG BASE/5ML	N50207 002	
	ERYTHROMYCIN ETHYLSUCCINATE			
AB	BARR	EQ 200MG BASE/5ML	N62055 001	

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

	E.E.S. 200			
AB	ABBOTT	EQ 200MG BASE/5ML	N61639 001	
	E.E.S. 400			
AB	+ ABBOTT	EQ 400MG BASE/5ML	N61639 002	
	ERYTHROMYCIN ETHYLSUCCINATE			
AB	ALPHARMA	EQ 200MG BASE/5ML	N62200 001	
AB		EQ 400MG BASE/5ML	N62200 002	
	PEDIAMYCIN			
AB	ROSS LABS	EQ 200MG BASE/5ML	N62304 001	
	PEDIAMYCIN 400			
AB	ROSS LABS	EQ 400MG BASE/5ML	N62304 002	

TABLET; ORAL

	E.E.S. 400			
AB	+ ABBOTT	EQ 400MG BASE	N61905 002	AUG 12, 1982
	ERYTHROMYCIN ETHYLSUCCINATE			
AB	BARR	EQ 400MG BASE	N62256 001	
AB	MYLAN	EQ 400MG BASE	N62847 001	SEP 14, 1988

TABLET, CHEWABLE; ORAL

	E.E.S.			
AB	+ ABBOTT	EQ 200MG BASE	N50297 002	
	ERYPED			
AB	ABBOTT	EQ 200MG BASE	N50297 003	JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL			
AB	BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001	MAY 20, 1988
	ERYZOLE			
AB	ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001	JUN 15, 1988
	PEDIAZOLE			
AB	+ ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001	

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

	ILOTYCIN GLUCEPTATE		
+	DISTA	EQ 250MG BASE/VIAL	N50370 001
+		EQ 500MG BASE/VIAL	N50370 002
+		EQ 1GM BASE/VIAL	N50370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

	ERYTHROCIN			
AP	+ ABBOTT	EQ 500MG BASE/VIAL	N50182 002	
AP		EQ 500MG BASE/VIAL	N50609 001	SEP 24, 1986
AP		EQ 500MG BASE/VIAL	N62638 001	OCT 31, 1986
AP	+	EQ 1GM BASE/VIAL	N50182 003	
AP		EQ 1GM BASE/VIAL	N50609 002	SEP 24, 1986
AP		EQ 1GM BASE/VIAL	N62638 002	OCT 31, 1986
	ERYTHROMYCIN			
AP	ELKINS SINN	EQ 500MG BASE/VIAL	N62563 001	MAR 28, 1985
AP		EQ 1GM BASE/VIAL	N62563 002	MAR 28, 1985
	ERYTHROMYCIN LACTOBIONATE			
AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N63253 001	JUL 30, 1993
AP		EQ 1GM BASE/VIAL	N63253 002	JUL 30, 1993
AP	LEDERLE	EQ 500MG BASE/VIAL	N62993 001	MAY 09, 1989
AP		EQ 1GM BASE/VIAL	N62993 002	MAY 09, 1989

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ERYTHROCIN STEARATE			
AB	ABBOTT	EQ 250MG BASE	N60359 001	
AB	+	EQ 500MG BASE	N60359 003	
	ERYTHROMYCIN STEARATE			
AB	BARR	EQ 250MG BASE	N61591 001	
AB		EQ 500MG BASE	N63179 001	MAY 15, 1990

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

AB	CHELSEA LABS	**EQ 250MG BASE**	**N62121 002**	
AB		**EQ 500MG BASE**	**N62121 001**	
AB	MYLAN	**EQ 250MG BASE**	**N61505 001**	
AB		**EQ 500MG BASE**	**N61505 002**	
AB	ZENITH GOLDLINE	**EQ 250MG BASE**	**N61461 001**	
AB		**EQ 500MG BASE**	**N61461 002**	

WYAMYCIN S

AB	WYETH AYERST	**EQ 250MG BASE**	**N61675 001**	
AB		**EQ 500MG BASE**	**N61675 002**	

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+	BAXTER PHARM PROD	10MG/ML	N19386 001	AUG 15, 1988
+		250MG/ML	N19386 002	DEC 31, 1986

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB	TEVA	**1MG**	**N74921 001**	JUL 10, 1997
AB		**2MG**	**N74921 002**	JUL 10, 1997
AB	WATSON LABS	**1MG**	**N74818 001**	AUG 19, 1997
AB		**2MG**	**N74818 002**	AUG 19, 1997
AB	ZENITH GOLDLINE	**1MG**	**N74826 001**	JUL 03, 1997
AB		**2MG**	**N74826 002**	JUL 03, 1997

PROSOM

AB	ABBOTT	**1MG**	**N19080 001**	DEC 26, 1990
AB +		**2MG**	**N19080 002**	DEC 26, 1990

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT	0.01%	N86069 001	JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX	WATSON LABS	0.05MG/24HR	N20655 001	DEC 20, 1996
BX		0.075MG/24HR	N20655 002	DEC 20, 1996
BX		0.1MG/24HR	N20655 003	DEC 20, 1996

CLIMARA

AB +	BERLEX LABS	**0.05MG/24HR**	**N20375 001**	DEC 22, 1994
AB +		**0.1MG/24HR**	**N20375 002**	DEC 22, 1994
BX +		0.025MG/24HR	N20375 004	MAR 05, 1999
BX +		0.075MG/24HR	N20375 003	MAR 23, 1998

ESCLIM

BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001	AUG 04, 1998
BX		0.0375MG/24HR	N20847 002	AUG 04, 1998
BX		0.05MG/24HR	N20847 003	AUG 04, 1998
BX		0.075MG/24HR	N20847 004	AUG 04, 1998
BX		0.1MG/24HR	N20847 005	AUG 04, 1998

ESTRADERM

BX +	NOVARTIS	0.05MG/24HR	N19081 002	SEP 10, 1986
BX +		0.1MG/24HR	N19081 003	SEP 10, 1986

ESTRADIOL

AB	MYLAN TECHNOLOGIES	**0.05MG/24HR**	**N75233 001**	FEB 24, 2000
AB		**0.1MG/24HR**	**N75182 001**	FEB 24, 2000

FEMPATCH

BX +	PARKE DAVIS	0.025MG/24HR	N20417 001	DEC 03, 1996

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE			
AB	+ NOVARTIS	0.0375MG/24HR	**N20323 001**	OCT 28, 1994
AB	+	0.05MG/24HR	**N20323 002**	OCT 28, 1994
AB	+	0.075MG/24HR	**N20323 003**	OCT 28, 1994
AB	+	0.1MG/24HR	**N20323 004**	OCT 28, 1994
	+	0.025MG/24HR	N20323 005	AUG 16, 2000
	VIVELLE-DOT			
AB	NOVARTIS	0.0375MG/24HR	**N20538 005**	JAN 08, 1999
AB		0.05MG/24HR	**N20538 006**	JAN 08, 1999
AB		0.075MG/24HR	**N20538 007**	JAN 08, 1999
AB		0.1MG/24HR	**N20538 008**	JAN 08, 1999

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING			
	+ PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001	APR 26, 1996

TABLET; ORAL

	ESTRACE			
AB	BRISTOL MYERS SQUIBB	0.5MG	**N81295 001**	JUN 30, 1993
AB		1MG	**N84499 001**	
AB	+	2MG	**N84500 001**	
	ESTRADIOL			
AB	APPLIED ANAL	0.5MG	**N40138 001**	JAN 30, 1998
AB		1MG	**N40138 002**	JAN 30, 1998
AB		2MG	**N40138 003**	JAN 30, 1998
AB	BARR	0.5MG	**N40197 001**	OCT 22, 1997
AB		1MG	**N40197 002**	OCT 22, 1997
AB		2MG	**N40197 003**	OCT 22, 1997

ESTRADIOL

TABLET; ORAL

	ESTRADIOL			
AB	ESI LEDERLE	0.5MG	**N40275 001**	DEC 29, 1998
AB		1MG	**N40275 002**	DEC 29, 1998
AB		2MG	**N40275 003**	DEC 29, 1998
AB	MYLAN	0.5MG	**N40326 001**	APR 21, 1999
AB		1MG	**N40326 002**	APR 21, 1999
AB		2MG	**N40326 003**	APR 21, 1999
AB	WATSON LABS	0.5MG	**N40114 003**	MAR 14, 1996
AB		1MG	**N40114 001**	MAR 14, 1996
AB		2MG	**N40114 002**	MAR 14, 1996
	GYNODIOL			
AB	DURAMED	0.5MG	**N40212 001**	DEC 29, 1997
AB		1MG	**N40212 002**	DEC 29, 1997
AB		2MG	**N40212 004**	DEC 29, 1997
		1.5MG	N40212 003	DEC 29, 1997
	INNOFEM			
AB	NOVO NORDISK	0.5MG	**N40312 001**	NOV 19, 1999
AB		1MG	**N40312 002**	NOV 19, 1999
AB		2MG	**N40312 003**	NOV 19, 1999

TABLET; VAGINAL

	VAGIFEM			
	+ NOVO NORDISK	25 UGM	N20908 001	MAR 26, 1999

FDA data supplied by DrugPatentWatch.com

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

	COMBIPATCH			
	AVENTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	
			AUG 07, 1998	
+		0.05MG/24HR;0.25MG/24HR	N20870 002	
			AUG 07, 1998	

TABLET; ORAL

	ACTIVELLE			
+	NOVO NORDISK	1MG;0.5MG	N20907 001	
			NOV 18, 1998	

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

	ORTHO-PREFEST			
+	JOHNSON RW	1MG,1MG;0.09MG,N/A	N21040 001	
			OCT 22, 1999	

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

		DEPO-ESTRADIOL			
AO	+	PHARMACIA AND UPJOHN	**5MG/ML**		**N85470 003**
		ESTRADIOL CYPIONATE			
AO		STERIS	**5MG/ML**		**N85620 001**

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

	LUNELLE			
+	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N20874 001	
			OCT 05, 2000	

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

		DEPO-TESTADIOL			
AO	+	PHARMACIA AND UPJOHN	**2MG/ML;50MG/ML**		**N17968 001**
		TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE			
AO		STERIS	**2MG/ML;50MG/ML**		**N85603 001**
				MAR 13, 1986	

ESTRADIOL VALERATE

INJECTABLE; INJECTION

		DELESTROGEN			
AO	+	BRISTOL MYERS SQUIBB	**20MG/ML**		**N09402 004**
AO	+		**40MG/ML**		**N09402 003**
	+		10MG/ML		N09402 002
		ESTRADIOL VALERATE			
AO		STERIS	**20MG/ML**		**N83547 001**
AO			**40MG/ML**		**N83714 001**

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	DITATE-DS			
+	SAVAGE LABS	8MG/ML;180MG/ML	N86423 001	
	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
+	STERIS	4MG/ML;90MG/ML	N85865 001	

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

	EMCYT		
+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N18045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

	PREMARIN		
+	AYERST	0.625MG/GM	N20216 001

INJECTABLE; INJECTION

	PREMARIN		
+	WYETH AYERST	25MG/VIAL	N10402 001

TABLET; ORAL

	PREMARIN		
	WYETH AYERST	0.3MG	N04782 003
+		0.625MG	N04782 004
		0.9MG	N04782 005
			JAN 26, 1984
+		1.25MG	N04782 001
		2.5MG	N04782 002

FDA data supplied by DrugPatentWatch.com

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

	PREMPHASE (PREMARIN;CYCRIN 14/14)			
+	WYETH AYERST	0.625MG,0.625MG;N/A,5MG	N20303 002	DEC 30, 1994
	PREMPHASE 14/14			
+	WYETH AYERST	0.625MG,0.625MG;N/A,5MG	N20527 002	NOV 17, 1995
	PREMPRO (PREMARIN;CYCRIN 14/14)			
+	WYETH AYERST	0.625MG,0.625MG;2.5MG, 2.5MG	N20303 001	DEC 30, 1994
	PREMPRO 14/14			
+	WYETH AYERST	0.625MG,0.625MG;2.5MG, 2.5MG	N20527 001	NOV 17, 1995
+		0.625MG,0.625MG;5MG,5MG	N20527 003	JAN 09, 1998

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

	PMB 200			
+	WYETH AYERST	0.45MG;200MG	N10971 005	
	PMB 400			
+	WYETH AYERST	0.45MG;400MG	N10971 003	

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN			
	DURAMED	0.625MG	N20992 002	MAR 24, 1999
		0.9MG	N20992 003	MAR 24, 1999
+		1.25MG	N20992 004	MAR 13, 2000

ESTROGENS, ESTERIFIED

TABLET; ORAL

	ESTRATAB			
BP	SOLVAY	0.3MG	N86715 001	
BP +		0.625MG	N83209 001	
	MENEST			
BP	MONARCH PHARMS	0.3MG	N84951 001	

ESTROGENS, ESTERIFIED

TABLET; ORAL

	MENEST			
BP	MONARCH PHARMS	0.625MG	N84948 001	
		1.25MG	N84950 001	
+		2.5MG	N84949 001	

ESTRONE

INJECTABLE; INJECTION

	ESTRONE			
+	STERIS	5MG/ML	N85239 001	

ESTROPIPATE

CREAM; VAGINAL

	OGEN			
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001	

TABLET; ORAL

	ESTROPIPATE			
AB	BARR	**0.75MG**	**N40135 001**	NOV 27, 1996
AB		**1.5MG**	**N40135 002**	NOV 27, 1996
AB		**3MG**	**N40135 003**	NOV 27, 1996
AB	DURAMED	**0.75MG**	**N40296 001**	NOV 01, 1999
AB		**1.5MG**	**N40296 002**	NOV 01, 1999
AB		**3MG**	**N40296 003**	NOV 01, 1999
AB	MYLAN	**0.75MG**	**N40359 001**	AUG 26, 1999
AB		**1.5MG**	**N40359 002**	AUG 26, 1999
AB		**3MG**	**N40359 003**	AUG 26, 1999
AB	WATSON LABS	**0.75MG**	**N81213 001**	SEP 23, 1993
AB		**1.5MG**	**N81214 001**	SEP 23, 1993
AB		**3MG**	**N81215 001**	SEP 23, 1993

FDA data supplied by DrugPatentWatch.com

ESTROPIPATE

TABLET; ORAL

	ESTROPIPATE			
AB	WATSON LABS	**6MG**	**N81216 001**	SEP 23, 1993
	OGEN .625			
AB	PHARMACIA AND UPJOHN	**0.75MG**	**N83220 001**	
	OGEN 1.25			
AB	PHARMACIA AND UPJOHN	**1.5MG**	**N83220 002**	
	OGEN 2.5			
AB +	PHARMACIA AND UPJOHN	**3MG**	**N83220 003**	
	OGEN 5			
AB	PHARMACIA AND UPJOHN	**6MG**	**N83220 004**	
	ORTHO-EST			
AB	JOHNSON RW	**0.75MG**	**N89567 001**	FEB 27, 1991
AB		**1.5MG**	**N89582 001**	JUL 17, 1991

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

	EDECRIN		
+	MERCK	EQ 50MG BASE/VIAL	N16093 001

ETHACRYNIC ACID

TABLET; ORAL

	EDECRIN		
	MERCK	25MG	N16092 001
+		50MG	N16092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	ETHAMBUTOL HCL			
AB	WEST WARD	**100MG**	**N75095 001**	NOV 30, 1999
AB		**400MG**	**N75095 002**	NOV 30, 1999
	MYAMBUTOL			
AB	LEDERLE	**100MG**	**N16320 001**	
AB +		**400MG**	**N16320 003**	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN			
+	QUESTCOR PHARM	50MG/ML	N19357 001	DEC 22, 1988

ETHCHLORVYNOL

CAPSULE; ORAL

	PLACIDYL		
+	ABBOTT	200MG	N10021 007
+		500MG	N10021 002
+		750MG	N10021 010

ETHINYL ESTRADIOL

TABLET; ORAL

	ESTINYL		
	SCHERING	0.02MG	N05292 001
		0.05MG	N05292 002
+		0.5MG	N05292 003

ETHINYL ESTRADIOL; *MULTIPLE*

SEE DESOGESTREL; ETHINYL ESTRADIOL

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	DEMULEN 1/35-21			
AB +	SEARLE	**0.035MG;1MG**	**N18168 001**	
	DEMULEN 1/50-21			
AB +	SEARLE	**0.05MG;1MG**	**N16927 001**	
	ZOVIA 1/35E-21			
AB	WATSON LABS	**0.035MG;1MG**	**N72720 001**	DEC 30, 1991
	ZOVIA 1/50E-21			
AB	WATSON LABS	**0.05MG;1MG**	**N72722 001**	DEC 30, 1991

TABLET; ORAL-28

	DEMULEN 1/35-28			
AB	SEARLE	**0.035MG;1MG**	**N18160 001**	
	DEMULEN 1/50-28			
AB	SEARLE	**0.05MG;1MG**	**N16936 001**	

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

	ZOVIA 1/35E-28			
AB	WATSON LABS	**0.035MG;1MG**	**N72721 001**	DEC 30, 1991
	ZOVIA 1/50E-28			
AB	WATSON LABS	**0.05MG;1MG**	**N72723 001**	DEC 30, 1991

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

	PREVEN EMERGENCY CONTRACEPTIVE KIT			
	+ GYNETICS	0.05MG;0.25MG	N20946 001	SEP 01, 1998

TABLET; ORAL-21

	ALESSE			
BX	+ WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997
	LEVLITE			
BX	+ BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998
	LEVORA 0.15/30-21			
AB	WATSON LABS	**0.03MG;0.15MG**	**N73592 001**	DEC 13, 1993
	NORDETTE-21			
AB	+ WYETH AYERST	**0.03MG;0.15MG**	**N18668 001**	MAY 10, 1982
	TRIPHASIL-21			
AB	+ WYETH AYERST	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N19192 001**	NOV 01, 1984
	TRIVORA-21			
AB	WATSON LABS	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N74538 001**	DEC 18, 1997

TABLET; ORAL-28

	ALESSE			
BX	WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997
	LEVLITE			
BX	BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998
	LEVORA 0.15/30-28			
AB	WATSON LABS	**0.03MG;0.15MG**	**N73594 001**	DEC 13, 1993

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

	NORDETTE-28			
AB	WYETH AYERST	**0.03MG;0.15MG**	**N18782 001**	JUL 21, 1982
	TRIPHASIL-28			
AB	WYETH AYERST	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N19190 001**	NOV 01, 1984
	TRIVORA-28			
AB	WATSON LABS	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG**	**N74538 002**	DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	WATSON LABS	**0.035MG;0.5MG**	**N17566 001**	
	GENCEPT 0.5/35-21			
AB	BARR	**0.035MG;0.5MG**	**N72692 001**	FEB 28, 1992
	GENCEPT 1/35-21			
AB	BARR	**0.035MG;1MG**	**N72693 001**	FEB 28, 1992
	GENCEPT 10/11-21			
AB	BARR	**0.035MG,0.035MG;0.5MG,1MG**	**N72694 001**	FEB 28, 1992
	MODICON 21			
AB	+ JOHNSON RW	**0.035MG;0.5MG**	**N17488 001**	
	NORCEPT-E 1/35 21			
AB	GYNOPHARMA	**0.035MG;1MG**	**N71545 001**	FEB 09, 1989
	NORETHIN 1/35E-21			
AB	WATSON LABS	**0.035MG;1MG**	**N71480 001**	APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	**0.035MG;0.5MG**	**N70684 001**	JAN 29, 1987
AB		**0.035MG;1MG**	**N70685 001**	JAN 29, 1987
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71043 001**	APR 01, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
AB	+ WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71041 001**	SEP 24, 1991

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORINYL 1+35 21-DAY			
AB	WATSON LABS	**0.035MG;1MG**	**N17565 001**	
	ORTHO-NOVUM 1/35-21			
AB	+ JOHNSON RW	**0.035MG;1MG**	**N17489 002**	
	ORTHO-NOVUM 10/11-21			
AB	+ JOHNSON RW	**0.035MG,0.035MG;0.5MG,1MG**	**N18354 001**	JAN 11, 1982
	ORTHO-NOVUM 7/7/7-21			
	+ JOHNSON RW	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N18985 001	APR 04, 1984
	OVCON-35			
	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127 001	
	TRI-NORINYL 21-DAY			
	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	WATSON LABS	**0.035MG;0.5MG**	**N17743 001**	
	GENCEPT 0.5/35-28			
AB	BARR	**0.035MG;0.5MG**	**N72695 001**	FEB 28, 1992
	GENCEPT 1/35-28			
AB	BARR	**0.035MG;1MG**	**N72696 001**	FEB 28, 1992
	GENCEPT 10/11-28			
AB	BARR	**0.035MG,0.035MG;0.5MG,1MG**	**N72697 001**	FEB 28, 1992
	MODICON 28			
AB	JOHNSON RW	**0.035MG;0.5MG**	**N17735 001**	
	NORCEPT-E 1/35 28			
AB	GYNOPHARMA	**0.035MG;1MG**	**N71546 001**	FEB 09, 1989
	NORETHIN 1/35E-28			
AB	WATSON LABS	**0.035MG;1MG**	**N71481 001**	APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	**0.035MG;0.5MG**	**N70686 001**	JAN 29, 1987
AB		**0.035MG;1MG**	**N70687 001**	JAN 29, 1987
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71044 001**	APR 01, 1988

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71042 001**	SEP 24, 1991
	NORINYL 1+35 28-DAY			
AB	WATSON LABS	**0.035MG;1MG**	**N17565 002**	
	ORTHO-NOVUM 1/35-28			
AB	JOHNSON RW	**0.035MG;1MG**	**N17919 002**	
	ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER			
AB	JOHNSON RW	**0.035MG,0.035MG;0.5MG,1MG**	**N18354 002**	JAN 11, 1982
	ORTHO-NOVUM 7/14-28			
AB	+ JOHNSON RW	**0.035MG,0.035MG;0.5MG,1MG**	**N19004 002**	APR 04, 1984
	ORTHO-NOVUM 7/7/7-28			
	JOHNSON RW	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N18985 002	APR 04, 1984
	OVCON-35			
	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001	
	OVCON-50			
	WARNER CHILCOTT	0.05MG;1MG	N17576 001	
	TRI-NORINYL 28-DAY			
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT		
+	PARKE DAVIS PHARMS	0.005MG;1MG	N21065 002 OCT 15, 1999

TABLET; ORAL-21

	ESTROSTEP 21		
+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130 001 OCT 09, 1996
	LOESTRIN 21 1.5/30		
+	PARKE DAVIS	0.03MG;1.5MG	N17875 001
	LOESTRIN 21 1/20		
+	PARKE DAVIS	0.02MG;1MG	N17876 001

TABLET; ORAL-28

	ESTROSTEP FE		
+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130 002 OCT 09, 1996

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

\+ PARKE DAVIS 0.03MG;1.5MG N17355 001

LOESTRIN FE 1/20

\+ PARKE DAVIS 0.02MG;1MG N17354 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO CYCLEN-21

\+ JOHNSON RW 0.035MG;0.25MG N19653 001 DEC 29, 1989

ORTHO TRI-CYCLEN

\+ JOHNSON RW 0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG N19697 002 JUL 03, 1992

TABLET; ORAL-28

ORTHO CYCLEN-28

JOHNSON RW 0.035MG;0.25MG N19653 002 DEC 29, 1989

ORTHO TRI-CYCLEN

JOHNSON RW 0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG N19697 001 JUL 03, 1992

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

AB \+ WYETH AYERST **0.03MG;0.3MG** **N17612 001**

LOW-OGESTREL-21

AB WATSON LABS **0.03MG;0.3MG** **N75288 001** JUL 28, 1999

OGESTREL 0.5/50-21

AB SCS **0.05MG;0.5MG** **N75406 001** DEC 15, 1999

OVRAL

AB \+ WYETH AYERST **0.05MG;0.5MG** **N16672 001**

TABLET; ORAL-28

LO/OVRAL-28

AB WYETH AYERST **0.03MG;0.3MG** **N17802 001**

LOW-OGESTREL-28

AB WATSON LABS **0.03MG;0.3MG** **N75288 002** JUL 28, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

OGESTREL 0.5/50-28

AB SCS **0.05MG;0.5MG** **N75406 002** DEC 15, 1999

OVRAL-28

AB WYETH AYERST **0.05MG;0.5MG** **N16806 001**

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

SAVAGE LABS 99% N09190 001

ETHIONAMIDE

TABLET; ORAL

TRECATOR-SC

\+ WYETH AYERST 250MG N13026 002

ETHOSUXIMIDE

CAPSULE; ORAL

ZARONTIN

\+ PARKE DAVIS 250MG N12380 001

SYRUP; ORAL

ETHOSUXIMIDE

AA COPLEY PHARM **250MG/5ML** **N81306 001** JUL 30, 1993

AA PHARM ASSOC **250MG/5ML** **N40253 001** NOV 22, 2000

ZARONTIN

AA PARKE DAVIS **250MG/5ML** **N80258 001**

ETHOTOIN

TABLET; ORAL

PEGANONE

ABBOTT 250MG N10841 001

\+ 500MG N10841 003

ETHYNODIOL DIACETATE; *MULTIPLE*

SEE ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

FDA data supplied by DrugPatentWatch.com

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURANEST
\+ ASTRAZENECA 1% N17751 005

ETIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
\+ MGI PHARMA 50MG/ML N19545 001 APR 20, 1987

TABLET; ORAL
DIDRONEL
PROCTER AND GAMBLE 200MG N17831 001
\+ 400MG N17831 002

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	AESGEN	300MG	N74929 001 JAN 30, 1998
AB	ENDO PHARMS	200MG	N74842 001 JUL 17, 1997
AB		300MG	N74842 002 JUL 17, 1997
AB	GENEVA PHARMS	200MG	N74840 001 AUG 29, 1997
AB		300MG	N74840 002 AUG 29, 1997
AB	GENEVA PHARMS TECH	200MG	N74942 001 SEP 30, 1997
AB		300MG	N74942 002 SEP 30, 1997
AB	GENPHARM	200MG	N75071 001 SEP 30, 1998
AB		300MG	N75071 002 SEP 30, 1998
AB	MYLAN	200MG	N74932 001 MAY 16, 1997

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	MYLAN	300MG	N74932 002 MAY 16, 1997
AB	NOVOPHARM NC	200MG	N75126 001 SEP 16, 1999
AB		300MG	N75126 002 SEP 16, 1999
AB	TARO	200MG	N75078 001 APR 30, 1998
AB		300MG	N75078 002 APR 30, 1998
AB	TORPHARM	200MG	N75419 001 JUL 28, 2000
AB		300MG	N75419 002 JUL 28, 2000
AB	WATSON LABS	200MG	N74844 001 DEC 23, 1997
AB		300MG	N74844 002 DEC 23, 1997
AB	ZENITH GOLDLINE	200MG	N74899 001 JUL 08, 1997
AB		300MG	N74899 002 JUL 08, 1997

LODINE

AB	WYETH AYERST	200MG	N18922 002 JAN 31, 1991
AB +		300MG	N18922 003 JAN 31, 1991

TABLET; ORAL
ETODOLAC

AB	AESGEN	400MG	N74927 001 OCT 30, 1997
AB	CHELSEA LABS	400MG	N75069 001 APR 16, 1998
AB	ENDO PHARMS	400MG	N74841 001 JUN 27, 1997
AB	EON	400MG	N74903 001 APR 11, 1997
AB		500MG	N74903 002 APR 19, 1999
AB	GENEVA PHARMS	400MG	N74839 001 JUL 11, 1997
AB	GENEVA PHARMS TECH	400MG	N74846 001 FEB 28, 1997

FDA data supplied by DrugPatentWatch.com

ETODOLAC

TABLET; ORAL

	ETODOLAC			
AB	GENPHARM	400MG	**N75012 001**	SEP 30, 1998
AB		500MG	**N75012 002**	SEP 30, 1998
AB	MYLAN	400MG	**N75104 001**	FEB 06, 1998
AB		500MG	**N75104 002**	NOV 20, 1998
AB	NOVOPHARM	400MG	**N74847 001**	APR 23, 1999
AB		500MG	**N74847 002**	APR 23, 1999
AB	PUREPAC PHARM	400MG	**N74819 001**	FEB 28, 1997
AB	RANBAXY	400MG	**N75226 001**	NOV 24, 1998
AB		500MG	**N75226 002**	NOV 24, 1998
AB	TARO PHARM INDS	400MG	**N75074 001**	MAR 11, 1998
AB		500MG	**N75074 002**	APR 25, 2000
AB	TEVA	400MG	**N75009 001**	NOV 26, 1997
AB		500MG	**N75009 002**	DEC 28, 1999
AB	WATSON LABS	400MG	**N74892 001**	APR 16, 1997
AB		500MG	**N74892 002**	OCT 29, 1998
AB	ZENITH GOLDLINE	400MG	**N74883 001**	FEB 28, 1997
AB		500MG	**N74883 002**	NOV 20, 1998
	LODINE			
AB	WYETH AYERST	400MG	**N18922 004**	JUL 29, 1993
AB +		500MG	**N18922 005**	JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	POINT HOLDINGS	400MG	**N75696 001**	JUL 31, 2000

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	TEVA	500MG	**N75665 002**	JUL 31, 2000
AB		600MG	**N75665 001**	JUL 31, 2000
	LODINE XL			
AB +	WYETH AYERST	400MG	**N20584 001**	OCT 25, 1996
AB +		500MG	**N20584 003**	JAN 20, 1998
AB +		600MG	**N20584 002**	OCT 25, 1996

ETOMIDATE

INJECTABLE; INJECTION

	AMIDATE			
AP +	ABBOTT	2MG/ML	**N18227 001**	SEP 07, 1982
	ETOMIDATE			
AP	BEDFORD	2MG/ML	**N74593 001**	NOV 04, 1996

ETOPOSIDE

CAPSULE; ORAL

	VEPESID			
+	BRISTOL	50MG	N19557 001	DEC 30, 1986

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	ABBOTT	20MG/ML	**N74320 001**	AUG 30, 1995
AP		20MG/ML	**N74351 001**	AUG 30, 1995
AP	AM PHARM PARTNERS	20MG/ML	**N74983 001**	SEP 30, 1998
AP	BEDFORD	20MG/ML	**N74290 001**	JUL 17, 1995
AP	GENSIA SICOR PHARMS	20MG/ML	**N74284 001**	FEB 10, 1994
AP		20MG/ML	**N74529 001**	JUL 24, 1996

FDA data supplied by DrugPatentWatch.com

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	MARSAM	**20MG/ML**	**N74968 001**	JAN 09, 1998
AP	PHARMACHEMIE	**20MG/ML**	**N74227 001**	FEB 22, 1996
AP	PIERRE FABRE	**20MG/ML**	**N74813 001**	JUL 09, 1997
AP	SUPERGEN	**20MG/ML**	**N74513 001**	MAR 14, 1996
	TOPOSAR			
AP	PHARMACIA AND UPJOHN	**20MG/ML**	**N74166 001**	FEB 27, 1995
	VEPESID			
AP +	BRISTOL MYERS SQUIBB	**20MG/ML**	**N18768 001**	NOV 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001	MAY 17, 1996
+		EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998

EXEMESTANE

TABLET; ORAL

AROMASIN

+	PHARMACIA AND UPJOHN	25MG	N20753 001	OCT 21, 1999

FAMCICLOVIR

TABLET; ORAL

FAMVIR

	SMITHKLINE BEECHAM	125MG	N20363 003	DEC 11, 1995
		250MG	N20363 001	APR 26, 1996
+		500MG	N20363 002	JUN 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID

+	MERCK	40MG/5ML	N19527 001	FEB 02, 1987

INJECTABLE; INJECTION

PEPCID

+	MERCK	10MG/ML	N19510 001	NOV 04, 1986

PEPCID PRESERVATIVE FREE

+	MERCK	10MG/ML	N19510 004	NOV 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+	MERCK	0.4MG/ML	N20249 001	FEB 18, 1994

TABLET; ORAL

PEPCID

	MERCK	20MG	N19462 001	OCT 15, 1986
+		40MG	N19462 002	OCT 15, 1986

TABLET, ORALLY DISINTEGRATING; ORAL

PEPCID RPD

	MERCK	20MG	N20752 001	MAY 28, 1998
+		40MG	N20752 002	MAY 28, 1998

FELBAMATE

SUSPENSION; ORAL

FELBATOL

+	WALLACE LABS	600MG/5ML	N20189 003	JUL 29, 1993

TABLET; ORAL

FELBATOL

	WALLACE LABS	400MG	N20189 001	JUL 29, 1993
+		600MG	N20189 002	JUL 29, 1993

FDA data supplied by DrugPatentWatch.com

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL				
+ ASTRAZENECA	2.5MG	N19834 004		SEP 22, 1994
+	5MG	N19834 001		JUL 25, 1991
+	10MG	N19834 002		JUL 25, 1991

FELODIPINE; *MULTIPLE*
SEE ENALAPRIL MALEATE; FELODIPINE

FENOFIBRATE

CAPSULE; ORAL

TRICOR (MICRONIZED)				
ABBOTT	67MG	N19304 002		FEB 09, 1998
	134MG	N19304 003		JUN 30, 1999
+	200MG	N19304 004		JUN 30, 1999

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM				
+ ABBOTT	EQ 10MG BASE/ML	N19922 001		SEP 23, 1997

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM				
AB GENEVA PHARMS	**EQ 200MG BASE**	**N72394 001**		OCT 17, 1988
AB	**EQ 300MG BASE**	**N72395 001**		OCT 17, 1988
AB PAR PHARM	**EQ 200MG BASE**	**N72437 001**		AUG 22, 1988
AB	**EQ 300MG BASE**	**N72438 001**		AUG 22, 1988
NALFON				
AB + DISTA	**EQ 300MG BASE**	**N17604 002**		

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON 200				
AB DISTA	**EQ 200MG BASE**	**N17604 003**		

TABLET; ORAL

FENOPROFEN CALCIUM				
AB CHELSEA LABS	**EQ 600MG BASE**	**N72407 001**		AUG 17, 1988
AB DANBURY PHARMA	**EQ 600MG BASE**	**N72602 001**		OCT 11, 1988
AB GENEVA PHARMS	**EQ 600MG BASE**	**N72396 001**		OCT 17, 1988
AB LEDERLE	**EQ 600MG BASE**	**N72326 001**		AUG 17, 1988
AB MUTUAL PHARM	**EQ 600MG BASE**	**N72902 001**		DEC 21, 1990
AB MYLAN	**EQ 600MG BASE**	**N72267 001**		AUG 17, 1988
AB PAR PHARM	**EQ 600MG BASE**	**N72429 001**		AUG 17, 1988
AB PUREPAC PHARM	**EQ 600MG BASE**	**N72274 001**		MAY 02, 1988
AB ZENITH GOLDLINE	**EQ 600MG BASE**	**N72557 001**		AUG 29, 1988
NALFON				
AB + DISTA	**EQ 600MG BASE**	**N17710 001**		

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC				
+ ALZA	0.6MG/24HR	N19813 004		AUG 07, 1990
+	1.2MG/24HR	N19813 003		AUG 07, 1990
+	1.8MG/24HR	N19813 002		AUG 07, 1990
+	2.4MG/24HR	N19813 001		AUG 07, 1990

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE				
AP ABBOTT	**EQ 0.05MG BASE/ML**	**N19115 001**		JAN 12, 1985

FDA data supplied by DrugPatentWatch.com

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

AP	ABBOTT	EQ 0.05MG BASE/ML	N70636 001	APR 30, 1990
AP		EQ 0.05MG BASE/ML	N70637 001	APR 30, 1990

FENTANYL CITRATE PRESERVATIVE FREE

AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001	SEP 24, 1991
AP +	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001	JUL 11, 1984
AP	MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998

SUBLIMAZE PRESERVATIVE FREE

AP +	AKORN MFG	EQ 0.05MG BASE/ML	N16619 001	

TROCHE/LOZENGE; ORAL
ACTIQ

	ANESTA	EQ 0.2MG BASE	N20747 001	NOV 04, 1998
		EQ 0.4MG BASE	N20747 002	NOV 04, 1998
		EQ 0.6MG BASE	N20747 003	NOV 04, 1998
		EQ 0.8MG BASE	N20747 004	NOV 04, 1998
		EQ 1.2MG BASE	N20747 005	NOV 04, 1998
+		EQ 1.6MG BASE	N20747 006	NOV 04, 1998

FENTANYL

	ANESTA	EQ 0.1MG BASE	N20195 007	OCT 30, 1995
		EQ 0.2MG BASE	N20195 001	OCT 04, 1993
		EQ 0.3MG BASE	N20195 002	OCT 04, 1993
+		EQ 0.4MG BASE	N20195 003	OCT 04, 1993

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL
FERRISELTZ

+	NYCOMED AMERSHAM	600MG/PACKET	N20292 001 OCT 14, 1997

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION
FERRLECIT

+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FERUMOXIDES

INJECTABLE; INJECTION
FERIDEX I.V.

+	ADV MAGNETICS	EQ 11.2MG IRON/ML	N20416 001 AUG 30, 1996

FERUMOXSIL

SUSPENSION; ORAL
GASTROMARK

+	ADV MAGNETICS	EQ 0.175MG IRON/ML	N20410 001 DEC 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL
ALLEGRA

+	AVENTIS PHARMS	60MG	N20625 001 JUL 25, 1996

TABLET; ORAL
ALLEGRA

	AVENTIS PHARMS	30MG	N20872 001 FEB 25, 2000
		60MG	N20872 002 FEB 25, 2000
+		180MG	N20872 004 FEB 25, 2000

FDA data supplied by DrugPatentWatch.com

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D
+ AVENTIS PHARMS 60MG;120MG N20786 001 DEC 24, 1997

FIBRINOLYSIN; *MULTIPLE*
SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

FINASTERIDE

TABLET; ORAL
PROPECIA
+ MERCK 1MG N20788 001 DEC 19, 1997
PROSCAR
+ MERCK 5MG N20180 001 JUN 19, 1992

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL
URISPAS
+ SMITHKLINE BEECHAM 100MG N16769 001

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
3M 50MG N18830 004 AUG 23, 1988
100MG N18830 001 OCT 31, 1985
+ 150MG N18830 003 JUN 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
AP BEDFORD **500MG/VIAL** **N75387 001** APR 16, 2000
FUDR
AP + ROCHE **500MG/VIAL** **N16929 001**

FLUCONAZOLE

FOR SUSPENSION; ORAL
DIFLUCAN
PFIZER 50MG/5ML N20090 001 DEC 23, 1993
+ 200MG/5ML N20090 002 DEC 23, 1993

INJECTABLE; INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 003 SEP 29, 1992
DIFLUCAN IN SODIUM CHLORIDE 0.9%
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 002 JAN 29, 1990

TABLET; ORAL
DIFLUCAN
PFIZER 50MG N19949 001 JAN 29, 1990
100MG N19949 002 JAN 29, 1990
150MG N19949 004 JUN 30, 1994
+ 200MG N19949 003 JAN 29, 1990

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON
ICN 250MG N17001 001
+ 500MG N17001 002

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARA
+ BERLEX 50MG/VIAL N20038 001 APR 18, 1991

FDA data supplied by DrugPatentWatch.com

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18
+ DOWNSTATE CLINCL 4-40mCi/ML N20306 001 AUG 19, 1994

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLORINEF
+ APOTHECON 0.1MG N10060 001

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON
+ HLR 0.1MG/ML N20073 001 DEC 20, 1991

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROBID
+ SYNTEX (USA) INC LLC 0.25MG/INH N18340 001 AUG 17, 1984

SPRAY, METERED; NASAL
NASALIDE
BX + DURA 0.025MG/SPRAY N18148 001
NASAREL
BX + DURA 0.025MG/SPRAY N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT CLAY PARK **0.01%** **N86810 001** MAR 04, 1982
AT **0.025%** **N86811 001** MAR 04, 1982
AT FOUGERA **0.01%** **N88170 001** DEC 16, 1982

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT FOUGERA **0.025%** **N88169 001** DEC 16, 1982
AT G AND W LABS **0.01%** **N89526 001** JUL 26, 1988
AT **0.025%** **N89525 001** JUL 26, 1988
AT TARO **0.01%** **N40035 001** OCT 31, 1994
AT **0.025%** **N40042 001** OCT 31, 1994
AT THAMES **0.01%** **N87102 001** APR 27, 1982
AT **0.025%** **N87104 001** APR 27, 1982

SYNALAR
AT + MEDICIS **0.01%** **N12787 004**
AT + **0.025%** **N12787 002**
AT + **0.025%** **N12787 005**

SYNALAR-HP
+ MEDICIS 0.2% N16161 002

OIL; TOPICAL
DERMA-SMOOTHE/FS
+ HILL DERMAC 0.01% N19452 001 FEB 03, 1988

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT FOUGERA **0.025%** **N88168 001** DEC 16, 1982
AT G AND W LABS **0.025%** **N89524 001** JUL 26, 1988
AT TARO **0.025%** **N40041 001** SEP 15, 1994

SYNALAR
AT + MEDICIS **0.025%** **N13960 001**

SHAMPOO; TOPICAL
FS SHAMPOO
+ HILL DERMAC 0.01% N20001 001 AUG 27, 1990

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT ALPHARMA **0.01%** **N87159 001** JUN 16, 1982

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	FOUGERA	0.01%	N88167 001	DEC 16, 1982
AT	THAMES	0.01%	N89124 001	SEP 11, 1985
	FLUONID			
AT	ALLERGAN HERBERT	0.01%	N87158 001	MAR 17, 1983
	SYNALAR			
AT	+ MEDICIS	0.01%	N15296 001	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

	NEO-SYNALAR			
	+ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	DRAXIS HLTH	0.05%	N72494 001	JAN 19, 1989
AB	FOUGERA	0.05%	N73030 001	OCT 17, 1994
AB	NMC	0.05%	N73085 001	FEB 14, 1992
AB	TARO	0.05%	N19117 001	JUN 26, 1984
AB	TEVA	0.05%	N72488 001	FEB 06, 1989
AB		0.05%	N72490 001	FEB 07, 1989
AB	THAMES	0.05%	N71500 001	JUN 10, 1987
	FLUOCINONIDE EMULSIFIED BASE			
AB	NMC	0.05%	N74204 001	JUN 13, 1995
	LIDEX			
AB	+ MEDICIS	0.05%	N16908 002	
	LIDEX-E			
AB	MEDICIS	0.05%	N16908 003	

FLUOCINONIDE

GEL; TOPICAL

	FLUOCINONIDE			
AB	FOUGERA	0.05%	N72933 001	DEC 30, 1994
AB	TARO	0.05%	N74935 001	JUL 29, 1997
AB	TEVA	0.05%	N72537 001	FEB 07, 1989
	LIDEX			
AB	+ MEDICIS	0.05%	N17373 001	

OINTMENT; TOPICAL

	FLUOCINONIDE			
AB	ALTANA	0.05%	N74905 001	AUG 26, 1997
AB	TARO	0.05%	N75008 001	JUN 30, 1999
AB	TEVA	0.05%	N73481 001	DEC 27, 1991
	LIDEX			
AB	+ MEDICIS	0.05%	N16909 002	

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	ALPHARMA	0.05%	N71535 001	DEC 02, 1988
AT	COPLEY PHARM	0.05%	N72522 001	SEP 28, 1990
AT	FOUGERA	0.05%	N72934 001	FEB 27, 1995
AT	TARO	0.05%	N74799 001	DEC 31, 1996
AT	TEVA	0.05%	N72511 001	FEB 07, 1989
AT	THAMES	0.05%	N72857 001	AUG 02, 1989
	LIDEX			
AT	+ MEDICIS	0.05%	N18849 001	APR 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

	FUNDUSCEIN-25		
	+ CIBA	25%	N17869 001

FDA data supplied by DrugPatentWatch.com

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

	FML			
	+ ALLERGAN	0.1%	N17760 001	SEP 04, 1985

SUSPENSION/DROPS; OPHTHALMIC

	FLUOR-OP			
AB	CIBA	**0.1%**	**N70185 001**	FEB 27, 1986
	FML			
AB	+ ALLERGAN	**0.1%**	**N16851 002**	JUL 28, 1982
	FML FORTE			
	ALLERGAN	0.25%	N19216 001	APR 23, 1986

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S			
+ ALLERGAN	0.1%;10%	N19525 001	SEP 29, 1989

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX			
+ ALCON	0.1%	N19079 001	FEB 11, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE			
+ ALCON	0.1%;0.3%	N50628 001	JUL 21, 1989

FLUOROURACIL

CREAM; TOPICAL

EFUDEX			
+ ICN	5%	N16831 003	
FLUOROPLEX			
+ ALLERGAN HERBERT	1%	N16988 001	

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL				
+ DERMIK LABS	0.5%		N20985 001	OCT 27, 2000

INJECTABLE; INJECTION

ADRUCIL				
AP	PHARMACIA AND UPJOHN	**50MG/ML**	**N40023 001**	OCT 18, 1991
AP	+	**50MG/ML**	**N81225 001**	AUG 28, 1991
FLUOROURACIL				
AP	AM PHARM PARTNERS	**50MG/ML**	**N40278 001**	SEP 30, 1998
AP		**50MG/ML**	**N40279 001**	SEP 30, 1998
AP	BEDFORD	**50MG/ML**	**N89508 001**	JAN 26, 1988
AP	BIGMAR	**50MG/ML**	**N40291 001**	MAR 24, 1999
AP		**50MG/ML**	**N40379 001**	NOV 15, 2000
AP	GENSIA SICOR PHARMS	**50MG/ML**	**N40333 001**	JAN 27, 2000
AP		**50MG/ML**	**N40334 001**	FEB 25, 2000
AP	+ ICN PUERTO RICO	**50MG/ML**	**N12209 001**	
AP	STERIS	**50MG/ML**	**N87792 001**	OCT 13, 1982

SOLUTION; TOPICAL

EFUDEX			
+ ICN	2%	N16831 001	
+	5%	N16831 002	
FLUOROPLEX			
+ ALLERGAN HERBERT	1%	N16765 001	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC			
LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992
	EQ 20MG BASE	N18936 001	DEC 29, 1987

FDA data supplied by DrugPatentWatch.com

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

	PROZAC			
+	LILLY	EQ 40MG BASE	N18936 003	JUN 15, 1999
	SARAFEM			
	LILLY	EQ 10MG BASE	N18936 007	JUL 06, 2000
+		EQ 20MG BASE	N18936 008	JUL 06, 2000

SOLUTION; ORAL

	PROZAC			
+	LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991

TABLET; ORAL

	PROZAC			
+	LILLY	EQ 10MG BASE	N20974 001	MAR 09, 1999

FLUOXYMESTERONE

TABLET; ORAL

	FLUOXYMESTERONE			
BP	ROSEMONT	10MG	N88342 001	OCT 21, 1983
	HALOTESTIN			
BP +	PHARMACIA AND UPJOHN	10MG	N10611 010	
		2MG	N10611 002	
		5MG	N10611 006	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

	FLUPHENAZINE DECANOATE			
AO	AM PHARM PARTNERS	**25MG/ML**	**N71413 001**	JUL 14, 1987
AO	BEDFORD	**25MG/ML**	**N74531 001**	AUG 30, 1996
AO	GENSIA SICOR PHARMS	**25MG/ML**	**N74795 001**	SEP 10, 1996
AO	KING PHARMS	**25MG/ML**	**N74966 001**	APR 16, 1998
	PROLIXIN DECANOATE			
AO +	APOTHECON	**25MG/ML**	**N16727 001**	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

	PROLIXIN ENANTHATE			
+	APOTHECON	25MG/ML	N16110 001	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	**5MG/ML**	**N73058 001**	AUG 30, 1991
AA	PHARM ASSOC	**5MG/ML**	**N74725 001**	SEP 16, 1996
	PERMITIL			
AA +	SCHERING	**5MG/ML**	**N16008 001**	
	PROLIXIN			
AA	APOTHECON	**5MG/ML**	**N70533 001**	NOV 07, 1985

ELIXIR; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	**2.5MG/5ML**	**N81310 001**	APR 29, 1993
AA	PHARM ASSOC	**2.5MG/5ML**	**N40146 001**	AUG 21, 1996
	PROLIXIN			
AA +	APOTHECON	**2.5MG/5ML**	**N12145 003**	

INJECTABLE; INJECTION

	FLUPHENAZINE HCL			
AP	AM PHARM PARTNERS	**2.5MG/ML**	**N89556 001**	APR 16, 1987
	PROLIXIN			
AP +	APOTHECON	**2.5MG/ML**	**N11751 005**	

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	GENEVA PHARMS	**1MG**	**N89583 001**	OCT 16, 1987
AB		**2.5MG**	**N89584 001**	OCT 16, 1987
AB		**5MG**	**N89585 001**	OCT 16, 1987
AB		**10MG**	**N89586 001**	OCT 16, 1987
AB	MYLAN	**1MG**	**N89801 001**	AUG 12, 1988

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	MYLAN	2.5MG	N89802 001	AUG 12, 1988
AB		5MG	N89803 001	AUG 12, 1988
AB		10MG	N89804 001	AUG 12, 1988
AB	PAR PHARM	1MG	N89740 001	AUG 25, 1988
AB		2.5MG	N89741 001	AUG 25, 1988
AB		5MG	N89742 001	AUG 25, 1988
AB		10MG	N89743 001	AUG 25, 1988
	PERMITIL			
BP	SCHERING	2.5MG	N12034 004	
BP		5MG	N12034 005	
BP		10MG	N12034 006	
	PROLIXIN			
AB	APOTHECON	1MG	N11751 004	
AB		2.5MG	N11751 001	
AB		5MG	N11751 003	
AB	+	10MG	N11751 002	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP		
	+ OCLASSEN	0.025%	N12806 003
	+	0.05%	N12806 002

LOTION; TOPICAL

	CORDRAN		
AT	+ OCLASSEN	0.05%	N13790 001

OINTMENT; TOPICAL

	CORDRAN		
	+ OCLASSEN	0.025%	N12806 004
	+	0.05%	N12806 001

TAPE; TOPICAL

	CORDRAN		
	+ OCLASSEN	0.004MG/SQ CM	N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	DALMANE			
AB	ICN	15MG	N16721 001	
AB	+	30MG	N16721 002	
	FLURAZEPAM HCL			
AB	CHELSEA LABS	15MG	N72368 001	MAR 30, 1989
AB		30MG	N72369 001	MAR 30, 1989
AB	DANBURY PHARMA	15MG	N71205 001	NOV 25, 1986
AB		30MG	N71068 001	NOV 25, 1986
AB	GENEVA PHARMS	15MG	N71716 001	JUL 31, 1991
AB		30MG	N71717 001	JUL 31, 1991
AB	MYLAN	15MG	N70344 001	NOV 27, 1985
AB		30MG	N70345 001	NOV 27, 1985
AB	PAR PHARM	15MG	N70444 001	MAR 20, 1986
AB		30MG	N70445 001	MAR 20, 1986
AB	PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987
AB		30MG	N71551 001	SEP 09, 1987
AB	WEST WARD	15MG	N71107 001	DEC 08, 1986
AB		30MG	N71108 001	DEC 08, 1986

FLURBIPROFEN

TABLET; ORAL

	ANSAID			
AB	PHARMACIA AND UPJOHN	50MG	N18766 002	OCT 31, 1988
AB	+	100MG	N18766 003	OCT 31, 1988
	FLURBIPROFEN			
AB	GENEVA PHARMS	50MG	N74448 001	JUL 28, 1995

FDA data supplied by DrugPatentWatch.com

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

AB	GENEVA PHARMS	100MG	N74448 002	JUL 28, 1995
AB	MYLAN	50MG	N74358 001	JUN 20, 1994
AB		100MG	N74358 002	JUN 20, 1994
AB	NOVOPHARM	50MG	N74405 002	MAY 24, 1995
AB		100MG	N74405 001	MAY 24, 1995
AB	SIDMAK LABS NJ	50MG	N74647 001	APR 01, 1997
AB		100MG	N74647 002	APR 01, 1997
AB	TEVA	100MG	N74431 001	MAY 31, 1995
AB	WARNER CHILCOTT	100MG	N74560 002	MAY 16, 1997
AB	ZENITH GOLDLINE	50MG	N74411 001	MAY 31, 1995
AB		100MG	N74411 002	MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

AT	AVENTIS BEHRING	0.03%	N74447 001	JAN 04, 1995

OCUFEN

AT	+ ALLERGAN	0.03%	N19404 001	DEC 31, 1986

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

	+ SCHERING	125MG	N18554 001	JAN 27, 1989

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

	GLAXO WELLCOME	0.044MG/INH	N20548 001	MAR 27, 1996
		0.11MG/INH	N20548 002	MAR 27, 1996
+		0.22MG/INH	N20548 003	MAR 27, 1996

CREAM; TOPICAL

CUTIVATE

+	GLAXO WELLCOME	0.05%	N19958 001	DEC 18, 1990

OINTMENT; TOPICAL

CUTIVATE

+	GLAXO WELLCOME	0.005%	N19957 001	DEC 14, 1990

POWDER; INHALATION

FLOVENT

+	GLAXO WELLCOME	0.044MG/INH	N20549 001	NOV 07, 1997
+		0.088MG/INH	N20549 002	NOV 07, 1997
+		0.22MG/INH	N20549 003	NOV 07, 1997

FLOVENT DISKUS 100

+	GLAXO	0.1MG/INH	N20833 002	SEP 29, 2000

FLOVENT DISKUS 250

+	GLAXO	0.25MG/INH	N20833 003	SEP 29, 2000

FLOVENT DISKUS 50

+	GLAXO	0.05MG/INH	N20833 001	SEP 29, 2000

SPRAY, METERED; NASAL

FLONASE

+	GLAXO WELLCOME	0.05MG/SPRAY	N20121 001	OCT 19, 1994

FDA data supplied by DrugPatentWatch.com

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

ADVAIR DISKUS 100/50				
+ GLAXO WELLCOME	0.1MG/INH; EQ 0.05MG BASE/INH		N21077 001	AUG 24, 2000
ADVAIR DISKUS 250/50				
+ GLAXO WELLCOME	0.25MG/INH; EQ 0.05MG BASE/INH		N21077 002	AUG 24, 2000
ADVAIR DISKUS 500/50				
+ GLAXO WELLCOME	0.5MG/INH; EQ 0.05MG BASE/INH		N21077 003	AUG 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

LESCOL				
NOVARTIS	EQ 20MG BASE		N20261 001	DEC 31, 1993
+	EQ 40MG BASE		N20261 002	DEC 31, 1993

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL				
+ NOVARTIS	80MG		N21192 001	OCT 06, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	EON	**25MG**	**N75888 001**	NOV 29, 2000
AB		**50MG**	**N75888 002**	NOV 29, 2000
AB		**100MG**	**N75888 003**	NOV 29, 2000
AB	MYLAN	**25MG**	**N75889 001**	NOV 29, 2000
AB		**50MG**	**N75889 002**	NOV 29, 2000
AB		**100MG**	**N75889 003**	NOV 29, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	PUREPAC PHARM	**25MG**	**N75901 001**	DEC 28, 2000
AB		**50MG**	**N75901 002**	DEC 28, 2000
AB		**100MG**	**N75901 003**	DEC 28, 2000

LUVOX

AB	SOLVAY	**25MG**	**N20243 001**	DEC 05, 1994
AB		**50MG**	**N20243 002**	DEC 05, 1994
AB +		**100MG**	**N20243 003**	DEC 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP	AM PHARM PARTNERS	**5MG/ML**	**N89202 001**	FEB 18, 1986
AP	LOCH	**5MG/ML**	**N81066 001**	DEC 29, 1993

FOLVITE

AP +	LEDERLE	**5MG/ML**	**N05897 008**	

TABLET; ORAL

FOLIC ACID

AA +	DANBURY PHARMA	**1MG**	**N80680 001**	
AA	ICN	**1MG**	**N80903 001**	
AA	IMPAX LABS	**1MG**	**N80686 001**	
AA	MK LABS	**1MG**	**N83526 001**	
AA	PVT FORM	**1MG**	**N85061 001**	
AA	TABLICAPS	**1MG**	**N83133 002**	
AA	WEST WARD	**1MG**	**N80600 001**	
AA	ZENITH GOLDLINE	**1MG**	**N83000 001**	

FOLICET

AA	MISSION PHARMA	**1MG**	**N87438 001**	

FOLIC ACID; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

FDA data supplied by DrugPatentWatch.com

FOLIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

	FOLLISTIM			
BX	ORGANON	75 IU/VIAL	N20582 001	SEP 29, 1997
BX		150 IU/VIAL	N20582 002	SEP 29, 1997
	GONAL-F			
BX	SERONO	75 IU/VIAL	N20378 001	SEP 29, 1997
BX		150 IU/VIAL	N20378 002	SEP 29, 1997
		37.5 IU/VIAL	N20378 003	MAY 25, 2000

FOMEPIZOLE

INJECTABLE; INJECTION

	ANTIZOL			
+	ORPHAN MEDCL	1GM/ML	N20696 001	DEC 04, 1997

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

	VITRAVENE PRESERVATIVE FREE			
+	CIBA VISION OPHTHLMC	6.6MG/ML	N20961 001	AUG 26, 1998

FOSCARNET SODIUM

INJECTABLE; INJECTION

	FOSCAVIR			
+	ASTRAZENECA	2.4GM/100ML	N20068 001	SEP 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

	MONUROL			
+	ZAMBON	EQ 3GM BASE/PACKET	N50717 001	DEC 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

	MONOPRIL			
	BRISTOL MYERS SQUIBB	10MG	N19915 002	MAY 16, 1991
		20MG	N19915 003	MAY 16, 1991
+		40MG	N19915 004	MAR 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	MONOPRIL-HCT			
	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	NOV 30, 1994
+		20MG;12.5MG	N20286 001	NOV 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

	CEREBYX			
+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N20450 001	AUG 05, 1996

FDA data supplied by DrugPatentWatch.com

FURAZOLIDONE

SUSPENSION; ORAL

	FUROXONE			
+	SHIRE	50MG/15ML	N11323 002	

TABLET; ORAL

	FUROXONE			
+	SHIRE	100MG	N11270 002	

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
AP	ABBOTT	**10MG/ML**	**N18667 001**	MAY 28, 1982
AP		**10MG/ML**	**N70578 001**	JUL 08, 1987
AP		**10MG/ML**	**N72080 001**	AUG 13, 1991
AP		**10MG/ML**	**N74337 001**	OCT 31, 1994
AP		**10MG/ML**	**N75241 001**	MAY 28, 1999
AP	AM PHARM PARTNERS	**10MG/ML**	**N18902 001**	MAY 22, 1984
AP	ELKINS SINN	**10MG/ML**	**N18267 001**	
AP	INTL MEDICATION	**10MG/ML**	**N18025 001**	
AP	LEDERLE	**10MG/ML**	**N71439 001**	SEP 14, 1990
AP	LUITPOLD	**10MG/ML**	**N18579 001**	NOV 30, 1983
AP	MARSAM	**10MG/ML**	**N74017 001**	JUN 30, 1994
	LASIX			
AP	+ AVENTIS PHARMS	**10MG/ML**	**N16363 001**	

SOLUTION; ORAL

	FUROSEMIDE			
AA	MORTON GROVE	**10MG/ML**	**N70655 001**	OCT 02, 1987
AA	ROXANE	**10MG/ML**	**N70434 001**	APR 22, 1987
		40MG/5ML	N70433 001	APR 22, 1987
	LASIX			
AA	+ AVENTIS PHARMS	**10MG/ML**	**N17688 001**	

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	DANBURY PHARMA	**20MG**	**N70412 001**	FEB 26, 1986
AB		**40MG**	**N70413 001**	FEB 26, 1986
AB		**80MG**	**N71594 001**	FEB 09, 1988
AB	GENEVA PHARMS	**20MG**	**N18569 002**	
AB		**40MG**	**N18569 001**	
AB		**80MG**	**N18569 005**	AUG 14, 1984
AB	INTL MEDICATION	**20MG**	**N18753 001**	FEB 28, 1984
AB		**40MG**	**N18753 002**	FEB 28, 1984
AB	KALAPHARM	**20MG**	**N18868 001**	JUN 28, 1983
AB		**40MG**	**N18868 002**	JUN 28, 1983
AB	LEDERLE	**20MG**	**N18415 001**	JUL 27, 1982
AB		**40MG**	**N18415 002**	JUL 27, 1982
AB		**80MG**	**N18415 003**	NOV 26, 1984
AB	MYLAN	**20MG**	**N18487 001**	
AB		**40MG**	**N18487 002**	
AB		**80MG**	**N70082 001**	OCT 29, 1986
AB	ROXANE	**20MG**	**N18823 001**	NOV 10, 1983
AB		**40MG**	**N18823 002**	NOV 10, 1983
AB		**80MG**	**N70086 001**	JAN 24, 1986
AB	WATSON LABS	**20MG**	**N70449 001**	NOV 22, 1985
AB		**20MG**	**N71379 001**	JAN 02, 1987
AB		**40MG**	**N70450 001**	NOV 22, 1985
AB		**80MG**	**N70528 001**	JAN 07, 1986
AB	ZENITH GOLDLINE	**20MG**	**N18413 001**	NOV 30, 1983

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	ZENITH GOLDLINE	**40MG**	**N18413 002**	NOV 30, 1983
	LASIX			
AB	AVENTIS PHARMS	**20MG**	**N16273 002**	
AB		**40MG**	**N16273 001**	
AB	+	**80MG**	**N16273 003**	

GABAPENTIN

CAPSULE; ORAL

	NEURONTIN			
	PARKE DAVIS PHARMS	100MG	N20235 001	DEC 30, 1993
		300MG	N20235 002	DEC 30, 1993
	+	400MG	N20235 003	DEC 30, 1993

TABLET; ORAL

	NEURONTIN			
	PARKE DAVIS	600MG	N20882 001	OCT 09, 1998
	+	800MG	N20882 002	OCT 09, 1998

GADODIAMIDE

INJECTABLE; INJECTION

	OMNISCAN			
	+ NYCOMED	287MG/ML	N20123 001	JAN 08, 1993

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

	MAGNEVIST			
	+ BERLEX	469.01MG/ML	N19596 001	JUN 02, 1988
	+ BERLEX LABS	469.01MG/ML	N21037 001	MAR 10, 2000

GADOTERIDOL

INJECTABLE; INJECTION

	PROHANCE			
	+ BRACCO	279.3MG/ML	N20131 001	NOV 16, 1992

GADOVERSETAMIDE

INJECTABLE; INJECTION

	OPTIMARK			
	+ MALLINCKRODT	330.9MG/ML	N20937 001	DEC 08, 1999
	+	330.9MG/ML	N20975 001	DEC 08, 1999
	OPTIMARK IN PLASTIC CONTAINER			
	+ MALLINCKRODT	330.9MG/ML	N20976 001	DEC 08, 1999

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

	GALLIUM CITRATE GA 67			
BS	DUPONT PHARMS	2mCi/ML	N17478 001	
BS	MALLINCKRODT	2mCi/ML	N18058 001	
	NEOSCAN			
BS	NYCOMED AMERSHAM	2mCi/ML	N17655 001	

GANCICLOVIR

CAPSULE; ORAL

	CYTOVENE			
	SYNTEX (USA) INC LLC	250MG	N20460 001	DEC 22, 1994
	+	500MG	N20460 002	DEC 12, 1997

IMPLANT; IMPLANTATION

	VITRASERT			
	+ BAUSCH AND LOMB	4.5MG	N20569 001	MAR 04, 1996

FDA data supplied by DrugPatentWatch.com

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
CYTOVENE IV
+ SYNTEX (USA) INC LLC EQ 500MG BASE/VIAL N19661 001 JUN 23, 1989

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON
+ ORGANON INC EQ 250 UGM BASE/0.5ML N21057 001 JUL 29, 1999

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN
+ BRISTOL MYERS SQUIBB 200MG/VIAL N21062 001 DEC 17, 1999
+ 400MG/VIAL N21062 002 DEC 17, 1999

TABLET; ORAL
TEQUIN
BRISTOL MYERS SQUIBB 200MG N21061 001 DEC 17, 1999
+ 400MG N21061 002 DEC 17, 1999

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMZAR
+ LILLY EQ 200MG BASE/VIAL N20509 001 MAY 15, 1996
+ EQ 1GM BASE/VIAL N20509 002 MAY 15, 1996

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
AB CHELSEA LABS **600MG** **N74442 001** APR 28, 1995

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
AB INVAMED **600MG** **N74615 001** SEP 29, 1995
AB LEDERLE **600MG** **N74270 001** SEP 27, 1993
AB MYLAN **600MG** **N74452 001** FEB 16, 1995
AB TEVA **600MG** **N74256 001** OCT 31, 1993
AB TORPHARM **600MG** **N75034 001** JUL 20, 1998

LOPID
AB + PARKE DAVIS PHARMS **600MG** **N18422 003** NOV 20, 1986

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH AYERST 5MG/VIAL N21174 001 MAY 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL
GARAMYCIN
AT + SCHERING **EQ 0.1% BASE** **N60462 001**
GENTAMICIN
AT CLAY PARK **EQ 0.1% BASE** **N62307 001**
GENTAMICIN SULFATE
AT BAUSCH AND LOMB **EQ 0.1% BASE** **N64056 001** APR 29, 1994
AT FOUGERA **EQ 0.1% BASE** **N62531 001** JUL 05, 1984
AT THAMES **EQ 0.1% BASE** **N62427 001** MAY 26, 1983

INJECTABLE; INJECTION
GARAMYCIN
AP + SCHERING **EQ 1MG BASE/ML** **N61716 002**
AP + **EQ 40MG BASE/ML** **N61716 001**
GENTAMICIN SULFATE
AP ABBOTT **EQ 10MG BASE/ML** **N62420 001** AUG 15, 1983

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP		ABBOTT	EQ 10MG BASE/ML	N62612 004 FEB 20, 1986
AP			EQ 40MG BASE/ML	N62420 002 AUG 15, 1983
AP		AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001 MAR 04, 1982
AP			EQ 40MG BASE/ML	N62356 002 MAR 04, 1982
AP			EQ 40MG BASE/ML	N62366 001 AUG 04, 1983
AP	+	ELKINS SINN	EQ 10MG BASE/ML	N62251 002
AP			EQ 40MG BASE/ML	N62251 001
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001 NOV 21, 1991
AP			EQ 40MG BASE/ML	N63106 002 NOV 21, 1991
AP		KALAPHARM	EQ 40MG BASE/ML	N62354 001 APR 05, 1982
AP		PHARM SPEC	EQ 40MG BASE/ML	N62340 001 MAR 28, 1983
AP		STERIS	EQ 10MG BASE/ML	N62318 002
AP			EQ 40MG BASE/ML	N62318 001

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	EQ 60MG BASE/100ML	N62414 006 AUG 15, 1983
AP			EQ 70MG BASE/100ML	N62414 007 AUG 15, 1983
AP			EQ 80MG BASE/100ML	N62414 008 AUG 15, 1983
AP			EQ 90MG BASE/100ML	N62414 009 AUG 15, 1983
AP			EQ 100MG BASE/100ML	N62414 010 AUG 15, 1983
AP			EQ 1.2MG BASE/ML	N62414 001 AUG 15, 1983
AP			EQ 1.4MG BASE/ML	N62414 002 AUG 15, 1983
AP			EQ 1.6MG BASE/ML	N62414 003 AUG 15, 1983
AP			EQ 1.8MG BASE/ML	N62414 004 AUG 15, 1983
AP			EQ 2MG BASE/ML	N62414 005 AUG 15, 1983

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	EQ 40MG BASE/100ML	N62814 008 AUG 28, 1987
AP			EQ 60MG BASE/100ML	N62814 009 AUG 28, 1987
AP			EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987
AP			EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987
AP			EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987
AP			EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987
AP			EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987
AP			EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987
AP			EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP			EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987
AP			EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP			EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987
AP			EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP			EQ 2.4MG BASE/ML	N62814 007 AUG 28, 1987

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	EQ 40MG BASE/100ML	N62373 003 SEP 07, 1982
AP			EQ 60MG BASE/100ML	N62373 004 SEP 07, 1982
AP			EQ 0.8MG BASE/ML	N62373 001 SEP 07, 1982
AP			EQ 80MG BASE/100ML	N62373 002 SEP 07, 1982
AP			EQ 100MG BASE/100ML	N62373 005 SEP 07, 1982
AP			EQ 120MG BASE/100ML	N62373 006 SEP 07, 1982
AP			EQ 1.2MG BASE/ML	N62373 007 SEP 07, 1982

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	EQ 1.6MG BASE/ML	N62373 008	SEP 07, 1982
AP		EQ 2MG BASE/ML	N62373 009	SEP 07, 1982
AP		EQ 2.4MG BASE/ML	N62373 010	SEP 07, 1982

U-GENCIN

AP	PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	
AP		EQ 40MG BASE/ML	N62248 002	

INJECTABLE; INTRATHECAL

GARAMYCIN

+	SCHERING	EQ 2MG BASE/ML	N50505 001	

OINTMENT; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50425 001	

GENTACIDIN

AT	CIBA	EQ 0.3% BASE	N62501 001	JUL 26, 1984

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995

OINTMENT; TOPICAL

GARAMYCIN

AT	+ SCHERING	EQ 0.1% BASE	N60463 001	

GENTAMICIN

AT	CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982

GENTAMICIN SULFATE

AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994
AT	FOUGERA	EQ 0.1% BASE	N62533 001	OCT 05, 1984
AT	THAMES	EQ 0.1% BASE	N62477 001	DEC 23, 1983

SOLUTION; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039 002	

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	ALLERGAN	EQ 0.3% BASE	N62452 001	OCT 10, 1984

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

AT	CIBA	EQ 0.3% BASE	N62480 001	MAR 30, 1984

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	N62635 001	JAN 08, 1987
AT	ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985
AT	BAUSCH AND LOMB	EQ 0.3% BASE	N64048 001	MAY 11, 1994
AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;0.6%	N50612 001	DEC 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;1%	N50586 001	JUN 10, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

+	SAVAGE LABS	0.4%	N83513 001	

GLATIRAMER ACETATE

INJECTABLE; INJECTION

COPAXONE

+	TEVA	20MG/VIAL	N20622 001	DEC 20, 1996

GLIMEPIRIDE

TABLET; ORAL

AMARYL

	AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995

FDA data supplied by DrugPatentWatch.com

GLIMEPIRIDE

TABLET; ORAL
AMARYL

	AVENTIS PHARMS	2MG	N20496 002	NOV 30, 1995
+		4MG	N20496 003	NOV 30, 1995

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	ALPHAPHARM	5MG	**N74438 001**	JUN 20, 1995
AB		10MG	**N74438 002**	JUN 20, 1995
AB	DURAMED	5MG	**N74550 001**	SEP 11, 1997
AB		10MG	**N74550 002**	SEP 11, 1997
AB	ENDO PHARMS	5MG	**N74378 001**	NOV 28, 1994
AB		10MG	**N74378 002**	NOV 28, 1994
AB	GENEVA PHARMS	5MG	**N74305 001**	APR 07, 1995
AB		10MG	**N74305 002**	APR 07, 1995
AB	INVAMED	5MG	**N74542 001**	JUN 20, 1995
AB		10MG	**N74542 002**	JUN 20, 1995
AB	MYLAN	5MG	**N74226 001**	MAY 10, 1994
AB		10MG	**N74226 002**	MAY 10, 1994
AB	NOVOPHARM	5MG	**N74387 001**	MAR 04, 1996
AB		10MG	**N74387 002**	MAR 04, 1996
AB	SIDMAK LABS NJ	5MG	**N74619 001**	APR 04, 1997
AB		10MG	**N74619 002**	APR 04, 1997
AB	WATSON LAB	5MG	**N74370 001**	NOV 22, 1994

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	WATSON LAB	10MG	**N74370 002**	NOV 22, 1994
AB	WATSON LABS	5MG	**N74223 001**	FEB 27, 1995
AB		10MG	**N74223 002**	FEB 27, 1995
AB	ZENITH GOLDLINE	5MG	**N74497 001**	AUG 31, 1995
AB		10MG	**N74497 002**	AUG 31, 1995

GLUCOTROL

AB	PFIZER	5MG	**N17783 001**	MAY 08, 1984
AB +		10MG	**N17783 002**	MAY 08, 1984

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

+	PFIZER	2.5MG	N20329 003	AUG 10, 1999
+		5MG	N20329 001	APR 26, 1994
+		10MG	N20329 002	APR 26, 1994

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

+	LILLY	EQ 1MG BASE/VIAL	N12122 001	

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001	JUN 22, 1998

FDA data supplied by DrugPatentWatch.com

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

	GLUCAGON			
+	LILLY	1MG/VIAL	N20928 001	SEP 11, 1998

GLUCONOLACTONE; *MULTIPLE*

SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

GLUTATHIONE DISULFIDE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

GLYBURIDE

TABLET; ORAL

	DIABETA			
BX	AVENTIS PHARMS	1.25MG	N17532 001	MAY 01, 1984
BX		2.5MG	N17532 002	MAY 01, 1984
BX		5MG	N17532 003	MAY 01, 1984
	GLYBURIDE			
AB	NOVOPHARM NC	**1.25MG**	**N74388 001**	AUG 29, 1995
AB		**2.5MG**	**N74388 002**	AUG 29, 1995
AB		**5MG**	**N74388 003**	AUG 29, 1995
	GLYBURIDE (MICRONIZED)			
AB	AVENTIS PHARMS	**1.5MG**	**N20055 001**	APR 17, 1992
AB		**3MG**	**N20055 002**	APR 17, 1992
AB		**6MG**	**N20055 003**	MAR 08, 2000
AB	GENEVA PHARMS TECH	**1.5MG**	**N75174 001**	JUN 22, 1998
AB		**3MG**	**N75174 002**	JUN 22, 1998
AB	MOVA	**1.5MG**	**N74591 001**	DEC 22, 1997

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)			
AB	MOVA	**3MG**	**N74591 002**	DEC 22, 1997
AB		**4.5MG**	**N74591 003**	DEC 22, 1997
AB		**6MG**	**N74591 004**	DEC 22, 1997
AB	MYLAN	**1.5MG**	**N74792 001**	JUN 26, 1998
AB		**3MG**	**N74792 002**	JUN 26, 1998
AB		**6MG**	**N74792 003**	AUG 17, 1999
AB	NOVOPHARM	**1.5MG**	**N74686 001**	APR 20, 1999
AB		**3MG**	**N74686 002**	APR 20, 1999
AB		**4.5MG**	**N74686 003**	APR 20, 1999
AB		**6MG**	**N74686 004**	APR 20, 1999
	GLYNASE			
AB	PHARMACIA AND UPJOHN	**1.5MG**	**N20051 001**	MAR 04, 1992
AB		**3MG**	**N20051 002**	MAR 04, 1992
AB	+	**6MG**	**N20051 004**	SEP 24, 1993
	MICRONASE			
AB	PHARMACIA AND UPJOHN	**1.25MG**	**N17498 001**	MAY 01, 1984
AB		**2.5MG**	**N17498 002**	MAY 01, 1984
AB	+	**5MG**	**N17498 003**	MAY 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOVANCE			
	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001	JUL 31, 2000
		2.5MG;500MG	N21178 002	JUL 31, 2000

FDA data supplied by DrugPatentWatch.com

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE
+ BRISTOL MYERS SQUIBB 5MG;500MG — N21178 003 JUL 31, 2000

GLYCERIN; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

GLYCINE

SOLUTION; IRRIGATION

	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER			
AT	BAXTER HLTHCARE	1.5GM/100ML	N17865 001	
	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	ABBOTT	1.5GM/100ML	N17633 001	
AT		1.5GM/100ML	N18315 001	
AT	B BRAUN	1.5GM/100ML	N16784 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE			
AP	GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991
AP	LUITPOLD	0.2MG/ML	N89335 001	JUL 23, 1986
	ROBINUL			
AP	+ ROBINS AH	0.2MG/ML	N17558 001	

TABLET; ORAL

	ROBINUL		
+	HORIZON PHARM	1MG	N12827 001
	ROBINUL FORTE		
+	HORIZON PHARM	2MG	N12827 002

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT
+ FERRING — 0.8MG/VIAL — N19687 001 OCT 10, 1989

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT
+ FERRING — 3.2MG/VIAL — N19687 002 OCT 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL
+ WYETH AYERST — EQ 0.1MG BASE/VIAL — N18123 001 SEP 30, 1982
+ — EQ 0.5MG BASE/VIAL — N18123 003 SEP 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

	A.P.L.			
AP	+ WYETH AYERST	5,000 UNITS/VIAL	N17055 001	
AP	+	10,000 UNITS/VIAL	N17055 002	
	+	20,000 UNITS/VIAL	N17055 003	
	CHORIONIC GONADOTROPIN			
AP	+ AM PHARM PARTNERS	10,000 UNITS/VIAL	N17067 002	
AP	+ STERIS	5,000 UNITS/VIAL	N17016 006	
AP	+	10,000 UNITS/VIAL	N17016 007	
	+	2,000 UNITS/VIAL	N17016 011	FEB 16, 1990
	PREGNYL			
AP	+ ORGANON	10,000 UNITS/VIAL	N17692 001	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX
+ ASTRAZENECA — EQ 3.6MG BASE — N19726 001 DEC 29, 1989
+ — EQ 10.8MG BASE — N20578 001 JAN 11, 1996

FDA data supplied by DrugPatentWatch.com

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
AT	BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N64047 001	JAN 31, 1996
	NEOSPORIN			
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL			
+ ROCHE	EQ 1MG BASE/ML	N20239 002	MAR 11, 1994

TABLET; ORAL

KYTRIL			
+ ROCHE	EQ 1MG BASE	N20305 001	MAR 16, 1995

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR			
OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997
	EQ 400MG BASE	N20695 002	MAY 14, 1998
+	EQ 600MG BASE	N20695 003	MAY 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN			
+ WYETH AYERST	250MG	N50051 001	

SUSPENSION; ORAL

GRIFULVIN V			
J AND J	125MG/5ML	N62483 001	JAN 26, 1984
+ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

	FULVICIN-U/F			
AB	SCHERING	250MG	N60569 002	
AB	+	500MG	N60569 001	
	GRIFULVIN V			
AB	J AND J	250MG	N62279 002	
AB		500MG	N62279 003	
		125MG	N62279 001	
	GRISACTIN			
AB	WYETH AYERST	500MG	N60212 001	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	FULVICIN P/G			
AB	SCHERING	125MG	N61996 001	
AB	+	250MG	N61996 002	
	FULVICIN P/G 165			
AB	SCHERING	165MG	N61996 003	APR 06, 1982
	FULVICIN P/G 330			
AB	+ SCHERING	330MG	N61996 004	APR 06, 1982
	GRIS-PEG			
AB	PEDINOL	125MG	N50475 001	
AB		250MG	N50475 002	
	GRISACTIN ULTRA			
AB	WYETH AYERST	125MG	N62178 001	
AB		165MG	N62438 001	NOV 17, 1983
AB		250MG	N62178 002	
AB		330MG	N62438 002	NOV 17, 1983
	ULTRAGRIS-165			
AB	SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992
	ULTRAGRIS-330			
AB	SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	COPLEY PHARM	EQ 4MG BASE	N74267 001	JUN 01, 1994

FDA data supplied by DrugPatentWatch.com

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	COPLEY PHARM	EQ 8MG BASE	N74267 002	JUN 01, 1994
AB	EON	EQ 4MG BASE	N74517 001	SEP 30, 1998
AB		EQ 8MG BASE	N74517 002	SEP 30, 1998
AB	WATSON LABS	EQ 4MG BASE	N74025 001	FEB 28, 1994
AB		EQ 8MG BASE	N74025 002	FEB 28, 1994
AB	ZENITH GOLDLINE	EQ 4MG BASE	N74149 001	APR 07, 1995
AB		EQ 8MG BASE	N74149 002	APR 07, 1995
	WYTENSIN			
AB	WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982
AB +		EQ 8MG BASE	N18587 002	SEP 07, 1982

GUANADREL SULFATE

TABLET; ORAL

	HYLOREL		
	PHARMACIA AND UPJOHN	10MG	N18104 001 DEC 29, 1982
+		25MG	N18104 002 DEC 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL

	ISMELIN		
	NOVARTIS	EQ 10MG SULFATE	N12329 001
+		EQ 25MG SULFATE	N12329 002

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	AMIDE PHARM	EQ 1MG BASE	N74673 001	FEB 28, 1997

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	AMIDE PHARM	EQ 2MG BASE	N74673 002	FEB 28, 1997
AB	GENPHARM	EQ 1MG BASE	N75109 001	NOV 25, 1998
AB		EQ 2MG BASE	N75109 002	NOV 25, 1998
AB	MYLAN	EQ 1MG BASE	N74796 001	JAN 27, 1997
AB		EQ 2MG BASE	N74796 002	JAN 27, 1997
AB	WATSON LABS	EQ 1MG BASE	N74145 001	OCT 17, 1995
AB		EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74145 002	OCT 17, 1995
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997
	TENEX			
AB	WYETH AYERST	EQ 1MG BASE	N19032 001	OCT 27, 1986
AB +		EQ 2MG BASE	N19032 002	NOV 07, 1988

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

	GUANIDINE HCL		
	SCHERING	125MG	N01546 001

HALAZEPAM

TABLET; ORAL

	PAXIPAM		
	SCHERING	20MG	N17736 003
+		40MG	N17736 004

HALCINONIDE

CREAM; TOPICAL

	HALOG		
+	WESTWOOD SQUIBB	0.1%	N17556 001

FDA data supplied by DrugPatentWatch.com

HALCINONIDE

CREAM; TOPICAL					
HALOG-E					
WESTWOOD SQUIBB	0.1%	N18234 001			
OINTMENT; TOPICAL					
HALOG					
+ WESTWOOD SQUIBB	0.1%	N17824 001			
SOLUTION; TOPICAL					
HALOG					
WESTWOOD SQUIBB	0.1%	N17823 001			

HALOBETASOL PROPIONATE

CREAM; TOPICAL					
ULTRAVATE					
+ WESTWOOD SQUIBB	0.05%	N19967 001 DEC 27, 1990			
OINTMENT; TOPICAL					
ULTRAVATE					
+ WESTWOOD SQUIBB	0.05%	N19968 001 DEC 17, 1990			

HALOPERIDOL

TABLET; ORAL						
HALDOL						
AB	JOHNSON RW	**0.5MG**	**N15921 001**			
AB		**1MG**	**N15921 002**			
AB		**2MG**	**N15921 003**			
AB	+	**5MG**	**N15921 004**			
AB		**10MG**	**N15921 005**			
AB	+	**20MG**	**N15921 006** FEB 02, 1982			
HALOPERIDOL						
AB	DANBURY PHARMA	**0.5MG**	**N70981 001** MAR 06, 1987			
AB		**1MG**	**N70982 001** MAR 06, 1987			
AB		**2MG**	**N70983 001** MAR 06, 1987			
AB		**5MG**	**N70984 001** MAR 06, 1987			

HALOPERIDOL

TABLET; ORAL					
HALOPERIDOL					
AB	GENEVA PHARMS	**0.5MG**	**N71206 001** NOV 17, 1986		
AB		**1MG**	**N71207 001** NOV 17, 1986		
AB		**2MG**	**N71208 001** NOV 17, 1986		
AB		**5MG**	**N71209 001** NOV 17, 1986		
AB		**10MG**	**N71210 001** MAR 11, 1988		
AB		**20MG**	**N71211 001** MAR 11, 1988		
AB	MYLAN	**0.5MG**	**N70276 001** JUN 10, 1986		
AB		**1MG**	**N70277 001** JUN 10, 1986		
AB		**2MG**	**N70278 001** JUN 10, 1986		
AB		**5MG**	**N70279 001** JUN 10, 1986		
AB	PAR PHARM	**0.5MG**	**N71233 001** NOV 03, 1986		
AB		**1MG**	**N71234 001** NOV 03, 1986		
AB		**2MG**	**N71235 001** NOV 03, 1986		
AB		**5MG**	**N71236 001** NOV 03, 1986		
AB		**10MG**	**N71237 001** JUL 20, 1987		
AB	ROXANE	**0.5MG**	**N71128 001** FEB 17, 1987		
AB		**1MG**	**N71129 001** FEB 17, 1987		
AB		**2MG**	**N71130 001** FEB 17, 1987		
AB		**5MG**	**N71131 001** FEB 17, 1987		
AB		**10MG**	**N71132 001** MAY 12, 1987		
AB		**20MG**	**N71133 001** MAY 12, 1987		

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALDOL			
AO	+ JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986
AO	+	EQ 100MG BASE/ML	N18701 002	JAN 31, 1997
	HALOPERIDOL DECANOATE			
AO	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74893 001	DEC 19, 1997
AO		EQ 100MG BASE/ML	N74893 002	DEC 19, 1997
AO	APOTEX	EQ 50MG BASE/ML	N75440 001	FEB 28, 2000
AO		EQ 100MG BASE/ML	N75440 002	FEB 28, 2000
AO	BEDFORD	EQ 50MG BASE/ML	N74811 001	JAN 30, 1998
AO		EQ 100MG BASE/ML	N75305 001	SEP 28, 1998
AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001	MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002	MAY 11, 1999
AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000
AO		EQ 100MG BASE/ML	N75176 002	FEB 09, 2000

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALDOL			
AA	+ JOHNSON RW	EQ 2MG BASE/ML	N15922 001	
	HALOPERIDOL			
AA	ALPHARMA	EQ 2MG BASE/ML	N70318 001	APR 11, 1986
AA	COPLEY PHARM	EQ 2MG BASE/ML	N71617 001	DEC 01, 1988
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001	FEB 26, 1993
AA	SILARX	EQ 2MG BASE/ML	N73364 001	SEP 28, 1993
AA	TEVA	EQ 2MG BASE/ML	N71015 001	AUG 25, 1987
	HALOPERIDOL INTENSOL			
AA	ROXANE	EQ 2MG BASE/ML	N72045 001	APR 12, 1988

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

	HALDOL			
AP	+ JOHNSON RW	EQ 5MG BASE/ML	N15923 001	
	HALOPERIDOL			
AP	STERIS	EQ 5MG BASE/ML	N70714 001	MAY 17, 1988

SOLUTION; ORAL

	HALOPERIDOL LACTATE			
	UDL	EQ 1MG BASE/ML	N74536 001	NOV 02, 1995

HALOTHANE

LIQUID; INHALATION

	FLUOTHANE			
AN	+ WYETH AYERST	99.99%	N11338 001	
	HALOTHANE			
AN	ABBOTT	99.99%	N83254 001	
AN	BH	99.99%	N84977 001	
AN	HALOCARBON	99.99%	N80810 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP-LOCK			
AP	ELKINS SINN	10 UNITS/ML	N17037 007	
AP		100 UNITS/ML	N17037 006	
	HEP-LOCK U/P			
AP	ELKINS SINN	10 UNITS/ML	N17037 010	JUN 10, 1983
AP		100 UNITS/ML	N17037 011	JUN 10, 1983
	HEPARIN LOCK FLUSH			
AP	ABBOTT	10 UNITS/ML	N05264 001	
AP		10 UNITS/ML	N40082 001	FEB 28, 1995
AP		10 UNITS/ML	N88097 001	APR 28, 1983
AP		10 UNITS/ML	N88346 001	MAY 18, 1983
AP		100 UNITS/ML	N40082 002	FEB 28, 1995
AP		100 UNITS/ML	N88098 001	APR 28, 1983

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN LOCK FLUSH			
AP		ABBOTT	100 UNITS/ML	N88347 001	MAY 18, 1983
AP		AM PHARM PARTNERS	10 UNITS/ML	N17029 007	MAY 06, 1982
AP			100 UNITS/ML	N17029 006	
AP	+	WYETH AYERST	10 UNITS/ML	N17007 008	
AP	+		100 UNITS/ML	N17007 009	
		HEPARIN LOCK FLUSH IN PLASTIC CONTAINER			
AP		ABBOTT	10 UNITS/ML	N05264 015	MAY 21, 1985
AP			100 UNITS/ML	N05264 016	MAY 21, 1985
		HEPARIN SODIUM			
AP		ABBOTT	2,500 UNITS/ML	N88099 001	APR 28, 1983
AP			5,000 UNITS/ML	N88100 001	APR 28, 1983
AP			10,000 UNITS/ML	N40095 001	JUL 26, 1996
AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001	
AP			1,000 UNITS/ML	N17979 001	
AP			5,000 UNITS/ML	N17651 006	
AP			10,000 UNITS/ML	N17029 003	
AP			10,000 UNITS/ML	N17979 002	
AP			20,000 UNITS/ML	N17029 004	
AP		ELKINS SINN	1,000 UNITS/ML	N17037 001	
AP			5,000 UNITS/ML	N17037 002	
AP			10,000 UNITS/ML	N17037 003	
AP			5,000 UNITS/0.5ML	N17037 013	APR 07, 1986
AP		LILLY	10,000 UNITS/ML	N05521 002	
AP		MARSAM	1,000 UNITS/ML	N40007 001	JUN 07, 1996
AP			1,000 UNITS/ML	N40008 001	OCT 10, 1995
AP	+	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N04570 001	
AP	+		5,000 UNITS/ML	N04570 002	
AP	+		10,000 UNITS/ML	N04570 003	
AP		WYETH AYERST	1,000 UNITS/ML	N17007 001	
AP	+		2,500 UNITS/ML	N17007 007	
AP			5,000 UNITS/ML	N17007 002	
AP			10,000 UNITS/ML	N17007 004	
AP			5,000 UNITS/0.5ML	N17007 010	
AP	+		20,000 UNITS/ML	N17007 006	
	+		7,500 UNITS/ML	N17007 003	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	200 UNITS/100ML	N18609 001	APR 28, 1982
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	200 UNITS/100ML	N18916 010	JUN 23, 1989
AP	B BRAUN	200 UNITS/100ML	N19953 001	JUL 20, 1992
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	10,000 UNITS/100ML	N19339 003	MAR 27, 1985
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
	ABBOTT	5,000 UNITS/100ML	N19339 001	MAR 27, 1985
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	ABBOTT	5,000 UNITS/100ML	N18916 006	JAN 31, 1984
	HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	200 UNITS/100ML	N18609 002	APR 28, 1982
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	200 UNITS/100ML	N18916 011	JUN 23, 1989
	HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	4,000 UNITS/100ML	N18814 001	OCT 31, 1983
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	4,000 UNITS/100ML	N19805 001	JAN 25, 1989
AP	B BRAUN	4,000 UNITS/100ML	N19952 001	JUL 20, 1992
	HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5,000 UNITS/100ML	N18814 003	JUL 09, 1985
AP		10,000 UNITS/100ML	N18814 004	JUL 02, 1987

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	N19339 004 MAR 27, 1985	
AP		5,000 UNITS/100ML	N19805 002 JAN 25, 1989	
AP		10,000 UNITS/100ML	N19339 002 MAR 27, 1985	
AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992	
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992	

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	ABBOTT	5,000 UNITS/100ML	N18916 007 JAN 31, 1984
		10,000 UNITS/100ML	N18916 008 JAN 31, 1984

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985	
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985	
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985	
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985	

HEPARIN SODIUM PRESERVATIVE FREE

AP	+ ABBOTT	2,500 UNITS/ML	N05264 014 APR 07, 1986	
AP	+	10,000 UNITS/ML	N89522 001 MAY 04, 1987	
	+	2,000 UNITS/ML	N05264 013 APR 07, 1986	
AP	+ AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP	MARSAM	1,000 UNITS/ML	N89464 001 JUN 03, 1986	
AP	PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984	

SODIUM HEPARIN

AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

	+ SANOFI SYNTHELABO	3%	N06882 001	

SOAP; TOPICAL

GAMOPHEN

	+ ARBROOK	2%	N06270 003	

SPONGE; TOPICAL

E-Z SCRUB

	+ BECTON DICKINSON	450MG	N17452 001	

PRE-OP

AT	+ DAVIS AND GECK	480MG	N17433 001	

PRE-OP II

AT	DAVIS AND GECK	480MG	N17433 002	

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

	+ SHIRE	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991	
	+	EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991	
	+	EQ 1MG BASE/ML	N19836 003 DEC 24, 1991	

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

	+ MISSION PHARMA	10MG	N86308 001	

HOMAPIN-5

	+ MISSION PHARMA	5MG	N86309 001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA	+ ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002 JUL 26, 1988	

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001 JUL 19, 1999	

FDA data supplied by DrugPatentWatch.com

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYDROCODONE COMPOUND			
AA	ALPHARMA	1.5MG/5ML;5MG/5ML	N88017 001	JUL 05, 1983
	MYCODONE			
AA	MORTON GROVE	1.5MG/5ML;5MG/5ML	N88008 001	MAR 03, 1983

TABLET; ORAL

	HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE			
AA	AMIDE PHARM	1.5MG;5MG	N40295 001	DEC 01, 2000
	HYCODAN			
AA	+ ENDO PHARMS	1.5MG;5MG	N05213 001	JUL 26, 1988
	TUSSIGON			
AA	JONES PHARMA	1.5MG;5MG	N88508 001	JUL 30, 1985

HYALURONIDASE

INJECTABLE; INJECTION

	WYDASE		
+	WYETH AYERST	150 UNITS/ML	N06343 002
+		150 UNITS/VIAL	N06343 006
+		1,500 UNITS/VIAL	N06343 005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL			
AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001	FEB 23, 2000
AP	+ LUITPOLD	20MG/ML	N40136 001	JUN 30, 1997

TABLET; ORAL

	APRESOLINE			
AA	+ NOVARTIS	10MG	N08303 004	
AA	+	25MG	N08303 001	
AA	+	50MG	N08303 002	
AA	+	100MG	N08303 005	
	HYDRALAZINE HCL			
AA	CAMALL	10MG	N88846 001	FEB 26, 1985

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL			
AA	CAMALL	25MG	N88847 001	FEB 26, 1985
AA		50MG	N88848 001	FEB 26, 1985
AA		100MG	N88849 001	FEB 26, 1985
AA	DANBURY PHARMA	25MG	N84504 001	
AA		50MG	N84503 001	
AA	GENEVA PHARMS	10MG	N83241 001	
AA		25MG	N83560 001	
AA		50MG	N83561 001	
AA	IMPAX LABS	50MG	N84923 001	
AA	LEDERLE	25MG	N86243 001	
AA		50MG	N86242 002	
AA	MUTUAL PHARM	10MG	N89359 001	JUL 25, 1986
AA		25MG	N89258 001	MAY 05, 1986
AA		50MG	N89259 001	MAY 05, 1986
AA	PAR PHARM	10MG	N87836 001	OCT 05, 1982
AA		25MG	N86961 002	
AA		50MG	N86962 001	
AA		100MG	N88391 001	SEP 27, 1983
AA	SIDMAK LABS NJ	10MG	N89097 001	DEC 18, 1985
AA		25MG	N88467 001	MAY 01, 1984
AA		50MG	N88468 001	MAY 01, 1984
AA		100MG	N89098 001	DEC 18, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	APRESAZIDE			
AB	NOVARTIS	25MG;25MG	N84735 001	
AB		50MG;50MG	N84810 001	
	HYDRA-ZIDE			
AB	PAR PHARM	25MG;25MG	N88957 001	OCT 21, 1985

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRA-ZIDE			
AB	PAR PHARM	50MG;50MG	N88946 001	OCT 21, 1985
+		100MG;50MG	N88961 001	OCT 21, 1985
	HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
AB	SUPERPHARM	50MG;50MG	N89201 001	FEB 09, 1987

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	CAM-AP-ES			
BP	CAMALL	25MG;15MG;0.1MG	N84897 001	
	RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
BP	DANBURY PHARMA	25MG;15MG;0.1MG	N85549 001	
	SER-AP-ES			
BP +	NOVARTIS	25MG;15MG;0.1MG	N12193 005	

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE			
AB	MYLAN	12.5MG	N75640 001	JAN 28, 2000
	MICROZIDE			
AB +	WATSON LABS	12.5MG	N20504 001	DEC 27, 1996

SOLUTION; ORAL

	HYDROCHLOROTHIAZIDE			
+	ROXANE	50MG/5ML	N88587 001	JUL 02, 1984

TABLET; ORAL

	ESIDRIX			
AB	NOVARTIS	25MG	N11793 005	
AB		50MG	N11793 008	
AB		100MG	N11793 009	
	HYDROCHLOROTHIAZIDE			
AB	CAMALL	25MG	N85683 001	
AB		50MG	N83965 001	
AB		50MG	N85672 001	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
AB	DANBURY PHARMA	25MG	N81189 001	JAN 24, 1992
AB		50MG	N83232 001	
AB		100MG	N81190 001	JAN 24, 1992
AB	EON	50MG	N85219 001	
AB	GENEVA PHARMS	25MG	N87565 001	MAR 09, 1982
AB		50MG	N84912 001	
AB	HALSEY	25MG	N83972 001	
AB		50MG	N83972 002	
AB	IMPAX LABS	25MG	N84029 001	
AB		50MG	N83607 002	
AB	LEDERLE	25MG	N87059 001	
AB		50MG	N87068 001	
AB		100MG	N87060 001	
AB	PHARMERAL	25MG	N84325 001	
AB		50MG	N84324 001	
AB	PUREPAC PHARM	25MG	N85054 002	
AB		50MG	N85208 001	
AB	PVT FORM	25MG	N85181 001	
AB		50MG	N85182 001	
AB		50MG	N86597 001	
AB	ROXANE	50MG	N84536 002	
AB	WEST WARD	50MG	N84878 001	
AB	ZENITH GOLDLINE	25MG	N83177 001	
AB		50MG	N83177 002	
AB		100MG	N85022 001	
	HYDRODIURIL			
AB	MERCK	25MG	N11835 003	
AB +		50MG	N11835 006	
AB		100MG	N11835 007	
	ORETIC			
AB	ABBOTT	25MG	N11971 001	
AB		50MG	N11971 002	

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
SEE CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE
SEE DESERPIDINE; HYDROCHLOROTHIAZIDE
SEE ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
SEE FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; *MULTIPLE*
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE			
	SANOFI SYNTHELABO	12.5MG;150MG	N20758 002	SEP 30, 1997
+		12.5MG;300MG	N20758 003	AUG 31, 1998

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

	PRINZIDE			
AB	MERCK	12.5MG;10MG	N19778 003	NOV 18, 1993
AB		12.5MG;20MG	N19778 001	FEB 16, 1989
AB +		25MG;20MG	N19778 002	FEB 16, 1989
	ZESTORETIC			
AB	ASTRAZENECA	12.5MG;10MG	N19888 003	NOV 18, 1993
AB		12.5MG;20MG	N19888 001	SEP 20, 1990
AB		25MG;20MG	N19888 002	JUL 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

	HYZAAR			
	MERCK	12.5MG;50MG	N20387 001	APR 28, 1995
+		25MG;100MG	N20387 002	NOV 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDORIL 15		
AB	MERCK	15MG;250MG	N13402 001
	ALDORIL 25		
AB	MERCK	25MG;250MG	N13402 002

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDORIL D30			
AB	MERCK	30MG;500MG	N13402 003	
	ALDORIL D50			
AB +	MERCK	50MG;500MG	N13402 004	
	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	DANBURY PHARMA	15MG;250MG	N70958 001	FEB 06, 1989
AB		25MG;250MG	N70959 001	JAN 19, 1989
AB		30MG;500MG	N71069 001	JAN 19, 1989
AB		50MG;500MG	N70960 001	FEB 06, 1989
AB	GENEVA PHARMS	15MG;250MG	N70182 001	JAN 15, 1986
AB		25MG;250MG	N70183 001	JAN 15, 1986
AB		30MG;500MG	N70543 001	JAN 15, 1986
AB		50MG;500MG	N70544 001	JAN 15, 1986
AB	LEDERLE	15MG;250MG	N72507 001	JUN 02, 1989
AB		25MG;250MG	N72508 001	JUN 02, 1989
AB		30MG;500MG	N72509 001	JUN 02, 1989
AB		50MG;500MG	N72510 001	JUN 02, 1989
AB	MYLAN	15MG;250MG	N70264 001	JAN 23, 1986
AB		25MG;250MG	N70265 001	JAN 23, 1986
AB	PAR PHARM	15MG;250MG	N70616 001	FEB 02, 1987
AB		25MG;250MG	N70612 001	FEB 02, 1987
AB		30MG;500MG	N70613 001	FEB 02, 1987
AB		50MG;500MG	N70614 001	FEB 02, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT				
	NOVARTIS	25MG;50MG	N18303 001	DEC 31, 1984
		25MG;100MG	N18303 002	DEC 31, 1984
+		50MG;100MG	N18303 003	DEC 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC				
	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001	JUN 27, 1997
+		25MG;15MG	N20729 002	JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50				
+	WYETH AYERST	50MG;120MG	N19059 002	JUL 03, 1985
INDERIDE LA 160/50				
+	WYETH AYERST	50MG;160MG	N19059 003	JUL 03, 1985
INDERIDE LA 80/50				
+	WYETH AYERST	50MG;80MG	N19059 001	JUL 03, 1985

TABLET; ORAL

INDERIDE-40/25				
AB	WYETH AYERST	**25MG;40MG**	**N18031 001**	
INDERIDE-80/25				
AB +	WYETH AYERST	**25MG;80MG**	**N18031 002**	
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE				
AB	BARR	**25MG;40MG**	**N70704 001**	OCT 01, 1986
AB		**25MG;80MG**	**N70705 001**	OCT 01, 1986
AB	CHELSEA LABS	**25MG;40MG**	**N70301 001**	APR 18, 1986
AB		**25MG;80MG**	**N70305 001**	APR 18, 1986

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE				
AB	GENEVA PHARMS	**25MG;40MG**	**N71060 001**	AUG 26, 1987
AB		**25MG;80MG**	**N71061 001**	AUG 26, 1987
AB	MYLAN	**25MG;40MG**	**N70946 001**	MAR 04, 1987
AB		**25MG;80MG**	**N70947 001**	APR 01, 1987
AB	PUREPAC PHARM	**25MG;40MG**	**N70851 001**	MAY 15, 1986
AB		**25MG;80MG**	**N70852 001**	MAY 15, 1986
AB	SIDMAK LABS NJ	**25MG;40MG**	**N72042 001**	MAR 14, 1988
AB		**25MG;80MG**	**N72043 001**	MAR 14, 1988

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC				
	PARKE DAVIS	12.5MG;EQ 10MG BASE	N20125 001	DEC 28, 1999
		12.5MG;EQ 20MG BASE	N20125 002	DEC 28, 1999
+		25MG;EQ 20MG BASE	N20125 003	DEC 28, 1999

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRO-RESERP				
BP	CAMALL	50MG;0.125MG	N84714 002	JUN 29, 1982
HYDROCHLOROTHIAZIDE W/ RESERPINE				
BP	DANBURY PHARMA	25MG;0.125MG	N84466 001	
BP		50MG;0.125MG	N84467 001	
HYDROPRES 25				
BP	MERCK	25MG;0.125MG	N11958 002	
HYDROPRES 50				
BP +	MERCK	50MG;0.125MG	N11958 003	
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
BP	WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

	ALDACTAZIDE			
AB	SEARLE	25MG;25MG	N12616 004	DEC 30, 1982
+		50MG;50MG	N12616 005	DEC 30, 1982
	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE			
AB	GENEVA PHARMS	25MG;25MG	N86881 001	
AB	HALSEY	25MG;25MG	N87267 001	
AB	MUTUAL PHARM	25MG;25MG	N89534 001	JUL 02, 1987
AB	MYLAN	25MG;25MG	N86513 001	
	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE			
AB	PARKE DAVIS	25MG;25MG	N87948 001	FEB 22, 1983
	SPIRONOLACTONE/HYDROCHLOROTHIAZIDE			
AB	DANBURY PHARMA	25MG;25MG	N87398 001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

	MICARDIS HCT			
	BOEHRINGER INGELHEIM	12.5MG;40MG	N21162 001	NOV 17, 2000
+		12.5MG;80MG	N21162 002	NOV 17, 2000

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

	TIMOLIDE 10-25			
+	MERCK	25MG;10MG	N18061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	DYAZIDE			
AB +	SMITHKLINE BEECHAM	25MG;37.5MG	N16042 003	MAR 03, 1994
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	BARR	25MG;37.5MG	N74970 001	JAN 06, 1998
AB	DURAMED	25MG;37.5MG	N75052 001	JUN 18, 1999

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	GENEVA PHARMS	25MG;37.5MG	N74821 001	JUN 05, 1997
AB +		25MG;50MG	N73191 001	JUL 31, 1991
AB	MYLAN	25MG;37.5MG	N74701 001	JUN 07, 1996
AB	ZENITH GOLDLINE	25MG;50MG	N74259 001	MAR 30, 1995

TABLET; ORAL

	MAXZIDE			
AB +	MYLAN	50MG;75MG	N19129 001	OCT 22, 1984
	MAXZIDE-25			
AB	MYLAN	25MG;37.5MG	N19129 003	MAY 13, 1988
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	BARR	25MG;37.5MG	N71251 002	MAY 05, 1998
AB		50MG;75MG	N71251 001	APR 17, 1988
AB	DANBURY PHARMA	50MG;75MG	N71969 001	APR 17, 1988
AB	GENEVA PHARMS	25MG;37.5MG	N73281 001	APR 30, 1992
AB		50MG;75MG	N72011 001	JUN 17, 1988
AB	SIDMAK LABS NJ	25MG;37.5MG	N74026 001	APR 26, 1996
AB		50MG;75MG	N73467 001	JAN 31, 1996
AB	WATSON LABS	25MG;37.5MG	N73449 001	SEP 23, 1993
AB		50MG;75MG	N71851 001	NOV 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

	DIOVAN HCT			
	NOVARTIS	12.5MG;80MG	N20818 001	MAR 06, 1998
+		12.5MG;160MG	N20818 002	MAR 06, 1998

FDA data supplied by DrugPatentWatch.com

HYDROCODONE BITARTRATE; *MULTIPLE*
SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE
SEE ASPIRIN; HYDROCODONE BITARTRATE
SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

	VICOPROFEN			
	+ KNOLL PHARM	7.5MG;200MG	N20716 001	SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	CODAMINE			
AA	ALPHARMA	**5MG/5ML;25MG/5ML**	**N75103 001**	SEP 29, 2000
	HYCOMINE			
AA	+ ENDO PHARMS	**5MG/5ML;25MG/5ML**	**N19410 001**	AUG 17, 1990
	HYCOMINE PEDIATRIC			
	ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N19411 001	AUG 17, 1990

HYDROCODONE POLISTIREX; *MULTIPLE*
SEE CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

HYDROCORTISONE

CREAM; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	**1%**	**N80706 006**	
	ANUSOL HC			
AT	PARKEDALE	**2.5%**	**N88250 001**	JUN 06, 1984
	DERMACORT			
AT	MONARCH PHARMS	**1%**	**N83011 002**	
	HC (HYDROCORTISONE)			
AT	C AND M PHARMA	**0.5%**	**N80482 003**	
AT		**1%**	**N80482 004**	
	HI-COR			
AT	C AND M PHARMA	**2.5%**	**N80483 001**	
	HYDROCORTISONE			
AT	ALPHARMA	**2.5%**	**N89682 001**	MAR 10, 1988

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	ALPHARMA US PHARM	**1%**	**N87795 001**	MAY 03, 1983
AT	ALTANA	**0.5%**	**N80848 002**	
AT		**1%**	**N80848 003**	
AT	CLAY PARK	**2.5%**	**N85025 001**	
AT	EVERYLIFE	**1%**	**N80452 002**	
AT	FOUGERA	**1%**	**N80693 003**	
AT		**2.5%**	**N89414 001**	DEC 16, 1986
AT	INGRAM PHARM	**0.5%**	**N80456 002**	
AT		**1%**	**N80456 003**	
AT	PHARMADERM	**2.5%**	**N89413 001**	DEC 16, 1986
AT	SYOSSET	**0.5%**	**N85527 001**	
AT	THAMES	**1%**	**N86155 001**	
AT		**2.5%**	**N88799 001**	NOV 09, 1984
AT	TOPIDERM	**1%**	**N89273 001**	FEB 17, 1989
	HYTONE			
AT	+ DERMIK LABS	**1%**	**N80472 003**	
AT	+	**2.5%**	**N80472 004**	
	NUTRACORT			
AT	HEALTHPOINT	**1%**	**N80442 003**	
	PENECORT			
AT	ALLERGAN HERBERT	**1%**	**N88216 001**	JUN 06, 1984
	PROCTOCORT			
AT	MONARCH PHARMS	**1%**	**N83011 001**	
	SYNACORT			
AT	MEDICIS	**1%**	**N87458 001**	
AT		**2.5%**	**N87457 001**	

ENEMA; RECTAL

	COLOCORT			
AB	PADDOCK	**100MG/60ML**	**N75172 001**	DEC 03, 1999
	CORTENEMA			
AB	+ SOLVAY	**100MG/60ML**	**N16199 001**	
	HYDROCORTISONE			
AB	COPLEY PHARM	**100MG/60ML**	**N74171 001**	MAY 27, 1994

LOTION; TOPICAL

	ACTICORT			
AT	BAKER NORTON	**1%**	**N86535 001**	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

LOTION; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	N83201 001	
	ALA-SCALP			
	DEL RAY LABS	2%	N83231 001	
	BETA-HC			
AT	BETA DERMAC	1%	N89495 001	
			JAN 25, 1988	
	CETACORT			
AT	HEALTHPOINT	0.5%	N80426 002	
AT		1%	N80426 001	
	EPICORT			
AT	BLULINE	0.5%	N83219 002	
	GLYCORT			
AT	HERAN	1%	N87489 001	
			OCT 03, 1983	
	HYDROCORTISONE			
AT	ALTANA	2.5%	N40351 001	
			JUL 25, 2000	
AT	MERICON	0.5%	N85282 001	
AT		1%	N85282 002	
			FEB 26, 1987	
AT	THAMES	2.5%	N40247 001	
			JUL 23, 1999	
	HYTONE			
AT	+ DERMIK LABS	1%	N80473 003	
AT	+	2.5%	N80473 004	
			NOV 30, 1982	
	NUTRACORT			
AT	HEALTHPOINT	1%	N80443 003	
AT		2.5%	N87644 001	
			AUG 24, 1982	
	STIE-CORT			
AT	STIEFEL	1%	N89066 001	
			NOV 25, 1985	
AT		2.5%	N89074 001	
			NOV 26, 1985	

OINTMENT; TOPICAL

	CORTRIL			
AT	+ PFIPHARMECS	1%	N09176 001	
AT	+	2.5%	N09176 002	
	HC (HYDROCORTISONE)			
AT	C AND M PHARMA	1%	N80481 002	
	HYDROCORTISONE			
AT	ALTANA	1%	N80489 003	
AT		1%	N80692 001	

HYDROCORTISONE

OINTMENT; TOPICAL

	HYDROCORTISONE			
AT	CLAY PARK	2.5%	N85027 001	
AT	FOUGERA	2.5%	N81203 001	
			MAY 28, 1993	
AT	NMC	1%	N87796 001	
			OCT 13, 1982	
AT	THAMES	1%	N86257 001	
AT		2.5%	N40310 001	
			DEC 29, 2000	
	HYDROCORTISONE IN ABSORBASE			
AT	CAROLINA MEDCL	1%	N88138 001	
			SEP 06, 1985	

POWDER; FOR RX COMPOUNDING

	H-CORT			
AA	TORCH	100%	N87834 001	
			MAR 29, 1982	
	HYDROCORTISONE			
AA	PADDOCK	100%	N88082 001	
			APR 08, 1983	
AA	PHARMA TEK	100%	N85982 001	

SOLUTION; TOPICAL

	PENECORT			
AT	ALLERGAN HERBERT	1%	N88214 001	
			JUN 06, 1984	
	TEXACORT			
AT	+ BIOGLAN PHAR	1%	N80425 001	
	+	2.5%	N81271 001	
			APR 17, 1992	

TABLET; ORAL

	CORTEF		
BP	PHARMACIA AND UPJOHN	10MG	N08697 001
BP		20MG	N08697 002
		5MG	N08697 003
	HYDROCORTISONE		
BP	IMPAX LABS	20MG	N80781 001
BP	LANNETT	20MG	N85070 001
BP	WEST WARD	20MG	N83365 001
	HYDROCORTONE		
BP	MERCK	10MG	N08506 007
BP +		20MG	N08506 011

HYDROCORTISONE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE; *MULTIPLE*
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-CORT-DOME
+ BAYER — 0.5%;EQ 3.5MG BASE/GM — N50237 006 JUN 05, 1984
+ — 1%;EQ 3.5MG BASE/GM — N50237 005 JUN 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
CORTISPORIN
AT + MONARCH PHARMS — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N50479 001**
NEO-OTOSOL-HC
AT ALCON — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N62423 001** AUG 25, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT BAUSCH AND LOMB — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N64053 001** DEC 29, 1995

SUSPENSION/DROPS; OPHTHALMIC
CORTISPORIN
AT + MONARCH PHARMS — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N50169 001**
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N62874 001** MAY 11, 1988

SUSPENSION/DROPS; OTIC
CORTISPORIN
AT + MONARCH PHARMS — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N60613 001**
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N62488 001** NOV 06, 1985

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
OTICAIR
AT BAUSCH AND LOMB — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N64065 001** AUG 28, 1996
PEDIOTIC
AT MONARCH PHARMS — **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** — **N62822 001** SEP 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
OTOBIOTIC
+ SCHERING — 5MG/ML; EQ 10,000 UNITS BASE/ML — N62302 001

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC
ACHROMYCIN
+ LEDERLE — 1.5%;1% — N50272 001

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL
CORTIFOAM
+ SCHWARZ PHARMA — 10% — N17351 001 FEB 10, 1982

CREAM; TOPICAL
HYDROCORTISONE ACETATE
+ FERNDALE LABS — 2.5% — N40259 001 JUL 29, 1999

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE
BP STERIS — 25MG/ML — N83128 001
HYDROCORTONE
BP MERCK — 25MG/ML — N08228 001
+ — 50MG/ML — N08228 004

LOTION; TOPICAL
DRICORT
+ INGRAM PHARM — 0.5% — N86207 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE
+ ALTANA 0.5% N80828 001

PASTE; TOPICAL
ORABASE HCA
COLGATE 0.5% N83205 001

POWDER; FOR RX COMPOUNDING
HYDROCORTISONE ACETATE
PHARMA TEK 100% N85981 001

HYDROCORTISONE ACETATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL
NEO-CORTEF
+ PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM N60751 002

SUSPENSION/DROPS; OPHTHALMIC
COR-OTICIN
+ AKORN 1.5%;EQ 3.5MG BASE/ML N60188 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN
+ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50218 001 AUG 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
TERRA-CORTRIL
+ PFIZER 1.5%;EQ 5MG BASE/ML N61016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%
BX COPLEY PHARM 1%;1% N89440 001 MAY 17, 1988
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

CREAM; TOPICAL
PRAMOSONE
FERNDALE LABS 0.5%;1% N83778 001
1%;1% N85368 001

LOTION; TOPICAL
PRAMOSONE
FERNDALE LABS 1%;1% N85980 001
2.5%;1% N85979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC
AT + KENWOOD LABS **1%;10%** **N80505 001**
U-CORT
AT THAMES **1%;10%** **N89472 001** JUN 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
+ YAMANOUCHI 0.1% N18514 001 MAR 31, 1982
LOCOID LIPOCREAM
+ YAMANOUCHI 0.1% N20769 001 SEP 08, 1997

OINTMENT; TOPICAL
LOCOID
+ YAMANOUCHI 0.1% N18652 001 OCT 29, 1982

SOLUTION; TOPICAL
LOCOID
+ YAMANOUCHI 0.1% N19116 001 FEB 25, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

	CORTEF			
+	PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N09900 001	

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

	PANDEL			
+	SAVAGE LABS	0.1%	N20453 001	FEB 28, 1997

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	HYDROCORTONE			
+	MERCK	EQ 50MG BASE/ML	N12052 001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-HYDROCORT			
AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N85932 001**	
AP		**EQ 100MG BASE/VIAL**	**N85929 001**	
AP		**EQ 250MG BASE/VIAL**	**N85930 001**	
AP		**EQ 500MG BASE/VIAL**	**N85931 001**	
	HYDROCORTISONE SODIUM SUCCINATE			
AP	INTL MEDICATION	**EQ 100MG BASE/VIAL**	**N87532 001**	MAR 19, 1982
	SOLU-CORTEF			
AP	+ PHARMACIA AND UPJOHN	**EQ 100MG BASE/VIAL**	**N09866 001**	
AP	+	**EQ 250MG BASE/VIAL**	**N09866 002**	
AP	+	**EQ 500MG BASE/VIAL**	**N09866 003**	
AP	+	**EQ 1GM BASE/VIAL**	**N09866 004**	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

	HYDROCORTISONE VALERATE			
AB	CLAY PARK	**0.2%**	**N75666 001**	MAY 24, 2000
AB	COPLEY PHARM	**0.2%**	**N74489 001**	AUG 12, 1998

HYDROCORTISONE VALERATE

CREAM; TOPICAL

	HYDROCORTISONE VALERATE			
AB	TARO	**0.2%**	**N75042 001**	AUG 25, 1998
	WESTCORT			
AB	+ WESTWOOD SQUIBB	**0.2%**	**N17950 001**	

OINTMENT; TOPICAL

	HYDROCORTISONE VALERATE			
AB	TARO	**0.2%**	**N75043 001**	AUG 25, 1998
	WESTCORT			
AB	+ WESTWOOD SQUIBB	**0.2%**	**N18726 001**	AUG 08, 1983

HYDROFLUMETHIAZIDE

TABLET; ORAL

	DIUCARDIN			
AB	WYETH AYERST	**50MG**	**N83383 001**	
	HYDROFLUMETHIAZIDE			
AB	PAR PHARM	**50MG**	**N88850 001**	MAY 31, 1985
	SALURON			
AB	+ SHIRE	**50MG**	**N11949 001**	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	RESERPINE AND HYDROFLUMETHIAZIDE			
BP	PAR PHARM	50MG;0.125MG	N88907 001	SEP 20, 1985
	SALUTENSIN			
BP	+ SHIRE	50MG;0.125MG	N12359 003	
	SALUTENSIN-DEMI			
	SHIRE	25MG;0.125MG	N12359 004	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
AP	+ KNOLL PHARM	**10MG/ML**	**N19034 001**	JAN 11, 1984

FDA data supplied by DrugPatentWatch.com

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
	+ KNOLL PHARM	250MG/VIAL	N19034 002	AUG 04, 1994
	HYDROMORPHONE HCL			
AP	ABBOTT	**10MG/ML**	**N74598 001**	JUN 19, 1997
AP	STERIS	**10MG/ML**	**N74317 001**	AUG 23, 1995

SOLUTION; ORAL

	DILAUDID			
AA	+ KNOLL PHARM	**5MG/5ML**	**N19891 001**	DEC 07, 1992
	HYDROMORPHONE HCL			
AA	ROXANE	**5MG/5ML**	**N74653 001**	JUL 29, 1998

TABLET; ORAL

	DILAUDID			
AB	+ KNOLL PHARM	**8MG**	**N19892 001**	DEC 07, 1992
	HYDROMORPHONE HCL			
AB	ROXANE	**8MG**	**N74597 001**	JUL 29, 1998

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROXOCOBALAMIN		
	+ STERIS	1MG/ML	N85998 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE		
	+ AKORN	1%	N00004 004

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREMYD			
	+ AKORN	1%;0.25%	N19261 001	JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

	HYDROXYCHLOROQUINE SULFATE			
AB	MYLAN	**200MG**	**N40274 001**	MAY 29, 1998
	HYDROXYCHLOROQUINE SULFATE			
AB	COPLEY PHARM	**200MG**	**N40081 001**	SEP 30, 1994
AB	GENEVA PHARMS	**200MG**	**N40104 001**	NOV 30, 1995
AB	GENEVA PHARMS TECH	**200MG**	**N40150 001**	JAN 27, 1996
AB	WATSON LABS	**200MG**	**N40133 001**	NOV 30, 1995
	PLAQUENIL			
AB	+ SANOFI SYNTHELABO	**200MG**	**N09768 001**	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

	HYDROXYPROGESTERONE CAPROATE		
	+ STERIS	250MG/ML	N17439 002

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

	LACRISERT		
	+ MERCK	5MG	N18771 001

HYDROXYUREA

CAPSULE; ORAL

	DROXIA			
	BRISTOL MYERS SQUIBB	200MG	N16295 002	FEB 25, 1998
		300MG	N16295 003	FEB 25, 1998
	+	400MG	N16295 004	FEB 25, 1998
	HYDREA			
AB	+ BRISTOL MYERS SQUIBB	**500MG**	**N16295 001**	
	HYDROXYUREA			
AB	BARR	**250MG**	**N75143 002**	SEP 21, 2000

FDA data supplied by DrugPatentWatch.com

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
AB	BARR	500MG	N75143 001	OCT 16, 1998
AB	+ DURAMED	250MG	N75020 002	JUN 26, 2000
AB		500MG	N75020 001	JUL 30, 1998
AB	PAR PHARM	500MG	N75340 001	FEB 24, 1999
AB	ROXANE	500MG	N74476 001	AUG 18, 1995

TABLET; ORAL

	HYDROXYUREA			
	+ BARR	1GM	N75734 001	AUG 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE			
AP	ELKINS SINN	50MG/ML	N85551 002	
	HYDROXYZINE HCL			
AP	ABBOTT	25MG/ML	N87416 001	
AP		50MG/ML	N86821 001	
AP		50MG/ML	N87546 001	
AP	AM PHARM PARTNERS	25MG/ML	N87329 001	
AP		25MG/ML	N88184 001	MAR 31, 1983
AP		50MG/ML	N87329 002	
AP		50MG/ML	N88185 001	MAR 31, 1983
AP	ELKINS SINN	25MG/ML	N85551 001	
AP	LUITPOLD	25MG/ML	N87408 001	
AP		50MG/ML	N87408 002	
AP	STERIS	25MG/ML	N85778 001	
AP		50MG/ML	N85779 001	
	VISTARIL			
AP	+ PFIZER	25MG/ML	N11111 001	
AP	+	50MG/ML	N11111 002	

SYRUP; ORAL

	ATARAX			
AA	+ ROERIG	10MG/5ML	N10485 001	
	HYDROXYZINE HCL			
AA	ALPHARMA	10MG/5ML	N86880 001	

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

	HYDROXYZINE HCL			
AA	HI TECH PHARMA	10MG/5ML	N40010 001	OCT 28, 1994
AA	MORTON GROVE	10MG/5ML	N87294 001	APR 12, 1982

TABLET; ORAL

	ATARAX			
AB	+ ROERIG	10MG	N10392 001	
AB	+	25MG	N10392 004	
AB	+	50MG	N10392 006	
AB	+	100MG	N10392 005	
	HYDROXYZINE HCL			
AB	DANBURY PHARMA	10MG	N88348 001	SEP 15, 1983
AB		25MG	N88349 001	SEP 15, 1983
AB		50MG	N88350 001	SEP 15, 1983
AB	GENEVA PHARMS	10MG	N87869 001	DEC 20, 1982
AB		25MG	N87870 001	DEC 20, 1982
AB		50MG	N87871 001	DEC 20, 1982
AB	MUTUAL PHARM	10MG	N89381 001	MAY 19, 1986
AB		25MG	N89382 001	MAY 19, 1986
AB		50MG	N89383 001	MAY 19, 1986
AB	PAR PHARM	10MG	N87602 001	JAN 22, 1982
AB		25MG	N87603 001	JAN 22, 1982
AB		50MG	N87604 001	JAN 22, 1982
AB	SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986
AB		25MG	N88618 001	JAN 10, 1986
AB		50MG	N88619 001	JAN 10, 1986
AB		100MG	N81054 001	SEP 25, 1995

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

AB	WATSON LABS	10MG	N81149 001	MAR 18, 1994
AB		25MG	N81150 001	MAR 18, 1994
AB		50MG	N81151 001	MAR 18, 1994

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	BARR	EQ 25MG HCL	N88496 001	JUN 15, 1984
AB		EQ 50MG HCL	N88487 001	JUN 15, 1984
AB		EQ 100MG HCL	N88488 001	JUN 15, 1984
AB	CHELSEA LABS	EQ 25MG HCL	N40156 001	JUL 15, 1996
AB		EQ 50MG HCL	N40156 002	JUL 15, 1996
AB	DANBURY PHARMA	EQ 25MG HCL	N81165 001	JUL 31, 1991
AB	EON	EQ 25MG HCL	N87479 001	
AB		EQ 50MG HCL	N86183 001	
AB	GENEVA PHARMS	EQ 25MG HCL	N81127 001	JUN 28, 1991
AB		EQ 50MG HCL	N81128 001	JUN 28, 1991
AB		EQ 100MG HCL	N81129 001	JUN 28, 1991
AB	VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983
AB	ZENITH GOLDLINE	EQ 25MG HCL	N87761 001	MAR 05, 1982
AB		EQ 50MG HCL	N87760 001	MAR 05, 1982

VISTARIL

AB	PFIZER	EQ 25MG HCL	N11459 002	
AB	+	EQ 50MG HCL	N11459 004	
AB		EQ 100MG HCL	N11459 006	

SUSPENSION; ORAL

VISTARIL

	PFIZER	EQ 25MG HCL/5ML	N11795 001	

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

BX	WHITEHALL ROBINS	100MG/5ML	N19833 002	SEP 19, 1989

IBUPROFEN

AB	ALPHARMA	100MG/5ML	N74978 001	MAR 25, 1998

MOTRIN

AB	+ MCNEIL CONS	100MG/5ML	N19842 001	SEP 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

	+ MCNEIL	40MG/ML	N20476 001	MAY 25, 1995

TABLET; ORAL

IBU

AB	BASF	400MG	N18197 001	
AB		400MG	N70083 001	FEB 22, 1985
AB		600MG	N70099 001	MAR 29, 1985
AB		800MG	N70745 001	JUL 23, 1986
		600MG	N70088 001	FEB 08, 1985

IBU-TAB

AB	ALRA	400MG	N71058 001	AUG 11, 1988
AB		600MG	N71059 001	AUG 11, 1988

IBUPROFEN

AB	DANBURY PHARMA	400MG	N70436 001	AUG 21, 1985
AB		600MG	N70437 001	AUG 21, 1985
AB		800MG	N71547 001	JUL 02, 1987
AB	GENEVA PHARMS	300MG	N70734 001	JUN 12, 1986
AB		400MG	N70735 001	JUN 12, 1986
AB		600MG	N70736 001	JUN 12, 1986
AB		800MG	N72169 001	DEC 11, 1987

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	INTERPHARM	400MG	N71334 001	NOV 25, 1986
AB		600MG	N71335 001	NOV 25, 1986
AB		800MG	N71935 001	OCT 13, 1987
AB	LEDERLE	400MG	N70629 001	SEP 19, 1986
AB		600MG	N70630 001	SEP 19, 1986
AB	MUTUAL PHARM	300MG	N71230 001	OCT 22, 1986
AB		400MG	N71231 001	OCT 22, 1986
AB		600MG	N71232 001	OCT 22, 1986
AB		800MG	N72004 001	NOV 18, 1987
AB	MYLAN	400MG	N70045 001	SEP 24, 1985
AB		600MG	N70057 001	SEP 24, 1985
AB		800MG	N71999 001	DEC 03, 1987
AB	OHM	400MG	N70818 001	DEC 26, 1985
AB	PAR PHARM	400MG	N70329 001	AUG 06, 1985
AB		600MG	N70330 001	AUG 06, 1985
AB		800MG	N70986 001	JUL 25, 1986
AB	PVT FORM	300MG	N71266 001	OCT 15, 1986
AB		400MG	N71267 001	OCT 15, 1986
AB		600MG	N71268 001	OCT 15, 1986
AB		800MG	N72300 001	JUL 01, 1988
AB	SIDMAK LABS NJ	400MG	N71666 001	JUN 18, 1987
AB		600MG	N71667 001	JUN 18, 1987

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	SIDMAK LABS NJ	800MG	N71668 001	JUN 18, 1987
AB	VINTAGE PHARMS	400MG	N71644 001	FEB 01, 1988
AB	ZENITH GOLDLINE	400MG	N71145 001	SEP 23, 1986
AB		600MG	N71146 001	SEP 23, 1986
AB		800MG	N71769 001	MAY 08, 1987

IBUPROHM

AB	OHM	400MG	N70469 001	AUG 29, 1985

MOTRIN

AB	MCNEIL CONS	300MG	N17463 003	
AB		400MG	N17463 002	
AB		600MG	N17463 004	
AB	+	800MG	N17463 005	MAY 22, 1985
		100MG	N20418 001	NOV 16, 1994

TABLET, CHEWABLE; ORAL

MOTRIN

	MCNEIL CONS	50MG	N20135 001	NOV 16, 1994
	+	100MG	N20135 002	NOV 16, 1994

IBUPROFEN; *MULTIPLE*

SEE HYDROCODONE BITARTRATE; IBUPROFEN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

+	PHARMACIA AND UPJOHN	0.1MG/ML	N20491 001	DEC 28, 1995

FDA data supplied by DrugPatentWatch.com

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN
+ PHARMACIA AND UPJOHN 5MG/VIAL N50661 002 SEP 27, 1990
+ 10MG/VIAL N50661 001 SEP 27, 1990
+ 20MG/VIAL N50661 003 APR 25, 1995

IDAMYCIN PFS
+ PHARMACIA AND UPJOHN 1MG/ML N50734 001 FEB 17, 1997

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC
DENDRID
AT + ALCON **0.1%** **N14169 001**
HERPLEX
AT + ALLERGAN **0.1%** **N13935 002**

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT
+ BRISTOL MYERS SQUIBB 1GM/VIAL;100MG/ML N19763 003 OCT 10, 1992
+ 3GM/VIAL;100MG/ML N19763 004 OCT 10, 1992

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME
GENZYME 200 UNITS/VIAL N20367 001 MAY 23, 1994
+ 400 UNITS/VIAL N20367 002 SEP 22, 1999

IMIPENEM; *MULTIPLE*
SEE CILASTATIN SODIUM; IMIPENEM

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL
IMIPRAMINE HCL
NOVARTIS 25MG/ML N86765 001

TABLET; ORAL
IMIPRAMINE HCL
AB GENEVA PHARMS **10MG** **N84936 002**
AB **25MG** **N83745 001**
AB **50MG** **N84937 001**
AB MUTUAL PHARM **10MG** **N81048 001** JUN 05, 1990
AB **25MG** **N81049 001** JUN 05, 1990
AB **50MG** **N81050 001** JUN 05, 1990
AB PAR PHARM **10MG** **N88292 001** OCT 21, 1983
AB **10MG** **N89422 001** JUL 14, 1987
AB **25MG** **N88262 001** OCT 21, 1983
AB **25MG** **N89497 001** JUL 14, 1987
AB **50MG** **N88276 001** OCT 21, 1983
AB ROXANE **10MG** **N83799 001**
AB **25MG** **N83799 002**
AB **50MG** **N83799 003**
AB TEVA **10MG** **N83729 001**
AB **25MG** **N83729 004**
AB **50MG** **N83729 003**

TOFRANIL
AB NOVARTIS **10MG** **N87844 001** MAY 22, 1984
AB **25MG** **N87845 001** MAY 22, 1984
AB + **50MG** **N87846 001** MAY 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL
TOFRANIL-PM
NOVARTIS EQ 75MG HCL N17090 001
EQ 100MG HCL N17090 004
EQ 125MG HCL N17090 003

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM				
+	NOVARTIS	EQ 150MG HCL	N17090 002	

IMIQUIMOD

CREAM; TOPICAL

ALDARA				
+	3M	5%	N20723 001	FEB 27, 1997

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE				
AP	ABBOTT	**EQ 5MG BASE/ML**	**N74616 001**	AUG 03, 1998
AP	BEDFORD	**EQ 5MG BASE/ML**	**N75513 001**	MAY 09, 2000
AMRINONE LACTATE				
AP	BAXTER PHARM PROD	**EQ 5MG BASE/ML**	**N75542 001**	MAY 10, 2000
INOCOR				
AP +	SANOFI SYNTHELABO	**EQ 5MG BASE/ML**	**N18700 001**	JUL 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE				
AB	ALPHAPHARM	**1.25MG**	**N75105 001**	JUL 23, 1998
AB		**2.5MG**	**N75105 002**	JUL 23, 1998
AB	INVAMED	**1.25MG**	**N74594 001**	MAY 23, 1996
AB		**2.5MG**	**N74594 002**	MAY 23, 1996
AB	MYLAN	**1.25MG**	**N74461 002**	MAR 26, 1997
AB		**2.5MG**	**N74461 001**	MAR 27, 1996
AB	PUREPAC PHARM	**1.25MG**	**N74722 001**	JUN 17, 1996

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE				
AB	PUREPAC PHARM	**2.5MG**	**N74722 002**	JUN 17, 1996
AB	TEVA	**1.25MG**	**N74498 002**	FEB 12, 1998
AB		**2.5MG**	**N74498 001**	OCT 31, 1996
AB	TRIGEN	**1.25MG**	**N75201 001**	DEC 04, 1998
AB		**2.5MG**	**N75201 002**	DEC 04, 1998
AB	WATSON LABS	**1.25MG**	**N74585 001**	SEP 26, 1996
AB		**2.5MG**	**N74585 002**	SEP 26, 1996
AB	ZENITH GOLDLINE	**1.25MG**	**N74299 002**	APR 29, 1996
AB		**2.5MG**	**N74299 001**	JUL 27, 1995
LOZOL				
AB	AVENTIS	**1.25MG**	**N18538 002**	APR 29, 1993
AB +		**2.5MG**	**N18538 001**	JUL 06, 1983

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN				
	MERCK	EQ 200MG BASE	N20685 003	MAR 13, 1996
		EQ 333MG BASE	N20685 005	DEC 17, 1998
+		EQ 400MG BASE	N20685 001	MAR 13, 1996

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE				
	NYCOMED AMERSHAM	1mCi/ML	N19044 001	DEC 24, 1985

FDA data supplied by DrugPatentWatch.com

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL
MPI INDIUM DTPA IN 111

	NYCOMED AMERSHAM	1mCi/ML	N17707 001 FEB 18, 1982	

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

	MALLINCKRODT	3mCi/ML	N20314 001 JUN 02, 1994	

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN

+	AKORN	25MG/VIAL	N11525 001	
+		50MG/VIAL	N11525 002	

INDOMETHACIN

CAPSULE; ORAL
INDO-LEMMON

AB	TEVA	25MG	N70266 001 NOV 07, 1985	
AB		50MG	N70267 001 NOV 07, 1985	

INDOCIN

AB	MERCK	25MG	N16059 001	
AB	+	50MG	N16059 002	

INDOMETHACIN

AB	GENEVA PHARMS	25MG	N70673 001 APR 29, 1987	
AB		50MG	N70674 001 APR 29, 1987	
AB	LEDERLE	25MG	N18851 001 MAY 18, 1984	
AB		50MG	N18851 002 MAY 18, 1984	
AB	MUTUAL PHARM	25MG	N70899 001 FEB 09, 1987	
AB		50MG	N70900 001 FEB 09, 1987	

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	MYLAN	25MG	N18858 001 APR 20, 1984	
AB		50MG	N18858 002 APR 20, 1984	
AB		50MG	N70624 001 SEP 04, 1985	
AB	NOVOPHARM	25MG	N71342 001 APR 18, 1988	
AB		50MG	N71343 001 APR 18, 1988	
AB	PAR PHARM	25MG	N18829 002 AUG 06, 1984	
AB		50MG	N18829 001 AUG 06, 1984	
AB		50MG	N70651 001 MAR 05, 1986	
AB	SIDMAK LABS NJ	25MG	N71148 001 MAR 18, 1987	
AB		50MG	N71149 001 MAR 18, 1987	
AB	ZENITH GOLDLINE	25MG	N70719 001 FEB 12, 1986	
AB		50MG	N70756 001 FEB 12, 1986	

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR

AB	+ EON	75MG	N74464 001 MAY 28, 1998	

INDOMETHACIN

AB	INWOOD LABS	75MG	N72410 001 MAR 15, 1989	

SUPPOSITORY; RECTAL
INDOCIN

AB	+ MERCK	50MG	N17814 001 AUG 13, 1984	

INDOMETHEGAN

AB	G AND W LABS	50MG	N73314 001 AUG 31, 1992	

SUSPENSION; ORAL
INDOCIN

AB	+ MERCK	25MG/5ML	N18332 001 OCT 10, 1985	

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN

SUSPENSION; ORAL
INDOMETHACIN
AB ROXANE 25MG/5ML N71412 001 MAR 18, 1987

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOCIN I.V.
+ MERCK EQ 1MG BASE/VIAL N18878 001 JAN 30, 1985

INSULIN ASPART RECOMBINANT

INJECTABLE; INJECTION
NOVOLOG
+ NOVO NORDISK 100 UNITS/ML N20986 001 JUN 07, 2000

INSULIN GLARGINE

INJECTABLE; INJECTION
LANTUS
+ AVENTIS PHARMS 100 UNITS/ML N21081 001 APR 20, 2000

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG
+ LILLY 100 UNITS/ML N20563 001 JUN 14, 1996

HUMALOG PEN
+ LILLY 100 UNITS/ML N20563 002 AUG 06, 1998

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N21018 001 DEC 22, 1999

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 75/25
+ LILLY 25 UNITS/ML;75 UNITS/ML N21017 001 DEC 22, 1999

INSULIN LISPRO PROTAMINE; *MULTIPLE*
SEE INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INSULIN PORK

INJECTABLE; INJECTION
ILETIN I
+ LILLY 500 UNITS/ML N17931 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
ILETIN II
+ LILLY 500 UNITS/ML N18344 002

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN R
+ LILLY 500 UNITS/ML N18780 004 MAR 31, 1994

VELOSULIN BR
+ NOVO NORDISK 100 UNITS/ML N21028 001 JUL 19, 1999

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR
SEE CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ QUESTCOR PHARM 100MG/ML N02282 001

FDA data supplied by DrugPatentWatch.com

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131
CIS 2.3mCi/ML N20084 001 MAR 25, 1994

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE
+ BRACCO 10.3% N09321 007
+ 52% N09321 003

IODIPAMIDE MEGLUMINE; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ NYCOMED 55% N20351 001 MAR 22, 1996
55% N20808 001 AUG 29, 1997
VISIPAQUE 320
+ NYCOMED 65.2% N20351 002 MAR 22, 1996
65.2% N20808 002 AUG 29, 1997

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPURAN I 131
MALLINCKRODT 0.25mCi/ML N16666 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE
IMP 1mCi/ML N19432 001 DEC 24, 1987

IOHEXOL

INJECTABLE; INJECTION
OMNIPAQUE 140
+ NYCOMED 30.2% N18956 005 NOV 30, 1988
OMNIPAQUE 210
+ NYCOMED 45.3% N18956 006 JUN 30, 1989

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350
+ NYCOMED 75.5% N18956 004 DEC 26, 1985
75.5% N20608 003 OCT 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ NYCOMED 38.8% N18956 001 DEC 26, 1985
OMNIPAQUE 240
+ NYCOMED 51.8% N18956 002 DEC 26, 1985
51.8% N20608 001 OCT 24, 1995
OMNIPAQUE 300
+ NYCOMED 64.7% N18956 003 DEC 26, 1985
64.7% N20608 002 OCT 24, 1995

SOLUTION; URETHRAL
OMNIPAQUE 70
+ NYCOMED 15.1% N18956 007 JUN 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL
AP ELKINS SINN PHARM **41%** **N74629 001** NOV 06, 1996
AP **51%** **N74629 004** MAR 31, 1998
AP **61%** **N74629 002** NOV 06, 1996

FDA data supplied by DrugPatentWatch.com

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

AP	ELKINS SINN PHARM	76%	N74629 003 NOV 06, 1996
AP	FAULDING	61%	N74734 001 DEC 10, 1996
AP		76%	N74734 002 DEC 10, 1996

IOPAMIDOL-200

AP	ABBOTT	41%	N74898 001 DEC 30, 1997
AP	COOK IMAGING	41%	N74881 001 JUL 28, 2000

IOPAMIDOL-200 IN PLASTIC CONTAINER

AP	ABBOTT	41%	N74636 001 DEC 30, 1997

IOPAMIDOL-250

AP	ABBOTT	51%	N74898 002 DEC 30, 1997
AP		51%	N75005 001 FEB 24, 1998
AP	AM PHARM PARTNERS	51%	N74679 001 APR 02, 1997
AP	COOK IMAGING	51%	N74881 002 JUL 28, 2000

IOPAMIDOL-250 IN PLASTIC CONTAINER

AP	ABBOTT	51%	N74636 002 DEC 30, 1997

IOPAMIDOL-300

AP	ABBOTT	61%	N74638 001 APR 30, 1997
AP		61%	N74898 003 DEC 30, 1997
AP		61%	N75005 002 FEB 24, 1998
AP	AM PHARM PARTNERS	61%	N74679 002 APR 02, 1997
AP	COOK IMAGING	61%	N74881 003 JUL 28, 2000

IOPAMIDOL-300 IN PLASTIC CONTAINER

AP	ABBOTT	61%	N74636 003 DEC 30, 1997
AP		61%	N74637 001 APR 03, 1997

IOPAMIDOL-370

AP	ABBOTT	76%	N74898 004 DEC 30, 1997

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-370

AP	ABBOTT	76%	N75005 003 FEB 24, 1998
AP	AM PHARM PARTNERS	76%	N74679 003 APR 02, 1997
AP	COOK IMAGING	76%	N74881 004 JUL 28, 2000

IOPAMIDOL-370 IN PLASTIC CONTAINER

AP	ABBOTT	76%	N74636 004 DEC 30, 1997

ISOVUE-128

+	BRACCO	26%	N18735 005 OCT 21, 1986

ISOVUE-200

AP	+ BRACCO	41%	N18735 006 JUL 07, 1987

ISOVUE-250

AP	+ BRACCO	51%	N18735 007 JUL 06, 1992
AP	+	51%	N20327 002 OCT 12, 1994

ISOVUE-300

AP	+ BRACCO	61%	N18735 002 DEC 31, 1985
AP	+	61%	N20327 003 OCT 12, 1994

ISOVUE-370

AP	+ BRACCO	76%	N18735 003 DEC 31, 1985
AP	+	76%	N20327 004 OCT 12, 1994

ISOVUE-M 200

+	BRACCO	41%	N18735 001 DEC 31, 1985

ISOVUE-M 300

+	BRACCO	61%	N18735 004 DEC 31, 1985

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

+	NYCOMED	500MG	N08032 001

FDA data supplied by DrugPatentWatch.com

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST 150
+ BERLEX LABS 31.2% N20220 004 MAY 10, 1995

ULTRAVIST 240
+ BERLEX LABS 49.9% N20220 003 MAY 10, 1995

ULTRAVIST 300
+ BERLEX LABS 62.3% N20220 002 MAY 10, 1995

ULTRAVIST 370
+ BERLEX LABS 76.9% N20220 001 MAY 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY
+ MALLINCKRODT 60% N13295 001
CONRAY 30
+ MALLINCKRODT 30% N16983 001
CONRAY 43
+ MALLINCKRODT 43% N13295 002

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II
MALLINCKRODT 17.2% N17057 002

SOLUTION; INTRAVESICAL, URETERAL
CYSTO-CONRAY
MALLINCKRODT 43% N17057 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION
VASCORAY
+ MALLINCKRODT 52%;26% N16783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
CONRAY 325
+ MALLINCKRODT 54.3% N17685 001
CONRAY 400
+ MALLINCKRODT 66.8% N14295 001

IOTHALAMATE SODIUM; *MULTIPLE*
SEE IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
QUESTCOR PHARM 250-300 uCi/ML N17279 001

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 160
+ MALLINCKRODT 34% N19710 003 DEC 30, 1988

OPTIRAY 240
+ MALLINCKRODT 51% N19710 002 DEC 30, 1988
+ 51% N20923 001 MAY 28, 1998

OPTIRAY 300
+ MALLINCKRODT 64% N19710 004 JAN 22, 1992

OPTIRAY 320
+ MALLINCKRODT 68% N19710 001 DEC 30, 1988
+ 68% N20923 002 MAY 29, 1998

OPTIRAY 350
+ MALLINCKRODT 74% N19710 005 JAN 22, 1992
+ 74% N20923 003 MAY 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION
HEXABRIX
+ MALLINCKRODT 39.3%;19.6% N18905 002 JUL 26, 1985

IOXAGLATE SODIUM; *MULTIPLE*
SEE IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

FDA data supplied by DrugPatentWatch.com

IOXILAN

INJECTABLE; INJECTION
OXILAN-300
COOK IMAGING 62% N20316 001 DEC 21, 1995

OXILAN-350
COOK IMAGING 73% N20316 002 DEC 21, 1995

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM
+ BRACCO 500MG N12967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.018MG/INH N19085 001 DEC 29, 1986

SOLUTION; INHALATION
ATROVENT
AN + BOEHRINGER INGELHEIM **0.02%** **N20228 001** SEP 29, 1993

IPRATROPIUM BROMIDE
AN ALPHARMA **0.02%** **N75111 001** APR 22, 1999
AN DEY **0.02%** **N74755 001** JAN 10, 1997
AN STERIPAK **0.02%** **N75313 001** FEB 07, 2000

SPRAY, METERED; NASAL
ATROVENT
+ BOEHRINGER INGELHEIM 0.021MG/SPRAY N20393 001 OCT 20, 1995
+ 0.042MG/SPRAY N20394 001 OCT 20, 1995

IPRATROPIUM BROMIDE; *MULTIPLE*
SEE ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI SYNTHELABO 75MG N20757 001 SEP 30, 1997
150MG N20757 002 SEP 30, 1997
+ 300MG N20757 003 SEP 30, 1997

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
+ PHARMACIA AND UPJOHN 20MG/ML N20571 001 JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD EQ 50MG IRON/ML N40024 001 FEB 23, 1996

INFED
BP + SCHEIN EQ 50MG IRON/ML N17441 001

PROFERDEX
BP LOTUS BIOCHEM EQ 50MG IRON/ML N17807 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER
+ LUITPOLD EQ 20MG BASE/ML N21135 001 NOV 06, 2000

ISOCARBOXAZID

TABLET; ORAL
MARPLAN
+ OXFORD PHARM 10MG N11961 001

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	BETA-2			
AN	NEPHRON	1%	N86711 001	
	ISOETHARINE HCL			
	INTL MEDICATION	0.08%	N86651 002	
		0.143%	N86651 004	
AN	+ ROXANE	1%	N86899 001	
	+	0.167%	N88226 001	
			SEP 16, 1983	
	+	0.2%	N87324 001	

ISOFLURANE

LIQUID; INHALATION

	FORANE			
AN	+ BAXTER PHARM PROD	99.9%	N17624 001	
	ISOFLURANE			
AN	ABBOTT	99.9%	N74097 001	
			JAN 25, 1993	
AN	HALOCARBON PRODS	99.9%	N75225 001	
			OCT 20, 1999	
AN	INHALON	99.9%	N74416 001	
			SEP 30, 1994	
AN	MARSAM	99.9%	N74393 001	
			MAY 12, 1995	
AN	RHODIA	99.9%	N74502 001	
			JUN 27, 1995	

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID			
	+ APOTHECON	100MG/ML	N08662 001	

SYRUP; ORAL

	ISONIAZID			
AA	+ CAROLINA MEDCL	50MG/5ML	N88235 001	
			NOV 10, 1983	
AA	MIKART	50MG/5ML	N81118 001	
			JUL 21, 1997	

TABLET; ORAL

	ISONIAZID			
AA	BARR	100MG	N80936 001	
AA		300MG	N80937 002	

ISONIAZID

TABLET; ORAL

	ISONIAZID			
AA	DANBURY PHARMA	300MG	N80521 001	
AA	DURAMED	300MG	N88119 001	
			MAR 17, 1983	
AA	+ EON	100MG	N08678 002	
AA	+	300MG	N08678 003	
AA	HALSEY	100MG	N80136 001	
AA		300MG	N83633 001	
AA	MIKART	100MG	N40090 001	
			JUN 26, 1997	
AA		300MG	N40090 002	
			JUN 26, 1997	
AA	WEST WARD	100MG	N80212 001	
AA		300MG	N87425 001	
	LANIAZID			
AA	LANNETT	100MG	N80140 002	
AA		300MG	N89776 001	
			JUN 13, 1988	
		50MG	N80140 001	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER			
+ AVENTIS PHARMS	50MG;300MG;120MG	N50705 001	
		MAY 31, 1994	

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE			
+ AVENTIS PHARMS	150MG;300MG	N61884 001	

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL			
+ 3M	0.12MG/INH	N10375 004	

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
AP	ABBOTT	0.2MG/ML	N83346 001	
		0.02MG/ML	N83283 001	

FDA data supplied by DrugPatentWatch.com

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

	ISOPROTERENOL HCL				
AP	ELKINS SINN	**0.2MG/ML**	**N83486 001**		
AP	INTL MEDICATION	**0.2MG/ML**	**N83724 001**		
	ISUPREL				
AP	+ ABBOTT	**0.2MG/ML**	**N10515 001**		

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

	MEDIHALER-ISO				
	+ 3M	0.08MG/INH	N10375 003		

ISOSORBIDE

SOLUTION; ORAL

	ISMOTIC				
	ALCON	100GM/220ML	N17063 001		

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DILATRATE-SR				
BC	SCHWARZ PHARMA	40MG	N19790 001 SEP 02, 1988		
	ISORDIL				
BC	+ WYETH AYERST	40MG	N12882 002 JUL 29, 1988		

TABLET; ORAL

	ISORDIL				
AB	WYETH AYERST	**5MG**	**N12093 007** JUL 29, 1988		
AB		**10MG**	**N12093 002** JUL 29, 1988		
AB		**20MG**	**N12093 006** JUL 29, 1988		
AB	+	**30MG**	**N12093 005** JUL 29, 1988		
AB		**40MG**	**N12093 001** JUL 29, 1988		
	ISOSORBIDE DINITRATE				
AB	DANBURY PHARMA	**5MG**	**N86034 001** JAN 06, 1988		

ISOSORBIDE DINITRATE

TABLET; ORAL

	ISOSORBIDE DINITRATE				
AB	DANBURY PHARMA	**10MG**	**N86032 001** JAN 07, 1988		
AB	GENEVA PHARMS	**5MG**	**N86221 001** JAN 07, 1988		
AB		**10MG**	**N86223 001** JAN 07, 1988		
AB		**20MG**	**N89367 001** APR 07, 1988		
AB	PAR PHARM	**5MG**	**N86923 001** MAR 12, 1987		
AB		**10MG**	**N86925 001** MAR 12, 1987		
AB		**20MG**	**N87537 001** OCT 02, 1987		
AB		**30MG**	**N87946 001** JAN 12, 1988		
AB	WEST WARD	**5MG**	**N86067 001** OCT 29, 1987		
AB		**10MG**	**N86066 001** OCT 29, 1987		
AB		**20MG**	**N88088 001** NOV 02, 1987		
	SORBITRATE				
AB	ASTRAZENECA	**20MG**	**N86405 002** AUG 21, 1990		
AB		**40MG**	**N88125 001** AUG 21, 1990		
BX		5MG	N16192 001 APR 01, 1996		
BX		10MG	N16192 002 APR 01, 1996		

TABLET; SUBLINGUAL

	ISORDIL				
AB	WYETH AYERST	**2.5MG**	**N12940 004** JUL 29, 1988		
AB		**5MG**	**N12940 003** JUL 29, 1988		
	+	10MG	N12940 005 JUL 29, 1988		
	ISOSORBIDE DINITRATE				
AB	DANBURY PHARMA	**2.5MG**	**N86033 001** FEB 26, 1988		
AB		**5MG**	**N86031 001** SEP 29, 1987		

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

	ISOSORBIDE DINITRATE			
AB	GENEVA PHARMS	2.5MG	N86225 001	FEB 19, 1988
AB		5MG	N86222 001	FEB 19, 1988
AB	WEST WARD	2.5MG	N86054 001	OCT 29, 1987
AB		5MG	N86055 001	NOV 02, 1987

TABLET, CHEWABLE; ORAL

	SORBITRATE			
	ASTRAZENECA	5MG	N16776 002	APR 01, 1996
+		10MG	N16776 003	APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE DINITRATE			
+	INWOOD LABS	40MG	N40009 001	DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO			
AB	ROBINS AH	20MG	N19091 001	DEC 30, 1991
	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	10MG	N75037 002	OCT 30, 1998
AB		20MG	N75037 001	OCT 30, 1998
AB	TEVA	20MG	N75147 001	NOV 27, 1998
AB	WEST WARD	20MG	N75361 001	OCT 05, 2000
	MONOKET			
AB	SCHWARZ	10MG	N20215 002	JUN 30, 1993
AB +		20MG	N20215 001	JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
AB +	SCHERING	30MG	N20225 001	AUG 12, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
AB +	SCHERING	60MG	N20225 002	AUG 12, 1993
AB +		120MG	N20225 003	MAR 30, 1995
	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	60MG	N75166 001	OCT 07, 1999
AB	DEXCEL LTD	60MG	N75522 001	APR 17, 2000
AB	ELAN PHARM	60MG	N75041 001	SEP 22, 1998
AB	KREMERS URBAN	30MG	N75155 002	JAN 13, 2000
AB		60MG	N75155 001	OCT 30, 1998
AB		120MG	N75155 003	AUG 04, 2000
AB	KV PHARM	30MG	N75395 001	MAR 16, 2000
AB		60MG	N75395 002	MAR 16, 2000
AB		120MG	N75395 003	MAR 16, 2000
AB	PUREPAC PHARM	30MG	N75306 001	DEC 31, 1998
AB		60MG	N75306 002	DEC 31, 1998
AB	ZENITH GOLDLINE	60MG	N75448 001	JUN 19, 2000

ISOSULFAN BLUE

INJECTABLE; INJECTION

	LYMPHAZURIN		
+	US SURGCL	1%	N18310 001

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE		
	HLR	10MG	N18662 002 MAY 07, 1982

FDA data supplied by DrugPatentWatch.com

ISOTRETINOIN

CAPSULE; ORAL					
ACCUTANE					
HLR	20MG	N18662 004 MAR 28, 1983			
+	40MG	N18662 003 MAY 07, 1982			

ISRADIPINE

CAPSULE; ORAL					
DYNACIRC					
NOVARTIS	2.5MG	N19546 001 DEC 20, 1990			
+	5MG	N19546 002 DEC 20, 1990			
TABLET, EXTENDED RELEASE; ORAL					
DYNACIRC CR					
+ NOVARTIS	5MG	N20336 001 JUN 01, 1994			
+	10MG	N20336 002 JUN 01, 1994			

ITRACONAZOLE

CAPSULE; ORAL					
SPORANOX					
+ JANSSEN	100MG	N20083 001 SEP 11, 1992			
INJECTABLE; INJECTION					
SPORANOX					
+ JANSSEN	10MG/ML	N20966 001 MAR 30, 1999			
SOLUTION; ORAL					
SPORANOX					
+ JANSSEN	10MG/ML	N20657 001 FEB 21, 1997			

IVERMECTIN

TABLET; ORAL					
STROMECTOL					
MERCK	3MG	N50742 002 OCT 08, 1998			
+	6MG	N50742 001 NOV 22, 1996			

KANAMYCIN SULFATE

CAPSULE; ORAL					
KANTREX					
+ APOTHECON	EQ 500MG BASE	N62726 001 MAR 06, 1987			
INJECTABLE; INJECTION					
KANAMYCIN SULFATE					
AP LOCH	**EQ 1GM BASE/3ML**	**N63025 001** JUL 31, 1992			
AP	**EQ 75MG BASE/2ML**	**N63021 001** JUL 31, 1992			
AP	**EQ 500MG BASE/2ML**	**N63022 001** JUL 31, 1992			
AP STERIS	**EQ 1GM BASE/3ML**	**N62520 003** MAY 09, 1985			
KANTREX					
AP + APOTHECON	**EQ 75MG BASE/2ML**	**N61901 003**			
AP +	**EQ 500MG BASE/2ML**	**N61901 001**			
AP +	**EQ 1GM BASE/3ML**	**N61901 002**			

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION					
KETALAR					
AP + PARKEDALE	**EQ 50MG BASE/ML**	**N16812 002**			
AP +	**EQ 100MG BASE/ML**	**N16812 003**			
+	EQ 10MG BASE/ML	N16812 001			
KETAMINE HCL					
AP ABBOTT	**EQ 50MG BASE/ML**	**N74549 001** JUN 27, 1996			
AP	**EQ 100MG BASE/ML**	**N74549 002** JUN 27, 1996			
AP BEDFORD	**EQ 50MG BASE/ML**	**N74524 001** MAR 22, 1996			
AP	**EQ 100MG BASE/ML**	**N74524 002** MAR 22, 1996			

FDA data supplied by DrugPatentWatch.com

KETOCONAZOLE

CREAM; TOPICAL

	KETOCONAZOLE			
AB	TEVA	2%	**N75581 001**	APR 25, 2000
	NIZORAL			
AB	+ MCNEIL CONS	2%	**N19084 001**	DEC 31, 1985

SHAMPOO; TOPICAL

	NIZORAL			
	+ MCNEIL CONS	2%	N19927 001	AUG 31, 1990

TABLET; ORAL

	KETOCONAZOLE			
AB	APPLIED ANAL	**200MG**	**N75341 001**	JUL 27, 1999
AB	MUTUAL PHARMA	**200MG**	**N75314 001**	JUN 15, 1999
AB	MYLAN	**200MG**	**N75597 001**	DEC 23, 1999
AB	NOVOPHARM	**200MG**	**N74971 001**	JUN 15, 1999
AB	SIDMAK LABS	**200MG**	**N75362 001**	JUN 15, 1999
AB	TARO	**200MG**	**N75319 001**	JUN 15, 1999
AB	TEVA	**200MG**	**N75273 001**	JUN 15, 1999
	NIZORAL			
AB	+ JANSSEN	**200MG**	**N18533 001**	

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	GENEVA PHARMS	**50MG**	**N74024 001**	DEC 29, 1995
AB		**75MG**	**N74024 002**	DEC 29, 1995
AB	LEDERLE	**25MG**	**N74014 001**	JAN 29, 1993
AB		**50MG**	**N74014 002**	JAN 29, 1993
AB		**75MG**	**N74014 003**	JAN 29, 1993

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	MYLAN	**50MG**	**N74035 002**	DEC 31, 1996
AB		**75MG**	**N74035 003**	DEC 31, 1996
AB	TEVA	**25MG**	**N73515 001**	DEC 22, 1992
AB		**50MG**	**N73516 001**	DEC 22, 1992
AB		**75MG**	**N73517 001**	DEC 22, 1992
	ORUDIS			
AB	WYETH AYERST	**25MG**	**N18754 001**	JUL 31, 1987
AB		**50MG**	**N18754 002**	JAN 09, 1986
AB	+	**75MG**	**N18754 003**	JAN 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	**100MG**	**N75270 002**	MAR 24, 1999
AB		**150MG**	**N75270 003**	MAR 24, 1999
AB		**200MG**	**N75270 001**	MAR 24, 1999
AB	ELAN PHARM	**200MG**	**N74879 001**	DEC 10, 1997
	ORUVAIL			
AB	WYETH AYERST	**100MG**	**N19816 003**	FEB 08, 1995
AB		**150MG**	**N19816 002**	FEB 08, 1995
AB	+	**200MG**	**N19816 001**	SEP 24, 1993

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	**15MG/ML**	**N74801 001**	JUN 05, 1997
AP		**15MG/ML**	**N74802 001**	JUN 05, 1997

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	15MG/ML	N74993 001	JAN 27, 1999
AP		30MG/ML	N74801 002	JUN 05, 1997
AP		30MG/ML	N74802 002	JUN 05, 1997
AP		30MG/ML	N74993 002	JAN 27, 1999
AP	APOTHECON	15MG/ML	N75348 001	NOV 28, 2000
AP		30MG/ML	N75348 002	NOV 28, 2000
AP	BAXTER PHARM PROD	15MG/ML	N75299 001	NOV 03, 1999
AP		30MG/ML	N75299 002	NOV 03, 1999
AP	BEDFORD	15MG/ML	N75222 001	APR 26, 1999
AP		15MG/ML	N75230 002	OCT 25, 1999
AP		30MG/ML	N75222 002	APR 26, 1999
AP		30MG/ML	N75228 001	APR 26, 1999
AP		30MG/ML	N75230 001	OCT 25, 1999
	TORADOL			
AP	+ SYNTEX (USA) INC LLC	15MG/ML	N19698 001	NOV 30, 1989
AP	+	30MG/ML	N19698 002	NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC

	ACULAR			
	+ ALLERGAN	0.5%	N19700 001	NOV 09, 1992
	ACULAR PRESERVATIVE FREE			
	+ ALLERGAN	0.5%	N20811 001	NOV 03, 1997

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
AB	CHELSEA LABS	10MG	N74955 001	SEP 19, 1997
AB	MYLAN	10MG	N74761 001	MAY 16, 1997
AB	SIDMAK LABS	10MG	N75284 001	JUN 23, 1999
AB	TEVA	10MG	N74754 001	MAY 16, 1997
	TORADOL			
AB	+ SYNTEX (USA) INC LLC	10MG	N19645 001	DEC 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR			
	+ CIBA	EQ 0.025% BASE	N21066 001	JUL 02, 1999

KRYPTON, KR-81M

GAS; INHALATION

	MPI KRYPTON 81M GAS GENERATOR			
	NYCOMED AMERSHAM	N/A	N18088 001	

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	ABBOTT	5MG/ML	N75239 001	NOV 29, 1999
AP		5MG/ML	N75240 001	NOV 29, 1999
AP	APOTHECON	5MG/ML	N75355 001	NOV 29, 1999
AP	BEDFORD	5MG/ML	N75303 001	MAY 28, 1999
AP	FAULDING	5MG/ML	N75242 001	SEP 30, 1999
AP	TAYLOR	5MG/ML	N75431 001	NOV 29, 1999
AP		5MG/ML	N75524 001	NOV 29, 1999

FDA data supplied by DrugPatentWatch.com

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	NORMODYNE				
AP	+ SCHERING	**5MG/ML**	**N18686 001**		AUG 01, 1984
	TRANDATE				
AP	+ FARO PHARMS	**5MG/ML**	**N19425 001**		DEC 31, 1985

TABLET; ORAL

	LABETALOL HCL				
AB	APOTHECON	**100MG**	**N75223 001**		NOV 20, 1998
AB		**200MG**	**N75223 002**		NOV 20, 1998
AB		**300MG**	**N75223 003**		NOV 20, 1998
AB	EON	**100MG**	**N75113 001**		AUG 04, 1998
AB		**200MG**	**N75113 002**		AUG 04, 1998
AB		**300MG**	**N75113 003**		AUG 04, 1998
AB	MUTUAL PHARM	**100MG**	**N75215 001**		JUL 29, 1999
AB		**200MG**	**N75215 002**		JUL 29, 1999
AB		**300MG**	**N75215 003**		JUL 29, 1999
AB	TEVA	**100MG**	**N74989 001**		SEP 30, 1998
AB		**200MG**	**N74989 002**		SEP 30, 1998
AB		**300MG**	**N74989 003**		SEP 30, 1998
AB	WATSON LABS	**100MG**	**N75133 001**		AUG 03, 1998
AB		**200MG**	**N75133 002**		AUG 03, 1998
AB		**300MG**	**N75133 003**		AUG 03, 1998
AB	ZENITH GOLDLINE	**100MG**	**N74787 001**		AUG 03, 1998
AB		**200MG**	**N74787 002**		AUG 03, 1998
AB		**300MG**	**N74787 003**		AUG 03, 1998

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	NORMODYNE				
AB	SCHERING	**100MG**	**N18687 001**		AUG 31, 1987
AB		**200MG**	**N18687 002**		AUG 01, 1984
AB	+	**300MG**	**N18687 003**		AUG 01, 1984
	TRANDATE				
AB	FARO PHARMS	**100MG**	**N18716 001**		MAY 24, 1985
AB		**200MG**	**N18716 002**		AUG 01, 1984
AB		**300MG**	**N18716 003**		AUG 01, 1984

LACTULOSE

FOR SOLUTION; ORAL

	LACTULOSE				
	+ INALCO	10GM/PACKET	N74712 001		DEC 10, 1997
	+	20GM/PACKET	N74712 002		DEC 10, 1997

SOLUTION; ORAL

	CHRONULAC				
AA	+ AVENTIS PHARMS	**10GM/15ML**	**N17884 001**		
	CONSTILAC				
AA	ALRA	**10GM/15ML**	**N71054 001**		JUL 26, 1988
	CONSTULOSE				
AA	ALPHARMA	**10GM/15ML**	**N70288 001**		AUG 15, 1988
	EVALOSE				
AA	COPLEY PHARM	**10GM/15ML**	**N73497 001**		MAY 28, 1993
	LACTULOSE				
AA	HI TECH PHARMA	**10GM/15ML**	**N74076 001**		JUL 03, 1995
AA	LACHMAN CONSULT	**10GM/15ML**	**N74138 001**		SEP 30, 1992
AA	MORTON GROVE	**10GM/15ML**	**N74602 001**		NOV 14, 1996
AA	PHARM ASSOC	**10GM/15ML**	**N74623 001**		JUL 30, 1996

FDA data supplied by DrugPatentWatch.com

LACTULOSE

SOLUTION; ORAL

	LACTULOSE			
AA	ROXANE	**10GM/15ML**	**N73591 001**	MAY 29, 1992
	LAXILOSE			
AA	TECHNILAB	**10GM/15ML**	**N73686 001**	MAY 28, 1993

SOLUTION; ORAL, RECTAL

	ACILAC			
AA	TECHNILAB	**10GM/15ML**	**N73685 001**	MAY 28, 1993
	CEPHULAC			
AA	+ AVENTIS PHARMS	**10GM/15ML**	**N17657 001**	
	CHOLAC			
AA	ALRA	**10GM/15ML**	**N71331 001**	JUL 26, 1988
	ENULOSE			
AA	ALPHARMA	**10GM/15ML**	**N71548 001**	AUG 15, 1988
	GENERLAC			
AA	MORTON GROVE	**10GM/15ML**	**N74603 001**	OCT 31, 1996
	HEPTALAC			
AA	COPLEY PHARM	**10GM/15ML**	**N73504 001**	MAY 28, 1993
	LACTULOSE			
AA	HI TECH PHARMA	**10GM/15ML**	**N74077 001**	JUL 03, 1995
AA	ROXANE	**10GM/15ML**	**N73590 001**	MAY 29, 1992

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR			
	+ GLAXO WELLCOME	10MG/ML	N20596 001	NOV 17, 1995
	EPIVIR-HBV			
	+ GLAXO WELLCOME	5MG/ML	N21004 001	DEC 08, 1998

TABLET; ORAL

	EPIVIR			
	+ GLAXO WELLCOME	150MG	N20564 001	NOV 17, 1995
	TABLET; ORAL			
	EPIVIR-HBV			
	+ GLAXO WELLCOME	100MG	N21003 001	DEC 08, 1998

LAMIVUDINE; *MULTIPLE*

SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

	COMBIVIR			
	+ GLAXO WELLCOME	150MG;300MG	N20857 001	SEP 26, 1997

LAMOTRIGINE

TABLET; ORAL

	LAMICTAL			
	GLAXO WELLCOME	25MG	N20241 005	DEC 27, 1994
		100MG	N20241 001	DEC 27, 1994
		150MG	N20241 002	DEC 27, 1994
	+	200MG	N20241 003	DEC 27, 1994

TABLET, CHEWABLE; ORAL

	LAMICTAL CD			
	GLAXO WELLCOME	5MG	N20764 001	AUG 24, 1998
		25MG	N20764 002	AUG 24, 1998
	+	100MG	N20764 003	AUG 24, 1998

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	PREVACID			
	TAP PHARM	15MG	N20406 001	MAY 10, 1995

FDA data supplied by DrugPatentWatch.com

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID
+ TAP PHARM 30MG N20406 002 MAY 10, 1995

LANSOPRAZOLE; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
XALATAN
+ PHARMACIA AND UPJOHN 0.005% N20597 001 JUN 05, 1996

LEFLUNOMIDE

TABLET; ORAL
ARAVA
AVENTIS PHARMS 10MG N20905 001 SEP 10, 1998
20MG N20905 002 SEP 10, 1998
+ 100MG N20905 003 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN
+ AVENTIS PHARMS 50MG/VIAL N20807 001 MAR 06, 1998

LETROZOLE

TABLET; ORAL
FEMARA
+ NOVARTIS 2.5MG N20726 001 JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP		BEDFORD	**EQ 50MG BASE/VIAL**	**N89384 001** SEP 14, 1987
AP			**EQ 100MG BASE/VIAL**	**N89717 001** MAR 28, 1988
AP		ELKINS SINN	**EQ 50MG BASE/VIAL**	**N70480 001** JAN 02, 1987
AP			**EQ 100MG BASE/VIAL**	**N81224 001** JUN 03, 1994
AP		GENSIA SICOR PHARMS	**EQ 50MG BASE/VIAL**	**N81278 001** SEP 28, 1993
AP			**EQ 100MG BASE/VIAL**	**N81277 001** SEP 28, 1993
AP			**EQ 350MG BASE/VIAL**	**N40174 001** JUN 12, 1997
AP	+	IMMUNEX	**EQ 50MG BASE/VIAL**	**N08107 002**
AP	+		**EQ 100MG BASE/VIAL**	**N08107 004** MAY 23, 1988
AP	+		**EQ 350MG BASE/VIAL**	**N08107 005** APR 05, 1989
AP		PHARMACHEMIE	**EQ 350MG BASE/VIAL**	**N40262 001** DEC 15, 1999
AP		PHARMACHEMIE USA	**EQ 50MG BASE/VIAL**	**N89628 001** APR 17, 1997
AP			**EQ 100MG BASE/VIAL**	**N89915 001** APR 17, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	+	ABBOTT	**EQ 10MG BASE/ML**	**N40147 001** JUN 25, 1997
AP		BEDFORD	**EQ 10MG BASE/ML**	**N40347 001** APR 25, 2000
AP	+		**EQ 200MG BASE/VIAL**	**N40056 001** MAY 23, 1995
AP			**EQ 350MG BASE/VIAL**	**N40335 001** APR 20, 2000
AP		BIGMAR	**EQ 200MG BASE/VIAL**	**N40258 001** FEB 26, 1999
	+		EQ 500MG BASE/VIAL	N40286 001 FEB 26, 1999
AP		GENSIA SICOR PHARMS	**EQ 10MG BASE/ML**	**N40332 001** JUN 28, 1999

WELLCOVORIN
+ GLAXO WELLCOME EQ 5MG BASE/ML N87439 001 OCT 19, 1982

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

AB	BARR	**EQ 5MG BASE**	**N71198 001**	SEP 24, 1987
AB		**EQ 25MG BASE**	**N71199 001**	SEP 24, 1987
AB	GENEVA PHARMS TECH	**EQ 15MG BASE**	**N75327 001**	MAR 24, 1999
AB	IMMUNEX	**EQ 10MG BASE**	**N71962 001**	NOV 19, 1987
AB		**EQ 15MG BASE**	**N71104 001**	MAR 04, 1987
BX		EQ 5MG BASE	N18459 001	JAN 30, 1986
AB	PAR PHARM	**EQ 5MG BASE**	**N74544 001**	AUG 28, 1997
AB		**EQ 25MG BASE**	**N74544 002**	AUG 28, 1997
AB	PHARMACHEMIE	**EQ 5MG BASE**	**N73099 001**	MAR 28, 1997
AB		**EQ 25MG BASE**	**N73101 001**	MAR 28, 1997
AB	ROXANE	**EQ 5MG BASE**	**N72733 001**	FEB 22, 1993
AB		**EQ 10MG BASE**	**N72734 001**	FEB 22, 1993
AB		**EQ 15MG BASE**	**N72735 001**	FEB 22, 1993
AB +		**EQ 25MG BASE**	**N72736 001**	FEB 22, 1993

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

+	ALZA	EQ 65MG BASE	N21088 001 MAR 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	BEDFORD LABS	**1MG/0.2ML**	**N74728 001**	AUG 04, 1998
AP	GENSIA SICOR PHARMS	**1MG/0.2ML**	**N75471 001**	OCT 25, 2000

LUPRON

AP +	TAP PHARM	**1MG/0.2ML**	**N19010 001**	APR 09, 1985

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	TAP PHARM	3.75MG/VIAL	N20011 001 OCT 22, 1990
+		7.5MG/VIAL	N19732 001 JAN 26, 1989
+		22.5MG/VIAL	N20517 001 DEC 22, 1995

LUPRON DEPOT-3

+	TAP PHARM	11.25MG/VIAL	N20708 001 MAR 07, 1997

LUPRON DEPOT-4

+	TAP PHARM	30MG/VIAL	N20517 002 MAY 30, 1997

LUPRON DEPOT-PED

+	TAP PHARM	7.5MG/VIAL	N20263 002 APR 16, 1993
+		11.25MG/VIAL	N20263 005 JAN 21, 1994
+		15MG/VIAL	N20263 006 JAN 21, 1994

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+	SEPRACOR	EQ 0.021% BASE	N20837 001 MAR 25, 1999
+		EQ 0.042% BASE	N20837 002 MAR 25, 1999

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

+	JANSSEN	EQ 50MG BASE	N20035 001 JUN 18, 1990

LEVETIRACETAM

TABLET; ORAL

KEPPRA

	UCB	250MG	N21035 001 NOV 30, 1999

FDA data supplied by DrugPatentWatch.com

LEVETIRACETAM

TABLET; ORAL				
KEPPRA				
UCB	500MG		N21035 002	NOV 30, 1999
+	750MG		N21035 003	NOV 30, 1999

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC				
BETAXON				
+ ALCON	EQ 0.5% BASE		N21114 001	FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
AKBETA				
AT AKORN	**0.25%**		**N74779 001**	OCT 29, 1996
AT	**0.5%**		**N74780 001**	OCT 29, 1996
BETAGAN				
AT + ALLERGAN	**0.25%**		**N19814 001**	JUN 28, 1989
AT +	**0.5%**		**N19219 002**	DEC 19, 1985
LEVOBUNOLOL HCL				
AT BAUSCH AND LOMB	**0.25%**		**N74307 001**	MAR 04, 1994
AT	**0.5%**		**N74326 001**	MAR 04, 1994
AT FALCON PHARMS	**0.25%**		**N74851 001**	OCT 28, 1996
AT	**0.5%**		**N74850 001**	OCT 28, 1996
AT NOVEX	**0.25%**		**N75473 001**	AUG 03, 2000
AT	**0.5%**		**N75475 001**	AUG 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
CHIROCAINE				
PURDUE PHARMA LP	EQ 2.5MG BASE/ML		N20997 001	AUG 05, 1999
	EQ 5MG BASE/ML		N20997 002	AUG 05, 1999
+	EQ 7.5MG BASE/ML		N20997 003	AUG 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC				
LIVOSTIN				
+ CIBA	EQ 0.05% BASE		N20219 001	NOV 10, 1993

LEVOCARNITINE

INJECTABLE; INJECTION				
CARNITOR				
+ SIGMA TAU	200MG/ML		N20182 001	DEC 16, 1992
SOLUTION; ORAL				
CARNITOR				
+ SIGMA TAU	1GM/10ML		N18948 002	APR 27, 1988
+	1GM/10ML		N19257 001	APR 10, 1986
TABLET; ORAL				
CARNITOR				
+ SIGMA TAU	330MG		N18948 001	DEC 27, 1985

LEVODOPA

CAPSULE; ORAL				
DOPAR				
+ ROBERTS LABS	250MG		N16913 001	
TABLET; ORAL				
DOPAR				
BD ROBERTS LABS	250MG		N16913 004	

FDA data supplied by DrugPatentWatch.com

LEVODOPA

TABLET; ORAL

	DOPAR			
BD	ROBERTS LABS	500MG	N16913 005	
	LARODOPA			
BD	ROCHE	250MG	N16912 003	
BD +		500MG	N16912 004	
		100MG	N16912 005	

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; LEVODOPA

LEVOFLOXACIN

INJECTABLE; INJECTION

	LEVAQUIN			
+	JOHNSON RW	25MG/ML	N20635 001	DEC 20, 1996
	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+	JOHNSON RW	5MG/ML	N20635 002	DEC 20, 1996
+		500MG/100ML	N20635 003	DEC 20, 1996

SOLUTION/DROPS; OPHTHALMIC

	QUIXIN			
+	SANTEN	0.5%	N21199 001	AUG 18, 2000

TABLET; ORAL

	LEVAQUIN			
	JOHNSON RW	250MG	N20634 001	DEC 20, 1996
		500MG	N20634 002	DEC 20, 1996
+		750MG	N20634 003	SEP 08, 2000

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

	ORLAAM			
+	ROXANE	10MG/ML	N20315 001	JUL 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CARBOCAINE W/ NEO-COBEFRIN			
AP	+ EASTMAN KODAK	0.05MG/ML;2%	**N12125 002**	
	ISOCAINE HCL W/ LEVONORDEFRIN			
AP	NOVOCOL	0.05MG/ML;2%	**N84697 001**	
	MEPIVACAINE HCL W/ LEVONORDEFRIN			
AP	GRAHAM CHEM	0.05MG/ML;2%	**N84850 002**	OCT 21, 1983
	POLOCAINE W/ LEVONORDEFRIN			
AP	ASTRAZENECA	0.05MG/ML;2%	**N89517 001**	APR 14, 1988
	SCANDONEST L			
AP	DEPROCO	0.05MG/ML;2%	**N88388 001**	OCT 10, 1984

LEVONORGESTREL

IMPLANT; IMPLANTATION

	LEVONORGESTREL			
BX +	WYETH AYERST	75MG/IMPLANT	N20627 001	AUG 15, 1996
	NORPLANT II			
BX	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996
	NORPLANT SYSTEM IN PLASTIC CONTAINER			
+	WYETH AYERST	36MG/IMPLANT	N20088 001	DEC 10, 1990

INTRAUTERINE DEVICE; INTRAUTERINE

	MIRENA			
+	BERLEX LABS	52MG	N21225 001	DEC 08, 2000

TABLET; ORAL

	PLAN B			
+	WOMENS CAPITAL	0.75MG	N21045 001	JUL 28, 1999

LEVONORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; LEVONORGESTREL

FDA data supplied by DrugPatentWatch.com

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN
+ ICN 2MG/ML N08719 001 DEC 19, 1991

TABLET; ORAL
LEVO-DROMORAN
AB + ICN **2MG** **N08720 001** DEC 19, 1991

LEVORPHANOL TARTRATE
AB ROXANE **2MG** **N74278 001** MAR 31, 2000

LEVOTHYROXINE SODIUM

TABLET; ORAL
UNITHROID
STEVENS J 0.025MG N21210 001 AUG 21, 2000
0.05MG N21210 002 AUG 21, 2000
0.075MG N21210 003 AUG 21, 2000
0.088MG N21210 004 AUG 21, 2000
0.1MG N21210 005 AUG 21, 2000
0.112MG N21210 006 AUG 21, 2000
0.125MG N21210 007 AUG 21, 2000
0.15MG N21210 008 AUG 21, 2000
0.175MG N21210 009 AUG 21, 2000
0.2MG N21210 010 AUG 21, 2000
+ 0.3MG N21210 011 AUG 21, 2000

LIDOCAINE

AEROSOL; ORAL
XYLOCAINE
+ ASTRAZENECA 10% N14394 001

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL
LIDOCAINE
+ NOVEN 23MG/PATCH N20575 001 MAY 21, 1996
+ 46.1MG/PATCH N20575 002 MAY 21, 1996

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM
+ TEIKOKU PHARMA USA 700MG/12HR N20612 001 MAR 19, 1999

OINTMENT; TOPICAL
ALPHACAINE
AT CARLISLE **5%** **N84947 001**
LIDOCAINE
AT FOUGERA **5%** **N80198 001**
AT GRAHAM CHEM **5%** **N80210 001**
AT THAMES **5%** **N86724 001**
XYLOCAINE
AT + ASTRAZENECA **5%** **N08048 001**

SOLUTION; TOPICAL
XYLOCAINE
+ ASTRAZENECA 5% N14127 001

LIDOCAINE; *MULTIPLE*
SEE CEFTRIAXONE SODIUM; LIDOCAINE

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N19941 001 DEC 30, 1992

DISC; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N20962 001 FEB 04, 1998

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

AP	ABBOTT	0.5%	N88328 001	MAY 17, 1984
AP		1%	N40013 001	JUN 23, 1995
AP		1%	N83158 001	
AP		1%	N88329 001	MAY 17, 1984
AP		2%	N40078 001	JUN 23, 1995
AP		2%	N83158 002	
AP		2%	N88294 001	MAY 17, 1984
AP		2%	N88331 001	MAY 17, 1984
AP		20%	N83158 003	
AP	ELKINS SINN	1%	N80407 001	
AP		2%	N80407 002	
AP	GRAHAM CHEM	2%	N80504 001	
AP	INTL MEDICATION	1%	N83173 001	
AP		2%	N83173 002	
AP	LUITPOLD	1%	N80850 001	
AP		2%	N83198 001	
AP	STERIS	1%	N80377 001	
AP		2%	N80377 002	
AP	WYETH AYERST	1%	N83083 001	
AP		2%	N83083 002	

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	200MG/100ML	N18967 001	MAR 30, 1984
AP		200MG/100ML	N19830 002	APR 08, 1992
AP	BAXTER HLTHCARE	200MG/100ML	N18461 002	

LIDOCAINE HCL 0.2% IN DEXTROSE 5%

AP	ABBOTT	200MG/100ML	N83158 005	

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	200MG/100ML	N18388 001	

LIDOCAINR HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	400MG/100ML	N18967 002	MAR 30, 1984
AP		400MG/100ML	N19830 003	APR 08, 1992
AP	BAXTER HLTHCARE	400MG/100ML	N18461 003	

LIDOCAINE HCL 0.4% IN DEXTROSE 5%

AP	ABBOTT	400MG/100ML	N83158 006	

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	400MG/100ML	N18388 002	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	800MG/100ML	N18967 003	MAR 30, 1984
AP		800MG/100ML	N19830 004	APR 08, 1992
AP	BAXTER HLTHCARE	800MG/100ML	N18461 004	FEB 22, 1982

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	800MG/100ML	N18388 003	NOV 05, 1982

LIDOCAINE HCL IN PLASTIC CONTAINER

AP	ABBOTT	0.5%	N88325 001	JUL 31, 1984
AP		1%	N88299 001	JUL 31, 1984
AP		1.5%	N88326 001	JUL 31, 1984
AP		2%	N88327 001	JUL 31, 1984
AP		10%	N88367 001	JUL 31, 1984
AP		20%	N88368 001	JUL 31, 1984
AP	AM PHARM PARTNERS	1%	N88586 001	JUL 24, 1985

LIDOCAINE HCL PRESERVATIVE FREE

AP	ABBOTT	1%	N80408 001	
AP		1.5%	N80408 002	
AP		4%	N88295 001	MAY 17, 1984
AP	AM PHARM PARTNERS	1%	N80404 002	
AP		2%	N17584 001	
AP		2%	N80404 003	
AP		4%	N17584 002	
AP	ELKINS SINN	1%	N84625 001	
AP		2%	N84625 002	
AP	INTL MEDICATION	20%	N17702 001	

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	ABBOTT	1%	N40302 001	SEP 28, 1998
AP		2%	N40302 002	SEP 28, 1998

LIDOCATON

AP	PHARMATON	2%	N84727 001	AUG 17, 1983

LIDOPEN

AP	MERIDIAN MEDCL TECHN	10%	N17549 001	

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	XYLOCAINE			
AP	+ ASTRAZENECA	0.5%	N06488 008	
AP	+	1%	N06488 007	
AP	+	1.5%	N06488 010	
AP	+	2%	N06488 002	
	XYLOCAINE 4% PRESERVATIVE FREE			
AP	+ ASTRAZENECA	4%	N10417 001	
	XYLOCAINE PRESERVATIVE FREE			
AP	ASTRAZENECA	1%	N16801 005	
			JAN 19, 1988	
AP		2%	N16801 001	
AP		4%	N16801 002	
AP	+	10%	N16801 003	
AP	+	20%	N16801 004	

INJECTABLE; SPINAL

	LIDOCAINE HCL 5% AND DEXTROSE 7.5%			
AP	ABBOTT	5%	N83914 001	
	XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
	+ ASTRAZENECA	1.5%	N16297 001	
	XYLOCAINE 5% W/ GLUCOSE 7.5%			
AP	+ ASTRAZENECA	5%	N10496 002	
			JUL 07, 1982	

JELLY; TOPICAL

	LIDOCAINE HCL			
AT	COPLEY PHARM	2%	N81318 001	
			APR 29, 1993	
AT	INTL MEDICATION	2%	N86283 001	
	XYLOCAINE			
AT	+ ASTRAZENECA	2%	N08816 001	

SOLUTION; ORAL

	LIDOCAINE HCL			
AT	HI TECH PHARMA	2%	N40014 001	
			JUL 10, 1995	
AT	MORTON GROVE	2%	N87872 001	
			NOV 18, 1982	
	LIDOCAINE HCL VISCOUS			
AT	ALPHARMA	2%	N86578 001	
	LIDOCAINE VISCOUS			
AT	ROXANE	2%	N88802 001	
			APR 26, 1985	
	XYLOCAINE VISCOUS			
AT	+ ASTRAZENECA	2%	N09470 001	

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	ANESTACON			
AT	+ POLYMEDICA	2%	N80429 001	
	LARYNG-O-JET KIT			
AT	INTL MEDICATION	4%	N86364 001	
	LIDOCAINE HCL			
AT	MORTON GROVE	4%	N87881 001	
			NOV 18, 1982	
AT	ROXANE	4%	N88803 001	
			APR 03, 1985	
	LTA II KIT			
AT	ABBOTT	4%	N80409 001	
AT		4%	N88542 001	
			JUL 31, 1984	
	PEDIATRIC LTA KIT			
AT	ABBOTT	2%	N85995 001	
	XYLOCAINE 4% PRESERVATIVE FREE			
AT	+ ASTRAZENECA	4%	N10417 002	

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*

SEE DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

SEE EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN			
PFIZER	2%;50MG/ML	N60567 001	
	2%;125MG/ML	N60567 002	

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN			
PHARMACIA AND UPJOHN	EQ 250MG BASE	N50316 001	
+	EQ 500MG BASE	N50316 002	

INJECTABLE; INJECTION

	LINCOCIN			
AP	+ PHARMACIA AND UPJOHN	**EQ 300MG BASE/ML**	**N50317 001**	
	LINCOMYCIN HCL			
AP	STERIS	**EQ 300MG BASE/ML**	**N63180 001**	
			APR 16, 1991	

FDA data supplied by DrugPatentWatch.com

LINDANE

LOTION; TOPICAL

		LINDANE			
AT	+	ALPHARMA	1%	N87313 001	
AT		MORTON GROVE	1%	N88190 001	
				AUG 16, 1984	

SHAMPOO; TOPICAL

		LINDANE			
AT	+	ALPHARMA	1%	N87266 001	
AT		MORTON GROVE	1%	N88191 001	
				SEP 18, 1984	

LINEZOLID

FOR SUSPENSION; ORAL

	ZYVOX			
+	PHARMACIA AND UPJOHN	100MG/5ML	N21132 001	
			APR 18, 2000	

INJECTABLE; INJECTION

	ZYVOX			
+	PHARMACIA AND UPJOHN	200MG/100ML	N21131 001	
			APR 18, 2000	

TABLET; ORAL

	ZYVOX			
	PHARMACIA AND UPJOHN	400MG	N21130 001	
			APR 18, 2000	
+		600MG	N21130 002	
			APR 18, 2000	

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

	TRIOSTAT			
+	JONES PHARMA	EQ 0.01MG BASE/ML	N20105 001	
			DEC 31, 1991	

TABLET; ORAL

	CYTOMEL			
	JONES PHARMA	EQ 0.005MG BASE	N10379 001	
		EQ 0.025MG BASE	N10379 002	
+		EQ 0.05MG BASE	N10379 003	

LIOTRIX (T4;T3)

TABLET; ORAL

		THYROLAR-0.25			
		FORREST LABS	0.0125MG;0.0031MG		N16807 001
		THYROLAR-0.5			
		FORREST LABS	0.025MG;0.00625MG		N16807 005
		THYROLAR-1			
		FORREST LABS	0.05MG;0.0125MG		N16807 004
		THYROLAR-2			
		FORREST LABS	0.1MG;0.025MG		N16807 002
		THYROLAR-3			
+		FORREST LABS	0.15MG;0.0375MG		N16807 003

LISINOPRIL

TABLET; ORAL

		PRINIVIL			
AB		MERCK	2.5MG		N19558 006
					JAN 28, 1994
AB			5MG		N19558 001
					DEC 29, 1987
AB			10MG		N19558 002
					DEC 29, 1987
AB			20MG		N19558 003
					DEC 29, 1987
AB			40MG		N19558 004
					OCT 25, 1988
		ZESTRIL			
AB		ASTRAZENECA	2.5MG		N19777 005
					APR 29, 1993
AB			5MG		N19777 001
					MAY 19, 1988
AB	+		10MG		N19777 002
					MAY 19, 1988
AB			20MG		N19777 003
					MAY 19, 1988
AB	+		40MG		N19777 004
					MAY 19, 1988
			30MG		N19777 006
					JAN 20, 1999

LISINOPRIL; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LISINOPRIL

FDA data supplied by DrugPatentWatch.com

LITHIUM CARBONATE

CAPSULE; ORAL

	ESKALITH			
AB	+ SMITHKLINE BEECHAM	300MG		N16860 001
	LITHIUM CARBONATE			
AB	ROXANE	300MG		N17812 001
		150MG		N17812 002
				JAN 28, 1987
		600MG		N17812 003
				JAN 28, 1987

TABLET; ORAL

	LITHIUM CARBONATE			
AB	+ PFIZER	300MG		N16834 001
AB	ROXANE	300MG		N18558 001
				JAN 29, 1982

TABLET, EXTENDED RELEASE; ORAL

	ESKALITH CR			
	+ SMITHKLINE BEECHAM	450MG		N18152 001
				MAR 29, 1982
	LITHOBID			
	+ SOLVAY	300MG		N18027 001

LITHIUM CITRATE

SYRUP; ORAL

	LITHIUM CITRATE			
AA	MORTON GROVE	EQ 300MG CARBONATE/5ML		N70755 001
				MAY 21, 1986
AA	+ ROXANE	EQ 300MG CARBONATE/5ML		N18421 001

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	ALOMIDE			
	+ ALCON	EQ 0.1% BASE		N20191 001
				SEP 23, 1993

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	MAXAQUIN			
	+ SEARLE	EQ 400MG BASE		N20013 001
				FEB 21, 1992

LOMUSTINE

CAPSULE; ORAL

	CEENU			
	BRISTOL MYERS SQUIBB	10MG		N17588 001
		40MG		N17588 002
	+	100MG		N17588 003

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	IMODIUM			
AB	+ MCNEIL CONS	2MG		N17694 001
	LOPERAMIDE HCL			
AB	GENEVA PHARMS	2MG		N72993 001
				AUG 28, 1992
AB	MYLAN	2MG		N72741 001
				SEP 18, 1991
AB	NOVOPHARM	2MG		N73122 001
				AUG 30, 1991
AB	ROXANE	2MG		N73080 001
				NOV 27, 1991
AB	TEVA	2MG		N73192 001
				APR 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

	KALETRA			
	+ ABBOTT	133.3MG;33.3MG		N21226 001
				SEP 15, 2000

SOLUTION; ORAL

	KALETRA			
	+ ABBOTT	80MG/ML;20MG/ML		N21251 001
				SEP 15, 2000

LORACARBEF

CAPSULE; ORAL

	LORABID			
	KING PHARMS	200MG		N50668 001
				DEC 31, 1991
	+	400MG		N50668 002
				APR 05, 1996

FDA data supplied by DrugPatentWatch.com

LORACARBEF

FOR SUSPENSION; ORAL
LORABID
KING PHARMS 100MG/5ML N50667 001 DEC 31, 1991
\+ 200MG/5ML N50667 002 DEC 31, 1991

LORATADINE

SYRUP; ORAL
CLARITIN
\+ SCHERING 1MG/ML N20641 001 OCT 10, 1996

TABLET; ORAL
CLARITIN
\+ SCHERING 10MG N19658 001 APR 12, 1993

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS
\+ SCHERING 10MG N20704 001 DEC 23, 1996

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D
\+ SCHERING 5MG;120MG N19670 001 NOV 14, 1994

CLARITIN-D 24 HOUR
\+ SCHERING 10MG;240MG N20470 001 AUG 23, 1996

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM INTENSOL
ROXANE 2MG/ML N72755 001 JUN 28, 1991

INJECTABLE; INJECTION
ATIVAN
AP \+ WYETH AYERST **2MG/ML** **N18140 001**

LORAZEPAM

INJECTABLE; INJECTION
ATIVAN
AP \+ WYETH AYERST **4MG/ML** **N18140 002**
LORAZEPAM
AP ABBOTT **2MG/ML** **N74243 001** APR 12, 1994
AP **2MG/ML** **N74280 001** MAY 27, 1994
AP **2MG/ML** **N74282 001** MAY 27, 1994
AP **2MG/ML** **N74300 001** APR 12, 1994
AP **4MG/ML** **N74243 002** APR 12, 1994
AP **4MG/ML** **N74280 002** MAY 27, 1994
AP **4MG/ML** **N74282 002** MAY 27, 1994
AP **4MG/ML** **N74300 003** MAR 19, 1997
AP AKORN **2MG/ML** **N74974 001** JUL 23, 1998
AP ELKINS SINN **2MG/ML** **N74496 001** SEP 28, 1998
AP **4MG/ML** **N74496 002** SEP 28, 1998
AP MARSAM **2MG/ML** **N74535 001** SEP 12, 1996
AP **2MG/ML** **N74551 001** SEP 12, 1996
AP **1MG/0.5ML** **N74551 003** SEP 12, 1996
AP **4MG/ML** **N74535 002** SEP 12, 1996
AP **4MG/ML** **N74551 002** SEP 12, 1996
AP MOVA **2MG/ML** **N74793 001** MAR 16, 2000
AP **4MG/ML** **N74793 002** MAR 16, 2000
AP STERIS **2MG/ML** **N74276 001** APR 15, 1994
AP **4MG/ML** **N74276 002** APR 15, 1994
AP TAYLOR **2MG/ML** **N75025 001** JUL 23, 1998

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

SOLUTION; ORAL

	LORAZEPAM			
	+ ROXANE	0.5MG/5ML	N74648 001	
			MAR 18, 1997	

TABLET; ORAL

	ATIVAN			
AB	WYETH AYERST	**0.5MG**	**N17794 001**	
AB		**1MG**	**N17794 002**	
AB	+	**2MG**	**N17794 003**	
	LORAZEPAM			
AB	DANBURY PHARMA	**0.5MG**	**N71117 001**	
			JUL 24, 1986	
AB		**1MG**	**N71118 001**	
			JUL 24, 1986	
AB		**2MG**	**N71110 001**	
			JUL 24, 1986	
AB	GENEVA PHARMS	**0.5MG**	**N71193 001**	
			APR 15, 1988	
AB		**1MG**	**N71194 001**	
			APR 15, 1988	
AB		**2MG**	**N71195 001**	
			APR 15, 1988	
AB	MUTUAL PHARM	**0.5MG**	**N72553 001**	
			MAR 29, 1991	
AB		**1MG**	**N72554 001**	
			MAR 29, 1991	
AB		**2MG**	**N72555 001**	
			MAR 29, 1991	
AB	MYLAN	**0.5MG**	**N71589 001**	
			OCT 13, 1987	
AB		**1MG**	**N71590 001**	
			OCT 13, 1987	
AB		**2MG**	**N71591 001**	
			OCT 13, 1987	
AB	PUREPAC PHARM	**0.5MG**	**N71403 001**	
			APR 21, 1987	
AB		**1MG**	**N71404 001**	
			APR 21, 1987	
AB		**2MG**	**N71141 001**	
			APR 21, 1987	
AB	WATSON LABS	**0.5MG**	**N71086 001**	
			MAR 23, 1987	
AB		**0.5MG**	**N72926 001**	
			OCT 31, 1991	
AB		**1MG**	**N71087 001**	
			MAR 23, 1987	

LORAZEPAM

TABLET; ORAL

	LORAZEPAM			
AB	WATSON LABS	**1MG**	**N72927 001**	
			OCT 31, 1991	
AB		**2MG**	**N71088 001**	
			MAR 23, 1987	
AB		**2MG**	**N72928 001**	
			OCT 31, 1991	

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR			
MERCK	25MG	N20386 001	
		APR 14, 1995	
+	50MG	N20386 002	
		APR 14, 1995	

LOSARTAN POTASSIUM; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

ALREX			
+ PHARMOS	0.2%	N20803 001	
		MAR 09, 1998	
LOTEMAX			
+ PHARMOS	0.5%	N20583 001	
		MAR 09, 1998	

LOVASTATIN

TABLET; ORAL

MEVACOR			
MERCK	10MG	N19643 002	
		MAR 28, 1991	
	20MG	N19643 003	
		AUG 31, 1987	
+	40MG	N19643 004	
		DEC 14, 1988	

FDA data supplied by DrugPatentWatch.com

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C
\+ WATSON LABS — EQ 25MG BASE/ML — N17658 001

INJECTABLE; INJECTION
LOXITANE IM
\+ WATSON LABS — EQ 50MG BASE/ML — N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXAPINE SUCCINATE
AB WATSON LABS — **EQ 5MG BASE** — **N72204 001** JUN 15, 1988
AB — **EQ 10MG BASE** — **N72205 001** JUN 15, 1988
AB — **EQ 25MG BASE** — **N72206 001** JUN 15, 1988
AB — **EQ 50MG BASE** — **N72062 001** JUN 15, 1988

LOXITANE
AB WATSON LABS — **EQ 5MG BASE** — **N17525 001**
AB — **EQ 10MG BASE** — **N17525 002**
AB \+ — **EQ 25MG BASE** — **N17525 003**
AB — **EQ 50MG BASE** — **N17525 004**

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
\+ BERTEK PHARMS — EQ 85MG BASE/GM — N16763 001

FOR SOLUTION; TOPICAL
SULFAMYLON
\+ MYLAN — 5% — N19832 003 JUN 05, 1998

MAGNESIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER
BAXTER HLTHCARE — 32MG/100ML;128MG/100ML; 234MG/100ML — N19047 001 JUN 15, 1984

MAGNESIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN — 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML — N19696 001 — SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN — **30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML** — **N18252 001**
AP — **30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML** — **N19711 001** — SEP 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER
ABBOTT — 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML — N17586 001

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE — **30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML** — **N17378 001**

PLASMA-LYTE A IN PLASTIC CONTAINER
AP BAXTER HLTHCARE — **30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML** — **N17378 002** — NOV 22, 1982

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER
B BRAUN — 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML — N19024 001 — JUN 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER
ABBOTT — 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML — N17637 002 — JUL 08, 1982

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
ABBOTT — 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML — N18406 002 — JUL 08, 1982

MAGNESIUM OXIDE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
AP ABBOTT — **500MG/ML** — **N75151 001** — APR 25, 2000
AP + AM PHARM PARTNERS — **500MG/ML** — **N19316 001** — SEP 08, 1986

FDA data supplied by DrugPatentWatch.com

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
+ ABBOTT 1GM/100ML N20488 001 JUL 11, 1995
+ 2GM/100ML N20488 002 JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER
+ ABBOTT 4GM/100ML N20309 001 JUN 24, 1994
+ 80MG/ML N20309 002 JUN 24, 1994

MAGNESIUM SULFATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
TIS-U-SOL
AT BAXTER HLTHCARE **20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML** **N18508 001** FEB 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER
AT BAXTER HLTHCARE **20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML** **N18336 001**

MALATHION

LOTION; TOPICAL
OVIDE
+ MEDICIS 0.5% N18613 001 AUG 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN
+ NYCOMED 37.9MG/ML N20652 001 NOV 26, 1997

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER
ABBOTT EQ 0.1MG MANGANESE/ML N18962 001 JUN 26, 1986

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL
LUMENHANCE
+ BRACCO 3.49MG/GM N20686 001 DEC 19, 1997

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10%
AP B BRAUN **10GM/100ML** **N16080 002**
MANNITOL 10% IN PLASTIC CONTAINER
AP ABBOTT **10GM/100ML** **N19603 002** JAN 08, 1987
AP B BRAUN **10GM/100ML** **N20006 002** JUL 26, 1993
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
AP B BRAUN **10GM/100ML** **N16080 006**
MANNITOL 15%
AP B BRAUN **15GM/100ML** **N16080 003**
MANNITOL 15% IN PLASTIC CONTAINER
AP ABBOTT **15GM/100ML** **N19603 003** JAN 08, 1990
AP B BRAUN **15GM/100ML** **N20006 003** JUL 26, 1993
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
AP B BRAUN **15GM/100ML** **N16080 005**
MANNITOL 20%
AP B BRAUN **20GM/100ML** **N14738 001**
AP **20GM/100ML** **N16080 004**
MANNITOL 20% IN PLASTIC CONTAINER
AP ABBOTT **20GM/100ML** **N19603 004** JAN 08, 1990
AP B BRAUN **20GM/100ML** **N20006 004** JUL 26, 1993
MANNITOL 25%
AP ABBOTT **12.5GM/50ML** **N16269 006** AUG 25, 1994
AP AM PHARM PARTNERS **12.5GM/50ML** **N80677 001**

FDA data supplied by DrugPatentWatch.com

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%			
AP	ASTRAZENECA	12.5GM/50ML	N89239 001	
			MAY 06, 1987	
AP		12.5GM/50ML	N89240 001	
			MAY 06, 1987	
AP	INTL MEDICATION	12.5GM/50ML	N83051 001	
AP	LUITPOLD	12.5GM/50ML	N87409 001	
			JAN 21, 1982	
	MANNITOL 5%			
AP	B BRAUN	5GM/100ML	N16080 001	
	MANNITOL 5% IN PLASTIC CONTAINER			
AP	ABBOTT	5GM/100ML	N19603 001	
			JAN 08, 1987	
AP	B BRAUN	5GM/100ML	N20006 001	
			JUL 26, 1993	
	MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%			
AP	B BRAUN	5GM/100ML	N16080 007	
	OSMITROL 10% IN WATER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 002	
	OSMITROL 10% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 006	
	OSMITROL 15% IN WATER			
AP	BAXTER HLTHCARE	15GM/100ML	N13684 004	
	OSMITROL 15% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	15GM/100ML	N13684 008	
	OSMITROL 20% IN WATER			
AP	BAXTER HLTHCARE	20GM/100ML	N13684 003	
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	20GM/100ML	N13684 007	
	OSMITROL 5% IN WATER			
AP	BAXTER HLTHCARE	5GM/100ML	N13684 001	
	OSMITROL 5% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML	N13684 005	

SOLUTION; IRRIGATION

	RESECTISOL IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML	N16772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

	SORBITOL-MANNITOL IN PLASTIC CONTAINER		
AT	ABBOTT	540MG/100ML;2.7GM/100ML	N17636 001
AT		540MG/100ML;2.7GM/100ML	N18316 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

	LUDIOMIL			
AB	NOVARTIS	25MG	N17543 001	
AB	+	50MG	N17543 002	
AB		75MG	N17543 003	
			SEP 30, 1982	
	MAPROTILINE HCL			
AB	MYLAN	25MG	N72284 001	
			OCT 03, 1988	
AB		50MG	N72285 001	
			OCT 03, 1988	
AB		75MG	N72286 001	
			OCT 03, 1988	
AB	WATSON LABS	25MG	N72162 001	
			JUN 01, 1988	
AB		50MG	N72163 001	
			JUN 01, 1988	
AB		75MG	N72164 001	
			JUN 01, 1988	

MASOPROCOL

CREAM; TOPICAL

	ACTINEX		
+	UNIV AZ CANCER CTR	10%	N19940 001
			SEP 04, 1992

MAZINDOL

TABLET; ORAL

	MAZANOR		
BP	WYETH AYERST	1MG	N17980 002
	SANOREX		
BP	NOVARTIS	1MG	N17247 001
+		2MG	N17247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	MEBENDAZOLE		
AB	COPLEY PHARM	100MG	N73580 001
			JAN 04, 1995
	VERMOX		
AB +	MCNEIL CONS	100MG	N17481 001

FDA data supplied by DrugPatentWatch.com

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE
+ LAYTON 2.5MG N10251 001

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
MUSTARGEN
+ MERCK 10MG/VIAL N06695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA	+ PFIZER	12.5MG	N10721 006	
AA	+	25MG	N10721 004	
AA	+	50MG	N10721 001	JAN 20, 1982

MECLIZINE HCL

AA	BUNDY	12.5MG	N84382 001	
AA		25MG	N84872 001	
AA	CAMALL	12.5MG	N85253 001	
AA		25MG	N85252 001	
AA	CHELSEA LABS	12.5MG	N85269 001	
AA		25MG	N85740 001	
AA	GENEVA PHARMS	12.5MG	N84843 002	MAY 22, 1989
AA		25MG	N84092 003	MAY 22, 1989
AA	PAR PHARM	12.5MG	N87127 001	
AA		25MG	N87128 001	
AA		50MG	N89674 001	MAR 31, 1988
AA	SIDMAK LABS NJ	12.5MG	N88732 001	DEC 11, 1985
AA		25MG	N88734 001	DEC 11, 1985
AA	VINTAGE PHARMS	12.5MG	N40179 001	JAN 30, 1997
AA		25MG	N40179 002	JAN 30, 1997
AA	ZENITH GOLDLINE	12.5MG	N84975 001	
AA		25MG	N84657 001	

TABLET, CHEWABLE; ORAL
ANTIVERT

AA	+ PFIZER	25MG	N10721 005

MECLIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL
MECLIZINE HCL

AA	SIDMAK LABS NJ	25MG	N88733 001 DEC 11, 1985

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

AB	DANBURY PHARMA	EQ 50MG BASE	N71468 001 APR 15, 1987
AB		EQ 100MG BASE	N71469 001 APR 15, 1987
AB	GENEVA PHARMS	EQ 50MG BASE	N72262 001 NOV 29, 1988
AB		EQ 100MG BASE	N72263 001 NOV 29, 1988
AB	MYLAN	EQ 50MG BASE	N71080 001 SEP 03, 1986
AB		EQ 100MG BASE	N71081 001 SEP 03, 1986

MECLOMEN

AB	PARKE DAVIS	EQ 50MG BASE	N18006 001	
AB	+	EQ 100MG BASE	N18006 002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA

+	PHARMACIA AND UPJOHN	150MG/ML	N20246 001 OCT 29, 1992
+		400MG/ML	N12541 003

TABLET; ORAL
AMEN

BP	AMARIN PHARMS	10MG	N83242 001

MEDROXYPROGESTERONE ACETATE

AB	BARR	2.5MG	N40159 001 AUG 09, 1996
AB		5MG	N40159 002 AUG 09, 1996
AB		10MG	N40159 003 AUG 09, 1996
AB	DURAMED	2.5MG	N40311 001 DEC 01, 1999

FDA data supplied by DrugPatentWatch.com

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	MEDROXYPROGESTERONE ACETATE				
AB	DURAMED	**5MG**	**N40311 002**		
			DEC 01, 1999		
AB		**10MG**	**N40311 003**		
			DEC 01, 1999		
BP	ROSEMONT	10MG	N88484 001		
			JUL 26, 1984		
	PROVERA				
AB	PHARMACIA AND UPJOHN	**2.5MG**	**N11839 001**		
AB		**5MG**	**N11839 003**		
AB	+	**10MG**	**N11839 004**		

MEDROXYPROGESTERONE ACETATE; *MULTIPLE*

SEE ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

SEE ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

MEDRYSONE

SUSPENSION; OPHTHALMIC

	HMS		
+	ALLERGAN	1%	N16624 003

MEFENAMIC ACID

CAPSULE; ORAL

	PONSTEL		
+	FIRST HORIZON	250MG	N15034 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

	LARIAM		
+	ROCHE	250MG	N19591 001
			MAY 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

	MEGACE		
+	BRISTOL MYERS SQUIBB	40MG/ML	N20264 001
			SEP 10, 1993

MEGESTROL ACETATE

TABLET; ORAL

	MEGACE		
AB	BRISTOL MYERS SQUIBB	**20MG**	**N16979 001**
AB	+	**40MG**	**N16979 002**
	MEGESTROL ACETATE		
AB	BARR	**20MG**	**N74621 002**
			AUG 16, 1996
AB		**40MG**	**N74621 001**
			NOV 30, 1995
AB	PAR PHARM	**20MG**	**N72422 001**
			AUG 08, 1988
AB		**40MG**	**N72423 001**
			AUG 08, 1988
AB	ROXANE	**20MG**	**N74458 001**
			SEP 29, 1995
AB		**40MG**	**N74458 002**
			SEP 29, 1995
AB	TEVA	**40MG**	**N74745 001**
			FEB 27, 1998

MELOXICAM

TABLET; ORAL

	MOBIC		
+	BOEHRINGER INGELHEIM	7.5MG	N20938 001
			APR 13, 2000

MELPHALAN

TABLET; ORAL

	ALKERAN		
+	GLAXO WELLCOME	2MG	N14691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

	ALKERAN		
+	GLAXO WELLCOME	EQ 50MG BASE/VIAL	N20207 001
			NOV 18, 1992

FDA data supplied by DrugPatentWatch.com

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	HUMEGON			
AB	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001	
			SEP 01, 1994	
AB		150 IU/VIAL;150 IU/VIAL	N20328 002	
			SEP 01, 1994	
	PERGONAL			
AB	+ SERONO	75 IU/AMP;75 IU/AMP	N17646 001	
AB	+	150 IU/AMP;150 IU/AMP	N17646 002	
			MAY 20, 1985	
	REPRONEX			
BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	
			AUG 27, 1999	
BX		150 IU/VIAL;150 IU/VIAL	N21047 002	
			AUG 27, 1999	

MEPENZOLATE BROMIDE

TABLET; ORAL

	CANTIL		
	+ AVENTIS PHARMS	25MG	N10679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL			
AP	+ ABBOTT	25MG/ML	N21171 001	
AP	+	50MG/ML	N21171 002	
AP	+	75MG/ML	N21171 003	
AP	+	100MG/ML	N21171 004	
	MEPERIDINE HCL			
AP	ASTRAZENECA	50MG/ML	N89784 001	
			MAR 31, 1989	
AP		100MG/ML	N89788 001	
			MAR 31, 1989	
AP	ELKINS SINN	25MG/ML	N80445 001	
AP		50MG/ML	N80445 002	
AP		75MG/ML	N80445 003	
AP		100MG/ML	N80445 004	
AP	STERIS	50MG/ML	N73444 001	
			MAR 17, 1992	
AP		100MG/ML	N73445 001	
			MAR 17, 1992	
AP	WYETH AYERST	25MG/ML	N80455 007	
AP		50MG/ML	N80455 008	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERIDINE HCL			
AP	WYETH AYERST	75MG/ML	N80455 009	
AP		100MG/ML	N80455 010	
	MEPERIDINE HCL PRESERVATIVE FREE			
AP	+ ABBOTT	10MG/ML	N88432 001	
			AUG 16, 1984	
AP	ASTRAZENECA	10MG/ML	N81002 001	
			JUL 30, 1993	
AP	FAULDING	10MG/ML	N40305 001	
			MAR 10, 1999	
AP	INTL MEDICATION	10MG/ML	N81309 001	
			AUG 30, 1993	
AP	MALLINCKRODT	10MG/ML	N40163 001	
			MAY 12, 1997	
AP	STERIS	10MG/ML	N73443 001	
			MAR 17, 1992	

SYRUP; ORAL

	DEMEROL			
AA	+ SANOFI SYNTHELABO	50MG/5ML	N05010 005	
	MEPERIDINE HCL			
AA	ROXANE	50MG/5ML	N88744 001	
			JAN 30, 1985	

TABLET; ORAL

	DEMEROL			
AA	+ SANOFI SYNTHELABO	50MG	N05010 001	
AA	+	100MG	N05010 004	
	MEPERIDINE HCL			
AA	AMIDE PHARM	50MG	N40331 001	
			MAY 28, 1999	
AA		100MG	N40331 002	
			MAY 28, 1999	
AA	BARR	50MG	N88639 001	
			JUL 02, 1984	
AA		100MG	N88640 001	
			SEP 19, 1984	
AA	DURAMED	50MG	N40318 001	
			OCT 05, 1999	
AA		100MG	N40318 002	
			OCT 05, 1999	
AA	HALSEY	50MG	N80448 001	
AA		100MG	N80448 002	
AA	MALLINCKRODT	50MG	N40352 001	
			JUN 13, 2000	

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

	MEPERIDINE HCL			
AA	MALLINCKRODT	100MG	N40352 002	JUN 13, 2000
AA	ROXANE	50MG	N40110 001	MAR 12, 1997
AA		100MG	N40110 002	MAR 12, 1997
AA	VINTAGE PHARMS	50MG	N40191 001	DEC 17, 1998
AA		100MG	N40191 002	DEC 17, 1998
AA	WATSON LABS	50MG	N40186 001	JUN 30, 1997
AA		100MG	N40186 002	JUN 30, 1997
AA	WYETH AYERST	50MG	N80454 001	

MEPERIDINE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERGAN		
+	WYETH AYERST	25MG/ML;25MG/ML	N11730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

	WYAMINE SULFATE		
+	WYETH AYERST	EQ 15MG BASE/ML	N08248 002

MEPHENYTOIN

TABLET; ORAL

	MESANTOIN		
+	NOVARTIS	100MG	N06008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CARBOCAINE			
AP	+ EASTMAN KODAK	3%	N12125 003	
AP	+ STERLING WINTHROP	1%	N12250 001	
AP	+	1.5%	N12250 005	
AP	+	2%	N12250 002	
	ISOCAINE HCL			
AP	NOVOCOL	3%	N80925 001	
	MEPIVACAINE HCL			
AP	GRAHAM CHEM	3%	N83559 001	
AP	INTL MEDICATION	1%	N87509 001	OCT 05, 1982
AP	STERIS	1%	N88769 001	NOV 20, 1984
AP		2%	N88770 001	NOV 20, 1984
	POLOCAINE			
AP	ASTRAZENECA	1%	N89407 001	DEC 01, 1986
AP		2%	N89410 001	DEC 01, 1986
AP		3%	N88653 001	AUG 21, 1984
	POLOCAINE-MPF			
AP	ASTRAZENECA	1%	N89406 001	DEC 01, 1986
AP		1.5%	N89408 001	DEC 01, 1986
AP		2%	N89409 001	DEC 01, 1986
	SCANDONEST PLAIN			
AP	DEPROCO	3%	N88387 001	OCT 10, 1984

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

MEPROBAMATE

TABLET; ORAL

	AMOSENE			
AA	FERNDALE LABS	400MG	N84030 001	
	EQUANIL			
AA	+ WYETH AYERST	200MG	N10028 005	
AA	+	400MG	N10028 004	

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE				
AA	CHELSEA LABS	200MG	N85720 001		
AA		400MG	N85721 001		
AA	DANBURY PHARMA	200MG	N83304 001		
AA		400MG	N83308 001		
AA	EON	200MG	N14547 002		
AA		400MG	N14547 001		
AA	GENEVA PHARMS	400MG	N80655 001		
AA	HALSEY	400MG	N80699 002		
AA	IMPAX LABS	200MG	N14322 002		
AA		400MG	N14322 001		
AA	MYLAN	400MG	N83618 001		
AA	ROXANE	600MG	N84332 001		
AA	SCHERER LABS	400MG	N83343 001		
AA	TABLICAPS	400MG	N83494 001		
AA	WEST WARD	200MG	N15417 003		
AA		400MG	N15417 002		
	MILTOWN				
AA	WALLACE LABS	200MG	N09698 004		
AA		400MG	N09698 002		
AA	+ WALLACE PHARMS	600MG	N83919 001		
	TRANMEP				
AA	SOLVAY	400MG	N16249 001		

MEPROBAMATE; *MULTIPLE*

SEE ASPIRIN; MEPROBAMATE

SEE ESTROGENS, CONJUGATED; MEPROBAMATE

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

	SOLAGE			
+	BRISTOL MYERS SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999

MERCAPTOPURINE

TABLET; ORAL

	PURINETHOL			
+	GLAXO WELLCOME	50MG	N09053 002	

MEROPENEM

INJECTABLE; INJECTION

	MERREM I.V.			
+	ASTRAZENECA	500MG/VIAL	N50706 003	JUN 21, 1996
+		1GM/VIAL	N50706 001	JUN 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

	PENTASA			
+	SHIRE	250MG	N20049 001	MAY 10, 1993

ENEMA; RECTAL

	ROWASA			
+	SOLVAY	4GM/60ML	N19618 001	DEC 24, 1987

TABLET, DELAYED RELEASE; ORAL

	ASACOL			
+	PROCTER AND GAMBLE	400MG	N19651 001	JAN 31, 1992

MESNA

INJECTABLE; INJECTION

	MESNEX			
+	ASTA	100MG/ML	N19884 001	DEC 30, 1988

MESNA; *MULTIPLE*

SEE IFOSFAMIDE; MESNA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

	SERENTIL			
+	NOVARTIS	EQ 25MG BASE/ML	N16997 001	

INJECTABLE; INJECTION

	SERENTIL			
+	NOVARTIS	EQ 25MG BASE/ML	N16775 001	

FDA data supplied by DrugPatentWatch.com

MESORIDAZINE BESYLATE

TABLET; ORAL
SERENTIL
NOVARTIS
EQ 10MG BASE N16774 001
EQ 25MG BASE N16774 002
EQ 50MG BASE N16774 003
\+ EQ 100MG BASE N16774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21
AB WATSON LABS **0.05MG;1MG** **N71539 001** APR 12, 1988

NORETHINDRONE AND MESTRANOL
AB WATSON LABS **0.05MG;1MG** **N70758 001** JUL 01, 1988

NORINYL 1+50 21-DAY
AB WATSON LABS **0.05MG;1MG** **N13625 002**

ORTHO-NOVUM 1/50 21
AB + JOHNSON RW **0.05MG;1MG** **N12728 004**

TABLET; ORAL-28
NORETHIN 1/50M-28
AB WATSON LABS **0.05MG;1MG** **N71540 001** APR 12, 1988

NORETHINDRONE AND MESTRANOL
AB WATSON LABS **0.05MG;1MG** **N70759 001** JUL 01, 1988

NORINYL 1+50 28-DAY
AB SEARLE **0.05MG;1MG** **N16659 001**

ORTHO-NOVUM 1/50 28
AB JOHNSON RW **0.05MG;1MG** **N16709 001**

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION
ALUPENT
\+ BOEHRINGER INGELHEIM 0.65MG/INH N16402 001

SOLUTION; INHALATION
ALUPENT
AN + BOEHRINGER INGELHEIM **0.4%** **N18761 002** OCT 10, 1986
AN + **0.6%** **N18761 001** JUN 30, 1983

METAPROTERENOL SULFATE

SOLUTION; INHALATION
ALUPENT
\+ BOEHRINGER INGELHEIM 5% N17659 001
METAPROTERENOL SULFATE
AN ALPHARMA **0.4%** **N71855 001** JUL 14, 1988
AN **0.6%** **N71726 001** JUL 14, 1988
AN DEY **0.4%** **N71786 001** AUG 05, 1988
AN **0.6%** **N70804 001** AUG 17, 1987

SYRUP; ORAL
ALUPENT
AA + BOEHRINGER INGELHEIM **10MG/5ML** **N17571 001**
METAPROTERENOL SULFATE
AA COPLEY PHARM **10MG/5ML** **N73034 001** AUG 30, 1991
AA MORTON GROVE **10MG/5ML** **N74702 001** MAR 24, 1997
AA NOVEX **10MG/5ML** **N75235 001** JAN 27, 2000
AA SILARX **10MG/5ML** **N73632 001** JUL 22, 1992
AA TEVA **10MG/5ML** **N72761 001** FEB 27, 1992

TABLET; ORAL
ALUPENT
AB BOEHRINGER INGELHEIM **10MG** **N15874 002**
AB + **20MG** **N15874 001**
METAPROTERENOL SULFATE
AB DANBURY PHARMA **10MG** **N73013 001** JAN 31, 1991
AB **20MG** **N72795 001** JAN 31, 1991
AB PAR PHARM **10MG** **N72024 001** JUN 28, 1988
AB **20MG** **N72025 001** JUN 28, 1988
AB TEVA **10MG** **N72519 001** MAR 30, 1990
AB **20MG** **N72520 001** MAR 30, 1990

FDA data supplied by DrugPatentWatch.com

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

	ARAMINE			
AP	+ MERCK	**EQ 10MG BASE/ML**	**N09509 002**	
			DEC 22, 1987	
	METARAMINOL BITARTRATE			
AP	AM PHARM PARTNERS	**EQ 10MG BASE/ML**	**N80722 001**	

METAXALONE

TABLET; ORAL

	SKELAXIN		
	+ CARNRICK	400MG	N13217 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE		
	BRISTOL MYERS SQUIBB	500MG	N20357 001
			MAR 03, 1995
		850MG	N20357 002
			MAR 03, 1995
	+	1GM	N20357 005
			NOV 05, 1998

TABLET, EXTENDED RELEASE; ORAL

	GLUCOPHAGE XR		
	+ BRISTOL MYERS SQUIBB	500MG	N21202 001
			OCT 13, 2000

METFORMIN HYDROCHLORIDE; *MULTIPLE*
SEE GLYBURIDE; METFORMIN HYDROCHLORIDE

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

	PROVOCHOLINE		
	METHAPHARM	100MG/VIAL	N19193 001
			OCT 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

	METHADONE HCL		
AA	ROXANE	**10MG/ML**	**N40180 001**
			APR 30, 1998
AA	UDL	**10MG/ML**	**N40088 001**
			NOV 30, 1994
	METHADONE HCL INTENSOL		
AA	ROXANE	**10MG/ML**	**N89897 001**
			SEP 06, 1988
	METHADOSE		
AA	+ MALLINCKRODT	**10MG/ML**	**N17116 002**

INJECTABLE; INJECTION

	DOLOPHINE HCL		
	+ ROXANE	10MG/ML	N06134 006

POWDER; FOR RX COMPOUNDING

	METHADONE HCL		
	MALLINCKRODT	50GM/BOT	N06383 002
		100GM/BOT	N06383 003
		500GM/BOT	N06383 004

SOLUTION; ORAL

	METHADONE HCL		
	+ ROXANE	5MG/5ML	N87393 001
	+	10MG/5ML	N87997 001
			AUG 30, 1982

SYRUP; ORAL

	DOLOPHINE HCL		
	+ ROXANE	10MG/30ML	N06134 004

TABLET; ORAL

	DOLOPHINE HCL		
AA	+ ROXANE	**5MG**	**N06134 002**
AA	+	**10MG**	**N06134 010**
	METHADONE HCL		
AA	EON	**5MG**	**N40241 001**
			MAY 29, 1998
AA		**10MG**	**N40241 002**
			MAY 29, 1998
AA	ROXANE	**5MG**	**N88108 001**
			MAR 08, 1983
AA		**10MG**	**N88109 001**
			MAR 08, 1983
	METHADOSE		
AA	MALLINCKRODT	**5MG**	**N40050 001**
			APR 15, 1993

FDA data supplied by DrugPatentWatch.com

METHADONE HYDROCHLORIDE

TABLET; ORAL

	METHADOSE				
AA	MALLINCKRODT	10MG	N40050 002	APR 15, 1993	

TABLET, DISPERSIBLE; ORAL

	METHADONE HCL				
AA	EON	40MG	N75082 001	MAR 25, 1998	
AA	+ ROXANE	40MG	N17058 001		
AA		40MG	N74081 001	APR 28, 1995	
	METHADOSE				
AA	MALLINCKRODT	40MG	N74184 001	APR 29, 1993	

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	DESOXYN				
AA	+ ABBOTT	5MG	N05378 002		
	METHAMPHETAMINE HCL				
AA	REXAR	5MG	N84931 001		
		10MG	N84931 002		

TABLET, EXTENDED RELEASE; ORAL

	DESOXYN				
	+ ABBOTT	5MG	N05378 004		
	+	10MG	N05378 003		
	+	15MG	N05378 005		

METHANTHELINE BROMIDE

TABLET; ORAL

	BANTHINE				
	+ SHIRE	50MG	N07390 001		

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE				
AB	APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE				
AB	APPLIED ANAL	50MG	N40011 002	JUL 17, 1997	
AB	COPLEY PHARM	25MG	N40001 001	JUN 30, 1993	
AB		50MG	N40001 002	JUN 30, 1993	
AB	GENEVA PHARMS	25MG	N40036 001	JUN 30, 1993	
AB		50MG	N40036 002	JUN 30, 1993	
AB	INVAMED	25MG	N40102 001	AUG 28, 1996	
AB		50MG	N40102 002	AUG 28, 1996	
AB	MIKART	25MG	N40062 001	JAN 27, 1994	
AB		50MG	N40062 002	JAN 27, 1994	
	NEPTAZANE				
AB	LEDERLE	25MG	N11721 002	NOV 25, 1991	
AB	+	50MG	N11721 001		

METHENAMINE HIPPURATE

TABLET; ORAL

	HIPREX				
AB	+ AVENTIS PHARMS	1GM	N17681 001		
	UREX				
AB	3M	1GM	N16151 001		

METHIMAZOLE

TABLET; ORAL

	METHIMAZOLE				
AB	GENPHARM	5MG	N40350 001	MAR 29, 2000	
AB		10MG	N40350 002	MAR 29, 2000	
AB	JONES PHARMA	5MG	N40320 001	MAR 31, 2000	
AB		10MG	N40320 002	MAR 31, 2000	

FDA data supplied by DrugPatentWatch.com

METHIMAZOLE

TABLET; ORAL

	TAPAZOLE				
AB	LILLY	5MG	N07517	002	
AB	+	10MG	N07517	004	

METHOCARBAMOL

INJECTABLE; INJECTION

	METHOCARBAMOL				
AP	STERIS	100MG/ML	N86459	001	
	ROBAXIN				
AP	+ ROBINS AH	100MG/ML	N11790	001	

TABLET; ORAL

	METHOCARBAMOL				
AA	CHELSEA LABS	500MG	N85180	001	
AA		750MG	N85192	001	
AA	DANBURY PHARMA	500MG	N84277	001	
AA		750MG	N84276	002	
AA	EON	500MG	N87283	001	
AA		750MG	N87282	001	
AA	GENEVA PHARMS	500MG	N84616	001	
AA		750MG	N84615	001	
AA	IMPAX LABS	500MG	N84927	001	
AA		750MG	N84928	001	
AA	LANNETT	750MG	N84756	001	
AA	LEDERLE	500MG	N85961	001	
AA		750MG	N85963	001	
AA	NYLOS	750MG	N85033	001	
AA	PAR PHARM	500MG	N86989	001	
AA		750MG	N86988	001	
AA	SUPERPHARM	500MG	N87589	001	
			JAN 22, 1982		
AA		750MG	N87590	001	
			JAN 22, 1982		
AA	TABLICAPS	500MG	N84846	001	
AA	WEST WARD	500MG	N85159	001	
AA		750MG	N85123	001	
	ROBAXIN				
AA	+ ROBINS AH	500MG	N11011	004	
	ROBAXIN-750				
AA	+ ROBINS AH	750MG	N11011	006	

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

	BREVITAL SODIUM				
	+ LILLY	500MG/VIAL	N11559	001	
	+	2.5GM/VIAL	N11559	002	
	+	5GM/VIAL	N11559	003	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	FOLEX				
AP	PHARMACIA AND UPJOHN	**EQ 50MG BASE/VIAL**	**N87695**	**002**	
			APR 08, 1983		
AP		**EQ 100MG BASE/VIAL**	**N87695**	**003**	
			APR 08, 1983		
		EQ 25MG BASE/VIAL	N87695	001	
			APR 08, 1983		
		EQ 250MG BASE/VIAL	N88954	001	
			OCT 24, 1985		
	METHOTREXATE				
AP	BIGMAR	**EQ 25MG BASE/ML**	**N40263**	**001**	
			FEB 26, 1999		
	METHOTREXATE LPF				
AP	+ LEDERLE	**EQ 25MG BASE/ML**	**N11719**	**007**	
			MAR 31, 1982		
	METHOTREXATE PRESERVATIVE FREE				
AP	BIGMAR	**EQ 1GM BASE/VIAL**	**N40266**	**001**	
			FEB 26, 1999		
AP		**EQ 25MG BASE/ML**	**N40265**	**001**	
			FEB 26, 1999		
	METHOTREXATE SODIUM				
AP	BEDFORD	**EQ 25MG BASE/ML**	**N89340**	**001**	
			SEP 16, 1986		
AP		**EQ 25MG BASE/ML**	**N89341**	**001**	
			SEP 16, 1986		
AP		**EQ 25MG BASE/ML**	**N89342**	**001**	
			SEP 16, 1986		
AP		**EQ 25MG BASE/ML**	**N89343**	**001**	
			SEP 16, 1986		
AP	+ LEDERLE	**EQ 25MG BASE/ML**	**N11719**	**005**	
AP	+	**EQ 50MG BASE/VIAL**	**N11719**	**003**	
AP	+	**EQ 100MG BASE/VIAL**	**N11719**	**006**	
	+	EQ 2.5MG BASE/ML	N11719	004	
	+	EQ 20MG BASE/VIAL	N11719	001	
AP	NORBROOK	**EQ 25MG BASE/ML**	**N88648**	**001**	
			MAY 09, 1986		

FDA data supplied by DrugPatentWatch.com

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE SODIUM			
AP	PHARMACHEMIE USA	**EQ 25MG BASE/ML**	**N89158 001**	JUL 08, 1988
	METHOTREXATE SODIUM PRESERVATIVE FREE			
AP +	LEDERLE	**EQ 1GM BASE/VIAL**	**N11719 009**	APR 07, 1988
	MEXATE-AQ			
AP	BRISTOL MYERS	**EQ 25MG BASE/ML**	**N88760 001**	FEB 14, 1985

TABLET; ORAL

	METHOTREXATE SODIUM			
AB	BARR	**EQ 2.5MG BASE**	**N81099 001**	OCT 15, 1990
AB	DURAMED	**EQ 2.5MG BASE**	**N40233 001**	JUN 17, 1999
AB +	LEDERLE	**EQ 2.5MG BASE**	**N08085 002**	
AB	MYLAN	**EQ 2.5MG BASE**	**N81235 001**	MAY 15, 1992
AB	ROXANE	**EQ 2.5MG BASE**	**N40054 001**	AUG 01, 1994

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	VASOXYL		
+	GLAXO WELLCOME	20MG/ML	N06772 001

METHOXSALEN

CAPSULE; ORAL

	8-MOP			
+	ICN	10MG	N09048 001	
	OXSORALEN-ULTRA			
+	ICN	10MG	N19600 001	OCT 30, 1986

INJECTABLE; INJECTION

	UVADEX		
+	THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

LOTION; TOPICAL

	OXSORALEN		
+	ICN	1%	N09048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

	METHSCOPOLAMINE BROMIDE			
AA	PVT FORM	**2.5MG**	**N80970 001**	
	PAMINE			
AA +	BRADLEY PHARMS	**2.5MG**	**N08848 001**	

METHSUXIMIDE

CAPSULE; ORAL

	CELONTIN		
	PARKE DAVIS	150MG	N10596 007
+		300MG	N10596 008

METHYCLOTHIAZIDE

TABLET; ORAL

	AQUATENSEN			
AB	WALLACE LABS	**5MG**	**N17364 001**	
	ENDURON			
AB	ABBOTT	**2.5MG**	**N12524 001**	
AB +		**5MG**	**N12524 004**	
	METHYCLOTHIAZIDE			
AB	CHELSEA LABS	**5MG**	**N88724 001**	SEP 06, 1984
AB	GENEVA PHARMS	**2.5MG**	**N89835 001**	AUG 18, 1988
AB		**5MG**	**N89837 001**	AUG 18, 1988
AB	MYLAN	**5MG**	**N87672 001**	AUG 17, 1982
AB	PAR PHARM	**2.5MG**	**N89135 001**	FEB 12, 1986
AB		**5MG**	**N89136 001**	FEB 12, 1986
AB	ZENITH GOLDLINE	**2.5MG**	**N87913 001**	JUN 03, 1982

METHYCLOTHIAZIDE; *MULTIPLE*
SEE DESERPIDINE; METHYCLOTHIAZIDE

FDA data supplied by DrugPatentWatch.com

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

	DIUTENSEN-R			
+	WALLACE LABS	2.5MG;0.1MG		N12708 005

METHYLDOPA

SUSPENSION; ORAL

	ALDOMET			
+	MERCK	250MG/5ML		N18389 001

TABLET; ORAL

	ALDOMET			
AB	MERCK	125MG		N13400 003
AB		250MG		N13400 001
AB	+	500MG		N13400 002
	METHYLDOPA			
AB	DANBURY PHARMA	250MG		N70703 001 JUN 06, 1986
AB		500MG		N70625 001 JUN 06, 1986
AB	GENEVA PHARMS	125MG		N71700 001 MAR 02, 1988
AB		250MG		N18934 001 JUN 29, 1984
AB		500MG		N18934 002 JUN 29, 1984
AB	LEDERLE	125MG		N70070 003 OCT 15, 1985
AB		250MG		N70084 001 OCT 15, 1985
AB		500MG		N70085 001 OCT 15, 1985
AB	MYLAN	250MG		N70075 001 APR 18, 1985
AB		500MG		N70076 001 APR 18, 1985
AB	PAR PHARM	125MG		N70535 001 JAN 02, 1987
AB		250MG		N70536 001 JAN 02, 1987
AB		500MG		N70537 001 JAN 02, 1987
AB	SIDMAK LABS NJ	125MG		N72126 001 JUL 07, 1988
AB		250MG		N72127 001 JUL 07, 1988

METHYLDOPA

TABLET; ORAL

	METHYLDOPA			
AB	SIDMAK LABS NJ	500MG		N72128 001 JUL 07, 1988
AB	SUPERPHARM	250MG		N70669 001 JUN 23, 1989
AB		500MG		N70670 001 JUN 23, 1989
AB	ZENITH GOLDLINE	250MG		N70098 001 FEB 20, 1986
AB		500MG		N70343 001 FEB 20, 1986

METHYLDOPA; *MULTIPLE*

SEE CHLOROTHIAZIDE; METHYLDOPA

SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	ALDOMET			
AP	+ MERCK	50MG/ML		N13401 001
	METHYLDOPATE HCL			
AP	ABBOTT	50MG/ML		N70698 001 JUN 15, 1987
AP		50MG/ML		N70699 001 JUN 15, 1987
AP	ELKINS SINN	50MG/ML		N70291 001 JUL 01, 1986
AP	GENSIA SICOR PHARMS	50MG/ML		N72974 001 NOV 22, 1991
AP	LUITPOLD	50MG/ML		N71279 001 OCT 02, 1987

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

	METHERGINE			
+	NOVARTIS	0.2MG/ML		N06035 004

TABLET; ORAL

	METHERGINE			
	NOVARTIS	0.2MG		N06035 003

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	METHYLPHENIDATE HCL				
AB	DANBURY PHARMA	**5MG**	**N40220 001**		
			AUG 29, 1997		
AB		**10MG**	**N40220 002**		
			AUG 29, 1997		
AB		**20MG**	**N40220 003**		
			AUG 29, 1997		
AB	MALLINCKRODT	**5MG**	**N40300 001**		
			NOV 27, 1998		
AB		**10MG**	**N40300 002**		
			NOV 27, 1998		
AB		**20MG**	**N40300 003**		
			NOV 27, 1998		
AB	MD PHARM	**5MG**	**N86429 001**		
AB		**10MG**	**N85799 001**		
AB		**20MG**	**N86428 001**		
	RITALIN				
AB	NOVARTIS	**5MG**	**N10187 003**		
AB		**10MG**	**N10187 006**		
AB	+	**20MG**	**N10187 010**		

TABLET, EXTENDED RELEASE; ORAL

	CONCERTA				
	+ ALZA	18MG	N21121 001		
			AUG 01, 2000		
	+	36MG	N21121 002		
			AUG 01, 2000		
	+	54MG	N21121 003		
			DEC 08, 2000		
	METADATE ER				
AB	+ MEDEVA	**10MG**	**N40306 001**		
			OCT 20, 1999		
AB	+ MEDEVA PHARMS CA	**20MG**	**N89601 001**		
			JUN 01, 1988		
	METHYLIN ER				
AB	MALLINCKRODT	**10MG**	**N75629 001**		
			MAY 09, 2000		
AB		**20MG**	**N75629 002**		
			MAY 09, 2000		
	RITALIN-SR				
AB	NOVARTIS	**20MG**	**N18029 001**		
			MAR 30, 1982		

METHYLPREDNISOLONE

TABLET; ORAL

	MEDROL				
AB	PHARMACIA AND UPJOHN	**4MG**	**N11153 001**		
AB		**8MG**	**N11153 004**		
AB		**16MG**	**N11153 003**		
AB		**24MG**	**N11153 005**		
AB	+	**32MG**	**N11153 006**		
		2MG	N11153 002		
	METHYLPREDNISOLONE				
AB	CHELSEA LABS	**4MG**	**N40232 001**		
			OCT 16, 1997		
AB	DURAMED	**4MG**	**N88497 001**		
			FEB 21, 1984		
AB	GENEVA PHARMS TECH	**4MG**	**N40194 001**		
			OCT 31, 1997		
AB	PAR PHARM	**16MG**	**N89207 001**		
			APR 25, 1988		
AB		**24MG**	**N89208 001**		
			APR 25, 1988		
AB		**32MG**	**N89209 001**		
			APR 25, 1988		
AB	TRIGEN	**4MG**	**N40189 001**		
			OCT 31, 1997		
AB		**8MG**	**N40189 002**		
			OCT 31, 1997		
AB	VINTAGE PHARMS	**4MG**	**N40183 001**		
			DEC 22, 1998		

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

	DEPO-MEDROL				
BP	PHARMACIA AND UPJOHN	20MG/ML	N11757 002		
BP		40MG/ML	N11757 001		
BP	+	80MG/ML	N11757 004		
	METHYLPREDNISOLONE ACETATE				
BP	STERIS	20MG/ML	N85597 001		
BP		40MG/ML	N85600 001		
BP		80MG/ML	N85595 001		

OINTMENT; TOPICAL

	MEDROL ACETATE				
	+ PHARMACIA AND UPJOHN	0.25%	N12421 001		

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-MEDROL ACETATE
+ PHARMACIA AND UPJOHN 0.25%;EQ 3.5MG BASE/GM N60611 002
1%;EQ 3.5MG BASE/GM N60611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED
AP ABBOTT **EQ 1GM BASE/VIAL** **N85852 001**
AP **EQ 1GM BASE/VIAL** **N89174 001**
AUG 18, 1987
AP **EQ 40MG BASE/VIAL** **N85853 001**
AP **EQ 125MG BASE/VIAL** **N85855 001**
AP **EQ 500MG BASE/VIAL** **N85854 001**
AP **EQ 500MG BASE/VIAL** **N89173 001**
AUG 18, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE
AP GENSIA SICOR PHARMS **EQ 1GM BASE/VIAL** **N81268 001**
NOV 30, 1992
AP **EQ 125MG BASE/VIAL** **N81266 001**
NOV 30, 1992
AP **EQ 500MG BASE/VIAL** **N81267 001**
NOV 30, 1992

SOLU-MEDROL
AP + PHARMACIA AND UPJOHN **EQ 40MG BASE/VIAL** **N11856 003**
AP + **EQ 125MG BASE/VIAL** **N11856 004**
AP + **EQ 500MG BASE/VIAL** **N11856 005**
AP + **EQ 1GM BASE/VIAL** **N11856 006**
+ EQ 2GM BASE/VIAL N11856 007
FEB 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL
TESTRED
BP + ICN 10MG N83976 001
VIRILON
BP STAR PHARMS FL 10MG N87750 001
NOV 24, 1982

TABLET; BUCCAL
ORETON
+ SCHERING 10MG N80281 001

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
BP IMPAX LABS 10MG N84287 001
BP + LILLY 10MG N80256 001

TABLET; ORAL
ANDROID 10
AB ICN **10MG** **N86450 001**
ANDROID 25
AB + ICN **25MG** **N87147 001**
METHYLTESTOSTERONE
BP IMPAX LABS 10MG N80767 002
BP 25MG N84310 001
BP LANNETT 10MG N87092 001
NOV 05, 1982
BP 25MG N87111 001
JAN 27, 1983
BP LILLY 25MG N80256 002

METHYSERGIDE MALEATE

TABLET; ORAL
SANSERT
+ NOVARTIS 2MG N12516 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIPRANOLOL
+ BAUSCH AND LOMB 0.3% N19907 001
DEC 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL
METOCLOPRAMIDE INTENSOL
ROXANE EQ 10MG BASE/ML N72995 001
JAN 30, 1992

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
AP ABBOTT **EQ 5MG BASE/ML** **N70505 001**
JUN 23, 1989

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989
AP		EQ 5MG BASE/ML	N73117 001	JAN 17, 1991
AP		EQ 5MG BASE/ML	N73118 001	JAN 17, 1991
AP		EQ 5MG BASE/ML	N74147 001	AUG 02, 1996
AP	FAULDING	EQ 5MG BASE/ML	N70847 001	NOV 07, 1988
AP		EQ 5MG BASE/ML	N71291 001	MAR 03, 1989
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N73135 001	NOV 27, 1991
	REGLAN			
AP	+ ROBINS AH	EQ 5MG BASE/ML	N17862 001	

SOLUTION; ORAL

	METOCLOPRAMIDE			
AA	JVL	EQ 5MG BASE/5ML	N74703 001	OCT 31, 1997
	METOCLOPRAMIDE HCL			
AA	ALPHARMA	EQ 5MG BASE/5ML	N71340 001	AUG 18, 1988
AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993
AA	PHARM ASSOC	EQ 5MG BASE/5ML	N72744 001	MAY 28, 1991
AA	ROXANE	EQ 5MG BASE/5ML	N72038 001	DEC 05, 1988
AA	SILARX	EQ 5MG BASE/5ML	N73680 001	OCT 27, 1992
AA	TEVA	EQ 5MG BASE/5ML	N70819 001	JUL 10, 1987
AA		EQ 5MG BASE/5ML	N71315 001	JUN 30, 1993
	REGLAN			
AA	+ ROBINS AH	EQ 5MG BASE/5ML	N18821 001	MAR 25, 1983

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	DANBURY PHARMA	EQ 10MG BASE	N70511 001	JAN 22, 1986

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	GENEVA PHARMS	EQ 10MG BASE	N72215 001	JAN 30, 1990
AB	INVAMED	EQ 5MG BASE	N74478 001	OCT 05, 1995
AB		EQ 10MG BASE	N74478 002	OCT 05, 1995
AB	LEDERLE	EQ 10MG BASE	N72639 001	MAY 09, 1991
AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997
AB		EQ 10MG BASE	N71536 001	APR 28, 1993
AB	PUREPAC PHARM	EQ 10MG BASE	N70581 001	OCT 17, 1985
AB	SIDMAK LABS NJ	EQ 5MG BASE	N72750 001	DEC 28, 1995
AB		EQ 10MG BASE	N71250 001	FEB 03, 1988
AB	TEVA	EQ 5MG BASE	N72801 001	JUN 15, 1993
AB		EQ 10MG BASE	N70184 001	JUL 29, 1985
	REGLAN			
AB	ROBINS AH	EQ 5MG BASE	N17854 002	MAY 05, 1987
AB	+	EQ 10MG BASE	N17854 001	

METOCURINE IODIDE

INJECTABLE; INJECTION

	METUBINE IODIDE		
+	LILLY	2MG/ML	N06632 003

METOLAZONE

TABLET; ORAL

	MYKROX		
+	MEDEVA	0.5MG	N19532 001 OCT 30, 1987
	ZAROXOLYN		
+	MEDEVA	2.5MG	N17386 001
		5MG	N17386 002
+		10MG	N17386 003

FDA data supplied by DrugPatentWatch.com

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

	TOPROL-XL				
+	ASTRAZENECA	EQ 50MG TARTRATE	N19962 001 JAN 10, 1992		
+		EQ 100MG TARTRATE	N19962 002 JAN 10, 1992		
+		EQ 200MG TARTRATE	N19962 003 JAN 10, 1992		

METOPROLOL TARTRATE

INJECTABLE; INJECTION

	LOPRESSOR				
AP	+ NOVARTIS	**1MG/ML**	**N18704 001** MAR 30, 1984		
	METOPROLOL TARTRATE				
AP	ABBOTT	**1MG/ML**	**N74133 001** DEC 21, 1993		
AP		**1MG/ML**	**N75160 001** JUL 06, 1998		
AP	STERIS	**1MG/ML**	**N74032 001** DEC 21, 1993		

TABLET; ORAL

	LOPRESSOR				
AB	NOVARTIS	**50MG**	**N17963 001**		
AB	+	**100MG**	**N17963 002**		
	METOPROLOL TARTRATE				
AB	APOTHECON	**50MG**	**N74258 001** JAN 27, 1994		
AB		**100MG**	**N74258 002** JAN 27, 1994		
AB	CARACO	**50MG**	**N74644 001** DEC 10, 1996		
AB		**100MG**	**N74644 002** DEC 10, 1996		
AB	COPLEY PHARM	**50MG**	**N74333 001** JAN 27, 1994		
AB		**100MG**	**N74333 002** JAN 27, 1994		
AB	GENEVA PHARMS	**50MG**	**N73288 001** MAR 25, 1994		
AB		**100MG**	**N73289 001** MAR 25, 1994		
AB	MUTUAL PHARM	**50MG**	**N73653 001** DEC 21, 1993		

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE				
AB	MUTUAL PHARM	**100MG**	**N73654 001** DEC 21, 1993		
AB	MYLAN	**50MG**	**N73666 001** DEC 21, 1993		
AB		**100MG**	**N73666 002** DEC 21, 1993		
AB	NOVOPHARM	**50MG**	**N74143 001** SEP 30, 1994		
AB		**100MG**	**N74143 002** SEP 30, 1994		
AB	PAR PHARM	**50MG**	**N74453 001** APR 27, 1995		
AB		**100MG**	**N74453 002** APR 27, 1995		
AB	TEVA	**50MG**	**N74141 001** JAN 31, 1995		
AB		**100MG**	**N74141 002** JAN 31, 1995		
AB	WATSON LABS	**50MG**	**N74217 001** MAY 27, 1994		
AB		**100MG**	**N74217 002** MAY 27, 1994		

METOPROLOL TARTRATE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

METRONIDAZOLE

CAPSULE; ORAL

	FLAGYL		
+	SEARLE	375MG	N20334 001 MAY 03, 1995

CREAM; TOPICAL

	METROCREAM		
+	GALDERMA LABS LP	0.75%	N20531 001 SEP 20, 1995
	NORITATE		
+	DERMIK LABS	1%	N20743 001 SEP 26, 1997

GEL; TOPICAL

	METROGEL		
+	GALDERMA LABS LP	0.75%	N19737 001 NOV 22, 1988

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE

GEL; VAGINAL

METROGEL-VAGINAL

+	3M	0.75%	N20208 001	AUG 17, 1992

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	**500MG/100ML**	**N18657 001**	
AP	+ SCS	**500MG/100ML**	**N18353 002**	

METRO I.V.

AP	+ B BRAUN	**500MG/100ML**	**N18674 001**	AUG 31, 1982

METRO I.V. IN PLASTIC CONTAINER

AP	+ B BRAUN	**500MG/100ML**	**N18900 001**	SEP 29, 1983

METRONIDAZOLE

AP	+ ABBOTT	**500MG/100ML**	**N18889 001**	NOV 18, 1983
AP	+ ELKINS SINN	**500MG/100ML**	**N18907 001**	MAR 30, 1984

METRONIDAZOLE IN PLASTIC CONTAINER

AP	+ ABBOTT	**500MG/100ML**	**N18890 002**	NOV 18, 1983

LOTION; TOPICAL

METROLOTION

+	GALDERMA LABS LP	0.75%	N20901 001	NOV 24, 1998

TABLET; ORAL

FLAGYL

AB	SEARLE	**250MG**	**N12623 001**	
AB	+	**500MG**	**N12623 003**	

METROMIDOL

AB	LABS AF	**250MG**	**N74523 001**	OCT 24, 1996
AB		**500MG**	**N74523 002**	OCT 24, 1996

METRONIDAZOLE

AB	DANBURY PHARMA	**250MG**	**N18764 001**	SEP 17, 1982
AB		**500MG**	**N18764 002**	DEC 20, 1982
AB	EON	**250MG**	**N18620 001**	MAR 04, 1982
AB		**500MG**	**N18620 002**	JUN 02, 1983

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB	GENEVA PHARMS	**250MG**	**N18740 001**	OCT 22, 1982
AB		**500MG**	**N18740 002**	OCT 22, 1982
AB	LNK	**250MG**	**N19029 001**	APR 10, 1984
AB	MUTUAL PHARM	**250MG**	**N70772 001**	JUL 16, 1986
AB		**500MG**	**N70773 001**	JUL 16, 1986
AB	PAR PHARM	**250MG**	**N18845 001**	AUG 18, 1983
AB		**250MG**	**N70040 001**	JAN 29, 1985
AB		**500MG**	**N18930 001**	AUG 18, 1983
AB		**500MG**	**N70039 001**	JAN 29, 1985
AB	SIDMAK LABS NJ	**250MG**	**N70027 001**	NOV 06, 1984
AB		**500MG**	**N70033 001**	DEC 06, 1984
AB	TEVA	**250MG**	**N70035 001**	DEC 20, 1984
AB		**500MG**	**N70044 001**	FEB 08, 1985
AB	ZENITH GOLDLINE	**250MG**	**N18517 001**	MAY 05, 1982
AB		**500MG**	**N18517 002**	MAY 05, 1982

PROTOSTAT

AB	JOHNSON RW	**250MG**	**N18871 001**	MAR 02, 1983
AB		**500MG**	**N18871 002**	MAR 02, 1983

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+	SEARLE	750MG	N20868 001	NOV 26, 1997

METRONIDAZOLE; *MULTIPLE*

SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.
+ SCS — EQ 500MG BASE/VIAL — N18353 001

METYRAPONE

CAPSULE; ORAL
METOPIRONE
+ NOVARTIS — 250MG — N12911 002 AUG 09, 1996

METYROSINE

CAPSULE; ORAL
DEMSER
+ MERCK — 250MG — N17871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	**150MG**	**N74865 001**	APR 13, 1998
AB		**200MG**	**N74865 002**	APR 13, 1998
AB		**250MG**	**N74865 003**	APR 13, 1998
AB	GENEVA PHARMS	**150MG**	**N74450 001**	MAY 16, 1996
AB		**200MG**	**N74450 002**	MAY 16, 1996
AB		**250MG**	**N74450 003**	MAY 16, 1996
AB	NOVOPHARM	**150MG**	**N74377 001**	MAY 16, 1995
AB		**200MG**	**N74377 002**	MAY 16, 1995
AB		**250MG**	**N74377 003**	MAY 16, 1995
AB	WATSON LABS	**150MG**	**N74711 001**	FEB 26, 1997
AB		**200MG**	**N74711 002**	FEB 26, 1997

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	**250MG**	**N74711 003**	FEB 26, 1997

MEXITIL

AB	BOEHRINGER INGELHEIM	**150MG**	**N18873 002**	DEC 30, 1985
AB		**200MG**	**N18873 003**	DEC 30, 1985
AB	+	**250MG**	**N18873 004**	DEC 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN

+ BAYER	EQ 1GM BASE/VIAL	N50549 001	
	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983
+	EQ 2GM BASE/VIAL	N50549 002	
	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982
+	EQ 3GM BASE/VIAL	N50549 003	
	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982
	EQ 3GM BASE/VIAL	N62697 001	JAN 22, 1987
+	EQ 4GM BASE/VIAL	N50549 004	
	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982
	EQ 4GM BASE/VIAL	N62697 002	JAN 22, 1987
+	EQ 20GM BASE/VIAL	N50549 005	MAR 02, 1988
	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM
+ JOHNSON AND JOHNSON — 2% — N17494 001

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK
+ PERSONAL PRODS — 1.2GM,2% — N20968 001 JUN 30, 1999

FDA data supplied by DrugPatentWatch.com

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

	MICONAZOLE NITRATE			
AB	ALPHARMA US PHARM	**200MG**	**N73508 001**	NOV 19, 1993
	MONISTAT 3			
AB	+ JOHNSON RW	**200MG**	**N18888 001**	AUG 15, 1984

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

	MIDAZOLAM HCL			
AP	ABBOTT	**EQ 1MG BASE/ML**	**N75293 001**	JUN 20, 2000
AP		**EQ 1MG BASE/ML**	**N75409 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75293 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75409 001**	JUN 20, 2000
AP	AESGEN	**EQ 1MG BASE/ML**	**N75154 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75154 001**	JUN 20, 2000
AP	APOTEX	**EQ 1MG BASE/ML**	**N75637 001**	OCT 31, 2000
AP		**EQ 5MG BASE/ML**	**N75637 002**	OCT 31, 2000
AP	APOTHECON	**EQ 1MG BASE/ML**	**N75620 001**	NOV 01, 2000
AP		**EQ 5MG BASE/ML**	**N75620 002**	NOV 01, 2000
AP		**EQ 5MG BASE/ML**	**N75641 001**	OCT 19, 2000
AP	ASTRAZENECA	**EQ 5MG BASE/ML**	**N75263 001**	JUN 26, 2000
AP	BAXTER PHARM PROD	**EQ 1MG BASE/ML**	**N75324 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75324 002**	JUN 20, 2000
AP	BEDFORD	**EQ 1MG BASE/ML**	**N75247 002**	JUN 23, 2000
AP		**EQ 5MG BASE/ML**	**N75247 001**	JUN 23, 2000
AP		**EQ 5MG BASE/ML**	**N75249 001**	JUN 23, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

	MIDAZOLAM HCL			
AP	BEN VENUE	**EQ 1MG BASE/ML**	**N75421 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75421 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75455 001**	JUN 20, 2000
AP	ESI LEDERLE	**EQ 1MG BASE/ML**	**N75243 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75243 002**	JUN 20, 2000
AP	FAULDING	**EQ 1MG BASE/ML**	**N75396 001**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75396 002**	JUN 20, 2000
AP		**EQ 5MG BASE/ML**	**N75484 001**	JUN 20, 2000
AP	TAYLOR	**EQ 5MG BASE/ML**	**N75481 001**	JUN 30, 2000
AP	TAYLOR PHARMA	**EQ 1MG BASE/ML**	**N75494 001**	JUN 30, 2000
AP		**EQ 5MG BASE/ML**	**N75494 002**	JUN 30, 2000
	VERSED			
AP	+ HLR	**EQ 1MG BASE/ML**	**N18654 002**	MAY 26, 1987
AP	+	**EQ 5MG BASE/ML**	**N18654 001**	DEC 20, 1985

SYRUP; ORAL

	VERSED			
	+ ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

	PROAMATINE			
	ROBERTS LABS	2.5MG	N19815 001	SEP 06, 1996
	+	5MG	N19815 002	SEP 06, 1996

FDA data supplied by DrugPatentWatch.com

MIFEPRISTONE

TABLET; ORAL
MIFEPREX
+ POPULATION COUNCIL 200MG N20687 001 SEP 28, 2000

MIGLITOL

TABLET; ORAL
GLYSET
PHARMACIA AND UPJOHN 25MG N20682 001 DEC 18, 1996
50MG N20682 002 DEC 18, 1996
+ 100MG N20682 003 DEC 18, 1996

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR
+ SANOFI SYNTHELABO EQ 1MG BASE/ML N19436 001 DEC 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
+ SANOFI SYNTHELABO EQ 20MG BASE/100ML N20343 003 AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN
AB LEDERLE **EQ 50MG BASE** **N50649 001** MAY 31, 1990
AB **EQ 100MG BASE** **N50649 002** MAY 31, 1990

MINOCYCLINE HCL
AB DANBURY PHARMA **EQ 50MG BASE** **N63181 001** DEC 30, 1991
AB **EQ 75MG BASE** **N63065 002** JUN 10, 1999
AB + **EQ 100MG BASE** **N63065 001** DEC 30, 1991
AB IMPAX LABS **EQ 50MG BASE** **N65005 001** MAR 23, 1999

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL
AB IMPAX LABS **EQ 100MG BASE** **N65005 002** MAR 23, 1999
AB RANBAXY **EQ 50MG BASE** **N65062 001** NOV 30, 2000
AB **EQ 75MG BASE** **N65062 002** NOV 30, 2000
AB **EQ 100MG BASE** **N65062 003** NOV 30, 2000
AB TEVA **EQ 50MG BASE** **N63011 001** MAR 02, 1992
AB **EQ 100MG BASE** **N63009 001** MAR 02, 1992

VECTRIN
AB MEDICIS **EQ 50MG BASE** **N63066 001** AUG 14, 1990
AB **EQ 75MG BASE** **N63067 002** SEP 15, 1999
AB **EQ 100MG BASE** **N63067 001** JUL 31, 1990

INJECTABLE; INJECTION
MINOCIN
+ LEDERLE EQ 100MG BASE/VIAL N50444 001

SUSPENSION; ORAL
MINOCIN
+ LEDERLE EQ 50MG BASE/5ML N50445 001

MINOXIDIL

TABLET; ORAL
LONITEN
AB PHARMACIA AND UPJOHN **2.5MG** **N18154 001**
AB + **10MG** **N18154 003**

MINOXIDIL
AB DANBURY PHARMA **2.5MG** **N71344 001** MAR 03, 1987
AB **10MG** **N71345 001** MAR 03, 1987
AB MUTUAL PHARM **2.5MG** **N72708 001** DEC 14, 1995
AB **10MG** **N72709 001** DEC 14, 1995

FDA data supplied by DrugPatentWatch.com

MINOXIDIL

TABLET; ORAL
MINOXIDIL

AB	PAR PHARM	2.5MG	N71826 001	NOV 14, 1988
AB		10MG	N71839 001	NOV 14, 1988

MIRTAZAPINE

TABLET; ORAL
REMERON

+	ORGANON	15MG	N20415 001	JUN 14, 1996
		30MG	N20415 002	JUN 14, 1996
		45MG	N20415 003	MAR 17, 1997

MISOPROSTOL

TABLET; ORAL
CYTOTEC

	SEARLE	0.1MG	N19268 003	SEP 21, 1990
+		0.2MG	N19268 001	DEC 27, 1988

MISOPROSTOL; *MULTIPLE*
SEE DICLOFENAC SODIUM; MISOPROSTOL

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	BEDFORD	5MG/VIAL	N64117 001	APR 19, 1995
AP		20MG/VIAL	N64117 002	APR 19, 1995
AP	ESI LEDERLE	5MG/VIAL	N64180 001	DEC 23, 1999
AP		20MG/VIAL	N64180 002	DEC 23, 1999

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	FAULDING	20MG/VIAL	N64106 001	NOV 29, 1995
AP	SUPERGEN	5MG/VIAL	N64144 001	APR 30, 1998
AP		20MG/VIAL	N64144 002	APR 30, 1998

MUTAMYCIN

AP	+ BRISTOL MYERS	5MG/VIAL	N62336 001	
AP	+	20MG/VIAL	N62336 002	
	+	40MG/VIAL	N62336 003	MAR 10, 1988

MITOTANE

TABLET; ORAL
LYSODREN

+	BRISTOL	500MG	N16885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVANTRONE

+	IMMUNEX	EQ 2MG BASE/ML	N19297 001	DEC 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON

+	ABBOTT	EQ 2MG BASE/ML	N20098 001	JAN 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ABBOTT	EQ 0.5MG BASE/ML	N20098 002	JAN 22, 1992
+		EQ 50MG BASE/100ML	N20098 003	JAN 22, 1992

FDA data supplied by DrugPatentWatch.com

MODAFINIL

TABLET; ORAL			
PROVIGIL			
CEPHALON	100MG		N20717 001 DEC 24, 1998
+	200MG		N20717 002 DEC 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL			
UNIVASC			
SCHWARZ PHARMA	7.5MG		N20312 001 APR 19, 1995
+	15MG		N20312 002 APR 19, 1995

MOEXIPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL			
MOBAN			
+ ENDO PHARMS	20MG/ML		N17938 001
TABLET; ORAL			
MOBAN			
ENDO PHARMS	5MG		N17111 004
	10MG		N17111 005
+	25MG		N17111 006
	50MG		N17111 007
+	100MG		N17111 008

MOMETASONE FUROATE

CREAM; TOPICAL			
ELOCON			
+ SCHERING	0.1%		N19625 001 MAY 06, 1987
LOTION; TOPICAL			
ELOCON			
+ SCHERING	0.1%		N19796 001 MAR 30, 1989

MOMETASONE FUROATE

OINTMENT; TOPICAL			
ELOCON			
+ SCHERING	0.1%		N19543 001 APR 30, 1987

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL			
NASONEX			
+ SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY		N20762 001 OCT 01, 1997

MONOBENZONE

CREAM; TOPICAL			
BENOQUIN			
+ ICN	20%		N08173 003

MONOCTANOIN

LIQUID; PERFUSION, BILIARY			
MOCTANIN			
ETHITEK	100%		N19368 001 OCT 29, 1985

MONTELUKAST SODIUM

TABLET; ORAL			
SINGULAIR			
+ MERCK	EQ 10MG BASE		N20829 002 FEB 20, 1998
TABLET, CHEWABLE; ORAL			
SINGULAIR			
MERCK	EQ 4MG BASE		N20830 002 MAR 03, 2000
+	EQ 5MG BASE		N20830 001 FEB 20, 1998

FDA data supplied by DrugPatentWatch.com

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

	ETHMOZINE			
	SHIRE	200MG	N19753 001	JUN 19, 1990
		250MG	N19753 002	JUN 19, 1990
+		300MG	N19753 003	JUN 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	KADIAN			
+	FAULDING	20MG	N20616 001	JUL 03, 1996
+		50MG	N20616 002	JUL 03, 1996
+		100MG	N20616 003	JUL 03, 1996

INJECTABLE; INJECTION

	ASTRAMORPH PF			
AP	ASTRAZENECA	**0.5MG/ML**	**N71050 001**	OCT 07, 1986
AP		**0.5MG/ML**	**N71051 001**	OCT 07, 1986
AP		**1MG/ML**	**N71052 001**	OCT 07, 1986
AP		**1MG/ML**	**N71053 001**	OCT 07, 1986
	DURAMORPH PF			
AP	+ ELKINS SINN	**0.5MG/ML**	**N18565 001**	SEP 18, 1984
AP	+	**1MG/ML**	**N18565 002**	SEP 18, 1984
	INFUMORPH			
+	ELKINS SINN	10MG/ML	N18565 003	JUL 19, 1991
+		25MG/ML	N18565 004	JUL 19, 1991
	MORPHINE SULFATE			
AP	+ ABBOTT	**0.5MG/ML**	**N19917 001**	OCT 30, 1992
AP		**0.5MG/ML**	**N71849 001**	MAY 11, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION

	MORPHINE SULFATE			
AP	ABBOTT	**0.5MG/ML**	**N73509 001**	SEP 30, 1992
AP	+	**1MG/ML**	**N19916 001**	OCT 30, 1992
AP		**1MG/ML**	**N71850 001**	MAY 11, 1988
AP		**1MG/ML**	**N73510 001**	SEP 30, 1992
AP	MALLINCKRODT	**1MG/ML**	**N20631 001**	JUL 03, 1996
+		2MG/ML	N20631 002	JUL 03, 1996
+	MERIDIAN MEDCL TECHN	15MG/ML	N19999 001	JUL 12, 1990
AP	STERIS	**0.5MG/ML**	**N73373 001**	SEP 30, 1991
AP		**0.5MG/ML**	**N73375 001**	SEP 30, 1991
AP		**1MG/ML**	**N73374 001**	SEP 30, 1991
AP		**1MG/ML**	**N73376 001**	SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	AB GENERICS	**15MG**	**N74862 001**	JUL 07, 1998
AB		**30MG**	**N74862 002**	JUL 07, 1998
AB		**60MG**	**N74862 003**	JUL 07, 1998
AB		**100MG**	**N74769 001**	JUL 02, 1998
AB		**200MG**	**N74769 002**	JUL 02, 1998
AB	ENDO PHARMS	**15MG**	**N75295 001**	OCT 28, 1998
AB		**30MG**	**N75295 002**	OCT 28, 1998
AB		**60MG**	**N75295 003**	OCT 28, 1998
AB		**100MG**	**N75295 004**	SEP 15, 2000
AB		**200MG**	**N75295 005**	SEP 15, 2000

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	ESI LEDERLE	**15MG**	**N75407 001**	JAN 28, 2000
	MS CONTIN			
AB	+ PURDUE FREDERICK	**15MG**	**N19516 003**	SEP 12, 1989
AB	+	**30MG**	**N19516 001**	MAY 29, 1987
AB	+	**60MG**	**N19516 002**	APR 08, 1988
AB	+	**100MG**	**N19516 004**	JAN 16, 1990
AB	+	**200MG**	**N19516 005**	NOV 08, 1993
	ORAMORPH SR			
BC	ROXANE	15MG	N19977 004	NOV 23, 1994
BC		30MG	N19977 001	AUG 15, 1991
BC		60MG	N19977 002	AUG 15, 1991
BC		100MG	N19977 003	AUG 15, 1991

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	AVELOX		
+	BAYER	EQ 400MG BASE	N21085 001 DEC 10, 1999

MUPIROCIN

OINTMENT; TOPICAL

	BACTROBAN		
+	SMITHKLINE BEECHAM	2%	N50591 001 DEC 31, 1987

MUPIROCIN CALCIUM

CREAM, AUGMENTED; TOPICAL

	BACTROBAN		
+	SMITHKLINE BEECHAM	2%	N50746 001 DEC 11, 1997

MUPIROCIN CALCIUM

OINTMENT; NASAL

	BACTROBAN		
+	SMITHKLINE BEECHAM	EQ 2% BASE	N50703 001 SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

	CELLCEPT		
+	ROCHE GLOBAL DEV	250MG	N50722 001 MAY 03, 1995

SUSPENSION; ORAL

	CELLCEPT		
+	ROCHE GLOBAL DEV	200MG/ML	N50759 001 OCT 01, 1998

TABLET; ORAL

	CELLCEPT		
+	ROCHE GLOBAL DEV	500MG	N50723 001 JUN 19, 1997

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

	CELLCEPT		
+	ROCHE GLOBAL DEV	500MG/VIAL	N50758 001 AUG 12, 1998

NABUMETONE

TABLET; ORAL

	NABUMETONE			
AB	COPLEY PHARM	**750MG**	**N75179 001**	JUN 06, 2000
AB	TEVA	**500MG**	**N75189 001**	MAY 26, 2000
	RELAFEN			
AB	SMITHKLINE BEECHAM	**500MG**	**N19583 001**	DEC 24, 1991
AB	+	**750MG**	**N19583 002**	DEC 24, 1991

FDA data supplied by DrugPatentWatch.com

NADOLOL

TABLET; ORAL

	CORGARD			
AB	APOTHECON	20MG	N18063 005	OCT 28, 1986
AB	+	40MG	N18063 001	
AB		80MG	N18063 002	
AB		120MG	N18063 003	
AB	+	160MG	N18063 004	
	NADOLOL			
AB	COPLEY PHARM	80MG	N74368 001	AUG 31, 1994
AB		120MG	N74368 002	AUG 31, 1994
AB		160MG	N74368 003	AUG 31, 1994
AB	INVAMED	20MG	N74501 001	NOV 09, 1995
AB		40MG	N74501 002	NOV 09, 1995
AB		80MG	N74501 003	NOV 09, 1995
AB	MYLAN	20MG	N74172 001	OCT 31, 1993
AB		40MG	N74172 002	OCT 31, 1993
AB		80MG	N74172 003	OCT 31, 1993
AB	ZENITH GOLDLINE	20MG	N74229 001	AUG 30, 1996
AB		40MG	N74229 002	AUG 30, 1996
AB		80MG	N74255 001	JAN 24, 1996
AB		120MG	N74255 002	JAN 24, 1996
AB		160MG	N74255 003	JAN 24, 1996

NADOLOL; *MULTIPLE*

SEE BENDROFLUMETHIAZIDE; NADOLOL

NAFARELIN ACETATE

SPRAY, METERED; NASAL

	SYNAREL		
+	SEARLE	EQ 0.2MG BASE/SPRAY	N19886 001 FEB 13, 1990

NAFCILLIN SODIUM

CAPSULE; ORAL

	UNIPEN		
+	WYETH AYERST	EQ 250MG BASE	N50111 001

INJECTABLE; INJECTION

	NAFCILLIN SODIUM		
AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984
AP	MARSAM	EQ 1GM BASE/VIAL	N62844 002 OCT 26, 1988
AP		EQ 2GM BASE/VIAL	N62844 004 OCT 26, 1988
AP		EQ 4GM BASE/VIAL	N62844 005 OCT 26, 1988
AP		EQ 10GM BASE/VIAL	N63008 001 SEP 29, 1988
AP		EQ 500MG BASE/VIAL	N62844 001 OCT 26, 1988
+		EQ 1.5GM BASE/VIAL	N62844 003 OCT 26, 1988
	NALLPEN		
AP	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001
AP		EQ 1GM BASE/VIAL	N61999 002
AP		EQ 2GM BASE/VIAL	N61999 003
AP		EQ 10GM BASE/VIAL	N61999 004

FDA data supplied by DrugPatentWatch.com

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NALLPEN IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — EQ 20MG BASE/ML — N50655 001 OCT 31, 1989
+ — EQ 2GM BASE/100ML — N50655 002 OCT 31, 1989

UNIPEN
AP + WYETH AYERST — **EQ 500MG BASE/VIAL** — **N50320 001**
AP — **EQ 500MG BASE/VIAL** — **N62717 001** DEC 16, 1986
AP + — **EQ 1GM BASE/VIAL** — **N62717 002** DEC 16, 1986
AP + — **EQ 2GM BASE/VIAL** — **N50320 003**
AP — **EQ 2GM BASE/VIAL** — **N62717 004** DEC 16, 1986
AP + — **EQ 4GM BASE/VIAL** — **N50320 004**
AP — **EQ 10GM BASE/VIAL** — **N50320 005**

UNIPEN IN PLASTIC CONTAINER
AP WYETH AYERST — **EQ 1GM BASE/VIAL** — **N50320 002**

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN
+ ALLERGAN HERBERT — 1% — N19599 001 FEB 29, 1988

GEL; TOPICAL
NAFTIN
+ ALLERGAN HERBERT — 1% — N19356 001 JUN 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
AP ABBOTT — **10MG/ML** — **N70914 001** FEB 03, 1989
AP — **10MG/ML** — **N70915 001** FEB 03, 1989
AP — **20MG/ML** — **N70916 001** FEB 03, 1989
AP — **20MG/ML** — **N70917 001** FEB 03, 1989

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
AP ABBOTT — **20MG/ML** — **N70918 001** FEB 03, 1989
+ — 1.5MG/ML — N20200 001 MAR 12, 1993
AP ASTRAZENECA — **10MG/ML** — **N72070 001** APR 10, 1989
AP — **20MG/ML** — **N72073 001** APR 10, 1989
AP KING PHARMS — **10MG/ML** — **N74471 001** MAR 19, 1998
AP — **20MG/ML** — **N74471 002** MAR 19, 1998

NUBAIN
AP + ENDO PHARMS — **10MG/ML** — **N18024 001**
AP + — **20MG/ML** — **N18024 002** MAY 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL
NEGGRAM
+ SANOFI SYNTHELABO — 250MG/5ML — N17430 001

TABLET; ORAL
NALIDIXIC ACID
AB DANBURY PHARMA — **1GM** — **N71919 001** JUN 29, 1988
AB — **250MG** — **N71936 001** JUN 29, 1988
AB — **500MG** — **N72061 001** JUN 29, 1988

NEGGRAM
AB SANOFI SYNTHELABO — **250MG** — **N14214 002**
AB — **500MG** — **N14214 004**
AB + — **1GM** — **N14214 005**

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX
+ BAXTER PHARM PROD — EQ 0.1MG BASE/ML — N20459 001 APR 17, 1995

FDA data supplied by DrugPatentWatch.com

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+	BAXTER PHARM PROD	EQ 1MG BASE/ML	N20459 002	APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

AP	ELKINS SINN	**0.4MG/ML**	**N70299 001**	SEP 24, 1986
AP	ELKINS SINN PHARM	**0.4MG/ML**	**N70298 001**	SEP 24, 1986
AP	WYETH AYERST	**0.02MG/ML**	**N70188 001**	SEP 24, 1986
AP		**0.02MG/ML**	**N70189 001**	SEP 24, 1986
AP		**0.4MG/ML**	**N70190 001**	SEP 24, 1986
AP		**0.4MG/ML**	**N70191 001**	SEP 24, 1986

NALOXONE HCL

AP	ABBOTT	**0.02MG/ML**	**N70171 001**	SEP 24, 1986
AP		**0.02MG/ML**	**N70252 001**	JAN 16, 1987
AP		**0.02MG/ML**	**N70253 001**	JAN 16, 1987
AP		**0.4MG/ML**	**N70254 001**	JAN 07, 1987
AP		**0.4MG/ML**	**N70255 001**	JAN 07, 1987
AP		**0.4MG/ML**	**N70256 001**	JAN 07, 1987
AP		**0.4MG/ML**	**N70257 001**	JAN 07, 1987
AP	ELKINS SINN	**0.02MG/ML**	**N71272 001**	MAY 24, 1988
AP		**1MG/ML**	**N71273 001**	MAY 24, 1988
AP		**1MG/ML**	**N71274 001**	MAY 24, 1988
AP		**1MG/ML**	**N71287 001**	MAY 24, 1988
AP	INTL MEDICATION	**0.4MG/ML**	**N70639 001**	SEP 24, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP	INTL MEDICATION	**1MG/ML**	**N72076 001**	MAR 24, 1988

NARCAN

AP	+ ENDO PHARMS	**0.02MG/ML**	**N16636 002**	
AP	+	**0.4MG/ML**	**N16636 001**	
AP	+	**1MG/ML**	**N16636 003**	JUN 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	RANBAXY	**EQ 0.5MG BASE; EQ 50MG BASE**	**N75523 001**	MAR 17, 2000
AB	WATSON LABS	**EQ 0.5MG BASE; EQ 50MG BASE**	**N74736 001**	JAN 21, 1997

TALWIN NX

AB	+ SANOFI SYNTHELABO	**EQ 0.5MG BASE; EQ 50MG BASE**	**N18733 001**	DEC 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HCL

AB	AMIDE PHARM	**50MG**	**N75274 001**	MAY 26, 1999
AB	BARR	**50MG**	**N74918 001**	MAY 08, 1998
AB	EON	**50MG**	**N75434 001**	MAR 08, 2000

REVIA

AB	+ DUPONT MERCK	**50MG**	**N18932 001**	NOV 20, 1984

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

AO	+ ORGANON	**50MG/ML**	**N13132 001**	JUN 12, 1986

FDA data supplied by DrugPatentWatch.com

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	DECA-DURABOLIN				
AO	+ ORGANON	**100MG/ML**	**N13132 002**		
			JUN 12, 1986		
AO	+	**200MG/ML**	**N13132 003**		
			JUN 12, 1986		
	NANDROLONE DECANOATE				
AO	STERIS	**50MG/ML**	**N86385 001**		
			JAN 13, 1984		
AO		**100MG/ML**	**N86598 001**		
			JAN 13, 1984		
AO		**200MG/ML**	**N88128 001**		
			DEC 05, 1983		

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

	DURABOLIN		
	+ ORGANON	25MG/ML	N11891 001
	+	50MG/ML	N11891 002

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	ALBALON		
AT	ALLERGAN	**0.1%**	**N80248 001**
	NAFAZAIR		
AT	BAUSCH AND LOMB	**0.1%**	**N40073 001**
			MAY 25, 1994
	NAPHAZOLINE HCL		
AT	TAYLOR	**0.1%**	**N83590 001**
	NAPHCON FORTE		
AT	+ ALCON	**0.1%**	**N80229 001**
	OPCON		
AT	BAUSCH AND LOMB	**0.1%**	**N87506 001**
	VASOCON		
AT	CIBA	**0.1%**	**N80235 002**
			MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

	NAPROSYN		
AB	+ SYNTEX (USA) INC LLC	**25MG/ML**	**N18965 001**
			MAR 23, 1987

NAPROXEN

SUSPENSION; ORAL

	NAPROXEN		
AB	ROXANE	**25MG/ML**	**N74190 001**
			MAR 30, 1994

TABLET; ORAL

	NAPROSYN		
AB	SYNTEX (USA) INC LLC	**250MG**	**N17581 002**
AB		**375MG**	**N17581 003**
AB	+	**500MG**	**N17581 004**
			APR 15, 1982
	NAPROXEN		
AB	CHELSEA LABS	**250MG**	**N74457 001**
			MAY 31, 1995
AB		**375MG**	**N74457 002**
			MAY 31, 1995
AB		**500MG**	**N74457 003**
			MAY 31, 1995
AB	COPLEY PHARM	**250MG**	**N74207 001**
			DEC 21, 1993
AB		**375MG**	**N74207 002**
			DEC 21, 1993
AB		**500MG**	**N74207 003**
			DEC 21, 1993
AB	DANBURY PHARMA	**250MG**	**N74163 001**
			FEB 10, 1995
AB		**375MG**	**N74163 002**
			FEB 10, 1995
AB		**500MG**	**N74163 003**
			FEB 10, 1995
AB	GENEVA PHARMS	**250MG**	**N74140 001**
			DEC 21, 1993
AB		**375MG**	**N74140 002**
			DEC 21, 1993
AB		**500MG**	**N74140 003**
			DEC 21, 1993
AB	LEDERLE	**250MG**	**N74105 001**
			DEC 21, 1993
AB		**375MG**	**N74105 002**
			DEC 21, 1993
AB		**500MG**	**N74105 003**
			DEC 21, 1993
AB	MOVA	**250MG**	**N74410 001**
			APR 28, 1995
AB		**375MG**	**N74410 002**
			APR 28, 1995

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	MOVA	500MG	N74410 003	APR 28, 1995
AB	MYLAN	250MG	N74121 001	DEC 21, 1993
AB		375MG	N74121 002	DEC 21, 1993
AB		500MG	N74121 003	DEC 21, 1993
AB	NOVOPHARM NC	250MG	N74129 001	DEC 21, 1993
AB		375MG	N74129 002	DEC 21, 1993
AB		500MG	N74129 003	DEC 21, 1993
AB	PUREPAC PHARM	250MG	N74263 001	DEC 21, 1993
AB		375MG	N74263 002	DEC 21, 1993
AB		500MG	N74263 003	DEC 21, 1993
AB	ROXANE	250MG	N74211 001	FEB 28, 1994
AB		375MG	N74211 002	FEB 28, 1994
AB		500MG	N74211 003	FEB 28, 1994
AB	SIDMAK LABS NJ	250MG	N74182 001	JUN 27, 1996
AB		375MG	N74182 002	JUN 27, 1996
AB		500MG	N74182 003	JUN 27, 1996
AB	TEVA	250MG	N74201 001	DEC 21, 1993
AB		250MG	N74216 001	APR 11, 1996
AB		375MG	N74201 002	DEC 21, 1993
AB		375MG	N74216 002	APR 11, 1996
AB		500MG	N74201 003	DEC 21, 1993
AB		500MG	N74216 003	APR 11, 1996

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	ZENITH GOLDLINE	250MG	N74111 001	FEB 28, 1995
AB		375MG	N74111 002	FEB 28, 1995
AB		500MG	N74111 003	FEB 28, 1995

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+ SYNTEX (USA) INC LLC	375MG	N20067 002	OCT 14, 1994
AB	+	500MG	N20067 003	OCT 14, 1994

NAPROXEN

AB	GENEVA PHARMS TECH	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998
AB		500MG	N74936 002	FEB 24, 1998
AB	SIDMAK LABS	375MG	N75337 001	MAY 26, 1999
AB		500MG	N75337 002	MAY 26, 1999
AB	TEVA	375MG	N75227 001	JUN 30, 1998
AB		500MG	N75227 002	JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	SYNTEX (USA) INC LLC	EQ 250MG BASE	N18164 001	

ANAPROX DS

AB	+ SYNTEX (USA) INC LLC	EQ 500MG BASE	N18164 003	SEP 30, 1987

NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB		EQ 500MG BASE	N74480 001	MAY 14, 1996

FDA data supplied by DrugPatentWatch.com

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	CHELSEA LABS	EQ 250MG BASE	N74455 001	MAY 31, 1995
AB		EQ 500MG BASE	N74455 002	MAY 31, 1995
AB	COPLEY PHARM	EQ 250MG BASE	N74289 001	JAN 27, 1994
AB		EQ 500MG BASE	N74289 002	JAN 27, 1994
AB	DANBURY PHARMA	EQ 250MG BASE	N74195 001	DEC 21, 1993
AB		EQ 500MG BASE	N74195 002	DEC 21, 1993
AB	GENEVA PHARMS	EQ 250MG BASE	N74162 001	DEC 21, 1993
AB		EQ 500MG BASE	N74162 002	DEC 21, 1993
AB	INVAMED	EQ 250MG BASE	N74495 001	DEC 05, 1994
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994
AB	MYLAN	EQ 250MG BASE	N74367 001	AUG 31, 1994
AB		EQ 500MG BASE	N74367 002	AUG 31, 1994
AB	NOVOPHARM	EQ 250MG BASE	N74142 001	DEC 21, 1993
AB		EQ 500MG BASE	N74142 002	DEC 21, 1993
AB	ROXANE	EQ 250MG BASE	N74257 001	DEC 21, 1993
AB		EQ 500MG BASE	N74257 002	DEC 21, 1993
AB	SIDMAK LABS NJ	EQ 250MG BASE	N74242 001	JUN 20, 1996
AB		EQ 500MG BASE	N74242 002	JUN 20, 1996
AB	TEVA	EQ 250MG BASE	N74198 001	DEC 21, 1993
AB		EQ 500MG BASE	N74198 002	DEC 21, 1993
AB	ZENITH GOLDLINE	EQ 250MG BASE	N74230 001	MAR 14, 1995
AB		EQ 500MG BASE	N74230 002	MAR 14, 1995

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN			
+	ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996
+		EQ 500MG BASE	N20353 002	JAN 05, 1996
+		EQ 750MG BASE	N20353 003	JAN 05, 1996

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

	AMERGE			
	GLAXO WELLCOME	EQ 1MG BASE	N20763 002	FEB 10, 1998
+		EQ 2.5MG BASE	N20763 001	FEB 10, 1998

NATAMYCIN

SUSPENSION; OPHTHALMIC

	NATACYN		
+	ALCON	5%	N50514 001

NATEGLINIDE

TABLET; ORAL

	STARLIX			
	NOVARTIS	60MG	N21204 001	DEC 22, 2000
+		120MG	N21204 002	DEC 22, 2000

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

	TILADE			
+	AVENTIS	1.75MG/INH	N19660 001	DEC 30, 1992

SOLUTION/DROPS; OPHTHALMIC

	ALOCRIL			
+	ALLERGAN	2%	N21009 001	DEC 08, 1999

FDA data supplied by DrugPatentWatch.com

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
+ BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994
100MG N20152 002 DEC 22, 1994
150MG N20152 003 DEC 22, 1994
200MG N20152 004 DEC 22, 1994
+ 250MG N20152 005 DEC 22, 1994

NELFINAVIR MESYLATE

FOR SUSPENSION; ORAL
VIRACEPT
+ AGOURON EQ 50MG BASE/SCOOPFUL N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
+ AGOURON EQ 250MG BASE N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK **100%** **N61579 001**

SOLUTION; ORAL
MYCIFRADIN
+ PHARMACIA AND UPJOHN EQ 87.5MG BASE/5ML N50285 001

TABLET; ORAL
NEOMYCIN SULFATE
+ TEVA EQ 350MG BASE N60304 001

NEOMYCIN SULFATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NEOMYCIN SULFATE; *MULTIPLE*
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SEE FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
STATROL
+ ALCON EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50344 002

SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES
AT STERIS **EQ 40MG BASE/ML; 200,000 UNITS/ML** **N62664 001** APR 08, 1986

NEOSPORIN G.U. IRRIGANT
AT MONARCH PHARMS **EQ 40MG BASE/ML; 200,000 UNITS/ML** **N60707 001**

SOLUTION/DROPS; OPHTHALMIC
STATROL
+ ALCON EQ 3.5MG BASE/ML; 16,250 UNITS/ML N50456 001
EQ 3.5MG BASE/ML; 16,250 UNITS/ML N62339 001 NOV 30, 1984

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
POLY-PRED
+ ALLERGAN EQ 0.35% BASE;10,000 UNITS/ML; 0.5% N50081 002

FDA data supplied by DrugPatentWatch.com

NETILMICIN SULFATE

INJECTABLE; INJECTION
NETROMYCIN
+ SCHERING EQ 100MG BASE/ML N50544 003 FEB 28, 1983

NEVIRAPINE

SUSPENSION; ORAL
VIRAMUNE
+ BOEHRINGER INGELHEIM 50MG/5ML N20933 001 SEP 11, 1998

TABLET; ORAL
VIRAMUNE
+ BOEHRINGER INGELHEIM 200MG N20636 001 JUN 21, 1996

NIACIN

TABLET; ORAL

	NIACIN		
AA	MK LABS	**500MG**	**N83525 001**
AA	TABLICAPS	**500MG**	**N84237 001**
AA	WOCKHARDT	**500MG**	**N81134 001** APR 28, 1992
	NIACOR		
AA	UPSHER SMITH	**500MG**	**N40378 001** MAY 03, 2000
	NICOLAR		
AA	+ AVENTIS	**500MG**	**N83823 001**

TABLET, EXTENDED RELEASE; ORAL
NIASPAN
+ KOS 375MG N20381 001 JUL 28, 1997
+ 500MG N20381 002 JUL 28, 1997
+ 750MG N20381 003 JUL 28, 1997
+ 1GM N20381 004 JUL 28, 1997

NIASPAN TITRATION STARTER PACK
+ KOS 375MG;500MG;750MG N20381 005 JUL 28, 1997

NIACINAMIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

	CARDENE		
AB	SYNTEX (USA) INC LLC	**20MG**	**N19488 001** DEC 21, 1988
AB	+	**30MG**	**N19488 002** DEC 21, 1988
	NICARDIPINE HCL		
AB	CHELSEA LABS	**20MG**	**N74670 001** OCT 28, 1996
AB		**30MG**	**N74670 002** OCT 28, 1996
AB	GENPHARM	**20MG**	**N74928 001** MAR 19, 1998
AB		**30MG**	**N74928 002** MAR 19, 1998
AB	MYLAN	**20MG**	**N74642 001** JUL 18, 1996
AB		**30MG**	**N74642 002** JUL 18, 1996
AB	TEVA	**20MG**	**N74540 001** OCT 28, 1996
AB		**30MG**	**N74540 002** OCT 28, 1996
AB	ZENITH GOLDLINE	**20MG**	**N74439 001** DEC 10, 1996
AB		**30MG**	**N74439 002** DEC 10, 1996

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR
+ SYNTEX (USA) INC LLC 30MG N20005 001 FEB 21, 1992

FDA data supplied by DrugPatentWatch.com

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR				
+ SYNTEX (USA) INC LLC	45MG		N20005 002	FEB 21, 1992
+	60MG		N20005 003	FEB 21, 1992

INJECTABLE; INJECTION

CARDENE				
+ SYNTEX (USA) INC LLC	2.5MG/ML		N19734 001	JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE				
SANO	7MG/24HR		N74645 001	OCT 20, 1997
	14MG/24HR		N74611 001	OCT 20, 1997
	21MG/24HR		N74612 001	OCT 20, 1997

INHALANT; INHALATION

NICOTROL				
+ PHARMACIA AND UPJOHN	4MG/CARTRIDGE		N20714 001	MAY 02, 1997

SPRAY, METERED; NASAL

NICOTROL				
+ PHARMACIA AND UPJOHN	0.5MG/SPRAY		N20385 001	MAR 22, 1996

NIFEDIPINE

CAPSULE; ORAL

ADALAT				
AB BAYER	**10MG**		**N19478 001**	NOV 27, 1985
AB	**20MG**		**N19478 002**	SEP 17, 1986
NIFEDIPINE				
AB CHASE LABS NJ	**10MG**		**N72409 001**	JUL 04, 1990

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE				
AB CHASE LABS NJ	**20MG**		**N73421 001**	JUN 19, 1991
AB FLEMINGTON PHARM	**10MG**		**N72781 001**	JUL 30, 1993
AB NOVOPHARM	**10MG**		**N72651 001**	FEB 19, 1992
AB PUREPAC PHARM	**10MG**		**N72579 001**	JAN 08, 1991
AB	**20MG**		**N72556 001**	SEP 20, 1990
AB SCHERER RP	**10MG**		**N73250 001**	OCT 08, 1991
AB	**20MG**		**N74045 001**	APR 30, 1992
PROCARDIA				
AB PFIZER	**10MG**		**N18482 001**	
AB +	**20MG**		**N18482 002**	JUL 24, 1986

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC				
AB1 + BAYER	**30MG**		**N20198 001**	APR 21, 1993
AB1 +	**60MG**		**N20198 002**	APR 21, 1993
BC +	90MG		N20198 003	APR 21, 1993
NIFEDIPINE				
AB1 BIOVAIL	**30MG**		**N75269 001**	DEC 04, 2000
AB1	**60MG**		**N75269 002**	DEC 04, 2000
AB2	**60MG**		**N75289 001**	SEP 27, 2000
AB1 ELAN PHARM	**30MG**		**N75128 001**	MAR 10, 2000
PROCARDIA XL				
AB2 + PFIZER	**60MG**		**N19684 002**	SEP 06, 1989
BC +	30MG		N19684 001	SEP 06, 1989
BC +	90MG		N19684 003	SEP 06, 1989

FDA data supplied by DrugPatentWatch.com

NILUTAMIDE

TABLET; ORAL
NILANDRON
AVENTIS PHARMS 50MG N20169 001 SEP 19, 1996
+ 150MG N20169 002 APR 30, 1999

NIMODIPINE

CAPSULE; ORAL
NIMOTOP
+ BAYER 30MG N18869 001 DEC 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR
+ ASTRAZENECA 10MG N20356 001 FEB 02, 1995
+ 20MG N20356 002 FEB 02, 1995
+ 30MG N20356 003 FEB 02, 1995
+ 40MG N20356 004 FEB 02, 1995

NITRIC OXIDE

GAS; INHALATION
INOMAX
INO 100PPM N20845 002 DEC 23, 1999
+ 800PPM N20845 003 DEC 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN
+ DURA 25MG/5ML N09175 001

TABLET; ORAL
FURADANTIN
AB PROCTER AND GAMBLE **50MG** **N08693 001**

NITROFURANTOIN

TABLET; ORAL
FURADANTIN
AB + PROCTER AND GAMBLE **100MG** **N08693 002**
NITROFURANTOIN
AB WATSON LAB **50MG** **N80447 001**
AB WHITEWORTH TOWN PLSN **100MG** **N84085 002**

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID
+ PROCTER AND GAMBLE 75MG;25MG N20064 001 DEC 24, 1991

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN
AB PROCTER AND GAMBLE **25MG** **N16620 003**
AB **50MG** **N16620 001**
AB + **100MG** **N16620 002**
NITROFURANTION
AB MYLAN **100MG** **N74967 002** JUL 09, 1997
NITROFURANTOIN
AB DANBURY PHARMA **25MG** **N73696 001** DEC 31, 1992
AB **50MG** **N73696 002** DEC 31, 1992
AB **100MG** **N73696 003** DEC 31, 1992
AB GENEVA PHARMS **25MG** **N74336 001** JAN 25, 1995
AB **50MG** **N74336 002** JAN 25, 1995
AB **100MG** **N74336 003** JAN 25, 1995
AB MYLAN **50MG** **N74967 001** JUL 09, 1997
AB ZENITH GOLDLINE **50MG** **N73671 001** JAN 28, 1993
AB **100MG** **N73652 001** JAN 28, 1993

NITROFURANTOIN, MACROCRYSTALLINE; *MULTIPLE*
SEE NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

FDA data supplied by DrugPatentWatch.com

NITROFURAZONE

CREAM; TOPICAL

	FURACIN				
	+ SHIRE	0.2%	N83789 001		

OINTMENT; TOPICAL

	FURACIN				
AT	+ SHIRE	**0.2%**	**N05795 001**		
	NITROFURAZONE				
AT	+ CLAY PARK	**0.2%**	**N84968 001**		
AT	THAMES	**0.2%**	**N86156 001**		
AT	WENDT	**0.2%**	**N86766 001**		

POWDER; TOPICAL

	FURACIN				
	ROBERTS LABS	0.2%	N83791 001		

SOLUTION; TOPICAL

	NITROFURAZONE				
AT	+ CLAY PARK	**0.2%**	**N85130 001**		
AT	WENDT	**0.2%**	**N87081 001**		

NITROGLYCERIN

AEROSOL; SUBLINGUAL

	NITROLINGUAL				
	+ POHL BOSKAMP	0.4MG/SPRAY	N18705 001 OCT 31, 1985		

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN				
AB1	3M	**0.1MG/HR**	**N89771 001** AUG 30, 1996		
AB1		**0.2MG/HR**	**N89772 001** AUG 30, 1996		
AB1		**0.4MG/HR**	**N89773 001** AUG 30, 1996		
AB1		**0.6MG/HR**	**N89774 001** AUG 30, 1996		
	NITRO-DUR				
AB1	+ KEY PHARMS	**0.1MG/HR**	**N20145 001** APR 04, 1995		
AB1	+	**0.2MG/HR**	**N20145 002** APR 04, 1995		
AB1	+	**0.4MG/HR**	**N20145 004** APR 04, 1995		

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITRO-DUR				
AB1	+ KEY PHARMS	**0.6MG/HR**	**N20145 005** APR 04, 1995		
BX	+	0.8MG/HR	N20145 006 APR 04, 1995		
	+	0.3MG/HR	N20145 003 APR 04, 1995		
	NITROGLYCERIN				
AB2	HERCON LABS	**0.2MG/HR**	**N89884 001** OCT 30, 1998		
AB2		**0.4MG/HR**	**N89885 001** OCT 30, 1998		
AB2		**0.6MG/HR**	**N89886 001** OCT 30, 1998		
AB2	MYLAN	**0.1MG/HR**	**N75033 001** FEB 06, 1998		
AB2		**0.2MG/HR**	**N74609 001** AUG 30, 1996		
AB2		**0.4MG/HR**	**N74607 001** AUG 30, 1996		
AB2		**0.6MG/HR**	**N74559 001** AUG 30, 1996		
AB1	MYLAN TECHNOLOGIES	**0.1MG/HR**	**N75076 001** NOV 12, 1999		
AB1		**0.2MG/HR**	**N75073 001** NOV 12, 1999		
AB1		**0.4MG/HR**	**N75075 001** NOV 12, 1999		
AB1		**0.6MG/HR**	**N74992 001** NOV 12, 1999		
	TRANSDERM-NITRO				
AB2	+ NOVARTIS	**0.1MG/HR**	**N20144 001** FEB 27, 1996		
AB2	+	**0.2MG/HR**	**N20144 002** FEB 27, 1996		
AB2	+	**0.4MG/HR**	**N20144 003** FEB 27, 1996		
AB2	+	**0.6MG/HR**	**N20144 004** FEB 27, 1996		
BX	+	0.8MG/HR	N20144 005 FEB 27, 1996		

INJECTABLE; INJECTION

	NITRO-BID				
AP	+ AVENTIS PHARMS	**5MG/ML**	**N18621 001** JAN 05, 1982		

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROGLYCERIN			
AP	+ ABBOTT	**5MG/ML**	**N18531 001**	
AP	LUITPOLD	**5MG/ML**	**N72034 001**	
			MAY 24, 1988	
	NITROGLYCERIN IN DEXTROSE 5%			
AP	ABBOTT	**10MG/100ML**	**N71846 001**	
			AUG 31, 1990	
AP		**0.1MG/ML**	**N74083 001**	
			OCT 26, 1994	
AP		**20MG/100ML**	**N71847 001**	
			AUG 31, 1990	
AP		**40MG/100ML**	**N71848 001**	
			AUG 31, 1990	
AP	+ BAXTER HLTHCARE	**10MG/100ML**	**N19970 001**	
			DEC 29, 1989	
AP	+	**20MG/100ML**	**N19970 002**	
			DEC 29, 1989	
AP	+	**40MG/100ML**	**N19970 003**	
			DEC 29, 1989	
	TRIDIL			
AP	+ FAULDING	**5MG/ML**	**N18537 001**	
	+	0.5MG/ML	N18537 002	
			JUN 16, 1983	

OINTMENT; TRANSDERMAL

	NITROGLYCERIN		
	+ ALTANA	2%	N87355 001
			JUL 08, 1988

SPRAY, METERED; SUBLINGUAL

	NITROLINGUAL PUMPSPRAY		
	+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002
			JAN 10, 1997

TABLET; SUBLINGUAL

	NITROSTAT		
	PARKE DAVIS	0.3MG	N21134 001
			MAY 01, 2000
		0.4MG	N21134 002
			MAY 01, 2000
	+	0.6MG	N21134 003
			MAY 01, 2000

NIZATIDINE

CAPSULE; ORAL

	AXID		
	LILLY	150MG	N19508 001
			APR 12, 1988
	+	300MG	N19508 002
			APR 12, 1988

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	LEVOPHED		
	+ ABBOTT	EQ 1MG BASE/ML	N07513 001

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RAVOCAINE AND NOVOCAIN W/ LEVOPHED		
	+ EASTMAN KODAK	EQ 0.033MG BASE/ML;2%; 0.4%	N08592 003

NORETHINDRONE

TABLET; ORAL

	NOR-QD		
	+ WATSON LABS	0.35MG	N17060 001

TABLET; ORAL-28

	MICRONOR		
	+ JOHNSON RW	0.35MG	N16954 001

NORETHINDRONE; *MULTIPLE*

SEE ETHINYL ESTRADIOL; NORETHINDRONE

SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL

	AYGESTIN			
AB	+ WYETH AYERST	**5MG**	**N18405 001**	
			APR 21, 1982	

FDA data supplied by DrugPatentWatch.com

NORETHINDRONE ACETATE; *MULTIPLE*
SEE ESTRADIOL; NORETHINDRONE ACETATE
SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
CHIBROXIN
+ MERCK 0.3% N19757 001 JUN 17, 1991

TABLET; ORAL
NOROXIN
+ MERCK 400MG N19384 002 OCT 31, 1986

NORGESTIMATE; *MULTIPLE*
SEE ESTRADIOL; NORGESTIMATE
SEE ETHINYL ESTRADIOL; NORGESTIMATE

NORGESTREL

TABLET; ORAL
OVRETTE
+ WYETH AYERST 0.075MG N17031 001

NORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORGESTREL

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL

BD	LILLY	EQ 10MG BASE	N14684 001
BD		EQ 25MG BASE	N14684 002
	NORTRIPTYLINE HCL		
AB	DANBURY PHARMA	**EQ 10MG BASE**	**N73553 001** MAR 30, 1992
AB		**EQ 25MG BASE**	**N73554 001** MAR 30, 1992
AB		**EQ 50MG BASE**	**N73555 001** MAR 30, 1992
AB		**EQ 75MG BASE**	**N73556 001** MAR 30, 1992

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	GENEVA PHARMS	**EQ 10MG BASE**	**N74054 001** DEC 31, 1992
AB		**EQ 25MG BASE**	**N74054 002** DEC 31, 1992
AB		**EQ 50MG BASE**	**N74054 003** DEC 31, 1992
AB		**EQ 75MG BASE**	**N74054 004** DEC 31, 1992
AB	GENEVA PHARMS TECH	**EQ 10MG BASE**	**N74835 001** JUN 30, 1997
AB		**EQ 25MG BASE**	**N74835 002** JUN 30, 1997
AB		**EQ 50MG BASE**	**N74835 003** JUN 30, 1997
AB		**EQ 75MG BASE**	**N74835 004** JUN 30, 1997
AB	MYLAN	**EQ 10MG BASE**	**N74234 001** JUL 26, 1993
AB		**EQ 25MG BASE**	**N74234 002** JUL 26, 1993
AB		**EQ 50MG BASE**	**N74234 003** JUL 26, 1993
AB		**EQ 75MG BASE**	**N74234 004** JUL 26, 1993
AB	TARO	**EQ 10MG BASE**	**N75520 004** MAY 08, 2000
AB		**EQ 25MG BASE**	**N75520 003** MAY 08, 2000
AB		**EQ 50MG BASE**	**N75520 001** MAY 08, 2000
AB		**EQ 75MG BASE**	**N75520 002** MAY 08, 2000
AB	TEVA	**EQ 10MG BASE**	**N73667 001** APR 11, 1996
AB		**EQ 10MG BASE**	**N74132 001** MAR 27, 1995
AB		**EQ 25MG BASE**	**N73667 002** APR 11, 1996
AB		**EQ 25MG BASE**	**N74132 002** MAR 27, 1995
AB		**EQ 50MG BASE**	**N73667 003** APR 11, 1996
AB		**EQ 50MG BASE**	**N74132 003** MAR 27, 1995

FDA data supplied by DrugPatentWatch.com

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	TEVA	EQ 75MG BASE	N73667 004	APR 11, 1996
AB		EQ 75MG BASE	N74132 004	MAR 27, 1995
	PAMELOR			
AB	NOVARTIS	EQ 10MG BASE	N18013 001	
AB		EQ 25MG BASE	N18013 002	
AB		EQ 50MG BASE	N18013 004	
AB	+	EQ 75MG BASE	N18013 003	

SOLUTION; ORAL

	AVENTYL HCL			
AA	+ LILLY	EQ 10MG BASE/5ML	N14685 001	
	NORTRIPTYLINE HCL			
AA	PHARM ASSOC	EQ 10MG BASE/5ML	N75606 001	AUG 28, 2000
	PAMELOR			
AA	NOVARTIS	EQ 10MG BASE/5ML	N18012 001	

NOVOBIOCIN SODIUM

CAPSULE; ORAL

	ALBAMYCIN			
	+ PHARMACIA AND UPJOHN	EQ 250MG BASE	N50339 001	

NYSTATIN

CREAM; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	N60575 001	
	NILSTAT			
AT	LEDERLE	100,000 UNITS/GM	N61445 001	
	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	N62949 001	JUN 13, 1988
AT	ALTANA	100,000 UNITS/GM	N62129 001	
AT	CLAY PARK	100,000 UNITS/GM	N62225 001	
AT	TARO	100,000 UNITS/GM	N64022 001	JAN 29, 1993
AT	TEVA	100,000 UNITS/GM	N61966 001	
AT	THAMES	100,000 UNITS/GM	N62457 001	JUL 28, 1983

NYSTATIN

OINTMENT; TOPICAL

	NILSTAT			
AT	+ LEDERLE	100,000 UNITS/GM	N61444 001	
	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	N62840 001	NOV 13, 1987
AT	ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982
AT	CLAY PARK	100,000 UNITS/GM	N62472 001	FEB 13, 1984

PASTILLE; ORAL

	MYCOSTATIN			
	+ BRISTOL MYERS SQUIBB	200,000 UNITS	N50619 001	APR 09, 1987

POWDER; ORAL

	NILSTAT			
AA	+ LEDERLE	100%	N50576 001	DEC 22, 1983
	NYSTATIN			
AA	PADDOCK	100%	N62613 001	NOV 26, 1985

POWDER; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	N60578 001	
	NYSTOP			
AT	PADDOCK	100,000 UNITS/GM	N64118 001	AUG 16, 1996

SUSPENSION; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	100,000 UNITS/ML	N61533 001	
	NILSTAT			
AA	+ LEDERLE	100,000 UNITS/ML	N50299 001	
	NYSTATIN			
AA	ALPHARMA	100,000 UNITS/ML	N62349 001	JUL 14, 1982
AA	BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001	FEB 28, 1994
AA	FOUGERA	100,000 UNITS/ML	N62517 001	JUN 07, 1984
AA	MORTON GROVE	100,000 UNITS/ML	N62512 001	OCT 29, 1984
AA	ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991

FDA data supplied by DrugPatentWatch.com

NYSTATIN

SUSPENSION; ORAL

	NYSTATIN			
AA	TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987
AA		100,000 UNITS/ML	N62776 001	DEC 17, 1987
AA	THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988
AA	UDL	100,000 UNITS/ML	N64142 001	JUN 25, 1998
	NYSTEX			
AA	SAVAGE LABS	100,000 UNITS/ML	N62519 001	JUL 06, 1984

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	500,000 UNITS	N60574 001	
	NILSTAT			
AA	LEDERLE	500,000 UNITS	N61151 001	
	NYSTATIN			
AA	EON	500,000 UNITS	N62065 001	
AA	MUTUAL PHARM	500,000 UNITS	N62838 001	DEC 22, 1988
AA	PAR PHARM	500,000 UNITS	N62474 001	DEC 22, 1983
AA	ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985
AA	TEVA	500,000 UNITS	N62506 001	JAN 16, 1984

TABLET; VAGINAL

	KOROSTATIN			
AT	HOLLAND RANTOS	100,000 UNITS	N61718 001	
	NILSTAT			
AT	LEDERLE	100,000 UNITS	N61325 001	
	NYSTATIN			
AT	FOUGERA	100,000 UNITS	N62459 001	NOV 09, 1983
AT	ODYSSEY PHARMS	100,000 UNITS	N62615 001	OCT 17, 1985
AT	PHARMADERM	100,000 UNITS	N62460 001	NOV 09, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCO-TRIACET II			
AT	TEVA	100,000 UNITS/GM;0.1%	N61954 002	SEP 20, 1985
	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N62606 001	MAY 15, 1985
	MYKACET			
AT	ALPHARMA US PHARM	100,000 UNITS/GM;0.1%	N62367 001	MAY 28, 1985
	MYTREX F			
AT	SAVAGE LABS	100,000 UNITS/GM;0.1%	N62597 001	OCT 08, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	100,000 UNITS/GM;0.1%	N62364 001	DEC 22, 1987
AT	THAMES	100,000 UNITS/GM;0.1%	N62347 001	MAR 30, 1987
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	100,000 UNITS/GM;0.1%	N62599 001	OCT 08, 1985

OINTMENT; TOPICAL

	MYCO-TRIACET II			
AT	TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985
	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N60572 001	JUN 28, 1985
	MYKACET			
AT	NMC	100,000 UNITS/GM;0.1%	N62733 001	MAR 09, 1987
	MYTREX F			
AT	SAVAGE LABS	100,000 UNITS/GM;0.1%	N62601 001	OCT 09, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985
AT	TARO	100,000 UNITS/GM;0.1%	N63305 001	MAR 29, 1993
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	100,000 UNITS/GM;0.1%	N62602 001	OCT 09, 1985

FDA data supplied by DrugPatentWatch.com

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN			
+ NOVARTIS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
+	EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
+	EQ 0.2MG BASE/ML	N19667 004	JUN 12, 1991
+	EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988
+	EQ 1MG BASE/ML	N19667 005	JUN 12, 1991
SANDOSTATIN LAR			
+ NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998
+	EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998
+	EQ 30MG BASE/VIAL	N21008 003	NOV 25, 1998

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN			
+ JOHNSON RW	20MG/ML	N20087 002	MAR 31, 1992
+	40MG/ML	N20087 003	MAR 31, 1992
FLOXIN IN DEXTROSE 5%			
+ JOHNSON RW	400MG/100ML	N20087 001	MAR 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ JOHNSON RW	4MG/ML	N20087 004	MAR 31, 1992
+	400MG/100ML	N20087 005	MAR 31, 1992

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX			
+ ALLERGAN	0.3%	N19921 001	JUL 30, 1993

SOLUTION/DROPS; OTIC

FLOXIN			
+ DAIICHI	0.3%	N20799 001	DEC 16, 1997

OFLOXACIN

TABLET; ORAL

FLOXIN			
JOHNSON RW	200MG	N19735 001	DEC 28, 1990
	300MG	N19735 002	DEC 28, 1990
+	400MG	N19735 003	DEC 28, 1990

OLANZAPINE

TABLET; ORAL

ZYPREXA			
+ LILLY	2.5MG	N20592 001	SEP 30, 1996
	5MG	N20592 002	SEP 30, 1996
	7.5MG	N20592 003	SEP 30, 1996
	10MG	N20592 004	SEP 30, 1996
+	15MG	N20592 005	SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZYPREXA ZYDIS			
LILLY	5MG	N21086 001	APR 06, 2000
	10MG	N21086 002	APR 06, 2000
	15MG	N21086 003	APR 06, 2000
+	20MG	N21086 004	APR 06, 2000

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PATANOL			
+ ALCON	EQ 0.1% BASE	N20688 001	DEC 18, 1996

FDA data supplied by DrugPatentWatch.com

OLSALAZINE SODIUM

CAPSULE; ORAL
DIPENTUM
+ PHARMACIA AND UPJOHN 250MG — N19715 001 JUL 31, 1990

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
ASTRAZENECA 10MG — N19810 003 OCT 05, 1995
+ 20MG — N19810 001 SEP 14, 1989
+ 40MG — N19810 002 JAN 15, 1998

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE — N20781 001 JAN 27, 1999
+ EQ 8MG BASE — N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN
+ GLAXO WELLCOME EQ 2MG BASE/ML — N20007 001 JAN 04, 1991

ZOFRAN IN PLASTIC CONTAINER
+ GLAXO WELLCOME EQ 0.64MG BASE/ML — N20403 001 JAN 31, 1995

ZOFRAN PRESERVATIVE FREE
+ GLAXO WELLCOME EQ 2MG BASE/ML — N20007 003 DEC 10, 1993

SOLUTION; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 4MG BASE/5ML — N20605 001 JAN 24, 1997

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
GLAXO WELLCOME EQ 4MG BASE — N20103 001 DEC 31, 1992
EQ 8MG BASE — N20103 002 DEC 31, 1992
+ EQ 24MG BASE — N20103 003 AUG 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
+ HLR 120MG — N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
NORFLEX
AP + 3M 30MG/ML — N13055 001
ORPHENADRINE CITRATE
AP STERIS 30MG/ML — N84779 001 MAR 15, 1982
AP 30MG/ML — N87062 001

TABLET, EXTENDED RELEASE; ORAL
NORFLEX
AB + 3M 100MG — N12157 001
ORPHENADRINE CITRATE
AB EON 100MG — N40327 001 FEB 15, 2000
AB GENEVA PHARMS TECH 100MG — N40284 001 JUN 19, 1998
AB IMPAX PHARM 100MG — N40368 001 JUN 23, 2000
AB KIEL 100MG — N40249 001 JAN 29, 1999

ORPHENADRINE CITRATE; *MULTIPLE*
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

FDA data supplied by DrugPatentWatch.com

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL
TAMIFLU
+ ROCHE — EQ 75MG BASE — N21087 001 OCT 27, 1999

FOR SUSPENSION; ORAL
TAMIFLU
+ ROCHE — EQ 12MG BASE/ML — N21246 001 DEC 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL
AB SMITHKLINE BEECHAM — **EQ 250MG BASE** — **N61336 001**
AB — **EQ 250MG BASE** — **N62241 001**
AB + — **EQ 500MG BASE** — **N61336 002**
AB — **EQ 500MG BASE** — **N62241 002**
OXACILLIN SODIUM
AB TEVA — **EQ 250MG BASE** — **N62222 001**
AB — **EQ 500MG BASE** — **N62222 002**

FOR SOLUTION; ORAL
BACTOCILL
AA SMITHKLINE BEECHAM — **EQ 250MG BASE/5ML** — **N62321 001**
OXACILLIN SODIUM
AA APOTHECON — **EQ 250MG BASE/5ML** — **N61457 001**
AA TEVA — **EQ 250MG BASE/5ML** — **N62252 001**

INJECTABLE; INJECTION
BACTOCILL
AP + SMITHKLINE BEECHAM — **EQ 1GM BASE/VIAL** — **N62736 001** DEC 19, 1986
AP + — **EQ 2GM BASE/VIAL** — **N62736 002** DEC 19, 1986

BACTOCILL IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — EQ 20MG BASE/ML — N50640 001 OCT 26, 1989
+ — EQ 40MG BASE/ML — N50640 002 OCT 26, 1989
OXACILLIN SODIUM
AP APOTHECON — **EQ 1GM BASE/VIAL** — **N61490 003**
AP — **EQ 1GM BASE/VIAL** — **N62737 001** DEC 23, 1986
AP — **EQ 2GM BASE/VIAL** — **N62737 002** DEC 23, 1986

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM
AP + APOTHECON — **EQ 10GM BASE/VIAL** — **N61490 006** MAY 09, 1991
AP — **EQ 250MG BASE/VIAL** — **N61490 001**
AP + — **EQ 500MG BASE/VIAL** — **N61490 002**
AP IBI — **EQ 250MG BASE/VIAL** — **N62798 004** DEC 11, 1995
AP — **EQ 500MG BASE/VIAL** — **N62798 005** DEC 11, 1995
AP — **EQ 1GM BASE/VIAL** — **N62798 001** DEC 11, 1995
AP — **EQ 2GM BASE/VIAL** — **N62798 002** DEC 11, 1995
EQ 125MG BASE/VIAL — N62798 003 DEC 11, 1995
AP MARSAM — **EQ 250MG BASE/VIAL** — **N62856 001** OCT 26, 1988
AP — **EQ 500MG BASE/VIAL** — **N62856 002** OCT 26, 1988
AP — **EQ 1GM BASE/VIAL** — **N62856 003** OCT 26, 1988
AP — **EQ 2GM BASE/VIAL** — **N62856 004** OCT 26, 1988
AP — **EQ 10GM BASE/VIAL** — **N62984 001** SEP 29, 1988
EQ 4GM BASE/VIAL — N62856 005 OCT 26, 1988

OXAMNIQUINE

CAPSULE; ORAL
VANSIL
+ PFIZER — 250MG — N18069 001

OXANDROLONE

TABLET; ORAL
OXANDRIN
+ BIO TECH GEN — 2.5MG — N13718 001

FDA data supplied by DrugPatentWatch.com

OXAPROZIN

TABLET; ORAL

	DAYPRO			
+	SEARLE	600MG	N18841 004	OCT 29, 1992

OXAZEPAM

CAPSULE; ORAL

	OXAZEPAM			
AB	DANBURY PHARMA	10MG	N72952 001	SEP 28, 1990
AB		15MG	N72953 001	SEP 28, 1990
AB		30MG	N72954 001	SEP 28, 1990
AB	GENEVA PHARMS	10MG	N71813 001	APR 19, 1988
AB		15MG	N71756 001	APR 19, 1988
AB		30MG	N71814 001	APR 19, 1988
AB	PUREPAC PHARM	10MG	N72251 001	APR 14, 1988
AB		15MG	N72252 001	APR 14, 1988
AB		30MG	N72253 001	APR 14, 1988
AB	ZENITH GOLDLINE	10MG	N70943 001	AUG 03, 1987
AB		15MG	N70944 001	AUG 03, 1987
AB		30MG	N70945 001	AUG 03, 1987
	SERAX			
AB	FAULDING	10MG	N15539 002	
AB		15MG	N15539 004	
AB	+	30MG	N15539 006	

TABLET; ORAL

	SERAX			
+	FAULDING	15MG	N15539 008	

OXCARBAZEPINE

TABLET; ORAL

	TRILEPTAL			
	NOVARTIS	150MG	N21014 001	JAN 14, 2000
		300MG	N21014 002	JAN 14, 2000
+		600MG	N21014 003	JAN 14, 2000

OXICONAZOLE NITRATE

CREAM; TOPICAL

	OXISTAT			
+	GLAXO WELLCOME	EQ 1% BASE	N19828 001	DEC 30, 1988

LOTION; TOPICAL

	OXISTAT			
+	GLAXO WELLCOME	EQ 1% BASE	N20209 001	SEP 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	CHOLEDYL SA			
+	PARKE DAVIS	400MG	N87863 001	MAY 24, 1983
+	WARNER CHILCOTT	600MG	N86742 001	

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

	DITROPAN			
AA	+ ALZA	5MG/5ML	N18211 001	
	OXYBUTYNIN CHLORIDE			
AA	MIKART	5MG/5ML	N75039 001	JAN 29, 1999
AA	MORTON GROVE	5MG/5ML	N74868 001	FEB 12, 1997
AA	NOVEX	5MG/5ML	N74997 001	OCT 15, 1997
AA	PHARM ASSOC	5MG/5ML	N75137 001	DEC 18, 1998

FDA data supplied by DrugPatentWatch.com

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

	OXYBUTYNIN CHLORIDE			
AA	SILARX	**5MG/5ML**	**N74520 001**	
			MAR 29, 1996	

TABLET; ORAL

	DITROPAN			
AB	+ ALZA	**5MG**	**N17577 001**	
	OXYBUTYNIN CHLORIDE			
AB	ROSEMONT	**5MG**	**N74625 001**	
			JUL 31, 1996	
AB	SIDMAK LABS NJ	**5MG**	**N71655 001**	
			NOV 14, 1988	
AB	VINTAGE PHARMS	**5MG**	**N75079 001**	
			OCT 31, 1997	

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL			
+ ALZA	5MG	N20897 001	
		DEC 16, 1998	
+	10MG	N20897 002	
		DEC 16, 1998	
+	15MG	N20897 003	
		JUN 22, 1999	

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXICODONE			
ROXANE	15MG	N21011 001	
		AUG 31, 2000	
+	30MG	N21011 002	
		AUG 31, 2000	

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN			
+ PURDUE PHARMA LP	10MG	N20553 001	
		DEC 12, 1995	
+	20MG	N20553 002	
		DEC 12, 1995	
+	40MG	N20553 003	
		DEC 12, 1995	
+	80MG	N20553 004	
		JAN 06, 1997	
+	160MG	N20553 005	
		MAR 15, 2000	

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYMETHOLONE

TABLET; ORAL

ANADROL-50			
+ UNIMED	50MG	N16848 001	

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

NUMORPHAN			
+ ENDO PHARMS	1MG/ML	N11707 002	
+	1.5MG/ML	N11707 001	

SUPPOSITORY; RECTAL

NUMORPHAN			
+ ENDO PHARMS	5MG	N11738 004	

OXYTETRACYCLINE; *MULTIPLE*
SEE LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	OXYTETRACYCLINE HCL		
AB	IMPAX LABS	**EQ 250MG BASE**	**N60760 001**
AB	PROTER	**EQ 250MG BASE**	**N60869 001**
AB	WEST WARD	**EQ 250MG BASE**	**N60770 001**
	TERRAMYCIN		
AB +	PFIZER	**EQ 250MG BASE**	**N50286 002**

OXYTETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE

+	PFIZER	EQ 5MG BASE/GM; 10,000 UNITS/GM		N61015 001

OXYTOCIN

INJECTABLE; INJECTION

	OXYTOCIN			
AP	AM PHARM PARTNERS	**10 USP UNITS/ML**		**N18248 001**
	PITOCIN			
AP	+ PARKEDALE	**10 USP UNITS/ML**		**N18261 001**
	SYNTOCINON			
AP	NOVARTIS	**10 USP UNITS/ML**		**N18245 001**

PACLITAXEL

INJECTABLE; INJECTION

	PACLITAXEL			
AP	BAKER NORTON	**6MG/ML**		**N75184 001** SEP 15, 2000
	TAXOL			
AP	+ BRISTOL MYERS SQUIBB	**6MG/ML**		**N20262 001** DEC 29, 1992

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

+	NOVARTIS	30MG/VIAL		N20036 001 OCT 31, 1991
+		60MG/VIAL		N20036 003 MAY 06, 1993
+		90MG/VIAL		N20036 004 MAY 06, 1993

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL
COTAZYM

+	ORGANON	30,000 USP UNITS;8,000 USP UNITS; 30,000 USP UNITS		N20580 001 DEC 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

	PANCURONIUM			
AP	ELKINS SINN	**1MG/ML**		**N72058 001** MAR 23, 1988
AP		**2MG/ML**		**N72059 001** MAR 23, 1988
AP		**2MG/ML**		**N72060 001** MAR 23, 1988
	PANCURONIUM BROMIDE			
AP	ABBOTT	**1MG/ML**		**N72320 001** JAN 19, 1989
AP		**2MG/ML**		**N72321 001** JAN 19, 1989
AP	ASTRAZENECA	**1MG/ML**		**N72210 001** MAR 31, 1988
AP		**2MG/ML**		**N72211 001** MAR 31, 1988
AP		**2MG/ML**		**N72213 001** MAR 31, 1988
AP	GENSIA SICOR PHARMS	**1MG/ML**		**N72759 001** JUL 31, 1990
AP		**2MG/ML**		**N72760 001** JUL 31, 1990
	PAVULON			
AP	+ ORGANON	**1MG/ML**		**N17015 002**
AP	+	**2MG/ML**		**N17015 001**

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PROTONIX

+	WYETH AYERST	EQ 40MG BASE		N20987 001 FEB 02, 2000

PANTOTHENIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

PARAMETHADIONE

CAPSULE; ORAL
PARADIONE

+	ABBOTT	150MG		N06800 003

FDA data supplied by DrugPatentWatch.com

PARAMETHADIONE

CAPSULE; ORAL
PARADIONE
ABBOTT — 300MG — N06800 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT — 0.005MG/ML — N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA + PARKEDALE — **EQ 250MG BASE** — **N62310 001**
PAROMOMYCIN SULFATE
AA CARACO — **EQ 250MG BASE** — **N64171 001** JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ SMITHKLINE BEECHAM — EQ 10MG BASE/5ML — N20710 001 JUN 25, 1997

TABLET; ORAL
PAXIL
SMITHKLINE BEECHAM — EQ 10MG BASE — N20031 001 DEC 29, 1992
EQ 20MG BASE — N20031 002 DEC 29, 1992
EQ 30MG BASE — N20031 003 DEC 29, 1992
+ EQ 40MG BASE — N20031 005 DEC 29, 1992

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM — EQ 12.5MG BASE — N20936 001 FEB 16, 1999
+ EQ 25MG BASE — N20936 002 FEB 16, 1999

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM — EQ 37.5MG BASE — N20936 003 DEC 06, 2000

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN
+ ENZON — 250 UNITS/ML — N19818 001 MAR 21, 1990

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN — 0.1% — N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB + ABBOTT — **18.75MG** — **N16832 001**
AB — **37.5MG** — **N16832 002**
AB + — **75MG** — **N16832 003**
PEMOLINE
AB AMIDE PHARM — **18.75MG** — **N75595 001** FEB 28, 2000
AB — **37.5MG** — **N75595 002** FEB 28, 2000
AB — **75MG** — **N75595 003** FEB 28, 2000
AB COPLEY PHARM — **18.75MG** — **N75030 003** FEB 22, 2000
AB — **37.5MG** — **N75030 001** JAN 29, 1999
AB — **75MG** — **N75030 002** JAN 29, 1999
AB GENEVA PHARMS TECH — **18.75MG** — **N75286 001** DEC 27, 1999
AB — **37.5MG** — **N75286 002** JUN 30, 1999

FDA data supplied by DrugPatentWatch.com

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	GENEVA PHARMS TECH	**75MG**	**N75286 003**	
			JUN 30, 1999	
AB	VINTAGE PHARMS	**18.75MG**	**N75328 001**	
			APR 19, 2000	
AB		**37.5MG**	**N75328 002**	
			APR 19, 2000	
AB		**75MG**	**N75328 003**	
			APR 19, 2000	
AB	WATSON LABS	**37.5MG**	**N75287 002**	
			SEP 18, 2000	
AB		**75MG**	**N75287 003**	
			SEP 18, 2000	

TABLET, CHEWABLE; ORAL

	CYLERT			
AB	+ ABBOTT	**37.5MG**	**N17703 001**	
	PEMOLINE			
AB	AMIDE PHARM	**37.5MG**	**N75678 001**	
			JUL 26, 2000	
AB	COPLEY PHARM	**37.5MG**	**N75555 001**	
			FEB 18, 2000	

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL		
+	SCHWARZ PHARMA	20MG	N18976 004
			JAN 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

	DENAVIR		
+	SMITHKLINE BEECHAM	1%	N20629 001
			SEP 24, 1996

PENICILLAMINE

CAPSULE; ORAL

	CUPRIMINE		
	MERCK	125MG	N19853 002
+		250MG	N19853 001

PENICILLAMINE

TABLET; ORAL

	DEPEN		
+	WALLACE LABS	250MG	N19854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

	BICILLIN L-A			
BC	+ KING PHARMS	600,000 UNITS/ML		N50141 001
	+	300,000 UNITS/ML		N50141 003
	PERMAPEN			
BC	PFIZER	600,000 UNITS/ML		N60014 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	BICILLIN C-R		
+	KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML	N50138 002
+		300,000 UNITS/ML; 300,000 UNITS/ML	N50138 001
	BICILLIN C-R 900/300		
+	KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML	N50138 003

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN		
TEVA	200,000 UNITS/5ML	N60307 002
	400,000 UNITS/5ML	N60307 004
PENICILLIN-2		
TEVA	250,000 UNITS/5ML	N60307 003

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM		
AP	MARSAM	**1,000,000 UNITS/VIAL**	**N62991 001**
			SEP 13, 1988
AP		**5,000,000 UNITS/VIAL**	**N62991 002**
			SEP 13, 1988
AP		**10,000,000 UNITS/VIAL**	**N62991 003**
			SEP 13, 1988
AP		**20,000,000 UNITS/VIAL**	**N62991 004**
			SEP 13, 1988

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	PFIZER	20,000,000 UNITS/VIAL	N60074 003	
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	20,000 UNITS/ML	N50638 001 JUN 25, 1990	
+		40,000 UNITS/ML	N50638 002 JUN 25, 1990	
+		60,000 UNITS/ML	N50638 003 JUN 25, 1990	
	PFIZERPEN			
AP	+ PFIZER	1,000,000 UNITS/VIAL	N60657 001	
AP	+	5,000,000 UNITS/VIAL	N60657 002	
AP	+	20,000,000 UNITS/VIAL	N60657 003	

TABLET; ORAL

	PENICILLIN G POTASSIUM			
AB	MYLAN	200,000 UNITS	N60781 001	
AB		250,000 UNITS	N60781 002	
AB		400,000 UNITS	N60781 003	
AB		500,000 UNITS	N60781 005	
+		800,000 UNITS	N60781 004	
AB	TEVA	200,000 UNITS	N60306 001	
AB		250,000 UNITS	N60306 002	
AB		400,000 UNITS	N60306 003	
AB		500,000 UNITS	N60306 004	
AB	WYETH AYERST	200,000 UNITS	N60413 001	
AB		250,000 UNITS	N60413 002	
AB		400,000 UNITS	N60413 003	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	PENICILLIN G PROCAINE			
	PFIZER	300,000 UNITS/VIAL	N60099 001	
+		1,500,000 UNITS/VIAL	N60099 002	
	PFIZERPEN-AS			
AP	+ PFIZER	300,000 UNITS/ML	N60286 001	
AP	+	600,000 UNITS/ML	N60286 002	
	WYCILLIN			
AP	KING PHARMS	300,000 UNITS/ML	N60101 002	
AP		600,000 UNITS/ML	N60101 001	

PENICILLIN G PROCAINE; *MULTIPLE*
SEE PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

PENICILLIN G SODIUM

INJECTABLE; INJECTION

	PENICILLIN G SODIUM			
+	MARSAM	5,000,000 UNITS/VIAL	N63014 001 SEP 13, 1988	

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

	BEEPEN-VK			
AA	SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N62270 001	
AA		EQ 250MG BASE/5ML	N62270 002	
	LEDERCILLIN VK			
AA	LEDERLE	EQ 125MG BASE/5ML	N60136 001	
AA		EQ 250MG BASE/5ML	N60136 002	
	PEN-VEE K			
AA	WYETH AYERST	EQ 125MG BASE/5ML	N60007 001	
AA		EQ 250MG BASE/5ML	N60007 002	
	PENICILLIN V POTASSIUM			
AA	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001	
AA		EQ 250MG BASE/5ML	N61529 002	
AA	MYLAN	EQ 125MG BASE/5ML	N61624 002	
AA		EQ 250MG BASE/5ML	N61624 001	
	PENICILLIN-VK			
AA	TEVA	EQ 125MG BASE/5ML	N60456 001	
AA		EQ 250MG BASE/5ML	N60456 002	
	V-CILLIN K			
AA	LILLY	EQ 125MG BASE/5ML	N60004 001	
AA		EQ 250MG BASE/5ML	N60004 002	
	VEETIDS			
AA	APOTHECON	EQ 125MG BASE/5ML	N61410 001	
AA		EQ 250MG BASE/5ML	N61410 002	

FOR SUSPENSION; ORAL

	PENICILLIN V POTASSIUM			
AA	CLONMEL	EQ 125MG BASE/5ML	N62981 001 FEB 10, 1989	
AA		EQ 250MG BASE/5ML	N62981 002 FEB 10, 1989	

TABLET; ORAL

	BEEPEN-VK			
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62273 001	
AB		EQ 500MG BASE	N62273 002	
	BETAPEN-VK			
AB	BRISTOL	EQ 250MG BASE	N61150 001	
AB		EQ 500MG BASE	N61150 002	

FDA data supplied by DrugPatentWatch.com

PENICILLIN V POTASSIUM

TABLET; ORAL

	LEDERCILLIN VK			
AB	LEDERLE	EQ 250MG BASE	N60134 001	
AB		EQ 500MG BASE	N60134 002	
	PEN-VEE K			
AB	WYETH AYERST	EQ 250MG BASE	N60006 002	
AB		EQ 500MG BASE	N60006 003	
	PENICILLIN V POTASSIUM			
AB	BIOCHEMIE	EQ 250MG BASE	N64071 001	NOV 30, 1995
AB		EQ 500MG BASE	N64071 002	NOV 30, 1995
AB	CLONMEL	EQ 250MG BASE	N62936 001	NOV 25, 1988
AB		EQ 500MG BASE	N62935 001	NOV 23, 1988
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001	
AB		EQ 500MG BASE	N61528 002	
AB	MYLAN	EQ 250MG BASE	N61530 001	
AB		EQ 500MG BASE	N61530 002	
	PENICILLIN-VK			
AB	TEVA	EQ 250MG BASE	N60711 002	
AB		EQ 500MG BASE	N60711 003	
	UTICILLIN VK			
AB	PHARMACIA AND UPJOHN	EQ 250MG BASE	N61651 001	
	V-CILLIN K			
AB	LILLY	EQ 250MG BASE	N60003 002	
AB +		EQ 500MG BASE	N60003 003	
		EQ 125MG BASE	N60003 001	
	VEETIDS			
AB	APOTHECON	EQ 250MG BASE	N61411 001	
AB		EQ 500MG BASE	N61411 002	

PENTAGASTRIN

INJECTABLE; INJECTION

	PEPTAVLON		
+	WYETH AYERST	0.25MG/ML	N17048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

	NEBUPENT			
+	AM PHARM PARTNERS	300MG/VIAL	N19887 001	JUN 15, 1989

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

	NEBUPENT			
	AM PHARM PARTNERS	600MG/VIAL	N19887 002	MAR 22, 1996

INJECTABLE; INJECTION

	PENTAM			
AP +	AM PHARM PARTNERS	**300MG/VIAL**	**N19264 001**	OCT 16, 1984
	PENTAMIDINE ISETHIONATE			
AP	ABBOTT	**300MG/VIAL**	**N73479 001**	JUN 30, 1992
AP	ELKINS SINN	**300MG/VIAL**	**N73617 001**	DEC 18, 1995
AP	STERIS	**300MG/VIAL**	**N74303 001**	AUG 17, 1995

PENTAZOCINE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
SEE ASPIRIN; PENTAZOCINE HYDROCHLORIDE
SEE NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

	TALWIN		
+	ABBOTT	EQ 30MG BASE/ML	N16194 001

PENTOBARBITAL

ELIXIR; ORAL

	NEMBUTAL		
+	ABBOTT	18.2MG/5ML	N83244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	NEMBUTAL SODIUM		
AA +	ABBOTT	**50MG**	**N84093 001**
AA +		**100MG**	**N83245 001**
+		30MG	N84095 001
	SODIUM PENTOBARBITAL		
AA	ICN	**100MG**	**N83264 001**

FDA data supplied by DrugPatentWatch.com

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

	NEMBUTAL SODIUM			
AP	+ ABBOTT	50MG/ML	**N83246 001**	
	SODIUM PENTOBARBITAL			
AP	WYETH AYERST	50MG/ML	**N83261 001**	

SUPPOSITORY; RECTAL

NEMBUTAL			
+ ABBOTT	30MG	N83247 001	JAN 25, 1982
+	60MG	N83247 002	JAN 25, 1982
+	120MG	N83247 003	JAN 25, 1982
+	200MG	N83247 004	JAN 25, 1982

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON			
+ ALZA	100MG	N20193 001	SEP 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT			
+ SUPERGEN	10MG/VIAL	N20122 001	OCT 11, 1991

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	BIOVAIL	**400MG**	**N75028 001**	JUL 20, 1998
AB	ESI LEDERLE	**400MG**	**N74877 001**	JUL 08, 1997
AB	IMPAX LABS	**400MG**	**N75093 001**	AUG 10, 1999
AB	MYLAN	**400MG**	**N74425 001**	JUL 08, 1997

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	PUREPAC PHARM	**400MG**	**N74878 001**	JUL 09, 1997
AB	SIDMAK LABS NJ	**400MG**	**N74874 001**	MAY 25, 1999
AB	TEVA	**400MG**	**N75199 001**	SEP 03, 1999
AB	TORPHARM	**400MG**	**N75191 001**	JUN 09, 1999
AB	WATSON LABS	**400MG**	**N75107 001**	SEP 04, 1998
	PENTOXIL			
AB	UPSHER SMITH	**400MG**	**N74962 001**	MAR 31, 1999
	TRENTAL			
AB	+ AVENTIS PHARMS	**400MG**	**N18631 001**	AUG 30, 1984

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS			
+ US ARMY	50%;50%	N21084 001	FEB 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERMAX			
+ LILLY	EQ 0.05MG BASE	N19385 001	DEC 30, 1988
	EQ 0.25MG BASE	N19385 002	DEC 30, 1988
	EQ 1MG BASE	N19385 003	DEC 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON			
SOLVAY PHARMA	2MG	N20184 001	DEC 30, 1993

FDA data supplied by DrugPatentWatch.com

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
SOLVAY PHARMA 4MG N20184 002 DEC 30, 1993
\+ 8MG N20184 003 DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL
ELIMITE
AB + ALLERGAN 5% **N19855 001** AUG 25, 1989
PERMETHRIN
AB ALPHARMA 5% **N74806 001** JAN 23, 1998

PERPHENAZINE

CONCENTRATE; ORAL
TRILAFON
\+ SCHERING 16MG/5ML N11557 001

INJECTABLE; INJECTION
TRILAFON
\+ SCHERING 5MG/ML N11213 002

TABLET; ORAL
PERPHENAZINE
AB GENEVA PHARMS **2MG** **N89683 001** DEC 08, 1988
AB **4MG** **N89684 001** DEC 08, 1988
AB **8MG** **N89685 001** DEC 08, 1988
AB **16MG** **N89686 001** DEC 08, 1988
AB VINTAGE PHARMS **2MG** **N40226 001** DEC 31, 1998
AB **4MG** **N40226 002** DEC 31, 1998
AB **8MG** **N40226 003** DEC 31, 1998
AB **16MG** **N40226 004** DEC 31, 1998

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE
AB ZENITH GOLDLINE **2MG** **N89707 001** SEP 10, 1987
AB **4MG** **N89708 001** SEP 10, 1987
AB **8MG** **N89456 001** SEP 10, 1987
AB **16MG** **N89457 001** SEP 10, 1987
TRILAFON
AB SCHERING **2MG** **N10775 001**
AB **4MG** **N10775 002**
AB **8MG** **N10775 003**
AB + **16MG** **N10775 004**

PERPHENAZINE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENACEMIDE

TABLET; ORAL
PHENURONE
\+ ABBOTT 500MG N07707 001

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
AA + EON **35MG** **N85633 001**
AA **35MG** **N85694 001**
AA **35MG** **N85695 001**
AA **35MG** **N85702 001**
X-TROZINE
AA SHIRE RICHWOOD **35MG** **N87394 001** SEP 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL
BC MALLINCKRODT 105MG N88021 001 SEP 21, 1982
PHENDIMETRAZINE TARTRATE
BC EON 105MG N18074 001
BC + GENEVA PHARMS 105MG N87378 001

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	X-TROZINE L.A.			
BC	SHIRE RICHWOOD	105MG	N87371 001	AUG 24, 1982

TABLET; ORAL

	BONTRIL PDM			
AA	AMARIN PHARMS	35MG	N85272 001	
	CAM-METRAZINE			
AA	+ CAMALL	35MG	N83922 001	
AA		35MG	N85318 001	
AA		35MG	N85320 001	
AA		35MG	N85321 001	
AA		35MG	N85511 001	
AA		35MG	N85756 001	
	PHENAZINE-35			
AA	CAMALL	35MG	N85512 001	
	PHENDIMETRAZINE TARTRATE			
AA	CAMALL	35MG	N85761 001	
AA		35MG	N85941 001	JUN 27, 1983
AA	EON	35MG	N85402 001	
AA		35MG	N85497 001	
AA		35MG	N85588 001	
AA		35MG	N85830 001	
AA	MIKART	35MG	N89452 001	OCT 30, 1991
AA	ROSEMONT	35MG	N84399 001	
	STATOBEX			
AA	TEVA	35MG	N86013 001	
	X-TROZINE			
AA	SHIRE RICHWOOD	35MG	N86550 001	
AA		35MG	N86551 001	
AA		35MG	N86552 001	
AA		35MG	N86553 001	
AA		35MG	N86554 001	

PHENELZINE SULFATE

TABLET; ORAL

	NARDIL			
	+ PARKE DAVIS	EQ 15MG BASE	N11909 002	

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIBENZYLINE			
	+ WELLSPRING PHARM	10MG	N08708 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	ADIPEX-P			
AA	+ TEVA	37.5MG	N88023 001	
				AUG 02, 1983
	OBY-TRIM			
AA	SHIRE RICHWOOD	30MG	N87764 001	
				MAR 18, 1982
	ONA-MAST			
AA	MAST MM	30MG	N86511 001	
AA		30MG	N86516 001	
	PHENTERMINE HCL			
AA	AMIDE PHARM	30MG	N40227 001	
				JUN 18, 1997
AA		37.5MG	N40228 001	
				JUN 19, 1997
AA	CAMALL	15MG	N86735 001	
AA		30MG	N85411 001	
AA		30MG	N85417 001	
AA		30MG	N86732 002	
AA		30MG	N87215 001	
AA		30MG	N87226 001	
AA		37.5MG	N87915 001	
				DEC 22, 1983
AA		37.5MG	N87918 001	
				DEC 22, 1983
AA		37.5MG	N87930 001	
				OCT 14, 1983
AA		37.5MG	N88610 001	
				JUN 04, 1984
AA		37.5MG	N88611 001	
				JUN 04, 1984
AA		37.5MG	N88625 001	
				AUG 23, 1984
		18.75MG	N88576 001	
				MAY 23, 1984
AA	+ EON	15MG	N87301 001	
AA	+	30MG	N86945 001	
				JUL 20, 1983
AA		30MG	N87190 001	
AA		30MG	N87208 001	

FDA data supplied by DrugPatentWatch.com

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	EON	30MG	N87223 001	
AA	KING PHARMS	30MG	N40083 001	MAR 07, 1997
AA	ROSEMONT	30MG	N84487 001	APR 09, 1982
AA		30MG	N88797 001	DEC 10, 1984

TABLET; ORAL

	ADIPEX-P			
AA	+ TEVA	37.5MG	N85128 001	
	ONA MAST			
AA	MAST MM	8MG	N86260 001	
	PHENTERMINE HCL			
AA	AMIDE PHARM	37.5MG	N40190 001	MAY 30, 1997
AA	+ CAMALL	8MG	N83923 001	
AA		8MG	N85319 001	
AA		37.5MG	N87805 001	DEC 06, 1982
AA		37.5MG	N88596 001	APR 04, 1984
AA	PUREPAC PHARM	37.5MG	N40276 001	NOV 25, 1998
AA	ROSEMONT	8MG	N83804 001	
AA		37.5MG	N88910 001	JUL 17, 1985
AA		37.5MG	N88917 001	JUL 17, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN			
	MEDEVA	EQ 15MG BASE	N11613 004	
	+	EQ 30MG BASE	N11613 002	

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

	PHENTOLAMINE MESYLATE			
AP	BEDFORD	5MG/VIAL	N40235 001	MAR 11, 1998

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

	REGITINE			
AP	+ NOVARTIS	5MG/VIAL	N08278 003	

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC			
AA	+ WYETH AYERST	5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984
	PROMETH VC PLAIN			
AA	ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984
	PROMETHAZINE VC PLAIN			
AA	MORTON GROVE	5MG/5ML;6.25MG/5ML	N88897 001	JAN 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A			
ALLERGAN	0.12%;0.1%	N07953 001	

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*

SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SEE HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PHENYTOIN

SUSPENSION; ORAL

	DILANTIN-125			
AB	+ PARKE DAVIS	125MG/5ML	N08762 001	
	PHENYTOIN			
AB	ALPHARMA	125MG/5ML	N89892 001	SEP 25, 1992

FDA data supplied by DrugPatentWatch.com

PHENYTOIN

TABLET, CHEWABLE; ORAL
DILANTIN
+ PARKE DAVIS 50MG N84427 001

PHENYTOIN SODIUM

INJECTABLE; INJECTION
DILANTIN
AP + PARKE DAVIS **50MG/ML** **N10151 001**
PHENYTOIN
AP ELKINS SINN **50MG/ML** **N84307 001**
PHENYTOIN SODIUM
AP ABBOTT **50MG/ML** **N89521 001**
MAR 17, 1987
AP **50MG/ML** **N89744 001**
DEC 18, 1987

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN
AB + PARKE DAVIS **100MG** **N84349 002**
+ 30MG N84349 001
EXTENDED PHENYTOIN SODIUM
AB MYLAN **100MG** **N40298 001**
DEC 28, 1998

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM
+ ZENITH GOLDLINE 100MG N80259 001

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
BP + MERCK 1MG/0.5ML N12223 002
BP + 10MG/ML N12223 001
PHYTONADIONE
BP INTL MEDICATION 1MG/0.5ML N83722 001
VITAMIN K1
BP ABBOTT 1MG/0.5ML N87954 001
JUL 25, 1983
BP 10MG/ML N87955 001
JUL 25, 1983

TABLET; ORAL
MEPHYTON
+ MERCK 5MG N10104 003

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC
OCUSERT PILO-40
+ AKORN 11MG N17548 001

INSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20
+ AKORN 5MG N17431 001

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC
PILOPINE HS
+ ALCON 4% N18796 001
OCT 01, 1984

TABLET; ORAL
SALAGEN
+ MGI PHARMA 5MG N20237 001
MAR 22, 1994

PILOCARPINE HYDROCHLORIDE; *MULTIPLE*
SEE BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PIMOZIDE

TABLET; ORAL
ORAP

	TEVA	1MG	N17473 003 AUG 27, 1997
+		2MG	N17473 001 JUL 31, 1984

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	GENEVA PHARMS	**5MG**	**N73608 001** MAR 29, 1993
AB		**10MG**	**N73609 001** MAR 29, 1993
AB	GENPHARM	**5MG**	**N74013 001** SEP 24, 1992
AB		**10MG**	**N74018 001** SEP 24, 1992
AB	MARTEC	**5MG**	**N74474 001** OCT 28, 1996
AB		**10MG**	**N74474 002** OCT 28, 1996
AB	MUTUAL PHARM	**5MG**	**N74063 001** JAN 27, 1994
AB		**10MG**	**N74063 002** JAN 27, 1994
AB	MYLAN	**5MG**	**N74019 001** SEP 03, 1992
AB		**10MG**	**N74019 002** SEP 03, 1992
AB	NOVOPHARM	**5MG**	**N73661 001** OCT 31, 1993
AB		**10MG**	**N73661 002** OCT 31, 1993
AB	TEVA	**5MG**	**N74123 001** APR 17, 1997
AB		**10MG**	**N74123 002** APR 17, 1997
AB	WATSON LABS	**5MG**	**N74437 001** FEB 27, 1995
AB		**10MG**	**N74437 002** FEB 27, 1995
AB	ZENITH GOLDLINE	**5MG**	**N73687 001** FEB 26, 1993

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ZENITH GOLDLINE	**10MG**	**N73687 002** FEB 26, 1993

VISKEN

AB	NOVARTIS	**5MG**	**N18285 001** SEP 03, 1982
AB	+	**10MG**	**N18285 002** SEP 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOS

	TAKEDA PHARMS NA	EQ 15MG BASE	N21073 001 JUL 15, 1999
		EQ 30MG BASE	N21073 002 JUL 15, 1999
+		EQ 45MG BASE	N21073 003 JUL 15, 1999

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION
ARDUAN

+	ORGANON	10MG/VIAL	N19638 001 JUN 26, 1990

PIPERACILLIN SODIUM

INJECTABLE; INJECTION
PIPRACIL

+	LEDERLE	EQ 2GM BASE/VIAL	N50545 002
		EQ 2GM BASE/VIAL	N62750 001 OCT 13, 1987
+		EQ 3GM BASE/VIAL	N50545 003
		EQ 3GM BASE/VIAL	N62750 002 OCT 13, 1987
+		EQ 4GM BASE/VIAL	N50545 004
		EQ 4GM BASE/VIAL	N62750 003 OCT 13, 1987

FDA data supplied by DrugPatentWatch.com

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

	ZOSYN			
+	WYETH AYERST	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993
+		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993
+		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993
+		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993
	ZOSYN IN PLASTIC CONTAINER			
+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001	FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998

PIPERAZINE CITRATE

SYRUP; ORAL

	MULTIFUGE			
AA	+ BLULINE	**EQ 500MG BASE/5ML**	**N09452 001**	
	PIPERAZINE CITRATE			
AA	LANNETT	**EQ 500MG BASE/5ML**	**N80963 001**	
AA	LUITPOLD	**EQ 500MG BASE/5ML**	**N80671 001**	

TABLET; ORAL

	PIPERAZINE CITRATE			
+	IMPAX LABS	EQ 250MG BASE	N80874 001	

PIPOBROMAN

TABLET; ORAL

	VERCYTE			
+	ABBOTT	25MG	N16245 002	

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

	MAXAIR			
+	3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986
+		EQ 0.2MG BASE/INH	N20014 001	NOV 30, 1992

PIROXICAM

CAPSULE; ORAL

	FELDENE			
AB	PFIZER	**10MG**	**N18147 002**	APR 06, 1982
AB	+	**20MG**	**N18147 003**	APR 06, 1982
	PIROXICAM			
AB	COPLEY PHARM	**10MG**	**N74103 001**	AUG 28, 1992
AB		**20MG**	**N74103 002**	AUG 28, 1992
AB	DANBURY PHARMA	**10MG**	**N74287 001**	MAY 16, 1996
AB		**20MG**	**N74287 002**	MAY 16, 1996
AB	EGIS	**10MG**	**N74808 001**	JUL 08, 1997
AB		**20MG**	**N74808 002**	JUL 08, 1997
AB	GENPHARM	**10MG**	**N74043 001**	SEP 22, 1992
AB		**20MG**	**N74043 002**	SEP 22, 1992
AB	MEPHA	**10MG**	**N74116 001**	JUN 15, 1993
AB		**20MG**	**N74118 001**	JUN 15, 1993
AB	MUTUAL PHARM	**10MG**	**N73535 001**	MAR 12, 1993
AB		**20MG**	**N73536 001**	MAR 12, 1993
AB	MYLAN	**10MG**	**N74102 001**	JUL 31, 1992
AB		**20MG**	**N74102 002**	JUL 31, 1992
AB	NOVOPHARM	**10MG**	**N73637 001**	JAN 28, 1994

FDA data supplied by DrugPatentWatch.com

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOVOPHARM	**20MG**	**N73638 001**	JAN 28, 1994
AB	SCS	**10MG**	**N74036 001**	MAY 29, 1992
AB		**20MG**	**N74036 002**	MAY 29, 1992
AB	TEVA	**10MG**	**N74131 001**	DEC 11, 1992
AB		**20MG**	**N74131 002**	DEC 11, 1992
AB	WATSON LABS	**10MG**	**N74460 001**	SEP 29, 1995
AB		**20MG**	**N74460 002**	SEP 29, 1995
AB	ZENITH GOLDLINE	**10MG**	**N74148 001**	JUN 03, 1996
AB		**20MG**	**N74148 002**	JUN 03, 1996

PLICAMYCIN

INJECTABLE; INJECTION
MITHRACIN

+	PFIZER	2.5MG/VIAL	N50109 001

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001 MAR 13, 1997

SOLUTION; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N19795 001 DEC 13, 1990

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
MIRALAX

+	BRAINTREE	17GM/SCOOPFUL	N20698 001 FEB 18, 1999

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
NULYTELY

+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 001 APR 22, 1991

NULYTELY-FLAVORED

+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
OCL

+	ABBOTT	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001 APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL
COLYTE

AA	+	SCHWARZ PHARMA	**227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT**	**N18983 010** JAN 31, 1989
AA	+		**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 007** JUN 12, 1987

COLYTE WITH FLAVOR PACKS

AA	+	SCHWARZ PHARMA	**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 012** OCT 08, 1998

COLYTE-FLAVORED

AA	+	SCHWARZ PHARMA	**227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT**	**N18983 008** NOV 14, 1991
AA	+		**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 009** NOV 14, 1991

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL

	GOLYTELY			
AA	+ BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002	JUN 02, 1992
AA	+	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N19011 001	JUL 13, 1984

FOR SUSPENSION; ORAL

	CO-LAV			
AA	COPLEY PHARM	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N73428 001	JAN 28, 1992
	COLOVAGE			
AA	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N71320 001	APR 20, 1988
	E-Z-EM PREP LYTE			
AA	E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N71278 001	NOV 21, 1988
	GLYCOPREP			
AA	GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N72319 001	DEC 23, 1988
	GO-EVAC			
AA	COPLEY PHARM	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73433 001	APR 28, 1992

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

	POLYMYXIN B SULFATE			
AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	N60716 001	
AP	PHARMA TEK	EQ 500,000 U BASE/VIAL	N63000 001	SEP 30, 1994

POWDER; FOR RX COMPOUNDING

	POLY-RX		
+	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001

POLYMYXIN B SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	TAYLOR PHARMA	10,000 UNITS/ML; EQ 1MG BASE/ML	N65006 001	DEC 17, 1998

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	POLYTRIM			
AT	+ ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N50567 001	OCT 20, 1988
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	N64120 001	FEB 14, 1997
AT	FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	APR 13, 1998

POLYTETRAFLUOROETHYLENE; *MULTIPLE*

SEE PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

FDA data supplied by DrugPatentWatch.com

POLYTHIAZIDE

TABLET; ORAL
RENESE
PFIZER 1MG N12845 001
2MG N12845 002
\+ 4MG N12845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIZIDE
PFIZER 0.5MG;EQ 1MG BASE N17986 001
0.5MG;EQ 2MG BASE N17986 002
\+ 0.5MG;EQ 5MG BASE N17986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL
RENESE-R
\+ PFIZER 2MG;0.25MG N13636 001

PORACTANT ALPHA

SUSPENSION; INTRATRACHEAL
CUROSURF
\+ DEY 80MG/ML N20744 001
NOV 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION
PHOTOFRIN
\+ AXCAN SCANDIPHARM 75MG/VIAL N20451 001
DEC 27, 1995

POTASSIUM ACETATE

INJECTABLE; INJECTION
POTASSIUM ACETATE IN PLASTIC CONTAINER
\+ ABBOTT 2MEQ/ML N18896 001
JUL 20, 1984

POTASSIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL
PASKALIUM
\+ GLENWOOD 500MG N09395 004

TABLET; ORAL
PASKALIUM
\+ GLENWOOD 1GM N09395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K
AB KV PHARM **8MEQ** **N18238 001**
MICRO-K 10
AB \+ KV PHARM **10MEQ** **N18238 002**
MAY 14, 1984
POTASSIUM CHLORIDE
AB KV PHARM **10MEQ** **N70980 001**
FEB 17, 1987
AB TEVA **8MEQ** **N73531 001**
APR 26, 1996
AB **10MEQ** **N73532 001**
APR 26, 1996

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
AP \+ ABBOTT **2MEQ/ML** **N80205 001**
AP **2MEQ/ML** **N83345 002**
\+ 1.5MEQ/ML N83345 001
AP AM PHARM PARTNERS **2MEQ/ML** **N80225 001**
AP **2MEQ/ML** **N87817 001**
OCT 20, 1982
\+ 3MEQ/ML N80225 003

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE				
AP	B BRAUN	2MEQ/ML	N85870 001		
AP	BAXTER HLTHCARE	2MEQ/ML	N85499 001		
AP	INTL MEDICATION	2MEQ/ML	N83163 001		
AP	LUITPOLD	2MEQ/ML	N87584 001		
AP		2MEQ/ML	N87585 001		
AP	PHARMA SERVE NY	2MEQ/ML	N86297 001		
AP		2MEQ/ML	N87362 001		
			MAR 08, 1983		
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	746MG/100ML	N19904 005		
			DEC 17, 1990		
+		14.9MG/ML	N19904 001		
			DEC 26, 1989		
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER				
AP +	ABBOTT	29.8MG/ML	N20161 006		
			AUG 11, 1998		
AP +	BAXTER HLTHCARE	29.8MG/ML	N19904 002		
			DEC 26, 1989		
+		1.49GM/100ML	N19904 006		
			DEC 17, 1990		
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
AP +	ABBOTT	2.24GM/100ML	N20161 003		
			AUG 11, 1998		
AP +	BAXTER HLTHCARE	2.24GM/100ML	N19904 003		
			DEC 26, 1989		
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER				
AP +	ABBOTT	2.98GM/100ML	N20161 004		
			AUG 11, 1998		
AP +	BAXTER HLTHCARE	2.98GM/100ML	N19904 004		
			DEC 26, 1989		
	POTASSIUM CHLORIDE IN PLASTIC CONTAINER				
AP	AM PHARM PARTNERS	2MEQ/ML	N88901 001		
			JAN 25, 1985		
AP		2MEQ/ML	N88908 001		
			JAN 25, 1985		

TABLET, EXTENDED RELEASE; ORAL

	K+10				
BC	ALRA	10MEQ	N70999 001		
			OCT 22, 1987		
	K+8				
AB	ALRA	8MEQ	N70998 001		
			JAN 25, 1993		
	K-DUR 10				
AB +	KEY PHARMS	10MEQ	N19439 002		
			JUN 13, 1986		

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	K-DUR 20				
AB +	KEY PHARMS	20MEQ	N19439 001		
			JUN 13, 1986		
	K-TAB				
BC	ABBOTT	10MEQ	N18279 001		
	KLOR-CON				
AB	UPSHER SMITH	8MEQ	N19123 001		
			APR 17, 1986		
BC		10MEQ	N19123 002		
			APR 17, 1986		
	KLOR-CON M10				
AB	UPSHER SMITH	10MEQ	N74726 002		
			AUG 09, 2000		
	KLOR-CON M20				
AB	UPSHER SMITH	20MEQ	N74726 001		
			NOV 20, 1998		
	KLOTRIX				
BC	APOTHECON	10MEQ	N17850 001		
	POTASSIUM CHLORIDE				
BC	ABBOTT	8MEQ	N18279 002		
			AUG 01, 1988		
AB	COPLEY PHARM	8MEQ	N70618 001		
			SEP 09, 1987		
	SLOW-K				
AB +	NOVARTIS	8MEQ	N17476 002		

POTASSIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

POTASSIUM CHLORIDE; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**150MG/100ML;900MG/100ML**	**N19708 004**	SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**149MG/100ML;900MG/100ML**	**N19686 001**	OCT 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**298MG/100ML;900MG/100ML**	**N19686 002**	OCT 17, 1988

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N17648 001**	
	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%			
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N17648 003	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N17648 002**	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

MISSION PHARMA	5MEQ	N19071 001	AUG 30, 1985
+	10MEQ	N19071 002	AUG 31, 1992

POTASSIUM LACTATE; *MULTIPLE*
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC

FDA data supplied by DrugPatentWatch.com

POTASSIUM PERCHLORATE

CAPSULE; ORAL
PERCHLORACAP
+ MALLINCKRODT 200MG N17551 001

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE
+ ALCON 5% N18634 001 DEC 17, 1986

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE
+ MERIDIAN MEDCL TECHN 300MG/ML N18986 001 APR 26, 1983

PROTOPAM CHLORIDE
+ WYETH AYERST 1GM/VIAL N14134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
+ PHARMACIA AND UPJOHN 0.125MG N20667 001 JUL 01, 1997
0.25MG N20667 002 JUL 01, 1997
0.5MG N20667 006 FEB 12, 1998
1MG N20667 003 JUL 01, 1997
+ 1.5MG N20667 005 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL
BRISTOL MYERS SQUIBB 10MG N19898 002 OCT 31, 1991
20MG N19898 003 OCT 31, 1991
+ 40MG N19898 004 MAR 22, 1993

FDA data supplied by DrugPatentWatch.com

PRAZIQUANTEL

TABLET; ORAL
BILTRICIDE
\+ BAYER 600MG N18714 001 DEC 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIPRESS

AB	PFIZER	**EQ 1MG BASE**	**N17442 002**	
AB	+	**EQ 2MG BASE**	**N17442 003**	
AB		**EQ 5MG BASE**	**N17442 001**	

PRAZOSIN HCL

AB	DANBURY PHARMA	**EQ 1MG BASE**	**N72352 001**	MAY 16, 1989
AB		**EQ 2MG BASE**	**N72333 001**	MAY 16, 1989
AB		**EQ 5MG BASE**	**N72609 001**	MAY 16, 1989
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N72576 001**	MAY 16, 1989
AB		**EQ 2MG BASE**	**N72577 001**	MAY 16, 1989
AB		**EQ 5MG BASE**	**N72578 001**	MAY 16, 1989
AB	LEDERLE	**EQ 1MG BASE**	**N72705 001**	MAY 16, 1989
AB		**EQ 2MG BASE**	**N72706 001**	MAY 16, 1989
AB		**EQ 5MG BASE**	**N72707 001**	MAY 16, 1989
AB	MYLAN	**EQ 1MG BASE**	**N72573 001**	MAY 16, 1989
AB		**EQ 2MG BASE**	**N72574 001**	MAY 16, 1989
AB		**EQ 5MG BASE**	**N72575 001**	MAY 16, 1989
AB	PUREPAC PHARM	**EQ 1MG BASE**	**N72991 001**	MAY 16, 1989
AB		**EQ 2MG BASE**	**N72921 001**	MAY 16, 1989
AB		**EQ 5MG BASE**	**N72992 001**	MAY 16, 1989
AB	ZENITH GOLDLINE	**EQ 1MG BASE**	**N71994 001**	SEP 12, 1988

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

AB	ZENITH GOLDLINE	**EQ 2MG BASE**	**N71995 001**	SEP 12, 1988
AB		**EQ 5MG BASE**	**N71745 001**	SEP 12, 1988

TABLET, EXTENDED RELEASE; ORAL
MINIPRESS XL

\+	PFIZER	2.5MG	N19775 001 JAN 29, 1992
\+		5MG	N19775 002 JAN 29, 1992

PRAZOSIN HYDROCHLORIDE; *MULTIPLE*
SEE POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

PREDNICARBATE

CREAM; TOPICAL
DERMATOP

\+	AVENTIS PHARMS	0.1%	N20279 001 OCT 29, 1993

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	COPLEY PHARM	**15MG/5ML**	**N40322 001**	JAN 19, 2000
AA	HALSEY	**15MG/5ML**	**N40287 001**	MAY 28, 1999
AA	UDL	**15MG/5ML**	**N40323 001**	MAY 13, 1999
AA	WE PHARMS	**15MG/5ML**	**N40192 001**	MAY 28, 1998

PRELONE

AA	+ MURO	**15MG/5ML**	**N89081 001**	FEB 04, 1986
	+	5MG/5ML	N89654 001	JAN 17, 1989

TABLET; ORAL
PREDNISOLONE

BX	CHELSEA LABS	5MG	N85085 002

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX	+ DANBURY PHARMA	5MG	N80354	001
BX	EVERYLIFE	2.5MG	N84439	002
BX		5MG	N84439	003
BX	LANNETT	5MG	N80531	002
BX	MARSHALL PHARMA	5MG	N80307	001
BX	SPERTI	2.5MG	N80358	002
BX		5MG	N80358	003
		1MG	N80358	001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	+ STERIS	25MG/ML	N83398	001
		50MG/ML	N83764	001
	+	50MG/ML	N85781	001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED

	+ ALCON	0.125%	N17468	001

ECONOPRED PLUS

AB	FALCON PHARMS	**1%**	**N17469**	**001**

PRED FORTE

AB	+ ALLERGAN	**1%**	**N17011**	**001**

PRED MILD

	+ ALLERGAN	0.12%	N17100	001

PREDNISOLONE ACETATE; *MULTIPLE*
SEE GENTAMICIN SULFATE; PREDNISOLONE ACETATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
BLEPHAMIDE S.O.P.

	+ ALLERGAN	0.2%;10%	N87748	001
			DEC 03, 1986	

CETAPRED

	+ ALCON	0.25%;10%	N87771	001
			AUG 06, 1993	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
METIMYD

AT	+ SCHERING	**0.5%;10%**	**N10210**	**002**
			SEP 09, 1984	

VASOCIDIN

AT	CIBA	**0.5%;10%**	**N88791**	**001**
			OCT 05, 1984	

SUSPENSION; OPHTHALMIC
BLEPHAMIDE

	+ ALLERGAN	0.2%;10%	N12813	002

SUSPENSION/DROPS; OPHTHALMIC
ISOPTO CETAPRED

	+ ALCON	0.25%;10%	N87547	001

METIMYD

AT	+ SCHERING	**0.5%;10%**	**N10210**	**001**

PREDAMIDE

AT	AKORN	**0.5%;10%**	**N88059**	**001**
			JUL 29, 1983	

SULPHRIN

AT	BAUSCH AND LOMB	**0.5%;10%**	**N88089**	**001**
			DEC 28, 1982	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
ORAPRED

	+ ASCENT PEDS	EQ 15MG BASE/5ML	N75117	001
			DEC 14, 2000	

PEDIAPRED

	+ MEDEVA	EQ 5MG BASE/5ML	N19157	001
			MAY 28, 1986	

SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

AT	+ CIBA	**EQ 0.9% PHOSPHATE**	**N80751**	**002**

INFLAMASE MILD

AT	+ CIBA	**EQ 0.11% PHOSPHATE**	**N80751**	**001**

PREDNISOLONE SODIUM PHOSPHATE

AT	AKORN	**EQ 0.11% PHOSPHATE**	**N83358**	**001**
AT		**EQ 0.9% PHOSPHATE**	**N83358**	**002**
AT	ALCON UNIVERSAL	**EQ 0.11% PHOSPHATE**	**N81043**	**001**
			OCT 24, 1991	
AT		**EQ 0.9% PHOSPHATE**	**N81044**	**001**
			OCT 24, 1991	

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	N40065 001	
			JUL 29, 1994	
AT		EQ 0.9% PHOSPHATE	N40070 001	
			JUL 29, 1994	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.23% PHOSPHATE;10%	N73630 001	
			MAY 27, 1993	
AT	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	N74449 001	
			DEC 29, 1995	

VASOCIDIN

AT	+ CIBA	EQ 0.23% PHOSPHATE;10%	N18988 001	
			AUG 26, 1988	

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

+	MERCK	20MG/ML	N10562 001

PREDNISONE

SOLUTION; ORAL

PREDNISONE

+	ROXANE	5MG/5ML	N88703 001	
			NOV 08, 1984	

PREDNISONE INTENSOL

+	ROXANE	5MG/ML	N88810 001	
			FEB 20, 1985	

TABLET; ORAL

DELTASONE

AB	+ PHARMACIA AND UPJOHN	2.5MG	N09986 005	
AB	+	5MG	N09986 002	
AB	+	10MG	N09986 006	
AB	+	20MG	N09986 007	
AB	+	50MG	N09986 008	

METICORTEN

AB	+ SCHERING	1MG	N09766 002	

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	CHELSEA LABS	5MG	N85084 002	
AB		10MG	N87773 001	
			JUL 13, 1982	
AB		20MG	N86813 001	
AB		50MG	N87772 001	
			JUL 13, 1982	
AB	DANBURY PHARMA	5MG	N80356 001	
AB		10MG	N85162 001	
AB		20MG	N85161 001	
BX	EVERYLIFE	1MG	N84440 001	
BX		2.5MG	N84440 002	
BX		5MG	N84440 003	
AB	GENEVA PHARMS	5MG	N80336 002	
AB		10MG	N89983 001	
			JAN 12, 1989	
AB		20MG	N85813 001	
AB		50MG	N89984 001	
			JAN 12, 1989	
AB	HALSEY	10MG	N86595 001	
BX	LANNETT	5MG	N80514 001	
BX		20MG	N84275 001	
BX	MARSHALL PHARMA	5MG	N80301 001	
AB	MUTUAL PHARM	5MG	N89245 001	
			DEC 04, 1985	
AB		10MG	N89246 001	
			DEC 04, 1985	
AB		20MG	N89247 001	
			DEC 04, 1985	
AB	PVT FORM	5MG	N80209 001	
AB	ROXANE	1MG	N87800 001	
			APR 22, 1982	
AB		2.5MG	N87801 001	
			APR 22, 1982	
AB		5MG	N80352 001	
AB		10MG	N84122 001	
AB		20MG	N87342 001	
AB		50MG	N84283 001	
AB	WEST WARD	5MG	N80292 001	
AB		10MG	N88832 001	
			DEC 04, 1985	
AB		20MG	N83677 001	
AB		50MG	N88465 001	
			JUN 01, 1984	

PRILOCAINE; *MULTIPLE*

SEE LIDOCAINE; PRILOCAINE

FDA data supplied by DrugPatentWatch.com

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST PLAIN
\+ ASTRAZENECA 4% N14763 007

PRILOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

PRIMAQUINE PHOSPHATE

TABLET; ORAL
PRIMAQUINE
\+ SANOFI SYNTHELABO EQ 15MG BASE N08316 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE
\+ ELAN PHARMA 250MG/5ML N10401 001

TABLET; ORAL
MYSOLINE
AB \+ ELAN PHARMA **250MG** **N09170 002**
50MG N09170 003
PRIMIDONE
AB DANBURY PHARMA **250MG** **N83551 001**
AB LANNETT **250MG** **N84903 001**

PROBENECID

TABLET; ORAL
PROBALAN
AB LANNETT **500MG** **N80966 001**
PROBENECID
AB DANBURY PHARMA **500MG** **N84442 004**
MAR 29, 1983
AB \+ MYLAN **500MG** **N84211 002**
AB ZENITH GOLDLINE **500MG** **N83740 001**
MAY 09, 1984

PROBENECID; *MULTIPLE*
SEE AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID
SEE COLCHICINE; PROBENECID

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PROCAINAMIDE HCL
AB DANBURY PHARMA **250MG** **N83287 001**
AB **375MG** **N84403 001**
AB **500MG** **N84280 001**
AB GENEVA PHARMS **250MG** **N89219 001**
JUL 01, 1986
AB **375MG** **N89220 001**
JUL 01, 1986
AB **500MG** **N89221 001**
JUL 01, 1986
AB LANNETT **250MG** **N83693 001**
AB ZENITH GOLDLINE **250MG** **N84604 001**
AB **375MG** **N84595 001**
AB **500MG** **N84606 001**
PRONESTYL
AB APOTHECON **250MG** **N07335 001**
AB **375MG** **N07335 004**
AB \+ **500MG** **N07335 003**

INJECTABLE; INJECTION
PROCAINAMIDE HCL
AP ABBOTT **100MG/ML** **N89069 001**
FEB 12, 1986
AP **500MG/ML** **N89070 001**
FEB 12, 1986
AP **500MG/ML** **N89537 001**
AUG 25, 1987
AP ELKINS SINN **100MG/ML** **N89029 001**
APR 17, 1986
AP **500MG/ML** **N89030 001**
APR 17, 1986
AP INTL MEDICATION **100MG/ML** **N88636 001**
JUL 31, 1984
AP **500MG/ML** **N88637 001**
JUL 31, 1984
PRONESTYL
AP \+ APOTHECON **100MG/ML** **N07335 002**
AP \+ **500MG/ML** **N07335 005**

TABLET; ORAL
PRONESTYL
APOTHECON 250MG N17371 001
375MG N17371 002
\+ 500MG N17371 003

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
AB	COPLEY PHARM	1GM	N40111 001	
			DEC 13, 1996	
AB		500MG	N88974 001	
			JUL 22, 1985	
AB		750MG	N89438 001	
			MAR 23, 1987	
AB	DANBURY PHARMA	250MG	N89026 001	
			OCT 22, 1985	
AB		500MG	N89027 001	
			OCT 22, 1985	
AB		750MG	N89042 001	
			OCT 22, 1985	
AB	GENEVA PHARMS	250MG	N89369 001	
			AUG 14, 1987	
AB		500MG	N89370 001	
			JAN 09, 1987	
AB		750MG	N89371 001	
			AUG 14, 1987	
AB	SIDMAK LABS NJ	500MG	N88959 001	
			DEC 02, 1985	
	PROCANBID			
	+ KING PHARMS	500MG	N20545 001	
			JAN 31, 1996	
	+	1GM	N20545 002	
			JAN 31, 1996	
	PRONESTYL-SR			
BC	APOTHECON	500MG	N87361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVOCAIN			
AP	+ ABBOTT	1%	N85362 003	
AP	+	2%	N85362 004	
	+	10%	N86797 001	
	PROCAINE HCL			
AP	ABBOTT	1%	N80416 001	
AP		2%	N80416 002	
AP	AM PHARM PARTNERS	1%	N80421 001	
AP		2%	N80421 002	
AP	ELKINS SINN	1%	N83315 001	
AP		2%	N83315 002	
AP	STERIS	1%	N80658 001	
AP		2%	N80658 002	

PROCAINE HYDROCHLORIDE; *MULTIPLE*
SEE NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE			
+ SIGMA TAU	EQ 50MG BASE	N16785 001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

	COMPAZINE			
AB	+ SMITHKLINE BEECHAM	25MG	N11127 002	
		2.5MG	N11127 003	
		5MG	N11127 001	
	COMPRO			
AB	PADDOCK	25MG	N40246 001	
			JUN 28, 2000	
	PROCHLORPERAZINE			
AB	G AND W LABS	25MG	N40058 001	
			NOV 24, 1993	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	COMPAZINE			
AP	+ SMITHKLINE BEECHAM	EQ 5MG BASE/ML	N10742 002	
	PROCHLORPERAZINE			
AP	ELKINS SINN	EQ 5MG BASE/ML	N87759 001	
			OCT 01, 1982	
	PROCHLORPERAZINE EDISYLATE			
AP	ABBOTT	EQ 5MG BASE/ML	N89703 001	
			APR 07, 1988	
AP	ELKINS SINN	EQ 5MG BASE/ML	N89903 001	
			AUG 29, 1989	
AP	STERIS	EQ 5MG BASE/ML	N89530 001	
			JUL 08, 1987	
AP	WYETH AYERST	EQ 5MG BASE/ML	N86348 001	

SYRUP; ORAL

COMPAZINE			
SMITHKLINE BEECHAM	EQ 5MG BASE/5ML	N11188 001	

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

	COMPAZINE			
	+ SMITHKLINE BEECHAM	EQ 10MG BASE	N11000 001	
		EQ 10MG BASE	N21019 001	
			OCT 06, 1999	
	+	EQ 15MG BASE	N11000 002	
		EQ 15MG BASE	N21019 002	
			OCT 06, 1999	
	+	EQ 30MG BASE	N11000 003	

TABLET; ORAL

	COMPAZINE			
AB	SMITHKLINE BEECHAM	**EQ 5MG BASE**	**N10571 001**	
AB		**EQ 10MG BASE**	**N10571 002**	
AB	+	**EQ 25MG BASE**	**N10571 003**	
	PROCHLORPERAZINE MALEATE			
AB	COPLEY PHARM	**EQ 5MG BASE**	**N40120 001**	
			JUL 11, 1996	
AB		**EQ 10MG BASE**	**N40120 002**	
			JUL 11, 1996	
AB	DURAMED	**EQ 5MG BASE**	**N40207 001**	
			MAY 01, 1997	
AB		**EQ 10MG BASE**	**N40207 002**	
			MAY 01, 1997	
AB	INVAMED	**EQ 5MG BASE**	**N40101 001**	
			JUL 19, 1996	
AB		**EQ 10MG BASE**	**N40101 002**	
			JUL 19, 1996	
AB		**EQ 25MG BASE**	**N40101 003**	
			JUL 19, 1996	
AB	MYLAN	**EQ 5MG BASE**	**N40185 002**	
			OCT 28, 1996	
AB		**EQ 10MG BASE**	**N40185 001**	
			OCT 28, 1996	
AB	TRIGEN	**EQ 5MG BASE**	**N40268 001**	
			FEB 27, 1998	
AB		**EQ 10MG BASE**	**N40268 002**	
			FEB 27, 1998	
AB	ZENITH GOLDLINE	**EQ 5MG BASE**	**N40162 001**	
			JAN 20, 1998	
AB		**EQ 10MG BASE**	**N40162 002**	
			JAN 20, 1998	

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

	KEMADRIN		
+	MONARCH PHARMS	5MG	N09818 003

PROGESTERONE

CAPSULE; ORAL

	PROMETRIUM		
	UNIMED PHARMS	100MG	N19781 001
			MAY 14, 1998
+		200MG	N19781 002
			OCT 15, 1999

GEL; VAGINAL

	CRINONE		
	COLUMBIA RES LABS	4%	N20701 001
			JUL 31, 1997
+		8%	N20701 002
			JUL 31, 1997
+		8%	N20756 001
			MAY 13, 1997

INJECTABLE; INJECTION

	PROGESTERONE		
+	STERIS	50MG/ML	N17362 002

INSERT, EXTENDED RELEASE; INTRAUTERINE

	PROGESTASERT		
	ALZA	38MG	N17553 001

PROGUANIL HYDROCHLORIDE; *MULTIPLE*

SEE ATOVAQUONE; PROGUANIL HYDROCHLORIDE

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	SPARINE		
+	WYETH AYERST	50MG/ML	N10349 006

TABLET; ORAL

	SPARINE		
	WYETH AYERST	25MG	N10348 001
+		50MG	N10348 002

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PHENERGAN			
AP	+ WYETH AYERST	25MG/ML	N08857 002	
AP	+	50MG/ML	N08857 003	
	PROMETHAZINE HCL			
AP	ABBOTT	25MG/ML	N40372 001	
			JUN 08, 2000	
AP		50MG/ML	N40372 002	
			JUN 08, 2000	
AP		50MG/ML	N83838 002	
AP	ELKINS SINN	25MG/ML	N83312 001	
AP		50MG/ML	N83312 002	
AP	STERIS	25MG/ML	N84591 001	
AP		50MG/ML	N80629 002	

SUPPOSITORY; RECTAL

	PHENERGAN		
BR	+ WYETH AYERST	25MG	N10926 001
BR	+	50MG	N11689 001
		12.5MG	N10926 002
	PROMETHACON		
BR	POLYMEDICA	25MG	N84901 001
BR		50MG	N84902 001
	PROMETHEGAN		
BR	G AND W LABS	50MG	N87165 001
			AUG 14, 1987

SYRUP; ORAL

	PHENERGAN FORTIS		
	+ WYETH AYERST	25MG/5ML	N08381 003
	PHENERGAN PLAIN		
AA	+ WYETH AYERST	6.25MG/5ML	N08381 004
			APR 18, 1984
	PROMETH PLAIN		
AA	ALPHARMA	6.25MG/5ML	N85953 001
	PROMETHAZINE HCL		
AA	HI TECH PHARMA	6.25MG	N40026 001
			SEP 25, 1998
AA	WHITEWORTH TOWN PLSN	6.25MG/5ML	N86395 001
	PROMETHAZINE PLAIN		
AA	MORTON GROVE	6.25MG/5ML	N87953 001
			NOV 15, 1982

TABLET; ORAL

	PHENERGAN		
BP	WYETH AYERST	12.5MG	N07935 002
BP		25MG	N07935 003

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

	PHENERGAN		
BP	+ WYETH AYERST	50MG	N07935 004
	PROMETHAZINE HCL		
BP	DANBURY PHARMA	25MG	N83426 001
BP		50MG	N83711 001
BP	GENEVA PHARMS	25MG	N84234 001
BP		50MG	N84176 001
BP	LANNETT	12.5MG	N80949 001
BP		25MG	N80949 002
BP		50MG	N80949 003
BP	PVT FORM	25MG	N83658 001

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SEE MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

	PROPAFENONE HCL		
AB	WATSON LABS	150MG	N75203 001
			OCT 24, 2000
AB		225MG	N75203 002
			OCT 24, 2000
	RYTHMOL		
AB	KNOLL PHARM	150MG	N19151 001
			NOV 27, 1989
AB		225MG	N19151 003
			NOV 20, 1992
	+	300MG	N19151 002
			NOV 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE		
BP	+ SHIRE	7.5MG	N08732 003
BP	+	15MG	N08732 002
	PROPANTHELINE BROMIDE		
BP	ROXANE	7.5MG	N80927 001

FDA data supplied by DrugPatentWatch.com

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	ROXANE	15MG	N80927	002

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
PROPARACAINE HCL

AT	TAYLOR PHARMA	**0.5%**	**N40277**	**001**
			MAR 16, 2000	

SOLUTION/DROPS; OPHTHALMIC
ALCAINE

AT	ALCON	**0.5%**	**N80027**	**001**

OPHTHAINE

AT	+ APOTHECON	**0.5%**	**N08883**	**001**

OPHTHETIC

AT	+ ALLERGAN	**0.5%**	**N12583**	**001**

PARACAINE

AT	OPTOPICS	**0.5%**	**N87681**	**001**
			AUG 05, 1982	

PROPARACAINE HCL

AT	BAUSCH AND LOMB	**0.5%**	**N40074**	**001**
			SEP 29, 1995	

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

AB	+ ASTRAZENECA	**10MG/ML**	**N19627**	**002**
			JUN 11, 1996	

PROPOFOL

AB	GENSIA SICOR PHARMS	**10MG/ML**	**N75102**	**001**
			JAN 04, 1999	
AB		**10MG/ML**	**N75392**	**001**
			SEP 19, 2000	

PROPOXYCAINE HYDROCHLORIDE; *MULTIPLE*
SEE NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

AA	+ LILLY	**32MG**	**N10997**	**001**
AA	+	**65MG**	**N10997**	**003**

DOLENE

AA	LEDERLE	**65MG**	**N80530**	**001**

KESSO-GESIC

AA	MK LABS	**65MG**	**N83544**	**001**

PROPOXYPHENE HCL

AA	GENEVA PHARMS	**65MG**	**N83125**	**002**
AA	ICN	**65MG**	**N80783**	**001**
AA	IMPAX LABS	**65MG**	**N83317**	**001**
AA	MYLAN	**32MG**	**N83528**	**001**
AA	TEVA	**65MG**	**N88615**	**001**
			OCT 22, 1984	
AA	WEST WARD	**65MG**	**N83501**	**001**
AA	WHITEWORTH TOWN PLSN	**65MG**	**N84551**	**001**
AA	ZENITH GOLDLINE	**65MG**	**N80269**	**001**

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL
DARVON-N

+ LILLY	50MG/5ML	N16861	001

TABLET; ORAL
DARVON-N

+ LILLY	100MG	N16862	002

PROPOXYPHENE NAPSYLATE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

+ WYETH AYERST	60MG	N18553	004
		MAR 18, 1987	

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	INDERAL LA				
	+ WYETH AYERST	80MG	N18553 002		APR 19, 1983
	+	120MG	N18553 003		APR 19, 1983
	+	160MG	N18553 001		APR 19, 1983

CONCENTRATE; ORAL

	PROPRANOLOL HCL INTENSOL				
	+ ROXANE	80MG/ML	N71388 001		MAY 15, 1987

INJECTABLE; INJECTION

	INDERAL				
AP	+ WYETH AYERST	**1MG/ML**	**N16419 001**		
	PROPRANOLOL HCL				
AP	BEDFORD	**1MG/ML**	**N75792 001**		AUG 29, 2000

SOLUTION; ORAL

	PROPRANOLOL HCL				
	+ ROXANE	20MG/5ML	N70979 001		MAY 15, 1987
	+	40MG/5ML	N70690 001		MAY 15, 1987

TABLET; ORAL

	INDERAL				
AB	+ WYETH AYERST	**10MG**	**N16418 001**		
AB		**20MG**	**N16418 003**		
AB		**40MG**	**N16418 002**		
AB		**60MG**	**N16418 009**		OCT 18, 1982
AB	+	**80MG**	**N16418 004**		
	PROPRANOLOL HCL				
AB	DANBURY PHARMA	**10MG**	**N70175 001**		MAY 13, 1986
AB		**20MG**	**N70176 001**		MAY 13, 1986
AB		**40MG**	**N70177 001**		MAY 13, 1986
AB		**80MG**	**N70178 001**		MAY 13, 1986
AB	GENEVA PHARMS	**10MG**	**N70663 001**		JUN 13, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL				
AB	GENEVA PHARMS	**20MG**	**N70664 001**		JUN 13, 1986
AB		**40MG**	**N70665 001**		JUN 13, 1986
AB		**60MG**	**N70666 001**		OCT 10, 1986
AB		**80MG**	**N70667 001**		JUN 13, 1986
AB	LEDERLE	**10MG**	**N70125 001**		JUL 30, 1985
AB		**20MG**	**N70126 001**		JUL 30, 1985
AB		**40MG**	**N70127 001**		JUL 30, 1985
AB		**60MG**	**N71495 001**		DEC 31, 1987
AB		**80MG**	**N70128 001**		JUL 30, 1985
AB		**90MG**	**N71496 001**		DEC 31, 1987
AB	MYLAN	**10MG**	**N70211 001**		NOV 19, 1985
AB		**20MG**	**N70212 001**		NOV 19, 1985
AB		**40MG**	**N70213 001**		NOV 19, 1985
AB		**80MG**	**N70214 001**		NOV 19, 1985
AB	PAR PHARM	**10MG**	**N70217 001**		AUG 01, 1986
AB		**20MG**	**N70218 001**		AUG 01, 1986
AB		**40MG**	**N70219 001**		AUG 01, 1986
AB		**60MG**	**N70220 001**		SEP 24, 1986
AB		**80MG**	**N70221 001**		APR 14, 1986
AB		**90MG**	**N71288 001**		OCT 22, 1986
AB	PUREPAC PHARM	**10MG**	**N70814 001**		NOV 03, 1986
AB		**20MG**	**N70815 001**		NOV 03, 1986

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	PUREPAC PHARM	40MG	N70816 001	NOV 03, 1986
AB		60MG	N70817 001	NOV 03, 1986
AB		80MG	N70757 001	NOV 03, 1986
AB	SIDMAK LABS NJ	10MG	N71972 001	APR 06, 1988
AB		20MG	N71973 001	APR 06, 1988
AB		40MG	N71974 001	APR 06, 1988
AB		60MG	N71975 001	APR 06, 1988
AB		80MG	N71976 001	APR 06, 1988
AB		90MG	N71977 001	APR 06, 1988
AB	TEVA	40MG	N70234 001	JUN 23, 1986
AB	WATSON LABS	10MG	N70548 001	JUL 10, 1986
AB		20MG	N70549 001	APR 11, 1986
AB		40MG	N70550 001	APR 11, 1986
AB		60MG	N71791 001	JUL 15, 1987
AB		80MG	N70551 001	JUL 10, 1986
AB		90MG	N71792 001	JUL 15, 1987

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	IMPAX LABS	50MG	N80159 001	
BD +	LEDERLE	50MG	N06188 001	
BD	PUREPAC PHARM	50MG	N80172 001	

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	WEST WARD	50MG	N80154 001

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

AP	AM PHARM PARTNERS	10MG/ML	N89454 001	APR 07, 1987
AP	ELKINS SINN	10MG/ML	N89474 001	NOV 05, 1986
AP		10MG/ML	N89475 001	NOV 05, 1986
AP +	LILLY	10MG/ML	N06460 002	

PROTIRELIN

INJECTABLE; INJECTION
THYREL TRH

+	FERRING	0.5MG/ML	N18087 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
PROTRIPTYLINE HCL

AB	SIDMAK LABS NJ	5MG	N73644 001	AUG 24, 1995
AB		10MG	N73645 001	AUG 24, 1995

VIVACTIL

AB	SIDMAK LABS	5MG	N16012 001
AB +		10MG	N16012 002

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRILITRON
+ NEWTRON PHARMS 30MG/5ML;1.25MG/5ML N88474 001 FEB 12, 1985

TABLET; ORAL
CORPHED
AA GENEVA PHARMS **60MG;2.5MG** **N88602 001** APR 11, 1985

PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL
AA + EON **60MG;2.5MG** **N88193 001** MAY 17, 1983

TRILITRON
AA NEWTRON PHARMS **60MG;2.5MG** **N88515 001** JAN 09, 1985

TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA SUPERPHARM **60MG;2.5MG** **N88578 001** FEB 21, 1985

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE LORATADINE; PSEUDOEPHEDRINE SULFATE

PYRAZINAMIDE

TABLET; ORAL
PYRAZINAMIDE
AB + LEDERLE **500MG** **N80157 001**
AB MIKART **500MG** **N81319 001** JUN 30, 1992

PYRAZINAMIDE; *MULTIPLE*
SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON
AP + ICN **5MG/ML** **N09830 001**
REGONOL
AP + ORGANON **5MG/ML** **N17398 001**

SYRUP; ORAL
MESTINON
+ ICN 60MG/5ML N15193 001

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
MESTINON
+ ICN 60MG N09829 002

TABLET, EXTENDED RELEASE; ORAL
MESTINON
+ ICN 180MG N11665 001

PYRIDOXINE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL
AP AM PHARM PARTNERS **100MG/ML** **N80618 001**
AP + STERIS **100MG/ML** **N80572 001**

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE
+ IMPAX LABS 25MG N80808 001

PYRILAMINE MALEATE; *MULTIPLE*
SEE PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

PYRIMETHAMINE

TABLET; ORAL						
DARAPRIM						
+ GLAXO WELLCOME	25MG	N08578 001				

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL						
FANSIDAR						
+ ROCHE	25MG;500MG	N18557 001				

QUAZEPAM

TABLET; ORAL						
DORAL						
WALLACE LABS	7.5MG	N18708 003 FEB 26, 1987				
+	15MG	N18708 001 DEC 27, 1985				

QUETIAPINE FUMARATE

TABLET; ORAL						
SEROQUEL						
ASTRAZENECA	EQ 25MG BASE	N20639 001 SEP 26, 1997				
	EQ 100MG BASE	N20639 002 SEP 26, 1997				
	EQ 150MG BASE	N20639 004 DEC 20, 1998				
+	EQ 200MG BASE	N20639 003 SEP 26, 1997				

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL						
ACCUPRIL						
PARKE DAVIS	EQ 5MG BASE	N19885 001 NOV 19, 1991				
	EQ 10MG BASE	N19885 002 NOV 19, 1991				
	EQ 20MG BASE	N19885 003 NOV 19, 1991				

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL						
ACCUPRIL						
+ PARKE DAVIS	EQ 40MG BASE	N19885 004 NOV 19, 1991				

QUINAPRIL HYDROCHLORIDE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

QUINETHAZONE

TABLET; ORAL						
HYDROMOX						
+ LEDERLE	50MG	N13264 001				

QUINIDINE GLUCONATE

INJECTABLE; INJECTION						
QUINIDINE GLUCONATE						
+ LILLY	80MG/ML	N07529 002 FEB 10, 1989				

TABLET, EXTENDED RELEASE; ORAL						
QUINAGLUTE						
+ BERLEX LABS	**324MG**	**N16647 001**				
QUINIDINE GLUCONATE						
DANBURY PHARMA	**324MG**	**N87810 001** SEP 29, 1982				
GENEVA PHARMS	**324MG**	**N89894 001** DEC 15, 1988				
MUTUAL PHARM	**324MG**	**N89338 001** FEB 11, 1987				

QUINIDINE SULFATE

TABLET; ORAL						
QUINIDINE SULFATE						
CHELSEA LABS	**200MG**	**N85140 002**				
DANBURY PHARMA	**200MG**	**N83288 001**				
	300MG	**N85583 001**				
EON	**200MG**	**N84631 001**				
	300MG	**N88072 001** SEP 26, 1983				
GENEVA PHARMS	**200MG**	**N84914 001**				

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	GENEVA PHARMS	300MG	N89839 001	
			SEP 29, 1988	
AB	IMPAX LABS	200MG	N83347 001	
AB	LANNETT	200MG	N83743 001	
AB	LEDERLE	200MG	N87011 001	
AB	MUTUAL PHARM	100MG	N81029 001	
			APR 14, 1989	
AB		200MG	N81030 001	
			APR 14, 1989	
AB		300MG	N81031 001	
			APR 14, 1989	
AB	PVT FORM	200MG	N83808 001	
AB +	ROXANE	200MG	N83640 001	
AB +		300MG	N85632 001	
AB	SMITHKLINE BEECHAM	200MG	N85175 001	
AB	SUPERPHARM	200MG	N88973 001	
			APR 10, 1985	
AB	WEST WARD	200MG	N83862 001	

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB +	ROBINS AH	300MG	N12796 002

QUINIDINE SULFATE

AB	COPLEY PHARM	300MG	N40045 001
			JUN 30, 1994

QUINUPRISTIN; *MULTIPLE*
SEE DALFOPRISTIN; QUINUPRISTIN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX

+	EISAI	20MG	N20973 002
			AUG 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL
EVISTA

+	LILLY	60MG	N20815 001
			DEC 09, 1997

RAMIPRIL

CAPSULE; ORAL
ALTACE

	KING PHARMS	1.25MG	N19901 001
			JAN 28, 1991
		2.5MG	N19901 002
			JAN 28, 1991
		5MG	N19901 003
			JAN 28, 1991
+		10MG	N19901 004
			JAN 28, 1991

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HCL

AB	DR REDDYS LABS LTD	EQ 150MG BASE	N75742 001
			NOV 29, 2000
AB		EQ 300MG BASE	N75742 002
			NOV 29, 2000
AB	GENEVA PHARMS	EQ 150MG BASE	N74655 001
			OCT 22, 1997
AB		EQ 300MG BASE	N74655 002
			OCT 22, 1997
AB	GENPHARM	EQ 150MG BASE	N75564 001
			OCT 27, 2000
AB		EQ 300MG BASE	N75564 002
			OCT 27, 2000

ZANTAC 150

AB	GLAXO WELLCOME	EQ 150MG BASE	N20095 001
			MAR 08, 1994

ZANTAC 300

AB +	GLAXO WELLCOME	EQ 300MG BASE	N20095 002
			MAR 08, 1994

GRANULE, EFFERVESCENT; ORAL
ZANTAC 150

+	GLAXO WELLCOME	EQ 150MG BASE/PACKET	N20251 002
			MAR 31, 1994

INJECTABLE; INJECTION
ZANTAC

+	GLAXO WELLCOME	EQ 25MG BASE/ML	N19090 001
			OCT 19, 1984

ZANTAC IN PLASTIC CONTAINER

+	GLAXO WELLCOME	EQ 1MG BASE/ML	N19593 002
			SEP 27, 1991

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC
\+ GLAXO WELLCOME — EQ 15MG BASE/ML — N19675 001 — DEC 30, 1988

TABLET; ORAL
RANITIDINE

AB	RANBAXY	**EQ 150MG BASE**	**N75439 001**	APR 19, 2000
AB		**EQ 300MG BASE**	**N75439 002**	APR 19, 2000

RANITIDINE HCL

AB	BOEHRINGER INGELHEIM	**EQ 150MG BASE**	**N74662 001**	AUG 29, 1997
AB		**EQ 300MG BASE**	**N74662 002**	AUG 29, 1997
AB	CHELSEA LABS	**EQ 150MG BASE**	**N74864 001**	OCT 20, 1997
AB		**EQ 300MG BASE**	**N74864 002**	OCT 20, 1997
AB	GENEVA PHARMS	**EQ 150MG BASE**	**N74467 001**	AUG 29, 1997
AB		**EQ 300MG BASE**	**N74467 002**	AUG 29, 1997
AB	GENPHARM	**EQ 150MG BASE**	**N74023 001**	AUG 22, 1997
AB		**EQ 300MG BASE**	**N74023 002**	AUG 22, 1997
AB	MYLAN	**EQ 150MG BASE**	**N74552 001**	JUL 30, 1998
AB		**EQ 300MG BASE**	**N74552 002**	JUL 30, 1998
AB	NOVOPHARM NC	**EQ 150MG BASE**	**N74488 001**	JUL 31, 1997
AB		**EQ 300MG BASE**	**N74488 002**	JUL 31, 1997
AB	PAR PHARM	**EQ 150MG BASE**	**N75180 001**	JAN 28, 1999
AB		**EQ 300MG BASE**	**N75180 002**	JAN 28, 1999
AB	RANBAXY	**EQ 150MG BASE**	**N75000 001**	JAN 30, 1998
AB		**EQ 300MG BASE**	**N75000 002**	JAN 30, 1998
AB	TORPHARM	**EQ 150MG BASE**	**N74680 001**	SEP 12, 1997

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	TORPHARM	**EQ 300MG BASE**	**N74680 002**	SEP 12, 1997
AB	WOCKHARDT	**EQ 150MG BASE**	**N75208 001**	DEC 17, 1998
AB		**EQ 300MG BASE**	**N75208 002**	DEC 17, 1998
AB	ZENITH GOLDLINE	**EQ 150MG BASE**	**N75165 001**	SEP 30, 1998
AB		**EQ 300MG BASE**	**N75165 002**	SEP 30, 1998

ZANTAC 150

AB	GLAXO WELLCOME	**EQ 150MG BASE**	**N18703 001**	JUN 09, 1983

ZANTAC 300

AB	+ GLAXO WELLCOME	**EQ 300MG BASE**	**N18703 002**	DEC 09, 1985

TABLET, EFFERVESCENT; ORAL
ZANTAC 150
\+ GLAXO WELLCOME — EQ 150MG BASE — N20251 001 — MAR 31, 1994

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION
RAPLON

ORGANON	100MG/VIAL	N20984 001	AUG 18, 1999
\+	200MG/VIAL	N20984 002	AUG 18, 1999

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA

ABBOTT	EQ 1MG BASE/VIAL	N20630 001	JUL 12, 1996
	EQ 2MG BASE/VIAL	N20630 002	JUL 12, 1996
\+	EQ 5MG BASE/VIAL	N20630 003	JUL 12, 1996

FDA data supplied by DrugPatentWatch.com

REPAGLINIDE

	TABLET; ORAL			
	PRANDIN			
	NOVO NORDISK	0.5MG	N20741 001	
			DEC 22, 1997	
		1MG	N20741 002	
			DEC 22, 1997	
+		2MG	N20741 003	
			DEC 22, 1997	

RESCINNAMINE

	TABLET; ORAL		
	MODERIL		
	PFIZER	0.25MG	N10686 003
+		0.5MG	N10686 006

RESERPINE

		TABLET; ORAL		
		RESERPINE		
BP		EON	0.1MG	N09838 001
BP	+		0.25MG	N09838 002
		SERPALAN		
BP		LANNETT	0.1MG	N10124 001
BP			0.25MG	N10124 002

RESERPINE; *MULTIPLE*

SEE CHLOROTHIAZIDE; RESERPINE
SEE CHLORTHALIDONE; RESERPINE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
SEE HYDROCHLOROTHIAZIDE; RESERPINE
SEE HYDROFLUMETHIAZIDE; RESERPINE
SEE METHYCLOTHIAZIDE; RESERPINE
SEE POLYTHIAZIDE; RESERPINE

RESERPINE; TRICHLORMETHIAZIDE

	TABLET; ORAL		
	METATENSIN #2		
	AVENTIS PHARMS	0.1MG;2MG	N12972 001
	METATENSIN #4		
+	AVENTIS PHARMS	0.1MG;4MG	N12972 002

RIBAVIRIN

	CAPSULE; ORAL			
	REBETOL			
+	SCHERING PLOUGH RES	200MG †	N20903 001	
			JUN 03, 1998	
	FOR SOLUTION; INHALATION			
	VIRAZOLE			
+	ICN	6GM/VIAL	N18859 001	
			DEC 31, 1985	

RIBOFLAVIN; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

RIFABUTIN

	CAPSULE; ORAL			
	MYCOBUTIN			
+	PHARMACIA AND UPJOHN	150MG	N50689 001	
			DEC 23, 1992	

RIFAMPIN

	CAPSULE; ORAL			
	RIFADIN			
AB	AVENTIS PHARMS	**150MG**	**N62303 001**	
AB	+	**300MG**	**N50420 001**	
	RIFAMPIN			
AB	EON	**150MG**	**N64150 002**	
			JAN 02, 1998	

† SEE SECTION 1.8 DESCRIPTION OF SPECIAL SITUATIONS

FDA data supplied by DrugPatentWatch.com

RIFAMPIN

CAPSULE; ORAL

	RIFAMPIN			
AB	EON	**300MG**	**N64150 001**	MAY 28, 1997
	RIMACTANE			
AB	GENEVA PHARMS	**300MG**	**N50429 001**	

INJECTABLE; INJECTION

	RIFADIN			
AP	+ AVENTIS PHARMS	**600MG/VIAL**	**N50627 001**	MAY 25, 1989
	RIFAMPIN			
AP	BEDFORD	**600MG/VIAL**	**N64217 001**	OCT 29, 1999

RIFAMPIN; *MULTIPLE*

SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SEE ISONIAZID; RIFAMPIN

RIFAPENTINE

TABLET; ORAL

	PRIFTIN		
+	AVENTIS PHARMS	150MG	N21024 001 JUN 22, 1998

RILUZOLE

TABLET; ORAL

	RILUTEK		
+	AVENTIS	50MG	N20599 001 DEC 12, 1995

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	FLUMADINE		
+	FOREST LABS	50MG/5ML	N19650 001 SEP 17, 1993

TABLET; ORAL

	FLUMADINE		
+	FOREST LABS	100MG	N19649 001 SEP 17, 1993

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

	VEXOL		
+	ALCON	1%	N20474 001 DEC 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

	ACTONEL		
	PROCTER AND GAMBLE	5MG	N20835 002 APR 14, 2000
+		30MG	N20835 001 MAR 27, 1998

RISPERIDONE

SOLUTION; ORAL

	RISPERDAL		
+	JANSSEN RES FDN	1MG/ML	N20588 001 JUN 10, 1996

TABLET; ORAL

	RISPERDAL		
	JANSSEN RES FDN	0.25MG	N20272 008 MAY 10, 1999
+		0.5MG	N20272 007 JAN 27, 1999
		1MG	N20272 001 DEC 29, 1993
		2MG	N20272 002 DEC 29, 1993
		3MG	N20272 003 DEC 29, 1993
+		4MG	N20272 004 DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RITODRINE HCL		
+	ABBOTT	10MG/ML	N71618 001 FEB 28, 1991
+		15MG/ML	N71619 001 FEB 28, 1991

FDA data supplied by DrugPatentWatch.com

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ABBOTT	30MG/100ML	N71438 001 JAN 22, 1991

RITONAVIR

CAPSULE; ORAL
NORVIR

+	ABBOTT	100MG	N20680 001 MAR 01, 1996
		100MG	N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR

+	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996

RITONAVIR; *MULTIPLE*
SEE LOPINAVIR; RITONAVIR

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

	NOVARTIS	EQ 1.5MG BASE	N20823 003 APR 21, 2000
		EQ 3MG BASE	N20823 004 APR 21, 2000
		EQ 4.5MG BASE	N20823 005 APR 21, 2000
+		EQ 6MG BASE	N20823 006 APR 21, 2000

SOLUTION; ORAL
EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N21025 001 APR 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT

	MERCK	EQ 5MG BASE	N20864 001 JUN 29, 1998
+		EQ 10MG BASE	N20864 002 JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT-MLT

	MERCK	EQ 5MG BASE	N20865 001 JUN 29, 1998
+		EQ 10MG BASE	N20865 002 JUN 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON

+	ORGANON	10MG/ML	N20214 002 MAR 17, 1994

ZEMURON (P/F)

+	ORGANON	10MG/ML	N20214 001 MAR 17, 1994

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999
+		25MG/5ML	N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001 MAY 20, 1999
		25MG	N21042 002 MAY 20, 1999
+		50MG	N21042 003 FEB 25, 2000

FDA data supplied by DrugPatentWatch.com

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP			
+ SMITHKLINE BEECHAM	EQ 0.25MG BASE	N20658 001	SEP 19, 1997
	EQ 0.5MG BASE	N20658 002	SEP 19, 1997
	EQ 1MG BASE	N20658 003	SEP 19, 1997
	EQ 2MG BASE	N20658 004	SEP 19, 1997
	EQ 3MG BASE	N20658 006	JAN 27, 1999
	EQ 4MG BASE	N20658 007	JAN 27, 1999
+	EQ 5MG BASE	N20658 005	SEP 19, 1997

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION

NAROPIN			
ASTRAZENECA	2MG/ML	N20533 001	SEP 24, 1996
	5MG/ML	N20533 003	SEP 24, 1996
	7.5MG/ML	N20533 004	SEP 24, 1996
+	10MG/ML	N20533 005	SEP 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA			
SMITHKLINE BEECHAM	EQ 2MG BASE	N21071 002	MAY 25, 1999
	EQ 4MG BASE	N21071 003	MAY 25, 1999
+	EQ 8MG BASE	N21071 004	MAY 25, 1999

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82			
BRACCO	N/A	N19414 001	DEC 29, 1989

SACROSIDASE

SOLUTION; ORAL

SUCRAID			
+ ORPHAN MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%			
+ ABBOTT	5%;5%	N18997 001	AUG 27, 1984
LIPOSYN II 20%			
+ ABBOTT	10%;10%	N18991 001	AUG 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT			
+ GLAXO WELLCOME	EQ 0.021MG BASE/INH	N20236 001	FEB 04, 1994

POWDER; INHALATION

SEREVENT			
+ GLAXO WELLCOME	EQ 0.046MG BASE/INH	N20692 001	SEP 19, 1997

SALMETEROL XINAFOATE; *MULTIPLE*
SEE FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET			
+ CYTOGEN	50mCi/ML	N20570 001	MAR 28, 1997

FDA data supplied by DrugPatentWatch.com

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP
+ NOVARTIS 1MG/72HR N17874 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA EVERYLIFE **100MG** **N85895 001**
AA ICN **100MG** **N85477 001**
SECONAL SODIUM
AA + LILLY **100MG** **N86101 002** OCT 03, 1983
+ 50MG N86101 001 OCT 03, 1983
SODIUM SECOBARBITAL
AA WEST WARD **100MG** **N84926 001**

INJECTABLE; INJECTION
SECOBARBITAL SODIUM
+ ELKINS SINN 100MG/VIAL N83281 001
SODIUM SECOBARBITAL
+ WYETH AYERST 50MG/ML N83262 001

SECRETIN

INJECTABLE; INJECTION
SECRETIN-FERRING
+ FERRING 75CU/VIAL N18290 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET **5MG** **N20647 001** MAY 15, 1996
SELEGILINE HCL
AB ESI LEDERLE **5MG** **N75352 001** NOV 30, 1998
AB TORPHARM **5MG** **N75321 001** DEC 04, 1998

TABLET; ORAL
SELEGILINE HCL
AB ALPHAPHARM **5MG** **N74866 001** NOV 26, 1997
AB APOTEX **5MG** **N74871 001** JUN 06, 1997
AB APOTHECON **5MG** **N74672 001** APR 01, 1997
AB ENDO PHARMS **5MG** **N74565 001** AUG 02, 1996
AB ESI LEDERLE **5MG** **N74641 001** AUG 02, 1996
AB NORTON WATERFORD **5MG** **N74756 001** NOV 25, 1998
AB NOVOPHARM NC **5MG** **N74537 001** AUG 02, 1996
AB + SOMERSET **5MG** **N19334 001** JUN 05, 1989
AB STASON **5MG** **N74912 001** APR 30, 1998
AB TEVA **5MG** **N74744 001** JAN 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
EXSEL
AT ALLERGAN HERBERT **2.5%** **N83892 001**
SELENIUM SULFIDE
AT ALPHARMA **2.5%** **N84394 001**
AT CLAY PARK **2.5%** **N89996 001** JAN 10, 1991
AT MORTON GROVE **2.5%** **N88228 001** SEP 01, 1983
SELSUN
AT + ABBOTT **2.5%** **N07936 001**

FDA data supplied by DrugPatentWatch.com

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SELENOMETHIONINE SE 75
+ CIS — 500 uCi/ML — N17322 001

SERMORELIN ACETATE

INJECTABLE; INJECTION
GEREF
+ SERONO — EQ 0.05MG BASE/AMP — N19863 001 DEC 28, 1990
+ — EQ 0.5MG BASE/VIAL — N20443 001 SEP 26, 1997
+ — EQ 1MG BASE/VIAL — N20443 002 SEP 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
ZOLOFT
+ PFIZER — EQ 20MG BASE/ML — N20990 001 DEC 07, 1999

TABLET; ORAL
ZOLOFT
PFIZER — EQ 25MG BASE — N19839 005 MAR 06, 1996
EQ 50MG BASE — N19839 001 DEC 30, 1991
+ — EQ 100MG BASE — N19839 002 DEC 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
RENAGEL
+ GELTEX — 403MG — N20926 001 OCT 30, 1998

TABLET; ORAL
RENAGEL
GELTEX — 400MG — N21179 001 JUL 12, 2000
+ — 800MG — N21179 002 JUL 12, 2000

SEVOFLURANE

LIQUID; INHALATION
ULTANE
+ ABBOTT — 100% — N20478 001 JUN 07, 1995

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL
MERIDIA
KNOLL PHARM — 5MG — N20632 001 NOV 22, 1997
10MG — N20632 002 NOV 22, 1997
+ — 15MG — N20632 003 NOV 22, 1997

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA
PFIZER — 25MG — N20895 001 MAR 27, 1998
50MG — N20895 002 MAR 27, 1998
+ — 100MG — N20895 003 MAR 27, 1998

SILVER SULFADIAZINE

CREAM; TOPICAL
SILVADENE
AB + KING PHARMS — **1%** — **N17381 001**
SSD
AB BASF — **1%** — **N18578 001** FEB 25, 1982
SSD AF
BX BASF — 1% — N18578 003 JUL 11, 1990
THERMAZENE
AB KENDALL LP — **1%** — **N18810 001** DEC 23, 1985

FDA data supplied by DrugPatentWatch.com

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX			
+ BRACCO	7.5MG/ML	N20773 001	OCT 29, 1998

SIMVASTATIN

TABLET; ORAL

ZOCOR			
+ MERCK	5MG	N19766 001	DEC 23, 1991
	10MG	N19766 002	DEC 23, 1991
	20MG	N19766 003	DEC 23, 1991
	40MG	N19766 004	DEC 23, 1991
+	80MG	N19766 005	JUL 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC			
+ BRACCO	0.005MG/VIAL	N17697 001	

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE			
+ WYETH AYERST	1MG/ML	N21083 001	SEP 15, 1999

SODIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SODIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER			
+ ABBOTT	2MEQ/ML	N18893 001	MAY 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN			
+ B BRAUN	100MG/ML;100MG/ML	N19530 001	DEC 23, 1987

FDA data supplied by DrugPatentWatch.com

SODIUM BICARBONATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

	BAROS			
	LAFAYETTE PHARMS	460MG/GM;420MG/GM	N18509 001	AUG 07, 1985

SODIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SODIUM CHLORIDE

INJECTABLE; INJECTION

	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP +	ABBOTT	**9MG/ML**	**N18800 001**	OCT 29, 1982
AP	AM PHARM PARTNERS	**9MG/ML**	**N88911 001**	FEB 07, 1985
	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	ABBOTT	**450MG/100ML**	**N18090 001**	
AP		**450MG/100ML**	**N19759 001**	JUN 08, 1988
AP	B BRAUN	**450MG/100ML**	**N19635 001**	MAR 09, 1988
AP	BAXTER HLTHCARE	**450MG/100ML**	**N18016 001**	
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	**900MG/100ML**	**N16366 001**	
AP		**9MG/ML**	**N18803 001**	OCT 29, 1982
AP		**9MG/ML**	**N19217 001**	JUL 13, 1984

SODIUM CHLORIDE

INJECTABLE; INJECTION

	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	**900MG/100ML**	**N19465 001**	JUL 15, 1985
AP		**9MG/ML**	**N19465 002**	JUL 15, 1985
AP		**900MG/100ML**	**N19480 001**	SEP 17, 1985
AP	AM PHARM PARTNERS	**9MG/ML**	**N88912 001**	JAN 10, 1985
AP	B BRAUN	**900MG/100ML**	**N17464 001**	
AP		**900MG/100ML**	**N19635 002**	MAR 09, 1988
AP	BAXTER HLTHCARE	**900MG/100ML**	**N16677 001**	
AP +		**9MG/ML**	**N16677 004**	OCT 30, 1985
AP		**900MG/100ML**	**N20178 001**	DEC 07, 1992
AP		**9MG/ML**	**N20178 002**	DEC 07, 1992
	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	3GM/100ML	N19022 001	NOV 01, 1983
	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5GM/100ML	N19022 002	NOV 01, 1983
	SODIUM CHLORIDE IN PLASTIC CONTAINER			
	ABBOTT	2.5MEQ/ML	N18897 001	JUL 20, 1984

SOLUTION FOR SLUSH; IRRIGATION

	SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER			
	BAXTER HLTHCARE	900MG/100ML	N19319 002	MAY 17, 1985

SOLUTION; IRRIGATION

	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AT	ABBOTT	**450MG/100ML**	**N17670 001**	
AT	BAXTER HLTHCARE	**450MG/100ML**	**N17864 001**	
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AT	ABBOTT	**900MG/100ML**	**N17514 001**	
AT		**900MG/100ML**	**N18314 001**	
AT	B BRAUN	**900MG/100ML**	**N16733 001**	
AT	BAXTER HLTHCARE	**900MG/100ML**	**N17427 001**	
AT		**900MG/100ML**	**N17867 001**	

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CITRATE; SODIUM ACETATE; SODIUM CHLORIDE

SODIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; SODIUM CHLORIDE
SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
BRACCO 200 uCi/ML N13993 001
SODIUM CHROMATE CR 51
MALLINCKRODT 100 uCi/ML N16708 001

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM GLUCONATE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL
SODIUM IODIDE I 123
AA MALLINCKRODT **100 uCi** **N71909 001**
FEB 28, 1989
AA **200 uCi** **N71910 001**
FEB 28, 1989
AA NYCOMED AMERSHAM **100 uCi** **N17630 001**
AA SYNCOR PHARMS **100 uCi** **N18671 001**
MAY 27, 1982
AA **200 uCi** **N18671 002**
MAY 27, 1982

SOLUTION; ORAL
SODIUM IODIDE I 123
NYCOMED AMERSHAM 2mCi/ML N17630 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE
\+ BRACCO 1-130mCi N10929 001

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE
\+ BRACCO 1-150mCi N10929 003
SODIUM IODIDE I 131
\+ CIS 100 uCi N17316 002
\+ MALLINCKRODT 15-100 uCi N16517 002
\+ 0.8-100mCi N16517 001

SOLUTION; ORAL
IODOTOPE
\+ BRACCO 7-106mCi/BOT N10929 002
SODIUM IODIDE I 131
\+ CIS 50mCi/ML N17315 001
\+ MALLINCKRODT 3.5-150mCi/VIAL N16515 001

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
AP ABBOTT **1.87GM/100ML** **N18249 001**
AP BAXTER HLTHCARE **1.87GM/100ML** **N16692 001**
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
AP B BRAUN **1.87GM/100ML** **N20004 001**
APR 21, 1992
SODIUM LACTATE IN PLASTIC CONTAINER
ABBOTT 5MEQ/ML N18947 001
SEP 05, 1984

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

SODIUM LACTATE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

		NITROPRESS		
AP	+ ABBOTT	**25MG/ML**	**N71961 001** AUG 01, 1988	
AP		**50MG/VIAL**	**N70566 001** JUN 09, 1986	
		SODIUM NITROPRUSSIDE		
AP	+ ELKINS SINN	**50MG/VIAL**	**N18581 001** JUL 28, 1982	
AP	GENSIA SICOR PHARMS	**25MG/ML**	**N73465 001** MAR 30, 1992	

SODIUM PHENYLACETATE; *MULTIPLE*
SEE SODIUM BENZOATE; SODIUM PHENYLACETATE

SODIUM PHENYLBUTYRATE

POWDER; ORAL

	BUPHENYL		
+	MEDICIS	3GM/TEASPOONFUL	N20573 001 APR 30, 1996

TABLET; ORAL

	BUPHENYL		
+	MEDICIS	500MG	N20572 001 MAY 13, 1996

SODIUM PHOSPHATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SODIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

SODIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

SODIUM PHOSPHATE, DIBASIC; SODIUM PHOSPHATE, MONOBASIC

INJECTABLE; INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER

	ABBOTT	142MG/ML;276MG/ML	N18892 001 MAY 10, 1983

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
VISICOL

+	INKINE	0.398GM;1.102GM	N21097 001 SEP 21, 2000

SODIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC
SEE SODIUM PHOSPHATE, DIBASIC; SODIUM PHOSPHATE, MONOBASIC

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; *MULTIPLE*
SEE SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
SODIUM PHOSPHATE P 32

	MALLINCKRODT	0.67mCi/ML	N11777 001

FDA data supplied by DrugPatentWatch.com

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

	KAYEXALATE			
AA	+ SANOFI SYNTHELABO	453.6GM/BOT	N11287 001	
	KIONEX			
AA	PADDOCK	454GM/BOT	N40029 001	FEB 06, 1998
	SODIUM POLYSTYRENE SULFONATE			
AA	CAROLINA MEDCL	454GM/BOT	N89910 001	JAN 19, 1989

SUSPENSION; ORAL, RECTAL

	SODIUM POLYSTYRENE SULFONATE			
AA	ROXANE	15GM/60ML	N89049 001	NOV 17, 1986
	SPS			
AA	CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982

SODIUM SULFATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

	SOTRADECOL			
	+ ELKINS SINN	1%	N05970 004	
	+	3%	N05970 005	

SODIUM THIOSULFATE

INJECTABLE; INJECTION

	SODIUM THIOSULFATE			
	+ US ARMY	250MG/ML	N20166 001	FEB 14, 1992

SOMATREM

INJECTABLE; INJECTION

	PROTROPIN			
	+ GENENTECH	5MG/VIAL	N19107 001	OCT 17, 1985
	+	10MG/VIAL	N19107 002	OCT 24, 1989

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

	BIO-TROPIN			
	+ BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995
	GENOTROPIN			
	+ PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	AUG 24, 1995
	+	13.8MG/VIAL	N20280 007	OCT 23, 1996
	GENOTROPIN PRESERVATIVE FREE			
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N20280 001	JAN 27, 1998
		0.4MG/VIAL	N20280 002	JAN 27, 1998
		0.6MG/VIAL	N20280 003	JAN 27, 1998
		0.8MG/VIAL	N20280 005	JAN 27, 1998
		1MG/VIAL	N20280 008	JAN 27, 1998
		1.2MG/VIAL	N20280 009	JAN 27, 1998
		1.4MG/VIAL	N20280 010	JAN 27, 1998
		1.5MG/VIAL	N20280 004	AUG 24, 1995
		1.6MG/VIAL	N20280 011	JAN 27, 1998
		1.8MG/VIAL	N20280 012	JAN 27, 1998
	+	2MG/VIAL	N20280 013	JAN 27, 1998
	HUMATROPE			
BX	+ LILLY	5MG/VIAL	N19640 004	MAR 08, 1987
BX		6MG/VIAL	N19640 005	FEB 04, 1999

FDA data supplied by DrugPatentWatch.com

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

	HUMATROPE				
	+ LILLY	12MG/VIAL	N19640 006 FEB 04, 1999		
	+	24MG/VIAL	N19640 007 FEB 04, 1999		
	NORDITROPIN				
BX	+ NOVO NORDISK	4MG/VIAL	N19721 001 MAY 08, 1995		
		5MG/1.5ML	N21148 001 JUN 20, 2000		
		10MG/1.5ML	N21148 002 JUN 20, 2000		
	+	8MG/VIAL	N19721 002 MAY 08, 1995		
	+	15MG/1.5ML	N21148 003 JUN 20, 2000		
	NUTROPIN				
BX	GENENTECH	5MG/VIAL	N20168 001 NOV 17, 1993		
	+	10MG/VIAL	N20168 002 NOV 17, 1993		
	NUTROPIN AQ				
	+ GENENTECH	5MG/ML	N20522 001 DEC 29, 1995		
	NUTROPIN DEPOT				
	+ GENENTECH	13.5MG/VIAL	N21075 001 DEC 22, 1999		
	+	18MG/VIAL	N21075 002 DEC 22, 1999		
	+	22.5MG/VIAL	N21075 003 DEC 22, 1999		
	SAIZEN				
BX	SERONO	5MG/VIAL	N19764 002 OCT 08, 1996		
BX		6MG/VIAL	N19764 001 OCT 08, 1996		
	SEROSTIM				
BX	SERONO	4MG/VIAL	N20604 003 JUL 25, 1997		
BX		5MG/VIAL	N20604 002 AUG 23, 1996		
BX	+	6MG/VIAL	N20604 001 AUG 23, 1996		

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	3GM/100ML	N17863 001
SORBITOL 3.3% IN PLASTIC CONTAINER			
	B BRAUN	3.3GM/100ML	N16741 001

SORBITOL; *MULTIPLE*
SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE			
AB	BERLEX LABS	**80MG**	**N19865 001** OCT 30, 1992	
AB		**120MG**	**N19865 005** APR 20, 1994	
AB	+	**160MG**	**N19865 002** OCT 30, 1992	
AB		**240MG**	**N19865 003** OCT 30, 1992	
	BETAPACE AF			
	BERLEX LABS	80MG	N21151 001 FEB 22, 2000	
		120MG	N21151 002 FEB 22, 2000	
	+	160MG	N21151 003 FEB 22, 2000	
	SOTALOL HCL			
AB	EON	**80MG**	**N75366 001** MAY 01, 2000	
AB		**120MG**	**N75366 002** MAY 01, 2000	
AB		**160MG**	**N75366 003** MAY 01, 2000	
AB		**240MG**	**N75366 004** MAY 01, 2000	
AB	GENPHARM	**80MG**	**N75237 001** MAY 01, 2000	
AB		**120MG**	**N75237 002** MAY 01, 2000	
AB		**160MG**	**N75237 003** MAY 01, 2000	
AB		**240MG**	**N75237 004** MAY 01, 2000	

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SOTALOL HCL			
AB	IMPAX PHARM	80MG	N75663 001	NOV 07, 2000
AB		120MG	N75663 002	NOV 07, 2000
AB		160MG	N75663 003	NOV 07, 2000
AB		240MG	N75663 004	NOV 07, 2000
AB	MYLAN	80MG	N75725 001	DEC 19, 2000
AB		120MG	N75725 002	DEC 19, 2000
AB		160MG	N75725 003	DEC 19, 2000
AB		240MG	N75725 004	DEC 19, 2000
AB	TEVA	80MG	N75429 001	MAY 01, 2000
AB		120MG	N75429 002	MAY 01, 2000
AB		160MG	N75429 003	MAY 01, 2000
AB		240MG	N75429 004	MAY 01, 2000
AB	WATSON LABS	80MG	N75238 001	JUL 13, 2000
AB		120MG	N75238 002	JUL 13, 2000
AB		160MG	N75238 003	JUL 13, 2000
AB		240MG	N75238 004	JUL 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 10%			
AP	+ FRESENIUS KABI	10%	N17643 001	
	INTRALIPID 20%			
AP	+ FRESENIUS KABI	20%	N18449 001	
AP	+	20%	N20248 001	AUG 07, 1996
	INTRALIPID 30%			
AP	+ FRESENIUS KABI	30%	N19942 001	DEC 30, 1993

SOYBEAN OIL

INJECTABLE; INJECTION

	LIPOSYN III 10%			
AP	+ ABBOTT	10%	N18969 001	SEP 24, 1984
	LIPOSYN III 20%			
AP	+ ABBOTT	20%	N18970 001	SEP 25, 1984
	LIPOSYN III 30%			
AP	+ ABBOTT	30%	N20181 001	JAN 13, 1998
	NUTRILIPID 10%			
AP	+ B BRAUN	10%	N19531 001	MAY 28, 1993
	NUTRILIPID 20%			
AP	+ B BRAUN	20%	N19531 002	MAY 28, 1993
	SOYACAL 10%			
AP	+ ALPHA THERA	10%	N18465 001	JUN 29, 1983
	SOYACAL 20%			
AP	+ ALPHA THERA	20%	N18786 001	JUN 29, 1983

SOYBEAN OIL; *MULTIPLE*

SEE SAFFLOWER OIL; SOYBEAN OIL

SPARFLOXACIN

TABLET; ORAL

	ZAGAM			
+	MYLAN	200MG	N20677 001	DEC 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	TROBICIN			
+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N50347 001	
+		EQ 4GM BASE/VIAL	N50347 002	

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE			
AB	SEARLE	25MG	N12151 009	DEC 30, 1983
AB		50MG	N12151 008	DEC 30, 1982
AB	+	100MG	N12151 010	DEC 30, 1983
	SPIRONOLACTONE			
AB	GENEVA PHARMS	25MG	N86809 001	
AB	HALSEY	25MG	N87265 001	
AB	MUTUAL PHARM	25MG	N89424 001	JUL 23, 1986
AB		50MG	N89424 002	AUG 11, 1999
AB		100MG	N89424 003	AUG 11, 1999
AB	MYLAN	25MG	N87086 001	
AB	PUREPAC PHARM	50MG	N40353 001	JUL 29, 1999
AB		100MG	N40353 002	JUL 29, 1999
AB	SUPERPHARM	25MG	N89364 001	NOV 07, 1986

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STANOZOLOL

TABLET; ORAL

	WINSTROL			
+	SANOFI SYNTHELABO	2MG	N12885 001	MAY 14, 1984

STAVUDINE

CAPSULE; ORAL

	ZERIT			
	BRISTOL MYERS SQUIBB	15MG	N20412 002	JUN 24, 1994
		20MG	N20412 003	JUN 24, 1994

STAVUDINE

CAPSULE; ORAL

	ZERIT			
	BRISTOL MYERS SQUIBB	30MG	N20412 004	JUN 24, 1994
+		40MG	N20412 005	JUN 24, 1994

FOR SOLUTION; ORAL

	ZERIT			
+	BRISTOL MYERS SQUIBB	1MG/ML	N20413 001	SEP 06, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

	STREPTOMYCIN SULFATE			
AP +	PFIZER	EQ 1GM BASE/VIAL	N60076 001	
+		EQ 1GM BASE/2.5ML	N60111 001	
+		EQ 5GM BASE/VIAL	N60076 002	
AP	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

	ZANOSAR			
+	PHARMACIA AND UPJOHN	1GM/VIAL	N50577 001	MAY 07, 1982

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

	METASTRON			
+	NYCOMED AMERSHAM	1mCi/ML	N20134 001	JUN 18, 1993

SUCCIMER

CAPSULE; ORAL

	CHEMET			
+	SANOFI SYNTHELABO	100MG	N19998 002	JAN 30, 1991

FDA data supplied by DrugPatentWatch.com

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

		ANECTINE			
AP	+	GLAXO WELLCOME	**20MG/ML**	**N08453 002**	
	+		500MG/VIAL	N08453 001	
	+		1GM/VIAL	N08453 004	
		QUELICIN			
AP	+	ABBOTT	**20MG/ML**	**N08845 006**	
		QUELICIN PRESERVATIVE FREE			
AP	+	ABBOTT	**20MG/ML**	**N08845 001**	
	+		50MG/ML	N08845 002	
	+		100MG/ML	N08845 004	
		SUCCINYLCHOLINE CHLORIDE			
AP		ORGANON	**20MG/ML**	**N80997 001**	

SUCRALFATE

SUSPENSION; ORAL

		CARAFATE			
	+	AVENTIS PHARMS	1GM/10ML	N19183 001	DEC 16, 1993

TABLET; ORAL

		CARAFATE			
AB	+	BLUE RIDGE	**1GM**	**N18333 001**	
		SUCRALFATE			
AB		RATIOPHARM	**1GM**	**N74415 001**	JUN 08, 1998
AB		TEVA	**1GM**	**N70848 001**	MAR 29, 1996

SUFENTANIL CITRATE

INJECTABLE; INJECTION

		SUFENTA			
AP	+	AKORN	**EQ 0.05MG BASE/ML**	**N19050 001**	MAY 04, 1984
		SUFENTANIL CITRATE			
AP		ELKINS SINN	**EQ 0.05MG BASE/ML**	**N74413 001**	DEC 15, 1995
		SULFENTANIL CITRATE			
AP		ABBOTT	**EQ 0.05MG BASE/ML**	**N74534 001**	DEC 11, 1996

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

CREAM; TOPICAL

		EXELDERM			
	+	WESTWOOD SQUIBB	1%	N18737 001	FEB 28, 1989

SULFACETAMIDE SODIUM

LOTION; TOPICAL

		KLARON			
	+	DERMIK LABS	10%	N19931 001	DEC 23, 1996

OINTMENT; OPHTHALMIC

		BLEPH-10			
AT		ALLERGAN	**10%**	**N84015 001**	
		CETAMIDE			
AT		ALCON	**10%**	**N80021 001**	
		SODIUM SULAMYD			
AT	+	SCHERING	**10%**	**N05963 002**	
		SULFACETAMIDE SODIUM			
AT		ALTANA	**10%**	**N80029 001**	

SOLUTION/DROPS; OPHTHALMIC

		BLEPH-10			
AT		ALLERGAN	**10%**	**N80028 001**	
		BLEPH-30			
AT		ALLERGAN	**30%**	**N80028 002**	
		ISOPTO CETAMIDE			
AT	+	ALCON	**15%**	**N80020 002**	
		OCUSULF-10			
AT		MIZA PHARMS USA	**10%**	**N80660 001**	
		SODIUM SULAMYD			
AT	+	SCHERING	**10%**	**N05963 001**	
AT	+		**30%**	**N05963 003**	
		SULF-15			
AT		CIBA	**15%**	**N89047 001**	OCT 31, 1995
		SULFACEL-15			
AT		OPTOPICS	**15%**	**N80024 001**	
		SULFACETAMIDE SODIUM			
AT		AKORN	**10%**	**N40215 001**	MAY 25, 1999
AT			**30%**	**N40216 001**	MAY 25, 1999
AT		ALCON UNIVERSAL	**10%**	**N89560 001**	OCT 18, 1988

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFACETAMIDE SODIUM			
AT	BAUSCH AND LOMB	**10%**	**N40066 001**	DEC 28, 1994
AT	STERIS	**30%**	**N89068 001**	MAY 05, 1987
	SULTEN-10			
AT	BAUSCH AND LOMB	**10%**	**N87818 001**	FEB 03, 1983

SULFACETAMIDE SODIUM; *MULTIPLE*

SEE FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFACYTINE

TABLET; ORAL

	RENOQUID		
+	GLENWOOD	250MG	N17569 001

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE		
+	EON	500MG	N40091 001 JUL 29, 1994

SULFADOXINE; *MULTIPLE*

SEE PYRIMETHAMINE; SULFADOXINE

SULFAMETHIZOLE

TABLET; ORAL

	THIOSULFIL		
+	WYETH AYERST	500MG	N08565 004

SULFAMETHOXAZOLE

TABLET; ORAL

	GANTANOL			
AB	+ ROCHE	**500MG**	**N12715 002**	

SULFAMETHOXAZOLE

TABLET; ORAL

	SULFAMETHOXAZOLE			
AB	GENEVA PHARMS	**500MG**	**N85844 001**	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	BACTRIM			
AP	+ ROCHE	**80MG/ML;16MG/ML**	**N18374 001**	
	SEPTRA			
AP	+ MONARCH PHARMS	**80MG/ML;16MG/ML**	**N18452 001**	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	ABBOTT	**80MG/ML;16MG/ML**	**N73199 001**	SEP 11, 1992
AP	ELKINS SINN	**80MG/ML;16MG/ML**	**N70627 001**	DEC 29, 1987
AP		**80MG/ML;16MG/ML**	**N70628 001**	DEC 29, 1987
AP	GENSIA SICOR PHARMS	**80MG/ML;16MG/ML**	**N73303 001**	OCT 31, 1991

SUSPENSION; ORAL

	BACTRIM PEDIATRIC			
AB	+ ROCHE	**200MG/5ML;40MG/5ML**	**N17560 002**	
	SEPTRA			
AB	MONARCH PHARMS	**200MG/5ML;40MG/5ML**	**N17598 001**	
	SEPTRA GRAPE			
AB	MONARCH PHARMS	**200MG/5ML;40MG/5ML**	**N17598 002**	FEB 12, 1986
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	HI TECH PHARMA	**200MG/5ML;40MG/5ML**	**N74650 001**	DEC 29, 1997
AB	TEVA	**200MG/5ML;40MG/5ML**	**N18812 001**	JAN 28, 1983
AB		**200MG/5ML;40MG/5ML**	**N18812 002**	JUN 10, 1983
AB		**200MG/5ML;40MG/5ML**	**N70028 001**	JUN 02, 1987
	SULFATRIM			
AB	ALPHARMA	**200MG/5ML;40MG/5ML**	**N18615 002**	JAN 07, 1983
	SULFATRIM PEDIATRIC			
AB	ALPHARMA	**200MG/5ML;40MG/5ML**	**N18615 001**	JAN 07, 1983
	TRIMETH/SULFA			
AB	NASKA	**200MG/5ML;40MG/5ML**	**N72399 001**	MAY 23, 1988

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	BACTRIM			
AB	ROCHE	400MG;80MG	N17377 001	
	BACTRIM DS			
AB	+ ROCHE	800MG;160MG	N17377 002	
	COTRIM			
AB	TEVA	400MG;80MG	N70034 001	MAY 16, 1985
	COTRIM D.S.			
AB	TEVA	800MG;160MG	N70048 001	MAR 18, 1985
	SEPTRA			
AB	MONARCH PHARMS	400MG;80MG	N17376 001	
	SEPTRA DS			
AB	MONARCH PHARMS	800MG;160MG	N17376 002	
	SULFAMETHOPRIM			
AB	PAR PHARM	400MG;80MG	N70022 001	FEB 15, 1985
	SULFAMETHOPRIM-DS			
AB	PAR PHARM	800MG;160MG	N70032 001	FEB 15, 1985
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	DANBURY PHARMA	400MG;80MG	N18852 001	MAY 09, 1983
AB	GENEVA PHARMS	400MG;80MG	N70889 001	NOV 13, 1986
AB		800MG;160MG	N70890 001	NOV 13, 1986
AB	MUTUAL PHARM	400MG;80MG	N71016 001	AUG 25, 1986
AB		800MG;160MG	N71017 001	AUG 25, 1986
AB	ROXANE	400MG;80MG	N72768 001	AUG 30, 1991
AB	SIDMAK LABS NJ	400MG;80MG	N70215 001	SEP 10, 1985
AB		800MG;160MG	N70216 001	SEP 10, 1985
AB	TEVA	400MG;80MG	N18242 001	
AB		800MG;160MG	N18242 002	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH			
AB	DANBURY PHARMA	800MG;160MG	N18854 001	MAY 09, 1983
AB	EON	800MG;160MG	N18598 004	MAY 19, 1982
AB	PLANTEX	800MG;160MG	N70037 001	JUN 02, 1987

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH			
AB	ROXANE	800MG;160MG	N72769 001	AUG 30, 1991
	SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH			
AB	PLANTEX	400MG;80MG	N70030 001	JUN 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

	AVC			
AT	+ KING PHARMS	15%	N06530 003	JAN 27, 1987
	SULFANILAMIDE			
AT	TEVA	15%	N88718 001	SEP 19, 1985

SUPPOSITORY; VAGINAL

	AVC			
	+ KING PHARMS	1.05GM	N06530 004	JAN 27, 1987

SULFAPYRIDINE

TABLET; ORAL

	SULFAPYRIDINE			
	+ LILLY	500MG	N00159 001	

SULFASALAZINE

SUSPENSION; ORAL

	AZULFIDINE			
	+ PHARMACIA AND UPJOHN	250MG/5ML	N86983 001	

TABLET; ORAL

	AZULFIDINE			
AB	+ PHARMACIA AND UPJOHN	500MG	N07073 001	
	SULFASALAZINE			
AB	CHELSEA LABS	500MG	N85828 001	
AB	DANBURY PHARMA	500MG	N87197 001	
AB	MUTUAL PHARM	500MG	N89590 001	OCT 19, 1987

FDA data supplied by DrugPatentWatch.com

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL

	AZULFIDINE EN-TABS			
+	PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983

SULFINPYRAZONE

CAPSULE; ORAL

	ANTURANE			
AB	+ NOVARTIS	**200MG**	**N11556 004**	
	SULFINPYRAZONE			
AB	BARR	**200MG**	**N87666 001**	SEP 17, 1982
AB	PAR PHARM	**200MG**	**N88934 001**	SEP 06, 1985
AB	ZENITH GOLDLINE	**200MG**	**N87770 001**	NOV 19, 1982

TABLET; ORAL

	ANTURANE			
AB	+ NOVARTIS	**100MG**	**N11556 003**	
	SULFINPYRAZONE			
AB	BARR	**100MG**	**N87665 001**	SEP 17, 1982
AB	PAR PHARM	**100MG**	**N88933 001**	SEP 06, 1985

SULFISOXAZOLE

TABLET; ORAL

	SOSOL			
AB	MK LABS	**500MG**	**N80036 001**	
	SULFISOXAZOLE			
AB	GENEVA PHARMS	**500MG**	**N85628 001**	
AB	ICN	**500MG**	**N80268 002**	
AB	ROXANE	**500MG**	**N80082 001**	
AB	+ ZENITH GOLDLINE	**500MG**	**N80142 001**	

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

	GANTRISIN PEDIATRIC			
+	ROCHE	EQ 500MG BASE/5ML	N09182 004	

SULFISOXAZOLE ACETYL

SYRUP; ORAL

	GANTRISIN			
+	ROCHE	EQ 500MG BASE/5ML	N09182 002	

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

SULINDAC

TABLET; ORAL

	CLINORIL			
AB	MERCK	**150MG**	**N17911 001**	
AB	+	**200MG**	**N17911 002**	
	SULINDAC			
AB	DANBURY PHARMA	**150MG**	**N71891 001**	APR 03, 1990
AB		**200MG**	**N71795 001**	APR 03, 1990
AB	GENEVA PHARMS	**150MG**	**N72712 001**	AUG 30, 1991
AB		**200MG**	**N72713 001**	AUG 30, 1991
AB	LEDERLE	**150MG**	**N73261 001**	SEP 06, 1991
AB		**200MG**	**N73262 001**	SEP 06, 1991
AB	MUTUAL PHARM	**150MG**	**N72050 001**	APR 17, 1991
AB		**200MG**	**N72051 001**	APR 17, 1991
AB	MYLAN	**150MG**	**N73038 001**	JUN 22, 1993
AB		**200MG**	**N73039 001**	JUN 22, 1993
AB	TEVA	**150MG**	**N72972 001**	FEB 28, 1992
AB		**200MG**	**N72973 001**	FEB 28, 1992
AB	WARNER CHILCOTT	**150MG**	**N72710 001**	MAR 25, 1991
AB		**200MG**	**N72711 001**	MAR 25, 1991

FDA data supplied by DrugPatentWatch.com

SUMATRIPTAN

SPRAY; NASAL
IMITREX
+ GLAXO WELLCOME 5MG/SPRAY N20626 001 AUG 26, 1997
+ 10MG/SPRAY N20626 002 AUG 26, 1997
+ 20MG/SPRAY N20626 003 AUG 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; INJECTION
IMITREX
+ GLAXO WELLCOME EQ 6MG BASE/0.5ML N20080 001 DEC 28, 1992

TABLET; ORAL
IMITREX
GLAXO WELLCOME EQ 25MG BASE N20132 002 JUN 01, 1995
+ EQ 50MG BASE N20132 003 JUN 01, 1995

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC
PROFENAL
+ ALCON 1% N19387 001 DEC 23, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX
FIRST HORIZON EQ 10MG BASE N20070 001 SEP 09, 1993
EQ 20MG BASE N20070 002 SEP 09, 1993
EQ 30MG BASE N20070 003 SEP 09, 1993
+ EQ 40MG BASE N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF
FUJISAWA HLTHCARE EQ 0.5MG BASE N50708 003 AUG 24, 1998
EQ 1MG BASE N50708 001 APR 08, 1994
+ EQ 5MG BASE N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF
+ FUJISAWA HLTHCARE EQ 5MG BASE/ML N50709 001 APR 08, 1994

OINTMENT; TOPICAL
PROTOPIC
FUJISAWA HLTHCARE 0.03% N50777 001 DEC 08, 2000
+ 0.1% N50777 002 DEC 08, 2000

TALC

AEROSOL, METERED; INTRAPLEURAL
SCLEROSOL
+ BRYAN 400MG/SPRAY N20587 001 DEC 24, 1997

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
AB + ASTRAZENECA EQ 20MG BASE N17970 002 MAR 21, 1994
EQ 10MG BASE N17970 001

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
+ BOEHRINGER INGELHEIM 0.4MG N20579 001 APR 15, 1997

TARTARIC ACID; *MULTIPLE*
SEE SODIUM BICARBONATE; TARTARIC ACID

FDA data supplied by DrugPatentWatch.com

TAZAROTENE

CREAM; TOPICAL
TAZORAC
+ ALLERGAN 0.05% N21184 001 SEP 29, 2000
+ 0.1% N21184 002 SEP 29, 2000

GEL; TOPICAL
TAZORAC
+ ALLERGAN 0.05% N20600 001 JUN 13, 1997
+ 0.1% N20600 002 JUN 13, 1997

TAZOBACTAM SODIUM; *MULTIPLE*
SEE PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO N/A N17833 001
PULMOLITE
BS CIS N/A N17776 001
TECHNESCAN MAA
BS MALLINCKRODT N/A N17842 001
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE N/A N17881 001 DEC 30, 1987

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE
CIS N/A N18263 001 MAR 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M HSA
NYCOMED AMERSHAM N/A N17775 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT
DIATIDE N/A N20887 001 SEP 14, 1998

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE
DUPONT PHARMS N/A N20256 001 NOV 23, 1994

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT
+ DIATIDE N/A N21012 001 AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
CIS N/A N18467 001 MAR 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC
NYCOMED AMERSHAM N/A N19829 001 DEC 30, 1988

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N18272 001 JAN 27, 1982

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION
CHOLETEC
BRACCO N/A N18963 001
JAN 21, 1987

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
CIS-MDP
AP CIS **N/A** **N18124 001**
MDP-BRACCO
AP BRACCO **N/A** **N18107 001**
OSTEOLITE
AP CIS **N/A** **N17972 001**
TECHNESCAN MDP KIT
AP DRAXIMAGE **N/A** **N18035 001**
TECHNETIUM TC 99M MPI MDP
AP NYCOMED AMERSHAM **N/A** **N18141 001**

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNESCAN MAG3
MALLINCKRODT N/A N19882 001
JUN 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN HDP
MALLINCKRODT N/A N18321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
AN-DTPA
AP CIS **N/A** **N17714 001**
DTPA
AP DRAXIMAGE **N/A** **N18511 001**
DEC 29, 1989
MPI DTPA KIT - CHELATE
AP NYCOMED AMERSHAM **N/A** **N17255 001**
TECHNETIUM TC-99M PENTETATE KIT
AP NYCOMED AMERSHAM **N/A** **N17264 002**

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE
CIS N/A N17684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION
CIS-PYRO
AP CIS **N/A** **N19039 001**
JUN 30, 1987
PHOSPHOTEC
AP BRACCO **N/A** **N17680 001**
TECHNESCAN PYP KIT
AP MALLINCKRODT **N/A** **N17538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN
CADEMA N/A N20063 001
JUN 11, 1992
ULTRATAG
MALLINCKRODT N/A N19981 001
JUN 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
DUPONT PHARMS N/A N19785 001
DEC 21, 1990
MIRALUMA
DUPONT PHARMS N/A N19785 003
MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
MALLINCKRODT 10-60mCi/ML N17725 001

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
DUPONT PHARMS 0.0083-2.7 CI/GENERATOR N17771 001
TECHNETIUM TC 99M GENERATOR
NYCOMED AMERSHAM 830-16,600mCi/GENERATOR N17693 001
ULTRA-TECHNEKOW FM
MALLINCKRODT 0.25-3 CI/GENERATOR N17243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT
NYCOMED AMERSHAM N/A N17944 001
MAY 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AN-SULFUR COLLOID
AP CIS **N/A** **N17858 001**
TECHNECOLL
AP MALLINCKRODT **N/A** **N17059 001**

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION
CARDIOTEC
BRACCO N/A N19928 001
DEC 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW
NYCOMED AMERSHAM N/A N20372 001
FEB 09, 1996

TELMISARTAN

TABLET; ORAL
MICARDIS
\+ BOEHRINGER INGELHEIM 20MG N20850 003
APR 04, 2000

TELMISARTAN

TABLET; ORAL
MICARDIS
BOEHRINGER INGELHEIM 40MG N20850 001
NOV 10, 1998
\+ 80MG N20850 002
NOV 10, 1998

TELMISARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TELMISARTAN

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
AB NOVARTIS **15MG** **N18163 001**
AB \+ **30MG** **N18163 002**
7.5MG N18163 003
OCT 25, 1991

TEMAZEPAM
AB DANBURY PHARMA **15MG** **N71446 001**
MAY 21, 1993
AB **30MG** **N71447 001**
MAY 21, 1993
AB GENEVA PHARMS **15MG** **N71427 001**
JAN 12, 1988
AB **30MG** **N71428 001**
JAN 12, 1988
AB MYLAN **15MG** **N70919 001**
JUL 07, 1986
AB **30MG** **N70920 001**
JUL 10, 1986
AB PAR PHARM **15MG** **N71456 001**
APR 21, 1987
AB **30MG** **N71457 001**
APR 21, 1987
AB PUREPAC PHARM **15MG** **N71638 001**
AUG 07, 1987
AB **30MG** **N71620 001**
AUG 07, 1987

FDA data supplied by DrugPatentWatch.com

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR					
SCHERING	5MG	N21029 001 AUG 11, 1999			
	20MG	N21029 002 AUG 11, 1999			
	100MG	N21029 003 AUG 11, 1999			
+	250MG	N21029 004 AUG 11, 1999			

TENIPOSIDE

INJECTABLE; INJECTION

VUMON					
+	BRISTOL MYERS SQUIBB	10MG/ML	N20119 001 JUL 14, 1992		

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN					
AB	ABBOTT	**EQ 1MG BASE**	**N20347 001** DEC 14, 1994		
AB	+	**EQ 2MG BASE**	**N20347 002** DEC 14, 1994		
AB		**EQ 5MG BASE**	**N20347 003** DEC 14, 1994		
AB		**EQ 10MG BASE**	**N20347 004** DEC 14, 1994		
TERAZOSIN HCL					
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N74823 001** MAR 30, 1998		
AB		**EQ 2MG BASE**	**N74823 002** MAR 30, 1998		
AB		**EQ 5MG BASE**	**N74823 003** MAR 30, 1998		
AB		**EQ 10MG BASE**	**N74823 004** MAR 30, 1998		
AB	INVAMED	**EQ 1MG BASE**	**N75667 001** JUL 28, 2000		
AB		**EQ 2MG BASE**	**N75667 002** JUL 28, 2000		
AB		**EQ 5MG BASE**	**N75667 003** JUL 28, 2000		

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL					
AB	INVAMED	**EQ 10MG BASE**	**N75667 004** JUL 28, 2000		
AB	MYLAN	**EQ 1MG BASE**	**N75140 002** FEB 11, 2000		
AB		**EQ 2MG BASE**	**N75140 003** FEB 11, 2000		
AB		**EQ 5MG BASE**	**N75140 001** FEB 11, 2000		
AB		**EQ 10MG BASE**	**N75140 004** FEB 11, 2000		
AB	MYLAN TECHNOLOGIES	**EQ 1MG BASE**	**N75384 001** DEC 01, 2000		
AB		**EQ 2MG BASE**	**N75384 002** DEC 01, 2000		
AB		**EQ 5MG BASE**	**N75384 003** DEC 01, 2000		
AB		**EQ 10MG BASE**	**N75384 004** DEC 01, 2000		

TABLET; ORAL

HYTRIN					
AB	ABBOTT	**EQ 1MG BASE**	**N19057 001** AUG 07, 1987		
AB	+	**EQ 2MG BASE**	**N19057 002** AUG 07, 1987		
AB		**EQ 5MG BASE**	**N19057 003** AUG 07, 1987		
AB		**EQ 10MG BASE**	**N19057 004** AUG 07, 1987		
TERAZOSIN HCL					
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N74315 001** DEC 31, 1998		
AB		**EQ 2MG BASE**	**N74315 002** DEC 31, 1998		
AB		**EQ 5MG BASE**	**N74315 003** DEC 31, 1998		
AB		**EQ 10MG BASE**	**N74315 004** DEC 31, 1998		
AB	INVAMED	**EQ 1MG BASE**	**N74657 001** APR 28, 2000		
AB		**EQ 2MG BASE**	**N74657 002** APR 28, 2000		
AB		**EQ 5MG BASE**	**N74657 003** APR 28, 2000		

FDA data supplied by DrugPatentWatch.com

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 10MG BASE	N74657 004 APR 28, 2000	
AB	NOVOPHARM	EQ 1MG BASE	N74446 001 MAY 18, 2000	
AB		EQ 2MG BASE	N74446 002 MAY 18, 2000	
AB		EQ 5MG BASE	N74446 003 MAY 18, 2000	
AB		EQ 10MG BASE	N74446 004 MAY 18, 2000	
AB	ZENITH GOLDLINE	EQ 1MG BASE	N74530 001 APR 21, 2000	
AB		EQ 2MG BASE	N74530 002 APR 21, 2000	
AB		EQ 5MG BASE	N74530 003 APR 21, 2000	
AB		EQ 10MG BASE	N74530 004 APR 21, 2000	

TERBINAFINE

GEL; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20846 001 APR 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20192 001 DEC 30, 1992

SOLUTION; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20749 001 OCT 17, 1997

TABLET; ORAL
LAMISIL

+	NOVARTIS	EQ 250MG BASE	N20539 001 MAY 10, 1996

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

+	NOVARTIS	1MG/ML	N18571 001

TABLET; ORAL
BRETHINE

	NOVARTIS	2.5MG	N17849 001
+		5MG	N17849 002

TERCONAZOLE

CREAM; VAGINAL
TERAZOL 3

+	JOHNSON RW	0.8%	N19964 001 FEB 21, 1991

TERAZOL 7

+	JOHNSON RW	0.4%	N19579 001 DEC 31, 1987

SUPPOSITORY; VAGINAL
TERAZOL 3

+	JOHNSON RW	80MG	N19641 001 MAY 24, 1988

TESTOLACTONE

TABLET; ORAL
TESLAC

+	BRISTOL MYERS SQUIBB	50MG	N16118 001

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX +	WATSON LABS	5MG/24HR	N20489 002 MAY 02, 1997
+		2.5MG/24HR	N20489 001 SEP 29, 1995

TESTODERM

BX +	ALZA	5MG/24HR	N20791 001 DEC 18, 1997
+		4MG/24HR	N19762 001 OCT 12, 1993

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
TESTODERM
+ ALZA 6MG/24HR N19762 002 OCT 12, 1993

GEL; TOPICAL
ANDROGEL
+ UNIMED PHARMS 1% N21015 001 FEB 28, 2000

INJECTABLE; INJECTION
TESTOSTERONE
+ STERIS 100MG/ML N86417 001 JUL 07, 1983

PELLET; IMPLANTATION
TESTOSTERONE
BARTOR 75MG N80911 001

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTOSTERONE
AO + PHARMACIA AND UPJOHN 100MG/ML N85635 002
AO + 200MG/ML N85635 003
TESTOSTERONE CYPIONATE
AO STERIS 100MG/ML N86029 001
AO 200MG/ML N86030 001

TESTOSTERONE CYPIONATE; *MULTIPLE*
SEE ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL
AO + BTG 200MG/ML N09165 003
TESTOSTERONE ENANTHATE
AO STERIS 200MG/ML N85598 001

TESTOSTERONE ENANTHATE; *MULTIPLE*
SEE ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE
+ STERIS 25MG/ML N80188 001
50MG/ML N80188 002
+ 100MG/ML N80188 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V
AB LEDERLE **250MG** **N50278 003**
AB + **500MG** **N50278 001**
BRISTACYCLINE
AB BRISTOL **250MG** **N61658 001**
AB **250MG** **N61888 001**
AB **500MG** **N61658 002**
AB **500MG** **N61888 002**
PANMYCIN
AB PHARMACIA AND UPJOHN **250MG** **N60347 001**
ROBITET
AB WYETH AYERST **250MG** **N61734 001**
AB **500MG** **N61734 002**
SUMYCIN
AB APOTHECON **250MG** **N60429 001**
AB **500MG** **N60429 003**
TETRACYCLINE HCL
AB BARR **250MG** **N61837 001**
AB **500MG** **N61837 002**
AB DANBURY PHARMA **250MG** **N62343 001**
AB **500MG** **N62343 002**
AB EON **250MG** **N61471 001**
AB HALSEY **250MG** **N60736 001**
AB **500MG** **N60736 002**
AB IMPAX LABS **250MG** **N60469 001**
AB **500MG** **N60469 003**
100MG N60469 002
AB LABS ATRAL **250MG** **N62752 001** AUG 12, 1988
AB **500MG** **N62752 002** AUG 12, 1988
AB MAST MM **250MG** **N62085 001**
AB MYLAN **250MG** **N60783 001**
AB **500MG** **N60783 002**
AB ROXANE **500MG** **N61214 002**
AB WEST WARD **250MG** **N60768 001**
AB **500MG** **N60768 002**

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	WYETH AYERST	**250MG**	**N61685**	**001**
AB		**500MG**	**N61685**	**002**
AB	ZENITH GOLDLINE	**250MG**	**N60704**	**001**
AB		**500MG**	**N60704**	**002**

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

+	ON SITE ALZA	12.7MG/FIBER	N50653	001
			MAR 25, 1994	

FOR SOLUTION; TOPICAL
TOPICYCLINE

+	ROBERTS LABS	2.2MG/ML	N50493	001

INJECTABLE; INJECTION
ACHROMYCIN

+	LEDERLE	250MG/VIAL	N50273	002
		500MG/VIAL	N50273	003

SUSPENSION; ORAL
ACHROMYCIN V

AB	+ LEDERLE	**125MG/5ML**	**N50263**	**002**

SUMYCIN

AB	APOTHECON	**125MG/5ML**	**N60400**	**001**

TABLET; ORAL
SUMYCIN

	APOTHECON	250MG	N61147	001
+		500MG	N61147	004

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
SEE HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX

	BRISTOL	EQ 100MG HCL	N61653	001
		EQ 250MG HCL	N61653	002
		EQ 250MG HCL	N61889	002
+		EQ 500MG HCL	N61653	003

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX

	BRISTOL	EQ 500MG HCL	N61889	001

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL
TYZINE

+	KENWOOD LABS	0.05%	N86576	002
		0.1%	N86576	001

SPRAY; NASAL
TYZINE

+	KENWOOD LABS	0.1%	N86576	003

THALIDOMIDE

CAPSULE; ORAL
THALOMID

+	CELGENE	50MG	N20785	001
			JUL 16, 1998	

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

AP	+	DUPONT PHARMS	**1mCi/ML**	**N17806**	**001**
AP	+	MALLINCKRODT	**1mCi/ML**	**N18150**	**001**
AP	+	NYCOMED AMERSHAM	**1mCi/ML**	**N18110**	**002**
				FEB 27, 1996	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
AEROLATE III

+	FLEMING PHARMS	65MG	N85075	003
			NOV 24, 1986	

AEROLATE JR

BC	FLEMING PHARMS	130MG	N85075	002
			NOV 24, 1986	

AEROLATE SR

BC	FLEMING PHARMS	260MG	N85075	001
			NOV 24, 1986	

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		SLO-BID			
AB		AVENTIS	**100MG**	**N87892 001**	JAN 31, 1985
AB			**125MG**	**N89540 001**	MAY 10, 1989
AB			**200MG**	**N87893 001**	JAN 31, 1985
AB	+		**300MG**	**N87894 001**	JAN 31, 1985
BC	+		50MG	N88269 001	JAN 31, 1985
BC			75MG	N89539 001	MAY 10, 1989
		THEO-24			
BC		UCB	100MG	N87942 001	AUG 22, 1983
BC			200MG	N87943 001	AUG 22, 1983
BC			300MG	N87944 001	AUG 22, 1983
			400MG	N81034 001	FEB 28, 1992
		THEOPHYLLINE			
AB		INWOOD LABS	**100MG**	**N40052 001**	FEB 14, 1994
AB			**125MG**	**N40052 002**	FEB 14, 1994
AB			**200MG**	**N40052 003**	FEB 14, 1994
AB			**300MG**	**N40052 004**	FEB 14, 1994

ELIXIR; ORAL

		ELIXOPHYLLIN			
AA		FORREST LABS	**80MG/15ML**	**N85186 001**	
		THEOPHYLLINE			
AA		ALPHARMA	**80MG/15ML**	**N85863 001**	
AA		MORTON GROVE	**80MG/15ML**	**N86748 001**	
AA		PHARM ASSOC	**80MG/15ML**	**N86720 001**	
AA		THAMES	**80MG/15ML**	**N89626 001**	OCT 28, 1988

INJECTABLE; INJECTION

		THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**40MG/100ML**	**N19826 001**	AUG 14, 1992

THEOPHYLLINE

INJECTABLE; INJECTION

		THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**80MG/100ML**	**N19826 002**	AUG 14, 1992
		THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**160MG/100ML**	**N19826 003**	AUG 14, 1992
		THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**320MG/100ML**	**N19826 006**	AUG 14, 1992
		THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	BAXTER HLTHCARE	**40MG/100ML**	**N18649 001**	JUL 26, 1982
AP	+		**80MG/100ML**	**N18649 002**	JUL 26, 1982
AP	+		**160MG/100ML**	**N18649 003**	JUL 26, 1982
AP	+		**200MG/100ML**	**N18649 004**	JUL 26, 1982
AP	+		**320MG/100ML**	**N18649 006**	NOV 13, 1985
AP	+		**400MG/100ML**	**N18649 005**	JUL 26, 1982
AP	+		**4MG/ML**	**N18649 007**	JUL 26, 1982
		THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	ABBOTT	**40MG/100ML**	**N19211 001**	DEC 14, 1984
AP	+		**80MG/100ML**	**N19211 002**	DEC 14, 1984
AP	+		**160MG/100ML**	**N19211 003**	DEC 14, 1984
AP	+		**200MG/100ML**	**N19211 004**	DEC 14, 1984
AP	+		**320MG/100ML**	**N19211 006**	JAN 20, 1988
AP	+		**400MG/100ML**	**N19211 005**	DEC 14, 1984
AP	+		**4MG/ML**	**N19211 007**	DEC 14, 1984

SOLUTION; ORAL

		AEROLATE			
	+	FLEMING PHARMS	150MG/15ML	N89141 001	DEC 03, 1986
		THEOLAIR			
AA	+	3M	**80MG/15ML**	**N86107 001**	

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

SOLUTION; ORAL

	THEOPHYLLINE			
AA	ROXANE	**80MG/15ML**	**N87449 001**	SEP 15, 1983

SYRUP; ORAL

	SLO-PHYLLIN			
AA	+ AVENTIS	**80MG/15ML**	**N85187 001**	

TABLET; ORAL

	QUIBRON-T			
	+ MONARCH PHARMS	300MG	N88656 001	AUG 22, 1985
	SLO-PHYLLIN			
	+ AVENTIS	100MG	N85202 001	
	+	200MG	N85204 001	
	THEOLAIR			
	+ 3M	125MG	N86399 001	
	+	250MG	N86399 002	

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR			
BC	MONARCH PHARMS	300MG	N87563 001	JUN 21, 1983
	T-PHYL			
BC	PURDUE FREDERICK	200MG	N88253 001	AUG 17, 1983
	THEO-DUR			
AB	+ KEY PHARMS	**100MG**	**N85328 001**	
AB	+	**200MG**	**N86998 001**	
AB	+	**300MG**	**N85328 002**	
AB	+	**450MG**	**N89131 001**	JUN 25, 1986
	THEOCHRON			
AB	INWOOD LABS	**100MG**	**N88320 001**	FEB 21, 1985
AB		**200MG**	**N88321 001**	FEB 21, 1985
AB		**300MG**	**N87400 002**	JAN 11, 1983
	THEOLAIR-SR			
BC	3M	200MG	N88369 001	JUL 16, 1987
BC		300MG	N88364 001	JUL 16, 1987
		250MG	N86363 002	JUL 16, 1987

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	THEOLAIR-SR			
	+ 3M	500MG	N89132 001	JUL 16, 1987
	THEOPHYLLINE			
AB	INWOOD LABS	**450MG**	**N40034 001**	APR 28, 1995
AB	SIDMAK LABS NJ	**100MG**	**N89807 001**	APR 30, 1990
AB		**200MG**	**N89808 001**	APR 30, 1990
AB		**300MG**	**N89763 001**	APR 30, 1990
AB		**450MG**	**N81236 001**	NOV 09, 1992
	UNI-DUR			
BC	+ SCHERING	400MG	N89822 001	JAN 04, 1995
BC	+	600MG	N89823 001	JAN 04, 1995
	UNIPHYL			
BC	PURDUE FREDERICK	400MG	N87571 001	SEP 01, 1982
BC		600MG	N40086 001	APR 15, 1996

THIABENDAZOLE

SUSPENSION; ORAL

	MINTEZOL			
	+ MERCK	500MG/5ML	N16097 001	

TABLET, CHEWABLE; ORAL

	MINTEZOL			
	+ MERCK	500MG	N16096 001	

THIAMINE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

FDA data supplied by DrugPatentWatch.com

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		THIAMINE HCL			
AP		ABBOTT	**100MG/ML**	**N40079 001**	
				MAY 03, 1996	
AP	+	AM PHARM PARTNERS	**100MG/ML**	**N80556 001**	
AP		ELKINS SINN	**100MG/ML**	**N80575 001**	
AP		STERIS	**100MG/ML**	**N80571 001**	
	+		200MG/ML	N80571 002	
AP		WYETH AYERST	**100MG/ML**	**N80553 001**	

THIAMINE HYDROCHLORIDE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

		TORECAN			
	+	NOVARTIS	5MG/ML	N12754 002	

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

		TORECAN			
	+	NOVARTIS	10MG	N13247 001	

TABLET; ORAL

		TORECAN			
	+	NOVARTIS	10MG	N12753 001	

THIOGUANINE

TABLET; ORAL

		THIOGUANINE			
	+	GLAXO WELLCOME	40MG	N12429 001	

THIORIDAZINE

SUSPENSION; ORAL

		MELLARIL-S			
		NOVARTIS	EQ 25MG HCL/5ML	N17923 001	
	+		EQ 100MG HCL/5ML	N17923 002	

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		MELLARIL			
AA	+	NOVARTIS	**30MG/ML**	**N11808 012**	
AA	+		**100MG/ML**	**N11808 018**	
		THIORIDAZINE HCL			
AA		ALPHARMA	**100MG/ML**	**N88229 001**	
				AUG 23, 1983	
AA		COPLEY PHARM	**30MG/ML**	**N89602 001**	
				NOV 09, 1987	
AA			**100MG/ML**	**N89603 001**	
				NOV 09, 1987	
AA		HI TECH PHARMA	**30MG/ML**	**N40125 001**	
				AUG 16, 1996	
AA			**100MG/ML**	**N40126 001**	
				AUG 16, 1996	
AA		PHARM ASSOC	**30MG/ML**	**N40187 001**	
				AUG 28, 1997	
AA			**100MG/ML**	**N40213 001**	
				MAY 29, 1998	
		THIORIDAZINE HCL INTENSOL			
AA		ROXANE	**30MG/ML**	**N88941 001**	
				DEC 16, 1985	
AA			**100MG/ML**	**N88942 001**	
				DEC 16, 1985	

TABLET; ORAL

		MELLARIL			
AB		NOVARTIS	**10MG**	**N11808 003**	
AB			**15MG**	**N11808 016**	
AB	+		**25MG**	**N11808 006**	
AB			**50MG**	**N11808 011**	
AB	+		**100MG**	**N11808 009**	
AB			**150MG**	**N11808 017**	
AB	+		**200MG**	**N11808 015**	
		THIORIDAZINE HCL			
AB		CHELSEA LABS	**10MG**	**N88561 001**	
				MAY 11, 1984	
AB			**25MG**	**N88567 001**	
				MAY 11, 1984	

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL			
AB	CHELSEA LABS	50MG	N88563 001	MAY 11, 1984
AB		100MG	N88564 001	MAY 11, 1984
AB	DANBURY PHARMA	10MG	N88476 001	NOV 08, 1983
AB		15MG	N88477 001	NOV 08, 1983
AB		25MG	N88478 001	NOV 08, 1983
AB		50MG	N88479 001	NOV 08, 1983
AB		100MG	N88736 001	JUL 24, 1984
AB		150MG	N88869 001	JUN 28, 1985
AB		200MG	N88872 001	APR 26, 1985
AB	GENEVA PHARMS	10MG	N88131 001	AUG 30, 1983
AB		15MG	N88132 001	AUG 30, 1983
AB		25MG	N88133 001	AUG 30, 1983
AB		50MG	N88134 001	AUG 30, 1983
AB		100MG	N88135 001	NOV 20, 1984
AB		150MG	N88136 001	SEP 17, 1986
AB		200MG	N88137 001	SEP 17, 1986
AB	HALSEY	50MG	N88370 001	NOV 18, 1983
AB	MUTUAL PHARM	10MG	N89431 001	AUG 01, 1986
AB		25MG	N89432 001	AUG 01, 1986
AB		50MG	N89433 001	AUG 01, 1986
AB		100MG	N89953 001	OCT 07, 1988
AB	MYLAN	10MG	N88001 001	MAR 15, 1983

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL			
AB	MYLAN	25MG	N88002 001	MAR 15, 1983
AB		50MG	N88003 001	MAR 15, 1983
AB		100MG	N88004 001	NOV 18, 1983
AB	TEVA	10MG	N88493 001	MAY 17, 1985
AB		100MG	N88456 001	MAY 17, 1985
AB	ZENITH GOLDLINE	10MG	N88270 001	APR 14, 1983
AB		15MG	N88271 001	APR 14, 1983
AB		25MG	N88272 001	APR 14, 1983
AB		50MG	N88194 001	APR 14, 1983

THIOTEPA

INJECTABLE; INJECTION

	THIOPLEX			
+	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994
	THIOTEPA			
+	IMMUNEX	15MG/VIAL	N11683 001	

THIOTHIXENE

CAPSULE; ORAL

	NAVANE			
AB	ROERIG	1MG	N16584 001	
AB		2MG	N16584 002	
AB +		5MG	N16584 003	
AB		10MG	N16584 004	
		20MG	N16584 005	
	THIOTHIXENE			
AB	DANBURY PHARMA	1MG	N70600 001	JUN 05, 1987
AB		2MG	N70601 001	JUN 05, 1987

FDA data supplied by DrugPatentWatch.com

THIOTHIXENE

CAPSULE; ORAL

	THIOTHIXENE			
AB	DANBURY PHARMA	5MG	**N70602 001**	JUN 05, 1987
AB		10MG	**N70603 001**	JUN 05, 1987
AB	GENEVA PHARMS	1MG	**N71610 001**	JUN 24, 1987
AB		2MG	**N71570 001**	JUN 24, 1987
AB		5MG	**N71529 001**	JUN 24, 1987
AB		10MG	**N71530 001**	JUN 24, 1987
AB	MYLAN	1MG	**N71090 001**	JUN 23, 1987
AB		2MG	**N71091 001**	JUN 23, 1987
AB		5MG	**N71092 001**	JUN 23, 1987
AB		10MG	**N71093 001**	JUN 23, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	NAVANE			
AA	+ ROERIG	EQ 5MG BASE/ML	**N16758 001**	
	THIOTHIXENE HCL			
AA	COPLEY PHARM	EQ 5MG BASE/ML	**N71554 001**	OCT 16, 1987
	THIOTHIXENE HCL INTENSOL			
AA	ROXANE	EQ 5MG BASE/ML	**N73494 001**	JUN 30, 1992

INJECTABLE; INJECTION

	NAVANE		
+	ROERIG	EQ 10MG BASE/VIAL	N16904 002

THONZONIUM BROMIDE; *MULTIPLE*

SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

THYROGLOBULIN

TABLET; ORAL

	THYROGLOBULIN		
+	IMPAX LABS	64.8MG	N80151 001

THYROTROPIN ALFA

INJECTABLE; INJECTION

	THYROGEN		
+	GENZYME	1.1MG/VIAL	N20898 001 NOV 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

	GABITRIL		
+	CEPHALON	2MG	N20646 005 APR 16, 1999
		4MG	N20646 001 SEP 30, 1997
		12MG	N20646 002 SEP 30, 1997
		16MG	N20646 003 SEP 30, 1997
+		20MG	N20646 004 SEP 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TICAR		
+	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N50497 001
+		EQ 3GM BASE/VIAL	N50497 002
		EQ 3GM BASE/VIAL	N62690 001 DEC 19, 1986
+		EQ 20GM BASE/VIAL	N50497 004
+		EQ 30GM BASE/VIAL	N50497 005 APR 04, 1984

TICARCILLIN DISODIUM; *MULTIPLE*

SEE CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

FDA data supplied by DrugPatentWatch.com

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID			
AB	+ SYNTEX (USA) INC LLC	**250MG**	**N19979 002**	OCT 31, 1991
	TICLOPIDINE HCL			
AB	DANBURY PHARMA	**250MG**	**N75309 001**	APR 26, 2000
AB	EON	**250MG**	**N75326 001**	AUG 20, 1999
AB	GENEVA PHARMS TECH	**250MG**	**N75318 001**	AUG 20, 1999
AB	GENPHARM	**250MG**	**N75161 001**	SEP 13, 1999
AB	MYLAN	**250MG**	**N75316 001**	NOV 02, 1999
AB	PUREPAC PHARM	**250MG**	**N75253 001**	AUG 20, 1999
AB	TEVA	**250MG**	**N75149 001**	AUG 20, 1999
AB	TORPHARM	**250MG**	**N75089 001**	JUL 01, 1999

TILUDRONATE DISODIUM

TABLET; ORAL

	SKELID		
+	SANOFI SYNTHELABO	EQ 200MG BASE	N20707 001 MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL		
+	SANTEN OY	EQ 0.25% BASE	N20439 001 MAR 31, 1995
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	FALCON PHARMS	**EQ 0.5% BASE**	**N20963 001**	OCT 21, 1998

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	FALCON PHARMS	**EQ 0.5% BASE**	**N20963 002**	OCT 21, 1998
	TIMOPTIC-XE			
AB	+ MERCK	**EQ 0.25% BASE**	**N20330 001**	NOV 04, 1993
AB	+	**EQ 0.5% BASE**	**N20330 002**	NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	**EQ 0.25% BASE**	**N74465 001**	MAR 25, 1997
AT		**EQ 0.25% BASE**	**N74515 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74466 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74516 001**	MAR 25, 1997
AT	BAUSCH AND LOMB	**EQ 0.25% BASE**	**N74778 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74776 001**	MAR 25, 1997
AT	FOUGERA	**EQ 0.25% BASE**	**N74667 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74668 001**	MAR 25, 1997
AT	NOVEX	**EQ 0.25% BASE**	**N75411 001**	SEP 08, 2000
AT		**EQ 0.5% BASE**	**N75412 001**	SEP 08, 2000
AT	PACIFIC PHARMA	**EQ 0.25% BASE**	**N74746 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74747 001**	MAR 25, 1997
	TIMOPTIC			
AT	+ MERCK	**EQ 0.25% BASE**	**N18086 001**	
AT	+	**EQ 0.5% BASE**	**N18086 002**	
	TIMOPTIC IN OCUDOSE			
	+ MERCK	EQ 0.25% BASE	N19463 001	NOV 05, 1986
	+	EQ 0.5% BASE	N19463 002	NOV 05, 1986

TABLET; ORAL

	BLOCADREN			
AB	MERCK	**5MG**	**N18017 001**	

FDA data supplied by DrugPatentWatch.com

TIMOLOL MALEATE

TABLET; ORAL

	BLOCADREN			
AB	MERCK	10MG	**N18017 002**	
AB	+	20MG	**N18017 004**	
	TIMOLOL MALEATE			
AB	DANBURY PHARMA	5MG	**N72917 001**	JUL 31, 1991
AB		10MG	**N72918 001**	JUL 31, 1991
AB		20MG	**N72919 001**	JUL 31, 1991
AB	GENEVA PHARMS	5MG	**N72550 001**	APR 13, 1989
AB		10MG	**N72551 001**	APR 13, 1989
AB		20MG	**N72552 001**	APR 13, 1989
AB	MYLAN	5MG	**N72666 001**	JUN 08, 1990
AB		10MG	**N72667 001**	JUN 08, 1990
AB		20MG	**N72668 001**	JUN 08, 1990

TIMOLOL MALEATE; *MULTIPLE*
SEE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SEE HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TINZAPARIN SODIUM

INJECTABLE; INJECTION

	INNOHEP			
+	DUPONT PHARMA	20,000 IU/ML	N20484 001	JUL 14, 2000

TIOPRONIN

TABLET; ORAL

	TIOPRONIN			
+	MISSION PHARMA	100MG	N19569 001	AUG 11, 1988

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

	AGGRASTAT			
+	MERCK	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998
+		EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

	ZANAFLEX			
	ELAN PHARMA	EQ 2MG BASE	N20397 002	FEB 04, 2000
+		EQ 4MG BASE	N20397 001	NOV 27, 1996

TOBRAMYCIN

OINTMENT; OPHTHALMIC

	TOBREX			
+	ALCON	0.3%	N50555 001	

SOLUTION; INHALATION

	TOBI			
+	PATHOGENESIS	300MG/5ML	N50753 001	DEC 22, 1997

SOLUTION/DROPS; OPHTHALMIC

	AKTOB			
AT	AKORN	**0.3%**	**N64096 001**	JAN 31, 1996
	TOBRAMYCIN			
AT	ALCON UNIVERSAL	**0.3%**	**N63176 001**	MAY 25, 1994
AT	BAUSCH AND LOMB	**0.3%**	**N64052 001**	NOV 29, 1993
	TOBREX			
AT	ALCON	**0.3%**	**N62535 001**	DEC 13, 1984
AT	+ FALCON PHARMS	**0.3%**	**N50541 001**	

TOBRAMYCIN; *MULTIPLE*
SEE DEXAMETHASONE; TOBRAMYCIN
SEE FLUOROMETHOLONE ACETATE; TOBRAMYCIN

FDA data supplied by DrugPatentWatch.com

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

AP	+ LILLY	**EQ 10MG BASE/ML**	**N50477 005**	
AP		**EQ 10MG BASE/ML**	**N62008 004**	
AP		**EQ 10MG BASE/ML**	**N62707 001**	APR 29, 1987
AP	+	**EQ 40MG BASE/ML**	**N62008 001**	
	+	EQ 1.2GM BASE/VIAL	N50519 001	

TOBRAMYCIN SULFATE

AP	ABBOTT	**EQ 10MG BASE/ML**	**N63080 001**	APR 30, 1991
AP		**EQ 10MG BASE/ML**	**N63112 001**	APR 30, 1991
AP		**EQ 40MG BASE/ML**	**N63111 001**	APR 30, 1991
AP		**EQ 40MG BASE/ML**	**N63116 001**	MAY 18, 1992
AP		**EQ 40MG BASE/ML**	**N63161 001**	MAY 29, 1991
AP	APOTHECON	**EQ 10MG BASE/ML**	**N64021 001**	MAY 31, 1994
AP		**EQ 40MG BASE/ML**	**N64021 002**	MAY 31, 1994
AP	ASTRAZENECA	**EQ 10MG BASE/ML**	**N63119 001**	OCT 31, 1994
AP		**EQ 40MG BASE/ML**	**N63120 001**	OCT 31, 1994
AP		**EQ 40MG BASE/ML**	**N63121 001**	OCT 31, 1994
AP		**EQ 40MG BASE/ML**	**N63122 001**	OCT 31, 1994
AP	ELKINS SINN	**EQ 10MG BASE/ML**	**N63128 001**	NOV 27, 1991
AP		**EQ 40MG BASE/ML**	**N63127 001**	NOV 27, 1991
AP	GENSIA SICOR PHARMS	**EQ 40MG BASE/ML**	**N63100 001**	JAN 30, 1992
AP	LEDERLE	**EQ 10MG BASE/ML**	**N63113 001**	APR 26, 1991
AP		**EQ 40MG BASE/ML**	**N63117 001**	APR 26, 1991
AP		**EQ 40MG BASE/ML**	**N63118 001**	JUL 29, 1991
AP	MARSAM	**EQ 10MG BASE/ML**	**N62945 001**	AUG 09, 1989
AP		**EQ 40MG BASE/ML**	**N62945 002**	AUG 09, 1989

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ ABBOTT	EQ 80MG BASE/100ML	N63081 001	JUL 31, 1990
+	EQ 1.2MG BASE/ML	N63081 003	JUL 31, 1990
+	EQ 1.6MG BASE/ML	N63081 006	JUN 02, 1993

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

	ASTRAZENECA	400MG	N18257 001	NOV 09, 1984
+		600MG	N18257 002	NOV 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

AB	DANBURY PHARMA	**100MG**	**N70513 001**	JAN 09, 1986
AB		**250MG**	**N70514 001**	JAN 09, 1986
AB		**500MG**	**N70515 001**	JAN 09, 1986
AB	GENEVA PHARMS	**100MG**	**N71633 001**	DEC 09, 1987
AB		**250MG**	**N70289 001**	MAR 13, 1986
AB		**500MG**	**N70290 001**	MAR 13, 1986
AB	MUTUAL PHARM	**100MG**	**N71357 001**	JUL 16, 1987
AB		**250MG**	**N71358 001**	JUL 16, 1987
AB		**500MG**	**N71359 001**	JUL 16, 1987
AB	MYLAN	**250MG**	**N70259 001**	JAN 02, 1986
AB		**500MG**	**N70913 001**	MAR 17, 1986

FDA data supplied by DrugPatentWatch.com

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	PAR PHARM	100MG	N70159 001	JAN 06, 1986
AB		250MG	N70160 001	JAN 06, 1986
AB		500MG	N70161 001	JAN 06, 1986
AB	ZENITH GOLDLINE	100MG	N18894 001	NOV 02, 1984
AB		250MG	N18894 002	NOV 02, 1984
AB		500MG	N18894 003	NOV 02, 1984
	TOLINASE			
AB	PHARMACIA AND UPJOHN	100MG	N15500 002	
AB		250MG	N15500 004	
AB	+	500MG	N15500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PRISCOLINE			
	+ NOVARTIS	25MG/ML	N06403 005	FEB 22, 1985

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE			
AB	+ CHELSEA LABS	500MG	N86109 001	
AB	DANBURY PHARMA	500MG	N87318 001	
AB	GENEVA PHARMS	500MG	N86574 001	
AB	LEDERLE	500MG	N86926 001	
AB	MYLAN	500MG	N86445 001	
AB	ZENITH GOLDLINE	500MG	N87093 001	

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

	ORINASE DIAGNOSTIC			
	+ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001	

TOLCAPONE

TABLET; ORAL

	TASMAR			
	ROCHE	100MG	N20697 001	JAN 29, 1998
	+	200MG	N20697 002	JAN 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLECTIN DS			
AB	+ JOHNSON RW	EQ 400MG BASE	N18084 001	
	TOLMETIN SODIUM			
AB	GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992
AB	MUTUAL PHARM	EQ 400MG BASE	N73311 001	NOV 27, 1991
AB	MYLAN	EQ 400MG BASE	N73393 001	MAY 27, 1993
AB	NOVOPHARM	EQ 400MG BASE	N73290 001	NOV 27, 1991
AB	PUREPAC PHARM	EQ 400MG BASE	N73308 001	JAN 24, 1992
AB	TEVA	EQ 400MG BASE	N73519 001	MAY 29, 1992
AB	ZENITH GOLDLINE	EQ 400MG BASE	N73392 001	JAN 24, 1992

TABLET; ORAL

	TOLECTIN			
AB	JOHNSON RW	EQ 200MG BASE	N17628 001	
	TOLECTIN 600			
AB	+ JOHNSON RW	EQ 600MG BASE	N17628 002	MAR 08, 1989
	TOLMETIN SODIUM			
AB	GENEVA PHARMS	EQ 200MG BASE	N73588 001	JUL 31, 1992
AB		EQ 600MG BASE	N74002 001	SEP 27, 1993
AB	MUTUAL PHARM	EQ 200MG BASE	N73310 001	NOV 27, 1991
AB	MYLAN	EQ 600MG BASE	N74473 001	AUG 30, 1994
AB	PUREPAC PHARM	EQ 600MG BASE	N73527 001	JUN 30, 1992

FDA data supplied by DrugPatentWatch.com

TOLMETIN SODIUM

TABLET; ORAL				
TOLMETIN SODIUM				
AB ZENITH GOLDLINE	**EQ 600MG BASE**	**N74399 001**		
		MAR 28, 1996		

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL				
DETROL LA				
+ PHARMACIA AND UPJOHN	2MG	N21228 001		
		DEC 22, 2000		
+	4MG	N21228 002		
		DEC 22, 2000		
TABLET; ORAL				
DETROL				
PHARMACIA AND UPJOHN	1MG	N20771 001		
		MAR 25, 1998		
+	2MG	N20771 002		
		MAR 25, 1998		

TOPIRAMATE

CAPSULE; ORAL				
TOPAMAX SPRINKLE				
JOHNSON RW	15MG	N20844 001		
		OCT 26, 1998		
+	25MG	N20844 002		
		OCT 26, 1998		
TABLET; ORAL				
TOPAMAX				
JOHNSON RW	25MG	N20505 004		
		DEC 24, 1996		
	100MG	N20505 001		
		DEC 24, 1996		
+	200MG	N20505 002		
		DEC 24, 1996		

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION				
HYCAMTIN				
+ SMITHKLINE	EQ 4MG BASE/VIAL	N20671 001		
		MAY 28, 1996		

TOREMIFENE CITRATE

TABLET; ORAL				
FARESTON				
+ ORION	EQ 60MG BASE	N20497 001		
		MAY 29, 1997		

TORSEMIDE

INJECTABLE; INJECTION				
DEMADEX				
+ ROCHE	10MG/ML	N20137 002		
		AUG 23, 1993		
TABLET; ORAL				
DEMADEX				
ROCHE	5MG	N20136 001		
		AUG 23, 1993		
	10MG	N20136 002		
		AUG 23, 1993		
+	20MG	N20136 003		
		AUG 23, 1993		
	100MG	N20136 004		
		AUG 23, 1993		

TRAMADOL HYDROCHLORIDE

TABLET; ORAL				
ULTRAM				
+ JOHNSON RW	50MG	N20281 002		
		MAR 03, 1995		

TRANDOLAPRIL

TABLET; ORAL				
MAVIK				
KNOLL PHARM	1MG	N20528 001		
		APR 26, 1996		
	2MG	N20528 002		
		APR 26, 1996		
+	4MG	N20528 003		
		APR 26, 1996		

FDA data supplied by DrugPatentWatch.com

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	TARKA			
+	KNOLL PHARM	1MG;240MG	N20591 003	OCT 22, 1996
+		2MG;180MG	N20591 001	OCT 22, 1996
+		2MG;240MG	N20591 004	OCT 22, 1996
+		4MG;240MG	N20591 002	OCT 22, 1996

TRANEXAMIC ACID

INJECTABLE; INJECTION

	CYKLOKAPRON			
+	PHARMACIA AND UPJOHN	100MG/ML	N19281 001	DEC 30, 1986

TRANYLCYPROMINE SULFATE

TABLET; ORAL

	PARNATE			
+	SMITHKLINE BEECHAM	EQ 10MG BASE	N12342 003	AUG 16, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	DESYREL			
AB	APOTHECON	**50MG**	**N18207 001**	
AB		**100MG**	**N18207 002**	
AB		**150MG**	**N18207 003**	MAR 25, 1985
AB	+	**300MG**	**N18207 004**	NOV 07, 1988
	TRAZODONE HCL			
AB	BARR	**50MG**	**N71258 001**	MAR 25, 1987
AB		**100MG**	**N71196 001**	MAR 25, 1987
AB		**150MG**	**N71196 002**	APR 26, 1999
AB		**300MG**	**N71196 003**	APR 26, 1999

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL			
AB	DANBURY PHARMA	**50MG**	**N70857 001**	OCT 10, 1986
AB		**100MG**	**N70858 001**	OCT 10, 1986
AB	GENEVA PHARMS	**50MG**	**N72484 001**	APR 30, 1990
AB		**100MG**	**N72483 001**	APR 30, 1990
AB	MUTUAL PHARM	**50MG**	**N73136 001**	MAR 24, 1993
AB		**100MG**	**N73137 001**	MAR 24, 1993
AB		**150MG**	**N73138 001**	DEC 22, 1995
AB	MYLAN	**50MG**	**N71405 001**	FEB 27, 1991
AB		**100MG**	**N71406 001**	FEB 27, 1991
AB	PUREPAC PHARM	**50MG**	**N71636 001**	APR 18, 1988
AB		**100MG**	**N71514 001**	APR 18, 1988
AB	SIDMAK LABS NJ	**50MG**	**N71523 001**	DEC 11, 1987
AB		**100MG**	**N71524 001**	DEC 11, 1987
AB		**150MG**	**N71525 001**	MAR 09, 1988
AB	TEVA	**50MG**	**N72192 001**	FEB 02, 1989
AB		**100MG**	**N72193 001**	FEB 02, 1989
AB		**150MG**	**N74357 001**	APR 30, 1997

TRETINOIN

CAPSULE; ORAL

	VESANOID			
+	ROCHE	10MG	N20438 001	NOV 22, 1995

CREAM; TOPICAL

	AVITA			
AB	BERTEK PHARMS	**0.025%**	**N20404 003**	JAN 14, 1997

FDA data supplied by DrugPatentWatch.com

TRETINOIN

CREAM; TOPICAL

	RENOVA			
	+ JOHNSON AND JOHNSON	0.02%	N21108 001	
			AUG 31, 2000	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.025%**	**N19049 001**	
			SEP 16, 1988	
AB	+	**0.05%**	**N17522 001**	
AB	+	**0.1%**	**N17340 001**	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75264 001**	
			DEC 24, 1998	
AB		**0.05%**	**N75265 001**	
			DEC 24, 1998	
AB		**0.1%**	**N75213 001**	
			DEC 24, 1998	

CREAM, AUGMENTED; TOPICAL

	RENOVA			
	+ JOHNSON AND JOHNSON	0.05%	N19963 001	
			DEC 29, 1995	

GEL; TOPICAL

	AVITA			
BT	BERTEK PHARMS	0.025%	N20400 001	
			JAN 29, 1998	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.025%**	**N17579 002**	
	+	0.01%	N17955 001	
	RETIN-A MICRO			
	+ JOHNSON AND JOHNSON	0.1%	N20475 001	
			FEB 07, 1997	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75529 001**	
			FEB 22, 2000	

SOLUTION; TOPICAL

	RETIN-A			
AT	+ JOHNSON AND JOHNSON	**0.05%**	**N16921 001**	
	TRETINOIN			
AT	COPLEY PHARM	**0.05%**	**N74873 001**	
			JUN 19, 1998	
AT	MORTON GROVE	**0.05%**	**N75260 001**	
			JAN 25, 1999	

TRETINOIN; *MULTIPLE*
SEE MEQUINOL; TRETINOIN

TRIAMCINOLONE

TABLET; ORAL

	ARISTOCORT			
BP	FUJISAWA HLTHCARE	4MG	N11161 007	
BP	+	8MG	N11161 011	
		1MG	N11161 009	
		2MG	N11161 004	
	KENACORT			
BP	BRISTOL MYERS SQUIBB	4MG	N11283 006	
BP		8MG	N11283 010	
	TRIAMCINOLONE			
BP	DANBURY PHARMA	4MG	N84270 001	
BP	IMPAX LABS	4MG	N84340 001	

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

	AZMACORT			
	+ AVENTIS	0.1MG/INH	N18117 001	
			APR 23, 1982	

AEROSOL, METERED; NASAL

	NASACORT			
	+ AVENTIS	0.055MG/INH	N19798 001	
			JUL 11, 1991	

CREAM; TOPICAL

	ARISTOCORT			
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 003**	
AT		**0.1%**	**N83016 004**	
AT		**0.5%**	**N83015 002**	
	ARISTOCORT A			
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 004**	
AT		**0.025%**	**N88818 001**	
			OCT 16, 1984	
AT		**0.1%**	**N83016 005**	
AT		**0.1%**	**N88819 001**	
			OCT 16, 1984	
AT		**0.5%**	**N83015 003**	
AT		**0.5%**	**N88820 001**	
			OCT 16, 1984	
	KENALOG			
AT	+ APOTHECON	**0.025%**	**N11601 003**	
AT	+	**0.1%**	**N11601 006**	
AT	+	**0.5%**	**N83943 001**	
	TRIACET			
AT	TEVA	**0.025%**	**N84908 001**	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	TRIACET			
AT	TEVA	0.1%	N84908 002	
AT		0.5%	N84908 003	
	TRIAMCINOLONE ACETONIDE			
AT	ALTANA	0.025%	N85692 001	
AT		0.1%	N85692 003	
AT		0.5%	N85692 002	
AT	AMBIX	0.025%	N87932 001	MAY 09, 1983
AT	CLAY PARK	0.025%	N86415 001	
AT		0.1%	N86414 001	
AT		0.5%	N86413 001	
AT	G AND W LABS	0.025%	N89797 001	MAY 31, 1991
AT		0.1%	N89798 001	MAY 31, 1991
AT	NMC	0.1%	N87798 001	JUN 04, 1982
AT	TARO	0.025%	N40038 001	OCT 26, 1994
AT		0.1%	N40039 001	NOV 26, 1997
AT	THAMES	0.025%	N86277 001	
AT		0.1%	N86276 001	
AT		0.5%	N86275 001	
AT	TOPIDERM	0.025%	N89274 001	FEB 21, 1989
AT		0.1%	N89275 001	FEB 21, 1989
AT		0.5%	N89276 001	FEB 21, 1989
	TRIDERM			
AT	DEL RAY LABS	0.1%	N88042 001	MAR 19, 1984
	TRYMEX			
AT	SAVAGE LABS	0.025%	N88196 001	MAR 25, 1983
AT		0.1%	N88197 001	MAR 25, 1983

DISC; TOPICAL

	KENALOG			
+	APOTHECON	0.147MG/GM	N12104 001	

INJECTABLE; INJECTION

	KENALOG-10			
+	APOTHECON	10MG/ML	N12041 001	

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

	KENALOG-40			
BP	APOTHECON	40MG/ML	N14901 001	
	TRIAMCINOLONE ACETONIDE			
	PARNELL	3MG/ML	N19503 001	OCT 16, 1987
BP	STERIS	40MG/ML	N85825 001	

LOTION; TOPICAL

	KENALOG			
AT	APOTHECON	0.025%	N84343 001	
AT +		0.1%	N84343 002	
	TRIAMCINOLONE ACETONIDE			
AT	MORTON GROVE	0.025%	N88450 001	APR 01, 1985
AT		0.1%	N88451 001	APR 03, 1985
AT	THAMES	0.1%	N89129 001	AUG 14, 1986

OINTMENT; TOPICAL

	ARISTOCORT			
AT	FUJISAWA HLTHCARE	0.1%	N80750 004	
AT		0.5%	N80745 002	
	ARISTOCORT A			
AT	FUJISAWA HLTHCARE	0.1%	N80750 003	
AT		0.1%	N88780 001	OCT 01, 1984
AT		0.5%	N80745 003	
	KENALOG			
AT	APOTHECON	0.025%	N11600 003	
AT		0.1%	N11600 001	
	TRIAMCINOLONE ACETONIDE			
AT	ALTANA	0.025%	N85691 001	
AT		0.1%	N85691 003	
AT		0.5%	N85691 002	
AT +	CLAY PARK	0.025%	N87356 001	
AT +		0.1%	N87357 001	
AT +		0.5%	N87385 001	
AT	G AND W LABS	0.025%	N89795 001	DEC 23, 1988
AT		0.1%	N89796 001	DEC 23, 1988
AT	NMC	0.1%	N87799 001	JUN 07, 1982
AT	TARO	0.025%	N40040 001	SEP 30, 1994

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	TARO	**0.1%**	**N40037 001**	
			SEP 30, 1994	
AT	THAMES	**0.1%**	**N87902 001**	
			DEC 27, 1982	

TRIAMCINOLONE ACETONIDE IN ABSORBASE

+	CAROLINA MEDCL	0.05%	N89595 001	
			MAR 23, 1995	

TRYMEX

AT	SAVAGE LABS	**0.025%**	**N88693 001**	
			AUG 02, 1984	
AT		**0.1%**	**N88691 001**	
			AUG 02, 1984	

PASTE; DENTAL
KENALOG IN ORABASE

AT	+ APOTHECON	**0.1%**	**N12097 001**	

ORACORT

AT	TARO	**0.1%**	**N70730 001**	
			OCT 01, 1986	

ORALONE

AT	THAMES	**0.1%**	**N71383 001**	
			JUL 06, 1987	

SPRAY, METERED; NASAL
NASACORT AQ

+	AVENTIS	0.055MG/SPRAY	N20468 001	
			MAY 20, 1996	

TRI-NASAL

+	MURO	0.05MG/SPRAY	N20120 001	
			FEB 04, 2000	

TRIAMCINOLONE ACETONIDE; *MULTIPLE*
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT

BP	+ LEDERLE	40MG/ML	N12802 001	
	+	25MG/ML	N11685 003	

TRIAMCINOLONE DIACETATE

BP	STERIS	40MG/ML	N84072 001	

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
ARISTOCORT

	FUJISAWA HLTHCARE	2MG/5ML	N11960 004	

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN

+	LEDERLE	5MG/ML	N16466 001	
+		20MG/ML	N16466 002	

TRIAMTERENE

CAPSULE; ORAL
DYRENIUM

	WELLSPRING PHARM	50MG	N13174 001	
+		100MG	N13174 002	

TRIAMTERENE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

TRIAZOLAM

TABLET; ORAL
HALCION

AB	PHARMACIA AND UPJOHN	**0.125MG**	**N17892 003**	
			APR 26, 1985	
AB	+	**0.25MG**	**N17892 001**	
			NOV 15, 1982	

TRIAZOLAM

AB	ALPHAPHARM	**0.125MG**	**N74031 001**	
			MAR 25, 1994	
AB		**0.25MG**	**N74031 002**	
			MAR 25, 1994	
AB	CHELSEA LABS	**0.125MG**	**N74445 001**	
			OCT 20, 1995	
AB		**0.25MG**	**N74445 002**	
			OCT 20, 1995	
AB	ROXANE	**0.125MG**	**N74224 001**	
			JUN 01, 1994	
AB		**0.25MG**	**N74224 002**	
			JUN 01, 1994	

FDA data supplied by DrugPatentWatch.com

TRICHLORMETHIAZIDE

TABLET; ORAL

	METAHYDRIN			
BP	AVENTIS PHARMS	2MG	N12594 001	
			JUN 16, 1988	
BP		4MG	N12594 002	
			JUN 16, 1988	
	NAQUA			
BP	+ SCHERING	4MG	N12265 002	
	TRICHLOREX			
BP	LANNETT	4MG	N83436 001	
BP		4MG	N85630 001	
	TRICHLORMETHIAZIDE			
BP	CAMALL	4MG	N85568 001	
BP	IMPAX LABS	4MG	N83967 001	
BP	PAR PHARM	2MG	N87007 001	
BP		4MG	N87005 001	

TRICHLORMETHIAZIDE; *MULTIPLE*

SEE RESERPINE; TRICHLORMETHIAZIDE

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

	SYPRINE		
+	MERCK	250MG	N19194 001
			NOV 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	STELAZINE			
AA	+ SMITHKLINE BEECHAM	**EQ 10MG BASE/ML**	**N11552 006**	
	TRIFLUOPERAZINE HCL			
AA	GENEVA PHARMS	**EQ 10MG BASE/ML**	**N85787 001**	
			APR 15, 1982	

INJECTABLE; INJECTION

	STELAZINE		
+	SMITHKLINE BEECHAM	EQ 2MG BASE/ML	N11552 005

TABLET; ORAL

	STELAZINE		
AB	SMITHKLINE BEECHAM	**EQ 1MG BASE**	**N11552 001**
AB		**EQ 2MG BASE**	**N11552 002**

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	STELAZINE			
AB	SMITHKLINE BEECHAM	**EQ 5MG BASE**	**N11552 003**	
AB	+	**EQ 10MG BASE**	**N11552 004**	
	TRIFLUOPERAZINE HCL			
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N85785 001**	
AB		**EQ 2MG BASE**	**N85786 001**	
AB		**EQ 5MG BASE**	**N85789 001**	
AB		**EQ 10MG BASE**	**N85788 001**	
AB	INVAMED	**EQ 1MG BASE**	**N40153 001**	
			OCT 25, 1996	
AB		**EQ 2MG BASE**	**N40153 002**	
			OCT 25, 1996	
AB		**EQ 5MG BASE**	**N40153 003**	
			OCT 25, 1996	
AB		**EQ 10MG BASE**	**N40153 004**	
			OCT 25, 1996	
AB	MYLAN	**EQ 1MG BASE**	**N40209 001**	
			JUL 07, 1997	
AB		**EQ 2MG BASE**	**N40209 002**	
			JUL 07, 1997	
AB		**EQ 5MG BASE**	**N40209 003**	
			JUL 07, 1997	
AB		**EQ 10MG BASE**	**N40209 004**	
			JUL 07, 1997	

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	VESPRIN		
+	APOTHECON	10MG/ML	N11325 004
+		20MG/ML	N11325 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

	TRIFLURIDINE			
AT	ALCON	**1%**	**N74311 001**	
			OCT 06, 1995	
	VIROPTIC			
AT	+ MONARCH PHARMS	**1%**	**N18299 001**	

FDA data supplied by DrugPatentWatch.com

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	ARTANE			
AA	+ LEDERLE	2MG/5ML	N06773 009	
	TRIHEXYPHENIDYL HCL			
AA	LIQUIPHARM	2MG/5ML	N89514 001	APR 07, 1989
AA	MIKART	2MG/5ML	N40251 001	SEP 27, 1999
AA	PHARM ASSOC	2MG/5ML	N40177 001	APR 17, 1997

TABLET; ORAL

	ARTANE			
AA	+ LEDERLE	2MG	N06773 005	
AA	+	5MG	N06773 003	
	TRIHEXYPHENIDYL HCL			
AA	DANBURY PHARMA	2MG	N84363 001	
AA		5MG	N84364 001	
AA	NYLOS	5MG	N85622 001	
AA	VINTAGE PHARMS	2MG	N40254 001	DEC 24, 1998
AA		5MG	N40254 002	DEC 24, 1998
AA	WATSON LAB	2MG	N40184 001	FEB 06, 1998
AA		5MG	N40184 002	FEB 06, 1998
AA	WEST WARD	2MG	N40337 002	FEB 16, 2000
AA		5MG	N40337 001	FEB 16, 2000

TRIMETHADIONE

CAPSULE; ORAL

	TRIDIONE		
+	ABBOTT	300MG	N05856 005

SOLUTION; ORAL

	TRIDIONE		
	ABBOTT	200MG/5ML	N05856 002

TABLET; ORAL

	TRIDIONE		
+	ABBOTT	150MG	N05856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TIGAN			
AP	+ KING PHARMS	100MG/ML	N17530 001	
	TRIMETHOBENZAMIDE HCL			
AP	ABBOTT	100MG/ML	N88804 001	APR 03, 1987
AP	STERIS	100MG/ML	N86577 001	OCT 19, 1982
AP		100MG/ML	N87939 001	DEC 28, 1982

TRIMETHOPRIM

TABLET; ORAL

	PROLOPRIM			
AB	MONARCH PHARMS	100MG	N17943 001	
AB	+	200MG	N17943 003	
	TRIMETHOPRIM			JUL 14, 1982
AB	DANBURY PHARMA	100MG	N70049 001	
AB	TEVA	100MG	N18679 001	JUN 06, 1985
AB		200MG	N71259 001	JUL 30, 1982
	TRIMPEX			JUN 18, 1987
AB	ROCHE	100MG	N17952 001	

TRIMETHOPRIM; *MULTIPLE*
SEE POLYMYXIN B SULFATE; TRIMETHOPRIM
SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

	PRIMSOL			
+	ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995
+		EQ 50MG BASE/5ML	N74973 001	JAN 24, 2000

TRIMETHOPRIM SULFATE; *MULTIPLE*
SEE POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

FDA data supplied by DrugPatentWatch.com

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN
+ MEDIMMUNE ONCOLOGY — EQ 25MG BASE/VIAL — N20326 001 DEC 17, 1993
+ — EQ 200MG BASE/VIAL — N20326 002 JUL 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
SURMONTIL
WYETH AYERST — EQ 25MG BASE — N16792 001
EQ 50MG BASE — N16792 002
+ — EQ 100MG BASE — N16792 003 SEP 15, 1982

TRIOXSALEN

TABLET; ORAL
TRISORALEN
+ ICN — 5MG — N12697 001

TRIPELENNAMINE CITRATE

ELIXIR; ORAL
PBZ
NOVARTIS — EQ 25MG HCL/5ML — N05914 004

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
PBZ
AA + NOVARTIS — **50MG** — **N05914 002**
+ — 25MG — N83149 001
TRIPELENNAMINE HCL
AA DANBURY PHARMA — **50MG** — **N80713 001**
AA IMPAX LABS — **50MG** — **N80785 001**
AA LANNETT — **50MG** — **N83557 001**
AA NYLOS — **50MG** — **N85412 001**

TABLET, EXTENDED RELEASE; ORAL
PBZ-SR
NOVARTIS — 100MG — N10533 001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
GYNE-SULF
AT G AND W LABS — **3.7%;2.86%;3.42%** — **N88607 001** JUN 09, 1986
SULTRIN
AT + JOHNSON RW — **3.7%;2.86%;3.42%** — **N05794 001**
TRIPLE SULFA
AT ALPHARMA — **3.7%;2.86%;3.42%** — **N87864 001** SEP 01, 1982
AT CLAY PARK — **3.7%;2.86%;3.42%** — **N87285 001** NOV 15, 1982
AT FOUGERA — **3.7%;2.86%;3.42%** — **N86424 001**
TRYSUL
AT SAVAGE LABS — **3.7%;2.86%;3.42%** — **N87887 001** JUL 23, 1982

TABLET; VAGINAL
SULTRIN
+ JOHNSON RW — 184MG;143.75MG;172.5MG — N05794 002

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPTORELIN PAMOATE

INJECTABLE; INJECTION
TRELSTAR DEPOT
+ DEBIO RECHERCHE — EQ 3.75MG BASE/VIAL — N20715 001 JUN 15, 2000

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL
TRIPLE SULFOID
+ PAL PAK — 167MG;167MG;167MG — N80094 001

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC
CERUMENEX
+ PURDUE FREDERICK — 10% — N11340 002

FDA data supplied by DrugPatentWatch.com

TROLEANDOMYCIN

CAPSULE; ORAL
TAO
+ PFIZER — EQ 250MG BASE — N50336 002

TROMETHAMINE

INJECTABLE; INJECTION
THAM
+ ABBOTT — 3.6GM/100ML — N13025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	MYDRIACYL			
AT	+ ALCON	0.5%	N84305 001	
AT	+	1%	N84306 001	
	TROPICACYL			
AT	AKORN	0.5%	N40314 001	SEP 29, 2000
AT		1%	N40315 001	SEP 29, 2000
	TROPICAMIDE			
AT	ALCON UNIVERSAL	1%	N89172 001	DEC 28, 1990
AT	BAUSCH AND LOMB	0.5%	N40067 001	JUL 27, 1994
AT		1%	N40064 001	JUL 27, 1994
AT	MIZA PHARMS USA	0.5%	N87636 001	JUL 30, 1982
AT		1%	N87637 001	AUG 09, 1982

TROPICAMIDE; *MULTIPLE*
SEE HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
PFIZER — EQ 100MG BASE — N20759 001 DEC 18, 1997

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
+ PFIZER — EQ 200MG BASE — N20759 002 DEC 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

AP	+ ABBOTT	3MG/ML	N06095 001	
AP	+ APOTHECON	3MG/ML	N05657 001	
AP	+ LILLY	3MG/ML	N06325 001	

TYLOXAPOL; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ CIBA — 0.15% — N21214 001 AUG 03, 2000

URACIL MUSTARD

CAPSULE; ORAL
URACIL MUSTARD
+ ROBERTS LABS — 1MG — N12892 001

UREA

INJECTABLE; INJECTION
UREAPHIL
+ ABBOTT — 40GM/VIAL — N12154 001

UREA; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; UREA

FDA data supplied by DrugPatentWatch.com

UREA, C-13

FOR SOLUTION; ORAL

	HELICOSOL		
+	METABOLIC SOLUTIONS	125MG/VIAL	N21092 001 DEC 17, 1999
	MERETEK UBT KIT (W/ PRANACTIN)		
+	MERETEK	125MG/VIAL	N20586 001 SEP 17, 1996
	PYLORI-CHEK BREATH TEST		
+	ALIMENTERICS	100MG/VIAL	N20900 001 FEB 04, 1999

UREA, C-14

CAPSULE; ORAL

	PYTEST		
+	BALLARD MEDCL	1 uCi	N20617 001 MAY 09, 1997
	PYTEST KIT		
+	BALLARD MEDCL	1 uCi	N20617 002 MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; SUBCUTANEOUS

	FERTINEX		
+	SERONO	75 IU/AMP	N19415 005 AUG 23, 1996
		150 IU/AMP	N19415 004 AUG 23, 1996

URSODIOL

CAPSULE; ORAL

	ACTIGALL		
AB	+ NOVARTIS	**300MG**	**N19594 002** DEC 31, 1987
	URSODIOL		
AB	AMIDE PHARM	**300MG**	**N75517 001** MAR 14, 2000
AB	COPLEY PHARM	**300MG**	**N75592 001** MAY 25, 2000

TABLET; ORAL

	URSO		
+	AXCAN SCANDIPHARM	250MG	N20675 001 DEC 10, 1997

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

	VALTREX		
+	GLAXO WELLCOME	EQ 500MG BASE	N20487 001 JUN 23, 1995

VALPROATE SODIUM

INJECTABLE; INJECTION

	DEPACON		
+	ABBOTT	EQ 100MG BASE/ML	N20593 001 DEC 30, 1996

VALPROIC ACID

CAPSULE; ORAL

	DEPAKENE		
AB	+ ABBOTT	**250MG**	**N18081 001**
	VALPROIC ACID		
AB	BANNER PHARMACAPS	**250MG**	**N73484 001** JUN 29, 1993
AB	PAR PHARM	**250MG**	**N70431 001** FEB 28, 1986
AB	ROSEMONT	**250MG**	**N70631 001** JUN 11, 1987
AB	SCHERER RP	**250MG**	**N70195 001** JUL 02, 1987
AB		**250MG**	**N73229 001** OCT 29, 1991

SYRUP; ORAL

	DEPAKENE		
AA	+ ABBOTT	**250MG/5ML**	**N18082 001**
	MYPROIC ACID		
AA	MORTON GROVE	**250MG/5ML**	**N70868 001** JUL 01, 1986
	VALPROIC ACID		
AA	COPLEY PHARM	**250MG/5ML**	**N73178 001** AUG 25, 1992
AA	HIGH TECH PHARMA	**250MG/5ML**	**N74060 001** JAN 13, 1995
AA	PHARM ASSOC	**250MG/5ML**	**N75379 001** DEC 15, 2000
AA	UDL	**250MG/5ML**	**N75782 001** DEC 22, 2000

FDA data supplied by DrugPatentWatch.com

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

+	ANTHRA	40MG/ML	N20892 001 SEP 25, 1998	

VALSARTAN

CAPSULE; ORAL
DIOVAN

	NOVARTIS	80MG	N20665 001 DEC 23, 1996	
+		160MG	N20665 002 DEC 23, 1996	

VALSARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; VALSARTAN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL
VANCOCIN HCL

	LILLY	EQ 125MG BASE	N50606 001 APR 15, 1986	
+		EQ 250MG BASE	N50606 002 APR 15, 1986	

FOR SOLUTION; ORAL
VANCOCIN HCL

AA	LILLY	**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983	
+		EQ 500MG BASE/6ML	N61667 001	

VANCOLED

AA	LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993	

INJECTABLE; INJECTION
VANCOCIN HCL

AP	+ LILLY	**EQ 500MG BASE/VIAL**	**N60180 001**	
AP		**EQ 500MG BASE/VIAL**	**N62476 001** MAR 15, 1984	
AP		**EQ 500MG BASE/VIAL**	**N62716 001** MAR 13, 1987	
AP		**EQ 500MG BASE/VIAL**	**N62812 001** NOV 17, 1987	

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL

AP	+ LILLY	**EQ 1GM BASE/VIAL**	**N60180 002** MAR 21, 1986	
AP		**EQ 1GM BASE/VIAL**	**N62476 002** MAR 21, 1986	
AP		**EQ 1GM BASE/VIAL**	**N62716 002** MAR 13, 1987	
AP		**EQ 1GM BASE/VIAL**	**N62812 002** NOV 17, 1987	
AP	+	**EQ 10GM BASE/VIAL**	**N62812 003** NOV 17, 1987	

VANCOCIN HCL IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993

VANCOLED

AP	+ LEDERLE	**EQ 500MG BASE/VIAL**	**N62682 001** JUL 22, 1986	
AP	+	**EQ 1GM BASE/VIAL**	**N62682 002** MAR 30, 1988	
AP	+	**EQ 5GM BASE/VIAL**	**N62682 004** MAY 11, 1988	
AP	+	**EQ 10GM BASE/VIAL**	**N62682 005** MAY 11, 1988	
	+	EQ 2GM BASE/VIAL	N62682 003 MAY 11, 1988	

VANCOMYCIN HCL

AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N62912 001** AUG 04, 1988	
AP		**EQ 1GM BASE/VIAL**	**N62933 001** OCT 29, 1992	
AP		**EQ 5GM BASE/VIAL**	**N63076 001** DEC 21, 1990	
AP		**EQ 500MG BASE/VIAL**	**N62911 001** AUG 04, 1988	
AP		**EQ 500MG BASE/VIAL**	**N62931 001** OCT 29, 1992	
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N62663 001** MAR 17, 1987	
AP		**EQ 1GM BASE/VIAL**	**N62663 002** JUL 31, 1987	
AP		**EQ 5GM BASE/VIAL**	**N62663 003** JUN 03, 1988	
AP		**EQ 10GM BASE/VIAL**	**N62663 004** NOV 28, 1997	
AP	ELKINS SINN	**EQ 500MG BASE/VIAL**	**N62879 001** AUG 02, 1988	

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	VANCOMYCIN HCL			
AP	ELKINS SINN	EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	NORCURON			
AP	+ ORGANON	10MG/VIAL	N18776 002	APR 30, 1984
AP	+	20MG/VIAL	N18776 003	JAN 03, 1992
	VECURONIUM BROMIDE			
AP	ABBOTT	10MG/VIAL	N75164 001	OCT 21, 1999
AP		20MG/VIAL	N75164 002	OCT 21, 1999
AP	BEDFORD	10MG/VIAL	N75549 001	JUN 13, 2000
AP		20MG/VIAL	N75549 002	JUN 13, 2000
AP	ESI LEDERLE	10MG/VIAL	N75218 001	AUG 23, 1999
AP		20MG/VIAL	N75218 002	AUG 23, 1999
AP	GENSIA	10MG/VIAL	N74688 001	AUG 25, 1999
AP		20MG/VIAL	N74688 002	AUG 25, 1999
AP	STERIS	10MG/VIAL	N74334 001	AUG 31, 1995
AP		20MG/VIAL	N74334 002	AUG 31, 1995

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	EFFEXOR XR			
	+ WYETH AYERST	EQ 37.5MG BASE	N20699 001	OCT 20, 1997
	+	EQ 75MG BASE	N20699 002	OCT 20, 1997
	+	EQ 150MG BASE	N20699 004	OCT 20, 1997

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

	EFFEXOR			
	+ WYETH AYERST	EQ 25MG BASE	N20151 002	DEC 28, 1993
		EQ 37.5MG BASE	N20151 006	DEC 28, 1993
		EQ 50MG BASE	N20151 003	DEC 28, 1993
		EQ 75MG BASE	N20151 004	DEC 28, 1993
	+	EQ 100MG BASE	N20151 005	DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	MYLAN	120MG	N75138 001	APR 20, 1999
AB		180MG	N75138 002	APR 20, 1999
AB		240MG	N75138 003	APR 20, 1999
	VERELAN			
AB	+ ELAN PHARM	120MG	N19614 001	MAY 29, 1990
AB	+	180MG	N19614 003	JAN 09, 1992
AB	+	240MG	N19614 002	MAY 29, 1990
	+	360MG	N19614 004	MAY 10, 1996
	VERELAN PM			
	+ ELAN PHARM	100MG	N20943 001	NOV 25, 1998
	+	200MG	N20943 002	NOV 25, 1998
	+	300MG	N20943 003	NOV 25, 1998

INJECTABLE; INJECTION

	ISOPTIN			
AP	+ KNOLL PHARM	2.5MG/ML	N18485 001	
	VERAPAMIL HCL			
AP	ABBOTT	2.5MG/ML	N70577 001	FEB 02, 1987

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	ABBOTT	2.5MG/ML	N70737 001	MAY 06, 1987
AP		2.5MG/ML	N70738 001	MAY 06, 1987
AP		2.5MG/ML	N70739 001	MAY 06, 1987
AP		2.5MG/ML	N70740 001	MAY 06, 1987
AP		2.5MG/ML	N75136 001	OCT 20, 1998
AP	BEDFORD	2.5MG/ML	N72888 001	JUL 28, 1995
AP	INTL MEDICATION	2.5MG/ML	N70451 001	DEC 16, 1985
AP	LUITPOLD	2.5MG/ML	N70225 001	NOV 12, 1985
AP		2.5MG/ML	N70617 001	NOV 12, 1985

TABLET; ORAL

CALAN

AB	SEARLE	40MG	N18817 003	FEB 23, 1988
AB		80MG	N18817 001	SEP 10, 1984
AB		120MG	N18817 002	SEP 10, 1984

ISOPTIN

AB	KNOLL PHARM	40MG	N18593 003	NOV 23, 1987
AB		80MG	N18593 001	MAR 08, 1982
AB +		120MG	N18593 002	MAR 08, 1982

VERAPAMIL HCL

AB	DANBURY PHARMA	80MG	N70855 001	SEP 24, 1986
AB		120MG	N70856 001	SEP 24, 1986
AB	GENEVA PHARMS	40MG	N73168 001	JUL 31, 1992
AB		80MG	N71423 001	MAY 24, 1988
AB		120MG	N71424 001	MAY 25, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

AB	LEDERLE	80MG	N71880 001	APR 05, 1988
AB		120MG	N71881 001	APR 05, 1988
AB	MUTUAL PHARM	80MG	N71488 001	JAN 13, 1988
AB		120MG	N71489 001	JAN 13, 1988
AB	MYLAN	80MG	N71482 001	FEB 15, 1989
AB		120MG	N71483 001	FEB 15, 1989
AB	PUREPAC PHARM	80MG	N71019 001	SEP 24, 1986
AB		120MG	N70468 001	SEP 24, 1986
AB	SIDMAK LABS NJ	40MG	N72751 001	FEB 23, 1996
AB		80MG	N72124 001	JAN 26, 1989
AB		120MG	N72125 001	JAN 26, 1989
AB	WATSON LABS	40MG	N72923 001	JUN 29, 1993
AB		40MG	N72924 001	JUN 29, 1993
AB		80MG	N70995 001	OCT 01, 1986
AB		80MG	N71366 001	OCT 01, 1986
AB		120MG	N70994 001	OCT 01, 1986
AB		120MG	N71367 001	OCT 01, 1986

TABLET, EXTENDED RELEASE; ORAL

COVERA-HS

BC +	SEARLE	180MG	N20552 001	FEB 26, 1996
BC +		240MG	N20552 002	FEB 26, 1996

ISOPTIN SR

AB +	KNOLL PHARM	120MG	N19152 003	MAR 06, 1991

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
AB	+ KNOLL PHARM	180MG	N19152 002	DEC 15, 1989
AB	+	240MG	N19152 001	DEC 16, 1986
	VERAPAMIL HCL			
AB	DURAMED	120MG	N75072 001	MAY 25, 1999
AB		240MG	N75072 003	MAY 25, 1999
AB	MYLAN	120MG	N74587 002	FEB 21, 1997
AB		180MG	N74587 003	SEP 09, 1997
AB		240MG	N74587 001	MAR 23, 1996
AB	SIDMAK LABS NJ	240MG	N72922 001	MAR 01, 1996
AB	ZENITH GOLDLINE	120MG	N73568 002	OCT 10, 1997
AB		180MG	N74330 001	JAN 31, 1994
AB		240MG	N73568 001	JUL 31, 1992

VERAPAMIL HYDROCHLORIDE; *MULTIPLE*
SEE TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

VERTEPORFIN

INJECTABLE; INJECTION

	VISUDYNE		
+	QLT	15MG/VIAL	N21119 001 APR 12, 2000

VIDARABINE

OINTMENT; OPHTHALMIC

	VIRA-A		
+	PARKEDALE	3%	N50486 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION

	VELBAN		
AP	+ LILLY	10MG/VIAL	N12665 001
	VINBLASTINE SULFATE		
	+ AM PHARM PARTNERS	1MG/ML	N89515 001 APR 29, 1987
AP	BEDFORD	10MG/VIAL	N89395 001 APR 09, 1987
AP	FAULDING	10MG/VIAL	N89565 001 AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	ONCOVIN		
AP	+ LILLY	1MG/ML	N14103 003 MAR 07, 1984
	VINCASAR PFS		
AP	PHARMACIA AND UPJOHN	1MG/ML	N71426 001 JUL 17, 1987
	VINCRISTINE SULFATE PFS		
AP	FAULDING	1MG/ML	N71484 001 APR 19, 1988
AP	GENSIA SICOR PHARMS	1MG/ML	N75493 001 SEP 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

	NAVELBINE		
+	GLAXO WELLCOME	EQ 10MG BASE/ML	N20388 001 DEC 23, 1994

VITAMIN A

CAPSULE; ORAL

	VITAMIN A		
+	WEST WARD	50,000 USP UNITS	N80985 001

VITAMIN A; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

FDA data supplied by DrugPatentWatch.com

VITAMIN A; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A			
AA	MK LABS	**EQ 50,000 UNITS BASE**	**N83457 001**	
		EQ 25,000 UNITS BASE	N83457 002	
AA	WEST WARD	**EQ 50,000 UNITS BASE**	**N80967 001**	
	VITAMIN A PALMITATE			
AA	ARCUM	**EQ 50,000 UNITS BASE**	**N83311 001**	
AA		**EQ 50,000 UNITS BASE**	**N83321 001**	

INJECTABLE; INJECTION

	AQUASOL A			
+	ASTRAZENECA	EQ 50,000 UNITS BASE/ML	N06823 001	

VITAMIN A PALMITATE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

VITAMIN E; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

WARFARIN SODIUM

INJECTABLE; INJECTION

	COUMADIN			
+	DUPONT MERCK	5MG/VIAL	N09218 024 FEB 07, 1995	

TABLET; ORAL

	COUMADIN			
AB	DUPONT MERCK	**1MG**	**N09218 022** MAR 01, 1990	
AB		**2MG**	**N09218 013**	
AB	+	**2.5MG**	**N09218 018**	
AB		**3MG**	**N09218 025** NOV 18, 1996	
AB		**4MG**	**N09218 023** AUG 24, 1993	
AB	+	**5MG**	**N09218 007**	
AB		**6MG**	**N09218 026** NOV 18, 1996	
AB		**7.5MG**	**N09218 016**	
AB	+	**10MG**	**N09218 005**	
	WARFARIN SODIUM			
AB	BARR	**1MG**	**N40145 001** MAR 26, 1997	
AB		**2MG**	**N40145 002** MAR 26, 1997	
AB		**2.5MG**	**N40145 003** MAR 26, 1997	
AB		**3MG**	**N40145 008** NOV 05, 1998	
AB		**4MG**	**N40145 004** MAR 26, 1997	
AB		**5MG**	**N40145 005** MAR 26, 1997	
AB		**6MG**	**N40145 009** NOV 05, 1998	
AB		**7.5MG**	**N40145 006** MAR 26, 1997	
AB		**10MG**	**N40145 007** MAR 26, 1997	
AB	GENEVA PHARMS TECH	**1MG**	**N40196 001** SEP 30, 1997	
AB		**2MG**	**N40196 002** SEP 30, 1997	
AB		**2.5MG**	**N40196 003** SEP 30, 1997	
AB		**3MG**	**N40196 008** JUL 26, 2000	
AB		**4MG**	**N40196 004** SEP 30, 1997	
AB		**5MG**	**N40196 005** SEP 30, 1997	
AB		**6MG**	**N40196 009** JUL 26, 2000	

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

AB	GENEVA PHARMS TECH	7.5MG	N40196 006	SEP 30, 1997
AB		10MG	N40196 007	SEP 30, 1997
AB	TARO	1MG	N40301 002	JUL 15, 1999
AB		2MG	N40301 003	JUL 15, 1999
AB		2.5MG	N40301 004	JUL 15, 1999
AB		3MG	N40301 005	JUL 15, 1999
AB		4MG	N40301 006	JUL 15, 1999
AB		5MG	N40301 007	JUL 15, 1999
AB		6MG	N40301 008	JUL 15, 1999
AB		7.5MG	N40301 009	JUL 15, 1999
AB		10MG	N40301 001	JUL 15, 1999

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18802 001	OCT 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18233 001	
AP		100%	N18801 001	OCT 27, 1982
AP		100%	N19869 001	DEC 26, 1989
AP	AM PHARM PARTNERS	100%	N88400 001	JAN 16, 1984
AP	B BRAUN	100%	N19077 001	MAR 02, 1984
AP		100%	N19633 001	FEB 29, 1988
AP	BAXTER HLTHCARE	100%	N18632 001	JUN 30, 1982

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	100%	N18632 002	APR 19, 1988

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION
STERILE WATER

AT	BAXTER HLTHCARE	100%	N17428 001

STERILE WATER IN PLASTIC CONTAINER

AT	ABBOTT	100%	N17513 001
AT		100%	N18313 001
AT	B BRAUN	100%	N16734 001
AT	BAXTER HLTHCARE	100%	N17866 001

XENON, XE-127

GAS; INHALATION
XENON XE 127

	MALLINCKRODT	5mCi/VIAL	N18536 001 OCT 01, 1982
		10mCi/VIAL	N18536 002 OCT 01, 1982

XENON, XE-133

GAS; INHALATION
XENON XE 133

AA	DUPONT PHARMS	10mCi/VIAL	N17284 001	
AA		20mCi/VIAL	N17284 002	
	GEN ELECTRIC	1-2.5 CI/AMP	N17550 003	
		5 CI/CYLINDER	N17550 001	
AA	MALLINCKRODT	10mCi/VIAL	N18327 001	MAR 09, 1982
AA		20mCi/VIAL	N18327 002	MAR 09, 1982

XYLOSE

POWDER; ORAL
XYLOSE

	+ LYNE	25GM/BOT	N18856 001	MAR 26, 1987

FDA data supplied by DrugPatentWatch.com

ZAFIRLUKAST

TABLET; ORAL
ACCOLATE
ASTRAZENECA 10MG N20547 003 SEP 17, 1999
\+ 20MG N20547 001 SEP 26, 1996

ZALCITABINE

TABLET; ORAL
HIVID
ROCHE 0.375MG N20199 001 JUN 19, 1992
\+ 0.75MG N20199 002 JUN 19, 1992

ZALEPLON

CAPSULE; ORAL
SONATA
WYETH AYERST 5MG N20859 001 AUG 13, 1999
\+ 10MG N20859 002 AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
\+ GLAXO WELLCOME 5MG N21036 001 JUL 26, 1999

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR
\+ GLAXO WELLCOME 100MG N19655 001 MAR 19, 1987

INJECTABLE; INJECTION
RETROVIR
\+ GLAXO WELLCOME 10MG/ML N19951 001 FEB 02, 1990

ZIDOVUDINE

SYRUP; ORAL
RETROVIR
GLAXO WELLCOME 50MG/5ML N19910 001 SEP 28, 1989

TABLET; ORAL
RETROVIR
\+ GLAXO WELLCOME 300MG N20518 002 OCT 04, 1996

ZIDOVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
SEE LAMIVUDINE; ZIDOVUDINE

ZILEUTON

TABLET; ORAL
ZYFLO
ABBOTT 300MG N20471 001 DEC 09, 1996
\+ 600MG N20471 003 DEC 09, 1996

ZINC ACETATE

CAPSULE; ORAL
GALZIN
TEVA EQ 25MG ZINC N20458 001 JAN 28, 1997
\+ EQ 50MG ZINC N20458 002 JAN 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER
\+ ABBOTT EQ 1MG ZINC/ML N18959 001 JUN 26, 1986

FDA data supplied by DrugPatentWatch.com

ZOLMITRIPTAN

TABLET; ORAL

ZOMIG		
IPR	2.5MG	N20768 001 NOV 25, 1997
+	5MG	N20768 002 NOV 25, 1997

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN		
LOREX	5MG	N19908 001 DEC 16, 1992
+	10MG	N19908 002 DEC 16, 1992

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN		
+ DAINIPPON	100MG	N20789 001 MAR 27, 2000

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
G AND W LABS	120MG	N18060 001	
	120MG	N72218 001	MAR 27, 1992
	325MG	N18060 003	DEC 18, 1986
	325MG	N72344 001	MAR 27, 1992
	650MG	N18060 002	
	650MG	N72237 001	MAR 27, 1992
ACETAMINOPHEN			
ABLE	120MG	N73106 001	FEB 27, 1995
	325MG	N73107 001	FEB 27, 1995
	650MG	N73108 001	FEB 27, 1995
ASCENT PEDS	120MG	N18337 003	SEP 12, 1983
	325MG	N18337 002	
+	650MG	N18337 001	
SUPPOSITORIA	120MG	N70607 001	APR 06, 1987
	650MG	N70608 001	DEC 01, 1986
INFANTS' FEVERALL			
ASCENT PEDS	80MG	N18337 004	AUG 26, 1992
NEOPAP			
POLYMEDICA	120MG	N16401 001	

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN			
PERRIGO	650MG	N75077 001	FEB 25, 2000
TYLENOL			
+ MCNEIL	650MG	N19872 001	JUN 08, 1994

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)			
+ BRISTOL MYERS	250MG;250MG;65MG	N20802 001	JAN 14, 1998

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS			
+ SCHERING PLOUGH	500MG;3MG;60MG	N19453 001	MAY 22, 1987

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT			
GUARDIAN DRUG	80MG;20MG	N71793 001	SEP 04, 1987
FOAMICON			
GENEVA PHARMS TECH	80MG;20MG	N72687 001	JUN 28, 1989
GAVISCON			
AVENTIS PHARMS	80MG;20MG	N18685 001	DEC 09, 1983
+	160MG;40MG	N18685 002	DEC 09, 1983

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			
+ CIBA	0.5%;0.05%	N18746 002	JUL 11, 1994

ASPIRIN; *MULTIPLE*

SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD			
+ SCHERING PLOUGH	3%;7.5%;3%	N20045 001	DEC 07, 1992

FDA data supplied by DrugPatentWatch.com

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
+ NASKA 500 UNITS/GM N62857 001 NOV 13, 1987

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
+ NASKA 400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62833 001 NOV 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-POLYMYXIN B SULFATE
+ NASKA 500 UNITS/GM; 10,000 UNITS/GM N62849 001 NOV 13, 1987

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK
+ ENVIRODERM 5% N20532 001 AUG 26, 1996

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIMETAPP
+ WHITEHALL ROBINS 2MG/5ML;12.5MG/5ML N13087 003 MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL
BROMATAPP
COPLEY PHARM 12MG;75MG N71099 001 JUL 02, 1987

DIMETAPP
+ WHITEHALL ROBINS 12MG;75MG N12436 003 MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE
+ ALZA 16MG;240MG N19672 001 MAR 29, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT 3
+ SYNTEX (USA) INC LLC 2% N20421 001 DEC 21, 1995

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL
PEPCID COMPLETE
+ MERCK 800MG;10MG;165MG N20958 001 OCT 16, 2000

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL
EXIDINE
+ XTTRIUM 4% N19127 001 DEC 24, 1984

SOLUTION; TOPICAL
BRIAN CARE
SOAPCO 4% N71419 001 DEC 17, 1987

CHG SCRUB
ECOLAB 4% N19258 002 JUL 22, 1986

CIDA-STAT
ECOLAB 2% N19258 001 JUL 22, 1986

DYNA-HEX
XTTRIUM 0.75% N20111 001 SEP 11, 1997

FDA data supplied by DrugPatentWatch.com

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE			
+ XTTRIUM	2%	N19422 001	DEC 17, 1985
	4%	N19125 001	DEC 24, 1984
HIBICLENS			
+ ASTRAZENECA	4%	N17768 001	
HIBISTAT			
+ ASTRAZENECA	0.5%	N18300 001	
MICRODERM			
J AND J	4%	N72255 001	APR 15, 1991
PREVACARE R			
J AND J	0.5%	N72292 001	JAN 28, 1992
STERI-STAT			
MATRIX MEDCL	4%	N70104 001	JUL 24, 1986

SPONGE; TOPICAL

BIOSCRUB			
GRIFFEN	4%	N19822 001	MAR 31, 1989
CHLORHEXIDINE GLUCONATE			
DESERET	4%	N72525 001	OCT 24, 1989
KENDALL IL	4%	N19490 001	MAR 27, 1987
E-Z SCRUB			
BECTON DICKINSON	4%	N73416 001	MAR 14, 2000
HIBICLENS			
+ ASTRAZENECA	4%	N18423 001	
MICRODERM			
J AND J	4%	N72295 001	FEB 28, 1991
PHARMASEAL SCRUB CARE			
PHARMASEAL	4%	N19793 001	DEC 02, 1988

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP			
+ MEDI FLEX HOSP	2%;70%	N20832 001	JUL 14, 2000

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE			
+ GENEVA PHARMS	12MG	N70797 001	AUG 12, 1988

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG	N07638 001	
+	12MG	N07638 002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE			
ALZA	16MG	N19746 002	NOV 18, 1994

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC			
+ SMITHKLINE	8MG;75MG	N18099 001	
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;75MG	N18809 001	MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC			
+ NOVARTIS	12MG;75MG	N19613 001	JUN 13, 1986
DEMAZIN			
+ SCHERING PLOUGH	4MG;25MG	N18556 001	MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;120MG	N19428 001	AUG 02, 1988

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG;120MG	N18397 001	

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200			
+ SMITHKLINE BEECHAM	200MG/20ML	N20951 001	JUL 09, 1999

TABLET; ORAL

CIMETIDINE			
DANBURY PHARMA	200MG	N75425 001	JUL 29, 1999
LEINER	200MG	N74961 001	JUN 19, 1998
PERRIGO	200MG	N75285 001	OCT 29, 1998
PHARM FORM	200MG	N74963 001	JUN 19, 1998
TORPHARM	100MG	N74948 001	JUN 19, 1998
ZENITH GOLDLINE	200MG	N75345 001	JUN 16, 1999
TAGAMET HB			
+ SMITHKLINE BEECHAM	200MG	N20238 002	AUG 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			
GENEVA PHARMS	1.34MG	N73458 001	OCT 31, 1993
PERRIGO	1.34MG	N74512 001	NOV 22, 1995
TEVA	1.34MG	N73282 002	DEC 03, 1992
TAVIST-1			
+ NOVARTIS	1.34MG	N20925 001	AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D			
+ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992
	1.34MG;75MG	N20640 001	AUG 09, 1996

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE			
TARO	1%	N72640 002	AUG 31, 1993
LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20888 001	OCT 27, 1989
MYCELEX			
BAYER	1%	N18183 002	APR 01, 1991

CREAM; VAGINAL

CLOTRIMAZOLE			
NMC	1%	N74165 001	JUL 16, 1993
TARO	1%	N72641 001	DEC 04, 1995
GYNE-LOTRIMIN			
+ SCHERING PLOUGH	1%	N18052 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	2%	N20574 001	NOV 24, 1998
MYCELEX-7			
BAYER	1%	N18230 002	DEC 26, 1991
TRIVAGIZOLE 3			
+ TARO	2%	N21143 001	APR 12, 2000

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK			
+ SCHERING PLOUGH	1%,200MG	N20526 002	JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+ SCHERING PLOUGH	1%,100MG	N20289 002	APR 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER	1%,100MG	N20389 002	JUN 23, 1994

LOTION; TOPICAL

LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20889 001	OCT 27, 1989

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE

SOLUTION; TOPICAL

LOTRIMIN AF			
+ SCHERING PLOUGH	1%	N20890 001	OCT 27, 1989
MYCELEX			
BAYER	1%	N18181 002	APR 01, 1991

TABLET; VAGINAL

GYNE-LOTRIMIN			
+ SCHERING PLOUGH	100MG	N17717 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	JUL 29, 1996
GYNIX			
COPLEY PHARM	100MG	N73249 001	FEB 13, 1998
MYCELEX-7			
BAYER	100MG	N18182 002	DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM			
+ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463 001	JAN 03, 1997

DEXBROMPHENIRAMINE MALEATE; *MULTIPLE*

SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

BROMPHERIL			
COPLEY PHARM	6MG;120MG	N89116 001	JAN 22, 1987
DISOPHROL			
SCHERING PLOUGH	6MG;120MG	N13483 004	SEP 13, 1982
DRIXORAL			
+ SCHERING PLOUGH	6MG;120MG	N13483 003	SEP 13, 1982

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM			
+ MEDEVA	EQ 30MG HBR/5ML	N18658 001	OCT 08, 1982

DOCOSANOL

CREAM; TOPICAL

ABREVA			
+ SMITHKLINE BEECHAM	10%	N20941 001	JUL 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE			
COPLEY PHARM	25MG	N88900 002	FEB 12, 1988
PERRIGO	25MG	N40167 001	SEP 18, 1996
UNISOM			
+ PFIZER	25MG	N18066 001	

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST			
+ STERLING	0.25MG/INH	N16803 001	
EPINEPHRINE			
ALPHARMA	0.2MG/INH	N87907 001	MAY 23, 1984
PRIMATENE MIST			
+ WHITEHALL ROBINS	0.2MG/INH	N16126 001	

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST			
WHITEHALL ROBINS	0.3MG/INH	N16126 002	

FDA data supplied by DrugPatentWatch.com

FAMOTIDINE

TABLET; ORAL
PEPCID AC
+ MERCK 10MG N20325 001 APR 28, 1995
10MG N20902 001 AUG 05, 1999

TABLET, CHEWABLE; ORAL
PEPCID AC
+ MERCK 10MG N20801 001 SEP 24, 1998

FAMOTIDINE; *MULTIPLE*
SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
+ PHARM FORM 200MG N74782 001 JUL 06, 1998

SUSPENSION; ORAL
CHILDREN'S ADVIL
WHITEHALL ROBINS 100MG/5ML N20589 001 JUN 27, 1996
CHILDREN'S ADVIL-FLAVORED
WHITEHALL ROBINS 100MG/5ML N20589 002 NOV 07, 1997
CHILDREN'S IBUPROFEN
PERRIGO 100MG/5ML N74937 001 DEC 22, 1998
CHILDREN'S MOTRIN
+ MCNEIL 100MG/5ML N20516 001 JUN 16, 1995
IBUPROFEN
ALPHARMA 100MG/5ML N74916 001 APR 30, 1999

SUSPENSION/DROPS; ORAL
CHILDREN'S MOTRIN
+ MCNEIL 40MG/ML N20603 001 JUN 10, 1996

IBUPROFEN

SUSPENSION/DROPS; ORAL
IBUPROFEN
PERRIGO 40MG/ML N75217 001 DEC 16, 1998
PEDIATRIC ADVIL
+ WHITEHALL ROBINS 100MG/2.5ML N20812 001 JAN 30, 1998

TABLET; ORAL
ACHES-N-PAIN
LEDERLE 200MG N71065 001 MAY 28, 1987
ADVIL
WHITEHALL LABS 200MG N18989 001 MAY 18, 1984
CAP-PROFEN
PERRIGO 200MG N72097 001 DEC 08, 1987
IBU-TAB 200
ALRA 200MG N71057 001 AUG 11, 1988
IBUPROFEN
DANBURY PHARMA 200MG N70435 001 MAR 05, 1986
GENEVA PHARMS 200MG N70733 001 SEP 19, 1986
INTERPHARM 200MG N71333 001 FEB 17, 1987
200MG N72199 001 MAY 23, 1988
INVAMED 200MG N71807 001 FEB 25, 1988
200MG N74525 001 DEC 15, 1995
200MG N74533 001 DEC 15, 1995
LEINER 200MG N74931 001 JUL 20, 1998
LNK 200MG N75010 001 MAR 01, 1999
200MG N75139 001 MAR 01, 1999
MCNEIL 200MG N73019 001 MAR 30, 1994
MUTUAL PHARM 200MG N71229 001 APR 01, 1987

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
MUTUAL PHARM	200MG	N72249 001 JAN 10, 1989
MYLAN	200MG	N71870 001 MAY 05, 1988
OHM	200MG	N71163 001 JUL 15, 1986
PAR PHARM	200MG	N70481 001 SEP 24, 1986
	200MG	N70985 001 OCT 02, 1987
	200MG	N71575 001 MAY 08, 1987
PERRIGO	200MG	N72096 001 DEC 08, 1987
	200MG	N72098 001 DEC 08, 1987
PVT FORM	200MG	N71732 001 SEP 10, 1987
	200MG	N71735 001 SEP 10, 1987
	200MG	N72299 001 JUL 01, 1988
	200MG	N73691 001 FEB 25, 1994
VINTAGE PHARMS	200MG	N71639 001 FEB 02, 1988
ZENITH GOLDLINE	200MG	N71144 001 JAN 20, 1987
	200MG	N72901 001 DEC 19, 1991
	200MG	N72903 001 DEC 19, 1991
IBUPROHM		
OHM	200MG	N71214 001 DEC 01, 1986
JUNIOR STRENGTH ADVIL		
WHITEHALL ROBINS	100MG	N20267 002 DEC 13, 1996
JUNIOR STRENGTH IBUPROFEN		
PERRIGO	100MG	N75367 001 APR 22, 1999
JUNIOR STRENGTH MOTRIN		
+ MCNEIL	100MG	N20602 001 JUN 10, 1996

IBUPROFEN

TABLET; ORAL

MEDIPREN		
MCNEIL	200MG	N70475 001 FEB 06, 1986
	200MG	N71215 001 JUN 26, 1986
MOTRIN IB		
MCNEIL	200MG	N19012 003 DEC 17, 1990
MOTRIN MIGRAINE PAIN		
+ MCNEIL	200MG	N19012 004 FEB 25, 2000
NUPRIN		
+ MCNEIL	200MG	N19012 001 MAY 18, 1984
	200MG	N19012 002 JUL 29, 1987
PROFEN		
PVT FORM	200MG	N71265 001 OCT 15, 1986
TAB-PROFEN		
PERRIGO	200MG	N72095 001 DEC 08, 1987

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL		
WHITEHALL ROBINS	50MG	N20944 001 DEC 18, 1998
CHILDREN'S MOTRIN		
MCNEIL	50MG	N20601 001 NOV 15, 1996
JUNIOR STRENGTH ADVIL		
WHITEHALL ROBINS	100MG	N20944 002 DEC 18, 1998
JUNIOR STRENGTH MOTRIN		
+ MCNEIL	100MG	N20601 003 NOV 15, 1996

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S MOTRIN COLD		
+ MCNEIL CONS	100MG/5ML;15MG/5ML	N21128 001 AUG 01, 2000

FDA data supplied by DrugPatentWatch.com

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL COLD AND SINUS			
+ WHITEHALL LABS	200MG;30MG	N19771 001	SEP 19, 1989
SINE-AID IB			
MCNEIL	200MG;30MG	N19899 001	DEC 31, 1992

IBUPROFEN POTASSIUM

CAPSULE; ORAL

ADVIL LIQUI-GELS			
+ WHITEHALL ROBINS	200MG	N20402 001	APR 20, 1995
ADVIL MIGRAINE LIQUI-GELS			
+ WHITEHALL ROBINS	200MG	N20402 002	MAR 16, 2000

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR ILETIN II (PORK)			
+ LILLY	100 UNITS/ML	N18344 001	
REGULAR PURIFIED PORK INSULIN			
NOVO NORDISK	100 UNITS/ML	N18381 001	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R			
+ LILLY	100 UNITS/ML	N18780 001	OCT 28, 1982
HUMULIN R PEN			
+ LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998
NOVOLIN R			
NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50			
LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992
HUMULIN 70/30			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 001	APR 25, 1989
HUMULIN 70/30 PEN			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002	AUG 06, 1998
NOVOLIN 70/30			
NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

VELOSULIN BR HUMAN			
+ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)		
+ LILLY	100 UNITS/ML	N17936 002

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH ILETIN II (PORK)		
+ LILLY	100 UNITS/ML	N18345 001
NPH PURIFIED PORK ISOPHANE INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N18623 001

FDA data supplied by DrugPatentWatch.com

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N			
+ LILLY	100 UNITS/ML	N18781 001	OCT 28, 1982
NOVOLIN N			
NOVO NORDISK	100 UNITS/ML	N19959 001	JUL 01, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN; *MULTIPLE*
SEE INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U			
+ LILLY	100 UNITS/ML	N19571 002	JUN 10, 1987

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE			
NOVO NORDISK	100 UNITS/ML	N18383 001	
LENTE ILETIN II (PORK)			
+ LILLY	100 UNITS/ML	N18347 001	

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L			
+ LILLY	100 UNITS/ML	N19377 002	SEP 30, 1985
NOVOLIN L			
NOVO NORDISK	100 UNITS/ML	N19965 001	JUN 25, 1991

ISOPROPYL ALCOHOL; *MULTIPLE*
SEE CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D			
+ MCNEIL CONS	1%	N20310 001	OCT 10, 1997

KETOPROFEN

TABLET; ORAL

ACTRON			
BAYER	12.5MG	N20499 001	OCT 06, 1995
ORUDIS KT			
+ WHITEHALL ROBINS	12.5MG	N20429 001	OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D			
+ MCNEIL	1MG/5ML	N19487 001	MAR 01, 1988
LOPERAMIDE HCL			
DURAMED	1MG/5ML	N74991 001	DEC 29, 1997
HI TECH PHARMA	1MG/5ML	N74352 001	NOV 17, 1995
MORTON GROVE	1MG/5ML	N74730 001	AUG 28, 1997
PERRIGO	1MG/5ML	N73243 001	JAN 21, 1992
ROXANE	1MG/5ML	N73079 001	APR 30, 1992
TEVA	1MG/5ML	N73478 001	JUN 23, 1995

TABLET; ORAL

IMODIUM A-D			
+ MCNEIL	2MG	N19860 001	NOV 22, 1989
LOPERAMIDE HCL			
ABLE	2MG	N73528 001	NOV 30, 1993
LEINER	2MG	N73254 001	JUL 30, 1993

FDA data supplied by DrugPatentWatch.com

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL			
LOPERAMIDE HCL			
OHM	2MG	N74091 001	DEC 10, 1992
PERRIGO	2MG	N74194 001	OCT 30, 1992
	2MG	N75232 001	JAN 06, 2000
TABLET, CHEWABLE; ORAL			
IMODIUM A-D			
+ MCNEIL	2MG	N20448 001	JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL			
IMODIUM ADVANCED			
MCNEIL CONS	2MG;125MG	N21140 001	NOV 30, 2000
TABLET, CHEWABLE; ORAL			
IMODIUM ADVANCED			
+ MCNEIL	2MG;125MG	N20606 001	JUN 26, 1996

MAGNESIUM HYDROXIDE; *MULTIPLE*
SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

MAGNESIUM TRISILICATE; *MULTIPLE*
SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

MICONAZOLE NITRATE

CREAM; VAGINAL			
MICONAZOLE 7			
NMC	2%	N74164 001	MAR 29, 1996
MICONAZOLE NITRATE			
COPLEY PHARM	2%	N74030 001	OCT 30, 1992

MICONAZOLE NITRATE

CREAM; VAGINAL			
MICONAZOLE NITRATE			
G AND W LABS	2%	N74366 001	FEB 22, 1996
PERRIGO	2%	N74760 001	MAY 15, 1997
TARO	2%	N74444 001	JAN 13, 1997
TEVA	2%	N74136 001	JAN 04, 1995
MONISTAT 3			
+ ADVANCED CARE PRODS	4%	N20827 001	MAR 30, 1998
MONISTAT 7			
+ ADV CARE	2%	N17450 002	FEB 15, 1991
CREAM, SUPPOSITORY; TOPICAL, VAGINAL			
M-ZOLE 3 COMBINATION PACK			
ALPHARMA US PHARM	2%,200MG	N74926 001	APR 16, 1999
M-ZOLE 7 DUAL PACK			
ALPHARMA	2%,100MG	N74586 001	JUL 17, 1997
MICONAZOLE NITRATE COMBINATION PACK			
PERRIGO	2%,200MG	N75329 001	APR 20, 1999
MONISTAT 7 COMBINATION PACK			
+ ADV CARE	2%,100MG	N20288 002	APR 26, 1993
MONISTAT-3 COMBINATION PACK			
+ ADV CARE	2%,200MG	N20670 002	APR 16, 1996
SUPPOSITORY; VAGINAL			
MICONAZOLE NITRATE			
ALPHARMA US PHARM	100MG	N73507 001	NOV 19, 1993
G AND W LABS	100MG	N74414 001	APR 30, 1997
+ PERRIGO	100MG	N74395 001	MAR 20, 1997
MONISTAT 7			
+ ADVANCED CARE PRODS	100MG	N18520 002	FEB 15, 1991

FDA data supplied by DrugPatentWatch.com

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)			
ALPHARMA	2%	N74588 001	APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001	APR 09, 1996
COPLEY PHARM	2%	N74500 001	MAY 23, 1996
HI TECH PHARMA	2%	N74731 001	DEC 24, 1996
MORTON GROVE	2%	N74767 001	FEB 28, 1997
NOVEX	2%	N74924 001	APR 29, 1998
PERRIGO	2%	N75357 001	JUL 30, 1999
SIGHT PHARMS	2%	N74743 002	OCT 18, 1996
TEVA	2%	N74589 001	APR 05, 1996
MINOXIDIL (FOR WOMEN)			
NOVEX	2%	N74924 002	APR 29, 1998
PERRIGO	2%	N75357 002	JUL 30, 1999
SIGHT PHARMS	2%	N74743 001	OCT 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)			
ALPHARMA	5%	N75518 001	NOV 17, 2000
TEVA	5%	N75619 001	NOV 17, 2000
ROGAINE (FOR MEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 002	FEB 09, 1996
ROGAINE (FOR WOMEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 003	FEB 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)			
+ PHARMACIA AND UPJOHN	5%	N20834 001	NOV 14, 1997

NAPHAZOLINE HYDROCHLORIDE; *MULTIPLE*

SEE ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHCON-A			
+ ALCON	0.025%;0.3%	N20226 001	JUN 08, 1994
OPCON-A			
+ BAUSCH AND LOMB	0.02675%;0.315%	N20065 001	JUN 08, 1994
VISINE-A			
PFIZER	0.025%;0.3%	N20485 001	JAN 31, 1996

NAPROXEN SODIUM

TABLET; ORAL

ALEVE			
+ BAYER	EQ 200MG BASE	N20204 002	JAN 11, 1994
NAPROXEN SODIUM			
INVAMED	EQ 200MG BASE	N74646 001	JAN 13, 1997
LEINER	EQ 200MG BASE	N74635 001	JAN 13, 1997
PAR PHARM	EQ 200MG BASE	N75168 001	JUL 28, 1998
PERRIGO	EQ 200MG BASE	N74661 001	JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001	FEB 27, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE COLD AND SINUS			
+ BAYER	EQ 200MG BASE;120MG	N21076 001	NOV 29, 1999

NEOMYCIN SULFATE; *MULTIPLE*

SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

FDA data supplied by DrugPatentWatch.com

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL			
+ NOVARTIS	7MG/24HR	N20076 004	NOV 12, 1999
+	14MG/24HR	N20076 005	NOV 12, 1999
+	21MG/24HR	N20076 006	NOV 12, 1999
NICODERM CQ			
+ AVENTIS PHARMS	7MG/24HR	N20165 006	AUG 02, 1996
+	14MG/24HR	N20165 005	AUG 02, 1996
+	21MG/24HR	N20165 004	AUG 02, 1996
NICOTROL			
+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001	JUL 03, 1996
PROSTEP			
+ ELAN PHARM	11MG/24HR	N19983 003	DEC 23, 1998
+	22MG/24HR	N19983 004	DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE			
+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 002	FEB 09, 1996
+	EQ 4MG BASE	N20066 002	FEB 09, 1996
NICORETTE (MINT)			
+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 003	DEC 23, 1998
+	EQ 4MG BASE	N20066 003	DEC 23, 1998
NICOTINE POLACRILEX			
WATSON LAB	EQ 2MG BASE	N74507 001	MAR 15, 1999
	EQ 4MG BASE	N74707 001	MAR 19, 1999

NIZATIDINE

TABLET; ORAL

AXID AR			
+ WHITEHALL ROBINS	75MG	N20555 001	MAY 09, 1996

OCTYL METHOXYCINNAMATE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYBENZONE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OCUCLEAR			
SCHERING PLOUGH	0.025%	N18471 001	MAY 30, 1986
VISINE L.R.			
+ PFIZER	0.025%	N19407 001	MAR 31, 1989

PERMETHRIN

LOTION; TOPICAL

NIX			
+ WARNER LAMBERT	1%	N19918 001	MAY 02, 1990
PERMETHRIN			
ALPHARMA	1%	N75014 001	MAR 28, 2000

PHENIRAMINE MALEATE; *MULTIPLE*
SEE NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE
+ PFIZER 4%;EQ 0.33% BASE N21043 001
MAR 07, 2000

POLYMYXIN B SULFATE; *MULTIPLE*
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE

POTASSIUM IODIDE

TABLET; ORAL
IOSAT
ANBEX 130MG N18664 001
OCT 14, 1982
THYRO-BLOCK
+ WALLACE LABS 130MG N18307 001

POVIDONE-IODINE

SOLUTION; TOPICAL
E-Z PREP
+ BECTON DICKINSON 10% N19382 001
JUL 25, 1989
POVIDONE IODINE
+ ALLEGIANCE HLTHCARE 1% N19522 001
MAR 31, 1989

SPONGE; TOPICAL
E-Z PREP
+ BECTON DICKINSON 5% N19382 002
JUL 25, 1989
E-Z PREP 220
+ BECTON DICKINSON 5% N19382 003
JUL 25, 1989
E-Z SCRUB 201
+ BECTON DICKINSON 20% N19240 001
NOV 29, 1985
E-Z SCRUB 241
+ BECTON DICKINSON 10% N19476 001
JAN 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL
+ ALZA 240MG N20021 002
DEC 15, 1992
PSEUDOEPHEDRINE HCL
PERRIGO 120MG N75153 001
FEB 26, 1999
SUDAFED 12 HOUR
+ WARNER WELLCOME 120MG N73585 001
OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
+ KV PHARM 120MG;5MG N72758 001
NOV 25, 1991

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
AFRINOL
+ SCHERING PLOUGH 120MG N18191 001

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRETHRINS; *MULTIPLE*
SEE PIPERONYL BUTOXIDE; PYRETHRINS

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

CHELSEA LABS	EQ 75MG BASE	N75212 001	JAN 14, 2000
DR REDDYS LABS LTD	EQ 75MG BASE	N75294 001	MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001	JAN 14, 2000
LEINER	EQ 75MG BASE	N75094 001	JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001	JAN 14, 2000
	EQ 75MG BASE	N75254 001	JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001	MAY 04, 2000
ZENITH GOLDLINE	EQ 75MG BASE	N75296 001	JAN 14, 2000

ZANTAC 75

+ WARNER LAMBERT	EQ 75MG BASE	N20520 001	DEC 19, 1995

SIMETHICONE; *MULTIPLE*
SEE LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE

+ BLAIREX	0.9%	N19912 001	SEP 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%;0.3%	N20231 001	JUL 11, 1997

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL
EXTRA-STRENGTH AIM

+ CHESEBROUGH PONDS	1.2%	N19518 002	AUG 06, 1986

PASTE; DENTAL
EXTRA-STRENGTH AIM

+ CHESEBROUGH PONDS	1.2%	N19518 001	JUN 03, 1987

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL

+ NOVARTIS	1%	N20980 001	MAR 09, 1999

SOLUTION; TOPICAL
LAMISIL AT

+ NOVARTIS	1%	N21124 001	MAR 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+ BRISTOL MYERS SQUIBB	6.5%	N20676 001	FEB 11, 1997

TRICLOSAN; *MULTIPLE*
SEE SODIUM FLUORIDE; TRICLOSAN

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N710497 (ANDA)

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC. — N100102 DEC 14, 1961

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N110912 SEP 02, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N100855 JUN 03, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N160918 MAR 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N780519 APR 23, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N820528 NOV 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N770420 MAY 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HEALTHCARE — N940404 JUL 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800077 NOV 06, 1980

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC N160527
JUN 22, 1970

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION N80022
AUG 23, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC N160907
MAY 16, 1973

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP N781211
JUN 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP FENWAL DIVISION N170401
DEC 06, 1977

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION N811012
JUN 28, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION
BAXTER HLTHCARE FENWAL DIV 2.2GM/100ML;0.9GM/100ML; 0.75GM/100ML;0.027GM/100ML N811104
MAY 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION
TERUMO MEDICAL CORP 0.9GM/100ML;0.877GM/100ML; 0.525GM/100ML;0.03GM/100ML N880217
OCT 07, 1988

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-2 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML — N820915 SEP 22, 1983

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-3 NUTRICEL ADDITIVE SYSTEM
CUTTER BIO — 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML — N820915 OCT 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
CDP BLOOD BAG UNIT IN PLASTIC CONTAINER
BAXTER HLTHCARE — N900224 DEC 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
ADSOL IN PLASTIC CONTAINER
BAXTER HLTH CARE — N900223 DEC 27, 1991

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N770822 MAY 17, 1978

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N760305 JUN 30, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION
NONE
HAEMONETICS CORPORATION — N980123 MAR 3, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
ALPHA THERPTC — N810416 APR 06, 1983

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160702 DEC 28, 1970

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781214 FEB 08, 1980

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION N770923
JAN 20, 1978

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION
PROMIT
PHARMALINK BASLAKEMEDEL AB N830715
OCT 30, 1984

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NACL 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB N830527
MAR 27, 1985

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB N830627
MAR 27, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE 10GM/100ML;5GM/100ML N840619
IV SYSTEMS FEB 22, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS 10GM/100ML;5GM/100ML N720563
OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 10GM/100ML;5GM/100ML N160375
JUL 25, 1967

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
AMERICAN MCGAW 10GM/100ML;5GM/100ML N160767
APR 6, 1970

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
CUTTER BIO 10GM/100ML;5GM/100ML N160653
SEP 23, 1969

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
PHARMACHEM 10GM/100ML;5GM/100ML N160836
NOV 14, 1972

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMACIA LABS 10GM/100ML;5GM/100ML N140716
JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS 10GM/100ML;0.9GM/100ML N840620
FEB 22, 1985

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS 10GM/100ML;0.9GM/100ML N720562
OCT 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB 10GM/100ML;0.9GM/100ML N140716
JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 10GM/100ML;0.9GM/100ML N160375
JUL 25, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC 10GM/100ML;0.9GM/100ML N160653
SEP 23, 1969

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 10GM/100ML;0.9GM/100ML N160836
NOV 14, 1972

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 10GM/100ML;0.9GM/100ML N160767
APR 6, 1970

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NACL IN 500 ML PVC BAGS

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830613
MAR 27, 1985

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830629
MAR 27, 1985

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK 6GM/100ML;5GM/100ML N060826
BASLAKEMEDEL AB

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK 6GM/100ML;5GM/100ML N060826
BASLAKEMEDEL AB JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 6GM/100ML;0.9 GM/100ML N090024
AUG 18, 1969

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC 6GM/100ML;0.9 GM/100ML N080716
MAR 13, 1953

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAIN 70
BAXTER HLTHCARE 6GM/100ML;0.9 GM/100ML N160607
IV SYSTEMS JAN 26, 1970

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 6GM/100ML;5GM/100ML N080819
MAR 31, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N080564
SEP 19, 1952

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N160759
AUG 19, 1970

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION
NONE
ABBOTT LABORATORIES - HOSPITAL PRODUCTS DIV N720746
FEB 07, 1996

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN
MCGAW, INC 6GM/100ML;0.9GM/100ML N160889
JUL 17, 1972

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN IN PLASTIC CONTAINER

MCGAW, INC	6GM/100ML;0.9GM/100ML	N890105	APR 04, 1991

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	6GM/100ML;0.9GM/100ML	N740193	JAN 30, 1995

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

GENSIA LABS, INC	6GM/100ML;0.9GM/100ML	N740592	NOV 12, 1998

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

MCGAW, INC	6GM/100ML;0.9GM/100ML	N740283	OCT 21, 1998

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION
HEXTEND

BIOTIME, INC	6GM/100ML	N200952	MAR 31, 1999

INDIUM IN^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR

MEDI-PHYSICS	N/A	N19862	DEC 29, 1992

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION ULTRAPURE
ULTRAPURE

MALLINCKRODT	N/A	N19841	SEP 27, 1994

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN

MCGAW, INC	10GM/100ML;0.9GM/100ML	N841207	MAY 19, 1987

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN IN PLASTIC CONTAINER

MCGAW, INC	10GM/100ML;0.9GM/100ML	N890104	APR 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION
FLUOSOL

ALPHA THERPTC	17.5GM/100ML;7.5GM/100ML	N860909	DEC 26, 1989

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

RED BLOOD CELL PROCESSING SOLUTION

INJECATABLE; INJECTION
REJUVESOL
CYTOSOL LABS, INCN/A — N950522
FEB 26, 1997

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE OPEN-CATHETER
ABBOTT LABS — 5,000 IU/VIAL — N761021
DEC 15, 1983

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS — 9,000 IU/VIAL — N761021

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS — 250,000 IU/VIAL — N761021

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

INJECTABLE; INJECTION
INJECTAPAP
JOHNSON RW 100MG/ML N17785 001 MAR 07, 1986

SUPPOSITORY; RECTAL
ACETAMINOPHEN
ROXANE 120MG N71010 001 MAY 12, 1987
650MG N71011 001 MAY 12, 1987
TYLENOL
MCNEIL 120MG N17756 002
650MG N17756 001

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
CODEINE, ASPIRIN, APAP FORMULA NO. 2
SCHERER LABS 150MG;180MG;15MG N85640 001
CODEINE, ASPIRIN, APAP FORMULA NO. 3
SCHERER LABS 150MG;180MG;30MG N85639 001
CODEINE, ASPIRIN, APAP FORMULA NO. 4
SCHERER LABS 150MG;180MG;60MG N85638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BANCAP
FOREST PHARMS 325MG;50MG N88889 001 JAN 16, 1986

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN
DANBURY PHARMA 325MG;50MG N87550 001 OCT 19, 1984
HALSEY 325MG;50MG N89568 001 OCT 05, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE
GRAHAM DM 325MG;50MG;40MG N88743 001 JUL 18, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE
GRAHAM DM 325MG;50MG;40MG N88765 001 MAR 27, 1985
325MG;50MG;40MG N89067 001 APR 19, 1985
MALLINCKRODT 325MG;50MG;40MG N88758 001 MAR 27, 1985
FEMCET
MALLINCKRODT 325MG;50MG;40MG N89102 001 JUN 19, 1985
MEDIGESIC PLUS
US CHEM 325MG;50MG;40MG N89115 001 JAN 14, 1986
TRIAD
MALLINCKRODT 325MG;50MG;40MG N89023 001 JUN 19, 1985

TABLET; ORAL
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE
GILBERT LABS 325MG;50MG;40MG N87629 001 NOV 13, 1984
ESGIC
FOREST PHARMS 325MG;50MG;40MG N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
SYNALGOS-DC-A
WYETH AYERST 356.4MG;30MG;16MG N89166 001 MAY 14, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
TEVA 300MG;30MG N88324 001 DEC 29, 1983
ACETAMINOPHEN W/ CODEINE #2
TEVA 300MG;15MG N88537 001 JUN 04, 1984
ACETAMINOPHEN W/ CODEINE #4
TEVA 300MG;60MG N88599 001 JUN 01, 1984

* SEE SECTION 1.12 DISCONTINUED SECTION

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PROVAL #3			
SOLVAY	325MG;30MG	N85685	001
TYLENOL W/ CODEINE NO. 3			
JOHNSON RW	300MG;30MG	N87422	001
TYLENOL W/ CODEINE NO. 4			
JOHNSON RW	300MG;60MG	N87421	001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE			
DURAMED	300MG;15MG	N88353	001
		FEB 06, 1984	
	300MG;30MG	N88354	001
		FEB 06, 1984	
	300MG;60MG	N88355	001
		FEB 06, 1984	
EON	300MG;15MG	N87433	001
	300MG;30MG	N85917	001
	300MG;60MG	N87423	001
GENEVA PHARMS	300MG;30MG	N85291	002
	300MG;60MG	N85964	001
HALSEY	300MG;15MG	N85795	001
	300MG;30MG	N85794	001
	300MG;60MG	N86549	001
KV PHARM	300MG;30MG	N85288	001
	300MG;60MG	N85365	001
	325MG;15MG	N85364	001
*	325MG;45MG	N85363	001
MIKART	300MG;60MG	N89244	001
		FEB 25, 1986	
ROXANE	500MG;15MG	N89511	001
		APR 25, 1989	
	500MG;30MG	N89512	001
		APR 25, 1989	
	500MG;60MG	N89513	001
		APR 25, 1989	
WARNER CHILCOTT	300MG;15MG	N85992	001
	300MG;30MG	N85218	002
ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
PUREPAC PHARM	300MG;30MG	N89080	001
		JUL 17, 1986	
SUPERPHARM	300MG;30MG	N89184	001
		OCT 18, 1985	
	300MG;30MG	N89253	001
		MAY 19, 1986	
ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
SUPERPHARM	300MG;60MG	N89185	001
		OCT 18, 1985	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
SUPERPHARM	300MG;60MG	N89254	001
		MAY 19, 1986	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2			
AM THERAP	300MG;15MG	N89478	001
		MAR 03, 1987	
	300MG;15MG	N89481	001
		MAR 03, 1987	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3			
AM THERAP	300MG;30MG	N89479	001
		MAR 03, 1987	
	300MG;30MG	N89482	001
		MAR 03, 1987	
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4			
AM THERAP	300MG;60MG	N89480	001
		MAR 03, 1987	
	300MG;60MG	N89483	001
		MAR 03, 1987	
ROXANE	300MG;60MG	N84667	001
ACETAMINOPHEN W/ CODEINE			
HALSEY	300MG;60MG	N87653	001
		APR 13, 1982	
LEDERLE	300MG;30MG	N87141	001
ACETAMINOPHEN W/ CODEINE NO. 2			
ROXANE	300MG;15MG	N84659	001
ACETAMINOPHEN W/ CODEINE PHOSPHATE			
CHELSEA LABS	300MG;15MG	N87277	001
		MAY 26, 1982	
	300MG;30MG	N87276	001
		MAY 26, 1982	
	300MG;60MG	N87275	001
		MAY 26, 1982	
HALSEY	300MG;15MG	N83871	001
	300MG;30MG	N83872	001
ROSEMONT	300MG;30MG	N87919	001
		JUN 22, 1982	
	300MG;60MG	N87920	001
		JUN 22, 1982	
VITARINE	300MG;30MG	N85676	001
WARNER CHILCOTT	300MG;60MG	N87306	001
WHITEWORTH TOWN PLSN	300MG;30MG	N84360	001
	300MG;60MG	N85607	001
APAP W/ CODEINE PHOSPHATE			
EVERYLIFE	325MG;30MG	N85217	001
CODEINE PHOSPHATE AND ACETAMINOPHEN			
ICN	300MG;30MG	N85896	001

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXO WELLCOME	300MG;30MG	N83951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXO WELLCOME	300MG;60MG	N83951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	N88037 001	MAR 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	N88715 001	MAR 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	N85856 001	
TYLENOL W/ CODEINE			
JOHNSON RW	325MG;7.5MG	N85056 001	
	325MG;15MG	N85056 002	
	325MG;30MG	N85056 003	
	325MG;60MG	N85056 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

BANCAP HC			
FOREST PHARMS	500MG;5MG	N87961 001	MAR 17, 1983
CO-GESIC			
CENT PHARMS	500MG;5MG	N89360 001	MAR 02, 1988

TABLET; ORAL

DURADYNE DHC			
FOREST PHARMS	500MG;5MG	N87809 001	MAR 17, 1983
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
BARR	500MG;5MG	N88577 001	DEC 21, 1984
HALSEY	500MG;5MG	N89554 001	JUN 12, 1987
ROSEMONT	500MG;5MG	N89290 001	MAY 29, 1987
	500MG;5MG	N89291 001	MAY 29, 1987
NORCET			
ABANA	500MG;5MG	N88871 001	MAY 15, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

TYCOLET			
JOHNSON RW	500MG;5MG	N89385 001	AUG 27, 1986
VICODIN			
KNOLL PHARM	500MG;5MG	N85667 001	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN			
HALSEY	500MG;5MG	N89994 001	MAY 04, 1989
TYLOX-325			
JOHNSON RW	325MG;5MG	N88246 001	NOV 08, 1984

TABLET; ORAL

OXYCODONE 2.5/APAP 500			
DUPONT MERCK	500MG;2.5MG	N85910 001	
OXYCODONE 5/APAP 500			
DUPONT MERCK	500MG;5MG	N85911 001	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX			
JOHNSON RW	500MG;4.5MG;0.38MG	N85375 001	

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET			
LILLY	325MG;32.5MG	N16844 001	
DOLENE AP-65			
LEDERLE	650MG;65MG	N85100 001	
PROPOXYPHENE HCL AND ACETAMINOPHEN			
MYLAN	325MG;32MG	N83689 001	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL			
PROPACET 100			
TEVA	650MG;100MG	N70107 001	JUN 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
HALSEY	325MG;50MG	N72105 001	MAY 13, 1988
	650MG;100MG	N72106 001	MAY 13, 1988
SUPERPHARM	650MG;100MG	N71319 001	JAN 06, 1987
TEVA	650MG;100MG	N70732 001	JAN 03, 1986
WATSON LAB	325MG;50MG	N70398 001	DEC 18, 1986
	650MG;100MG	N70399 001	DEC 18, 1986

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL			
DIAMOX			
LEDERLE	500MG	N12945 001	
TABLET; ORAL			
ACETAZOLAMIDE			
ALRA	250MG	N83320 001	
ASCOT	250MG	N87686 001	OCT 20, 1982
VANGARD	250MG	N87654 001	FEB 05, 1982
WATSON LAB	250MG	N84498 002	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION			
ACETAZOLAMIDE SODIUM			
QUAD PHARMS	EQ 500MG BASE/VIAL	N89619 001	JAN 13, 1988

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC			
ACETIC ACID			
KV PHARM	2%	N85493 001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC			
ORLEX			
PROCTER AND GAMBLE	2%	N86845 001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC			
BOROFAIR			
PHARMAFAIR	2%;0.79%	N88606 001	AUG 21, 1985

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC			
TRIDESILON			
BAYER	2%;0.05%	N17914 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC			
ACETIC ACID W/ HYDROCORTISONE			
KV PHARM	2%;1%	N85492 001	
HYDROCORTISONE AND ACETIC ACID			
BAUSCH AND LOMB	2%;1%	N40097 001	OCT 31, 1994
ORLEX HC			
PROCTER AND GAMBLE	2%;1%	N86844 001	

ACETOHEXAMIDE

TABLET; ORAL			
ACETOHEXAMIDE			
ROSEMONT	250MG	N70753 001	NOV 03, 1986
	500MG	N70754 001	NOV 03, 1986
DYMELOR			
LILLY	250MG	N13378 002	
	500MG	N13378 001	

FDA data supplied by DrugPatentWatch.com

ACETOPHENAZINE MALEATE

TABLET; ORAL
TINDAL
SCHERING 20MG N12254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE
SALPIX
JOHNSON RW 53% N09008 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE
QUAD PHARMS 10% N71740 001 AUG 11, 1987
20% N71741 001 AUG 11, 1987

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
MUCOMYST W/ ISOPROTERENOL
MEAD JOHNSON 10%;0.05% N17366 001

ACETYLDIGITOXIN

TABLET; ORAL
ACYLANID
NOVARTIS 0.1MG N09436 001

ACRISORCIN

CREAM; TOPICAL
AKRINOL
SCHERING 2MG/GM N12470 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR
LEK PHARM 200MG N74750 001 APR 22, 1997
ROXANE 200MG N74570 002 APR 22, 1997

TABLET; ORAL
ACYCLOVIR
LEK PHARM 400MG N74658 001 APR 22, 1997
800MG N74658 002 APR 22, 1997
* NOVOPHARM 200MG N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM
APOTHECON EQ 500MG BASE/VIAL N74897 001 FEB 27, 1998
EQ 1GM BASE/VIAL N74897 002 FEB 27, 1998
ZOVIRAX
GLAXO WELLCOME EQ 250MG BASE/VIAL N18603 003 AUG 30, 1983

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION
CHROMALBIN
ISO TEX 250 uCi/VIAL N17835 002
500 uCi/VIAL N17835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
ALBUMOTOPE 125 I
ISO TEX 5-50 uCi/AMP N17836 001
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)
BAYER 2.5 uCi/AMP N17846 001

FDA data supplied by DrugPatentWatch.com

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION			
MEGATOPE			
ISO TEX	5 uCi/AMP		N17837 004
	20 uCi/AMP		N17837 005
	2mCi/VIAL		N17837 003

ALBUTEROL SULFATE

SOLUTION; INHALATION			
ALBUTEROL SULFATE			
COPLEY PHARM	EQ 0.083% BASE		N73495 001
			MAY 28, 1993
	EQ 0.5% BASE		N73307 001
			NOV 27, 1991
SYRUP; ORAL			
ALBUTEROL SULFATE			
MOVA	EQ 2MG BASE/5ML		N74302 001
			SEP 30, 1994
WATSON LABS	EQ 2MG BASE/5ML		N73165 001
			APR 29, 1993
VENTOLIN			
GLAXO WELLCOME	EQ 2MG BASE/5ML		N19621 001
			JUN 10, 1987
TABLET; ORAL			
ALBUTEROL SULFATE			
AM THERAP	EQ 2MG BASE		N72449 001
			DEC 05, 1989
	EQ 4MG BASE		N72450 001
			DEC 05, 1989
COPLEY PHARM	EQ 2MG BASE		N72966 001
			NOV 22, 1991
	EQ 4MG BASE		N72967 001
			NOV 22, 1991
MEDEVA PHARMS CA	EQ 2MG BASE		N73120 001
			SEP 29, 1992
	EQ 4MG BASE		N73121 001
			SEP 29, 1992
WARNER CHILCOTT	EQ 2MG BASE		N72817 001
			JAN 09, 1990
	EQ 4MG BASE		N72818 001
			JAN 09, 1990

ALCOHOL

INJECTABLE; INJECTION			
ALCOHOL 5% IN DEXTROSE 5%			
MILES	5ML/100ML		N83483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION			
ALCOHOL 5% IN DEXTROSE 5% IN WATER			
BAXTER HLTHCARE	5ML/100ML;5GM/100ML		N83256 001

ALKAVERVIR

TABLET; ORAL			
VERILOID			
3M	2MG		N07336 002
	3MG		N07336 003

ALLOPURINOL

TABLET; ORAL			
ALLOPURINOL			
CHELSEA LABS	100MG		N18785 001
			SEP 28, 1984
	300MG		N18785 002
			SEP 28, 1984
HALSEY	100MG		N70466 001
			DEC 24, 1985
	300MG		N70467 001
			DEC 24, 1985
PUREPAC PHARM	100MG		N70579 001
			APR 14, 1986
	300MG		N70580 001
			APR 14, 1986
SUPERPHARM	100MG		N70950 001
			NOV 30, 1988
WATSON LAB	100MG		N18241 001
			NOV 16, 1984
	300MG		N18241 002
			NOV 16, 1984
LOPURIN			
KNOLL PHARM	100MG		N18297 001
	300MG		N18297 002

FDA data supplied by DrugPatentWatch.com

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
ROXANE 0.25MG N74199 001 OCT 19, 1993
0.5MG N74199 002 OCT 19, 1993
1MG N74199 003 OCT 19, 1993

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
PHARMACIA AND UPJOHN 0.005MG/ML N20755 001 OCT 31, 1997
EDEX
SCHWARZ PHARMA 0.005MG/VIAL N20649 001 JUN 12, 1997

ALSEROXYLON

TABLET; ORAL
RAUTENSIN
NOVARTIS 2MG N09215 001
RAUWILOID
3M 2MG N08867 001

ALUMINUM ACETATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE
PENNEX 80MG;20MG N89449 001 NOV 27, 1987

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL
WATSON LAB 100MG N71382 001 JAN 21, 1987

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
SYMADINE
SOLVAY 100MG N71000 001 SEP 04, 1986
SYMMETREL
ENDO PHARMS 100MG N16020 001

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT
FUJISAWA HLTHCARE 0.025% N18116 001

AMDINOCILLIN

INJECTABLE; INJECTION
COACTIN
ROCHE 250MG/VIAL N50565 001 DEC 21, 1984
500MG/VIAL N50565 002 DEC 21, 1984
1GM/VIAL N50565 003 DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE
ASTRAZENECA EQ 50MG BASE/ML N63167 001 DEC 14, 1995
EQ 250MG BASE/ML N63169 001 DEC 14, 1995
ELKINS SINN EQ 50MG BASE/ML N63274 001 MAY 18, 1992
AMIKIN
APOTHECON EQ 50MG BASE/ML N50495 001
EQ 50MG BASE/ML N62562 001 SEP 20, 1984
EQ 250MG BASE/ML N50495 002
EQ 250MG BASE/ML N62562 002 SEP 20, 1984
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
APOTHECON EQ 5MG BASE/ML N50618 002 NOV 30, 1987

FDA data supplied by DrugPatentWatch.com

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
APOTHECON EQ 10MG BASE/ML N50618 001
NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 3.5% IN PLASTIC CONTAINER
ABBOTT 3.5% N18804 001
MAY 15, 1984
3.5% N18875 001
AUG 08, 1984
AMINOSYN II 3.5% IN PLASTIC CONTAINER
ABBOTT 3.5% N19491 001
OCT 10, 1986
AMINOSYN II 5%
ABBOTT 5% N19438 002
APR 03, 1986
AMINOSYN-HBC 7% IN PLASTIC CONTAINER
ABBOTT 7% N19400 001
JUL 23, 1986
FREAMINE 8.5%
B BRAUN 8.5% N16822 001
FREAMINE II 8.5%
B BRAUN 8.5% N16822 002
NEOPHAM 6.4%
FRESENIUS KABI 6.4% N18792 001
JAN 17, 1984
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER HLTHCARE 15% N20107 001
FEB 05, 1993
NOVAMINE 8.5%
FRESENIUS KABI 8.5% N17957 002
AUG 09, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 001
SEP 12, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 002
SEP 12, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 004
SEP 12, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004
NOV 07, 1988
5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 003
SEP 12, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19118 001
OCT 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML N19120 001
OCT 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML N19119 001
OCT 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19505 002
NOV 07, 1986

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N19713 006 SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N19506 001 NOV 07, 1986
	3.5%;5GM/100ML	N19713 002 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N19713 001 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N19713 004 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N19504 002 NOV 07, 1986
	4.25%;25GM/100ML	N19713 005 SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N19565 001 DEC 17, 1986
	5%;25GM/100ML	N19713 003 SEP 09, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML	N19682 003 NOV 01, 1988
	4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML	N19712 002 SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML; 22.4MG/100ML;261MG/100ML; 205MG/100ML	N19564 002 DEC 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML; 22.4MG/100ML;261MG/100ML; 205MG/100ML	N19564 004 DEC 16, 1986

AMINO ACIDS, DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML	N19564 001 DEC 16, 1986
	3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML	N19712 001 SEP 08, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML	N19564 003 DEC 16, 1986

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML	N18804 002 MAY 15, 1984

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML N18875 002 AUG 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M
ABBOTT 3.5%;21MG/100ML;128MG/100ML; 234MG/100ML N17789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
AMINOSYN II 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;32MG/100ML;128MG/100ML; 222MG/100ML;49MG/100ML N19493 001 OCT 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
VEINAMINE 8%
FRESENIUS KABI 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 006 APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
AMINOSYN II 3.5% M
ABBOTT 3.5%;30MG/100ML;97MG/100ML; 120MG/100ML;49MG/100ML N19437 007 APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
AM PHARM PARTNERS 250MG/ML N70522 001 JUN 17, 1986
QUAD PHARMS 250MG/ML N70694 001 MAR 04, 1986

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
AMINOHIPPURATE SODIUM
QUAD PHARMS 20% N89821 001 JUL 14, 1988

AMINOPHYLLINE

ENEMA; RECTAL
SOMOPHYLLIN
FISONS 300MG/5ML N18232 001 APR 02, 1982

INJECTABLE; INJECTION
AMINOPHYLLIN
SEARLE 25MG/ML N87243 001 MAY 24, 1982
25MG/ML N87621 001 MAY 24, 1982

AMINOPHYLLINE
AM PHARM PARTNERS 25MG/ML N84568 001
25MG/ML N87200 001
25MG/ML N87250 001 JAN 06, 1982
25MG/ML N87431 001
25MG/ML N87886 001 AUG 30, 1983

FDA data supplied by DrugPatentWatch.com

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AM PHARM PARTNERS	25MG/ML	N88407 001 JAN 25, 1984
INTL MEDICATION	25MG/ML	N87867 001 NOV 10, 1983
	25MG/ML	N87868 001 NOV 10, 1983
KING PHARMS	25MG/ML	N86606 001
PHARMA SERVE NY	25MG/ML	N87387 001 JUN 03, 1983
SMITH AND NEPHEW	25MG/ML	N88429 001 MAY 30, 1985
	25MG/ML	N88749 001 MAY 30, 1985

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	100MG/100ML	N18924 001 DEC 12, 1984
	200MG/100ML	N18924 002 DEC 12, 1984
	400MG/100ML	N18924 003 DEC 12, 1984
	500MG/100ML	N18924 004 DEC 12, 1984

SOLUTION; ORAL
AMINOPHYLLINE

MORTON GROVE	105MG/5ML	N88156 001 DEC 05, 1983

SOMOPHYLLIN

FISONS	105MG/5ML	N86466 001

SOMOPHYLLIN-DF

FISONS	105MG/5ML	N87045 001

TABLET; ORAL
AMINOPHYLLIN

SEARLE	100MG	N02386 002
	200MG	N02386 003

AMINOPHYLLINE

ASCOT	100MG	N87522 001 FEB 12, 1982
	200MG	N87523 001 FEB 12, 1982
BARR	100MG	N88297 001 AUG 19, 1983
	200MG	N88298 001 AUG 19, 1983

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

CHELSEA LABS	100MG	N85567 001
	200MG	N85564 001
DURAMED	100MG	N88182 001 MAR 31, 1983
	200MG	N88183 001 MAR 31, 1983
GENEVA PHARMS	100MG	N85261 003
HALSEY	100MG	N84674 001
ICN	200MG	N84563 001
IMPAX LABS	100MG	N84574 001
	200MG	N84576 001
KV PHARM	100MG	N85284 001
	200MG	N85289 001
LANNETT	100MG	N84588 001
	200MG	N84588 002
PAL PAK	100MG	N84533 001
PANRAY	100MG	N84552 001
	200MG	N84552 002
PUREPAC PHARM	100MG	N84699 001
	200MG	N85333 001
VANGARD	100MG	N88314 001 OCT 03, 1983
	200MG	N88319 001 OCT 03, 1983
VINTAGE PHARMS	100MG	N85409 001
	200MG	N85410 001

TABLET, DELAYED RELEASE; ORAL
AMINOPHYLLINE

IMPAX LABS	100MG	N84577 001
	200MG	N84575 001
TABLICAPS	100MG	N84632 002
VALE	100MG	N84531 001
	200MG	N84530 001

TABLET, EXTENDED RELEASE; ORAL
PHYLLOCONTIN

PURDUE FREDERICK	225MG	N86760 001

AMINOSALICYLATE SODIUM

POWDER; ORAL
P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	N80947 001

FDA data supplied by DrugPatentWatch.com

AMINOSALICYLATE SODIUM

POWDER; ORAL
SODIUM AMINOSALICYLATE
HEXCEL 100% N80097 001

TABLET; ORAL
PARASAL SODIUM
PANRAY 500MG N06811 006
1GM N06811 011
TEEBACIN
CONSOLIDATED MIDLAND 500MG N07320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL
NEOPASALATE
WALLACE LABS 846MG;112MG N80059 002

AMINOSALICYLIC ACID

TABLET; ORAL
PARASAL
PANRAY 500MG N06811 001
1GM N06811 002

AMINOSALICYLIC ACID; *MULTIPLE*
SEE AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL
REZIPAS
BRISTOL MYERS SQUIBB EQ 500MG BASE/GM N09052 001

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
AMITRIPTYLINE HCL
STERIS 10MG/ML N85594 001

TABLET; ORAL
AMITID
BRISTOL MYERS SQUIBB 10MG N86454 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITID
BRISTOL MYERS SQUIBB 25MG N86454 002
50MG N86454 003
75MG N86454 004
100MG N86454 005
AMITRIL
WARNER CHILCOTT 10MG N83939 001
25MG N83937 001
50MG N83938 002
75MG N84957 001
100MG N85093 001
150MG N86295 001
AMITRIPTYLINE HCL
AM THERAP 25MG N88672 001 NOV 20, 1984
50MG N88673 001 NOV 20, 1984
75MG N88674 001 NOV 20, 1984
100MG N88675 001 NOV 20, 1984
CHELSEA LABS 10MG N85816 001
25MG N85817 001
50MG N85815 001
75MG N85819 001
100MG N85820 001
150MG N85821 001
COPLEY PHARM 10MG N88421 001 APR 30, 1984
25MG N88422 001 APR 30, 1984
50MG N88423 001 APR 30, 1984
75MG N88424 001 APR 30, 1984
100MG N88425 001 APR 30, 1984
150MG N88426 001 APR 30, 1984
DANBURY PHARMA 10MG N88620 001 MAR 02, 1984
25MG N88621 001 MAR 02, 1984
50MG N88622 001 MAR 02, 1984

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

DANBURY PHARMA	75MG	N88633 001
		MAR 02, 1984
	100MG	N88634 001
		MAR 02, 1984
	150MG	N88635 001
		MAR 02, 1984
HALSEY	10MG	N85744 001
	10MG	N85923 001
	25MG	N85627 001
	25MG	N85922 001
	50MG	N85745 001
	50MG	N85925 001
	50MG	N87557 001
		MAR 05, 1982
	75MG	N85743 001
	75MG	N85926 001
		MAY 20, 1983
	100MG	N85742 002
		MAY 11, 1982
	100MG	N85927 001
		MAY 20, 1983
	150MG	N89423 001
		FEB 17, 1987
LEDERLE	10MG	N86744 001
	10MG	N87366 001
		JAN 04, 1982
	25MG	N86746 001
	25MG	N87367 001
		MAY 03, 1982
	50MG	N86743 001
	50MG	N87181 001
		JAN 04, 1982
	75MG	N86745 001
	75MG	N87369 001
		JAN 04, 1982
	100MG	N86747 001
	100MG	N87368 001
		MAY 03, 1982
	150MG	N87370 001
		JAN 04, 1982
MEDEVA PHARMS CA	10MG	N85864 001
	25MG	N85935 001
	50MG	N85936 001
	100MG	N86336 001
	150MG	N86335 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

PAR PHARM	10MG	N88697 001
		SEP 25, 1984
	25MG	N88698 001
		SEP 25, 1984
	50MG	N88699 001
		SEP 25, 1984
	75MG	N88700 001
		SEP 25, 1984
	100MG	N88701 001
		SEP 25, 1984
	150MG	N88702 001
		SEP 25, 1984
PUREPAC PHARM	10MG	N88075 001
		SEP 16, 1983
	10MG	N88084 001
		JUL 18, 1983
	25MG	N88076 001
		MAY 20, 1983
	25MG	N88085 001
		JUL 18, 1983
	50MG	N88077 001
		SEP 16, 1983
	50MG	N88105 001
		JUL 18, 1983
	75MG	N88078 001
		SEP 16, 1983
	75MG	N88106 001
		JUL 18, 1983
	100MG	N88079 001
		SEP 16, 1983
	100MG	N88107 001
		JUL 18, 1983
ROSEMONT	25MG	N87775 001
		FEB 10, 1982
ROXANE	10MG	N86002 001
	10MG	N86144 001
	25MG	N85944 001
	25MG	N86145 001
	50MG	N85945 001
	50MG	N86143 001
	75MG	N86004 001
	75MG	N86147 001
	100MG	N86003 001
	100MG	N86146 001
	150MG	N86090 001

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

ROXANE	150MG	N86148 001
TEVA	10MG	N86610 001
	25MG	N86859 001
	50MG	N86857 001
	75MG	N86860 001
	100MG	N86854 001
	150MG	N86853 001
VANGARD	10MG	N87632 001 FEB 01, 1982
	50MG	N87616 001 FEB 08, 1982
	75MG	N87617 001 FEB 05, 1982
	100MG	N87639 001 FEB 08, 1982
WEST WARD	10MG	N87647 001 MAR 05, 1982
	25MG	N87278 001

ENDEP

ROCHE	10MG	N83639 001
	25MG	N83639 002
	50MG	N83639 003
	75MG	N83639 004
	100MG	N83639 005
	150MG	N85303 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

HALSEY	EQ 12.5MG BASE;5MG	N70765 001 DEC 10, 1986
	EQ 25MG BASE;10MG	N70766 001 DEC 10, 1986
ROSEMONT	EQ 12.5MG BASE;5MG	N70477 001 JAN 12, 1988
	EQ 25MG BASE;10MG	N70478 001 JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
ETRAFON-A

SCHERING	10MG;4MG	N14713 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

CHELSEA LABS	50MG;4MG	N71558 001 MAR 02, 1987
DANBURY PHARMA	10MG;2MG	N72539 001 FEB 15, 1989
	10MG;4MG	N72540 001 FEB 15, 1989
	25MG;2MG	N72541 001 FEB 15, 1989
	25MG;4MG	N72134 001 FEB 15, 1989
	50MG;4MG	N72135 001 FEB 15, 1989
HALSEY	10MG;2MG	N71077 001 NOV 12, 1986
	10MG;4MG	N71078 001 NOV 12, 1986
	25MG;2MG	N70297 001 NOV 12, 1986
	25MG;4MG	N71079 001 NOV 12, 1986
PAR PHARM	10MG;2MG	N70565 001 SEP 11, 1986
	10MG;4MG	N70620 001 SEP 11, 1986
	25MG;2MG	N70621 001 SEP 11, 1986
	25MG;4MG	N70595 001 SEP 11, 1986
	50MG;4MG	N70574 001 SEP 11, 1986
WATSON LAB	10MG;2MG	N70373 001 AUG 25, 1986
	10MG;4MG	N70375 001 AUG 25, 1986
	25MG;2MG	N70374 001 AUG 25, 1986
	25MG;4MG	N70376 001 AUG 25, 1986
	50MG;4MG	N70377 001 NOV 04, 1986
ZENITH GOLDLINE	10MG;2MG	N70935 001 SEP 11, 1986
	10MG;4MG	N70937 001 SEP 11, 1986

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL
ZENITH GOLDLINE 25MG;2MG N70936 001 SEP 11, 1986
25MG;4MG N70938 001 SEP 11, 1986
50MG;4MG N70939 001 SEP 12, 1986
TRIAVIL 2-10
LOTUS BIOCHEM 10MG;2MG N14715 004
TRIAVIL 2-25
LOTUS BIOCHEM 25MG;2MG N14715 002
TRIAVIL 4-10
LOTUS BIOCHEM 10MG;4MG N14715 003
TRIAVIL 4-25
LOTUS BIOCHEM 25MG;4MG N14715 005
TRIAVIL 4-50
LOTUS BIOCHEM 50MG;4MG N14715 006

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE
ABBOTT 5MEQ/ML N83130 001
SEARLE 3MEQ/ML N86205 001
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
MCGAW 900MG/100ML N06580 001
AMMONIUM CHLORIDE 2.14%
B BRAUN 40MEQ/100ML N85734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL
CAMOQUIN HCL
PARKE DAVIS EQ 200MG BASE N06441 001

AMOXAPINE

TABLET; ORAL
ASENDIN
LEDERLE 25MG N18021 001
50MG N18021 002
100MG N18021 003
150MG N18021 004

AMOXICILLIN

CAPSULE; ORAL
AMOXIL
SMITHKLINE BEECHAM 250MG N50459 001
250MG N62216 003
500MG N50459 002
TRIMOX
APOTHECON 250MG N62098 001
250MG N62152 001
500MG N62098 002
500MG N62152 002
UTIMOX
PARKE DAVIS 250MG N62107 001
500MG N62107 002

FOR SUSPENSION; ORAL
AMOXICILLIN
MYLAN 125MG/5ML N62090 001
250MG/5ML N62090 002
AMOXIL
SMITHKLINE BEECHAM 125MG/5ML N50460 001
250MG/5ML N50460 002
50MG/ML N50460 005
LAROTID
SMITHKLINE BEECHAM 50MG/ML N50460 006
POLYMOX
APOTHECON 125MG/5ML N61851 001
125MG/5ML N62323 001
250MG/5ML N61851 002
250MG/5ML N62323 002
TRIMOX
APOTHECON 125MG/5ML N62099 001
125MG/5ML N62154 001
250MG/5ML N62099 002
250MG/5ML N62154 002
UTIMOX
PARKE DAVIS 125MG/5ML N62127 001
250MG/5ML N62127 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL
DELCOBESE
TEVA 1.25MG;1.25MG;1.25MG; 1.25MG N83564 001

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL
- DELCOBESE
  - TEVA
    - 2.5MG;2.5MG;2.5MG;2.5MG 3.75MG;3.75MG;3.75MG; — N83564 002
    - 3.75MG — N83564 003
    - 5MG;5MG;5MG;5MG — N83564 004

TABLET; ORAL
- DELCOBESE
  - TEVA
    - 1.25MG;1.25MG;1.25MG; 1.25MG — N83563 004
    - 2.5MG;2.5MG;2.5MG;2.5MG — N83563 003
    - 3.75MG;3.75MG;3.75MG; 3.75MG — N83563 002
    - 5MG;5MG;5MG;5MG — N83563 001

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
- BIPHETAMINE 12.5
  - MEDEVA
    - EQ 6.25MG BASE; EQ 6.25MG BASE — N10093 007
- BIPHETAMINE 20
  - MEDEVA
    - EQ 10MG BASE;EQ 10MG BASE — N10093 003
- BIPHETAMINE 7.5
  - MEDEVA
    - EQ 3.75MG BASE; EQ 3.75MG BASE — N10093 009

AMPHETAMINE SULFATE

TABLET; ORAL
- AMPHETAMINE SULFATE
  - LANNETT
    - 5MG — N83901 001 AUG 31, 1984
    - 10MG — N83901 002 AUG 31, 1984

AMPHETAMINE SULFATE; *MULTIPLE*
- SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

INJECTABLE; INJECTION
- AMPHOTERICIN B
  - AM PHARM PARTNERS
    - 50MG/VIAL — N62728 001 APR 13, 1987

OINTMENT; TOPICAL
- FUNGIZONE
  - APOTHECON
    - 3% — N50313 001

AMPICILLIN SODIUM

INJECTABLE; INJECTION
- AMPICILLIN SODIUM
  - CONSOLIDATED PHARM
    - EQ 125MG BASE/VIAL — N61936 005
    - EQ 250MG BASE/VIAL — N61936 001
    - EQ 500MG BASE/VIAL — N61936 002
    - EQ 1GM BASE/VIAL — N61936 003
    - EQ 2GM BASE/VIAL — N61936 004
  - INTL MEDICATION
    - EQ 1GM BASE/VIAL — N62634 002 JAN 09, 1987
    - EQ 2GM BASE/VIAL — N62634 003 JAN 09, 1987
  - LILLY
    - EQ 500MG BASE/VIAL — N62565 001 APR 04, 1985
    - EQ 1GM BASE/VIAL — N62565 002 APR 04, 1985
    - EQ 2GM BASE/VIAL — N62565 003 JUN 24, 1986
- PENBRITIN-S
  - WYETH AYERST
    - EQ 125MG BASE/VIAL — N50072 001
    - EQ 250MG BASE/VIAL — N50072 002
    - EQ 500MG BASE/VIAL — N50072 003
    - EQ 1GM BASE/VIAL — N50072 004
    - EQ 2GM BASE/VIAL — N50072 005
    - EQ 4GM BASE/VIAL — N50072 006
- POLYCILLIN-N
  - BRISTOL
    - EQ 125MG BASE/VIAL — N50309 001
    - EQ 250MG BASE/VIAL — N50309 002
    - EQ 500MG BASE/VIAL — N50309 003
    - EQ 1GM BASE/VIAL — N50309 004
    - EQ 2GM BASE/VIAL — N50309 005
- TOTACILLIN-N
  - SMITHKLINE BEECHAM
    - EQ 1GM BASE/VIAL — N62727 001 DEC 19, 1986
    - EQ 2GM BASE/VIAL — N62727 002 DEC 19, 1986

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN			
PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003	DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL			
PARKE DAVIS	EQ 250MG BASE	N62041 001	
	EQ 500MG BASE	N62041 002	
AMPICILLIN			
LEDERLE	EQ 250MG BASE	N62208 001	
	EQ 500MG BASE	N62208 002	
VITARINE	EQ 250MG BASE	N61387 001	
	EQ 500MG BASE	N61387 003	
AMPICILLIN TRIHYDRATE			
MYLAN	EQ 250MG BASE	N61755 001	
	EQ 500MG BASE	N61755 002	
PUREPAC PHARM	EQ 250MG BASE	N61853 001	
ZENITH GOLDLINE	EQ 250MG BASE	N60765 001	
	EQ 500MG BASE	N60765 002	
PENBRITIN			
WYETH AYERST	EQ 250MG BASE	N60908 001	
	EQ 500MG BASE	N60908 002	
PFIZERPEN-A			
PFIZER	EQ 250MG BASE	N62050 001	
	EQ 500MG BASE	N62050 002	
POLYCILLIN			
BRISTOL	EQ 250MG BASE	N50310 001	
	EQ 500MG BASE	N50310 002	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE	N50056 001	
	EQ 250MG BASE	N62157 002	
PRINCIPEN '500'			
APOTHECON	EQ 500MG BASE	N50056 002	
	EQ 500MG BASE	N62157 001	
TOTACILLIN			
SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001	
	EQ 500MG BASE	N60060 002	

FOR SUSPENSION; ORAL

AMCILL			
PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001	
	EQ 250MG BASE/5ML	N62030 002	

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE			
PUREPAC PHARM	EQ 125MG BASE/5ML	N61980 001	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	500MG/5ML	N60625 004	
PENBRITIN			
WYETH AYERST	EQ 100MG BASE/ML	N50019 001	
	EQ 125MG BASE/5ML	N50019 002	
	EQ 250MG BASE/5ML	N50019 003	
PFIZERPEN-A			
PFIZER	EQ 125MG BASE/5ML	N62049 001	
	EQ 250MG BASE/5ML	N62049 002	
POLYCILLIN			
APOTHECON	EQ 125MG BASE/5ML	N62297 001	
	EQ 250MG BASE/5ML	N62297 002	
BRISTOL	EQ 125MG BASE/5ML	N50308 001	
	EQ 250MG BASE/5ML	N50308 002	
	EQ 500MG BASE/5ML	N50308 003	
	EQ 100MG BASE/ML	N50308 004	
PRINCIPEN '125'			
APOTHECON	EQ 125MG BASE/5ML	N60127 002	
	EQ 125MG BASE/5ML	N62151 001	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE/5ML	N60127 001	
	EQ 250MG BASE/5ML	N62151 002	
TOTACILLIN			
SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N62223 001	
	EQ 250MG BASE/5ML	N62223 002	

TABLET, CHEWABLE; ORAL

POLYCILLIN			
BRISTOL	EQ 125MG BASE	N50093 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID			
APOTHECON	EQ 389MG BASE;111MG	N50488 001	
	EQ 389MG BASE;111MG	N62150 001	

FOR SUSPENSION; ORAL

POLYCILLIN-PRB			
APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001	
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N50457 001	

FDA data supplied by DrugPatentWatch.com

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL
LERITINE
MERCK EQ 25MG BASE N10585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION
LERITINE
MERCK 25MG/ML N10520 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL
ANISOTROPINE METHYLBROMIDE
WATSON LAB 50MG N86046 001
VALPIN 50
ENDO PHARMS 50MG N13428 001

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12 LYOPHILIZED
ASTRAZENECA 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL; 15MG/VIAL;5 UGM/VIAL;0.4MG/VIAL; 40MG/VIAL;4MG/VIAL;3.6MG/VIAL; 3MG/VIAL;1MG/VIAL; 10MG/VIAL N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 9+3
AM PHARM PARTNERS 10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML N18440 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
BEROCCA PN
ROCHE 50MG/ML;0.03MG/ML;0.0025MG/ML; 7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML; 2MG/ML;1.8MG/ML;1.5MG/ML; 1,650 IU/ML;5 IU/ML N06071 003 OCT 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
VITAPED
FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER
BAYER 650MG N16030 001
MEASURIN
BAYER 650MG N16030 002

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL
SAVAGE LABS 650MG;50MG N88305 001 OCT 13, 1983

FDA data supplied by DrugPatentWatch.com

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE
CHELSEA LABS 325MG;50MG;40MG N86231 002 FEB 12, 1985

TABLET; ORAL
BUTALBITAL ASPIRIN AND CAFFEINE
QUANTUM PHARMICS 325MG;50MG;40MG N88972 001 JUN 18, 1985

BUTALBITAL COMPOUND
ZENITH GOLDLINE 325MG;50MG;40MG N85441 002 OCT 31, 1984

BUTALBITAL, ASPIRIN & CAFFEINE
HALSEY 325MG;50MG;40MG N89448 001 DEC 01, 1986

BUTALBITAL, ASPIRIN AND CAFFEINE
CHELSEA LABS 325MG;50MG;40MG N86237 002 MAR 23, 1984

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
COMPOUND 65
ALRA 389MG;32.4MG;65MG N84553 002 AUG 17, 1983

PROPOXYPHENE COMPOUND 65
ZENITH GOLDLINE 389MG;32.4MG;65MG N83077 002 DEC 07, 1984

PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE
CHELSEA LABS 389MG;32.4MG;65MG N85732 002 SEP 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL COMPOUND
WATSON LAB 325MG;200MG N88809 001 OCT 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL
VICOPRIN
KNOLL PHARM 500MG;5MG N86333 001 SEP 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL
MEPRO-ASPIRIN
EON 325MG;200MG N89127 001 MAR 02, 1987

MEPROBAMATE AND ASPIRIN
PAR PHARM 325MG;200MG N89126 001 AUG 19, 1986

Q-GESIC
QUANTUM PHARMICS 325MG;200MG N88740 001 JUN 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL AND ASPIRIN
MCNEIL 325MG;400MG N89193 001 FEB 12, 1986

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
CODOXY
HALSEY 325MG;4.5MG;0.38MG N87464 001 JUL 01, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)
ROXANE 325MG;2.25MG;0.19MG N87742 001 JUN 04, 1982

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL
DARVON-N W/ ASA
LILLY 325MG;100MG N16829 001

TABLET; ORAL
DARVON-N W/ ASA
LILLY 325MG;100MG N16863 001

ATENOLOL

TABLET; ORAL
ATENOLOL
APOTHECON 50MG N73317 001 MAR 20, 1992

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL			
ATENOLOL			
APOTHECON	100MG	N73318	001
		MAR 20, 1992	

ATROPINE

INJECTABLE; INJECTION			
ATROPINE			
SOLVAY	EQ 2MG SULFATE/0.7ML	N71295	001
		JAN 30, 1987	

ATROPINE SULFATE

AEROSOL, METERED; INHALATION			
ATROPINE SULFATE			
US ARMY	EQ 0.36MG BASE/INH	N20056	001
		SEP 19, 1990	

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL			
MOTOFEN HALF-STRENGTH			
AMARIN PHARMS	0.025MG;0.5MG	N17744	001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL			
COLONAID			
WALLACE LABS	0.025MG/5ML;2.5MG/5ML	N85735	001
LOMANATE			
ALPHARMA	0.025MG/5ML;2.5MG/5ML	N85746	001
TABLET; ORAL			
COLONAID			
WALLACE LABS	0.025MG;2.5MG	N85737	001
DI-ATRO			
MD PHARM	0.025MG;2.5MG	N85266	001
DIPHENOXYLATE HCL AND ATROPINE SULFATE			
ASCOT	0.025MG;2.5MG	N87934	001
		JUL 19, 1983	
CHELSEA LABS	0.025MG;2.5MG	N85876	001
HALSEY	0.025MG;2.5MG	N85506	001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL			
DIPHENOXYLATE HCL AND ATROPINE SULFATE			
HEATHER	0.025MG;2.5MG	N86798	001
LEDERLE	0.025MG;2.5MG	N86950	001
PARKE DAVIS	0.025MG;2.5MG	N87131	001
ROXANE	0.025MG;2.5MG	N86057	001
DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
EON	0.025MG;2.5MG	N86173	001
ICN	0.025MG;2.5MG	N87195	001
		FEB 16, 1982	
KV PHARM	0.025MG;2.5MG	N85659	001
ROSEMONT	0.025MG;2.5MG	N87842	001
		MAR 29, 1982	
LO-TROL			
VANGARD	0.025MG;2.5MG	N88009	001
		MAR 25, 1983	
LOFENE			
LANNETT	0.025MG;2.5MG	N85372	001
LOGEN			
SUPERPHARM	0.025MG;2.5MG	N88962	001
		MAY 10, 1985	
LOW-QUEL			
HALSEY	0.025MG;2.5MG	N85211	001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION			
MEPERIDINE AND ATROPINE SULFATE			
WYETH AYERST	0.4MG/ML;50MG/ML	N85121	001
	0.4MG/ML;75MG/ML	N85121	002
	0.4MG/ML;100MG/ML	N85121	003

AZATHIOPRINE

TABLET; ORAL			
IMURAN			
FARO PHARMS	25MG	N16324	002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION			
AZATHIOPRINE			
QUAD PHARMS	EQ 100MG BASE/VIAL	N71056	001
		JUN 08, 1988	

FDA data supplied by DrugPatentWatch.com

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN

BAYER	EQ 2GM BASE/VIAL	N50562 001 SEP 03, 1982
	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
	EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
	EQ 3GM BASE/VIAL	N50562 002 SEP 03, 1982
	EQ 3GM BASE/VIAL	N62388 002 SEP 08, 1982
	EQ 3GM BASE/VIAL	N62417 002 OCT 12, 1982
	EQ 4GM BASE/VIAL	N50562 003 SEP 03, 1982
	EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
	EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION
AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB	10MG/ML	N50632 003 MAY 24, 1989

BACAMPICILLIN HYDROCHLORIDE

TABLET; ORAL
SPECTROBID

PFIZER	800MG	N50520 002 SEP 12, 1983

BACITRACIN

INJECTABLE; INJECTION
BACITRACIN

PFIZER	50,000 UNITS/VIAL	N60282 001
QUAD PHARMS	10,000 UNITS/VIAL	N62696 001 APR 17, 1987
	50,000 UNITS/VIAL	N62696 002 APR 17, 1987

OINTMENT; OPHTHALMIC
BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	N60734 001

BACITRACIN

LILLY	500 UNITS/GM	N60687 001
PHARMADERM	500 UNITS/GM	N62158 001
PHARMAFAIR	500 UNITS/GM	N62453 001 MAR 28, 1984

OINTMENT; TOPICAL
BACITRACIN

COMBE	500 UNITS/GM	N62799 001 MAY 14, 1987

POWDER; FOR RX COMPOUNDING
BACITRACIN

PADDOCK	5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MYCITRACIN

PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N61048 001

FDA data supplied by DrugPatentWatch.com

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL
LANABIOTIC
COMBE 500 UNITS/GM; 5,000 UNITS/GM N50598 001 SEP 22, 1986

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62389 001 JUL 02, 1982

OINTMENT; TOPICAL
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62381 001 SEP 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
LANABIOTIC
COMBE 400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM; 5,000 UNITS/GM N62499 001 JUN 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62386 001 SEP 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN
PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62167 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL
POLYSPORIN
GLAXO WELLCOME 10,000 UNITS/GM; 2,000,000 UNITS/GM N50167 002 MAR 01, 1985

OINTMENT; OPHTHALMIC
OCUMYCIN
PHARMAFAIR 500 UNITS/GM; 10,000 UNITS/GM N62430 001 APR 08, 1983

BACLOFEN

TABLET; ORAL
BACLOFEN
ROSEMONT 10MG N71260 001 MAY 06, 1988
20MG N71261 001 MAY 06, 1988

BENDROFLUMETHIAZIDE

TABLET; ORAL
NATURETIN-2.5
APOTHECON 2.5MG N12164 001

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
BENOXINATE HCL
SOLA BARNES HIND 0.4% N84149 001

BENTIROMIDE

SOLUTION; ORAL
CHYMEX
SAVAGE LABS 500MG/7.5ML N18366 001 DEC 29, 1983

FDA data supplied by DrugPatentWatch.com

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DIDREX
PHARMACIA AND UPJOHN 25MG N12427 003

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL
EMETE-CON
ROERIG EQ 100MG BASE N16818 006

BENZTHIAZIDE

TABLET; ORAL
AQUATAG
SOLVAY 25MG N16001 001
50MG N16001 002
BENZTHIAZIDE
PVT FORM 50MG N83206 001
EXNA
AH ROBINS INC 50MG N12489 001
FOVANE
PFIZER 50MG N12128 002
URESE
PFIZER 25MG N12128 003

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
QUANTUM PHARMICS 0.5MG N88514 001 JAN 31, 1984
1MG N88510 001 JAN 31, 1984
2MG N88511 001 JAN 31, 1984
ROSEMONT 0.5MG N89211 001 JUN 14, 1988
1MG N89212 001 JUN 14, 1988
2MG N89213 001 JUN 14, 1988

BENZYL BENZOATE

EMULSION; TOPICAL
BENZYL BENZOATE
LANNETT 50% N84535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
BEPADIN
WALLACE LABS 200MG N19001 001 DEC 28, 1990
300MG N19001 002 DEC 28, 1990
400MG N19001 003 DEC 28, 1990
VASCOR
JOHNSON RW 400MG N19002 003 DEC 28, 1990

BETA-CAROTENE

CAPSULE; ORAL
SOLATENE
ROCHE 30MG N17589 001

BETAMETHASONE

CREAM; TOPICAL
CELESTONE
SCHERING 0.2% N14762 001

BETAMETHASONE BENZOATE

CREAM; TOPICAL
UTICORT
PARKE DAVIS 0.025% N16998 002

GEL; TOPICAL
UTICORT
PARKE DAVIS 0.025% N17244 001

LOTION; TOPICAL
UTICORT
PARKE DAVIS 0.025% N17528 001

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE BENZOATE

OINTMENT; TOPICAL
UTICORT
PARKE DAVIS 0.025% N18089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
CLAY PARK EQ 0.05% BASE N72536 001 JAN 31, 1990
PHARMADERM EQ 0.05% BASE N19136 001 JUN 26, 1984

CREAM, AUGMENTED; TOPICAL
DIPROLENE
SCHERING EQ 0.05% BASE N19408 001 JAN 31, 1986

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
ALPHARMA EQ 0.05% BASE N71085 001 FEB 03, 1987
PHARMADERM EQ 0.05% BASE N70274 001 AUG 12, 1985

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE
CLAY PARK EQ 0.05% BASE N72526 001 JAN 31, 1990
PHARMADERM EQ 0.05% BASE N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
CLAY PARK EQ 0.1% BASE N70053 001 JUN 10, 1986
PHARMADERM EQ 0.1% BASE N18860 002 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70485 001 MAY 29, 1987

VALISONE
SCHERING EQ 0.01% BASE N16322 002
EQ 0.1% BASE N16322 001

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE
PHARMADERM EQ 0.1% BASE N18870 001 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70484 001 MAY 29, 1987

VALISONE
SCHERING EQ 0.1% BASE N16932 001

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
CLAY PARK EQ 0.1% BASE N71478 001 DEC 23, 1987
PHARMADERM EQ 0.1% BASE N18864 001 AUG 31, 1983
PHARMAFAIR EQ 0.1% BASE N70486 001 MAY 29, 1987

VALISONE
SCHERING EQ 0.1% BASE N16740 001

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
HISTALOG
LILLY 50MG/ML N09344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION
BETHANECHOL CHLORIDE
QUAD PHARMS 5MG/ML N89815 001 APR 12, 1988

URECHOLINE
MERCK 5MG/ML N06536 001

TABLET; ORAL
BETHANECHOL CHLORIDE
ASCOT 10MG N88288 001 JUN 08, 1983
25MG N88289 001 JUN 08, 1983
CHELSEA LABS 5MG N85841 001
10MG N85842 001
25MG N85839 001
DANBURY PHARMA 5MG N84402 001

FDA data supplied by DrugPatentWatch.com

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE		
DANBURY PHARMA	10MG	N84408 001
	25MG	N84441 001
	50MG	N87444 001
EON	5MG	N84353 001
	10MG	N84378 001
	10MG	N84379 001
	25MG	N84383 001
	25MG	N84384 001
LANNETT	5MG	N84702 001
	10MG	N84712 001
	25MG	N84074 001
WATSON LAB	5MG	N85230 002
	10MG	N85228 001
	25MG	N85229 001
	50MG	N87397 001
ZENITH GOLDLINE	25MG	N84689 001
DUVOID		
ROBERTS LABS	10MG	N86262 001
	25MG	N86263 001
	50MG	N85882 003
MYOTONACHOL		
GLENWOOD	5MG	N84188 001
	10MG	N84188 003
	25MG	N84188 004
URECHOLINE		
MERCK	5MG	N06536 003
	10MG	N06536 002
	25MG	N06536 004
	50MG	N06536 005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN		
ROBINS AH	10MG	N17675 001
	25MG	N17675 002

BIOTIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

BIOTIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE		
AM PHARM PARTNERS	50MG/ML	N70134 001 APR 29, 1986
	100MG/ML	N71298 001 FEB 13, 1987
ASTRAZENECA	50MG/ML	N71151 001 AUG 10, 1987
	50MG/ML	N71152 001 AUG 10, 1987
	50MG/ML	N71153 001 AUG 10, 1987
QUAD PHARMS	50MG/ML	N71181 001 FEB 16, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%		
ABBOTT	200MG/100ML	N19005 002 APR 29, 1986
	400MG/100ML	N19005 003 APR 29, 1986
	800MG/100ML	N19005 001 APR 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
ABBOTT	800MG/100ML	N19008 001 APR 29, 1986
BAXTER HLTHCARE	200MG/100ML	N19837 002 APR 12, 1989
	400MG/100ML	N19837 001 APR 12, 1989
BRETYLOL		
FAULDING	50MG/ML	N17954 001

FDA data supplied by DrugPatentWatch.com

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
BROMOCRIPTINE MESYLATE
LEK PHARM EQ 5MG BASE N75100 001
DEC 10, 1998

TABLET; ORAL
BROMOCRIPTINE MESYLATE
LEK PHARM EQ 2.5MG BASE N74631 001
JAN 13, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
AMBODRYL
PARKE DAVIS 25MG N07984 001

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL
BROMPHENIRAMINE MALEATE
ALPHARMA 2MG/5ML N86936 001
PHARM ASSOC 2MG/5ML N87517 001
ROSEMONT 2MG/5ML N87964 001
JAN 25, 1983

INJECTABLE; INJECTION
BROMPHENIRAMINE MALEATE
STERIS 100MG/ML N83820 001
DIMETANE-TEN
WYETH AYERST 10MG/ML N11418 002

TABLET; ORAL
BROMPHENIRAMINE MALEATE
ANABOLIC 4MG N86187 001
BARR 4MG N84468 001
CHELSEA LABS 4MG N85769 001
DANBURY PHARMA 4MG N83123 001
GENEVA PHARMS 4MG N83215 001
NEWTRON PHARMS 4MG N86987 001
PAR PHARM 4MG N87009 001
PIONEER PHARMS 4MG N88604 001
JUL 13, 1984
VITARINE 4MG N85850 001
ZENITH GOLDLINE 4MG N84351 001
DIMETANE
WHITEHALL ROBINS 4MG N10799 003

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
DIMETANE
WHITEHALL ROBINS 8MG N10799 010
JUN 10, 1983
12MG N10799 011
JUN 10, 1983

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DC
ROBINS AH 2MG/5ML;10MG/5ML; 12.5MG/5ML N11694 006
MAR 29, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
BIPHETAP
MORTON GROVE 4MG/5ML;25MG/5ML N88687 001
SEP 26, 1984
BROMANATE
ALPHARMA 4MG/5ML;25MG/5ML N88688 001
FEB 06, 1985

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL
BUCLADIN-S
STUART PHARMS 50MG N10911 006

BUDESONIDE

POWDER, METERED; INHALATION
PULMICORT
ASTRAZENECA 0.32MG/INH N20441 003
JUN 24, 1997

SUSPENSION; INHALATION
PULMICORT RESPULES
ASTRAZENECA 1MG/2ML N20929 003
AUG 08, 2000

FDA data supplied by DrugPatentWatch.com

BUPROPION HYDROCHLORIDE

TABLET; ORAL
WELLBUTRIN
GLAXO WELLCOME 50MG N18644 001
DEC 30, 1985

TABLET, EXTENDED RELEASE; ORAL
ZYBAN
GLAXO WELLCOME 100MG N20711 002
MAY 14, 1997

BUTABARBITAL SODIUM

CAPSULE; ORAL
BUTICAPS
WALLACE LABS 15MG N85381 001
30MG N85381 002
50MG N85381 003
100MG N85381 004

ELIXIR; ORAL
BUTABARB
ALPHARMA 30MG/5ML N85873 001
BUTABARBITAL SODIUM
MORTON GROVE 30MG/5ML N85383 001
BUTALAN
LANNETT 33.3MG/5ML N85880 001
SARISOL
HALSEY 30MG/5ML N84723 001

TABLET; ORAL
BUTABARBITAL SODIUM
CHELSEA LABS 15MG N85764 001
30MG N85772 001
EON 15MG N85938 001
30MG N85934 001
GENEVA PHARMS 15MG N84292 003
FEB 09, 1982
30MG N84272 002
SOLVAY 16.2MG N83606 001
32.4MG N83898 001
48.6MG N83897 001
97.2MG N83896 001
TEVA 15MG N88632 001
MAY 18, 1985
30MG N88631 001
MAY 01, 1985

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM
WHITEWORTH TOWN PLSN 15MG N83325 002
30MG N83337 001
SARISOL NO. 1
HALSEY 15MG N84719 001
SARISOL NO. 2
HALSEY 30MG N84719 002
SODIUM BUTABARBITAL
LANNETT 100MG N85881 001
WEST WARD 15MG N85418 001
30MG N85432 001
ZENITH GOLDLINE 15MG N83484 001
30MG N84040 001

BUTALBITAL; *MULTIPLE*
SEE ACETAMINOPHEN; BUTALBITAL
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL
SEE ASPIRIN; BUTALBITAL; CAFFEINE

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT
SYNTEX (USA) INC LLC 2% N19215 001
NOV 25, 1985

SUPPOSITORY; VAGINAL
FEMSTAT
SYNTEX (USA) INC LLC 100MG N19359 001
NOV 25, 1985

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT
G AND W LABS 100MG;2MG N86557 001
OCT 04, 1983

TABLET; ORAL
CAFERGOT
NOVARTIS 100MG;1MG N06620 001

CALCITONIN HUMAN

INJECTABLE; INJECTION
CIBACALCIN
NOVARTIS 0.5MG/VIAL N18470 001
OCT 31, 1986

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
AVENTIS 400 IU/VIAL N17497 001
MIACALCIN
NOVARTIS 100 IU/ML N17808 001
JUL 03, 1986

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION
ISOPAQUE 280
NYCOMED 0.35MG/ML;140.1MG/ML;
461.8MG/ML N17506 001

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;
120MG/100ML;330MG/100ML;
88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;500MG/100ML;
74MG/100ML N18269 002
JAN 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;2.5GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 006
JAN 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;1.5GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 001
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
B BRAUN 29MG/100ML;4.25GM/100ML;15MG/100ML;
610MG/100ML;560MG/100ML N18460 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;1.5GM/100ML;15MG/100ML;
560MG/100ML;390MG/100ML N18460 002
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;5GM/100ML;5MG/100ML;
530MG/100ML;450MG/100ML N18460 008
JAN 29, 1986

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER
B BRAUN 26MG/100ML;4.25GM/100ML;15MG/100ML; 560MG/100ML;390MG/100ML N18460 004

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML N19634 002 FEB 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001
MILES 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N18499 001
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 005 OCT 17, 1988
20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML N19685 006 OCT 17, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 007 OCT 17, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 003 OCT 17, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
ABBOTT 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 001 OCT 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 538MG/100ML;448MG/100ML N19395 001 MAR 26, 1986
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 538MG/100ML;448MG/100ML N19395 002 MAR 26, 1986
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 538MG/100ML;448MG/100ML N19395 003 MAR 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TPN ELECTROLYTES IN PLASTIC CONTAINER
ABBOTT 16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML N19399 001 JUN 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N18899 001 OCT 31, 1983

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ACETATED RINGER'S IN PLASTIC CONTAINER
B BRAUN 20MG/100ML;30MG/100ML;380MG/100ML; 600MG/100ML N18725 001 NOV 29, 1982

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML;30MG/100ML; 860MG/100ML	N18462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19485 001 OCT 24, 1985
B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001
MILES	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18417 001

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	N80001 001
	EQ 90MG CALCIUM/5ML	N83159 001
AM PHARM PARTNERS	EQ 90MG CALCIUM/5ML	N89373 001 APR 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N06470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION
ISOPAQUE 440

NYCOMED	0.78MG/ML;75.9MG/ML;0.15MG/ML; 16.6MG/ML	N16847 001

CANDICIDIN

OINTMENT; VAGINAL
VANOBID

AVENTIS PHARMS	0.6MG/GM	N61596 001

TABLET; VAGINAL
VANOBID

AVENTIS PHARMS	3MG	N61613 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN

BRISTOL MYERS SQUIBB	37.5MG	N18343 006 SEP 17, 1986
	75MG	N18343 007 JUN 13, 1995
	150MG	N18343 004 JUN 13, 1995

CAPTOPRIL

PUREPAC PHARM	12.5MG	N74640 001 MAR 31, 1997
	25MG	N74640 002 MAR 31, 1997
	50MG	N74640 003 MAR 31, 1997
	100MG	N74640 004 MAR 31, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

DANBURY PHARMA	50MG;25MG	N74832 001 DEC 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR
CARBACHOL

PHARMAFAIR	0.01%	N70292 001 MAY 21, 1986

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

ROSEMONT	200MG	N70300 001 MAY 15, 1986
WARNER CHILCOTT	200MG	N70429 001 JAN 02, 1987

FDA data supplied by DrugPatentWatch.com

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION			
GEOPEN			
ROERIG	EQ 1GM BASE/VIAL	N50306	001
	EQ 2GM BASE/VIAL	N50306	004
	EQ 5GM BASE/VIAL	N50306	002
	EQ 10GM BASE/VIAL	N50306	006
	EQ 30GM BASE/VIAL	N50306	007
PYOPEN			
SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N50298	001
	EQ 2GM BASE/VIAL	N50298	002
	EQ 5GM BASE/VIAL	N50298	003
	EQ 10GM BASE/VIAL	N50298	006
	EQ 20GM BASE/VIAL	N50298	007

CARBIDOPA; LEVODOPA

TABLET; ORAL			
CARBIDOPA AND LEVODOPA			
WATSON LABS	10MG;100MG	N73381	001
		SEP 28, 1993	
	25MG;100MG	N73382	001
		SEP 28, 1993	
	25MG;250MG	N73383	001
		SEP 28, 1993	

CARBINOXAMINE MALEATE

ELIXIR; ORAL			
CLISTIN			
MCNEIL	4MG/5ML	N08955	001
TABLET; ORAL			
CLISTIN			
* JOHNSON RW	4MG	N08915	001

CARISOPRODOL

CAPSULE; ORAL			
SOMA			
WALLACE LABS	250MG	N11792	003
TABLET; ORAL			
CARISOPRODOL			
EON	350MG	N89566	001
		AUG 30, 1988	

CARISOPRODOL

TABLET; ORAL			
CARISOPRODOL			
PIONEER PHARMS	350MG	N89390	001
		OCT 13, 1988	
WATSON LAB	350MG	N85433	001
RELA			
SCHERING	350MG	N12155	001

CARISOPRODOL; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL

CARPHENAZINE MALEATE

CONCENTRATE; ORAL			
PROKETAZINE			
WYETH AYERST	50MG/ML	N14173	001
TABLET; ORAL			
PROKETAZINE			
WYETH AYERST	12.5MG	N12768	001
	25MG	N12768	002
	50MG	N12768	004

CARPROFEN

TABLET; ORAL			
RIMADYL			
ROCHE	100MG	N18550	002
		DEC 31, 1987	
	150MG	N18550	003
		DEC 31, 1987	

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL			
CARTROL			
ABBOTT	10MG	N19204	003
		DEC 28, 1988	

FDA data supplied by DrugPatentWatch.com

CEFACLOR

CAPSULE; ORAL
CEFACLOR

LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
	EQ 500MG BASE	N64107 002 APR 27, 1995
TEVA	EQ 250MG BASE	N64081 001 SEP 16, 1996
	EQ 500MG BASE	N64081 002 SEP 16, 1996

FOR SUSPENSION; ORAL
CEFACLOR

LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
	EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
	EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
	EQ 375MG BASE/5ML	N64110 001 APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

PUREPAC PHARM	EQ 500MG BASE	N63017 001 JAN 05, 1989
TEVA	EQ 500MG BASE	N62695 001 FEB 10, 1989

DURICEF

BRISTOL MYERS SQUIBB	EQ 250MG BASE	N50512 002

ULTRACEF

BRISTOL	EQ 500MG BASE	N62378 001 MAR 16, 1982

FOR SUSPENSION; ORAL
CEFADROXIL

APOTHECON	EQ 125MG BASE/5ML	N62334 001
	EQ 250MG BASE/5ML	N62334 002
	EQ 500MG BASE/5ML	N62334 003
TEVA	EQ 125MG BASE/5ML	N62698 001 MAR 01, 1989
	EQ 250MG BASE/5ML	N62698 002 MAR 01, 1989

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

TEVA	EQ 500MG BASE/5ML	N62698 003 MAR 01, 1989

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	N62376 001 MAR 16, 1982
	EQ 250MG BASE/5ML	N62376 002 MAR 16, 1982
	EQ 500MG BASE/5ML	N62376 003 MAR 16, 1982

TABLET; ORAL
ULTRACEF

APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982
BRISTOL	EQ 1GM BASE	N62408 001 AUG 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL

LILLY	EQ 500MG BASE/VIAL	N50504 001

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF

SMITHKLINE BEECHAM	EQ 250MG BASE/VIAL	N50461 001

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N50566 003 JUN 08, 1983
	EQ 20MG BASE/ML	N50566 004 JUN 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N50566 001 JUN 08, 1983
	EQ 20MG BASE/ML	N50566 002 JUN 08, 1983

CEFAZOLIN SODIUM

AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986
	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AM PHARM PARTNERS	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986
	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987
BEDFORD	EQ 250MG BASE/VIAL	N62894 001 JUL 21, 1988
	EQ 500MG BASE/VIAL	N62894 002 JUL 21, 1988
	EQ 1GM BASE/VIAL	N62894 003 JUL 21, 1988
	EQ 5GM BASE/VIAL	N62894 004 JUL 21, 1988
	EQ 10GM BASE/VIAL	N62894 005 JUL 21, 1988
ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
	EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
	EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
	EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
	EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
	EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N50571 001 DEC 30, 1987
	EQ 1GM BASE/VIAL	N50571 002 DEC 30, 1987
	EQ 2GM BASE/VIAL	N50571 003 DEC 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N50637 002 DEC 11, 1989

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN	EQ 20MG BASE/ML	N50683 001 DEC 29, 1992
	EQ 40MG BASE/ML	N50683 002 DEC 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

SMITHKLINE BEECHAM	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION
CERADON

TAKEDA	EQ 1GM BASE/VIAL	N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984
	EQ 40MG BASE/ML	N50581 001 SEP 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE; INJECTION
CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N50633 002 JAN 31, 1989
	EQ 2GM BASE/VIAL	N50633 003 JAN 31, 1989
	EQ 10GM BASE/VIAL	N50633 005 JAN 31, 1989

FDA data supplied by DrugPatentWatch.com

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
BANAN
SANKYO — EQ 50MG BASE/5ML — N50688 002 AUG 07, 1992
EQ 100MG BASE/5ML — N50688 001 AUG 07, 1992

TABLET; ORAL
BANAN
SANKYO — EQ 100MG BASE — N50687 001 AUG 07, 1992
EQ 200MG BASE — N50687 002 AUG 07, 1992

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ
GLAXO WELLCOME — 500MG/VIAL — N50646 001 SEP 27, 1990

PENTACEF
SMITHKLINE BEECHAM — 1GM/VIAL — N63322 001 NOV 07, 1995
1GM/VIAL — N64006 001 MAR 31, 1992
2GM/VIAL — N63322 002 NOV 07, 1995
2GM/VIAL — N64006 002 MAR 31, 1992
6GM/VIAL — N64008 001 MAR 31, 1992
10GM/VIAL — N64008 002 MAR 31, 1992

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER
GLAXO WELLCOME — EQ 10MG BASE/ML — N50634 001 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
FUJISAWA HLTHCARE — EQ 20MG BASE/ML — N50589 001 OCT 03, 1984
EQ 40MG BASE/ML — N50589 002 OCT 03, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN
HLR — EQ 500MG BASE/VIAL — N62654 001 APR 30, 1987
ROCHE — EQ 250MG BASE/VIAL — N62510 001 MAR 12, 1985
EQ 500MG BASE/VIAL — N62510 002 MAR 12, 1985
EQ 1GM BASE/VIAL — N62510 003 MAR 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
HLR — EQ 10MG BASE/ML — N50624 001 FEB 11, 1987

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND
MISSION PHARMA — 2.5GM/PACKET — N18757 002 DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN
APOTHECON — EQ 250MG BASE — N62973 001 NOV 08, 1988
EQ 500MG BASE — N62974 001 NOV 23, 1988
PUREPAC PHARM — EQ 250MG BASE — N62809 001 APR 22, 1987
EQ 500MG BASE — N62809 002 APR 22, 1987
YOSHITOMI — EQ 250MG BASE — N62872 001 JUN 20, 1988

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

CAPSULE; ORAL		
CEPHALEXIN		
YOSHITOMI	EQ 500MG BASE	N62871 001 JUL 05, 1988
FOR SUSPENSION; ORAL		
CEPHALEXIN		
VITARINE	EQ 125MG BASE/5ML	N62779 001 DEC 22, 1987
	EQ 250MG BASE/5ML	N62781 001 DEC 22, 1987
KEFLEX		
LILLY	EQ 125MG BASE/5ML	N50406 001
	EQ 250MG BASE/5ML	N50406 002
	EQ 100MG BASE/ML	N50406 003
TABLET; ORAL		
CEPHALEXIN		
BARR	EQ 250MG BASE	N62826 001 AUG 17, 1987
	EQ 500MG BASE	N62827 001 AUG 17, 1987
VITARINE	EQ 250MG BASE	N62863 001 AUG 11, 1988
	EQ 500MG BASE	N62863 002 AUG 11, 1988
	EQ 1GM BASE	N62863 003 AUG 11, 1988

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL		
KEFTAB		
LILLY	EQ 250MG BASE	N50614 001 OCT 29, 1987
	EQ 333MG BASE	N50614 003 MAY 16, 1988

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION		
CEPHALOTHIN		
INTL MEDICATION	EQ 500MG BASE/VIAL	N62426 001 MAY 03, 1985

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION		
CEPHALOTHIN		
INTL MEDICATION	EQ 1GM BASE/VIAL	N62426 002 MAY 03, 1985
	EQ 2GM BASE/VIAL	N62426 003 MAY 03, 1985
	EQ 4GM BASE/VIAL	N62426 004 MAY 03, 1985
CEPHALOTHIN SODIUM		
ABBOTT	EQ 1GM BASE/VIAL	N62547 001 SEP 11, 1985
	EQ 1GM BASE/VIAL	N62548 001 SEP 11, 1985
	EQ 2GM BASE/VIAL	N62547 002 SEP 11, 1985
	EQ 2GM BASE/VIAL	N62548 002 SEP 11, 1985
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N62666 002 JUN 10, 1987
	EQ 2GM BASE/VIAL	N62666 001 JUN 10, 1987
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER		
BAXTER HLTHCARE	EQ 20MG BASE/ML	N62422 003 JAN 31, 1984
	EQ 20MG BASE/ML	N62422 005 JUL 16, 1991
	EQ 20MG BASE/ML	N62730 001 MAR 05, 1987
	EQ 40MG BASE/ML	N62422 004 JAN 31, 1984
	EQ 40MG BASE/ML	N62422 006 JUL 16, 1991
	EQ 40MG BASE/ML	N62730 002 MAR 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER		
BAXTER HLTHCARE	EQ 20MG BASE/ML	N62422 001 JAN 31, 1984
	EQ 40MG BASE/ML	N62422 002 JAN 31, 1984
SEFFIN		
GLAXO WELLCOME	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983
	EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983
	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983

FDA data supplied by DrugPatentWatch.com

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL		
APOTHECON	EQ 1GM BASE/VIAL	N50446 001
	EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
	EQ 2GM BASE/VIAL	N50446 002
	EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
	EQ 4GM BASE/VIAL	N50446 003
	EQ 20GM BASE/VIAL	N50446 004
	EQ 500MG BASE/VIAL	N50446 005
CEPHAPIRIN SODIUM		
AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
	EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
	EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
	EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986
	EQ 20GM BASE/VIAL	N62723 005 NOV 17, 1986
ELKINS SINN	EQ 500MG BASE/VIAL	N62720 001 JUL 02, 1987
	EQ 1GM BASE/VIAL	N62720 002 JUL 02, 1987
	EQ 2GM BASE/VIAL	N62720 003 JUL 02, 1987
	EQ 20GM BASE/VIAL	N62720 004 JUL 02, 1987

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE		
BARR	250MG	N62850 001 APR 22, 1988
	500MG	N62851 001 APR 22, 1988
VITARINE	250MG	N62813 001 FEB 25, 1988
	500MG	N62813 002 FEB 25, 1988
ZENITH GOLDLINE	250MG	N62762 001 MAR 06, 1987

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE		
ZENITH GOLDLINE	500MG	N62762 002 MAR 06, 1987
VELOSEF '250'		
ERSANA	250MG	N50548 001
VELOSEF '500'		
ERSANA	500MG	N50548 002

FOR SUSPENSION; ORAL

CEPHRADINE		
BARR	125MG/5ML	N62858 001 MAY 19, 1988
	250MG/5ML	N62859 001 MAY 19, 1988

INJECTABLE; INJECTION

VELOSEF		
APOTHECON	250MG/VIAL	N61976 001
	500MG/VIAL	N61976 002
	1GM/VIAL	N61976 004
	2GM/VIAL	N61976 003
	4GM/VIAL	N61976 005

TABLET; ORAL

VELOSEF		
BRISTOL MYERS SQUIBB	1GM	N50530 001

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL		
BAYER	0.05MG	N20740 001 JUN 26, 1997
	0.1MG	N20740 002 JUN 26, 1997

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN		
PHARMACIA AND UPJOHN	0.02MG/ML	N18296 001

FDA data supplied by DrugPatentWatch.com

CHENODIOL

TABLET; ORAL
CHENIX
AXCAN SCANDIPHARM 250MG N18513 002 JUL 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL
ULO
3M 25MG/5ML N12126 001

CHLORAMPHENICOL

CAPSULE; ORAL
AMPHICOL
FERRANTE 100MG N60058 001
250MG N60058 002

CREAM; TOPICAL
CHLOROMYCETIN
PARKE DAVIS 1% N50183 001

INJECTABLE; INJECTION
CHLOROMYCETIN
PARKE DAVIS 250MG/ML N50153 001

OINTMENT; OPHTHALMIC
CHLOROFAIR
PHARMAFAIR 1% N62439 001 APR 21, 1983
ECONOCHLOR
ALCON 1% N61648 001

SOLUTION/DROPS; OPHTHALMIC
CHLOROFAIR
PHARMAFAIR 0.5% N62437 001 APR 14, 1983
ECONOCHLOR
ALCON 0.5% N61645 001
OPHTHOCHLOR
PARKEDALE 0.5% N61220 001
OPTOMYCIN
OPTOPICS 0.5% N62171 001 MAR 31, 1982

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
PARKEDALE 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CHLOROMYXIN
PARKE DAVIS 1%;10,000 UNITS/GM N50203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC
CHLOROPTIC-P S.O.P.
ALLERGAN 1%;0.5% N61188 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
PARKE DAVIS EQ 150MG BASE/5ML N62301 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL
ELKINS SINN EQ 1GM BASE/VIAL N62406 001 NOV 09, 1982
MYCHEL-S
ANGUS EQ 1GM BASE/VIAL N60132 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL
LIBRELEASE
ICN 30MG N17813 001 SEP 12, 1983

TABLET; ORAL
LIBRITABS
ICN 5MG N85482 001

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE

TABLET; ORAL			
LIBRITABS			
ICN	10MG	N85481	001
	25MG	N85488	001

CHLORDIAZEPOXIDE; *MULTIPLE*

SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL			
MENRIUM 10-4			
ROCHE	10MG;0.4MG	N14740	006
MENRIUM 5-2			
ROCHE	5MG;0.2MG	N14740	002
MENRIUM 5-4			
ROCHE	5MG;0.4MG	N14740	004

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
A-POXIDE			
ABBOTT	5MG	N85447	001
	5MG	N85517	001
	10MG	N85447	002
	10MG	N85518	001
	25MG	N85447	003
	25MG	N85513	001
CHLORDIAZEPOXIDE HCL			
ASCOT	5MG	N87525	001
		JAN 07, 1982	
	10MG	N87524	001
		JAN 07, 1982	
	25MG	N87512	001
		JAN 07, 1982	
EON	5MG	N84919	001
	10MG	N84920	001
	25MG	N84823	001
HALSEY	5MG	N85340	001
	10MG	N85339	001
	25MG	N84685	001
LEDERLE	5MG	N86892	001
	5MG	N87234	001
	10MG	N86876	001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL			
CHLORDIAZEPOXIDE HCL			
LEDERLE	10MG	N87037	001
	25MG	N86893	001
	25MG	N87231	001
MAST MM	10MG	N86217	001
MYLAN	5MG	N84886	001
	10MG	N84601	001
	25MG	N84887	001
PARKE DAVIS	5MG	N85163	001
	10MG	N84598	001
	25MG	N85164	001
PIONEER PHARMS	10MG	N89533	001
		JUL 15, 1988	
	25MG	N89558	001
		JUL 15, 1988	
PUREPAC PHARM	5MG	N85155	001
	10MG	N84939	002
	25MG	N85144	001
ROXANE	5MG	N84706	001
	10MG	N84700	001
	25MG	N84705	001
SUPERPHARM	5MG	N88987	001
		APR 25, 1985	
	10MG	N88986	001
		APR 25, 1985	
	25MG	N88988	001
		APR 25, 1985	
TEVA	5MG	N88705	001
		JAN 18, 1985	
	10MG	N88706	001
		JAN 18, 1985	
	25MG	N86494	001
	25MG	N88707	001
		JAN 18, 1985	
VANGARD	5MG	N88129	001
		MAR 28, 1983	
	10MG	N88010	001
		MAR 28, 1983	
	25MG	N88130	001
		MAR 28, 1983	
WEST WARD	5MG	N85014	001
	10MG	N85000	001
	25MG	N85294	001
ZENITH GOLDLINE	5MG	N83741	001
	10MG	N83742	001
	25MG	N83570	001

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM		
ICN	5MG	N12249 002
	10MG	N12249 001
	25MG	N12249 003
LYGEN		
ALRA	5MG	N85107 001
	10MG	N85009 001
	25MG	N85108 001

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE		
XTTRIUM	2.5%	N19421 001
		DEC 17, 1985

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197		
BRACCO	0.6-1.4mCi/ML	N17269 001

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF		
ASTRAZENECA	2%	N09435 003
	3%	N09435 004

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE		
MD PHARM	EQ 150MG BASE	N87228 001
PUREPAC PHARM	EQ 150MG BASE	N80886 001

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE		
SANOFI SYNTHELABO	EQ 300MG BASE; EQ 45MG BASE	N14860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE		
CHELSEA LABS	500MG	N86796 001
		AUG 15, 1983
EON	250MG	N85485 001
LEDERLE	250MG	N86940 001
	500MG	N86938 001
WATSON LAB	250MG	N85165 001
	500MG	N84026 001
		SEP 01, 1982

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND CHLOROTHIAZIDE		
PAR PHARM	150MG;250MG	N70783 001
		NOV 06, 1987
	250MG;250MG	N70654 001
		NOV 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE W/ RESERPINE		
WATSON LAB	250MG;0.125MG	N84853 001
	500MG;0.125MG	N88151 001
		JUN 09, 1983

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE		
BANNER PHARMACAPS	12MG	N84652 001
TACE		
AVENTIS PHARMS	25MG	N11444 001
	72MG	N16235 001

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

TELDRIN		
SMITHKLINE	8MG	N17369 001
	12MG	N17369 002

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION			
CHLOR-TRIMETON			
SCHERING PLOUGH	10MG/ML	N08826	001
	100MG/ML	N08794	001
CHLORPHENIRAMINE MALEATE			
BEL MAR	10MG/ML	N80821	001
ELKINS SINN	10MG/ML	N80797	001
STERIS	10MG/ML	N83593	001
	100MG/ML	N86095	001
PYRIDAMAL 100			
BEL MAR	100MG/ML	N83733	001
SYRUP; ORAL			
CHLOR-TRIMETON			
SCHERING	2MG/5ML	N06921	006
CHLORPHENIRAMINE MALEATE			
PHARM ASSOC	2MG/5ML	N87520	001
		FEB 10, 1982	
TABLET; ORAL			
ANTAGONATE			
BAYER	4MG	N83381	001
CHLOR-TRIMETON			
SCHERING	4MG	N06921	002
CHLORPHENIRAMINE MALEATE			
ANABOLIC	4MG	N83078	001
BELL PHARMA	4MG	N83062	001
CHELSEA LABS	4MG	N85139	001
DANBURY PHARMA	4MG	N80696	001
ELKINS SINN	4MG	N80938	001
HALSEY	4MG	N80700	001
IMPAX LABS	4MG	N80809	001
KV PHARM	4MG	N87164	001
LEDERLE	4MG	N86941	001
NEWTRON PHARMS	4MG	N86519	001
PANRAY	4MG	N83243	001
PHARMERAL	4MG	N83753	001
PIONEER PHARMS	4MG	N88556	001
		JUL 13, 1984	
PUREPAC PHARM	4MG	N86306	001
PVT FORM	4MG	N80786	001
ROXANE	4MG	N80626	001
VITARINE	4MG	N85837	001
WATSON LAB	4MG	N80791	001
ZENITH GOLDLINE	4MG	N80779	001
KLOROMIN			
HALSEY	4MG	N83629	001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL			
PHENETRON			
LANNETT	4MG	N80846	001

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL			
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL			
CHELSEA LABS	12MG;75MG	N88681	001
		SEP 29, 1987	
COLD CAPSULE IV			
GRAHAM DM	12MG;75MG	N18793	001
		APR 25, 1985	
COLD CAPSULE V			
GRAHAM DM	8MG;75MG	N18794	001
		APR 23, 1985	
TABLET, EXTENDED RELEASE; ORAL			
TRIAMINIC-12			
NOVARTIS	12MG;75MG	N18115	001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL			
CODIMAL-L.A. 12			
SCHWARZ PHARMA	12MG;120MG	N18935	001
		APR 15, 1985	
ISOCLOR			
FISONS	8MG;120MG	N18747	001
		MAR 06, 1986	
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
KV PHARM	12MG;120MG	N71455	001
		MAR 01, 1989	
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE			
GRAHAM DM	8MG;120MG	N18844	001
		MAR 20, 1985	
	12MG;120MG	N18843	001
		MAR 18, 1985	

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PENNTUSS		
FISONS	EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML	N18928 001 AUG 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM		
MEDEVA	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE		
PARKE DAVIS	EQ 65MG BASE	N14696 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HCL		
MORTON GROVE	30MG/ML	N87032 001 JUL 08, 1982
	100MG/ML	N87053 001

INJECTABLE; INJECTION

CHLORPROMAZINE HCL		
AM PHARM PARTNERS	25MG/ML	N84911 001
MARSAM	25MG/ML	N89563 001 APR 15, 1988
STERIS	25MG/ML	N85591 001
WYETH AYERST	25MG/ML	N80370 001

SYRUP; ORAL

CHLORPROMAZINE HCL		
ALPHARMA	10MG/5ML	N86712 001

TABLET; ORAL

CHLORPROMAZINE HCL		
CHELSEA LABS	10MG	N85959 001
	25MG	N85956 001

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL		
CHELSEA LABS	50MG	N85960 001
	100MG	N85957 001
	200MG	N85958 001
KNOLL PHARM	10MG	N84414 001
	25MG	N84415 001
	50MG	N84411 001
	100MG	N84412 001
	200MG	N84413 001
KV PHARM	10MG	N85750 002 JAN 04, 1982
	25MG	N85751 001
	50MG	N85484 001
	100MG	N85752 001
	200MG	N85748 002 JAN 04, 1982
LEDERLE	25MG	N84801 001
	50MG	N84800 001
	100MG	N84789 001
	200MG	N84802 001
PUREPAC PHARM	10MG	N80403 004
	25MG	N80403 001
	50MG	N80403 002
	100MG	N80403 003
	200MG	N80403 005
PVT FORM	25MG	N80340 001
	50MG	N80340 002
	200MG	N80340 003
ROXANE	10MG	N85331 001
	25MG	N85331 002
	50MG	N85331 003
	100MG	N85331 004
	200MG	N85331 005
VANGARD	10MG	N88038 001 AUG 16, 1982
	25MG	N87645 001
	50MG	N87646 001
WEST WARD	10MG	N87783 001 SEP 16, 1982
	25MG	N87865 001 SEP 16, 1982
	50MG	N87878 001 SEP 15, 1982
	100MG	N87884 001 SEP 15, 1982

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL			
CHLORPROMAZINE HCL			
WEST WARD	200MG	N87880 001	SEP 16, 1982
ZENITH GOLDLINE	10MG	N83549 001	
	25MG	N83549 002	
	50MG	N83549 003	
	100MG	N83574 001	
	200MG	N83575 001	
PROMAPAR			
PARKE DAVIS	10MG	N86886 001	
	25MG	N84423 001	
	50MG	N86887 001	
	100MG	N86888 001	
	200MG	N86885 001	

CHLORPROPAMIDE

TABLET; ORAL			
CHLORPROPAMIDE			
BARR	100MG	N88812 001	OCT 19, 1984
	100MG	N89446 001	NOV 17, 1986
	250MG	N88813 001	OCT 19, 1984
	250MG	N89447 001	NOV 17, 1986
CHELSEA LABS	100MG	N86865 001	SEP 24, 1984
	250MG	N86866 001	
DURAMED	100MG	N88918 001	OCT 16, 1984
	250MG	N88919 001	OCT 16, 1984
EON	250MG	N84669 001	
HALSEY	100MG	N89321 001	JAN 16, 1986
	250MG	N88662 001	JAN 09, 1986
ROSEMONT	100MG	N88708 001	AUG 30, 1984
	250MG	N88709 001	AUG 30, 1984
SUPERPHARM	250MG	N88695 001	SEP 17, 1984

CHLORPROPAMIDE

TABLET; ORAL			
CHLORPROPAMIDE			
TEVA	100MG	N88768 001	OCT 11, 1984
WATSON LAB	100MG	N88608 001	APR 12, 1984
	250MG	N88568 001	APR 12, 1984
ZENITH GOLDLINE	100MG	N88840 001	OCT 25, 1984
	250MG	N87353 001	
GLUCAMIDE			
TEVA	250MG	N88641 001	OCT 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL			
TARACTAN			
ROCHE	100MG/5ML	N16149 002	
INJECTABLE; INJECTION			
TARACTAN			
ROCHE	12.5MG/ML	N12487 001	
TABLET; ORAL			
TARACTAN			
ROCHE	10MG	N12486 005	
	25MG	N12486 004	
	50MG	N12486 003	
	100MG	N12486 001	

CHLORTHALIDONE

TABLET; ORAL			
CHLORTHALIDONE			
ABBOTT	25MG	N87364 001	
	50MG	N87384 001	
ASCOT	25MG	N87698 001	OCT 20, 1982
	50MG	N87699 001	OCT 20, 1982
CHELSEA LABS	50MG	N87082 001	
DANBURY PHARMA	25MG	N87296 001	
	25MG	N87706 001	

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

DANBURY PHARMA	50MG	N87521 001
	50MG	N87689 001
EON	50MG	N87118 001
HALSEY	25MG	N87292 001
	50MG	N87293 001
KV PHARM	25MG	N87311 001
	50MG	N87312 001
LEDERLE	25MG	N87451 001
	50MG	N87450 001
MUTUAL PHARM	25MG	N89738 001
		SEP 19, 1988
	50MG	N89739 001
		SEP 19, 1988
PIONEER PHARMS	50MG	N89591 001
		JUL 21, 1988
PUREPAC PHARM	25MG	N88139 001
		JUL 16, 1986
	50MG	N88140 001
		AUG 11, 1983
ROSEMONT	50MG	N89052 001
		JUN 01, 1987
SUPERPHARM	25MG	N87473 001
		FEB 09, 1983
	50MG	N87247 001
		FEB 09, 1983
TEVA	50MG	N88651 001
		MAY 30, 1985
VANGARD	25MG	N88012 001
		JUL 14, 1982
	50MG	N88073 001
		MAR 25, 1983
WARNER CHILCOTT	25MG	N87515 001
		JAN 24, 1983
	50MG	N87516 001
		FEB 09, 1983
WATSON LAB	25MG	N87050 001
	50MG	N87029 001
ZENITH GOLDLINE	25MG	N87555 001
	50MG	N87947 001
		FEB 27, 1984

THALITONE

MONARCH PHARMS	25MG	N88051 001
		NOV 12, 1982

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL
LOPRESSIDONE

NOVARTIS	25MG;100MG	N19451 001
		DEC 31, 1987
	25MG;200MG	N19451 002
		DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

CHELSEA LABS	250MG	N86948 001
		AUG 09, 1982
DANBURY PHARMA	250MG	N86901 001
PIONEER PHARMS	250MG	N89592 001
		JAN 06, 1989
	500MG	N89948 001
		JAN 06, 1989

PARAFLEX

JOHNSON RW	250MG	N11300 003

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001
		MAY 26, 1988
	EQ 4GM RESIN/BAR	N71739 001
		MAY 26, 1988

TABLET; ORAL
QUESTRAN

APOTHECON	EQ 1GM RESIN	N73403 001
		APR 28, 1994

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE

AM PHARM PARTNERS	EQ 0.004MG CHROMIUM/ML	N19271 001
		MAY 05, 1987

FDA data supplied by DrugPatentWatch.com

CHYMOPAPAIN

INJECTABLE; INJECTION			
CHYMODIACTIN			
KNOLL PHARM	10,000 UNITS/VIAL	N18663 001	NOV 10, 1982
DISCASE			
KNOLL PHARM	12,500 UNITS/VIAL	N18625 001	JAN 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC			
ALPHA CHYMAR			
SOLA BARNES HIND	750 UNITS/VIAL	N11837 001	
CATARASE			
CIBA	150 UNITS/VIAL	N18121 001	
	300 UNITS/VIAL	N16938 001	

CIMETIDINE

TABLET; ORAL			
CIMETIDINE			
LEK LJUBLJANA	200MG	N74250 001	JUN 29, 1995
	300MG	N74250 002	JUN 29, 1995
	400MG	N74250 003	JUN 29, 1995
	800MG	N74250 004	JUN 29, 1995
LEK PHARM	100MG	N75122 001	JUN 19, 1998
	200MG	N75122 002	JUN 19, 1998
PERRIGO	100MG	N74972 001	JUN 19, 1998
ROXANE	300MG	N74361 001	DEC 23, 1994
	400MG	N74361 002	DEC 23, 1994
	800MG	N74371 001	DEC 23, 1994
TAGAMET HB			
* SMITHKLINE BEECHAM	100MG	N20238 001	JUN 19, 1995

CIPROFLOXACIN

INJECTABLE; INJECTION			
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAYER	200MG/100ML	N19858 001	DEC 26, 1990

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL			
PROPULSID			
JANSSEN	EQ 1MG BASE/ML	N20398 001	SEP 15, 1995
TABLET; ORAL			
PROPULSID			
JANSSEN	EQ 10MG BASE	N20210 001	JUL 29, 1993
	EQ 20MG BASE	N20210 002	DEC 23, 1993
TABLET, ORALLY DISINTEGRATING; ORAL			
PROPULSID QUICKSOLV			
JANSSEN	EQ 20MG BASE	N20767 001	NOV 07, 1997

CISPLATIN

INJECTABLE; INJECTION			
PLATINOL-AQ			
BRISTOL MYERS	0.5MG/ML	N18057 003	JUL 18, 1984

CITALOPRAM HYDROBROMIDE

TABLET; ORAL			
CELEXA			
FOREST LABS	EQ 60MG BASE	N20822 004	JUL 17, 1998

CLEMASTINE FUMARATE

TABLET; ORAL			
CLEMASTINE FUMARATE			
TEVA	1.34MG	N73282 001	JAN 31, 1992

FDA data supplied by DrugPatentWatch.com

CLEMASTINE FUMARATE

TABLET; ORAL
TAVIST-1
NOVARTIS 1.34MG N17661 002
1.34MG N17661 003
AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TAVIST D
NOVARTIS EQ 1MG BASE;75MG N18298 001
DEC 15, 1982

CLIDINIUM BROMIDE

CAPSULE; ORAL
QUARZAN
ROCHE 2.5MG N10355 001
5MG N10355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN
PHARMACIA AND UPJOHN EQ 75MG BASE N61809 001
EQ 150MG BASE N61809 002
CLINDAMYCIN HCL
DANBURY PHARMA EQ 75MG BASE N63082 001
JUL 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
PHARMACIA AND UPJOHN EQ 75MG BASE/5ML N61827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
PHARMACIA AND UPJOHN EQ 2% BASE N50680 001
AUG 11, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE
PHARMACIA AND UPJOHN EQ 150MG BASE/ML N61839 001
CLINDAMYCIN PHOSPHATE
AM PHARM PARTNERS EQ 150MG BASE/ML N62747 001
JUN 03, 1988
ASTRAZENECA EQ 150MG BASE/ML N62928 001
FEB 13, 1989
BEDFORD EQ 150MG BASE/ML N63163 001
JUN 30, 1994
DUPONT MERCK EQ 150MG BASE/ML N62908 001
FEB 01, 1989
MARSAM EQ 150MG BASE/ML N62913 001
OCT 20, 1988
QUAD PHARMS EQ 150MG BASE/ML N62795 001
DEC 21, 1987
EQ 150MG BASE/ML N62877 001
MAR 15, 1988
SOLOPAK EQ 150MG BASE/ML N62819 001
MAR 15, 1988
EQ 150MG BASE/ML N62852 001
MAR 17, 1988
STERIS EQ 150MG BASE/ML N62900 001
JUN 08, 1988
EQ 150MG BASE/ML N63079 001
MAR 05, 1990
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
AM PHARM PARTNERS EQ 12MG BASE/ML N50636 001
DEC 22, 1989

SOLUTION; TOPICAL
CLEOCIN T
PHARMACIA AND UPJOHN EQ 1% BASE N62363 001
FEB 08, 1982

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL
NYSTAFORM
BAYER 10MG/GM;100,000 UNITS/GM N50235 001

FDA data supplied by DrugPatentWatch.com

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

CHELSEA LABS	500MG	N71603 001 SEP 18, 1987
GENEVA PHARMS	500MG	N72191 001 MAY 02, 1988

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

AM THERAP	0.1MG	N70881 001 JUL 08, 1986
	0.2MG	N70882 001 JUL 08, 1986
	0.3MG	N70883 001 JUL 08, 1986
DURAMED	0.1MG	N71103 001 AUG 14, 1986
	0.2MG	N71102 001 AUG 14, 1986
	0.3MG	N71101 001 AUG 14, 1986
HALSEY	0.2MG	N70924 001 SEP 04, 1987
	0.3MG	N70923 001 SEP 04, 1987
INTERPHARM	0.1MG	N71252 001 OCT 01, 1986
	0.2MG	N71253 001 OCT 01, 1986
	0.3MG	N71254 001 OCT 01, 1986
PAR PHARM	0.1MG	N70461 001 JUL 08, 1986
	0.2MG	N70460 001 JUL 08, 1986
	0.3MG	N70459 001 JUL 08, 1986
TEVA	0.1MG	N70747 001 JUL 08, 1986
	0.2MG	N70702 001 JUL 08, 1986
	0.3MG	N70659 001 JUL 08, 1986

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

WARNER CHILCOTT	0.1MG	N72138 001 JUN 13, 1988
	0.2MG	N72139 001 JUN 13, 1988
	0.3MG	N72140 001 JUN 13, 1988
WATSON LAB	0.1MG	N70395 001 MAR 23, 1987
	0.2MG	N70396 001 MAR 23, 1987
	0.3MG	N70397 001 MAR 23, 1987

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AM THERAP	3.75MG	N71429 001 JUN 23, 1987
	7.5MG	N71430 001 JUN 23, 1987
	15MG	N71431 001 JUN 23, 1987
CHELSEA LABS	3.75MG	N71878 001 MAR 15, 1988
	7.5MG	N71879 001 MAR 15, 1988
	15MG	N71860 001 MAR 15, 1988
PUREPAC PHARM	3.75MG	N71924 001 APR 25, 1988
	7.5MG	N71925 001 APR 25, 1988
	15MG	N71926 001 APR 25, 1988
QUANTUM PHARMICS	3.75MG	N71549 001 SEP 12, 1988
	7.5MG	N71550 001 SEP 12, 1988
	15MG	N71522 001 SEP 12, 1988
ROSEMONT	3.75MG	N71242 001 JUN 23, 1987

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL			
CLORAZEPATE DIPOTASSIUM			
ROSEMONT	7.5MG	N71243 001	JUN 23, 1987
	15MG	N71244 001	JUN 23, 1987
SEARLE	3.75MG	N71727 001	DEC 18, 1987
	7.5MG	N71728 001	DEC 18, 1987
	15MG	N71729 001	DEC 18, 1987
WARNER CHILCOTT	3.75MG	N71774 001	MAR 01, 1988
	7.5MG	N71775 001	MAR 01, 1988
	15MG	N71776 001	MAR 01, 1988
TRANXENE			
ABBOTT	3.75MG	N17105 001	
	7.5MG	N17105 002	
	15MG	N17105 003	
TABLET; ORAL			
CLORAZEPATE DIPOTASSIUM			
AM THERAP	3.75MG	N71747 001	JUN 23, 1987
	7.5MG	N71748 001	JUN 23, 1987
	15MG	N71749 001	JUN 23, 1987
LEDERLE	3.75MG	N72013 001	DEC 15, 1987
	7.5MG	N72014 001	DEC 15, 1987
	15MG	N72015 001	DEC 15, 1987
PUREPAC PHARM	3.75MG	N72330 001	AUG 08, 1988
	7.5MG	N72331 001	AUG 08, 1988
	15MG	N72332 001	AUG 08, 1988
QUANTUM PHARMICS	3.75MG	N71730 001	OCT 26, 1987
	7.5MG	N71731 001	OCT 26, 1987

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL			
CLORAZEPATE DIPOTASSIUM			
QUANTUM PHARMICS	15MG	N71702 001	OCT 26, 1987
WARNER CHILCOTT	3.75MG	N71828 001	MAR 03, 1988
	7.5MG	N71829 001	MAR 03, 1988
	15MG	N71830 001	MAR 03, 1988

CLOTRIMAZOLE

TABLET; VAGINAL			
MYCELEX-G			
BAYER	500MG	N19069 001	APR 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL			
CLOXACILLIN SODIUM			
APOTHECON	EQ 250MG BASE	N61452 001	
	EQ 500MG BASE	N61452 002	
CLOXAPEN			
SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001	
	EQ 500MG BASE	N62233 002	
FOR SOLUTION; ORAL			
CLOXACILLIN SODIUM			
NOVOPHARM	EQ 125MG BASE/5ML	N62978 001	APR 06, 1989
TEGOPEN			
APOTHECON	EQ 125MG BASE/5ML	N50192 001	
	EQ 125MG BASE/5ML	N61453 001	

CLOZAPINE

TABLET; ORAL			
CLOZAPINE			
GENEVA PHARMS	25MG	N74546 001	AUG 30, 1996
	100MG	N74546 002	AUG 30, 1996

FDA data supplied by DrugPatentWatch.com

COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

N/A; N/A
RUBRATOPE-60 KIT

BRACCO	N/A;N/A;N/A;N/A	N16090 001

CODEINE PHOSPHATE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CODEINE PHOSPHATE
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE VC W/ CODEINE

HALSEY	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88870 001 MAR 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88816 001 NOV 22, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE W/ CODEINE

HALSEY	10MG/5ML;6.25MG/5ML	N88739 001 DEC 23, 1988

PROMETHAZINE W/ CODEINE

CENCI	10MG/5ML;6.25MG/5ML	N88814 001 NOV 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE

GLAXO WELLCOME	10MG/5ML;30MG/5ML; 1.25MG/5ML	N12575 003 APR 04, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI	10MG/5ML;30MG/5ML; 1.25MG/5ML	N89018 001 JUL 23, 1986

CODEINE POLISTIREX; *MULTIPLE*
SEE CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

COLCHICINE; PROBENECID

TABLET; ORAL

PROBEN-C

CHELSEA LABS	0.5MG;500MG	N85552 001

PROBENECID AND COLCHICINE

BEECHAM	0.5MG;500MG	N84321 001
EON	0.5MG;500MG	N86130 001

PROBENECID W/ COLCHICINE

LEDERLE	0.5MG;500MG	N86954 001
WATSON LAB	0.5MG;500MG	N83221 001

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S

PARKE DAVIS	EQ 25MG BASE/5ML	N50355 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7

SEARLE	89MG	N17408 001

TATUM-T

SEARLE	120MG	N18205 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE	25 UNITS/VIAL	N08317 002
	40 UNITS/VIAL	N08317 004

FDA data supplied by DrugPatentWatch.com

CORTICOTROPIN

INJECTABLE; INJECTION			
ACTHAR			
AVENTIS	25 UNITS/VIAL	N07504	002
	40 UNITS/VIAL	N07504	003
CORTICOTROPIN			
STERIS	40 UNITS/VIAL	N88772	001
		NOV 21, 1984	
PURIFIED CORTROPHIN GEL			
ORGANON	40 UNITS/ML	N08975	001
	80 UNITS/ML	N08975	002

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION			
CORTROPHIN-ZINC			
ORGANON	40 UNITS/ML	N09854	001

CORTISONE ACETATE

INJECTABLE; INJECTION			
CORTISONE ACETATE			
PHARMACIA AND UPJOHN	25MG/ML	N08126	002
STERIS	25MG/ML	N83147	003
	25MG/ML	N85677	001
	50MG/ML	N83147	004
	50MG/ML	N85677	002
TABLET; ORAL			
CORTISONE ACETATE			
BARR	25MG	N83471	001
ELKINS SINN	25MG	N80836	001
EVERYLIFE	25MG	N84246	001
HEATHER	25MG	N85736	001
IMPAX LABS	25MG	N09458	001
INWOOD LABS	25MG	N80731	001
LANNETT	25MG	N80694	001
PANRAY	5MG	N08284	002
	25MG	N08284	001
PUREPAC PHARM	25MG	N80493	001
VITARINE	25MG	N80333	001
WHITEWORTH TOWN PLSN	25MG	N80341	001
ZENITH GOLDLINE	25MG	N80630	001
	25MG	N83536	001

CROMOLYN SODIUM

CAPSULE; INHALATION			
INTAL			
AVENTIS	20MG	N16990	001
CAPSULE; ORAL			
GASTROCROM			
MEDEVA	100MG	N19188	001
		DEC 22, 1989	

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION			
UNITENSEN			
WALLACE LABS	260 CSR UNIT/ML	N08814	001

CRYPTENAMINE TANNATES

TABLET; ORAL			
UNITENSEN			
WALLACE LABS	260 CSR UNIT	N09217	001

CUPRIC SULFATE

INJECTABLE; INJECTION			
CUPRIC SULFATE			
AM PHARM PARTNERS	EQ 0.4MG COPPER/ML	N19350	001
		MAY 05, 1987	

CYANOCOBALAMIN

INJECTABLE; INJECTION			
BERUBIGEN			
PHARMACIA AND UPJOHN	1MG/ML	N06798	001
BETALIN 12			
LILLY	0.1MG/ML	N80855	001
	1MG/ML	N80855	002
COBAVITE			
STERIS	0.1MG/ML	N83013	001
	1MG/ML	N83064	001
CYANOCOBALAMIN			
AKORN	1MG/ML	N87969	001
		NOV 10, 1983	
AM PHARM PARTNERS	0.03MG/ML	N80510	003

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN			
AM PHARM PARTNERS	0.1MG/ML	N80510	001
	1MG/ML	N80510	002
	1MG/ML	N83075	001
AVENTIS PHARMS	1MG/ML	N80564	001
DELL LABS	0.03MG/ML	N80689	001
	0.1MG/ML	N80689	002
	1MG/ML	N80689	003
LUITPOLD	0.03MG/ML	N80668	001
SOLOPAK	1MG/ML	N87551	001
		FEB 29, 1984	
STERIS	0.1MG/ML	N83120	001
WARNER CHILCOTT	1MG/ML	N07085	002
REDISOL			
MERCK	1MG/ML	N06668	010
RUBIVITE			
BEL MAR	0.03MG/ML	N10791	004
	0.05MG/ML	N10791	001
	0.1MG/ML	N10791	002
	0.12MG/ML	N10791	005
	1MG/ML	N10791	003
RUBRAMIN PC			
BRISTOL MYERS SQUIBB	0.1MG/ML	N06799	002
RUVITE			
SAVAGE LABS	1MG/ML	N80570	002
VI-TWEL			
BERLEX	1MG/ML	N07012	002

CYANOCOBALAMIN; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR			
ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N11208	001

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL

RUBRATOPE-60			
BRACCO	0.5-1 uCi	N16090	002

CYANOCOBALAMIN, CO-60; *MULTIPLE*

SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W			
WYETH AYERST	125MG/5ML	N50508	001
	250MG/5ML	N50508	002
	500MG/5ML	N50508	003

TABLET; ORAL

CYCLAPEN-W			
WYETH AYERST	250MG	N50509	001
	500MG	N50509	002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE			
GLAXO WELLCOME	50MG/ML	N09495	001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL			
MERCK	5MG	N17821	001

FDA data supplied by DrugPatentWatch.com

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
AK-PENTOLATE			
AKORN	1%	N85555	001
CYCLOPENTOLATE HCL			
SOLA BARNES HIND	1%	N84150	001
	1%	N84863	001
PENTOLAIR			
PHARMAFAIR	0.5%	N88643	001
		FEB 09, 1987	
	1%	N88150	001
		FEB 25, 1983	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION			
CYTOXAN			
BRISTOL MYERS SQUIBB	100MG/VIAL	N12142	001
	200MG/VIAL	N12142	002
	500MG/VIAL	N12142	003
	1GM/VIAL	N12142	004
		AUG 30, 1982	
	2GM/VIAL	N12142	005
		AUG 30, 1982	

CYCLOSPORINE

CAPSULE; ORAL			
NEORAL			
NOVARTIS	50MG	N50715	003
		JUL 14, 1995	
SOLUTION; ORAL			
CYCLOSPORINE			
ABBOTT	100MG/ML	N65025	001
		MAR 03, 2000	

CYCLOTHIAZIDE

TABLET; ORAL			
ANHYDRON			
LILLY	2MG	N13157	002
FLUIDIL			
PHARMACIA AND UPJOHN	2MG	N18173	001

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL			
PAGITANE			
LILLY	1.25MG	N08951	001
	2.5MG	N08951	002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL			
CYPROHEPTADINE HCL			
HALSEY	2MG/5ML	N89199	001
		JUL 03, 1986	
MORTON GROVE	2MG/5ML	N87001	001
		NOV 04, 1982	
NASKA	2MG/5ML	N89021	001
		DEC 21, 1987	
TABLET; ORAL			
CYPROHEPTADINE HCL			
AM THERAP	4MG	N88798	001
		FEB 15, 1985	
ASCOT	4MG	N87685	001
		OCT 25, 1982	
CHELSEA LABS	4MG	N86165	001
DANBURY PHARMA	4MG	N86580	001
DURAMED	4MG	N88232	001
		OCT 25, 1983	
HALSEY	4MG	N89057	001
		JUL 03, 1986	
KV PHARM	4MG	N86737	001
MD PHARM	4MG	N87566	001
		NOV 10, 1982	
MYLAN	4MG	N86678	001
PIONEER PHARMS	4MG	N87839	001
		FEB 08, 1984	
SUPERPHARM	4MG	N87405	001
VITARINE	4MG	N87284	001
WATSON LAB	4MG	N85245	001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION			
CYSTEINE HCL			
FRESENIUS KABI	7.25%	N19523	001
		OCT 22, 1986	

FDA data supplied by DrugPatentWatch.com

CYTARABINE

INJECTABLE; INJECTION		
CYTARABINE		
QUAD PHARMS	100MG/VIAL	N71248 001 DEC 30, 1987
	500MG/VIAL	N71249 001 DEC 30, 1987

DACARBAZINE

INJECTABLE; INJECTION		
DACARBAZINE		
AM PHARM PARTNERS	100MG/VIAL	N70962 001 AUG 28, 1986
	200MG/VIAL	N70990 001 AUG 28, 1986
QUAD PHARMS	100MG/VIAL	N70821 001 OCT 09, 1986
	200MG/VIAL	N70822 001 OCT 09, 1986
	500MG/VIAL	N71563 001 MAY 06, 1988

DANAZOL

CAPSULE; ORAL		
DANAZOL		
AM THERAP	200MG	N71569 001 DEC 30, 1987

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION		
CERUBIDINE		
AVENTIS	EQ 20MG BASE/VIAL	N61876 001
WYETH AYERST	EQ 20MG BASE/VIAL	N50484 001

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION		
SYNCURINE		
GLAXO WELLCOME	1MG/ML	N06931 002

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL		
DECLOMYCIN		
LEDERLE	150MG	N50262 001
SYRUP; ORAL		
DECLOMYCIN		
LEDERLE	75MG/5ML	N50257 001

DESERPIDINE

TABLET; ORAL		
HARMONYL		
ABBOTT	0.1MG	N10796 001
	0.25MG	N10796 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL		
METHYCLOTHIAZIDE AND DESERPIDINE		
WATSON LAB	0.25MG;5MG	N88486 001 AUG 10, 1984
	0.5MG;5MG	N88452 001 AUG 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL		
PERTOFRANE		
AVENTIS	25MG	N13621 001
	50MG	N13621 002
TABLET; ORAL		
DESIPRAMINE HCL		
ROSEMONT	25MG	N71864 001 SEP 09, 1987
	50MG	N71865 001 SEP 09, 1987
	75MG	N71866 001 SEP 09, 1987
	100MG	N71867 001 SEP 09, 1987

FDA data supplied by DrugPatentWatch.com

DESLANOSIDE

INJECTABLE; INJECTION
CEDILANID-D
NOVARTIS 0.2MG/ML N09282 002

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN
ORGANON 0.15MG;0.03MG N20071 001 DEC 10, 1992

DESONIDE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; DESONIDE

DESOXIMETASONE

OINTMENT; TOPICAL
TOPICORT
AVENTIS PHARMS 0.05% N18594 001 JAN 17, 1985

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION
DOCA
ORGANON 5MG/ML N01104 001

PELLET; IMPLANTATION
PERCORTEN
NOVARTIS 125MG N05151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION
PERCORTEN
NOVARTIS 25MG/ML N08822 001

DEXAMETHASONE

AEROSOL; TOPICAL
AEROSEB-DEX
ALLERGAN HERBERT 0.01% N83296 002

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
ALPHARMA 0.5MG/5ML N88997 001 OCT 10, 1986

GEL; TOPICAL
DECADERM
MERCK 0.1% N13538 001

SUSPENSION/DROPS; OPHTHALMIC
DEXAMETHASONE
STERIS 0.1% N89170 001 MAY 09, 1989

TABLET; ORAL
DEXAMETHASONE
CHELSEA LABS 0.75MG N85818 001
1.5MG N85840 001
GENEVA PHARMS 0.75MG N80399 001
HALSEY 0.25MG N84013 001
0.25MG N84764 001
0.5MG N84084 001
0.5MG N84766 001
0.75MG N84081 001
0.75MG N84765 001
1.5MG N84086 001
1.5MG N84763 001
IMPAX LABS 0.75MG N85376 001
PHOENIX LABS NY 0.75MG N83806 001
PVT FORM 0.75MG N83420 001
ROXANE 0.25MG N84614 001
UPSHER SMITH 0.75MG N87534 001
1.5MG N87533 001
WATSON LAB 0.75MG N84457 001
WHITEWORTH TOWN PLSN 0.75MG N84327 001
DEXONE 0.5
SOLVAY 0.5MG N84991 001
DEXONE 0.75
SOLVAY 0.75MG N84993 001
DEXONE 1.5
SOLVAY 1.5MG N84990 001
DEXONE 4
SOLVAY 4MG N84992 001
HEXADROL
ORGANON 0.5MG N12675 004
0.75MG N12675 007
1.5MG N12675 009

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN
PHARMAFAIR 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62411 001 MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC
DEXASPORIN
PHARMAFAIR 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62428 001 MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL
DEXACORT
MEDEVA EQ 0.1MG PHOSPHATE/INH N14242 001

AEROSOL, METERED; INHALATION
DEXACORT
MEDEVA EQ 0.1MG PHOSPHATE/INH N13413 001

CREAM; TOPICAL
DECADRON
MERCK EQ 0.1% PHOSPHATE N11983 002

INJECTABLE; INJECTION
DEXACEN-4
CENT PHARMS EQ 4MG PHOSPHATE/ML N84342 001
DEXAMETHASONE
AM PHARM PARTNERS EQ 4MG PHOSPHATE/ML N88448 001 JAN 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE
AKORN EQ 4MG PHOSPHATE/ML N84493 001
AM PHARM PARTNERS EQ 4MG PHOSPHATE/ML N87065 001
BEL MAR EQ 4MG PHOSPHATE/ML N84752 001
INTL MEDICATION EQ 20MG PHOSPHATE/ML N88522 001 FEB 17, 1984
QUAD PHARMS EQ 4MG PHOSPHATE/ML N89280 001 MAR 18, 1987
EQ 10MG PHOSPHATE/ML N89281 001 MAR 18, 1987
EQ 20MG PHOSPHATE/ML N89282 001 MAR 18, 1987
EQ 24MG PHOSPHATE/ML N89372 001 MAR 18, 1987

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
STERIS EQ 4MG PHOSPHATE/ML N83702 001
EQ 4MG PHOSPHATE/ML N84355 001
EQ 24MG PHOSPHATE/ML N85606 001
WYETH AYERST EQ 4MG PHOSPHATE/ML N85641 001
HEXADROL
ORGANON EQ 20MG PHOSPHATE/ML N14694 004

OINTMENT; OPHTHALMIC
DEXAIR
PHARMAFAIR EQ 0.05% PHOSPHATE N88071 001 DEC 28, 1982

SOLUTION/DROPS; OPHTHALMIC
DEXAIR
PHARMAFAIR EQ 0.1% PHOSPHATE N88433 001 DEC 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE
SOLA BARNES HIND EQ 0.1% PHOSPHATE N84170 001
EQ 0.1% PHOSPHATE N84173 001

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC
NEODECADRON
MERCK EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM N50324 001

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
BAUSCH AND LOMB EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML N64055 001 OCT 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
PHARMAFAIR EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML N62539 001 JAN 10, 1985

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL
DISOMER
SCHERING 2MG/5ML N11814 002

FDA data supplied by DrugPatentWatch.com

DEXBROMPHENIRAMINE MALEATE

TABLET; ORAL
DISOMER
SCHERING 2MG N11814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL
DISOPHROL
SCHERING 2MG;60MG N12394 002

TABLET, EXTENDED RELEASE; ORAL
DISOBROM
GENEVA PHARMS 6MG;120MG N70770 001 SEP 30, 1991
RESPORAL
PIONEER PHARMS 6MG;120MG N89139 001 JUN 16, 1988

DEXPANTHENOL; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

DEXTROAMPHETAMINE ADIPATE; *MULTIPLE*
SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE RESIN COMPLEX; *MULTIPLE*
SEE AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL
DEXAMPEX
TEVA 15MG N85355 001

ELIXIR; ORAL
DEXEDRINE
SMITHKLINE BEECHAM 5MG/5ML N83902 001

TABLET; ORAL
DEXAMPEX
TEVA 5MG N83735 001
10MG N83735 002
DEXTROAMPHETAMINE SULFATE
GENEVA PHARMS 5MG N85370 001
10MG N85371 001
HALSEY 10MG N83930 001
LANNETT 5MG N83903 001
10MG N83903 003
15MG N85652 001
MAST MM 5MG N86521 001
PUREPAC PHARM 5MG N84125 001
VITARINE 5MG N84986 001
10MG N85892 001
FERNDEX
FERNDALE LABS 5MG N84001 001

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*
SEE AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE DM
HALSEY 15MG/5ML;6.25MG/5ML N88913 001 MAR 02, 1987

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
MILES 10GM/100ML N18504 001
DEXTROSE 2.5% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML N19626 001 FEB 02, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 38.5% IN PLASTIC CONTAINER		
ABBOTT	38.5GM/100ML	N18923 001 SEP 19, 1984
DEXTROSE 50% IN PLASTIC CONTAINER		
ABBOTT	500MG/ML	N19445 001 JUN 03, 1986
DEXTROSE 60%		
B BRAUN	60GM/100ML	N17995 002 SEP 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER		
B BRAUN	60GM/100ML	N17995 001
BAXTER HLTHCARE	60GM/100ML	N20047 002 JUL 02, 1991
DEXTROSE 7.7% IN PLASTIC CONTAINER		
B BRAUN	7.7GM/100ML	N19626 003 FEB 02, 1988

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;37MG/100ML	N19699 001 SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;75MG/100ML	N19699 002 SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;110MG/100ML	N19699 003 SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML	N19699 005 SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%		
B BRAUN	5GM/100ML;75MG/100ML; 200MG/100ML	N18268 009
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;150MG/100ML; 200MG/100ML	N18268 004
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML; 200MG/100ML	N18268 005
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;300MG/100ML; 200MG/100ML	N18268 006
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;75MG/100ML; 330MG/100ML	N18268 011 JAN 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;150MG/100ML; 330MG/100ML	N18268 012 JAN 18, 1986

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML; 330MG/100ML	N18268 013	JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML; 330MG/100ML	N18268 014	JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML; 450MG/100ML	N18268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML; 450MG/100ML	N18268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML; 450MG/100ML	N18268 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 450MG/100ML	N18008 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 450MG/100ML	N18008 002

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;200MG/100ML	N18386 001

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;450MG/100ML	N18229 001

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;450MG/100ML	N18030 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;900MG/100ML	N18376 001

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML;300MG/100ML	N18055 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N18030 005

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;200MG/100ML	N18030 004
MILES	5GM/100ML;200MG/100ML	N18399 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;225MG/100ML	N19482 001	OCT 04, 1985

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;300MG/100ML	N19486 001	OCT 04, 1985
MILES	5GM/100ML;300MG/100ML	N18501 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;330MG/100ML	N18030 003

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;450MG/100ML	N19484 001	OCT 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N18030 002	
MILES	5GM/100ML;450MG/100ML	N18400 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;900MG/100ML	N19483 001	OCT 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N18026 001	
MILES	5GM/100ML;900MG/100ML	N18500 001	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

KNOLL PHARM	1MG	N12302 005
	2MG	N12302 002
	4MG	N12302 004
	6MG	N12302 006

FDA data supplied by DrugPatentWatch.com

DEZOCINE

INJECTABLE; INJECTION

DALGAN		
ASTRAZENECA	5MG/ML	N19082 001 DEC 29, 1989
	10MG/ML	N19082 002 DEC 29, 1989
	15MG/ML	N19082 003 DEC 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282		
BERLEX	60%	N87726 001 SEP 23, 1982
CARDIOGRAFIN		
BRACCO	85%	N11620 002
UROVIST MEGLUMINE DIU/CT		
BERLEX	30%	N87739 001 SEP 23, 1982

SOLUTION; URETERAL

UROVIST CYSTO		
BERLEX	30%	N87729 001 SEP 23, 1982
UROVIST CYSTO PEDIATRIC		
BERLEX	30%	N87731 001 SEP 23, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292		
BERLEX	52%;8%	N87724 001 SEP 23, 1982
ANGIOVIST 370		
BERLEX	66%;10%	N87723 001 SEP 23, 1982
DIATRIZOATE-60		
INTL MEDICATION	52%;8%	N88166 001 JUN 17, 1983
HYPAQUE-M, 75%		
NYCOMED	50%;25%	N10220 003
HYPAQUE-M, 90%		
NYCOMED	60%;30%	N10220 002

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-60		
MALLINCKRODT	52%;8%	N87074 001
MD-76		
MALLINCKRODT	66%;10%	N87073 001

SOLUTION; ORAL, RECTAL

GASTROVIST		
BERLEX	66%;10%	N87728 001 SEP 23, 1982

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-50		
MALLINCKRODT	50%	N87075 001
UROVIST SODIUM 300		
BERLEX	50%	N87725 001 SEP 23, 1982

DIATRIZOATE SODIUM; *MULTIPLE*

SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE		
ROCHE	15MG	N18179 001

INJECTABLE; INJECTION

DIAZEPAM		
AM PHARM PARTNERS	5MG/ML	N70662 001 JUN 25, 1986
LEDERLE	5MG/ML	N71308 001 JUL 17, 1987
MARSAM	5MG/ML	N72371 001 JAN 29, 1993
STERIS	5MG/ML	N70911 001 AUG 28, 1986
	5MG/ML	N70912 001 AUG 28, 1986
	5MG/ML	N70930 001 DEC 01, 1986

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

US ARMY	5MG/ML	N20124 001 DEC 05, 1990
WARNER CHILCOTT	5MG/ML	N71613 001 OCT 22, 1987
	5MG/ML	N71614 001 OCT 22, 1987

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL
DIAZEPAM

CHELSEA LABS	2MG	N70456 001 NOV 01, 1985
	5MG	N70457 001 NOV 01, 1985
	10MG	N70458 001 NOV 01, 1985
DURAMED	2MG	N70894 001 AUG 27, 1986
	5MG	N70895 001 AUG 27, 1986
	10MG	N70896 001 AUG 27, 1986
FERNDALE LABS	2MG	N70903 001 APR 01, 1987
	5MG	N70904 001 APR 01, 1987
	10MG	N70905 001 APR 01, 1987
HALSEY	2MG	N70987 001 AUG 15, 1986
	5MG	N70996 001 AUG 15, 1986
	10MG	N70956 001 AUG 15, 1986
MARTEC	10MG	N72402 001 APR 25, 1989
PIONEER PHARMS	2MG	N70787 001 AUG 02, 1988
	5MG	N70788 001 AUG 02, 1988
	10MG	N70776 001 AUG 02, 1988

DIAZEPAM

TABLET; ORAL
DIAZEPAM

ROXANE	2MG	N70356 001 JUN 17, 1986
	5MG	N70357 001 JUN 17, 1986
	10MG	N70358 001 JUN 17, 1986
WARNER CHILCOTT	2MG	N70209 001 SEP 04, 1985
	5MG	N70210 001 SEP 04, 1985
	10MG	N70222 001 SEP 04, 1985
ZENITH GOLDLINE	2MG	N70360 001 SEP 04, 1985
	5MG	N70361 001 SEP 04, 1985
	10MG	N70362 001 SEP 04, 1985

Q-PAM

QUANTUM PHARMICS	2MG	N70423 001 DEC 12, 1985
	2MG	N72431 001 APR 29, 1988
	5MG	N70424 001 DEC 12, 1985
	5MG	N72432 001 APR 29, 1988
	10MG	N70425 001 DEC 12, 1985
	10MG	N72433 001 APR 29, 1988

DIAZOXIDE

CAPSULE; ORAL
PROGLYCEM

BAKER NORTON	100MG	N17425 002

INJECTABLE; INJECTION
DIAZOXIDE

AM PHARM PARTNERS	15MG/ML	N71519 001 AUG 26, 1987
QUAD PHARMS	15MG/ML	N71908 001 JAN 26, 1988

FDA data supplied by DrugPatentWatch.com

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N06203 001

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM

NOVARTIS	25MG	N20142 001 NOV 24, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

FALCON PHARMS	0.1% †	N20809 001 MAY 04, 1998

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DYCILL

SMITHKLINE BEECHAM	EQ 250MG BASE	N60254 002
	EQ 500MG BASE	N60254 003

FOR SUSPENSION; ORAL
DYNAPEN

APOTHECON	EQ 62.5MG BASE/5ML	N50337 002

DICUMAROL

CAPSULE; ORAL
DICUMAROL

LILLY	25MG	N05509 003
	50MG	N05509 001

TABLET; ORAL
DICUMAROL

ABBOTT	50MG	N05545 004
	100MG	N05545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL

PIONEER PHARMS	10MG	N89361 001 JAN 10, 1989
WATSON LAB	10MG	N83179 001 FEB 12, 1986

SYRUP; ORAL
DICYCLOMINE HCL

ALPHARMA	10MG/5ML	N84479 001

TABLET; ORAL
DICYCLOMINE HCL

HALSEY	20MG	N84600 001 JUL 29, 1985
PIONEER PHARMS	20MG	N88585 001 AUG 20, 1986
WATSON LAB	20MG	N84361 001 FEB 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL
VIDEX

BRISTOL MYERS SQUIBB	375MG/PACKET	N20155 006 OCT 09, 1991

DIENESTROL

CREAM; VAGINAL
DV

AVENTIS PHARMS	0.01%	N83518 001

ESTRAGUARD

SOLVAY	0.01%	N84436 001

SUPPOSITORY; VAGINAL
DV

AVENTIS PHARMS	0.7MG	N83517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL
HETRAZAN

LEDERLE	50MG	N06459 001

† SEE SECTION 1.8 DESCRIPTION OF SPECIAL SITUATIONS

FDA data supplied by DrugPatentWatch.com

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL		
DIETHYLPROPION HCL		
CHELSEA LABS	25MG	N85741 001
EON	25MG	N85916 001
MEDEVA PHARMS CA	25MG	N85544 001
TEVA	25MG	N88642 001
		SEP 20, 1984
TENUATE		
AVENTIS PHARMS	25MG	N17668 001
TEPANIL		
3M	25MG	N11673 001
TABLET, EXTENDED RELEASE; ORAL		
TENUATE		
AVENTIS PHARMS	75MG	N17669 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION		
STILBESTROL		
BRISTOL MYERS SQUIBB	0.2MG/ML	N04056 003
	0.5MG/ML	N04056 004
	1MG/ML	N04056 005
	5MG/ML	N04056 006
SUPPOSITORY; VAGINAL		
DIETHYLSTILBESTROL		
LILLY	0.1MG	N04040 001
	0.5MG	N04040 002
STILBESTROL		
BRISTOL MYERS SQUIBB	0.1MG	N04056 001
	0.5MG	N04056 002
TABLET; ORAL		
DIETHYLSTILBESTROL		
LILLY	0.1MG	N04041 002
	0.5MG	N04041 003
	1MG	N04041 004
	5MG	N04041 005
STILBESTROL		
TABLICAPS	0.5MG	N83004 001
	1MG	N83002 001
	5MG	N83006 001
STILBETIN		
BRISTOL MYERS SQUIBB	0.1MG	N04056 007
	0.25MG	N04056 017

DIETHYLSTILBESTROL

TABLET; ORAL		
STILBETIN		
BRISTOL MYERS SQUIBB	0.5MG	N04056 008
	1MG	N04056 009
	5MG	N04056 010
TABLET, DELAYED RELEASE; ORAL		
DIETHYLSTILBESTROL		
LILLY	0.1MG	N04039 002
	0.25MG	N04039 005
	0.5MG	N04039 003
	1MG	N04039 004
	5MG	N04039 006
STILBESTROL		
TABLICAPS	0.5MG	N83003 001
	1MG	N83005 001
	5MG	N83007 001
STILBETIN		
BRISTOL MYERS SQUIBB	0.1MG	N04056 011
	0.5MG	N04056 012
	1MG	N04056 013
	5MG	N04056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION		
STILPHOSTROL		
BAYER	250MG/5ML	N10010 001
TABLET; ORAL		
STILPHOSTROL		
BAYER	50MG	N10010 002

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*

SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLUNISAL

TABLET; ORAL		
DIFLUNISAL		
PUREPAC PHARM	250MG	N74285 001
		MAY 07, 1996
	500MG	N74285 002
		MAY 07, 1996

FDA data supplied by DrugPatentWatch.com

DIGITOXIN

INJECTABLE; INJECTION
CRYSTODIGIN
LILLY 0.2MG/ML N84100 005

DIGOXIN

CAPSULE; ORAL
LANOXICAPS
GLAXO WELLCOME 0.15MG N18118 004 SEP 24, 1984

INJECTABLE; INJECTION
DIGOXIN
AM PHARM PARTNERS 0.25MG/ML N83217 001

TABLET; ORAL
LANOXIN
GLAXO WELLCOME 0.0625MG N20405 001 SEP 30, 1997
0.1875MG N20405 003 SEP 30, 1997
0.375MG N20405 005 SEP 30, 1997
0.5MG N20405 006 SEP 30, 1997

DIHYDROCODEINE BITARTRATE; *MULTIPLE*
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
EMBOLEX
NOVARTIS 0.5MG/0.7ML;5,000 UNITS/0.7ML; 7.46MG/0.7ML N18885 002 NOV 30, 1984
0.5MG/0.5ML;2,500 UNITS/0.5ML; 5.33MG/0.5ML N18885 001 NOV 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SR
AVENTIS PHARMS 180MG N19471 004 JAN 23, 1989

TABLET; ORAL
DILTIAZEM HCL
NOVOPHARM 30MG N74084 001 FEB 25, 1994
60MG N74084 002 FEB 25, 1994

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
ELKINS SINN 50MG/ML N84767 001
STERIS 50MG/ML N83531 001

LIQUID; ORAL
DIMENHYDRINATE
ALRA 12.5MG/4ML N80715 001

TABLET; ORAL
DIMENHYDRINATE
ANABOLIC 50MG N85985 001
CHELSEA LABS 50MG N85166 001
HEATHER 50MG N80841 001

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION
PROSTIN F2 ALPHA
PHARMACIA AND UPJOHN EQ 5MG BASE/ML N17434 001

DIPHEMANIL METHYLSULFATE

TABLET; ORAL
PRANTAL
SCHERING 100MG N08114 004

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL		
PARKE DAVIS	25MG	N05845 007
	50MG	N05845 001
DIPHENHYDRAMINE HCL		
ALRA	25MG	N80519 004
	50MG	N80519 003
ANABOLIC	25MG	N83634 001
	50MG	N83275 001
CHELSEA LABS	25MG	N85138 001
ELKINS SINN	25MG	N85701 001
	50MG	N85701 002
EON	25MG	N80845 002
	50MG	N80845 001
HALSEY	50MG	N87914 001
		JUN 04, 1984
HEATHER	25MG	N84524 001
	50MG	N83953 001
IMPAX LABS	50MG	N80807 002
LANNETT	25MG	N80868 001
	50MG	N80868 002
LEDERLE	25MG	N86874 001
	50MG	N86875 001
PERRIGO	25MG	N83061 001
	50MG	N83061 002
PIONEER PHARMS	25MG	N89101 001
		DEC 20, 1985
	50MG	N88880 001
		DEC 20, 1985
PUREPAC PHARM	25MG	N85156 001
	50MG	N85150 001
ROXANE	50MG	N80635 001
SUPERPHARM	50MG	N89041 001
		MAY 15, 1985
TEVA	25MG	N85874 001
	50MG	N85874 002
VANGARD	25MG	N88034 001
		OCT 27, 1982
	50MG	N87630 001
WATSON LAB	25MG	N83797 001
	50MG	N83797 002
WEST WARD	50MG	N83567 001
WHITEWORTH TOWN PLSN	25MG	N83441 001
	50MG	N80800 001
ZENITH GOLDLINE	25MG	N80762 001
	50MG	N80762 002

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

BELIX		
HALSEY	12.5MG/5ML	N86586 001
		OCT 03, 1983
BENADRYL		
PARKE DAVIS	12.5MG/5ML	N05845 004
DIBENIL		
CENCI	12.5MG/5ML	N88304 001
		DEC 16, 1983
DIPHEN		
ROSEMONT	12.5MG/5ML	N84640 001
DIPHENHYDRAMINE HCL		
BUNDY	12.5MG/5ML	N83674 001
CENCI	12.5MG/5ML	N87941 001
		DEC 17, 1982
KV PHARM	12.5MG/5ML	N85621 001
LEDERLE	12.5MG/5ML	N86937 001
NASKA	12.5MG/5ML	N88680 001
		MAY 31, 1985
PERRIGO	12.5MG/5ML	N83063 001
PUREPAC PHARM	12.5MG/5ML	N83237 001
		JAN 25, 1982
PVT FORM	12.5MG/5ML	N85287 001
HYDRAMINE		
ALPHARMA	12.5MG/5ML	N80763 002

INJECTABLE; INJECTION

BENADRYL		
PARKE DAVIS	10MG/ML	N06146 001
DIPHENHYDRAMINE HCL		
AM PHARM PARTNERS	10MG/ML	N87066 001
BEL MAR	10MG/ML	N80822 001
ELKINS SINN	50MG/ML	N83183 001
STERIS	10MG/ML	N83533 001

SYRUP; ORAL

ANTITUSSIVE		
PERRIGO	12.5MG/5ML	N71292 001
		APR 10, 1987
BELDIN		
HALSEY	12.5MG/5ML	N89179 001
		JUN 05, 1986
BENYLIN		
PARKE DAVIS	12.5MG/5ML	N06514 004
DIPHEN		
MORTON GROVE	12.5MG/5ML	N70118 001
		OCT 01, 1985

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

DIPHENHYDRAMINE HCL		
ALPHARMA	12.5MG/5ML	N70497 001 APR 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	N73611 001 AUG 20, 1992
HI TECH PHARMA	12.5MG/5ML	N72416 001 SEP 28, 1990
HYDRAMINE		
ALPHARMA	12.5MG/5ML	N70205 001 JAN 28, 1986
SILPHEN		
SILARX	12.5MG/5ML	N72646 001 FEB 27, 1992
VICKS FORMULA 44		
PROCTER AND GAMBLE	12.5MG/5ML	N70524 001 JAN 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN		
PARKE DAVIS	12.5MG/5ML;30MG/5ML	N19014 001 JUN 11, 1985

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*

SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL		
SMITHKLINE BEECHAM	5MG	N11945 001

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE		
PUREPAC PHARM	50MG	N89426 001 JUL 12, 1990
	75MG	N89427 001 JUL 12, 1990

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE		
HALSEY	EQ 100MG BASE	N70351 001 DEC 17, 1985
	EQ 150MG BASE	N70352 001 DEC 17, 1985
INTERPHARM	EQ 100MG BASE	N71190 001 JAN 15, 1987
	EQ 150MG BASE	N71191 001 JAN 15, 1987
MYLAN	EQ 100MG BASE	N70138 001 JUN 14, 1985
	EQ 150MG BASE	N70139 001 JUN 14, 1985
SUPERPHARM	EQ 150MG BASE	N70941 001 FEB 09, 1987
WATSON LAB	EQ 100MG BASE	N70240 001 FEB 02, 1986
	EQ 150MG BASE	N70241 001 FEB 02, 1986

DISULFIRAM

TABLET; ORAL

ANTABUSE		
WYETH AYERST	250MG	N07883 003
	500MG	N07883 002
DISULFIRAM		
CHELSEA LABS	250MG	N87973 001 AUG 05, 1983
	500MG	N87974 001 AUG 05, 1983
DANBURY PHARMA	250MG	N86889 001
	500MG	N86890 001
PAR PHARM	250MG	N88792 001 AUG 14, 1984
	500MG	N88793 001 AUG 14, 1984

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP		
ABBOTT	EQ 250MG BASE	N19794 001 JUL 11, 1990

FDA data supplied by DrugPatentWatch.com

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE CP

ABBOTT	EQ 500MG BASE	N19794 002 JUL 11, 1990

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

ABBOTT	40MG/ML	N70656 001 JAN 24, 1989
	80MG/ML	N70657 001 JAN 24, 1989
AM PHARM PARTNERS	40MG/ML	N18549 001 MAR 11, 1983
	40MG/ML	N70012 001 JUN 12, 1985
	40MG/ML	N70058 001 MAR 20, 1985
	80MG/ML	N70059 001 MAR 20, 1985
	160MG/ML	N70364 001 DEC 04, 1985
ASTRAZENECA	40MG/ML	N70087 001 OCT 23, 1985
	80MG/ML	N70089 001 OCT 23, 1985
	80MG/ML	N70090 001 OCT 23, 1985
	160MG/ML	N70093 001 OCT 23, 1985
	160MG/ML	N70094 001 OCT 23, 1985
SMITH AND NEPHEW	40MG/ML	N70011 001 AUG 29, 1985
	40MG/ML	N70046 001 AUG 29, 1985
	80MG/ML	N70047 001 AUG 29, 1985
WARNER CHILCOTT	40MG/ML	N18138 001
	40MG/ML	N70558 001 SEP 20, 1985
	80MG/ML	N70559 001 SEP 20, 1985

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

CHELSEA LABS	EQ 10MG BASE	N70952 001 MAR 04, 1987
	EQ 25MG BASE	N70953 001 MAY 15, 1986
	EQ 50MG BASE	N70954 001 MAY 15, 1986
	EQ 75MG BASE	N71763 001 FEB 09, 1988
	EQ 100MG BASE	N70955 001 MAY 15, 1986
	EQ 150MG BASE	N71764 001 FEB 09, 1988
HALSEY	EQ 25MG BASE	N71502 001 FEB 18, 1988
	EQ 50MG BASE	N71653 001 FEB 18, 1988
	EQ 75MG BASE	N71654 001 FEB 18, 1988
	EQ 100MG BASE	N71521 001 FEB 18, 1988
LOTUS BIOCHEM	EQ 10MG BASE	N16987 001
	EQ 25MG BASE	N16987 002
	EQ 50MG BASE	N16987 003
	EQ 75MG BASE	N16987 006
	EQ 100MG BASE	N16987 004
	EQ 150MG BASE	N16987 007 APR 13, 1987
PUREPAC PHARM	EQ 10MG BASE	N73054 001 DEC 28, 1990
	EQ 25MG BASE	N72109 001 DEC 28, 1990
	EQ 50MG BASE	N73055 001 DEC 28, 1990
	EQ 75MG BASE	N72386 001 SEP 08, 1988
	EQ 100MG BASE	N72110 001 SEP 08, 1988
	EQ 150MG BASE	N72387 001 SEP 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	N70972 001 SEP 29, 1987
	EQ 25MG BASE	N70973 001 SEP 29, 1987
	EQ 50MG BASE	N70931 001 SEP 29, 1987

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL		
DOXEPIN HCL		
QUANTUM PHARMICS	EQ 75MG BASE	N70932 001 SEP 29, 1987
	EQ 100MG BASE	N72375 001 MAR 15, 1989
	EQ 150MG BASE	N72376 001 MAR 15, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL		
DOXYCYCLINE HYCLATE		
HALSEY	EQ 50MG BASE	N62119 002 MAY 24, 1985
	EQ 100MG BASE	N62119 001 MAY 24, 1985
HEATHER	EQ 50MG BASE	N62463 001 DEC 07, 1983
	EQ 100MG BASE	N62463 002 DEC 07, 1983
INTERPHARM	EQ 50MG BASE	N62763 001 SEP 02, 1988
	EQ 100MG BASE	N62763 002 SEP 02, 1988
PAR PHARM	EQ 50MG BASE	N62434 001 OCT 19, 1984
	EQ 100MG BASE	N62442 001 DEC 22, 1983
PVT FORM	EQ 50MG BASE	N62631 001 JUL 24, 1986
	EQ 100MG BASE	N62631 002 JUL 24, 1986
RANBAXY	EQ 50MG BASE	N62479 001 DEC 23, 1983
	EQ 100MG BASE	N62479 002 DEC 23, 1983
SUPERPHARM	EQ 50MG BASE	N62469 001 OCT 31, 1984
	EQ 100MG BASE	N62469 002 OCT 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	N62594 001 DEC 05, 1985
	EQ 100MG BASE	N62594 002 DEC 05, 1985

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION		
DOXYCYCLINE HYCLATE		
QUAD PHARMS	EQ 100MG BASE/VIAL	N62643 001 FEB 13, 1986
	EQ 200MG BASE/VIAL	N62643 002 FEB 13, 1986
TABLET; ORAL		
DOXYCYCLINE HYCLATE		
CHELSEA LABS	EQ 50MG BASE	N62392 001 MAR 31, 1983
	EQ 100MG BASE	N62392 002 MAR 31, 1983
HEATHER	EQ 100MG BASE	N62462 001 MAY 11, 1983
INTERPHARM	EQ 100MG BASE	N62764 001 SEP 02, 1988
SUPERPHARM	EQ 100MG BASE	N62494 001 FEB 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	N62593 001 AUG 28, 1985
DOXYCYCLINE HYLATE		
HOUBA	EQ 50MG BASE	N62269 003

DOXYLAMINE SUCCINATE

CAPSULE; ORAL		
UNISOM		
PFIZER	25MG	N19440 001 FEB 05, 1986
TABLET; ORAL		
DECAPRYN		
AVENTIS PHARMS	12.5MG	N06412 015
	25MG	N06412 014
DOXY-SLEEP-AID		
PAR PHARM	25MG	N70156 001 JUL 02, 1987
DOXYLAMINE SUCCINATE		
QUANTUM PHARMICS	25MG	N88603 001 AUG 07, 1984

FDA data supplied by DrugPatentWatch.com

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN
* AVENTIS PHARMS 10MG;10MG N10598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION
DROLBAN
LILLY 50MG/ML N12936 001

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AM PHARM PARTNERS 2.5MG/ML N70992 001 NOV 17, 1986
2.5MG/ML N70993 001 NOV 17, 1986
ASTRAZENECA 2.5MG/ML N72018 001 OCT 20, 1988
2.5MG/ML N72019 001 OCT 19, 1988
2.5MG/ML N72020 001 OCT 19, 1988
2.5MG/ML N72021 001 OCT 19, 1988
QUAD PHARMS 2.5MG/ML N71941 001 AUG 17, 1988
2.5MG/ML N71942 001 AUG 17, 1988
SMITH AND NEPHEW 2.5MG/ML N71750 001 SEP 06, 1988
SOLOPAK 2.5MG/ML N71754 001 SEP 06, 1988
2.5MG/ML N71755 001 SEP 06, 1988
STERIS 2.5MG/ML N73520 001 NOV 27, 1991
2.5MG/ML N73521 001 NOV 27, 1991
2.5MG/ML N73523 001 NOV 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL
ASTRAZENECA 2.5MG/ML; EQ 0.05MG BASE/ML N72028 001 APR 13, 1989
INNOVAR
AKORN MFG 2.5MG/ML; EQ 0.05MG BASE/ML N16049 001

DYDROGESTERONE

TABLET; ORAL
GYNOREST
SOLVAY 5MG N17388 001
10MG N17388 002

DYPHYLLINE

ELIXIR; ORAL
NEOTHYLLINE
TEVA 160MG/15ML N07794 003

INJECTABLE; INJECTION
NEOTHYLLINE
TEVA 250MG/ML N09088 001

TABLET; ORAL
NEOTHYLLINE
TEVA 200MG N07794 001
400MG N07794 002

EDETATE CALCIUM DISODIUM

TABLET; ORAL
CALCIUM DISODIUM VERSENATE
3M 500MG N08922 002

EDETATE DISODIUM

INJECTABLE; INJECTION
DISODIUM EDETATE
STERIS 150MG/ML N84356 001
SODIUM VERSENATE
3M 200MG/ML N10573 001

FDA data supplied by DrugPatentWatch.com

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE			
STERIS	10MG/ML	N40044 001	MAR 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE			
STERIS	10MG/ML	N40043 001	MAR 20, 1996

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL			
AVENTIS PHARMS	200MG/ML	N19879 002	NOV 28, 1990

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST		
ASTRAZENECA	0.005MG/ML;0.5%	N17751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HCL W/ EPINEPHRINE		
CARLISLE	0.01MG/ML;2%	N84720 001
	0.02MG/ML;2%	N84732 001
LIDOCAINE HCL W/ EPINEPHRINE		
ABBOTT	0.01MG/ML;1%	N83154 001
BEL MAR	0.01MG/ML;1%	N80820 001
	0.01MG/ML;2%	N80757 001
STERIS	0.01MG/ML;1%	N85463 001
XYLOCAINE W/ EPINEPHRINE		
ASTRAZENECA	0.005MG/ML;1%	N10418 006
	0.005MG/ML;1.5%	N10418 010
	0.005MG/ML;2%	N10418 008
	0.02MG/ML;2%	N06488 005

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL W/ EPINEPHRINE		
BEL MAR	0.02MG/ML;1%	N80758 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL W/ EPINEPHRINE		
BEL MAR	0.02MG/ML;2%	N80759 001

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER-EPI		
3M	0.3MG/INH	N10374 003

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN		
LILLY	50,000 IU	N80884 001
VITAMIN D		
CHASE CHEM	50,000 IU	N80747 001
EVERYLIFE	50,000 IU	N80956 001
LANNETT	50,000 IU	N80825 001
VITARINE	50,000 IU	N84053 001
WEST WARD	50,000 IU	N83102 001

ERGOCALCIFEROL; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

HALSEY	1MG	N88891 001
		NOV 01, 1985
WATSON LAB	1MG	N86433 001
		MAY 27, 1982

GERIMAL

CHELSEA LABS	1MG	N88207 001
		MAR 22, 1984

HYDERGINE

NOVARTIS	0.5MG	N17993 003

TABLET; SUBLINGUAL
ALKERGOT

EON	0.5MG	N85153 001
	1MG	N87417 001

CIRCANOL

3M	0.5MG	N84868 001
	1MG	N85809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB	1MG	N85020 002

ERGOLOID MESYLATES

HALSEY	0.5MG	N87407 001
	1MG	N87552 001
KV PHARM	0.5MG	N85899 001
	0.5MG	N86265 001
	1MG	N85900 001
	1MG	N86264 001
LEDERLE	0.5MG	N86984 001
	1MG	N86985 001
SUPERPHARM	0.5MG	N89233 001
		SEP 23, 1986
	1MG	N89234 001
		SEP 23, 1986
VANGARD	0.5MG	N88013 001
		SEP 20, 1982
	1MG	N88014 001
		SEP 20, 1982
WATSON LAB	0.5MG	N84930 001
	1MG	N85177 001

HYDROGENATED ERGOT ALKALOIDS

ZENITH GOLDLINE	0.5MG	N87186 001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE

3M	0.36MG/INH	N12102 001

TABLET; SUBLINGUAL
ERGOSTAT

PARKE DAVIS	2MG	N88337 001
		JUN 08, 1984

WIGRETTES

ORGANON	2MG	N86750 001
		JUL 29, 1982

ERGOTAMINE TARTRATE; *MULTIPLE*
SEE CAFFEINE; ERGOTAMINE TARTRATE

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

PARKE DAVIS	250MG	N62546 001
		JUL 25, 1985
	250MG	N62618 001
		SEP 25, 1985
WARNER CHILCOTT	250MG	N62338 001

ERYC 125

PARKE DAVIS	125MG	N62648 001
		OCT 24, 1985

ERYC SPRINKLES

FAULDING	125MG	N50593 001
		JUL 22, 1985

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

PHARMADERM	5MG/GM	N62446 001
		SEP 26, 1983
PHARMAFAIR	5MG/GM	N62481 001
		APR 05, 1984

POWDER; FOR RX COMPOUNDING
ERYTHROMYCIN

PADDOCK	100%	N50610 001
		NOV 07, 1986

SOLUTION; TOPICAL
ERYTHROMYCIN

ALPHARMA	1.5%	N62328 001
		APR 19, 1982

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

ALPHARMA	2%	N62327 001 APR 19, 1982
	2%	N62342 001 FEB 25, 1982
	2%	N62957 001 JUL 21, 1988
LILLY	2%	N50532 001
PHARMAFAIR	1.5%	N62485 001 JUL 11, 1984
	2%	N62616 001 JUL 25, 1985

TABLET, DELAYED RELEASE; ORAL
R-P MYCIN

SOLVAY	250MG	N61659 001

ROBIMYCIN

ROBINS AH	250MG	N61633 001

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	N62162 001
ZENITH GOLDLINE	EQ 250MG BASE	N62237 001

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE/5ML	N62169 001 OCT 17, 1990
	EQ 250MG BASE/5ML	N62169 002 OCT 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	N62362 001 DEC 17, 1982

ILOSONE

LILLY	EQ 125MG BASE/5ML	N61894 001
	EQ 250MG BASE/5ML	N61894 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL
ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML; EQ 600MG BASE/5ML	N50599 001 SEP 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL
PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	N62305 001

SUSPENSION; ORAL
E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	N62198 001
	EQ 400MG BASE/5ML	N62198 002

ERYTHROMYCIN ETHYLSUCCINATE

DISTA	EQ 200MG BASE/5ML	N62177 001
	EQ 400MG BASE/5ML	N62177 002
NASKA	EQ 400MG BASE/5ML	N62674 001 MAR 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML	N62231 001
	EQ 400MG BASE/5ML	N62231 002
PHARMAFAIR	EQ 200MG BASE/5ML	N62559 001 MAR 15, 1985
	EQ 400MG BASE/5ML	N62558 001 MAR 15, 1985

WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	N62123 002
	EQ 400MG BASE/5ML	N62123 001

SUSPENSION/DROPS; ORAL
PEDIAMYCIN

ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

TABLET; ORAL
E.E.S. 400

ABBOTT	EQ 400MG BASE	N61905 001

TABLET, CHEWABLE; ORAL
PEDIAMYCIN

ROSS LABS	EQ 200MG BASE	N62306 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN

ABBOTT	EQ 500MG BASE/VIAL	N62586 001 JAN 04, 1988
	EQ 1GM BASE/VIAL	N62586 002 JAN 04, 1988

ERYTHROMYCIN LACTOBIONATE

AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N62604 001 NOV 24, 1986

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION			
ERYTHROMYCIN LACTOBIONATE			
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N62604 002	
		NOV 24, 1986	
QUAD PHARMS	EQ 500MG BASE/VIAL	N62660 001	
		NOV 24, 1986	
	EQ 1GM BASE/VIAL	N62660 003	
		NOV 24, 1986	

ERYTHROMYCIN STEARATE

TABLET; ORAL			
BRISTAMYCIN			
BRISTOL	EQ 250MG BASE	N61304 001	
	EQ 250MG BASE	N61887 001	
ERYPAR			
PARKE DAVIS	EQ 250MG BASE	N62032 001	
	EQ 500MG BASE	N62032 002	
WARNER CHILCOTT	EQ 250MG BASE	N62322 001	
ERYTHROCIN STEARATE			
ABBOTT	EQ 125MG BASE	N60359 002	
ERYTHROMYCIN STEARATE			
LEDERLE	EQ 250MG BASE	N62089 001	
	EQ 500MG BASE	N62089 002	
PUREPAC PHARM	EQ 250MG BASE	N61743 001	
ETHRIL 250			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	N61605 001	
ETHRIL 500			
BRISTOL MYERS SQUIBB	EQ 500MG BASE	N61605 002	
PFIZER-E			
PFIZER	EQ 250MG BASE	N61791 001	
	EQ 500MG BASE	N61791 002	

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION			
BREVIBLOC			
BAXTER PHARM PROD	100MG/ML	N19386 003	
		DEC 31, 1986	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL			
ESTRADIOL			
JOHNSON RW	0.05MG/24HR	N21048 001	
		SEP 20, 1999	
	0.075MG/24HR	N21048 002	
		SEP 20, 1999	
	0.1MG/24HR	N21048 003	
		SEP 20, 1999	
NOVARTIS	0.0375MG/24HR	N20538 001	
		JUL 31, 1996	
	0.05MG/24HR	N20538 003	
		JUL 31, 1996	
	0.075MG/24HR	N20538 002	
		JUL 31, 1996	
	0.1MG/24HR	N20538 004	
		JUL 31, 1996	

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION			
DEPO-ESTRADIOL			
PHARMACIA AND UPJOHN	1MG/ML	N85470 001	
	3MG/ML	N85470 002	
ESTRADIOL CYPIONATE			
QUAD PHARMS	5MG/ML	N89310 001	
		FEB 09, 1987	

ESTRADIOL VALERATE

INJECTABLE; INJECTION			
ESTRADIOL VALERATE			
STERIS	10MG/ML	N83546 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION			
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
STERIS	8MG/ML;180MG/ML	N85860 001	

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL			
MILPREM-200			
WALLACE PHARMS	0.45MG;200MG	N11045 002	

FDA data supplied by DrugPatentWatch.com

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL			
MILPREM-400			
WALLACE PHARMS	0.45MG;400MG	N11045	001

ESTROGENS, ESTERIFIED

TABLET; ORAL			
AMNESTROGEN			
BRISTOL MYERS SQUIBB	0.3MG	N83266	001
	0.625MG	N83266	002
	1.25MG	N83266	003
	2.5MG	N83266	004
ESTERIFIED ESTROGENS			
GENEVA PHARMS	1.25MG	N85302	001
PVT FORM	0.625MG	N83414	001
	1.25MG	N83765	001
	2.5MG	N85907	001
ESTRATAB			
SOLVAY	1.25MG	N83856	001
	2.5MG	N83857	001
EVEX			
SYNTEX (USA) INC LLC	0.625MG	N84215	001
	1.25MG	N83376	002
FEMOGEN			
PVT FORM	0.625MG	N85076	001
	1.25MG	N85008	001
	2.5MG	N85007	001

ESTROGENS, ESTERIFIED; *MULTIPLE*
SEE CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

ESTRONE

INJECTABLE; INJECTION			
ESTROGENIC SUBSTANCE			
WYETH AYERST	2MG/ML	N83488	001
ESTRONE			
STERIS	2MG/ML	N83397	001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
STERIS	2MG/ML	N85237	001
		NOV 23, 1982	
THEELIN			
PARKEDALE	1MG/ML	N03977	001
	2MG/ML	N03977	002

ESTRONE

INJECTABLE; INJECTION			
THEELIN			
PARKEDALE	5MG/ML	N03977	003

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL			
MYAMBUTOL			
LEDERLE	200MG	N16320	002
	500MG	N16320	004

ETHCHLORVYNOL

CAPSULE; ORAL			
ETHCHLORVYNOL			
BANNER PHARMACAPS	100MG	N84463	001
	200MG	N84463	002
	500MG	N84463	003
	750MG	N84463	004
PLACIDYL			
ABBOTT	100MG	N10021	004

ETHINAMATE

CAPSULE; ORAL			
VALMID			
DISTA	500MG	N09750	001

ETHINYL ESTRADIOL

TABLET; ORAL			
FEMINONE			
PHARMACIA AND UPJOHN	0.05MG	N16649	001
LYNORAL			
ORGANON	0.01MG	N05490	003
	0.05MG	N05490	002

ETHINYL ESTRADIOL; *MULTIPLE*
SEE DESOGESTREL; ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28			
NORQUEST FE			
SEARLE	0.035MG;75MG;1MG	N18926 001	
		JUL 18, 1986	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28			
NORLESTRIN FE 1/50			
PARKE DAVIS	0.05MG;75MG;1MG	N16766 001	
NORLESTRIN FE 2.5/50			
PARKE DAVIS	0.05MG;75MG;2.5MG	N16854 001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21			
N.E.E. 1/35 21			
LPI	0.035MG;1MG	N71541 001	
		DEC 14, 1987	
ORTHO-NOVUM 7/14-21			
JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 001	
		APR 04, 1984	
OVCON-50			
WARNER CHILCOTT	0.05MG;1MG	N18128 001	
TABLET; ORAL-28			
N.E.E. 1/35 28			
LPI	0.035MG;1MG	N71542 001	
		DEC 14, 1987	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21			
NORLESTRIN 21 1/50			
PARKE DAVIS	0.05MG;1MG	N16749 001	
NORLESTRIN 21 2.5/50			
PARKE DAVIS	0.05MG;2.5MG	N16852 001	
TABLET; ORAL-28			
NORLESTRIN 28 1/50			
PARKE DAVIS	0.05MG;1MG	N16723 001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL			
PARSIDOL			
PARKE DAVIS	10MG	N09078 003	
	50MG	N09078 006	
	100MG	N09078 008	

ETHOXZOLAMIDE

TABLET; ORAL			
CARDRASE			
PHARMACIA AND UPJOHN	62.5MG	N11047 002	
	125MG	N11047 001	
ETHAMIDE			
ALLERGAN	125MG	N16144 001	

ETHYLESTRENOL

ELIXIR; ORAL			
MAXIBOLIN			
ORGANON	2MG/5ML	N14006 002	
TABLET; ORAL			
MAXIBOLIN			
ORGANON	2MG	N14005 002	

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20			
OVULEN			
SEARLE	1MG;0.1MG	N16029 002	
TABLET; ORAL-21			
OVULEN-21			
SEARLE	1MG;0.1MG	N16029 003	
TABLET; ORAL-28			
OVULEN-28			
SEARLE	1MG;0.1MG	N16705 001	

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
DURANEST			
ASTRAZENECA	0.5%	N17751 003	

FDA data supplied by DrugPatentWatch.com

ETIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

ETOPOSIDE

CAPSULE; ORAL		
VEPESID		
BRISTOL	100MG	N19557 002 DEC 30, 1986
INJECTABLE; INJECTION		
ETOPOSIDE		
GENSIA SICOR PHARMS	20MG/ML	N74510 001 JUN 29, 1995
STERIS	20MG/ML	N74228 001 OCT 15, 1996

ETRETINATE

CAPSULE; ORAL		
TEGISON		
ROCHE	10MG	N19369 001 SEP 30, 1986
	25MG	N19369 002 SEP 30, 1986

EVANS BLUE

INJECTABLE; INJECTION		
EVANS BLUE		
* PARKE DAVIS	0.5%	N08041 001

FENOFIBRATE

CAPSULE; ORAL		
LIPIDIL		
ABBOTT	100MG	N19304 001 DEC 31, 1993

FENOPROFEN CALCIUM

CAPSULE; ORAL		
FENOPROFEN CALCIUM		
AM THERAP	EQ 200MG BASE	N72307 001 AUG 22, 1988

FENOPROFEN CALCIUM

CAPSULE; ORAL		
FENOPROFEN CALCIUM		
AM THERAP	EQ 300MG BASE	N72308 001 AUG 22, 1988
DANBURY PHARMA	EQ 200MG BASE	N72981 001 AUG 19, 1991
	EQ 300MG BASE	N72982 001 AUG 19, 1991
HALSEY	EQ 200MG BASE	N72355 001 AUG 17, 1988
	EQ 300MG BASE	N72356 001 AUG 17, 1988
QUANTUM PHARMICS	EQ 200MG BASE	N72214 001 AUG 17, 1988
	EQ 300MG BASE	N71738 001 AUG 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	N72946 001 APR 30, 1991
	EQ 300MG BASE	N72472 001 APR 30, 1991
WATSON LABS	EQ 200MG BASE	N72294 001 AUG 17, 1988
	EQ 300MG BASE	N72293 001 AUG 17, 1988
TABLET; ORAL		
FENOPROFEN CALCIUM		
AM THERAP	EQ 600MG BASE	N72309 001 AUG 17, 1988
HALSEY	EQ 600MG BASE	N72357 001 AUG 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	N72194 001 AUG 17, 1988
ROSEMONT	EQ 600MG BASE	N72362 001 AUG 17, 1988
WATSON LABS	EQ 600MG BASE	N72165 001 AUG 17, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION		
FENTANYL CITRATE		
STERIS	EQ 0.05MG BASE/ML	N73488 001 JUN 30, 1992

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FDA data supplied by DrugPatentWatch.com

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION
FERROUS CITRATE FE 59
MALLINCKRODT 25 uCi/ML N16729 001

FERROUS FUMARATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL
FOLVRON
LEDERLE 182MG;0.33MG N06012 003

FIBRINOGEN, I-125

INJECTABLE; INJECTION
IBRIN
AMERSHAM 154 uCi/VIAL N17879 001
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR
ABBOTT 140 uCi/ML N17787 001

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
3M 200MG N18830 002
OCT 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
QUAD PHARMS 500MG/VIAL N71055 001
AUG 24, 1987

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
PFIZER 2MG/ML N19950 005
JUL 08, 1994

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
PFIZER 2MG/ML N19950 004
JUL 08, 1994

FLUMETHASONE PIVALATE

CREAM; TOPICAL
LOCORTEN
NOVARTIS 0.03% N16379 001

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCET
ALPHARMA 0.025% N88360 001
JAN 16, 1984

FLUOCINOLONE ACETONIDE
ALPHARMA 0.01% N88361 001
JAN 16, 1984
PHARMADERM 0.01% N88047 001
DEC 16, 1982
0.025% N88045 001
DEC 16, 1982
PHARMAFAIR 0.01% N88499 001
AUG 02, 1984
0.025% N88506 001
AUG 02, 1984
ROSEMONT 0.01% N88757 001
FEB 11, 1985
0.025% N88756 001
MAR 28, 1985

FLUONID
ALLERGAN HERBERT 0.025% N87156 002
SEP 06, 1984

FLUOTREX
SAVAGE LABS 0.01% N88174 001
MAY 06, 1983
0.025% N88173 001
MAR 09, 1983

GEL; TOPICAL
FLUONID
ALLERGAN HERBERT 0.025% N87300 001
MAY 27, 1982

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE

PHARMADERM	0.025%	N88046 001 DEC 16, 1982
PHARMAFAIR	0.025%	N88507 001 FEB 27, 1984
ROSEMONT	0.025%	N88742 001 FEB 08, 1985

FLUONID

ALLERGAN HERBERT	0.025%	N87157 001 SEP 06, 1984

FLUOTREX

SAVAGE LABS	0.025%	N88172 001 MAR 09, 1983

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

BAUSCH AND LOMB	0.01%	N40059 001 DEC 20, 1993
MORTON GROVE	0.01%	N88312 001 JAN 27, 1984
PHARMADERM	0.01%	N88048 001 DEC 16, 1982
PHARMAFAIR	0.01%	N88449 001 FEB 08, 1984

FLUOTREX

SAVAGE LABS	0.01%	N88171 001 MAR 09, 1983

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

CLAY PARK	0.05%	N71790 001 JUL 13, 1988

FLUOROMETHOLONE

CREAM; TOPICAL
OXYLONE

PHARMACIA AND UPJOHN	0.025%	N11748 001

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	N17959 001
	50MG/ML	N81222 001 JUN 28, 1991

FLUOROURACIL

ABIC	50MG/ML	N88929 001 MAR 04, 1986
AM PHARM PARTNERS	50MG/ML	N89152 001 MAR 21, 1986
	50MG/ML	N89428 001 JAN 12, 1987
	50MG/ML	N89519 001 MAR 12, 1987
MARCHAR	50MG/ML	N87791 001 JAN 18, 1983
QUAD PHARMS	50MG/ML	N89368 001 FEB 03, 1987
	50MG/ML	N89455 001 FEB 03, 1987
SMITH AND NEPHEW	50MG/ML	N88766 001 DEC 28, 1984
	50MG/ML	N88767 001 DEC 28, 1984
	50MG/ML	N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

LILLY	EQ 60MG BASE	N18936 004 JUN 15, 1999

TABLET; ORAL
PROZAC

* LILLY	EQ 20MG BASE	N20974 002 MAR 09, 1999

FLUOXYMESTERONE

TABLET; ORAL
ANDROID-F

ICN	10MG	N87196 001

FDA data supplied by DrugPatentWatch.com

FLUOXYMESTERONE

TABLET; ORAL		
FLUOXYMESTERONE		
ICN	10MG	N88221 001 MAY 05, 1983
WATSON LAB	2MG	N88260 001 DEC 06, 1983
	5MG	N88265 001 DEC 06, 1983
	10MG	N88309 001 DEC 06, 1983
ORA-TESTRYL		
BRISTOL MYERS SQUIBB	2MG	N11359 001
	5MG	N11359 002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION		
FLUPHENAZINE		
QUAD PHARMS	25MG/ML	N70762 001 FEB 20, 1986

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
FLUPHENAZINE HCL		
QUAD PHARMS	2.5MG/ML	N89800 001 JUN 08, 1988
TABLET; ORAL		
FLUPHENAZINE HCL		
WATSON LAB	1MG	N88555 001 DEC 18, 1987
	2.5MG	N88544 001 DEC 18, 1987
	5MG	N88527 001 DEC 18, 1987
	10MG	N88550 001 DEC 18, 1987
PERMITIL		
SCHERING	0.25MG	N12034 001
TABLET, EXTENDED RELEASE; ORAL		
PERMITIL		
SCHERING	1MG	N12419 004

FLUPREDNISOLONE

TABLET; ORAL		
ALPHADROL		
PHARMACIA AND UPJOHN	1.5MG	N12259 002

FLURANDRENOLIDE

LOTION; TOPICAL		
FLURANDRENOLIDE		
ALPHARMA	0.05%	N87203 001 APR 29, 1982

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL		
CORDRAN-N		
LILLY	0.05%;EQ 3.5MG BASE/GM	N50346 001
OINTMENT; TOPICAL		
CORDRAN-N		
LILLY	0.05%;EQ 3.5MG BASE/GM	N50345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL		
FLURAZEPAM HCL		
HALSEY	15MG	N70454 001 AUG 04, 1986
	15MG	N71808 001 JAN 07, 1988
	30MG	N70455 001 AUG 04, 1986
	30MG	N71809 001 JAN 07, 1988
ROSEMONT	15MG	N70562 001 JUL 09, 1987
	30MG	N70563 001 JUL 09, 1987
SUPERPHARM	15MG	N71659 001 AUG 04, 1988
	30MG	N71660 001 AUG 04, 1988
WARNER CHILCOTT	15MG	N71767 001 DEC 04, 1987

FDA data supplied by DrugPatentWatch.com

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

WARNER CHILCOTT	30MG	N71768 001
		DEC 04, 1987

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX

SOLVAY	150MG	N20243 004
		DEC 05, 1994

FOLIC ACID

TABLET; ORAL
FOLIC ACID

ANABOLIC	1MG	N84915 001
BARR	1MG	N89177 001
		JAN 08, 1986
CHELSEA LABS	1MG	N85141 002
EON	1MG	N84472 001
EVERYLIFE	1MG	N80755 001
HALSEY	1MG	N83598 001
LANNETT	1MG	N80816 001
LILLY	1MG	N06135 003
PHARMERAL	1MG	N84158 001
PIONEER PHARMS	1MG	N88949 001
		SEP 13, 1985
PUREPAC PHARM	1MG	N80784 001
ROSEMONT	1MG	N87828 001
		MAY 13, 1982
UDL	1MG	N88199 001
		MAR 29, 1983
VANGARD	1MG	N88730 001
		MAR 23, 1984
VINTAGE PHARMS	1MG	N86296 001
WATSON LAB	1MG	N83141 001
WHITEWORTH TOWN PLSN	1MG	N80691 002

FOLVITE

LEDERLE	1MG	N05897 004

FOLIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOLIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

FOLIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FOLIC ACID; *MULTIPLE*
SEE FERROUS SULFATE; FOLIC ACID

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AM PHARM PARTNERS	10MG/ML	N18507 001
		JUL 30, 1982
	10MG/ML	N19036 001
		AUG 13, 1984
ASTRAZENECA	10MG/ML	N70014 001
		SEP 09, 1985
	10MG/ML	N70095 001
		SEP 09, 1985
	10MG/ML	N70096 001
		SEP 09, 1985
ORGANON	10MG/ML	N70017 001
		DEC 15, 1986
SMITH AND NEPHEW	10MG/ML	N70023 001
		FEB 05, 1986
	10MG/ML	N70078 001
		FEB 05, 1986
STERIS	10MG/ML	N70019 001
		SEP 22, 1986
	10MG/ML	N70604 001
		JAN 02, 1987
WARNER CHILCOTT	10MG/ML	N18420 001
		FEB 26, 1982
WYETH AYERST	10MG/ML	N18670 001
		JUL 20, 1982

TABLET; ORAL
FUROSEMIDE

CHELSEA LABS	20MG	N18369 001
		MAY 14, 1982

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

TABLET; ORAL
FUROSEMIDE

CHELSEA LABS	40MG	N18369 002 MAY 14, 1982
EON	40MG	N18750 002 JUL 30, 1984
HALSEY	20MG	N70043 001 SEP 26, 1985
	40MG	N18790 001 NOV 29, 1983
	80MG	N70100 001 JAN 26, 1988
SUPERPHARM	20MG	N18370 002 JUN 26, 1984
	40MG	N18370 001 FEB 10, 1983
WARNER CHILCOTT	20MG	N18419 001 JAN 31, 1983
	40MG	N18419 002 JAN 31, 1983
	80MG	N18419 003 NOV 13, 1984

GABAPENTIN

SOLUTION; ORAL
NEURONTIN

PARKE DAVIS	250MG/5ML	N21129 001 MAR 02, 2000

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL

DAVIS AND GECK	20MG/ML	N07842 001
	100MG/ML	N07842 002

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

NYCOMED AMERSHAM	1mCi/ML	N17700 001

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

SOLOPAK	25MG/ML	N19961 002 JAN 17, 1991

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL

MYLAN	300MG	N73466 001 JAN 25, 1993
PUREPAC PHARM	300MG	N72929 001 JAN 29, 1993

LOPID

PARKE DAVIS PHARMS	200MG	N18422 001
	300MG	N18422 002

TABLET; ORAL
GEMFIBROZIL

PUREPAC PHARM	600MG	N74360 001 AUG 31, 1994
WATSON LABS	600MG	N74156 001 OCT 24, 1994

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	N62458 001 SEP 01, 1983

GENTAMICIN SULFATE

ALPHARMA	EQ 0.1% BASE	N62471 001 SEP 27, 1983
PHARMADERM	EQ 1MG BASE/GM	N62530 001 JUL 05, 1984

INJECTABLE; INJECTION
APOGEN

KING PHARMS	EQ 10MG BASE/ML	N62289 001
	EQ 40MG BASE/ML	N62289 002

BRISTAGEN

BRISTOL	EQ 40MG BASE/ML	N62288 001

GARAMYCIN

SCHERING	EQ 10MG BASE/ML	N61739 001

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAFAIR		
PHARMAFAIR	EQ 40MG BASE/ML	N62493 001 AUG 28, 1985
GENTAMICIN		
INTL MEDICATION	EQ 1MG BASE/ML	N62325 003 JUN 23, 1982
	EQ 100MG BASE/100ML	N62325 004 JUN 23, 1982
	EQ 40MG BASE/ML	N62325 001
GENTAMICIN SULFATE		
ABBOTT	EQ 60MG BASE/100ML	N62413 006 AUG 11, 1983
	EQ 70MG BASE/100ML	N62413 007 AUG 11, 1983
	EQ 80MG BASE/100ML	N62413 008 AUG 11, 1983
	EQ 90MG BASE/100ML	N62413 009 AUG 11, 1983
	EQ 100MG BASE/100ML	N62413 010 AUG 11, 1983
	EQ 1.2MG BASE/ML	N62413 001 AUG 11, 1983
	EQ 1.4MG BASE/ML	N62413 002 AUG 11, 1983
	EQ 1.6MG BASE/ML	N62413 003 AUG 11, 1983
	EQ 1.8MG BASE/ML	N62413 004 AUG 11, 1983
	EQ 2MG BASE/ML	N62413 005 AUG 11, 1983
SOLOPAK	EQ 10MG BASE/ML	N62507 001 JUN 06, 1985
	EQ 40MG BASE/ML	N62507 002 JUN 06, 1985
WYETH AYERST	EQ 10MG BASE/ML	N62264 001
	EQ 40MG BASE/ML	N62264 002
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	EQ 60MG BASE/100ML	N62588 006 JAN 06, 1986
	EQ 70MG BASE/100ML	N62588 007 JAN 06, 1986
	EQ 80MG BASE/100ML	N62588 008 JAN 06, 1986
	EQ 90MG BASE/100ML	N62588 009 JAN 06, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	EQ 100MG BASE/100ML	N62588 010 JAN 06, 1986
	EQ 1.2MG BASE/ML	N62588 001 JAN 06, 1986
	EQ 1.4MG BASE/ML	N62588 002 JAN 06, 1986
	EQ 1.6MG BASE/ML	N62588 003 JAN 06, 1986
	EQ 1.8MG BASE/ML	N62588 004 JAN 06, 1986
	EQ 2MG BASE/ML	N62588 005 JAN 06, 1986

OINTMENT; OPHTHALMIC

GENTAFAIR		
PHARMAFAIR	EQ 3MG BASE/GM	N62443 001 MAY 26, 1983

OINTMENT; TOPICAL

GENTAFAIR		
PHARMAFAIR	EQ 0.1% BASE	N62444 001 MAY 26, 1983
GENTAMICIN SULFATE		
ALPHARMA	EQ 0.1% BASE	N62496 001 MAR 14, 1984
PHARMADERM	EQ 0.1% BASE	N62534 001 OCT 10, 1984

SOLUTION/DROPS; OPHTHALMIC

GENTAFAIR		
PHARMAFAIR	EQ 0.3% BASE	N62440 001 MAY 03, 1983
GENTAMICIN SULFATE		
PACO	EQ 3MG BASE/ML	N62932 001 NOV 07, 1988

GENTIAN VIOLET

TAMPON; VAGINAL

GENAPAX		
KEY PHARMS	5MG	N85017 001

FDA data supplied by DrugPatentWatch.com

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
PFIZER 2.5MG N17783 003
MAY 11, 1993

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
LILLY EQ 10MG BASE/VIAL N12122 002
QUAD PHARMS EQ 1MG BASE/VIAL N71022 001
MAR 04, 1987
EQ 10MG BASE/VIAL N71023 001
MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN
AVENTIS 500MG N09519 008

TABLET; ORAL
DORIDEN
AVENTIS 250MG N09519 002
500MG N09519 005
GLUTETHIMIDE
CHELSEA LABS 500MG N85763 001
DANBURY PHARMA 500MG N84362 001
GENEVA PHARMS 500MG N83234 002
HALSEY 250MG N89458 001
OCT 10, 1986
500MG N89459 001
OCT 10, 1986
LANNETT 250MG N83475 001
500MG N85571 001
MEDEVA PHARMS CA 500MG N85171 001
VITARINE 500MG N87297 001

GLYBURIDE

TABLET; ORAL
GLYNASE
* PHARMACIA AND UPJOHN 4.5MG N20051 003
SEP 24, 1993

GLYCINE

SOLUTION; IRRIGATION
GLYCINE 1.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 1.5GM/100ML N18522 001
FEB 19, 1982

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
ABBOTT 0.2MG/ML N89393 001
JUN 15, 1988
AM PHARM PARTNERS 0.2MG/ML N88475 001
JUN 12, 1984
QUAD PHARMS 0.2MG/ML N89397 001
DEC 09, 1986
STERIS 0.2MG/ML N86947 001
JUN 24, 1983
ROBINUL
ROBINS AH 0.2MG/ML N14764 001

TABLET; ORAL
GLYCOPYRROLATE
CHELSEA LABS 2MG N86178 001
DANBURY PHARMA 1MG N86902 001
2MG N86900 001
WATSON LAB 1MG N85562 001
2MG N85563 001

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL
WYETH AYERST EQ 0.2MG BASE/VIAL N18123 002
SEP 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN
AM PHARM PARTNERS 5,000 UNITS/VIAL N17067 001
15,000 UNITS/VIAL N17067 004
20,000 UNITS/VIAL N17067 003
BEL MAR 5,000 UNITS/VIAL N17054 001
10,000 UNITS/VIAL N17054 002

FDA data supplied by DrugPatentWatch.com

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION			
CHORIONIC GONADOTROPIN			
QUAD PHARMS	5,000 UNITS/VIAL	N89312 001	DEC 04, 1986
	5,000 UNITS/VIAL	N89313 001	DEC 04, 1986
	10,000 UNITS/VIAL	N89314 001	DEC 04, 1986
	10,000 UNITS/VIAL	N89315 001	DEC 04, 1986
	20,000 UNITS/VIAL	N89316 001	DEC 04, 1986
STERIS	2,000 UNITS/VIAL	N17016 009	DEC 27, 1984
	15,000 UNITS/VIAL	N17016 010	FEB 15, 1985
	20,000 UNITS/VIAL	N17016 004	
FOLLUTEIN			
BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N17056 001	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC			
NEO-POLYCIN			
DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60427 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62818 001	OCT 11, 1988
STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN			
PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001	AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION			
KYTRIL			
ROCHE	EQ 3MG BASE/ML	N20239 001	DEC 29, 1993

GRANISETRON HYDROCHLORIDE

TABLET; ORAL			
KYTRIL			
ROCHE	EQ 2MG BASE	N20305 002	JUN 15, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL			
GRISACTIN			
WYETH AYERST	125MG	N50051 002	
TABLET; ORAL			
GRIFULVIN V			
J AND J	125MG	N60618 001	
	250MG	N60618 002	
	500MG	N60618 003	

GUANABENZ ACETATE

TABLET; ORAL			
WYTENSIN			
WYETH AYERST	EQ 16MG BASE	N18587 003	SEP 07, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL			
GUANETHIDINE MONOSULFATE			
WATSON LAB	EQ 10MG SULFATE	N86113 001	MAR 26, 1985
	EQ 25MG SULFATE	N86114 001	MAR 26, 1985

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL			
ESIMIL			
NOVARTIS	10MG;25MG	N13553 001	

FDA data supplied by DrugPatentWatch.com

GUANFACINE HYDROCHLORIDE

TABLET; ORAL			
TENEX			
WYETH AYERST	EQ 3MG BASE	N19032 003	NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL			
HALOG			
WESTWOOD SQUIBB	0.025%	N17818 001	
OINTMENT; TOPICAL			
HALOG			
BRISTOL MYERS SQUIBB	0.025%	N18125 001	

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL			
HALFAN			
SMITHKLINE BEECHAM	250MG	N20250 001	JUL 24, 1992

HALOPERIDOL

TABLET; ORAL			
HALDOL SOLUTAB			
JOHNSON RW	1MG	N17079 001	
HALOPERIDOL			
DANBURY PHARMA	10MG	N72113 001	AUG 27, 1991
	20MG	N72353 001	AUG 27, 1991
DURAMED	0.5MG	N71216 001	DEC 04, 1986
	1MG	N71217 001	DEC 04, 1986
	2MG	N71218 001	DEC 04, 1986
	5MG	N71219 001	DEC 04, 1986
	10MG	N71220 001	JUL 07, 1987
	20MG	N71221 001	JUL 07, 1987

HALOPERIDOL

TABLET; ORAL			
HALOPERIDOL			
HALSEY	0.5MG	N71156 001	JAN 02, 1987
	1MG	N71157 001	JAN 02, 1987
	2MG	N71172 001	JAN 02, 1987
	5MG	N71212 001	JAN 07, 1988
	10MG	N71173 001	JAN 07, 1988
	20MG	N71177 001	JAN 07, 1988
LEDERLE	0.5MG	N72727 001	SEP 19, 1989
	1MG	N72728 001	SEP 19, 1989
	2MG	N72729 001	SEP 19, 1989
	5MG	N72730 001	SEP 19, 1989
	10MG	N72731 001	SEP 19, 1989
	20MG	N72732 001	SEP 19, 1989
PAR PHARM	20MG	N71328 001	JUL 20, 1987
PUREPAC PHARM	0.5MG	N71071 001	NOV 03, 1986
	1MG	N71072 001	NOV 03, 1986
	2MG	N71073 001	NOV 03, 1986
	5MG	N71074 001	NOV 03, 1986
	10MG	N71075 001	AUG 04, 1987
	20MG	N71076 001	AUG 04, 1987
QUANTUM PHARMICS	0.5MG	N71255 001	FEB 17, 1987
	1MG	N71269 001	FEB 17, 1987
	2MG	N71256 001	FEB 17, 1987

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

QUANTUM PHARMICS	5MG	N71257 001 FEB 17, 1987
ROYCE LABS	0.5MG	N71722 001 DEC 24, 1987
	1MG	N71723 001 DEC 24, 1987
	2MG	N71724 001 DEC 24, 1987
	5MG	N71725 001 DEC 24, 1987
	10MG	N72121 001 DEC 24, 1987
	20MG	N72122 001 DEC 24, 1987
SCS	0.5MG	N70720 001 JUN 10, 1986
	1MG	N70721 001 JUN 10, 1986
	2MG	N70722 001 JUN 10, 1986
	5MG	N70723 001 JUN 10, 1986
	10MG	N70724 001 JUN 10, 1986
	20MG	N70725 001 SEP 24, 1986
WATSON LAB	0.5MG	N71571 001 JUN 03, 1988
	1MG	N71572 001 JUN 03, 1988
	2MG	N71573 001 JUN 03, 1988
	5MG	N71374 001 JUN 03, 1988
	10MG	N71375 001 JUN 03, 1988
	20MG	N71376 001 JUN 03, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

MORTON GROVE	EQ 2MG BASE/ML	N70710 001 MAR 07, 1986

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

SCS	EQ 2MG BASE/ML	N70726 001 JUN 10, 1986

INJECTABLE; INJECTION
HALOPERIDOL

AM PHARM PARTNERS	EQ 5MG BASE/ML	N71187 001 JAN 20, 1987
MARSAM	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993
QUAD PHARMS	EQ 5MG BASE/ML	N71082 001 JAN 02, 1987
SMITH AND NEPHEW	EQ 5MG BASE/ML	N70802 001 DEC 14, 1987
SOLOPAK	EQ 5MG BASE/ML	N70800 001 DEC 14, 1987
	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
	EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
	EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HALOPROGIN

CREAM; TOPICAL
HALOTEX

WESTWOOD SQUIBB	1%	N16942 001

SOLUTION; TOPICAL
HALOTEX

WESTWOOD SQUIBB	1%	N16943 001

HEPARIN CALCIUM

INJECTABLE; INJECTION
CALCIPARINE

SANOFI SYNTHELABO	25,000 UNITS/ML	N18237 001

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER		
AM PHARM PARTNERS	10 UNITS/ML	N17029 017
		DEC 05, 1985
	100 UNITS/ML	N17029 018
		DEC 05, 1985
HEPARIN LOCK FLUSH		
ABBOTT	100 UNITS/ML	N05264 010
AM PHARM PARTNERS	100 UNITS/ML	N17651 010
INTL MEDICATION	10 UNITS/ML	N86357 001
	500 UNITS/ML	N86357 002
LUITPOLD	10 UNITS/ML	N89063 001
		OCT 09, 1985
	100 UNITS/ML	N89064 001
		OCT 09, 1985
PARKE DAVIS	10 UNITS/ML	N17346 006
SMITH AND NEPHEW	10 UNITS/ML	N87904 001
		APR 20, 1983
	10 UNITS/ML	N87958 001
		APR 20, 1983
	10 UNITS/ML	N88458 001
		JUL 26, 1984
	10 UNITS/ML	N88580 001
		OCT 25, 1984
	100 UNITS/ML	N87906 001
		APR 20, 1983
	100 UNITS/ML	N87959 001
		APR 20, 1983
	100 UNITS/ML	N88460 001
		JUL 26, 1984
	100 UNITS/ML	N88581 001
		OCT 25, 1984
SOLOPAK	10 UNITS/ML	N87903 001
		APR 20, 1983
	10 UNITS/ML	N88457 001
		OCT 25, 1984
	100 UNITS/ML	N87905 001
		APR 20, 1983
	100 UNITS/ML	N88459 001
		JUL 26, 1984
STERIS	100 UNITS/ML	N17064 001
HEPARIN LOCK FLUSH PRESERVATIVE FREE		
AM PHARM PARTNERS	10 UNITS/ML	N17029 011
		SEP 22, 1987
	100 UNITS/ML	N17029 012
		SEP 22, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER		
AM PHARM PARTNERS	10 UNITS/ML	N17029 008
		SEP 22, 1987
	100 UNITS/ML	N17029 009
		SEP 22, 1987
HEPARIN SODIUM		
AKORN	1,000 UNITS/ML	N17486 001
	5,000 UNITS/ML	N17486 002
	10,000 UNITS/ML	N17486 003
	20,000 UNITS/ML	N17486 004
	40,000 UNITS/ML	N17486 005
AM PHARM PARTNERS	1,000 UNITS/ML	N17033 001
	1,000 UNITS/ML	N17651 005
	5,000 UNITS/ML	N17029 002
	5,000 UNITS/ML	N17979 003
	10,000 UNITS/ML	N17651 003
	20,000 UNITS/ML	N17651 008
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N17130 001
	5,000 UNITS/ML	N17130 002
	10,000 UNITS/ML	N17130 003
	20,000 UNITS/ML	N17130 004
DELL LABS	1,000 UNITS/ML	N17540 001
	5,000 UNITS/ML	N17540 002
	10,000 UNITS/ML	N17540 003
	20,000 UNITS/ML	N17540 004
	40,000 UNITS/ML	N17540 005
LILLY	1,000 UNITS/ML	N05521 001
	20,000 UNITS/ML	N05521 004
LUITPOLD	1,000 UNITS/ML	N87452 001
		OCT 31, 1983
ORGANON	1,000 UNITS/ML	N00552 008
	5,000 UNITS/ML	N00552 009
	10,000 UNITS/ML	N00552 010
PARKE DAVIS	1,000 UNITS/ML	N17346 001
	5,000 UNITS/ML	N17346 002
	7,500 UNITS/ML	N17346 003
	10,000 UNITS/ML	N17346 004
	20,000 UNITS/ML	N17346 005
PHARM SPEC	1,000 UNITS/ML	N17780 001
	5,000 UNITS/ML	N17780 002
	10,000 UNITS/ML	N17780 003
	20,000 UNITS/ML	N17780 004
	40,000 UNITS/ML	N17780 005
SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001
		JUL 26, 1984
SOLOPAK	1,000 UNITS/ML	N87043 001

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM		
SOLOPAK	5,000 UNITS/ML	N87077 001
	10,000 UNITS/ML	N87107 001
	5,000 UNITS/0.5ML	N87395 001
	10,000 UNITS/0.5ML	N87363 001
STERIS	1,000 UNITS/ML	N17064 002
	2,500 UNITS/ML	N17064 015
	3,000 UNITS/ML	N17064 016
	4,000 UNITS/ML	N17064 017
	5,000 UNITS/ML	N17064 003
	6,000 UNITS/ML	N17064 018
	7,500 UNITS/ML	N17064 019
	10,000 UNITS/ML	N17064 004
	20,000 UNITS/ML	N17064 005
	40,000 UNITS/ML	N17064 006
WYETH AYERST	15,000 UNITS/ML	N17007 005
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
MCGAW	200 UNITS/100ML	N19130 001 DEC 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	200 UNITS/100ML	N19042 001 MAR 29, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%		
ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2,000 UNITS/100ML	N18814 002 JUL 09, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%		
ABBOTT	10,000 UNITS/100ML	N18911 001 JAN 30, 1985
	10,000 UNITS/100ML	N18916 005 JAN 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	10,000 UNITS/100ML	N18911 003 JAN 30, 1985
	10,000 UNITS/100ML	N18916 002 JAN 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%		
ABBOTT	5,000 UNITS/100ML	N18911 007 JAN 30, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	5,000 UNITS/100ML	N18911 005 JAN 30, 1985
	5,000 UNITS/100ML	N18916 003 JAN 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
MCGAW	200 UNITS/100ML	N19130 003 DEC 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%		
ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985
	10,000 UNITS/100ML	N18911 008 JAN 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19134 001 MAR 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	10,000 UNITS/100ML	N19802 002 JUL 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%		
ABBOTT	5,000 UNITS/100ML	N18911 004 JAN 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	5,000 UNITS/100ML	N18916 009 JAN 31, 1984
B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	5,000 UNITS/100ML	N19802 003 JUL 20, 1992
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	500 UNITS/100ML	N18609 003 APR 28, 1982

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 1,000 UNITS/100ML N19130 002 DEC 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT 100 UNITS/ML N18911 002 JAN 30, 1985
100 UNITS/ML N18916 004 JAN 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT 1,000 UNITS/100ML N18916 001 JAN 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 1,000 UNITS/100ML N19042 004 MAR 29, 1985
LIPO-HEPIN
3M 1,000 UNITS/ML N17027 006
1,000 UNITS/0.5ML N17027 001
5,000 UNITS/ML N17027 008
5,000 UNITS/0.5ML N17027 002
10,000 UNITS/ML N17027 009
7,500 UNITS/0.5ML N17027 010
10,000 UNITS/0.5ML N17027 003
20,000 UNITS/ML N17027 007
15,000 UNITS/0.5ML N17027 011
20,000 UNITS/0.5ML N17027 004
40,000 UNITS/ML N17027 005
LIQUAEMIN LOCK FLUSH
ORGANON 100 UNITS/ML N00552 007
LIQUAEMIN SODIUM
ORGANON 1,000 UNITS/ML N00552 004
5,000 UNITS/ML N00552 003
10,000 UNITS/ML N00552 005
20,000 UNITS/ML N00552 001
40,000 UNITS/ML N00552 002
LIQUAEMIN SODIUM PRESERVATIVE FREE
ORGANON 1,000 UNITS/ML N00552 011 APR 11, 1986
5,000 UNITS/ML N00552 012 APR 11, 1986
10,000 UNITS/ML N00552 013 APR 11, 1986
PANHEPRIN
ABBOTT 1,000 UNITS/ML N05264 004
5,000 UNITS/ML N05264 006

HEPARIN SODIUM

INJECTABLE; INJECTION
PANHEPRIN
ABBOTT 10,000 UNITS/ML N05264 007
20,000 UNITS/ML N05264 008
40,000 UNITS/ML N05264 009
SODIUM HEPARIN
AM PHARM PARTNERS 5,000 UNITS/ML N17033 002
10,000 UNITS/ML N17033 003
20,000 UNITS/ML N17033 004

HEPARIN SODIUM; *MULTIPLE*
SEE DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

HETACILLIN

FOR SUSPENSION; ORAL
VERSAPEN
BRISTOL EQ 225MG AMPICIL/5ML N61398 002
EQ 112.5MG AMPICIL/ML N61398 001

FOR SUSPENSION; ORAL
VERSAPEN
BRISTOL EQ 112.5MG AMPICIL/5ML N50060 001
EQ 112.5MG AMPICIL/ML N50060 003

HETACILLIN POTASSIUM

CAPSULE; ORAL
VERSAPEN-K
BRISTOL EQ 225MG AMPICIL N61396 001
EQ 450MG AMPICIL N61396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL
SEPTISOL
VESTAL LABS 0.23% N17424 001
TURGEX
XTTRIUM 3% N18375 001

EMULSION; TOPICAL
HEXA-GERM
HUNTINGTON LABS 3% N17411 001

FDA data supplied by DrugPatentWatch.com

HEXACHLOROPHENE

EMULSION; TOPICAL		
PHISOHEX		
SANOFI SYNTHELABO	3%	N08402 001
SOY-DOME		
BAYER	3%	N17405 001
TURGEX		
XTTRIUM	3%	N19055 001
		NOV 30, 1984
SOLUTION; TOPICAL		
DIAL		
DIAL	0.25%	N17421 002
GERMA-MEDICA		
HUNTINGTON LABS	1%	N17412 001
GERMA-MEDICA "MG"		
HUNTINGTON LABS	0.25%	N17412 002
SEPTI-SOFT		
CALGON	0.25%	N17460 001
SEPTISOL		
VESTAL LABS	0.25%	N17423 001
SPONGE; TOPICAL		
HEXASCRUB		
PROF DSPLS	3%	N18363 001
PHISO-SCRUB		
SANOFI SYNTHELABO	3%	N17446 001
SCRUBTEAM SURGICAL SPONGEBRUSH		
3M	330MG	N17413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION		
MYLAXEN		
WALLACE LABS	20MG/ML	N09789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL		
TRAL		
ABBOTT	25MG	N10599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL		
CYCLAINE		
MERCK	5%	N08472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION		
HISTAMINE PHOSPHATE		
LILLY	EQ 0.1MG BASE/ML	N00734 003
	EQ 0.2MG BASE/ML	N00734 002
	EQ 1MG BASE/ML	N00734 001

HOMATROPINE METHYLBROMIDE

TABLET, CHEWABLE; ORAL		
EQUIPIN		
MISSION PHARMA	3MG	N86310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL		
HYDROPANE		
HALSEY	1.5MG/5ML;5MG/5ML	N88066 001
		JUN 28, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
APRESOLINE		
NOVARTIS	20MG/ML	N08303 003
HYDRALAZINE HCL		
AM PHARM PARTNERS	20MG/ML	N89532 001
		AUG 11, 1987
SMITH AND NEPHEW	20MG/ML	N88518 001
		APR 20, 1984
SOLOPAK	20MG/ML	N88517 001
		AUG 22, 1985
TABLET; ORAL		
DRALZINE		
TEVA	25MG	N84301 001
HYDRALAZINE HCL		
AMIDE PHARM	25MG	N88560 001
		OCT 04, 1984

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

AMIDE PHARM	50MG	N88649 001 OCT 18, 1984
ASCOT	25MG	N88310 001 DEC 19, 1984
	50MG	N88311 001 DEC 19, 1984
CHELSEA LABS	25MG	N85532 002 MAY 24, 1982
	50MG	N85533 002 MAY 25, 1982
EON	50MG	N85088 001
HALSEY	10MG	N88728 001 APR 11, 1985
	10MG	N89218 001 JAN 22, 1986
	25MG	N84106 002
	25MG	N89130 001 JAN 15, 1986
	50MG	N84107 002
	50MG	N89222 001 JAN 22, 1986
	100MG	N88729 001 APR 11, 1985
	100MG	N89178 001 JAN 15, 1986
IMPAX LABS	25MG	N84922 001
PUREPAC PHARM	25MG	N88177 001 JUL 29, 1983
	50MG	N88178 001 AUG 15, 1983
QUANTUM PHARMICS	10MG	N88671 001 MAY 01, 1984
	25MG	N88657 001 JUN 15, 1984
	50MG	N88652 001 MAY 08, 1984
	100MG	N88686 001 MAY 01, 1984
ROSEMONT	25MG	N87780 001 MAR 29, 1982
	50MG	N87751 001 MAR 29, 1982
SUPERPHARM	10MG	N88787 001 AUG 28, 1984

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

SUPERPHARM	25MG	N88788 001 AUG 28, 1984
	50MG	N88789 001 AUG 28, 1984
VANGARD	25MG	N87712 001
	50MG	N87908 001 MAY 07, 1982
VITARINE	25MG	N86088 001
WEST WARD	25MG	N88240 001 MAY 27, 1983
	50MG	N88241 001 MAY 27, 1983
ZENITH GOLDLINE	10MG	N84443 001
	25MG	N84437 001
	50MG	N84469 002
	100MG	N84581 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
APRESAZIDE

NOVARTIS	100MG;50MG	N84811 001

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982
	50MG;50MG	N87213 001 FEB 08, 1982
	100MG;50MG	N87609 001 FEB 08, 1982
SUPERPHARM	25MG;25MG	N89200 001 FEB 09, 1987
WATSON LAB	25MG;25MG	N85457 001 MAR 04, 1982
	50MG;50MG	N85446 001 MAR 04, 1982
	100MG;50MG	N85440 001 MAR 04, 1982

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50

ZENITH GOLDLINE	100MG;50MG	N88358 001 APR 10, 1984

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25

ZENITH GOLDLINE	25MG;25MG	N88356 001 APR 10, 1984

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
- HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50
  - ZENITH GOLDLINE — 50MG;50MG — N88357 001 — APR 10, 1984

TABLET; ORAL
- APRESOLINE-ESIDRIX
  - NOVARTIS — 25MG;15MG — N12026 002
- HYDRALAZINE AND HYDROCHLORTHIAZIDE
  - CHELSEA LABS — 25MG;15MG — N85827 001
- HYDROCHLOROTHIAZIDE W/ HYDRALAZINE
  - WATSON LAB — 25MG;15MG — N85373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
- HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE
  - ZENITH GOLDLINE — 25MG;15MG;0.1MG — N84291 001
- HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE
  - MYLAN — 25MG;15MG;0.1MG — N87085 001
- HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE
  - CHELSEA LABS — 25MG;15MG;0.1MG — N85771 001
- HYDRAP-ES
  - EON — 25MG;15MG;0.1MG — N84876 001
- HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE
  - WATSON LAB — 25MG;15MG;0.1MG — N83770 001
- HYDROSERPINE PLUS (R-H-H)
  - ZENITH GOLDLINE — 25MG;15MG;0.1MG — N83877 001
- RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
  - DANBURY PHARMA — 25MG;15MG;0.1MG — N87556 001
  - HALSEY — 25MG;15MG;0.1MG — N88570 001 — APR 10, 1984
  - SOLVAY — 25MG;15MG;0.1MG — N88376 001 — OCT 28, 1983
- RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
  - LEDERLE — 25MG;15MG;0.1MG — N87709 001 — MAY 13, 1982
- SER-A-GEN
  - SOLVAY — 25MG;15MG;0.1MG — N87210 001
- UNIPRES
  - SOLVAY — 25MG;15MG;0.1MG — N85893 001
  - 25MG;15MG;0.1MG — N86298 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL
- DRALSERP
  - EON — 25MG;0.1MG — N84617 001
- SERPASIL-APRESOLINE
  - NOVARTIS — 25MG;0.1MG — N09296 004
  - 50MG;0.2MG — N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL
- HYDROCHLOROTHIAZIDE
  - MORTON GROVE — 50MG/5ML — N89661 001 — JUN 20, 1988
- HYDROCHLOROTHIAZIDE INTENSOL
  - ROXANE — 100MG/ML — N88588 001 — JUL 02, 1984

TABLET; ORAL
- HYDRO-D
  - HALSEY — 25MG — N86504 001
  - 50MG — N83891 002
- HYDROCHLOROTHIAZIDE
  - ALRA — 25MG — N86369 001
  - 50MG — N83554 001
  - ASCOT — 25MG — N87539 001 — FEB 03, 1982
  - 50MG — N87540 001 — FEB 03, 1982
  - BARR — 50MG — N84771 001
  - CHELSEA LABS — 25MG — N85232 002
  - 50MG — N85233 001
  - 50MG — N86087 001
  - 50MG — N86594 001
  - 100MG — N87002 001
  - ELKINS SINN — 50MG — N85152 002
  - EON — 25MG — N83899 001
  - HALSEY — 100MG — N83972 003
  - HEATHER — 50MG — N84135 001
  - IMPAX LABS — 100MG — N85098 001
  - INWOOD LABS — 25MG — N84776 001
  - 25MG — N85067 001
  - 50MG — N84776 002
  - MAST MM — 25MG — N86192 001
  - 50MG — N86192 002
  - MYLAN — 25MG — N84880 001
  - 50MG — N85112 001

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE		
ROSEMONT	25MG	N87827 001
		APR 19, 1982
	50MG	N87752 001
		APR 19, 1982
ROXANE	25MG	N85004 001
	50MG	N85005 001
SOLVAY	25MG	N85323 001
SUPERPHARM	25MG	N88827 001
		DEC 28, 1984
	50MG	N88828 001
		DEC 28, 1984
	100MG	N88829 001
		DEC 28, 1984
TEVA	25MG	N88924 001
		FEB 07, 1985
	50MG	N88923 001
		FEB 07, 1985
VANGARD	25MG	N87638 001
	50MG	N87610 001
WARNER CHILCOTT	25MG	N87586 001
		MAY 03, 1982
	50MG	N87587 001
		MAY 03, 1982
WATSON LAB	25MG	N83458 001
	50MG	N83456 001
	100MG	N85099 001
WEST WARD	25MG	N84899 001
WHITEWORTH TOWN PLSN	25MG	N83809 002
	50MG	N83809 001
	100MG	N85347 001
ZENITH GOLDLINE	50MG	N84658 001
ZIDE		
SOLVAY	50MG	N83925 001

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE

SEE GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE		
SANOFI SYNTHELABO	12.5MG;75MG	N20758 001
		SEP 30, 1997

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE		
SCHERING	25MG;100MG	N19046 001
		APR 06, 1987
	25MG;200MG	N19046 002
		APR 06, 1987
	25MG;300MG	N19046 003
		APR 06, 1987
	25MG;400MG	N19046 004
		APR 06, 1987
TRANDATE HCT		
GLAXO WELLCOME	25MG;100MG	N19174 001
		APR 10, 1987
	25MG;200MG	N19174 002
		APR 10, 1987
	25MG;300MG	N19174 003
		APR 10, 1987
	25MG;400MG	N19174 004
		APR 10, 1987

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE		
INVAMED	15MG;250MG	N70829 001
		MAR 09, 1987
	25MG;250MG	N70830 001
		MAR 09, 1987
NOVOPHARM	15MG;250MG	N71819 001
		APR 08, 1988
	25MG;250MG	N71820 001
		APR 08, 1988
	30MG;500MG	N71821 001
		APR 08, 1988
	50MG;500MG	N71822 001
		APR 08, 1988
PARKE DAVIS	15MG;250MG	N71897 001
		NOV 23, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE		
PARKE DAVIS	25MG;250MG	N71898 001 NOV 23, 1987
	30MG;500MG	N71899 001 NOV 23, 1987
	50MG;500MG	N71900 001 NOV 23, 1987
PUREPAC PHARM	15MG;250MG	N70853 001 OCT 08, 1986
	25MG;250MG	N70688 001 APR 24, 1986
	30MG;500MG	N70854 001 OCT 08, 1986
	50MG;500MG	N70689 001 APR 24, 1986
WATSON LAB	15MG;250MG	N70365 001 MAR 19, 1986
	25MG;250MG	N70366 001 APR 16, 1986
	30MG;500MG	N70367 001 MAR 19, 1986
	50MG;500MG	N70368 001 APR 16, 1986
WATSON LABS	15MG;250MG	N71920 001 AUG 29, 1988
	25MG;250MG	N71921 001 AUG 29, 1988
	30MG;500MG	N71922 001 AUG 29, 1988
	50MG;500MG	N71923 001 AUG 29, 1988
ZENITH GOLDLINE	15MG;250MG	N71458 001 MAR 08, 1988
	25MG;250MG	N71459 001 MAR 08, 1988
	30MG;500MG	N71460 001 MAR 08, 1988
	50MG;500MG	N71461 001 MAR 08, 1988

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE		
NOVARTIS	25MG;5MG	N18872 001 JUL 22, 1987

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE		
NOVARTIS	25MG;10MG	N18872 002 JUL 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE		
DURAMED	25MG;40MG	N71126 001 MAR 02, 1987
	25MG;80MG	N71127 001 MAR 02, 1987
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE		
DANBURY PHARMA	25MG;40MG	N71498 001 DEC 18, 1991
	25MG;80MG	N71501 001 DEC 18, 1991
WARNER CHILCOTT	25MG;40MG	N71771 001 JAN 26, 1988
	25MG;80MG	N71772 001 JAN 26, 1988
ZENITH GOLDLINE	25MG;40MG	N71552 001 DEC 01, 1988
	25MG;80MG	N71553 001 DEC 01, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50		
WHITEWORTH TOWN PLSN	50MG;0.125MG	N85338 001
HYDRO-SERP "25"		
EON	25MG;0.125MG	N84827 001
HYDRO-SERP "50"		
EON	50MG;0.125MG	N85213 001
HYDROCHLOROTHIAZIDE W/ RESERPINE		
CHELSEA LABS	25MG;0.125MG	N86330 002
	50MG;0.125MG	N86331 001
PHARMERAL	25MG;0.125MG	N85421 001
	50MG;0.125MG	N85420 001
ROXANE	50MG;0.125MG	N84603 001
WATSON LAB	25MG;0.125MG	N85317 001
	50MG;0.125MG	N83666 001
ZENITH GOLDLINE	25MG;0.1MG	N83572 001

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
- HYDROCHLOROTHIAZIDE W/ RESERPINE
  - ZENITH GOLDLINE 25MG;0.125MG N83571 001
  - 50MG;0.1MG N83568 001
  - 50MG;0.125MG N83573 001
- RESERPINE AND HYDROCHLOROTHIAZIDE
  - BARR 25MG;0.125MG N84580 001
  - 50MG;0.125MG N84579 001
  - GENEVA PHARMS 50MG;0.125MG N88200 001 JAN 31, 1984
- SERPASIL-ESIDRIX #1
  - NOVARTIS 25MG;0.1MG N11878 003
- SERPASIL-ESIDRIX #2
  - NOVARTIS 50MG;0.1MG N11878 005

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
- SPIRONOLACTONE + HYDROCHLOROTHIAZIDE
  - ASCOT 25MG;25MG N88025 001 NOV 23, 1984
- SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
  - PUREPAC PHARM 25MG;25MG N87999 001 NOV 06, 1985
  - SUPERPHARM 25MG;25MG N89137 001 AUG 26, 1985
- SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
  - CHELSEA LABS 25MG;25MG N86026 001
  - LEDERLE 25MG;25MG N87511 001
  - PUREPAC PHARM 25MG;25MG N88054 001 AUG 18, 1983
  - ROSEMONT 25MG;25MG N87651 001
  - UPSHER SMITH 25MG;25MG N87553 001
  - VANGARD 25MG;25MG N87655 001
  - WATSON LAB 25MG;25MG N85974 001
  - ZENITH GOLDLINE 25MG;25MG N87004 002 MAY 24, 1982

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
- DYAZIDE
  - SMITHKLINE BEECHAM 25MG;50MG N16042 002
- TRIAMTERENE AND HYDROCHLOROTHIAZIDE
  - NOVARTIS 25MG;37.5MG N74857 001 SEP 09, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
- TRIAMTERENE AND HYDROCHLOROTHIAZIDE
  - VITARINE 25MG;50MG N71737 001 FEB 12, 1988

TABLET; ORAL
- TRIAMTERENE AND HYDROCHLOROTHIAZIDE
  - AM THERAP 50MG;75MG N72022 001 APR 17, 1988
  - QUANTUM PHARMICS 50MG;75MG N71980 001 APR 17, 1988

HYDROCODONE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE
SEE ASPIRIN; HYDROCODONE BITARTRATE
SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL
- MAGNACORT
  - PFIZER 0.5% N10554 001

HYDROCORTISONE

AEROSOL; TOPICAL
- AEROSEB-HC
  - ALLERGAN HERBERT 0.5% N85805 001

CREAM; TOPICAL
- CORT-DOME
  - BAYER 0.5% N09585 003
  - 1% N09585 001
- ELDECORT
  - ICN 1% N80459 001
  - 2.5% N84055 001
- FLEXICORT
  - WESTWOOD SQUIBB 0.5% N87136 003 APR 08, 1982
  - 1% N87136 002 APR 08, 1982
  - 2.5% N87136 001 APR 08, 1982
- H-CORT
  - PHARM ASSOC 0.5% N86823 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

CREAM; TOPICAL

HC #1		
BAYER	0.5%	N80438 001
HC #4		
BAYER	1%	N80438 002
HYDROCORTISONE		
ALPHARMA	2.5%	N89754 001
		FEB 01, 1989
AMBIX	1%	N86080 001
	2.5%	N86271 001
CLAY PARK	0.5%	N84970 002
	1%	N85026 001
EVERYLIFE	0.5%	N80452 001
G AND W LABS	1%	N84059 001
NASKA	1%	N89706 001
		MAR 10, 1988
PHARMADERM	1%	N88845 001
		FEB 27, 1986
PHARMAFAIR	1%	N87838 001
		JUL 28, 1982
ROSEMONT	1%	N88027 001
		SEP 27, 1983
	2.5%	N88029 001
		SEP 27, 1983
STIEFEL	1%	N86170 001
TEVA	0.5%	N80400 002
	1%	N80400 003
	1%	N85191 001
	2.5%	N80400 004
THAMES	0.5%	N86154 001
WHITEWORTH TOWN PLSN	1%	N80496 002
ZENITH GOLDLINE	1%	N85733 001
NOGENIC HC		
ZENITH GOLDLINE	1%	N87427 001
		APR 04, 1988
NUTRACORT		
HEALTHPOINT	0.5%	N80442 002
SYNACORT		
MEDICIS	0.5%	N87459 001

GEL; TOPICAL

NUTRACORT		
HEALTHPOINT	1%	N84698 001
PENECORT		
ALLERGAN HERBERT	1%	N88215 001
		JUN 06, 1984

HYDROCORTISONE

INJECTABLE; INJECTION

CORTEF		
PHARMACIA AND UPJOHN	50MG/ML	N09864 001

LOTION; TOPICAL

BALNEOL-HC		
SOLVAY	1%	N88041 001
		DEC 03, 1982
CORT-DOME		
BAYER	0.5%	N09895 003
	1%	N09895 001
DERMACORT		
SOLVAY	0.5%	N84573 002
	1%	N86462 001
H-CORT		
PHARM ASSOC	0.5%	N86824 001
HYDROCORTISONE		
ALPHARMA	0.5%	N87317 001
		JUN 07, 1982
	1%	N87315 001
		JUN 07, 1982
CLAY PARK	0.5%	N85662 001
	1%	N85663 001
NASKA	1%	N89705 001
		APR 25, 1988
THAMES	1%	N89024 001
		FEB 12, 1986
NUTRACORT		
HEALTHPOINT	0.5%	N80443 002

OINTMENT; TOPICAL

HC (HYDROCORTISONE)		
C AND M PHARMA	0.5%	N80481 001
HYDROCORTISONE		
ALTANA	0.5%	N80489 002
AMBIX	1%	N86079 001
	2.5%	N86272 001
CLAY PARK	0.5%	N84969 003
	1%	N85028 001
NASKA	1%	N89704 001
		MAR 10, 1988
PHARMADERM	1%	N88842 001
		FEB 09, 1987
ROSEMONT	1%	N88061 001
		SEP 27, 1983
	2.5%	N88039 001
		SEP 27, 1983

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

OINTMENT; TOPICAL

HYDROCORTISONE		
THAMES	0.5%	N86256 001
HYTONE		
DERMIK LABS	1%	N80474 003
	2.5%	N80474 004
PENECORT		
ALLERGAN HERBERT	2.5%	N88217 001
		JUN 06, 1984

TABLET; ORAL

CORTRIL		
PFIZER	10MG	N09127 005
	20MG	N09127 003
HYDROCORTISONE		
ANABOLIC	20MG	N83140 001
BARR	20MG	N83999 001
DANBURY PHARMA	20MG	N80355 001
ELKINS SINN	20MG	N80624 001
EON	20MG	N80642 002
FERRANTE	10MG	N80568 001
	20MG	N80568 002
INWOOD LABS	20MG	N80732 001
PANRAY	10MG	N09659 001
	20MG	N09659 002
PARKE DAVIS	20MG	N84243 001
PUREPAC PHARM	10MG	N84247 003
		AUG 31, 1982
	20MG	N80395 001
	20MG	N84247 002
ROXANE	10MG	N88539 001
		MAR 21, 1984
WHITEWORTH TOWN PLSN	10MG	N80344 001
	20MG	N80344 002

TABLET; VAGINAL

CORTRIL		
PFIPHARMECS	10MG	N09796 001

HYDROCORTISONE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE

SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE		
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62394 001
		SEP 29, 1982
OTOCORT		
STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE		
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001
		SEP 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE		
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001
		SEP 18, 1985
OTICAIR		
PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62399 001
		NOV 18, 1982
OTOBIONE		
SCHERING	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N61816 001
OTOCORT		
STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001
		JUL 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

PYOCIDIN		
FORREST LABS	5MG/ML; EQ 10,000 UNITS BASE/ML	N61606 001

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM		
BIOGLAN	1%;10%	N86008 001
CALMURID HC		
PHARMACIA AND UPJOHN	1%;10%	N83947 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HEMSOL-HC
ABLE 1% N81274 001
JUN 19, 1992

HYDROCORTISONE ACETATE
CENCI 1% N80419 001
JAN 25, 1982
PARKE DAVIS 1% N89914 001
JAN 03, 1989
PUREPAC PHARM 0.5% N86050 001
1% N86052 001

INJECTABLE; INJECTION
CORTEF ACETATE
PHARMACIA AND UPJOHN 50MG/ML N09378 002
CORTRIL
PFIZER 25MG/ML N09164 001
HYDROCORTISONE ACETATE
AKORN 25MG/ML N09637 001
50MG/ML N09637 002
BEL MAR 25MG/ML N83739 001
50MG/ML N83739 002
STERIS 25MG/ML N83759 001
50MG/ML N83759 002
50MG/ML N85214 001

OINTMENT; OPHTHALMIC, OTIC
HYDROCORTONE
MERCK 1.5% N09018 003

OINTMENT; TOPICAL
CORTEF ACETATE
PHARMACIA AND UPJOHN 1% N08917 002
* 2.5% N08917 001

HYDROCORTISONE ACETATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-CORTEF
PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM N61049 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-CORTEF
PHARMACIA AND UPJOHN 2.5%;EQ 3.5MG BASE/GM N61049 002

OINTMENT; OPHTHALMIC
NEO-CORTEF
PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM N60610 001
1.5%;EQ 3.5MG BASE/GM N60610 002

OINTMENT; TOPICAL
NEO-CORTEF
PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM N60751 001
2.5%;EQ 3.5MG BASE/GM N60751 003

SUSPENSION/DROPS; OPHTHALMIC
NEO-CORTEF
PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/ML N60612 002
1.5%;EQ 3.5MG BASE/ML N60612 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL
PRAMOSONE
FERNDALE LABS 0.5%;1% N83213 002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
YAMANOUCHI 0.1% N18795 001
JAN 07, 1983

OINTMENT; TOPICAL
LOCOID
YAMANOUCHI 0.1% N19106 001
JUL 03, 1984

SOLUTION; TOPICAL
LOCOID
YAMANOUCHI 0.1% N19819 001
SEP 15, 1988

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM PHOSPHATE

QUAD PHARMS	EQ 50MG BASE/ML	N89581 001 MAY 28, 1987

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT		
ABBOTT	EQ 1GM BASE/VIAL	N89580 001 APR 11, 1989
	EQ 100MG BASE/VIAL	N85928 001
	EQ 100MG BASE/VIAL	N89577 001 APR 11, 1989
	EQ 250MG BASE/VIAL	N89578 001 APR 11, 1989
	EQ 500MG BASE/VIAL	N89579 001 APR 11, 1989
HYDROCORTISONE SODIUM SUCCINATE		
AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N88670 001 JUN 08, 1984
	EQ 100MG BASE/VIAL	N88667 001 JUN 08, 1984
	EQ 100MG BASE/VIAL	N88712 001 JUN 08, 1984
	EQ 250MG BASE/VIAL	N88668 001 JUN 08, 1984
	EQ 500MG BASE/VIAL	N88669 001 JUN 08, 1984
ELKINS SINN	EQ 1GM BASE/VIAL	N87569 001
	EQ 100MG BASE/VIAL	N86619 001
	EQ 250MG BASE/VIAL	N87567 001
	EQ 500MG BASE/VIAL	N87568 001
STERIS	EQ 1GM BASE/VIAL	N84748 001
	EQ 100MG BASE/VIAL	N84737 002
	EQ 100MG BASE/VIAL	N84738 001
	EQ 250MG BASE/VIAL	N84737 001
	EQ 500MG BASE/VIAL	N84747 001

HYDROFLUMETHIAZIDE

TABLET; ORAL
HYDROFLUMETHIAZIDE

CHELSEA LABS	50MG	N88528 001 AUG 15, 1984

HYDROFLUMETHIAZIDE

TABLET; ORAL
HYDROFLUMETHIAZIDE

WATSON LAB	50MG	N88031 001 APR 06, 1983

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE		
ROSEMONT	50MG;0.125MG	N88195 001 OCT 26, 1983
WATSON LAB	25MG;0.125MG	N88127 001 MAR 22, 1983
	50MG;0.125MG	N88110 001 MAR 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE		
ZENITH GOLDLINE	50MG;0.125MG	N88932 001 JAN 11, 1985

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL		
MERCK	1MG/ML	N80778 001
HYDROXOCOBALAMIN		
AM PHARM PARTNERS	1MG/ML	N84921 001
STERIS	1MG/ML	N85528 001
HYDROXOMIN		
BEL MAR	1MG/ML	N84629 001

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN		
BRISTOL MYERS SQUIBB	125MG/ML	N10347 004
	125MG/ML	N16911 001
	250MG/ML	N10347 002
	250MG/ML	N16911 002
HYDROXYPROGESTERONE CAPROATE		
AKORN	125MG/ML	N18004 001
QUAD PHARMS	125MG/ML	N89330 001 JAN 02, 1987
	250MG/ML	N89331 001 JAN 02, 1987

FDA data supplied by DrugPatentWatch.com

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION		
HYDROXYPROGESTERONE CAPROATE		
STERIS	125MG/ML	N17439 001

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION		
HYDROXYSTILBAMIDINE ISETHIONATE		
AVENTIS PHARMS	225MG/AMP	N09166 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
HYDROXYZINE HCL		
ALTANA	25MG/ML	N87273 001
		APR 20, 1982
	50MG/ML	N87273 002
		APR 20, 1982
PHARMAFAIR	25MG/ML	N88862 001
		FEB 14, 1986
	25MG/ML	N89106 001
		FEB 14, 1986
	50MG/ML	N88881 001
		FEB 14, 1986
	50MG/ML	N89107 001
		FEB 14, 1986
SMITH AND NEPHEW	25MG/ML	N87592 001
SOLOPAK	25MG/ML	N86822 001
	25MG/ML	N87591 001
	50MG/ML	N87310 001
	50MG/ML	N87593 001
	50MG/ML	N87595 001
	50MG/ML	N87596 001
STERIS	25MG/ML	N87274 001
	50MG/ML	N87274 002
WYETH AYERST	25MG/ML	N86258 001
	50MG/ML	N86258 002
ORGATRAX		
ORGANON	25MG/ML	N87014 001
	50MG/ML	N87014 002
SYRUP; ORAL		
HYDROXYZINE HCL		
ALPHARMA	10MG/5ML	N88785 001
		FEB 03, 1988

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL		
HYDROXYZINE HCL		
KV PHARM	10MG/5ML	N87730 001
		JUL 01, 1982
TABLET; ORAL		
HYDROXYZINE HCL		
AMIDE PHARM	10MG	N89071 001
		JUL 22, 1986
	25MG	N89072 001
		JUL 22, 1986
	50MG	N89073 001
		JUL 22, 1986
CHELSEA LABS	10MG	N86827 001
	25MG	N86829 001
	50MG	N86836 001
EON	10MG	N87246 002
	25MG	N85247 001
	50MG	N87245 001
HALSEY	10MG	N88409 001
		NOV 15, 1983
	10MG	N89366 001
		MAY 02, 1988
	25MG	N87857 001
		APR 18, 1983
	25MG	N89117 001
		MAY 02, 1988
	50MG	N87860 001
		APR 18, 1983
	50MG	N89396 001
		MAY 02, 1988
	100MG	N87862 001
		APR 18, 1983
KV PHARM	10MG	N87819 001
		JUN 23, 1982
	25MG	N87820 001
		JUN 23, 1982
	50MG	N87821 001
		JUN 23, 1982
	100MG	N87822 001
		JUN 23, 1982
PUREPAC PHARM	10MG	N88120 001
		SEP 25, 1984
	25MG	N88121 001
		SEP 25, 1984
	50MG	N88122 001
		SEP 25, 1984

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

QUANTUM PHARMICS	10MG	N88540 001 OCT 22, 1985
	25MG	N88551 001 OCT 22, 1985
	50MG	N88529 001 OCT 22, 1985
ROSEMONT	10MG	N89121 001 MAR 20, 1986
	25MG	N89122 001 MAR 20, 1986
	50MG	N89123 001 MAR 20, 1986
SUPERPHARM	10MG	N88794 001 DEC 05, 1984
	25MG	N88795 001 DEC 05, 1984
	50MG	N88796 001 DEC 05, 1984
ZENITH GOLDLINE	10MG	N87216 001
	25MG	N87410 001
	50MG	N87411 001

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HY-PAM "25"

TEVA	EQ 25MG HCL	N88713 001 MAR 04, 1985

HYDROXYZINE PAMOATE

CHELSEA LABS	EQ 25MG HCL	N86840 001 JUL 01, 1982
	EQ 50MG HCL	N86705 001 JUL 01, 1982
	EQ 100MG HCL	N86728 001 OCT 05, 1982
DANBURY PHARMA	EQ 50MG HCL	N87767 001 AUG 16, 1982
	EQ 100MG HCL	N87790 001 AUG 16, 1982
DURAMED	EQ 25MG HCL	N88593 001 FEB 29, 1984
	EQ 50MG HCL	N88594 001 FEB 29, 1984

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

DURAMED	EQ 100MG HCL	N88595 001 FEB 29, 1984
PAR PHARM	EQ 25MG HCL	N87656 001 JUN 11, 1982
	EQ 25MG HCL	N89145 001 MAR 17, 1986
	EQ 50MG HCL	N87657 001 JUN 11, 1982
	EQ 50MG HCL	N89146 001 MAR 17, 1986
	EQ 100MG HCL	N87658 001 JUN 11, 1982
SUPERPHARM	EQ 25MG HCL	N89031 001 JAN 02, 1987
	EQ 50MG HCL	N89032 001 JAN 02, 1987
	EQ 100MG HCL	N89033 001 JAN 02, 1987
VANGARD	EQ 25MG HCL	N88392 001 SEP 19, 1983
WATSON LAB	EQ 25MG HCL	N86698 001
	EQ 50MG HCL	N86695 001
	EQ 100MG HCL	N86697 001

IBUPROFEN

CAPSULE; ORAL
MIDOL

* BAYER	200MG	N70626 001 SEP 02, 1987
*	200MG	N71002 001 SEP 02, 1987

SUSPENSION; ORAL
IBU

KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989

TABLET; ORAL
IBU-TAB

ALRA	800MG	N71965 001 AUG 11, 1988

IBUPRIN

SIDMAK LABS NJ	200MG	N71773 001 JUL 16, 1987

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
BARR	200MG	N70493 001 DEC 24, 1985
	200MG	N70908 001 SEP 26, 1986
	200MG	N71462 001 OCT 02, 1986
	400MG	N70079 001 JUL 24, 1985
	600MG	N70080 001 JUL 24, 1985
	800MG	N71448 001 FEB 18, 1987
CHELSEA LABS	200MG	N71765 001 SEP 04, 1987
	300MG	N71338 001 DEC 01, 1986
	400MG	N70038 001 SEP 06, 1985
	600MG	N70041 001 SEP 06, 1985
	800MG	N71911 001 OCT 13, 1987
DANBURY PHARMA	200MG	N71905 001 MAR 08, 1988
HALSEY	200MG	N71027 001 SEP 29, 1987
	300MG	N71028 001 MAR 23, 1987
	400MG	N71029 001 MAR 23, 1987
	600MG	N71030 001 MAR 23, 1987
	800MG	N72137 001 FEB 05, 1988
INVAMED	400MG	N72064 001 JAN 14, 1988
	600MG	N72065 001 JAN 14, 1988
	800MG	N71938 001 JAN 14, 1988
KNOLL PHARM	600MG	N70556 001 JUN 14, 1985
	800MG	N71264 001 JUL 25, 1986

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
MCNEIL	400MG	N70081 001 JUN 16, 1986
	600MG	N70476 001 JUN 16, 1986
PAR PHARM	300MG	N70328 001 AUG 06, 1985
PUREPAC PHARM	200MG	N71122 001 OCT 03, 1986
	200MG	N71664 001 FEB 03, 1987
	300MG	N71123 001 SEP 19, 1986
	400MG	N71124 001 SEP 19, 1986
	600MG	N71125 001 SEP 19, 1986
	800MG	N71964 001 FEB 01, 1988
SUPERPHARM	600MG	N70709 001 APR 25, 1986
TEVA	200MG	N73141 001 MAY 29, 1992
	400MG	N73343 001 JUN 30, 1992
	600MG	N73344 001 JUN 30, 1992
	800MG	N73345 001 JUN 30, 1992
ZENITH GOLDLINE	200MG	N71154 001 OCT 27, 1987
	200MG	N72040 001 APR 29, 1988
MIDOL		
BAYER	200MG	N70591 001 SEP 02, 1987
	200MG	N71001 001 SEP 02, 1987
NUPRIN		
BRISTOL MYERS	200MG	N72035 001 FEB 16, 1988
	200MG	N72036 001 FEB 16, 1988
RUFEN		
BASF	600MG	N18197 002 MAR 05, 1984

FDA data supplied by DrugPatentWatch.com

IDOXURIDINE

OINTMENT; OPHTHALMIC			
STOXIL			
SMITHKLINE BEECHAM	0.5%	N15868 001	
SOLUTION/DROPS; OPHTHALMIC			
STOXIL			
SMITHKLINE BEECHAM	0.1%	N13934 001	

IFOSFAMIDE

INJECTABLE; INJECTION			
IFEX			
BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001	DEC 30, 1988
	3GM/VIAL	N19763 002	DEC 30, 1988

IMIPRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION			
TOFRANIL			
NOVARTIS	12.5MG/ML	N11838 002	
TABLET; ORAL			
IMIPRAMINE HCL			
CHELSEA LABS	10MG	N85875 001	
	25MG	N85878 001	
	50MG	N85877 001	
EON	10MG	N85200 001	
	25MG	N84869 002	
	50MG	N85133 001	
LEDERLE	10MG	N86269 001	
	25MG	N86267 001	
	50MG	N86268 001	
ROSEMONT	25MG	N87776 001	FEB 10, 1982
VANGARD	10MG	N88036 001	NOV 03, 1982
	25MG	N87619 001	FEB 09, 1982
	50MG	N87631 001	JAN 04, 1982
WATSON LAB	10MG	N85220 001	
	25MG	N84252 002	
	50MG	N85221 001	

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL			
IMIPRAMINE HCL			
WEST WARD	25MG	N88222 001	MAY 26, 1983
	50MG	N88223 001	MAY 26, 1983
JANIMINE			
ABBOTT	10MG	N17895 001	
	25MG	N17895 002	
	50MG	N17895 003	
PRAMINE			
ALRA	10MG	N83827 001	
	25MG	N83827 002	
	50MG	N83827 003	
PRESAMINE			
AVENTIS	10MG	N11836 006	
	25MG	N11836 003	
	50MG	N11836 007	

INDAPAMIDE

TABLET; ORAL			
INDAPAMIDE			
NOVOPHARM	1.25MG	N74665 001	APR 04, 1997
	2.5MG	N74665 002	APR 04, 1997

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
DECABID			
LILLY	EQ 50MG BASE	N19693 001	DEC 29, 1989
	EQ 75MG BASE	N19693 002	DEC 29, 1989
	EQ 100MG BASE	N19693 003	DEC 29, 1989

INDOCYANINE GREEN

INJECTABLE; INJECTION			
CARDIO-GREEN			
AKORN	10MG/VIAL	N11525 003	

FDA data supplied by DrugPatentWatch.com

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN
AKORN 40MG/VIAL N11525 004

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
CHELSEA LABS 25MG N18690 001 JUL 31, 1984
50MG N18690 002 JUL 31, 1984
50MG N71635 001 MAY 18, 1987
DANBURY PHARMA 25MG N72996 001 JUL 31, 1991
50MG N72997 001 JUL 31, 1991
DURAMED 25MG N70326 001 OCT 18, 1985
50MG N70327 001 OCT 18, 1985
HALSEY 25MG N70067 001 OCT 03, 1986
25MG N70782 001 JUN 03, 1987
50MG N70068 001 OCT 03, 1986
50MG N70635 001 JUN 03, 1987
PARKE DAVIS 25MG N18806 001 NOV 23, 1984
50MG N18806 002 NOV 23, 1984
PIONEER PHARMS 25MG N70813 001 AUG 11, 1986
50MG N70592 001 AUG 11, 1986
ROXANE 25MG N70353 001 JUN 18, 1985
50MG N70354 001 JUN 18, 1985
SUPERPHARM 25MG N70487 001 OCT 10, 1986
50MG N70488 001 OCT 10, 1986

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
WATSON LAB 25MG N70784 001 AUG 20, 1986
50MG N70785 001 AUG 20, 1986
WATSON LABS 25MG N70529 001 OCT 18, 1985
50MG N70530 001 OCT 18, 1985
ZENITH GOLDLINE 25MG N18730 001 MAY 04, 1984
50MG N18730 002 MAY 04, 1984

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR
MERCK 75MG N18185 001 FEB 23, 1982

INSULIN PORK

INJECTABLE; INJECTION
INSULIN
NOVO NORDISK 40 UNITS/ML N17926 001
REGULAR INSULIN
NOVO NORDISK 100 UNITS/ML N17926 003

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION
REGULAR ILETIN II
LILLY 100 UNITS/ML N18478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
VELOSULIN
NOVO NORDISK 100 UNITS/ML N18193 001

FDA data supplied by DrugPatentWatch.com

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN NORDISK MIXTARD (PORK)
NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N18195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN BR
LILLY 100 UNITS/ML N19529 001
APR 28, 1986

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN R
NOVO NORDISK 100 UNITS/ML N18778 001
AUG 30, 1983

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
MIXTARD HUMAN 70/30
NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19585 001
MAR 11, 1988
NOVOLIN 70/30
NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19441 001
JUL 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
NOVO NORDISK 40 UNITS/ML N17929 001

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH ILETIN I (BEEF-PORK)
LILLY 40 UNITS/ML N17936 001

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION
NPH ILETIN II
LILLY 100 UNITS/ML N18479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN INSULATARD NPH NORDISK
NOVO NORDISK 100 UNITS/ML N18194 001

INSULIN SUSP ISOPHANE PURIFIED PORK; *MULTIPLE*
SEE INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
INSULATARD NPH HUMAN
NOVO NORDISK 100 UNITS/ML N19449 001
MAY 30, 1986
NOVOLIN N
NOVO NORDISK 100 UNITS/ML N19065 001
JAN 23, 1985

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN; *MULTIPLE*
SEE INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION
PROTAMINE, ZINC & ILETIN I (BEEF-PORK)
LILLY 40 UNITS/ML N17932 001
100 UNITS/ML N17932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II
LILLY 100 UNITS/ML N18476 001
PROTAMINE ZINC INSULIN
BRISTOL MYERS SQUIBB 40 UNITS/ML N17928 001

FDA data supplied by DrugPatentWatch.com

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC INSULIN
BRISTOL MYERS SQUIBB 100 UNITS/ML N17928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II (PORK)
LILLY 100 UNITS/ML N18346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN
NOVO NORDISK 40 UNITS/ML N17998 001
100 UNITS/ML N17998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION
ULTRALENTE INSULIN
NOVO NORDISK 100 UNITS/ML N17997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION
ULTRALENTE
NOVO NORDISK 100 UNITS/ML N18385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN U
LILLY 40 UNITS/ML N19571 001
JUN 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION
SEMILENTE INSULIN
NOVO NORDISK 100 UNITS/ML N17996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION
SEMILENTE
NOVO NORDISK 100 UNITS/ML N18382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION
LENTE ILETIN II
LILLY 100 UNITS/ML N18477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION
LENTARD
NOVO NORDISK 100 UNITS/ML N18384 001

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN L
NOVO NORDISK 100 UNITS/ML N18777 001
AUG 30, 1983

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

INVERT SUGAR

INJECTABLE; INJECTION
TRAVERT 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10GM/100ML N16717 001

IOCETAMIC ACID

TABLET; ORAL
CHOLEBRINE
MALLINCKRODT 750MG N17129 001

FDA data supplied by DrugPatentWatch.com

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION
RENOVUE-65
BRACCO 65% N17902 001
RENOVUE-DIP
BRACCO 24% N17903 001

IODIPAMIDE SODIUM

INJECTABLE; INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N09321 001

IODOHIPPURATE SODIUM, I-123

INJECTABLE; INJECTION
NEPHROFLOW
NYCOMED AMERSHAM 1mCi/ML N18289 001
DEC 28, 1984

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPUTOPE
BRACCO 1-2mCi/VIAL N15419 002
IODOHIPPURATE SODIUM I 131
CIS 0.2mCi/ML N17313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION
CHOLOVUE
BRACCO 9.9% N18077 001
40.3% N18076 001

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-200
BRACCO 41% N20327 001
OCT 12, 1994

IOPHENDYLATE

INJECTABLE; INJECTION
PANTOPAQUE
ALCON 100% N05319 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N13319 001

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190
BERLEX LABS 40.6% N19580 001
DEC 07, 1989
OSMOVIST 240
BERLEX LABS 51.3% N19580 002
DEC 07, 1989

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N12968 001

IPODATE SODIUM

CAPSULE; ORAL
BILIVIST
BERLEX 500MG N87768 001
AUG 11, 1982

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRON DEXTRAN

INJECTABLE; INJECTION
IRON DEXTRAN
FISONS EQ 50MG IRON/ML N10787 002

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BRONKOSOL		
SANOFI SYNTHELABO	0.25%	N12339 009
	1%	N12339 008
ISOETHARINE HCL		
ALPHARMA	1%	N87101 001
ASTRAZENECA	0.062%	N87937 001
		NOV 15, 1982
	0.062%	N89614 001
		JUN 13, 1991
	0.125%	N87938 001
		NOV 15, 1982
	0.125%	N89615 001
		JUN 13, 1991
	0.167%	N88470 001
		MAR 14, 1984
	0.167%	N89616 001
		JUN 13, 1991
	0.2%	N88471 001
		MAR 14, 1984
	0.2%	N89617 001
		JUN 13, 1991
	0.25%	N88472 001
		MAR 14, 1984
	0.25%	N89618 001
		JUN 13, 1991
BAXTER HLTHCARE	0.08%	N88144 001
		JUL 29, 1983
	0.14%	N88145 001
		MAR 26, 1984
	0.25%	N88146 001
		AUG 01, 1983
DEY	0.08%	N88187 001
		DEC 03, 1982
	0.1%	N87389 001
	0.17%	N87390 001
	0.25%	N88188 001
		DEC 03, 1982
	1%	N86763 001
INTL MEDICATION	0.077%	N86651 001
	0.1%	N86651 003
	0.167%	N86651 005
	0.2%	N86651 006
	0.25%	N86651 007
	1%	N86651 008
PARKE DAVIS	0.5%	N85997 001
	1%	N85889 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL		
ROXANE	0.1%	N87396 001
	0.125%	N87025 001
	0.25%	N88275 001
		JUN 03, 1983
ISOETHARINE HCL S/F		
DEY	0.08%	N89817 001
		NOV 22, 1988
	0.1%	N89818 001
		NOV 22, 1988
	0.17%	N89819 001
		NOV 22, 1988
	0.25%	N89820 001
		NOV 22, 1988
	1%	N89252 001
		SEP 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER		
SANOFI SYNTHELABO	0.34MG/INH	N12339 007
ISOETHARINE MESYLATE		
ALPHARMA	0.34MG/INH	N87858 001
		AUG 21, 1984

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL		
MERCK	0.025%	N10656 001

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID		
QUAD PHARMS	100MG/ML	N89816 001
		OCT 28, 1988
RIMIFON		
ROCHE	25MG/ML	N08420 002
	100MG/ML	N08420 003

FDA data supplied by DrugPatentWatch.com

ISONIAZID

SYRUP; ORAL

LANIAZID		
LANNETT	50MG/5ML	N89243 001
		FEB 03, 1986
RIMIFON		
ROCHE	50MG/5ML	N08420 001

TABLET; ORAL

DOW-ISONIAZID		
DOW PHARM	300MG	N80330 002
HYZYD		
WALLACE LABS	100MG	N80134 003
	300MG	N80134 004
INH		
NOVARTIS	300MG	N80935 001
ISONIAZID		
ANABOLIC	100MG	N84050 001
CHELSEA LABS	100MG	N85790 001
	300MG	N85784 001
DANBURY PHARMA	50MG	N80522 001
	100MG	N80523 001
DURAMED	100MG	N88231 001
		MAR 17, 1983
HALSEY	50MG	N83632 001
IMPAX LABS	100MG	N80153 001
LILLY	100MG	N08499 002
	300MG	N08499 003
MK LABS	100MG	N80941 001
PANRAY	50MG	N08428 001
	100MG	N08428 002
	300MG	N08428 003
PERRIGO	100MG	N83060 001
PHARMAVITE	100MG	N85091 001
PHOENIX LABS NY	50MG	N80368 001
	100MG	N80368 002
PUREPAC PHARM	50MG	N80132 003
		JUL 14, 1982
	100MG	N80132 004
		JUL 14, 1982
WATSON LAB	100MG	N80401 001
	300MG	N83178 001
WHITEWORTH TOWN PLSN	100MG	N80120 002
ZENITH GOLDLINE	100MG	N80270 001
	300MG	N83610 001
NYDRAZID		
BRISTOL MYERS SQUIBB	100MG	N08392 003
STANOZIDE		
EVERYLIFE	100MG	N80126 001

ISONIAZID

TABLET; ORAL

STANOZIDE		
EVERYLIFE	300MG	N80126 002

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID		
SMITHKLINE BEECHAM	EQ 5MG BASE	N10744 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL		
ALPHARMA	0.12MG/INH	N85904 001
ISUPREL		
SANOFI SYNTHELABO	0.103MG/INH	N11178 001

DISC; INHALATION

NORISODRINE AEROTROL		
ABBOTT	0.25%	N16814 001

INJECTABLE; INJECTION

ISOPROTERENOL HCL		
AM PHARM PARTNERS	0.2MG/ML	N83431 001

SOLUTION; INHALATION

AEROLONE		
LILLY	0.25%	N07245 001
ISOPROTERENOL HCL		
ARMOUR PHARM	0.031%	N87935 001
		NOV 18, 1982
	0.062%	N87936 001
		NOV 18, 1982
DEY	0.5%	N86764 001
		JAN 04, 1982
PARKE DAVIS	0.25%	N85994 001
	0.5%	N85540 001
ISUPREL		
SANOFI SYNTHELABO	0.5%	N06327 002
	1%	N06327 003
VAPO-ISO		
FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL		
SANOFI SYNTHELABO	10MG	N06328 001

FDA data supplied by DrugPatentWatch.com

ISOPROTERENOL HYDROCHLORIDE

TABLET; RECTAL, SUBLINGUAL
ISUPREL
SANOFI SYNTHELABO 15MG N06328 002

ISOPROTERENOL HYDROCHLORIDE; *MULTIPLE*
SEE ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION
DUO-MEDIHALER
3M 0.16MG/INH;0.24MG/INH N13296 001

ISOPROTERENOL SULFATE

POWDER; INHALATION
NORISODRINE
ABBOTT 10% N06905 003
25% N06905 002

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE
HALSEY 5MG N86166 002 SEP 19, 1986
10MG N86169 001 SEP 19, 1986
20MG N86167 001 SEP 19, 1986
30MG N87564 001 SEP 18, 1986
SUPERPHARM 5MG N89190 001 FEB 17, 1987
10MG N89191 001 FEB 17, 1987
20MG N89192 001 FEB 17, 1987
SORBITRATE
ASTRAZENECA 30MG N88124 001 AUG 21, 1990

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE
HALSEY 2.5MG N84204 001 SEP 18, 1986
5MG N86168 001 SEP 18, 1986
10MG N87545 001 SEP 18, 1986
SORBITRATE
ASTRAZENECA 2.5MG N16191 002 APR 01, 1996
5MG N16191 001 APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL
ISORDIL
WYETH AYERST 40MG N12882 001 JUL 29, 1988

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
APOTHECON EQ 500MG BASE N60516 001
EQ 500MG BASE N61911 001

INJECTABLE; INJECTION
KANAMYCIN
ELKINS SINN EQ 75MG BASE/2ML N62324 001
EQ 500MG BASE/2ML N62324 002
EQ 1GM BASE/3ML N62324 003
KANAMYCIN SULFATE
AM PHARM PARTNERS EQ 75MG BASE/2ML N62504 001 APR 05, 1984
EQ 500MG BASE/2ML N62504 002 APR 05, 1984
EQ 1GM BASE/3ML N62504 003 APR 05, 1984
INTL MEDICATION EQ 500MG BASE/2ML N62466 001 SEP 30, 1983
EQ 1GM BASE/3ML N62466 002 SEP 30, 1983
PHARMAFAIR EQ 1GM BASE/3ML N62669 001 MAY 07, 1987
EQ 75MG BASE/2ML N62668 001 MAY 07, 1987

FDA data supplied by DrugPatentWatch.com

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

PHARMAFAIR	EQ 500MG BASE/2ML	N62672 001 MAY 07, 1987
QUAD PHARMS	EQ 75MG BASE/2ML	N62642 001 FEB 03, 1986
	EQ 500MG BASE/2ML	N62642 002 FEB 03, 1986
	EQ 1GM BASE/3ML	N62642 003 FEB 03, 1986
SOLOPAK	EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986
	EQ 500MG BASE/2ML	N62605 001 FEB 26, 1986
	EQ 1GM BASE/3ML	N62605 002 FEB 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	N63092 001 OCT 11, 1989

KANTREX

APOTHECON	EQ 75MG BASE/2ML	N61655 003
	EQ 75MG BASE/2ML	N62564 001 SEP 21, 1984
	EQ 500MG BASE/2ML	N61655 001
	EQ 500MG BASE/2ML	N62564 002 SEP 21, 1984
	EQ 1GM BASE/3ML	N61655 002
	EQ 1GM BASE/3ML	N62564 003 SEP 21, 1984

KLEBCIL

KING PHARMS	EQ 75MG BASE/2ML	N62170 001
	EQ 500MG BASE/2ML	N62170 002
	EQ 1GM BASE/3ML	N62170 003

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL

QUAD PHARMS	EQ 10MG BASE/ML	N71949 001 APR 11, 1988
	EQ 50MG BASE/ML	N71950 001 APR 11, 1988
	EQ 100MG BASE/ML	N71951 001 APR 11, 1988

KETOCONAZOLE

SUSPENSION; ORAL
NIZORAL

JANSSEN	100MG/5ML	N70767 001 NOV 07, 1986

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

ROXANE	10MG	N74790 001 JUN 26, 1997

LABETALOL HYDROCHLORIDE

TABLET; ORAL
NORMODYNE

SCHERING	400MG	N18687 004 AUG 01, 1984

TRANDATE

FARO PHARMS	400MG	N18716 004 AUG 01, 1984

LABETALOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

LACTULOSE

SOLUTION; ORAL
DUPHALAC

SOLVAY	10GM/15ML	N72372 001 MAR 22, 1989

LACTULOSE

MORTON GROVE	10GM/15ML	N71841 001 SEP 22, 1988
PACO	10GM/15ML	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL
GENERLAC

MORTON GROVE	10GM/15ML	N71842 001 SEP 27, 1988

LACTULOSE

PACO	10GM/15ML	N72029 001 AUG 25, 1992

FDA data supplied by DrugPatentWatch.com

LACTULOSE

SOLUTION; ORAL, RECTAL		
LACTULOSE		
SOLVAY	10GM/15ML	N17906 001
PORTALAC		
SOLVAY	10GM/15ML	N72374 001 MAR 22, 1989

LAMOTRIGINE

TABLET; ORAL		
LAMICTAL		
GLAXO WELLCOME	50MG	N20241 006 DEC 27, 1994
	250MG	N20241 004 DEC 27, 1994

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL		
LEUCOVORIN CALCIUM		
IMMUNEX	EQ 60MG BASE/VIAL	N08107 003 JAN 30, 1987
INJECTABLE; INJECTION		
LEUCOVORIN CALCIUM		
ABIC	EQ 3MG BASE/ML	N89352 001 JUN 01, 1988
	EQ 50MG BASE/VIAL	N89353 001 JUN 01, 1988
AM PHARM PARTNERS	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986
IMMUNEX	EQ 3MG BASE/ML	N08107 001
QUAD PHARMS	EQ 5MG BASE/ML	N89503 001 OCT 05, 1987
	EQ 5MG BASE/ML	N89504 001 DEC 22, 1987
	EQ 50MG BASE/VIAL	N89496 001 MAR 05, 1987
	EQ 100MG BASE/VIAL	N89636 001 DEC 24, 1987
WELLCOVORIN		
GLAXO WELLCOME	EQ 25MG BASE/VIAL	N89833 001 JAN 23, 1989
	EQ 50MG BASE/VIAL	N89465 001 JAN 23, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION		
WELLCOVORIN		
GLAXO WELLCOME	EQ 100MG BASE/VIAL	N89834 001 JAN 23, 1989
TABLET; ORAL		
LEUCOVORIN CALCIUM		
PAR PHARM	EQ 5MG BASE	N71600 001 OCT 14, 1987
	EQ 25MG BASE	N71598 001 OCT 14, 1987
WELLCOVORIN		
GLAXO WELLCOME	EQ 5MG BASE	N18342 001 JUL 08, 1983
	EQ 25MG BASE	N18342 002 JUL 08, 1983

LEUPROLIDE ACETATE

INJECTABLE; INJECTION		
LUPRON DEPOT-PED		
TAP PHARM	3.75MG/VIAL,7.5MG/VIAL	N20263 003 APR 16, 1993
	7.5MG/VIAL,7.5MG/VIAL	N20263 004 APR 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION		
LORFAN		
ROCHE	1MG/ML	N10423 001

LEVODOPA

CAPSULE; ORAL		
BENDOPA		
ICN	100MG	N16948 003
	250MG	N16948 001
	500MG	N16948 002
DOPAR		
ROBERTS LABS	100MG	N16913 003
	500MG	N16913 002
LARODOPA		
ROCHE	100MG	N16912 002

FDA data supplied by DrugPatentWatch.com

LEVODOPA

CAPSULE; ORAL
LARODOPA
ROCHE 250MG N16912 001
500MG N16912 006

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; LEVODOPA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL W/ LEVONORDEFRIN
SOLVAY 0.05MG/ML;2% N85010 001

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN
EASTMAN KODAK 0.05MG/ML;2%;0.4% N08592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION
NORPLANT
POPULATION COUNCIL 36MG/IMPLANT N19897 001 DEC 10, 1990

LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS

CAPSULE; ORAL
NOVRAD
LILLY EQ 50MG BASE N12928 006
EQ 100MG BASE N12928 004

SUSPENSION; ORAL
NOVRAD
LILLY EQ 50MG BASE/5ML N12928 002

LIDOCAINE

OINTMENT; TOPICAL
ALPHACAINE
CARLISLE 5% N84944 001
5% N84946 001

SUPPOSITORY; RECTAL
XYLOCAINE
ASTRAZENECA 100MG N13077 001

LIDOCAINE; *MULTIPLE*
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ALPHACAINE HCL
CARLISLE 2% N84721 001
LIDOCAINE HCL
ABBOTT 1.5% N88330 001 MAY 17, 1984
10% N87980 001 FEB 02, 1983
20% N89362 001 MAY 25, 1988
AKORN 1% N85037 001
2% N85037 002
AM PHARM PARTNERS 1% N80390 001
1% N80420 001
1% N86761 001
1.5% N80420 005
2% N17508 001
2% N80390 002
2% N80420 002
2% N80420 004
2% N86761 002
4% N17508 002
20% N17508 004
BEL MAR 1% N80710 001
2% N80760 001
DELL LABS 1% N83387 001
2% N83388 001
ELKINS SINN 0.5% N85131 001
4% N84626 001
INTL MEDICATION 1% N17701 002

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

INTL MEDICATION	1GM/VIAL	N18543 001
	2%	N17701 001
	2GM/VIAL	N18543 002
MILES	1%	N80414 001
	2%	N80414 002
SEARLE	1%	N83135 001
	2%	N83135 002
STERIS	1%	N83627 001
	2%	N83627 002

LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	100MG/100ML	N18461 001

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	200MG/100ML	N18954 001
		JUL 09, 1985

LIDOCAINE HCL PRESERVATIVE FREE

INTL MEDICATION	4%	N17702 002

XYLOCAINE

ASTRAZENECA	1%	N10418 005
	1.5%	N10418 009
	2%	N10418 007

SOLUTION; ORAL
LIDOCAINE HCL VISCOUS

INTL MEDICATION	2%	N86389 001
		FEB 02, 1982

SOLUTION; TOPICAL
LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL	4%	N87931 001
		JUN 10, 1983

LIDOCAINE HCL

PACO	4%	N89688 001
		JUN 30, 1989

PEDIATRIC LTA KIT

ABBOTT	2%	N88572 001
		JUL 31, 1984

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOMYCIN HCL

QUAD PHARMS	EQ 300MG BASE/ML	N62784 001
		MAR 14, 1988

LINDANE

CREAM; TOPICAL
KWELL

REED AND CARNRICK	1%	N06309 001
	1%	N84218 001

LOTION; TOPICAL
GAMENE

SOLA BARNES HIND	1%	N84989 001

KWELL

REED AND CARNRICK	1%	N06309 003
	1%	N84218 002

SCABENE

STIEFEL	1%	N86769 001

SHAMPOO; TOPICAL
GAMENE

SOLA BARNES HIND	1%	N84988 001

KWELL

REED AND CARNRICK	1%	N10718 001
	1%	N84219 001

SCABENE

STIEFEL	1%	N87940 001
		APR 08, 1983

LIOTHYRONINE SODIUM

TABLET; ORAL
LIOTHYRONINE SODIUM

WATSON LAB	EQ 0.025MG BASE	N85755 001
		JAN 25, 1982
	EQ 0.05MG BASE	N85753 001
		FEB 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL
EUTHROID-0.5

PARKE DAVIS	0.03MG;0.0075MG	N16680 001

FDA data supplied by DrugPatentWatch.com

LIOTRIX (T4;T3)

TABLET; ORAL
- EUTHROID-1
  - PARKE DAVIS — 0.06MG;0.015MG — N16680 002
- EUTHROID-2
  - PARKE DAVIS — 0.12MG;0.03MG — N16680 003
- EUTHROID-3
  - PARKE DAVIS — 0.18MG;0.045MG — N16680 004
- THYROLAR-5
  - FORREST LABS — 0.25MG;0.0625MG — N16807 006

LITHIUM CARBONATE

CAPSULE; ORAL
- LITHIUM CARBONATE
  - ROSEMONT — 300MG — N72542 001 FEB 01, 1989
  - WATSON LAB — 300MG — N70407 001 MAR 19, 1987
- LITHONATE
  - SOLVAY — 300MG — N16782 001

TABLET; ORAL
- ESKALITH
  - SMITHKLINE BEECHAM — 300MG — N17971 001
- LITHANE
  - BAYER — 300MG — N18833 001 JUL 18, 1985
- LITHOTABS
  - SOLVAY — 300MG — N16980 001

LITHIUM CITRATE

SYRUP; ORAL
- LITHONATE
  - SOLVAY — EQ 300MG CARBONATE/5ML — N17672 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
- IMODIUM
  - MCNEIL CONS — 2MG — N17690 001

SOLUTION; ORAL
- IMODIUM
  - JANSSEN — 1MG/5ML — N19037 001 JUL 31, 1984

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
- LOPERAMIDE HCL
  - ALPHARMA — 1MG/5ML — N73187 001 SEP 15, 1992
  - WATSON LABS — 1MG/5ML — N73062 001 MAY 28, 1993

LORAZEPAM

TABLET; ORAL
- LORAZ
  - QUANTUM PHARMICS — 0.5MG — N70200 001 AUG 09, 1985
  - 1MG — N70201 001 AUG 09, 1985
  - 2MG — N70202 001 AUG 09, 1985
- LORAZEPAM
  - AM THERAP — 0.5MG — N70727 001 MAR 07, 1986
  - 1MG — N70728 001 MAR 07, 1986
  - 2MG — N70729 001 MAR 07, 1986
  - HALSEY — 0.5MG — N70472 001 DEC 10, 1985
  - 0.5MG — N71434 001 SEP 01, 1987
  - 1MG — N70473 001 DEC 10, 1985
  - 1MG — N71435 001 SEP 01, 1987
  - 2MG — N70474 001 DEC 10, 1985
  - 2MG — N71436 001 SEP 01, 1987
  - PAR PHARM — 0.5MG — N70675 001 DEC 01, 1986
  - 1MG — N70676 001 DEC 01, 1986
  - 2MG — N70677 001 DEC 01, 1986
  - ROSEMONT — 1MG — N70539 001 DEC 22, 1986
  - 2MG — N70540 001 DEC 22, 1986

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

TABLET; ORAL
LORAZEPAM

SUPERPHARM	0.5MG	N71245 001 FEB 09, 1987
	1MG	N71246 001 FEB 09, 1987
	2MG	N71247 001 FEB 09, 1987
WARNER CHILCOTT	1MG	N71038 001 JAN 12, 1988
	2MG	N71039 001 JAN 12, 1988

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX

PHARMOS	0.5%	N20841 001 MAR 09, 1998

LOXAPINE SUCCINATE

TABLET; ORAL
LOXITANE

WATSON LABS	EQ 10MG BASE	N17525 006
	EQ 25MG BASE	N17525 007
	EQ 50MG BASE	N17525 008

LYPRESSIN

SOLUTION; NASAL
DIAPID

NOVARTIS	0.185MG/ML	N16755 001

MAGNESIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001 APR 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

ABBOTT	14MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N18406 001

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001 JAN 25, 1985

MAGNESIUM TRISILICATE; *MULTIPLE*
SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE

AM PHARM PARTNERS	EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10%

ABBOTT	10GM/100ML	N16269 002
MILES	10GM/100ML	N16472 002

MANNITOL 15%

ABBOTT	15GM/100ML	N16269 003
MILES	15GM/100ML	N16472 005

MANNITOL 20%

ABBOTT	20GM/100ML	N16269 004
MILES	20GM/100ML	N16472 004

MANNITOL 25%

ABBOTT	12.5GM/50ML	N16269 005
AM PHARM PARTNERS	12.5GM/50ML	N86754 001
MERCK	12.5GM/50ML	N05620 001
STERIS	12.5GM/50ML	N87460 001 JUN 27, 1983

MANNITOL 5%

ABBOTT	5GM/100ML	N16269 001

SOLUTION; IRRIGATION
RESECTISOL

B BRAUN	5GM/100ML	N16704 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION
SORBITOL-MANNITOL

ABBOTT	540MG/100ML;2.7GM/100ML	N80224 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL
MAPROTILINE HCL

AM THERAP	25MG	N72129 001 JAN 14, 1988
	50MG	N72130 001 JAN 14, 1988
	75MG	N72131 001 JAN 14, 1988
WATSON LAB	25MG	N71943 001 DEC 30, 1987
	50MG	N71944 001 DEC 30, 1987
	75MG	N71945 001 DEC 30, 1987

MAZINDOL

TABLET; ORAL
MAZANOR

WYETH AYERST	2MG	N17980 001

MEBUTAMATE

TABLET; ORAL
DORMATE

WALLACE PHARMS	600MG	N17374 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

ANABOLIC	25MG	N85891 001
KV PHARM	12.5MG	N85524 001
	25MG	N85523 001
SUPERPHARM	12.5MG	N89113 001 AUG 20, 1985

FDA data supplied by DrugPatentWatch.com

MECLIZINE HYDROCHLORIDE

TABLET; ORAL			
MECLIZINE HCL			
SUPERPHARM	25MG	N89114 001	AUG 20, 1985
UDL	12.5MG	N88256 001	JUN 13, 1983
	25MG	N88257 001	JUN 13, 1983
VANGARD	12.5MG	N87877 001	APR 20, 1982
	25MG	N87620 001	JAN 04, 1982
WATSON LAB	12.5MG	N85195 001	
ZENITH GOLDLINE	12.5MG	N83784 001	
TABLET, CHEWABLE; ORAL			
MECLIZINE HCL			
ANABOLIC	25MG	N86392 001	
ZENITH GOLDLINE	25MG	N84976 001	

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL			
MECLAN			
JOHNSON AND JOHNSON	1%	N50518 001	

MECLOFENAMATE SODIUM

CAPSULE; ORAL			
MECLODIUM			
QUANTUM PHARMICS	EQ 50MG BASE	N71380 001	JUL 14, 1987
	EQ 100MG BASE	N71381 001	JUL 14, 1987
MECLOFENAMATE SODIUM			
AM THERAP	EQ 50MG BASE	N71362 001	FEB 10, 1987
	EQ 100MG BASE	N71363 001	FEB 10, 1987
BARR	EQ 50MG BASE	N72848 001	MAR 20, 1989
	EQ 100MG BASE	N72809 001	MAR 20, 1989
CHELSEA LABS	EQ 50MG BASE	N71640 001	AUG 11, 1987

MECLOFENAMATE SODIUM

CAPSULE; ORAL			
MECLOFENAMATE SODIUM			
CHELSEA LABS	EQ 100MG BASE	N71641 001	AUG 11, 1987
PAR PHARM	EQ 50MG BASE	N72077 001	MAR 10, 1988
	EQ 100MG BASE	N72078 001	MAR 10, 1988
ROSEMONT	EQ 50MG BASE	N71007 001	MAR 25, 1988
	EQ 100MG BASE	N71008 001	MAR 25, 1988
VITARINE	EQ 50MG BASE	N71710 001	JUN 15, 1988
	EQ 100MG BASE	N71684 001	JUN 15, 1988
WATSON LAB	EQ 50MG BASE	N70400 001	NOV 25, 1986
	EQ 100MG BASE	N70401 001	NOV 25, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION			
DEPO-PROVERA			
* PHARMACIA AND UPJOHN	100MG/ML	N12541 002	
TABLET; ORAL			
CURRETAB			
SOLVAY	10MG	N85686 001	
CYCRIN			
ESI	2.5MG	N81239 001	OCT 30, 1992
	5MG	N81240 001	OCT 30, 1992
	10MG	N89386 001	SEP 09, 1987

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL			
MEFLOQUINE HCL			
US ARMY WALTER REED	250MG	N19578 001	MAY 02, 1989

FDA data supplied by DrugPatentWatch.com

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

ROSEMONT	20MG	N70646 001 OCT 02, 1987
	40MG	N70647 001 OCT 02, 1987

MEGLUMINE; *MULTIPLE*
SEE CALCIUM; MEGLUMINE; METRIZOIC ACID

MEGLUMINE METRIZOATE; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION
KAPPADIONE

LILLY	10MG/ML	N05725 001

SYNKAYVITE

ROCHE	5MG/ML	N03718 004
	10MG/ML	N03718 006
	37.5MG/ML	N03718 008

TABLET; ORAL
SYNKAYVITE

ROCHE	5MG	N03718 010

MENADIONE

TABLET; ORAL
MENADIONE

LILLY	5MG	N02139 003

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
MENOTROPINS

FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001 JAN 30, 1997
	150 IU/VIAL;150 IU/VIAL	N73599 001 JAN 30, 1997

MEPENZOLATE BROMIDE

SOLUTION; ORAL
CANTIL

AVENTIS PHARMS	25MG/5ML	N10679 004

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL

SANOFI SYNTHELABO	25MG/ML	N05010 007
	50MG/ML	N05010 002
	75MG/ML	N05010 009
	100MG/ML	N05010 003

MEPERIDINE HCL

ASTRAZENECA	25MG/ML	N89781 001 MAR 31, 1989
	50MG/ML	N89782 001 MAR 31, 1989
	50MG/ML	N89783 001 MAR 31, 1989
	75MG/ML	N89785 001 MAR 31, 1989
	100MG/ML	N89786 001 MAR 31, 1989
	100MG/ML	N89787 001 MAR 31, 1989
ELKINS SINN	25MG/ML	N88279 001 JUN 15, 1984
	50MG/ML	N88280 001 JUN 15, 1984
	75MG/ML	N88281 001 JUN 15, 1984
	100MG/ML	N88282 001 JUN 15, 1984
INTL MEDICATION	10MG/ML	N86332 001
KNOLL PHARM	25MG/ML	N80388 001
	50MG/ML	N80385 001
	50MG/ML	N80387 001
	75MG/ML	N80389 001
	100MG/ML	N80386 001
PARKE DAVIS	50MG/ML	N80364 002
	75MG/ML	N80364 003
	100MG/ML	N80364 001

MEPERIDINE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE
WYETH AYERST EQ 30MG BASE/ML N08248 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL
SOLVAY 3% N84777 002 APR 18, 1982

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

MEPREDNISONE

TABLET; ORAL
BETAPAR
SCHERING 4MG N16053 002

MEPROBAMATE

CAPSULE; ORAL
EQUANIL
WYETH AYERST 400MG N12455 002

CAPSULE, EXTENDED RELEASE; ORAL
MEPROSPAN
WALLACE PHARMS 200MG N11284 001
400MG N11284 002

TABLET; ORAL
BAMATE
ALRA 200MG N80380 001
400MG N80380 002
MEPRIAM
TEVA 400MG N16069 001
MEPROBAMATE
ANABOLIC 200MG N84220 001
400MG N84589 001
BARR 600MG N84230 001
CHELSEA LABS 600MG N85719 001
DANBURY PHARMA 600MG N84274 001

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
ELKINS SINN 200MG N15426 002
400MG N15426 001
HALSEY 200MG N80699 001
HEATHER 400MG N16928 003
600MG N84329 001
ICN 200MG N15139 006
400MG N15139 005
LANNETT 200MG N14882 002
400MG N14882 001
LEDERLE 400MG N86299 001
LEE KM 400MG N89538 001 NOV 25, 1987
MALLARD 400MG N15072 002
MK LABS 200MG N14368 004
400MG N14368 002
PARKE DAVIS 200MG N84744 001
400MG N84744 002
PERRIGO 200MG N84546 001
400MG N84547 001
PHARMAVITE 400MG N84438 001
PHARMERAL 400MG N84153 001
PUREPAC PHARM 200MG N84804 001
400MG N84804 002
PVT FORM 400MG N14601 001
ROSEMONT 200MG N87825 001 MAR 18, 1982
400MG N87826 001 MAR 18, 1982
SOLVAY 200MG N84435 001
STANLABS PHARM 200MG N14474 002
400MG N14474 004
VANGARD 400MG N88011 001 JUL 14, 1982
WHITEWORTH TOWN PLSN 200MG N83830 001
400MG N83442 001
ZENITH GOLDLINE 200MG N15438 001
400MG N15438 002
600MG N84181 001
NEURAMATE
HALSEY 200MG N14359 002
400MG N14359 001
TRANMEP
SOLVAY 400MG N84369 001

MEPROBAMATE; *MULTIPLE*
SEE ASPIRIN; MEPROBAMATE

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE; *MULTIPLE*
SEE ESTROGENS, CONJUGATED; MEPROBAMATE

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE
STERIS 100MG/ML;50MG/ML N84875 001

MESALAMINE

SUPPOSITORY; RECTAL
ROWASA
SOLVAY 500MG N19919 001 DEC 18, 1990

MESTRANOL; *MULTIPLE*
SEE ETHYNODIOL DIACETATE; MESTRANOL

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL
WATSON LABS 0.1MG;2MG N13625 004

TABLET; ORAL-21
NORINYL 1+80 21-DAY
SEARLE 0.08MG;1MG N16724 001
ORTHO-NOVUM 1/80 21
JOHNSON RW 0.08MG;1MG N16715 001
ORTHO-NOVUM 10-21
JOHNSON RW 0.06MG;10MG N12728 001
ORTHO-NOVUM 2-21
JOHNSON RW 0.1MG;2MG N12728 005

TABLET; ORAL-28
NORINYL 1+80 28-DAY
SEARLE 0.08MG;1MG N16725 001
ORTHO-NOVUM 1/80 28
JOHNSON RW 0.08MG;1MG N16715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL
ENOVID
SEARLE 0.075MG;5MG N10976 008
0.15MG;9.85MG N10976 005

TABLET; ORAL-20
ENOVID
SEARLE 0.075MG;5MG N10976 004
ENOVID-E
SEARLE 0.1MG;2.5MG N10976 006

TABLET; ORAL-21
ENOVID-E 21
SEARLE 0.1MG;2.5MG N10976 007

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE
ASTRAZENECA 0.4% N71275 001 JUL 27, 1988
0.6% N71018 001 JUL 27, 1988
DEY 0.33% N71806 001 AUG 05, 1988
0.5% N71805 001 AUG 05, 1988
5% N70805 001 AUG 17, 1987
MORTON GROVE 5% N72190 001 JUN 07, 1988
PROMETA
MURO 5% N73340 001 MAR 30, 1992

SYRUP; ORAL
METAPROTERENOL SULFATE
MORTON GROVE 10MG/5ML N71656 001 OCT 13, 1987
PROMETA
MURO 10MG/5ML N72023 001 SEP 15, 1988

TABLET; ORAL
METAPROTERENOL SULFATE
AM THERAP 10MG N72054 001 JUN 23, 1988

FDA data supplied by DrugPatentWatch.com

METAPROTERENOL SULFATE

TABLET; ORAL
METAPROTERENOL SULFATE

AM THERAP	20MG	N72055 001 JUN 23, 1988
ROSEMONT	10MG	N71013 001 JAN 25, 1988
	20MG	N71014 001 JAN 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

AM PHARM PARTNERS	EQ 10MG BASE/ML	N80431 001
ELKINS SINN	EQ 10MG BASE/ML	N83363 001
SEARLE	EQ 10MG BASE/ML	N86418 001
	EQ 20MG BASE/ML	N86418 002

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N20357 003 NOV 05, 1998
	750MG	N20357 004 NOV 05, 1998

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
RONDOMYCIN

WALLACE LABS	EQ 140MG BASE	N60641 001
	EQ 280MG BASE	N60641 002

SYRUP; ORAL
RONDOMYCIN

WALLACE LABS	EQ 70MG BASE/5ML	N60641 003

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL
WESTADONE

EON	2.5MG	N17108 001

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL
WESTADONE

EON	5MG	N17108 002
	10MG	N17108 003
	40MG	N17108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
METHAMPEX

TEVA	10MG	N83889 001

METHAMPHETAMINE HCL

TEVA	5MG	N86359 001

METHARBITAL

TABLET; ORAL
GEMONIL

ABBOTT	100MG	N08322 001

METHDILAZINE

TABLET, CHEWABLE; ORAL
TACARYL

WESTWOOD SQUIBB	3.6MG	N11950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL
METHDILAZINE HCL

ALPHARMA	4MG/5ML	N87122 001

TACARYL

WESTWOOD SQUIBB	4MG/5ML	N11950 007

TABLET; ORAL
TACARYL

WESTWOOD SQUIBB	8MG	N11950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN

APOTHECON	EQ 900MG BASE/VIAL	N50117 001

FDA data supplied by DrugPatentWatch.com

METHICILLIN SODIUM

INJECTABLE; INJECTION			
STAPHCILLIN			
APOTHECON	EQ 900MG BASE/VIAL	N61449	001
	EQ 3.6GM BASE/VIAL	N50117	002
	EQ 3.6GM BASE/VIAL	N61449	002
	EQ 5.4GM BASE/VIAL	N50117	003
	EQ 5.4GM BASE/VIAL	N61449	003

METHIXENE HYDROCHLORIDE

TABLET; ORAL			
TREST			
NOVARTIS	1MG	N13420	001

METHOCARBAMOL

INJECTABLE; INJECTION			
METHOCARBAMOL			
MARSAM	100MG/ML	N89849	001
		DEC 27, 1991	
TABLET; ORAL			
DELAXIN			
FERNDALE LABS	500MG	N85454	001
FORBAXIN			
FORREST LABS	750MG	N85136	001
METHOCARBAMOL			
AM THERAP	500MG	N89417	001
		FEB 11, 1987	
	750MG	N89418	001
		FEB 11, 1987	
ASCOT	500MG	N87660	001
		OCT 27, 1982	
	750MG	N87661	001
		OCT 27, 1982	
HALSEY	500MG	N84488	001
	750MG	N84486	001
HEATHER	500MG	N84675	001
	750MG	N84924	001
INWOOD LABS	500MG	N85137	001
KV PHARM	500MG	N85660	001
	750MG	N85658	001
MYLAN	500MG	N84259	001
	750MG	N84323	001
PHARMERAL	500MG	N84231	002

METHOCARBAMOL

TABLET; ORAL			
METHOCARBAMOL			
PHARMERAL	750MG	N84471	001
PIONEER PHARMS	500MG	N88731	001
		DEC 13, 1985	
	750MG	N89082	001
		DEC 13, 1985	
PUREPAC PHARM	500MG	N85718	001
	750MG	N85718	002
ROXANE	500MG	N88646	001
		FEB 29, 1984	
	750MG	N88647	001
		FEB 29, 1984	
SOLVAY	500MG	N84448	001
	750MG	N84449	001
UPSHER SMITH	500MG	N87453	001
	750MG	N87454	001
WATSON LAB	500MG	N83605	001
	750MG	N83605	002
ZENITH GOLDLINE	500MG	N84648	001
	750MG	N84649	001

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOTREXATE SODIUM

INJECTABLE; INJECTION			
ABITREXATE			
ABIC	EQ 25MG BASE/ML	N89161	001
		MAR 10, 1987	
	EQ 50MG BASE/VIAL	N89354	001
		JUL 17, 1987	
	EQ 100MG BASE/VIAL	N89355	001
		JUL 17, 1987	
	EQ 250MG BASE/VIAL	N89356	001
		JUL 17, 1987	
FOLEX PFS			
PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	N81242	001
		AUG 23, 1991	
	EQ 25MG BASE/ML	N89180	001
		JAN 03, 1986	
METHOTREXATE SODIUM			
AM PHARM PARTNERS	EQ 2.5MG BASE/ML	N89323	001
		JUN 13, 1986	

FDA data supplied by DrugPatentWatch.com

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM

AM PHARM PARTNERS	EQ 20MG BASE/VIAL	N88935 001 OCT 11, 1985
	EQ 25MG BASE/ML	N89263 001 JUN 13, 1986
	EQ 25MG BASE/ML	N89322 001 JUN 13, 1986
	EQ 50MG BASE/VIAL	N88936 001 OCT 11, 1985
	EQ 100MG BASE/VIAL	N88937 001 OCT 11, 1985
QUAD PHARMS	EQ 20MG BASE/VIAL	N89293 001 JUL 10, 1986
	EQ 25MG BASE/ML	N89308 001 JUL 10, 1986
	EQ 25MG BASE/ML	N89309 001 JUL 10, 1986
	EQ 50MG BASE/VIAL	N89294 001 JUL 10, 1986
	EQ 100MG BASE/VIAL	N89295 001 JUL 10, 1986
	EQ 250MG BASE/VIAL	N89296 001 JUL 10, 1986

MEXATE

BRISTOL	EQ 20MG BASE/VIAL	N86358 001
	EQ 50MG BASE/VIAL	N86358 002
	EQ 100MG BASE/VIAL	N86358 003
	EQ 250MG BASE/VIAL	N86358 004

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

IMMUNEX	20MG/ML	N15865 001

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
VASOXYL

GLAXO WELLCOME	10MG/ML	N06772 002

METHOXSALEN

CAPSULE; ORAL
METHOXSALEN

GENEVA PHARMS	10MG	N87781 001 JUN 08, 1982

METHOXYFLURANE

LIQUID; INHALATION
PENTHRANE

ABBOTT	99.9%	N13056 001

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

CHELSEA LABS	2.5MG	N88750 001 SEP 06, 1984
MYLAN	2.5MG	N87671 001 AUG 17, 1982
ROSEMONT	5MG	N88745 001 MAR 21, 1985
WATSON LAB	2.5MG	N85487 001 MAR 11, 1982
	5MG	N85476 001 MAR 11, 1982
ZENITH GOLDLINE	5MG	N87786 001 MAY 18, 1982

METHYCLOTHIAZIDE; *MULTIPLE*
SEE DESERPIDINE; METHYCLOTHIAZIDE

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL
EUTRON

ABBOTT	5MG;25MG	N16047 001

METHYLDOPA

TABLET; ORAL
METHYLDOPA

CHELSEA LABS	125MG	N70260 001 JUN 24, 1985

FDA data supplied by DrugPatentWatch.com

METHYLDOPA

TABLET; ORAL
METHYLDOPA

CHELSEA LABS	250MG	N70261 001 JUN 24, 1985
	500MG	N70262 001 JUN 24, 1985
DURAMED	250MG	N71006 001 DEC 16, 1986
	500MG	N71009 001 DEC 16, 1986
HALSEY	125MG	N70073 001 OCT 09, 1986
	125MG	N71751 001 MAR 28, 1988
	250MG	N70060 001 OCT 09, 1986
	250MG	N71752 001 MAR 28, 1988
	500MG	N70074 001 OCT 09, 1986
	500MG	N71753 001 MAR 28, 1988
NOVOPHARM	125MG	N71105 001 DEC 05, 1986
	250MG	N71106 001 DEC 05, 1986
	500MG	N71067 001 DEC 05, 1986
PARKE DAVIS	125MG	N70331 001 APR 15, 1986
	250MG	N70332 001 APR 15, 1986
	500MG	N70333 001 APR 15, 1986
PUREPAC PHARM	125MG	N70749 001 FEB 07, 1986
	250MG	N70750 001 FEB 07, 1986
	500MG	N70452 001 FEB 07, 1986
ROXANE	125MG	N70192 001 APR 25, 1986
	250MG	N70193 001 APR 25, 1986
	500MG	N70194 001 APR 25, 1986

METHYLDOPA

TABLET; ORAL
METHYLDOPA

WATSON LAB	125MG	N70245 001 FEB 25, 1986
	250MG	N70246 001 FEB 25, 1986
	500MG	N70247 001 FEB 25, 1986

METHYLDOPA; *MULTIPLE*
SEE CHLOROTHIAZIDE; METHYLDOPA
SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AM PHARM PARTNERS	50MG/ML	N70652 001 JUN 03, 1986
FAULDING	50MG/ML	N70691 001 JUN 19, 1987
	50MG/ML	N70849 001 JUN 19, 1987
MARSAM	50MG/ML	N71812 001 DEC 22, 1987
QUAD PHARMS	50MG/ML	N71024 001 SEP 18, 1986
SMITH AND NEPHEW	50MG/ML	N70841 001 JAN 02, 1987

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

CHELSEA LABS	4MG	N86161 001 FEB 09, 1982
	16MG	N86159 001 FEB 09, 1982
EON	4MG	N87341 001
HEATHER	4MG	N85650 001

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC
NEO-MEDROL
PHARMACIA AND UPJOHN 0.1%;EQ 3.5MG BASE/GM N60645 001

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL
MEDROL
PHARMACIA AND UPJOHN 40MG/BOT N18102 001

INJECTABLE; INJECTION
M-PREDROL
BEL MAR 40MG/ML N86666 001
80MG/ML N87135 001
METHYLPREDNISOLONE ACETATE
AKORN 40MG/ML N86903 001
OCT 20, 1982
80MG/ML N86903 002
OCT 20, 1982
STERIS 20MG/ML N87248 001
40MG/ML N85374 001
80MG/ML N86507 001

OINTMENT; TOPICAL
MEDROL ACETATE
PHARMACIA AND UPJOHN 1% N12421 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED
ABBOTT EQ 1GM BASE/VIAL N89576 001
FEB 22, 1991
EQ 40MG BASE/VIAL N89573 001
FEB 22, 1991
EQ 125MG BASE/VIAL N89574 001
FEB 22, 1991
EQ 500MG BASE/VIAL N89575 001
FEB 22, 1991
METHYLPREDNISOLONE
ELKINS SINN EQ 125MG BASE/VIAL N86906 002
EQ 500MG BASE/VIAL N86906 003
EQ 1GM BASE/VIAL N86906 004
ORGANON EQ 500MG BASE/VIAL N87535 001
JUN 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE
ORGANON EQ 1GM BASE/VIAL N87535 002
JUN 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE
AM PHARM PARTNERS EQ 1GM BASE/VIAL N88679 001
JUN 08, 1984
EQ 1GM BASE/VIAL N89188 001
MAR 28, 1986
EQ 1GM BASE/VIAL N89189 001
MAR 28, 1986
EQ 40MG BASE/VIAL N88676 001
JUN 08, 1984
EQ 40MG BASE/VIAL N89143 001
MAR 28, 1986
EQ 125MG BASE/VIAL N88677 001
JUN 08, 1984
EQ 125MG BASE/VIAL N89144 001
MAR 28, 1986
EQ 500MG BASE/VIAL N88678 001
JUN 08, 1984
EQ 500MG BASE/VIAL N89186 001
MAR 28, 1986
EQ 500MG BASE/VIAL N89187 001
MAR 28, 1986
ELKINS SINN EQ 40MG BASE/VIAL N86906 001
INTL MEDICATION EQ 1GM BASE/VIAL N87852 001
FEB 09, 1983
EQ 40MG BASE/VIAL N87812 001
FEB 09, 1983
EQ 125MG BASE/VIAL N87813 001
FEB 09, 1983
EQ 500MG BASE/VIAL N87851 001
FEB 09, 1983
QUAD PHARMS EQ 1GM BASE/VIAL N89267 001
JAN 22, 1986
EQ 40MG BASE/VIAL N89264 001
JAN 22, 1986
EQ 125MG BASE/VIAL N89265 001
JAN 22, 1986
EQ 500MG BASE/VIAL N89266 001
JAN 22, 1986
STERIS EQ 1GM BASE/VIAL N88524 001
JUL 24, 1984
EQ 40MG BASE/VIAL N86953 001
JUL 22, 1982

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

STERIS	EQ 125MG BASE/VIAL	N87030 001
		JUL 22, 1982
	EQ 500MG BASE/VIAL	N88523 001
		JUL 24, 1984

METHYLTESTOSTERONE

CAPSULE; ORAL
METHYLTESTOSTERONE

HEATHER	10MG	N84967 001

TABLET; BUCCAL
ANDROID 5

ICN	5MG	N87222 001

TABLET; BUCCAL/SUBLINGUAL
METANDREN

NOVARTIS	5MG	N03240 004
	10MG	N03240 005

METHYLTESTOSTERONE

PUREPAC PHARM	10MG	N80308 001
	10MG	N80475 001
PVT FORM	5MG	N83836 001
ROSEMONT	10MG	N80271 001
TABLICAPS	10MG	N85125 001

TABLET; ORAL
METANDREN

NOVARTIS	10MG	N03240 001
	25MG	N03240 003

METHYLTESTOSTERONE

DANBURY PHARMA	10MG	N80933 001
	25MG	N80931 001
INWOOD LABS	10MG	N80839 001
	25MG	N80973 001
KV PHARM	10MG	N84312 001
PARKE DAVIS	10MG	N84244 001
	25MG	N84241 001
PUREPAC PHARM	10MG	N80309 001
	10MG	N80475 002
	25MG	N80310 001
	25MG	N80475 003
PVT FORM	5MG	N80214 001
	10MG	N80214 002

METHYLTESTOSTERONE

TABLET; ORAL
METHYLTESTOSTERONE

PVT FORM	25MG	N80214 003
TABLICAPS	10MG	N80313 001
	25MG	N85270 001
WEST WARD	10MG	N84331 001
	25MG	N84331 002
	25MG	N84642 001

ORETON METHYL

SCHERING	10MG	N03158 001
	25MG	N03158 002

METHYPRYLON

CAPSULE; ORAL
NOLUDAR

ROCHE	300MG	N09660 008

ELIXIR; ORAL
NOLUDAR

ROCHE	50MG/5ML	N09660 007

TABLET; ORAL
NOLUDAR

ROCHE	50MG	N09660 002
	200MG	N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AM PHARM PARTNERS	EQ 10MG BASE/2ML	N70293 001
		JAN 24, 1986
BEDFORD	EQ 5MG BASE/ML	N72155 001
		MAR 30, 1992
	EQ 5MG BASE/ML	N72244 001
		MAR 30, 1992
	EQ 5MG BASE/ML	N72247 001
		MAY 18, 1992
FAULDING	EQ 5MG BASE/ML	N71990 001
		JAN 18, 1989
NORBROOK	EQ 10MG BASE/2ML	N70892 001
		AUG 26, 1988
QUAD PHARMS	EQ 10MG BASE/2ML	N70671 001
		MAY 27, 1986

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

SMITH AND NEPHEW	EQ 10MG BASE/2ML	N70622 001 MAR 02, 1987
	EQ 5MG BASE/ML	N70623 001 MAR 02, 1987

REGLAN

ROBINS AH	EQ 10MG BASE/ML	N17862 004 MAY 28, 1987

SOLUTION; ORAL
METOCLOPRAMIDE HCL

MORTON GROVE	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987
PACO	EQ 5MG BASE/5ML	N71665 001 DEC 05, 1988

TABLET; ORAL
CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	N72384 001 JUN 02, 1988
	EQ 10MG BASE	N70294 001 JUL 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	N70632 001 OCT 28, 1985

MAXOLON

KING PHARMS	EQ 10MG BASE	N70106 001 MAR 04, 1986

METOCLOPRAMIDE HCL

CHELSEA LABS	EQ 10MG BASE	N70453 001 JUN 06, 1986
HALSEY	EQ 10MG BASE	N70660 001 FEB 10, 1987
	EQ 10MG BASE	N70906 001 OCT 28, 1986
INTERPHARM	EQ 10MG BASE	N71213 001 SEP 24, 1986
INVAMED	EQ 5MG BASE	N72436 001 JUN 22, 1989
	EQ 10MG BASE	N70850 001 FEB 03, 1987
PAR PHARM	EQ 10MG BASE	N70342 001 MAR 25, 1986
ROSEMONT	EQ 10MG BASE	N70339 001 JUL 29, 1985

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987
SUPERPHARM	EQ 10MG BASE	N70926 001 JUN 26, 1987
WATSON LAB	EQ 10MG BASE	N70363 001 MAR 02, 1987
WATSON LABS	EQ 10MG BASE	N70645 001 MAY 11, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION
METOCURINE IODIDE

QUAD PHARMS	2MG/ML	N89443 001 JUN 01, 1988

METOLAZONE

TABLET; ORAL
DIULO

SEARLE	2.5MG	N18535 001
	5MG	N18535 002
	10MG	N18535 003

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N19786 001 DEC 27, 1989
	EQ 200MG TARTRATE	N19786 002 DEC 27, 1989
	EQ 300MG TARTRATE	N19786 003 DEC 27, 1989
	EQ 400MG TARTRATE	N19786 004 DEC 27, 1989

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

PUREPAC PHARM	50MG	N74380 001 JUL 29, 1994
	100MG	N74380 002 JUL 29, 1994

METOPROLOL TARTRATE; *MULTIPLE*
SEE CHLORTHALIDONE; METOPROLOL TARTRATE

METRIZAMIDE

INJECTABLE; INJECTION
AMIPAQUE

NYCOMED	2.5GM/VIAL	N17982 003 SEP 12, 1983
	3.75GM/VIAL	N17982 001
	6.75GM/VIAL	N17982 002
	13.5GM/VIAL	N17982 004 SEP 12, 1983

METRIZOATE MAGNESIUM; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

METRIZOATE SODIUM; *MULTIPLE*
SEE CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

METRIZOIC ACID; *MULTIPLE*
SEE CALCIUM; MEGLUMINE; METRIZOIC ACID

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

AM PHARM PARTNERS	500MG/100ML	N70071 001 DEC 03, 1984
INTL MEDICATION	500MG/100ML	N70004 001 MAY 08, 1985

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

STERIS	500MG/100ML	N70042 001 DEC 20, 1984
	500MG/100ML	N70170 001 APR 01, 1986

TABLET; ORAL
METRONIDAZOLE

CHELSEA LABS	250MG	N18599 001 SEP 17, 1982
	500MG	N18599 002 FEB 13, 1984
HALSEY	250MG	N18818 001 FEB 16, 1983
	250MG	N70021 001 APR 02, 1985
	500MG	N18818 002 FEB 16, 1983
	500MG	N70593 001 FEB 27, 1986
SUPERPHARM	250MG	N70008 001 DEC 11, 1984
	500MG	N70009 001 DEC 11, 1984
SATRIC		
SAVAGE LABS	250MG	N70029 001 MAR 19, 1985
	500MG	N70731 001 JUN 08, 1987

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
METRONIDAZOLE HCL

AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N70295 001 OCT 15, 1985

METYRAPONE

TABLET; ORAL
METOPIRONE

NOVARTIS	250MG	N12911 001

FDA data supplied by DrugPatentWatch.com

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION			
MEZLIN			
BAYER	EQ 1GM BASE/VIAL	N62333 001	
	EQ 2GM BASE/VIAL	N62333 002	
	EQ 3GM BASE/VIAL	N62333 003	
	EQ 4GM BASE/VIAL	N62333 004	

MICONAZOLE

INJECTABLE; INJECTION			
MONISTAT			
JANSSEN	10MG/ML	N18040 001	

MICONAZOLE NITRATE

LOTION; TOPICAL			
MONISTAT-DERM			
JOHNSON AND JOHNSON	2%	N17739 001	
TAMPON; VAGINAL			
MONISTAT 5			
PERSONAL PRODS	100MG	N18592 001	OCT 27, 1989

MILRINONE LACTATE

INJECTABLE; INJECTION			
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER			
SANOFI SYNTHELABO	EQ 10MG BASE/100ML	N20343 001	AUG 09, 1994
	EQ 15MG BASE/100ML	N20343 002	AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL			
MINOCIN			
LEDERLE	EQ 50MG BASE	N50315 002	
	EQ 100MG BASE	N50315 001	
INJECTABLE; INJECTION			
MINOCIN			
LEDERLE	EQ 100MG BASE/VIAL	N62139 001	

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL			
MINOCYCLINE HCL			
* LEDERLE	EQ 50MG BASE	N50451 003	AUG 10, 1982
*	EQ 100MG BASE	N50451 002	AUG 10, 1982

MINOXIDIL

TABLET; ORAL			
MINODYL			
QUANTUM PHARMICS	2.5MG	N72153 001	JUL 13, 1988
	10MG	N71534 001	MAR 19, 1987
MINOXIDIL			
ROSEMONT	2.5MG	N71537 001	DEC 16, 1988
ROYCE LABS	2.5MG	N71799 001	NOV 10, 1987
	10MG	N71796 001	NOV 10, 1987

MITOMYCIN

INJECTABLE; INJECTION			
MUTAMYCIN			
BRISTOL	5MG/VIAL	N50450 001	
	20MG/VIAL	N50450 002	

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL			
MOBAN			
ENDO PHARMS	5MG	N17111 001	
	10MG	N17111 002	
	25MG	N17111 003	

MOXALACTAM DISODIUM

INJECTABLE; INJECTION			
MOXAM			
LILLY	EQ 250MG BASE/VIAL	N50550 001	

FDA data supplied by DrugPatentWatch.com

MOXALACTAM DISODIUM

INJECTABLE; INJECTION		
MOXAM		
LILLY	EQ 500MG BASE/VIAL	N50550 002
	EQ 1GM BASE/VIAL	N50550 003
	EQ 2GM BASE/VIAL	N50550 004
	EQ 10GM BASE/VIAL	N50550 008

NABILONE

CAPSULE; ORAL		
CESAMET		
LILLY	1MG	N18677 001 DEC 26, 1985

NAFCILLIN SODIUM

FOR SOLUTION; ORAL		
UNIPEN		
WYETH AYERST	EQ 250MG BASE/5ML	N50199 001
INJECTABLE; INJECTION		
NALLPEN		
SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62755 001 DEC 19, 1986
	EQ 2GM BASE/VIAL	N62755 002 DEC 19, 1986
UNIPEN		
WYETH AYERST	EQ 20GM BASE/VIAL	N50320 006
TABLET; ORAL		
UNIPEN		
WYETH AYERST	EQ 500MG BASE	N50462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION		
NALBUPHINE		
AM PHARM PARTNERS	10MG/ML	N70751 001 JUL 02, 1986
	20MG/ML	N70752 001 SEP 24, 1986
QUAD PHARMS	10MG/ML	N70692 001 MAR 25, 1986

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION		
NALBUPHINE		
QUAD PHARMS	20MG/ML	N70693 001 SEP 24, 1986
NALBUPHINE HCL		
ASTRAZENECA	10MG/ML	N72071 001 APR 10, 1989
	10MG/ML	N72072 001 APR 10, 1989
	20MG/ML	N72074 001 APR 10, 1989
	20MG/ML	N72075 001 APR 10, 1989

NALIDIXIC ACID

TABLET; ORAL		
NALIDIXIC ACID		
HALSEY	1GM	N70272 001 JUN 29, 1988
	250MG	N70270 001 JUN 29, 1988
	500MG	N70271 001 JUN 29, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION		
NALOXONE		
ELKINS SINN	0.4MG/ML	N70496 001 SEP 24, 1986
NALOXONE HCL		
ABBOTT	0.4MG/ML	N70172 001 SEP 24, 1986
AM PHARM PARTNERS	0.02MG/ML	N70648 001 NOV 17, 1986
	0.02MG/ML	N70661 001 NOV 17, 1986
	0.4MG/ML	N70649 001 NOV 17, 1986
	1MG/ML	N71604 001 DEC 16, 1988
ASTRAZENECA	0.02MG/ML	N72081 001 APR 11, 1989

FDA data supplied by DrugPatentWatch.com

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

ASTRAZENECA	0.02MG/ML	N72082 001 APR 11, 1989
	0.02MG/ML	N72083 001 APR 11, 1989
	0.02MG/ML	N72084 001 APR 11, 1989
	0.02MG/ML	N72085 001 APR 11, 1989
	0.4MG/ML	N72086 001 APR 11, 1989
	0.4MG/ML	N72087 001 APR 11, 1989
	0.4MG/ML	N72088 001 APR 11, 1989
	0.4MG/ML	N72089 001 APR 11, 1989
	0.4MG/ML	N72090 001 APR 11, 1989
	1MG/ML	N72091 001 APR 11, 1989
	1MG/ML	N72092 001 APR 11, 1989
	1MG/ML	N72093 001 APR 11, 1989
INTL MEDICATION	0.4MG/ML	N70417 001 SEP 24, 1986
	1MG/ML	N72115 001 APR 27, 1988
MARSAM	0.4MG/ML	N71811 001 JUL 19, 1988
QUAD PHARMS	0.02MG/ML	N70678 001 DEC 18, 1986
	0.4MG/ML	N70679 001 DEC 18, 1986
	1MG/ML	N70680 001 DEC 18, 1986
SMITH AND NEPHEW	0.02MG/ML	N71671 001 NOV 17, 1987
	0.4MG/ML	N71681 001 NOV 17, 1987
	0.4MG/ML	N71682 001 NOV 17, 1987
SOLOPAK	0.02MG/ML	N71672 001 NOV 17, 1987

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

SOLOPAK	0.4MG/ML	N71683 001 NOV 17, 1987
STERIS	0.4MG/ML	N71339 001 NOV 18, 1987

NARCAN

DUPONT MERCK	0.4MG/ML	N71083 001 JUL 28, 1988
	1MG/ML	N71084 001 JUL 28, 1988
	1MG/ML	N71311 001 JUL 28, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AKORN	100MG/ML	N87519 001 SEP 28, 1983
AM PHARM PARTNERS	100MG/ML	N88290 001 OCT 03, 1983
	200MG/ML	N88317 001 OCT 14, 1983
QUAD PHARMS	50MG/ML	N89248 001 JUN 25, 1986
	100MG/ML	N89249 001 JUN 25, 1986
	200MG/ML	N89250 001 JUN 25, 1986
STERIS	50MG/ML	N87598 001 OCT 06, 1983
	50MG/ML	N88554 001 FEB 10, 1986
	100MG/ML	N87599 001 OCT 06, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

QUAD PHARMS	25MG/ML	N89297 001 OCT 01, 1986
	50MG/ML	N89298 001 OCT 01, 1986

FDA data supplied by DrugPatentWatch.com

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

STERIS	25MG/ML	N86386 001 JUN 17, 1983
	50MG/ML	N87488 001 JUN 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAFAZAIR

PHARMAFAIR	0.1%	N88101 001 APR 15, 1983

NAPROXEN

TABLET; ORAL
NAPROXEN

HAMILTON PHARMS	250MG	N74110 001 OCT 30, 1992
	375MG	N74110 002 OCT 30, 1992
	500MG	N74110 003 OCT 30, 1992

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

HAMILTON PHARMS	EQ 250MG BASE	N74106 001 AUG 31, 1993
	EQ 500MG BASE	N74106 002 AUG 31, 1993
PUREPAC PHARM	EQ 250MG BASE	N74319 001 MAR 20, 1995
	EQ 500MG BASE	N74319 002 MAR 20, 1995

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE

AVENTIS	0.5%	N20750 001 OCT 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE

BRISTOL MYERS SQUIBB	300MG	N20152 006 DEC 22, 1994

NEOMYCIN SULFATE

TABLET; ORAL
MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	N60520 001

NEOBIOTIC

PFIZER	EQ 350MG BASE	N60475 001

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	EQ 350MG BASE	N60365 001
EON	EQ 350MG BASE	N61586 001
LANNETT	EQ 350MG BASE	N60607 001
LILLY	EQ 350MG BASE	N60385 001
ROXANE	EQ 350MG BASE	N62173 001

NEOMYCIN SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SEE FLURANDRENOLIDE; NEOMYCIN SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
SEE METHYLPREDNISOLONE; NEOMYCIN SULFATE

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
NEOSPORIN

GLAXO WELLCOME	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50176 002 JAN 14, 1985

FDA data supplied by DrugPatentWatch.com

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC
NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	N61039	002
	EQ 3.5MG BASE/GM;0.5%	N61039	001

SUSPENSION/DROPS; OPHTHALMIC
NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	N61037	001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC
NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE	N50378	001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	N62598	001
		JUL 21, 1986	

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	N62600	001
		JUL 21, 1986	
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	N62595	001
		JUL 21, 1986	

OINTMENT; TOPICAL
MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	N62609	001
		MAY 23, 1986	

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	N62608	001
		MAY 23, 1986	
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	N62607	001
		MAY 23, 1986	

NETILMICIN SULFATE

INJECTABLE; INJECTION
NETROMYCIN

SCHERING	EQ 10MG BASE/ML	N50544	001
		FEB 28, 1983	

NETILMICIN SULFATE

INJECTABLE; INJECTION
NETROMYCIN

SCHERING	EQ 25MG BASE/ML	N50544	002
		FEB 28, 1983	

NIACIN

CAPSULE; ORAL
WAMPOCAP

WALLACE LABS	500MG	N11073	003

TABLET; ORAL
NIACIN

CHELSEA LABS	500MG	N85172	001
DANBURY PHARMA	500MG	N83305	001
EVERYLIFE	500MG	N83203	001
GENEVA PHARMS	500MG	N83306	001
HALSEY	500MG	N83453	001
IMPAX LABS	500MG	N83115	001
PUREPAC PHARM	500MG	N83271	001
WATSON LAB	500MG	N83136	001
WEST WARD	500MG	N83718	001
ZENITH GOLDLINE	500MG	N83180	001

NIACINAMIDE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL		
TPN SUSPENSION		
INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003

NICLOSAMIDE

TABLET, CHEWABLE; ORAL		
NICLOCIDE		
BAYER	500MG	N18669 001 MAY 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL		
HABITROL		
NOVARTIS	7MG/24HR	N20076 001 NOV 27, 1991
	14MG/24HR	N20076 002 NOV 27, 1991
	21MG/24HR	N20076 003 NOV 27, 1991
PROSTEP		
ELAN PHARM	11MG/24HR	N19983 001 JAN 28, 1992
	22MG/24HR	N19983 002 JAN 28, 1992

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL		
NIFEDIPINE		
MYLAN	30MG	N75108 001 DEC 17, 1999

NITROFURANTOIN

CAPSULE; ORAL		
NITROFURANTOIN		
WATSON LAB	50MG	N84326 001
	100MG	N84326 002
TABLET; ORAL		
FURALAN		
LANNETT	50MG	N80017 001

NITROFURANTOIN

TABLET; ORAL		
FURALAN		
LANNETT	100MG	N80017 002
NITROFURANTOIN		
CHELSEA LABS	50MG	N85797 001
	100MG	N85796 001
ELKINS SINN	50MG	N80003 001
	100MG	N80003 002
EON	50MG	N80043 001
	100MG	N80043 002
WATSON LAB	100MG	N80447 002
ZENITH GOLDLINE	50MG	N80078 002
	100MG	N80078 001

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION		
IVADANTIN		
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N12402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL		
NITROFURANTOIN MACROCRYSTALLINE		
WATSON LAB	50MG	N70248 001 JUN 24, 1988
	100MG	N70249 001 JUN 24, 1988

NITROFURAZONE

DRESSING; TOPICAL		
ACTIN-N		
SHERWOOD MEDCL	0.2%	N17343 001
OINTMENT; TOPICAL		
NITROFURAZONE		
AMBIX	0.2%	N86077 001
LANNETT	0.2%	N84393 001

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN

INJECTABLE; INJECTION

NITRO IV		
POHL BOSKAMP	5MG/ML	N18672 002 AUG 30, 1983
NITRO-BID		
AVENTIS PHARMS	10MG/ML	N71159 001 FEB 28, 1990
NITROGLYCERIN		
AM PHARM PARTNERS	5MG/ML	N70077 001 DEC 13, 1985
	5MG/ML	N71203 001 MAY 08, 1987
INTL MEDICATION	5MG/ML	N70026 001 SEP 10, 1985
LUITPOLD	5MG/ML	N71492 001 MAY 24, 1988
QUAD PHARMS	5MG/ML	N71094 001 JUL 31, 1987
	10MG/ML	N71095 001 JUL 31, 1987
SMITH AND NEPHEW	5MG/ML	N70633 001 JUN 19, 1986
	5MG/ML	N70634 001 JUN 19, 1986
NITROL		
RORER	0.8MG/ML	N18774 001 JAN 19, 1983
NITRONAL		
POHL BOSKAMP	1MG/ML	N18672 001 AUG 30, 1983
NITROSTAT		
PARKE DAVIS	0.8MG/ML	N18588 001
	5MG/ML	N18588 002 DEC 23, 1983
	5MG/ML	N70863 001 JAN 08, 1987
	10MG/ML	N70871 001 JAN 08, 1987
	10MG/ML	N70872 001 JAN 08, 1987

NONOXYNOL-9

AEROSOL; VAGINAL

DELFEN		
PERSONAL PRODS	12.5%	N14349 002

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983

NORETHINDRONE

TABLET; ORAL

NORLUTIN		
PARKE DAVIS	5MG	N10895 002

NORETHINDRONE; *MULTIPLE*

SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

SEE ETHINYL ESTRADIOL; NORETHINDRONE

SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE		
PARKE DAVIS	5MG	N12184 002

NORETHINDRONE ACETATE; *MULTIPLE*

SEE ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

NORETHYNODREL; *MULTIPLE*

SEE MESTRANOL; NORETHYNODREL

NYSTATIN

CREAM; TOPICAL

CANDEX		
BAYER	100,000 UNITS/GM	N61810 001
MYKINAC		
ALPHARMA	100,000 UNITS/GM	N62387 001 JUL 29, 1982

LOTION; TOPICAL

CANDEX		
BAYER	100,000 UNITS/ML	N50233 001

FDA data supplied by DrugPatentWatch.com

NYSTATIN

OINTMENT; TOPICAL
MYCOSTATIN
WESTWOOD SQUIBB 100,000 UNITS/GM N60571 001
MYKINAC
ALPHARMA 100,000 UNITS/GM N62731 001
SEP 22, 1986

POWDER; ORAL
BARSTATIN 100
BARLAN 100% N62489 001
APR 27, 1988

SUPPOSITORY; VAGINAL
NYSERT
PROCTER AND GAMBLE 100,000 UNITS N50478 001

SUSPENSION; ORAL
NYSTATIN
ALPHARMA 100,000 UNITS/ML N62571 001
OCT 29, 1985
MORTON GROVE 100,000 UNITS/ML N62835 001
NOV 19, 1987
PHARMADERM 100,000 UNITS/ML N62518 001
JUL 06, 1984
PHARMAFAIR 100,000 UNITS/ML N62541 001
JAN 16, 1985

TABLET; ORAL
NYSTATIN
CHELSEA LABS 500,000 UNITS N62402 001
DEC 16, 1982
QUANTUM PHARMICS 500,000 UNITS N62525 001
OCT 29, 1984

TABLET; VAGINAL
MYCOSTATIN
BRISTOL MYERS SQUIBB 100,000 UNITS N60577 001
NYSTATIN
CHELSEA LABS 100,000 UNITS N62176 001
EON 100,000 UNITS N61965 001
QUANTUM PHARMICS 100,000 UNITS N62509 001
APR 03, 1984
TEVA 100,000 UNITS N62502 001
DEC 23, 1983

NYSTATIN; *MULTIPLE*
SEE CLIOQUINOL; NYSTATIN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II
APOTHECON 100,000 UNITS/GM;0.1% N60576 002
MAY 01, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE
ALPHARMA 100,000 UNITS/GM;0.1% N63010 001
DEC 20, 1988
CLAY PARK 100,000 UNITS/GM;0.1% N62186 002
JUN 06, 1985
PHARMAFAIR 100,000 UNITS/GM;0.1% N62657 001
JUL 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE
PHARMADERM 100,000 UNITS/GM;0.1% N62596 001
OCT 08, 1985

OINTMENT; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE
PHARMAFAIR 100,000 UNITS/GM;0.1% N62656 001
JUL 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE
PHARMADERM 100,000 UNITS/GM;0.1% N62603 001
OCT 09, 1985

OLANZAPINE

TABLET; ORAL
ZYPREXA
LILLY 20MG N20592 006
SEP 09, 1997

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
ASCOT 100MG N88067 001
APR 06, 1983
GENEVA PHARMS 100MG N85046 001
WATSON LAB 100MG N84303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL
DISIPAL
3M 50MG N10653 001

FDA data supplied by DrugPatentWatch.com

OXACILLIN SODIUM

CAPSULE; ORAL		
OXACILLIN SODIUM		
APOTHECON	EQ 250MG BASE	N61450 002
	EQ 500MG BASE	N61450 001
PROSTAPHLIN		
APOTHECON	EQ 500MG BASE	N50118 002
FOR SOLUTION; ORAL		
PROSTAPHLIN		
APOTHECON	EQ 250MG BASE/5ML	N50194 001
INJECTABLE; INJECTION		
BACTOCILL		
SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61334 009 MAR 26, 1982
	EQ 1GM BASE/VIAL	N61334 006 MAR 26, 1982
	EQ 2GM BASE/VIAL	N61334 007 MAR 26, 1982
	EQ 4GM BASE/VIAL	N61334 008 MAR 26, 1982
	EQ 10GM BASE/VIAL	N61334 010
OXACILLIN SODIUM		
APOTHECON	EQ 250MG BASE/VIAL	N50195 001
	EQ 500MG BASE/VIAL	N50195 002
	EQ 1GM BASE/VIAL	N50195 003
	EQ 2GM BASE/VIAL	N50195 004
	EQ 4GM BASE/VIAL	N50195 005
ELKINS SINN	EQ 250MG BASE/VIAL	N62711 001 FEB 03, 1989
	EQ 500MG BASE/VIAL	N62711 002 FEB 03, 1989
	EQ 1GM BASE/VIAL	N62711 003 FEB 03, 1989
	EQ 2GM BASE/VIAL	N62711 004 FEB 03, 1989
	EQ 4GM BASE/VIAL	N62711 005 FEB 03, 1989
	EQ 10GM BASE/VIAL	N62711 006 FEB 03, 1989

OXAZEPAM

CAPSULE; ORAL		
OXAZEPAM		
AM THERAP	10MG	N71955 001 MAR 03, 1988
AM THERAP	15MG	N71956 001 MAR 03, 1988
AM THERAP	30MG	N71957 001 MAR 03, 1988
HALSEY	10MG	N70957 001 AUG 10, 1987
HALSEY	15MG	N71025 001 AUG 10, 1987
HALSEY	30MG	N71026 001 AUG 10, 1987
MYLAN	10MG	N71713 001 OCT 20, 1987
MYLAN	15MG	N71714 001 OCT 20, 1987
MYLAN	30MG	N71715 001 OCT 20, 1987
ZAXOPAM		
QUANTUM PHARMICS	10MG	N70650 001 MAR 01, 1988
QUANTUM PHARMICS	15MG	N70640 001 MAR 01, 1988
QUANTUM PHARMICS	30MG	N70641 001 MAR 01, 1988
TABLET; ORAL		
OXAZEPAM		
DANBURY PHARMA	15MG	N71494 001 APR 21, 1987
HALSEY	15MG	N70683 001 JAN 16, 1987
PARKE DAVIS	15MG	N71508 001 FEB 02, 1987

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL		
TRASICOR		
NOVARTIS	20MG	N18166 001 DEC 28, 1983
	40MG	N18166 002 DEC 28, 1983
	80MG	N18166 003 DEC 28, 1983

FDA data supplied by DrugPatentWatch.com

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL
TRASICOR
NOVARTIS 160MG N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984
OXTRIPHYLLINE
MORTON GROVE 100MG/5ML N88243 001 DEC 05, 1983

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS 50MG/5ML N09268 011
OXTRIPHYLLINE PEDIATRIC
MORTON GROVE 50MG/5ML N88242 001 DEC 05, 1983

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL
PARKE DAVIS 100MG N09268 003
200MG N09268 007
OXTRIPHYLLINE
WATSON LAB 100MG N87866 001 AUG 25, 1983
200MG N87835 001 AUG 25, 1983

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE
QUANTUM PHARMICS 5MG N72296 001 DEC 08, 1988
ROSEMONT 5MG N70746 001 MAR 10, 1988
WATSON LAB 5MG N72485 001 APR 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ROXICODONE
ROXANE 10MG N20932 001 OCT 26, 1998
30MG N20932 002 OCT 26, 1998

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYPHENBUTAZONE

TABLET; ORAL
OXYPHENBUTAZONE
WATSON LAB 100MG N88399 001 SEP 17, 1984
TANDEARIL
NOVARTIS 100MG N12542 004 SEP 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL
DARICON
PFIZER 10MG N11612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL
ANTRENYL
NOVARTIS 5MG N08492 002

FDA data supplied by DrugPatentWatch.com

OXYTETRACYCLINE

TABLET; ORAL
TERRAMYCIN
PFIZER 250MG N50287 001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
PFIZER EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
OXY-KESSO-TETRA
FERRANTE EQ 250MG BASE N60179 001
OXYTETRACYCLINE HCL
PUREPAC PHARM EQ 250MG BASE N60634 001
TERRAMYCIN
PFIZER EQ 125MG BASE N50286 001

INJECTABLE; INJECTION
TERRAMYCIN
PFIZER EQ 250MG BASE/VIAL N60586 001
EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
PFIZER EQ 100MG BASE; 100,000 UNITS N61009 001

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
WYETH AYERST 10 USP UNITS/ML N18243 001

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
ABBOTT 1 USP UNIT/100ML N19185 004 MAR 29, 1985
2 USP UNITS/100ML N19185 003 MAR 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
ABBOTT 2 USP UNITS/100ML N19185 002 MAR 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
ABBOTT 1 USP UNIT/100ML N19185 001 MAR 29, 1985

SOLUTION; NASAL
SYNTOCINON
NOVARTIS 40 USP UNITS/ML N12285 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
ASTRAZENECA 2MG/ML N72212 001 MAR 31, 1988
QUAD PHARMS 1MG/ML N72209 001 JUN 03, 1988
2MG/ML N72208 001 JUN 03, 1988

PANTOTHENIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

PARAMETHADIONE

SOLUTION; ORAL
PARADIONE
ABBOTT 300MG/ML N06800 002

FDA data supplied by DrugPatentWatch.com

PARAMETHASONE ACETATE

TABLET; ORAL
HALDRONE
LILLY 1MG N12772 005
2MG N12772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL
EUTONYL
ABBOTT 10MG N13448 002
25MG N13448 003
50MG N13448 004

PARGYLINE HYDROCHLORIDE; *MULTIPLE*
SEE METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
PARKEDALE EQ 250MG BASE N60521 001

SYRUP; ORAL
HUMATIN
PARKE DAVIS EQ 125MG BASE/5ML N60522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
* SMITHKLINE BEECHAM EQ 10MG BASE N20885 001
OCT 09, 1998
* EQ 20MG BASE N20885 002
OCT 09, 1998
* EQ 30MG BASE N20885 003
OCT 09, 1998
* EQ 40MG BASE N20885 004
OCT 09, 1998

TABLET; ORAL
PAXIL
SMITHKLINE BEECHAM EQ 50MG BASE N20031 004
DEC 29, 1992

PENBUTOLOL SULFATE

TABLET; ORAL
LEVATOL
SCHWARZ PHARMA 10MG N18976 001
DEC 30, 1987

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION
BICILLIN L-A
WYETH AYERST 300,000 UNITS/ML N50131 001

SUSPENSION; ORAL
BICILLIN
WYETH AYERST 300,000 UNITS/5ML N50126 002

TABLET; ORAL
BICILLIN
WYETH AYERST 200,000 UNITS N50128 001

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL
PENICILLIN G POTASSIUM
MYLAN 200,000 UNITS/5ML N60752 003
250,000 UNITS/5ML N60752 002
400,000 UNITS/5ML N60752 001
PUREPAC PHARM 250,000 UNITS/5ML N61740 001
400,000 UNITS/5ML N61740 002
PENTIDS '200'
APOTHECON 200,000 UNITS/5ML N62149 001
PENTIDS '400'
APOTHECON 400,000 UNITS/5ML N62149 002
PFIZERPEN G
PFIZER 400,000 UNITS/5ML N60587 001

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
APOTHECON 1,000,000 UNITS/VIAL N60362 001
5,000,000 UNITS/VIAL N60362 003
10,000,000 UNITS/VIAL N60362 004
20,000,000 UNITS/VIAL N60362 002
CONSOLIDATED PHARM 500,000 UNITS/VIAL N60806 001
1,000,000 UNITS/VIAL N60806 002
5,000,000 UNITS/VIAL N60806 003
10,000,000 UNITS/VIAL N60806 004

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION			
PENICILLIN G POTASSIUM			
LILLY	200,000 UNITS/VIAL	N60384	004
	500,000 UNITS/VIAL	N60384	003
	1,000,000 UNITS/VIAL	N60384	002
	5,000,000 UNITS/VIAL	N60384	001
	20,000,000 UNITS/VIAL	N60384	005
	20,000,000 UNITS/VIAL	N60601	001
PARKE DAVIS	1,000,000 UNITS/VIAL	N62003	001
	5,000,000 UNITS/VIAL	N62003	002
TABLET; ORAL			
PENICILLIN G POTASSIUM			
APOTHECON	250,000 UNITS	N60392	003
LILLY	250,000 UNITS	N60403	001
PUREPAC PHARM	200,000 UNITS	N61588	001
	250,000 UNITS	N61588	002
	400,000 UNITS	N61588	003
ZENITH GOLDLINE	400,000 UNITS	N60073	004
PENTIDS '200'			
APOTHECON	200,000 UNITS	N62155	001
PENTIDS '250'			
APOTHECON	250,000 UNITS	N62155	002
PENTIDS '400'			
APOTHECON	400,000 UNITS	N60392	004
	400,000 UNITS	N62155	003
PENTIDS '800'			
APOTHECON	800,000 UNITS	N60392	005
	800,000 UNITS	N62155	004
PFIZERPEN G			
PFIZER	50,000 UNITS	N60075	001
	100,000 UNITS	N60075	002
	200,000 UNITS	N60075	003
	250,000 UNITS	N60075	004
	400,000 UNITS	N60075	005
	800,000 UNITS	N60075	006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION			
DURACILLIN A.S.			
LILLY	300,000 UNITS/ML	N60093	001
PENICILLIN G PROCAINE			
CONSOLIDATED PHARM	300,000 UNITS/ML	N60800	001
	600,000 UNITS/1.2ML	N60800	002
PARKE DAVIS	300,000 UNITS/ML	N62029	001

PENICILLIN G SODIUM

INJECTABLE; INJECTION			
PENICILLIN G SODIUM			
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	N61935	001
COPANOS	5,000,000 UNITS/VIAL	N61051	001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	N61046	001

PENICILLIN V

FOR SUSPENSION; ORAL			
V-CILLIN			
LILLY	125MG/0.6ML	N60002	001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL			
BETAPEN-VK			
APOTHECON	EQ 125MG BASE/5ML	N61149	001
	EQ 250MG BASE/5ML	N61149	002
PENAPAR-VK			
PARKE DAVIS	EQ 125MG BASE/5ML	N62002	001
	EQ 250MG BASE/5ML	N62002	002
PENICILLIN V POTASSIUM			
PUREPAC PHARM	EQ 125MG BASE/5ML	N61758	001
	EQ 250MG BASE/5ML	N61758	002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML	N61815	001
	EQ 250MG BASE/5ML	N61815	002
VEETIDS '125'			
APOTHECON	EQ 125MG BASE/5ML	N61206	001
	EQ 125MG BASE/5ML	N62153	001
VEETIDS '250'			
APOTHECON	EQ 250MG BASE/5ML	N61206	002
	EQ 250MG BASE/5ML	N62153	002
TABLET; ORAL			
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE	N60006	001
PENAPAR-VK			
PARKE DAVIS	EQ 250MG BASE	N62001	001
	EQ 500MG BASE	N62001	002
PENICILLIN V POTASSIUM			
PUREPAC PHARM	EQ 125MG BASE	N61571	001
	EQ 250MG BASE	N61571	002
	EQ 500MG BASE	N61571	003
ZENITH GOLDLINE	EQ 125MG BASE	N60518	001

FDA data supplied by DrugPatentWatch.com

PENICILLIN V POTASSIUM

TABLET; ORAL			
PENICILLIN V POTASSIUM			
ZENITH GOLDLINE	EQ 250MG BASE	N60518	002
	EQ 500MG BASE	N60518	003
PFIZERPEN VK			
PFIZER	EQ 250MG BASE	N61836	001
	EQ 500MG BASE	N61836	002
UTICILLIN VK			
PHARMACIA AND UPJOHN	EQ 500MG BASE	N61651	002
VEETIDS '250'			
APOTHECON	EQ 250MG BASE	N61164	001
	EQ 250MG BASE	N62156	002
VEETIDS '500'			
APOTHECON	EQ 500MG BASE	N61164	002
	EQ 500MG BASE	N62156	001

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION			
PENTACARINAT			
ARMOUR PHARM	300MG/VIAL	N73447	001
		APR 28, 1994	

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL			
TALWIN 50			
SANOFI SYNTHELABO	EQ 50MG BASE	N16732	001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION			
YTTERBIUM YB 169 DTPA			
3M	2mCi/ML	N17518	001

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
PENTOBARBITAL SODIUM			
LANNETT	50MG	N85937	001
	100MG	N85915	001
VITARINE	100MG	N83284	001
WHITEWORTH TOWN PLSN	100MG	N83338	001

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
SODIUM PENTOBARBITAL			
ANABOLIC	100MG	N84590	001
CHELSEA LABS	100MG	N85791	001
ELKINS SINN	100MG	N83368	001
EVERYLIFE	100MG	N83259	001
HALSEY	100MG	N84677	001
PARKE DAVIS	100MG	N84156	001
PERRIGO	100MG	N84560	001
PUREPAC PHARM	100MG	N83301	001
WYETH AYERST	100MG	N83239	001
ZENITH GOLDLINE	50MG	N83461	001
	100MG	N83461	002
INJECTABLE; INJECTION			
PENTOBARBITAL SODIUM			
ELKINS SINN	50MG/ML	N83270	001
TABLET; ORAL			
PENTOBARBITAL SODIUM			
VITARINE	100MG	N83285	001
SODIUM PENTOBARBITAL			
ANABOLIC	100MG	N84238	001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION			
ANSOLYSEN			
WYETH AYERST	10MG/ML	N09372	001

PERFLUBRON

LIQUID; ORAL			
IMAGENT			
ALLIANCE PHARM	100%	N20091	001
		AUG 13, 1993	

PERMETHRIN

LOTION; TOPICAL			
NIX			
GLAXO WELLCOME	1%	N19435	001
		MAR 31, 1986	

FDA data supplied by DrugPatentWatch.com

PERPHENAZINE

SYRUP; ORAL
TRILAFON
SCHERING 2MG/5ML N11294 002

TABLET, EXTENDED RELEASE; ORAL
TRILAFON
SCHERING 8MG N11361 002

PERPHENAZINE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL
AZO GANTANOL
ROCHE 100MG;500MG N13294 001
SEP 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
ROCHE 50MG;500MG N19358 001
AUG 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENAZINE
MAST MM 35MG N86523 001
35MG N86524 001
35MG N86525 001
PHENDIMETRAZINE TARTRATE
VITARINE 35MG N85634 001
35MG N85645 001
35MG N85670 001
35MG N86403 001
35MG N86408 001
35MG N86410 001
35MG N87424 001
SPRX-3
SOLVAY 35MG N85897 001
STATOBEX
TEVA 35MG N85507 001

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
MELFIAT-105
NUMARK 105MG N87487 001
OCT 13, 1982
PHENDIMETRAZINE TARTRATE
GRAHAM DM 105MG N87214 001
MAY 26, 1982
105MG N88020 001
AUG 16, 1982
105MG N88028 001
AUG 16, 1982
105MG N88062 001
SEP 13, 1982
105MG N88063 001
SEP 10, 1982
105MG N88111 001
OCT 18, 1982
SPRX-105
NUMARK 105MG N88024 001
DEC 22, 1982

TABLET; ORAL
ADPHEN
FERNDALE LABS 35MG N83655 001
ALPHAZINE
EON 35MG N85034 001
DI-METREX
PVT FORM 35MG N85698 001
MELFIAT
NUMARK 35MG N83790 002
METRA
FOREST PHARMS 35MG N83754 001
PHENAZINE
MAST MM 35MG N87305 001
PHENDIMETRAZINE TARTRATE
ANABOLIC 35MG N86020 001
BARR 35MG N83644 001
35MG N83684 001
35MG N83686 001
35MG N83687 001
35MG N84831 001
35MG N84834 001
35MG N84835 001
CHELSEA LABS 35MG N85767 001
35MG N85768 001
35MG N85770 001
35MG N85773 001

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

FERNDALE LABS	35MG	N86834 001 SEP 15, 1983
GENEVA PHARMS	35MG	N86365 001
	35MG	N86370 001
INWOOD LABS	35MG	N84740 001
	35MG	N84741 001
	35MG	N84742 001
	35MG	N84743 001
KV PHARM	35MG	N84138 001
	35MG	N84141 001
	35MG	N85525 001
MFG CHEMISTS	35MG	N85914 001
NUMARK	35MG	N83790 001
PVT FORM	35MG	N85199 001
	35MG	N85697 001
ROSEMONT	35MG	N83805 001
	35MG	N84398 001
SOLVAY	35MG	N83993 001
VITARINE	35MG	N85519 001
	35MG	N86005 001
	35MG	N86106 001
ZENITH GOLDLINE	35MG	N83682 001
	35MG	N85611 001
	35MG	N85612 001

PLEGINE

WYETH AYERST	35MG	N12248 001

STATOBEX-G

TEVA	35MG	N85095 001

PHENINDIONE

TABLET; ORAL
HEDULIN

AVENTIS PHARMS	50MG	N08767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG	N10460 005

TABLET, EXTENDED RELEASE; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG	N11752 004

PHENMETRAZINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	75MG	N11752 003

PHENPROCOUMON

TABLET; ORAL
LIQUAMAR

ORGANON	3MG	N11228 001

PHENSUXIMIDE

CAPSULE; ORAL
MILONTIN

PARKE DAVIS	500MG	N08855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

SMITHKLINE BEECHAM	30MG	N17352 001

OBESTIN-30

FERNDALE LABS	30MG	N87144 001

PHENTERMINE HCL

CHELSEA LABS	30MG	N86740 001 MAR 21, 1985
DURAMED	30MG	N88948 001 APR 25, 1986
EON	37.5MG	N88414 001 OCT 19, 1983
LANNETT	30MG	N87022 001 FEB 03, 1983
ROSEMONT	30MG	N88430 001 MAR 27, 1984
TEVA	30MG	N86911 001
	30MG	N87126 001
	30MG	N87777 001 NOV 01, 1985
	30MG	N88612 001 APR 04, 1984
	30MG	N88613 001 APR 09, 1984
	30MG	N88614 001 APR 09, 1984

FDA data supplied by DrugPatentWatch.com

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL			
PHENTERMINE HCL			
VITARINE	30MG	N87202	001
	30MG	N87235	001
ZENITH GOLDLINE	30MG	N86329	001
TABLET; ORAL			
PHENTERMINE HCL			
CHELSEA LABS	8MG	N85739	001
EON	8MG	N85671	001
	8MG	N85689	001
	30MG	N88605	001
		SEP 28, 1987	
VITARINE	8MG	N86453	001
	8MG	N86456	001
ZENITH GOLDLINE	8MG	N85553	001
TORA			
SOLVAY	8MG	N84035	001

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL			
PHENTERMINE RESIN 30			
QUANTUM PHARMICS	EQ 30MG BASE	N89120	001
		FEB 04, 1988	

PHENYL AMINOSALICYLATE

POWDER; ORAL			
PHENY-PAS-TEBAMIN			
PURDUE FREDERICK	50%	N11695	002
TABLET; ORAL			
PHENY-PAS-TEBAMIN			
PURDUE FREDERICK	500MG	N11695	003

PHENYLBUTAZONE

CAPSULE; ORAL			
AZOLID			
AVENTIS	100MG	N87260	001
BUTAZOLIDIN			
NOVARTIS	100MG	N08319	009

PHENYLBUTAZONE

CAPSULE; ORAL			
PHENYLBUTAZONE			
CHELSEA LABS	100MG	N87756	001
		DEC 17, 1982	
GENEVA PHARMS	100MG	N87774	001
		JUN 16, 1982	
HALSEY	100MG	N88994	001
		DEC 04, 1985	
ZENITH GOLDLINE	100MG	N88218	001
		JUN 24, 1983	
TABLET; ORAL			
AZOLID			
AVENTIS	100MG	N87091	001
BUTAZOLIDIN			
NOVARTIS	100MG	N08319	008
PHENYLBUTAZONE			
CHELSEA LABS	100MG	N86151	001
DANBURY PHARMA	100MG	N87674	001
		APR 21, 1982	
GENEVA PHARMS	100MG	N84339	001
HALSEY	100MG	N88863	001
		DEC 04, 1985	

PHENYLEPHRINE BITARTRATE; *MULTIPLE*
SEE ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL			
PHERAZINE VC			
HALSEY	5MG/5ML;6.25MG/5ML	N88868	001
		MAR 02, 1987	
PROMETHAZINE VC PLAIN			
CENCI	5MG/5ML;6.25MG/5ML	N88815	001
		NOV 22, 1985	

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PHENYLPROPANOLAMINE POLISTIREX; *MULTIPLE*
SEE CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

PHENYTOIN

SUSPENSION; ORAL		
DILANTIN-30		
PARKE DAVIS	30MG/5ML	N08762 002

PHENYTOIN SODIUM

INJECTABLE; INJECTION		
PHENYTOIN SODIUM		
AM PHARM PARTNERS	50MG/ML	N89003 001 MAY 31, 1985
MARSAM	50MG/ML	N89501 001 OCT 13, 1987
	50MG/ML	N89779 001 NOV 27, 1992
SMITH AND NEPHEW	50MG/ML	N88519 001 DEC 19, 1984
	50MG/ML	N88521 001 DEC 18, 1984
SOLOPAK	50MG/ML	N88520 001 DEC 17, 1984
STERIS	50MG/ML	N85434 001
WARNER CHILCOTT	50MG/ML	N89900 001 MAR 30, 1990

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL		
EXTENDED PHENYTOIN SODIUM		
SIDMAK LABS NJ	100MG	N89441 001 DEC 18, 1986
PHENYTEX		
WATSON LAB	100MG	N88711 001 DEC 21, 1984

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL		
DIPHENYLAN SODIUM		
LANNETT	30MG	N80857 001
	100MG	N80857 002
PHENYTOIN SODIUM		
CHELSEA LABS	100MG	N85894 001
PHARMERAL	100MG	N85435 001
PROMPT PHENYTOIN SODIUM		
DANBURY PHARMA	100MG	N80905 001

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

INJECTABLE; INJECTION		
KONAKION		
ROCHE	1MG/0.5ML	N11745 001
	10MG/ML	N11745 003
PHYTONADIONE		
SMITHKLINE BEECHAM	1MG/0.5ML	N84060 001
	10MG/ML	N84060 002
VITAMIN K1		
ABBOTT	10MG/ML	N87956 001 JUL 25, 1983

PHYTONADIONE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL		
PINDAC		
LEO PHARM	12.5MG	N19456 001 DEC 28, 1989
	25MG	N19456 002 DEC 28, 1989

FDA data supplied by DrugPatentWatch.com

PINDOLOL

TABLET; ORAL
PINDOLOL

PUREPAC PHARM	5MG	N74125 001 APR 28, 1993
	10MG	N74125 002 APR 28, 1993

PINDOLOL; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PINDOLOL

PIPERACETAZINE

TABLET; ORAL
QUIDE

DOW PHARM	10MG	N13615 001
	25MG	N13615 002

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR		
GLAXO WELLCOME	EQ 500MG BASE/5ML	N09102 001
BRYREL		
SANOFI SYNTHELABO	EQ 500MG BASE/5ML	N17796 001
PIPERAZINE CITRATE		
ALPHARMA	EQ 500MG BASE/5ML	N80774 001
VERMIDOL		
SOLVAY	EQ 500MG BASE/5ML	N80992 001

TABLET; ORAL

ANTEPAR		
GLAXO WELLCOME	EQ 500MG BASE	N09102 003

PIPOBROMAN

TABLET; ORAL
VERCYTE

ABBOTT	10MG	N16245 001

PIROXICAM

CAPSULE; ORAL
PIROXICAM

ROXANE	10MG	N73651 001 FEB 26, 1993
	20MG	N73651 002 FEB 26, 1993

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION
ESTRADURIN

WYETH AYERST	40MG/AMP	N10753 001

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL
COLYTE

SCHWARZ PHARMA	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005 OCT 26, 1984
	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004 OCT 26, 1984

FOR SUSPENSION; ORAL
PEG-LYTE

INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

FOR SOLUTION; ORAL
COLYTE

SCHWARZ PHARMA	360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006 OCT 26, 1984

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

GLAXO WELLCOME	EQ 500,000 U BASE/VIAL	N62036 001

FDA data supplied by DrugPatentWatch.com

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING
POLYMYXIN B SULFATE

PADDOCK	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983

POLYMYXIN B SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE
SEE CHLORAMPHENICOL; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POTASSIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

POTASSIUM AMINOSALICYLATE

POWDER; ORAL
POTASSIUM AMINOSALICYLATE

HEXCEL	100%	N80098 001	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE

SAVAGE LABS	8MEQ	N73398 001	JAN 28, 1992
	10MEQ	N72427 001	MAR 28, 1990

FOR SUSPENSION, EXTENDED RELEASE; ORAL
MICRO-K LS

KV PHARM	20MEQ/PACKET	N19561 003	AUG 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

ABBOTT	1MEQ/ML	N80205 003	
	1MEQ/ML	N83345 003	
	2.4MEQ/ML	N80205 004	
	3.2MEQ/ML	N80205 005	
AKORN	2MEQ/ML	N88286 001	SEP 05, 1985
AM PHARM PARTNERS	2MEQ/ML	N80204 001	
	2MEQ/ML	N84290 001	
	2MEQ/ML	N86713 001	
	2MEQ/ML	N86714 001	
	2MEQ/ML	N87787 001	APR 20, 1982
	2MEQ/ML	N87885 001	FEB 03, 1983
ELKINS SINN	2MEQ/ML	N80203 001	
LILLY	2MEQ/ML	N07865 002	
LUITPOLD	2MEQ/ML	N80221 001	
	2MEQ/ML	N80736 001	
MILES	1MEQ/ML	N80195 002	
	2MEQ/ML	N80195 001	
	3MEQ/ML	N80195 003	
	4MEQ/ML	N80195 004	
SEARLE	1MEQ/ML	N86219 001	
	2MEQ/ML	N86219 002	
	2MEQ/ML	N86220 002	
	3MEQ/ML	N86219 003	
	3MEQ/ML	N86220 001	
	4MEQ/ML	N86219 004	
STERIS	2MEQ/ML	N86208 001	
	2MEQ/ML	N89163 001	MAR 10, 1988
	2MEQ/ML	N89421 001	JAN 02, 1987

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
STERIS 3MEQ/ML N86210 001
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER
ABBOTT 745MG/100ML N20161 001 NOV 30, 1992
14.9MG/ML N20161 005 NOV 30, 1992
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
ABBOTT 1.49GM/100ML N20161 002 NOV 30, 1992

TABLET, EXTENDED RELEASE; ORAL
KAON CL
SAVAGE LABS 6.7MEQ N17046 001
KAON CL-10
SAVAGE LABS 10MEQ N17046 002
TEN-K
NOVARTIS 10MEQ N19381 001 APR 16, 1986

POTASSIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

POTASSIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;900MG/100ML N19708 001 SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N19708 002 SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 110MG/100ML;900MG/100ML N19708 003 SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N19708 005 SEP 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 300MG/100ML;900MG/100ML N19708 006 SEP 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N18722 001 NOV 09, 1982
BAXTER HLTHCARE 75MG/100ML;900MG/100ML N17648 004
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
B BRAUN 150MG/100ML;900MG/100ML N18722 002 NOV 09, 1982

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML;900MG/100ML	N18722 003 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML;900MG/100ML	N18722 004 NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E

ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL
POTASSIUM CITRATE

MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988
	20MEQ/PACKET	N19647 001 OCT 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE

ROXANE	1GM/ML	N18551 001 FEB 19, 1982

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE

QUAD PHARMS	1GM/VIAL	N72224 001 NOV 23, 1988
WYETH AYERST	300MG/ML	N18799 001 DEC 13, 1982

TABLET; ORAL
PROTOPAM CHLORIDE

WYETH AYERST	500MG	N14122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX

PHARMACIA AND UPJOHN	1.25MG	N20667 004 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAZEPAM

CAPSULE; ORAL
CENTRAX

PARKE DAVIS	5MG	N18144 001
	10MG	N18144 002
	20MG	N18144 003 MAY 10, 1982

PRAZEPAM

ROSEMONT	5MG	N70427 001 NOV 06, 1987
	10MG	N70428 001 NOV 06, 1987

TABLET; ORAL
CENTRAX

PARKE DAVIS	10MG	N17415 001

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL		
AM THERAP	EQ 1MG BASE	N72782 001
		MAY 16, 1989
	EQ 2MG BASE	N72783 001
		MAY 16, 1989
	EQ 5MG BASE	N72784 001
		MAY 16, 1989

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP		
AVENTIS PHARMS	0.1%	N19568 001
		SEP 23, 1991

PREDNISOLONE

CREAM; TOPICAL

METI-DERM		
SCHERING	0.5%	N10209 002

TABLET; ORAL

CORTALONE		
HALSEY	1MG	N80304 003
	2.5MG	N80304 002
	5MG	N80304 001
DELTA-CORTEF		
PHARMACIA AND UPJOHN	5MG	N09987 004
FERNISOLONE-P		
FERNDALE LABS	5MG	N83941 001
PREDNISOLONE		
BARR	5MG	N84426 002
BUNDY	5MG	N83675 001
CHELSEA LABS	5MG	N85415 001
	5MG	N85416 001
ELKINS SINN	5MG	N80625 001
EON	5MG	N84773 001
EVERYLIFE	1MG	N84439 001
FERRANTE	2.5MG	N80562 001
	5MG	N80562 002
GENEVA PHARMS	5MG	N80339 001
HEATHER	5MG	N80326 001
ICN	5MG	N80236 001
IMPAX LABS	5MG	N80780 001

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE		
INWOOD LABS	5MG	N80748 001
PANRAY	1MG	N80351 001
	5MG	N80351 002
PERRIGO	5MG	N84542 001
PHOENIX LABS NY	5MG	N80322 001
PUREPAC PHARM	5MG	N80325 001
PVT FORM	5MG	N80211 001
ROXANE	5MG	N80327 002
SUPERPHARM	5MG	N88892 001
		FEB 26, 1985
TABLICAPS	5MG	N85170 001
TEVA	5MG	N80398 001
UDL	5MG	N87987 001
		JAN 18, 1983
VITARINE	5MG	N80534 001
WEST WARD	5MG	N80324 001
WHITEWORTH TOWN PLSN	5MG	N80342 001
ZENITH GOLDLINE	5MG	N80378 001
STERANE		
PFIZER	5MG	N09996 001

PREDNISOLONE; *MULTIPLE*
SEE CHLORAMPHENICOL; PREDNISOLONE

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE		
SCHERING	25MG/ML	N10255 002
PREDNISOLONE ACETATE		
AKORN	25MG/ML	N83032 001
	50MG/ML	N84492 001
BEL MAR	25MG/ML	N83738 001
	50MG/ML	N83738 002
CENT PHARMS	25MG/ML	N84717 001
	50MG/ML	N84717 002
STERIS	25MG/ML	N83654 001
	40MG/ML	N83767 001
STERANE		
PFIZER	25MG/ML	N11446 001

PREDNISOLONE ACETATE; *MULTIPLE*
SEE NEOMYCIN SULFATE; PREDNISOLONE ACETATE

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
PREDSULFAIR
PHARMAFAIR 0.5%;10% N88032 001
APR 15, 1983

SUSPENSION/DROPS; OPHTHALMIC
PREDSULFAIR
PHARMAFAIR 0.5%;10% N88007 001
APR 19, 1983
PREDSULFAIR II
PHARMAFAIR 0.2%;10% N88837 001
DEC 24, 1985

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL
MERCK EQ 20MG PHOSPHATE/ML N11583 002
PREDNISOLONE SODIUM PHOSPHATE
STERIS EQ 20MG PHOSPHATE/ML N80517 001

OINTMENT; OPHTHALMIC, OTIC
HYDELTRASOL
MERCK EQ 0.25% PHOSPHATE N11028 001

SOLUTION/DROPS; OPHTHALMIC
METRETON
SCHERING EQ 0.5% PHOSPHATE N83834 001
PREDAIR
PHARMAFAIR EQ 0.11% PHOSPHATE N88415 001
FEB 29, 1984
PREDAIR FORTE
PHARMAFAIR EQ 0.9% PHOSPHATE N88165 001
MAR 28, 1983
PREDNISOLONE SODIUM PHOSPHATE
SOLA BARNES HIND EQ 0.11% PHOSPHATE N84171 001
EQ 0.9% PHOSPHATE N84168 001
EQ 0.9% PHOSPHATE N84169 001
EQ 0.9% PHOSPHATE N84172 001

PREDNISOLONE SODIUM PHOSPHATE; *MULTIPLE*
SEE NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULSTER
AKORN EQ 0.23% PHOSPHATE;10% N74511 001
JUL 30, 1996

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
PREDNISOLONE TEBUTATE
STERIS 20MG/ML N83362 001
FEB 17, 1984

PREDNISONE

SOLUTION; ORAL
PREDNISONE
MORTON GROVE 5MG/5ML N89726 001
AUG 02, 1988

SYRUP; ORAL
LIQUID PRED
MURO 5MG/5ML N87611 002
SEP 07, 1982

TABLET; ORAL
CORTAN
HALSEY 20MG N87480 001
DELTA-DOME
BAYER 5MG N80293 001
FERNISONE
FERNDALE LABS 5MG N83364 001
METICORTEN
SCHERING 5MG N09766 001
ORASONE
SOLVAY 1MG N83009 001
5MG N83009 002
10MG N83009 003
20MG N83009 004
50MG N85999 001
PARACORT
PARKE DAVIS 5MG N10962 002
PREDNICEN-M
SCHWARZ PHARMA 5MG N84655 001
PREDNISONE
AM THERAP 5MG N89387 001
NOV 06, 1986

FDA data supplied by DrugPatentWatch.com

PREDNISONE

TABLET; ORAL

PREDNISONE

AM THERAP	10MG	N89388 001
		NOV 06, 1986
	20MG	N89389 001
		NOV 06, 1986
BUNDY	5MG	N83676 001
DANBURY PHARMA	50MG	N86867 001
DURAMED	5MG	N88394 001
		OCT 04, 1983
	10MG	N88395 001
		OCT 04, 1983
	20MG	N88396 001
		OCT 04, 1983
ELKINS SINN	5MG	N80491 001
	20MG	N85811 001
EON	5MG	N84774 001
FERRANTE	2.5MG	N80563 001
	5MG	N80563 002
HALSEY	5MG	N80300 001
	5MG	N80701 001
	20MG	N84634 001
	50MG	N86596 001
HEATHER	5MG	N80320 001
	10MG	N84341 001
	20MG	N84417 001
	20MG	N85543 001
	50MG	N86946 001
ICN	5MG	N80237 001
IMPAX LABS	5MG	N80782 001
INTERPHARM	5MG	N89597 001
		OCT 05, 1987
	10MG	N89598 001
		OCT 05, 1987
	20MG	N89599 001
		OCT 05, 1987
INWOOD LABS	1MG	N80328 001
	2.5MG	N80306 001
	5MG	N80279 001
KV PHARM	5MG	N84236 001
LEDERLE	5MG	N86968 001
NYLOS	5MG	N85115 001
PANRAY	1MG	N80350 001
	2.5MG	N80350 002
	5MG	N80350 003
PERRIGO	5MG	N83059 001
PHARMAVITE	5MG	N84662 002

PREDNISONE

TABLET; ORAL

PREDNISONE

PHOENIX LABS NY	5MG	N80321 001
	20MG	N83807 001
PUREPAC PHARM	5MG	N80353 001
	10MG	N86062 001
	20MG	N86061 001
PVT FORM	20MG	N85151 001
REXALL	5MG	N80232 001
ROXANE	20MG	N17109 001
	25MG	N87833 001
		MAY 04, 1982
SCHERER LABS	5MG	N80371 001
SPERTI	1MG	N80359 001
	2.5MG	N80359 002
	5MG	N80359 003
SUPERPHARM	5MG	N88865 001
		OCT 25, 1984
	10MG	N88866 001
		OCT 25, 1984
	20MG	N88867 001
		OCT 25, 1984
TEVA	5MG	N80397 001
UDL	5MG	N87984 001
		JAN 18, 1983
	10MG	N87985 001
		JAN 18, 1983
	20MG	N87986 001
		JAN 18, 1983
UPSHER SMITH	5MG	N87471 001
	20MG	N87470 001
VANGARD	5MG	N87682 001
		JAN 15, 1982
	20MG	N87701 001
		JAN 15, 1982
VITARINE	5MG	N80334 001
	5MG	N80506 001
WHITEWORTH TOWN PLSN	2.5MG	N84913 001
	5MG	N80343 001
	10MG	N89028 001
		JUL 24, 1986
	20MG	N84913 002
ZENITH GOLDLINE	5MG	N80283 001
	10MG	N84133 001
	20MG	N84134 001

SERVISONE

LEDERLE	5MG	N80223 001

FDA data supplied by DrugPatentWatch.com

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST
ASTRAZENECA 1% N14763 004
2% N14763 005
3% N14763 003

PRIMAQUINE PHOSPHATE; *MULTIPLE*
SEE CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

PRIMIDONE

TABLET; ORAL
PRIMIDONE
WATSON LAB 250MG N85052 001

PROBENECID

TABLET; ORAL
BENEMID
MERCK 500MG N07898 004
PROBENECID
CHELSEA LABS 500MG N86150 002
APR 23, 1982
LEDERLE 500MG N86917 001

PROBENECID; *MULTIPLE*
SEE AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID
SEE COLCHICINE; PROBENECID

PROBUCOL

TABLET; ORAL
LORELCO
AVENTIS PHARMS 250MG N17535 001
500MG N17535 002
JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PROCAINAMIDE HCL
ASCOT 250MG N87542 001
JAN 08, 1982
375MG N87697 001
MAR 01, 1983
500MG N87543 001
JAN 08, 1982
CHELSEA LABS 250MG N85167 001
375MG N87020 001
500MG N87021 001
LANNETT 500MG N84696 001
LEDERLE 250MG N86942 001
375MG N86952 001
500MG N86943 001
ROXANE 250MG N88989 001
APR 26, 1985
500MG N88990 001
APR 26, 1985
VANGARD 250MG N87643 001
JUN 01, 1982
500MG N87875 001
JUN 01, 1982
WATSON LAB 250MG N83795 001
500MG N84357 001
PROCAN
PARKE DAVIS 250MG N85804 001
375MG N87502 001
500MG N85079 001
PROCAPAN
PANRAY 250MG N83553 002

INJECTABLE; INJECTION
PROCAINAMIDE HCL
AM PHARM PARTNERS 100MG/ML N89415 001
NOV 17, 1986
500MG/ML N89416 001
NOV 17, 1986
PHARMAFAIR 100MG/ML N88824 001
NOV 20, 1985
500MG/ML N88830 001
NOV 20, 1985
QUAD PHARMS 100MG/ML N89256 001
MAY 30, 1986
500MG/ML N89257 001
MAY 30, 1986

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION			
PROCAINAMIDE HCL			
SMITH AND NEPHEW	100MG/ML	N88530 001	
		MAR 04, 1985	
	500MG/ML	N88531 001	
		MAR 04, 1985	
SOLOPAK	500MG/ML	N88532 001	
		MAR 04, 1985	
STERIS	100MG/ML	N87079 001	
	500MG/ML	N87080 001	
WARNER CHILCOTT	100MG/ML	N89528 001	
		MAY 03, 1988	
	500MG/ML	N89529 001	
		MAY 03, 1988	
TABLET, EXTENDED RELEASE; ORAL			
PROCAINAMIDE HCL			
INVAMED	500MG	N89284 001	
		JUN 23, 1986	
INWOOD LABS	500MG	N89840 001	
		MAR 06, 1989	
SIDMAK LABS NJ	250MG	N88958 001	
		DEC 02, 1985	
WATSON LAB	1GM	N89520 001	
		JAN 15, 1987	
	250MG	N88533 001	
		DEC 03, 1984	
	500MG	N88534 001	
		DEC 03, 1984	
	750MG	N88535 001	
		NOV 03, 1984	
PROCAN SR			
PARKE DAVIS	250MG	N86468 001	
PARKEDALE	1GM	N88489 001	
		JAN 16, 1985	
	500MG	N86065 001	
	750MG	N87510 001	
		APR 01, 1982	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
PROCAINE HCL			
AM PHARM PARTNERS	1%	N80384 002	
	2%	N80384 003	
BEL MAR	1%	N80711 001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
PROCAINE HCL			
BEL MAR	2%	N80756 001	
MILES	1%	N80415 001	
	2%	N80415 002	
SEARLE	1%	N86202 001	
	2%	N86202 002	
STERIS	1%	N83535 001	
	2%	N83535 002	

PROCAINE HYDROCHLORIDE; *MULTIPLE*

SEE EPINEPHRINE; PROCAINE HYDROCHLORIDE

SEE LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION			
ACHROMYCIN			
LEDERLE	40MG/VIAL;100MG/VIAL	N50276 001	
	40MG/VIAL;250MG/VIAL	N50276 003	
TETRACYN			
PFIZER	40MG/VIAL;100MG/VIAL	N60285 002	
	40MG/VIAL;250MG/VIAL	N60285 003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION			
DICURIN PROCAINE			
LILLY	100MG/ML;50MG/ML	N08869 001	

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL			
COMPAZINE			
SMITHKLINE BEECHAM	EQ 10MG BASE/ML	N11276 001	
PROCHLORPERAZINE			
ALPHARMA	EQ 10MG BASE/ML	N87153 001	
		JUN 08, 1982	
PROCHLORPERAZINE EDISYLATE			
MORTON GROVE	EQ 10MG BASE/ML	N88598 001	
		OCT 25, 1984	

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION			
PROCHLORPERAZINE EDISYLATE			
ELKINS SINN	EQ 5MG BASE/ML	N89523 001	
		MAY 03, 1988	
MARSAM	EQ 5MG BASE/ML	N89675 001	
		DEC 05, 1988	
QUAD PHARMS	EQ 5MG BASE/ML	N89637 001	
		FEB 01, 1988	
	EQ 5MG BASE/ML	N89638 001	
		FEB 01, 1988	
SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001	
		DEC 04, 1986	
STERIS	EQ 5MG BASE/ML	N89605 001	
		JUL 08, 1987	
	EQ 5MG BASE/ML	N89606 001	
		JUL 08, 1987	
SYRUP; ORAL			
PROCHLORPERAZINE EDISYLATE			
ALPHARMA	EQ 5MG BASE/5ML	N87154 001	
		SEP 01, 1982	
MORTON GROVE	EQ 5MG BASE/5ML	N88597 001	
		OCT 25, 1984	

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL			
COMPAZINE			
SMITHKLINE BEECHAM	EQ 75MG BASE	N11000 004	
TABLET; ORAL			
PROCHLORPERAZINE			
WATSON LAB	EQ 5MG BASE	N85580 001	
	EQ 10MG BASE	N85178 001	
	EQ 25MG BASE	N85579 001	
PROCHLORPERAZINE MALEATE			
DURAMED	EQ 5MG BASE	N89484 001	
		JAN 20, 1987	
	EQ 10MG BASE	N89485 001	
		JAN 20, 1987	
	EQ 25MG BASE	N89486 001	
		JAN 20, 1987	

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL		
KEMADRIN		
MONARCH PHARMS	2MG	N09818 005

PROGESTERONE

CAPSULE; ORAL		
PROMETRIUM		
UNIMED PHARMS	300MG	N19781 003
		OCT 15, 1999
INJECTABLE; INJECTION		
PROGESTERONE		
LILLY	25MG/ML	N09238 002
	50MG/ML	N09238 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL		
SPARINE		
WYETH AYERST	30MG/ML	N10942 001
	100MG/ML	N10942 004
INJECTABLE; INJECTION		
PROMAZINE HCL		
STERIS	25MG/ML	N84510 001
	50MG/ML	N84517 001
SPARINE		
WYETH AYERST	25MG/ML	N10349 008
SYRUP; ORAL		
SPARINE		
WYETH AYERST	10MG/5ML	N10942 003
TABLET; ORAL		
SPARINE		
WYETH AYERST	10MG	N10348 006
	100MG	N10348 003
	200MG	N10348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
PROMETHAZINE HCL		
AKORN	25MG/ML	N83955 002

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
PROMETHAZINE HCL		
AKORN	50MG/ML	N83955 001
KNOLL PHARM	25MG/ML	N84223 001
	50MG/ML	N84222 001
MARSAM	25MG/ML	N89463 001
		MAY 02, 1988
	50MG/ML	N89477 001
		MAY 02, 1988
STERIS	25MG/ML	N83532 001
	50MG/ML	N83532 002
ZIPAN-25		
ALTANA	25MG/ML	N83997 001
ZIPAN-50		
ALTANA	50MG/ML	N83997 002
SYRUP; ORAL		
MYMETHAZINE FORTIS		
ROSEMONT	25MG/5ML	N87996 001
		JAN 18, 1983
PROMETH FORTIS		
ALPHARMA	25MG/5ML	N84772 001
PROMETHAZINE		
CENCI	6.25MG/5ML	N89013 001
		SEP 20, 1985
PROMETHAZINE HCL		
KV PHARM	6.25MG/5ML	N85388 001
	25MG/5ML	N85385 001
PHARM ASSOC	6.25MG/5ML	N87518 001
TABLET; ORAL		
PROMETHAZINE HCL		
CHELSEA LABS	12.5MG	N85986 001
	25MG	N85684 001
	50MG	N85664 001
DANBURY PHARMA	12.5MG	N83712 001
EON	25MG	N85146 001
	50MG	N85146 002
GENEVA PHARMS	12.5MG	N84233 001
HALSEY	12.5MG	N84555 001
	25MG	N84554 001
	50MG	N84557 001
IMPAX LABS	25MG	N84214 002
		JUL 07, 1982
KNOLL PHARM	12.5MG	N84160 001
	25MG	N84166 001
	50MG	N84539 001

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL		
PROMETHAZINE HCL		
PVT FORM	12.5MG	N83214 001
TABLICAPS	12.5MG	N84080 001
	25MG	N84027 001
TEVA	25MG	N89109 001
		SEP 10, 1985
WATSON LAB	12.5MG	N83401 001
	25MG	N83204 001
	50MG	N83403 001
ZENITH GOLDLINE	12.5MG	N83604 001
	25MG	N83603 001
	50MG	N83613 001
REMSED		
DUPONT MERCK	25MG	N83176 002
	50MG	N83176 001

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION		
PRO-BANTHINE		
SEARLE	30MG/VIAL	N08843 001
TABLET; ORAL		
PROPANTHELINE BROMIDE		
ASCOT	15MG	N87663 001
		OCT 25, 1982
DANBURY PHARMA	15MG	N83029 002
GENEVA PHARMS	15MG	N80928 001
HEATHER	15MG	N85780 001
IMPAX LABS	15MG	N84541 002
MYLAN	15MG	N83706 001
PAR PHARM	15MG	N88377 001
		DEC 08, 1983
PVT FORM	15MG	N80977 001
TABLICAPS	15MG	N84428 001
WATSON LAB	15MG	N83151 001

FDA data supplied by DrugPatentWatch.com

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR		
PHARMAFAIR	0.5%	N88087 001 JUN 07, 1983
PROPARACAINE HCL		
SOLA BARNES HIND	0.5%	N84144 001
	0.5%	N84151 001

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE		
FORREST LABS	N/A	N11657 001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON		
WYETH AYERST	20MG/ML	N12382 002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN		
ASTRAZENECA	10MG/ML	N19627 001 OCT 02, 1989

PROPOXYCAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPHENE 65		
HALSEY	65MG	N83538 002
PROPOXYPHENE HCL		
ALRA	65MG	N83184 001
ANABOLIC	65MG	N83185 001
CHELSEA LABS	65MG	N85190 001
DANBURY PHARMA	65MG	N80908 002
EON	32MG	N84014 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL		
EON	65MG	N83688 001
	65MG	N83870 002
	65MG	N86495 001
HALSEY	65MG	N83186 001
MYLAN	65MG	N83299 001
PUREPAC PHARM	65MG	N83278 001
PVT FORM	32MG	N83464 001
	65MG	N83113 001
ROXANE	32MG	N83089 001
	65MG	N83089 002
ZENITH GOLDLINE	32MG	N83597 001
PROPOXYPHENE HCL 65		
WARNER CHILCOTT	65MG	N83786 001

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
SEE ASPIRIN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HCL		
INWOOD LABS	60MG	N72499 001 APR 11, 1989
	80MG	N72500 001 APR 11, 1989
	120MG	N72501 001 APR 11, 1989
	160MG	N72502 001 APR 11, 1989

INJECTABLE; INJECTION

PROPRANOLOL HCL		
SMITH AND NEPHEW	1MG/ML	N70135 001 APR 15, 1986
	1MG/ML	N70137 001 APR 15, 1986

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION			
PROPRANOLOL HCL			
SOLOPAK	1MG/ML	N70136 001	APR 15, 1986
SOLUTION; ORAL			
PROPRANOLOL HCL			
MORTON GROVE	20MG/5ML	N71984 001	MAR 03, 1989
	40MG/5ML	N71985 001	MAR 03, 1989
SUSPENSION; ORAL			
INDERAL			
WYETH AYERST	10MG/ML	N19536 001	DEC 12, 1986
TABLET; ORAL			
INDERAL			
WYETH AYERST	90MG	N16418 010	OCT 18, 1982
PROPRANOLOL HCL			
CHELSEA LABS	10MG	N70140 001	JUL 30, 1985
	20MG	N70141 001	JUL 30, 1985
	40MG	N70142 001	JUL 30, 1985
	60MG	N70143 001	JAN 15, 1987
	80MG	N70144 001	JUL 30, 1985
DANBURY PHARMA	60MG	N71098 001	OCT 06, 1986
	90MG	N71183 001	OCT 06, 1986
DURAMED	10MG	N70306 001	SEP 09, 1985
	20MG	N70307 001	SEP 09, 1985
	40MG	N70308 001	SEP 09, 1985
	60MG	N70309 001	OCT 01, 1986
	80MG	N70310 001	SEP 09, 1985

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL			
PROPRANOLOL HCL			
DURAMED	90MG	N71327 001	OCT 01, 1986
HALSEY	10MG	N70319 001	OCT 22, 1985
	20MG	N70320 001	OCT 22, 1985
	40MG	N70103 001	OCT 22, 1985
	60MG	N70321 001	SEP 24, 1986
	80MG	N70322 001	AUG 04, 1986
INTERPHARM	10MG	N71368 001	MAY 05, 1987
	20MG	N71369 001	MAY 05, 1987
	40MG	N71370 001	MAY 05, 1987
	80MG	N71371 001	MAY 05, 1987
INVAMED	10MG	N71658 001	JUL 05, 1988
	20MG	N71687 001	JUL 05, 1988
	40MG	N71688 001	JUL 05, 1988
	60MG	N72197 001	JUL 05, 1988
	80MG	N71689 001	JUL 05, 1988
	90MG	N72198 001	JUL 05, 1988
LEDERLE	10MG	N72117 001	JUN 23, 1988
	20MG	N72118 001	JUN 23, 1988
	40MG	N72119 001	JUN 23, 1988
	80MG	N72120 001	JUN 23, 1988
MYLAN	60MG	N72275 001	JUN 09, 1989
ROXANE	10MG	N70516 001	JUL 07, 1986

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

ROXANE	20MG	N70517 001	JUL 07, 1986
	40MG	N70518 001	JUL 07, 1986
	60MG	N70519 001	SEP 24, 1986
	80MG	N70520 001	JUL 07, 1986
	90MG	N70521 001	SEP 24, 1986
SCHERING	10MG	N70120 001	AUG 06, 1985
	20MG	N70121 001	AUG 06, 1985
	40MG	N70122 001	AUG 06, 1985
	60MG	N70123 001	OCT 29, 1986
	80MG	N70124 001	AUG 06, 1985
SUPERPHARM	10MG	N71515 001	JUN 08, 1988
	20MG	N71516 001	JUN 08, 1988
	40MG	N71517 001	JUN 08, 1988
	80MG	N71518 001	JUN 08, 1988
TEVA	10MG	N70232 001	OCT 07, 1987
	20MG	N70233 001	JUN 23, 1986
WARNER CHILCOTT	10MG	N70438 001	SEP 15, 1986
	20MG	N70439 001	SEP 15, 1986
	40MG	N70440 001	SEP 15, 1986
	60MG	N70441 001	SEP 24, 1986
	80MG	N70442 001	SEP 15, 1986
WATSON LAB	10MG	N70378 001	MAR 19, 1987

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

WATSON LAB	20MG	N70379 001 MAR 19, 1987
	40MG	N70380 001 MAR 19, 1987
	60MG	N70381 001 MAR 19, 1987
	80MG	N70382 001 MAR 19, 1987
ZENITH GOLDLINE	10MG	N72063 001 JUL 29, 1988
	20MG	N72066 001 JUL 29, 1988
	40MG	N72067 001 JUL 29, 1988
	60MG	N72068 001 JUL 29, 1988
	80MG	N72069 001 JUL 29, 1988

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

PROPYLIODONE

SUSPENSION; INTRATRACHEAL
DIONOSIL AQUEOUS

GLAXO WELLCOME	50%	N09309 001

DIONOSIL OILY

GLAXO WELLCOME	60%	N09309 002

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

ANABOLIC	50MG	N80285 001
CHELSEA LABS	50MG	N85201 001
DANBURY PHARMA	50MG	N80932 001
HALSEY	50MG	N80015 001
	50MG	N83982 001
KNOLL PHARM	50MG	N84075 001
LANNETT	50MG	N80016 001
LILLY	50MG	N06213 001

FDA data supplied by DrugPatentWatch.com

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

PERRIGO	50MG	N84543 001
TABLICAPS	50MG	N80840 001
ZENITH GOLDLINE	50MG	N80215 001

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

PHARMACIA AND UPJOHN	50MG/VIAL	N07413 001
	250MG/VIAL	N07413 002
		AUG 02, 1984
QUAD PHARMS	10MG/ML	N89306 001
		MAY 30, 1986
	50MG/VIAL	N89307 001
		MAY 30, 1986

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION
AMINOSOL 5%

ABBOTT	5%	N05932 012
		JAN 31, 1985

HYPROTIGEN 5%

B BRAUN	5%	N06170 003
		JAN 10, 1984

PROTIRELIN

INJECTABLE; INJECTION
THYPINONE

ABBOTT	0.5MG/ML	N17638 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL
VENTAIRE

AVENTIS PHARMS	2MG	N83459 001

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NOVAFED

AVENTIS PHARMS	120MG	N17603 001

SUDAFED 12 HOUR

* GLAXO WELLCOME	120MG	N17941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ACTIFED

GLAXO WELLCOME	120MG;5MG	N18996 001
		JUN 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG;5MG	N71798 001
		MAR 16, 1989

SYRUP; ORAL
ACTAHIST

CENCI	30MG/5ML;1.25MG/5ML	N88344 001
		FEB 09, 1984

HISTAFED

CENCI	30MG/5ML;1.25MG/5ML	N88283 001
		APR 20, 1984

MYFED

ROSEMONT	30MG/5ML;1.25MG/5ML	N88116 001
		MAR 04, 1983

TABLET; ORAL
ALLERFED

PVT FORM	60MG;2.5MG	N88860 001
		JAN 31, 1985

TRIPHED

TEVA	60MG;2.5MG	N88630 001
		MAY 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LAB	60MG;2.5MG	N88318 002
		JAN 13, 1984

FDA data supplied by DrugPatentWatch.com

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE
WEST WARD 60MG;2.5MG N88117 001 APR 19, 1983
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
ZENITH GOLDLINE 60MG;2.5MG N85273 001 DEC 12, 1984

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
PSEUDO-12
MEDEVA EQ 60MG HCL/5ML N19401 001 JUN 19, 1987

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE
SOLVAY 30MG N89572 001 NOV 27, 1990

PYRIDOXINE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
HEXA-BETALIN
LILLY 100MG/ML N80854 001
PYRIDOXINE HCL
AKORN 100MG/ML N87967 001 OCT 01, 1982

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL
BEL MAR 100MG/ML N80761 001
DELL LABS 50MG/ML N83771 001
100MG/ML N83772 001
ELKINS SINN 100MG/ML N80581 001
LUITPOLD 100MG/ML N80669 001
STERIS 100MG/ML N83760 001

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E
SEE DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE
SEE NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE
CHELSEA LABS 25MG N85231 001

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER
PROCTER AND GAMBLE 0.3% N19412 002 MAR 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL
POVAN
PARKE DAVIS EQ 50MG BASE/5ML N11964 001

TABLET; ORAL
POVAN
PARKE DAVIS EQ 50MG BASE N12485 002

FDA data supplied by DrugPatentWatch.com

QUINESTROL

TABLET; ORAL
ESTROVIS
PARKE DAVIS 0.1MG N16768 002
0.2MG N16768 003

QUINETHAZONE; RESERPINE

TABLET; ORAL
HYDROMOX R
LEDERLE 50MG;0.125MG N13927 001

QUINIDINE GLUCONATE

TABLET; ORAL
QUINACT
BERLEX 266MG N85978 001
400MG N86099 001

TABLET, EXTENDED RELEASE; ORAL
DURAQUIN
WARNER CHILCOTT 330MG N17917 001
QUINALAN
LANNETT 324MG N88081 001
FEB 10, 1986
QUINATIME
WATSON LAB 324MG N87448 001
QUINIDINE GLUCONATE
ASCOT 324MG N88582 001
JUN 17, 1985
CHELSEA LABS 324MG N87785 001
JAN 24, 1983
HALSEY 324MG N89476 001
APR 10, 1987
ROXANE 324MG N88431 001
JAN 06, 1984
SUPERPHARM 324MG N89164 001
NOV 21, 1985

QUINIDINE POLYGALACTURONATE

TABLET; ORAL
CARDIOQUIN
PURDUE FREDERICK 275MG N11642 002

QUINIDINE SULFATE

CAPSULE; ORAL
CIN-QUIN
SOLVAY 200MG N85296 001
300MG N85297 001
QUINIDINE SULFATE
LILLY 200MG N85103 001

TABLET; ORAL
CIN-QUIN
SOLVAY 100MG N85299 001
200MG N84932 001
300MG N85298 001
QUINIDINE SULFATE
BARR 200MG N84177 001
DANBURY PHARMA 100MG N85584 001
ELKINS SINN 200MG N83622 001
EVERYLIFE 200MG N83439 001
HALSEY 200MG N83583 001
ICN 200MG N83393 001
KV PHARM 200MG N85276 001
LEDERLE 200MG N86176 001
LILLY 200MG N85038 001
PERRIGO 200MG N85322 001
PHARMAVITE 200MG N84627 001
PUREPAC PHARM 200MG N84003 001
ROSEMONT 200MG N87837 001
APR 14, 1982
SCHERER LABS 200MG N85068 001
VANGARD 200MG N87909 001
JUL 13, 1982
VINTAGE PHARMS 200MG N83963 001
WARNER CHILCOTT 200MG N83879 001
WHITEWORTH TOWN PLSN 200MG N85444 001
ZENITH GOLDLINE 200MG N84549 001
QUINORA
KEY PHARMS 200MG N83576 001
SCHERING 300MG N85222 001

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC
GLAXO WELLCOME 400MG N20559 001
AUG 08, 1996

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION			
ZANTAC IN PLASTIC CONTAINER			
GLAXO WELLCOME	EQ 50MG BASE/100ML	N19593	001
		DEC 17, 1986	
TABLET, EFFERVESCENT; ORAL			
ZANTAC 75			
* WARNER LAMBERT	EQ 75MG BASE	N20745	001
		FEB 26, 1998	

RAUWOLFIA SERPENTINA

TABLET; ORAL			
HIWOLFIA			
BOWMAN PHARMS	50MG	N09276	003
	50MG	N09276	005
	100MG	N09276	004
HYSERPIN			
PHYS PRODS VA	50MG	N10581	001
KOGLUCOID			
PANRAY	50MG	N09278	001
	100MG	N09278	002
RAUDIXIN			
APOTHECON	50MG	N08842	001
	100MG	N08842	002
RAUSERPIN			
FERNDALE LABS	50MG	N09926	002
	100MG	N09926	004
RAUVAL			
PAL PAK	50MG	N09108	002
	100MG	N09108	004
RAUWOLFIA SERPENTINA			
BUNDY	50MG	N09477	001
	100MG	N09477	002
DANBURY PHARMA	50MG	N80907	001
	100MG	N80914	001
HALSEY	50MG	N80498	001
	100MG	N80498	002
ICN	50MG	N09668	001
	100MG	N09668	002
IMPAX LABS	50MG	N09273	001
	100MG	N09273	002
PUREPAC PHARM	50MG	N80842	001
	100MG	N80842	002
PVT FORM	50MG	N80583	001
	100MG	N80583	002

RAUWOLFIA SERPENTINA

TABLET; ORAL			
RAUWOLFIA SERPENTINA			
SOLVAY	50MG	N80500	001
	100MG	N80500	002
TABLICAPS	50MG	N83867	001
	100MG	N83444	001
ZENITH GOLDLINE	50MG	N11521	001
	100MG	N11521	002
WOLFINA			
FOREST PHARMS	50MG	N09255	008
	100MG	N09255	006

RESCINNAMINE

CAPSULE; ORAL			
CINNASIL			
PANRAY	0.5MG	N84736	001

RESERPINE

ELIXIR; ORAL			
SERPASIL			
NOVARTIS	0.2MG/4ML	N09115	005
INJECTABLE; INJECTION			
SANDRIL			
LILLY	2.5MG/ML	N10012	001
SERPASIL			
NOVARTIS	2.5MG/ML	N09434	002
TABLET; ORAL			
HISERPIA			
BOWMAN PHARMS	0.1MG	N09631	002
	0.25MG	N09631	004
RAU-SED			
BRISTOL MYERS SQUIBB	0.1MG	N09357	001
	0.25MG	N09357	004
	0.5MG	N09357	006
	1MG	N09357	008
RESERPINE			
BARR	0.25MG	N80721	002
BELL PHARMA	0.1MG	N83058	001
	0.25MG	N83058	002
BUNDY	0.1MG	N09663	001
	0.25MG	N09663	003

FDA data supplied by DrugPatentWatch.com

RESERPINE

TABLET; ORAL
RESERPINE

CHELSEA LABS	0.25MG	N85401	001
DANBURY PHARMA	0.1MG	N80679	001
	0.25MG	N80393	001
	1MG	N80749	001
ELKINS SINN	0.1MG	N83145	001
	0.25MG	N83145	002
EVERYLIFE	0.1MG	N10441	001
	0.25MG	N10441	002
	0.5MG	N10441	003
	1MG	N10441	004
HALSEY	0.1MG	N80457	002
	0.25MG	N80457	001
	1MG	N80457	003
ICN	0.1MG	N09667	001
	0.25MG	N09667	002
IMPAX LABS	0.1MG	N09627	001
	0.25MG	N09627	002
MARSHALL PHARMA	0.1MG	N80492	001
	0.25MG	N80492	002
MK LABS	0.1MG	N80525	002
	0.25MG	N80525	001
MYLAN	1MG	N84974	001
PHARMAVITE	0.25MG	N84663	001
PUREPAC PHARM	0.1MG	N80753	002
	0.25MG	N80753	001
PVT FORM	0.1MG	N86117	001
	0.25MG	N80582	001
	0.25MG	N85775	001
	1MG	N80582	002
REXALL	0.25MG	N80637	001
ROXANE	0.1MG	N09859	001
	0.25MG	N09859	002
SOLVAY	0.25MG	N80446	001
TABLICAPS	0.25MG	N85207	001
TEVA	0.1MG	N89020	001
		MAR 07, 1985	
	0.25MG	N89019	001
		MAR 07, 1985	
WEST WARD	0.1MG	N80975	001
	0.25MG	N80975	002
	1MG	N80975	003
WHITEWORTH TOWN PLSN	0.1MG	N80723	001
	0.25MG	N80723	002
	1MG	N80723	003
ZENITH GOLDLINE	0.1MG	N11185	001

RESERPINE

TABLET; ORAL
RESERPINE

ZENITH GOLDLINE	0.25MG	N11185 002
SANDRIL		
LILLY	0.1MG	N09376 004
	0.25MG	N09376 001
SERPANRAY		
PANRAY	0.1MG	N09391 001
	0.25MG	N09391 002
	1MG	N09391 004
SERPASIL		
NOVARTIS	0.1MG	N09115 001
	0.25MG	N09115 003
	1MG	N09115 004
SERPATE		
VALE	0.1MG	N09453 001
	0.25MG	N09453 002
SERPIVITE		
VITARINE	0.25MG	N09645 002

RESERPINE; *MULTIPLE*
SEE CHLOROTHIAZIDE; RESERPINE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
SEE HYDRALAZINE HYDROCHLORIDE; RESERPINE
SEE HYDROCHLOROTHIAZIDE; RESERPINE
SEE HYDROFLUMETHIAZIDE; RESERPINE
SEE QUINETHAZONE; RESERPINE

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUIVAL

SCHERING	0.1MG;4MG	N12265 003
TRICHLORMETHIAZIDE W/ RESERPINE		
WATSON LAB	0.1MG;4MG	N85248 001

RIBOFLAVIN; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

RISPERIDONE

TABLET; ORAL
RISPERDAL
JANSSEN RES FDN — 5MG — N20272 005 — DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
AM PHARM PARTNERS — 10MG/ML — N71188 001 — JUL 23, 1987
15MG/ML — N71189 001 — JUL 23, 1987
QUAD PHARMS — 10MG/ML — N70700 001 — OCT 06, 1986
15MG/ML — N70701 001 — OCT 06, 1986
YUTOPAR
ASTRAZENECA — 10MG/ML — N18580 001
15MG/ML — N18580 002

TABLET; ORAL
YUTOPAR
ASTRAZENECA — 10MG — N18555 001

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION
ROBENGATOPE
BRACCO — 0.5mCi/VIAL — N16224 001

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION
ROBENGATOPE
BRACCO — 1mCi/VIAL — N16224 002
2mCi/VIAL — N16224 003
SODIUM ROSE BENGAL I 131
SORIN — 0.5mCi/ML — N17318 001

SAFFLOWER OIL

INJECTABLE; INJECTION
LIPOSYN 10%
ABBOTT — 10% — N18203 001
LIPOSYN 20%
ABBOTT — 20% — N18614 001

SARALASIN ACETATE

INJECTABLE; INJECTION
SARENIN
PROCTER AND GAMBLE — EQ 0.6MG BASE/ML — N18009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
LANNETT — 50MG — N85909 001
100MG — N85903 001
PARKE DAVIS — 100MG — N84762 001
PUREPAC PHARM — 100MG — N85867 001
VITARINE — 100MG — N85898 001
100MG — N86273 001
WHITEWORTH TOWN PLSN — 100MG — N85798 001
WYETH AYERST — 100MG — N86390 001
ZENITH GOLDLINE — 100MG — N85869 001
SODIUM SECOBARBITAL
ANABOLIC — 100MG — N84422 001
BARR — 100MG — N84225 001
CHELSEA LABS — 100MG — N85792 001
HALSEY — 100MG — N84676 001
KV PHARM — 100MG — N85285 001
PERRIGO — 100MG — N84561 001

INJECTABLE; INJECTION
SECONAL SODIUM
LILLY — 50MG/ML — N07392 002

FDA data supplied by DrugPatentWatch.com

SECOBARBITAL SODIUM

SUPPOSITORY; RECTAL
SECONAL SODIUM

LILLY	30MG	N86530	001
	60MG	N86530	002
	120MG	N86530	003
	200MG	N86530	004

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

THAMES	2.5%	N86209	001
ZENITH GOLDLINE	2.5%	N85777	001

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SELENOMETHIONINE SE 75

MALLINCKRODT	100 uCi/ML	N17098	001
NYCOMED AMERSHAM	250 uCi/ML	N17257	001

SETHOTOPE

BRACCO	85-550 uCi/ML	N17047	001

SERACTIDE ACETATE

INJECTABLE; INJECTION
ACTHAR GEL-SYNTHETIC

ARMOUR PHARM	40 UNITS/ML	N17861	001
	80 UNITS/ML	N17861	002

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
ZOLOFT

PFIZER	EQ 150MG BASE	N19839	003
		DEC 30, 1991	
	EQ 200MG BASE	N19839	004
		DEC 30, 1991	

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC

QUESTCOR PHARM	1%	N19608	001
		NOV 30, 1989	

SODIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM BICARBONATE

INJECTABLE; INJECTION
SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT	0.9MEQ/ML	N19443	001
		JUN 03, 1986	
	1MEQ/ML	N19443	002
		JUN 03, 1986	

SODIUM BICARBONATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AM PHARM PARTNERS 9MG/ML N88909 001
FEB 07, 1985
SODIUM CHLORIDE
ABBOTT 20GM/100ML N17013 001
B BRAUN 20GM/100ML N17038 001
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 450MG/100ML N18184 001
MILES 450MG/100ML N18503 001
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 9MG/ML N19218 001
JUL 13, 1984
MILES 900MG/100ML N18502 001
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
AM PHARM PARTNERS 234MG/ML N19329 001
APR 22, 1987
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
B BRAUN 3GM/100ML N19635 003
MAR 09, 1988
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML N19635 004
MAR 09, 1988

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
ABBOTT 450MG/100ML N18380 001
BAXTER HLTHCARE 450MG/100ML N18497 001
FEB 19, 1982
SODIUM CHLORIDE IN PLASTIC CONTAINER
MILES 900MG/100ML N18247 001

SODIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SODIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
BRACCO 2mCi/VIAL N13993 002

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

FDA data supplied by DrugPatentWatch.com

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18
NYCOMED AMERSHAM 2mCi/ML N17042 001

SODIUM GLUCONATE; *MULTIPLE*
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL
SODIUM IODIDE I 123
SYNCOR PHARMS 400 uCi N18671 003
MAY 27, 1982

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
CIS 50 uCi N17316 001
MALLINCKRODT 0.8-100mCi N16515 002

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
B BRAUN 1.87GM/100ML N18186 001

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NIPRIDE
ROCHE 50MG/VIAL N17546 001
NITROPRESS
ABBOTT 50MG/VIAL N18450 001
50MG/VIAL N71555 001
NOV 16, 1987
SODIUM NITROPRUSSIDE
AM PHARM PARTNERS 50MG/VIAL N70031 001
JAN 17, 1985

SODIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
PHOSPHOTOPE
BRACCO 1-8mCi/VIAL N10927 001
SODIUM PHOSPHATE P 32
MALLINCKRODT 1.5mCi/VIAL N11777 002

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
MORTON GROVE 453.6GM/BOT N88786 001
SEP 11, 1984

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
MORTON GROVE 15GM/60ML N88717 001
SEP 11, 1984

FDA data supplied by DrugPatentWatch.com

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
ROXANE 15GM/60ML N88453 001 NOV 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION
SODIUM SUCCINATE
ELKINS SINN 30% N80516 001

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SOMATROPIN

INJECTABLE; INJECTION
ASELLACRIN 10
SERONO 10 IU/VIAL N17726 001
ASELLACRIN 2
SERONO 2 IU/VIAL N17726 002 JUL 21, 1983
CRESCORMON
GENENTECH 4 IU/VIAL N17992 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
HUMATROPE
LILLY 2MG/VIAL N19640 001 JUN 23, 1987

SORBITOL

SOLUTION; IRRIGATION
SORBITOL 3% IN PLASTIC CONTAINER
BAXTER HLTHCARE 3GM/100ML N18512 001 MAY 27, 1982

SORBITOL; *MULTIPLE*
SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX LABS 320MG N19865 004 OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
TRAVAMULSION 10%
BAXTER HLTHCARE 10% N18660 001 FEB 26, 1982
TRAVAMULSION 20%
BAXTER HLTHCARE 20% N18758 001 FEB 15, 1983

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL
RENORMAX
SCHERING 3MG N20240 001 DEC 29, 1994
6MG N20240 002 DEC 29, 1994
12MG N20240 003 DEC 29, 1994
24MG N20240 004 DEC 29, 1994

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
ASCOT 25MG N87687 001 OCT 20, 1982
CHELSEA LABS 25MG N87078 001
LEDERLE 25MG N87634 001
PUREPAC PHARM 25MG N87998 001 OCT 14, 1983
25MG N88053 001 AUG 25, 1983
UPSHER SMITH 25MG N87554 001
VANGARD 25MG N87648 001 FEB 01, 1982

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

WARNER CHILCOTT	25MG	N87952 001 NOV 18, 1982
WATSON LAB	25MG	N86898 002 MAR 02, 1982
ZENITH GOLDLINE	25MG	N87108 001

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STAVUDINE

CAPSULE; ORAL
ZERIT

BRISTOL MYERS SQUIBB	5MG	N20412 001 JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	N60684 001
LILLY	EQ 1GM BASE/2ML	N60404 001
	EQ 1GM BASE/VIAL	N60107 001
	EQ 5GM BASE/VIAL	N60107 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE

GLAXO WELLCOME	50MG/ML	N08453 003

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	N85400 001 FEB 04, 1982

SUCOSTRIN

APOTHECON	20MG/ML	N08847 001
	100MG/ML	N08847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTANIL CITRATE

STERIS	EQ 0.05MG BASE/ML	N74406 001 DEC 15, 1995

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

SOLUTION; TOPICAL
EXELDERM

WESTWOOD SQUIBB	1%	N18738 001 AUG 30, 1985

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
SULFAIR 10

PHARMAFAIR	10%	N88000 001 DEC 22, 1982

SOLUTION/DROPS; OPHTHALMIC

OCUSULF-30		
MIZA PHARMS USA	30%	N80660 002
SODIUM SULFACETAMIDE		
AKORN	10%	N83021 001
	15%	N83021 002
	30%	N83021 003
SOLA BARNES HIND	10%	N84143 001
	10%	N84145 001
	30%	N84146 001
	30%	N84147 001
SULF-10		
CIBA	10%	N80025 001
SULFACETAMIDE SODIUM		
PHARMAFAIR	10%	N88947 001 MAY 17, 1985
SULFAIR 10		
PHARMAFAIR	10%	N87949 001 DEC 13, 1982
SULFAIR FORTE		
PHARMAFAIR	30%	N88385 001 OCT 13, 1983

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFAIR-15		
PHARMAFAIR	15%	N88186 001 MAY 25, 1983

SULFACETAMIDE SODIUM; *MULTIPLE*

SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE		
ABBOTT	300MG	N04125 005
EVERYLIFE	500MG	N80088 001
IMPAX LABS	500MG	N80081 001
LANNETT	500MG	N80084 001
LEDERLE	500MG	N04054 001
LILLY	500MG	N04122 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX		
LILLY	250MG/5ML;250MG/5ML	N06317 007

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM		
LEDERLE	250MG/ML	N04054 002

SULFAMERAZINE; *MULTIPLE*

SEE SULFADIAZINE; SULFAMERAZINE

SULFAMETER

TABLET; ORAL

SULLA		
BERLEX	500MG	N16000 002

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL		
FOREST PHARMS	1GM	N86012 001
PROKLAR		
FOREST PHARMS	500MG	N80273 001
THIOSULFIL		
WYETH AYERST	250MG	N08565 001

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL		
ROCHE	500MG/5ML	N13664 002

TABLET; ORAL

GANTANOL-DS		
ROCHE	1GM	N12715 003
SULFAMETHOXAZOLE		
ASCOT	500MG	N87662 001 OCT 20, 1982
BARR	500MG	N87189 001 JUL 25, 1983
HEATHER	500MG	N86163 001
WATSON LAB	1GM	N86000 001
	500MG	N85053 001
UROBAK		
SHIONOGI	500MG	N87307 001

SULFAMETHOXAZOLE; *MULTIPLE*

SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOPRIM		
QUAD PHARMS	80MG/ML;16MG/ML	N71341 001 AUG 07, 1987
SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AM PHARM PARTNERS	80MG/ML;16MG/ML	N70223 001 DEC 29, 1987
BEDFORD	80MG/ML;16MG/ML	N72383 001 APR 29, 1992
STERIS	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL		
BACTRIM		
ROCHE	200MG/5ML;40MG/5ML	N17560 001
SULMEPRIM		
ROSEMONT	200MG/5ML;40MG/5ML	N70063 001 AUG 01, 1986
SULMEPRIM PEDIATRIC		
ROSEMONT	200MG/5ML;40MG/5ML	N70064 001 AUG 01, 1986
TRIMETH/SULFA		
ALPHARMA	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
	200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988
TABLET; ORAL		
SULFAMETHOXAZOLE & TRIMETHOPRIM		
HEATHER	400MG;80MG	N18946 001 AUG 10, 1984
	800MG;160MG	N18946 002 AUG 10, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM		
CHELSEA LABS	400MG;80MG	N70002 001 NOV 07, 1984
	800MG;160MG	N70000 001 NOV 07, 1984
EON	400MG;80MG	N18598 003 MAY 19, 1982
HALSEY	400MG;80MG	N70006 001 NOV 14, 1984
INTERPHARM	400MG;80MG	N71299 001 OCT 27, 1987
	800MG;160MG	N71300 001 OCT 27, 1987
MARTEC	400MG;80MG	N72408 001 DEC 07, 1988
ROSEMONT	400MG;80MG	N70203 001 NOV 08, 1985
	800MG;160MG	N70204 001 NOV 08, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH		
HALSEY	800MG;160MG	N70007 001 NOV 14, 1984
MARTEC	800MG;160MG	N72417 001 DEC 07, 1988
SULFATRIM-DS		
SUPERPHARM	800MG;160MG	N70066 001 JUN 24, 1985

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL		
SULFATRIM-SS		
SUPERPHARM	400MG;80MG	N70065 002 JUN 24, 1985
UROPLUS DS		
SHIONOGI	800MG;160MG	N71816 001 SEP 28, 1987
UROPLUS SS		
SHIONOGI	400MG;80MG	N71815 001 SEP 28, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL		
SULFABID		
PURDUE FREDERICK	500MG/5ML	N13093 001
TABLET; ORAL		
SULFABID		
PURDUE FREDERICK	500MG	N13092 002

SULFASALAZINE

SUSPENSION; ORAL		
AZULFIDINE		
PHARMACIA AND UPJOHN	250MG/5ML	N18605 001
TABLET; ORAL		
S.A.S.-500		
SOLVAY	500MG	N83450 001
SULFASALAZINE		
EON	500MG	N86184 001
LEDERLE	500MG	N80197 001
SUPERPHARM	500MG	N89339 001 OCT 26, 1987
WATSON LAB	500MG	N84964 001
TABLET, DELAYED RELEASE; ORAL		
SULFASALAZINE		
WATSON LAB	500MG	N88052 001 MAY 24, 1983

FDA data supplied by DrugPatentWatch.com

SULFINPYRAZONE

CAPSULE; ORAL
SULFINPYRAZONE

VANGARD	200MG	N88666 001 FEB 17, 1984

TABLET; ORAL
SULFINPYRAZONE

DANBURY PHARMA	100MG	N87667 001 MAY 26, 1982
ZENITH GOLDLINE	100MG	N87769 001 JUN 01, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN		
ROCHE	500MG	N06525 001
SOXAZOLE		
ALRA	500MG	N80366 001
SULFALAR		
PARKE DAVIS	500MG	N84955 001
SULFISOXAZOLE		
BARR	500MG	N84031 001
CHELSEA LABS	500MG	N85534 001
HEATHER	500MG	N80189 001
IMPAX LABS	500MG	N80109 001
LANNETT	500MG	N80085 001
LEDERLE	500MG	N87649 001
PHARMERAL	500MG	N84385 001
PUREPAC PHARM	500MG	N80087 001
VITARINE	500MG	N87332 001
WEST WARD	500MG	N80379 001
SULSOXIN		
SOLVAY	500MG	N80040 001

SULFISOXAZOLE; *MULTIPLE*
SEE PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

SULFISOXAZOLE ACETYL

EMULSION; ORAL
LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N09182 009

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION
GANTRISIN

ROCHE	EQ 400MG BASE/ML	N06917 001

OINTMENT; OPHTHALMIC
GANTRISIN

ROCHE	EQ 4% BASE	N08414 002

SOLUTION/DROPS; OPHTHALMIC
GANTRISIN

ROCHE	EQ 4% BASE	N07757 002
SULFISOXAZOLE DIOLAMINE		
SOLA BARNES HIND	EQ 4% BASE	N84148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL
DIASONE SODIUM

ABBOTT	165MG	N06044 003

SULFUR

POWDER; TOPICAL
BENSULFOID

POYTHRESS	33.32%	N02918 001

SUMATRIPTAN SUCCINATE

TABLET; ORAL
IMITREX

GLAXO WELLCOME	EQ 100MG BASE	N20132 001 JUN 01, 1995

SUTILAINS

OINTMENT; TOPICAL
TRAVASE

KNOLL PHARM	82,000 UNITS/GM	N12828 001

FDA data supplied by DrugPatentWatch.com

TALBUTAL

TABLET; ORAL
LOTUSATE
SANOFI SYNTHELABO 120MG N09410 005

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE
MYLAN EQ 10MG BASE N74732 001 JUN 26, 2000
PHARMACHEMIE EQ 10MG BASE N74539 001 MAY 31, 2000

TANNIC ACID; *MULTIPLE*
SEE CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION
TC 99M-LUNGAGGREGATE
NYCOMED AMERSHAM 5mCi/ML N17848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN
SYNCOR PHARMS N/A N17916 001
AN-MAA
CIS N/A N17792 001
LUNGAGGREGATE REAGENT
NYCOMED AMERSHAM N/A N17838 001
TECHNETIUM TC 99M MAA
NYCOMED AMERSHAM N/A N17773 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION
INSTANT MICROSPHERES
3M N/A N17832 001

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
NYCOMED AMERSHAM N/A N17653 001
MPI STANNOUS DIPHOSPHONATE
NYCOMED AMERSHAM N/A N17667 001
OSTEOSCAN
MALLINCKRODT N/A N17454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
NYCOMED AMERSHAM N/A N17562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION
RENOTEC
BRACCO N/A N17045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
GLUCOSCAN
DUPONT PHARMS N/A N17907 001

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
AMERSCAN MDP KIT
NYCOMED AMERSHAM N/A N18335 001 AUG 05, 1982

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION
SODIUM POLYPHOSPHATE-TIN KIT
NYCOMED AMERSHAM N/A N17664 001

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL			
SODIUM PERTECHNETATE TC 99M			
CIS	12mCi/ML	N17321 001	
	24mCi/ML	N17321 002	
	48mCi/ML	N17321 003	
NYCOMED AMERSHAM	2-100mCi/ML	N17471 001	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL			
MINITEC			
BRACCO	0.22-2.22 CI/GENERATOR	N17339 001	

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL			
TECHNETIUM TC 99M SULFUR COLLOID			
NYCOMED AMERSHAM	4mCi/ML	N17456 001	
SOLUTION; ORAL			
TECHNETIUM TC 99M SULFUR COLLOID			
MALLINCKRODT	3mCi/ML	N17724 001	

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL			
TECHNETIUM TC 99M TSC			
NYCOMED AMERSHAM	N/A	N17784 001	
TESULOID			
BRACCO	N/A	N16923 001	

TEMAZEPAM

CAPSULE; ORAL			
TEMAZ			
QUANTUM PHARMICS	15MG	N70564 001	OCT 15, 1985
	30MG	N70547 001	OCT 15, 1985
TEMAZEPAM			
DURAMED	15MG	N71708 001	SEP 29, 1988

TEMAZEPAM

CAPSULE; ORAL			
TEMAZEPAM			
DURAMED	30MG	N71709 001	SEP 29, 1988
HALSEY	15MG	N71174 001	JUL 10, 1986
	30MG	N71175 001	JUL 10, 1986
ROSEMONT	15MG	N70489 001	JUL 07, 1986
	30MG	N70490 001	JUL 07, 1986
WATSON LAB	15MG	N70383 001	MAR 23, 1987
	30MG	N70384 001	MAR 23, 1987

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION			
BRETHAIRE			
NOVARTIS	0.2MG/INH	N18762 001	AUG 17, 1984
BRICANYL			
AVENTIS PHARMS	0.2MG/INH	N18000 001	MAR 19, 1985
INJECTABLE; INJECTION			
BRICANYL			
AVENTIS PHARMS	1MG/ML	N17466 001	
TABLET; ORAL			
BRICANYL			
AVENTIS PHARMS	2.5MG	N17618 001	
	5MG	N17618 002	

TERIPARATIDE ACETATE

INJECTABLE; INJECTION			
PARATHAR			
AVENTIS	200 UNITS/VIAL	N19498 001	DEC 23, 1987

FDA data supplied by DrugPatentWatch.com

TESTOLACTONE

INJECTABLE; INJECTION
TESLAC
BRISTOL MYERS SQUIBB 100MG/ML N16119 001

TABLET; ORAL
TESLAC
BRISTOL MYERS SQUIBB 250MG N16118 002

TESTOSTERONE

INJECTABLE; INJECTION
TESTOSTERONE
STERIS 25MG/ML N86420 001 MAY 10, 1983
50MG/ML N86419 001 AUG 23, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTOSTERONE
PHARMACIA AND UPJOHN 50MG/ML N85635 001
TESTOSTERONE CYPIONATE
QUAD PHARMS 100MG/ML N89326 001 OCT 28, 1988
200MG/ML N89327 001 OCT 28, 1988
STERIS 100MG/ML N84401 001
200MG/ML N84401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL
BTG 200MG/ML N09165 001
TESTOSTERONE ENANTHATE
QUAD PHARMS 100MG/ML N89324 001 SEP 16, 1986
200MG/ML N89325 001 SEP 16, 1986
STERIS 100MG/ML N83667 001
100MG/ML N85599 001
200MG/ML N83667 002

TESTOSTERONE ENANTHATE; *MULTIPLE*
SEE ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE
BEL MAR 25MG/ML N80741 001
50MG/ML N80742 001
100MG/ML N80743 001
ELKINS SINN 25MG/ML N80276 001
LILLY 50MG/ML N80254 002
QUAD PHARMS 100MG/ML N89283 001 NOV 03, 1986
STERIS 25MG/ML N85490 001
50MG/ML N85490 002
100MG/ML N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
CYCLOPAR
WARNER CHILCOTT 250MG N61725 001
250MG N62175 001
250MG N62332 001
500MG N61725 002
500MG N62332 002
RETET
SOLVAY 250MG N61443 001
500MG N61443 002
SUMYCIN
APOTHECON 100MG N60429 002
125MG N60429 004
TETRACHEL
ANGUS 250MG N60343 001
500MG N60343 003
TETRACYCLINE HCL
CHELSEA LABS 250MG N62103 001
500MG N62103 002
ELKINS SINN 250MG N60059 001
FERRANTE 125MG N60173 001
250MG N60173 002
HEATHER 250MG N61148 001
500MG N61148 002
ICN 250MG N60471 001
500MG N60471 002
KNOLL PHARM 250MG N61802 001

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

KNOLL PHARM	500MG	N61802 002
PUREPAC PHARM	250MG	N60290 001
	500MG	N60290 002
PVT FORM	250MG	N62686 001 JUL 24, 1986
	500MG	N62686 002 JUL 24, 1986
SUPERPHARM	250MG	N62540 001 MAR 21, 1985
	500MG	N62540 002 MAR 21, 1985
WARNER CHILCOTT	250MG	N62300 001
	500MG	N62300 002

TETRACYN

PFIPHARMECS	250MG	N60082 003
	500MG	N60082 004

INJECTABLE; INJECTION
TETRACYN

PFIZER	250MG/VIAL	N60096 001
	500MG/VIAL	N60096 002

OINTMENT; OPHTHALMIC
ACHROMYCIN

STORZ	10MG/GM	N50266 001

SUSPENSION; ORAL
TETRACYCLINE HCL

ALPHARMA	125MG/5ML	N60633 001
FERRANTE	125MG/5ML	N60174 001
PROTER	125MG/5ML	N60446 001
PUREPAC PHARM	125MG/5ML	N60291 001

TETRACYN

PFIPHARMECS	125MG/5ML	N60095 001

TETRAMED

ZENITH GOLDLINE	125MG/5ML	N61468 001

SUSPENSION/DROPS; OPHTHALMIC
ACHROMYCIN

STORZ	1%	N50268 001

TABLET; ORAL
PANMYCIN

PHARMACIA AND UPJOHN	250MG	N61705 001
	500MG	N61705 002

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL
SUMYCIN

APOTHECON	50MG	N61147 003
	100MG	N61147 002

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX

BRISTOL	EQ 250MG HCL	N50212 002
	EQ 500MG HCL	N50212 003

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N18548 001 DEC 30, 1982

THEOPHYLLINE

CAPSULE; ORAL
BRONKODYL

SANOFI SYNTHELABO	100MG	N85264 001
	200MG	N85264 002

ELIXOPHYLLIN

FORREST LABS	100MG	N85545 001 JUL 31, 1984
	200MG	N83921 001 JUL 31, 1984

SOMOPHYLLIN-T

FISONS	100MG	N87155 001 FEB 25, 1985
	200MG	N87155 002 FEB 25, 1985
	250MG	N87155 003 FEB 25, 1985

THEOPHYLLINE

KV PHARM	100MG	N85263 001
	200MG	N85263 002

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE; ORAL

THEOPHYLLINE		
SCHERER RP	100MG	N84731 002 NOV 07, 1986
	200MG	N84731 001 NOV 07, 1986
	250MG	N84731 003 NOV 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

ELIXOPHYLLIN SR		
FORREST LABS	125MG	N86826 001 JAN 29, 1985
	250MG	N86826 002 JAN 29, 1985
SLO-PHYLLIN		
AVENTIS	60MG	N85206 001 MAY 24, 1982
	125MG	N85203 001 MAY 24, 1982
	250MG	N85205 001 MAY 24, 1982
SOMOPHYLLIN-CRT		
GRAHAM DM	50MG	N87763 001 FEB 27, 1985
	100MG	N87194 001
	200MG	N88382 001 FEB 27, 1985
	250MG	N87193 001
	300MG	N88383 001 FEB 27, 1985
THEO-DUR		
SCHERING	50MG	N88022 001 SEP 10, 1985
	75MG	N88015 001 SEP 10, 1985
	125MG	N88016 001 SEP 10, 1985
	200MG	N87995 001 SEP 10, 1985
THEOBID		
WHITBY	260MG	N85983 001 MAR 20, 1985
THEOBID JR.		
WHITBY	130MG	N87854 001 MAR 20, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOCLEAR L.A.-130		
SCHWARZ PHARMA	130MG	N86569 001 MAY 27, 1982
THEOCLEAR L.A.-260		
SCHWARZ PHARMA	260MG	N86569 002 MAY 27, 1982
THEOPHYL-SR		
JOHNSON RW	125MG	N86480 001 FEB 08, 1985
	250MG	N86471 001 FEB 08, 1985
THEOPHYLLINE		
CENT PHARMS	125MG	N88654 001 FEB 12, 1985
	250MG	N88689 001 FEB 12, 1985
EON	260MG	N87462 001 MAY 11, 1982
FAULDING	100MG	N89976 001 JAN 04, 1995
	200MG	N89977 001 JAN 04, 1995
	300MG	N89932 001 JAN 04, 1995
THEOPHYLLINE-SR		
SCHERER RP	300MG	N88255 001 JUN 12, 1986
THEOVENT		
SCHERING	125MG	N87010 001 JAN 31, 1985
	250MG	N87910 001 JAN 31, 1985

ELIXIR; ORAL

ELIXOMIN		
CENCI	80MG/15ML	N88303 001 JAN 25, 1984
LANOPHYLLIN		
LANNETT	80MG/15ML	N84578 001
THEOLIXIR		
PANRAY	80MG/15ML	N84559 001
THEOPHYL-225		
JOHNSON RW	112.5MG/15ML	N86485 001
THEOPHYLLINE		
ALPHARMA	80MG/15ML	N89223 001 MAY 27, 1988

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

ELIXIR; ORAL
THEOPHYLLINE

CENCI	80MG/15ML	N87679 001 APR 15, 1982
HALSEY	80MG/15ML	N85169 001
PERRIGO	80MG/15ML	N85952 001
ROXANE	80MG/15ML	N84739 001

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N19083 001 NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N19083 002 NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N19083 003 NOV 07, 1984

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N19212 001 NOV 07, 1984
	200MG/100ML	N19826 004 AUG 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	400MG/100ML	N19212 002 NOV 07, 1984
	4MG/ML	N19212 003 NOV 07, 1984
	400MG/100ML	N19826 005 AUG 14, 1992

SUSPENSION; ORAL
ELIXICON

FORREST LABS	100MG/5ML	N85502 001

SYRUP; ORAL
ACCURBRON

AVENTIS PHARMS	150MG/15ML	N88746 001 NOV 22, 1985

AQUAPHYLLIN

FERNDALE LABS	80MG/15ML	N87917 001 JAN 18, 1983

THEOCLEAR-80

CENT PHARMS	80MG/15ML	N87095 001 MAR 01, 1982

THEOPHYLLINE

ALPHARMA	80MG/15ML	N86001 001

THEOPHYLLINE

SYRUP; ORAL
THEOPHYLLINE

ALPHARMA	150MG/15ML	N86545 001

TABLET; ORAL
THEOCLEAR-100

CENT PHARMS	100MG	N85353 002

THEOCLEAR-200

CENT PHARMS	200MG	N85353 001

THEOPHYL-225

JOHNSON RW	225MG	N84726 001

TABLET, CHEWABLE; ORAL
THEOPHYL

JOHNSON RW	100MG	N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL
DURAPHYL

FORREST LABS	100MG	N88503 001 APR 03, 1985
	200MG	N88504 001 APR 03, 1985
	300MG	N88505 001 APR 03, 1985

LABID

PROCTER AND GAMBLE	250MG	N87225 001

SUSTAIRE

ROERIG	100MG	N85665 001
	300MG	N85665 002

THEOPHYLLINE; *MULTIPLE*
SEE MERSALYL SODIUM; THEOPHYLLINE
SEE PROCAINE MERETHOXYLLINE; THEOPHYLLINE

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL
SYNOPHYLATE

CENT PHARMS	EQ 165MG BASE/15ML	N06333 008

TABLET; ORAL
ASBRON

NOVARTIS	EQ 150MG BASE	N85148 001

FDA data supplied by DrugPatentWatch.com

THIAMINE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		
BETALIN S		
LILLY	100MG/ML	N80853 001
THIAMINE HCL		
AKORN	100MG/ML	N87968 001 OCT 01, 1982
AM PHARM PARTNERS	100MG/ML	N80509 001
BEL MAR	100MG/ML	N80718 001
	200MG/ML	N80712 001
DELL LABS	100MG/ML	N83775 001
LUITPOLD	100MG/ML	N80667 001
PARKE DAVIS	100MG/ML	N80770 001
STERIS	100MG/ML	N83534 001
	200MG/ML	N83534 002

THIAMINE HYDROCHLORIDE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

THIAMYLAL SODIUM

INJECTABLE; INJECTION		
SURITAL		
PARKEDALE	1GM/VIAL	N07600 003
	5GM/VIAL	N07600 005
	10GM/VIAL	N07600 009

THIOPENTAL SODIUM

SUSPENSION; RECTAL		
PENTOTHAL		
ABBOTT	400MG/GM	N11679 001

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL		
THIORIDAZINE HCL		
ALPHARMA	30MG/ML	N87766 001 APR 26, 1983
GENEVA PHARMS	30MG/ML	N88307 001 NOV 23, 1983
	100MG/ML	N88308 001 NOV 23, 1983
MORTON GROVE	30MG/ML	N88258 001 JUL 25, 1983
	100MG/ML	N88227 001 JUL 05, 1983
TABLET; ORAL		
THIORIDAZINE HCL		
CHELSEA LABS	15MG	N88562 001 MAY 11, 1984
DANBURY PHARMA	25MG	N88755 001 JUL 24, 1984
HALSEY	10MG	N88375 001 NOV 18, 1983
	15MG	N88461 001 NOV 18, 1983
	25MG	N87264 001 NOV 18, 1983
	100MG	N88379 001 NOV 16, 1983
	150MG	N88737 001 SEP 26, 1984
	200MG	N88738 001 OCT 16, 1984
MYLAN	10MG	N88332 001 JUN 27, 1983
	25MG	N88333 001 JUN 27, 1983
	50MG	N88334 001 JUN 27, 1983
	100MG	N88335 001 NOV 18, 1983

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

PAR PHARM	10MG	N88351 001 DEC 05, 1983
	15MG	N88352 001 DEC 05, 1983
	25MG	N88336 001 DEC 05, 1983
	50MG	N88322 001 DEC 05, 1983
	100MG	N88480 001 DEC 29, 1983
	150MG	N89764 001 FEB 09, 1988
	200MG	N89765 001 FEB 09, 1988
ROXANE	10MG	N88663 001 MAR 15, 1984
	25MG	N88664 001 MAR 15, 1984
	50MG	N88665 001 MAR 15, 1984
	100MG	N89048 001 FEB 26, 1985
SUPERPHARM	10MG	N89103 001 JUL 02, 1985
	25MG	N89104 001 JUL 02, 1985
	50MG	N89105 001 JUL 02, 1985
WATSON LAB	10MG	N88412 001 SEP 12, 1983
	15MG	N88345 001 JUL 28, 1983
	25MG	N88296 001 JUL 28, 1983
	50MG	N88323 001 JUL 28, 1983
	100MG	N88284 001 AUG 25, 1983
	150MG	N88410 001 MAR 05, 1984
	200MG	N88381 001 MAR 14, 1984
WEST WARD	10MG	N88658 001 MAR 26, 1984

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

WEST WARD	15MG	N88659 001 MAR 26, 1984
	25MG	N88660 001 MAR 26, 1984
	50MG	N88661 001 MAR 26, 1984
ZENITH GOLDLINE	100MG	N88273 001 OCT 03, 1983

THIOTHIXENE

CAPSULE; ORAL
THIOTHIXENE

AM THERAP	1MG	N71884 001 AUG 12, 1987
	2MG	N71885 001 AUG 12, 1987
	5MG	N71886 001 AUG 12, 1987
	10MG	N71887 001 AUG 12, 1987
	20MG	N72200 001 DEC 17, 1987
CHELSEA LABS	2MG	N71626 001 JUN 25, 1987
	5MG	N71627 001 JUN 25, 1987
	10MG	N71628 001 JUN 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

ALPHARMA	EQ 5MG BASE/ML	N70969 001 OCT 16, 1987
PACO	EQ 1MG BASE/ML	N71917 001 SEP 20, 1989
	EQ 5MG BASE/ML	N71939 001 DEC 16, 1988
TEVA	EQ 5MG BASE/ML	N71184 001 JUN 22, 1987

FDA data supplied by DrugPatentWatch.com

THIOTHIXENE HYDROCHLORIDE

INJECTABLE; INJECTION			
NAVANE			
ROERIG	EQ 2MG BASE/ML	N16904 001	

THYROGLOBULIN

TABLET; ORAL			
PROLOID			
PARKE DAVIS	16MG	N02245 009	
	32MG	N02245 005	
	65MG	N02245 002	
	100MG	N02245 008	
	130MG	N02245 010	
	200MG	N02245 007	
	325MG	N02245 004	

THYROTROPIN

INJECTABLE; INJECTION			
THYTROPAR			
AVENTIS	10 IU/VIAL	N08682 001	

TICARCILLIN DISODIUM

INJECTABLE; INJECTION			
TICAR			
SMITHKLINE BEECHAM	EQ 6GM BASE/VIAL	N50497 003	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL			
TICLID			
SYNTEX (USA) INC LLC	125MG	N19979 001	MAR 24, 1993

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC			
TIMOLOL MALEATE			
FALCON PHARMS	EQ 0.25% BASE	N74261 001	APR 28, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC			
TIMOLOL MALEATE			
FALCON PHARMS	EQ 0.5% BASE	N74262 001	APR 28, 1995
TABLET; ORAL			
TIMOLOL MALEATE			
NOVOPHARM	5MG	N72648 001	JUN 16, 1993
	10MG	N72649 001	JUN 16, 1993
	20MG	N72650 001	JUN 16, 1993
QUANTUM PHARMICS	5MG	N72466 001	MAY 19, 1989
	10MG	N72467 001	MAY 19, 1989
	20MG	N72468 001	MAY 19, 1989
ROSEMONT	5MG	N72001 001	APR 11, 1989
	10MG	N72002 001	APR 11, 1989
	20MG	N72003 001	APR 11, 1989
WATSON LAB	5MG	N72269 001	APR 11, 1989
	10MG	N72270 001	APR 11, 1989
	20MG	N72271 001	APR 11, 1989

TIOCONAZOLE

CREAM; TOPICAL			
TZ-3			
PFIZER	1%	N18682 001	FEB 18, 1983

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION			
TOBRAMYCIN SULFATE			
APOTHECON	EQ 40MG BASE/ML	N64026 001	MAY 31, 1994

FDA data supplied by DrugPatentWatch.com

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

BARR	100MG	N70162 001 JAN 14, 1986
	250MG	N70163 001 JAN 14, 1986
	500MG	N70164 001 JAN 14, 1986
DURAMED	100MG	N70165 001 JAN 10, 1986
	250MG	N70166 001 JAN 10, 1986
	500MG	N70167 001 JAN 10, 1986
INTERPHARM	250MG	N71270 001 SEP 23, 1986
	500MG	N71271 001 SEP 23, 1986
ROSEMONT	100MG	N71355 001 JAN 11, 1988
	250MG	N70168 001 APR 02, 1986
	500MG	N70169 001 APR 02, 1986
SUPERPHARM	250MG	N70763 001 JUN 16, 1986
	500MG	N70764 001 JUN 16, 1986
WATSON LAB	100MG	N70242 001 AUG 01, 1986
	250MG	N70243 001 AUG 01, 1986
	500MG	N70244 001 AUG 01, 1986

TOLBUTAMIDE

TABLET; ORAL
ORINASE

PHARMACIA AND UPJOHN	250MG	N10670 002
	500MG	N10670 001

TOLBUTAMIDE

ALRA	500MG	N86141 001
ASCOT	500MG	N87541 001 MAR 01, 1983
BARR	500MG	N87121 001

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

EON	500MG	N12678 001
PARKE DAVIS	500MG	N86047 001
PUREPAC PHARM	500MG	N88950 001 JUN 17, 1985
SUPERPHARM	500MG	N88893 001 NOV 19, 1984
VANGARD	500MG	N87876 001 APR 20, 1982
WATSON LAB	250MG	N89110 001 MAY 29, 1987
	500MG	N89111 001 MAY 29, 1987

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

TEVA	EQ 600MG BASE	N74729 001 FEB 27, 1997

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX SPRINKLE

JOHNSON RW	50MG	N20844 003 OCT 26, 1998

TABLET; ORAL
TOPAMAX

JOHNSON RW	50MG	N20505 005 DEC 24, 1996
	300MG	N20505 003 DEC 24, 1996
	400MG	N20505 006 DEC 24, 1996

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM

JOHNSON RW	100MG	N20281 001 MAR 03, 1995

FDA data supplied by DrugPatentWatch.com

TRANEXAMIC ACID

TABLET; ORAL
CYKLOKAPRON
PHARMACIA AND UPJOHN 500MG N19280 001 DEC 30, 1986

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
AM THERAP 50MG N71139 001 OCT 29, 1986
100MG N71140 001 OCT 29, 1986
QUANTUM PHARMICS 100MG N70921 001 DEC 01, 1986
ROSEMONT 50MG N70491 001 APR 29, 1987
100MG N70492 001 APR 29, 1987
WATSON LAB 50MG N71112 001 NOV 17, 1986
100MG N71113 001 NOV 17, 1986
TRIALODINE
QUANTUM PHARMICS 50MG N70942 001 DEC 01, 1986

TRETINOIN

SWAB; TOPICAL
RETIN-A
JOHNSON AND JOHNSON 0.05% N16921 002

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT
FUJISAWA HLTHCARE 16MG N11161 010
KENACORT
BRISTOL MYERS SQUIBB 1MG N11283 003
2MG N11283 008
TRIAMCINOLONE
BARR 2MG N84286 001
2MG N84318 001

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE
BARR 4MG N84267 001
4MG N84319 001
8MG N84268 001
8MG N84320 001
CHELSEA LABS 4MG N85834 001
GENEVA PHARMS 4MG N85601 001
MYLAN 2MG N84406 001
PUREPAC PHARM 2MG N84020 002
4MG N84020 003
ROXANE 2MG N84708 001
4MG N84709 001
8MG N84707 001
TEVA 4MG N84775 001
ZENITH GOLDLINE 4MG N83750 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
FLUTEX
ZENITH GOLDLINE 0.025% N85539 001
0.1% N85539 002
0.5% N85539 003
KENALOG-H
APOTHECON 0.1% N86240 001
TRIACORT
SOLVAY 0.1% N87113 001
TRIAMCINOLONE ACETONIDE
ALPHARMA 0.025% N87797 001 JUN 07, 1982
MORTON GROVE 0.025% N88094 001 SEP 01, 1983
0.1% N88095 001 SEP 01, 1983
0.5% N88096 001 SEP 01, 1983
PHARMADERM 0.025% N87990 001 JUL 07, 1983
0.1% N87991 001 JUL 07, 1983
0.5% N87992 001 JUL 07, 1983
PHARMAFAIR 0.025% N87921 001 AUG 10, 1982

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

PHARMAFAIR	0.1%	N87912 001 AUG 10, 1982
	0.5%	N87922 001 AUG 10, 1982

TRIATEX

ZENITH GOLDLINE	0.025%	N87430 001 NOV 01, 1988
	0.1%	N87429 001 NOV 01, 1988
	0.5%	N87428 001 NOV 01, 1988

TRYMEX

SAVAGE LABS	0.5%	N88198 001 MAR 25, 1983

GEL; TOPICAL
ARISTOGEL

FUJISAWA HLTHCARE	0.1%	N83380 001

LOTION; TOPICAL
KENALOG

BRISTOL MYERS SQUIBB	0.025%	N11602 003
	0.1%	N11602 001

TRIAMCINOLONE ACETONIDE

ALPHARMA	0.025%	N87191 001 SEP 08, 1982
	0.1%	N87192 001 SEP 08, 1982

OINTMENT; TOPICAL
ARISTOCORT A

FUJISAWA HLTHCARE	0.5%	N88781 001 OCT 05, 1984

FLUTEX

ZENITH GOLDLINE	0.025%	N87375 001 NOV 01, 1988
	0.1%	N87377 001 NOV 01, 1988
	0.5%	N87376 001 NOV 01, 1988

KENALOG

APOTHECON	0.5%	N83944 001

TRIAMCINOLONE ACETONIDE

ALPHARMA	0.5%	N89913 001 DEC 23, 1988

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

MORTON GROVE	0.025%	N88090 001 SEP 01, 1983
	0.1%	N88091 001 SEP 01, 1983
	0.5%	N88092 001 SEP 01, 1983
PHARMADERM	0.025%	N88692 001 AUG 02, 1984
	0.1%	N88690 001 AUG 02, 1984

TRIAMCINOLONE ACETONIDE; *MULTIPLE*
SEE NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

AKORN	25MG/ML	N85122 001
	40MG/ML	N86394 001
STERIS	40MG/ML	N85529 001

SYRUP; ORAL
KENACORT

BRISTOL MYERS SQUIBB	EQ 4MG BASE/5ML	N12515 001

TRIAMTERENE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

TRIAZOLAM

TABLET; ORAL
HALCION

PHARMACIA AND UPJOHN	0.5MG	N17892 002 NOV 15, 1982

FDA data supplied by DrugPatentWatch.com

TRICHLORMETHIAZIDE

TABLET; ORAL

NAQUA			
SCHERING	2MG	N12265	001
TRICHLORMAS			
MAST MM	4MG	N86259	001
TRICHLORMETHIAZIDE			
CHELSEA LABS	2MG	N86458	001
	4MG	N85962	001
DANBURY PHARMA	2MG	N83847	001
	4MG	N83855	001
EON	4MG	N86171	001
WATSON LAB	4MG	N83462	001

TRICHLORMETHIAZIDE; *MULTIPLE*
SEE RESERPINE; TRICHLORMETHIAZIDE

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS			
AVENTIS PHARMS	1.5GM/15ML	N16830	001

TABLET; ORAL

TRICLOS			
AVENTIS PHARMS	750MG	N16809	002

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON			
LEDERLE	10MG/ML	N09729	001

TABLET; ORAL

PATHILON			
LEDERLE	25MG	N09489	005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

TRIFLUOPERAZINE HCL			
MORTON GROVE	EQ 10MG BASE/ML	N88143	001
		JUL 26, 1983	

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIFLUOPERAZINE HCL			
QUAD PHARMS	EQ 2MG BASE/ML	N89893	001
		OCT 17, 1988	

TABLET; ORAL

TRIFLUOPERAZINE HCL			
DURAMED	EQ 1MG BASE	N88967	001
		APR 23, 1985	
	EQ 2MG BASE	N88968	001
		APR 23, 1985	
	EQ 5MG BASE	N88969	001
		APR 23, 1985	
	EQ 10MG BASE	N88970	001
		APR 23, 1985	
WATSON LAB	EQ 1MG BASE	N85975	001
		JUN 23, 1988	
	EQ 2MG BASE	N85976	001
		JUN 23, 1988	
	EQ 5MG BASE	N85973	001
		JUN 23, 1988	
	EQ 10MG BASE	N88710	001
		JUN 23, 1988	
ZENITH GOLDLINE	EQ 1MG BASE	N87612	001
		NOV 19, 1982	
	EQ 2MG BASE	N87613	001
		NOV 19, 1982	
	EQ 5MG BASE	N87328	001
		NOV 19, 1982	
	EQ 10MG BASE	N87614	001
		NOV 19, 1982	

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN			
APOTHECON	EQ 50MG HCL/5ML	N11491	004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN			
APOTHECON	3MG/ML	N11325	005

TABLET; ORAL

VESPRIN			
BRISTOL MYERS SQUIBB	10MG	N11123	001

FDA data supplied by DrugPatentWatch.com

TRIFLUPROMAZINE HYDROCHLORIDE

TABLET; ORAL
VESPRIN
BRISTOL MYERS SQUIBB 25MG N11123 002
50MG N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE
LEDERLE 5MG N06773 010
5MG N12947 001

TABLET; ORAL
TREMIN
SCHERING 2MG N80381 001
5MG N80381 003
TRIHEXYPHENIDYL HCL
VANGARD 2MG N88035 001
JUL 30, 1982
WATSON LAB 2MG N85117 001
5MG N85105 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI SYNTHELABO 30MG N18719 002
DEC 31, 1984
60MG N18719 001
DEC 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
TEMARIL
ALLERGAN HERBERT EQ 5MG BASE N11316 004

SYRUP; ORAL
TEMARIL
ALLERGAN HERBERT EQ 2.5MG BASE/5ML N11316 003
TRIMEPRAZINE TARTRATE
ALPHARMA EQ 2.5MG BASE/5ML N85015 001
FEB 18, 1982

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
MORTON GROVE EQ 2.5MG BASE/5ML N88285 001
APR 11, 1985

TABLET; ORAL
TEMARIL
ALLERGAN HERBERT EQ 2.5MG BASE N11316 001

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD
ROCHE 50MG/ML N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
SMITH AND NEPHEW 100MG/ML N88960 001
APR 04, 1986
100MG/ML N89043 001
APR 04, 1986
SOLOPAK 100MG/ML N89094 001
APR 04, 1986

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM
HALSEY 100MG N70494 001
JAN 22, 1986
200MG N70495 001
SEP 24, 1986
TRIMPEX 200
ROCHE 200MG N17952 002
NOV 09, 1982

TRIMETHOPRIM; *MULTIPLE*
SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

FDA data supplied by DrugPatentWatch.com

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

ROSEMONT	EQ 25MG BASE	N71283 001 DEC 08, 1987
	EQ 50MG BASE	N71284 001 DEC 08, 1987
	EQ 100MG BASE	N71285 001 DEC 08, 1987

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

ANABOLIC	50MG	N83037 001
BARR	50MG	N80744 001
CHELSEA LABS	50MG	N85188 001
HEATHER	50MG	N83989 001
PARKE DAVIS	25MG	N83625 001
	50MG	N83626 001
WATSON LAB	50MG	N80790 001

TABLET, EXTENDED RELEASE; ORAL
PBZ-SR

NOVARTIS	50MG	N10533 002

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
VAGILIA

TEVA	3.7%;2.86%;3.42%	N88821 001 NOV 09, 1987

TABLET; VAGINAL
TRIPLE SULFA

FOUGERA	184MG;143.75MG;172.5MG	N88463 001 JAN 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	N88462 001 JAN 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
ACTIDIL

GLAXO WELLCOME	1.25MG/5ML	N11496 002 JUL 01, 1983

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
MYIDYL

ROSEMONT	1.25MG/5ML	N87963 001 JAN 18, 1983

TRIPROLIDINE HCL

ALPHARMA	1.25MG/5ML	N85940 001
HALSEY	1.25MG/5ML	N88735 001 JAN 17, 1985
PHARM ASSOC	1.25MG/5ML	N87514 001 FEB 10, 1982

TABLET; ORAL
ACTIDIL

GLAXO WELLCOME	2.5MG	N11110 002 JUL 01, 1983

TRIPROLIDINE HCL

DANBURY PHARMA	2.5MG	N85094 001
VITARINE	2.5MG	N85610 001

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
LANTRISUL

LANNETT	167MG/5ML;167MG/5ML; 167MG/5ML	N80123 002

NEOTRIZINE

LILLY	167MG/5ML;167MG/5ML; 167MG/5ML	N06317 012

SULFALOID

FOREST PHARMS	167MG/5ML;167MG/5ML; 167MG/5ML	N80100 001

SULFOSE

WYETH AYERST	167MG/5ML;167MG/5ML; 167MG/5ML	N80013 002

TERFONYL

BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML; 167MG/5ML	N06904 002

TRIPLE SULFA

ALPHARMA	167MG/5ML;167MG/5ML; 167MG/5ML	N80280 001

FDA data supplied by DrugPatentWatch.com

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL			
TRIPLE SULFAS			
LEDERLE	167MG/5ML;167MG/5ML; 167MG/5ML	N06920	003
TABLET; ORAL			
NEOTRIZINE			
LILLY	167MG;167MG;167MG	N06317	011
SULFA-TRIPLE #2			
IMPAX LABS	167MG;167MG;167MG	N80079	001
SULFALOID			
FOREST PHARMS	167MG;167MG;167MG	N80099	001
SULFOSE			
WYETH AYERST	167MG;167MG;167MG	N80013	001
TERFONYL			
BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N06904	001
TRIPLE SULFA			
PUREPAC PHARM	167MG;167MG;167MG	N80086	001
TRIPLE SULFAS			
LEDERLE	167MG;167MG;167MG	N06920	002

TROGLITAZONE

TABLET; ORAL			
PRELAY			
SANKYO	200MG	N20719	001
		JAN 29, 1997	
	300MG	N20719	003
		AUG 04, 1997	
	400MG	N20719	002
		JAN 29, 1997	
REZULIN			
PARKE DAVIS PHARMS	200MG	N20720	001
		JAN 29, 1997	
	300MG	N20720	003
		AUG 04, 1997	
	400MG	N20720	002
		JAN 29, 1997	

TROLEANDOMYCIN

SUSPENSION; ORAL			
TAO			
PFIZER	EQ 125MG BASE/5ML	N50332	001

TROMETHAMINE; *MULTIPLE*
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC			
MYDRIACYL			
ALCON	0.5%	N12111	002
	1%	N12111	004
MYDRIAFAIR			
PHARMAFAIR	0.5%	N88274	001
		SEP 16, 1983	
	1%	N88230	001
		SEP 16, 1983	
TROPICAMIDE			
AKORN	1%	N88447	001
		AUG 28, 1985	
STERIS	0.5%	N89171	001
		DEC 28, 1990	

TROVAFLOXACIN MESYLATE; *MULTIPLE*
SEE AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION			
TUBOCURARINE CHLORIDE			
QUAD PHARMS	3MG/ML	N89442	001
		AUG 12, 1988	

TYROPANOATE SODIUM

CAPSULE; ORAL			
BILOPAQUE			
NYCOMED	750MG	N13731	001

TYROSINE; *MULTIPLE*
SEE NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL			
VIRAC REX			
CHESEBROUGH PONDS	0.5%;1.8%	N11914	001

FDA data supplied by DrugPatentWatch.com

UNDECOYLIUM CHLORIDE IODINE COMPLEX; *MULTIPLE*
SEE UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

UREA

INJECTABLE; INJECTION
STERILE UREA
ABBOTT 40GM/VIAL N17698 001

UREA; *MULTIPLE*
SEE HYDROCORTISONE; UREA

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
METRODIN
SERONO 75 IU/AMP N19415 002 SEP 18, 1986
150 IU/AMP N19415 003 SEP 18, 1986

URSODIOL

CAPSULE; ORAL
ACTIGALL
NOVARTIS 150MG N19594 001 DEC 31, 1987

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
GLAXO WELLCOME EQ 1GM BASE N20487 002 JUN 23, 1995

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL
VANCOLED
LEDERLE EQ 500MG BASE/6ML N63321 003 OCT 15, 1993

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HCL
QUAD PHARMS EQ 500MG BASE/VIAL N62845 001 JUL 15, 1988
EQ 1GM BASE/VIAL N62845 002 JUL 15, 1988
VANCOR
PHARMACIA AND UPJOHN EQ 500MG BASE/VIAL N62956 001 AUG 01, 1988
EQ 1GM BASE/VIAL N62956 002 AUG 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION
PITRESSIN TANNATE
PARKE DAVIS 5 PRESSOR UNITS/ML N03402 001

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR
WYETH AYERST EQ 100MG BASE N20699 003 OCT 20, 1997

TABLET; ORAL
EFFEXOR
WYETH AYERST EQ 12.5MG BASE N20151 001 DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
CALAN
SEARLE 2.5MG/ML N18925 001 MAR 30, 1984
2.5MG/ML N19038 001 MAR 30, 1984
VERAPAMIL HCL
AM PHARM PARTNERS 2.5MG/ML N70348 001 MAY 01, 1986
MARSAM 2.5MG/ML N72233 001 FEB 26, 1993

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION		
VERAPAMIL HCL		
MARSAM	2.5MG/ML	N73485 001 SEP 27, 1993
QUAD PHARMS	2.5MG/ML	N70672 001 MAR 07, 1986
SMITH AND NEPHEW	2.5MG/ML	N70696 001 JUL 31, 1987
	2.5MG/ML	N70697 001 JUL 31, 1987
SOLOPAK	2.5MG/ML	N70695 001 JUL 31, 1987
TABLET; ORAL		
CALAN		
SEARLE	160MG	N18817 004 FEB 23, 1988
VERAPAMIL HCL		
CHELSEA LABS	40MG	N72799 001 APR 28, 1989
HALSEY	80MG	N70482 001 SEP 24, 1986
	120MG	N70483 001 SEP 24, 1986
WARNER CHILCOTT	80MG	N70340 001 SEP 24, 1986
	120MG	N70341 001 SEP 24, 1986

VERATRUM VIRIDE

TABLET; ORAL		
VERTAVIS		
WALLACE LABS	130 CSR UNIT	N05691 002

VIDARABINE

INJECTABLE; INJECTION		
VIRA-A		
PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION		
VINBLASTINE SULFATE		
AM PHARM PARTNERS	10MG/VIAL	N89011 001 NOV 18, 1985
QUAD PHARMS	1MG/ML	N89311 001 MAR 23, 1987
	10MG/VIAL	N89365 001 AUG 07, 1986

VINCRISTINE SULFATE

INJECTABLE; INJECTION		
ONCOVIN		
LILLY	1MG/VIAL	N14103 001
	5MG/VIAL	N14103 002
VINCREX		
BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001 JUL 12, 1988
VINCRISTINE SULFATE		
ABIC	1MG/ML	N70873 001 FEB 19, 1987
AM PHARM PARTNERS	1MG/ML	N70411 001 SEP 10, 1986
FAULDING	1MG/VIAL	N71559 001 APR 11, 1988
	2MG/VIAL	N71560 001 APR 11, 1988
	5MG/VIAL	N71561 001 APR 11, 1988
QUAD PHARMS	1MG/ML	N70777 001 APR 29, 1986
	1MG/ML	N70778 001 MAY 01, 1986
	1MG/VIAL	N71222 001 MAR 07, 1988
	2MG/VIAL	N71223 001 MAR 07, 1988
	5MG/VIAL	N71937 001 MAR 07, 1988

VIOMYCIN SULFATE

INJECTABLE; INJECTION		
VIOCIN SULFATE		
PFIZER	EQ 1GM BASE/VIAL	N61086 001

FDA data supplied by DrugPatentWatch.com

VIOMYCIN SULFATE

INJECTABLE; INJECTION		
VIOCIN SULFATE		
PFIZER	EQ 5GM BASE/VIAL	N61086 002

VITAMIN A

CAPSULE; ORAL		
AQUASOL A		
ASTRAZENECA	25,000 USP UNITS	N83080 002
	50,000 USP UNITS	N83080 001
VITAMIN A		
BANNER PHARMACAPS	50,000 USP UNITS	N83973 001
CHASE CHEM	50,000 IU	N83351 001
EVERYLIFE	50,000 IU	N83134 001
IMPAX LABS	50,000 USP UNITS	N80952 001

VITAMIN A; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL		
AFAXIN		
STERLING WINTHROP	EQ 50,000 UNITS BASE	N83187 001
ALPHALIN		
LILLY	EQ 50,000 UNITS BASE	N80883 001
DEL-VI-A		
DEL RAY LABS	EQ 50,000 UNITS BASE	N80830 001
VI-DOM-A		
BAYER	EQ 50,000 UNITS BASE	N80972 001
VITAMIN A		
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	N80702 001
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	N80860 001
CHASE CHEM	EQ 50,000 UNITS BASE	N80746 001
	EQ 50,000 UNITS BASE	N83207 001
ELKINS SINN	EQ 50,000 UNITS BASE	N85479 001
EVERYLIFE	EQ 50,000 UNITS BASE	N80943 001

VITAMIN A PALMITATE

CAPSULE; ORAL		
VITAMIN A		
EVERYLIFE	EQ 50,000 UNITS BASE	N83114 001
IMPAX LABS	EQ 50,000 UNITS BASE	N80953 001
	EQ 50,000 UNITS BASE	N80955 001
WHARTON LABS	EQ 50,000 UNITS BASE	N83665 001
ZENITH GOLDLINE	EQ 50,000 UNITS BASE	N83035 001
	EQ 50,000 UNITS BASE	N83190 001
VITAMIN A PALMITATE		
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	N83948 001
	EQ 50,000 UNITS BASE	N83981 001
VITAMIN A SOLUBILIZED		
TEVA	EQ 50,000 UNITS BASE	N80921 001
INJECTABLE; INJECTION		
VITAMIN A PALMITATE		
BEL MAR	EQ 50,000 UNITS BASE/ML	N80819 001

VITAMIN A PALMITATE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

VITAMIN E; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

FDA data supplied by DrugPatentWatch.com

WARFARIN POTASSIUM

TABLET; ORAL
ATHROMBIN-K
PURDUE FREDERICK 2MG N11771 007
5MG N11771 004
10MG N11771 005
25MG N11771 006

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN
DUPONT MERCK 50MG/VIAL N09218 020
75MG/VIAL N09218 012

TABLET; ORAL
ATHROMBIN
PURDUE FREDERICK 5MG N11771 003
10MG N11771 002
25MG N11771 001
PANWARFIN
ABBOTT 2MG N17020 001
2.5MG N17020 002
5MG N17020 003
7.5MG N17020 004
10MG N17020 005
WARFARIN SODIUM
ROSEMONT 2MG N88719 001
JUN 27, 1985
2.5MG N88720 001
AUG 06, 1985
5MG N88721 001
JUL 02, 1985
WATSON LAB 2MG N86123 001
AUG 17, 1982
2.5MG N86120 001
AUG 17, 1982
5MG N86119 001
AUG 17, 1982
7.5MG N86118 001
AUG 17, 1982
10MG N86122 001
AUG 17, 1982

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER
AM PHARM PARTNERS 100% N89099 001
DEC 29, 1987
100% N89100 001
DEC 29, 1987

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION
STERILE WATER IN PLASTIC CONTAINER
MILES 100% N18246 001

XENON, XE-133

GAS; INHALATION
XENON XE 133
NYCOMED AMERSHAM 1 CI/AMP N17256 002
10mCi/VIAL N17687 002
20mCi/VIAL N17687 003
XENON XE 136-192.S.
NYCOMED AMERSHAM 10mCi/VIAL N17687 001

INJECTABLE; INJECTION
XENON XE 133
DUPONT PHARMS 6.3mCi/ML N17283 001
NYCOMED AMERSHAM 1.3-1.7 CI/AMP N17256 001

SOLUTION; INHALATION, INJECTION
XENEISOL
MALLINCKRODT 18-25mCi/AMP N17262 002

XYLOSE

POWDER; ORAL
XYLO-PFAN
SAVAGE LABS 25GM/BOT N17605 001

ZIDOVUDINE

TABLET; ORAL
RETROVIR
GLAXO WELLCOME 200MG N20518 001
DEC 19, 1995

FDA data supplied by DrugPatentWatch.com

ZINC ACETATE; *MULTIPLE*
SEE CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

ZINC SULFATE

INJECTABLE; INJECTION
ZINC SULFATE

AM PHARM PARTNERS	EQ 1MG ZINC/ML	N19229 002 MAY 05, 1987

FDA data supplied by DrugPatentWatch.com

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
1,5-(Butylimino)-1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD= 5/12/98 MA=
1,5-(Butylimino)-1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD= 5/29/98 MA=
1-(11-dodecylamino-10-hy droxyundecyl)-3,7-dimeth TN=	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 1/18/00 MA=
111Indium pentetreotide TN=SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University 1600 Canal St. 10th Floor New Orleans LA 70112 DD= 6/10/99 MA=
15AU81 TN=	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp. 68 T.W. Alexander Dr. P.O. Box 14186 Research Triangle Park NC 27709 DD= 6/4/97 MA=
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Street Seattle WA 98119-4007 DD= 2/10/99 MA=
2'-3'-dideoxyadenosine TN=	Treatment of aquired immunodeficiency syndrome.	National Cancer Institute, Dct NIH, Exec. Plaza N., Room 7-18 Bethesda MD 20892 DD= 7/21/87 MA=
2'-deoxycytidine TN=	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D. Massey Cancer Center, VCU P.O. Box 980230 Richmond VA 23298-0230 DD= 9/9/96 MA=
2-0-desulfated heparin TN=Aeropin	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health 50 North Medical Drive, Room Salt Lake City UT 84132 DD= 9/17/93 MA=
24,25 dihydroxycholecalciferol TN=	Treatment of uremic osteodystrophy.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443 DD= 2/27/87 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
3'-azido-2',3'dideoxyuridine TN=AZDU	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 1401 Harbor Bay Parkway Alameda CA 94501 DD= 11/20/89 MA=
3,4-diaminopyridine TN=	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company 37 Cleveland Avenue P.O. Box 5290 Princeton NJ 08540 DD= 12/18/90 MA=
3,5,3'-triiodothyroacetate TN=	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D. University of Vermont 84 Beartown Road Underhill VT 05489 DD= 9/20/99 MA=
3-(3,5-Dimethyl-1H-2ylme thylene)-1,3-dihydro-ind TN=	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080 DD= 2/23/00 MA=
3-(3,5-dimethyl-1H-2ylme thylene)-1,3-dihydro-ind TN=	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA DD= 9/11/98 MA=
4-aminosalicylic acid TN=Pamisyl (P-D),	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D. University Of Vermont Given C-317 Burlington VT 05405 DD= 12/13/89 MA=
40SD02 TN=	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc. 1095 10th Ave., S.E. Minneapolis MN 55414 DD= 12/21/98 MA=
5,6-dihydro-5-azacytidine TN=	Treatment of malignant mesothelioma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263 DD= 5/11/92 MA=
5-aza-2'-deoxycytidine TN=	Treatment of acute leukemia.	Pharmachemie U.S.A., Inc. 1510 Delp Dr. Kulpsville PA 19443 DD= 8/3/87 MA=
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Research Triangle Park NC DD= 9/2/99 MA=
5a8, monoclonal antibody to CD4 TN=	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 12/20/93 MA=
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 4/6/99 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 7/27/99 MA=
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 7/6/99 MA=
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard San Mateo CA 94404-1593 DD= 3/24/97 MA=
8-methoxsalen TN=Uvadex	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc. Oaklands Corporate Center 437 Creamery Way Exton PA 19341 DD= 6/22/93 MA=
8-methoxsalen TN=Uvadex	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc. Oaklands Corporate Center 437 Creamery Way Exton PA 19341 DD= 5/12/94 MA=
9-cis retinoic acid TN=Panretin	Treatment of acute promyelocytic leukemia.	Ligand Pharmaceuticals, Inc. 9393 Towne Centre Drive Suite 100 San Diego CA 92121 DD= 4/10/92 MA=
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534 DD= 1/2/97 MA=
9-nitro-20-(S)-camptothecin TN=	Treatment of pancreatic cancer.	Stehlin Foundation for Cancer 1315 St. Joseph Parkway, Suite Houston TX 77002 DD= 9/16/96 MA=
Abetimus TN=	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121 DD= 7/28/00 MA=
Acetylcysteine TN=Mucomyst/Mucomyst 10	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Apothecon P.O. Box 4500 Princeton NJ 08543-4500 DD= 8/13/87 MA=
Aconiazide TN=	Treatment of tuberculosis.	Lincoln Diagnostics P.O. Box 1128 Decatur IL 62525 DD= 6/20/88 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Adeno-associated viral-based vector TN=	Treatment of cystic fibrosis.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101 DD= 2/15/95 MA=
Adenosine TN=	For use in conjunction with BCNU in the treatment of brain tumors.	Medco Research, Inc. 8455 Beverly Boulevard Suite 308 Los Angeles CA 90048 DD= 8/1/89 MA=
Adenovirus-based vector Factor VIII TN=MiniAdFVIII	Treatment of hemophilia A.	GenStar Therapeutics Corporation 10835 Altman Row Suite 150 San Diego CA 92121 DD= 12/15/99 MA=
Aerosolized pooled immune globulin TN=	Treatment of respiratory syncytial virus lower respiratory tract disease.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090 DD= 1/3/89 MA=
AI-RSA TN=	Treatment of autoimmune uveitis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173 DD= 10/8/92 MA=
Albendazole TN=Albenza	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101 DD= 1/17/96 MA= 6/11/96
Albendazole TN=Albenza	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2)	SmithKline Beecham One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101 DD= 1/18/96 MA= 6/11/96
Aldesleukin TN=Proleukin	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. Emeryville CA 94608-2916 DD= 11/24/98 MA=
Aldesleukin TN=Proleukin	Treatment of primary immunodeficiency disease associated with T-cell defects.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916 DD= 3/22/89 MA=
Aldesleukin TN=Proleukin	Treatment of metastatic renal cell carcinoma.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916 DD=9/14/88 MA= 5/5/92
Aldesleukin TN=Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916 DD= 9/10/96 MA= 1/9/98

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Aldesleukin TN=Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville CA 94608-2916 DD= 7/31/98 MA=
Alemtuzumab TN=Campath	Treatment of chronic lymphocytic leukemia.	Millennium and ILEX Partners, LP 75 Sidney Street Cambridge MA 02138 DD= 10/20/97 MA=
Alglucerase injection TN=Ceredase	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 7/21/95 MA=
Alglucerase injection TN=Ceredase	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 3/11/85 MA= 4/5/91
Alitretinoin TN=Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego CA 92121-1117 DD= 3/24/98 MA= 2/2/99
Allogeneic human retinal pigment epithelial TN=Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza 50 Division Street, Suite 503 Somerville NJ 08876 DD= 7/18/97 MA=
Allogeneic peripheral blood mononuclear cells TN=CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs CA 90670 DD= 6/13/97 MA=
Allopurinol riboside TN=	Treatment of cutaneous and visceral leishmaniasis.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709 DD= 12/4/85 MA=
Allopurinol riboside TN=	Treatment of Chagas' disease.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709 DD= 12/4/85 MA=
Allopurinol sodium TN=Zyloprim	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot	Catalytica Pharmaceuticals, Inc PO Box 1887 Greenville NC 27835-1887 DD= 10/16/92 MA= 5/17/96
Allopurinol sodium TN=Zyloprim	Ex-vivo preservation of cadaveric kidneys for transplantation	Burroughs Wellcome Company 3030 Cornwallis Road Research Triangle Pk NC 27709 DD= 11/9/87 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Alpha-1-antitrypsin (recombinant DNA Origin) TN=	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916 DD= 1/1/84 MA=
Alpha-galactosidase A TN=Fabrase	Treatment of Fabry's disease.	Desnick, Robert J. M.D. The Mount Sinai School Of Fifth Avenue at 100th Street, New York NY 10029 DD= 7/20/90 MA=
Alpha-galactosidase A TN=CC-galactosidase	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305 DD= 6/17/91 MA=
Alpha-galactosidase A TN=Replagal	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge MA 02139 DD= 6/22/98 MA=
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, National Institutes of Health, Building 31, Room 9N-222 Bethesda MD 20892-2560 DD= 8/19/97 MA=
Alpha1-proteinase inhibitor (human) TN=	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901 DD= 11/24/99 MA=
Alpha1-proteinase inhibitor (human) TN= Prolastin	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation Pharmaceutical Division, 400 Morgan Lane New Haven CT 06516 DD= 12/7/84 MA= 12/2/87
Alprostadil TN=	Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.	Schwarz Pharma, Inc. P.O. Box 2038 Milwaukee WI 53201 DD= 10/20/93 MA=
Alronidase TN=Aldurazyme	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc. 371 Bel Marin Keys Boulevard, Novato CA 94949-5608 DD= 9/24/97 MA=
Altretamine TN=Hexalen	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 2/9/84 MA= 12/26/90
Amifostine TN=Ethyol	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite #400 West Conshohocken PA 19428 DD= 11/24/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Amifostine TN=Ethyol	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428 DD= 10/4/99 MA=
Amifostine TN=Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken PA 19428 DD= 5/12/98 MA= 6/24/99
Amifostine TN=Ethyol	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 5/30/90 MA= 12/8/95
Amifostine TN=Ethyol	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 5/30/90 MA=
Amifostine TN=Ethyol	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 5/30/90 MA=
Amiloride HCl solution for inhalation TN=	Treatment of cystic fibrosis.	Glaxo Wellcome Research and 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 7/18/90 MA=
Aminocaproic acid TN=Caprogel	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School Department of Ophthalomology 880 Kempsville Road, Suite 2500 Norfolk VA 23502-3990 DD= 1/6/95 MA=
Aminosalicylate sodium TN=	Treatment of Crohn's disease.	Syncom Pharmaceuticals, Inc. 66 Hanover Road Florham Park NJ 07932 DD= 4/6/93 MA=
Aminosalicylic acid TN=Paser Granules	Treatment of tuberculosis infections.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540 DD= 2/19/92 MA= 6/30/94
Aminosidine TN=Paromomycin	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D. University of Illinois at 833 South Wood Street (m/c886) Chicago IL 60612 DD= 9/9/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Aminosidine TN=Gabbromicina	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D. University of Illinois at 833 South Wood Street (m/c886) Chicago IL 60612 DD= 11/15/93 MA=
Aminosidine TN=Gabbromicina	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D. University Of Illinois At 833 South Wood Street (m/c886) Chicago IL 60612 DD= 5/14/93 MA=
Amiodarone TN=Amio-Aqueous	Treatment of incessant ventricular tachycardia.	Wyeth-Ayerst Research PO Box 8299 Philadelphia PA 19101-8299 DD= 8/17/93 MA=
Amiodarone HCl TN=Cordarone	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories P.O. Box 8299 Philadelphia PA 19101 DD= 3/16/94 MA= 8/3/95
Ammonium tetrathiomolybdate TN=	Treatment of Wilson's disease.	Brewer, George J. M.D. University Of Michigan Medical 4708 Medical Science Building II Ann Arbor MI 48109 DD= 1/31/94 MA=
Amphotericin B lipid complex TN=Abelcet	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 9/23/96 MA=
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive fungal infections.	Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 12/3/96 MA= 10/18/96
Amphotericin B lipid complex TN=Abelcet	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 5/6/96 MA=
Amphotericin B lipid complex TN=Abelcet	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 6/27/96 MA=
Amphotericin B lipid complex TN=Abelcet	Treatment of invasive protothecosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 8/21/96 MA=
Amphotericin B lipid complex TN=Abelcet	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 5/6/96 MA=
Amsacrine TN=Amsidyl	Treatment of acute adult leukemia.	Warner-Lambert Company Parke-Davis Pharmaceutical 2800 Plymouth Road Ann Arbor MI 48106 DD= 12/7/84 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Anagrelide TN=Agrylin	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp. Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274 DD= 6/11/85 MA=
Anagrelide TN=Agrylin	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp. Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274 DD= 7/14/86 MA=
Anagrelide TN=Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724 DD= 1/27/88 MA= 3/14/97
Ananain, comosain TN=Vianain	For the enzymatic debridement of severe burns.	Genzyme Corporation One Kendall Square Cambridge MA 02139 DD= 1/21/92 MA=
Anaritide acetate TN=Auriculin	Improvement of early renal allograft function following renal transplantation.	Scios, Inc. 2450 Bayshore Parkway Mountain View CA 94043 DD= 4/10/92 MA=
Anaritide acetate TN=Auriculin	Treatment of patients with acute renal failure.	Scios, Inc. 2450 Bayshore Parkway Mountain View CA 94043 DD= 8/27/92 MA=
Ancestim TN=Stemgen	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 7/5/95 MA=
Ancrod TN=Viprinex	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company 3000 Continental Dr., North Mt. Olive NJ 07828 DD= 11/12/97 MA=
Angiotensin 1-7 TN=	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660 DD= 2/16/00 MA=
Anti pan T lymphocyte monoclonal antibody TN=Anti-t Lymphocyte	For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 1/29/86 MA=
Anti pan T lymphocyte monoclonal antibody TN=Anti-t Lymphocyte	For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 1/29/86 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Anti-CD45 monoclonal antibodies TN=	Prevention of acute graft rejection of human organ transplants.	Baxter Healthcare Corporation 1620 Waukegan Road Mcgaw Park IL 60085 DD= 9/10/90 MA=
Anti-cytomegalovirus monoclonal antibodies TN=	Prevention of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102 DD= 5/3/90 MA=
Anti-cytomegalovirus monoclonal antibodies TN=	Treatment of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102 DD= 5/3/90 MA=
Anti-cytomegalovirus monoclonal antibodies TN=	Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102 DD= 5/2/90 MA=
Anti-cytomegalovirus monoclonal antibodies TN=	Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102 DD= 5/2/90 MA=
Anti-tap-72 immunotoxin TN=Xomazyme-791	Treatment of metastatic colorectal adenocarcinoma.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 3/6/87 MA=
Anti-thymocyte Globulin (Rabbitt) TN=Thymoglobulin	Treatment of myelodysplastic syndrome (MDS)	SangStat Medical Corporation 6300 Dumbarton Circle Freemont CA 94555 DD= 9/6/00 MA=
Anti-thymocyte serum TN=Nashville Rabbit	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research 1600 Hayes Street Nashville TN 37203 DD= 6/2/93 MA=
Antiepilepsirine TN=	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital 700 Children's Drive Columbus OH 43205 DD= 3/23/89 MA=
Antihemophilic factor (human) TN=Alphanate	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032-3520 DD= 1/5/96 MA=
Antihemophilic factor (recombinant) TN=Kogenate	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation 1884 Miles Avenue Elkhart IN 46515 DD= 9/25/89 MA= 2/25/93
Antihemophilic factor (recombinant) TN=ReFacto	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Genetics Institute, Inc. 87 CambridgePark Drive Cambridge MA 02140 DD= 2/8/96 MA= 3/6/00

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Antihemophilic factor/von Willebrand TN=Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King Of Prussia PA 19406-0901 DD= 10/16/92 MA= 4/1/99
Antimelanoma Antibody XMMME-001-DTPA 111 TN=Antimelanoma	Diagnostic use in imaging systemic and nodal melanoma metastasis.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 11/14/84 MA=
Antimelanoma Antibody XMMME-001-RTA TN=Antimelanoma	Treatment of stage III melanoma not amenable to surgical resection.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 11/14/84 MA=
Antipyrine Test TN=	For use as an index of hepatic drug-metabolizing capacity.	Upsher-Smith Laboratories, Inc 4905 23rd Avenue North Minneapolis MN 55447 DD= 2/21/85 MA=
Antithrombin III (human) TN=Thrombate III	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation Pharmaceutical Division, 400 Morgan Lane New Haven CT 06516 DD= 11/26/84 MA= 12/30/91
Antithrombin III (human) TN=ATnativ	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB Lindhagensgatan 133 SE-112 87 Stockholm Sweden SE DD= 2/8/85 MA= 12/31/89
Antithrombin III (human) concentrate IV TN=Kybernin P	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901 DD= 7/2/85 MA=
Antithrombin III human TN=Antithrombin III	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone	American National Red Cross 9312 Old Georgetown Road Bethesda MD 20814 DD= 1/2/86 MA=
Antivenin, crotalidae polyvalent immune Fab TN=CroFab	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc. 1207 17th Ave. S., Suite 103 Nashville TN 37212 DD= 1/12/94 MA= 10/2/00
Antivenom (crotalidae) purified (avian) TN=	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc. 5445 East Cheryl Parkway Madison WI 53711 DD= 2/12/91 MA=
AP1903 TN=	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge MA 02139-4234 DD= 11/24/99 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
APL 400-020 V-Beta DNA vaccine TN=	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and 211 Bailey Rd. West Henrietta NY 14586-9728 DD= 3/8/95 MA=
Apomorphine TN=	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon SN5 8RU Wiltshire UK DD= 10/20/97 MA=
Apomorphine TN=	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc. 1110 Lake Cook Rd. Suite 257 Buffalo Grove IL 60089 DD= 7/17/95 MA=
Apomorphine HCl TN=	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Mylan Pharmaceuticals, Inc. 781 Chestnut Ridge Rd. PO Box 4310 Morgantown WV 26505-4310 DD= 4/22/93 MA=
Aprotinin TN=Trasylol	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary	Bayer Corporation Pharmaceutical Division 400 Morgan Lane West Haven CT 06516 DD= 11/17/93 MA= 12/29/93
Arcitumomab TN=99m Tc-labeled	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 5/10/96 MA=
Arginine butyrate TN=	Treatment of sickle cell disease and beta thalassemia.	Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139-4242 DD= 5/25/94 MA=
Arginine butyrate TN=	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D. Boston University Cancer Research Center Boston MA 02118 DD= 4/7/92 MA=
Arsenic trioxide TN=Trisenox	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite Seattle WA 98119 DD= 4/28/00 MA=
arsenic trioxide TN=Trisenox	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 7/17/00 MA=
Arsenic trioxide TN=Trisenox	Treatment of acute promyelocytic leukemia.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle WA 98119 DD= 3/3/98 MA= 9/25/00

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research Via Appia , Geneva 27 Switzerland CH DD= 7/19/99 MA=
As-101 TN=	Treatment of acquired immunodeficiency syndrome.	NPDC-AS101, Inc. 783 Jersey Avenue New Brunswick NJ 08901 DD= 11/9/87 MA=
Atovaquone TN=Mepron	Treatment and suppression of Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive PO Box 13398 Research Triangle Park NC DD= 3/16/93 MA=
Atovaquone TN=Mepron	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 3/16/93 MA=
Atovaquone TN=Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count	Glaxo Wellcome Research and 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 8/14/91 MA= 1/5/99
Atovaquone TN=Mepron	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 9/10/90 MA= 11/25/92
Autologous DNP-conjugated tumor TN=M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City MO 64111 DD= 2/23/99 MA=
Autolymphocyte therapy TN=	Treatment of renal cell carcinoma.	Cytogen Corporation 600 College Road East CN 5308 Princeton NJ 08540-5308 DD= 7/12/94 MA=
Azathioprine TN=Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York NY 10019 DD= 9/14/99 MA=
B2036-PEG TN=Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin TX 78701 DD= 6/24/97 MA=
Bacitracin TN=Altracin	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc. One Executive Drive P.O. Box 1399 Fort Lee NJ 07024 DD= 3/13/84 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Baclofen TN=Lioresal Intrathecal	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and	Medtronic, Inc. 800 53rd Avenue N.E. Minneapolis MN 55432 DD= 11/10/87 MA= 6/25/92
Baclofen TN=Lioresal Intrathecal	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc. 800 53rd Avenue N.E. P.O. 1250 Minneapolis MN 55440-9087 DD= 9/26/94 MA=
Baclofen TN=	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc. 1400 Providence Highway Norwood MA 02062 DD= 12/16/91 MA=
Basiliximab TN=Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 12/12/97 MA= 5/12/98
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research 1100 Fairview Avenue North Seattle WA 98109 DD= 3/27/98 MA=
Benzoate and phenylacetate TN=Ucephan	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or	B. Braun Medical Inc. 2525 McGaw Avenue P.O. Box 19791 Irvine CA 92623 DD= 1/21/86 MA= 12/23/87
benzoate/phenylacetate TN=Ammonul	For the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road Scottsdale AZ 85258 DD= 11/22/93 MA=
Benzydamine hydrochloride TN=Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge NJ 07661 DD= 5/18/98 MA=
Benzylpenicillin, benzylpenicilloic, TN=Pre-Pen/MDM	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	Hollister-Stier Laboratories LLC PO Box 3145 Spokane WA 99220-3145 DD= 9/29/87 MA=
Beractant TN=Survanta	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories 625 Cleveland Avenue Columbus OH 43215 DD= 12/20/93 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Beractant TN=Survanta	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue Columbus OH 43215 DD= 2/5/86 MA= 7/1/91
Beractant TN=Survanta	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue Columbus OH 43215 DD= 2/5/86 MA= 7/1/91
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box Research Triangle Park NC 27709 DD= 4/29/99 MA=
Beta alethine TN=Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park MD 20742 DD= 3/24/97 MA=
Beta alethine TN=Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park MD 20742 DD= 3/24/97 MA=
Betaine TN=Cystadane	Treatment of homocystinuria.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305 DD= 5/16/94 MA= 10/25/96
Bethanidine sulfate TN=	Prevention of recurrence of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048 DD= 11/24/89 MA=
Bethanidine sulfate TN=	Treatment of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048 DD= 9/20/88 MA=
Bexarotene TN=Targretin	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego CA 92121 DD= 6/18/99 MA= 12/29/99
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge NJ 07661 DD= 2/3/98 MA=
Bis(4-fluorophenyl)pheny lacetamide TN=	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709 DD= 3/2/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Bispecific antibody 520c9x22 TN=	For in vivo serotherapy of patients with ovarian cancer.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953 DD= 10/5/93 MA=
Bleomycin TN=Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego CA 92121-1334 DD= 2/9/99 MA=
Bleomycin sulfate TN=Blenoxane	Treatment of malignant pleural effusion.	Bristol-Myers Squibb P.O. Box 4000 Princeton NJ 08543 DD= 9/17/93 MA= 2/20/96
BMY-45622 TN=	Treatment of ovarian cancer.	Bristol-Myers Squibb 5 Research Parkway Wallingford CT 06492 DD= 10/15/90 MA=
Bosentan TN=	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd. 1840 Gateway Dr. 2nd Floor San Mateo CA 94404 DD= 10/6/00 MA=
Botulinum toxin type A TN=Botox	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713 DD= 3/22/84 MA= 12/29/89
Botulinum toxin type A TN=Botox	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713 DD= 3/22/84 MA= 12/29/89
Botulinum toxin type A TN=Dysport	Treatment of essential blepharospasm.	Porton International, Inc. 1155 15th Street, N.W., #315 Washington DC 20005 DD= 3/23/89 MA=
Botulinum toxin type A TN=Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH GB DD= 8/12/98 MA=
Botulinum toxin type A TN=Botox	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534 DD= 12/6/91 MA=
Botulinum toxin type A TN=Dysport	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead Berkshire SL6 4UH England GB DD= 10/20/99 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Botulinum toxin type A TN=	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research 1261 Furnace Brook Parkway Quincy MA 02169 DD= 9/15/92 MA=
Botulinum toxin type A TN=Botox	Treatment of cervical dystonia.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534 DD= 8/20/86 MA= 12/21/00
Botulinum toxin type B TN=NeuroBloc	Treatment of cervical dystonia.	Elan Pharmaceuticals, Inc. 800 Gateway Blvd. South San Francisco CA 94080 DD= 1/16/92 MA=12/8/00
Botulinum toxin type F TN=Dysport	Treatment of essential blepharospasm.	Ipsen Limited (name Milford MA DD= 12/5/91 MA=
Botulinum toxin type F TN=Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited (name Milford MA DD= 10/24/91 MA=
Botulism immune globulin TN=	Treatment of infant botulism.	California Department of Health 2151 Berkeley Way Berkeley CA 94704-1011 DD= 1/31/89 MA=
Bovine colostrum TN=	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM 1030 North Parkview Drive Bismarck ND 58501 DD= 11/19/90 MA=
Bovine immunoglobulin concentrate, TN=Sporidin-G	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc. 4001 Lexington Avenue North Arden Hills MN 55126 DD= 3/1/94 MA=
Bovine whey protein concentrate TN=Immuno-C	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised	Biomune Systems, Inc. 540 Arapeen Drive, Suite 202 Salt Lake City UT 84108 DD= 9/30/93 MA=
Branched chain amino acids TN=	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center One Gustave L. Levy Place New York NY 10029 DD= 12/23/88 MA=
Brimonidine TN=Alphagan	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534 DD= 2/7/00 MA=
Bromhexine TN=Bisolvon	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Boehringer Ingelheim 900 Ridgebury Road, Box 368 Ridgefield CT 06877-0368 DD= 5/15/89 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Broxuridine TN=Broxine/Neomark	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest IL 60045 DD= 9/18/95 MA=
Buffered intrathecal electrolyte/dextrose TN=Elliotts B Solution	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305 DD= 8/24/94 MA= 9/27/96
Buprenorphine hydrochloride TN=Subutex	Treatment of opiate addiction in opiate users.	Reckitt & Colman 1901 Huguenot Road Richmond VA 23235 DD= 6/15/94 MA=
Buprenorphine in combination with TN= Suboxone	Treatment of opiate addiction in opiate users.	Reckitt & Colman 1901 Huguenot Road Richmond VA 23235 DD= 10/27/94 MA=
Busulfan TN=Spartaject	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham PA 19044-2310 DD= 4/21/94 MA=
Busulfan TN=Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 7/28/94 MA= 2/4/99
Busulfan TN=Spartaject	Treatment of primary brain malignancies.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583 DD= 7/7/97 MA=
Butyrylcholinesterase TN=	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850 DD= 3/25/92 MA=
Butyrylcholinesterase TN=	Treatment of post-surgical apnea.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850 DD= 9/30/92 MA=
BW 12C TN=	Treatment of sickle cell disease.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Pk NC 27709 DD= 10/23/87 MA=
C1 esterase inhibitor (human) TN=	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032 DD= 8/21/96 MA=
C1-esterase-inhibitor, human, pasteurized TN=Berinert P	Prevention and/or treatment of acute attacks of hereditary angioedema.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901 DD= 10/16/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
C1-inhibitor TN=C1-inhibitor (human)	Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203 DD= 8/30/90 MA=
C1-inhibitor TN=C1-inhibitor (human)	Treatment of acute attacks of angioedema.	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203 DD= 8/30/90 MA=
Caffeine TN=Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence KS 66047 DD= 9/20/88 MA= 9/21/99
Calcitonin salmon nasal spray TN=Miacalcin Nasal	Treatment of symptomatic Paget's disease (osteitis deformans).	Sandoz Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936 DD= 10/29/90 MA=
Calcitonin-human for injection TN=Cibacalcin	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical 59 Route 10 East Hanover NJ 07936 DD= 1/20/87 MA= 10/31/86
Calcium acetate TN=Phos-Lo	Treatment of hyperphosphatemia in end stage renal failure.	Braintree Laboratories 60 Columbian Street P.O. Box 361 Braintree MA 02184 DD= 12/22/88 MA= 12/10/90
Calcium acetate TN=	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company 28101 Ballard Road, Suite F Lake Forest IL 60045 DD= 6/27/89 MA=
Calcium carbonate TN=R & D calcium	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc. 4204 Glencoe Avenue Marina Del Rey CA 90292 DD= 6/6/90 MA=
Calcium gluconate TN=Calgonate	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive Warwick RI 02886 DD= 11/20/97 MA=
Calcium gluconate gel TN=H-F Gel	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	LTR Pharmaceuticals, Inc. 145 Sakonnet Blvd. Narragansett RI 02882 DD= 5/21/91 MA=
Calcium gluconate gel 2.5% TN=	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc. 3940 Quebec Avenue North Minneapolis MN 55427 DD= 9/10/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Calfactant TN=Infasurf	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park 1576 Sweet Home Road Amherst NY 14228 DD= 9/5/00 MA=
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60, avenue du General de Gaulle 92046 Paris La Defense FR DD= 1/20/98 MA=
Carbovir TN=	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 12/13/89 MA=
Carmustine TN=	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066 DD= 7/3/00 MA=
Cascara sagrada fluid extract TN=	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation 102 Tremont Way Augusta GA 30907 DD= 3/21/89 MA=
CD4 human truncated 369 AA polypeptide TN= Soluble T4	Treatment of acquired immunodeficiency syndrome.	SmithKline Beecham Route 23 & Woodmont Ave., P.O. King Of Prussia PA 19406 DD= 11/21/89 MA=
CD5-T lymphocyte immunotoxin TN= Xomazyme-H65	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 8/27/87 MA=
CDP571 TN=	Treatment of Crohn's disease.	Celltech Chiroscience Limited 216 Bath Road Slough SL1 4EN Berkshire UK DD= 12/11/97 MA=
Centruroides immune F(ab)2 TN= Alacramyn	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de Amores #1034 Col Del Valle C.P. 03100 Mexico D.F. DD= 6/12/00 MA=
Ceramide trihexosidase/alpha-gala TN=	Treatment of Fabry's disease.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 1/19/88 MA=
Cetiedil citrate injection TN=	Treatment of sickle cell disease crisis.	Baker Cummins Pharmaceuticals, DD= 12/22/88 MA=
Cetuximab TN=	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876 DD= 7/3/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Chenodiol TN=Chenix	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic	Solvay 901 Sawyer Road Marietta GA 30062 DD= 9/21/84 MA= 7/28/83
Chimeric (human-murine) G250 IgG monoclonal TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 7/24/00 MA=
Chimeric M-T412 (human-murine) IgG TN=	Treatment of multiple sclerosis.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 6/5/91 MA=
Chimeric, humanized monoclonal antibody to TN=	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850 DD= 8/3/00 MA=
Chlorhexidine gluconate mouthrinse TN=Peridex	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company Sharon Wood Technical Center 11370 Reed Hartman Highway Cincinnati OH 45241 DD= 8/18/86 MA=
Choline chloride TN=Intrachol	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 2/10/94 MA=
Chondrocyte-alginate gel suspension TN=	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc. 61 Moulton Street Cambridge MA 02138 DD= 12/1/97 MA=
Chondroitinase TN=	Treatment of patients undergoing vitrectomy.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Pkwy. Tampa FL 33637 DD= 2/9/95 MA=
Ciliary neurotrophic factor TN=	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc 777 Old Saw Mill River Road Tarrytown NY 10591 DD= 1/30/92 MA=
Ciliary neurotrophic factor, recombinant TN=	Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).	Syntex-Synergen Neuroscience 3200 Walnut Street Boulder CO 80301 DD= 5/8/92 MA=
Ciliary neurotrophic factor, recombinant TN=	Treatment of spinal muscular atrophies. Boulder CO 80301	Syntex-Synergen Neuroscience 3200 Walnut Street DD= 4/2/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cisplatin/epinephrine TN=IntraDose	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612 DD= 4/3/00 MA=
Cisplatin/epinephrine TN=IntraDose	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612 DD= 9/7/00 MA=
Citric acid, glucono-delta-lactone TN=Renacidin Irrigation	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc. P.O. Box 2500 Smithtown NY 11787 DD= 8/28/89 MA= 10/2/90
Cladribine TN=Leustatin Injection	Treatment of non-Hodgkin's lymphoma.	R. W. Johnson Pharmaceutical Route 202 South, P.O. Box 300 Raritan NJ 08869-0602 DD= 4/19/93 MA=
Cladribine TN=Leustatin Injection	Treatment of chronic lymphocytic leukemia.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869-0602 DD= 12/31/90 MA=
Cladribine TN=Mylinax	Treatment of the chronic progressive form of multiple sclerosis.	R. W. Johnson Pharmaceutical Route 202 PO Box 300 Raritan NJ 08869-0602 DD= 4/19/94 MA=
Cladribine TN=Leustatin Injection	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869 DD= 11/15/90 MA= 2/26/93
Cladribine TN=Leustatin	Treatment of acute myeloid leukemia.	R. W. Johnson Pharmaceutical Route 202 P.O. Box 300 Raritan NJ 08869 DD= 7/20/90 MA=
Clindamycin TN=Cleocin	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 10/28/88 MA=
Clindamycin TN=Cleocin	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 10/28/88 MA=
Clofazimine TN=Lamprene	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical 59 Route 10 East Hanover NJ 07936 DD= 6/11/84 MA= 12/15/86
Clonazepam TN=Klonopin	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 8/4/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Clonidine TN=Duraclon	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal	Roxane Laboratories, Inc. PO Box 16532 Columbus OH 43216-6532 DD= 1/24/89 MA= 10/2/96
Clostridial collagenase TN=	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. State University of New York at School of Medicine, Health Stony Brook NY 11794-8181 DD= 5/23/96 MA=
Clotrimazole TN=	Treatment of sickle cell disease.	Brugnara, Carlo M.D. The Children's Hospital 300 Longwood Avenue, Bader 760 Boston MA 02115 DD= 4/24/95 MA=
Coagulation factor IX TN=Mononine	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company 500 Arcola Road, P.O. Box 1200 Collegeville PA 19426 DD= 6/27/89 MA= 8/20/92
Coagulation Factor IX (human) TN=AlphaNine	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032 DD= 7/5/90 MA= 12/31/90
Coagulation Factor IX (recombinant) TN=BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge MA 02140 DD= 10/3/94 MA= 2/11/97
Coagulation factor VIIa (recombinant) TN=NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, 100 Overlook Center Suite 200 Princeton NJ 08540-7810 DD= 6/6/88 MA= 3/25/99
Colchicine TN=	For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.	Pharmacontrol Corporation 661 Palisade Ave., P.O. Box 931 Englewood Cliffs NJ 07632 DD= 12/9/85 MA=
Colfosceril palmitate, cetyl alcohol, tyloxapol TN=Exosurf Neonatal for	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 10/20/89 MA= 8/2/90
Colfosceril palmitate, cetyl alcohol, tyloxapol TN=Exosurf Neonatal for	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 10/20/89 MA= 8/2/90
Colfosceril palmitate, cetyl alcohol, tyloxapol TN=Exosurf	Treatment of adult respiratory distress syndrome.	Glaxo Wellcome Research and 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709 DD= 1/11/93 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Collagenase (lyophilized) for TN=Plaquase	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook NY 11563-2358 DD= 3/12/96 MA=
Corticorelin ovine triflutate TN=Acthrel	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901 DD= 11/24/89 MA= 5/23/96
Corticotropin-releasing factor, human TN=Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, 1387 Marina Way South Richmond CA 94804 DD= 4/6/98 MA=
Coumarin TN=Onkolox	Treatment of renal cell carcinoma.	Drossapharm LTD 4002 Basel Switzerland CH DD= 12/22/94 MA=
Cromolyn sodium TN=Gastrocrom	Treatment of mastocytosis.	Fisons Corporation 755 Jefferson Rd P.O. Box 1710 Rochester NY 14603 DD= 3/8/84 MA= 12/22/89
Cromolyn sodium 4% ophthalmic solution TN=Opticrom 4%	Treatment of vernal keratoconjunctivitis.	Fisons Corporation 755 Jefferson Rd. P.O. Box 1710 Rochester NY 14603 DD= 7/24/85 MA= 10/3/84
Cryptosporidium hyperimmune bovine TN=	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation 56 Evergreen Drive Portland ME 04103 DD= 12/30/91 MA=
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle WA 98119 DD= 4/16/99 MA=
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle WA 98119 DD= 4/16/99 MA=
CY-1503 TN=Cylexin	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation 3525 John Hopkins Court San Diego CA 92121 DD= 12/22/93 MA=
CY-1503 TN=Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego CA 92121 DD= 7/18/97 MA=
CY-1899 TN=	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation 3525 John Hopkins Court San Diego CA 92121 DD= 3/16/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cyclosporine 2% ophthalmic ointment TN=	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534 DD= 8/1/91 MA=
Cyclosporine 2% ophthalmic ointment TN=	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534 DD= 8/1/91 MA=
Cyclosporine in combination with omega-3 TN=	Prevention of solid organ graft rejection.	RTP Pharma Corporation 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280 DD= 12/6/00 MA=
Cyclosporine ophthalmic TN=Optimmune	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia College Of Veterinary Medicine Department of Small Animal Athens GA 30602 DD= 11/9/88 MA=
Cyproterone acetate TN=Androcur	Treatment of severe hirsutism.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470 DD= 10/26/84 MA=
Cysteamine TN=Cystagon	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown WV 26504 DD= 1/25/91 MA= 8/15/94
Cysteamine TN=	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D. University of Michigan Medical 300 NIB, 1192 SE Ann Arbor MI 48109-0408 DD= 5/1/86 MA=
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 8/19/97 MA=
Cystic fibrosis gene therapy TN=	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322 DD= 6/30/92 MA=
Cystic fibrosis Tr gene therapy (recombinant TN=AdGVCFTR.10	Treatment of cystic fibrosis.	GenVec, Inc. 12111 Parklawn Drive Rockville MD 20852 DD= 3/9/95 MA=
Cystic fibrosis transmembrane TN=	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322 DD= 1/14/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cystic fibrosis transmembrane TN=	Treatment of cystic fibrosis.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878 DD= 1/8/93 MA=
Cytarabine liposomal TN=DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego CA 92121 DD= 6/2/93 MA= 4/1/99
Cytomegalovirus immune globulin (human) TN= CytoGam	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Massachussetts Public Health 305 South Street Boston MA 02130-3597 DD= 8/3/87 MA= 12/4/98
Cytomegalovirus immune globulin intravenous TN=	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation Pharmaceutical Division, 400 Morgan Lane New Haven CT 06516 DD= 1/28/91 MA=
Daclizumab TN=Zenapax	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 3/5/93 MA= 12/10/97
Dantrolene sodium TN=Dantrium	Treatment of the neuroleptic malignant syndrome.	Norwich Eaton Pharmaceuticals P.O. Box 191 Norwich NY 13815 DD= 12/14/87 MA=
Dapsone TN=	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540 DD= 11/7/94 MA=
Dapsone USP TN=Dapsone	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540 DD= 12/24/91 MA=
Dapsone USP TN=Dapsone	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540 DD= 1/8/92 MA=
Daunorubicin citrate liposome injection TN=DaunoXome	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas CA 91773 DD= 5/14/93 MA= 4/8/96
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands NL DD= 3/8/99 MA=
Decitabine TN=	Treatment of myelodysplastic syndromes.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583 DD= 3/8/99 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Defibrotide TN=	Treatment of thrombotic thrombocytopenic purpura.	Crinos International Via Belvedere 1 Villa Guardia, Italy 22079 DD= 7/5/85 MA=
Dehydroepiandrosterone TN=	Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.	Genelabs Technologies, Inc. 505 Penobscot Drive Redwood City CA 94063 DD= 7/13/94 MA=
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405 DD= 1/29/97 MA=
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405 DD= 1/28/97 MA=
Denileukin diftitox TN=Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton MA 01748 DD= 8/21/96 MA= 2/5/99
Deoxyribose, phosphorothioate TN=	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966 DD= 7/31/00 MA=
Deslorelin TN=Somagard	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp. Meridian Center II Four Industrial Way West Eatontown NJ 07724-2274 DD= 11/5/87 MA=
Desmopressin acetate TN=	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901 DD= 1/22/91 MA= 3/7/94
Dexamethasone TN=	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals, Inc. 639 N. Pastoria Avenue Sunnyvale CA 94086-2917 DD= 9/11/98 MA=
Dexrazoxane TN=Zinecard	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199 DD= 12/17/91 MA= 5/26/95
Dextran 70 TN=Dehydrex	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc. 30 Forest Notch Cohasset MA 02025 DD= 3/5/90 MA=
Dextran and deferoxamine TN=Bio-Rescue	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc. 1095 10th Avenue S.E. Minneapolis MN 55414 DD= 3/8/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Dextran sulfate (inhaled, aerosolized) TN= Uendex	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University Of Utah Medical 50 North Medical Drive, Room Salt Lake City UT 84132 DD= 10/5/90 MA=
Dextran sulfate sodium TN=	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, 2-31 Koraibashi, Higashi-ku Osaka 541, Japan DD= 11/19/87 MA=
Dianeal peritoneal dialysis solution with TN= Nutrineal	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation 1620 Waukegan Road McGaw Park IL 60085 DD= 6/11/92 MA=
Diazepam viscous solution for rectal TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco CA 94080 DD= 2/25/92 MA= 7/29/97
Diaziquone TN=	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Warner-Lambert Company 2800 Plymouth Rd., P.O. Box 1047 Ann Arbor MI 48106 DD= 11/10/83 MA=
Dideoxyinosine TN=	Treatment of acquired immunodeficiency syndrome.	Bristol-Myers Squibb DD= 6/22/88 MA=
Diethyldithiocarbamate TN=Imuthiol	Treatment of AIDS.	Connaught Laboratories Route 611, P.O. Box 187 Swiftwater PA 18370 DD= 4/3/86 MA=
Digoxin immune FAB (Ovine) TN=Digibind	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 11/1/84 MA= 4/22/86
Digoxin immune fab(ovine) TN=Digidote	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp. 1301 Piccard Drive Rockville MD 20850 DD= 3/11/85 MA=
Dihydrotestosterone TN=Androgel -DHT	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Deerfield IL 60015-2544 DD= 2/5/96 MA=
Dimethyl sulfoxide TN=	Treatment of cutaneous manifestations of scleroderma.	Research Industries Corp. DD= 6/6/86 MA=
Dimethyl sulfoxide TN=	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Pharma 21 c/o Univ. of Calif., San Diego 9500 Gilman Dr. La Jolla CA 92093-0624 DD= 11/22/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710 DD= 4/6/98 MA=
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710 DD= 4/15/97 MA=
Dipalmitoylphosphatidylc holine TN= ALEC	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc. 33 Flying Point Road Southampton NY 11968 DD= 7/28/88 MA=
Disaccharide tripeptide glycerol dipalmitoyl TN= Immther	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc. 3505 Riverview Circle Moorhead MN 56560 DD= 3/1/90 MA=
Disodium clodronate TN=	Treatment of hypercalcemia of malignancy.	Discovery Experimental & 29949 S.R. 54 West Wesley Chapel FL 33543 DD= 6/16/93 MA=
Disodium clodronate tetrahydrate TN= Bonefos	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton NJ 08540 DD= 3/5/90 MA=
Disodium silibinin dihemisuccinate TN= Legalon	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Pharmaquest Corporation 4470 Redwood Highway San Rafael CA 94903 DD= 7/10/86 MA=
DMP 777 TN=	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company Chestnut Run, Maple Run Centre Rd. Wilmington DE 19805 DD= 6/4/96 MA=
DNA-lipid complex (DMRIE/DOPE)/plasmid TN= Leuvectin	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088 DD= 4/28/00 MA=
DNP-Modified autologous tumor vaccine TN= O-Vax	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc. 4520 Main Street Suite 930 Kansas City MO 64111 DD= 9/21/00 MA=
Dornase alfa TN=Pulmozyme	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 1/16/91 MA= 12/30/93

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Doxorubicin liposome TN=Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View CA 94039-7210 DD= 11/4/98 MA= 6/28/99
Dronabinol TN=Marinol	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite Buffalo Grove IL 60089-1862 DD= 1/15/91 MA= 12/22/92
Duramycin TN=	Treatment of cystic fibrosis.	MoliChem Medicines Inc. 207 South Elliott Road PMB#231 Chapel Hill NC 27514 DD= 12/11/97 MA=
Dynamine TN=	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation 200 First Street Southwest Rochester MN 55905 DD= 2/5/90 MA=
Dynamine TN=	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation 200 First Street Southwest Rochester MN 55905 DD= 10/16/91 MA=
Eflornithine HCl TN=Ornidyl	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Marion Merrell Dow, Inc. P.O. Box 9627 Kansas City MO 64134 DD= 4/18/86 MA=
Eflornithine HCl TN=Ornidyl	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel P.O. Box 9627 Kansas City MO 64134 DD= 4/23/86 MA= 11/28/90
Elcatonin TN=	Intrathecal treatment of intractable pain.	Innapharma, Inc. 10 Mountainview Road Upper Saddle River NJ 07458 DD= 9/25/95 MA=
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical 2800 Plymouth Road Ann Arbor MI 48105 DD= 1/28/97 MA=
Encapsulated porcine islet preparation TN=BetaRx	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx 2825 Santa Monica Blvd. 2nd Floor Santa Monica CA 90404-2429 DD= 7/5/95 MA=
Enisoprost TN=	For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077 DD= 10/20/89 MA=
Enisoprost TN=	For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077 DD= 10/20/89 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Epidermal growth factor (human) TN=	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Ethicon, Inc. P.O. Box 151 Somerville NJ 08876 DD= 3/6/85 MA=
Epidermal growth factor (human) TN=	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision 500 Iolab Drive Claremont CA 91711 DD= 10/5/87 MA=
Epirubicin TN=Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo MI 49001-0199 DD= 9/14/99 MA= 9/15/99
Epoetin alfa TN=Epogen	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 7/1/91 MA= 12/31/90
Epoetin alfa TN=	Treatment of myelodysplastic syndrome.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869-0602 DD= 12/20/93 MA=
Epoetin alfa TN=Epogen	Treatment of anemia associated with end stage renal disease.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 4/10/86 MA= 6/1/89
Epoetin alpha TN=Procrit	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Route 202 South P.O. Box 300 Raritan NJ 08869 DD= 8/27/87 MA=
Epoetin alpha TN=Procrit	Treatment of anemia of prematurity in preterm infants.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869-0602 DD= 7/21/88 MA=
Epoetin alpha TN=Procrit	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869 DD= 3/7/89 MA=
Epoetin beta TN=Marogen	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc. 3780 Hawthorn Court Waukegan IL 60087 DD= 10/22/87 MA=
Epoprostenol TN=Flolan	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 9/25/85 MA= 9/20/95
Epoprostenol TN=Flolan	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 3/29/84 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Epoprostenol TN=Cycloprostin	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Upjohn Company 301 Henrietta Street Kalamazoo MI 49001 DD= 10/29/84 MA=
Epoprostenol TN=Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park NC DD= 3/22/99 MA= 4/14/00
Erwinia L-asparaginase TN=Erwinase	Treatment of acute lymphocytic leukemia.	Porton International, Inc. 7114 Springbrook Terrace, #200 Spotsylvania VA 22553 DD= 7/30/86 MA=
Erwinia L-asparaginase TN=	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force	Lyphomed, Inc. DD= 1/25/85 MA=
Erythropoietin (human, recombinant) TN=	Treatment of anemia associated with end stage renal disease.	Organon Teknika Corporation DD= 11/19/87 MA=
Erythropoietin (recombinant human) TN=	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp P.O. Box 516, 107/2 MS10 St. Louis MO 63166 DD= 8/19/87 MA=
Etanercept TN=Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying	Immunex Corporation 51 University St. Seattle WA 98101-2936 DD= 10/27/98 MA= 5/27/99
Etanercept TN=Enbrel	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle WA 98101-2936 DD= 4/6/99 MA=
Ethanolamine oleate TN=Ethamolin	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	Block Drug Company, Inc. 257 Cornelison Avenue Jersey City NJ 07302 DD= 3/22/84 MA= 12/22/88
Ethinyl Estradiol, USP TN=	Treatment of Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 6/22/88 MA=
Ethiofos TN=	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	U.S. Bioscience DD= 8/1/89 MA=
Ethyl eicosapentaenoate TN=	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Polmaise Road, Stirling FK7 9JQ United Kingdom UK DD= 4/6/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Etidronate disodium TN=Didronel	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 3/21/86 MA=4/21/87
Etidronate disodium TN=Didronel IV infusion	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 5/2/91 MA=
Etidronate disodium TN=Didronel IV Infusion	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318 DD= 5/2/91 MA=
Etiocholanedione TN=	Treatment of Prader-Willi syndrome.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583 DD= 5/7/96 MA=
Etiocholanedione TN=	Treatment of aplastic anemia.	SuperGen, Inc. Two Annabel Lane, Suite 220 Suite 10 San Ramon CA 94583 DD= 11/3/95 MA=
Exemestane TN=Aromasin	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo MI 49001-0199 DD= 9/19/91 MA= 10/21/99
Exisulind TN=	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	Cell Pathways, Inc. 702 Electronic Drive Horsham PA 19044 DD= 2/14/94 MA=
Factor XIII concentrate (human) pasteurized TN=Fibrogammin P	Treatment of congenital factor XIII deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901 DD= 1/16/85 MA=
Factor XIII, recombinant TN=	Treatment of congenital factor XIII deficiency.	Zymogenetics, Inc. 4225 Roosevelt Way Seattle WA 98105 DD= 4/22/93 MA=
Fampridine TN=Neurelan	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 15 Skyline Dr. Hawthorne NY 10532 DD= 6/2/97 MA=
Fampridine TN=Neurelan	Relief of symptoms of multiple sclerosis.	Acorda Therapeutics 15 Skyline Dr. Hawthorne NY 10532 DD= 6/2/87 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Felbamate TN=Felbatol	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories 301B College Road East Princeton NJ 08540 DD= 1/24/89 MA= 7/29/93
FIAU TN=	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc. 100 Pelican Way San Rafael CA 94901 DD= 7/24/92 MA=
Fibrinogen (human) TN=	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032 DD= 8/23/95 MA=
Fibronectin (human plasma derived) TN=	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc. 310 East 67th Street New York NY 10021 DD= 9/5/88 MA=
Fibronectin (plasma derived) TN=	Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated.	Chiron Vision 9342 Jeronimo Road Irvine CA 92718 DD= 12/5/88 MA=
Filgrastim TN=Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799 DD= 11/7/96 MA= 4/2/98
Filgrastim TN=Neupogen	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 10/1/90 MA=6/15/94
Filgrastim TN=Neupogen	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 11/7/90 MA= 12/19/94
Filgrastim TN=Neupogen	Treatment of myelodysplastic syndrome.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 8/30/90 MA=
Filgrastim TN=Neupogen	Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799 DD= 9/3/91 MA=
Filgrastim TN=Neupogen	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320 DD= 7/17/95 MA= 12/28/95
Flucinolone TN=	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Parkway Tampa FL 33637 DD= 7/31/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Fludarabine phosphate TN=Fludara	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc. 15049 San Pablo Avenue P.O. Box 4099 Richmond CA 94804-0099 DD= 4/18/89 MA=
Fludarabine phosphate TN=Fludara	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box Richmond CA 94804 DD= 4/18/89 MA= 4/18/91
Flumecinol TN=Zixoryn	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Farmacon, Inc. Post House, Suite 213 1720 Post Road East Westport CT 06880-5643 DD= 1/15/85 MA=
Flunarizine TN=Sibelium	Treatment of alternating hemiplegia.	Janssen Research Foundation P.O. Box 200 Titusville NJ 08560 DD= 1/6/86 MA=
Fluorouracil TN=Adrucil	For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid 401 N. Middletown Road Pearl River NY 10965 DD= 2/6/89 MA=
Fluorouracil TN=	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 10/27/89 MA=
Fluorouracil TN=	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - 92213 Saint-Cloud Cedex France FR DD= 6/29/00 MA=
Fluorouracil TN=	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 4/18/90 MA=
Fluoxetine TN=Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Box 1230, One Gustave L. Levy New York NY 10029-6574 DD= 4/30/99 MA=
Follitropin alfa, recombinant TN=Gonal-F	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 12/21/98 MA= 5/24/00
Fomepizole TN=Antizole	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 12/22/88 MA= 12/4/97

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Fomepizole TN=Antizole	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 12/22/88 MA= 12/8/00
Fosphenytoin TN=Cerebyx	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road Ann Arbor MI 48106 DD= 6/4/91 MA= 8/5/96
Fructose-1,6-diphosphate TN=Cordox	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Questcor Pharmaceuticals, Inc. 26118 Research Road Hayward CA 94545 DD= 5/29/98 MA=
Gabapentin TN=Neurontin	Treatment of amyotrophic lateral sclerosis.	Warner-Lambert Company Parke-Davis Pharmaceutical 2800 Plymouth Road Ann Arbor MI 48105 DD= 7/5/95 MA=
Gallium nitrate injection TN=Ganite	Treatment of hypercalcemia of malignancy. Elk Grove Village IL 60007	Solopak Pharmaceutical Co. 1845 Tonne Road DD= 12/5/88 MA= 1/17/91
Gamma hydroxybutyrate TN=	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc. 18-01 River Road Fair Lawn NJ 07410 DD= 12/22/87 MA=
Gamma-hydroxybutyric acid TN=	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.	Sigma Chemical Company DD= 1/22/85 MA=
Gammalinolenic acid TN=	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D. University of Massachusetts 55 Lake Avenue Worcester MA 01655 DD= 7/27/94 MA=
Ganaxolone TN=	Treatment of infantile spasms.	Purdue Pharma L.P. 100 Connecticut Ave. Norwalk CT 06850-3590 DD= 5/25/94 MA=
Ganciclovir intravitreal implant TN=Vitrasert Implant	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron 9342 Jeronimo Road Irvine CA 92718-1903 DD= 6/7/95 MA= 3/4/96
Ganciclovir sodium TN=Cytovene	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Syntex (USA), Inc. 3401 Hillview Avenue Palo Alto CA 94304 DD= 10/31/85 MA= 6/23/89
Gancyclovir TN=	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Burroughs Wellcome Company 3030 Cornwallis Road DD= 6/7/85 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Gangliosides as sodium salts TN=Cronassial	Treatment of retinitis pigmentosa.	Fidia Pharmaceutical Corp. 1401 Eye Street, N.W. Suite 900 Washington DC 20005 DD= 11/17/88 MA=
Gavilimomab TN=	Acute graft-versus-host disease (aGVHD)	Abgenix, Inc. 7601 Dumbarton Circle Fremont CA 94555 DD= 11/20/00 MA=
Gemtuzumab zogamicin TN=Mylotarg	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 Philadelphia PA 19101-8299 DD= 11/24/99 MA= 5/17/00
Gene plasmid hVEGF165 driven by human TN=	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Eurogene Ltd. 6 Warren Mews London W1P 5DJ UK DD= 10/24/00 MA=
Gentamicin impregnated PMMA beads on surgical TN=Septopal	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc. 9 West 57th Street Suite 3825 New York NY 10019-2701 DD= 1/31/91 MA=
Gentamicin liposome injection TN=Maitec	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 7/10/90 MA=
Glatiramer acetate TN=Copaxone	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA 1510 Delp Drive Kulpsville PA 19443 DD= 11/9/87 MA= 12/20/96
Glutamine TN=	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Nutritional Restart 4364 South Alston Avenue Durham NC 27713 DD= 3/6/95 MA=
Glyceol TN=	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Chugai Pharmaceutical Co., Ltd. DD= 2/22/90 MA=
Glyceryl trioleate and glyceryl trierucate TN=	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D. Johns Hopkins University Kennedy Krieger Institute, 707 Baltimore MD 21205 DD= 2/14/95 MA=
Gonadorelin acetate TN=Lutrepulse	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901 DD= 4/22/87 MA= 10/10/89
Gossypol TN=	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D. The New York Hospital - Cornell 525 East 68th Street, Box 70 New York NY 10021 DD= 10/22/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322 DD= 3/25/97 MA=
Granulocyte macrophage-colony TN=Leucomax	Treatment of myelodysplastic syndrome.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 8/7/89 MA=
Granulocyte macrophage-colony TN=Leucomax	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 5/4/90 MA=
Granulocyte macrophage-colony TN=Leucomax	Treatment of neutropenia associated with bone marrow transplants.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 12/12/89 MA=
Granulocyte macrophage-colony TN=Leucomax	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 6/6/89 MA=
Granulocyte macrophage-colony TN=Leucomax	Treatment of neutropenia due to hairy cell leukemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 5/3/90 MA=
Group B streptococcus immune globulin TN=	Treatment of neonates for disseminated group B streptococcal infection.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852 DD= 5/8/90 MA=
Growth hormone releasing factor TN=	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	ICN Pharmaceuticals, Inc. ICN Plaza 3300 Hyland Avenue Costa Mesa CA 92626 DD= 8/7/89 MA=
Guanethidine monosulfate TN=Ismelin	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/6/86 MA=
Guanfacine TN=Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona CA 91718-1900 DD= 8/5/99 MA=
Gusperimus TN=Spanidin	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb 5 Research Parkway P.O. Box 5100 Wallingford CT 06492-7660 DD= 6/27/96 MA=
h5G1.1-mAb TN=	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 9/21/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Halofantrine TN=Halfan	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101 DD= 11/4/91 MA= 7/24/92
Halofuginone TN=Stenorol	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd. Textile House, 2 Koifman St. Tel-Aviv 68012 Israel IL DD= 2/7/00 MA=
Heme arginate TN=Normosang	Treatment of myelodysplastic syndromes.	Berlex Laboratories, Inc. 15049 San Pablo Avenue Richmond CA 94804-0099 DD= 3/1/94 MA=
Heme arginate TN=Normosang	Treatment of symptomatic stage of acute porphyria.	Berlex Laboratories, Inc. 15049 San Pablo Avenue Richmond CA 94804-0099 DD= 3/10/88 MA=
Hemin TN=Panhematin	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP	Abbott Laboratories Diagnostics Division Abbott Park IL 60064 DD= 3/16/84 MA= 7/20/83
Hemin and zinc mesoporphyrin TN=Hemex	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D. University Of Massachusetts 55 Lake Avenue North Worcester MA 01655 DD= 12/20/93 MA=
Hepatitis B immune globulin intravenous TN=Nabi-HB	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	NABI 12280 Wilkins Avenue Rockville MD 20852 DD= 3/8/95 MA=
Herpes simplex virus Gene TN=	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878 DD= 10/16/92 MA=
Histamine TN=Maxamine	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego CA 92122 DD= 12/15/99 MA=
Histamine TN=Maxamine	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego CA 92122 DD= 2/1/00 MA=
Histrelin TN=	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D. University of Texas Medical Route J-09, 700 The Strand Galveston TX 77550 DD= 5/3/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Histrelin acetate TN=Supprelin Injection	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724 DD= 8/10/88 MA= 12/24/91
HIV neutralizing antibodies TN=Immupath	Treatment of acquired immunodeficiency syndrome.	Hemacare Corporation 4954 Van Nuys Boulevard Sherman Oaks CA 91403 DD= 3/24/92 MA=
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN=Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego CA 92121 DD= 9/30/99 MA=
HPA-23 TN=	Treatment of acquired immunodeficiency syndrome.	Rhone-Poulenc Rorer Pharm. 500 Arcola Road Collegeville PA 19426 DD= 7/17/85 MA=
Human acid precursor alpha-glucosidase, TN=	Treatment of glycogen storage disease type II.	Pharming/Genzyme LLC c/o Genzyme Corporation 1 Mountain Rd. Framingham MA 01701-9322 DD= 9/10/96 MA=
Human IgM monoclonal antibody (C-58) To CMV TN=Centovir	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 8/7/89 MA=
Human IgM monoclonal antibody (C-58) To CMV TN=Centovir	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 8/7/89 MA=
Human immunodeficiency virus immune globulin TN=Hivig	Treatment of HIV-infected pediatric patients.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487 DD= 1/4/95 MA=
Human immunodeficiency virus immune globulin TN=	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	NABI 5800 Park of Commerce Blvd., Boca Raton FL 33487 DD= 3/25/92 MA=
Human immunodeficiency virus immune globulin TN=	Treatment of AIDS.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487 DD= 11/21/89 MA=
Human T-lymphotropic virus type III Gp160 TN=Vaxsyn HIV-1	Treatment of AIDS.	MicroGeneSys, Inc. 1000 Research Parkway Meriden CT 06450 DD= 11/20/89 MA=
Humanized anti-CD2 monoclonal antibody TN=	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878 DD= 11/13/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Humanized anti-human CD2 MAb TN=MEDI-507	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic	Biotransplant, Inc. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown MA 02129 DD= 9/17/98 MA=
Humanized anti-tac TN=Zenapax	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 3/5/93 MA=
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego CA 92121 DD= 2/9/99 MA=
Hydroxycobalamin TN=CYANOKIT	Treatment of acute cyanide poisoning	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 9/22/00 MA=
Hydroxycobalamin/sodium thiosulfate TN=	Treatment of severe acute cyanide poisoning.	Hall, Alan H., M.D. Mile 5.0 Pass Creek Road PO Box 24 Elk Mountain WY 82324 DD= 10/4/85 MA=
Hydroxyurea TN=Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb P.O. Box 4000 Princeton NJ 08543 DD= 10/1/90 MA= 2/25/98
Hypericin TN=	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suite 210 Wilmington DE 19808 DD= 2/7/00 MA=
Hypericin TN=	Treatment of glioblastoma multiforme.	Nexell Therapeutics 2751 Centerville Rd., Suite 210 Wilmington DE 19808 DD= 8/3/00 MA=
Ibuprofen i.v. solution TN=Salprofen	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC 1720 Post Road East Suite 213 Westport CT 06880-5643 DD= 10/29/96 MA=
Ibuprofen i.v. solution TN=	Treatment of patent ductus arteriosus.	Farmacon-IL-LLC 1720 Post Road East Suite 213 Westport CT 06880-5643 DD= 10/29/96 MA=
Icodextrin 7.5% with Electrolytes Peritoneal TN=Extraneal (with 7.5%	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road McGaw Park IL 60085 DD= 7/18/97 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Idarubicin TN=Idamycin	Treatment of chronic myelogenous leukemia.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 12/2/92 MA=
Idarubicin TN=Idamycin	Treatment of myelodysplastic syndromes.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 12/1/92 MA=
Idarubicin HCl for injection TN=Idamycin	Treatment of acute lymphoblastic leukemia in pediatric patients.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 2/12/91 MA=
Idarubicin HCl for injection TN=Idamycin	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc. P.O. Box 16529 Columbus OH 43216 DD= 7/25/88 MA= 9/27/90
Idoxuridine TN=	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest IL 60045 DD= 4/8/96 MA=
Ifosfamide TN=Ifex	Treatment of testicular cancer.	Bristol-Myers Squibb 5 Research Parkway, P.O. Box Wallingford CT 06492 DD= 1/20/87 MA= 12/30/88
Ifosfamide TN=Ifex	Treatment of bone sarcomas.	Bristol-Myers Squibb P.O. Box 4000 Princeton NJ 08543-4000 DD= 8/7/85 MA=
Ifosfamide TN=Ifex	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb P.O. Box 4000 Princeton NJ 08543 DD= 8/7/85 MA=
IL-4 Pseudomonas Toxin Fusion Protein TN=	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121 DD= 4/6/00 MA=
Iloprost solution for infusion TN=	Treatment of heparin-associated thrombocytopenia.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470 DD= 5/14/90 MA=
Iloprost solution for infusion TN=	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470 DD= 9/21/89 MA=
Imciromab pentetate TN=Myoscint	Detecting early necrosis as anindication of rejection of orthotopic cardiac transplants.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 1/25/89 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Imexon TN=	Treatment of multiple myeloma.	AmpliMed Corporation 2321 Camino La Zorrela Tucson AZ 85718 DD= 11/8/96 MA=
Imiglucerase TN=Cerezyme	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 11/5/91 MA= 5/23/94
Immune globulin intravenous (human) TN=Immune Globulin	Treatment of patients with acute myocarditis.	Immuno Clinical Research Corp. 750 Lexington Avenue New York NY 10022 DD= 11/22/93 MA=
Immune globulin intravenous (human) TN=Iveegam, Immuno	Treatment of juvenile rheumatoid arthritis.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor New York NY 10022 DD= 12/16/92 MA=
Immune globulin intravenous (human) TN=Iveegam, Immuno	Treatment of polymyositis/dermatomyositis.	Immuno Clinical Research Corp. 155 East 56th Street New York NY 10022 DD= 10/13/92 MA=
Immune globulin intravenous, human TN=Gamimune N	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation Pharmaceutical Division, 400 Morgan Lane New Haven CT 06516 DD= 2/18/93 MA= 12/27/93
Imported fire ant venom, allergenic extract TN=	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc. Research Center 27 Village Lane Wallingford CT 06492 DD= 5/12/92 MA=
Indium In 111 murine monoclonal antibody FAB TN=Myoscint	To aid in the diagnosis of myocarditis.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 8/7/89 MA=
Indium In-111 altumomab pentetate TN=Hybri-ceaker	Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.	Hybritech, Inc. 11095 Torreyanna Road San Diego CA 92196 DD= 2/6/90 MA=
Indium-In-111 murine MAb(2B8-MX-DTPA) & TN=Melimmune	Treatment of B-cell non-Hodgkin's lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121 DD= 9/6/94 MA=
Infliximab TN=Remicade	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; a nd treatment of patients	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307 DD= 11/14/95 MA= 8/24/98

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval	
Inosine pranobex TN=Isoprinosine	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals 897 West Sixteenth Street Newport Beach CA 92663 DD= 9/20/88	MA=
Interferon alfa-2a TN=Roferon A	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 6/6/89	MA= 10/19/95
Interferon alfa-2a (recombinant) TN=Roferon-A	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 5/14/90	MA=
Interferon alfa-2a (recombinant) TN=Roferon-A	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 5/11/90	MA=
Interferon alfa-2a (recombinant) TN=Roferon-A	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 4/18/88	MA=
Interferon alfa-2a (recombinant) TN=Roferon-A	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199 DD= 10/27/89	MA=
Interferon alfa-2a (recombinant) TN=Roferon-A	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07119 DD= 5/2/90	MA=
Interferon alfa-2a (recombinant) TN=Roferon-A	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 12/14/87	MA= 11/21/88
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of ovarian carcinoma.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 8/3/87	MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of carcinoma in situ of the urinary bladder.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 8/10/88	MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of acute hepatitis B.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 11/17/88	MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of invasive carcinoma of the cervix.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 4/18/88	MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of chronic myelogenous leukemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 6/22/87	MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of chronic delta hepatitis.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 5/4/90 MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of primary malignant brain tumors.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 5/13/88 MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of laryngeal (respiratory) papillomatosis.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 8/17/88 MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of metastatic renal cell carcinoma.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 6/22/87 MA=
Interferon alfa-2b (recombinant) TN=Intron A	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 6/24/87 MA= 11/21/88
Interferon alfa-nl TN=Wellferon	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 10/16/87 MA=
Interferon alfa-nl TN=Wellferon	Treatment of AIDS related Kaposi's sarcoma.	Burroughs Wellcome Company 3030 Cornwallis Road Research Triangle Pk NC 27709 DD= 8/25/86 MA=
Interferon beta (recombinant human) TN=Avonex	Treatment of primary brain tumors.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 1/13/93 MA=
Interferon beta (recombinant) TN=R-IFN-beta	For the systemic treatment of metastatic renal cell carcinoma.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 2/12/91 MA=
Interferon beta (recombinant) TN=r-HuIFN-beta	For the systemic treatment of cutaneous T-cell lymphoma.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 4/18/91 MA=
Interferon beta (recombinant) TN=r-HuIFN-beta	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 5/9/91 MA=
Interferon beta, recombinant human TN=Betaseron	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box Richmond CA 94804 DD= 11/15/88 MA=
Interferon beta-1a TN=Avonex	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 12/16/91 MA= 5/16/96

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Interferon beta-1a TN=Rebif	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 3/11/96 MA=
Interferon Beta-1a TN=Avonex	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 10/14/98 MA=
Interferon beta-1a (recombinant human) TN=	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 7/24/92 MA=
Interferon beta-1a (recombinant human) TN=Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 1/7/99 MA=
Interferon beta-1a (recombinant) TN=Rebif	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 12/2/92 MA=
Interferon beta-1a (recombinant) TN=r-HuIFN-beta	For the systemic treatment of cutaneous malignant melanoma.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 4/3/91 MA=
Interferon beta-1b TN=Betaseron	Treatment of multiple sclerosis.	Chiron Corp. & Berlex 4560 Horton Street Emeryville CA 94608 DD= 11/17/88 MA= 7/23/93
Interferon gamma 1-b TN=Actimmune	Treatment of chronic granulomatous disease.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 9/30/88 MA= 12/20/90
Interferon gamma-1b TN=Actimmune	Treatment of renal cell carcinoma.	Genentech, Inc. 1 DNA Way South San Francisco CA DD= 12/4/95 MA=
Interferon gamma-1b TN=Actimmune	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	InterMune Pharmaceuticals, Inc. 3294 West Bayshore Road Palo Alto CA 94303 DD= 9/30/96 MA= 2/10/00
Interleukin-1 alpha, human recombinant TN=	For the promotion of early engraftment in bone marrow transplantation.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 6/17/91 MA=
Interleukin-1 alpha, human recombinant TN=	For hematopoietic potentiation in aplastic anemia.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 6/17/91 MA=
Interleukin-1 receptor antagonist, human TN=Antril	Treatment of juvenile rheumatoid arthritis.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 9/23/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Interleukin-1 receptor antagonist, human TN=Antril	Prevention and treatment of graft versus host disease in transplant recipients.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 10/16/92 MA=
Interleukin-2 TN=Teceleukin	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 5/3/90 MA=
Interleukin-2 TN=Teleleukin	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 2/6/90 MA=
Interleukin-2 TN=Teceleukin	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 2/5/90 MA=
Interleukin-2 TN=Teceleukin	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 5/11/90 MA=
Interleukin-3 human (recombinant) TN=	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	Immunex Corporation 51 University Street Seattle WA 98101 DD= 5/20/91 MA=
Interleukin-3, human, recombinant TN=	For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or	Sandoz Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936 DD= 9/30/93 MA=
Iobenguane Sulfate I 131 TN=	For use as a diagnostic adjunct in patients with pheochromocytoma.	University of Michigan UH B1 H410/0028 1500 E. Medical Center Drive Ann Arbor MI 48109-0028 DD= 11/14/84 MA= 3/21/90
Iodine 131 6B-iodomethyl-19-norchol TN=	For use in adrenal cortical imaging.	David E. Kuhl, M.D. University of Michigan Medical B1G412 /0028 University Hospital Ann Arbor MI 48109-0028 DD= 8/1/84 MA=
Iodine I 123 murine monoclonal antibody to TN=	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 9/30/88 MA=
Iodine I 123 murine monoclonal antibody to TN=	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 9/30/88 MA=
Iodine I 123 murine monoclonal antibody to TN=	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 11/7/88 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Iodine I 131 bis(indium-diethylenetri TN=Pentacea	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd. Morris Plains NJ 07950 DD= 2/22/00 MA=
Iodine I 131 Lym-1 Monoclonal Antibody TN=	Treatment of B-cell lymphoma.	Lederle Laboratories Division American Cyanamide Company Pearl River NY 10965 DD= 11/2/87 MA=
Iodine I 131 murine monoclonal antibody TN=Immurait, LI-2-I-131	Treatment of B-cell leukemia and B-cell lymphoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 9/18/89 MA=
Iodine I 131 murine monoclonal antibody to TN=	Treatment of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 9/30/88 MA=
Iodine I 131 murine monoclonal antibody to TN=	Treatment of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 9/30/88 MA=
Iodine I 131 murine monoclonal antibody to TN=	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 11/7/88 MA=
Iodine I-131 radiolabeled chimeric TN=131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin CA 92780-7017 DD= 2/12/99 MA=
Isobutyramide TN=	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032 DD= 5/25/94 MA=
Isobutyramide TN=Isobutyramide oral	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D. Boston University Cancer Research Center Boston MA 02118 DD= 12/18/92 MA=
Japanese encephalitis vaccine (live, TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul South Korea KR DD= 5/19/99 MA=
Ketoconazole TN=Nizoral	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Pharmedic Company 28101 Ballard Road Lake Forest IL 60045 DD= 3/27/91 MA=
L-2-oxothiazolidine-4-ca rboxylic acid TN=Procysteine	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor Cambridge MA 02139 DD= 6/14/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
L-2-oxothiazolidine-4-carboxylic acid TN=Procysteine	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor Cambridge MA 02139 DD= 7/30/96 MA=
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona CA 91718-1900 DD= 1/20/99 MA=
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience Inc. 6111 Royalmount, #100 Montreal, Quebec Canada H4P 2T4 CA DD= 1/6/98 MA=
L-baclofen TN=	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D. University Of Pittsburgh School Pittsburgh PA 15261 DD= 7/13/90 MA=
L-baclofen TN=Neuralgon	Treatment of intractable spasticity in children with cerebral palsy.	Pharmascience Inc. 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4 Canada CA DD= 1/30/92 MA=
L-baclofen TN=Neuralgon	Treatment of intractable spasticity associated with spinal cord injury or multiple sclerosis.	Pharmascience Inc. 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4 Canada CA DD= 12/17/91 MA=
L-cycloserine TN=	Treatment of Gaucher's disease.	Lev, Meir M.D. The City College, City Convent Avenue at 138 Street New York NY 10031 DD= 8/1/89 MA=
L-cysteine TN=	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Orphan Pharmaceuticals, U.S.A., 1101 Kermit Dr. Suite 608 Nashville TN 37217 DD= 5/16/94 MA=
L-glutamyl-L-tryptophan TN=	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland WA 98033-7869 DD= 10/20/99 MA=
L-leucovorin TN=Isovorin	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Lederle Laboratories Division of American Cyanamid 401 N. Middletown Road Pearl River NY 10965 DD= 8/1/91 MA=
L-leucovorin TN=Isovorin	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid 401 N. Middletown Road Pearl River NY 10965 DD= 12/18/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
L-threonine TN=	Treatment of spasticity associated with familial spastic paraparesis.	Interneuron Pharmaceuticals, 99 Hayden Ave., Suite 200 Lexington MA 02421-7966 DD= 7/24/92 MA=
L-threonine TN=Threostat	Treatment of amyotrophic lateral sclerosis.	Tyson And Associates 12832 Chadron Avenue Hawthorne CA 90250 DD= 2/6/89 MA=
Lactic acid TN=Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale NY 11735 DD= 6/29/99 MA=
Lactobin TN=Lactobin	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Roxane Laboratories, Inc. P.O. Box 16532 Columbus OH 43216-6532 DD= 9/12/9 MA=
Lamotrigine TN=Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709 DD= 8/23/95 MA= 8/24/98
Lanreotide, Somatostatin TN=Ipstyl	Treatment for acromegly	IPSEN, Inc. 27 Maple Street Milford MA 01757 DD= 9/11/00 MA=
Leflunomide TN=	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W. Rush-Presbyterian-St. Luke's 1653 West Congress Parkway Chicago IL 60612-3833 DD= 10/18/96 MA=
Lepirudin TN=Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DE DD= 2/13/97 MA= 3/6/98
Leucovorin TN=Leucovorin calcium	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 8/17/88 MA= 8/31/88
Leucovorin TN=Leucovorin calcium	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 12/8/86 MA= 12/12/91
Leucovorin calcium TN=Wellcovorin	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Glaxo Wellcome Research and 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 6/23/88 MA=
Leupeptin TN=	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc. S.U.N.Y. at Stony Brook H.S.C. T18-020 Stony Brook NY 11794-8181 DD= 9/18/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Leuprolide acetate TN=Lupron Injection	Treatment of central precocious puberty.	Tap Pharmaceuticals, Inc. 2355 Waukegan Road Deerfield IL 60015 DD= 7/25/88 MA= 4/16/93
Levocabastine HCl ophthalmic suspension TN=	Treatment of vernal keratoconjunctivitis.	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 94608 DD= 2/29/88 MA=
Levocarnitine TN=Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite Gaithersburg MD 20877 DD= 4/7/97 MA=
Levocarnitine TN=Carnitor	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 7/26/84 MA= 12/22/88
Levocarnitine TN=Carnitor	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 2/28/84 MA= 4/10/86
Levocarnitine TN=Carnitor	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Gaithersburg MD 20877 DD= 9/6/88 MA= 12/15/99
Levocarnitine TN=Carnitor	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 11/22/93 MA=
Levocarnitine TN=Carnitor	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 11/15/89 MA=
Levocarnitine TN=Carnitor	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 11/15/89 MA=
Levocarnitine TN=Carnitor	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877 DD= 11/24/86 MA=
Levodopa and carbidopa TN=Duodopa	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11322 Acuff La. Lenexa KS 66215 DD= 1/18/00 MA=
Levomethadyl acetate hydrochloride TN=Orlaam	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation 8180 Greensboro Drive, Suite McLean VA 22102 DD= 1/24/84 MA= 7/9/93
Lidocaine patch 5% TN=Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Teikoku Pharma USA, Inc. 745-D Camden Ave. Campbell CA 95008-4146 DD= 10/24/95 MA= 3/19/99

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Liothyronine sodium injection TN=Triostat	Treatment of myxedema coma/precoma.	SmithKline Beecham One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101 DD= 7/30/90 MA= 12/31/91
Lipid/DNA human cystic fibrosis gene TN=	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322 DD= 4/8/96 MA=
Liposomal amphotericin B TN=AmBisome	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 12/10/96 MA= 8/11/97
Liposomal amphotericin B TN=AmBisome	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 12/6/96 MA= 8/11/97
Liposomal amphotericin B TN=AmBisome	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 12/10/96 MA=
Liposomal cyclosporin A TN=Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation	Vernon Knight, M.D. Baylor College of Medicine, One Baylor Plaza Houston TX 77030 DD= 4/30/98 MA=
Liposomal N-Acetylglucosminyl-N-Ac TN=ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044 DD= 6/10/98 MA=
Liposomal N-Acetylglucosminyl-N-Ac TN=ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044 DD= 6/10/98 MA=
Liposomal nystatin TN=Nyotran	Treatment of invasive fungal infections.	Aronex Pharmaceuticals, Inc. 8707 Technology Forest Place The Woodlands TX 77381-1191 DD= 6/13/00 MA=
Liposomal prostaglandin E1 injection TN=	Treatment of acute respiratory distress syndrome.	Liposome Company, Inc. One Research Way Princeton NJ 08540 DD= 4/25/96 MA=
Liposomal-cis-bis-neodec anoato-trans-R,R-1,2-dia TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands TX 77381 DD= 9/1/99 MA=
Liposome encapsulated recombinant TN=	Treatment of cancers of the kidney and renal pelvis.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512 DD= 6/20/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Liposome encapsulated recombinant TN=	Treatment of brain and CNS tumors.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512 DD= 11/25/91 MA=
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle WA 98119 DD= 6/10/99 MA=
Lodoxamide tromethamine TN=Alomide Ophthalmic	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 DD= 10/16/91 MA= 9/23/93
Loxoribine TN=	Treatment of common variable immunodeficiency.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869 DD= 2/24/92 MA=
Lucinactant TN=Surfaxin	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc. 350 South Main Street Suite 307 Doylestown PA 18901 DD= 7/17/95 MA=
Lucinactant TN=Surfaxin	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc. 350 South Main Street Suite 307 Doylestown PA 18901 DD= 10/18/95 MA=
Lucinactant TN=Surfaxin	Treatment of meconium aspiration syndrome in newborn infants.	Discovery Laboratories, Inc. 350 South Main Street Suite 307 Doylestown PA 18901 DD= 7/30/96 MA=
Lysine acetylsalicylate injectable TN=	Treatment of pain and fever secondary to sickle cell disease crisis.	G.D. Searle & Company DD= 8/1/89 MA=
Mafenide acetate solution antimicrobial agent to control TN=Sulfamylon solution	For use as an adjunctive topical bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown WV 26504-4310 DD= 7/18/90 MA= 6/5/98
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association 3 Francis St. Belmont MA 02478 DD= 5/25/99 MA=
MART-1 adenoviral gene therapy for malignant TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322 DD= 3/28/97 MA=
Matrix metalloproteinase inhibitor TN=Galardin	Treatment of corneal ulcers.	Glycomed, Inc 860 Atlantic Avenue Alameda CA 94501 DD= 12/5/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Mazindol TN=Sanorex	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D. 176 Memorial Drive Jesup GA 31545 DD= 12/8/86 MA=
Mecamylamine TN=Inversine	Treatment of Tourette's syndrome.	Layton Bioscience, Inc. 105 Reservoir Rd. Atherton CA 94027 DD= 10/14/98 MA=
Mecasermin TN=	Treatment of growth hormone insufficency syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 12/12/95 MA=
Mecasermin TN=Myotrophin	Treatment of amyotrophic lateral sclerosis.	Cephalon, Inc. 145 Brandywine Parkway West Chester PA 19380-4245 DD= 8/5/91 MA=
Mefloquine HCl TN=Lariam	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 4/13/88 MA= 5/2/89
Mefloquine HCl TN=Mephaquin	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG 4143 Dornach POSTFASH 137 Aesch Basel, Switzerland CH DD= 7/22/87 MA=
Mefloquine HCl TN=Mephaquin	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG 4143 Dornach POSTFASH 137 Aesch Basel, Switzerland CH DD= 7/22/87 MA=
Mefloquine HCl TN=Lariam	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 4/13/88 MA= 5/2/89
Megestrol acetate TN=Megace	Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb 2400 West Lloyd Expressway Evansville IN 47721 DD= 4/13/88 MA= 9/10/93
Melanoma cell vaccine TN=	Treatment of invasive melanoma.	Morton, Donald L. M.D. John Wayne Cancer Institute 2200 Santa Monica Boulevard Santa Monica CA 90404 DD= 10/13/94 MA=
Melanoma vaccine TN=Melacine Hamilton MT 59840	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc. 533 Old Corvallis Road DD= 12/20/89 MA=
Melatonin TN=	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D. Oregon Health Sciences 3181 S.W. Sam Jackson Park Road Portland OR 97201 DD= 11/15/93 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Melphalan TN=Alkeran For	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 2/24/92 MA= 11/18/92
Melphalan TN=Alkeran for	For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.	Glaxo Wellcome Research and 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 3/3/92 MA=
Meropenem TN=Merrem IV	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 DD= 4/27/00 MA=
Mesna TN=	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.	Asta Medica , Inc. 890 East St. Tewksbury MA 01876-1496 DD= 12/16/87 MA=
Mesna TN=Mesnex	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation 65 Challenger Road Ridgefield Park NJ 07660 DD= 11/14/85 MA= 12/30/88
Methionine/L-methionine TN=	Treatment of AIDS myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Philips Building, Suite 2R; 10 New York NY 10003 DD= 8/21/96 MA=
Methotrexate TN=Rheumatrex	Treatment of juvenile rheumatoid arthritis.	Wyeth-Ayerst Laboratories P.O. Box 8299 Philadelphia PA 19101-8299 DD= 8/23/93 MA=
Methotrexate sodium TN=Methotrexate	Treatment of osteogenic sarcoma.	Lederle Laboratories Division of American Cyanamid 401 N. Middletown Road Pearl River NY 10965 DD= 10/21/85 MA= 4/7/88
Methotrexate with laurocapram TN=Methotrexate/azone	Topical treatment of mycosis fungoides.	Durham Pharmaceuticals LLC 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280 DD= 10/15/90 MA=
Methoxsalen TN=Uvadex	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Theraks, Inc. 437 Creamery Way Exton PA 19431 DD= 10/14/98 MA=
Methylnaltrexone TN=	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	University of Chicago 5841 South Maryland Avenue MC 4028 Chicago IL 60637 DD= 6/17/96 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Metronidazole TN=Metrogel	Treatment of perioral dermatitis.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163 DD= 10/24/91 MA=
Metronidazole (topical) TN=Metrogel	Treatment of acne rosacea.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163 DD= 10/22/87 MA= 11/22/88
Metronidazole (topical) TN=Flagyl	Treatment of grade III and IV, anaerobically infected, decubitus ulcers.	Searle 4901 Searle Parkway Skokie IL 60077 DD= 11/24/87 MA=
Microbubble contrast agent TN=Filmix	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc. 55 Knollwood Road Farmington CT 06032 DD= 11/16/90 MA=
Midodrine HCl TN=Amatine	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. Meridian Center III 6 Industrial Way West Eatontown NJ 07724 DD= 12/5/96 MA= 9/6/96
Minocycline HCl TN=Minocin Intravenous	Treatment of chronic malignant pleural effusion.	Lederle Laboratories Division Pearl River NY 10965 DD= 6/19/92 MA=
Mitoguazone TN=Zyrkamine	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263 DD= 3/18/94 MA=
Mitolactol TN=	As adjuvant therapy in the treatment of primary brain tumors.	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713 DD= 7/12/95 MA=
Mitolactol TN=	Treatment of recurrent invasive or metastatic squamous carcinoma of the cervix.	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713 DD= 1/23/89 MA=
Mitomycin-C TN=	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc. 3100 Airway Avenue, Suite 106 Costa Mesa CA 92626 DD= 8/20/93 MA=
Mitoxantrone TN=Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle WA 98101 DD= 8/13/99 MA= 10/13/00
Mitoxantrone TN=Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle WA 98101 DD= 8/13/99 MA= 10/13/00
Mitoxantrone TN=Novantrone	Treatment of hormone refractory prostate cancer.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 8/21/96 MA= 11/13/96

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Mitoxantrone HCl TN=Novantrone	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories Division of American Cyanamid 401 N. Middletown Road Pearl River NY 10965 DD= 7/13/87 MA= 12/23/87
MN14 monoclonal antibody to carcinoembryonic TN=Cea-Cide	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 11/24/98 MA=
MN14 monoclonal antibody to carcinoembryonic TN=Cea-Cide	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains NJ 07950 DD= 9/18/98 MA=
Modafinil TN=Provigil	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc. 145 Brandywine Parkway West Chester PA 19380 DD= 3/15/93 MA= 12/24/98
Molgramostim TN=Leucomax	Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 1/24/89 MA=
Molgramostim TN=Leucomax	Treatment of aplastic anemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033 DD= 9/25/89 MA=
Monoclonal Ab(murine) anti-idiotype TN=Melimmune	Treatment of invasive cutaneous melanoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121 DD= 9/19/94 MA=
Monoclonal antibodies (murine or human) to TN=	Treatment of B-cell lymphoma.	IDEC Pharmaceuticals Corporation 11011 Torreyana Road San Diego CA 92121 DD= 5/6/86 MA=
Monoclonal antibodies PM-81 and AML-2-23 TN=	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953 DD= 3/12/90 MA=
Monoclonal antibody 17-1a TN=Panorex	Treatment of pancreatic cancer.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355 DD= 4/4/88 MA=
Monoclonal antibody for immunization against TN=	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc. 2825 Santa Monica Blvd., Suite Santa Monica CA 90404 DD= 1/7/93 MA=
Monoclonal antibody PM-81 TN=	Adjunctive treatment of acute myelogenous leukemia.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801 DD= 6/27/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Monoclonal antibody to cytomegalovirus (human) TN=	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043 DD= 9/13/91 MA=
Monoclonal antibody to cytomegalovirus (human) TN=	Treatment of cytomegalovirus retinitis in patients with AIDS.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043 DD= 11/15/91 MA=
Monoclonal antibody to hepatitis B virus TN=	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Protein Design Labs, Inc. 34801 Campus Dr. Fremont CA 94555 DD= 6/17/91 MA=
Monoclonal antibody-B43.13 TN=Ovarex MAb-B43.13	Treatment of epithelial ovarian cancer.	AltaRex US Corp. 610 Lincoln Street Waltham MA 02451 DD= 11/25/96 MA=
Monoclonal antiendotoxin antibody XMMEn-0e5 TN=	Treatment of patients with gram-negative sepsis which has progressed to shock.	Pfizer, Inc. 235 East 42nd Street New York NY 10017 DD= 11/4/85 MA=
Monolaurin TN=Glylorin	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc. 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709 DD= 4/29/93 MA=
Monooctanoin TN=Moctanin	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc. 7855 Gross Point Road, Unit L Skokie IL 60077 DD= 5/30/84 MA= 10/31/85
Morphine sulfate concentrate TN=Infumorph	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003 DD= 7/12/90 MA= 7/19/91
Mucoid exopolysaccharide Pseudomonas hyperimmune TN=MEP IGIV	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852 DD= 1/9/91 MA=
Mucoid exopolysaccharide Pseudomonas hyperimmune TN=MEP IGIV	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852 DD= 11/7/90 MA=
Multi-vitamin infusion (neonatal formula) TN=	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P. 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 12/12/89 MA=
Murine MAb (Lym-1) and Iodine 131-I TN=Oncolym	Treatment of B-cell non-Hodgkin's lymphoma.	Berlex Laboratories 15049 San Pablo Ave. PO Box 4099 Richmond CA 94804-0099 DD= 11/27/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Murine MAb to polymorphic epithelial TN=Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma plc West Africa House Hanger Lane Ealing London W5 3QR UK DD= 3/22/99 MA=
Mycobacterium avium sensitin RS-10 TN=	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut 5 Artillerivej DK-2300 Copenhagen S Denmark DD= 10/11/95 MA=
Myelin TN=	Treatment of multiple sclerosis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173 DD= 6/27/91 MA=
N-acetyl-procainamide TN=	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas 3560 Pennsylvania Avenue, Suite Dubuque IA 52002 DD= 12/10/96 MA=
N-acetylcysteinate TN=Nacystelyn Dry	For the management of cystic fibrosis	Galephar Pharmaceutical Road 198, No. 100 km. 14.7 Juncos Industrial Park Juncos PR 00777-3873 DD= 12/27/00 MA=
N-acetylgalactosamine-4-sulfatase, recombinant TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato CA 94949-5608 DD= 2/17/99 MA=
N-acetylprocainamide TN=Napa	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048 DD= 3/23/90 MA=
Nafarelin acetate TN=Synarel Nasal	Treatment of central precocious puberty.	Syntex (USA), Inc. 3401 Hillview Avenue Palo Alto CA 94303 DD= 7/20/88 MA= 2/26/92
Naltrexone HCl TN=Trexan	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent	DuPont Pharmaceuticals E.I. Du Pont De Nemours & Co. Wilmington DE 19880 DD= 3/11/85 MA= 11/30/84
Natural human lymphoblastoid TN=	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206 DD= 1/18/00 MA=
Natural human lymphoblastoid TN=	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences. Inc. 800 West 9th Avenue Amarillo TX 79101 DD= 8/10/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
NDROGE TN=	Treatment of postanoxic intention myoclonus.	WATSON Laboratories, Inc. 33 Ralph Avenue P.O. Box 30 Copiaque NY 11726-0030 DD= 11/1/84 MA=
Nebacumab TN=Centoxin	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355 DD= 10/1/86 MA=
Neurotrophin-1 TN=	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D. 6560 Fannin, Scurlock Tower, Houston TX 77303 DD= 9/13/94 MA=
NG-29 TN=Somatrel	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901 DD= 8/8/89 MA=
Nifedipine TN=	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D. MetroHealth Medical Center 3395 Scranton Road Cleveland OH 44109 DD= 6/13/91 MA=
Nitazoxanide TN=Cryptaz	Treatment of immunocompromised patients with cryptosporidiosis.	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607 DD= 12/12/96 MA=
Nitisinone TN=Orfadin	Treatment of tyrosinemia type 1.	Swedish Orphan AB Drottninggatan 98 SE-111 60 Stockholm Sweden SE DD= 5/16/95 MA=
Nitric oxide TN=INOmax	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton NJ 08809 DD= 6/22/93 MA= 12/23/99
Nitric oxide TN=	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton NJ 08809 DD= 7/10/95 MA=
Octreotide TN=Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 8/24/98 MA= 11/25/98
Octreotide TN=Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 8/24/98 MA= 11/25/98
Octreotide TN=Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 8/24/98 MA= 11/25/98

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Ofloxacin TN=Ocuflox Ophthalmic	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713 DD= 4/18/91 MA= 5/22/96
OM 401 TN=Drepanol	Prophylactic treatment of sickle cell disease.	Omex International, Inc. 6001 Savoy, Suite 110 Houston TX 77036 DD= 10/24/91 MA=
Omega-3 (n-3) polyunsaturated fatty TN=	Prevention of organ graft rejection.	Research Triangle 4364 South Alston Avenue Durham NC 27713 DD= 11/22/95 MA=
Omega-3 (n-3) polyunsaturated fatty TN=Omacor	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway DD= 5/4/00 MA=
Oncorad Ov103 TN=	Treatment of ovarian cancer.	Cytogen Corporation 600 College Road East Princeton NJ 08540 DD= 4/24/90 MA=
Oprelvekin TN=Neumega	Prevention of severe chemotherapy-induced	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge MA 02140 DD= 12/17/96 MA= 11/25/97
Orgotein for injection TN=	Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase.	Oxis International, Inc. 6040 N. Cutter Circle, Suite 317 Portland OR 97217-3935 DD= 12/22/94 MA=
Oxaliplatin TN=	Treatment of ovarian cancer.	Debio Pharm S.A. Rue des Terreaux 17 CH-1000 Lausanne 9 Switzerland CH DD= 10/6/92 MA=
Oxandrolone TN=Oxandrin	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 9/6/91 MA=
Oxandrolone TN=Hepandrin	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Bio-Technology General Corp. 70 Wood Avenue South Iselin NJ 08830 DD= 3/18/94 MA=
Oxandrolone TN=Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. 70 Wood Avenue South Iselin NJ 08830 DD= 4/22/97 MA=
Oxandrolone TN=	Treatment of constitutional delay of growth and puberty.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 10/5/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Oxandrolone TN=Oxandrin	Treatment of short stature associated with Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 7/5/90 MA=
Oxybate TN=Xyrem	Treatment of narcolepsy.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 11/7/94 MA=
Oxymorphone TN=Numorphan H.P.	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical P.O. Box 80027 Wilmington DE 19880 DD= 3/19/85 MA=
Oxypurinol TN=	Treatment of hyperuricemia in patients intolerant to allopurinol.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263 DD= 11/9/98 MA=
P1, P4-Di(uridine 5'-tetraphosphate), TN=	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470 Durham NC 27703 DD= 10/27/98 MA=
Paclitaxel TN=Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb 5 Research Parkway P.O. Box 5100 Wallingford CT 06492-7660 DD= 3/25/97 MA= 8/4/97
Paclitaxel TN=Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, 4400 Biscayne Boulevard Miami FL 33137 DD= 4/15/97 MA=
Papain, trypsin, and chymotrypsin TN=Wobe-Mugos	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc. 14851 N. Scottsdale Rd. Scottsdale AZ 85254 DD= 12/21/98 MA=
Papaverine topical gel TN=	Treatment of sexual dysfunction in spinal cord injury patients.	Pharmedic Company 417 Harvester Court Wheeling IL 60090 DD= 2/6/92 MA=
Parovirus B19 (recombinant VP1 and TN=MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878 DD= 5/7/99 MA=
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 2420 Castillo Street, Suite 100 Santa Barbara CA 93105 DD= 2/18/97 MA=
PEG-glucocerebrosidase TN=Lysodase	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental 49 Convent Dr. MSC4405 Bldg. 49, Room B1EE16 Bethesda MD 20892-4405 DD= 12/9/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
PEG-interleukin-2 TN=	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation 4560 Horton Street Emeryville CA 94608 DD= 2/1/90 MA=
Pegademase bovine TN=Adagen	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Enzon, Inc. 20 Kingsbridge Road Piscataway NJ 08854 DD= 5/29/84 MA= 3/21/90
Pegaspargase TN=Oncaspar	Treatment of acute lymphocytic leukemia.	Enzon, Inc. 20 Kingsbridge Road Piscataway NJ 08854 DD= 10/20/89 MA= 2/1/94
Peginterferon alfa-2a TN=PEGASYS	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley NJ 07110-1199 DD= 7/13/98 MA=
Peginterferon alfa-2a TN=PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley NJ 07110-1199 DD= 9/30/99 MA=
Pegylated arginine deiminase TN=Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341 DD= 4/12/99 MA=
Pegylated arginine deiminase TN=Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341 DD= 3/26/99 MA=
Pegylated recombinant human megakaryocyte TN=MEGAGEN	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1789 DD= 10/20/97 MA=
Peldesine TN=	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244 DD= 10/5/93 MA=
Pentamidine isethionate TN=Pentam 300	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 2/28/84 MA= 10/16/84
Pentamidine isethionate TN=Nebupent	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 1/12/88 MA= 6/15/89
Pentamidine isethionate TN=	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901 DD= 10/29/84 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Pentamidine isethionate (inhalation) TN=Pneumopent	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation 755 Jefferson Rd., P.O. Box 1710 Rochester NY 14603 DD= 10/5/87 MA=
Pentastarch TN=Pentaspan	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals E.I. Du Pont De Nemours & Co. Wilmington DE 19898 DD= 8/28/85 MA= 5/19/87
Pentosan polysulfate sodium TN=Elmiron	Treatment of interstitial cystitis.	Alza Corporation 950 Page Mill Rd. PO Box 10950 Palo Alto CA 94303-0802 DD= 8/7/85 MA= 9/26/96
Pentostatin TN=Nipent	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc. Two Annabel Lane Suite 220 San Ramon CA 94583 DD= 1/29/91 MA=
Pentostatin TN=Nipent	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon CA 94583 DD= 3/27/98 MA=
Pentostatin TN=Nipent	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583 DD= 11/24/99 MA=
Pentostatin for injection TN=Nipent	Treatment of hairy cell leukemia.	SuperGen, Inc. Two Annabel Lane Suite 220 San Ramon CA 94583 DD= 9/10/87 MA= 10/11/91
Perfosfamide TN=Pergamid	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Scios Nova, Inc. 2450 Bayshore Parkway Mountain View CA 94043 DD= 12/4/89 MA=
Pergolide TN=Permax	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Medical University of South 171 Ashley Avenue, Room PH246 Charleston SC 29425 DD= 11/20/97 MA=
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Pharmaceutical Research 1300 Gould Dr. Gainesville GA 30504 DD= 3/6/98 MA=
Phenylalanine ammonia-lyase TN=Phenylase	Treatment of hyperphenylalaninemia.	Ibex Technologies, Inc. 5485 Pare Montreal, Quebec Canada H4P 1P7 CA DD= 3/8/95 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Phenylbutyrate TN=	Treatment of acute promyelocytic leukemia.	Elan Corporation 1300 Gould Dr. Gainesville GA 30504 DD= 1/19/00 MA=
Phosphocysteamine TN=	Treatment of cystinosis.	Medea Research Laboratories Port Jefferson Business Center 200 Wilson Street, Building D-6 Port Jefferson NY 11776 DD= 9/12/88 MA=
Physostigmine Salicylate TN=Antilirium	Treatment of Friedreich's and other inherited ataxias.	Forest Pharmaceuticals, Inc. 150 East 58th Street New York NY 10155 DD= 1/16/85 MA=
Pilocarpine TN=Salagen	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318 DD= 9/24/90 MA= 3/22/94
Pilocarpine HCl TN=Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318 DD= 2/28/92 MA= 2/11/98
Piracetam TN=Nootropil	Treatment of myoclonus.	UCB Pharma, Inc. 1950 Lake Park Drive Smyrna GA 30080 DD= 10/2/87 MA=
Piritrexim isethionate TN=	Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709 DD= 6/13/88 MA=
Polifeprosan 20 with carmustine TN=Gliadel	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore MD 21224 DD= 12/13/89 MA= 9/23/96
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross GA 30092 DD= 8/5/97 MA=
Poloxamer 188 TN=Florcor	Treatment of severe burns requiring hospitalization.	CytRx Corporation 154 Technology Parkway Norcross GA 30092 DD= 2/22/90 MA=
Poloxamer 188 TN=Flocor	Treatment of sickle cell crisis.	CytRx Corporation 154 Technology Parkway Norcross GA 30092 DD= 6/27/89 MA=
Poloxamer 331 TN=Protox	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation 154 Technology Parkway Norcross GA 30092 DD= 3/21/91 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Poly I: poly C12U TN=Ampligen	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103 DD= 12/9/93 MA=
Poly I: poly C12U TN=Ampligen	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103 DD= 5/20/91 MA=
Poly I: poly C12U TN=Ampligen	Treatment of AIDS.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103 DD= 7/19/88 MA=
Poly I: poly C12U TN=Ampligen	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103 DD= 12/9/93 MA=
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and 3202 Cleveland Avenue N.W. Washington DC 20008 DD= 3/17/97 MA=
Polyethylene glycol-modified uricase TN=Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341 DD= 9/14/99 MA=
Polyethylene glycol-modified uricase TN=Zurase	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341 DD= 12/21/98 MA=
Polymeric oxygen TN=	Treatment of sickle cell anemia.	Capmed USA P.O. Box 14 Bryn Mawr PA 19010 DD= 3/25/92 MA=
Porcine fetal neural dopaminergic cells TN=NeuroCell-PD	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin, Inc. One Kendall Square Cambridge MA 02139-1562 DD= 12/17/96 MA=
Porcine fetal neural dopaminergic cells TN=NeuroCell-PD	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin, Inc. One Kendall Square Cambridge MA 02139-1562 DD= 12/17/96 MA=
Porcine fetal neural gabaergic cells and/or TN=NeuroCell-HD	Treatment of Huntington's disease.	Diacrin, Inc. One Kendall Square Cambridge MA 02129-1562 DD= 12/10/96 MA=
Porcine fetal neural gabaergic cells and/or TN=NeuroCell-HD	Treatment of Huntington's disease.	Diacrin, Inc. One Kendall Square Cambridge MA 02139-1562 DD= 12/10/96 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Porcine Sertoli cells aseptically prepared for TN=N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza 50 Division Street, Suite 503 Somerville NJ 08876 DD= 6/24/97 MA=
Porfimer sodium TN=Photofrin	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc. Lederle Laboratories 401 North Middletown Road Pearl River NY 10965 DD= 6/6/89 MA= 12/27/95
Porfimer sodium TN=Photofrin	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc. Lederle Laboratories 401 North Middletown Road Pearl River NY 10965 DD= 11/15/89 MA=
Porfiromycin TN=Promycin	Treatment of cervical cancer.	Boehringer Ingelheim 900 Ridgebury Road PO Box 368 Ridgefield CT 06877 DD= 3/13/97 MA=
Porfiromycin TN=Promycin	Treatment of head and neck cancer.	Boehringer Ingelheim 900 Ridgebury Road PO Box 368 Ridgefield CT 06877 DD= 9/19/95 MA=
Potassium citrate TN=Urocit-K	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health 5323 Harry Hines Blvd Dallas TX 75235 DD= 9/16/85 MA= 8/30/85
Potassium citrate TN=Urocit-K	Prevention of uric acid nephrolithiasis.	University of Texas Health 5323 Harry Hines Boulevard Dallas TX 75235 DD= 11/1/84 MA= 8/30/85
Potassium citrate TN=Urocit-K	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health 5323 Harry Hines Blvd Dallas TX 75235 DD= 5/29/84 MA= 8/30/85
Potassium citrate and citric acid TN=	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Willen Drug Company DD= 2/14/86 MA=
Pr-122 (redox-phenytoin) TN=	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615 DD= 7/5/90 MA=
PR-225 (redox-acyclovir) TN=	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	Pharmos 2 Innovation Drive Alachua FL 32615 DD= 5/29/90 MA=
PR-239 (redox penicillin G) TN=	Treatment of AIDS associated neurosyphilis.	Pharmos 2 Innovation Drive Alachua FL 32615 DD= 5/23/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Pr-320 (molecusol-carbamazepine TN=	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615 DD= 7/20/90 MA=
Pramiracetam Sulfate TN=	For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.	Cambridge Neuroscience, Inc. 1 Kendall Square, Bldg. 700 Cambridge MA 02139 DD= 11/4/91 MA=
Praziquantel TN=	Treatment of neurocysticercosis.	EM Pharmaceuticals, Inc. DD= 4/18/88 MA=
Prednimustine TN=Sterecyt	Treatment of malignant non-Hodgkin's lymphomas.	Pharmacia Inc. P.O. Box 16529 Columbus OH 43216-6529 DD= 6/17/85 MA=
Primaquine phosphate TN=	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016 DD= 7/23/93 MA=
Progesterone TN=	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc. 311 Bonnie Circle Corona CA 91720 DD= 12/22/94 MA=
Propamidine isethionate 0.1% ophthalmic solution TN=Brolene	Treatment of acanthamoeba keratitis.	Bausch & Lomb Pharmaceuticals Division 8500 Hidden River Parkway Tampa FL 33637 DD= 3/10/88 MA=
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles CA 90032 DD= 6/12/98 MA=
Prostaglandin E1 in lipid emulsion TN=Lipo-PGE1	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032 DD= 9/10/96 MA=
Protein C concentrate TN=Protein C	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor New York NY 10022 DD= 4/22/93 MA=
Protein C concentrate TN=Protein C	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203 DD= 6/23/92 MA=
Protein C concentrate TN=Protein C	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor New York NY 10022 DD= 6/19/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Protirelin TN=	Prevention of infant respiratory distress syndrome associated with prematurity.	UCB Pharma, Inc. 1950 Lake Park Drive Smyrna GA 30080 DD= 8/24/93 MA=
Protirelin injection TN=	Treatment of amyothrophic lateral sclerosis.	Abbott Laboratories DD= 1/10/85 MA=
Pulmonary surfactant replacement TN=	Prevention and treatment of infant respiratory distress syndrome.	Scios Nova, Inc. 2450 Bayshore Parkway Mountain View CA 94043 DD= 12/5/88 MA=
Pulmonary surfactant replacement, porcine TN=Curosurf	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories 2751 Napa Valley Corporate Drive Napa CA 94558 DD= 8/2/93 MA= 11/18/99
Purified extract of Pseudomonas aeruginosa TN=ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge MA 02139 DD= 9/22/97 MA=
Purified type II collagen TN=Colloral	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02421 DD= 2/9/95 MA=
pVGI.1(VEGF2) TN=	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center 4364 South Alston Ave. Durham NC 27713-2280 DD= 11/9/99 MA=
Quinacrine hydrochloride TN=	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Lyphomed, Inc. DD= 10/17/84 MA=
Radiolabeled monoclonal antibody to CD22 antigen TN=LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains NJ 07950 DD= 7/13/98 MA=
Recombinant bactericidal/permeabilit TN=Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710 DD= 6/22/98 MA=
Recombinant glycine2-human TN=	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA DD= 6/29/00 MA=
Recombinant human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Genzyme Corporation 15 Pleasant Street P.O. Box 9322 Framingham MA 01701-9322 DD= 8/19/97 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Recombinant human antithrombin III TN=	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, P.O. Framingham MA 01701 DD= 4/6/00 MA=
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium BE DD= 2/23/99 MA=
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium BE DD= 2/23/99 MA=
Recombinant human CD4 immunoglobulin G TN=	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 8/30/90 MA=
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park MD 20742 DD= 7/13/98 MA=
Recombinant human gelsolin TN=	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 3/6/95 MA=
Recombinant human gelsolin TN=	Treatment of the respiratory symptoms of cystic fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02124 DD= 1/12/94 MA=
Recombinant human highly phosphorylated acid TN=TBD	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 9/20/00 MA=
Recombinant human insulin-like growth TN=IGF-1	Treatment of growth hormone receptor deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199 DD= 6/7/95 MA=
Recombinant human insulin-like growth TN=IGF-1	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199 DD= 6/7/95 MA=
Recombinant human insulin-like growth TN=	Treatment of post-poliomyelitis syndrome.	Cephalon, Inc. 145 Brandywine Parkway West Chester PA 19380-4245 DD= 10/13/95 MA=
Recombinant human insulin-like growth TN=PV802	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000 Australia AU DD= 2/16/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Recombinant human insulin-like growth TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara CA 95054 DD= 6/15/99 MA=
Recombinant human interleukin-12 TN=	Treatment of renal cell carcinoma.	Genetics Institute, Inc. 87 CambridgePark Drive Cambridge MA 02140 DD= 10/20/97 MA=
Recombinant human keratinocyte growth TN=	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799 DD= 12/20/99 MA=
Recombinant human luteinizing hormone TN=LHadi	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 10/7/94 MA=
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080 DD= 4/16/99 MA=
Recombinant human relaxin TN=	Treatment of progressive systemic sclerosis.	Connetics Corporation 3400 West Bayshore Road Palo Alto CA 94303 DD= 11/3/95 MA=
Recombinant human superoxide dismutase TN=Oxsodrol	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 4/18/91 MA=
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco CA DD= 9/29/97 MA=
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 3/22/99 MA=
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 3/22/99 MA=
Recombinant humanized MAb 5c8 TN=	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 10/14/98 MA=
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 2/3/98 MA=
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 2/18/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Recombinant methionyl brain-derived TN=	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799 DD= 11/28/94 MA=
Recombinant methionyl human stem cell factor TN=	Treatment of primary bone marrow failure.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 11/22/95 MA=
Recombinant retroviral vector - TN=	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878 DD= 11/15/93 MA=
Recombinant secretory leucocyte protease TN=	Treatment of congenital alpha-1 antitrypsin deficiency.	Amgen Inc. 3200 Walnut Street Boulder CO 80301 DD= 3/29/91 MA=
Recombinant secretory leucocyte protease TN=	Treatment of cystic fibrosis.	Amgen, Inc. 3200 Walnut Street Boulder CO 80301 DD= 3/29/91 MA=
Recombinant soluble human CD4 TN=Receptin	Treatment of acquired immunodeficiency syndrome.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142 DD= 11/20/89 MA=
Recombinant soluble human CD4 (rCD4) TN=	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 3/23/89 MA=
Recombinant urate oxidase TN=	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355 DD= 10/11/00 MA=
Recombinant urate oxidase TN=	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355 DD= 10/11/00 MA=
Recombinant vaccinia (human papillomavirus) TN=TA-HPV	Treatment of cervical cancer.	Cantab Pharmaceuticals Research 310 Cambridge Science Park Cambridge CB4 OWG Great Britain GB DD= 8/24/94 MA=
Reduced L-glutathione TN=Cachexon	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical 146 Flanders Drive Hillsborough NJ 08876 DD= 2/14/94 MA=
Remacemide TN=Ecovia	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 3/6/00 MA=
Respiratory syncytial virus immune globulin TN=Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachussetts 35 West Watkins Mill Road Gaithersburg MD 20878 DD= 9/27/90 MA= 1/18/96

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Respiratory Syncytial Virus Immune Globulin TN=Hypermune RSV	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg MD 20878 DD= 9/27/90 MA=
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322 DD= 5/6/97 MA=
RGG0853, E1A lipid complex TN=	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101 DD= 10/27/97 MA=
Rho (D) immune globulin intravenous (human) TN=WinRho SD	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc. 104 Chancellor Matheson Road Winnipeg, Manitoba Canada R3T 2N2 CA DD= 11/9/93 MA= 3/24/95
Ribavirin TN=Virazole	Treatment of hemorrhagic fever with renal syndrome.	ICN Pharmaceuticals, Inc. ICN Plaza 3300 Hyland Avenue Costa Mesa CA 92626 DD= 4/12/91 MA=
Ricin (blocked) conjugated murine mca TN=	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 1/24/91 MA=
Ricin (blocked) conjugated murine MCA TN=	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 11/17/88 MA=
Ricin (blocked) conjugated murine MCA TN=	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 2/1/90 MA=
Ricin (blocked) conjugated murine MCA TN=	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 8/3/89 MA=
Ricin (blocked) conjugated murine MCA TN=	Treatment of small cell lung cancer.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 1/25/91 MA=
Ricin (blocked) conjugated murine TN=	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139 DD= 9/6/94 MA=
Rifabutin TN=	Treatment of disseminated Mycobacterium avium complex disease.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199 DD= 12/18/89 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Rifabutin TN=Mycobutin	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc. P.O. Box 16529 Columbus OH 43216 DD= 12/18/89 MA= 12/23/92
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle WA 98119 DD= 4/13/99 MA=
Rifampin TN=Rifadin I.V.	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel P.O. Box 9627 Kansas City MO 64134 DD= 12/9/85 MA= 5/25/89
Rifampin, isoniazid, pyrazinamide TN=Rifater	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Kansas City MO 64134 DD= 9/12/85 MA= 5/31/94
Rifapentine TN=Priftin	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc. P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627 DD= 6/9/95 MA=
Rifapentine TN=Priftin	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc. P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627 DD= 3/12/96 MA=
Rifapentine TN=Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627 DD= 6/9/95 MA= 6/22/98
Rifaximin TN=Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road, Suite 205 Palo Alto CA 94303 DD= 2/10/98 MA=
RII retinamide TN=	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham PA 19044-2310 DD= 5/6/93 MA=
Riluzole TN=Rilutek	Treatment of Huntington's disease.	Rhone-Poulenc Rorer 500 Arcola Road PO Box 5096 Collegeville PA 19426-0800 DD= 10/15/96 MA=
Riluzole TN=Rilutek	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer 500 Arcola Road, P.O. Box 1200 Collegeville PA 19426 DD= 3/16/93 MA= 12/12/95
Rituximab TN=Rituxan	Treatment of non-Hodgkin's B-cell lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121 DD= 6/13/94 MA= 11/26/97

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Roquinimex TN=Linomide	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199 DD= 7/1/93 MA=
rSP-C lung surfactant TN=Venticute	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 78467 Konstanz Germany DE DD= 4/3/00 MA=
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Philips Building, Suite 2Q; 10 New York NY 10003 DD= 4/30/98 MA=
Sacrosidase TN=Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305 DD= 12/10/93 MA= 4/9/98
Sargramostim TN=Leukine	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 3/6/95 MA= 9/15/95
Sargramostim TN=Leukine	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation 51 University Street Seattle WA 98101 DD= 5/3/90 MA= 3/5/91
Satumomab pendetide TN=Oncoscint CR/OV	Detection of ovarian carcinoma.	Cytogen Corporation 600 College Road East Princeton NJ 08540 DD= 9/25/89 MA= 12/29/92
SB-408075 TN=	For pancreatic cancer	SmithKline Beecham 1250 S. Collegeville Road Collegeville PA 19426-0989 DD= 12/7/00 MA=
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth NJ 07033 DD= 4/12/99 MA=
Secalciferol TN=Osteo-D	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA 650 Cathill Rd. Sellersville PA 18960 DD= 7/26/93 MA=
Secretory leukocyte protease inhibitor TN=	Treatment of bronchopulmonary dysplasia.	Synergen, Inc. 1885 33rd Street Boulder CO 80301 DD= 6/30/92 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Selegiline HCl TN=Eldepryl	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc. 777 South Harbor Island Tampa FL 33602 DD= 11/7/84 MA= 6/5/89
Sermorelin acetate TN=Geref	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 2/13/90 MA=
Sermorelin acetate TN=Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 9/14/88 MA= 9/26/97
Sermorelin acetate TN=Geref	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 12/5/91 MA=
Serratia marcescens extract (polyribosomes) TN=Imuvert	Treatment of primary brain malignancies.	Cell Technology, Inc. 1668 Valtec Lane Boulder CO 80306 DD= 9/7/88 MA=
Short chain fatty acid enema TN=Colomed	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D. 1000 Central Street, Suite 615 Evanston IL 60201 DD= 8/19/97 MA=
Short chain fatty acid solution TN=Colomed	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer 1000 Central Street, Suite 615 Evanston IL 60201 DD= 5/29/90 MA=
Silver sulfadiazine and cerium nitrate TN=Flammacerium	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli PA 19301 DD= 11/17/99 MA=
SK&F 110679 TN=	For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	SmithKline Beecham One Franklin Plaza Philadelphia PA 19101 DD= 5/23/90 MA=
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite Saint-Laurent, Quebec Canada H4S 2A1 CA DD= 4/6/99 MA=
Sodium dichloroacetate TN=Ceresine	Treatment of severe head injury.	Questcor Pharmaceuticals, Inc. 26118 Research Road Hayward CA 94545 DD= 6/14/99 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Sodium dichloroacetate TN=	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610 DD= 6/11/90 MA=
Sodium dichloroacetate TN=	Treatment of congenital lactic acidosis.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610 DD= 6/11/90 MA=
Sodium dichloroacetate TN=	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D. University Of Florida P.O. Box 100277 Gainesville FL 32610 DD= 11/10/94 MA=
Sodium dichloroacetate TN=	Treatment of congenital lactic acidosis.	Questcor Pharmaceuticals, Inc. 26118 Research Road Hayward CA 94545 DD= 12/31/97 MA=
Sodium monomercaptoundecahydro- TN=	For use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.	Theragenics Corporation DD= 12/18/84 MA=
Sodium Monomercaptoundecahydro- TN=Borocell	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& 877 Main Street, Suite 402 Boise ID 83702 DD= 4/15/92 MA=
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Pharmaceutical Research 1300 Gould Dr. Gainesville GA 30504 DD= 4/24/98 MA=
sodium phenylbutyrate TN=Buphenyl	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road Scottsdale AZ 85258 DD= 11/22/93 MA= 7/29/94
sodium phenylbutyrate TN=	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road Scottsdale AZ 85258 DD= 7/2/92 MA=
Sodium tetradecyl sulfate TN=Sotradecol	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003 DD= 6/10/86 MA=
Soluble complement receptor type 1 TN=	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc. 119 Fourth Ave. Needham MA 02494-2725 DD= 3/6/00 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Soluble recombinant human complement TN=	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc. 119 Fourth Avenue Needham Heights MA 02194 DD= 11/21/94 MA=
Somatostatin TN=Zecnil	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901 DD= 6/20/88 MA=
Somatostatin TN=	Treatment of bleeding esophageal varices.	UCB Pharmaceuticals, Inc. 1950 Lake Park Drive Smyrna GA 30080 DD= 12/22/94 MA=
Somatrem for injection TN=Protropin	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 12/9/85 MA= 10/17/85
Somatrem for injection TN=Protropin	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 12/9/85 MA=
Somatropin TN=Humatrope	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 DD= 5/8/90 MA= 3/11/97
Somatropin TN=Norditropin	Treatment of short stature associated with Turner's syndrome.	Novo Nordisk Pharmaceuticals 100 Overlook Center Suite 200 Princeton NJ 08540 DD= 11/5/87 MA=
Somatropin TN=Norditropin	Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in	Novo Nordisk Pharmaceuticals 100 Overlook Center Suite 200 Princeton NJ 08540 DD= 9/1/87 MA=
Somatropin TN=Biotropin	Treatment of cachexia associated with AIDS.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 2/12/93 MA=
Somatropin TN=Nutropin	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 3/6/87 MA= 10/17/85
Somatropin TN=Genotropin	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199 DD= 9/6/94 MA= 10/31/97
Somatropin (rDNA) TN=Saizen	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 5/3/89 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Somatropin (r-DNA) TN=Serostim	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 3/6/95 MA=
Somatropin (r-DNA) for injection TN=Serostim	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 3/26/96 MA=
Somatropin (rDNA origin) TN=Saizen	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 3/6/87 MA= 10/8/96
Somatropin (rDNA origin) TN=Nutropin Depot	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way South San Francisco CA DD= 10/28/99 MA= 12/22/99
Somatropin (rDNA origin) injection TN=Norditropin	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals 100 Overlook Center Suite 200 Princeton NJ 08540 DD= 7/10/87 MA= 6/20/00
somatropin [rDNA] TN=Genotropin	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company 7000 Portage Road Kalamazoo MI 49001 DD= 12/27/00 MA=
Somatropin [rDNA] TN=Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo MI 49001-0199 DD= 7/6/99 MA= 6/20/00
Somatropin for injection TN=Nutropin	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 3/23/89 MA= 12/30/96
Somatropin for injection TN=Serostim	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 11/15/91 MA= 8/23/96
Somatropin for injection TN=Nutropin	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 11/18/96 MA= 12/15/97
Somatropin for injection TN=Humatrope	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 DD= 6/12/86 MA= 3/8/87
Somatropin for injection TN=Nutropin	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080 DD= 8/4/89 MA= 11/17/93

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Sorivudine TN=BRAVAVIR	Treatment of herpes zoster (shingles) in immunocompromised patients.	Bristol-Myers Squibb 5 Research Parkway P.O. Box 5100 Wallingford CT 06492 DD= 11/9/95 MA=
Sotalol HCl TN=Betapace	Prevention of life threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470 DD= 9/23/88 MA=
Sotalol HCl TN=Betapace	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470 DD= 9/23/88 MA= 10/30/92
Spiramycin TN=Rovamycine	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.	Rhone-Poulenc Rorer 500 Arcola Road Collegeville PA 19426 DD= 10/17/84 MA=
ST1-RTA immunotoxin (SR 44163) TN=	Treatment of patients with B-chronic lymphocytic leukemia.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355 DD= 8/12/87 MA=
ST1-RTA immunotoxin (SR 44163) TN=	Prevention of acute graft versus host disease in allogenic bone marrow transplantation.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355 DD= 8/12/87 MA=
Sterile talc TN=Steritalc	Treatment of malignant pleural effusion.	Novatech SA Avenue du Vent des Dames - Z.I. 13685 Aubagne France DD= 12/8/97 MA=
Sterile talc TN=Steritalc	Treatment of pneumothorax.	Novatech SA Avenue du Vent des Dames - Z.I. 13685 Aubagne France DD= 12/8/97 MA=
Sterile talc powder TN=Sclerosol	Treatment of malignant pleural effusion.	Bryan Corporation 4 Plympton Street Woburn MA 01801 DD= 9/18/95 MA= 12/24/97
SU101 TN=	Treatment of malignant glioma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA DD= 5/25/95 MA=
SU101 TN=	Treatment of ovarian cancer.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA DD= 3/12/96 MA=
Succimer TN=Chemet	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016-1389 DD= 11/5/90 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Succimer TN=Chemet capsules	Treatment of lead poisoning in children.	Bock Pharmacal Company P.O. Box 419056 Saint Louis MO 63141-9056 DD= 5/9/84 MA= 12/22/88
Succimer TN=Chemet	Treatment of mercury intoxication.	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016-1389 DD= 3/22/91 MA=
Sucralfate TN=	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Fuisz Technologies, Ltd. 14555 Avion at Lakeside Chantilly VA 20151 DD= 7/15/93 MA=
Sucralfate suspension TN=	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570 DD= 3/4/91 MA=
Sucralfate suspension TN=	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570 DD= 3/12/90 MA=
Sulfadiazine TN=	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc. 227-15 North Conduit Avenue Laurelton NY 11413 DD= 3/14/94 MA= 7/29/94
Sulfapyridine TN=	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540 DD= 9/10/90 MA=
Superoxide dismutase (human) TN=	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially	Pharmacia-Chiron Partnership 4560 Horton Street Emeryville CA 94608 DD= 3/6/85 MA=
Superoxide dismutase (recombinant human) TN=Oxsodrol	Prevention of reperfusion injury to donor organ tissue.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830 DD= 5/17/88 MA=
Suramin TN=Metaret	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical 2800 Plymouth Road Ann Arbor MI 48105-2430 DD= 5/6/97 MA=
Surface active extract of saline lavage of TN=Infasurf	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc. 1576 Sweet Home Road Amherst NY 14228 DD= 6/7/85 MA= 7/1/98
Surfactant (human) (amniotic fluid derived) TN=Human Surf	Prevention and treatment of neonatal respiratory distress syndrome.	Merritt, T. Allen M.D. 2516 Stockton Boulevard Sacramento CA 95817 DD= 3/25/87 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Synsorb Pk TN=	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc. 201, 1204 Kensington Road, N.W. Calgary, Alberta Canada T2N 3P5 CA DD= 7/17/95 MA=
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/16/99 MA=
Synthetic human secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/16/99 MA=
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/16/99 MA=
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/18/99 MA=
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/18/99 MA=
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 6/18/99 MA=
Synthetic porcine secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=
T4 endonuclease V, liposome encapsulated TN=	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics 205 Buffalo Avenue Freeport NY 11520 DD= 6/27/89 MA=
Tacrolimus TN=Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015 DD= 4/6/98 MA=
TAK-603 TN=	Treatment of Crohn's disease.	Tap Holdings Inc. 2355 Waukegan Road Deerfield IL 60015 DD= 5/13/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Technetium Tc 99m pterotetramide TN=	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906 DD= 2/16/00 MA=
Technetium Tc99m anti-melanoma murine TN=Oncotrac Melanoma	For use in detecting, by imaging, metastases of malignant melanoma.	NeoRx Corporation 410 West Harrison Seattle WA 98119-4007 DD= 6/2/87 MA=
Technetium Tc99m murine monoclonal antibody TN=LymphoScan	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 4/7/92 MA=
Technetium Tc99m murine monoclonal antibody to TN=Immuraid, hCG-Tc-99m	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 8/7/89 MA=
Technetium Tc99m murine monoclonal antibody to TN=AFP-Scan	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 8/1/89 MA=
Technetium Tc99m murine monoclonal antibody to TN=Immuraid, AFP-Scan	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950 DD= 8/1/89 MA=
Technetium Tc99m rh-Annexin V TN=Apomate	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation 124 Mount Auburn Street Suite 200 North Cambridge MA 02138 DD= 11/3/00 MA=
Temoporfin TN=Foscan	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Stirling Scotland FK9 4TZ GB DD= 10/28/99 MA=
Temozolomide TN=Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research 2000 Galloping Hill Rd. Kenilworth NJ 07033 DD= 10/5/98 MA= 8/11/99
Temozolomide TN=Temodal	Treatment of advanced metastatic melanoma.	Schering-Plough Research 2000 Galloping Hill Rd. Kenilworth NJ 07033 DD= 10/14/98 MA=
Teniposide TN=Vumon for injection	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb 5 Research Parkway P.O. Box 5100 Wallingford CT 06492 DD= 11/1/84 MA= 7/14/92

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Teriparatide TN=Parathar	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, 27 Maple St. Milford MA 01757 DD= 10/28/99 MA=
Teriparatide TN=Parathar	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or	Rhone-Poulenc Rorer 500 Arcola Road Collegeville PA 19426 DD= 1/9/87 MA= 12/23/87
Terlipressin TN=Glypressin	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901 DD= 3/6/86 MA=
Testosterone TN=Androgel	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Deerfield IL 60015-2544 DD= 2/5/96 MA=
Testosterone TN=TheraDerm	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories Research Park 417 Wakara Way Salt Lake City UT 84108 DD= 9/22/97 MA=
Testosterone propionate ointment 2% TN=	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc. 1990 N.W. 44th Street Pompano Beach FL 33064 DD= 7/31/91 MA=
Testosterone sublingual TN=	Treatment of constitutional delay of growth and puberty in boys.	Bio-Technology General Corp. 70 Wood Avenue South Iselin NJ 08830 DD= 1/16/91 MA=
Tetrabenazine TN=	Treatment of Huntington's disease.	Lifehealth Limited Doltie House Kingfisher Way Wallsend Tyne & Wear NE28 9NX UK DD= 12/11/97 MA=
Tetrabenazine TN=	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited Doltie house Kinfisher Way Wallsend Tyne & Wear NE28 9NX UK DD= 5/12/98 MA=
Tetraiodothyroacetic acid TN=	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489 DD= 5/1/00 MA=
Thalidomide TN=Synovir	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059 DD= 3/11/96 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090 DD= 11/15/88 MA=
Thalidomide TN=	Prevention of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite Beltsville MD 20705 DD= 3/5/90 MA=
Thalidomide TN=Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059 DD= 7/26/95 MA= 7/16/98
Thalidomide TN=	Treatment of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite Beltsville MD 20705 DD= 3/5/90 MA=
Thalidomide TN=	Treatment of primary brain malignancies.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059 DD= 2/27/98 MA=
Thalidomide TN=	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite Beltsville MD 20705 DD= 5/15/95 MA=
Thalidomide TN=Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059 DD= 4/6/99 MA=
Thalidomide TN=	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090 DD= 9/19/88 MA=
Thalidomide TN=	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation P.O. Box 4914 7 Powder Horn Srive Warren NJ 07059 DD= 5/1/95 MA=
Thalidomide TN=Thalomid	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059 DD= 10/14/98 MA=
Thalidomide TN=	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090 DD= 9/19/88 MA=
Thalidomide TN=	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059 DD= 1/12/93 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment of Kaposi's sarcoma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059 DD= 7/29/98 MA=
Thymalfasin TN=Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo CA 94404-1593 DD= 1/8/98 MA=
Thymalfasin TN=Zadaxin	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo CA 94404-1593 DD= 5/3/91 MA=
Thymalfasin TN=Zadaxin	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc. 901 Mariner's Blvd., Suite 205 San Mateo CA 94404 DD= 3/6/00 MA=
Thymoxamine HCl TN=	Reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 91711 DD= 11/16/87 MA=
Thyrotropin alpha TN=Thyrogen	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation One Kendall Square Cambridge MA 02139 DD= 2/24/92 MA= 11/30/98
Tiapride TN=	Treatment of Tourette's syndrome.	Sanofi-Synthelabo, Inc. 9 Great Valley Parkway PO Box 3026 Malvern PA 19355 DD= 4/21/98 MA=
Tiazofurin (2-Beta-D-ribofuranosyl- TN=	Chronic myelogenous leukemia (CML)	ICN Pharmaceuticals, Inc. (ICN) 3300 Hyland Avenue Costa Mesa CA 92626 DD= 12/27/00 MA=
Tiopronin TN=Thiola	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D. The University of Texas Health 5323 Harry Hines Boulevard Dallas TX 75235 DD= 1/17/86 MA= 8/11/88
Tiratricol TN=Triacana	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine	Laphal Laboratoires 48 Bis, Rue des Belles-Feuilles 75116 Paris France FR DD= 8/13/91 MA=
Tizanidine HCl TN=Zanaflex	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc. 800 Gateway Boulevard South San Francisco CA 94080 DD= 1/31/94 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Tobramycin TN=Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle WA 98119 DD= 6/18/99 MA=
Tobramycin for inhalation TN=TOBI	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Pathogenesis Corporation 201 Elliott Avenue West, Suite Seattle WA 98119 DD= 10/13/94 MA= 12/22/97
Tocophersolan oral solution (vitamin TN=	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Sterling Winthrop 9 Great Valley Parkway Malvern PA 19355 DD= 4/15/88 MA=
Topiramate TN=Topamax	Treatment of Lennox-Gastaut syndrome.	R. W. Johnson Pharmaceutical Route 202, P.O. Box 300 Raritan NJ 08869-0602 DD= 11/25/92 MA=
Toremifene TN=Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland DD= 9/19/91 MA= 5/29/97
Toremifene TN=	Treatment of desmoid tumors.	Orion Corporation P.O. Box 65 02101 Espoo Finland DD= 8/17/93 MA=
Tositumomab and iodine I 131 tositumomab TN=Bexxar	Treatment of non-Hodgkin's B-cell lymphoma.	Coulter Pharmaceutical, Inc. 550 California Avenue Suite 200 Palo Alto CA 94306 DD= 5/16/94 MA=
Tranexamic acid TN=Cyklokapron	Treatment of patients with congenital coagulopathies who are undergoing surgical procedures (e.g. dental extractions).	Pharmacia Inc. P.O. Box 16529 Columbus OH 43216 DD= 10/29/85 MA= 2/30/86
Tranexamic acid TN=Cyklokapron	Treatment of patients undergoing prostatectomy where there is hemorrhage or risk of hemorrhage as a result of increased fibrinolysis or fibrinogenolysis.	Pharmacia Inc. P.O. Box 16529 Columbus OH 43216 DD= 7/23/87 MA=
Tranexamic acid TN=Cyklokapron	Treatment of hereditary angioneurotic edema.	Pharmacia Inc. P.O. Box 16529 Columbus OH 43216 DD= 9/9/85 MA=
Transforming growth factor-beta 2 TN=	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Drive Santa Clara CA 95054 DD= 12/18/92 MA=
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Roslin, Edinburgh EH25 9PP Scotland GB DD= 3/6/98 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Roslin, Edinburgh EH25 9PP Scotland GB DD= 5/19/99 MA=
Trastuzumab TN=Herceptin	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc. 1 DNA Way South San Francisco CA DD= 12/14/99 MA=
Treosulfan TN=Ovastat	Treatment of ovarian cancer.	Medac GmbH Fehlandtstrasse 3 D-20354 Hamburg Germany DE DD= 5/16/94 MA=
Tretinoin TN=Atragen	Treatment of acute and chronic leukemia.	Aronex Pharmaceuticals, Inc. 8707 Technology Forest Place The Woodlands TX 77381-1191 DD= 1/14/93 MA=
Tretinoin TN=Vesanoid	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 10/24/90 MA= 11/22/95
Tretinoin TN=	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing 34 Sherrill Rd. Marshfield MA 02050 DD= 4/15/85 MA=
Trientine HCl TN=Syprine	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research Division Of Merck And Company West Point PA 19486 DD= 12/24/84 MA= 11/8/85
Trimetrexate TN=Neutrexin	Treatment of metastatic osteogenic sarcoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428 DD= 8/10/00 MA=
Trimetrexate glucuronate TN=	Treatment of pancreatic adenocarcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 7/25/85 MA=
Trimetrexate glucuronate TN=	Treatment of metastatic carcinoma of the head and neck (i.e. buccal cavity, pharynx, and larynx).	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 7/25/85 MA=
Trimetrexate glucuronate TN=	Treatment of patients with advanced non-small cell carcinoma of the lung.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 1/13/88 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Trimetrexate glucuronate TN=Neutrexin	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 5/15/86 MA= 12/17/93
Trimetrexate glucuronate TN=	Treatment of metastatic colorectal adenocarcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428 DD= 7/25/85 MA=
Triptorelin pamoate TN=Decapeptyl Injection	For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.	Debio R.A. Inc. 7929 Westpark Drive, Suite 400 Mclean VA 22102 DD= 8/10/90 MA=
Trisaccharides A and B TN=	Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives.	Chembiomed, Ltd. P.O. Box 8050, Edmonton, Alberta CA DD= 8/3/87 MA=
Trisaccharides A and B TN=Biosynject	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd. P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA DD= 4/12/87 MA=
Trisaccharides A and B TN=Biosynject	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd. P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA DD= 4/15/88 MA=
Trisaccharides A and B TN=Biosynject	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd. P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA DD= 4/20/87 MA=
Trisodium citrate concentration TN=Hemocitrate	For use in leukapheresis procedures.	Hemotec Medical Products, Inc. Box 19255 Johnston RI 02919 DD= 6/15/95 MA=
Troleandomycin TN=	Treatment of severe steroid-requiring asthma.	Szefler, Stanley M. M.D. National Jewish Center for 1400 Jackson Street Denver CO 80206 DD= 9/21/89 MA=
Tumor necrosis factor-binding protein 1 TN=	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 1/6/93 MA=
Tumor necrosis factor-binding protein TN=	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 1/6/93 MA=

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Tyloxapol TN=Supervent	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health 50 North Medical Drive, Room Salt Lake City UT 84132-0001 DD= 3/8/95 MA=
Ubiquinone TN=Ubiqgel	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon 30 New York Ave. PO Box 331 Westbury NY 11590 DD= 12/14/99 MA=
Uridine 5'-triphosphate TN=	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite Durham NC 27703 DD= 12/4/95 MA=
Uridine 5'-triphosphate TN=	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite Durham NC 27703 DD= 6/26/96 MA=
Urofollitropin TN=Fertinex	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 12/5/97 MA=
Urofollitropin TN=Metrodin	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061 DD= 11/25/87 MA= 9/18/86
Urogastrone TN=	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision 500 Iolab Drive Claremont CA 91711 DD= 11/1/84 MA=
Ursodiol TN=Actigall	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 2/19/91 MA=
Ursodiol TN=URSO	Treatment of patients with primary biliary cirrhosis.	Axcan Pharma Inc. 597 Laurier Blvd Mount St. Hilaire Quebec H7L Canada CA DD= 6/20/91 MA= 12/10/97
Valine, isoleucine and leucine TN=VIL	Treatment of hyperphenylalaninemia.	Leas Research Products 78 Fallon Drive North Haven CT 06473 DD= 1/5/96 MA=
Valrubicin TN=Valstar	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton NJ 08540 DD= 5/23/94 MA= 9/25/98

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vapreotide TN=Octastatin	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 3/6/00 MA=
Vapreotide TN=Octastatin	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
Vapreotide TN=Octastatin	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
Vasoactive intestinal polypeptide TN=	Treatment of acute esophageal food impaction.	Research Triangle 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280 DD= 6/23/93 MA=
Vigabatrin TN=Sabril	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627 Kansas City MO 64137 DD= 6/12/00 MA=
Viloxazine HCl TN=Catatrol	Treatment of cataplexy.	Stuart Pharmaceuticals Division of ICI Americas Wilmington DE 19897 DD= 6/11/84 MA=
Viloxazine HCl TN=Catatrol	Treatment of narcolepsy.	Stuart Pharmaceuticals Division of ICI Americas Wilmington DE 19897 DD= 6/11/84 MA=
Xenogeneic hepatocytes TN=HepatAssist Liver	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave. Lexington MA 02421-7995 DD= 11/27/98 MA=
Yttrium-90 radiolabeled humanized monoclonal TN=Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains NJ 07950 DD= 8/3/99 MA=
Zalcitabine TN=Hivid	Treatment of AIDS.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110 DD= 6/28/88 MA= 6/19/92
Zalcitabine TN=	Treatment of AIDS.	National Cancer Institute, DCT NIH, Executive Plaza North, Room Bethesda MD 20892 DD= 12/9/86 MA=
Zidovudine TN=Retrovir	Treatment of AIDS related complex.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 5/12/87 MA= 3/19/87

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2000

Name: **Generic Name** **TN=Trade Name**	**Indication Designated:**	**Sponsor & Address** **DD=Date Designated** **MA=Marketing Approval**
Zidovudine TN=Retrovir	Treatment of AIDS.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709 DD= 7/17/85 MA= 3/19/87
Zinc acetate TN=Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443 DD= 11/6/85 MA= 1/28/97
Zoledronate TN=Zometa, Zabel	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936-1080 DD= 8/18/00 MA=

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG; 40MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG; 40MG

ACETAMINOPHEN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

AMINOPHYLLINE
TABLET; ORAL
100MG
200MG

ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

ASPIRIN; CAFFEINE; CARISOPRODOL
TABLET; ORAL
160MG; 32MG; 200MG

ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
160MG; 32MG; 200MG; 16MG

ASPIRIN; CARISOPRODOL
TABLET; ORAL
325MG; 200MG

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
325MG; 200MG; 16MG

ASPIRIN; MEPROBAMATE
TABLET; ORAL
325MG; 200MG

ASPIRIN; METHOCARBAMOL
TABLET; ORAL
325MG; 400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG; 25MG;
50MG; 100MG

PREDNISONE
TABLET; ORAL
1MG; 2.5MG; 5MG; 10MG;
20MG; 25MG; 50MG

FDA data supplied by DrugPatentWatch.com

** 8 **

8-HOUR BAYER, ASPIRIN (OTC)
8-MOP, METHOXSALEN

** A **

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
A.P.L., GONADOTROPIN, CHORIONIC
A/T/S, ERYTHROMYCIN
ABELCET, AMPHOTERICIN B
ABITREXATE, METHOTREXATE SODIUM
ABREVA, DOCOSANOL (OTC)
ACCOLATE, ZAFIRLUKAST
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURBRON, THEOPHYLLINE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACCUTANE, ISOTRETINOIN
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ACILAC, LACTULOSE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACOVA, ARGATROBAN
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
ACTH, CORTICOTROPIN
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
ACTHAR, CORTICOTROPIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICORT, HYDROCORTISONE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ACTIGALL, URSODIOL
ACTIN-N, NITROFURAZONE
ACTINEX, MASOPROCOL
ACTIQ, FENTANYL CITRATE
ACTISITE, TETRACYCLINE HYDROCHLORIDE
ACTIVELLE, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACTRON, KETOPROFEN (OTC)
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUTECT, TECHNETIUM TC-99M APCITIDE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR, ACYCLOVIR SODIUM
ACYLANID, ACETYLDIGITOXIN
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE

FDA data supplied by DrugPatentWatch.com

ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADPHEN, PHENDIMETRAZINE TARTRATE
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL, IBUPROFEN (OTC)
AEROBID, FLUNISOLIDE
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
AEROSPORIN, POLYMYXIN B SULFATE
AFAXIN, VITAMIN A PALMITATE
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGENERASE, AMPRENAVIR
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKRINOL, ACRISORCIN
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBAMYCIN, NOVOBIOCIN SODIUM
ALBENZA, ALBENDAZOLE
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% IN D5-W, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALESSE, ETHINYL ESTRADIOL
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALKERGOT, ERGOLOID MESYLATES
ALLAY, ACETAMINOPHEN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALPHA CHYMAR, CHYMOTRYPSIN
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE
ALPHADERM, HYDROCORTISONE
ALPHADROL, FLUPREDNISOLONE
ALPHAGAN, BRIMONIDINE TARTRATE
ALPHALIN, VITAMIN A PALMITATE
ALPHAREDISOL, HYDROXOCOBALAMIN
ALPHATREX, BETAMETHASONE DIPROPIONATE
ALPHAZINE, PHENDIMETRAZINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTACE, RAMIPRIL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)
ALUPENT, METAPROTERENOL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMEN, MEDROXYPROGESTERONE ACETATE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLIN, AMINOPHYLLINE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMIPAQUE, METRIZAMIDE
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED

FDA data supplied by DrugPatentWatch.com

AMOSENE, MEPROBAMATE
AMOXAPINE, AMOXAPINE
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHICOL, CHLORAMPHENICOL
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRINONE, INAMRINONE LACTATE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 10/660, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGIO-CONRAY, IOTHALAMATE SODIUM
ANGIOMAX, BIVALIRUDIN
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
ANHYDRON, CYCLOTHIAZIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
ANOQUAN, ACETAMINOPHEN
ANSAID, FLURBIPROFEN
ANSOLYSEN, PENTOLINIUM TARTRATE
ANSPOR, CEPHRADINE
ANTABUSE, DISULFIRAM
ANTAGON, GANIRELIX ACETATE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
ANTEPAR, PIPERAZINE CITRATE
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
APHTHASOL, AMLEXANOX
APOGEN, GENTAMICIN SULFATE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AQUAMEPHYTON, PHYTONADIONE
AQUAPHYLLIN, THEOPHYLLINE
AQUASOL A, VITAMIN A
AQUASOL A, VITAMIN A PALMITATE
AQUATAG, BENZTHIAZIDE
AQUATENSEN, METHYCLOTHIAZIDE
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
ARAMINE, METARAMINOL BITARTRATE
ARAVA, LEFLUNOMIDE
ARDUAN, PIPECURONIUM BROMIDE
AREDIA, PAMIDRONATE DISODIUM
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ARFONAD, TRIMETHAPHAN CAMSYLATE
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
AROMASIN, EXEMESTANE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL, MESALAMINE
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
ASENDIN, AMOXAPINE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATARAX, HYDROXYZINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL

FDA data supplied by DrugPatentWatch.com

ATENOLOL, ATENOLOL
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRIDOX, DOXYCYCLINE HYCLATE
ATROMID-S, CLOFIBRATE
ATROPEN, ATROPINE
ATROPINE AND DEMEROL, ATROPINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE, ATROPINE
ATROVENT, IPRATROPIUM BROMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AVITA, TRETINOIN
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXOTAL, ASPIRIN
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE, AZATHIOPRINE SODIUM
AZDONE, ASPIRIN
AZELEX, AZELAIC ACID
AZLIN, AZLOCILLIN SODIUM
AZMACORT, TRIAMCINOLONE ACETONIDE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
AZOLID, PHENYLBUTAZONE
AZOPT, BRINZOLAMIDE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
DISULFIRAM, DISULFIRAM

** B **

BACI-RX, BACITRACIN
BACIGUENT, BACITRACIN
BACIIM, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN
BACITRACIN, BACITRACIN (OTC)
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTOCILL, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALNEOL-HC, HYDROCORTISONE
BAMATE, MEPROBAMATE
BANAN, CEFPODOXIME PROXETIL
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
BANTHINE, METHANTHELINE BROMIDE
BAROS, SODIUM BICARBONATE
BARSTATIN 100, NYSTATIN
BAYCOL, CERIVASTATIN SODIUM
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENDOPA, LEVODOPA
BENEMID, PROBENECID
BENOQUIN, MONOBENZONE
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
BENSULFOID, SULFUR
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE

FDA data supplied by DrugPatentWatch.com

BENZONATATE, BENZONATATE
BENZTHIAZIDE, BENZTHIAZIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BENZYL BENZOATE, BENZYL BENZOATE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BERUBIGEN, CYANOCOBALAMIN
BETA-2, ISOETHARINE HYDROCHLORIDE
BETA-HC, HYDROCORTISONE
BETA-VAL, BETAMETHASONE VALERATE
BETADERM, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPAR, MEPREDNISONE
BETAPEN-VK, PENICILLIN V POTASSIUM
BETAPRONE, PROPIOLACTONE
BETATREX, BETAMETHASONE VALERATE
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETIMOL, TIMOLOL
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BILIVIST, IPODATE SODIUM
BILOPAQUE, TYROPANOATE SODIUM
BILTRICIDE, PRAZIQUANTEL
BIO-TROPIN, SOMATROPIN RECOMBINANT
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
BIPHETAP, BROMPHENIRAMINE MALEATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLENOXANE, BLEOMYCIN SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BLOCADREN, TIMOLOL MALEATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BOROFAIR, ACETIC ACID, GLACIAL
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BRETYLOL, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRICANYL, TERBUTALINE SULFATE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
BRONKAID MIST, EPINEPHRINE (OTC)
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUCET, ACETAMINOPHEN
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPAR, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTABARB, BUTABARBITAL SODIUM
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTABARBITAL, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
BUTALAN, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL COMPOUND, ASPIRIN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTAZOLIDIN, PHENYLBUTAZONE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

** C **

C-SOLVE-2, ERYTHROMYCIN
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CALAN, VERAPAMIL HYDROCHLORIDE
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
CALCIJEX, CALCITRIOL
CALCIMAR, CALCITONIN, SALMON
CALCIPARINE, HEPARIN CALCIUM
CALCITONIN-SALMON, CALCITONIN, SALMON
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CALDEROL, CALCIFEDIOL
CALMURID HC, HYDROCORTISONE
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANDEX, NYSTATIN
CANTIL, MEPENZOLATE BROMIDE
CAP-PROFEN, IBUPROFEN (OTC)
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL WITH CODEINE, ACETAMINOPHEN
CAPITROL, CHLOROXINE
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARAFATE, SUCRALFATE
CARBACHOL, CARBACHOL
CARBAMAZEPINE, CARBAMAZEPINE
CARBASTAT, CARBACHOL
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR, LEVOCARNITINE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CATARASE, CHYMOTRYPSIN
CAVERJECT, ALPROSTADIL
CECLOR CD, CEFACLOR

FDA data supplied by DrugPatentWatch.com

CECLOR, CEFACLOR
CEDAX, CEFTIBUTEN DIHYDRATE
CEDILANID-D, DESLANOSIDE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFMAX, CEFMENOXIME HYDROCHLORIDE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEFTIN, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEFZIL, CEFPROZIL
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTRAX, PRAZEPAM
CEPHALEXIN, CEPHALEXIN
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CEPHRADINE, CEPHRADINE
CEPHULAC, LACTULOSE
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CERADON, CEFOTIAM HYDROCHLORIDE
CEREBYX, FOSPHENYTOIN SODIUM
CEREDASE, ALGLUCERASE
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERNEVIT-12, ALPHA-TOCOPHEROL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETACORT, HYDROCORTISONE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CETROTIDE, CETRORELIX
CHEMET, SUCCIMER
CHENIX, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHIBROXIN, NORFLOXACIN
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHLOROFAIR, CHLORAMPHENICOL
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROMYXIN, CHLORAMPHENICOL
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLOROTRIANISENE, CHLOROTRIANISENE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEBRINE, IOCETAMIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHOLYBAR, CHOLESTYRAMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CHRONULAC, LACTULOSE
CHYMEX, BENTIROMIDE
CHYMODIACTIN, CHYMOPAPAIN
CIBACALCIN, CALCITONIN HUMAN
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIN-QUIN, QUINIDINE SULFATE
CINNASIL, RESCINNAMINE
CINOBAC, CINOXACIN
CINOXACIN, CINOXACIN
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIRCANOL, ERGOLOID MESYLATES
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISPLATIN, CISPLATIN
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARITIN REDITABS, LORATADINE
CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
CLARITIN-D, LORATADINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLISTIN, CARBINOXAMINE MALEATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFIBRATE, CLOFIBRATE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CLOXAPEN, CLOXACILLIN SODIUM
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
CO-GESIC, ACETAMINOPHEN
CO-LAV, POLYETHYLENE GLYCOL 3350
COACTIN, AMDINOCILLIN
COBAVITE, CYANOCOBALAMIN
CODAMINE, HYDROCODONE BITARTRATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
CODOXY, ASPIRIN
COGENTIN, BENZTROPINE MESYLATE
COGNEX, TACRINE HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLBENEMID, COLCHICINE
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
COLESTID, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLONAID, ATROPINE SULFATE
COLOVAGE, POLYETHYLENE GLYCOL 3350
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIPATCH, ESTRADIOL
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
COMPOUND 65, ASPIRIN
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCENTRAID, DESMOPRESSIN ACETATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
COPAXONE, GLATIRAMER ACETATE
COPPER T MODEL TCU 380A, COPPER
COR-OTICIN, HYDROCORTISONE ACETATE
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN-N, FLURANDRENOLIDE
COREG, CARVEDILOL

FDA data supplied by DrugPatentWatch.com

CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
CORT-DOME, HYDROCORTISONE
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTENEMA, HYDROCORTISONE
CORTICOTROPIN, CORTICOTROPIN
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTONE, CORTISONE ACETATE
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COTAZYM, LIPASE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRESCORMON, SOMATROPIN
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOPTIC, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSTODIGIN, DIGITOXIN
CU-7, COPPER
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALPHA
CURRETAB, MEDROXYPROGESTERONE ACETATE
CUTIVATE, FLUTICASONE PROPIONATE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLACILLIN, CYCLACILLIN
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
CYCLAPEN-W, CYCLACILLIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOCORT, AMCINONIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYCRIN, MEDROXYPROGESTERONE ACETATE
CYKLOKAPRON, TRANEXAMIC ACID
CYLERT, PEMOLINE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE, ANHYDROUS
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYTADREN, AMINOGLUTETHIMIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTRIX (T4;T3)
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
CYTOXAN, CYCLOPHOSPHAMIDE

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DALGAN, DEZOCINE
DALMANE, FLURAZEPAM HYDROCHLORIDE
DANAZOL, DANAZOL
DANOCRINE, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARANIDE, DICHLORPHENAMIDE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEAPRIL-ST, ERGOLOID MESYLATES
DECA-DURABOLIN, NANDROLONE DECANOATE
DECABID, INDECAINIDE HYDROCHLORIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON-LA, DEXAMETHASONE ACETATE
DECAPRYN, DOXYLAMINE SUCCINATE
DECASPRAY, DEXAMETHASONE
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DEL-VI-A, VITAMIN A PALMITATE
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DELATESTRYL, TESTOSTERONE ENANTHATE
DELAXIN, METHOCARBAMOL
DELCOBESE, AMPHETAMINE ADIPATE
DELESTROGEN, ESTRADIOL VALERATE
DELFEN, NONOXYNOL-9 (OTC)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELTA-CORTEF, PREDNISOLONE
DELTA-DOME, PREDNISONE
DELTALIN, ERGOCALCIFEROL
DELTASONE, PREDNISONE
DEMADEX, TORSEMIDE
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMI-REGROTON, CHLORTHALIDONE
DEMSER, METYROSINE
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DENAVIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPINAR, CYANOCOBALAMIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMACORT, HYDROCORTISONE
DERMATOP, PREDNICARBATE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESYREL, TRAZODONE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
DEXACIDIN, DEXAMETHASONE
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
DHC PLUS, ACETAMINOPHEN
DI-ATRO, ATROPINE SULFATE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAL, HEXACHLOROPHENE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAPID, LYPRESSIN
DIASONE SODIUM, SULFOXONE SODIUM
DIASTAT, DIAZEPAM
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE

FDA data supplied by DrugPatentWatch.com

DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICOPAC KIT, CYANOCOBALAMIN
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIENESTROL, DIENESTROL
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DIFFERIN, ADAPALENE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISCASE, CHYMOPAPAIN
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISODIUM EDETATE, EDETATE DISODIUM
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITATE-DS, ESTRADIOL VALERATE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
DIULO, METOLAZONE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIUTENSEN-R, METHYCLOTHIAZIDE
DIZAC, DIAZEPAM
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DOCA, DESOXYCORTICOSTERONE ACETATE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOLOBID, DIFLUNISAL
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
DOMEBORO, ACETIC ACID, GLACIAL
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOPAR, LEVODOPA
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIDEN, GLUTETHIMIDE
DORMATE, MEBUTAMATE
DORYX, DOXYCYCLINE HYCLATE

FDA data supplied by DrugPatentWatch.com

DOSTINEX, CABERGOLINE
DOVONEX, CALCIPOTRIENE
DOW-ISONIAZID, ISONIAZID
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRALSERP, HYDRALAZINE HYDROCHLORIDE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
DRICORT, HYDROCORTISONE ACETATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIZE, CHLORPHENIRAMINE MALEATE
DROLBAN, DROMOSTANOLONE PROPIONATE
DROPERIDOL, DROPERIDOL
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
DUPHALAC, LACTULOSE
DURABOLIN, NANDROLONE PHENPROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
DURACLON, CLONIDINE HYDROCHLORIDE
DURADYNE DHC, ACETAMINOPHEN
DURAGESIC, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DURAPHYL, THEOPHYLLINE
DURAQUIN, QUINIDINE GLUCONATE
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DUVOID, BETHANECHOL CHLORIDE
DV, DIENESTROL
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
DYCLONE, DYCLONINE HYDROCHLORIDE
DYMELOR, ACETOHEXAMIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNABAC, DIRITHROMYCIN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
DYNAPEN, DICLOXACILLIN SODIUM
DYRENIUM, TRIAMTERENE

** E **

E-BASE, ERYTHROMYCIN
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
E-MYCIN, ERYTHROMYCIN
E-SOLVE 2, ERYTHROMYCIN
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED PLUS, PREDNISOLONE ACETATE
ECONOPRED, PREDNISOLONE ACETATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE DISODIUM, EDETATE DISODIUM
EDEX, ALPROSTADIL
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
EFUDEX, FLUOROURACIL
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
ELDECORT, HYDROCORTISONE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELIMITE, PERMETHRIN
ELIXICON, THEOPHYLLINE
ELIXOMIN, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM

FDA data supplied by DrugPatentWatch.com

ELOCON, MOMETASONE FUROATE
EMADINE, EMEDASTINE DIFUMARATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
EMGEL, ERYTHROMYCIN
EMLA, LIDOCAINE
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ENFLURANE, ENFLURANE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
ENULOSE, LACTULOSE
EPI E Z PEN JR, EPINEPHRINE
EPICORT, HYDROCORTISONE
EPIFOAM, HYDROCORTISONE ACETATE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EQUAGESIC, ASPIRIN
EQUANIL, MEPROBAMATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
ERCATAB, CAFFEINE
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERY-TAB, ERYTHROMYCIN
ERYC 125, ERYTHROMYCIN
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYCETTE, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
ESCLIM, ESTRADIOL
ESGIC, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
ESTAZOLAM, ESTAZOLAM
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ESTINYL, ETHINYL ESTRADIOL
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
ESTRING, ESTRADIOL
ESTROGENIC SUBSTANCE, ESTRONE
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
ESTROVIS, QUINESTROL
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
ETHAMIDE, ETHOXZOLAMIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHIODOL, ETHIODIZED OIL
ETHMOZINE, MORICIZINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

ETOPOSIDE, ETOPOSIDE
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
EURAX, CROTAMITON
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
EVALOSE, LACTULOSE
EVANS BLUE, EVANS BLUE
EVEX, ESTROGENS, ESTERIFIED
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE TARTRATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXNA, BENZTHIAZIDE
EXOSURF NEONATAL, CETYL ALCOHOL
EXSEL, SELENIUM SULFIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)
VIVELLE-DOT, ESTRADIOL

** F **

FACTREL, GONADORELIN HYDROCHLORIDE
FAMVIR, FAMCICLOVIR
FANSIDAR, PYRIMETHAMINE
FARESTON, TOREMIFENE CITRATE
FASTIN, PHENTERMINE HYDROCHLORIDE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FEMARA, LETROZOLE
FEMCET, ACETAMINOPHEN
FEMHRT, ETHINYL ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FEMOGEN, ESTROGENS, ESTERIFIED
FEMPATCH, ESTRADIOL
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT ONE, BUTOCONAZOLE NITRATE
FEMSTAT, BUTOCONAZOLE NITRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE
FERIDEX I.V., FERUMOXIDES
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
FERRISELTZ, FERRIC AMMONIUM CITRATE
FERRLECIT, FERRIC SODIUM GLUCONATE
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FERTINEX, UROFOLLITROPIN
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAXEDIL, GALLAMINE TRIETHIODIDE
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLEXICORT, HYDROCORTISONE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLORINEF, FLUDROCORTISONE ACETATE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLOROPRYL, ISOFLUROPHATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUDARA, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18
FLUIDIL, CYCLOTHIAZIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOR-OP, FLUOROMETHOLONE
FLUORINE F-18, SODIUM FLUORIDE, F-18
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOTHANE, HALOTHANE
FLUOTREX, FLUOCINOLONE ACETONIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE, FLUPHENAZINE DECANOATE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOAMICON, ALUMINUM HYDROXIDE (OTC)
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FOLIC ACID, FOLIC ACID
FOLICET, FOLIC ACID
FOLLISTIM, FOLLITROPIN ALFA/BETA
FOLLUTEIN, GONADOTROPIN, CHORIONIC
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FORANE, ISOFLURANE
FORBAXIN, METHOCARBAMOL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTOVASE, SAQUINAVIR
FOSAMAX, ALENDRONATE SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOVANE, BENZTHIAZIDE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FS SHAMPOO, FLUOCINOLONE ACETONIDE
FUDR, FLOXURIDINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
FUNGIZONE, AMPHOTERICIN B
FURACIN, NITROFURAZONE
FURADANTIN, NITROFURANTOIN
FURALAN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUROXONE, FURAZOLIDONE

** G **

GABITRIL, TIAGABINE HYDROCHLORIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
GALZIN, ZINC ACETATE
GAMENE, LINDANE
GAMOPHEN, HEXACHLOROPHENE
GANITE, GALLIUM NITRATE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
GARAMYCIN, GENTAMICIN SULFATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GASTROMARK, FERUMOXSIL
GASTROVIST, DIATRIZOATE MEGLUMINE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GEMONIL, METHARBITAL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENAPAX, GENTIAN VIOLET
GENCEPT 0.5/35-21, ETHINYL ESTRADIOL
GENCEPT 0.5/35-28, ETHINYL ESTRADIOL
GENCEPT 1/35-21, ETHINYL ESTRADIOL
GENCEPT 1/35-28, ETHINYL ESTRADIOL
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
GENERLAC, LACTULOSE
GENESA, ARBUTAMINE HYDROCHLORIDE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GENTACIDIN, GENTAMICIN SULFATE
GENTAFAIR, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN, GENTAMICIN SULFATE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
GEOPEN, CARBENICILLIN DISODIUM
GEREF, SERMORELIN ACETATE
GERIMAL, ERGOLOID MESYLATES
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
GLIADEL, CARMUSTINE
GLIPIZIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPREP, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYCORT, HYDROCORTISONE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GO-EVAC, POLYETHYLENE GLYCOL 3350
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
GVS, GENTIAN VIOLET
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
GYNIX, CLOTRIMAZOLE (OTC)
GYNODIOL, ESTRADIOL
GYNOREST, DYDROGESTERONE

** H **

H-CORT, HYDROCORTISONE
H.P. ACTHAR GEL, CORTICOTROPIN
H.R.-50, HYDROCHLOROTHIAZIDE
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
HALCION, TRIAZOLAM
HALDOL SOLUTAB, HALOPERIDOL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALDRONE, PARAMETHASONE ACETATE
HALFAN, HALOFANTRINE HYDROCHLORIDE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOTESTIN, FLUOXYMESTERONE
HALOTEX, HALOPROGIN
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HECTOROL, DOXERCALCIFEROL
HEDULIN, PHENINDIONE
HELICOSOL, UREA, C-13
HELIDAC, BISMUTH SUBSALICYLATE
HEMABATE, CARBOPROST TROMETHAMINE
HEMSOL-HC, HYDROCORTISONE ACETATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN

FDA data supplied by DrugPatentWatch.com

PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATASOL 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPFLUSH-10, HEPARIN SODIUM
HEPTALAC, LACTULOSE
HERPLEX, IDOXURIDINE
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HEXA-GERM, HEXACHLOROPHENE
HEXABRIX, IOXAGLATE MEGLUMINE
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HEXALEN, ALTRETAMINE
HEXASCRUB, HEXACHLOROPHENE
HI-COR, HYDROCORTISONE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
HIPREX, METHENAMINE HIPPURATE
HISERPIA, RESERPINE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HIVID, ZALCITABINE
HIWOLFIA, RAUWOLFIA SERPENTINA
HMS, MEDRYSONE
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATIN, PAROMOMYCIN SULFATE
HUMATROPE, SOMATROPIN RECOMBINANT
HUMEGON, MENOTROPINS (FSH;LH)
HUMORSOL, DEMECARIUM BROMIDE
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
HY-PAM "25", HYDROXYZINE PAMOATE
HY-PHEN, ACETAMINOPHEN
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCET, ACETAMINOPHEN
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXOMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
HYGROTON, CHLORTHALIDONE
HYLOREL, GUANADREL SULFATE
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
HYPERSTAT, DIAZOXIDE
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
HYSERPIN, RAUWOLFIA SERPENTINA
HYTONE, HYDROCORTISONE
HYTRIN, TERAZOSIN HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
HYZYD, ISONIAZID

** I **

IBRIN, FIBRINOGEN, I-125
IBU, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
IMAGENT, PERFLUBRON
IMDUR, ISOSORBIDE MONONITRATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMURAN, AZATHIOPRINE

FDA data supplied by DrugPatentWatch.com

IMURAN, AZATHIOPRINE SODIUM
INAPSINE, DROPERIDOL
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDO-LEMMON, INDOMETHACIN
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
INDOMETHEGAN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
INFUMORPH, MORPHINE SULFATE
INH, ISONIAZID
INJECTAPAP, ACETAMINOPHEN
INNOFEM, ESTRADIOL
INNOHEP, TINZAPARIN SODIUM
INNOVAR, DROPERIDOL
INOCOR, INAMRINONE LACTATE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
INTAL, CROMOLYN SODIUM
INTEGRILIN, EPTIFIBATIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROPIN, DOPAMINE HYDROCHLORIDE
INULIN AND SODIUM CHLORIDE, INULIN
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
INVERSINE, MECAMYLAMINE HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
IONAMIN, PHENTERMINE RESIN COMPLEX
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONTOCAINE, EPINEPHRINE
IOPAMIDOL, IOPAMIDOL
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRON DEXTRAN, IRON DEXTRAN
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISMELIN, GUANETHIDINE MONOSULFATE
ISMO, ISOSORBIDE MONONITRATE
ISMOTIC, ISOSORBIDE
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISONIAZID, ISONIAZID
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
IVADANTIN, NITROFURANTOIN SODIUM
IVY BLOCK, BENTOQUATAM (OTC)

** J **

JANIMINE, IMIPRAMINE HYDROCHLORIDE
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

** K **

K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
K-LEASE, POTASSIUM CHLORIDE
K-TAB, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KAFOCIN, CEPHALOGLYCIN
KAINAIR, PROPARACAINE HYDROCHLORIDE
KALETRA, LOPINAVIR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KANTREX, KANAMYCIN SULFATE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLEBCIL, KANAMYCIN SULFATE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KLOROMIN, CHLORPHENIRAMINE MALEATE
KLOTRIX, POTASSIUM CHLORIDE
KOGLUCOID, RAUWOLFIA SERPENTINA
KONAKION, PHYTONADIONE
KOROSTATIN, NYSTATIN
KWELL, LINDANE
KYTRIL, GRANISETRON HYDROCHLORIDE

** L **

LABETALOL HCL, LABETALOL HYDROCHLORIDE
LABID, THEOPHYLLINE
LAC-HYDRIN, AMMONIUM LACTATE

FDA data supplied by DrugPatentWatch.com

LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMPRENE, CLOFAZIMINE
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANOXICAPS, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
LANTUS, INSULIN GLARGINE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LAXILOSE, LACTULOSE
LEDERCILLIN VK, PENICILLIN V POTASSIUM
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVLITE, ETHINYL ESTRADIOL
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVOPROME, METHOTRIMEPRAZINE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXXEL, ENALAPRIL MALEATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)

FDA data supplied by DrugPatentWatch.com

LIPIDIL, FENOFIBRATE
LIPITOR, ATORVASTATIN CALCIUM
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LIPO-HEPIN, HEPARIN SODIUM
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LIQUID PRED, PREDNISONE
LITHANE, LITHIUM CARBONATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LITHOTABS, LITHIUM CARBONATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LOCORTEN, FLUMETHASONE PIVALATE
LODINE XL, ETODOLAC
LODINE, ETODOLAC
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOFENE, ATROPINE SULFATE
LOGEN, ATROPINE SULFATE
LOMANATE, ATROPINE SULFATE
LOMOTIL, ATROPINE SULFATE
LONITEN, MINOXIDIL
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORABID, LORACARBEF
LORAZ, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORCET-HD, ACETAMINOPHEN
LORELCO, PROBUCOL
LORFAN, LEVALLORPHAN TARTRATE
LORTAB, ACETAMINOPHEN
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN AF, CLOTRIMAZOLE (OTC)
LOTRIMIN, CLOTRIMAZOLE
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOTUSATE, TALBUTAL
LOVENOX, ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOW-QUEL, ATROPINE SULFATE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
LOZOL, INDAPAMIDE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
LUNELLE, ESTRADIOL CYPIONATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
LYMPHAZURIN, ISOSULFAN BLUE
LYNORAL, ETHINYL ESTRADIOL
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
LYSODREN, MITOTANE

** M **

M-PREDROL, METHYLPREDNISOLONE ACETATE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

FDA data supplied by DrugPatentWatch.com

M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
M.V.C. 9+3, ASCORBIC ACID
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MANDOL, CEFAMANDOLE NAFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
MAOLATE, CHLORPHENESIN CARBAMATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MAREZINE, CYCLIZINE LACTATE
MARINOL, DRONABINOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
MAXIBOLIN, ETHYLESTRENOL
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MAXITROL, DEXAMETHASONE
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAZANOR, MAZINDOL
MD-50, DIATRIZOATE SODIUM
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEASURIN, ASPIRIN (OTC)
MEBENDAZOLE, MEBENDAZOLE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLODIUM, MECLOFENAMATE SODIUM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MECLOMEN, MECLOFENAMATE SODIUM
MEDIGESIC PLUS, ACETAMINOPHEN
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
MEDIPREN, IBUPROFEN (OTC)
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MENADIONE, MENADIONE
MENEST, ESTROGENS, ESTERIFIED
MENOTROPINS, MENOTROPINS (FSH;LH)
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE

FDA data supplied by DrugPatentWatch.com

MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MEPRIAM, MEPROBAMATE
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE AND ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MEPROSPAN, MEPROBAMATE
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
MERREM I.V., MEROPENEM
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
MESANTOIN, MEPHENYTOIN
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAHYDRIN, TRICHLORMETHIAZIDE
METANDREN, METHYLTESTOSTERONE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE, SR-89
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
METOPIRONE, METYRAPONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRA, PHENDIMETRAZINE TARTRATE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METRODIN, UROFOLLITROPIN
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METROMIDOL, METRONIDAZOLE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METUBINE IODIDE, METOCURINE IODIDE
MEVACOR, LOVASTATIN
MEXATE, METHOTREXATE SODIUM
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MEXATE-AQ, METHOTREXATE SODIUM
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MEXITIL, MEXILETINE HYDROCHLORIDE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MIACALCIN, CALCITONIN, SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICRAININ, ASPIRIN
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
MICRONASE, GLYBURIDE
MICRONOR, NORETHINDRONE
MICROSUL, SULFAMETHIZOLE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MIDOL, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILONTIN, PHENSUXIMIDE
MILOPHENE, CLOMIPHENE CITRATE
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
MINITRAN, NITROGLYCERIN
MINIZIDE, POLYTHIAZIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINODYL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINTEZOL, THIABENDAZOLE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRADON, ANISINDIONE
MIRALAX, POLYETHYLENE GLYCOL 3350
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MITHRACIN, PLICAMYCIN
MITOMYCIN, MITOMYCIN
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MIXTARD HUMAN 70/30, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
MOBAN, MOLINDONE HYDROCHLORIDE
MOBIC, MELOXICAM
MOCTANIN, MONOCTANOIN
MODERIL, RESCINNAMINE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MODRASTANE, TRILOSTANE
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT DUAL- PAK, MICONAZOLE NITRATE
MONISTAT, MICONAZOLE
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-DERM, MICONAZOLE NITRATE
MONOCID, CEFONICID SODIUM
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONOPRIL, FOSINOPRIL SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
MOXAM, MOXALACTAM DISODIUM
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MS CONTIN, MORPHINE SULFATE
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE
MUCOMYST, ACETYLCYSTEINE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE
MULTI-12, ALPHA-TOCOPHEROL ACETATE
MULTIFUGE, PIPERAZINE CITRATE
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MUTAMYCIN, MITOMYCIN
MVC PLUS, ASCORBIC ACID
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
MYCHEL, CHLORAMPHENICOL
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCO-TRIACET II, NYSTATIN
MYCOBUTIN, RIFABUTIN
MYCODONE, HOMATROPINE METHYLBROMIDE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
MYDRIACYL, TROPICAMIDE
MYDRIAFAIR, TROPICAMIDE
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYKACET, NYSTATIN
MYKINAC, NYSTATIN

FDA data supplied by DrugPatentWatch.com

MYKROX, METOLAZONE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
MYLERAN, BUSULFAN
MYLOTARG, GEMTUZUMAB OZOGAMICIN
MYMETHASONE, DEXAMETHASONE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
MYOTONACHOL, BETHANECHOL CHLORIDE
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
MYSOLINE, PRIMIDONE
MYTELASE, AMBENONIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN

** N **

N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
NALIDIXIC ACID, NALIDIXIC ACID
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALLPEN, NAFCILLIN SODIUM
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NASALCROM, CROMOLYN SODIUM (OTC)
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
NAVELBINE, VINORELBINE TARTRATE
NEBCIN, TOBRAMYCIN SULFATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEGGRAM, NALIDIXIC ACID
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEO-OTOSOL-HC, HYDROCORTISONE
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
NEO-RX, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOBIOTIC, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPASALATE, AMINOSALICYLATE SODIUM
NEOPHAM 6.4%, AMINO ACIDS
NEORAL, CYCLOSPORINE
NEOSAR, CYCLOPHOSPHAMIDE
NEOSCAN, GALLIUM CITRATE, GA-67
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NEOTHYLLINE, DYPHYLLINE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NEPHRAMINE 5.4%, AMINO ACIDS
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
NEPTAZANE, METHAZOLAMIDE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NETROMYCIN, NETILMICIN SULFATE
NEURAMATE, MEPROBAMATE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEUTREXIN, TRIMETREXATE GLUCURONATE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NICLOCIDE, NICLOSAMIDE
NICODERM CQ, NICOTINE (OTC)
NICOLAR, NIACIN
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMOTOP, NIMODIPINE
NIPENT, PENTOSTATIN
NIPRIDE, SODIUM NITROPRUSSIDE
NITRO IV, NITROGLYCERIN
NITRO-BID, NITROGLYCERIN
NITRO-DUR, NITROGLYCERIN
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURAZONE, NITROFURAZONE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROL, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN
NIX, PERMETHRIN (OTC)
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NOGENIC HC, HYDROCORTISONE
NOLUDAR, METHYPRYLON
NOLVADEX, TAMOXIFEN CITRATE
NOR-QD, NORETHINDRONE
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL
NORCET, ACETAMINOPHEN
NORCO, ACETAMINOPHEN
NORCURON, VECURONIUM BROMIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN, SOMATROPIN RECOMBINANT
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORITATE, METRONIDAZOLE

FDA data supplied by DrugPatentWatch.com

NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
NORMIFLO, ARDEPARIN SODIUM
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPLANT II, LEVONORGESTREL
NORPLANT SYSTEM, LEVONORGESTREL
NORPLANT, LEVONORGESTREL
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORQUEST FE, ETHINYL ESTRADIOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
NOVOCAIN, PROCAINE HYDROCHLORIDE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NUBAIN, NALBUPHINE HYDROCHLORIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
NUPRIN, IBUPROFEN (OTC)
NUROMAX, DOXACURIUM CHLORIDE
NUTRACORT, HYDROCORTISONE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
NYDRAZID, ISONIAZID
NYSERT, NYSTATIN
NYSTAFORM, CLIOQUINOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTEX, NYSTATIN
NYSTOP, NYSTATIN

** O **

OBESTIN-30, PHENTERMINE HYDROCHLORIDE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
OCL, POLYETHYLENE GLYCOL 3350
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUMYCIN, BACITRACIN ZINC
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLUX FOAM, CLOBETASOL PROPIONATE
OMNICEF, CEFDINIR
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM

FDA data supplied by DrugPatentWatch.com

OMNISCAN, GADODIAMIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
ONCOVIN, VINCRISTINE SULFATE
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIMINE, AZATADINE MALEATE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
OPTOMYCIN, CHLORAMPHENICOL
ORA-TESTRYL, FLUOXYMESTERONE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACORT, TRIAMCINOLONE ACETONIDE
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
ORALONE, TRIAMCINOLONE ACETONIDE
ORAMORPH SR, MORPHINE SULFATE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORASONE, PREDNISONE
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
ORNADE, CHLORPHENIRAMINE MALEATE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-NOVUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORTHO-PREFEST, ESTRADIOL
ORUDIS KT, KETOPROFEN (OTC)
ORUDIS, KETOPROFEN
ORUVAIL, KETOPROFEN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OTICAIR, HYDROCORTISONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
OTOCORT, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXANDRIN, OXANDROLONE
OXAZEPAM, OXAZEPAM
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

FDA data supplied by DrugPatentWatch.com

OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYLONE, FLUOROMETHOLONE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN, OXYTOCIN

** P **

P.A.S. SODIUM, AMINOSALICYLATE SODIUM
PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAGITANE, CYCRIMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMINE, METHSCOPOLAMINE BROMIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANCURONIUM, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANHEPRIN, HEPARIN SODIUM
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PANRETIN, ALITRETINOIN
PANTOPAQUE, IOPHENDYLATE
PANWARFIN, WARFARIN SODIUM
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PARACAINE, PROPARACAINE HYDROCHLORIDE
PARACORT, PREDNISONE
PARADIONE, PARAMETHADIONE
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PARAPLATIN, CARBOPLATIN
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PARATHAR, TERIPARATIDE ACETATE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PASKALIUM, POTASSIUM AMINOSALICYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PATHILON, TRIDIHEXETHYL CHLORIDE
PATHOCIL, DICLOXACILLIN SODIUM
PAVULON, PANCURONIUM BROMIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIPAM, HALAZEPAM
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
PEDIOTIC, HYDROCORTISONE
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PEMOLINE, PEMOLINE
PEN-VEE K, PENICILLIN V POTASSIUM
PENAPAR-VK, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENECORT, HYDROCORTISONE
PENETREX, ENOXACIN
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
PENTACARINAT, PENTAMIDINE ISETHIONATE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PENTHRANE, METHOXYFLURANE
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM

FDA data supplied by DrugPatentWatch.com

PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOTHAL, THIOPENTAL SODIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PEPTAVLON, PENTAGASTRIN
PERCHLORACAP, POTASSIUM PERCHLORATE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PERGONAL, MENOTROPINS (FSH;LH)
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMAX, PERGOLIDE MESYLATE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
PHENAZINE, PHENDIMETRAZINE TARTRATE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENURONE, PHENACEMIDE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PHENYTOIN, PHENYTOIN
PHENYTOIN, PHENYTOIN SODIUM
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PHOSLO, CALCIUM ACETATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN
PHYLLOCONTIN, AMINOPHYLLINE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDAC, PINACIDIL
PINDOLOL, PINDOLOL
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PIPRACIL, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PITRESSIN TANNATE, VASOPRESSIN TANNATE
PLACIDYL, ETHCHLORVYNOL
PLAN B, LEVONORGESTREL
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
PLAVIX, CLOPIDOGREL BISULFATE
PLEGINE, PHENDIMETRAZINE TARTRATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYSPORIN, BACITRACIN ZINC
POLYSPORIN, BACITRACIN ZINC (OTC)
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTALAC, LACTULOSE
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVAN, PYRVINIUM PAMOATE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE
PRANTAL, DIPHEMANIL METHYLSULFATE
PRAVACHOL, PRAVASTATIN SODIUM
PRAZEPAM, PRAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PRECEF, CEFORANIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNICEN-M, PREDNISONE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELAY, TROGLITAZONE
PRELONE, PREDNISOLONE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPRO 14/14, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PRIFTIN, RIFAPENTINE
PRILOSEC, OMEPRAZOLE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROAMATINE, MIDODRINE HYDROCHLORIDE
PROBALAN, PROBENECID

FDA data supplied by DrugPatentWatch.com

PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROBEN-C, COLCHICINE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROCTOCORT, HYDROCORTISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFENAL, SUPROFEN
PROFERDEX, IRON DEXTRAN
PROGESTASERT, PROGESTERONE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROKETAZINE, CARPHENAZINE MALEATE
PROKLAR, SULFAMETHIZOLE
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROLOPRIM, TRIMETHOPRIM
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETA, METAPROTERENOL SULFATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHACON, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSOM, ESTAZOLAM
PROSTAPHLIN, OXACILLIN SODIUM
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS

FDA data supplied by DrugPatentWatch.com

PROTOSTAT, METRONIDAZOLE
PROTRIPTYLINE HCL, PROTRIPTYLINE HYDROCHLORIDE
PROTROPIN, SOMATREM
PROVAL #3, ACETAMINOPHEN
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSORCON, DIFLORASONE DIACETATE
PULMICORT RESPULES, BUDESONIDE
PULMICORT, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PYLORI-CHEK BREATH TEST, UREA, C-13
PYOCIDIN, HYDROCORTISONE
PYOPEN, CARBENICILLIN DISODIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
PYRILAMINE MALEATE, PYRILAMINE MALEATE
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

** Q **

Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM
QUARZAN, CLIDINIUM BROMIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
QUIDE, PIPERACETAZINE
QUINACT, QUINIDINE GLUCONATE
QUINAGLUTE, QUINIDINE GLUCONATE
QUINALAN, QUINIDINE GLUCONATE
QUINATIME, QUINIDINE GLUCONATE
QUINIDEX, QUINIDINE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUINORA, QUINIDINE SULFATE
QUIXIN, LEVOFLOXACIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
R-P MYCIN, ERYTHROMYCIN
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAMUNE, SIROLIMUS
RAPLON, RAPACURONIUM BROMIDE
RAU-SED, RESERPINE
RAUDIXIN, RAUWOLFIA SERPENTINA
RAUSERPIN, RAUWOLFIA SERPENTINA
RAUTENSIN, ALSEROXYLON
RAUVAL, RAUWOLFIA SERPENTINA
RAUWILOID, ALSEROXYLON
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN
RAXAR, GREPAFLOXACIN HYDROCHLORIDE
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT
REBETOL, RIBAVIRIN
REDISOL, CYANOCOBALAMIN
REFLUDAN, LEPIRUDIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
REGROTON, CHLORTHALIDONE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
RELA, CARISOPRODOL
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
REMERON, MIRTAZAPINE
REMSED, PROMETHAZINE HYDROCHLORIDE
RENACIDIN, CITRIC ACID

FDA data supplied by DrugPatentWatch.com

RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENESE, POLYTHIAZIDE
RENESE-R, POLYTHIAZIDE
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOQUID, SULFACYTINE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVA, TRETINOIN
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
REPRONEX, MENOTROPINS (FSH;LH)
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
RESTORIL, TEMAZEPAM
RETET, TETRACYCLINE HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETROVIR, ZIDOVUDINE
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE
REVERSOL, EDROPHONIUM CHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
REZULIN, TROGLITAZONE
RHINOCORT, BUDESONIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RIMACTANE, RIFAMPIN
RIMADYL, CARPROFEN
RIMIFON, ISONIAZID
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RISPERDAL, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
ROBIMYCIN, ERYTHROMYCIN
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
ROBITET, TETRACYCLINE HYDROCHLORIDE
ROCALTROL, CALCITRIOL
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMAZICON, FLUMAZENIL
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
RUBRAMIN PC, CYANOCOBALAMIN
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
RUFEN, IBUPROFEN
RUVITE, CYANOCOBALAMIN
RYTHMOL, PROPAFENONE HYDROCHLORIDE

** S **

S.A.S.-500, SULFASALAZINE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALPIX, ACETRIZOATE SODIUM
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE

FDA data supplied by DrugPatentWatch.com

SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDRIL, RESERPINE
SANOREX, MAZINDOL
SANSAC, ERYTHROMYCIN
SANSERT, METHYSERGIDE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SARENIN, SARALASIN ACETATE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SATRIC, METRONIDAZOLE
SCABENE, LINDANE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCLEROSOL, TALC
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SECONAL SODIUM, SECOBARBITAL SODIUM
SECRETIN-FERRING, SECRETIN
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SEDAPAP, ACETAMINOPHEN
SEFFIN, CEPHALOTHIN SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SELSUN, SELENIUM SULFIDE
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
SEMPREX-D, ACRIVASTINE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTI-SOFT, HEXACHLOROPHENE
SEPTISOL, HEXACHLOROPHENE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERAX, OXAZEPAM
SERENTIL, MESORIDAZINE BESYLATE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERPANRAY, RESERPINE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SERPATE, RESERPINE
SERPIVITE, RESERPINE
SERVISONE, PREDNISONE
SERZONE, NEFAZODONE HYDROCHLORIDE
SETHOTOPE, SELENOMETHIONINE, SE-75
SHADE UVAGUARD, AVOBENZONE (OTC)
SILDIMAC, SILVER SULFADIAZINE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
SILVADENE, SILVER SULFADIAZINE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINEQUAN, DOXEPIN HYDROCHLORIDE
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SLOW-K, POTASSIUM CHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SODIUM SULAMYD, SULFACETAMIDE SODIUM
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SODIUM VERSENATE, EDETATE DISODIUM
SOLAGE, MEQUINOL
SOLARAZE, DICLOFENAC SODIUM
SOLATENE, BETA-CAROTENE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-CRT, THEOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
SONATA, ZALEPLON
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SONORX, SIMETHICONE-CELLULOSE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
SORBITRATE, ISOSORBIDE DINITRATE
SORIATANE, ACITRETIN
SOSOL, SULFISOXAZOLE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOXAZOLE, SULFISOXAZOLE
SOY-DOME, HEXACHLOROPHENE
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL
SPARINE, PROMAZINE HYDROCHLORIDE
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123
SPECTAZOLE, ECONAZOLE NITRATE
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRX-105, PHENDIMETRAZINE TARTRATE
SPRX-3, PHENDIMETRAZINE TARTRATE
SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STANOZIDE, ISONIAZID
STAPHCILLIN, METHICILLIN SODIUM
STARLIX, NATEGLINIDE
STATICIN, ERYTHROMYCIN
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
STATROL, NEOMYCIN SULFATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
STIE-CORT, HYDROCORTISONE
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
STIMATE, DESMOPRESSIN ACETATE
STOXIL, IDOXURIDINE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIFON FORTE DSC, CHLORZOXAZONE
STROMECTOL, IVERMECTIN
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFABID, SULFAPHENAZOLE

FDA data supplied by DrugPatentWatch.com

SULFACEL-15, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
SULFALAR, SULFISOXAZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFANILAMIDE, SULFANILAMIDE
SULFAPYRIDINE, SULFAPYRIDINE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE
SULFISOXAZOLE, SULFISOXAZOLE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULINDAC, SULINDAC
SULLA, SULFAMETER
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
SULPHRIN, PREDNISOLONE ACETATE
SULSOXIN, SULFISOXAZOLE
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
SULTEN-10, SULFACETAMIDE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
SUPPRELIN, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SURITAL, THIAMYLAL SODIUM
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
SUSTAIRE, THEOPHYLLINE
SUSTIVA, EFAVIRENZ
SYMADINE, AMANTADINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
SYNAREL, NAFARELIN ACETATE
SYNCURINE, DECAMETHONIUM BROMIDE
SYNERCID, DALFOPRISTIN
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
SYNTOCINON, OXYTOCIN
SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

T-PHYL, THEOPHYLLINE
T-STAT, ERYTHROMYCIN
TAB-PROFEN, IBUPROFEN (OTC)
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
TACE, CHLOROTRIANISENE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TANDEARIL, OXYPHENBUTAZONE
TAO, TROLEANDOMYCIN
TAPAZOLE, METHIMAZOLE
TARACTAN, CHLORPROTHIXENE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASMAR, TOLCAPONE
TATUM-T, COPPER
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE

FDA data supplied by DrugPatentWatch.com

TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TAZORAC, TAZAROTENE
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TECZEM, DILTIAZEM MALATE
TEEBACIN, AMINOSALICYLATE SODIUM
TEGISON, ETRETINATE
TEGOPEN, CLOXACILLIN SODIUM
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TELEPAQUE, IOPANOIC ACID
TEMARIL, TRIMEPRAZINE TARTRATE
TEMAZ, TEMAZEPAM
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEN-K, POTASSIUM CHLORIDE
TENATHAN, BETHANIDINE SULFATE
TENCON, ACETAMINOPHEN
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
TEQUIN, GATIFLOXACIN
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TESLAC, TESTOLACTONE
TESLASCAN, MANGAFODIPIR TRISODIUM
TESSALON, BENZONATATE
TESTODERM, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
TESTRED, METHYLTESTOSTERONE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
TETRACHEL, TETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
THEELIN, ESTRONE
THEO-24, THEOPHYLLINE
THEO-DUR, THEOPHYLLINE

FDA data supplied by DrugPatentWatch.com

THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
THEOLIXIR, THEOPHYLLINE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE-SR, THEOPHYLLINE
THEOVENT, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOPLEX, THIOTEPA
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
THIOTEPA, THIOTEPA
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
THYPINONE, PROTIRELIN
THYREL TRH, PROTIRELIN
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
THYROGEN, THYROTROPIN ALFA
THYROGLOBULIN, THYROGLOBULIN
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)
THYTROPAR, THYROTROPIN
TIAMATE, DILTIAZEM MALATE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TICLID, TICLOPIDINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TILADE, NEDOCROMIL SODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAL, ACETOPHENAZINE MALEATE
TIOPRONIN, TIOPRONIN
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TOBI, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOLINASE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TONOCARD, TOCAINIDE HYDROCHLORIDE
TOPAMAX SPRINKLE, TOPIRAMATE
TOPAMAX, TOPIRAMATE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE
TOPOSAR, ETOPOSIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORA, PHENTERMINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE

FDA data supplied by DrugPatentWatch.com

TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TORNALATE, BITOLTEROL MESYLATE
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPN SUSPENSION, NIACINAMIDE
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRANCOPAL, CHLORMEZANONE
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRANSDERM SCOP, SCOPOLAMINE
TRANSDERM-NITRO, NITROGLYCERIN
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TRASYLOL, APROTININ BOVINE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASE, SUTILAINS
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRECATOR-SC, ETHIONAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TREST, METHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRI-NASAL, TRIAMCINOLONE ACETONIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIACORT, TRIAMCINOLONE ACETONIDE
TRIAD, ACETAMINOPHEN
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAPRIN, ACETAMINOPHEN
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
TRICHLOREX, TRICHLORMETHIAZIDE
TRICHLORMAS, TRICHLORMETHIAZIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRICLOS, TRICLOFOS SODIUM
TRICOR (MICRONIZED), FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDESILON, ACETIC ACID, GLACIAL
TRIDESILON, DESONIDE
TRIDIL, NITROGLYCERIN
TRIDIONE, TRIMETHADIONE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRILEPTAL, OXCARBAZEPINE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRIMOX, AMOXICILLIN
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
TRINALIN, AZATADINE MALEATE
TRIOSTAT, LIOTRIX (T4;T3)
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE
TRISORALEN, TRIOXSALEN
TRITEC, RANITIDINE BISMUTH CITRATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
TROVAN, TROVAFLOXACIN MESYLATE
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
TRUPHYLLINE, AMINOPHYLLINE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
TURGEX, HEXACHLOROPHENE
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLENOL, ACETAMINOPHEN (OTC)
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
TYMTRAN, CERULETIDE DIETHYLAMINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)

** U **

U-CORT, HYDROCORTISONE ACETATE
U-GENCIN, GENTAMICIN SULFATE
UCEPHAN, SODIUM BENZOATE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE

FDA data supplied by DrugPatentWatch.com

ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNI-DUR, THEOPHYLLINE
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
UNIPHYL, THEOPHYLLINE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
URETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
UNITHROID, LIOTRIX (T4;T3)
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD
UREAPHIL, UREA
URECHOLINE, BETHANECHOL CHLORIDE
URESE, BENZTHIAZIDE
UREX, METHENAMINE HIPPURATE
URISPAS, FLAVOXATE HYDROCHLORIDE
UROBAK, SULFAMETHOXAZOLE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
URSO, URSODIOL
URSODIOL, URSODIOL
UTICILLIN VK, PENICILLIN V POTASSIUM
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
UVADEX, METHOXSALEN

** V **

V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VAGIFEM, ESTRADIOL
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VAGISTAT-1, TIOCONAZOLE (OTC)
VALISONE, BETAMETHASONE VALERATE
VALIUM, DIAZEPAM
VALMID, ETHINAMATE
VALNAC, BETAMETHASONE VALERATE
VALPIN 50, ANISOTROPINE METHYLBROMIDE
VALPROIC ACID, VALPROIC ACID
VALRELEASE, DIAZEPAM
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOBID, CANDICIDIN
VANSIL, OXAMNIQUINE
VANTIN, CEFPODOXIME PROXETIL
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE
VASCORAY, IOTHALAMATE MEGLUMINE
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VASOXYL, METHOXAMINE HYDROCHLORIDE
VECTRIN, MINOCYCLINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VEETIDS, PENICILLIN V POTASSIUM
VEINAMINE 8%, AMINO ACIDS
VELBAN, VINBLASTINE SULFATE
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE
VELOSEF, CEPHRADINE
VELOSULIN BR HUMAN, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN
VELOSULIN, INSULIN PURIFIED PORK (OTC)
VELTANE, BROMPHENIRAMINE MALEATE
VENOFER, IRON SUCROSE
VENTAIRE, PROTOKYLOL HYDROCHLORIDE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE

FDA data supplied by DrugPatentWatch.com

VEPESID, ETOPOSIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VERILOID, ALKAVERVIR
VERMIDOL, PIPERAZINE CITRATE
VERMOX, MEBENDAZOLE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM
VERSED, MIDAZOLAM HYDROCHLORIDE
VERTAVIS, VERATRUM VIRIDE
VESANOID, TRETINOIN
VESPRIN, TRIFLUPROMAZINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VEXOL, RIMEXOLONE
VI-DOM-A, VITAMIN A PALMITATE
VI-TWEL, CYANOCOBALAMIN
VIADUR, LEUPROLIDE ACETATE
VIAGRA, SILDENAFIL CITRATE
VIBISONE, CYANOCOBALAMIN
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCASAR PFS, VINCRISTINE SULFATE
VINCREX, VINCRISTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VIOXX, ROFECOXIB
VIRA-A, VIDARABINE
VIRAC REX, UNDECOYLIUM CHLORIDE
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIRILON, METHYLTESTOSTERONE
VIROPTIC, TRIFLURIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITAPED, ASCORBIC ACID
VITRASERT, GANCICLOVIR
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VOLMAX, ALBUTEROL SULFATE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VONTROL, DIPHENIDOL HYDROCHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
VUMON, TENIPOSIDE

** W **

WAMPOCAP, NIACIN
WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
WESTADONE, METHADONE HYDROCHLORIDE
WESTCORT, HYDROCORTISONE VALERATE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
WINSTROL, STANOZOLOL
WOLFINA, RAUWOLFIA SERPENTINA
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYCILLIN, PENICILLIN G PROCAINE
WYDASE, HYALURONIDASE
WYGESIC, ACETAMINOPHEN
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE

** X **

X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM

FDA data supplied by DrugPatentWatch.com

XELODA, CAPECITABINE
XENEISOL, XENON, XE-133
XENICAL, ORLISTAT
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XYLO-PFAN, XYLOSE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOSE, XYLOSE

** Y **

YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
YUTOPAR, RITODRINE HYDROCHLORIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE
ZAGAM, SPARFLOXACIN
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAXOPAM, OXAZEPAM
ZEBETA, BISOPROLOL FUMARATE
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZEMPLAR, PARICALCITOL
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIBA-RX, BACITRACIN ZINC
ZIDE, HYDROCHLOROTHIAZIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZOCOR, SIMVASTATIN
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLYSE, CHYMOTRYPSIN
ZOMIG, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE
ZYFLO, ZILEUTON
ZYLOPRIM, ALLOPURINOL
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYVOX, LINEZOLID

FDA data supplied by DrugPatentWatch.com

** 3 **

3M
* 3M CO
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
* 3M MEDICAL PRODUCTS DIV
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
* 3M PHARMACEUTICALS INC
ALDARA, IMIQUIMOD
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CIRCANOL, ERGOLOID MESYLATES
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIPO-HEPIN, HEPARIN SODIUM
MAXAIR, PIRBUTEROL ACETATE
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
PROVENTIL-HFA, ALBUTEROL SULFATE
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
RAUWILOID, ALSEROXYLON
SODIUM VERSENATE, EDETATE DISODIUM
TAMBOCOR, FLECAINIDE ACETATE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE
VERILOID, ALKAVERVIR

** A **

AB GENERICS
* AB GENERICS LP
MORPHINE SULFATE, MORPHINE SULFATE

ABANA
* ABANA PHARMACEUTICALS INC
NORCET, ACETAMINOPHEN

ABBOTT
* ABBOTT LABORATORIES
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
ALCOHOL 5% IN D5-W, ALCOHOL
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE AND DEMEROL, ATROPINE SULFATE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DROPERIDOL, DROPERIDOL
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KALETRA, LOPINAVIR
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NORVIR, RITONAVIR
NOVOCAIN, PROCAINE HYDROCHLORIDE
NUROMAX, DOXACURIUM CHLORIDE
OMNICEF, CEFDINIR
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
TALWIN, PENTAZOCINE LACTATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZYFLO, ZILEUTON

* ABBOTT LABORATORIES HOSP PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIDATE, ETOMIDATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMRINONE, INAMRINONE LACTATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
ENFLURANE, ENFLURANE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE, FENTANYL CITRATE
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN III 30%, SOYBEAN OIL
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANHEPRIN, HEPARIN SODIUM
PENTHRANE, METHOXYFLURANE
PENTOTHAL, THIOPENTAL SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
UREAPHIL, UREA
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYLERT, PEMOLINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIASONE SODIUM, SULFOXONE SODIUM
DICUMAROL, DICUMAROL
DROPERIDOL, DROPERIDOL
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ERY-TAB, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
FENTANYL CITRATE, FENTANYL CITRATE
GEMONIL, METHARBITAL
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYTRIN, TERAZOSIN HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
JANIMINE, IMIPRAMINE HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPIDIL, FENOFIBRATE
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LTA II KIT, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5%, MANNITOL

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NITROPRESS, SODIUM NITROPRUSSIDE
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORVIR, RITONAVIR
OCL, POLYETHYLENE GLYCOL 3350
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
PANWARFIN, WARFARIN SODIUM
PARADIONE, PARAMETHADIONE
PCE, ERYTHROMYCIN
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEGANONE, ETHOTOIN
PHENURONE, PHENACEMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLACIDYL, ETHCHLORVYNOL
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROSOM, ESTAZOLAM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SELSUN, SELENIUM SULFIDE
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THYPINONE, PROTIRELIN
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRICOR (MICRONIZED), FENOFIBRATE
TRIDIONE, TRIMETHADIONE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VITAMIN K1, PHYTONADIONE

ABIC
* ABIC LTD
ABITREXATE, METHOTREXATE SODIUM
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
VINCRISTINE SULFATE, VINCRISTINE SULFATE

ABLE
* ABLE LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HEMSOL-HC, HYDROCORTISONE ACETATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)

ADV CARE
* ADVANCED CARE PRODUCTS DIV ORTHO PHARMACEUTICAL CORP
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

ADV MAGNETICS
* ADVANCED MAGNETICS INC
FERIDEX I.V., FERUMOXIDES
GASTROMARK, FERUMOXSIL

ADVANCED CARE PRODS
* ADVANCED CARE PRODUCTS
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)

AESGEN
* AESGEN INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ETODOLAC, ETODOLAC
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

AGOURON
* AGOURON PHARMACEUTICALS INC
RESCRIPTOR, DELAVIRDINE MESYLATE
VIRACEPT, NELFINAVIR MESYLATE

AH ROBINS INC
* AH ROBINS INC
EXNA, BENZTHIAZIDE

AKORN
* AKORN INC
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CHLORAMPHENICOL, CHLORAMPHENICOL
COR-OTICIN, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
INAPSINE, DROPERIDOL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SUFENTA, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE

AKORN MFG
* AKORN MANUFACTURING INC
INNOVAR, DROPERIDOL
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE

AL HIKMA
* AL HIKMA PHARMACEUTICALS
NAPROXEN SODIUM, NAPROXEN SODIUM

ALCON
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED, PREDNISOLONE ACETATE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISMOTIC, ISOSORBIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
NEO-OTOSOL-HC, HYDROCORTISONE
PANTOPAQUE, IOPHENDYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PROFENAL, SUPROFEN
STATROL, NEOMYCIN SULFATE
TOBRADEX, DEXAMETHASONE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TRIFLURIDINE, TRIFLURIDINE
VEXOL, RIMEXOLONE
ZOLYSE, CHYMOTRYPSIN

ALCON UNIVERSAL
* ALCON UNIVERSAL LTD
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE

ALIMENTERICS
* ALIMENTERICS INC
PYLORI-CHEK BREATH TEST, UREA, C-13

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLENDALE PHARMS
* ALLENDALE PHARMACEUTICALS
TODAY, NONOXYNOL-9 (OTC)

ALLERGAN
* ALLERGAN
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN, BRIMONIDINE TARTRATE

FDA data supplied by DrugPatentWatch.com

AZELEX, AZELAIC ACID
ELIMITE, PERMETHRIN
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
POLYTRIM, POLYMYXIN B SULFATE
TAZORAC, TAZAROTENE

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
ETHAMIDE, ETHOXZOLAMIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
HMS, MEDRYSONE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERGAN HERBERT

* ALLERGAN HERBERT DIV ALLERGAN INC
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
EXSEL, SELENIUM SULFIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOROPLEX, FLUOROURACIL
PENECORT, HYDROCORTISONE

* ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
FLUOROPLEX, FLUOROURACIL
NAFTIN, NAFTIFINE HYDROCHLORIDE
PENECORT, HYDROCORTISONE
TEMARIL, TRIMEPRAZINE TARTRATE

ALLIANCE PHARM

* ALLIANCE PHARMACEUTICAL CORP
IMAGENT, PERFLUBRON

ALPHA THERA

* ALPHA THERAPEUTIC CORP
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL

ALPHAPHARM

* ALPHAPHARM PARTY LTD
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM

ALPHARMA

* ALPHARMA INC
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE

* ALPHARMA USPD INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARB, BUTABARBITAL SODIUM
CAPITAL AND CODEINE, ACETAMINOPHEN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CODAMINE, HYDROCODONE BITARTRATE
CONSTULOSE, LACTULOSE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ENULOSE, LACTULOSE
EPINEPHRINE, EPINEPHRINE (OTC)
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE

FDA data supplied by DrugPatentWatch.com

FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LOMANATE, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYKINAC, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PHENYTOIN, PHENYTOIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARM
* ALPHARMA US PHARMACEUTICAL DIV
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN

ALRA
* ALRA LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
BAMATE, MEPROBAMATE
CHOLAC, LACTULOSE
COMPOUND 65, ASPIRIN
CONSTILAC, LACTULOSE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
SOXAZOLE, SULFISOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ALTANA
* ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE

ALZA
* ALZA CORP
AMPHOTEC, AMPHOTERICIN B
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DURAGESIC, FENTANYL
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
ELMIRON, PENTOSAN POLYSULFATE SODIUM
PROGESTASERT, PROGESTERONE
TESTODERM, TESTOSTERONE
VIADUR, LEUPROLIDE ACETATE

AM PHARM PARTNERS
* AMERICAN PHARMACEUTICAL PARTNERS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIGOXIN, DIGOXIN
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPFLUSH-10, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M.V.C. 9+3, ASCORBIC ACID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 25%, MANNITOL

FDA data supplied by DrugPatentWatch.com

METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NITROGLYCERIN, NITROGLYCERIN
OXYTOCIN, OXYTOCIN
PENTAM, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
ZINC SULFATE, ZINC SULFATE

AM THERAP
* AMERICAN THERAPEUTICS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
LORAZEPAM, LORAZEPAM
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
OXAZEPAM, OXAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
THIOTHIXENE, THIOTHIXENE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

AMARIN PHARMS
* AMARIN PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMEN, MEDROXYPROGESTERONE ACETATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN

AMBIX
* AMBIX LABORATORIES DIV ORGANICS CORP AMERICA
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

AMERSHAM
* AMERSHAM CORP SUB RADIOCHEMICAL CENTER
IBRIN, FIBRINOGEN, I-125

AMIDE PHARM
* AMIDE PHARMACEUTICAL INC
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
DIGOXIN, DIGOXIN
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
URSODIOL, URSODIOL

ANABOLIC
* ANABOLIC INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANDRX
* ANDRX CORP
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE

ANDRX PHARMS
* ANDRX PHARMACEUTICALS INC
CARTIA XT, DILTIAZEM HYDROCHLORIDE
KETOPROFEN, KETOPROFEN

ANESTA
* ANESTA CORP
ACTIQ, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE

ANGELINI
* ANGELINI PHARMACEUTICALS INC
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE

ANGUS
* ANGUS CHEMICAL CO
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
TETRACHEL, TETRACYCLINE HYDROCHLORIDE

ANTHRA
* ANTHRA PHARMACEUTICALS INC
VALSTAR PRESERVATIVE FREE, VALRUBICIN

APOTEX
* APOTEX CORP
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

APOTHECON
* APOTHECON INC DIV BRISTOL MYERS SQUIBB
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BETAPEN-VK, PENICILLIN V POTASSIUM
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHALEXIN, CEPHALEXIN
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CORGARD, NADOLOL
CORZIDE, BENDROFLUMETHIAZIDE
DESYREL, TRAZODONE HYDROCHLORIDE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DYNAPEN, DICLOXACILLIN SODIUM
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FLORINEF, FLUDROCORTISONE ACETATE
FUNGIZONE, AMPHOTERICIN B
KANTREX, KANAMYCIN SULFATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOTRIX, POTASSIUM CHLORIDE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MUCOMYST, ACETYLCYSTEINE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NYDRAZID, ISONIAZID
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE

FDA data supplied by DrugPatentWatch.com

POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
PRECEF, CEFORANIDE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROSTAPHLIN, OXACILLIN SODIUM
QUESTRAN, CHOLESTYRAMINE
RAUDIXIN, RAUWOLFIA SERPENTINA
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STAPHCILLIN, METHICILLIN SODIUM
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEGOPEN, CLOXACILLIN SODIUM
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIMOX, AMOXICILLIN
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEETIDS, PENICILLIN V POTASSIUM
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF, CEPHRADINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE

* APOTHECON SUB BRISTOL MYERS SQUIBB CO
ATENOLOL, ATENOLOL
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
TRIMOX, AMOXICILLIN
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VESPRIN, TRIFLUPROMAZINE

APOTHEKERNES
* APOTHEKERNES LABORATORIUM A/S
BACITRACIN, BACITRACIN

APPLIED ANAL
* APPLIED ANALYTICAL INDUSTRIES
METHAZOLAMIDE, METHAZOLAMIDE

* APPLIED ANALYTICAL INDUSTRIES INC
AZATHIOPRINE, AZATHIOPRINE
ESTRADIOL, ESTRADIOL
KETOCONAZOLE, KETOCONAZOLE

ARBROOK
* ARBROOK INC
GAMOPHEN, HEXACHLOROPHENE

ARCUM
* ARCUM PHARMACEUTICAL CORP
VITAMIN A PALMITATE, VITAMIN A PALMITATE

ARMENPHARM
* ARMENPHARM LTD
MYCHEL, CHLORAMPHENICOL

ARMOUR PHARM
* ARMOUR PHARMACEUTICAL CO
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
DEPINAR, CYANOCOBALAMIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
PENTACARINAT, PENTAMIDINE ISETHIONATE

ASCENT PEDS
* ASCENT PEDIATRICS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ASCHER
* BF ASCHER AND CO INC
DRIZE, CHLORPHENIRAMINE MALEATE
HY-PHEN, ACETAMINOPHEN

ASCOT
* ASCOT HOSP PHARMACEUTICALS INC DIV TRAVENOL LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ASTA
* ASTA MEDICA INC
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
OPTIVAR, AZELASTINE HYDROCHLORIDE
* ASTA PHARMA AG
MESNEX, MESNA

ASTRAZENECA
* ASTRAZENECA LP
AMIKACIN SULFATE, AMIKACIN SULFATE
AQUASOL A, VITAMIN A
AQUASOL A, VITAMIN A PALMITATE
ASTRAMORPH PF, MORPHINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITONIN-SALMON, CALCITONIN, SALMON
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DALGAN, DEZOCINE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DYCLONE, DYCLONINE HYDROCHLORIDE
EMLA, LIDOCAINE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FOSCAVIR, FOSCARNET SODIUM
FUROSEMIDE, FUROSEMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
PRILOSEC, OMEPRAZOLE
RHINOCORT, BUDESONIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
TENORMIN, ATENOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPROL-XL, METOPROLOL SUCCINATE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
YUTOPAR, RITODRINE HYDROCHLORIDE
* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
LEXXEL, ENALAPRIL MALEATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NOLVADEX, TAMOXIFEN CITRATE
PLENDIL, FELODIPINE
PULMICORT RESPULES, BUDESONIDE
PULMICORT, BUDESONIDE
SORBITRATE, ISOSORBIDE DINITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TONOCARD, TOCAINIDE HYDROCHLORIDE
* ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
DIPRIVAN, PROPOFOL
MERREM I.V., MEROPENEM
SEROQUEL, QUETIAPINE FUMARATE
SULAR, NISOLDIPINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZOLADEX, GOSERELIN ACETATE

ATRIX
* ATRIX LABORATORIES INC
ATRIDOX, DOXYCYCLINE HYCLATE

AVENTIS
* AVENTIS PHARMACEUTICAL PRODUCTS INC
ACTHAR, CORTICOTROPIN
AZMACORT, TRIAMCINOLONE ACETONIDE
AZOLID, PHENYLBUTAZONE

FDA data supplied by DrugPatentWatch.com

CALCIMAR, CALCITONIN, SALMON
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
COMBIPATCH, ESTRADIOL
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEMI-REGROTON, CHLORTHALIDONE
DORIDEN, GLUTETHIMIDE
H.P. ACTHAR GEL, CORTICOTROPIN
HYGROTON, CHLORTHALIDONE
INTAL, CROMOLYN SODIUM
LOVENOX, ENOXAPARIN SODIUM
LOZOL, INDAPAMIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NICOLAR, NIACIN
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PARATHAR, TERIPARATIDE ACETATE
PENETREX, ENOXACIN
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
REGROTON, CHLORTHALIDONE
RILUTEK, RILUZOLE
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SYNERCID, DALFOPRISTIN
TAXOTERE, DOCETAXEL
THYTROPAR, THYROTROPIN
TILADE, NEDOCROMIL SODIUM

AVENTIS BEHRING
* AVENTIS BEHRING LLC
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
STIMATE, DESMOPRESSIN ACETATE

AVENTIS PHARMS
* AVENTIS PHARMACEUTICALS INC
A/T/S, ERYTHROMYCIN
ACCURBRON, THEOPHYLLINE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
ARAVA, LEFLUNOMIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BRICANYL, TERBUTALINE SULFATE
CANTIL, MEPENZOLATE BROMIDE
CARAFATE, SUCRALFATE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CEPHULAC, LACTULOSE
CHRONULAC, LACTULOSE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DECAPRYN, DOXYLAMINE SUCCINATE
DERMATOP, PREDNICARBATE
DIABETA, GLYBURIDE
DV, DIENESTROL
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GLYBURIDE (MICRONIZED), GLYBURIDE
HEDULIN, PHENINDIONE
HIPREX, METHENAMINE HIPPURATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
LANTUS, INSULIN GLARGINE
LASIX, FUROSEMIDE
LOPROX, CICLOPIROX
LORELCO, PROBUCOL
METAHYDRIN, TRICHLORMETHIAZIDE
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NITRO-BID, NITROGLYCERIN
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
PENLAC, CICLOPIROX
PRIFTIN, RIFAPENTINE
REFLUDAN, LEPIRUDIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TACE, CHLOROTRIANISENE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TRENTAL, PENTOXIFYLLINE
TRICLOS, TRICLOFOS SODIUM
VANOBID, CANDICIDIN
VENTAIRE, PROTOKYLOL HYDROCHLORIDE

AXCAN SCANDIPHARM
* AXCAN SCANDIPHARM INC
CHENIX, CHENODIOL
PHOTOFRIN, PORFIMER SODIUM
URSO, URSODIOL

AYERST
* AYERST LABORATORIES INC

FDA data supplied by DrugPatentWatch.com

PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED

** B **

B BRAUN

* B BRAUN MEDICAL INC
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
UCEPHAN, SODIUM BENZOATE

BAKER NORTON
* BAKER NORTON
PROGLYCEM, DIAZOXIDE
* BAKER NORTON PHARMACEUTICALS INC
ACTICORT, HYDROCORTISONE
PACLITAXEL, PACLITAXEL
PROGLYCEM, DIAZOXIDE

BALLARD MEDCL
* BALLARD MEDICAL PRODUCTS INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

BANNER PHARMACAPS
* BANNER PHARMACAPS INC
BENZONATATE, BENZONATATE
CHLOROTRIANISENE, CHLOROTRIANISENE
CLOFIBRATE, CLOFIBRATE
ETHCHLORVYNOL, ETHCHLORVYNOL
VALPROIC ACID, VALPROIC ACID
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

BARLAN
* BARLAN PHARMACAL CO INC
BARSTATIN 100, NYSTATIN

BARR
* BARR LABORATORIES INC
ACETOHEXAMIDE, ACETOHEXAMIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CORTISONE ACETATE, CORTISONE ACETATE
DANAZOL, DANAZOL
DIAZEPAM, DIAZEPAM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
E-BASE, ERYTHROMYCIN
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
FOLIC ACID, FOLIC ACID
GENCEPT 0.5/35-21, ETHINYL ESTRADIOL
GENCEPT 0.5/35-28, ETHINYL ESTRADIOL
GENCEPT 1/35-21, ETHINYL ESTRADIOL
GENCEPT 1/35-28, ETHINYL ESTRADIOL
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARTOR

* BARTOR PHARMACAL CO
TESTOSTERONE, TESTOSTERONE

BASF

* BASF CORP
IBU, IBUPROFEN
LOPURIN, ALLOPURINOL
RUFEN, IBUPROFEN
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
SULPHRIN, PREDNISOLONE ACETATE
SULTEN-10, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NYSTATIN, NYSTATIN
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

* BAUSCH AND LOMB SURGICAL INC
VITRASERT, GANCICLOVIR

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CERNEVIT-12, ALPHA-TOCOPHEROL
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATASOL 8%, AMINO ACIDS
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER PHARM PROD
* BAXTER PHARMACEUTICAL PRODUCTS INC
AMRINONE LACTATE, INAMRINONE LACTATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ETHRANE, ENFLURANE
FORANE, ISOFLURANE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE

BAYER
* BAYER CORP
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
AZLIN, AZLOCILLIN SODIUM
BILTRICIDE, PRAZIQUANTEL
CANDEX, NYSTATIN
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CORT-DOME, HYDROCORTISONE
DELTA-DOME, PREDNISONE
DOMEBORO, ACETIC ACID, GLACIAL
DTIC-DOME, DACARBAZINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
LITHANE, LITHIUM CARBONATE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NICLOCIDE, NICLOSAMIDE
NIMOTOP, NIMODIPINE
NYSTAFORM, CLIOQUINOL
PRECOSE, ACARBOSE
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
SOY-DOME, HEXACHLOROPHENE
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
TRASYLOL, APROTININ BOVINE
TRIDESILON, ACETIC ACID, GLACIAL
VI-DOM-A, VITAMIN A PALMITATE
* BAYER CORP CONSUMER CARE DIV
8-HOUR BAYER, ASPIRIN (OTC)
ACTRON, KETOPROFEN (OTC)
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
MEASURIN, ASPIRIN (OTC)
MIDOL, IBUPROFEN (OTC)
MYCELEX, CLOTRIMAZOLE
MYCELEX, CLOTRIMAZOLE (OTC)
* BAYER CORP PHARMACEUTICAL DIV
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BAYCOL, CERIVASTATIN SODIUM
CIPRO, CIPROFLOXACIN

BECTON DICKINSON
* BECTON DICKINSON AND CO
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
* BECTON DICKINSON SURGICAL SYSTEM
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD
* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMRINONE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

FDA data supplied by DrugPatentWatch.com

ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BUMETANIDE, BUMETANIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE

BEDFORD LABS
* BEDFORD LABORATORIES INC
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE

BEECHAM
* BEECHAM LABORATORIES DIV BEECHAM INC
PROBENECID AND COLCHICINE, COLCHICINE

BEL MAR
* BEL MAR LABORATORIES INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXOMIN, HYDROXOCOBALAMIN
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M-PREDROL, METHYLPREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VITAMIN A PALMITATE, VITAMIN A PALMITATE

BELL PHARMA
* BELL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
RESERPINE, RESERPINE

BEN VENUE
* BEN VENUE LABORATORIES INC
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

BERLEX
* BERLEX LABORATORIES INC SUB SCHERING AG
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
BILIVIST, IPODATE SODIUM
FLUDARA, FLUDARABINE PHOSPHATE
GASTROVIST, DIATRIZOATE MEGLUMINE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
QUINACT, QUINIDINE GLUCONATE
SULLA, SULFAMETER
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
VI-TWEL, CYANOCOBALAMIN

BERLEX LABS
* BERLEX LABORATORIES INC
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CLIMARA, ESTRADIOL
LEVLITE, ETHINYL ESTRADIOL
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MIRENA, LEVONORGESTREL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
QUINAGLUTE, QUINIDINE GLUCONATE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE

BERTEK PHARMS
* BERTEK PHARMACEUTICALS INC
AVITA, TRETINOIN
MENTAX, BUTENAFINE HYDROCHLORIDE
SULFAMYLON, MAFENIDE ACETATE

BETA DERMAC
* BETA DERMACEUTICALS INC
BETA-HC, HYDROCORTISONE

BH
* BH CHEMICALS INC
HALOTHANE, HALOTHANE

BIGMAR
* BIGMAR INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM

BIO TECH GEN
* BIO TECHNOLOGY GENERAL CORP
BIO-TROPIN, SOMATROPIN RECOMBINANT
OXANDRIN, OXANDROLONE

BIOCHEMIE
* BIOCHEMIE GMBH
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

BIOGLAN
* BIOGLAN LABORATORIES LTD
ALPHADERM, HYDROCORTISONE

BIOGLAN PHAR
* BIOGLAN PHARMA INC
C-SOLVE-2, ERYTHROMYCIN
TEXACORT, HYDROCORTISONE
ZONALON, DOXEPIN HYDROCHLORIDE

BIOVAIL
* BIOVAIL CORP INTERNATIONAL
TIAZAC, DILTIAZEM HYDROCHLORIDE
* BIOVAIL LABORATORIES INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
* BIOVAIL TECHNOLOGIES
CEDAX, CEFTIBUTEN DIHYDRATE

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLOCK DRUG
* BLOCK DRUG CO INC
APHTHASOL, AMLEXANOX

BLUE RIDGE
* BLUE RIDGE LABORATORIES INC
CARAFATE, SUCRALFATE

BLULINE
* BLULINE LABORATORIES INC
EPICORT, HYDROCORTISONE
MULTIFUGE, PIPERAZINE CITRATE

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
ALUPENT, METAPROTERENOL SULFATE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
MEXITIL, MEXILETINE HYDROCHLORIDE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
* BOEHRINGER INGELHEIM CORP
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
ALUPENT, METAPROTERENOL SULFATE
ATROVENT, IPRATROPIUM BROMIDE
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
MOBIC, MELOXICAM
PERSANTINE, DIPYRIDAMOLE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

VIRAMUNE, NEVIRAPINE

BONE CARE
* BONE CARE INTERNATIONAL INC
HECTOROL, DOXERCALCIFEROL

BOWMAN PHARMS
* BOWMAN PHARMACEUTICALS INC
HISERPIA, RESERPINE
HIWOLFIA, RAUWOLFIA SERPENTINA

BRACCO
* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PROHANCE, GADOTERIDOL
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
SETHOTOPE, SELENOMETHIONINE, SE-75
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SONORX, SIMETHICONE-CELLULOSE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

BRADLEY PHARMS
* BRADLEY PHARMACEUTICALS INC
PAMINE, METHSCOPOLAMINE BROMIDE

BRAINTREE
* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
MIRALAX, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
PHOSLO, CALCIUM ACETATE

BRIGHTSTONE
* BRIGHTSTONE PHARMA INC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

BRISTOL
* BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO
BETAPEN-VK, PENICILLIN V POTASSIUM
BICNU, CARMUSTINE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
LYSODREN, MITOTANE
MEXATE, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRECEF, CEFORANIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEPESID, ETOPOSIDE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM

BRISTOL MYERS
* BRISTOL MYERS CO

FDA data supplied by DrugPatentWatch.com

MEXATE-AQ, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
* BRISTOL MYERS PRODUCTS INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
NUPRIN, IBUPROFEN (OTC)

BRISTOL MYERS SQUIBB
* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
FOLLUTEIN, GONADOTROPIN, CHORIONIC
GLUCOVANCE, GLYBURIDE
HALOG, HALCINONIDE
MEGACE, MEGESTROL ACETATE
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
ORA-TESTRYL, FLUOXYMESTERONE
PRAVACHOL, PRAVASTATIN SODIUM
SOLAGE, MEQUINOL
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
TESLAC, TESTOLACTONE
VINCREX, VINCRISTINE SULFATE
* BRISTOL MYERS SQUIBB CO
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CAPOTEN, CAPTOPRIL
CEENU, LOMUSTINE
DELESTROGEN, ESTRADIOL VALERATE
DROXIA, HYDROXYUREA
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ESTRACE, ESTRADIOL
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
FUNGIZONE, AMPHOTERICIN B
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
MYCOSTATIN, NYSTATIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYDRAZID, ISONIAZID
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
RAU-SED, RESERPINE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBRAMIN PC, CYANOCOBALAMIN
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TESLAC, TESTOLACTONE
VAGISTAT-1, TIOCONAZOLE (OTC)
VELOSEF, CEPHRADINE
VEPESID, ETOPOSIDE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VIDEX EC, DIDANOSINE
VITAMIN A, VITAMIN A PALMITATE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
BLENOXANE, BLEOMYCIN SULFATE
BUSPAR, BUSPIRONE HYDROCHLORIDE
CEFZIL, CEFPROZIL
CYTOXAN, CYCLOPHOSPHAMIDE
DEAPRIL-ST, ERGOLOID MESYLATES
DOVONEX, CALCIPOTRIENE
ESTRACE, ESTRADIOL
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MONOPRIL, FOSINOPRIL SODIUM
PARAPLATIN, CARBOPLATIN
SERZONE, NEFAZODONE HYDROCHLORIDE
STADOL, BUTORPHANOL TARTRATE
TAXOL, PACLITAXEL
TEQUIN, GATIFLOXACIN
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE
* BRISTOL MYERS SQUIBB SPA
PENICILLIN G SODIUM, PENICILLIN G SODIUM

BRYAN
* BRYAN CORP
SCLEROSOL, TALC

BTG
* BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP
DELATESTRYL, TESTOSTERONE ENANTHATE

BUNDY

FDA data supplied by DrugPatentWatch.com

* CM BUNDY CO
BUTABARBITAL, BUTABARBITAL SODIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE

** C **

C AND M PHARMA
* C AND M PHARMACAL INC
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HI-COR, HYDROCORTISONE

CADEMA
* CADEMA MEDICAL PRODUCTS INC
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT

CALGON
* CALGON CORP DIV MERCK AND CO INC
SEPTI-SOFT, HEXACHLOROPHENE

CAMALL
* CAMALL CO INC
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE

CARACO
* CARACO PHARMACEUTICAL LABORATORIES LTD
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE

CARDERM
* CARDERM CAPITAL LP
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE

CARLISLE
* CARLISLE LABORATORIES INC
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE

CARLSBAD
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
DICLOFENAC SODIUM, DICLOFENAC SODIUM

CARNRICK
* CARNRICK LABORATORIES INC DIV GW CARNRICK CO
CAPITAL WITH CODEINE, ACETAMINOPHEN
SKELAXIN, METAXALONE

CAROLINA MEDCL
* CAROLINA MEDICAL PRODUCTS CO
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALYTICA PHARMS
* CATALYTICA PHARMACEUTICALS INC
ALOPRIM, ALLOPURINOL SODIUM

CELGENE
* CELGENE CORP
THALOMID, THALIDOMIDE

CELL THERAP
* CELL THERAPEUTICS INC
TRISENOX, ARSENIC TRIOXIDE

CENCI
* CENCI POWDER PRODUCTS INC
THEOPHYLLINE, THEOPHYLLINE
* HR CENCI LABORATORIES INC
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ELIXOMIN, THEOPHYLLINE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE

CENT PHARMS
* CENTRAL PHARMACEUTICALS INC

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
AZDONE, ASPIRIN
CO-GESIC, ACETAMINOPHEN
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

CENTURY PHARMS
* CENTURY PHARMACEUTICALS INC
P.A.S. SODIUM, AMINOSALICYLATE SODIUM

CEPHALON
* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
PROVIGIL, MODAFINIL

CHAMBERLIN PARENTERL
* CHAMBERLIN PARENTERAL CORP
HEPARIN SODIUM, HEPARIN SODIUM

CHASE CHEM
* CHASE CHEMICAL CO LP
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

CHASE LABS NJ
* CHASE LABORATORIES INC
NIFEDIPINE, NIFEDIPINE

CHELSEA LABS
* CHELSEA LABORATORIES INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GERIMAL, ERGOLOID MESYLATES
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN

FDA data supplied by DrugPatentWatch.com

ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBEN-C, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RESERPINE, RESERPINE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TOLBUTAMIDE, TOLBUTAMIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAZOLAM, TRIAZOLAM
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

CHESEBROUGH PONDS
* CHESEBROUGH PONDS INC
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)
VIRAC REX, UNDECOYLIUM CHLORIDE

CIBA
* CIBA VISION CORP DIV NOVARTIS CO
CARBASTAT, CARBACHOL
CATARASE, CHYMOTRYPSIN
DEXACIDIN, DEXAMETHASONE
FLUOR-OP, FLUOROMETHOLONE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
GENTACIDIN, GENTAMICIN SULFATE
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
RESCULA, UNOPROSTONE ISOPROPYL
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VOLTAREN, DICLOFENAC SODIUM
ZADITOR, KETOTIFEN FUMARATE

CIBA VISION OPHTHLMC
* CIBA VISION OPHTHALMICS
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM

CIS
* CIS BIOINDUSTRIES COMPAGNIE
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
* CIS US INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

FDA data supplied by DrugPatentWatch.com

SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE

CLAY PARK
* CLAY PARK LABORATORIES INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIDESILON, DESONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

CLINTEC NUTR
* CLINTEC NUTRITION CO SUB CLINIQUE
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CLONMEL
* CLONMEL HEALTHCARE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

COLGATE
* COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE
* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLLAGENEX
* COLLAGENEX INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLUMBIA RES LABS
* COLUMBIA RESEARCH LABORATORIES INC
CRINONE, PROGESTERONE

COMBE
* COMBE INC
BACITRACIN, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)

CONNETICS
* CONNETICS CORP
LUXIQ, BETAMETHASONE VALERATE
OLUX FOAM, CLOBETASOL PROPIONATE
RIDAURA, AURANOFIN

CONSOLIDATED MIDLAND
* CONSOLIDATED MIDLAND CORP
TEEBACIN, AMINOSALICYLATE SODIUM

CONSOLIDATED PHARM
* CONSOLIDATED PHARMACEUTICAL GROUP INC
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

CONTROLLED THERAP
* CONTROLLED THERAPEUTICS (SCOTLAND) LTD
CERVIDIL, DINOPROSTONE

COOK IMAGING
* COOK IMAGING CORP
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

COPANOS
* JOHN D COPANOS AND CO INC
PENICILLIN G SODIUM, PENICILLIN G SODIUM
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE

COPLEY PHARM
* COPLEY PHARMACEUTICAL INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CO-LAV, POLYETHYLENE GLYCOL 3350
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
ETHOSUXIMIDE, ETHOSUXIMIDE
EVALOSE, LACTULOSE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
GO-EVAC, POLYETHYLENE GLYCOL 3350
GUANABENZ ACETATE, GUANABENZ ACETATE
GYNIX, CLOTRIMAZOLE (OTC)
HALOPERIDOL, HALOPERIDOL LACTATE
HEPTALAC, LACTULOSE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEBENDAZOLE, MEBENDAZOLE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAZOLAMIDE, METHAZOLAMIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
PEMOLINE, PEMOLINE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID

COR
* COR THERAPEUTICS INC
INTEGRILIN, EPTIFIBATIDE

COREPHARMA
* COREPHARMA LLC
CARISOPRODOL, CARISOPRODOL

CUMBERLAND SWAN
* CUMBERLAND SWAN INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

CYTOGEN
* CYTOGEN CORP
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

** D **

DAIICHI
* DAIICHI PHARMACEUTICAL CO LTD
FLOXIN, OFLOXACIN

DAINIPPON
* DAINIPPON PHARMACEUTICAL USA CORP
ZONEGRAN, ZONISAMIDE

DANBURY PHARMA
* DANBURY PHARMACAL INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

COL-PROBENECID, COLCHICINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NALIDIXIC ACID, NALIDIXIC ACID
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFINPYRAZONE, SULFINPYRAZONE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
FLAXEDIL, GALLAMINE TRIETHIODIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DEBIO RECHERCHE

FDA data supplied by DrugPatentWatch.com

* DEBIO RECHERCHE PHARMACEUTIQUE SA
TRELSTAR DEPOT, TRIPTORELIN PAMOATE

DEL RAY LABS
* DEL RAY LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
DEL-VI-A, VITAMIN A PALMITATE
TRIDERM, TRIAMCINOLONE ACETONIDE

DELL LABS
* DELL LABORATORIES INC
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIK LABS
* DERMIK LABORATORIES INC
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
FLUOROURACIL, FLUOROURACIL
HYTONE, HYDROCORTISONE
NORITATE, METRONIDAZOLE
PSORCON, DIFLORASONE DIACETATE
* DERMIK LABORATORIES INC SUB RORER
HYTONE, HYDROCORTISONE
KLARON, SULFACETAMIDE SODIUM

DESERET
* DESERET MEDICAL INC DIV BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

DEXCEL LTD
* DEXCEL LTD
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEY
* DEY LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CUROSURF, PORACTANT ALPHA
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE

DHL
* DHL LABORATORIES INC
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DIAL
* DIAL CORP DIV GREYHOUND CO
DIAL, HEXACHLOROPHENE

DIATIDE
* DIATIDE INC
ACUTECT, TECHNETIUM TC-99M APCITIDE
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE

DISTA
* DISTA PRODUCTS CO DIV ELI LILLY AND CO
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
VALMID, ETHINAMATE

DOW PHARM
* DOW PHARMACEUTICAL CORP SUB DOW CHEMICAL CO
DOW-ISONIAZID, ISONIAZID
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
QUIDE, PIPERACETAZINE

DOWNSTATE CLINCL
* DOWNSTATE CLINICAL PET CENTER
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18

DPT
* DPT LABORATORIES INC
EMBELINE, CLOBETASOL PROPIONATE

DR REDDYS LABS LTD
* DR REDDYS LABORATORIES LTD
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

DRAXIMAGE

FDA data supplied by DrugPatentWatch.com

* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DRAXIS HLTH
* DRAXIS HEALTH INC
FLUOCINONIDE, FLUOCINONIDE

DUNHALL
* DUNHALL PHARMACEUTICALS INC
TRIAPRIN, ACETAMINOPHEN

DUPONT MERCK
* DUPONT MERCK PHARMACEUTICAL CO
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COUMADIN, WARFARIN SODIUM
NARCAN, NALOXONE HYDROCHLORIDE
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
REMSED, PROMETHAZINE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE

DUPONT PHARMA
* DUPONT PHARMACEUTICALS CO
INNOHEP, TINZAPARIN SODIUM

DUPONT PHARMS
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
LODOSYN, CARBIDOPA
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SUSTIVA, EFAVIRENZ
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
XENON XE 133, XENON, XE-133

DURA
* DURA PHARMACEUTICALS INC
FURADANTIN, NITROFURANTOIN
* DURA TRADING CO LTD
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE

DURAMED
* DURAMED PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HCL, CIMETIDINE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM
ESTROPIPATE, ESTROPIPATE
GLIPIZIDE, GLIPIZIDE
GYNODIOL, ESTRADIOL
HALOPERIDOL, HALOPERIDOL
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TOLAZAMIDE, TOLAZAMIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

DUSA
* DUSA PHARMACEUTICAL INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DYNAPHARM
* DYNAPHARM INC
COLOVAGE, POLYETHYLENE GLYCOL 3350

** E **

E Z EM
* E Z EM CO INC
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350

EASTMAN KODAK
* EASTMAN KODAK CO
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EGIS
* EGIS PHARMACEUTICALS
PIROXICAM, PIROXICAM

EGIS PHARMS
* EGIS PHARMACEUTICALS LTD
CAPTOPRIL, CAPTOPRIL

EISAI
* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE

ELAN PHARM
* ELAN PHARMACEUTICAL RESEARCH CORP
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOPROFEN, KETOPROFEN
NAPRELAN, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

ELAN PHARMA
* ELAN PHARMA INTERNATIONAL LTD
MYSOLINE, PRIMIDONE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ELAN PHARMS
* ELAN PHARMACEUTICALS INC
DIASTAT, DIAZEPAM

ELKINS SINN
* ELKINS SINN DIV AH ROBINS CO INC
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN, KANAMYCIN SULFATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXACILLIN SODIUM, OXACILLIN SODIUM
PANCURONIUM, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYTOIN, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE

FDA data supplied by DrugPatentWatch.com

PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

ELKINS SINN PHARM
* ELKINS SINN PHARMACEUTICAL CO
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
NALOXONE, NALOXONE HYDROCHLORIDE

ENDO LABS
* ENDO LABORATORIES INC DIV DUPONT MERCK PHARMACEUTICAL CO
CAPTOPRIL, CAPTOPRIL
* ENDO LABORATORIES LLC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ETODOLAC, ETODOLAC
GLIPIZIDE, GLIPIZIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MOBAN, MOLINDONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARCAN, NALOXONE HYDROCHLORIDE
NUBAIN, NALBUPHINE HYDROCHLORIDE
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
VALPIN 50, ANISOTROPINE METHYLBROMIDE

ENVIRODERM
* ENVIRODERM PHARMACEUTICALS INC
IVY BLOCK, BENTOQUATAM (OTC)

ENZON
* ENZON INC
ADAGEN, PEGADEMASE BOVINE

EON
* EON LABORATORIES MANUFACTURING INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALKERGOT, ERGOLOID MESYLATES
ALPHAZINE, PHENDIMETRAZINE TARTRATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DRALSERP, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE, FUROSEMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOCIN SR, INDOMETHACIN
ISONIAZID, ISONIAZID
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
RIFAMPIN, RIFAMPIN
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SULFADIAZINE TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
WESTADONE, METHADONE HYDROCHLORIDE

ERSANA
* ERSANA INC SUB ER SQUIBB AND SONS
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE

ESI
* ESI PHARMACAL
CYCRIN, MEDROXYPROGESTERONE ACETATE

ESI LEDERLE
* ESI LEDERLE GENERICS
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* ESI LEDERLE INC
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFOXITIN, CEFOXITIN SODIUM
ESTRADIOL, ESTRADIOL
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MORPHINE SULFATE, MORPHINE SULFATE
PENTOXIFYLLINE, PENTOXIFYLLINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

ETHITEK
* ETHITEK PHARMACEUTICALS CO
MOCTANIN, MONOCTANOIN

EVERYLIFE
* EVERYLIFE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
CORTISONE ACETATE, CORTISONE ACETATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
STANOZIDE, ISONIAZID
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

FDA data supplied by DrugPatentWatch.com

** F **

FALCON PHARMS
* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
* FALCON PHARMACEUTICALS LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ECONOPRED PLUS, PREDNISOLONE ACETATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FARO PHARMS
* FARO PHARMACEUTICALS INC
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
TRANDATE, LABETALOL HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

FAULDING
* FAULDING INC
KADIAN, MORPHINE SULFATE
* FAULDING PHARMACEUTICAL CO
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BRETYLOL, BRETYLIUM TOSYLATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CYTARABINE, CYTARABINE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
INTROPIN, DOPAMINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
LABETALOL HCL, LABETALOL HYDROCHLORIDE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
SERAX, OXAZEPAM
TRIDIL, NITROGLYCERIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
* FAULDING PHARMACEUTICALS SUB FH FAULDING AND CO LTD
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
* FH FAULDING AND CO LTD
DORYX, DOXYCYCLINE HYCLATE
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
THEOPHYLLINE, THEOPHYLLINE

FERNDALE LABS
* FERNDALE LABORATORIES INC
ADPHEN, PHENDIMETRAZINE TARTRATE
AMOSENE, MEPROBAMATE
AQUAPHYLLIN, THEOPHYLLINE
DELAXIN, METHOCARBAMOL
DIAZEPAM, DIAZEPAM
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
OBESTIN-30, PHENTERMINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PRAMOSONE, HYDROCORTISONE ACETATE
RAUSERPIN, RAUWOLFIA SERPENTINA
STRIFON FORTE DSC, CHLORZOXAZONE

FERRANTE
* JOHN J FERRANTE
AMPHICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FERRING
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
CONCENTRAID, DESMOPRESSIN ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
MENOTROPINS, MENOTROPINS (FSH;LH)
REPRONEX, MENOTROPINS (FSH;LH)
SECRETIN-FERRING, SECRETIN
THYREL TRH, PROTIRELIN

FIRST HORIZON
* FIRST HORIZON PHARMACEUTICAL CORP
COGNEX, TACRINE HYDROCHLORIDE
PONSTEL, MEFENAMIC ACID

FISONS
* FISONS CORP
IRON DEXTRAN, IRON DEXTRAN
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)

FDA data supplied by DrugPatentWatch.com

PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE

FLEMING PHARMS
* FLEMING AND CO PHARMACEUTICALS INC
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE

FLEMINGTON PHARM
* FLEMINGTON PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE

FOREST LABS
* FOREST LABORATORIES INC
CELEXA, CITALOPRAM HYDROBROMIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
TESSALON, BENZONATATE

FOREST PHARMS
* FOREST PHARMACEUTICALS INC
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
DURADYNE DHC, ACETAMINOPHEN
ESGIC, ACETAMINOPHEN
METRA, PHENDIMETRAZINE TARTRATE
MICROSUL, SULFAMETHIZOLE
PROKLAR, SULFAMETHIZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
WOLFINA, RAUWOLFIA SERPENTINA

FORREST LABS
* FORREST LABORATORIES INC
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BETAPRONE, PROPIOLACTONE
DURAPHYL, THEOPHYLLINE
ELIXICON, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
FORBAXIN, METHOCARBAMOL
PYOCIDIN, HYDROCORTISONE
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)

FOUGERA
* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

FRESENIUS
* FRESENIUS USA INC
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI
* FRESENIUS KABI CLAYTON L P
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
NEOPHAM 6.4%, AMINO ACIDS
VITAPED, ASCORBIC ACID
* FRESENIUS KABI CLAYTON R&D INC
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
VEINAMINE 8%, AMINO ACIDS

FRESENIUS MEDCL
* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FUJISAWA HLTHCARE
* FUJISAWA HEALTHCARE INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CYCLOCORT, AMCINONIDE
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS

** G **

G AND W LABS
* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
HYDROCORTISONE, HYDROCORTISONE
INDOMETHEGAN, INDOMETHACIN
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRUPHYLLINE, AMINOPHYLLINE

GALDERMA LABS LP
* YALDERMA LABORATORIES LP
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE

GELTEX
* GELTEX PHARMACEUTICALS INC
RENAGEL, SEVELAMER HYDROCHLORIDE

GEN ELECTRIC
* GENERAL ELECTRIC CO
XENON XE 133, XENON, XE-133

GENENTECH
* GENENTECH INC
CRESCORMON, SOMATROPIN
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
PROTROPIN, SOMATREM

GENEVA PHARMS
* GENEVA PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ATENOLOL, ATENOLOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERCATAB, CAFFEINE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETOPROFEN, KETOPROFEN
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METHAZOLAMIDE, METHAZOLAMIDE
METHOCARBAMOL, METHOCARBAMOL
METHOXSALEN, METHOXSALEN
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAZEPAM, OXAZEPAM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIMACTANE, RIFAMPIN
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

GENEVA PHARMS TECH
* GENEVA PHARMACEUTICALS TECHNOLOGY CORP
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
FOAMICON, ALUMINUM HYDROXIDE (OTC)
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
NAPROXEN, NAPROXEN
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PEMOLINE, PEMOLINE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

GENPHARM
* GENPHARM INC
ACYCLOVIR, ACYCLOVIR
AZATHIOPRINE, AZATHIOPRINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
* GENPHARM PHARMACEUTICALS INC
ATENOLOL, ATENOLOL
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM

GENSIA
* GENSIA LABORATORIES LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE

GENSIA AUTOMEDICS
* GENSIA AUTOMEDICS INC
GENESA, ARBUTAMINE HYDROCHLORIDE

GENSIA SICOR PHARMS
* GENSIA SICOR PHARMACEUTICALS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

FDA data supplied by DrugPatentWatch.com

LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PROPOFOL, PROPOFOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

GENZYME
* GENZYME CORP
CEREDASE, ALGLUCERASE
CEREZYME, IMIGLUCERASE
THYROGEN, THYROTROPIN ALFA

GILBERT LABS
* GILBERT LABORATORIES
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN

GILEAD
* GILEAD SCIENCES INC
DAUNOXOME, DAUNORUBICIN CITRATE
VISTIDE, CIDOFOVIR

GLAXO
* GLAXO INC
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXO WELLCOME
* GLAXO WELLCOME INC
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
AEROSPORIN, POLYMYXIN B SULFATE
AGENERASE, AMPRENAVIR
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANTEPAR, PIPERAZINE CITRATE
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
CEFTIN, CEFUROXIME AXETIL
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
COMBIVIR, LAMIVUDINE
CUTIVATE, FLUTICASONE PROPIONATE
DARAPRIM, PYRIMETHAMINE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
EMGEL, ERYTHROMYCIN
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EXOSURF NEONATAL, CETYL ALCOHOL
FLOLAN, EPOPROSTENOL SODIUM
FLONASE, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LANOXICAPS, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LEUKERAN, CHLORAMBUCIL
LOTRONEX, ALOSETRON HYDROCHLORIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MAREZINE, CYCLIZINE LACTATE
MEPRON, ATOVAQUONE
MYLERAN, BUSULFAN
NAVELBINE, VINORELBINE TARTRATE
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NIX, PERMETHRIN
OXISTAT, OXICONAZOLE NITRATE
POLYSPORIN, BACITRACIN ZINC (OTC)
PURINETHOL, MERCAPTOPURINE
RELENZA, ZANAMIVIR
RETROVIR, ZIDOVUDINE
SEFFIN, CEPHALOTHIN SODIUM
SEREVENT, SALMETEROL XINAFOATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SYNCURINE, DECAMETHONIUM BROMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
THIOGUANINE, THIOGUANINE
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRITEC, RANITIDINE BISMUTH CITRATE
TRIZIVIR, ABACAVIR SULFATE
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VASOXYL, METHOXAMINE HYDROCHLORIDE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL

FDA data supplied by DrugPatentWatch.com

VENTOLIN, ALBUTEROL SULFATE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZIAGEN, ABACAVIR SULFATE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE

GLENWOOD
* GLENWOOD INC
MYOTONACHOL, BETHANECHOL CHLORIDE
PASKALIUM, POTASSIUM AMINOSALICYLATE
RENOQUID, SULFACYTINE

GOLDLINE
* GOLDLINE LABORATORIES INC
GLYCOPREP, POLYETHYLENE GLYCOL 3350

GRAHAM CHEM
* GRAHAM CHEMICAL CO
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE

GRAHAM DM
* DM GRAHAM LABORATORIES INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SOMOPHYLLIN-CRT, THEOPHYLLINE

GRIFFEN
* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GRUPPO LEPETIT
* GRUPPO LEPETIT SPA SUB MERRELL DOW PHARMACEUTICALS INC
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

GUARDIAN DRUG
* GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUILFORD PHARMS
* GUILFORD PHARMACEUTICALS INC
GLIADEL, CARMUSTINE

GYNETICS
* GYNETICS INC
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL

GYNOPHARMA
* GYNOPHARMA INC
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL

** H **

HALLMARK PHARMS
* HALLMARK PHARMACEUTICALS
CAPTOPRIL, CAPTOPRIL

HALOCARBON
* HALOCARBON LABORATORIES DIV HALOCARBON PRODUCTS CORP
HALOTHANE, HALOTHANE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE

HALSEY
* HALSEY DRUG CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE

FDA data supplied by DrugPatentWatch.com

CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CODOXY, ASPIRIN
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KLOROMIN, CHLORPHENIRAMINE MALEATE
LORAZEPAM, LORAZEPAM
LOW-QUEL, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NALIDIXIC ACID, NALIDIXIC ACID
NEURAMATE, MEPROBAMATE
NIACIN, NIACIN
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

HAMILTON PHARMS
* HAMILTON PHARMACEUTICALS LTD
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

HEALTHPOINT
* HEALTHPOINT LTD
AKNE-MYCIN, ERYTHROMYCIN
CETACORT, HYDROCORTISONE
CLODERM, CLOCORTOLONE PIVALATE

FDA data supplied by DrugPatentWatch.com

CORMAX, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
NUTRACORT, HYDROCORTISONE
SANSAC, ERYTHROMYCIN

HEATHER
* HEATHER DRUG CO INC
CORTISONE ACETATE, CORTISONE ACETATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

HERAN
* HERAN PHARMACEUTICAL INC
GLYCORT, HYDROCORTISONE

HERCON LABS
* HERCON LABORATORIES CORP
NITROGLYCERIN, NITROGLYCERIN

HEXCEL
* HEXCEL CHEMICAL PRODUCTS
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM

HI TECH PHARMA
* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ERYTHRO-STATIN, ERYTHROMYCIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE

HIGH TECH PHARMA
* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HILL DERMAC
* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
FS SHAMPOO, FLUOCINOLONE ACETONIDE

HLR
* HLR TECHNOLOGY
ACCUTANE, ISOTRETINOIN
FORTOVASE, SAQUINAVIR
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
SORIATANE, ACITRETIN
VERSED, MIDAZOLAM HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT

HOLLAND RANTOS
* HOLLAND RANTOS CO INC
KOROSTATIN, NYSTATIN

HOLLISTER STIER LABS
* HOLLISTER STIER LABORATORIES
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE

HORIZON PHARM
* HORIZON PHARMACEUTICAL CORP
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE

HOUBA
* HOUBA INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE

HUNTINGTON LABS
* HUNTINGTON LABORATORIES INC
GERMA-MEDICA "MG", HEXACHLOROPHENE

FDA data supplied by DrugPatentWatch.com

GERMA-MEDICA, HEXACHLOROPHENE
HEXA-GERM, HEXACHLOROPHENE

** I **

IBI
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM

ICN
* ICN PHARMACEUTICALS INC
8-MOP, METHOXSALEN
AMINOPHYLLINE, AMINOPHYLLINE
ANCOBON, FLUCYTOSINE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
BENDOPA, LEVODOPA
BENOQUIN, MONOBENZONE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
DALMANE, FLURAZEPAM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
EFUDEX, FLUOROURACIL
ELDECORT, HYDROCORTISONE
FLUOXYMESTERONE, FLUOXYMESTERONE
FOLIC ACID, FOLIC ACID
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRISORALEN, TRIOXSALEN
VIRAZOLE, RIBAVIRIN

ICN PUERTO RICO
* ICN PUERTO RICO INC
FLUOROURACIL, FLUOROURACIL

IMMUNEX
* IMMUNEX CORP
AMICAR, AMINOCAPROIC ACID
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOPROME, METHOTRIMEPRAZINE
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
THIOPLEX, THIOTEPA
THIOTEPA, THIOTEPA

IMP
* IMP INC
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123

IMPAX LABS
* IMPAX LABORATORIES INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE

FDA data supplied by DrugPatentWatch.com

SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THYROGLOBULIN, THYROGLOBULIN
TRIAMCINOLONE, TRIAMCINOLONE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

IMPAX PHARM
* IMPAX PHARMACEUTICALS
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

INALCO
* INALCO SPA
LACTULOSE, LACTULOSE

INGRAM PHARM
* INGRAM PHARMACEUTICAL CO
DRICORT, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE

INHALON
* INHALON PHARMACEUTICALS INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE

INKINE
* INKINE PHARMACEUTICAL CO INC
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

INO
* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INTERPHARM
* INTERPHARM INC
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TOLAZAMIDE, TOLAZAMIDE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN, GENTAMICIN SULFATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INTL MINERALS
* INTERNATIONAL MINERALS CHEMICAL CORP
TPN SUSPENSION, NIACINAMIDE

INVAMED
* INVAMED INC
CAPTOPRIL, CAPTOPRIL

FDA data supplied by DrugPatentWatch.com

CIMETIDINE, CIMETIDINE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
METHAZOLAMIDE, METHAZOLAMIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE

INWOOD LABS
* INWOOD LABORATORIES INC SUB FOREST LABORATORIES INC
CARBAMAZEPINE, CARBAMAZEPINE
CORTISONE ACETATE, CORTISONE ACETATE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

IOMED
* IOMED INC
IONTOCAINE, EPINEPHRINE

IPHARM
* IPHARM DIV LYPHOMED INC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN

IPR
* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ZOMIG, ZOLMITRIPTAN

ISO TEX
* ISO TEX DIAGNOSTICS INC
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

** J **

J AND J
* JOHNSON AND JOHNSON CONSUMER PRODUCTS INC
ERYCETTE, ERYTHROMYCIN
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
* JOHNSON AND JOHNSON MEDICAL INC
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)

JACOBUS
* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN
* JANSSEN PHARMACEUTICA INC
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MONISTAT, MICONAZOLE
NIZORAL, KETOCONAZOLE
* JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
SPORANOX, ITRACONAZOLE

JANSSEN RES FDN
* JANSSEN RESEARCH FDN
RISPERDAL, RISPERIDONE

JOHNSON AND JOHNSON
* JOHNSON AND JOHNSON CONSUMER COMPANIES INC
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MONISTAT-DERM, MICONAZOLE NITRATE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
SPECTAZOLE, ECONAZOLE NITRATE

JOHNSON RW
* RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
DIENESTROL, DIENESTROL
ESTRADIOL, ESTRADIOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE

FDA data supplied by DrugPatentWatch.com

ORTHO-PREFEST, ESTRADIOL
TOPAMAX SPRINKLE, TOPIRAMATE
TOPAMAX, TOPIRAMATE
ULTRAM, TRAMADOL HYDROCHLORIDE

* RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARM
CLISTIN, CARBINOXAMINE MALEATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
HALDOL SOLUTAB, HALOPERIDOL
HALDOL, HALOPERIDOL
INJECTAPAP, ACETAMINOPHEN
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MONISTAT 3, MICONAZOLE NITRATE
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-NOVUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PROTOSTAT, METRONIDAZOLE
SALPIX, ACETRIZOATE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
VASCOR, BEPRIDIL HYDROCHLORIDE

JONES PHARMA
* JONES PHARMA INC
CYTOMEL, LIOTRIX (T4;T3)
METHIMAZOLE, METHIMAZOLE
TRIOSTAT, LIOTRIX (T4;T3)
TUSSIGON, HOMATROPINE METHYLBROMIDE

JVL
* JVL CORP
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE

** K **

KALAPHARM
* KALAPHARM INC
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE

KENDALL IL
* KENDALL CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE

KENDALL LP
* KENDALL CO LP
THERMAZENE, SILVER SULFADIAZINE

KENWOOD LABS
* KENWOOD LABORATORIES DIV BRADLEY PHARMACEUTICALS
CARMOL HC, HYDROCORTISONE ACETATE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

KEY PHARMS
* KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
GENAPAX, GENTIAN VIOLET
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
NITRO-DUR, NITROGLYCERIN
QUINORA, QUINIDINE SULFATE
THEO-DUR, THEOPHYLLINE

KIEL
* KIEL LABORATORIES INC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

FDA data supplied by DrugPatentWatch.com

KING PHARMS
* KING PHARMACEUTICALS INC
ALTACE, RAMIPRIL
AMINOPHYLLINE, AMINOPHYLLINE
APOGEN, GENTAMICIN SULFATE
AVC, SULFANILAMIDE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CROMOPTIC, CROMOLYN SODIUM
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KLEBCIL, KANAMYCIN SULFATE
LORABID, LORACARBEF
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
SILVADENE, SILVER SULFADIAZINE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
WYCILLIN, PENICILLIN G PROCAINE

KNOLL PHARM
* KNOLL PHARMACEUTICAL CO
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
CHOLOXIN, DEXTROTHYROXINE SODIUM
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE
TARKA, TRANDOLAPRIL
* KNOLL PHARMACEUTICAL CO SUB BASF CORP
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHYMODIACTIN, CHYMOPAPAIN
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DISCASE, CHYMOPAPAIN
E-MYCIN, ERYTHROMYCIN
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
ISOPTIN, VERAPAMIL HYDROCHLORIDE
LOPURIN, ALLOPURINOL
MAVIK, TRANDOLAPRIL
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRAVASE, SUTILAINS
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE

KOS
* KOS PHARMACEUTICALS INC
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN

KREMERS URBAN
* KREMERS URBAN CO
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

KRKA DD NOVO MESTO
* KRKA DD NOVO MESTO
ENALAPRIL MALEATE, ENALAPRIL MALEATE

KV PHARM
* KV PHARMACEUTICAL CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
AMINOPHYLLINE, AMINOPHYLLINE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FEMSTAT ONE, BUTOCONAZOLE NITRATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
THEOPHYLLINE, THEOPHYLLINE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

FDA data supplied by DrugPatentWatch.com

LABS AF
* LABORATORIOS APLICACIONES FARMACEUTICAS SA DE CV
METROMIDOL, METRONIDAZOLE

LABS ATRAL
* LABORATORIOS ATRAL SARL
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

LACHMAN CONSULT
* LACHMAN CONSULTANT SERVICES INC
LACTULOSE, LACTULOSE

LAFAYETTE PHARMS
* LAFAYETTE PHARMACEUTICALS INC
BAROS, SODIUM BICARBONATE

LANNETT
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BENZYL BENZOATE, BENZYL BENZOATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALAN, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
FOLIC ACID, FOLIC ACID
FURALAN, NITROFURANTOIN
GLUTETHIMIDE, GLUTETHIMIDE
HYDROCORTISONE, HYDROCORTISONE
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
LOFENE, ATROPINE SULFATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURAZONE, NITROFURAZONE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINALAN, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPALAN, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TRICHLOREX, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VELTANE, BROMPHENIRAMINE MALEATE
VITAMIN D, ERGOCALCIFEROL

LAYTON
* LAYTON BIOSCIENCE INC
INVERSINE, MECAMYLAMINE HYDROCHLORIDE

LEDERLE
* LEDERLE LABORATORIES DIV AMERICAN CYANAMID CO
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ASENDIN, AMOXAPINE
ATENOLOL, ATENOLOL
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
CEFACLOR, CEFACLOR
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAZEPAM, DIAZEPAM

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
IBUPROFEN, IBUPROFEN
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEDERCILLIN VK, PENICILLIN V POTASSIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
NAPROXEN, NAPROXEN
NEPTAZANE, METHAZOLAMIDE
NILSTAT, NYSTATIN
PATHILON, TRIDIHEXETHYL CHLORIDE
PIPRACIL, PIPERACILLIN SODIUM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
SERVISONE, PREDNISONE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFASALAZINE, SULFASALAZINE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
SUPRAX, CEFIXIME
TOLBUTAMIDE, TOLBUTAMIDE
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

* LEDERLE PARENTERALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAMOX, ACETAZOLAMIDE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
FUROSEMIDE, FUROSEMIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOLED, VANCOMYCIN HYDROCHLORIDE

* LEDERLE PIPERACILLIN INC DIV AMERICAN CYANAMID CO
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM

LEE KM

* KM LEE LABORATORIES INC
MEPROBAMATE, MEPROBAMATE

LEINER

* LEINER HEALTH PRODUCTS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

LEK LJUBLJANA

* LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO
CIMETIDINE, CIMETIDINE

LEK PHARM

* LEK PHARMACEUTICAL AND CHEMICAL CO DD
ACYCLOVIR, ACYCLOVIR
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CIMETIDINE, CIMETIDINE (OTC)
ENALAPRIL MALEATE, ENALAPRIL MALEATE

LEO PHARM

* LEO PHARMACEUTICAL PRODUCTS LTD
PINDAC, PINACIDIL

FDA data supplied by DrugPatentWatch.com

LIFE LABS
* LIFE LABORATORIES INC
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE

LIGAND
* LIGAND PHARMACEUTICALS INC
PANRETIN, ALITRETINOIN
TARGRETIN, BEXAROTENE

LILLY
* ELI LILLY AND CO
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
ALPHALIN, VITAMIN A PALMITATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ANHYDRON, CYCLOTHIAZIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AXID, NIZATIDINE
BACITRACIN, BACITRACIN
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CESAMET, NABILONE
CINOBAC, CINOXACIN
CORDRAN-N, FLURANDRENOLIDE
CRYSTODIGIN, DIGITOXIN
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DECABID, INDECAINIDE HYDROCHLORIDE
DELTALIN, ERGOCALCIFEROL
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DROLBAN, DROMOSTANOLONE PROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
ERYTHROMYCIN, ERYTHROMYCIN
EVISTA, RALOXIFENE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HALDRONE, PARAMETHASONE ACETATE
HEPARIN SODIUM, HEPARIN SODIUM
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ISONIAZID, ISONIAZID
KAFOCIN, CEPHALOGLYCIN
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
MANDOL, CEFAMANDOLE NAFATE
MENADIONE, MENADIONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METUBINE IODIDE, METOCURINE IODIDE
MOXAM, MOXALACTAM DISODIUM
NEBCIN, TOBRAMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)

FDA data supplied by DrugPatentWatch.com

ONCOVIN, VINCRISTINE SULFATE
PAGITANE, CYCRIMINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERMAX, PERGOLIDE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROZAC, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
SANDRIL, RESERPINE
SECONAL SODIUM, SECOBARBITAL SODIUM
SEROMYCIN, CYCLOSERINE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAPYRIDINE, SULFAPYRIDINE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TAPAZOLE, METHIMAZOLE
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VELBAN, VINBLASTINE SULFATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

* ELI LILLY INDUSTRIES INC
DARVON-N, PROPOXYPHENE NAPSYLATE
DYMELOR, ACETOHEXAMIDE
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS

* LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
CECLOR, CEFACLOR
ILOSONE, ERYTHROMYCIN ESTOLATE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

LILLY RES LABS
* LILLY RESEARCH LABORATORIES
DYNABAC, DIRITHROMYCIN

LIPOSOME

* LIPOSOME CO INC
ABELCET, AMPHOTERICIN B

LIQUIPHARM
* LIQUIPHARM INC
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

LNK
* LNK INTERNATIONAL INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METRONIDAZOLE, METRONIDAZOLE

LOCH
* LOCH PHARMACEUTICALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FOLIC ACID, FOLIC ACID
KANAMYCIN SULFATE, KANAMYCIN SULFATE

LOREX
* LOREX PHARMACEUTICALS
AMBIEN, ZOLPIDEM TARTRATE
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE

LOTUS BIOCHEM
* LOTUS BIOCHEMICAL CORP
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOMAR, ERGOTAMINE TARTRATE
PROFERDEX, IRON DEXTRAN
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE

LPI
* LPI HOLDINGS INC
N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN

FDA data supplied by DrugPatentWatch.com

DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

LYNE
* LYNE LABORATORIES INC
XYLOSE, XYLOSE

** M **

MALLARD
* MALLARD INC
MEPROBAMATE, MEPROBAMATE

MALLINCKRODT
* MALLINCKRODT CHEMICAL INC
ANEXSIA 10/660, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
BONTRIL, PHENDIMETRAZINE TARTRATE
BUCET, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
FEMCET, ACETAMINOPHEN
HYDROCET, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORCET-HD, ACETAMINOPHEN
LORTAB, ACETAMINOPHEN
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TENCON, ACETAMINOPHEN
TRIAD, ACETAMINOPHEN
* MALLINCKRODT INC
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MD-50, DIATRIZOATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTISON, ALBUMIN HUMAN
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OXYCET, ACETAMINOPHEN
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
XENEISOL, XENON, XE-133
* MALLINCKRODT MEDICAL INC
ANGIO-CONRAY, IOTHALAMATE SODIUM
CHOLEBRINE, IOCETAMIC ACID
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HEXABRIX, IOXAGLATE MEGLUMINE
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
PERCHLORACAP, POTASSIUM PERCHLORATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID

FDA data supplied by DrugPatentWatch.com

THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
VASCORAY, IOTHALAMATE MEGLUMINE
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133

MARCHAR
* MARCHAR LABORATORIES INC LTD
FLUOROURACIL, FLUOROURACIL

MARSAM
* MARSAM PHARMACEUTICALS INC
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFACLOR, CEFACLOR
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
ISOFLURANE, ISOFLURANE
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HCL, NALOXONE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MARSHALL PHARMA
* MARSHALL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM

MARTEC
* MARTEC PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
DIAZEPAM, DIAZEPAM
PINDOLOL, PINDOLOL
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
* MARTEC SCIENTIFIC INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM

MAST MM
* MM MAST AND CO
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
PHENAZINE, PHENDIMETRAZINE TARTRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRICHLORMAS, TRICHLORMETHIAZIDE

MATRIX MEDCL
* MATRIX MEDICAL CORP
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)

MAYRAND
* MAYRAND INC
SEDAPAP, ACETAMINOPHEN

MCGAW
* MCGAW INC
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MEDIPREN, IBUPROFEN (OTC)
METHOCARBAMOL AND ASPIRIN, ASPIRIN
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN

FDA data supplied by DrugPatentWatch.com

NUPRIN, IBUPROFEN (OTC)
SINE-AID IB, IBUPROFEN (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
* MCNEIL PHARMACEUTICAL CO DIV MCNEILAB INC
CLISTIN, CARBINOXAMINE MALEATE

MCNEIL CONS
* MCNEIL CONSUMER HEALTHCARE
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MOTRIN, IBUPROFEN
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
VERMOX, MEBENDAZOLE

MD PHARM
* MD PHARMACEUTICAL INC
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DI-ATRO, ATROPINE SULFATE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE

MEAD JOHNSON
* MEAD JOHNSON AND CO SUB BRISTOL MYERS CO
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE

MEDEVA
* MEDEVA AMERICAS INC
SEMPREX-D, ACRIVASTINE
* MEDEVA INC
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
* MEDEVA PHARMACEUTICALS INC
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
GASTROCROM, CROMOLYN SODIUM
IONAMIN, PHENTERMINE RESIN COMPLEX
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
MYKROX, METOLAZONE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
ZAROXOLYN, METOLAZONE

MEDEVA PHARMS CA
* MEDEVA PHARMACEUTICALS CA INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
GLUTETHIMIDE, GLUTETHIMIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE

MEDEVA PHARMS MA
* MEDEVA PHARMACEUTICALS MA INC
ALBUTEROL, ALBUTEROL

MEDI FLEX HOSP
* MEDI FLEX HOSP PRODUCTS INC
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
BUPHENYL, SODIUM PHENYLBUTYRATE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
OVIDE, MALATHION
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
VECTRIN, MINOCYCLINE HYDROCHLORIDE

MEDIMMUNE ONCOLOGY
* MEDIMMUNE ONCOLOGY INC
ETHYOL, AMIFOSTINE
NEUTREXIN, TRIMETREXATE GLUCURONATE

MEDS (TMC)
* MEDICINES CO (TMC)
ANGIOMAX, BIVALIRUDIN

MEDTRONIC
* MEDTRONIC INC
LIORESAL, BACLOFEN

MEPHA
* MEPHA AG
PIROXICAM, PIROXICAM

MERCK
* MERCK AND CO INC
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALPHAREDISOL, HYDROXOCOBALAMIN
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AQUAMEPHYTON, PHYTONADIONE
ARAMINE, METARAMINOL BITARTRATE

FDA data supplied by DrugPatentWatch.com

BENEMID, PROBENECID
COGENTIN, BENZTROPINE MESYLATE
COLBENEMID, COLCHICINE
CORTONE, CORTISONE ACETATE
CUPRIMINE, PENICILLAMINE
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
DARANIDE, DICHLORPHENAMIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECASPRAY, DEXAMETHASONE
DEMSER, METYROSINE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DOLOBID, DIFLUNISAL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLOROPRYL, ISOFLUROPHATE
FOSAMAX, ALENDRONATE SODIUM
HUMORSOL, DEMECARIUM BROMIDE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYZAAR, HYDROCHLOROTHIAZIDE
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
MANNITOL 25%, MANNITOL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEPHYTON, PHYTONADIONE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MINTEZOL, THIABENDAZOLE
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
REDISOL, CYANOCOBALAMIN
SINGULAIR, MONTELUKAST SODIUM
SYPRINE, TRIENTINE HYDROCHLORIDE
TIAMATE, DILTIAZEM MALATE
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
URECHOLINE, BETHANECHOL CHLORIDE

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
ALDOMET, METHYLDOPA
BLOCADREN, TIMOLOL MALEATE
CHIBROXIN, NORFLOXACIN
CLINORIL, SULINDAC
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DECADRON-LA, DEXAMETHASONE ACETATE
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
LACRISERT, HYDROXYPROPYL CELLULOSE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEVACOR, LOVASTATIN
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
NOROXIN, NORFLOXACIN
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
STROMECTOL, IVERMECTIN
TECZEM, DILTIAZEM MALATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VIOXX, ROFECOXIB
ZOCOR, SIMVASTATIN

MERETEK
* MERETEK DIAGNOSTICS INC
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13

MERICON
* MERICON INDUSTRIES INC
HYDROCORTISONE, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ATROPEN, ATROPINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
EPI E Z PEN JR, EPINEPHRINE
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

METABOLIC SOLUTIONS
* METABOLIC SOLUTIONS INC
HELICOSOL, UREA, C-13

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

MFG CHEMISTS
* MANUFACTURING CHEMISTS INC
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

MGI PHARMA
* MGI PHARMA INC
DIDRONEL, ETIDRONATE DISODIUM
HEXALEN, ALTRETAMINE
SALAGEN, PILOCARPINE HYDROCHLORIDE

MIKART
* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

MILES
* MILES LABORATORIES INC
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20%, MANNITOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE

MILEX
* MILEX PRODUCTS INC
MILOPHENE, CLOMIPHENE CITRATE

MISSION PHARMA
* MISSION PHARMACAL CO
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
FOLICET, FOLIC ACID
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
LITHOSTAT, ACETOHYDROXAMIC ACID
POTASSIUM CITRATE, POTASSIUM CITRATE
TIOPRONIN, TIOPRONIN

MIZA PHARMS USA
* MIZA PHARMACEUTICALS USA INC
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
TROPICAMIDE, TROPICAMIDE

MJ PHARMS
* MJ PHARMACEUTICALS LTD
CEPHALEXIN, CEPHALEXIN

FDA data supplied by DrugPatentWatch.com

MK LABS
* MK LABORATORIES INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
ISONIAZID, ISONIAZID
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NIACIN, NIACIN
RESERPINE, RESERPINE
SOSOL, SULFISOXAZOLE
VITAMIN A, VITAMIN A PALMITATE

MONARCH PHARMS
* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
DERMACORT, HYDROCORTISONE
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE
POLYSPORIN, BACITRACIN ZINC
PROCTOCORT, HYDROCORTISONE
PROLOPRIM, TRIMETHOPRIM
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE
* MORTON GROVE ACQUISITION CORP
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
* MORTON GROVE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
BIPHETAP, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCODONE, HOMATROPINE METHYLBROMIDE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYMETHASONE, DEXAMETHASONE
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
NYSTATIN, NYSTATIN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

MOVA
* MOVA PHARMACEUTICALS CORP
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL, CAPTOPRIL
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
GLYBURIDE (MICRONIZED), GLYBURIDE
LORAZEPAM, LORAZEPAM
NAPROXEN, NAPROXEN

MURO
* MURO PHARMACEUTICAL INC
BROMFED-DM, BROMPHENIRAMINE MALEATE
LIQUID PRED, PREDNISONE
PRELONE, PREDNISOLONE
PROMETA, METAPROTERENOL SULFATE
TRI-NASAL, TRIAMCINOLONE ACETONIDE
VOLMAX, ALBUTEROL SULFATE

MUTUAL PHARM
* MUTUAL PHARMACEUTICAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MUTUAL PHARMA
* MUTUAL PHARMACAL CO
KETOCONAZOLE, KETOCONAZOLE

MYLAN
* MYLAN LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
ETODOLAC, ETODOLAC
IBUPROFEN, IBUPROFEN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMYLON, MAFENIDE ACETATE
SULINDAC, SULINDAC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZAGAM, SPARFLOXACIN

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
ESTRADIOL, ESTRADIOL

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN, NITROGLYCERIN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

** N **

NASKA
* NASKA PHARMACAL CO INC DIV RUGBY DARBY GROUP COSMETICS
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
HYDROCORTISONE, HYDROCORTISONE
TRIMETH/SULFA, SULFAMETHOXAZOLE

NASTECH
* NASTECH PHARMACEUTICAL CO INC
NASCOBAL, CYANOCOBALAMIN

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-2, ISOETHARINE HYDROCHLORIDE

NEWTRON PHARMS
* NEWTRON PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE

NMC
* NMC LABORATORIES INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE, HYDROCORTISONE
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALNAC, BETAMETHASONE VALERATE

NORBROOK
* NORBROOK LABORATORIES LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE

NORTON WATERFORD
* NORTON WATERFORD LTD
ALBUTEROL, ALBUTEROL
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

NOVARTIS
* NOVARTIS CONSUMER HEALTH INC
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
RAUTENSIN, ALSEROXYLON
TRANSDERM SCOP, SCOPOLAMINE
* NOVARTIS PHARMACEUTICALS CORP
ACTIGALL, URSODIOL
ACYLANID, ACETYLDIGITOXIN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AREDIA, PAMIDRONATE DISODIUM
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BUTAZOLIDIN, PHENYLBUTAZONE
CAFERGOT, CAFFEINE
CATAFLAM, DICLOFENAC POTASSIUM
CEDILANID-D, DESLANOSIDE
CIBACALCIN, CALCITONIN HUMAN
CLOZARIL, CLOZAPINE
CYTADREN, AMINOGLUTETHIMIDE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DESFERAL, DEFEROXAMINE MESYLATE
DIAPID, LYPRESSIN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE TARTRATE
FEMARA, LETROZOLE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INH, ISONIAZID
ISMELIN, GUANETHIDINE MONOSULFATE
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LIORESAL, BACLOFEN
LOCORTEN, FLUMETHASONE PIVALATE
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MESANTOIN, MEPHENYTOIN
METANDREN, METHYLTESTOSTERONE
METHERGINE, METHYLERGONOVINE MALEATE
METOPIRONE, METYRAPONE
MIACALCIN, CALCITONIN, SALMON
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
NEORAL, CYCLOSPORINE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
REGITINE, PHENTOLAMINE MESYLATE
RESTORIL, TEMAZEPAM
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANOREX, MAZINDOL
SANSERT, METHYSERGIDE MALEATE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERENTIL, MESORIDAZINE BESYLATE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SLOW-K, POTASSIUM CHLORIDE
STARLIX, NATEGLINIDE
SYNTOCINON, OXYTOCIN
TANDEARIL, OXYPHENBUTAZONE
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEN-K, POTASSIUM CHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TRANSDERM-NITRO, NITROGLYCERIN
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TREST, METHIXENE HYDROCHLORIDE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRILEPTAL, OXCARBAZEPINE
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM

NOVEN
* NOVEN PHARMACEUTICALS INC
LIDOCAINE, LIDOCAINE

NOVEX
* NOVEX PHARMA
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
ACTIVELLE, ESTRADIOL
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
INNOFEM, ESTRADIOL
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)

FDA data supplied by DrugPatentWatch.com

INSULIN, INSULIN PORK (OTC)
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
MIXTARD HUMAN 70/30, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
NORDITROPIN, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
PRANDIN, REPAGLINIDE
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
VAGIFEM, ESTRADIOL
VELOSULIN BR HUMAN, INSULIN SEMISYNTHETIC PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN
VELOSULIN, INSULIN PURIFIED PORK (OTC)

NOVOCOL
* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE

NOVOPHARM
* NOVOPHARM LTD
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE, CIMETIDINE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
ETODOLAC, ETODOLAC
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLMETIN SODIUM, TOLMETIN SODIUM
* NOVOPHARM PHARMACEUTICAL CO
FLURBIPROFEN, FLURBIPROFEN

NOVOPHARM NC
* NOVOPHARM NC INC
ALPRAZOLAM, ALPRAZOLAM
ATENOLOL, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CEFACLOR, CEFACLOR
ETODOLAC, ETODOLAC
GLYBURIDE, GLYBURIDE
NAPROXEN, NAPROXEN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

NUMARK
* NUMARK LABORATORIES INC
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
SPRX-105, PHENDIMETRAZINE TARTRATE

NYCOMED
* NYCOMED INC
AMIPAQUE, METRIZAMIDE
BILOPAQUE, TYROPANOATE SODIUM
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE

FDA data supplied by DrugPatentWatch.com

ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNISCAN, GADODIAMIDE
TELEPAQUE, IOPANOIC ACID
TESLASCAN, MANGAFODIPIR TRISODIUM
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL

NYCOMED AMERSHAM
* NYCOMED AMERSHAM
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
DICOPAC KIT, CYANOCOBALAMIN
FERRISELTZ, FERRIC AMMONIUM CITRATE
FLUORINE F-18, SODIUM FLUORIDE, F-18
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
METASTRON, STRONTIUM CHLORIDE, SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
NEOSCAN, GALLIUM CITRATE, GA-67
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133

NYLOS
* NYLOS TRADING CO INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
METHOCARBAMOL, METHOCARBAMOL
PREDNISONE, PREDNISONE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

** O **

OCLASSEN
* OCLASSEN PHARMACEUTICALS INC
CONDYLOX, PODOFILOX
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE

ODYSSEY PHARMS
* ODYSSEY PHARMACEUTICALS INC
NYSTATIN, NYSTATIN
URECHOLINE, BETHANECHOL CHLORIDE

OHM
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)
* OHM LABORATORIES INC
CHLORZOXAZONE, CHLORZOXAZONE
IBUPROFEN, IBUPROFEN
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)

OHMEDA
* OHMEDA PHARMACEUTICAL PRODUCTS DIV INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ENLON, EDROPHONIUM CHLORIDE
SUPRANE, DESFLURANE

ON SITE ALZA
* ON SITE ALZA JOINT VENTURE
ACTISITE, TETRACYCLINE HYDROCHLORIDE

ONY
* ONY INC

FDA data supplied by DrugPatentWatch.com

INFASURF PRESERVATIVE FREE, CALFACTANT

OPR DEVELOP LP
* OPR DEVELOPMENT LP
CAFCIT, CAFFEINE CITRATE

OPTOPICS
* OPTOPICS LABORATORIES CORP
OPTOMYCIN, CHLORAMPHENICOL
PARACAINE, PROPARACAINE HYDROCHLORIDE
SULFACEL-15, SULFACETAMIDE SODIUM

ORGANICS LAGRANGE
* ORGANICS LAGRANGE INC
CORTICOTROPIN, CORTICOTROPIN

ORGANON
* ORGANON INC SUB AKZO NOBEL INC
MIRCETTE, DESOGESTREL
RAPLON, RAPACURONIUM BROMIDE
* ORGANON INC SUB AKZONA INC
ARDUAN, PIPECURONIUM BROMIDE
CALDEROL, CALCIFEDIOL
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
COTAZYM, LIPASE
DECA-DURABOLIN, NANDROLONE DECANOATE
DESOGEN, DESOGESTREL
DOCA, DESOXYCORTICOSTERONE ACETATE
DURABOLIN, NANDROLONE PHENPROPIONATE
FOLLISTIM, FOLLITROPIN ALFA/BETA
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HUMEGON, MENOTROPINS (FSH;LH)
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LYNORAL, ETHINYL ESTRADIOL
MAXIBOLIN, ETHYLESTRENOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
NORCURON, VECURONIUM BROMIDE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
PAVULON, PANCURONIUM BROMIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
REGONOL, PYRIDOSTIGMINE BROMIDE
REMERON, MIRTAZAPINE
REVERSOL, EDROPHONIUM CHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE

ORGANON INC
* ORGANON INC
ANTAGON, GANIRELIX ACETATE
CYCLESSA, DESOGESTREL

ORION
* ORION CORP
COMTAN, ENTACAPONE
FARESTON, TOREMIFENE CITRATE

ORPHAN MEDCL
* ORPHAN MEDICAL INC
ANTIZOL, FOMEPIZOLE
BUSULFEX, BUSULFAN
CYSTADANE, BETAINE, ANHYDROUS
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
SUCRAID, SACROSIDASE

OTSUKA
* OTSUKA AMERICA PHARMACEUTICAL INC
RAXAR, GREPAFLOXACIN HYDROCHLORIDE
* OTSUKA PHARMACEUTICAL CO LTD
PLETAL, CILOSTAZOL

OXFORD PHARM
* OXFORD PHARMACEUTICAL SERVICES INC
MARPLAN, ISOCARBOXAZID

** P **

PACIFIC PHARMA
* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACO
* PACO PHARMACEUTICAL SERVICES INC
LACTULOSE, LACTULOSE
* PACO RESEARCH CORP
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE

PADDOCK
* PADDOCK LABORATORIES INC
BACITRACIN, BACITRACIN

FDA data supplied by DrugPatentWatch.com

CLINDA-DERM, CLINDAMYCIN PHOSPHATE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
KIONEX, SODIUM POLYSTYRENE SULFONATE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

PAL PAK
* PAL PAK INC
AMINOPHYLLINE, AMINOPHYLLINE
RAUVAL, RAUWOLFIA SERPENTINA
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

PANRAY
* PANRAY CORP SUB ORMONT DRUG AND CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CINNASIL, RESCINNAMINE
CORTISONE ACETATE, CORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
KOGLUCOID, RAUWOLFIA SERPENTINA
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
SERPANRAY, RESERPINE
THEOLIXIR, THEOPHYLLINE

PAR PHARM
* PAR PHARMACEUTICAL INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISULFIRAM, DISULFIRAM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE AND ASPIRIN, ASPIRIN
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NYSTATIN, NYSTATIN
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE

FDA data supplied by DrugPatentWatch.com

SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
VALPROIC ACID, VALPROIC ACID

PARKE DAVIS

* PARKE DAVIS
ACCURETIC, HYDROCHLOROTHIAZIDE
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
* PARKE DAVIS DIV WARNER LAMBERT CO
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTRAX, PRAZEPAM
CEREBYX, FOSPHENYTOIN SODIUM
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLYBAR, CHOLESTYRAMINE
COLY-MYCIN S, COLISTIN SULFATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERYC 125, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESTROVIS, QUINESTROL
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EVANS BLUE, EVANS BLUE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HUMATIN, PAROMOMYCIN SULFATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MECLOMEN, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MILONTIN, PHENSUXIMIDE
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
OXAZEPAM, OXAZEPAM
PARACORT, PREDNISONE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PENAPAR-VK, PENICILLIN V POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PITRESSIN TANNATE, VASOPRESSIN TANNATE
POVAN, PYRVINIUM PAMOATE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFALAR, SULFISOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
ZARONTIN, ETHOSUXIMIDE
* PARKE DAVIS LABORATORIES DIV WARNER LAMBERT CO
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL
* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYXIN, CHLORAMPHENICOL
DILANTIN, PHENYTOIN SODIUM
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMPATCH, ESTRADIOL
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
NEURONTIN, GABAPENTIN

FDA data supplied by DrugPatentWatch.com

NITROSTAT, NITROGLYCERIN
UTICORT, BETAMETHASONE BENZOATE
ZARONTIN, ETHOSUXIMIDE

PARKE DAVIS PHARMS
* PARKE DAVIS PHARMACEUTICALS LTD
FEMHRT, ETHINYL ESTRADIOL
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
REZULIN, TROGLITAZONE

PARKEDALE
* PARKEDALE PHARMACEUTICALS INC
ACTH, CORTICOTROPIN
ANUSOL HC, HYDROCORTISONE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
HUMATIN, PAROMOMYCIN SULFATE
KETALAR, KETAMINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
PITOCIN, OXYTOCIN
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
SURITAL, THIAMYLAL SODIUM
THEELIN, ESTRONE
VIRA-A, VIDARABINE

PARNELL
* PARNELL PHARMACEUTICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PATHOGENESIS
* PATHOGENESIS CORP
TOBI, TOBRAMYCIN

PEACHTREE
* PEACHTREE PHARMACEUTICALS
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

PEDINOL
* PEDINOL PHARMACAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE

PENNEX
* PENNEX PRODUCTS CO INC
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)

PERIO PRODS
* PERIO PRODUCTS LTD
PERIOCHIP, CHLORHEXIDINE GLUCONATE

PERRIGO
* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAP-PROFEN, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEPROBAMATE, MEPROBAMATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TAB-PROFEN, IBUPROFEN (OTC)
THEOPHYLLINE, THEOPHYLLINE
* PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

PERSONAL PRODS
* PERSONAL PRODUCTS CO
DELFEN, NONOXYNOL-9 (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT DUAL- PAK, MICONAZOLE NITRATE

PFIPHARMECS
* PFIPHARMECS DIV PFIZER INC
CORTRIL, HYDROCORTISONE
TETRACYN, TETRACYCLINE HYDROCHLORIDE

PFIZER
* PFIZER AGRICULTURAL DIV
ANTIVERT, MECLIZINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
VIAGRA, SILDENAFIL CITRATE

FDA data supplied by DrugPatentWatch.com

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
TROVAN, TROVAFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
* PFIZER INC
CEFOBID, CEFOPERAZONE SODIUM
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIZIDE, POLYTHIAZIDE
PROCARDIA, NIFEDIPINE
RENESE, POLYTHIAZIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
UNASYN, AMPICILLIN SODIUM
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
* PFIZER LABORATORIES DIV PFIZER INC
BACITRACIN, BACITRACIN
CARDURA, DOXAZOSIN MESYLATE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
FOVANE, BENZTHIAZIDE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MITHRACIN, PLICAMYCIN
MODERIL, RESCINNAMINE
NEOBIOTIC, NEOMYCIN SULFATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PROCARDIA XL, NIFEDIPINE
RENESE-R, POLYTHIAZIDE
SINEQUAN, DOXEPIN HYDROCHLORIDE
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TAO, TROLEANDOMYCIN
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
URESE, BENZTHIAZIDE
VANSIL, OXAMNIQUINE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS INC
TAO, TROLEANDOMYCIN
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER IRELAND PHARM
* PFIZER IRELAND PHARMACEUTICALS, TABLET PLANT
LIPITOR, ATORVASTATIN CALCIUM

PHARM ASSOC
* PHARMACEUTICAL ASSOC INC
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

ETHOSUXIMIDE, ETHOSUXIMIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
H-CORT, HYDROCORTISONE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARM FORM
* PHARMACEUTICAL FORMULATIONS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)

PHARM SPEC
* PHARMACEUTICAL SPECIALIST ASSOC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM

PHARMA SERVE NY
* PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMA TEK
* PHARMA TEK INC
AMPHOTERICIN B, AMPHOTERICIN B
BACI-RX, BACITRACIN
BACIIM, BACITRACIN
COLISTIMETHATE, COLISTIMETHATE SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
NEO-RX, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
ZIBA-RX, BACITRACIN ZINC

PHARMACHEMIE
* PHARMACHEMIE BV
CISPLATIN, CISPLATIN
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

PHARMACHEMIE USA
* PHARMACHEMIE USA INC
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN
* PHARMACIA AND UPJOHN CO
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ALBAMYCIN, NOVOBIOCIN SODIUM
ALPHADROL, FLUPREDNISOLONE
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACIGUENT, BACITRACIN
BACITRACIN, BACITRACIN
BERUBIGEN, CYANOCOBALAMIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CALMURID HC, HYDROCORTISONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CAVERJECT, ALPROSTADIL
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTISONE ACETATE, CORTISONE ACETATE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOSAR-U, CYTARABINE
DELTA-CORTEF, PREDNISOLONE
DELTASONE, PREDNISONE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIPENTUM, OLSALAZINE SODIUM
DIZAC, DIAZEPAM

FDA data supplied by DrugPatentWatch.com

DOSTINEX, CABERGOLINE
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLUIDIL, CYCLOTHIAZIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FRAGMIN, DALTEPARIN SODIUM
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HALOTESTIN, FLUOXYMESTERONE
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM, HEPARIN SODIUM
HYLOREL, GUANADREL SULFATE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LONITEN, MINOXIDIL
LUNELLE, ESTRADIOL CYPIONATE
MAOLATE, CHLORPHENESIN CARBAMATE
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MICRONASE, GLYBURIDE
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCOBUTIN, RIFABUTIN
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEOSAR, CYCLOPHOSPHAMIDE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
OXYLONE, FLUOROMETHOLONE
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PSORCON, DIFLORASONE DIACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
TOLINASE, TOLAZAMIDE
TOPOSAR, ETOPOSIDE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TYMTRAN, CERULETIDE DIETHYLAMINE
U-GENCIN, GENTAMICIN SULFATE
UTICILLIN VK, PENICILLIN V POTASSIUM
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANTIN, CEFPODOXIME PROXETIL
VINCASAR PFS, VINCRISTINE SULFATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZANOSAR, STREPTOZOCIN
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN CO NUTRITION DIV
ELLENCE, EPIRUBICIN HYDROCHLORIDE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CONSUMER HEALTHCARE
NASALCROM, CROMOLYN SODIUM (OTC)

PHARMADERM

* PHARMADERM DIV ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

FDA data supplied by DrugPatentWatch.com

PHARMAFAIR
* PHARMAFAIR INC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BOROFAIR, ACETIC ACID, GLACIAL
CARBACHOL, CARBACHOL
CHLOROFAIR, CHLORAMPHENICOL
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAFAIR, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KAINAIR, PROPARACAINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
MYDRIAFAIR, TROPICAMIDE
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OCUMYCIN, BACITRACIN ZINC
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC

PHARMASEAL
* PHARMASEAL DIV BAXTER HEALTHCARE CORP
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

PHARMATON
* PHARMATON LTD
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE

PHARMAVITE
* PHARMAVITE PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE

PHARMERAL
* PHARMERAL INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
SULFISOXAZOLE, SULFISOXAZOLE

PHARMOS
* PHARMOS CORP
ALREX, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE

PHOENIX LABS NY
* PHOENIX LABORATORIES INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DEXAMETHASONE, DEXAMETHASONE
ISONIAZID, ISONIAZID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

PHYS PRODS VA
* PHYSICIANS PRODUCTS CO INC DIV INTERNATIONAL LATEX CORP
HYSERPIN, RAUWOLFIA SERPENTINA

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
ETOPOSIDE, ETOPOSIDE

PIONEER PHARMS
* PIONEER PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
INDOMETHACIN, INDOMETHACIN
METHOCARBAMOL, METHOCARBAMOL
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)

PLANTEX
* PLANTEX USA INC DIV IKAPHARM INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO
NITRO IV, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN

POINT HOLDINGS
* POINT HOLDINGS INC
ETODOLAC, ETODOLAC

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)
PROMETHACON, PROMETHAZINE HYDROCHLORIDE

POPULATION COUNCIL
* POPULATION COUNCIL
COPPER T MODEL TCU 380A, COPPER
MIFEPREX, MIFEPRISTONE
NORPLANT, LEVONORGESTREL
* POPULATION COUNCIL CENTER FOR BIOMEDICAL RESEARCH
NORPLANT II, LEVONORGESTREL

POYTHRESS
* WILLIAM P POYTHRESS AND CO INC
BENSULFOID, SULFUR

PROCTER AND GAMBLE
* PROCTER AND GAMBLE CO
DANTRIUM, DANTROLENE SODIUM
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBL
ACTONEL, RISEDRONATE SODIUM
ASACOL, MESALAMINE
DANTRIUM, DANTROLENE SODIUM
DIDRONEL, ETIDRONATE DISODIUM
FURADANTIN, NITROFURANTOIN
IVADANTIN, NITROFURANTOIN SODIUM
LABID, THEOPHYLLINE
MACROBID, NITROFURANTOIN
NYSERT, NYSTATIN
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
SARENIN, SARALASIN ACETATE

PROF DSPLS
* PROFESSIONAL DISPOSABLES INC
HEXASCRUB, HEXACHLOROPHENE

PROMETHEUS LABS
* PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE

PROTER
* PROTER LABORATORY SPA
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

PURDUE FREDERICK
* PURDUE FREDERICK CO
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
DHC PLUS, ACETAMINOPHEN
MS CONTIN, MORPHINE SULFATE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHYLLOCONTIN, AMINOPHYLLINE
SULFABID, SULFAPHENAZOLE
T-PHYL, THEOPHYLLINE
UNIPHYL, THEOPHYLLINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM
* PUREPAC PHARMACEUTICAL CO DIV PUREPAC INC
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

PRODUCT NAME INDEX LISTED BY APPLICANT

ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPTOPRIL, CAPTOPRIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LORAZEPAM, LORAZEPAM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFISOXAZOLE, SULFISOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

PVT FORM

* PRIVATE FORMULATIONS INC
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
BENZTHIAZIDE, BENZTHIAZIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DI-METREX, PHENDIMETRAZINE TARTRATE

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
FEMOGEN, ESTROGENS, ESTERIFIED
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MEPROBAMATE, MEPROBAMATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

** Q **

QLT
* QLT PHOTO THERAPEUTICS INC
VISUDYNE, VERTEPORFIN

QUAD PHARMS
* QUAD PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AZATHIOPRINE, AZATHIOPRINE SODIUM
BACITRACIN, BACITRACIN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZOXIDE, DIAZOXIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLUPHENAZINE, FLUPHENAZINE DECANOATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
ISONIAZID, ISONIAZID
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NITROGLYCERIN, NITROGLYCERIN
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROTAMINE SULFATE, PROTAMINE SULFATE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE

QUANTUM PHARMICS
* QUANTUM PHARMICS LTD
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HALOPERIDOL, HALOPERIDOL

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LORAZ, LORAZEPAM
MECLODIUM, MECLOFENAMATE SODIUM
MINODYL, MINOXIDIL
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
TEMAZ, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZAXOPAM, OXAZEPAM

QUESTCOR PHARM
* QUESTCOR PHARMACEUTICALS INC
ETHAMOLIN, ETHANOLAMINE OLEATE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
INULIN AND SODIUM CHLORIDE, INULIN
SILDIMAC, SILVER SULFADIAZINE

** R **

R AND D LABS
* R AND D LABORATORIES INC
FERRLECIT, FERRIC SODIUM GLUCONATE

R AND S PHARMA
* R AND S PHARMA INC
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE

RACHELLE
* RACHELLE LABORATORIES INC
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE

RANBAXY
* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
* RANBAXY PHARMACEUTICALS INC
AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

RATIOPHARM
* RATIOPHARM GMBH AND CO ARZNEIMITTEL
SUCRALFATE, SUCRALFATE

RECKITT AND COLMAN
* RECKITT AND COLMAN PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE

REED AND CARNRICK
* REED AND CARNRICK PHARMACEUTICALS DIV BLOCK DRUG CO INC
KWELL, LINDANE

RES INDS
* RESEARCH INDUSTRIES CORP
RIMSO-50, DIMETHYL SULFOXIDE

REXALL
* REXALL DRUG CO
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE

REXAR
* REXAR PHARMACAL
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE

RHODIA
* RHODIA LTD
ISOFLURANE, ISOFLURANE

ROACO
* TJ ROACO LTD
BETADERM, BETAMETHASONE VALERATE

ROBERTS AND HAUCK
* ROBERTS AND HAUCK PHARMACEUTICALS INC
ANOQUAN, ACETAMINOPHEN

ROBERTS LABS
* ROBERTS LABORATORIES INC
DOPAR, LEVODOPA
DUVOID, BETHANECHOL CHLORIDE
FURACIN, NITROFURAZONE
PROAMATINE, MIDODRINE HYDROCHLORIDE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD

FDA data supplied by DrugPatentWatch.com

ROBINS AH
* AH ROBINS CO
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DOPRAM, DOXAPRAM HYDROCHLORIDE
ISMO, ISOSORBIDE MONONITRATE
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
QUINIDEX, QUINIDINE SULFATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBIMYCIN, ERYTHROMYCIN
ROBINUL, GLYCOPYRROLATE
TENATHAN, BETHANIDINE SULFATE

ROCHE
* HOFFMANN LA ROCHE INC
ARFONAD, TRIMETHAPHAN CAMSYLATE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BEROCCA PN, ASCORBIC ACID
BUMEX, BUMETANIDE
COACTIN, AMDINOCILLIN
DEMADEX, TORSEMIDE
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
FANSIDAR, PYRIMETHAMINE
FUDR, FLOXURIDINE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
HIVID, ZALCITABINE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KONAKION, PHYTONADIONE
KYTRIL, GRANISETRON HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LORFAN, LEVALLORPHAN TARTRATE
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
NIPRIDE, SODIUM NITROPRUSSIDE
NOLUDAR, METHYPRYLON
QUARZAN, CLIDINIUM BROMIDE
RIMADYL, CARPROFEN
RIMIFON, ISONIAZID
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
SOLATENE, BETA-CAROTENE
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TARACTAN, CHLORPROTHIXENE
TASMAR, TOLCAPONE
TEGISON, ETRETINATE
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
VALIUM, DIAZEPAM
VALRELEASE, DIAZEPAM
VERSED, MIDAZOLAM HYDROCHLORIDE
VESANOID, TRETINOIN

ROCHE GLOBAL DEV
* ROCHE GLOBAL DEVELOPMENT DIV SYNTEX (USA) LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROERIG
* ROERIG DIV PFIZER INC
ATARAX, HYDROXYZINE HYDROCHLORIDE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEOPEN, CARBENICILLIN DISODIUM
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
SUSTAIRE, THEOPHYLLINE

RORER
* RORER PHARMACEUTICAL CORP SUB RORER GROUP
NITROL, NITROGLYCERIN

ROSEMONT
* ROSEMONT PHARMACEUTICAL CORP
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETOHEXAMIDE, ACETOHEXAMIDE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE, CHLORTHALIDONE
CLOFIBRATE, CLOFIBRATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PRAZEPAM, PRAZEPAM
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VALPROIC ACID, VALPROIC ACID
WARFARIN SODIUM, WARFARIN SODIUM

ROSS LABS
* ROSS LABORATORIES DIV ABBOTT LABORATORIES INC
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
SURVANTA, BERACTANT

ROXANE
* ROXANE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTULOSE, LACTULOSE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
ORAMORPH SR, MORPHINE SULFATE
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
PIROXICAM, PIROXICAM
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAZOLAM, TRIAZOLAM

ROYCE LABS
* ROYCE LABORATORIES INC
HALOPERIDOL, HALOPERIDOL
MINOXIDIL, MINOXIDIL

** S **

SABEX
* SABEX INC
MULTI-12, ALPHA-TOCOPHEROL ACETATE

SALIX
* SALIX PHARMACEUTICALS INC
COLAZAL, BALSALAZIDE DISODIUM

SANKYO
* SANKYO PHARMA INC
WELCHOL, COLESEVELAM HYDROCHLORIDE
* SANKYO USA CORP
BANAN, CEFPODOXIME PROXETIL
PRELAY, TROGLITAZONE

SANO
* SANO CORP
NICOTINE, NICOTINE

SANOFI SYNTHELABO
* SANOFI SYNTHELABO INC
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
CALCIPARINE, HEPARIN CALCIUM
CHEMET, SUCCIMER
DANOCRINE, DANAZOL
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
INOCOR, INAMRINONE LACTATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
LOTUSATE, TALBUTAL
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MODRASTANE, TRILOSTANE
MYTELASE, AMBENONIUM CHLORIDE
NEGGRAM, NALIDIXIC ACID

FDA data supplied by DrugPatentWatch.com

PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
SKELID, TILUDRONATE DISODIUM
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TORNALATE, BITOLTEROL MESYLATE
TRANCOPAL, CHLORMEZANONE
WINSTROL, STANOZOLOL

SANTEN
* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
QUIXIN, LEVOFLOXACIN

SANTEN OY
* SANTEN OY
BETIMOL, TIMOLOL

SAVAGE LABS
* SAVAGE LABORATORIES INC DIV ALTANA INC
ALPHATREX, BETAMETHASONE DIPROPIONATE
AXOTAL, ASPIRIN
BETATREX, BETAMETHASONE VALERATE
CHYMEX, BENTIROMIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DITATE-DS, ESTRADIOL VALERATE
ETHIODOL, ETHIODIZED OIL
FLUOTREX, FLUOCINOLONE ACETONIDE
GVS, GENTIAN VIOLET
K-LEASE, POTASSIUM CHLORIDE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN
NYSTEX, NYSTATIN
PANDEL, HYDROCORTISONE PROBUTATE
RUVITE, CYANOCOBALAMIN
SATRIC, METRONIDAZOLE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
XYLO-PFAN, XYLOSE

SCHEIN
* SCHEIN PHARMACEUTICAL INC
INFED, IRON DEXTRAN

SCHERER LABS
* SCHERER LABORATORIES INC
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE

SCHERER RP
* RP SCHERER CORP
NIFEDIPINE, NIFEDIPINE
* RP SCHERER NORTH AMERICA
NIFEDIPINE, NIFEDIPINE
THEOPHYLLINE, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID
* RP SCHERER NORTH AMERICA DIV RP SCHERER CORP
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
THEOPHYLLINE-SR, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID

SCHERING
* SCHERING CORP
CLARITIN REDITABS, LORATADINE
CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
IMDUR, ISOSORBIDE MONONITRATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
QUINORA, QUINIDINE SULFATE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
TEMODAR, TEMOZOLOMIDE
THEO-DUR, THEOPHYLLINE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
* SCHERING CORP SUB SCHERING PLOUGH CORP
AKRINOL, ACRISORCIN
BETAPAR, MEPREDNISONE
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CLARITIN, LORATADINE
CLARITIN-D, LORATADINE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DISOMER, DEXBROMPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
ELOCON, MOMETASONE FUROATE
ESTINYL, ETHINYL ESTRADIOL
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GARAMYCIN, GENTAMICIN SULFATE
HYPERSTAT, DIAZOXIDE
LOTRIMIN, CLOTRIMAZOLE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
MIRADON, ANISINDIONE
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NETROMYCIN, NETILMICIN SULFATE
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
OPTIMINE, AZATADINE MALEATE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
PAXIPAM, HALAZEPAM
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
PRANTAL, DIPHEMANIL METHYLSULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
RELA, CARISOPRODOL
SODIUM SULAMYD, SULFACETAMIDE SODIUM
THEOVENT, THEOPHYLLINE
TINDAL, ACETOPHENAZINE MALEATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRINALIN, AZATADINE MALEATE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE

SCHERING PLOUGH

* SCHERING PLOUGH CORP
NASONEX, MOMETASONE FUROATE MONOHYDRATE
* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
LOTRIMIN AF, CLOTRIMAZOLE (OTC)
LOTRIMIN, CLOTRIMAZOLE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCHERING PLOUGH RES

* SCHERING PLOUGH RESEARCH INSTITUTE
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN

SCHWARZ

* SCHWARZ GMBH
MONOKET, ISOSORBIDE MONONITRATE

SCHWARZ PHARMA

* SCHWARZ PHARMA AG
EDEX, ALPROSTADIL
* SCHWARZ PHARMA INC
CO-GESIC, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DILATRATE-SR, ISOSORBIDE DINITRATE
EPIFOAM, HYDROCORTISONE ACETATE
LEVATOL, PENBUTOLOL SULFATE
PREDNICEN-M, PREDNISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE

SCS

* SCS PHARMACEUTICALS
ATENOLOL, ATENOLOL
CARBIDOPA AND LEVODOPA, CARBIDOPA
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE

FDA data supplied by DrugPatentWatch.com

FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM

SEARLE

* GD SEARLE AND CO
AMINOPHYLLIN, AMINOPHYLLINE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
CELEBREX, CELECOXIB
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CU-7, COPPER
CYTOTEC, MISOPROSTOL
DAYPRO, OXAPROZIN
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORQUEST FE, ETHINYL ESTRADIOL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
TATUM-T, COPPER

* SEARLE PHARMACEUTICALS INC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DIULO, METOLAZONE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
FLAGYL, METRONIDAZOLE
OVULEN-28, ETHYNODIOL DIACETATE
SYNAREL, NAFARELIN ACETATE

SEPRACOR

* SEPRACOR INC
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SEPTODONT

* SEPTODONT INC
OCTOCAINE, EPINEPHRINE

SERONO

* SERONO LABORATORIES INC
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
FERTINEX, UROFOLLITROPIN
GEREF, SERMORELIN ACETATE
GONAL-F, FOLLITROPIN ALFA/BETA
METRODIN, UROFOLLITROPIN
OVIDREL, CHORIOGONADOTROPIN ALFA
PERGONAL, MENOTROPINS (FSH;LH)
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT

SERONO INC

* SERONO INC
CETROTIDE, CETRORELIX

SHERWOOD MEDCL

* SHERWOOD MEDICAL CO
ACTIN-N, NITROFURAZONE

SHIONOGI

* SHIONOGI USA INC
UROBAK, SULFAMETHOXAZOLE
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE

SHIRE

* SHIRE LABORATORIES INC
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
BANTHINE, METHANTHELINE BROMIDE
CARBATROL, CARBAMAZEPINE
ETHMOZINE, MORICIZINE HYDROCHLORIDE
FURACIN, NITROFURAZONE
FUROXONE, FURAZOLIDONE
PENTASA, MESALAMINE
PRO-BANTHINE, PROPANTHELINE BROMIDE
SALURON, HYDROFLUMETHIAZIDE

FDA data supplied by DrugPatentWatch.com

SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SUPPRELIN, HISTRELIN ACETATE

SHIRE RICHWOOD
* SHIRE RICHWOOD INC
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE

SIDMAK LABS
* SIDMAK LABORATORIES INC
ALBUTEROL, ALBUTEROL
CYCLOSPORINE, CYCLOSPORINE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NAPROXEN, NAPROXEN
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

SIDMAK LABS NJ
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DISULFIRAM, DISULFIRAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FLURBIPROFEN, FLURBIPROFEN
GLIPIZIDE, GLIPIZIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HCL, PROTRIPTYLINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SIGHT PHARMS
* SIGHT PHARMACEUTICALS INC
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)

SIGMA TAU
* SIGMA TAU PHARMACEUTICALS INC
CARNITOR, LEVOCARNITINE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SILARX
* SILARX PHARMACEUTICALS INC
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

SKYEPHARMA
* SKYEPHARMA INC
DEPOCYT, CYTARABINE
SOLARAZE, DICLOFENAC SODIUM

SMITH AND NEPHEW
* SMITH AND NEPHEW SOLOPAK DIV SMITH AND NEPHEW
AMINOPHYLLINE, AMINOPHYLLINE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN

FDA data supplied by DrugPatentWatch.com

PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SMITHKLINE
* SMITHKLINE BEECHAM CORP
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
* SMITHKLINE CONSUMER PRODUCTS DIV SMITHKLINE AND FRENCH LABOR
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)

SMITHKLINE BEECHAM
* SMITHKLINE BEECHAM
MONOCID, CEFONICID SODIUM
* SMITHKLINE BEECHAM CONSUMER HEALTHCARE
ABREVA, DOCOSANOL (OTC)
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
* SMITHKLINE BEECHAM CONSUMER HEALTHCARE LP
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
* SMITHKLINE BEECHAM PHARMACEUTICALS
ALBENZA, ALBENDAZOLE
AMOXIL, AMOXICILLIN
ANCEF, CEFAZOLIN SODIUM
ANSPOR, CEPHRADINE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AVANDIA, ROSIGLITAZONE MALEATE
BACTOCILL, OXACILLIN SODIUM
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BEEPEN-VK, PENICILLIN V POTASSIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CLOXAPEN, CLOXACILLIN SODIUM
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
COREG, CARVEDILOL
DARBID, ISOPROPAMIDE IODIDE
DENAVIR, PENCICLOVIR SODIUM
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
FASTIN, PHENTERMINE HYDROCHLORIDE
HALFAN, HALOFANTRINE HYDROCHLORIDE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
LAROTID, AMOXICILLIN
NALLPEN, NAFCILLIN SODIUM
ORNADE, CHLORPHENIRAMINE MALEATE
PARNATE, TRANYLCYPROMINE SULFATE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PHYTONADIONE, PHYTONADIONE
PYOPEN, CARBENICILLIN DISODIUM
QUINIDINE SULFATE, QUINIDINE SULFATE
RELAFEN, NABUMETONE
REQUIP, ROPINIROLE HYDROCHLORIDE
STOXIL, IDOXURIDINE
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TAZICEF, CEFTAZIDIME
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
URISPAS, FLAVOXATE HYDROCHLORIDE
VONTROL, DIPHENIDOL HYDROCHLORIDE
* SMITHKLINE BEECHAM PHARMACEUTICALS CO
COMPAZINE, PROCHLORPERAZINE MALEATE
FAMVIR, FAMCICLOVIR
MONOCID, CEFONICID SODIUM
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
TAZICEF, CEFTAZIDIME

SNOWBRAND
* SNOWBRAND PHARMACEUTICALS INC
EVOXAC, CEVIMELINE HYDROCHLORIDE

SOAPCO
* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOLA BARNES HIND
* SOLA BARNES HIND
ALPHA CHYMAR, CHYMOTRYPSIN
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GAMENE, LINDANE

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE

SOLOPAK
* SOLOPAK LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DROPERIDOL, DROPERIDOL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
* SOLOPAK MEDICAL PRODUCTS INC
CYANOCOBALAMIN, CYANOCOBALAMIN
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* SOLOPAK PHARMACEUTICALS INC
GANITE, GALLIUM NITRATE

SOLVAY
* SOLVAY PHARMACEUTICALS
AQUATAG, BENZTHIAZIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ATROPINE, ATROPINE
BALNEOL-HC, HYDROCORTISONE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CIN-QUIN, QUINIDINE SULFATE
CORTENEMA, HYDROCORTISONE
CURRETAB, MEDROXYPROGESTERONE ACETATE
DERMACORT, HYDROCORTISONE
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DUPHALAC, LACTULOSE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
GYNOREST, DYDROGESTERONE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LACTULOSE, LACTULOSE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOTABS, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
ORASONE, PREDNISONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTALAC, LACTULOSE
PROVAL #3, ACETAMINOPHEN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
R-P MYCIN, ERYTHROMYCIN
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RETET, TETRACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
S.A.S.-500, SULFASALAZINE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SPRX-3, PHENDIMETRAZINE TARTRATE
SULSOXIN, SULFISOXAZOLE
SYMADINE, AMANTADINE HYDROCHLORIDE
TORA, PHENTERMINE HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRIACORT, TRIAMCINOLONE ACETONIDE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
VERMIDOL, PIPERAZINE CITRATE
ZIDE, HYDROCHLOROTHIAZIDE

SOLVAY PHARMA
* SOLVAY PHARMA INC
ACEON, PERINDOPRIL ERBUMINE

SOMERSET
* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SORIN
* SORIN BIOMEDICA SPA
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131

SPEAR PHARMS
* SPEAR PHARMACEUTICALS INC
TRETINOIN, TRETINOIN

SPERTI
* SPERTI DRUG PRODUCTS INC
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

STANLABS PHARM

FDA data supplied by DrugPatentWatch.com

* STANLABS PHARMACEUTICAL CO SUB SIMPAK CORP
MEPROBAMATE, MEPROBAMATE

STAR PHARMS FL
* STAR PHARMACEUTICALS INC
VIRILON, METHYLTESTOSTERONE

STASON
* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

STERIPAK
* STERIPAK
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

STERIS
* STERIS LABORATORIES INC
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COBAVITE, CYANOCOBALAMIN
CORTICOTROPIN, CORTICOTROPIN
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISODIUM EDETATE, EDETATE DISODIUM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDETATE DISODIUM, EDETATE DISODIUM
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRONE, ESTRONE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
MVC PLUS, ASCORBIC ACID
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OTOCORT, HYDROCORTISONE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROGESTERONE, PROGESTERONE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TROPICAMIDE, TROPICAMIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

STERLING
* STERLING HEALTH DIV STERLING WINTHROP INC
BRONKAID MIST, EPINEPHRINE (OTC)

STERLING WINTHROP
* STERLING WINTHROP INC
AFAXIN, VITAMIN A PALMITATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

STEVENS J
* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LIOTRIX (T4;T3)

STIEFEL
* STIEFEL LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
SCABENE, LINDANE
STIE-CORT, HYDROCORTISONE

STORZ
* STORZ OPHTHALMICS INC SUB AMERICAN CYANAMID CO
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE

STUART PHARMS
* STUART PHARMACEUTICALS DIV ICI AMERICAS
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE

SUMMERS
* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUPERGEN
* SUPERGEN INC
ETOPOSIDE, ETOPOSIDE
MITOMYCIN, MITOMYCIN
NIPENT, PENTOSTATIN

SUPERPHARM
* SUPERPHARM CORP
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LOGEN, ATROPINE SULFATE
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFASALAZINE, SULFASALAZINE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE

SUPPOSITORIA
* SUPPOSITORIA LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)

SYNCOR PHARMS
* SYNCOR PHARMACEUTICALS INC
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
SODIUM IODIDE I 123, SODIUM IODIDE, I-123

SYNTEX (USA) INC LLC
* SYNTEX (USA) INC LLC
AEROBID, FLUNISOLIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
EC-NAPROSYN, NAPROXEN
EVEX, ESTROGENS, ESTERIFIED
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
NAPROSYN, NAPROXEN
TICLID, TICLOPIDINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE

SYOSSET
* SYOSSET LABORATORIES INC
E-SOLVE 2, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE

** T **

TABLICAPS
* TABLICAPS INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
STILBESTROL, DIETHYLSTILBESTROL

TAKEDA
* TAKEDA CHEMICAL INDUSTRIES LTD
CERADON, CEFOTIAM HYDROCHLORIDE

TAKEDA PHARMS NA
* TAKEDA PHARMACEUTICALS NORTH AMERICA INC
ACTOS, PIOGLITAZONE HYDROCHLORIDE

TAP PHARM
* TAP PHARMACEUTICAL PRODUCTS INC
CEFMAX, CEFMENOXIME HYDROCHLORIDE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN

TARGET RES
* TARGET RESEARCH ASSOC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

TARO
* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE
* TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINONIDE, FLUOCINONIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORACORT, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

TARO PHARM INDS
* TARO PHARMACEUTICAL INDUSTRIES LTD
CARBAMAZEPINE, CARBAMAZEPINE
ETODOLAC, ETODOLAC

TAYLOR
* TAYLOR PHARMACEUTICALS
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA
* TAYLOR PHARMACAL CO
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TECHNILAB
* TECHNILAB INC
ACILAC, LACTULOSE
LAXILOSE, LACTULOSE

TEIKOKU PHARMA USA
* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TEVA
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CINOXACIN, CINOXACIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
COPAXONE, GLATIRAMER ACETATE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
CYCLACILLIN, CYCLACILLIN
DELCOBESE, AMPHETAMINE ADIPATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE

FDA data supplied by DrugPatentWatch.com

DOXY-LEMMON, DOXYCYCLINE HYCLATE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FLUOCINONIDE, FLUOCINONIDE
FLURBIPROFEN, FLURBIPROFEN
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLUCAMIDE, CHLORPROPAMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HY-PAM "25", HYDROXYZINE PAMOATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDO-LEMMON, INDOMETHACIN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPRIAM, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYCO-TRIACET II, NYSTATIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTHYLLINE, DYPHYLLINE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORAP, PIMOZIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RESERPINE, RESERPINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFANILAMIDE, SULFANILAMIDE
SULINDAC, SULINDAC
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIACET, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE

THAMES

* THAMES PHARMACAL CO INC
ACETIC ACID, ACETIC ACID, GLACIAL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORALONE, TRIAMCINOLONE ACETONIDE

FDA data supplied by DrugPatentWatch.com

SELENIUM SULFIDE, SELENIUM SULFIDE
THEOPHYLLINE, THEOPHYLLINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
U-CORT, HYDROCORTISONE ACETATE

THERAKOS
* THERAKOS INC
UVADEX, METHOXSALEN

TOPIDERM
* TOPIDERM INC
HYDROCORTISONE, HYDROCORTISONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TORCH
* TORCH LABORATORIES INC
H-CORT, HYDROCORTISONE

TORPHARM
* TORPHARM INC
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLONAZEPAM, CLONAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
GEMFIBROZIL, GEMFIBROZIL
PENTOXIFYLLINE, PENTOXIFYLLINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE

TRIGEN
* TRIGEN LABORATORIES INC
INDAPAMIDE, INDAPAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

TX BIOTECH
* TEXAS BIOTECHNOLOGY CORP
ACOVA, ARGATROBAN

** U **

UCB
* UCB PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
THEO-24, THEOPHYLLINE

UDL
* UDL LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FOLIC ACID, FOLIC ACID
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
VALPROIC ACID, VALPROIC ACID

UNIMED
* UNIMED INC
ANADROL-50, OXYMETHOLONE
MARINOL, DRONABINOL

UNIMED PHARMS
* UNIMED PHARMACEUTICALS INC
ANDROGEL, TESTOSTERONE
PROMETRIUM, PROGESTERONE
TEVETEN, EPROSARTAN MESYLATE

UNITED GUARDIAN
* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNIV AZ CANCER CTR
* UNIV ARIZONA CANCER CENTER
ACTINEX, MASOPROCOL

UPSHER SMITH
* UPSHER SMITH LABORATORIES INC
DEXAMETHASONE, DEXAMETHASONE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NIACOR, NIACIN
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREDNISONE, PREDNISONE
PREVALITE, CHOLESTYRAMINE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE

US ARMY
* UNITED STATES ARMY OFFICE SURGEON GENERAL
ATROPINE SULFATE, ATROPINE SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
* US ARMY MEDICAL RESEARCH MATERIEL COMMAND
DIAZEPAM, DIAZEPAM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER

FDA data supplied by DrugPatentWatch.com

US ARMY WALTER REED
* UNITED STATES ARMY WALTER REED ARMY INSTITUTE RESEARCH
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE

US CHEM
* US CHEMICAL MARKETING GROUP INC
MEDIGESIC PLUS, ACETAMINOPHEN

US SURGCL
* UNITED STATES SURGICAL CORP DIV TYCO HEALTHCARE PRODUCTS GRO
LYMPHAZURIN, ISOSULFAN BLUE

** V **

VALE
* VALE CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
SERPATE, RESERPINE

VANGARD
* VANGARD LABORATORIES INC DIV MIDWAY MEDICAL CO
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
TOLBUTAMIDE, TOLBUTAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VESTAL LABS
* VESTAL LABORATORIES DIV CHEMED CORP
SEPTISOL, HEXACHLOROPHENE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOLIC ACID, FOLIC ACID
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PERPHENAZINE, PERPHENAZINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
QUINIDINE SULFATE, QUINIDINE SULFATE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VITARINE
* VITARINE PHARMACEUTICALS INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GLUTETHIMIDE, GLUTETHIMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPIVITE, RESERPINE
SULFISOXAZOLE, SULFISOXAZOLE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VITAMIN D, ERGOCALCIFEROL

VIVUS
* VIVUS INC
MUSE, ALPROSTADIL

** W **

WALLACE LABS

FDA data supplied by DrugPatentWatch.com

* WALLACE LABORATORIES DIV CARTER WALLACE INC
AQUATENSEN, METHYCLOTHIAZIDE
ASTELIN, AZELASTINE HYDROCHLORIDE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
COLONAID, ATROPINE SULFATE
DEPEN, PENICILLAMINE
DIUTENSEN-R, METHYCLOTHIAZIDE
DORAL, QUAZEPAM
FELBATOL, FELBAMATE
HYZYD, ISONIAZID
LUFYLLIN, DYPHYLLINE
MILTOWN, MEPROBAMATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
NEOPASALATE, AMINOSALICYLATE SODIUM
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
SOMA, CARISOPRODOL
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
VERTAVIS, VERATRUM VIRIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
WAMPOCAP, NIACIN

WALLACE PHARMS
* WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC
DORMATE, MEBUTAMATE
MEPROSPAN, MEPROBAMATE
MICRAININ, ASPIRIN
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN

WARNER CHILCOTT
* WARNER CHILCOTT BERMUDA LTD
CHOLEDYL SA, OXTRIPHYLLINE
DORYX, DOXYCYCLINE HYCLATE
* WARNER CHILCOTT DIV WARNER LAMBERT CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DURAQUIN, QUINIDINE GLUCONATE
ERYPAR, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LORAZEPAM, LORAZEPAM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE, SPIRONOLACTONE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* WARNER CHILCOTT INC
CARBAMAZEPINE, CARBAMAZEPINE
CYANOCOBALAMIN, CYANOCOBALAMIN
ERYC, ERYTHROMYCIN
ESTRACE, ESTRADIOL
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULINDAC, SULINDAC
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

WARNER LAMBERT
* WARNER LAMBERT CO CONSUMER PRODUCTS DIV
NIX, PERMETHRIN (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
* WARNER LAMBERT CONSUMER HEALTHCARE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

WARNER WELLCOME
* WARNER WELLCOME CONSUMER HEALTH PRODUCTS
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

WARRICK PHARMS
* WARRICK PHARMACEUTICALS
CROMOLYN SODIUM, CROMOLYN SODIUM

WATSON LAB
* WATSON LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CARISOPRODOL COMPOUND, ASPIRIN

FDA data supplied by DrugPatentWatch.com

CARISOPRODOL, CARISOPRODOL
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LITHIUM CARBONATE, LITHIUM CARBONATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PRIMIDONE, PRIMIDONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINATIME, QUINIDINE GLUCONATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
WARFARIN SODIUM, WARFARIN SODIUM

WATSON LABS

* WATSON LABORATORIES
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALORA, ESTRADIOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
BACLOFEN, BACLOFEN
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE,

FDA data supplied by DrugPatentWatch.com

ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CLONAZEPAM, CLONAZEPAM
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM, LORAZEPAM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICROZIDE, HYDROCHLOROTHIAZIDE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL, MESTRANOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PEMOLINE, PEMOLINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

WE PHARMS
* WE PHARMACEUTICALS INC
PREDNISOLONE, PREDNISOLONE

WELLSPRING PHARM
* WELLSPRING PHARMACEUTICAL CORP
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

WENDT
* WENDT LABORATORIES INC
NITROFURAZONE, NITROFURAZONE

WEST WARD
* WEST WARD PHARMACEUTICAL CORP
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

WESTWOOD SQUIBB
* WESTWOOD SQUIBB PHARMACEUTICALS INC
CAPITROL, CHLOROXINE
DOVONEX, CALCIPOTRIENE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FLEXICORT, HYDROCORTISONE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOTEX, HALOPROGIN
LAC-HYDRIN, AMMONIUM LACTATE
MYCOSTATIN, NYSTATIN
STATICIN, ERYTHROMYCIN
T-STAT, ERYTHROMYCIN
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
WESTCORT, HYDROCORTISONE VALERATE

WESTWOOD SQUIBB CLTN
* WESTWOOD SQUIBB COLTON HOLDINGS PARTNERSHIP
VANIQA, EFLORNITHINE HYDROCHLORIDE

WHARTON LABS
* WHARTON LABORATORIES INC DIV US ETHICALS
VITAMIN A, VITAMIN A PALMITATE

WHITBY
* WHITBY PHARMACEUTICALS INC
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE

WHITEHALL LABS
* WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL, IBUPROFEN (OTC)

WHITEHALL ROBINS
* WHITEHALL ROBINS HEALTHCARE
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
ORUDIS KT, KETOPROFEN (OTC)
PEDIATRIC ADVIL, IBUPROFEN (OTC)
* WHITEHALL ROBINS HEALTHCARE DIV AMERICAN HOME PRODUCTS CORP
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
PRIMATENE MIST, EPINEPHRINE (OTC)

WHITEWORTH TOWN PLSN
* WHITEWORTH TOWNE PAULSEN INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
H.R.-50, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
NITROFURANTOIN, NITROFURANTOIN
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

WOCKHARDT
* WOCKHARDT AMERICAS INC
CAPTOPRIL, CAPTOPRIL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* WOCKHARDT LTD
NIACIN, NIACIN

WOMEN FIRST HLTHCARE
* WOMEN FIRST HEALTHCARE INC
ESCLIM, ESTRADIOL

WOMENS CAPITAL
* WOMENS CAPITAL CORP
PLAN B, LEVONORGESTREL

WYETH AYERST
* WYETH AYERST LABORATORIES
A.P.L., GONADOTROPIN, CHORIONIC
ALESSE, ETHINYL ESTRADIOL
ANSOLYSEN, PENTOLINIUM TARTRATE
ANTABUSE, DISULFIRAM
ATIVAN, LORAZEPAM
ATROMID-S, CLOFIBRATE
AYGESTIN, NORETHINDRONE ACETATE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORDARONE, AMIODARONE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLAPEN-W, CYCLACILLIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EQUAGESIC, ASPIRIN
EQUANIL, MEPROBAMATE
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTROGENIC SUBSTANCE, ESTRONE
FACTREL, GONADORELIN HYDROCHLORIDE
FLUOTHANE, HALOTHANE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
ISORDIL, ISOSORBIDE DINITRATE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LODINE XL, ETODOLAC
LODINE, ETODOLAC
MAZANOR, MAZINDOL
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MYLOTARG, GEMTUZUMAB OZOGAMICIN
NALOXONE, NALOXONE HYDROCHLORIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORMIFLO, ARDEPARIN SODIUM
NORPLANT SYSTEM, LEVONORGESTREL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
ORUDIS, KETOPROFEN
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OXYTOCIN, OXYTOCIN
PATHOCIL, DICLOXACILLIN SODIUM
PEN-VEE K, PENICILLIN V POTASSIUM

FDA data supplied by DrugPatentWatch.com

PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PEPTAVLON, PENTAGASTRIN
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PLEGINE, PHENDIMETRAZINE TARTRATE
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPRO 14/14, ESTROGENS, CONJUGATED
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROKETAZINE, CARPHENAZINE MALEATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
RAPAMUNE, SIROLIMUS
ROBITET, TETRACYCLINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SONATA, ZALEPLON
SPARINE, PROMAZINE HYDROCHLORIDE
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SURMONTIL, TRIMIPRAMINE MALEATE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
TENEX, GUANFACINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
TRECATOR-SC, ETHIONAMIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYDASE, HYALURONIDASE
WYGESIC, ACETAMINOPHEN
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE
ZOSYN, PIPERACILLIN SODIUM

* WYETH AYERST RESEARCH
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
ORUVAIL, KETOPROFEN

** X **

XTTRIUM
* XTTRIUM LABORATORIES INC
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
TURGEX, HEXACHLOROPHENE

** Y **

YAMANOUCHI
* YAMANOUCHI EUROPE BV
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

YOSHITOMI
* YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN

** Z **

ZAMBON
* ZAMBON CORP
MONUROL, FOSFOMYCIN TROMETHAMINE

ZENITH GOLDLINE
* ZENITH GOLDLINE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CLOZAPINE, CLOZAPINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* ZENITH GOLDLINE PHARMACEUTICALS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALLAY, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUMETANIDE, BUMETANIDE
BUTALBITAL COMPOUND, ASPIRIN
C-SOLVE-2, ERYTHROMYCIN
CAPTOPRIL, CAPTOPRIL

FDA data supplied by DrugPatentWatch.com

CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTEX, TRIAMCINOLONE ACETONIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METRONIDAZOLE, METRONIDAZOLE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NOGENIC HC, HYDROCORTISONE
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

* ZENITH GOLDLINE SHREVEPORT INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

ZILA

* ZILA PHARMACEUTICALS INC
PERIDEX, CHLORHEXIDINE GLUCONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL
AEROSOL, METERED
BAR, CHEWABLE
CAPSULE
CAPSULE, COATED PELLETS
CAPSULE, DELAYED REL PELLETS
CAPSULE, EXTENDED RELEASE
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, SUPPOSITORY
DISC
DRESSING
DRUG DELIVERY SYSTEM
ELIXIR
EMULSION
ENEMA
FIBER, EXTENDED RELEASE
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULE, EFFERVESCENT
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LIQUID, EXTENDED RELEASE
LOTION
LOTION, AUGMENTED
LOTION, SHAMPOO
N/A
OIL
OINTMENT
OINTMENT, AUGMENTED
PASTE
PASTILLE
PELLET
POWDER
POWDER, METERED
SHAMPOO
SOAP
SOLUTION
SOLUTION FOR SLUSH
SOLUTION/DROPS
SOLUTION, CONCENTRATE
SOLUTION, GEL FORMING/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION/DROPS
SUSPENSION, EXTENDED RELEASE
SWAB
SYRUP
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, DISPERSIBLE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, ORALLY DISINTEGRATING
TAMPON
TAPE
TROCHE/LOZENGE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
BUCCAL/SUBLINGUAL
DENTAL
ENDOCERVICAL
FOR RX COMPOUNDING
IM-IV
IMPLANTATION
INHALATION
INJECTION
INTRACRANIAL
INTRALYMPHATIC
INTRAMUSCULAR
INTRAOCULAR
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVASCULAR
INTRAVENOUS
INTRAVESICAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-20
ORAL-21
ORAL-28
OTIC
PERFUSION, BILIARY
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TOPICAL, VAGINAL
TRANSDERMAL
URETERAL
URETHRAL
VAGINAL

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
EQ	EQUIVALENT TO
ELECT	ELECTROLYTE
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
INH	INHALATION
IU	INTERNATIONAL UNITS
KIU	KALLIKREIN INHIBITOR UNITS
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UGM	MICROGRAM
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* page. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second full NDA. Applications qualifying for periods of exclusivity are:

(1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) (2) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.

(2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new use or indication, this does not preclude the approval of an ANDA application or 505(b)(2) application for the drug product with indications not covered by the exclusivity.

(3) A supplement to a new drug application for a drug containing a previously approved active ingredient (including any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent application for a change approved in the supplement may not be *made effective* for *three years* from the date of approval of the original supplement.

FDA data supplied by DrugPatentWatch.com

The Act requires that patent information must now be filed with all newly submitted Section 505 drug applications, and that no NDA may be approved after September 24, 1984, without the submission of pertinent patent information to the Agency. The patent numbers and the expiration dates of appropriate patents claiming
drug products that are the subject of approved applications will be published in this *Addendum* or in the monthly Cumulative Supplement to this publication. Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient or ingredients; drug product patents, which include formulation/composition patents; and use patents for a particular approved indication or method of using the product. NDA holders or applicants amending or supplementing applications with formulation/composition patent information are asked to declare that the patent(s) is appropriate for publication and refers to an approved product or one for which approval is being sought. The Agency asks all applicants or application holders with use patents to provide information as to the approved indications or uses covered by such patents. This information will be included in the Cumulative Supplement to the List as it becomes available.

Since all parts of this publication are subject to changes, additions, or deletions, the *Addendum* must be used in conjunction with the most current Cumulative Supplement.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009		NCE	DEC 17, 2003
		5089500	JUN 26, 2009	U-248	PED	MAY 17, 2001
		5047407	NOV 17, 2009		PED	JUN 17, 2004
		5905082	MAY 18, 2016			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4828838	SEP 17, 2005			
		5034394*PED	DEC 26, 2009			
		5047407*PED	MAY 17, 2010			
		5089500*PED	DEC 26, 2009	U-248		
		5905082*PED	NOV 18, 2016			
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
020482 001	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 002	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		I-252	SEP 29, 2001
					I-253	SEP 29, 2001
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U-296	NP	JAN 14, 2001
		4943565	JUL 24, 2007			
019872 001	ACETAMINOPHEN;TYLENOL	5004613	JUL 27, 2007			
		4820522	JUL 27, 2007			
		4968509	NOV 06, 2007			
019806 001	ACRIVASTINE;SEMPREX-D	4501893	FEB 01, 2003			
		4650807	MAR 26, 2008	U-93		
020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
		RE34440	MAR 31, 2010	U-275		
020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
		RE34440	MAY 31, 2010	U-275		
020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
		RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
019937 002	ADENOSINE;ADENOCARD	4673563	JUN 16, 2004	U-38		
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
		5731296	MAR 24, 2015	U-221		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020666 001	ALBENDAZOLE;ALBENZA				ODE	JUN 11, 2003
					NCE	JUN 11, 2001
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015			
018062 001	ALBUTEROL SULFATE;PROVENTIL	4499108	JUN 08, 2003			
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010		I-262	JUN 02, 2002
		5605674	FEB 25, 2014		I-235	SEP 23, 2001
		5225183	JUL 06, 2010			
		5766573	JUN 16, 2015			
019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
019604 001	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
019604 002	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012		I-309	SEP 29, 2003
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-272	JUN 16, 2002
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		5994329	JUL 17, 2018			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
					NCE	FEB 02, 2004
020298 001	ALLOPURINOL SODIUM;ALOPRIM				ODE	MAY 17, 2003
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 004	ALPRAZOLAM;XANAX	5061494	OCT 29, 2008			
		4508726	SEP 16, 2002	U-46		
020379 001	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 002	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 003	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 004	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020700 001	ALPROSTADIL;MUSE	5242391	SEP 07, 2010	U-155		
		4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
020700 002	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		
020700 003	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
		5242391	SEP 07, 2010	U-155		
020700 004	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		I-283	JUN 24, 2002
		5591731	JUL 31, 2012		ODE	JUN 24, 2006
		5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
020221 002	AMIFOSTINE;ETHYOL	5242471	JUL 31, 2012		I-283	JUN 24, 2002
		5591731	JUL 31, 2012		ODE	JUN 24, 2006
		5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
018678 001	AMINO ACIDS;BRANCHAMIN 4%	4438144	MAR 20, 2001			
018684 001	AMINO ACIDS;BRANCHAMIN 4%	4438144	MAR 20, 2001			
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5079262	JUL 28, 2009	U-289	NCE	DEC 03, 2004
		5211938	MAY 18, 2010	U-289		
		5422093	JUL 28, 2009	U-289		
074346 001	AMINOSALICYLIC ACID;PASER				ODE	JUN 30, 2001
020377 001	AMIODARONE HYDROCHLORIDE;CORDARONE				ODE	AUG 03, 2002
020511 001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243	NCE	DEC 17, 2001
020364 002	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 003	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020364 004	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4	AUG 25, 2003
					PED	FEB 25, 2004
050724 001	AMPHOTERICIN B;ABELCET				ODE	OCT 18, 2003
050740 001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
		5723490	MAR 03, 2015	U-257		
		5646180	JUL 08, 2014	U-257		
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
019779 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	5212196	MAY 18, 2010	U-120		
		4517199	MAY 14, 2002	U-15		
020258 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	4517199	MAY 14, 2002	U-15		
020304 001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220	NCE	SEP 12, 2002
		5234404	AUG 10, 2010	U-220		
		5395970	MAR 07, 2012			
020227 002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
020883 001	ARGATROBAN;ACOVA				NCE	JUN 30, 2005
021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
020884 001	ASPIRIN;AGGRENOX	6015577	JAN 18, 2017	U-302	NC	NOV 22, 2002
012365 005	ASPIRIN;SOMA COMPOUND	4534973	AUG 13, 2002			
012366 002	ASPIRIN;SOMA COMPOUND W/ CODEINE	4534974	AUG 13, 2002			
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	NCE	DEC 17, 2001
		5686104	NOV 11, 2014	U-213	I-218	JUL 10, 2001
		5969156	JUL 08, 2016		I-219	JUL 10, 2001
		6126971	JAN 19, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	NCE	DEC 17, 2001
		5686104	NOV 11, 2014	U-213	I-218	JUL 10, 2001
		5969156	JUL 08, 2016		I-219	JUL 10, 2001
		6126971	JAN 19, 2013			
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	NCE	DEC 17, 2001
		5686104	NOV 11, 2014	U-213	I-218	JUL 10, 2001
		5969156	JUL 08, 2016		I-219	JUL 10, 2001
		6126971	JAN 19, 2013			
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162	I-281	DEC 02, 2002
		5686104	NOV 11, 2014	U-213	I-218	JUL 10, 2001
		5969166	JUL 08, 2016		I-219	JUL 10, 2001
		6126971	JAN 19, 2013			
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013			
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013			
020259 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69		
		5053432	OCT 01, 2008			
020500 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69	ODE	JAN 05, 2006
		5053432	OCT 01, 2008		I-255	JAN 05, 2002
019677 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
019678 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
019459 001	AVOBENZONE;PHOTOPLEX	4387089	JUN 07, 2002			
020045 001	AVOBENZONE;SHADE UVAGUARD	4387089	JUN 07, 2002			
		4522807	JUN 11, 2002			
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207	NCE	NOV 01, 2001
021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
		5164194*PED	MAY 01, 2011		NDF	MAY 22, 2003
					PED	MAY 01, 2002
					PED	NOV 22, 2003
020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2001		NCE	JUL 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020532 001	BENTOQUATAM;IVY BLOCK				NCE	AUG 26, 2001
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020576 001	BETAINE, ANHYDROUS;CYSTADANE				NCE	OCT 25, 2001
					ODE	OCT 25, 2003
019408 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
019716 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4775529	MAY 21, 2007			
019555 001	BETAMETHASONE DIPROPIONATE;DIPROLENE AF	4489071	DEC 09, 2003			
020010 001	BETAMETHASONE DIPROPIONATE;LOTRISONE				NP	DEC 08, 2003
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191		
019845 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC S	4911920	MAR 27, 2007			
021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
021056 001	BEXAROTENE;TARGRETIN				NCE	DEC 29, 2004
					NDF	JUN 28, 2003
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
		4472382	SEP 18, 2001	U-197		
		5389613	SEP 18, 2001	U-197		
020873 001	BIVALIRUDIN;ANGIOMAX				NCE	DEC 15, 2005
050443 001	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
020816 001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
		5378703	AUG 31, 2010	U-224		
		5461081	OCT 24, 2012	U-225		
020535 002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002
019672 001	BROMPHENIRAMINE MALEATE;EFIDAC 24 PSEUDOEPHEDRINE HCL/BRO	4673405	MAR 18, 2003			
		4810502	MAR 14, 2006			
		4662880	MAR 14, 2006			
		4801461	MAR 14, 2006			
020441 002	BUDESONIDE;PULMICORT	4524769	JUN 25, 2002		D-45	OCT 08, 2001
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4524769	JUN 25, 2002			
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020746 001	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
020746 002	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013			
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5427798	AUG 12, 2013			
		5358970	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
		6150365*PED	FEB 05, 2020	U-361		
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
		6150365*PED	FEB 05, 2020			
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
		6150365*PED	FEB 05, 2020			
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019			
		6150365*PED	FEB 05, 2020	U-361		
021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
		5015646	MAY 14, 2008			
021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177	NCE	OCT 18, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019890 001	BUTORPHANOL TARTRATE;STADOL	4464378	AUG 07, 2001	U-60		
020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005		NCE	DEC 23, 2001
020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
					NE	SEP 21, 2002
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
		5759565	MAR 31, 2015			
018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
		6051567	AUG 02, 2019			
018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
		6051567	AUG 02, 2019			
018044 001	CALCITRIOL;ROCALTROL				I-240	NOV 20, 2001
021068 001	CALCITRIOL;ROCALTROL				NDF	NOV 20, 2001
					I-240	NOV 20, 2001
019976 001	CALCIUM ACETATE;PHOSLO	4870105	SEP 26, 2006			
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U-349	NC	OCT 15, 2003
		5817340	DEC 01, 2012		PED	APR 15, 2004
		5989588	SEP 30, 2015	U-349		
		5989588*PED	MAR 30, 2018	U-349		
		4283408*PED	APR 15, 2001			
		5229137*PED	NOV 16, 2012			
		5817340*PED	JUN 01, 2013			
018469 001	CALCIUM CHLORIDE;BSS PLUS	4443432	OCT 05, 2001			
		4550022	OCT 29, 2002			
020577 001	CALCIUM CHLORIDE;ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272		
020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272		
018343 001	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 002	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 003	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 004	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 005	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 006	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 007	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
020712 001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020712 002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020234 001	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 002	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 003	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
019856 001	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019856 002	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
020637 001	CARMUSTINE;GLIADEL	5179189	JAN 19, 2010		ODE	SEP 23, 2003
		4789724	JUL 12, 2005			
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013			
		5972986	OCT 14, 2017	U-299		
		5760068	JUN 02, 2015	U-299		
020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013			
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NCE	JUN 26, 2002
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
					NS	MAY 24, 2002
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	JAN 26, 2011		I-303	JUL 21, 2003
					NS	JUL 21, 2003
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4312860	AUG 20, 2003			
		4826821	MAY 02, 2006			
		5110806	MAY 02, 2006			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
		5340821	AUG 23, 2011	U-309		
		5580880	JUN 06, 2015	U-310		
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
020774 001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
019746 002	CHLORPHENIRAMINE MALEATE;EFIDAC 24 CHLORPHENIRAMINE MALEAT	4576604	MAR 18, 2003			
		4673405	MAR 18, 2003			
		4857330	AUG 15, 2006			
019574 001	CHLORTHALIDONE;THALITONE	4933360	JUN 12, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
071621 001	CHOLESTYRAMINE;CHOLYBAR	4778676	OCT 18, 2005			
071739 001	CHOLESTYRAMINE;CHOLYBAR	4778676	OCT 18, 2005			
021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
018663 001	CHYMOPAPAIN;CHYMODIACTIN	4439423	MAY 13, 2001			
018663 002	CHYMOPAPAIN;CHYMODIACTIN	4439423	MAY 13, 2001			
021022 001	CICLOPIROX;PENLAC				NDF	DEC 17, 2002
020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010		NCE	JUN 26, 2001
020863 001	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
020863 002	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
020238 002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
		4670444	DEC 09, 2003	U-36		
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
		4844902	FEB 11, 2008			
019847 001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4808583	FEB 28, 2006			
020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		
020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
020210 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020210 002	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020398 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79		
		5648093	JUL 15, 2014			
020551 001	CISATRACURIUM BESYLATE;NIMBEX	5453510	SEP 26, 2012	U-127	D-48	OCT 15, 2001
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127	D-48	OCT 15, 2001
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127	D-48	OCT 15, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018057 001	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 002	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 003	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
018057 004	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
020615 001	CLONIDINE HYDROCHLORIDE;DURACLON				ODE	OCT 02, 2003
018891 001	CLONIDINE;CATAPRES-TTS-1	4559222	MAY 04, 2003			
018891 002	CLONIDINE;CATAPRES-TTS-2	4559222	MAY 04, 2003			
018891 003	CLONIDINE;CATAPRES-TTS-3	4559222	MAY 04, 2003			
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003		NCE	NOV 17, 2002
		4847265	FEB 12, 2008			
		5576328	JAN 31, 2014			
020574 001	CLOTRIMAZOLE;GYNE-LOTRIMIN 3				NP	NOV 24, 2001
021143 001	CLOTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
		5679717	APR 29, 2014	U-323		
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U-323		
		5917007	APR 29, 2014	U-323		
		5919832	JUN 10, 2014			
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U-323		
		5607669	JUN 10, 2014	U-323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U-323		
		5624963	APR 29, 2014	U-323		
020162 001	CORTICORELIN OVINE TRIFLUTATE;ACTHREL	4415558	JUN 08, 2001		NCE	MAY 23, 2001
020479 001	CROMOLYN SODIUM;GASTROCROM	4515805	MAY 07, 2002	U-130		
019722 001	CYANOCOBALAMIN;NASCOBAL	4724231	APR 16, 2005	U-157		
012142 006	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 007	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 008	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 009	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 010	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
020392 001	CYSTEAMINE BITARTRATE;CYSTAGON				ODE	AUG 15, 2001
020392 002	CYSTEAMINE BITARTRATE;CYSTAGON				ODE	AUG 15, 2001
021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
					NP	APR 01, 2002
020287 001	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003
020287 003	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
					I-259	MAR 30, 2002
					D-60	AUG 03, 2003
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010		NCE	DEC 24, 2001
019849 001	DAPIPRAZOLE HYDROCHLORIDE;REV-EYES	4252721	FEB 07, 2003			
050704 002	DAUNORUBICIN CITRATE;DAUNOXOME				ODE	APR 08, 2003
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
020118 001	DESFLURANE;SUPRANE	4762856	FEB 02, 2007	U-67		
017922 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013		I-40	MAR 25, 2001
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013		I-40	MAR 25, 2001
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5763407	JUN 29, 2013			
020355 001	DESMOPRESSIN ACETATE;STIMATE				ODE	MAR 07, 2001
021090 001	DESOGESTREL;CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
		4544554	SEP 26, 2003			
		4628051	SEP 26, 2003			
020713 001	DESOGESTREL;MIRCETTE	4921843	OCT 20, 2008		NP	APR 22, 2001
		RE35724	OCT 20, 2008			
021038 001	DEXMEDETOMIDINE;PRECEDEX				NCE	DEC 17, 2004
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339	ODE	MAY 26, 2002
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339	ODE	MAY 26, 2002
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
019082 001	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 002	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 003	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
020648 001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020648 002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
		5653972	NOV 16, 2014	U-239		
020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007		I-213	FEB 25, 2001
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180		
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180		
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180		
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180		
020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
					D-58	OCT 28, 2002
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		5616566	AUG 29, 2006	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		5616566	AUG 29, 2006	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		5616566	AUG 29, 2006	U-180		
021183 001	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 002	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 003	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 004	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
018885 001	DIHYDROERGOTAMINE MESYLATE;EMBOLEX	4451458	MAY 29, 2001			
018885 002	DIHYDROERGOTAMINE MESYLATE;EMBOLEX	4451458	MAY 29, 2001			
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
		4462983	JUL 31, 2001	U-227		
		5169849	DEC 08, 2009	U-227		
020062 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5470584	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5002776	MAR 26, 2008			
020062 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			
		5002776	MAR 26, 2008			
		4894240	JAN 16, 2007			
		5439689	AUG 08, 2012	U-107		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020062 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			
020062 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5470584	MAY 20, 2011			
019471 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
020092 001	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 002	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 003	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		I-133	JAN 30, 2001
		6162463	APR 28, 2018			
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		I-133	JAN 30, 2001
		6162463	APR 28, 2018			
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		I-133	JAN 30, 2001
		6162463	APR 28, 2018			
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		I-133	JAN 30, 2001
		6162463	APR 28, 2018			
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		I-133	JAN 30, 2001
		6162463	APR 28, 2018			
020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
020507 001	DILTIAZEM MALATE;TECZEM	4472380	SEP 18, 2001			
		4968507	JUL 25, 2006			
		4880631	SEP 24, 2007			
		4983598	JAN 08, 2008			
020506 001	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020506 002	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 003	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020411 001	DINOPROSTONE;CERVIDIL	4931288	JAN 16, 2007			
		5269321	DEC 14, 2010	U-110		
019617 001	DINOPROSTONE;PREPIDIL	4680312	JUL 14, 2004			
018723 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 002	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 003	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019680 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019794 001	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
019794 002	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
		4913906	APR 03, 2007			
020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-282	DEC 23, 2002
		5438072	NOV 22, 2013		NCE	MAY 14, 2001
		5698582	JUL 03, 2012		I-231	JUN 22, 2001
		5714512	JUL 03, 2012			
020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011		NCE	SEP 11, 2002
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011		NCE	SEP 11, 2002
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011		NCE	SEP 11, 2002
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010		NCE	NOV 25, 2001
		6140321	JUN 07, 2014			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010		NCE	NOV 25, 2001
		6140321	JUN 07, 2014			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103	NC	APR 07, 2001
		4619939	OCT 28, 2003	U-104		
020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U-103		
		4619939	OCT 28, 2003	U-104		
019946 001	DOXACURIUM CHLORIDE;NUROMAX	4701460	MAR 06, 2005			
020126 001	DOXEPIN HYDROCHLORIDE;ZONALON	4395420	DEC 09, 2001	U-95		
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
		5707980	FEB 11, 2117	U-278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
		5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004
050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		
020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		
020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U-257		
		5811423	AUG 07, 2012	U-256		
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4720489	JAN 19, 2005	U-334	NP	JUL 27, 2003
		5648394	JUL 15, 2014	U-334		
020706 001	EMEDASTINE DIFUMARATE;EMADINE				NCE	DEC 29, 2002
020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4472380	SEP 18, 2001			
		4374829	DEC 30, 2001	U-3		
		4703038	OCT 07, 2005	U-3		
019221 001	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
		4472380*PED	MAR 18, 2002			
019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
		4472380*PED	MAR 18, 2002			
019616 004	ENOXACIN;PENETREX	4442101	FEB 04, 2002			
		4359578	NOV 16, 2001			
019616 005	ENOXACIN;PENETREX	4442101	FEB 04, 2002			
		4359578	NOV 16, 2001			
020164 001	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122	I-248	DEC 31, 2001
		4692435	DEC 24, 2004	U-123	I-217	JAN 30, 2001
		5389618	FEB 14, 2012		I-222	MAR 27, 2001
					I-315	NOV 17, 2003
020164 002	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
					I-222	MAR 27, 2001
					I-217	JAN 30, 2001
					I-315	NOV 17, 2003
020164 003	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
					I-315	NOV 17, 2003
020164 004	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
					I-315	NOV 17, 2003
020164 005	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
					I-315	NOV 17, 2003
020796 001	ENTACAPONE;COMTAN				NCE	OCT 19, 2004
050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
020444 001	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002
020444 002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020738 004	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020738 005	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U-244		
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U-244		
018706 001	ERGOLOID MESYLATES;HYDERGINE LC	4366145	JUN 24, 2001			
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLE	RE36247	MAY 02, 2006		I-295	APR 11, 2003
					NC	NOV 18, 2001
					I-242	NOV 18, 2001
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020375 001	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 002	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
020870 001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020870 002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
086069 001	ESTRADIOL;ESTRACE	4436738	MAR 15, 2002			
019081 002	ESTRADIOL;ESTRADERM	4379454	FEB 17, 2001			
019081 003	ESTRADIOL;ESTRADERM	4379454	FEB 17, 2001			
020538 001	ESTRADIOL;ESTRADIOL	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020538 002	ESTRADIOL;ESTRADIOL	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 003	ESTRADIOL;ESTRADIOL	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 004	ESTRADIOL;ESTRADIOL	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U-306		
		5188835	JUN 12, 2007	U-306		
020417 001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
		5382573	JAN 17, 2012			
020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
020323 001	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 002	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 003	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 004	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
		5300291	APR 05, 2011		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
		5210081	FEB 26, 2012			
020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006	U-284		
020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			
020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			
083209 001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
086715 001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	4962098	OCT 09, 2007	U-112		
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	4962098	OCT 09, 2007	U-112		
021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
018985 001	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-21	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018985 002	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-28	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018977 001	ETHINYL ESTRADIOL;TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
018977 002	ETHINYL ESTRADIOL;TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			
075665 001	ETODOLAC;ETODOLAC				PC	FEB 13, 2001
075665 002	ETODOLAC;ETODOLAC				PC	FEB 13, 2001
075696 001	ETODOLAC;ETODOLAC				PC	FEB 04, 2001
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
		4966768	OCT 30, 2007			
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
		4966768	OCT 30, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
		4966768	OCT 30, 2007			
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	AUG 04, 2007			
020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
		4904650	JUL 07, 2006		ODE	OCT 21, 2006
020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96	I-232	JUN 12, 2001
020363 002	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96	I-232	JUN 12, 2001
020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96	I-232	JUN 12, 2001
019462 001	FAMOTIDINE;PEPCID	4283408*PED	APR 15, 2001			
019462 002	FAMOTIDINE;PEPCID	4283408*PED	APR 15, 2001			
019510 001	FAMOTIDINE;PEPCID	4283408*PED	APR 15, 2001			
019527 001	FAMOTIDINE;PEPCID	4283408*PED	APR 15, 2001			
020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015	U-205	D-47	NOV 09, 2001
		5854267	DEC 29, 2015	U-267	PED	MAY 09, 2002
		4283408*PED	APR 15, 2001			
		5667794*PED	NOV 02, 2015	U-205		
		5854267*PED	JUN 29, 2016	U-267		
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U-267		
		5075114	DEC 24, 2008			
		4283408*PED	APR 15, 2001			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
020902 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-368		
		5854267*PED	JUN 29, 2016	U-368		
		5667794	MAY 02, 2015	U-368		
		5667794*PED	NOV 02, 2015	U-368		
		4283408*PED	APR 15, 2001			
		4820524	FEB 20, 2007			
		4820524*PED	AUG 20, 2007			
019510 004	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4283408*PED	APR 15, 2001			
020249 001	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4238408*PED	APR 15, 2001			
020752 001	FAMOTIDINE;PEPCID RPD	4283408*PED	APR 15, 2001			
020752 002	FAMOTIDINE;PEPCID RPD	4283408*PED	APR 15, 2001			
020189 001	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
020189 002	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
020189 003	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019922 001	FENOLDOPAM MESYLATE;CORLOPAM				NCE	SEP 23, 2002
020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	NP	NOV 04, 2001
020195 001	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 002	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 003	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 007	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
020416 001	FERUMOXIDES;FERIDEX I.V.	4951675	AUG 28, 2007	U-143	NCE	AUG 30, 2001
		5102652	FEB 06, 2009			
		5248492	SEP 28, 2010			
		4770183	SEP 13, 2005	U-145		
		4827945	MAY 09, 2006	U-144		
		5055288	OCT 08, 2008			
		5219554	JUN 15, 2010			
020410 001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171	NCE	DEC 06, 2001
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U-170		
		4951675	SEP 13, 2005	U-169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U-169		
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139	NCE	JUL 25, 2001
		5578610	NOV 26, 2013			
		5855912	FEB 28, 2015	U-192		
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017			
		6113942	FEB 28, 2015	U-138		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
		5578610	NOV 26, 2013			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
020788 001	FINASTERIDE;PROPECIA	4760071	JUN 19, 2006			
		5571817	NOV 05, 2013	U-259		
		5547957	OCT 15, 2013	U-236		
		5886184	NOV 19, 2012			
020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262	I-221	MAR 20, 2001
		5886184	NOV 19, 2012			
		5942519	OCT 23, 2018	U-280		
018830 001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
019949 004	FLUCONAZOLE;DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
		4416682	JUN 02, 2001			
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
020073 001	FLUMAZENIL;ROMAZICON	4316839	OCT 10, 2004			
018340 001	FLUNISOLIDE;AEROBID	4933168	JUN 12, 2007			
018148 001	FLUNISOLIDE;NASALIDE	4933168	JUN 12, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020409 001	FLUNISOLIDE;NASAREL	4782047	MAY 22, 2006			
		4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
020985 001	FLUOROURACIL;FLUOROURACIL				NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JUN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JAN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
018554 001	FLUTAMIDE;EULEXIN	4329364	MAY 11, 2001	U-23		
		4472382	SEP 18, 2001	U-24		
		5712251	SEP 18, 2001	U-216		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003		I-267	JUN 17, 2002
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		I-258	DEC 11, 2001
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
021192 001	FLUVASTATIN SODIUM;LESCOL XL				NDF	OCT 06, 2003
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011			
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011			
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
		5767251	JUN 16, 2015		ODE	MAY 24, 2007
020696 001	FOMEPIZOLE;ANTIZOL				NCE	DEC 04, 2002
					ODE	DEC 04, 2004
					ODE	DEC 08, 2007
					I-319	DEC 08, 2003
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003		NCE	AUG 05, 2001
		4925860	AUG 05, 2007		ODE	AUG 05, 2003
020235 001	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-125	PED	MAR 29, 2002
		4894476*PED	NOV 02, 2008		D-43	SEP 29, 2001
		5084479*PED	JUL 02, 2010	U-125	I-311	OCT 12, 2003
		4894476	MAY 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
		5084479*PED	JUL 02, 2010	U-125	I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-125	PED	MAR 29, 2002
		4894476	MAY 02, 2008		D-43	SEP 29, 2001
		5084479*PED	JUL 02, 2010		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479	JAN 02, 2010	U-258		
		5084479*PED	JUL 02, 2010	U-258		
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		5084479	JAN 02, 2010	U-258		
		4894476*PED	NOV 02, 2008			
		5084479*PED	JUL 02, 2010	U-258		
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021129 001	GABAPENTIN;NEURONTIN				I-311	OCT 12, 2003
020123 001	GADODIAMIDE;OMNISCAN	4687659	MAY 04, 2007	U-76		
019596 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	4647447	MAR 03, 2004			
		4963344	MAR 03, 2004			
		4957939	MAR 03, 2004			
		5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020131 001	GADOTERIDOL;PROHANCE	4885363	DEC 05, 2006			
020937 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020975 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020976 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
019961 002	GALLIUM NITRATE;GANITE	4529593	JAN 17, 2005	U-49		
019661 001	GANCICLOVIR SODIUM;CYTOVENE IV	4355032	JUN 23, 2003	U-64		
		4423050	MAY 21, 2001	U-34		
		4507305	MAY 21, 2001	U-35		
020460 001	GANCICLOVIR;CYTOVENE	4355032	JUN 23, 2003	U-64		
		4423050	MAY 21, 2001	U-64		
		4642346	JUN 24, 2005			
		4507305	MAY 21, 2001	U-64		
020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
		4423050	MAY 21, 2001	U-64		
		4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
020569 001	GANCICLOVIR;VITRASERT	5378475	JAN 03, 2012		ODE	MAR 04, 2003
021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015			
021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010		NCE	MAY 15, 2001
		5464826	NOV 07, 2012	U-146	I-234	AUG 26, 2001
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U-146	NCE	MAY 15, 2001
		4808614	MAY 15, 2010		I-234	AUG 26, 2001
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U-320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		NCE	DEC 20, 2001
		6054430	MAY 24, 2014		ODE	DEC 20, 2003
020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020329 001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5024843	SEP 05, 2009			
		5091190	JUN 18, 2008	U-111		
		4612008	SEP 16, 2003			
		5082668	SEP 16, 2003			
		5545413	JUL 02, 2008	U-150		
020329 002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5082668	SEP 16, 2003			
		5091190	JUN 18, 2008	U-111		
		5545413	JUL 02, 2008	U-150		
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
021178 001	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
021178 002	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
021178 003	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
020051 001	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
020051 002	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 003	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 004	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
019726 001	GOSERELIN ACETATE;ZOLADEX	5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
020578 001	GOSERELIN ACETATE;ZOLADEX	4767628	AUG 30, 2005			
		5366734	NOV 22, 2011			
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
020695 001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013		NCE	NOV 06, 2002
019967 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007		NC	DEC 28, 2002
		4344949	OCT 03, 2002	U-3		
020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
					NC	MAR 06, 2001
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
					NC	MAR 06, 2001
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
019129 001	HYDROCHLOROTHIAZIDE;MAXZIDE	4444769	JUL 27, 2002			
019129 003	HYDROCHLOROTHIAZIDE;MAXZIDE-25	4444769	JUL 27, 2002			
021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
		4472380	SEP 18, 2001			
019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4472380	SEP 18, 2001			
		4374829	DEC 29, 2001			
019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4472380	SEP 18, 2001			
		4374829	DEC 29, 2001	U-3		
020729 001	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
		4472380	SEP 18, 2001			
019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
		4472380	SEP 18, 2001			
019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4472380	SEP 18, 2001			
		4374829	DEC 29, 2001	U-3		
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007			
		4788220*PED	JAN 08, 2008			
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
021128 001	IBUPROFEN;CHILDREN'S MOTRIN COLD				NP	AUG 01, 2003
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020135 001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
019012 004	IBUPROFEN;MOTRIN MIGRAINE PAIN				NP	FEB 26, 2003
020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009		D-50	MAY 13, 2002
019763 001	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 002	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
020367 001	IMIGLUCERASE;CEREZYME	5236838	AUG 17, 2010		ODE	MAY 23, 2001
		5549892	AUG 27, 2013	U-252		
020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172	NCE	FEB 27, 2002
		5238944	AUG 24, 2010			
019693 001	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 002	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 003	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
020685 001	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132	NCE	MAR 13, 2001
020685 003	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132	NCE	MAR 13, 2001
020685 005	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020986 001	INSULIN ASPART RECOMBINANT;NOVOLOG				NCE	JUN 07, 2005
021081 001	INSULIN GLARGINE;LANTUS				PED	OCT 20, 2005
					NCE	APR 20, 2005
020563 001	INSULIN LISPRO;HUMALOG	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50	5461031	JUN 26, 2014		NC	DEC 22, 2002
		5474978	JUN 16, 2014			
		5514646	MAY 07, 2013			
		5747642	JUN 16, 2014			
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014		NC	DEC 22, 2002
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
021028 001	INSULIN RECOMBINANT HUMAN;VELOSULIN BR				NP	JUL 19, 2002
020084 001	IOBENGUANE SULFATE I 131;IOBENGUANE SULFATE I 131	4584187	APR 22, 2003		ODE	MAR 25, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020351 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011		NCE	MAR 22, 2001
020808 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020351 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011		NCE	MAR 22, 2001
020808 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
019432 001	IOFETAMINE HYDROCHLORIDE I-123;SPECTAMINE	4360511	NOV 23, 2001			
020220 004	IOPROMIDE;ULTRAVIST 150	4364921	MAR 06, 2005	U-113		
020220 003	IOPROMIDE;ULTRAVIST 240	4364921	MAR 06, 2005	U-113		
020220 002	IOPROMIDE;ULTRAVIST 300	4364921	MAR 06, 2005	U-113		
020220 001	IOPROMIDE;ULTRAVIST 370	4364921	MAR 06, 2005	U-113		
019710 003	IOVERSOL;OPTIRAY 160	4396598	OCT 26, 2002	U-31		
019710 002	IOVERSOL;OPTIRAY 240	4396598	OCT 26, 2002	U-30		
020923 001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
019710 004	IOVERSOL;OPTIRAY 300	4396598	OCT 26, 2002	U-61		
019710 001	IOVERSOL;OPTIRAY 320	4396598	OCT 26, 2002	U-28		
				U-29		
020923 002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
019710 005	IOVERSOL;OPTIRAY 350	4396598	OCT 26, 2002	U-62		
020923 003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
020393 001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-243	NOV 09, 2001
020757 001	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757 002	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757 003	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		I-299	APR 20, 2003
					NCE	JUN 14, 2001
040024 001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
050705 001	ISONIAZID;RIFATER				ODE	MAY 31, 2001
018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
019546 001	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
019546 002	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
020336 001	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4466972	AUG 21, 2003	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		5030456	JUL 09, 2008			
		4950486	AUG 21, 2007			
020336 002	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		4466972	AUG 21, 2003	U-3		
		4950486	AUG 21, 2007			
		5030456	JUL 09, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
020657 001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015			
		4727064	FEB 23, 2005			
020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005			
019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
019927 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
020310 001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
		5456851	APR 07, 2014			
019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
		5110493	MAY 05, 2009	U-75		
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE	4454151	MAR 22, 2002			
021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
020857 001	LAMIVUDINE;COMBIVIR	4828838*PED	MAR 17, 2006		PED	MAY 17, 2001
		4833130*PED	MAR 17, 2006			
		4837208	SEP 17, 2005			
		5047407*PED	AUG 08, 2009			
		4724232*PED	MAR 17, 2006			
		4818538*PED	MAR 17, 2006			
		5859021*PED	NOV 15, 2012	U-248		
		5905082*PED	NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*PED	APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*PED	MAR 17, 2006			
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		PED	MAY 17, 2001
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		PED	MAY 17, 2001
		6004968	MAR 20, 2018			
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
		5532246	JUL 02, 2013	U-250	PED	JUN 08, 2002
		5905082	MAY 18, 2016			
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		5905082*PED	NOV 18, 2016			
021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
		5532246	JUL 02, 2013	U-250	PED	MAY 17, 2001
		6004968	MAR 20, 2018		PED	JUN 08, 2002
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		6004968*PED	SEP 20, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020241 001	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020241 002	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020241 003	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020241 004	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020241 005	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020241 006	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020764 001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-247	DEC 14, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020764 002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-247	DEC 14, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020764 003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-247	DEC 14, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
					I-238	AUG 24, 2001
020406 001	LANSOPRAZOLE;PREVACID	5093132	SEP 03, 2008		M-1	JUL 06, 2002
		5045321	SEP 03, 2008		I-227	MAR 12, 2001
		4689333	JUL 29, 2005	U-126	D-42	JUL 20, 2001
		5026560	JUN 25, 2008		I-316	NOV 30, 2003
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
020406 002	LANSOPRAZOLE;PREVACID	4689333	JUL 29, 2005	U-126	M-1	JUL 06, 2002
		5026560	JUN 25, 2008		I-227	MAR 12, 2001
		5045321	SEP 03, 2008		D-42	JUL 20, 2001
		5093132	SEP 03, 2008		I-316	NOV 30, 2003
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260	NCE	JUN 05, 2001
		5422368	MAR 22, 2011	U-260		
		4599353	JUL 28, 2006	U-260		
020905 001	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020905 002	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020905 003	LEFLUNOMIDE;ARAVA	5679709	OCT 21, 2014	U-247	NCE	SEP 10, 2003
020807 001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
					NCE	MAR 06, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020726 001	LETROZOLE;FEMARA	4978672	DEC 18, 2007	U-203	NCE	JUL 25, 2002
					I-318	JAN 10, 2004
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5480656	JAN 02, 2013			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	APR 17, 2007			
		4849228	JUL 18, 2006			
		5575987	NOV 19, 2013			
		5716640	SEP 02, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5480656	JAN 02, 2013			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5476663	APR 17, 2007			
		5575987	NOV 19, 2013			
		5643607	JUL 01, 2014			
		5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652441	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4954298	NOV 01, 2004			
		5476663	APR 17, 2007			
		5575987	NOV 19, 2013			
		5480656	JAN 02, 2013			
		4677191	JUL 03, 2005			
		4849228	JUL 18, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5716640	SEP 02, 2013			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		5476663	APR 17, 2007			
		5575987	NOV 19, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		5330767	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	NOV 19, 2013			
		5476663	APR 17, 2007			
		5716640	SEP 02, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5476663	APR 17, 2007			
		4849228	JUL 18, 2006			
		5575987	NOV 19, 2013			
		5716640	SEP 02, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	APR 17, 2007			
		4849228	JUL 18, 2006			
		5575987	NOV 19, 2013			
		5716640	SEP 02, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	APR 17, 2007			
		5575987	NOV 19, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5643607	JUL 01, 2014			
		5716640	SEP 02, 2013			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	MAY 20, 2014			
		4652441	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5643607	JUL 01, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5716640	SEP 02, 2013			
021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U-316	NP	MAR 03, 2003
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
		6156331	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332	NP	MAR 25, 2002
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332	NP	MAR 25, 2002
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U-42		
021035 001	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 002	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021035 003	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4911920	MAR 27, 2007	U-369	NP	FEB 23, 2003
		5540918	JUL 30, 2013			
020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 02, 2004			
020182 001	LEVOCARNITINE;CARNITOR				I-280	DEC 15, 2002
					ODE	DEC 15, 2006
020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-246	DEC 17, 2001
		4382892	SEP 02, 2001		I-305	FEB 02, 2003
020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-246	DEC 17, 2001
		4382892	SEP 02, 2001		I-305	FEB 02, 2003
020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010			
020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-246	DEC 17, 2001
		4382892	SEP 02, 2001		I-305	FEB 02, 2003
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	4382892	SEP 02, 2001		I-246	DEC 17, 2001
		5053407	DEC 20, 2010		I-305	FEB 02, 2003
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	4382892	SEP 02, 2001		I-246	DEC 17, 2001
		5053407	DEC 20, 2010		I-305	FEB 02, 2003
021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
		5503407	OCT 01, 2008			
		4551456	NOV 14, 2003			
		5053407	OCT 01, 2008			
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
019941 001	LIDOCAINE;EMLA	4529601	JUL 16, 2002		I-260	MAR 11, 2002
		4562060	DEC 31, 2002		I-215	FEB 04, 2001
					I-314	JAN 28, 2003
020962 001	LIDOCAINE;EMLA				NP	FEB 04, 2001
020575 001	LIDOCAINE;LIDOCAINE	5446070	FEB 27, 2011			
		5234957	FEB 27, 2011			
		5332576	JUL 26, 2011			
020575 002	LIDOCAINE;LIDOCAINE	5332576	JUL 26, 2011			
		5234957	FEB 27, 2011			
		5446070	FEB 27, 2011			
020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
					ODE	MAR 19, 2006
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
020191 001	LODOXAMIDE TROMETHAMINE;ALOMIDE	5457126	OCT 10, 2012	U-117		
020013 001	LOMEFLOXACIN HYDROCHLORIDE;MAXAQUIN	4528287	FEB 21, 2006	U-36		
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		5716641	MAY 21, 2012	U-226		
021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5612054	SEP 28, 2010			
		5248505	SEP 28, 2010			
021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U-351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U-352	NCE	MAR 01, 2001
		5541206	JUL 30, 2013	U-348		
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U-348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U-351	NCE	MAR 01, 2001
		5635523	JUN 03, 2014	U-352		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
		4282233*PED	DEC 19, 2002	U-77		
		6132758	JUN 01, 2018			
020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019670 001	LORATADINE;CLARITIN-D	4282233	JUN 19, 2002	U-77		
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		5314697*PED	APR 23, 2013			
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			
		5314697	APR 23, 2013			
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
021047 001	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
019832 003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
					ODE	JUN 05, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007		NCE	NOV 26, 2002
		4992554	FEB 12, 2008			
		5091169	FEB 25, 2009			
		5223243	JUN 29, 2010	U-237		
		4647447	MAR 03, 2004	U-238		
019940 001	MASOPROCOL;ACTINEX	4695590	APR 17, 2008			
		5008294	APR 15, 2008	U-68		
019591 001	MEFLOQUINE HYDROCHLORIDE;LARIAM	4579855	OCT 01, 2004			
020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011			
020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
020207 001	MELPHALAN HYDROCHLORIDE;ALKERAN	4997651	NOV 18, 2008			
020922 001	MEQUINOL;SOLAGE	5194247	MAR 16, 2010	U-294	NC	DEC 10, 2004
		5470567	MAR 19, 2010	U-294		
019651 001	MESALAMINE;ASACOL	5541170	JUL 30, 2013	U-141		
		5541171	JUL 30, 2013	U-141		
020049 001	MESALAMINE;PENTASA	4496553	JAN 29, 2002	U-78		
		4980173	JAN 29, 2002	U-78		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019618 001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
		RE33239	MAY 12, 2004			
019884 001	MESNA;MESNEX	4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-307	OCT 22, 2001
					PED	APR 22, 2002
					PED	JUN 15, 2004
					I-320	DEC 15, 2003
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-307	OCT 22, 2001
					PED	APR 22, 2002
					PED	JUN 15, 2004
					I-320	DEC 15, 2003
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-307	OCT 22, 2001
					PED	APR 22, 2002
					PED	JUN 15, 2004
					I-320	DEC 15, 2003
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-307	OCT 22, 2001
					PED	APR 22, 2002
					PED	JUN 15, 2004
					I-320	DEC 15, 2003
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-307	OCT 22, 2001
					PED	APR 22, 2002
					PED	JUN 15, 2004
					I-320	DEC 15, 2003
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR				NDF	OCT 13, 2003
019600 001	METHOXSALEN;OXSORALEN-ULTRA	4454152	DEC 21, 2001			
020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
		5036102	JUL 30, 2008	U-273		
		4999375	MAR 12, 2008			
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
017862 001	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
017862 004	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
019532 001	METOLAZONE;MYKROX	4517179	APR 29, 2003			
019786 003	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019786 004	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107		
		5001161	MAR 19, 2008			
		5081154	JAN 14, 2009			
019737 001	METRONIDAZOLE;METROGEL	4837378	JUN 06, 2006			
020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5536743	JUL 16, 2013	U-137		
		4837378	JUN 06, 2006			
		5840744	JAN 15, 2008	U-370		
020901 001	METRONIDAZOLE;METROLOTION				NDF	NOV 24, 2001
020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
020827 001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
020942 001	MIDAZOLAM HYDROCHLORIDE;VERSED				PED	APR 15, 2002
					NDF	OCT 15, 2001
019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
					NCE	SEP 06, 2001
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
					NCE	SEP 06, 2001
020687 001	MIFEPRISTONE;MIFEPREX	4386085	JAN 08, 2002		NCE	SEP 28, 2005
		4447424	JAN 08, 2002			
		4626531	OCT 12, 2004			
020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111	NCE	DEC 18, 2001
020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111	NCE	DEC 18, 2001
020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111	NCE	DEC 18, 2001
019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
020415 001	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		NCE	JUN 14, 2001
020415 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		NCE	JUN 14, 2001
020415 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		NCE	JUN 14, 2001
021208 001	MIRTAZAPINE;REMERON	5977099	JUN 26, 2017			
021208 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
021208 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4820738	APR 11, 2006	U-98	ODE	NOV 13, 2003
021120 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
020098 001	MIVACURIUM CHLORIDE;MIVACRON	4761418	JAN 22, 2006			
020098 002	MIVACURIUM CHLORIDE;MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006			
020717 001	MODAFINIL;PROVIGIL	5618845	OCT 06, 2014	U-255	ODE	DEC 24, 2005
		4927855	MAY 22, 2007	U-255	NCE	DEC 24, 2003
020717 002	MODAFINIL;PROVIGIL	5618845	OCT 06, 2014	U-255	ODE	DEC 24, 2005
		4927855	MAY 22, 2007	U-255	NCE	DEC 24, 2003
020312 001	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020312 002	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001		I-285	DEC 02, 2002
		5837699	JAN 27, 2014	U-249		
		6127353	OCT 03, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019543 001	MOMETASONE FUROATE;ELOCON	4472393	SEP 18, 2001			
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4472393	SEP 18, 2001			
019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
		4472393	SEP 18, 2001			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	I-300	MAR 03, 2003
					NS	MAR 03, 2003
					NCE	FEB 20, 2003
020616 001	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
020616 002	MORPHINE SULFATE;KADIAN	5378474	MAR 23, 2010			
		5202128	APR 13, 2010			
020616 003	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U-298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U-298		
		5849752	DEC 05, 2016	U-298		
019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
019886 001	NAFARELIN ACETATE;SYNAREL	4234571	JUN 11, 2011			
021076 001	NAPROXEN SODIUM;ALEVE COLD AND SINUS				NC	NOV 29, 2002
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
021204 001	NATEGLINIDE;STARLIX				NCE	DEC 22, 2005
021204 002	NATEGLINIDE;STARLIX				NCE	DEC 22, 2005
021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U-304	NP	DEC 08, 2002
		4760072	JUL 26, 2005			
019660 001	NEDOCROMIL SODIUM;TILADE	4474787	OCT 02, 2006			
		4760072	JUL 26, 2005			
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257	NCE	MAR 14, 2002

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257	NCE	MAR 14, 2002
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
					D-49	SEP 11, 2001
020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011		NDF	SEP 11, 2001
					NCE	JUN 21, 2001
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK	6080428	MAY 27, 2017	U-331		
019734 001	NICARDIPINE HYDROCHLORIDE;CARDENE	4880823	NOV 14, 2006			
		5164405	NOV 17, 2009			
020005 001	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 002	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 003	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
020076 001	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 002	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 003	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020165 004	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
020165 005	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
020165 006	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
		4917120	APR 17, 2007			
		4800903	JAN 31, 2006			
		4793366	DEC 27, 2005			
		5167242	JUN 08, 2010			
		5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
019983 001	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
019983 002	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
020198 001	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 002	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 003	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
019684 001	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 002	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 003	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
020169 001	NILUTAMIDE;NILANDRON				NCE	SEP 19, 2001
018869 001	NIMODIPINE;NIMOTOP	4406906	SEP 27, 2002	U-22		
020356 001	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 002	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 003	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020356 004	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020064 001	NITROFURANTOIN;MACROBID	4772473	JUN 16, 2006			
		4798725	JUN 16, 2006			
020145 001	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 002	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 003	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 004	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 005	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020145 006	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			
021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
020144 001	NITROGLYCERIN;TRANSDERM-NITRO	4849226	DEC 04, 2001	U-158		
		4812313	DEC 04, 2001	U-158		
		4954344	DEC 04, 2001	U-158		
020144 002	NITROGLYCERIN;TRANSDERM-NITRO	4849226	DEC 04, 2001	U-158		
		4812313	DEC 04, 2001	U-158		
		4954344	DEC 04, 2001	U-158		
020144 003	NITROGLYCERIN;TRANSDERM-NITRO	4812313	DEC 04, 2001	U-158		
		4954344	DEC 04, 2001	U-158		
		4849226	DEC 04, 2001	U-158		
020144 004	NITROGLYCERIN;TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
		4849226	DEC 04, 2001	U-158		
		4812313	DEC 04, 2001	U-158		
020144 005	NITROGLYCERIN;TRANSDERM-NITRO	4849226	DEC 04, 2001	U-158		
		4812313	DEC 04, 2001	U-158		
		4954344	DEC 04, 2001	U-158		
019508 001	NIZATIDINE;AXID	4375547	APR 12, 2002			
019508 002	NIZATIDINE;AXID	4375547	APR 12, 2002			
020555 001	NIZATIDINE;AXID AR	4375547	OCT 02, 2002		I-220	APR 01, 2001
					D-39	APR 01, 2001
019757 001	NORFLOXACIN;CHIBROXIN	4551456	NOV 14, 2003	U-57		
019384 002	NORFLOXACIN;NOROXIN	4639458	JAN 22, 2005			
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
		4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
		4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
		4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019735 001	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
020087 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2001			
020087 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2001			
020087 001	OFLOXACIN;FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
020087 004	OFLOXACIN;FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
020087 005	OFLOXACIN;FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		ODE	MAY 22, 2003
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-307	I-313	NOV 09, 2003
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-307	I-313	NOV 09, 2003
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-307	I-313	NOV 09, 2003
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011			
		5817657	APR 23, 2011	U-360		
		5627178	APR 23, 2011	U-363		
		5817655	APR 23, 2011	U-364		
				U-364		
020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
		5605897	FEB 25, 2014	U-176	NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-307	I-313	NOV 09, 2003
		5919485	MAR 24, 2015	U-308		
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 005	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307	I-297	MAR 17, 2003
		5919485	MAR 24, 2015	U-308	I-313	NOV 09, 2003
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020592 006	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307	I-297	MAR 17, 2003
		5919485	MAR 24, 2015	U-308	I-313	NOV 09, 2003
		5817656	APR 23, 2011	U-360		
		5817657	APR 23, 2011	U-363		
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 24, 2014	U-184	I-301	MAR 20, 2003
		4871865	OCT 03, 2006		NCE	DEC 18, 2001
		4923892	MAY 08, 2007	U-174		
		5116863	DEC 18, 2010			
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
019810 001	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188	I-229	JUN 29, 2001
		4786505	APR 20, 2007	U-108		
		4255431	APR 05, 2001	U-108		
		4853230	APR 20, 2007	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
019810 002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108	I-229	JUN 29, 2001
		4255431	APR 05, 2001	U-108		
		4853230	APR 20, 2007	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019810 003	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
		4853230	APR 20, 2007	U-108		
		4786505	APR 20, 2007	U-108		
		4255431	APR 05, 2001	U-108		
		4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
		5578628	JUN 24, 2006	U-44		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44	I-269	AUG 27, 2002
		4695578	JAN 25, 2005			
		5578628	JUN 24, 2006	U-44		
		5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44	I-269	AUG 27, 2002
		4695578	JAN 25, 2005			
		5578628	JUN 24, 2006	U-44		
		5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
		5578628	JUN 24, 2006	U-44		
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005	U-183		
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE FREE	5578628	JUN 24, 2006	U-44		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-329		
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2004		NCE	APR 23, 2004
		6004996	JAN 06, 2018			
021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		I-317	NOV 17, 2003
		5952375	FEB 02, 2016			
015539 002	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 004	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 006	OXAZEPAM;SERAX	4620974	NOV 04, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		4861598	AUG 29, 2006			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		4861598	AUG 29, 2006			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020932 002	OXYCODONE HYDROCHLORIDE;ROXICODONE				NS	OCT 26, 2001
					NP	OCT 26, 2001
075184 001	PACLITAXEL;PACLITAXEL				PC	APR 21, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020262 001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198	D-57	JUN 20, 2003
		5670537	AUG 03, 2012	U-198	I-270	OCT 25, 2002
		5496804	MAR 09, 2013	U-204	ODE	AUG 04, 2004
		6096331	FEB 22, 2013		I-226	APR 09, 2001
					I-230	JAN 08, 2002
020036 001	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005			
020036 003	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005			
020036 004	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005			
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
020819 001	PARICALCITOL;ZEMPLAR	5246925	SEP 21, 2010	U-314	NCE	APR 17, 2003
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5811436	SEP 22, 2015			
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
		4721723	DEC 29, 2006	U-12		
		6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR				NDF	FEB 16, 2002
021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
		5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	DEC 24, 2008		NCE	SEP 24, 2001
020193 001	PENTOSAN POLYSULFATE SODIUM;ELMIRON	5180715	JAN 19, 2010	U-159	NCE	SEP 26, 2001
					ODE	SEP 26, 2003
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;	5607979	MAY 30, 2015		NCE	FEB 17, 2005
019385 001	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 002	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 003	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
020184 001	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 002	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 003	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	MAR 22, 2001
					ODE	FEB 11, 2005
					I-212	FEB 11, 2001
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
020014 001	PIRBUTEROL ACETATE;MAXAIR	4664107	MAY 12, 2004			
020529 001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004			
		5057616	OCT 15, 2008			
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
		6048901	APR 20, 2019	U-343		
020744 001	PORACTANT ALPHA;CUROSURF				NCE	NOV 18, 2004
020451 001	PORFIMER SODIUM;PHOTOFRIN	4866168	MAR 10, 2004		ODE	DEC 27, 2002
		5028621	MAR 10, 2004		I-241	DEC 22, 2001
		5438071	AUG 01, 2012			
		4649151	MAR 10, 2004			
		4932934	JUN 12, 2007	U-128		
		5145863	DEC 15, 2009	U-129		
019439 002	POTASSIUM CHLORIDE;K-DUR 10	4863743	SEP 05, 2006	U-99		
019439 001	POTASSIUM CHLORIDE;K-DUR 20	4863743	SEP 05, 2006	U-99		
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	JUN 27, 2006	U-231		
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	JUN 27, 2006	U-231		
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	JUN 27, 2006	U-231		
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	JUN 27, 2006	U-231		
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	JUN 27, 2006	U-231		
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					I-225	MAR 27, 2001
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					I-225	MAR 27, 2001
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					I-225	MAR 27, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019775 001	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019775 002	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
075117 001	PREDNISOLONE SODIUM PHOSPHATE;ORAPRED				PC	JUL 02, 2001
019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
020545 001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
020701 002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
019781 001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
		5714520*PED	SEP 22, 2015			
		5731355	MAR 22, 2015	U-217		
		5731355*PED	SEP 22, 2015	U-217		
		5731356	MAR 22, 2015	U-218		
		5731356*PED	SEP 22, 2015	U-218		
		5908869	MAR 22, 2015	U-270		
		5908869*PED	SEP 22, 2015	U-270		
019536 001	PROPRANOLOL HYDROCHLORIDE;INDERAL	4600708	JUL 19, 2005			
020021 002	PSEUDOEPHEDRINE HYDROCHLORIDE;EFIDAC 24 PSEUDOEPHEDRINE HCL	4801461	MAR 14, 2006			
		4576604	MAR 18, 2003			
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001		I-271	SEP 30, 2002
		5393763	JUL 28, 2012	U-114	NCE	DEC 09, 2002
		5457117	JUL 28, 2012	U-114		
		5478847	MAR 02, 2014	U-114		
		5641790	JUN 24, 2014			
		5629425	SEP 19, 2014			
		5731327	MAR 24, 2015			
		5731342	JAN 27, 2017			
		5747510	MAR 02, 2014			
		5811120	MAR 02, 2014			
		5972383	MAR 02, 2014	U-287		
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008	U-3		
019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008	U-3		
019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008	U-3		
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008	U-3	I-310	OCT 04, 2003
		4587258	JAN 27, 2005			
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
		5008256	JUL 17, 2009			
		5256684	OCT 26, 2010	U-199		
		5403830	APR 04, 2012	U-200		
		5407688	APR 04, 2012	U-201		
		5601848	FEB 11, 2014	U-202		
		5456925	OCT 10, 2012			
019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002	U-121		
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2001			
019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002	U-121		
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		5068249	NOV 26, 2008			
		5068249*PED	MAY 26, 2009			
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4521431	JUN 04, 2002		I-228	JUN 08, 2001
		4880636	MAY 13, 2008		PED	DEC 08, 2001
		4880636*PED	NOV 13, 2008			
		4521431*PED	DEC 04, 2002			
020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583	FEB 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
					NCE	JUL 12, 2001
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
					NCE	JUL 12, 2001
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
					NCE	JUL 12, 2001
020741 001	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006			
		4873080	OCT 10, 2006			
020741 002	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006	U-214		
		4873080	OCT 10, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020741 003	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
		5312924	OCT 10, 2006	U-214		
		4873080	OCT 10, 2006			
020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	I-249	DEC 09, 2001
		5914128	DEC 22, 2017		NP	JUN 03, 2001
		6051252	DEC 22, 2017			
021024 001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
					ODE	JUN 22, 2005
020599 001	RILUZOLE;RILUTEK				ODE	DEC 12, 2002
020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U-100		
020835 001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		I-291	APR 14, 2003
		6165513	JUN 10, 2018		I-290	APR 14, 2003
					I-293	APR 14, 2003
					NCE	MAR 27, 2003
020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		NCE	MAR 27, 2003
		6165513	JUN 10, 2018		I-291	APR 14, 2003
					I-293	APR 14, 2003
					I-290	APR 14, 2003
020272 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009	U-90		
020272 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009	U-90		
020272 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009	U-90		
020272 004	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009	U-90		
020272 005	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009			
020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
		4804663	DEC 29, 2007	U-90		
020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5158952	OCT 27, 2009	U-90		
020588 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90		
		5453425	JUL 11, 2014			
		5616587	JUL 11, 2014			
020659 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190	NCE	MAR 01, 2001
		5484801	JAN 28, 2014			
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			
020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190	NCE	MAR 01, 2001
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		5948436	SEP 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014		NCE	MAR 01, 2001
		5846987	DEC 29, 2012	U-347		
		5541206	JUL 30, 2013	U-348		
		5635523	JUN 03, 2014	U-347		
020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020214 002	ROCURONIUM BROMIDE;ZEMURON	4894369	APR 13, 2008			
020214 001	ROCURONIUM BROMIDE;ZEMURON (P/F)	4894369	APR 13, 2008			
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
021042 003	ROFECOXIB;VIOXX				NCE	MAY 20, 2004
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	NOV 25, 2017			
		6063811	MAY 16, 2017	U-266		
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010		NCE	SEP 24, 2001
		4695576	SEP 22, 2004		D-64	NOV 02, 2003
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		NCE	SEP 24, 2001
		4870086	JUL 28, 2010		D-64	NOV 02, 2003
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		NCE	SEP 24, 2001
		4870086	JUL 28, 2010		D-64	NOV 02, 2003
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		NCE	SEP 24, 2001
		4870086	JUL 28, 2010		D-64	NOV 02, 2003
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4400358	AUG 23, 2002			
020772 001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
					NCE	APR 09, 2003
020236 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		I-216	FEB 05, 2001
		5380922	JAN 10, 2012		M-5	JUN 30, 2003
		5225445	FEB 12, 2008	U-182		
		5126375	FEB 12, 2008			
020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		I-237	SEP 25, 2001
		5225445	FEB 12, 2008	U-211	I-236	SEP 25, 2001
		5380922	JAN 10, 2012		M-5	JUN 30, 2003
		5590645	MAR 01, 2011			
		5126375	FEB 12, 2008			
		D342994	JAN 04, 2008			
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
020628 001	SAQUINAVIR MESYLATE;INVIRASE	5196438	NOV 19, 2010			
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
019863 001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
		4703035	DEC 28, 2004	U-47		
020443 001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002		ODE	SEP 26, 2004
		4703035	DEC 28, 2004			
020443 002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002		ODE	SEP 26, 2004
		4703035	DEC 28, 2004			
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152		
		4962128	NOV 02, 2009	U-12		
				U-152		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152		
		4962128	NOV 02, 2009	U-12		
				U-152		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152		
		4962128	NOV 02, 2009	U-12		
				U-152		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152		
		4962128	NOV 02, 2009	U-12		
				U-152		
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
		4536518	DEC 30, 2005	U-152		
		4962128	NOV 02, 2009	U-12		
				U-152		
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
		4940731	AUG 30, 2009	U-312		
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017			
		6074668	JAN 09, 2018			
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007			
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007			
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
		4929629	MAY 29, 2007			
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
019608 001	SILVER SULFADIAZINE;SILDIMAC	4563184	JAN 07, 2003			
020773 001	SIMETHICONE-CELLULOSE;SONORX				NP	OCT 29, 2001
019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
					D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
					D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
					D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
					D-46	JUL 10, 2001
					I-239	JUL 10, 2001

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
					NS	JUL 10, 2001
					I-239	JUL 10, 2001
					D-46	JUL 10, 2001
021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U-291		
		5308847	MAY 03, 2011	U-292		
		5403833	APR 04, 2012	U-293		
		5536729	SEP 30, 2013			
020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
					ODE	APR 30, 2003
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	APR 01, 2017	U-359	NP	SEP 21, 2003
019107 001	SOMATREM;PROTROPIN	4658021	APR 14, 2004			
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
					ODE	OCT 31, 2004
					ODE	JUN 20, 2007
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
					ODE	JUN 20, 2007
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE				ODE	OCT 31, 2004
					ODE	JUN 20, 2007
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5716338	FEB 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
					M-2	DEC 01, 2002
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
020604 001	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 002	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
020181 001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
020677 001	SPARFLOXACIN;ZAGAM	4795751	OCT 28, 2006	U-160	NCE	DEC 19, 2001
020240 001	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 002	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 003	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 004	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
040091 001	SULFADIAZINE;SULFADIAZINE				ODE	JUL 29, 2001
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
019387 001	SUPROFEN;PROFENAL	4559343	DEC 17, 2002			
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020587 001	TALC;SCLEROSOL				NCE	DEC 24, 2002
					ODE	DEC 24, 2004
017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002		I-244	OCT 29, 2001
017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002		I-244	OCT 29, 2001
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2009			
		4772475	FEB 27, 2006			
020600 001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
020600 002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
021184 001	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
021184 002	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
020887 001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
		5645815	JUL 08, 2014			
		5443815	AUG 22, 2012			
020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5279811	NOV 23, 2008	U-101		
		5431900	JUL 11, 2012	U-336		
021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
019829 001	TECHNETIUM TC-99M EXAMETAZIME KIT;CERETEC	4615876	OCT 07, 2003			
		4789736	DEC 06, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018963 001	TECHNETIUM TC-99M MEBROFENIN KIT;CHOLETEC	4418208	JAN 21, 2001			
018321 001	TECHNETIUM TC-99M OXIDRONATE KIT;TECHNESCAN HDP	4432963	FEB 21, 2001			
		4497744	FEB 05, 2002			
019981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT;ULTRATAG	4755375	JUL 05, 2005	U-51		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	SEP 09, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	4705849	NOV 10, 2004			
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008		NCE	FEB 09, 2001
020850 001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
020850 002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
018163 003	TEMAZEPAM;RESTORIL	5030632	JUL 09, 2008	U-70		
		5326758	JUL 09, 2008	U-70		
		5211954	MAY 18, 2010			
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
					ODE	AUG 11, 2006
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
		4680291	JUL 14, 2004	U-281		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006			
020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
		5681849	OCT 28, 2014			
020846 001	TERBINAFINE;LAMISIL				NP	APR 29, 2001
019641 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
019579 001	TERCONAZOLE;TERAZOL 7	4358449	NOV 09, 2001			
020489 001	TESTOSTERONE;ANDRODERM	4863970	SEP 05, 2006			
		4983395	JAN 08, 2009			
		5152997	OCT 06, 2009			
		5164190	NOV 17, 2008			
		4849224	JUL 18, 2006			
		4855294	AUG 08, 2006			
021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
019762 001	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4725439	FEB 16, 2005			
		4867982	FEB 16, 2005			
		5840327	AUG 15, 2016			
019762 002	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		5840327	AUG 15, 2016			
020791 001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371	NCE	JUL 16, 2003
					ODE	JUL 16, 2005
087563 001	THEOPHYLLINE;QUIBRON-T/SR	4465660	AUG 14, 2001			
020898 001	THYROTROPIN ALFA;THYROGEN				ODE	NOV 30, 2005
					NCE	NOV 30, 2003
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
019979 001	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
019979 002	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010		NCE	MAR 07, 2002
		4980171	APR 06, 2009			
020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
020439 001	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020439 002	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020397 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX				NCE	NOV 27, 2001
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020697 001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020697 002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020771 001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	MAY 05, 2015	U-318		
020771 002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	MAY 05, 2015	U-318		
021228 001	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
					NCE	MAR 25, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021228 002	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
					NCE	MAR 25, 2003
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					NCE	DEC 24, 2001
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					NCE	DEC 24, 2001
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					NCE	DEC 24, 2001
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					NCE	DEC 24, 2001
020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010		I-256	NOV 30, 2001
					NCE	MAY 28, 2001
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2009	U-196	ODE	MAY 29, 2004
					NCE	MAY 29, 2002
020136 001	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 003	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 004	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006		D-38	FEB 13, 2001
		4861786	JUL 08, 2007			
020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
					D-44	AUG 21, 2001
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
					D-44	AUG 21, 2001
					D-63	DEC 23, 2002
					PED	JUN 23, 2003
020528 001	TRANDOLAPRIL;MAVIK	4233361	JUN 12, 2007		NCE	APR 26, 2001
		5744496	APR 28, 2015	U-229		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020528 002	TRANDOLAPRIL;MAVIK	4233361	JUN 12, 2007		NCE	APR 26, 2001
		5744496	APR 28, 2015	U-229		
020528 003	TRANDOLAPRIL;MAVIK	4233361	JUN 12, 2007		NCE	APR 26, 2001
		5744496	APR 28, 2015	U-229		
020591 001	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
020591 002	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
020591 003	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
020591 004	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
		5045317	SEP 03, 2008	U-179		
019963 001	TRETINOIN;RENOVA	4877805	OCT 31, 2006	U-131		
		4603146	JUL 29, 2003	U-131		
021108 001	TRETINOIN;RENOVA				NP	AUG 31, 2003
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134		
020438 001	TRETINOIN;VESANOID				ODE	NOV 22, 2002
019798 001	TRIAMCINOLONE ACETONIDE;NASACORT	4767612	JAN 23, 2007	U-85		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U-295		
074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
		5962461	AUG 07, 2016			
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4694007	MAY 20, 2006	U-91		
		4376858	MAY 09, 2004			
		6017922	MAY 18, 2018			
020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010		NCE	JUN 15, 2005
		5225205	JUL 20, 2010			
		5192741	MAR 09, 2010			
020719 001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008		I-275	JUN 16, 2002
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008		I-275	JUN 16, 2002
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 003	TROGLITAZONE;PRELAY	5602133	SEP 15, 2013	U-173	I-275	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 001	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020720 003	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	I-276	JUN 16, 2002
		4572912	NOV 09, 2008		NCE	JAN 29, 2002
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U-333		
		5166178	NOV 24, 2009	U-333		
		5212200	MAY 18, 2010	U-333		
		5208256	MAY 21, 2011	U-333		
		5221763	JUN 22, 2010			
021092 001	UREA, C-13;HELICOSOL				NP	DEC 17, 2002
020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147	NCE	SEP 17, 2001
		5140993	AUG 24, 2009	U-148		
020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				NCE	SEP 17, 2001
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		ODE	DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
		4567182	JAN 28, 2003			
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4567182	JAN 28, 2003			
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
		4957924	JUN 23, 2009			
020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
					ODE	SEP 25, 2005
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007			
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-251	MAR 11, 2002
020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
019614 001	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 002	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 003	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007		NP	NOV 25, 2001
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007		NP	NOV 25, 2001
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007		NP	NOV 25, 2001
021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012			
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U-357		
		5798349	AUG 25, 2015	U-357		
		5756541	MAR 11, 2016	U-357		
014103 003	VINCRISTINE SULFATE;ONCOVIN	4619935	OCT 28, 2003			
020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
020547 001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189	I-268	SEP 17, 2002
		5583152	SEP 26, 2010		NCE	SEP 26, 2001
		4859692	SEP 26, 2010			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		5482963	JAN 09, 2013			
		6143775	DEC 11, 2011			
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NCE	SEP 26, 2001
		5294636	DEC 11, 2011		I-268	SEP 17, 2002
		5319097	DEC 11, 2011		NS	SEP 17, 2002
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
		6143775	DEC 11, 2011			
020199 001	ZALCITABINE;HIVID	5028595	JUL 02, 2008	U-65		
		4879277	NOV 07, 2006	U-65		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020199 002	ZALCITABINE;HIVID	4879277	NOV 07, 2006	U-65		
		5028595	JUL 02, 2008	U-65		
020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		I-294	APR 26, 2003
		4778054	OCT 18, 2005		NCE	JUL 26, 2004
		4811731	JUL 29, 2006			
		5035237	JUL 30, 2008			
		5360817	NOV 01, 2011			
		5648379	JUL 15, 2014	U-274		
		4627432	DEC 09, 2003			
019655 001	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
019910 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
019951 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4837208	SEP 17, 2005			
020518 001	ZIDOVUDINE;RETROVIR	4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
020518 002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
020471 001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168	NCE	DEC 09, 2001
020471 003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168	NCE	DEC 09, 2001
020458 001	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020458 002	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
019908 001	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
019908 002	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, THE FOLLOWING ABBREVIATIONS HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THIS PAGE FOR AN EXPLANATION OF THE PATENT AND EXCLUSIVITY ABBREVIATIONS FOUND IN THE ADDENDUM.

ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)
I	NEW INDICATION (SEE REFERENCES, BELOW)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PED	PEDIATRIC EXCLUSIVITY
PC	PATENT CHALLENGE
U	PATENT USE CODE (SEE REFERENCES, BELOW)

REFERENCES
NEW DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW DOSING SCHEDULE

D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS
D-30 5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
D-35 FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS
D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVE TWICE DAILY
D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40 ONCE-A-DAY DOSING REGIMEN
D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46 NEW DOSING REGIMEN OF 80MG DAILY
D-47 TAKE DRUG "15 MINUTES TO 1 HOUR" PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN
D-48 ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49 PEDIATRIC DOSING GUIDELINES
D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56 ADDITION OF POSTPRANDIAL DOSING
D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML

NEW INDICATION

I-1 DYSMENORRHEA
I-2 CHOLANGIOPANCREATOGRAPHY
I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-5 HYSTEROSALPINGOGRAPHY
I-6 TREATMENT OF JUVENILE ARTHRITIS
I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10 PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11 RELIEF OF MILD TO MODERATE PAIN
I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14 SEBORRHEIC DERMATITIS
I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN *IN VITRO* FERTILIZATION PROGRAM
I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19 HERNIOGRAPHY
I-20 KNEE ARTHROGRAPHY
I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24 TREATMENT OF RHEUMATOID ARTHRITIS
I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26 TREATMENT OF LIVER FLUKES
I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30 TREATMENT OF TINEA PEDIS
I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32 PEDIATRIC MYELOGRAPHY
I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40 PRIMARY NOCTURNAL ENURESIS
I-41 MIGRAINE HEADACHE PROPHYLAXIS
I-42 HERPES ZOSTER
I-43 HERPES SIMPLEX ENCEPHALITIS
I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48 PEDIATRIC ANGIOCARDIOGRAPHY
I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-52 PEDIATRIC EXCRETORY UROGRAPHY
I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54 RENAL CONCENTRATION CAPACITY TEST
I-55 HYPERTENSION
I-56 EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61 FEMALE ANDROGENETIC ALOPECIA
I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66 UNCOMPLICATED GONORRHEA
I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68 CENTRAL PRECOCIOUS PUBERTY
I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71 VARICELLA INFECTIONS (CHICKENPOX)
I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76 PREVENTION OF OSTEOPOROSIS
I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82 TREATMENT OF TRAVELERS' DIARRHEA
I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88 MANAGEMENT OF ENDOMETRIOSIS
I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90 INTENSIVE CARE UNIT SEDATION
I-91 MONOTHERAPY USE FOR HYPERTENSION
I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE ($AaDO_2$) IS LESS THAN OR EQUAL TO 55 TORR
I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163 TREATMENT OF PHOTOPHOBIA
I-164 CHRONIC BACTERIAL PROSTATITIS
I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166 TREATMENT OF BULIMIA
I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174 PELVIC INFLAMMATORY DISEASE
I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177 TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194 CONGESTIVE HEART FAILURE
I-195 USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198 USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211 FOR USE IN THE PEDIATRIC POPULATION
I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214 TREATMENT OF OSTEOPOROSIS
I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET

I-220 TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH

I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN

I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS

I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL

I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

I-230 IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER

I-245 TREATMENT OF ACUTE SINUSITIS

I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY

I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY

I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA

I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)

I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER

I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIa and IIb)

I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS

I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE

I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III

I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH

I-288 CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE

I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

I-290 TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS

I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS.

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER

I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
NEW INDICATION

I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

MISCELLANEOUS EXCLUSIVITY CODES

M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2 APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION

REFERENCES
PATENT USE CODE

U-1 PREVENTION OF PREGNANCY
U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3 TREATMENT OF HYPERTENSION
U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5 METHOD OF PRODUCING BRONCHODILATION
U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7 INCREASING CARDIAC CONTRACTILITY
U-8 ACUTE MYOCARDIAL INFARCTION
U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16 USE IN LUNG SCANNING PROCEDURES
U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19 TREATMENT OF INFLAMMATION
U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21 TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINES

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/ DECONGESTANT
U-94	TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATING NEUROGENERATIVE DISEASES
U-126 TREATMENT OF GASTRITIS
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128 METHODS FOR TREATMENT OF TUMORS
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131 PHOTODAMAGED SKIN
U-132 INHIBITING HIV PROTEASE
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134 TREATMENT OF ACNE VULGARIS
U-135 ANTITUMOR AGENT
U-136 PROCESS FOR WASTE NITROGEN REMOVAL
U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
U-138 TREATMENT OF ALLERGIC RHINITIS
U-139 TREATMENT OF ALLERGIC REACTIONS
U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141 TREATMENT OF ULCERATIVE COLITIS
U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}CO_2$
U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155 TREATMENT OF ERECTILE DYSFUNCTION
U-156 METHOD OF PROVIDING ANESTHESIA
U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158 ANGINA
U-159 TREATMENT OF INTERSTITIAL CYSTITIS
U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167 METHOD FOR TREATING HIV-1 INFECTION
U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172 TREATMENT OF GENITAL WARTS
U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174 USE AS AN ANTIHISTAMINE AGENT
U-175 METHOD OF TREATING MALIGNANT TUMORS
U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177 FUNGICIDE
U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185 METHOD OF TREATING HYPERTENSION
U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192 USE IN TREATING ALLERGIC REACTIONS
U-193 PSORIASIS
U-194 TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196 TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205 METHOD FOR TREATING HEARTBURN
U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
U-207 USE AS NASAL SPRAY
U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT- TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

*U.S. Government Printing Office: 2001 — 472-432/21007